<SEC-DOCUMENT>0001193125-12-208797.txt : 20120503
<SEC-HEADER>0001193125-12-208797.hdr.sgml : 20120503
<ACCEPTANCE-DATETIME>20120503170104
ACCESSION NUMBER:		0001193125-12-208797
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20120331
FILED AS OF DATE:		20120503
DATE AS OF CHANGE:		20120503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALNYLAM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001178670
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770602661
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50743
		FILM NUMBER:		12810647

	BUSINESS ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		(617) 551-8200

	MAIL ADDRESS:	
		STREET 1:		300 THIRD STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ALNYLAM PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20020724
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d335938d10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 10-Q
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the quarterly period ended March&nbsp;31, 2012 </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OR </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commission File Number 000-50743
</B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>ALNYLAM PHARMACEUTICALS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Its Charter) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>77-0602661</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incorporation or Organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>300 Third Street, Cambridge, MA</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>02142</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of Principal Executive Offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(617) 551-8200 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Registrant&#146;s Telephone Number, Including Area Code) </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by
check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule&nbsp;12b-2 of the Exchange Act. (Check one): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated&nbsp;filer&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(do not check if smaller reporting company)</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Exchange Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At April&nbsp;30, 2012, the registrant had 51,949,931 shares of Common Stock, $0.01 par value per share, outstanding. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>PAGE<BR>NUMBER</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART I. FINANCIAL INFORMATION</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ITEM&nbsp;1. FINANCIAL STATEMENTS (Unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_1">CONDENSED CONSOLIDATED BALANCE SHEETS AS OF MARCH 31, 2012 AND DECEMBER 31, 2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_2">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_3">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND
2011</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_4">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_5">ITEM&nbsp;2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_6">ITEM&nbsp;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_7">ITEM&nbsp;4. CONTROLS AND PROCEDURES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II. OTHER INFORMATION</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_8">ITEM&nbsp;1. LEGAL PROCEEDINGS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_12">ITEM&nbsp;1A. RISK FACTORS </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_9">ITEM&nbsp;5. OTHER INFORMATION</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_10">ITEM&nbsp;6. EXHIBITS</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc335938_11">SIGNATURES</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_1"></A>ALNYLAM PHARMACEUTICALS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands, except share and per share amounts) </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8" COLSPAN="9"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSETS</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">137,356</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Billed and unbilled collaboration receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,468</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">152,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,407</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,643</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment in joint venture (Regulus Therapeutics Inc.)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">564</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Intangible assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">231</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="9"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,006</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investment in joint venture (Regulus Therapeutics Inc.)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80,990</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred rent, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue, net of current portion</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78,487</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commitments and contingencies (Notes 4, 5 and 6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholders&#146; equity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.01&nbsp;par value, 5,000,000&nbsp;shares authorized and no shares issued and outstanding at March&nbsp;31,
2012 and December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01&nbsp;par value, 125,000,000&nbsp;shares authorized; 51,893,258&nbsp;shares issued and outstanding at
March&nbsp;31, 2012; 42,721,942 shares issued and outstanding at December&nbsp;31, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">519</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">427</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">609,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">518,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(165</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(412,364</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(400,996</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">197,378</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,997</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total liabilities and stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">281,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_2"></A>ALNYLAM PHARMACEUTICALS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands, except per share amounts) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net revenues from research collaborators</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> (1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative </FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other income (expense):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity in loss of joint venture (Regulus Therapeutics Inc.)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">223</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">382</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss per common share - basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted average common shares used to compute basic and diluted net loss per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Comprehensive loss:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unrealized gain (loss) on marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Non-cash stock-based compensation expenses included in operating expenses are as
follows:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_3"></A>ALNYLAM PHARMACEUTICALS, INC. </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(In thousands) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from operating activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,121</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,339</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,156</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Charge for 401(k) company stock match</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">96</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">138</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity in loss of joint venture (Regulus Therapeutics Inc.)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Realized gain on sale of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Billed and unbilled collaboration receivables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,300</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income taxes receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,669</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prepaid expenses and other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,932</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,970</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,461</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued expenses and other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,780</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20,069</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in restricted cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(118,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,790</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and maturities of marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,042</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from exercise of stock options and other types of equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds from issuance of common stock, net of offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payments for repurchase of common stock for employee tax withholding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying notes are an integral part of these condensed consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_4"></A>ALNYLAM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Unaudited) </B></FONT></P>
 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Basis of Presentation and Principles of Consolidation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. (the &#147;Company&#148; or
&#147;Alnylam&#148;) are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) applicable to interim periods and, in the opinion of management, include all
normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. The Company&#146;s condensed consolidated financial statements have also been prepared on a basis substantially consistent with,
and should be read in conjunction with, the Company&#146;s audited consolidated financial statements for the year ended December&nbsp;31, 2011, which were included in the Company&#146;s Annual Report on Form 10-K that was filed with the Securities
and Exchange Commission (the &#147;SEC&#148;) on February&nbsp;13, 2012. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of the
Company&#146;s operations for any interim period are not necessarily indicative of the results of the Company&#146;s operations for any other interim period or for a full fiscal year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accompanying condensed consolidated financial statements reflect the operations of the Company and Alnylam U.S., Inc., Alnylam Europe
AG (&#147;Alnylam Europe&#148;), Alnylam Securities Corporation and Meltemi Biotherapeutics, Inc., wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have been eliminated. The Company uses the equity
method of accounting to account for its investment in Regulus Therapeutics Inc. (&#147;Regulus&#148;). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Use of Estimates
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect&nbsp;the reported amounts of assets and liabilities and&nbsp;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&nbsp;the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Loss Per Common Share </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company computes basic net loss&nbsp;per common share by dividing net loss&nbsp;attributable to common stockholders by the weighted
average number of common shares outstanding. The Company computes diluted net loss&nbsp;per common share by dividing net loss&nbsp;attributable to common stockholders by the weighted average number of common shares and dilutive potential common
share equivalents then outstanding. Potential common shares consist of shares issuable upon the exercise of stock options (using the treasury stock method) and unvested restricted stock awards. Because the inclusion of potential common shares would
be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth for the periods presented the potential common shares (prior to consideration of the treasury stock
method) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive, in thousands: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;
31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options to purchase common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,085</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,869</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unvested restricted common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">658</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,982</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Restricted Stock Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, as part of its post-restructuring retention program, the Company granted an aggregate of 508,928 shares of restricted
stock to its retained employees, excluding the Company&#146;s chief executive officer and president and chief operating officer. These restricted stock awards were valued at $5.3 million on the grant date and vest in full on the second anniversary
of the grant date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company recognized an aggregate of $0.5 million and $0.1 million of stock-based compensation expense
related to all restricted stock awards granted for the three months ended March&nbsp;31, 2012 and 2011, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Public Offering
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2012, the Company sold an aggregate of 8,625,000 shares of its common stock through an underwritten public
offering at a price to the public of $10.75 per share. As a result of the offering, the Company received aggregate net proceeds of approximately $86.8 million, after deducting underwriting discounts and commissions and other estimated offering
expenses of approximately $5.9 million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fair Value Measurements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables present information about the Company&#146;s assets that are measured at fair value on a recurring basis at
March&nbsp;31, 2012 and December&nbsp;31, 2011, and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level&nbsp;1 inputs utilize quoted prices
(unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level&nbsp;2 inputs utilize data points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair values determined by
Level&nbsp;3 inputs utilize unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The fair value hierarchy level is determined by the lowest level of
significant input. Financial assets measured at fair value on a recurring basis are summarized as follows, in thousands: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>At</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;&nbsp;March&nbsp;31,&nbsp;&nbsp;
</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>in
Active<BR>Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Observable<BR>Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Level
 3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,791</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities (fixed income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">181,121</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">181,121</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial paper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities (equity holdings)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">315,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">255,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>At</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;
31,<BR>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Quoted&nbsp;Prices</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>in
Active<BR>Markets<BR>(Level 1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Observable<BR>Inputs<BR>(Level 2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Level
 3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities (fixed income)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73,722</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial paper</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Marketable securities (equity holdings)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">257,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three months ended March&nbsp;31, 2012, there were no transfers between Level 1 and Level 2
financial assets. The carrying amounts reflected in the Company&#146;s condensed consolidated balance sheets for cash, collaboration receivables, other current assets, accounts payable and accrued expenses approximate fair value due to their
short-term maturities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investments in Marketable Securities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company invests its excess cash balances in short-term and long-term marketable debt and equity securities. The Company classifies its
investments in marketable debt securities as either held-to-maturity or available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented, the Company classified all of its
investments in debt and equity securities as available-for-sale. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized holding gains and losses (the adjustment to fair value) in
accumulated other comprehensive income (loss), a component of stockholders&#146; equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any adjustment to fair value reflects a
decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#147;other than temporary&#148; and, if so, marks the investment to market through a charge to its condensed
consolidated statements of comprehensive loss. The Company did not record any impairment charges related to its fixed income marketable securities during the current period. The Company&#146;s marketable securities are classified as cash equivalents
if the original maturity, from the date of purchase, is 90&nbsp;days or less, and as marketable securities if the original maturity, from the date of purchase, is in excess of 90&nbsp;days. The Company&#146;s cash equivalents are composed of money
market funds, U.S. government obligations and commercial paper. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company obtains fair value measurement data for its
marketable securities from independent pricing services. The Company performs validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand the methods and data sources
used. Additionally, the Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize the Company&#146;s marketable securities at March&nbsp;31, 2012 and December&nbsp;31, 2011, in thousands:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31, 2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Gains</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Losses</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial paper (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113,304</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes (Due after 1&nbsp;year through 2&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18,870</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations (Due after 1&nbsp;year through 2&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">255,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(147</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">255,178</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December&nbsp;31, 2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amortized</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Cost</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Gains</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Gross</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Unrealized</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Losses</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fair&nbsp;Value</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial paper (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,273</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,245</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Corporate notes (Due after 1&nbsp;year through 2&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,592</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,594</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations (Due within 1&nbsp;year)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Government obligations (Due after 1&nbsp;year through 2&nbsp;years)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,202</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">190,581</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Subsequent Events </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company evaluated all events or transactions that occurred after March&nbsp;31, 2012 through the date these condensed consolidated financial statements were issued. During this period, the Company did
not have any material recognized subsequent events. However, the Company did have the following nonrecognized subsequent event, which is more fully described in Note 7: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, the Company exercised its option under its July 2007 amended and restated collaboration agreement (the &#147;Medtronic Agreement&#148;)
with Medtronic, Inc. (&#147;Medtronic&#148;) to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent Accounting Pronouncements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2011, the Financial Accounting Standards Board (&#147;FASB&#148;) issued a new accounting standard that clarifies the application
of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and
interim reporting periods beginning on or after December&nbsp;15, 2011. The Company adopted this amendment on January&nbsp;1, 2012. The adoption of this new standard did not have a material impact on the Company&#146;s condensed consolidated
financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, the FASB issued an amendment to the accounting guidance for presentation of comprehensive
income. Under the amended guidance, a company may present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two
separate but consecutive statements. In either case, a company is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income and a
total amount for comprehensive income. For public companies, the amendment is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2011, and shall be applied retrospectively. The Company adopted this
amendment on January&nbsp;1, 2012. Other than a change in presentation, the adoption of this guidance did not have a material impact on the Company&#146;s condensed consolidated financial statements. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. SIGNIFICANT AGREEMENTS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the Company&#146;s total consolidated net revenues from research collaborators, for the
periods indicated, in thousands: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roche/Arrowhead</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Takeda</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total net revenues from research collaborators</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Platform Alliances </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Roche/Arrowhead Alliance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2007, the Company and, for limited
purposes, Alnylam Europe, entered into a license and collaboration agreement (the &#147;LCA&#148;) with F. Hoffmann-La Roche Ltd (&#147;Roche Basel&#148;) and Hoffmann-La Roche Inc. (together with Roche Basel, &#147;Roche&#148;). Under the LCA,
which became effective in August 2007, the Company granted Roche a non-exclusive license to the Company&#146;s intellectual property, including delivery-related intellectual property existing as of the date of the LCA, to develop and commercialize
therapeutic products that function through RNA interference (&#147;RNAi&#148;), subject to the Company&#146;s existing contractual obligations to third parties. In November 2010, Roche announced the discontinuation of certain activities in research
and early development, including its RNAi research efforts. The remaining deliverables under the LCA currently remain in effect. In October 2011, Arrowhead Research Corporation (&#147;Arrowhead&#148;) announced its acquisition of RNA therapeutics
assets from Roche, including the LCA. As a result of the assignment, Arrowhead has all of the rights and obligations of Roche under the LCA. The license is initially limited to four therapeutic areas, and may be expanded to include additional
therapeutic areas upon payment to the Company by Arrowhead of an additional $50.0 million for each additional therapeutic area, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In consideration for the rights the Company granted under the LCA, Roche paid the Company $273.5 million in upfront cash payments. In addition, in exchange for the Company&#146;s contributions under the
LCA, for each RNAi therapeutic product developed by Arrowhead, its affiliates or sublicensees under the LCA, the Company is entitled to receive milestone payments upon achievement of specified development and sales events, totaling up to an
aggregate of $100.0 million per therapeutic target, together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the Company and Roche also established a discovery collaboration in October 2009 (&#147;Discovery
Collaboration&#148;), subject to the Company&#146;s existing contractual obligations to third parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2007, the
Company executed a common stock purchase agreement (the &#147;Common Stock Purchase Agreement&#148;) with Roche Finance Ltd, an affiliate of Roche. In connection with the execution of the LCA and the Common Stock Purchase Agreement, the Company also
executed a share purchase agreement (the &#147;Alnylam Europe Purchase Agreement&#148;) with Alnylam Europe and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Roche Beteiligungs GmbH, an affiliate of Roche (&#147;Roche Germany&#148;). Under the terms of the Alnylam Europe Purchase Agreement, the Company sold substantially all of the non-intellectual
property assets of Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0 million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In summary, the Company
received upfront payments totaling $331.0 million under the Roche alliance, which included an upfront payment under the LCA of $273.5 million, $42.5 million under the Common Stock Purchase Agreement and $15.0 million under the Alnylam Europe
Purchase Agreement. The Company initially recorded $278.2 million of these proceeds as deferred revenue in connection with this alliance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the deliverables under these agreements included the license, the Alnylam Europe assets and employees, the steering committees (joint steering committee and future technology
committee) and the services under the Discovery Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and assets of Alnylam Europe are not
separable from the undelivered services (i.e., the steering committees and Discovery Collaboration) and, accordingly, the license and the services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a
single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the Arrowhead alliance, the steering committee services and the Discovery Collaboration services are the final deliverables and all such
services will end, contractually, five years from the effective date of the LCA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is recognizing the revenue
related to these agreements on a straight-line basis over five years because the Company cannot reasonably estimate the total level of effort required to complete its service obligations under the LCA, and therefore, cannot utilize a proportional
performance model. The Company will continue to recognize the revenue related to these agreements on a straight-line basis over five years through August 2012. At March&nbsp;31, 2012, deferred revenue under the LCA was $23.3 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Takeda Alliance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In May 2008, the Company entered into a license and collaboration agreement (the &#147;Takeda Agreement&#148;) with Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) to pursue the development and
commercialization of RNAi therapeutics. Under the Takeda Agreement, the Company granted to Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&#146;s intellectual property, including delivery-related intellectual property,
controlled by the Company as of the date of the agreement or during the five years thereafter, to develop, manufacture, use and commercialize RNAi therapeutics, subject to the Company&#146;s existing contractual obligations to third parties. The
license initially is limited to the fields of oncology and metabolic disease and may be expanded at Takeda&#146;s option to include other therapeutic areas, subject to specified conditions. Under the Takeda Agreement, Takeda is the Company&#146;s
exclusive platform partner in the Asian territory, as defined in the Takeda Agreement, through May 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration for
the rights granted to Takeda under the Takeda Agreement, Takeda agreed to pay the Company $150.0 million in upfront and near-term technology transfer payments. In addition, the Company has the option, exercisable until the start of Phase III
development, to opt-in under a 50-50 profit sharing agreement to the development and commercialization in the United States of up to four Takeda licensed products and would be entitled to opt-in rights for two additional products for each additional
field expansion, if any, elected by Takeda under the Takeda Collaboration Agreement. In June 2008, Takeda paid the Company an upfront payment of $100.0 million and agreed to pay to the Company an additional $50.0 million upon achievement of
specified technology transfer milestones. Of this $50.0 million, $20.0 million was paid to the Company in October 2008, $20.0 million was paid to the Company in March 2010, and $10.0 million was paid to the Company in March 2011 (collectively, the
&#147;Technology Transfer Milestones&#148;). If Takeda elects to expand its license to additional therapeutic areas, Takeda will be required to pay the Company $50.0 million for each additional field selected, if any. In addition, for each RNAi
therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled to receive specified development and commercialization milestones, totaling up to $171.0 million per product, together with royalty payments based on
worldwide annual net sales, if any. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Takeda Agreement, the Company and Takeda are also collaborating on the
research of RNAi therapeutics directed to one or two disease targets agreed to by the parties (the &#147;Research Collaboration&#148;), subject to the Company&#146;s existing contractual obligations with third parties. Takeda also has the option,
subject to certain conditions, to collaborate with the Company on the research and development of RNAi drug delivery technology for targets agreed to by the parties. In addition, Takeda has a right of first negotiation for the development and
commercialization of the Company&#146;s RNAi therapeutic products in the Asian territory, excluding the Company&#146;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a similar right of first negotiation to
participate with Takeda in the development and commercialization of licensed products in the United States. The </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
collaboration is governed by a joint technology transfer committee (the &#147;JTTC&#148;), a joint research collaboration committee (the &#147;JRCC&#148;) and a joint delivery collaboration
committee (the &#147;JDCC&#148;), each of which is comprised of an equal number of representatives from each party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Company determined that the deliverables under the Takeda Agreement include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer activities and the services that the Company will be obligated to perform under the
Research Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and undelivered services (i.e., the joint committees and the Research
Collaboration) are not separable and, accordingly, the license and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue recognition
pattern on the final deliverable. Under the Takeda Agreement, the last elements to be delivered are the JDCC and JTTC services, each of which has a life of no more than seven years. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is recognizing the upfront payment of $100.0 million and the Technology Transfer Milestones of $50.0 million, the receipt of
which the Company believed was probable at the commencement of the collaboration, on a straight-line basis over seven years because the Company is unable to reasonably estimate the level of effort to fulfill these obligations, primarily because the
effort required under the Research Collaboration is largely unknown, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company will recognize as revenue a portion of the milestone payment equal to
the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. At March&nbsp;31, 2012, deferred revenue under the Takeda Agreement was $69.3 million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Product Alliances </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Kyowa Hakko Kirin Alliance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2008, the Company entered into a
license and collaboration agreement (the &#147;Kyowa Hakko Kirin Agreement&#148;) with Kyowa Hakko Kirin Co., Ltd. (&#147;Kyowa Hakko Kirin&#148;). Under the Kyowa Hakko Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to
its intellectual property in Japan and other markets in Asia (the &#147;Licensed Territory&#148;) for the development and commercialization of an RNAi therapeutic for the treatment of respiratory syncytial virus (&#147;RSV&#148;) infection. The
Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program (&#147;Additional Compounds&#148;). The Company retains all development and commercialization rights
worldwide outside of the Licensed Territory, subject to its agreement with Cubist Pharmaceuticals, Inc. (&#147;Cubist&#148;) described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Kyowa Hakko Kirin Agreement, in June 2008, Kyowa Hakko Kirin paid the Company an upfront cash payment of $15.0&nbsp;million. In addition, Kyowa Hakko Kirin is required to make
payments to the Company upon achievement of specified development and sales milestones totaling up to $78.0&nbsp;million, and royalty payments based on annual net sales, if any, of RNAi therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its
affiliates and sublicensees in the Licensed Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The collaboration between Kyowa Hakko Kirin and the Company is
governed by a joint steering committee that is comprised of an equal number of representatives from each party. Under the agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to the development activities
to be undertaken in the Licensed Territory, with the initial focus on Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the development plan that are reasonably necessary for the regulatory approval and
commercialization of an RNAi therapeutic for the treatment of RSV in Japan and the rest of the Licensed Territory. The Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement unless Kyowa Hakko Kirin elects,
prior to the first commercial sale of the product in the Licensed Territory, to manufacture the product itself or arrange for a third party to manufacture the product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company has determined that the deliverables under the Kyowa Hakko Kirin Agreement include the license, the joint steering committee, the manufacturing services and any Additional Compounds. The
Company has determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the individual deliverables are not separable and, accordingly, must be accounted for as a single unit of accounting.
When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company is currently unable to reasonably estimate its period of performance under the Kyowa Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the
fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The Company is deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate its period of performance. The Company will continue to
reassess whether it can reasonably estimate the period of performance to fulfill its obligations under the Kyowa Hakko Kirin Agreement. At March&nbsp;31, 2012, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&nbsp;million.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cubist Alliance </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In January 2009, the Company entered into a license and collaboration agreement with Cubist (the &#147;Cubist Agreement&#148;) to develop and commercialize therapeutic products (&#147;Licensed
Products&#148;) based on certain of the Company&#146;s RNAi technology for the treatment of RSV infection. Licensed Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV inhibitors. In November 2009, the
Company and Cubist entered into an amendment to the Cubist Agreement (the &#147;Amendment&#148;), which provides that the Company and Cubist would focus their collaboration and joint development efforts on ALN-RSV02, a second-generation compound,
intended for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant to the terms of the Amendment, the Company is
continuing to develop ALN-RSV01 for adult transplant patients at its sole discretion and expense. Cubist has the right to opt into collaborating with the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time
following the completion of the Company&#146;s Phase IIb trial of ALN-RSV01, subject to the payment by Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the Company&#146;s development expenses for
ALN-RSV01. In December 2010, the Company and Cubist jointly made a portfolio decision to put the development of ALN-RSV02 on hold. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration for the rights granted to Cubist under the Cubist Agreement, in January
2009, Cubist paid the Company an upfront cash payment of $20.0&nbsp;million. Cubist is also obligated under the Cubist Agreement to pay the Company milestone payments, totaling up to an aggregate of $82.5&nbsp;million, upon the achievement of
specified development and sales events in the &#147;Royalty Territory,&#148; which includes all geographic territories excluding North America and Asia. In addition, if Licensed Products are successfully developed, Cubist will be required to pay to
the Company royalties on net sales of Licensed Products in the Royalty Territory, if any, subject to offsets under certain circumstances. Upon achievement of certain development milestones, the Company will have the right to convert the North
American co-development and profit sharing arrangement into a royalty-bearing license and, in addition to royalties on net sales in North America, will be entitled to receive additional milestone payments totaling up to an aggregate of
$130.0&nbsp;million upon achievement of specified development and sales events in North America, subject to the timing of the conversion by the Company and the regulatory status of Licensed Products at the time of conversion. If the Company makes
the conversion to a royalty-bearing license with respect to North America, then North America becomes part of the Royalty Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company determined that the deliverables under the Cubist Agreement include the licenses, technology transfer related to the ALN-RSV program, the joint steering committee and the development and
manufacturing services that the Company is obligated to perform during the development period. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the licenses and
undelivered services are not separable and, accordingly, the licenses and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue
recognition pattern on the final deliverable. Under the Cubist Agreement, the last element to be delivered is the development and manufacturing services, which have an expected life of approximately eight years. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company is recognizing the upfront payment of $20.0&nbsp;million on a straight-line basis over approximately eight years because the
Company is unable to reasonably estimate the level of effort to fulfill its performance obligations, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company will recognize as revenue a portion
of the milestone payment, equal to the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. The Company will recognize the remaining portion of the milestone over the
remaining performance period on a straight-line basis. At March&nbsp;31, 2012, deferred revenue under the Cubist Agreement was $11.8&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for developing Licensed Products in North America, and each bears one-half of the related development costs, provided
that under the terms of the Amendment, the Company is funding the advancement of ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue generating arrangements that involve cost sharing between the parties, the
Company presents the results of activities for which it acts as the principal on a gross basis and reports any payments received from, or made to, other collaborators based on other applicable GAAP or, in the absence of other applicable GAAP,
analogy to authoritative accounting literature or a reasonable, rational and consistently applied accounting policy election. As the Company is not considered the principal under the Cubist Agreement, the Company records any amounts due from Cubist
as a reduction of research and development expense. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. INCOME TAXES </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company expects to continue to generate U.S. taxable losses in 2012 and has recorded no income tax provision for
the three months ended March&nbsp;31, 2012 and 2011. </FONT></P> <P><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2011, the Internal Revenue Service completed its audits of the Company&#146;s 2008
and 2009 tax years. Subsequently, the 2010 tax year was reviewed by the Joint Committee of the Internal Revenue Service (&#147;Joint Committee&#148;). In March 2012, the Company received the final report from the Joint Committee. The review of tax
years 2008 through 2010 is complete. The Company did not record any tax expense related to these audits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company
continues to recognize fully its tax benefits which are offset by a valuation allowance to the extent that it is more likely than not that the deferred tax assets will not be realized. At March&nbsp;31, 2012, the Company had $0.1&nbsp;million of
total gross unrecognized tax benefits that, if recognized, would favorably impact the Company&#146;s effective income tax rate in future periods. </FONT></P>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.&nbsp;REGULUS </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2007, the Company and Isis Pharmaceuticals, Inc. (&#147;Isis&#148;) established Regulus, a company focused
on the discovery, development and commercialization of microRNA therapeutics, a potential new class of drugs to treat the pathways of human disease. Regulus, which initially was established as a limited liability company, converted to a C
corporation in January 2009 and changed its name to Regulus Therapeutics Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration for the Company&#146;s and
Isis&#146; initial interests in Regulus, each party granted Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic applications as well as certain patents in the microRNA field. In addition, the Company made an
initial cash contribution to Regulus of $10.0 million, resulting in the Company and Isis making approximately equal aggregate initial capital contributions to Regulus. In March 2009, the Company and Isis each purchased $10.0 million of Series A
preferred stock of Regulus. In October 2010, in connection with its strategic alliance with Regulus formed in June 2010, Sanofi made a $10.0 million equity investment in Regulus. At March&nbsp;31, 2012, the Company, Isis and Sanofi owned
approximately 45%, 46% and 9%, respectively, of Regulus. Regulus continues to operate as an independent company with a separate board of directors, scientific advisory board and management team, some of whom have options to purchase common stock of
Regulus. Members of the board of directors of Regulus who are the Company&#146;s employees or Isis&#146; employees are not eligible to receive options to purchase Regulus common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company reviewed the consolidation guidance that defines a variable interest entity (&#147;VIE&#148;) and concluded that Regulus
currently qualifies as a VIE. The Company does not consolidate Regulus as the Company lacks the power to direct the activities that could significantly impact the economic success of this entity. Under the equity method of accounting, because the
Company has guaranteed the debt of Regulus, the Company will continue to recognize its share of any future losses up to a maximum negative carrying value, or liability, equivalent to the amount of debt guaranteed by the Company. The Company&#146;s
maximum exposure to loss related to this VIE&nbsp;is limited to the carrying value of the Company&#146;s investment, as well the portion of Regulus&#146; debt, including accrued interest, guaranteed by the Company, which was $5.5 million at
March&nbsp;31, 2012. At March&nbsp;31, 2012, the total negative carrying value of the Company&#146;s investment in Regulus in its condensed consolidated balance sheets was a liability of $0.3 million. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company accounts for its investment in Regulus using the equity method of accounting. Summary results of Regulus&#146; operations for
the three months ended March&nbsp;31, 2012 and 2011 and balance sheets at March&nbsp;31, 2012 and December&nbsp;31, 2011 are presented in the tables below, in thousands (unaudited): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Statement of Comprehensive Loss Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,441</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;5,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;5,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(139</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,289</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>December<BR>31, 2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and marketable securities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,508</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,929</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,295</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,881</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,220</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,817</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; (deficit) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(742</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,197</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.&nbsp;COMMITMENTS AND CONTINGENCIES </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Litigation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Tekmira Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;16, 2011, Tekmira and Protiva
Biotherapeutics, Inc. filed a civil complaint against the Company in the Business Litigation Section of the Suffolk County Superior Court in Boston, Massachusetts, and on June&nbsp;3, 2011, the plaintiffs filed an amended complaint adding AlCana
Technologies, Inc. (&#147;AlCana&#148;), a research collaborator of the Company, as a defendant. The amended complaint alleges misappropriation of the plaintiffs&#146; confidential and proprietary information and trade secrets, civil conspiracy, and
tortious interference with contractual relationships by the Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive
trade practices by the Company. The plaintiffs seek, among other relief, injunctive relief, unspecified compensatory and punitive damages, attorneys&#146; fees, the termination of licenses that the plaintiffs provided to the Company and the
relinquishment and transfer of certain of the Company&#146;s intellectual property, including patents covering the Company&#146;s MC3 technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;6, 2011, the Company timely served and filed an answer to the plaintiffs&#146; original complaint denying the plaintiffs&#146; claims, and asserted counterclaims against the plaintiffs. On
June&nbsp;28, 2011, the Company timely served and filed an answer to the plaintiffs&#146; amended complaint denying the plaintiffs&#146; claims and asserted counterclaims against the plaintiffs for breach of contract, defamation, breach of covenant
not to sue, breach of patent prosecution and non-use provisions, misappropriation of confidential and proprietary information and trade secrets, unjust enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations
of Massachusetts statutes. The Company is seeking monetary damages, attorneys&#146; fees and equitable relief on its counterclaims. In September 2011, the Court granted the plaintiffs&#146; motion to dismiss the Company&#146;s counterclaim for
defamation. The plaintiffs did not move to dismiss any of the Company&#146;s other counterclaims, all of which remain pending. The case is currently in discovery and the Company expects a trial to start in October 2012. The Company intends to
vigorously defend itself in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against the Company and the Company could be required to pay substantial damages. The Company has also incurred, and
will continue to incur during the pendency of the litigation, significant costs, and the defense of this litigation has diverted, and until resolved will continue to divert, the attention of the Company&#146;s management and other resources that
would otherwise be engaged in other activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company has not recorded an estimate of the possible loss associated with
this legal proceeding. Although Tekmira has not specified the amount of monetary damages it is seeking, it has suggested that it believes such amount is significant and could include but not be limited to the disgorgement of cash funds the Company
has received under certain of its collaboration agreements, future milestones and royalties associated with certain of the Company&#146;s pipeline products, and other damages. Significant judgment is required to determine both the likelihood of a
loss and the estimated amount of any such loss. The Company currently believes that the likelihood of a loss is more than remote but less than probable, and is unable to estimate a possible range of loss for this legal proceeding due to many
factors, including: the current state of the litigation proceedings and discovery process, the inability to assess the amount of damages until expert reports are obtained, uncertainties regarding the potential for settlement discussions and the
tendency of plaintiffs to maintain very high demands until cases reach critical juncture, such as the filing of dispositive motions or serious mediation. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>University of Utah Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;22, 2011, The University of
Utah (the &#147;University&#148;) filed a civil complaint in the United States District Court for the District of Massachusetts against the Company, Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH
(together, &#147;Max Planck&#148;), the Whitehead Institute for Biomedical Research (&#147;Whitehead&#148;), the Massachusetts Institute of Technology (&#147;MIT&#148;) and the University of Massachusetts (&#147;UMass&#148;), claiming a professor at
the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl patents. The University did not serve the original complaint on the Company or the other defendants. On July&nbsp;6, 2011, the University filed an amended
complaint alleging substantially the same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was served on the Company on July&nbsp;14, 2011. The University is seeking changes to the inventorship of the Tuschl
patents, unspecified damages and other relief. On October&nbsp;31, 2011, the Company, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on October&nbsp;31, 2011, UMass filed a motion to dismiss on separate grounds, which the
Company, Max Planck, Whitehead and MIT have joined. On December&nbsp;31, 2011, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the University filed a second amended complaint dropping UMass as a defendant and adding as defendants several UMass officials. Although the Company believes it has meritorious defenses and
intends to vigorously defend itself in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule against the Company. In addition, the defense of litigation and related matters are costly and may divert the
attention of the Company&#146;s management and other resources that would otherwise be engaged in other activities. The Company has not recorded an estimate of the possible loss associated with this legal proceeding due to the uncertainties related
to both the likelihood and the amount of any possible loss or range of loss. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tekmira Infringement Litigation
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;17, 2012, the Company filed a complaint in the United States District Court for the District of
Massachusetts against Tekmira for patent infringement arising from Tekmira&#146;s research activities providing lipid nanoparticles- (&#147;LNP&#148;-) formulated small interfering RNA (&#147;siRNA&#148;) molecules to a pharmaceutical collaborator.
As alleged in the complaint, the Company does not believe Tekmira&#146;s activities are protected under the exemption from patent infringement for drug development. Pursuant to the complaint, the Company believes Tekmira has infringed a number of
issued patents related to siRNA and LNP technologies, including: U.S. Patent No.&nbsp;7,695,902; U.S. Patent No.&nbsp;6,858,225; U.S. Patent No.&nbsp;6,815,432; U.S. Patent No.&nbsp;6,534,484; U.S. Patent No.&nbsp;6,586,410; and U.S. Patent
No.&nbsp;6,858,224. Under the Company&#146;s contractual right to enforce U.S. Patent No.&nbsp;7,695,902 owned by Isis, the Company joined Isis to the suit as a co-plaintiff. On March&nbsp;2, 2012, Tekmira filed a motion to dismiss five of the six
claims of the Company&#146;s complaint for lack of standing.&nbsp;The Company filed an opposition to this motion and Tekmira has filed a reply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company and Isis are seeking judgment that Tekmira has infringed the patents at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including
attorneys&#146; fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company&#146;s accounting policy for accrual of legal costs is to recognize such expenses as
incurred. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.&nbsp;2012 RESTRUCTURING </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, the Company&#146;s Board of Directors approved, and the Company implemented, a strategic corporate
restructuring pursuant to which the Company reduced its overall workforce by approximately 33%, to approximately 115 employees. The Company expects the reduction in personnel costs, along with other external costs, to result in savings of
approximately $20.0 million in its 2012 operating expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three months ended March&nbsp;31, 2012, the Company
substantially completed the implementation of the strategic corporate restructuring and recorded $3.9&nbsp;million of restructuring-related costs in operating expenses, including employee severance, benefits and related costs. The Company expects to
pay substantially all of these restructuring costs during 2012. The Company does not expect to incur any additional significant costs associated with this restructuring. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes the components of the Company&#146;s restructuring expenses recorded in operating expenses and in current liabilities, in thousands: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Charges</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Incurred<BR>Through</B></FONT><br>
<FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amounts</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid<BR>Through</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amounts</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Accrued&nbsp;at</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,<BR>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee severance, benefits and related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. SUBSEQUENT EVENT </B></FONT></P>
 <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2007, the Company entered into the Medtronic Agreement to pursue the development of RNAi therapeutics for the
treatment of neurodegenerative disorders using implantable infusion systems. ALN-HTT is an RNAi therapeutic candidate targeting the huntingtin gene, for the treatment of Huntington&#146;s disease, which the Company has been developing in
collaboration with Medtronic under the Medtronic Agreement. In November 2010, the Company and Medtronic entered into an agreement with CHDI Foundation, Inc. (&#147;CHDI&#148;), under which CHDI agreed to initially fund approximately 50% of the costs
of the ALN-HTT program up to the point at which an investigational new drug application can be filed with the United States Food and Drug Administration or a comparable foreign regulatory filing can be made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2012, as part of the Company&#146;s alignment of resources following its strategic corporate restructuring, the Company
exercised its option under the Medtronic Agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. Medtronic has the right to continue
development of the ALN-HTT program. If Medtronic decides to continue the ALN-HTT program, it would assume responsibility for future development plans. The Company intends to continue to supply ALN-HTT for the program and, if Medtronic continues the
program, the Company would be compensated for such supply in accordance with the terms of the Medtronic Agreement. The Company would be entitled to certain development milestones, as well as royalties on annual net sales, if any. The Company
continues to be obligated to repay CHDI for its pro-rata share of funding received through the effective date of its opt-out, with interest, in the event that a product is ultimately commercialized from the funded research. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_5"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>This Quarterly Report on Form 10-Q contains forward-looking statements that involve
risks and uncertainties. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the
Securities Exchange Act of 1934. Without limiting the foregoing, the words &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;intends,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; &#147;target,&#148; &#147;goal&#148; and similar expressions are intended to identify forward-looking statements, although not all
forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any
obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of
certain important factors, including those set forth in this Item&nbsp;2 &#151; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; as well as under Part&nbsp;II, Item&nbsp;1A &#151; &#147;Risk
Factors&#148; and elsewhere in this Quarterly Report on Form 10-Q. You should carefully review those factors and also carefully review the risks outlined in other documents that we file from time to time with the Securities and Exchange Commission,
or SEC. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for selectively silencing and regulating
the expression of specific genes. Since many diseases are caused by the inappropriate activity of specific genes, the ability to silence genes selectively through RNAi could provide a new way to treat a wide range of human diseases. We believe that
drugs that work through RNAi have the potential to become a broad new class of drugs, like small molecule, protein and antibody drugs. Using our intellectual property and the expertise we have built in RNAi, we are developing a set of biological and
chemical methods and know-how that we apply in a systematic way to develop RNAi therapeutics for a variety of diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
core product strategy, which we refer to as &#147;Alnylam 5x15,&#148; is focused on the development and commercialization of novel RNAi therapeutics for the treatment of genetically defined diseases with high unmet medical need. Under our core
product strategy, we expect to have five RNAi therapeutic programs in clinical development, including programs in advanced stages, on our own or with one or more collaborators, by the end of 2015. As part of this strategy, our goal is to develop
product candidates with the following shared characteristics: a genetically defined target and disease; the potential to have a significant impact in high unmet need patient populations; the ability to leverage our existing RNAi delivery platform;
the opportunity to monitor an early biomarker in Phase I clinical trials for human proof of concept; and the existence of clinically relevant endpoints for the filing of a new drug application, or NDA, with a focused patient database and possible
accelerated paths for commercialization. Our core programs currently in clinical or pre-clinical development are: ALN-TTR for the treatment of transthyretin-mediated amyloidosis, or ATTR; ALN-APC for the treatment of hemophilia; ALN-PCS for the
treatment of severe hypercholesterolemia; ALN-HPN for the treatment of refractory anemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. We intend to focus on developing and commercializing
ALN-TTR and ALN-APC on our own in the United States and potentially certain other countries, and we intend to enter into alliances to advance our ALN-PCS, ALN-HPN and ALN-TMP programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While focusing our efforts on our core product strategy, we also intend to continue to advance additional development programs through
existing or future alliances. We have three partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus, or RSV, infection, ALN-VSP for the treatment of liver cancers and
ALN-HTT for the treatment of Huntington&#146;s disease, or HD. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our most advanced core product development program, ALN-TTR,
targets the transthyretin, or TTR, gene, for the treatment of ATTR, a hereditary, systemic disease associated with severe morbidity and mortality caused by a mutation in the TTR gene that leads to the extracellular deposition of amyloid fibrils. In
November 2011, we reported preliminary clinical results from our ALN-TTR01 Phase I, multinational clinical trial showing that ALN-TTR01 was generally safe and well tolerated and resulted in statistically significant lowering of TTR serum levels in
ATTR patients. We have completed enrollment in the ALN-TTR01 Phase I trial and expect to present final data in the first half of 2012. ALN-TTR01 employs a first-generation lipid nanoparticle, or LNP, formulation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In parallel with the completion of the ALN-TTR01 Phase I clinical trial, we are also advancing ALN-TTR02 utilizing the same siRNA as
ALN-TTR01, formulated in a proprietary second-generation LNP with the MC3 lipid. In pre-clinical studies, this second-generation LNP technology demonstrated an over 10-fold improvement in potency. We expect ALN-TTR02 to be our lead
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
development candidate for our ALN-TTR program. In March 2012, we initiated a Phase I clinical trial with ALN-TTR02. The ALN-TTR02 Phase I clinical trial is being conducted in the United Kingdom
as a randomized, single-blind, placebo-controlled, single-ascending dose study, enrolling up to 32 healthy volunteer subjects. The primary objective of the study is to evaluate the safety and tolerability of a single dose of ALN-TTR02, with subjects
being enrolled into five sequential cohorts of increasing doses ranging from 0.01 to 0.50 mg/kg. Secondary objectives of this study include the characterization of pharmacokinetics of ALN-TTR02 and the assessment of clinical activity as measured by
effects on serum TTR levels through at least day 56 following a single dose. The Committee for Orphan Medicinal Products of the European Medicines Agency adopted a positive opinion for ALN-TTR01 designation as an orphan medicinal product for the
treatment of familial amyloidotic polyneuropathy. In April 2011, the European Commission officially designated ALN-TTR01 as an orphan drug. This designation also applies to ALN-TTR02. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also plan to advance ALN-TTRsc, which utilizes a GalNAc-conjugate delivery technology and subcutaneous dose administration, into
clinical development. Pre-clinical studies have shown that once-weekly dosing with ALN-TTRsc enables robust and sustained silencing of TTR over a multi-week period. We believe that ALN-TTRsc has the potential to provide product differentiation and
expansion in the ATTR indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our second core product development program is ALN-APC. ALN-APC is an RNAi therapeutic
targeting protein C, a genetically defined target, for the treatment of hemophilia. Hemophilia is a hereditary disorder caused by genetic deficiencies of various blood clotting factors, resulting in recurrent bleeds into joints, muscles and other
major internal organs. Pre-clinical studies of an siRNA targeting protein C showed dose-dependent silencing of the protein C&nbsp;messenger RNA, or mRNA. Further, administration of a small interfering RNA, or siRNA, resulted in marked reductions in
protein C plasma levels. We are exploring both systemically delivered LNP and subcutaneously delivered GalNAc-conjugate approaches for ALN-APC with the goal of selecting the clinical candidate and advancing the ALN-APC program toward the clinic.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our third core development program is ALN-PCS for the treatment of severe hypercholesterolemia. In April 2012, we reported
clinical data from our Phase I clinical trial of ALN-PCS. ALN-PCS employs the same proprietary second-generation LNP formulation, specifically using the MC3 lipid, as ALN-TTR02. We are developing ALN-PCS for the treatment of severe
hypercholesterolemia. ALN-PCS targets a gene called proprotein convertase subtilisin/kexin type 9, or PCSK9, which is involved in the regulation of LDL receptor levels on hepatocytes and the metabolism of LDL cholesterol, or LDL-c, which is also
commonly referred to as &#147;bad&#148; cholesterol. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase I clinical trial was conducted as a randomized, single-blind,
placebo-controlled, single-ascending dose study in healthy volunteer subjects with elevated baseline LDL-c (greater than 116mg/dL). The primary objective of the study was to evaluate the safety and tolerability of a single dose of ALN-PCS. Secondary
objectives included assessment of pharmacodynamic effects of the drug on plasma PCSK9 protein levels and evaluation of clinical efficacy as measured by LDL-c levels. A total of 32 subjects were enrolled into six sequential dose cohorts ranging from
0.015 to 0.400 mg/kg in a 3-to-1 randomization of drug to placebo. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this study, administration of ALN-PCS resulted in
rapid, dose-dependent and durable reductions in LDL-c of up to 50% relative to baseline and placebo, with a statistically significant mean reduction of 41% (p&lt;0.01) at the 0.400 mg/kg dose level. In addition, ALN-PCS administration resulted in
rapid, dose-dependent and durable knockdown of PCSK9 protein levels in plasma of up to 84% relative to baseline and placebo, with a statistically significant mean reduction of 68% in the highest dose group of 0.400 mg/kg (p&lt;0.0001). There was
also a dose-dependent increase in the proportion of subjects who achieved &#147;target&#148; levels of LDL-c of less than 100 mg/dL (p&lt;0.05). We believe the effects of a single dose of ALN-PCS support a once-monthly dose administration regimen
for future studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALN-PCS was shown to be safe and well tolerated in this study and there were no serious adverse events
related to study drug administration. There were no drug-related discontinuations and no liver enzyme elevations. There was also no significant change compared to baseline in levels of high-density lipoprotein, or HDL, also referred to as
&#147;good&#148; cholesterol, consistent with the phenotype observed in human PCSK9 loss-of-function mutations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to
partner our ALN-PCS program prior to initiating a Phase II clinical trial. Our other two core development programs, ALN-HPN for the treatment of refractory anemia and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia and
sickle cell anemia, are in pre-clinical development. We plan to partner each of these programs prior to initiating a Phase I clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As noted above, while focusing our efforts on our core product strategy, we also intend to continue to advance additional partner-based development programs through existing or future alliances. We have
three partner-based programs in clinical or pre-clinical development, including ALN-RSV for the treatment of RSV, ALN-VSP for the treatment of liver cancers and ALN-HTT for the treatment of HD. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2007, we entered into an amended and restated collaboration agreement with
Medtronic, Inc., or Medtronic, to pursue the development of RNAi therapeutics for the treatment of neurodegenerative disorders using implantable infusion systems. ALN-HTT is an RNAi therapeutic candidate targeting the huntingtin gene, for the
treatment of HD, which we have been developing in collaboration with Medtronic under this agreement. In November 2010, we and Medtronic entered into an agreement with CHDI Foundation, Inc., or CHDI, under which CHDI agreed to initially fund
approximately 50% of the costs of the ALN-HTT program up to the point at which an investigational new drug application, or IND, can be filed with the United States Food and Drug Administration, or FDA, or a comparable foreign regulatory filing can
be made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with our January 2012 strategic corporate restructuring, we determined to align our resources to focus
on our lead programs, ALN-TTR and ALN-APC. In April 2012, as part of this alignment of resources, we exercised our option under the Medtronic agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development
program and move to a royalty and milestone licensing structure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Medtronic has the right to continue development of the
ALN-HTT program. If Medtronic decides to continue the ALN-HTT program, it would assume responsibility for future development plans. We intend to transition the program to Medtronic, and intend to continue to supply ALN-HTT for the program, as well
as provide technical support to Medtronic, as requested. If Medtronic continues the program, we would be compensated for the supply of ALN-HTT, and would be entitled to certain development milestones, as well as royalties on annual net sales, if
any. We continue to be obligated to repay CHDI for our pro-rata share of funding received through the effective date of our opt-out, with interest, in the event that a product is ultimately commercialized from the funded research. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we and Medtronic may jointly agree to collaborate on additional product development programs for the treatment of other
neurodegenerative diseases, which can be addressed by the delivery of siRNAs to the human nervous system through implantable infusion devices, under the amended and restated collaboration agreement, which remains in effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continue to work internally and with third-party collaborators with the goal of developing new technologies to deliver our RNAi
therapeutics both directly to specific sites of disease, and systemically by intravenous or subcutaneous administration. We have numerous RNAi therapeutic delivery collaborations and intend to continue to collaborate with government, academic and
corporate third parties to evaluate different delivery options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the strength of our intellectual property
portfolio relating to the development and commercialization of siRNAs as therapeutics provides us a leading position with respect to this therapeutic modality. Our intellectual property portfolio includes ownership of, or exclusive rights to, issued
patents and pending patent applications claiming fundamental features of siRNAs and RNAi therapeutics as well as those claiming crucial chemical modifications and promising delivery technologies. We believe that no other company possesses a
portfolio of such broad and exclusive rights to the patents and patent applications required for the commercialization of RNAi therapeutics. Given the importance of our intellectual property portfolio to our business operations, we intend to
vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our expertise in RNAi therapeutics and broad intellectual property estate have allowed us to form
alliances with leading pharmaceutical companies, including Isis Pharmaceuticals, Inc., or Isis, Medtronic, Novartis Pharma AG, or Novartis, Biogen Idec Inc., or Biogen Idec, F. Hoffmann-La&nbsp;Roche Ltd, or Roche (which assigned its rights and
obligations to Arrowhead Research Corporation, or Arrowhead, during 2011), Takeda Pharmaceutical Company Limited, or Takeda, Kyowa Hakko Kirin Co., Ltd., or Kyowa Hakko, and Cubist Pharmaceuticals, Inc., or Cubist. We have previously entered, and in
the future we intend to enter, into contracts with government agencies, including the National Institute of Allergy and Infectious Diseases, or NIAID, a component of the National Institutes of Health, or NIH. We have also established collaborations
with and, in some instances, received funding from, major medical and disease associations, including CHDI. Finally, to further enable the field and monetize our intellectual property rights, we also grant licenses to biotechnology companies for the
development and commercialization of RNAi therapeutics for specified targets in which we have no direct strategic interest, under our InterfeRx</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">tm</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> program, and to research companies that commercialize RNAi reagents or services under our research product licenses.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also seek to form or advance new ventures and opportunities in areas outside our primary focus on RNAi therapeutics.
Through an internal effort we refer to as Alnylam Biotherapeutics, we are advancing the application of RNAi technology to improve the manufacturing processes for biologics, including recombinant proteins and monoclonal antibodies. We have formed,
and intend to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
form additional, collaborations through this effort with third-party biopharmaceutical companies. In October 2011, we entered into a collaboration with GlaxoSmithKline, or GSK, for influenza
vaccine production, under our VaxiRNA&#153; platform, an RNAi technology developed under our Alnylam Biotherapeutics initiative, for the enhanced production of viruses used in the manufacture of vaccine products. Additionally, in 2007, we and Isis
established Regulus Therapeutics Inc., or Regulus, a company focused on the discovery, development and commercialization of microRNA therapeutics. Regulus has formed collaborations with GSK and Sanofi to advance its efforts. Given the broad
applications for RNAi technology, in addition to our efforts on Alnylam Biotherapeutics, VaxiRNA and Regulus, we believe new ventures and opportunities will be available to us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, our Board of Directors approved, and we implemented, a strategic corporate restructuring pursuant to which we reduced
our overall workforce by approximately 33%, to approximately 115 employees. The goal of the restructuring was to align our resources to focus on what we believe to be our highest value opportunities, including a focus on ALN-TTR for the treatment of
ATTR and ALN-APC for the treatment of hemophilia as our lead programs, while advancing other pipeline programs through existing alliances and new collaborations. We expect the reduction in personnel costs, along with other external costs, to result
in savings of approximately $20.0 million in our 2012 operating expenses. During the three months ended March&nbsp;31, 2012, we substantially completed the implementation of the strategic corporate restructuring and recorded $3.9&nbsp;million of
restructuring-related costs in operating expenses, including employee severance, benefits and related costs. We expect to pay substantially all of these restructuring costs during 2012. We do not expect to incur any additional significant costs
associated with this restructuring. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have incurred significant losses since we commenced operations in 2002 and expect such
losses to continue for the foreseeable future. At March&nbsp;31, 2012, we had an accumulated deficit of $412.4&nbsp;million. Historically, we have generated losses principally from costs associated with research and development activities,
acquiring, filing and expanding intellectual property rights and general administrative costs. As a result of planned expenditures for research and development activities relating to our drug development programs, including the development of drug
delivery technologies and clinical trial costs, extension of the capabilities of our technology platform, including through business initiatives, continued management and growth of our patent portfolio, collaborations and general corporate
activities, we expect to incur additional operating losses for the foreseeable future. We anticipate that our operating results will fluctuate for the foreseeable future. Therefore, period-to-period comparisons should not be relied upon as
predictive of the results in future periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we currently have programs focused on a number of therapeutic areas, we
are unable to predict when, if ever, we will successfully develop or be able to commence sales of any product. To date, a substantial portion of our total net revenues has been derived from collaboration revenues from strategic alliances with Roche,
Takeda, Cubist and Novartis, and from the United States government in connection with our development of treatments for hemorrhagic fever viruses, including Ebola. We expect our sources of potential funding for the next several years to be derived
primarily from new and existing strategic alliances, which may include license and other fees, funded research and development and milestone payments, government and foundation funding, and proceeds from the sale of equity or debt. In July 2011, we
filed a shelf registration statement with the SEC for an indeterminate number of shares of common stock and/or other securities, in an amount up to an aggregate of $150.0 million, for future issuance. In February 2012, we sold an aggregate of
8,625,000 shares of our common stock through an underwritten public offering at a price to the public of $10.75 per share. As a result of the offering, we received aggregate net proceeds of approximately $86.8 million, after deducting underwriting
discounts and commissions and other estimated offering expenses of approximately $5.9 million. We intend to use these proceeds for general corporate purposes, ultimately focused on advancing our clinical pipeline, in particular our ALN-TTR02 and
ALN-APC programs, as well as for working capital, capital expenditures, and general and administrative expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and
Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since our inception, we have focused on drug discovery and development programs. Research and development
expenses represent a substantial percentage of our total operating expenses. Under our core product strategy, we expect to have five RNAi therapeutic programs in clinical development by the end of 2015, including programs in advanced stages, on our
own or with one or more collaborators. While focusing our efforts on our core product strategy, we also intend to continue to advance additional partner-based development programs through existing or future alliances. In addition, we continue to
work internally and with third-party collaborators to develop new technologies to deliver our RNAi therapeutics both directly to specific sites of disease, and systemically by intravenous or subcutaneous administration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There is a risk that any drug discovery or development program may not produce revenue for a
variety of reasons, including the possibility that we will not be able to adequately demonstrate the safety and efficacy of the product candidate. Moreover, there are uncertainties specific to any new field of drug discovery, including RNAi. The
successful development of any product candidate we develop is highly uncertain. Due to the numerous risks associated with developing drugs, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts necessary to
complete the development of, or the period, if any, in which material net cash inflows will commence from, any potential product candidate. These risks include the uncertainty of: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to discover new product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to progress product candidates into pre-clinical and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and cost of our pre-clinical trials and other research and development activities, including those related to developing
safe and effective ways of delivering siRNAs into cells and tissues; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, rate of progress and cost of any clinical trials we commence; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical trial results; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the terms, timing and success of any collaboration, licensing and other arrangements that we may establish; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost, timing and success of regulatory filings and approvals or potential changes in regulations that govern our industry or the way in which they
are interpreted or enforced; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of establishing sufficient sales, marketing and distribution capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost and timing of establishing sufficient clinical and commercial supplies for any product candidates and products that we may
develop;</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limits on our ability to research, develop, or manufacture our product candidates as a result of contractual obligations to third parties or
intellectual property held by third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any
such legal disputes; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing technological and market developments. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure to complete any stage of the development of any potential products in a timely manner could have a material adverse effect on
our operations, financial position and liquidity. A discussion of some of the risks and uncertainties associated with completing our projects on schedule, or at all, and the potential consequences of failing to do so, are set forth in Part II,
Item&nbsp;1A below under the heading &#147;Risk Factors.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Strategic Alliances </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant component of our business plan is to enter into strategic alliances and collaborations with pharmaceutical and biotechnology
companies, academic institutions, research foundations and others, as appropriate, to gain access to funding, capabilities, technical resources and intellectual property to further our development efforts and to generate revenues. We also seek to
form or advance new ventures and opportunities in areas outside our primary focus on RNAi therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To generate revenues
from our intellectual property rights, we also grant licenses to biotechnology companies under our InterfeRx program for the development and commercialization of RNAi therapeutics for specified targets in which we have no direct strategic interest.
We also license key aspects of our intellectual property to companies active in the research products and services market, which includes the manufacture and sale of reagents. We expect our InterfeRx and research product licenses to generate modest
near-term revenues that we can re-invest in the development of our proprietary RNAi therapeutics pipeline. At March&nbsp;31, 2012, we had granted such licenses, on both an exclusive and non-exclusive basis, to approximately 20&nbsp;companies.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since delivery of RNAi therapeutics remains a major objective of our research activities, we also look to form collaboration
and licensing arrangements with other companies and academic institutions to gain access to delivery technologies. For example, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
have entered into agreements with Arrowhead, Tekmira Pharmaceuticals Corporation, or Tekmira, the Massachusetts Institute of Technology, or MIT, The University of British Columbia, or UBC, and
AlCana Technologies, Inc., or AlCana, among others, to focus on various delivery strategies. We have also entered into license agreements with Isis, Max Planck Innovation GmbH (formerly known as Garching Innovation GmbH), or Max Planck Innovation,
Tekmira, MIT, Cancer Research Technology Limited, or CRT, Whitehead Institute for Biomedical Research, or Whitehead, and The University of Texas Southwestern Medical Center, or UTSW, as well as a number of other entities, to obtain rights to
intellectual property in the field of RNAi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finally, we seek funding for the development of our proprietary RNAi therapeutics
pipeline from the government and foundations. For example, in 2010, we completed a contract awarded to us by the NIAID to advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including the Ebola
virus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Alnylam Biotherapeutics </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since 2009, we have advanced our efforts regarding the application of RNAi technologies to improve the manufacturing processes for biologics, including recombinant proteins and monoclonal antibodies.
These applications of RNAi technology, which we are advancing in an internal effort we refer to as Alnylam Biotherapeutics, have the potential to create new business opportunities. In particular, we are advancing RNAi technologies to improve the
quantity and quality of biologics manufacturing processes using mammalian cell culture, such as Chinese hamster ovary, or CHO, cells. This RNAi technology potentially could be applied to the improvement of manufacturing processes for existing
marketed drugs, new drugs in development and for the emerging biosimilars market. We have developed proprietary delivery lipids that enable the efficient delivery of siRNAs into CHO cells when grown in suspension culture, as well as other cell
systems that are used for the manufacture of biologics. Studies have demonstrated that silencing certain target genes involved in certain CHO cell apoptotic and metabolic pathways resulted in improved cell viability as compared with untreated cells.
Additional studies demonstrated the ability to target a viral infection of CHO cells and alter glycosylation pathways. We have formed two collaborations around our Alnylam Biotherapeutics initiative with leading biotechnology and pharmaceutical
companies and plan to seek additional collaborations with established biologic manufacturers, selling licenses, products and services. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>VaxiRNA </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
also applying RNAi technology to improve the manufacturing processes for vaccines in an effort called VaxiRNA. The VaxiRNA platform stems from work we have performed as part of our Alnylam Biotherapeutics efforts. With VaxiRNA, we are using siRNAs
that silence specific genes in vaccine production systems, such as cells or chicken eggs, which limit or prevent the efficient growth of viruses used in the manufacture of vaccine products. New innovations in vaccine manufacturing are needed to
enable the scale and speed of global immunization for a number of pathogens. In October 2011, we formed a VaxiRNA collaboration with GSK for influenza vaccine production. Under the terms of the agreement, GSK has agreed to provide research funding
and certain success-based milestone payments to us. If successfully applied in the manufacture of commercial product, we will also have the right to receive payments on unit product sales, if any. In addition, GSK has obtained an option for VaxiRNA
applications toward two additional vaccine products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>microRNA Therapeutics </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Regulus.</B>&nbsp;In September 2007, we and Isis established Regulus, a company focused on the discovery, development and
commercialization of microRNA therapeutics. Regulus leverages our and Isis&#146; technologies, know-how and intellectual property relating to microRNA therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Regulus, which initially was established as a limited liability company, converted to a C corporation as of January&nbsp;2, 2009 and changed its name to Regulus Therapeutics Inc. In consideration for our
and Isis&#146; initial interests in Regulus, we and Isis each granted Regulus exclusive licenses to our intellectual property for certain microRNA therapeutics as well as certain patents in the microRNA field. At March&nbsp;31, 2012, we, Isis and
Sanofi owned approximately 45%, 46% and 9%, respectively, of Regulus. Regulus continues to operate as an independent company with a separate board of directors, scientific advisory board and management team, some of whom have options to purchase
common stock of Regulus. Members of the board of directors of Regulus who are our employees or Isis&#146; employees are not eligible to receive options to purchase Regulus common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulus is exploring therapeutic opportunities that arise from microRNA dysregulation. Since microRNAs are believed to regulate broad
networks of genes and biological pathways, microRNA therapeutics define a new and potentially high-impact strategy </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to target multiple nodes on disease pathways. microRNAs are small non-coding RNAs that regulate the expression of other genes. There are approximately 700 microRNAs that have been identified in
the human genome, and these are believed to regulate the expression of up to 30% of all human genes. Since microRNAs may act as master regulators of the genome and are often found to be dysregulated in disease, microRNAs potentially represent an
exciting new platform for drug discovery and development. Regulus is advancing microRNA therapeutics in several areas including fibrosis, hepatitis&nbsp;C virus, or HCV, infection, immuno-inflammatory diseases, metabolic and cardiovascular diseases,
and oncology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2008, Regulus entered into a worldwide strategic alliance with GSK to discover, develop and market
novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. In connection with this alliance, Regulus received $20.0&nbsp;million in upfront payments from GSK, including a
$15.0&nbsp;million option fee and a loan of $5.0&nbsp;million (guaranteed by us and Isis) that will convert into Regulus common stock under certain specified circumstances. Regulus is eligible to receive development, regulatory and sales milestone
payments for each of the four microRNA-targeted therapeutics discovered and developed as part of the alliance, and would also receive royalty payments on worldwide sales of products resulting from the alliance, if any. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2010, Regulus and GSK established a new collaboration to develop and commercialize microRNA therapeutics targeting miR-122 in
all fields, with the treatment of HCV infection as the lead indication. Under the terms of this collaboration, Regulus received $8.0&nbsp;million in upfront payments from GSK, including a $3.0&nbsp;million license fee and a loan of $5.0&nbsp;million
(guaranteed by us and Isis) that will convert into Regulus common stock under certain specified circumstances. Consistent with the original GSK alliance, Regulus is eligible to receive development, regulatory and sales milestone payments, as well as
royalty payments on worldwide sales of products resulting from the alliance, if any, as Regulus and GSK advance microRNA therapeutics targeting miR-122. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010, Regulus entered into a global, strategic alliance with Sanofi to discover, develop and commercialize microRNA therapeutics on up to four microRNA targets. Under the terms of this alliance,
Regulus received $25.0&nbsp;million in upfront fees and is entitled to annual research support for three years with the option to extend research support for two additional years. In addition, Regulus is eligible to receive royalties on microRNA
therapeutic products commercialized by Sanofi, if any. Sanofi will support 100% of the costs of clinical development and commercialization of each program. The alliance will initially focus on the therapeutic area of fibrosis. Regulus and Sanofi
will collaborate on up to four microRNA targets, including Regulus&#146; lead fibrosis program targeting miR-21. Sanofi also received an option for a broader technology alliance with Regulus that provides Regulus certain rights to participate in
development and commercialization of resulting products. If exercised, this option is worth up to an additional $50.0&nbsp;million to Regulus. We and Isis are each eligible to receive 7.5% of all potential upfront and milestone payments, in addition
to single-digit royalties on product sales, if any. We received $1.9&nbsp;million from Regulus in connection with this alliance, representing 7.5% of the $25.0&nbsp;million upfront payment from Sanofi to Regulus. In addition, in October 2010, Sanofi
made a $10.0&nbsp;million equity investment in Regulus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Intellectual Property </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The strength of our intellectual property portfolio relating to the development and commercialization of siRNAs as therapeutics is
essential to our business strategy. We own or license issued patents and pending patent applications in the United States and in key markets around the world claiming fundamental features of siRNAs and RNAi therapeutics as well as those claiming
crucial chemical modifications and promising delivery technologies. Specifically, we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their
use as therapeutics, and RNAi-related mechanisms; chemical modifications to siRNAs that improve their suitability for therapeutic uses; siRNAs directed to specific targets as treatments for particular diseases;&nbsp;delivery technologies, such as in
the field of cationic liposomes; and all aspects of our specific development candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that no other company
possesses a portfolio of such broad and exclusive rights to the patents and patent applications required for the commercialization of RNAi therapeutics. Our intellectual property portfolio for RNAi therapeutics includes over 1,800 active cases and
over 700 granted or issued patents, of which over 300 are issued or granted in the United States, the European Union and Japan. We continue to seek to grow our portfolio through the creation of new technology in this field. In addition, we are very
active in our evaluation of third-party technologies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our expertise in RNAi therapeutics and broad intellectual property
portfolio have allowed us to form alliances with leading companies, including Isis, Medtronic, Novartis, Biogen, Roche, Takeda, Kyowa Hakko Kirin and Cubist, as well as license agreements with other biotechnology companies interested in developing
RNAi therapeutic products and research companies that commercialize RNAi reagents or services. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Given the importance of our intellectual property portfolio to our business operations, we
intend to vigorously enforce our rights and defend against challenges that have arisen or may arise in this area. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting
Policies and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There have been no significant changes to our critical accounting policies since the beginning of
this fiscal year. Our critical accounting policies are described in the &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section of our Annual Report on Form 10-K for the year ended
December&nbsp;31, 2011, which we filed with the SEC on February&nbsp;13, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following data summarizes the results of our operations for the periods indicated, in thousands: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Net Revenues from Research Collaborators </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generate revenues through research collaborations. The following table summarizes our total consolidated net revenues from research
collaborators, for the periods indicated, in thousands: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months
Ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roche/Arrowhead</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,994</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Takeda</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,493</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,768</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total net revenues from research collaborators</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net revenues from research collaborators remained consistent during the three months ended March&nbsp;31,
2012 as compared to the three months ended March&nbsp;31, 2011. Beginning in the second half of 2012, we expect net revenues from research collaborators to decrease significantly as we complete our remaining performance obligations under the
Roche/Arrowhead alliance in the third quarter of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total deferred revenue of $120.8 million at March&nbsp;31, 2012
consists of payments we have received from collaborators, primarily Roche/Arrowhead, Takeda, Kyowa Hakko Kirin and Cubist, but have not yet recognized pursuant to our revenue recognition policies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the foreseeable future, we expect our revenues to continue to be derived primarily from our alliances with Roche/Arrowhead<B>,</B>
through the third quarter of 2012, Takeda and Cubist, and other strategic alliances, as well as new collaborations, foundation funding, government contracts and licensing activities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our operating expenses for the periods indicated, in thousands and as a percentage of total operating expenses, together with the changes, in thousands and percentages:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="53%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ended</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;of&nbsp;Total</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Operating</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Ended</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;of&nbsp;Total</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Operating</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase&nbsp;(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expenses</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Expenses</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31,480</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,573</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,093</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and development.</I></B> The following table summarizes the components of our research and
development expenses for the periods indicated, in thousands and as a percentage of total research and development expenses, together with the changes, in thousands and percentages: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months<BR>Ended<BR>March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Expense</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months<BR>Ended</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Expense</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase&nbsp;(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Category</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Category</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation and related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,261</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,332</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facilities-related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(163</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trial and manufacturing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,276</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">External services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,088</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lab supplies and materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,682</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(678</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">744</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(134</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses decreased during the three months ended March&nbsp;31, 2012 as compared
to the three months ended March&nbsp;31, 2011 due primarily to lower clinical trial and manufacturing costs related to our ALN-RSV and ALN-VSP programs, partially offset by additional expenses related to the advancement of our ALN-TTR program. In
addition, external services expenses decreased, due primarily to lower pre-clinical expenses for our ALN-TTR and ALN-PCS programs as we further advance these programs in the clinic. Lab supplies and materials and compensation and related expenses
also decreased due primarily to the reduction in workforce in connection with our January 2012 strategic corporate restructuring. Partially offsetting these decreases was a one-time charge related to the 2012 restructuring, including employee
severance, benefits and related costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect to continue to devote a substantial portion of our resources to research and
development expenses as we continue development of our and our collaborators&#146; product candidates and focus on continuing to develop drug delivery-related technologies, however, we expect that research and development expenses will decrease for
the remainder of 2012 due primarily to the reduction in workforce related to our January 2012 strategic corporate restructuring. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A significant portion of our research and development costs are not tracked by project as they benefit multiple projects or our technology platform and because our most-advanced programs are in the early
stages of clinical development. However, our collaboration agreements contain cost-sharing arrangements pursuant to which certain costs incurred under the project are reimbursed. Costs reimbursed under the agreements typically include certain direct
external costs and a negotiated full-time equivalent labor rate for the actual time worked on the project. In addition, we have been reimbursed under government contracts for certain allowable costs including direct internal and external costs. As a
result, although a significant portion of our research and development expenses are not tracked on a project-by-project basis, we do track direct external costs attributable to, and the actual time our employees worked on, our collaborations and
government contracts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and administrative. </I></B>The following table summarizes the components of
our general and administrative expenses for the periods indicated, in thousands and as a percentage of total general and administrative expenses, together with the changes, in thousands and percentages: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months<BR>Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Expense</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months<BR>Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase&nbsp;(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,&nbsp;2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Category</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March&nbsp;31,&nbsp;2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Category</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consulting and professional services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,744</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,476</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation and related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,057</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-cash stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(389</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restructuring</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facilities-related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(254</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total general and administrative expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses remained consistent during the three months ended March&nbsp;31, 2012
as compared to the three months ended March&nbsp;31, 2011. For the remainder of 2012, we expect that general and administrative expenses will decrease due primarily to the reduction in workforce related to our January 2012 strategic corporate
restructuring. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other income (expense) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We incurred $0.9 million and $1.1 million of equity in loss of joint venture (Regulus Therapeutics Inc.) for the three months ended March&nbsp;31, 2012 and 2011, respectively, related to our share of the
net losses incurred by Regulus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income was $0.2 million for the three months ended March&nbsp;31, 2012 as compared
to $0.4 million for the three months ended March&nbsp;31, 2011. The decrease was due primarily to lower average cash, cash equivalent and marketable securities balances. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes our cash
flow activities for the periods indicated, in thousands: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adjustments to reconcile net loss to net cash (used in) provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,087</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,671</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in operating assets and liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(24,934</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,309</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30,215</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6,305</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash (used in) provided by investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(65,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,287</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,489</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70,228</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents, end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61,739</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,590</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Since we commenced operations in 2002, we have generated significant losses. At March&nbsp;31, 2012, we
had an accumulated deficit of $412.4&nbsp;million. At March&nbsp;31, 2012, we had cash, cash equivalents and marketable securities of $316.9 million, compared to cash, cash equivalents and marketable securities of $260.8&nbsp;million at
December&nbsp;31, 2011. In February 2012, we sold an aggregate of 8,625,000 shares of our common stock through an underwritten public offering at a price to the public of $10.75 per share. As a result of the offering, we received aggregate net
proceeds of approximately $86.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses of approximately $5.9 million. We intend to use these proceeds for general corporate purposes, ultimately focused
on advancing our clinical pipeline, in particular our ALN-TTR02 and ALN-APC programs, as well as for working capital, capital expenditures, and general and administrative expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We invest primarily in cash equivalents, U.S.&nbsp;government obligations, high-grade corporate notes and commercial paper. Our
investment objectives are, primarily, to assure liquidity and preservation of capital and, secondarily, to obtain investment income. All of our investments in debt securities are recorded at fair value and are available-for-sale. Fair value is
determined based on quoted market prices and models using observable data inputs. We have not recorded any impairment charges related to our fixed income marketable securities at March&nbsp;31, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have required significant amounts of cash to fund our operating activities as a result of net losses since our inception. For the three
months ended March&nbsp;31, 2012, net cash used in operating activities of $30.2 million was due primarily to our net loss and a decrease in deferred revenue of $20.1 million. In addition, net cash used in operating activities is adjusted for
non-cash items to reconcile net loss to net cash used in or provided by operating activities. These non-cash adjustments consist primarily of stock-based compensation, equity in loss of joint venture (Regulus Therapeutics Inc.), and depreciation and
amortization. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that we will require significant amounts of cash to fund our operating activities for the foreseeable
future as we continue to develop and advance our research and development initiatives. The actual amount of overall expenditures will depend on numerous factors, including the timing of expenses, the timing and terms of collaboration agreements or
other strategic transactions, if any, and the timing and progress of our research and development efforts. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing
activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the three months ended March&nbsp;31, 2012, net cash used in investing activities of $65.6 million
resulted primarily from net purchases of marketable securities. For the three months ended March&nbsp;31, 2011, net cash provided by investing activities of $22.3 million resulted primarily from net sales and maturities of marketable securities.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the three months ended March&nbsp;31, 2012, net cash of $87.3 million provided by financing activities was due primarily to proceeds received from our February 2012 underwritten public offering, as
well proceeds from the issuance of common stock in connection with stock option exercises. For the three months ended March&nbsp;31, 2011, net cash provided by financing activities was due to proceeds from the issuance of common stock in connection
with stock option exercises. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Capital Requirements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not know when, if ever, we will successfully develop or be able to commence sales of any product. Therefore, we anticipate that we
will continue to generate significant losses for the foreseeable future as a result of planned expenditures for research and development activities relating to our drug development programs, including the development of drug delivery technologies
and clinical trial costs, extension of the capabilities of our technology platform, including through business initiatives, continued management and growth of our patent portfolio, collaborations and general corporate activities. In February 2012,
we sold an aggregate of 8,625,000 shares of our common stock through an underwritten public offering at a price to the public of $10.75 per share. As a result of the offering, we received aggregate net proceeds of approximately $86.8 million, after
deducting underwriting discounts and commissions and other estimated offering expenses of approximately $5.9 million. We intend to use these proceeds for general corporate purposes, ultimately focused on advancing our clinical pipeline, in
particular our ALN-TTR02 and ALN-APC programs, as well as for working capital, capital expenditures, and general and administrative expenses. Based on our current operating plan, we believe that our existing cash, cash equivalents and fixed income
marketable securities, for which we have not recognized any impairment charges, together with the cash we expect to generate under our current alliances, will be sufficient to fund our planned operations through at least the end of 2013. For reasons
discussed below, we may require significant additional funds earlier than we currently expect in order to develop, conduct clinical trials for and commercialize any product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the future, we may seek additional funding through additional collaborative arrangements and public or private financings. During the
current downturn in global financial markets, some companies have experienced difficulties accessing their cash equivalents and investment securities and raising capital generally, which have had a material adverse impact on their liquidity. The
current economic downturn has diminished the availability of capital and may limit our ability to access these markets to obtain financing in the future. As a result of these and other factors, additional funding may not be available to us on
acceptable terms or at all. In addition, the terms of any additional financing may further adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to
our existing stockholders may result. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. If we are unable to obtain funding on a timely
basis, we may be required to significantly delay or curtail one or more of our research or development programs. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to
some of our technologies or product candidates that we would otherwise pursue. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we are able to raise additional funds in a timely manner, our future capital
requirements may vary from what we expect and will depend on many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our progress in demonstrating that siRNAs can be active as drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to develop relatively standard procedures for selecting and modifying siRNA product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">progress in our research and development programs, as well as the magnitude of these programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of funding under current and future government or foundation contracts, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the resources, time and costs required to successfully initiate and complete our pre-clinical and clinical trials, obtain regulatory approvals, and
obtain and maintain licenses to third-party intellectual property; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to manufacture, or contract with third-parties for the manufacture of, our product candidates for clinical testing and commercial sale;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to achieve anticipated cost reductions as a result of, and to successfully manage the potential impact of, our January 2012 strategic
corporate restructuring and workforce reduction on our culture, collaborative relationships and business operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any
such legal disputes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">progress in the research and development programs of Regulus;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of sales and royalties, if any, from our potential products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Commitments </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The disclosure of our contractual obligations and commitments is set forth under the heading &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations &#151;
Contractual Obligations and Commitments&#148; in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2011. There have been no material changes in our contractual obligations and commitments since December&nbsp;31, 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In May 2011, the Financial Accounting Standards Board, or FASB, issued a new accounting standard that clarifies the application of certain existing fair value measurement guidance and expands the
disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective basis for annual and interim reporting periods beginning on or after December&nbsp;15, 2011.
We adopted this amendment on January&nbsp;1, 2012. The adoption of this new standard did not have a material impact on our condensed consolidated financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2011, the FASB issued an amendment to the accounting guidance for presentation of comprehensive income. Under the amended guidance, a company may present the total of comprehensive income, the
components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
statements. In either case, a company is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other
comprehensive income and a total amount for comprehensive income. For public companies, the amendment is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2011, and shall be applied
retrospectively. We adopted this amendment on January&nbsp;1, 2012. Other than a change in presentation, the adoption of this guidance did not have a material impact on our condensed consolidated financial statements.</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_6"></A>ITEM&nbsp;3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of our investment portfolio, we own financial instruments that are sensitive to market risks. The investment
portfolio is used to preserve our capital until it is required to fund operations, including our research and development activities. Our marketable securities consist of U.S.&nbsp;government and municipal obligations, high-grade corporate notes and
commercial paper. All of our investments in debt securities are classified as available-for-sale and are recorded at fair value. Our available-for-sale investments in debt securities are sensitive to changes in interest rates and changes in the
credit ratings of the issuers. Interest rate changes would result in a change in the net fair value of these financial instruments due to the difference between the market interest rate and the market interest rate at the date of purchase of the
financial instrument. If market interest rates were to increase immediately and uniformly by 50 basis points, or one-half of a percentage point, from levels at March&nbsp;31, 2012, the net fair value of our interest-sensitive financial instruments
would have resulted in a hypothetical decline of $1.2 million. A downgrade in the credit rating of an issuer of a debt security or further deterioration of the credit markets could result in a decline in the fair value of the debt instruments. Our
investment guidelines prohibit investment in auction rate securities and we do not believe we have any direct exposure to losses relating from mortgage-based securities or derivatives related thereto such as credit-default swaps. We have not
recorded any impairment charges to our fixed income marketable securities at March&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_7"></A>ITEM&nbsp;4.
CONTROLS AND PROCEDURES. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our management, with the participation of our chief executive officer and vice president of
finance and treasurer, evaluated the effectiveness of our disclosure controls and procedures as of March&nbsp;31, 2012. The term &#147;disclosure controls and procedures,&#148; as defined in Rules&nbsp;13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act
is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#146;s management, including its principal executive and principal financial officers, as appropriate to allow
timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies
its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March&nbsp;31, 2012, our chief executive officer and vice president of finance and
treasurer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No change in our internal control over financial reporting (as defined in Rules&nbsp;13a&#150;15(d) and 15d&#150;15(d) under the Exchange Act) occurred during the three months ended March&nbsp;31, 2012
that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II. OTHER INFORMATION </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_8"></A>ITEM&nbsp;1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LEGAL PROCEEDINGS. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tekmira Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;16, 2011, Tekmira and Protiva Biotherapeutics, Inc. filed a civil complaint against us in the Business Litigation Section of the Suffolk County Superior Court, in Boston, Massachusetts, and
in June 2011, the plaintiffs filed an amended complaint adding AlCana, a research collaborator of ours, as a defendant. The amended complaint alleges misappropriation of the plaintiffs&#146; confidential and proprietary information and trade
secrets, civil conspiracy, and tortious interference with contractual relationships by us and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising,
and unfair and deceptive trade practices by us. The plaintiffs seek, among other relief, injunctive relief, unspecified compensatory and punitive damages, attorneys&#146; fees, the termination of licenses that the plaintiffs provided to us and the
relinquishment and transfer of certain of our intellectual property, including patents covering our MC3 technology. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
April&nbsp;6, 2011, we timely served and filed an answer to the plaintiffs&#146; original complaint denying the plaintiffs&#146; claims, and asserted counterclaims against the plaintiffs. On June&nbsp;28, 2011, we timely served and filed an answer
to the plaintiffs&#146; amended complaint denying the plaintiffs&#146; claims and asserted counterclaims against the plaintiffs for breach of contract, defamation, breach of covenant not to sue, breach of patent prosecution and non-use provisions,
misappropriation of confidential and proprietary information and trade secrets, unjust enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of Massachusetts statutes. We are seeking monetary damages,
attorneys&#146; fees and equitable relief on our counterclaims. In September 2011, the Court granted the plaintiffs&#146; motion to dismiss our counterclaim for defamation. The plaintiffs did not move to dismiss any of our other counterclaims, all
of which remain pending. The case is currently in discovery and we expect a trial to start in October 2012. We intend to vigorously defend ourselves in this matter. However, litigation is subject to inherent uncertainty and this matter could be
decided against us and we could be required to pay substantial damages. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have also incurred, and will continue to incur
during the pendency of the litigation, significant costs, and the defense of this litigation has diverted, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other
activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>University of Utah Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;22, 2011, The University of Utah, or Utah, filed a civil complaint in the United States District Court for the District of Massachusetts against us, Max Planck Gesellschaft Zur Forderung Der
Wissenschaften E.V. and Max Planck Innovation, together, Max Planck, Whitehead, MIT and the University of Massachusetts, or UMass, claiming a professor at Utah is the sole inventor, or in the alternative, a joint inventor, of the Tuschl patents.
Utah did not serve the original complaint on us or the other defendants. On July&nbsp;6, 2011, Utah filed an amended complaint alleging substantially the same claims against us, Max Planck, Whitehead, MIT and UMass. The amended complaint was served
on us on July&nbsp;14, 2011. Utah is seeking changes to the inventorship of the Tuschl patents, unspecified damages and other relief. On October&nbsp;31, 2011, we, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on
October&nbsp;31, 2011, UMass filed a motion to dismiss on separate grounds, which we, Max Planck, Whitehead and MIT have joined. On December&nbsp;31, 2011, Utah filed a second amended complaint dropping UMass as a defendant and adding as defendants
several UMass officials. Although we believe we have meritorious defenses and intend to vigorously defend ourselves in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule against us. In addition, the defense
of litigation and related matters are costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Tekmira Infringement Litigation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;17, 2012, we filed a
complaint in the United States District Court for the District of Massachusetts against Tekmira for patent infringement arising from Tekmira&#146;s research activities providing LNP-formulated siRNA molecules to a pharmaceutical collaborator. As
alleged in the complaint, we do not believe Tekmira&#146;s activities are protected under the exemption from patent infringement for drug development. Pursuant to the complaint, we believe Tekmira has infringed a number of issued patents related to
siRNA and LNP technologies, including: U.S. Patent No.&nbsp;7,695,902; U.S. Patent No.&nbsp;6,858,225; U.S. Patent No.&nbsp;6,815,432; U.S. Patent No.&nbsp;6,534,484; U.S. Patent No.&nbsp;6,586,410; and U.S. Patent No.&nbsp;6,858,224. Under our
contractual right to enforce U.S. Patent No.&nbsp;7,695,902 owned by Isis, we joined Isis to the suit as a co-plaintiff. On March&nbsp;2, 2012, Tekmira filed a motion to dismiss five of the six claims of our complaint for lack of standing.&nbsp;We
filed an opposition to this motion and Tekmira has filed a reply. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and Isis are seeking judgment that Tekmira has infringed the patents at issue, a
permanent injunction enjoining the infringing activities, damages, and costs and expenses, including attorneys&#146; fees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although we are vigorously asserting our rights in this case, litigation is subject to inherent uncertainty and a court could ultimately
rule against us. In addition, litigation is costly and may divert the attention of our management and other resources that would otherwise be engaged in other activities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_12"></A>ITEM&nbsp;1A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISK FACTORS. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Our
business is subject to numerous risks. We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings
with the SEC, press releases, communications with investors and oral statements. All statements other than statements relating to historical matters should be considered forward-looking statements. When used in this report, the words
&#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;may,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;will,&#148; &#147;plan,&#148; &#147;target,&#148; &#147;goal&#148; and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these words. Any or all of our forward-looking statements in this Quarterly Report on Form&nbsp;10-Q and in any other public statements we make may turn out to be wrong.
They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in the discussion below will be important in determining future results. Consequently, no forward-looking statement
can be guaranteed. Actual future results may vary materially from those anticipated in forward-looking statements. We explicitly disclaim any obligation to update any forward-looking statements to reflect events or circumstances that arise after the
date hereof. You are advised, however, to consult any further disclosure we make in our reports filed with the SEC. </I></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Business </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Being an Early Stage Company </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Because we are an
early-stage development stage company, there is limited information about our ability to successfully overcome many of the risks and uncertainties encountered by companies in the biopharmaceutical industry. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As an early-stage development stage company, we have limited experience and have not yet demonstrated an ability to successfully overcome
many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">execute product development activities using unproven technologies related to both RNAi and to the delivery of siRNAs to the relevant tissues and
cells; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">build and maintain a strong intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">gain regulatory acceptance for the development of our product candidates and market success for any products we commercialize;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">develop and maintain successful strategic alliances;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals and commercialization. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, commercialize products, raise
capital, expand our business or continue our operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The approach we are taking to discover and develop novel RNAi
therapeutics is unproven and may never lead to marketable products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have concentrated our efforts and therapeutic
product research on RNAi technology, and our future success depends on the successful development of this technology and products based on it. Neither we nor any other company has received regulatory approval to market therapeutics utilizing siRNAs,
the class of molecule we are trying to develop into drugs. The scientific discoveries that form the basis for our efforts to discover and develop new drugs are relatively new. The scientific evidence to support the feasibility of developing drugs
based on these discoveries is both preliminary and limited. Skepticism as to the feasibility of developing RNAi therapeutics has been expressed in scientific literature. For example, there are potential challenges to achieving safe RNAi therapeutics
based on the so-called off-target effects and activation of the interferon response. In addition, decisions by other companies with respect to their RNAi development efforts may increase skepticism in the marketplace regarding the potential for RNAi
therapeutics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Relatively few product candidates based on these discoveries have ever been tested in
animals or humans. siRNAs may not naturally possess the inherent properties typically required of drugs, such as the ability to be stable in the body long enough to reach the tissues in which their effects are required, nor the ability to enter
cells within these tissues in order to exert their effects. We currently have only limited data, and no conclusive evidence, to suggest that we can introduce these drug-like properties into siRNAs. We may spend large amounts of money trying to
introduce these properties, and may never succeed in doing so. In addition, these compounds may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory studies, and they may interact with human
biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable product, we may not become profitable and the value of our common stock will decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, our focus solely on RNAi technology for developing drugs, as opposed to multiple, more proven technologies for drug development,
increases the risks associated with the ownership of our common stock. If we are not successful in developing a product candidate using RNAi technology, we may be required to change the scope and direction of our product development activities. In
that case, we may not be able to identify and implement successfully an alternative product development strategy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our
Financial Results and Need for Financing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have a history of losses and may never become and remain consistently
profitable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have experienced significant operating losses since our inception. At March&nbsp;31, 2012, we had an
accumulated deficit of $412.4 million. To date, we have not developed any products nor generated any revenues from the sale of products. Further, we do not expect to generate any such revenues in the foreseeable future. We expect to continue to
incur annual net operating losses over the next several years and will require substantial resources over the next several years as we expand our efforts to discover, develop and commercialize RNAi therapeutics. We anticipate that the majority of
any revenues we generate over the next several years will be from alliances with pharmaceutical and biotechnology companies or funding from contracts with the government or foundations, but cannot be certain that we will be able to secure or
maintain these alliances or contracts, or meet the obligations or achieve any milestones that we may be required to meet or achieve to receive payments. We anticipate that revenues derived from such sources will not be sufficient to make us
consistently profitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that to become and remain consistently profitable, we must succeed in discovering,
developing and commercializing novel drugs with significant market potential. This will require us to be successful in a range of challenging activities, including pre-clinical testing and clinical trial stages of development, obtaining regulatory
approval for these novel drugs and manufacturing, marketing and selling them. We may never succeed in these activities, and may never generate revenues that are significant enough to achieve profitability. Even if we do achieve profitability, we may
not be able to sustain or increase profitability on a quarterly or annual basis. If we cannot become and remain consistently profitable, the market price of our common stock could decline. In addition, we may be unable to raise capital, expand our
business, develop additional product candidates or continue our operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional
funds to complete our research and development activities and if additional funds are not available, we may need to critically limit, significantly scale back or cease our operations. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have used substantial funds to develop our RNAi technologies and will require substantial funds to conduct further research and
development, including pre-clinical testing and clinical trials of our product candidates, and to manufacture and market any products that are approved for commercial sale. Because we cannot be certain of the length of time or activities associated
with successful development of our product candidates, we are unable to estimate the actual funds we will require to develop and commercialize them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our future capital requirements and the period for which we expect our existing resources to support our operations may vary from what we expect. We have based our expectations on a number of factors,
many of which are difficult to predict or are outside of our control, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our progress in demonstrating that siRNAs can be active as drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to develop relatively standard procedures for selecting and modifying siRNA product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">progress in our research and development programs, as well as the magnitude of these programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of milestone and other payments, if any, from present and future collaborators, if any; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of funding under current and future government or foundation contracts, if any; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain and establish additional collaborative arrangements and/or new business initiatives; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the resources, time and costs required to initiate and complete our pre-clinical and clinical trials, obtain regulatory approvals, and obtain and
maintain licenses to third-party intellectual property; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to manufacture, or contract with third-parties for the manufacture of, our product candidates for clinical testing and commercial sale;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the resources, time and cost required for the preparation, filing, prosecution, maintenance and enforcement of patent claims;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to achieve the anticipated cost reductions as a result of, and to successfully manage the potential impact of, our January 2012 strategic
corporate restructuring and workforce reduction on our culture, collaborative relationships and business operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with legal activities, including litigation, arising in the course of our business activities and our ability to prevail in any
such legal disputes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">progress in the research and development programs of Regulus;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing, receipt and amount of sales and royalties, if any, from our potential products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our estimates and predictions relating to these factors are incorrect, we may need to modify our operating plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if our estimates are correct, we will be required to seek additional funding in the future and intend to do so through either
collaborative arrangements, future public equity offerings, private equity offerings or debt financings, or a combination of one or more of these funding sources. Additional funds may not be available to us on acceptable terms or at all. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise
additional funds by issuing equity securities, under our shelf registration statement or otherwise, further dilution to our stockholders will result. In addition, as a condition to providing additional funds to us, future investors may demand, and
may be granted, rights superior to those of existing stockholders. Moreover, our investor rights agreement with Novartis provides Novartis with the right generally to maintain its ownership percentage in us, subject to certain exceptions. These
rights continue until the earlier of any sale by Novartis of shares of our common stock and the expiration or termination of our license agreement with Novartis, subject to certain exceptions. Pursuant to the terms of its investor rights agreement
with us, over the past five years, Novartis purchased an aggregate of 335,033 shares of our common stock, resulting in aggregate payments to us of $7.6 million. At March&nbsp;31, 2012, Novartis held 10.8% of our outstanding common stock. While the
exercise of these rights by Novartis has provided us with funding, and the exercise in the future by Novartis may provide us with additional funding under some circumstances, these exercises have caused, and any future exercise of these rights by
Novartis will also cause further, dilution to our stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid
before holders of equity securities received any distribution of corporate assets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to obtain funding on a
timely basis, we may be required to significantly delay or curtail one or more of our research or development programs or undergo additional reductions in our workforce or other corporate restructuring activities. We also could be required to seek
funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If the estimates we make, or the assumptions on which we rely, in preparing our condensed consolidated financial statements prove
inaccurate, our actual results may vary from those reflected in our projections and accruals. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these condensed consolidated financial statements requires us to make
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of charges accrued by us and related disclosure of contingent assets and
liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be
correct. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The investment of our cash, cash equivalents and marketable securities is subject to risks which may cause
losses and affect the liquidity of these investments. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At March&nbsp;31, 2012, we had $316.9 million in cash, cash
equivalents and marketable securities. We historically have invested these amounts in corporate bonds, commercial paper, securities issued by the U.S. government obligations, certificates of deposit and money market funds meeting the criteria of our
investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, market and interest rate risks, including the impact of U.S. sub-prime mortgage defaults that have affected various
sectors of the financial markets and caused credit and liquidity issues. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our condensed consolidated financial
statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of
operations, liquidity and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Dependence on Third Parties </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our license and collaboration agreements with pharmaceutical companies are important to our business. If these pharmaceutical
companies do not successfully develop drugs pursuant to these agreements or we develop drugs targeting the same diseases as our non-exclusive licensees, our business could be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In July 2007, we entered into a license and collaboration agreement with Roche. Under the license and collaboration agreement we granted
Roche a non-exclusive license to our intellectual property to develop and commercialize therapeutic products that function through RNAi, subject to our existing contractual obligations to third parties. In November 2010, Roche announced the
discontinuation of certain activities in research and early development, including their RNAi research efforts. In October 2011, Arrowhead Research Corporation, or Arrowhead, announced its acquisition of RNA therapeutics assets from Roche, including
our license and collaboration agreement with Roche. As a result of the assignment, Arrowhead now has all of the rights and obligations of Roche under that agreement. The license is limited to four therapeutic areas and may be expanded to include
additional therapeutic areas, upon payment to us by Arrowhead of an additional $50.0 million for each additional therapeutic area, if any. In addition, in exchange for our contributions under the collaboration agreement, for each RNAi therapeutic
product developed by Arrowhead, its affiliates, or sublicensees under the collaboration agreement, we are entitled to receive milestone payments upon achievement of specified development and sales events, totaling up to an aggregate of $100.0
million per therapeutic target, together with royalty payments based on worldwide annual net sales, if any. Our receipt of milestone payments under this agreement is dependent upon Arrowhead&#146;s ability to successfully develop and commercialize
RNAi therapeutic products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2008, we entered into a similar license and collaboration agreement with Takeda, which is
limited to two therapeutic areas, and which may be expanded to include additional therapeutic areas, upon payment to us by Takeda of an additional $50.0 million for each additional therapeutic area, if any. For each RNAi therapeutic product
developed by Takeda, its affiliates and sublicensees, we are entitled to receive specified development and commercialization milestones, totaling up to $171.0 million per product, together with royalty payments based on worldwide annual net sales,
if any. In addition, we agreed that we will not grant any other party rights to develop RNAi therapeutics in the Asian territory through May 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In September 2010, Novartis exercised its right under our collaboration and license agreement to select 31 designated gene targets, for which Novartis has exclusive rights to discover, develop and
commercialize RNAi therapeutic products using our intellectual property and technology. Under the terms of the collaboration and license agreement, for any RNAi therapeutic products Novartis develops against these targets, we are entitled to receive
milestone payments upon achievement of certain specified development and annual net sales events, up to an aggregate of $75.0 million per therapeutic product, as well as royalties on annual net sales of any such product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Takeda, Novartis or Arrowhead fails to successfully develop products using our technology, we may not receive any milestone or royalty
payments under our agreements with them. In addition, even if Takeda is not successful in its efforts, we are limited in our ability to form alliances with other parties in the Asian territory until May 2013. We also have the option under the Takeda
agreement, exercisable until the start of Phase III development, to opt-in under a 50-50 profit sharing agreement to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
development and commercialization in the United States of up to four Takeda licensed products, and would be entitled to opt-in rights for two additional products for each additional field
expansion, if any, elected by Takeda under the collaboration agreement. If Takeda fails to successfully develop products, we may not realize any economic benefit from these opt-in rights. Finally, Takeda could become a competitor of ours in the
development of RNAi-based drugs targeting the same diseases that we choose to target. Takeda has significantly greater financial resources than we do and far more experience in developing and marketing drugs, which could put us at a competitive
disadvantage if we were to compete with them in the development of RNAi-based drugs targeting the same disease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may
not be able to execute our business strategy if we are unable to enter into alliances with other companies that can provide business and scientific capabilities and funds for the development and commercialization of our product candidates. If we are
unsuccessful in forming or maintaining these alliances on terms favorable to us, our business may not succeed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do
not have any capability for sales, marketing or distribution and have limited capabilities for drug development. In addition, we believe that other companies are expending substantial resources in developing safe and effective means of delivering
siRNAs to relevant cell and tissue types. Accordingly, we have entered into alliances with other companies and collaborators that we believe can provide such capabilities, and we intend to enter into additional such alliances in the future. For
example, we intend to enter into worldwide or specific geographic collaborations relating to (1)&nbsp;RNAi platform and/or multi-target discovery alliances, and (2)&nbsp;select RNAi therapeutic programs in our pipeline, including ALN-PCS, ALN-HPN,
ALN-TMP and ALN-VSP. In such alliances, we expect our current, and may expect our future, collaborators to provide substantial capabilities in delivery of RNAi therapeutics to the relevant cell or tissue type, clinical development, regulatory
affairs, and/or marketing, sales and distribution. For example, under our agreements with MIT, Tekmira, UBC and AlCana, and Arrowhead, among others, we have access to certain existing delivery technologies and/or are developing additional delivery
capabilities. In addition, under certain of our other alliances, we may expect our collaborators to develop, market and/or sell certain of our product candidates. We may have limited or no control over the development, sales, marketing and
distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these third parties. For example, we will rely entirely on Kyowa Hakko Kirin for development and commercialization of any RNAi
products for the treatment of RSV in Asia. If Kyowa Hakko Kirin is not successful in its commercialization efforts, our future revenues from RNAi therapeutics for the treatment of RSV may be adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may not be successful in entering into such alliances on terms favorable to us due to various factors, including our ability to
successfully demonstrate proof of concept for our technology in man, our ability to demonstrate the safety and efficacy of our specific drug candidates, our ability to manufacture or have manufactured RNAi therapeutics, the strength of our
intellectual property and/or concerns around challenges to our intellectual property. Even if we do succeed in securing any such alliances, we may not be able to maintain them if, for example, development or approval of a product candidate is
delayed, challenges are raised as to the validity or scope of our intellectual property or sales of an approved drug are lower than we expected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Furthermore, any delay in entering into collaboration agreements would likely either delay the development and commercialization of our certain of our product candidates and reduce their competitiveness
even if they reach the market, or prevent the development of certain product candidates. Any such delay related to our collaborations could adversely affect our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For certain product candidates that we may develop, we have formed collaborations to fund all or part of the costs of drug development and commercialization, such as our collaborations with Takeda, Cubist
and Medtronic. We may not, however, be able to enter into additional collaborations for ALN-PCS, ALN-HPN, ALN-TMP or ALN-VSP, and the terms of any collaboration agreement we do secure may not be favorable to us. If we are not successful in our
efforts to enter into future collaboration arrangements with respect to one or more of these product candidates, we may not have sufficient funds to develop that or any other product candidate internally, or to bring any product candidates to
market. If we do not have sufficient funds to develop and bring our product candidates to market, we will not be able to generate sales revenues from these product candidates, and this will substantially harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If any collaborator terminates or fails to perform its obligations under agreements with us, the development and commercialization
of our product candidates could be delayed or terminated. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our dependence on collaborators for capabilities and
funding means that our business could be adversely affected if any collaborator terminates its collaboration agreement with us or fails to perform its obligations under that agreement. Our current or future collaborations, if any, may not be
scientifically or commercially successful. Disputes may arise in the future with respect to the ownership of rights to technology or products developed with collaborators, which could have an adverse effect on our ability to develop and
commercialize any affected product candidate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current collaborations allow, and we expect that any future collaborations will allow,
either party to terminate the collaboration for a material breach by the other party. Our agreement with Kyowa Hakko Kirin for the development and commercialization of RSV therapeutics for the treatment of RSV infection in Japan and other major
markets in Asia may be terminated by Kyowa Hakko Kirin without cause upon 180-days&#146; prior written notice to us, subject to certain conditions, and our agreement with Cubist relating to the development and commercialization of certain RSV
therapeutics in territories outside of Asia may be terminated by Cubist at any time upon as little as three months&#146; prior written notice, if such notice is given prior to the acceptance for filing of the first application for regulatory
approval of a licensed product. If we were to lose a commercialization collaborator, we would have to attract a new collaborator or develop internal sales, distribution and marketing capabilities, which would require us to invest significant amounts
of financial and management resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if we have a dispute with a collaborator over the ownership of technology
or other matters, or if a collaborator terminates its collaboration with us, for breach or otherwise, or determines not to pursue the research and development of RNAi therapeutics, it could delay our development of product candidates, result in the
need for additional company resources to develop product candidates, make it more difficult for us to attract new collaborators and could adversely affect how we are perceived in the business and financial communities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For example, in March 2011, Tekmira filed a civil complaint against us claiming misappropriation of its confidential and proprietary
information and trade secrets, civil conspiracy and tortious interference with contractual relationships, unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising,
and unfair and deceptive trade practices by us. As a result of the litigation, we have been required to expend additional resources and management attention that would otherwise be engaged in other activities. Moreover, a collaborator, or in the
event of a change in control of a collaborator or the assignment of a collaboration agreement to a third-party, the successor entity or assignee, could determine that it is in its interests to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pursue alternative technologies or develop alternative products, either on its own or jointly with others, that may be competitive with the products on
which it is collaborating with us or which could affect its commitment to the collaboration with us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pursue higher-priority programs or change the focus of its development programs, which could affect the collaborator&#146;s commitment to us;&nbsp;or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if it has marketing rights, choose to devote fewer resources to the marketing of our product candidates, if any are approved for marketing, than it
does for product candidates developed without us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of these occur, the development and
commercialization of one or more product candidates could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue such development and commercialization on our own. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Regulus is important to our business. If Regulus does not successfully develop drugs pursuant to our license and collaboration
agreement, our business could be adversely affected. In addition, disagreements between us and Isis regarding the development of microRNA technology may cause significant delays and other impediments in the development of this technology, which
could negatively affect the value of the technology and our investment in Regulus. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2007, we and Isis
formed Regulus, of which we owned approximately 45% at March&nbsp;31, 2012, to discover, develop and commercialize microRNA therapeutics. Regulus is exploring therapeutic opportunities that arise from dysregulation of microRNAs. Neither Regulus nor
any other company has received regulatory approval to market therapeutics utilizing microRNA technology. In connection with the establishment of Regulus, we exclusively licensed to Regulus our intellectual property rights covering microRNA
technology. Generally, we do not have rights to pursue microRNA therapeutics independently of Regulus. If Regulus is unable to discover, develop and commercialize microRNA therapeutics, our business could be adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In April 2008, Regulus formed a collaboration with GSK pursuant to which GSK provided Regulus with a loan for $5.0 million, plus
interest. In February 2010, Regulus formed an additional collaboration with GSK pursuant to which GSK provided Regulus with an additional $5.0 million loan, plus interest. These loans are guaranteed equally by us and Isis. If Regulus is unable to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
repay GSK or convert the loans into Regulus common stock, we could be liable for our share of these obligations, and our business could be adversely affected. In addition, Regulus operates as an
independent company, governed by a board of directors. We and Isis each can elect an equal number of directors to serve on the Regulus board. Regulus researches and develops microRNA projects and programs pursuant to an operating plan that is
approved by its board. Any disagreements between Isis and us regarding a development decision or any other decision submitted to Regulus&#146; board may cause significant delays in the development and commercialization of microRNA technology and
could negatively affect the value of our investment in Regulus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We rely on third parties to conduct our clinical
trials, and if they fail to fulfill their obligations, our development plans may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on
independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We have contracted, and we plan to continue to contract
with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. Although we depend heavily on these parties, we do not control them and therefore, we cannot be assured that these
third-parties will adequately perform all of their contractual obligations to us. If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is
compromised due to failure by such third-party to adhere to our protocols or regulatory requirements or if such third-parties otherwise fail to meet deadlines, our development plans may be delayed or terminated. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have very limited manufacturing experience or resources and we must incur significant costs to develop this expertise or rely on
third parties to manufacture our products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have very limited manufacturing experience. Our internal manufacturing
capabilities are limited to small-scale production of non-current good manufacturing practice, or cGMP, material for use in <I>in vitro </I>and <I>in vivo </I>experiments. Some of our product candidates utilize specialized formulations, such as
liposomes or LNPs, whose scale-up and manufacturing could be very difficult. We also have very limited experience in such scale-up and manufacturing, requiring us to depend on a limited number of third parties, who might not be able to deliver in a
timely manner, or at all. In order to develop products, apply for regulatory approvals and commercialize our products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. We may manufacture
clinical trial materials ourselves or we may rely on others to manufacture the materials we will require for any clinical trials that we initiate. There are a limited number of manufacturers that supply synthetic siRNAs. We currently rely on several
contract manufacturers for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our contract manufacturers to meet our delivery time requirements or provide adequate amounts of
material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional
expense to us. To fulfill our siRNA requirements, we may also need to secure alternative suppliers of synthetic siRNAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition to the manufacture of the synthetic siRNAs, we may have additional manufacturing requirements related to the technology required to deliver the siRNA to the relevant cell or tissue type, such as LNPs or conjugates. In some cases, the
delivery technology we utilize is highly specialized or proprietary, and for technical and legal reasons, we may have access to only one or a limited number of potential manufacturers for such delivery technology. For example, under our agreements
with Tekmira, we are obligated, subject to certain exceptions specified in our contract with Tekmira, to utilize Tekmira for the manufacture of all LNP-formulated product candidates covered by Tekmira&#146;s intellectual property beginning during
pre-clinical development and continuing through Phase II clinical trials. Failure by manufacturers to properly formulate our siRNAs for delivery could result in unusable product. Furthermore, a breach by such manufacturers of their contractual
obligations or a dispute with such manufacturers would cause delays in our discovery and development process, as well as additional expense to us. Given the limited number of suppliers for our delivery technology and other materials, in the future,
we expect to develop our own capabilities to manufacture drug substance, including siRNAs and siRNA conjugates, and/or finished drug product, including LNP formulations, as permitted under our manufacturing agreement with Tekmira, for human clinical
use. If we develop these manufacturing capabilities by building our own manufacturing facility, it will require substantial expenditures. Also, we will likely need to hire and train employees to staff a new facility. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing process for any products that we may develop is subject to FDA and foreign regulatory authority approval process and we
will need to contract with manufacturers who can meet all applicable FDA and foreign regulatory authority requirements on an ongoing basis. In addition, if we receive the necessary regulatory approval for any product candidate, we also expect to
rely on third parties, including our commercial collaborators, to produce materials required for commercial supply. We may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
experience difficulty in obtaining adequate manufacturing capacity for our needs. If we are unable to obtain or maintain contract manufacturing for these product candidates, or to do so on
commercially reasonable terms, we may not be able to successfully develop and commercialize our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that
we have existing, or enter into future, manufacturing arrangements with third parties, we depend, and will depend in the future, on these third parties to perform their obligations in a timely manner and consistent with contractual and regulatory
requirements, including those related to quality control and quality assurance. The failure of a third-party manufacturer to perform its obligations as expected, or, if we elect to manufacture all or a portion of our product candidates ourselves,
our failure to execute on our manufacturing requirements could adversely affect our business in a number of ways, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our current or future collaborators may not be able to initiate or continue clinical trials of products that are under development;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our current or future collaborators may be delayed in submitting regulatory applications, or receiving regulatory approvals, for our product
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may lose the cooperation of our collaborators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our products could be the subject of inspections by regulatory authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to cease distribution or recall some or all batches of our products;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ultimately, we may not be able to meet commercial demands for our products. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials
ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different third-party manufacturer, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills required to
manufacture our products or product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate
supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with
quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.
Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. This would increase our reliance on such manufacturer or require us to obtain a license from such
manufacturer in order to have another third-party manufacture our products or product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have no sales,
marketing or distribution experience and would have to invest significant financial and management resources to establish these capabilities. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have no sales, marketing or distribution experience. We currently expect to rely heavily on third parties to launch and market certain of our product candidates, if approved. However, if we elect to
develop internal sales, distribution and marketing capabilities as part of our core product strategy, we will need to invest significant financial and management resources. For core products where we decide to perform sales, marketing and
distribution functions ourselves, we could face a number of additional risks, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to attract and build a significant marketing or sales force; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the cost of establishing a marketing or sales force may not be justifiable in light of the revenues generated by any particular product;&nbsp;and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our direct sales and marketing efforts may not be successful. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we are unable to develop our own sales, marketing and distribution capabilities, we will not be able to successfully commercialize our
core products without reliance on third parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The current credit and financial market conditions may exacerbate certain risks
affecting our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Due to the tightening of global credit, there may be a disruption or delay in the performance
of our third-party contractors, suppliers or collaborators. We rely on third parties for several important aspects of our business, including significant portions of our manufacturing needs, development of product candidates and conduct of clinical
trials. If such third parties are unable to satisfy their commitments to us, our business could be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to
Managing Our Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to attract and retain qualified key management and scientists, staff,
consultants and advisors, our ability to implement our business plan may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are highly
dependent upon our senior management and scientific staff. The loss of the service of any of the members of our senior management, including Dr.&nbsp;John Maraganore, our Chief Executive Officer, may significantly delay or prevent the achievement of
product development and other business objectives. Our employment agreements with our key personnel are terminable without notice. We do not carry key man life insurance on any of our employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face intense competition for qualified individuals from numerous pharmaceutical and biotechnology companies, universities,
governmental entities and other research institutions, many of which have substantially greater resources with which to reward qualified individuals than we do. In addition, as a result of our September 2010 and January 2012 corporate restructurings
and workforce reductions, we may face additional challenges in retaining our existing employees and recruiting new employees to join our company as our business needs change. We may be unable to attract and retain suitably qualified individuals, and
our failure to do so could have an adverse effect on our ability to implement our future business plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our corporate
restructuring and workforce reduction plan may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2012, we announced a corporate restructuring and workforce reduction plan pursuant to which we reduced our workforce by
approximately 33%. We took these actions in order to reduce costs, streamline operations and improve our cost structure, and we expect that this restructuring plan will result in significant savings in 2012 operating expenses. The workforce
reduction was substantially completed at the end of the first quarter of 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a result of the reduction in workforce, we
recorded a restructuring charge of $3.9 million and are obligated to make future payments to reduce this obligation, the majority of which we expect to be made during the first half of 2012. The restructuring charges were based on a number of
assumptions. Actual results may differ materially and additional charges not currently expected may be incurred in connection with, or as a result of, these reductions. In addition, we may not realize, in full or in part, the anticipated benefits,
savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. If we are unable to achieve the anticipated benefits, savings or improvements in our cost structure in the
expected time frame or other unforeseen events occur, our business and results of operations may be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
restructuring plan has been and may continue to be disruptive to our operations. For example, cost savings measures may distract management from our core business, harm our reputation, yield unanticipated consequences, such as attrition beyond
planned reductions in workforce, or increased difficulties in our day-to-day operations, and may adversely affect employee morale. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific,
manufacturing and sales and marketing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing our products and product candidates in the
future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may have difficulty expanding our operations successfully as we seek to evolve from a company primarily
involved in discovery and pre-clinical testing into one that develops and commercializes drugs. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite our recent
workforce reduction in connection with our strategic corporate restructuring, we expect that as we seek to increase the number of product candidates we are developing we will need to expand our operations in the future. This growth may place a
strain on our administrative and operational infrastructure. If product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing and sales capabilities or contract
with other organizations to provide these capabilities for us. As our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers and other organizations.
Our ability to manage our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement
improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business and operations could suffer in the event of system failures. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural
disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations. For example, the loss of pre-clinical trial data or data from completed or ongoing clinical trials for our product
candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate
disclosure of confidential or proprietary information, we could incur liability and the development of our product candidates could be delayed. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Industry </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Development, Clinical Testing and
Regulatory Approval of Our Product Candidates </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any product candidates we develop may fail in development or be
delayed to a point where they do not become commercially viable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before obtaining regulatory approval for the
commercial distribution of our product candidates, we must conduct, at our own expense, extensive pre-clinical tests and clinical trials to demonstrate the safety and efficacy in humans of our product candidates. Pre-clinical and clinical testing is
expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome, and the historical failure rate for product candidates is high. We currently have several programs in clinical development. We are
developing ALN-RSV01 for the treatment of RSV infection. We recently completed enrollment in a Phase IIb clinical trial to evaluate the clinical efficacy endpoints as well as safety of aerosolized ALN-RSV01 in adult lung transplant patients
naturally infected with RSV. The objective of this Phase IIb clinical trial was to repeat and extend the clinical results observed in a Phase IIa clinical trial. We do not yet know the results of this study. In addition, in August 2011, we completed
a Phase I clinical trial for ALN-VSP, our first systemically delivered RNAi therapeutic. We are developing ALN-VSP for the treatment of primary and secondary liver cancer. In July 2010, we initiated a Phase I clinical trial for ALN-TTR01, our second
systemically delivered RNAi therapeutic, which targets the transthyretin, or TTR, gene for the treatment of ATTR. In September 2011, we initiated a Phase I clinical trial for ALN-PCS for the treatment of severe hypercholesteremia. ALN-PCS is
formulated in a proprietary second-generation LNP formulation. In March 2012, we initiated a Phase I clinical trial for ALN-TTR02, a second-generation systemically delivered RNAi therapeutic, for the treatment of ATTR. However, we may not be able to
further advance these or any other product candidate through clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we enter into clinical trials, the results
from pre-clinical testing or early clinical trials of a product candidate may not predict the results that will be obtained in subsequent human clinical trials of that product candidate or any other product candidate. For example, ALN-RSV01 may not
demonstrate the same results in the Phase IIb clinical trial as it did in our Phase IIa clinical trial. In addition, ALN-VSP, ALN-PCS and ALN-TTR02 employ novel delivery formulations that have yet to be extensively evaluated in human clinical trials
and proven safe and effective. We, the FDA or other applicable regulatory authorities, or an institutional review board, or IRB, or similar foreign review board or committee, may suspend clinical trials of a product candidate at any time for various
reasons, including if we or they believe the subjects or patients participating in such trials are being exposed to unacceptable health risks. Among other reasons, adverse side effects of a product candidate on subjects or patients in a clinical
trial could result in the FDA or foreign regulatory authorities suspending or terminating the trial and refusing to approve a particular product candidate for any or all indications of use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials of a new product candidate require the enrollment of a sufficient number of patients, including patients who are
suffering from the disease the product candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors, including the size of the patient population, the age and condition of the
patients, the stage and severity of disease, the nature of the protocol, the proximity of patients to clinical sites, the availability of effective treatments for the relevant disease, the seasonality of infections and the eligibility criteria for
the clinical trial. In our ALN-VSP clinical trial, one patient with advanced pancreatic neuroendocrine cancer with extensive involvement of the liver developed hepatic failure five days following the second dose of ALN-VSP and subsequently died;
this was deemed possibly related to the study drug. Six additional patients treated at the same dose did not exhibit any evidence of hepatotoxicity. In August 2011, we announced the completion of the ALN-VSP clinical trial. In our ALN-PCS clinical
trial, we reported preliminary safety data that a mild, transient rash was observed in five subjects, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
including two who received placebo. In addition, our ALN-TTR01 trial targets a small population of patients suffering from ATTR. Delays or difficulties in patient enrollment or difficulties
retaining trial participants can result in increased costs, longer development times or termination of a clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials also require the review, oversight and approval of IRBs, which continually review clinical investigations and protect the
rights and welfare of human subjects. Inability to obtain or delay in obtaining IRB approval can prevent or delay the initiation and completion of clinical trials, and the FDA or foreign regulatory authorities may decide not to consider any data or
information derived from a clinical investigation not subject to initial and continuing IRB review and approval in support of a marketing application. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our product candidates that we develop may encounter problems during clinical trials that will cause us, an IRB or regulatory authorities to delay, suspend or terminate these trials, or that will delay or
confound the analysis of data from these trials. If we experience any such problems, we may not have the financial resources to continue development of the product candidate that is affected, or development of any of our other product candidates. We
may also lose, or be unable to enter into, collaborative arrangements for the affected product candidate and for other product candidates we are developing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A failure of one of more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, pre-clinical testing and the clinical trial
process that could delay or prevent regulatory approval or our ability to commercialize our product candidates, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our pre-clinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct
additional pre-clinical testing or clinical trials, or we may abandon projects that we expect to be promising; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in filing INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators or IRBs in order to
commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conditions imposed on us by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">problems in engaging IRBs to oversee clinical trials or problems in obtaining or maintaining IRB approval of trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delays in enrolling patients and volunteers into clinical trials, and variability in the number and types of patients and volunteers available for
clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">high drop-out rates for patients and volunteers in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inadequate supply or quality of product candidate materials or other materials necessary for the conduct of our clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">greater than anticipated clinical trial costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our
product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">poor effectiveness of our product candidates during clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site or records of any clinical or pre-clinical investigation;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a
timely manner, or at all; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">governmental or regulatory delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our technology in particular;&nbsp;or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">varying interpretations of data by the FDA and similar foreign regulatory agencies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even if we successfully complete clinical trials of our product candidates, any given product candidate may not prove to be a safe and
effective treatment for the diseases for which it was being tested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The regulatory approval process may be delayed for
any products we develop that require the use of specialized drug delivery devices, which may require us to incur additional costs and delay receipt of any potential product revenue. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Some product candidates that we develop may need to be administered using specialized drug delivery devices that deliver RNAi
therapeutics directly to diseased parts of the body. While we expect to rely on drug delivery systems that have been approved by the FDA or other regulatory agencies to deliver drugs like ours to diseased parts of the body, we, or our collaborator,
may need to modify the design or labeling of such delivery device for some products we may develop. In such an event, the FDA may regulate the product as a combination product or require additional approvals or clearances for the modified delivery
device. Further, to the extent the specialized delivery device is owned by another company, we would need that company&#146;s cooperation to implement the necessary changes to the device, or its labeling, and to obtain any additional approvals or
clearances. In cases where we do not have an ongoing collaboration with the company that makes the device, obtaining such additional approvals or clearances and the cooperation of such other company could significantly delay and increase the cost of
obtaining marketing approval, which could reduce the commercial viability of our product candidate. In addition, the use of a specialized delivery system, even if previously approved, could complicate the design or analysis of clinical trials for
our RNAi therapeutics. In summary, we may be unable to find, or experience delays in finding, suitable drug delivery systems to administer RNAi therapeutics directly to diseased parts of the body, which could negatively affect our ability to
successfully commercialize these RNAi therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain United States or foreign regulatory
approval and, as a result, unable to commercialize our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our product candidates are subject to
extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, marketing and distribution of drugs. Rigorous pre-clinical
testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory
requirements is costly, time consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our collaborators to begin selling
them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory
approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the
product candidate. The standards that the FDA and its foreign counterparts use when regulating us are not always applied predictably or uniformly and can change. Any analysis we perform of data from pre-clinical and clinical activities is subject to
confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or
administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations,
guidance or interpretations will be changed, or what the impact of such changes, if any, may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because the drugs we are
developing may represent a new class of drug, the FDA and its foreign counterparts have not yet established any definitive policies, practices or guidelines in relation to these drugs. While we believe the product candidates that we are currently
developing are regulated as new drugs under the Federal Food, Drug, and Cosmetic Act, the FDA could decide to regulate them or other products we may develop as biologics under the Public Health Service Act. The lack of policies, practices or
guidelines may hinder or slow review by the FDA of any regulatory filings that we may submit. Moreover, the FDA may respond to these submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in
the clinical development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical
trials that the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been
increased public and political pressure on the FDA with respect to the approval process for new drugs, and the FDA&#146;s standards, especially regarding drug safety, appear to have become more stringent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenues from the
particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions. In
addition, the FDA has the authority to require a Risk Evaluation and Mitigation Strategy, or REMS, plan as part of an NDA or biologics license application, or BLA, or after approval, which may impose further requirements or restrictions on the
distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring
treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party
reimbursement. The foreign regulatory approval process varies among countries and includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions.
Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even
if we obtain regulatory approvals, our marketed drugs will be subject to ongoing regulatory review. If we fail to comply with continuing U.S. and foreign requirements, our approvals could be limited or withdrawn, we could be subject to other
penalties, and our business would be seriously harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Following any initial regulatory approval of any drugs we may
develop, we will also be subject to continuing regulatory review, including the review of adverse drug experiences and clinical results that are reported after our drug products are made commercially available. This would include results from any
postmarketing tests or surveillance to monitor the safety and efficacy of the drug product required as a condition of approval or agreed to by us. Any regulatory approvals that we receive for our product candidates may also be subject to limitations
on the approved uses for which the product may be marketed. Other ongoing regulatory requirements include, among other things, submissions of safety and other post-marketing information and reports, registration and listing, as well as continued
compliance with cGMP requirements and good clinical practices for any clinical trials that we conduct post-approval. In addition, we are conducting, and intend to continue to conduct, clinical trials for our product candidates, and we intend to seek
approval to market our product candidates, in jurisdictions outside of the United States, and therefore will be subject to, and must comply with, regulatory requirements in those jurisdictions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has significant post-market authority, including, for example, the authority to require labeling changes based on new safety
information and to require post-market studies or clinical trials to evaluate serious safety risks related to the use of a drug and to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after
approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
manufacturer and manufacturing facilities we use to make any of our product candidates will also be subject to periodic review and inspection by the FDA and other regulatory agencies. The discovery of any new or previously unknown problems with our
third-party manufacturers, manufacturing processes or facilities, may result in restrictions on the drug or manufacturer or facility, including withdrawal of the drug from the market. We do not have, and currently do not intend to develop, the
ability to manufacture material for our clinical trials or on a commercial scale. We may manufacture clinical trial materials or we may contract a third party to manufacture these materials for us. Reliance on third-party manufacturers entails risks
to which we would not be subject if we manufactured products ourselves, including reliance on the third-party manufacturer for regulatory compliance. Our product promotion and advertising is also subject to regulatory requirements and continuing
regulatory review. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we or our collaborators, manufacturers or service providers fail to comply with applicable continuing
regulatory requirements in the United States or foreign jurisdictions in which we may seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, refusal by the FDA to approve
pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and
criminal prosecution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we receive regulatory approval to market our product candidates, the market
may not be receptive to our product candidates upon their commercial introduction, which will prevent us from becoming profitable. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The product candidates that we are developing are based upon new technologies or therapeutic approaches. Key participants in pharmaceutical marketplaces, such as physicians, third-party payors and
consumers, may not accept a product intended to improve therapeutic results based on RNAi technology. As a result, it may be more difficult for us to convince the medical community and third-party payors to accept and use our product, or to provide
favorable reimbursement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other factors that we believe will materially affect market acceptance of our product candidates
include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of our receipt of any marketing approvals, the terms of any approvals and the countries in which approvals are obtained;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the safety and efficacy of our product candidates, as demonstrated in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">relative convenience and ease of administration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the willingness of patients to accept potentially new routes of administration; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the success of our physician education programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability of adequate government and third-party payor reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the pricing of our products, particularly as compared to alternative treatments;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of alternative effective treatments for the diseases that product candidates we develop are intended to treat and the relative risks,
benefits and costs of the treatments. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we or our collaborators, manufacturers or service providers
fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a manufacturer of pharmaceuticals, we are subject to federal, state, and foreign healthcare laws and regulations pertaining to fraud
and abuse and patients&#146; rights. These laws and regulations include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing
remuneration, directly or indirectly, to induce either the referral of an individual for a healthcare item or service, or the purchasing or ordering of an item or service, for which payment may be made under a federal healthcare program such as
Medicare or Medicaid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal false claims law, which prohibits, among other things, individuals or entities from knowingly presenting or causing to be presented,
claims for payment by government funded programs such as Medicare or Medicaid that are false or fraudulent, and which may apply to us by virtue of statements and representations made to customers or third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. federal Health Insurance Portability and Accountability Act, or HIPAA, and Health Information Technology for Economic and Clinical Health, or
HITECH, Act, which prohibit executing a scheme to defraud healthcare programs; impose requirements relating to the privacy, security, and transmission of individually identifiable health information; and require notification to affected individuals
and regulatory authorities of certain breaches of security of individually identifiable health information; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">state laws comparable to each of the above federal laws, such as, for example, anti-kickback and false claims laws applicable to commercial insurers
and other non-federal payors, requirements for mandatory corporate regulatory compliance programs, and laws relating to patient data privacy and security. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our
operations, loss of eligibility to obtain approvals from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our
financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation
could cause us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and
regulations may be costly to us in terms of money, time and resources. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we or our collaborators, manufacturers or service
providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation
and lead to reduced acceptance of our products by the market. These enforcement actions include, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse regulatory inspection findings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on, or prohibitions against, marketing our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on, or prohibitions against, importation or exportation of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension of review or refusal to approve pending applications or supplements to approved applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exclusion from participation in government-funded healthcare programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exclusion from eligibility for the award of government contracts for our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of product approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizures; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">civil and criminal penalties and fines. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Any drugs we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The regulations that govern marketing approvals, pricing and reimbursement for new drugs vary widely from country to country. Some
countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical
pricing remains subject to continuing governmental control even after initial approval is granted. Although we intend to monitor these regulations, our programs are currently in the early stages of development and we will not be able to assess the
impact of price regulations for a number of years. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product and negatively impact
the revenues we are able to generate from the sale of the product in that country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to commercialize any products
successfully also will depend in part on the extent to which reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Even if we
succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs
are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients, such as government and private
insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged for pharmaceutical products. If the price we are able to charge for any products we develop
is inadequate in light of our development and other costs, our profitability could be adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently expect that any drugs we develop may need to be administered under the
supervision of a physician. Under currently applicable U.S. law, drugs that are not usually self-administered may be eligible for coverage by the Medicare program if: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are incident to a physician&#146;s services; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are reasonable and necessary for the diagnosis or treatment of the illness or injury for which they are administered according to accepted
standards of medical practice; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they are not excluded as immunizations;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">they have been approved by the FDA. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There may be significant delays in obtaining coverage for newly-approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA. Moreover, eligibility for
coverage does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient
to cover our costs and may not be made permanent. Reimbursement may be based on payments allowed for lower-cost drugs that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or
imperfections in Medicare data. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from
countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and
adequate reimbursement rates from both government-funded and private payors for new drugs that we develop and for which we obtain regulatory approval could have a material adverse effect on our operating results, our ability to raise capital needed
to commercialize products, and our overall financial condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the efforts of governments and third-party
payors to contain or reduce the cost of healthcare and legislative and regulatory proposals to broaden the availability of healthcare will continue to affect the business and financial condition of pharmaceutical and biopharmaceutical companies. A
number of legislative and regulatory changes in the healthcare system in the United States and other major healthcare markets have been proposed in recent years, and such efforts have expanded substantially in recent years. These developments have
included prescription drug benefit legislation that was enacted and took effect in January 2006, healthcare reform legislation enacted by certain states, and major healthcare reform legislation that was passed by Congress and enacted into law in the
United States in 2010. These developments could, directly or indirectly, affect our ability to sell our products, if approved, at a favorable price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In particular, in March 2010, the Patient Protection and Affordable Care Act, or PPACA, and a related reconciliation bill were signed into law. This new legislation changes the current system of
healthcare insurance and benefits intended to broaden coverage and control costs. The new law also contains provisions that will affect companies in the pharmaceutical industry and other healthcare related industries by imposing additional costs and
changes to business practices. Provisions affecting pharmaceutical companies include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mandatory rebates for drugs sold into the Medicaid program have been increased, and the rebate requirement has been extended to drugs used in
risk-based Medicaid managed care plans. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 340B Drug Pricing Program under the Public Health Services Act has been extended to require mandatory discounts for drug products sold to certain
critical access hospitals, cancer hospitals and other covered entities. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical companies are required to offer discounts on brand-name drugs to patients who fall within the Medicare Part&nbsp;D coverage gap,
commonly referred to as the &#147;Donut Hole.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmaceutical companies are required to pay an annual non-tax deductible fee to the federal government based on each company&#146;s market share of
prior year total sales of branded products to certain federal healthcare programs, such as Medicare, Medicaid, Department of Veterans Affairs and Department of Defense. Since we expect our branded pharmaceutical sales to constitute a small portion
of the total federal health program pharmaceutical market, we do not expect this annual assessment to have a material impact on our financial condition. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The new law provides that approval of an application for a follow-on biologic product may not become effective until 12 years after the date on which
the prior innovator biologic product was first licensed by the FDA, with a possible six-month extension for pediatric products. After this exclusivity ends, it will be easier for generic manufacturers to enter the market, which is likely to reduce
the pricing for such products and could affect the company&#146;s profitability. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The full effects of the
U.S. healthcare reform legislation cannot be known until the new law is implemented through regulations or guidance issued by the Centers for Medicare&nbsp;&amp; Medicaid Services and other federal and state healthcare agencies. The financial impact
of the U.S. healthcare reform legislation over the next few years will depend on a number of factors, including but not limited, to the policies reflected in implementing regulations and guidance, and changes in sales volumes for products affected
by the new system of rebates, discounts and fees. The new legislation may also have a positive impact on our future net sales, if any, by increasing the aggregate number of persons with healthcare coverage in the United States, but such increases
are unlikely to be realized until approximately 2014 at the earliest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Moreover, we cannot predict what healthcare reform
initiatives may be adopted in the future. Further federal and state legislative and regulatory developments are likely, and we expect ongoing initiatives in the United States to increase pressure on drug pricing. Such reforms could have an adverse
effect on anticipated revenues from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop drug candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There is a substantial risk of product liability claims in our business. If we are unable to obtain sufficient insurance, a product
liability claim against us could adversely affect our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business exposes us to significant potential
product liability risks that are inherent in the development, testing, manufacturing and marketing of human therapeutic products. Product liability claims could delay or prevent completion of our clinical development programs. If we succeed in
marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs, and potentially a recall of our products or more serious
enforcement action, limitations on the approved indications for which they may be used, or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in injury to our reputation, costs to
defend the related litigation, a diversion of management&#146;s time and our resources, and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of
development and may need to obtain higher levels prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product
liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on
our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety,
our business could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development involves the use of hazardous materials,
chemicals and various radioactive compounds. We maintain quantities of various flammable and toxic chemicals in our facilities in Cambridge that are required for our research and development activities. We are subject to federal, state and local
laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our Cambridge facility comply with the relevant
guidelines of the City of Cambridge and the Commonwealth of Massachusetts. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of
accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace
safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of biohazardous materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not
provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive
materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or
regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Patents, Licenses and Trade Secrets </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are not able to obtain and enforce patent protection for our discoveries, our ability to develop and commercialize our product
candidates will be harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success depends, in part, on our ability to protect proprietary methods and
technologies that we develop under the patent and other intellectual property laws of the United States and other countries, so that we can prevent others from unlawfully using our inventions and proprietary information. However, we may not hold
proprietary rights to some patents required for us to commercialize our proposed products. Because certain U.S. patent applications are confidential until the patents issue, such as applications filed prior to November&nbsp;29, 2000, or applications
filed after such date which will not be filed in foreign countries, third parties may have filed patent applications for technology covered by our pending patent applications without our being aware of those applications, and our patent applications
may not have priority over those applications. For this and other reasons, we may be unable to secure desired patent rights, thereby losing desired exclusivity. Further, we may be required to obtain licenses under third-party patents to market our
proposed products or conduct our research and development or other activities. If licenses are not available to us on acceptable terms, we will not be able to market the affected products or conduct the desired activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy depends on our ability to rapidly identify and seek patent protection for our discoveries. In addition, we may rely on
third-party collaborators to file patent applications relating to proprietary technology that we develop jointly during certain collaborations. The process of obtaining patent protection is expensive and time-consuming. If our present or future
collaborators fail to file and prosecute all necessary and desirable patent applications at a reasonable cost and in a timely manner, our business will be adversely affected. Despite our efforts and the efforts of our collaborators to protect our
proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. While issued patents are presumed valid, this does not guarantee that the patent will survive a validity challenge or be held
enforceable. Any patents we have obtained, or obtain in the future, may be challenged, invalidated, adjudged unenforceable or circumvented by parties attempting to design around our intellectual property. Moreover, third parties or the United States
Patent and Trademark Office, or USPTO, may commence interference proceedings involving our patents or patent applications. For example, during 2011, the USPTO declared an interference between our issued patent covering ALN-VSP, our RNAi therapeutic
undergoing clinical testing for the treatment of liver cancers, and a pending third-party application assigned to Protiva (which was acquired by Tekmira in 2008), the effect of which called into question the validity and/or enforceability of our
patent. The interference proceedings are ongoing. If Protiva is successful in obtaining a dominating claim, we would require a license to Protiva&#146;s patent to commercialize ALN-VSP in the United States. Any challenge to, finding of
unenforceability or invalidation or circumvention of, our patents or patent applications, would be costly, would require significant time and attention of our management and could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our pending patent applications may not result in issued patents. The patent position of pharmaceutical or biotechnology companies,
including ours, is generally uncertain and involves complex legal and factual considerations. The standards that the USPTO and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. Similarly,
the ultimate degree of protection that will be afforded to biotechnology inventions, including ours, in the United States and foreign countries, remains uncertain and is dependent upon the scope of the protection decided upon by patent offices,
courts and lawmakers. Moreover, there are periodic discussions in the Congress of the United States and in international jurisdictions about modifying various aspects of patent law. For example, the America Invents Act was recently enacted into law
and includes a number of changes to the patent laws of the United States. If any changes to the patent laws are enacted and do not provide adequate protection for discoveries, including our ability to pursue infringers of our patents for substantial
damages, our business could be adversely affected. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accordingly, we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in
any patents issued to us or to others. We also rely to a certain extent on trade secrets, know-how and technology, which are not protected by patents, to maintain our competitive position. If any trade secret, know-how or other technology not
protected by a patent were to be disclosed to or independently developed by a competitor, our business and financial condition could be materially adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We license patent rights from third-party owners. If such owners do not properly or successfully obtain, maintain or enforce the patents underlying such licenses, our competitive position and
business prospects will be harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a party to a number of licenses that give us rights to third-party
intellectual property that is necessary or useful for our business. In particular, we have obtained licenses from, among others, CRT, Isis, MIT, Whitehead, Max Planck Innovation, Tekmira, UTSW and Arrowhead. We also intend to enter into additional
licenses to third-party intellectual property in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in part on the ability of our licensors to obtain, maintain and
enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents
issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than
we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.
In addition, we sublicense our rights under various third-party licenses to our collaborators. Any impairment of these sublicensed rights could result in reduced revenues under our collaboration agreements or result in termination of an agreement by
one or more of our collaborators. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other companies or organizations may challenge our patent rights or may assert patent
rights that prevent us from developing and commercializing our products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">RNAi is a relatively new scientific field,
the commercial exploitation of which has resulted in many different patents and patent applications from organizations and individuals seeking to obtain patent protection in the field. We have obtained grants and issuances of RNAi patents and have
licensed many of these patents from third parties on an exclusive basis. The issued patents and pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions
and processes relating to the discovery, development, manufacture and commercialization of RNAi therapeutics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specifically,
we have a portfolio of patents, patent applications and other intellectual property covering: fundamental aspects of the structure and uses of siRNAs, including their manufacture and use as therapeutics, and RNAi-related mechanisms; chemical
modifications to siRNAs that improve their suitability for therapeutic uses; siRNAs directed to specific targets as treatments for particular diseases; and delivery technologies, such as in the field of cationic liposomes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As the field of RNAi therapeutics is maturing, patent applications are being fully processed by national patent offices around the world.
There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. It is likely that there will be significant litigation and other proceedings, such as interference, reexamination and opposition
proceedings, in various patent offices relating to patent rights in the RNAi field. For example, various third parties have initiated oppositions to patents in our Kreutzer-Limmer and Tuschl II series in the European Patent Office, or EPO, and in
other jurisdictions. We expect that additional oppositions will be filed in the EPO and elsewhere, and other challenges will be raised relating to other patents and patent applications in our portfolio. In many cases, the possibility of appeal
exists for either us or our opponents, and it may be years before final, unappealable rulings are made with respect to these patents in certain jurisdictions. The timing and outcome of these and other proceedings is uncertain and may adversely
affect our business if we are not successful in defending the patentability and scope of our pending and issued patent claims. In addition, third parties may attempt to invalidate our intellectual property rights. Even if our rights are not directly
challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time
and attention of our management and could have a material adverse effect on our business and our ability to successfully compete in the field of RNAi. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are many issued and pending patents that claim aspects of oligonucleotide chemistry that we may need to apply to our siRNA therapeutic candidates. There are also many issued patents that claim
targeting genes or portions of genes that may be relevant for siRNA drugs we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a
license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we become involved in patent litigation or other proceedings related to a determination of rights, we could incur substantial costs and expenses, substantial liability for damages or be required
to stop our product development and commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third parties may sue us for infringing their patent
rights. Likewise, we may need to resort to litigation to enforce a patent issued or licensed to us or to determine the scope and validity of proprietary rights of others. For example, on January&nbsp;17, 2012, we filed a complaint in the United
States District Court for the District of Massachusetts against Tekmira for patent infringement arising </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
from Tekmira&#146;s research activities providing LNP-formulated siRNA molecules to a pharmaceutical collaborator. As alleged in the complaint, we do not believe Tekmira&#146;s activities are
protected under the exemption from patent infringement for drug development. Pursuant to the complaint, we believe Tekmira has infringed a number of issued patents related to siRNA and LNP technologies, including: U.S. Patent No.&nbsp;7,695,902;
U.S. Patent No.&nbsp;6,858,225; U.S. Patent No.&nbsp;6,815,432; U.S. Patent No.&nbsp;6,534,484; U.S. Patent No.&nbsp;6,586,410; and U.S. Patent No.&nbsp;6,858,224. Under our contractual right to enforce U.S. Patent No.&nbsp;7,695,902 owned by Isis,
we joined Isis to the suit as a co-plaintiff. We and Isis are seeking judgment that Tekmira has infringed the patents at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including attorneys&#146;
fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, a third party may claim that we have improperly obtained or used its confidential or proprietary
information. For example, in March 2011, Tekmira and Protiva filed a civil complaint against us in the Business Litigation Section of the Suffolk County Superior Court, in Boston, Massachusetts, and in June 2011, the plaintiffs filed an amended
complaint adding AlCana, a research collaborator of ours, as a defendant. The amended complaint alleges misappropriation of the plaintiffs&#146; confidential and proprietary information and trade secrets, civil conspiracy and tortious interference
with contractual relationships by us and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising, unfair and deceptive trade practices by us. The
plaintiffs seek, among other relief, injunctive relief, unspecified compensatory and punitive damages, attorneys&#146; fees, the termination of licenses that the plaintiffs provided to us and the relinquishment and transfer of certain of our
intellectual property rights, including patents covering our MC3 technology. In April 2011, we served and filed an answer to the plaintiffs&#146; original complaint denying the plaintiffs&#146; claims and asserted counterclaims against the
plaintiffs. In June 2011, we served and filed an answer to the plaintiffs&#146; amended complaint denying the plaintiffs&#146; claims and asserted counterclaims against the plaintiffs for breach of contract, defamation, breach of covenant not to
sue, breach of patent prosecution and non-use provisions, misappropriation of confidential and proprietary information and trade secrets, unjust enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations of
Massachusetts statutes. We are seeking monetary damages, attorneys&#146; fees and equitable relief on our counterclaims. In September 2011, the Court granted the plaintiffs&#146; motion to dismiss our counterclaim for defamation. The plaintiffs did
not move to dismiss any of our other counterclaims, all of which remain pending. The case is currently in discovery and we expect a trial to start in October 2012. We intend to vigorously defend ourselves in this matter. However, litigation is
subject to inherent uncertainty and this matter could ultimately be decided against us and we could be required to pay substantial damages. We have also incurred, and will continue to incur during the pendency of the litigation, significant costs,
and the defense of this litigation has diverted, and until resolved will continue to divert, the attention of our management and other resources that would otherwise be engaged in other activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Furthermore, third parties may challenge the inventorship of our patents or licensed patents. For example, in March 2011, the University
of Utah, or Utah, filed a complaint in the United States District Court for the District of Massachusetts against us, Max Planck, Whitehead, MIT and UMass, claiming that a professor of Utah is the sole inventor, or in the alternative, a joint
inventor of certain of our in-licensed patents. The original complaint was not served on any of the parties and, in July 2011, Utah filed an amended complaint containing substantially the same claims as the original complaint against us, Max Planck,
Whitehead, MIT and UMass. The amended complaint alleges the defendants have incorrectly determined inventorship of some of our in-licensed patents and further claims unjust enrichment, unfair competition, false advertising and seeks correction of
inventorship, injunctive relief and unspecified damages. In October 2011, we, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss and UMass filed a motion to dismiss on separate grounds, which we, Max Planck, Whitehead and MIT have
joined. In December 2011, Utah filed a second amended complaint dropping UMass as a defendant and adding as defendants several UMass officials. We intend to vigorously defend ourselves in this matter, however, litigation is subject to inherent
uncertainty and a court could ultimately rule against us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in connection with certain license and collaboration
agreements, we have agreed to indemnify certain third parties for certain costs incurred in connection with litigation relating to intellectual property rights or the subject matter of the agreements. The cost to us of any litigation or other
proceeding relating to intellectual property rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#146;s efforts. Some of our competitors may be able to sustain the costs of complex patent
litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of any litigation could delay our research and development efforts and limit our ability to
continue our operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any parties successfully claim that our creation or use of proprietary technologies infringes
upon or otherwise violates their intellectual property rights, we might be forced to pay damages, potentially including treble damages, if we are found to have willfully infringed on such parties&#146; patent rights. In addition to any damages we
might have to pay, a court could require us to stop the infringing activity or obtain a license. Any license required under any patent may not be made available on commercially acceptable terms, if at all. In addition, such licenses are likely to be
non-exclusive and, therefore, our competitors may have access to the same technology licensed to us. If we fail to obtain a required license and are unable to design around a patent, we may be unable to effectively market some of our technology and
products, which could limit our ability to generate revenues or achieve profitability and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
possibly prevent us from generating revenue sufficient to sustain our operations. Moreover, we expect that a number of our collaborations will provide that royalties payable to us for licenses to
our intellectual property may be offset by amounts paid by our collaborators to third parties who have competing or superior intellectual property positions in the relevant fields, which could result in significant reductions in our revenues from
products developed through collaborations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with our obligations under any licenses or related
agreements, we could lose license rights that are necessary for developing and protecting our RNAi technology and any related product candidates that we develop, or we could lose certain exclusive rights to grant sublicenses. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current licenses impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding,
royalty, diligence, sublicensing, insurance, patent prosecution and enforcement, and other obligations on us. If we breach any of these obligations, the licensor may have the right to terminate the license or render the license non-exclusive, which
could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. For example, in connection with its lawsuit against us, Tekmira
has alleged that we breached our license agreements with it and Protiva and is seeking that the court terminate such license agreements. If this matter is decided in Tekmira&#146;s favor, we could lose access to certain aspects of our LNP delivery
technology, including MC3, which would adversely impact certain of our clinical development programs, or be required to pay additional milestones and royalties to Tekmira. In addition, while we cannot currently determine the amount of the royalty
obligations we will be required to pay on sales of future products, if any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully
develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators,
employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of
unauthorized disclosure of confidential information. In addition, others may independently discover trade secrets and proprietary information, and in such cases we could not assert any trade secret rights against such party. Costly and
time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Competition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>The pharmaceutical market is intensely competitive. If we are unable to compete effectively with existing drugs, new treatment methods and new technologies, we may be unable to commercialize
successfully any drugs that we develop. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pharmaceutical market is intensely competitive and rapidly changing. Many
large pharmaceutical and biotechnology companies, academic institutions, governmental agencies and other public and private research organizations are pursuing the development of novel drugs for the same diseases that we are targeting or expect to
target. Many of our competitors have: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">much greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and commercialization of
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">more extensive experience in pre-clinical testing, conducting clinical trials, obtaining regulatory approvals, and in manufacturing, marketing and
selling pharmaceutical products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates that are based on previously tested or accepted technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">products that have been approved or are in late stages of development;&nbsp;and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborative arrangements in our target markets with leading companies and research institutions. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will face intense competition from drugs that have already been approved and accepted by the medical community for the treatment of
the conditions for which we may develop drugs. We also expect to face competition from new drugs that enter the market. We believe a significant number of drugs are currently under development, and may become commercially available in the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
future, for the treatment of conditions for which we may try to develop drugs. For instance, we are currently evaluating RNAi therapeutics for ATTR, hemophilia, severe hypercholesterolemia,
refractory anemia, hemoglobinopathies, including beta-thalassemia and sickle-cell anemia, RSV, liver cancers and HD, and have a number of additional discovery programs targeting other diseases. These drugs may be more effective, safer, less
expensive, or marketed and sold more effectively, than any products we develop. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we successfully develop product
candidates, and obtain approval for them, we will face competition based on many different factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the safety and effectiveness of our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing and scope of regulatory approvals for these products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the availability and cost of manufacturing, marketing and sales capabilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">price; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reimbursement coverage;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">patent position. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our competitors may develop or commercialize products with significant advantages over any products we develop based on any of the factors listed above or on other factors. Our competitors may therefore
be more successful in commercializing their products than we are, which could adversely affect our competitive position and business. Competitive products may make any products we develop obsolete or noncompetitive before we can recover the expenses
of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and the ability to execute on our business plan. Furthermore, we also face competition
from existing and new treatment methods that reduce or eliminate the need for drugs, such as the use of advanced medical devices. The development of new medical devices or other treatment methods for the diseases we are targeting could make our
product candidates noncompetitive, obsolete or uneconomical. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face competition from other companies that are working
to develop novel drugs and technology platforms using technology similar to ours. If these companies develop drugs more rapidly than we do or their technologies, including delivery technologies, are more effective, our ability to successfully
commercialize drugs may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the competition we face from competing drugs in
general, we also face competition from other companies working to develop novel drugs using technology that competes more directly with our own. We are aware of multiple companies that are working in the field of RNAi. In addition, we granted
licenses or options for licenses to Isis, GeneCare Research Institute Co., Ltd., Benitec Ltd., Arrowhead and its subsidiary, Calando Pharmaceuticals, Inc., Tekmira, Quark Pharmaceuticals, Inc., Sylentis S.A.U. and others under which these companies
may independently develop RNAi therapeutics against a limited number of targets. Any of these companies may develop its RNAi technology more rapidly and more effectively than us. Merck&nbsp;&amp; Co., Inc., or Merck, was one of our collaborators and
a licensee under our intellectual property for specified disease targets until September 2007, at which time we and Merck agreed to terminate our collaboration. As a result of its acquisition of Sirna Therapeutics, Inc. in December 2006, and in
light of the mutual termination of our collaboration, Merck, which has substantially more resources and experience in developing drugs than we do, may become a direct competitor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, as a result of agreements that we have entered into, Arrowhead, as the assignee of Roche, and Takeda have obtained
non-exclusive licenses, and Novartis has obtained specific exclusive licenses for 31 gene targets, to certain aspects of our technology that give them the right to compete with us in certain circumstances We also compete with companies working to
develop antisense-based drugs. Like RNAi therapeutics, antisense drugs target mRNAs, in order to suppress the activity of specific genes. Isis is currently marketing an antisense drug and has several antisense product candidates in clinical trials.
The development of antisense drugs is more advanced than that of RNAi therapeutics, and antisense technology may become the preferred technology for drugs that target mRNAs to silence specific genes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to competition with respect to RNAi and with respect to specific products, we
face substantial competition to discover and develop safe and effective means to deliver siRNAs to the relevant cell and tissue types. Safe and effective means to deliver siRNAs to the relevant cell and tissue types may be developed by our
competitors, and our ability to successfully commercialize a competitive product would be adversely affected. In addition, substantial resources are being expended by third parties in the effort to discover and develop a safe and effective means of
delivering siRNAs into the relevant cell and tissue types, both in academic laboratories and in the corporate sector. Some of our competitors have substantially greater resources than we do, and if our competitors are able to negotiate exclusive
access to those delivery solutions developed by third parties, we may be unable to successfully commercialize our product candidates. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Our Common Stock </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If our stock price fluctuates,
purchasers of our common stock could incur substantial losses. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The market price of our common stock has and may
continue to fluctuate significantly in response to factors that are beyond our control. The stock market in general has recently experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical and biotechnology
companies have been extremely volatile, and have experienced fluctuations that often have been unrelated or disproportionate to the operating performance of these companies. These broad market fluctuations could result in extreme fluctuations in the
price of our common stock, which could cause purchasers of our common stock to incur substantial losses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may incur
significant costs from class action litigation due to our expected stock volatility. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stock price may fluctuate
for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of our collaborators and/or competitors, the addition or departure of our key personnel, variations in our
quarterly operating results and changes in market valuations of pharmaceutical and biotechnology companies. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities
class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without merit, we could incur substantial costs defending the lawsuit. The lawsuit
could also divert the time and attention of our management. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Novartis&#146; ownership of our common stock could delay or
prevent a change in corporate control. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At March&nbsp;31, 2012, Novartis held 10.8% of our outstanding common stock
and has the right to maintain its ownership percentage until the earlier of any sale by Novartis of shares of our common stock and the expiration or termination of our collaboration and license agreement, subject to certain exceptions. This
concentration of ownership may harm the market price of our common stock by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delaying, deferring or preventing a change in control of our company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impeding a merger, consolidation, takeover or other business combination involving our company;&nbsp;or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Sales of additional shares of our common stock could result in dilution to existing stockholders and cause the price of our common
stock to decline. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of substantial amounts of our common stock in the public market, or the availability of such
shares for sale, by us or others could adversely affect the price of our common stock. Novartis has rights, subject to certain conditions, to require us to file registration statements covering its shares or to include its shares in registration
statements that we file. In addition, if Novartis decides to sell a portion of its shares in a rapid or disorderly manner, our stock price could be negatively impacted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Anti-takeover provisions in our charter documents and under Delaware law and our
stockholder rights plan could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provisions in our certificate of incorporation and our bylaws may delay or prevent an acquisition of us or a change in our management. In
addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of
directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a classified board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a prohibition on actions by our stockholders by written consent; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations on the removal of directors;&nbsp;and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our board of directors has adopted a stockholder rights plan, the provisions of which could
make it difficult for a potential acquirer of Alnylam to consummate an acquisition transaction. Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which
prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting
stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_9"></A>ITEM&nbsp;5. OTHER INFORMATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lease Agreement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;10, 2012, we entered into a non-cancelable real property lease agreement with BMR-Fresh Pond Research Park LLC, pursuant to which we are leasing approximately 15,000 square feet of office and laboratory space located at 665 Concord
Avenue, Cambridge, Massachusetts. The term of the lease expires August&nbsp;31, 2017. We have the option to extend the lease for two successive five-year extensions. Our operating lease obligations through 2017 under this lease will be $2.6 million.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Medtronic Agreement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In July 2007, we entered into an amended and restated collaboration agreement with Medtronic to pursue the development of RNAi therapeutics for the treatment of neurodegenerative disorders using
implantable infusion systems. ALN-HTT is an RNAi therapeutic candidate targeting the huntingtin gene, for the treatment of HD, which we have been developing in collaboration with Medtronic under this agreement. In November 2010, we and Medtronic
entered into an agreement with CHDI, under which CHDI agreed to initially fund approximately 50% of the costs of the ALN-HTT program up to the point at which an IND can be filed with the FDA or a comparable foreign regulatory filing can be made.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with our January 2012 strategic corporate restructuring, we determined to align our resources to focus on our
lead programs, ALN-TTR and ALN-APC. In April 2012, as part of this alignment of resources, we exercised our option under the Medtronic agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program
and move to a royalty and milestone licensing structure. Medtronic has the right to continue development of the ALN-HTT program. If Medtronic decides to continue the ALN-HTT program, it would assume responsibility for future development plans. We
intend to transition the program to Medtronic, and intend to continue to supply ALN-HTT for the program, as well as provide technical support to Medtronic, as requested. If Medtronic continues the program, we would be compensated for the supply of
ALN-HTT, and would be entitled to certain development milestones, as well as royalties on annual net sales, if any. We continue to be obligated to repay CHDI for our pro-rata share of funding received through the effective date of our opt-out, with
interest, in the event that a product is ultimately commercialized from the funded research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we and Medtronic
may jointly agree to collaborate on additional product development programs for the treatment of other neurodegenerative diseases, which can be addressed by the delivery of siRNAs to the human nervous system through implantable infusion devices,
under the amended and restated collaboration agreement, which remains in effect. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_10"></A>ITEM&nbsp;6. EXHIBITS.
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012 Annual Incentive Program</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;10.2&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease entered into as of February 10, 2012 by and between BMR-Fresh Pond Research Park LLC and the Registrant</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computation of Consolidated Ratios of Earnings/Deficiencies to Fixed Charges</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;31.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of principal executive officer pursuant to Rule&nbsp;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of
Chapter&nbsp;63 of Title 18 of the United States Code.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;32.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certification of principal financial officer pursuant to Rule&nbsp;13a-14(b) promulgated under the Securities Exchange Act of 1934, as amended, and Section&nbsp;1350 of
Chapter&nbsp;63 of Title 18 of the United States Code.</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;101+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following materials from Registrant&#146;s Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2012, formatted in XBRL (Extensible Business Reporting
Language): (i)&nbsp;the Condensed Consolidated Balance Sheets, (ii)&nbsp;the Condensed Consolidated Statements of Comprehensive Loss, (iii)&nbsp;the Condensed Consolidated Statements of Cash Flows, and (iv)&nbsp;Notes to Condensed Consolidated
Financial Statements, tagged as blocks of text.</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates confidential treatment requested as to certain portions, which portions were omitted and filed separately with the Securities and Exchange Commission pursuant
to a Confidential Treatment Request. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with Rule 406T of Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed to be
&#147;furnished&#148; and not &#147;filed.&#148; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc335938_11"></A>SIGNATURES </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its
behalf by the undersigned, thereunto duly authorized. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John M. Maraganore</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">John M. Maraganore, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Executive
Officer)</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May&nbsp;3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael P. Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael P. Mason</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice
President of Finance and Treasurer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Principal Financial and Accounting Officer)</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d335938dex101.htm
<DESCRIPTION>2012 ANNUAL INCENTIVE PROGRAM
<TEXT>
<HTML><HEAD>
<TITLE>2012 Annual Incentive Program</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Alnylam Pharmaceuticals, Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2012 Annual Incentive Program
</B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary Description </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
March 2012, the Compensation Committee of the Board of Directors (the &#147;Board&#148;) of Alnylam Pharmaceuticals, Inc. (&#147;Alnylam&#148; or the &#147;Company&#148;) approved the 2012 Annual Incentive Program (the &#147;Bonus Plan&#148;) to
incent and reward all regular employees based upon their performance relative to pre-established 2012 corporate and individual goals and objectives, and retain company employees by establishing an important element of Alnylam&#146;s total rewards
package consistent with Alnylam&#146;s compensation philosophy and operating strategy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eligibility </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All regular employees, who are employed by the Company both before July 1, 2012 and on December 31, 2012 (collectively, &#147;Plan Participants&#148;),
are eligible to receive an annual cash bonus (a &#147;Bonus Award&#148;) based upon achievement of individual and corporate goals and objectives for 2012. The Compensation Committee may, in its discretion, include employees who join the Company
after July 1, 2012 as Plan Participants. Bonus Awards for Plan Participants who have been employed with the Company for less than one year as of December 31, 2012 may be pro-rated by the Compensation Committee, in its discretion. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Goals </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The corporate goals for 2012 were
proposed by the Company&#146;s executive officers and approved by the Board. Bonus Awards for the Company&#146;s executive officers will be based entirely upon achievement of the corporate goals. Individual objectives for Plan Participants who are
non-executive officers or director-level employees were approved by the Company&#146;s Chief Executive Officer, and individual objectives for all other Plan Participants were approved by the employees&#146; direct supervisors and the Vice President
of Human Resources. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Bonus Plan, each Plan Participant has an established target award, as set forth in the table below, representing a percentage of the Plan
Participant&#146;s annual base salary for 2012 (a &#147;Target Award&#148;). Each Bonus Award will range from 0% to 100% of a Plan Participant&#146;s Target Award (capped at 100%), thus making each Plan Participant&#146;s Target Award the maximum
Bonus Award achievable in 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:163pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012 Annual Incentive Program Target Awards</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title/Level</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Target&nbsp;Award</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(%&nbsp;of&nbsp;Base&nbsp;
Salary)</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Operating Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Director/Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20%</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Associate Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15%</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Regular Employees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5%</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonus Awards under the Bonus Plan, if any, will be determined by first establishing a bonus pool (the
&#147;Bonus Pool&#148;). The Bonus Pool will be calculated by (1) aggregating each Plan Participant&#146;s Target Award and then (2) multiplying that sum by a modifier established by the Compensation Committee that is based on the Company&#146;s
performance as measured against the 2012 corporate goals (the &#147;Corporate Performance Level&#148;). The Corporate Performance Level will range from 0% to 100%; provided, however, that if the Corporate Performance Level for 2012 falls below a
threshold of 50%, no Bonus Awards will be paid under the Bonus Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bonus Pool will then be allocated among the Plan Participants based
on each Plan Participant&#146;s title/level and salary (as reflected by their Target Award percentage) and (i) with respect to Plan Participants who are executive officers, the Corporate Performance Level, as well as each executive officer&#146;s
contributions to achievement of the 2012 corporate goals, (ii) with respect to Plan Participants who are non-executive officers or director-level employees, performance against their individual objectives for 2012 and contributions to achievement of
the 2012 corporate goals, and (ii) with respect to all other Plan Participants, performance against their individual objectives for 2012. The Compensation Committee retains the discretion under the Bonus Plan to adjust upward or downward any Bonus
Award and/or the Bonus Pool as it deems appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In December 2012, the Compensation Committee will evaluate the Company&#146;s
performance against the established corporate goals, as well as the individual performance and contributions of the Plan Participants, establish the Bonus Pool and determine the amount of the Bonus Awards, if any, to be granted under the Bonus Plan.
Any Bonus Awards granted to Plan Participants under the Bonus Plan will be made in cash and are expected to be paid in January 2013. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration; Amendment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Bonus
Plan is administered by the Compensation Committee. The Compensation Committee has full power and authority to interpret and make all decisions regarding the Bonus Plan, and its decisions and interpretations are final and binding on all Plan
Participants. The Compensation Committee or the full Board may amend the Bonus Plan in any manner at any time without the consent of any Plan Participant. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d335938dex102.htm
<DESCRIPTION>LEASE ENTERED INTO AS OF FEBRUARY 10, 2012
<TEXT>
<HTML><HEAD>
<TITLE>Lease entered into as of February 10, 2012</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Confidential Materials omitted and filed separately with the </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities and
Exchange Commission. Asterisks denote omissions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">LEASE </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">by and between </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-FRESH POND RESEARCH PARK LLC, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC., </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>LEASE </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LEASE (this &#147;<U>Lease</U>&#148;) is entered into as of this 10</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of February, 2012 (the &#147;<U>Execution Date</U>&#148;), by
and between BMR-FRESH POND RESEARCH PARK LLC, a Delaware limited liability company (&#147;<U>Landlord</U>&#148;), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation (&#147;<U>Tenant</U>&#148;). </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>RECITALS </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A. WHEREAS, Landlord owns certain real property (together with adjacent real property owned by Landlord, the &#147;<U>Property</U>&#148;) and the improvements on the Property located in Cambridge,
Massachusetts, including the building located at 665 Concord Avenue, Cambridge, Massachusetts (the &#147;<U>Building</U>&#148;) and other buildings located on such Property; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. WHEREAS, Landlord wishes to lease to Tenant, and Tenant desires to lease from Landlord, the Premises (as defined below), pursuant to
the terms and conditions of this Lease, as detailed below. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AGREEMENT </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Lease
of Premises</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1. Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the portion of the Property
on which the Building sits and all improvements and appurtenances related thereto, including the Building, as shown on <U>Exhibit A</U> attached hereto, including exclusive shafts, cable runs, mechanical spaces and rooftop areas, for use by Tenant
in accordance with the Permitted Use (as defined below) and no other uses (the &#147;<U>Premises</U>&#148;). The Property and all landscaping, parking facilities, private drives and other improvements and appurtenances related thereto, including the
Building and other buildings located on the Property, are hereinafter collectively referred to as the &#147;<U>Project</U>.&#148; All portions of the Project that are for the non-exclusive use of tenants of the Project generally, including
driveways, sidewalks, parking areas and landscaped areas, but excluding the common areas of any other building in the Project, are hereinafter referred to as &#147;<U>Common Area</U>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. <U>Basic Lease Provisions</U>. For convenience of the parties, certain basic provisions of this Lease are set forth herein. The provisions set forth herein are subject to the remaining terms and
conditions of this Lease and are to be interpreted in light of such remaining terms and conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1. This Lease shall
take effect upon the Execution Date and, except as specifically otherwise provided within this Lease, each of the provisions hereof shall be binding upon and inure to the benefit of Landlord and Tenant from the date of execution and delivery hereof
by all parties hereto. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2. In the definitions below, each current Rentable Area (as defined below) is expressed
in rentable square footage. Rentable Area and &#147;<U>Tenant&#146;s Pro Rata Shares</U>&#148; are all subject to adjustment as provided in this Lease. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:78pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition or Provision</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Means&nbsp;the&nbsp;Following&nbsp;(As&nbsp;of&nbsp;the&nbsp;Term<BR>Commencement&nbsp;Date)</B></FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximate Rentable Area of Premises</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150&nbsp;square&nbsp;feet</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximate Rentable Area of Building</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150&nbsp;square feet</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximate Rentable Area of Project</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,176&nbsp;square&nbsp;feet</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s Pro Rata Share of Building</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100%</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s Pro Rata Share of Project</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.99%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3. Initial monthly and annual installments of Base Rent for the Premises (&#147;<U>Base Rent</U>&#148;)
as of the Term Commencement Date (as defined below): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:19pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dates</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Square&nbsp;Feet&nbsp;of<BR>Rentable&nbsp;Area</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base&nbsp;Rent&nbsp;per<BR>Square&nbsp;Foot&nbsp;of<BR>Rentable&nbsp;Area</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Monthly&nbsp;Base<BR>Rent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Annual&nbsp;Base<BR>Rent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 1-3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 4-15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.00&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,400.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">484,800.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 16-27</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.96&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,612.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">499,344.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 28-39</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.95&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,861.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">514,342.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 40-51</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.97&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,149.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">529,795.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 52-63</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.02&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,475.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">545,703.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4. Estimated Term Commencement Date: June&nbsp;1, 2012 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5. Estimated Term Expiration Date: August&nbsp;31, 2017 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.6. Security Deposit: $161,600.00, subject to increase in accordance with the terms hereof </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.7. Permitted Use: Office, laboratory [**] use in conformity with all federal, state, municipal and local laws, codes, ordinances, rules and regulations of Governmental Authorities (as defined below),
committees, associations, or other regulatory committees, agencies or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
governing bodies having jurisdiction over the Premises, the Building, the Property, the Project, Landlord or Tenant, including both statutory and common law and hazardous waste rules and
regulations (&#147;<U>Applicable Laws</U>&#148;) </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8. Address for Rent Payment:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-Fresh Pond Research Park LLC</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">P.O. Box 51919, Unit E</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Los Angeles, CA 90051-6219</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9. Address for Notices to Landlord:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-Fresh Pond Research Park LLC</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">17190 Bernardo Center Drive</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Diego, California 92128</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Vice President, Real Estate Counsel</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10. Address for Notices to Tenant:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alnylam Pharmaceuticals, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">300 Third Street</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cambridge, Massachusetts 02142</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Chief Operating Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">With a copy to:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Faber Daeufer Itrato&nbsp;&amp; Cabot PC</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">950 Winter Street, Suite 4500</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waltham, Massachusetts 02451</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Brian Connelly</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11.Address for Invoices to Tenant:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alnylam Pharmaceuticals, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">300 Third Street</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cambridge, Massachusetts 02142</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Controller</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.12. The following Exhibits are attached hereto and incorporated herein by reference: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="88%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Premises</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;B</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Work Letter</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledgement of Term Commencement Date and Term Expiration Date</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant Manual</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;E</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Letter of Credit</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;F</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rules and Regulations</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;G</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shuttle Service Description</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;H</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s Personal Property</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;I</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Estoppel Certificate</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;J</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CAM Pools and Maintenance Matrix</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;K</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserved Parking</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Term</U>. The actual term of this Lease (as the same may be extended pursuant to <U>Article 42</U> hereof, and as
the same may be earlier terminated in accordance with this Lease, the &#147;<U>Term</U>&#148;) shall commence on the actual Term Commencement Date (as defined in <U>Article 4</U>) and end on the date that is sixty-three (63)&nbsp;months after the
actual Term Commencement Date (such date, the &#147;<U>Term Expiration Date</U>&#148;), subject to earlier termination of this Lease as provided herein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Possession and Commencement Date</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1. The &#147;<U>Term Commencement Date</U>&#148; shall be the earlier of (a)&nbsp;the Estimated Term Commencement Date and (b)&nbsp;the
date that the (i)&nbsp;the work to the interior of the Building described in the Work Letter (the &#147;<U>Premises Improvements</U>&#148;) and (ii)&nbsp;the base building improvements described in the Work Letter (the &#147;<U>Base Building
Improvements</U>&#148; and together with the Premises Improvements, the &#147;<U>Tenant Improvements</U>&#148;) is Substantially Complete; <U>provided</U>, however, that the Estimated Term Commencement Date shall be extended, on a day-for-day basis,
for each day of Landlord Delay (defined below). Tenant shall execute and deliver to Landlord written acknowledgment of the actual Term Commencement Date and the Term Expiration Date within ten (10)&nbsp;days after Tenant takes occupancy of the
Premises, in the form attached as <U>Exhibit C</U> hereto. Failure to execute and deliver such acknowledgment, however, shall not affect the Term Commencement Date or Landlord&#146;s or Tenant&#146;s liability hereunder. Failure by Tenant to obtain
validation by any medical review board or other similar governmental licensing of the Premises required for the Permitted Use by Tenant shall not serve to extend the Term Commencement Date. The term &#147;<U>Substantially Complete</U>&#148; or
&#147;<U>Substantial Completion</U>&#148; means that the Tenant Improvements are substantially complete in accordance with the Approved Plans (as defined in the Work Letter), except for minor punch list items. Upon Substantial Completion, Tenant
shall deliver to Landlord (i)&nbsp;a certificate of occupancy for the Premises suitable for the Permitted Use and (ii)&nbsp;a Certificate of Substantial Completion in the form of the American Institute of Architects document G704, executed by the
project architect and the general contractor. Landlord, at Tenant&#146;s sole cost and expense, agrees to provide Tenant with any reasonable assistance needed to obtain the certificate of occupancy for the Premises. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used herein, &#147;<U>Landlord Delay</U>&#148; shall mean and refer to: (a)&nbsp;delays due to the remediation of Pre-Existing
Hazardous Conditions (as defined in <U>Section&nbsp;5</U>) and (b)&nbsp;any other delay solely due to Landlord&#146;s actions or inactions. No such Landlord Delay shall be deemed to have commenced unless Landlord shall have failed to cure the same
within two business days after Landlord&#146;s receipt of written notice thereof from Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2. Tenant shall cause the
Premises Improvements to be constructed in the Premises pursuant to the Work Letter attached hereto as <U>Exhibit B</U> (the &#147;<U>Work Letter</U>&#148;) at a cost to Landlord not to exceed Five Hundred Thirty Thousand Two Hundred Fifty Dollars
($530,250) (based upon Thirty-Five Dollars ($35) per square foot of Rentable Area (as defined below)) (the &#147;<U>Premises Allowance</U>&#148;). Tenant shall cause the Base Building Improvements to be constructed in the Premises pursuant to the
Work Letter at a cost to Landlord not to exceed One Million Five Hundred Fifteen Thousand Dollars ($1,515,000) (based upon One Hundred Dollars ($100) per square foot of Rentable Area (as defined below)) (the &#147;<U>Base Building
Allowance</U>&#148;). The Premises Allowance coupled with the Base Building Allowance shall be referred to herein as the &#147;<U>TI Allowance</U>.&#148; The TI Allowance may be applied to the costs of (n)&nbsp;construction, (o)&nbsp;space planning,
architect, engineering and other related services performed by third parties unaffiliated with Tenant, (p)&nbsp;building permits and other taxes, fees, charges and levies by Governmental Authorities (as defined below) for permits or for inspections
of the Tenant Improvements, and (q)&nbsp;costs and expenses for labor, material, equipment and fixtures. In no event shall the TI </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Allowance be used for (v)&nbsp;the cost of work that is not authorized by the Approved Plans (as defined in the Work Letter) or otherwise approved in writing by Landlord, (w)&nbsp;payments to
Tenant or any affiliates of Tenant, (x)&nbsp;the purchase of any furniture, personal property or other non-building system equipment, (y)&nbsp;costs resulting from any default by Tenant of its obligations under this Lease or (z)&nbsp;costs that are
recoverable by Tenant from a third party (e.g., insurers, warrantors, or tortfeasors). Landlord shall not charge for and shall not be entitled to recover any fees or costs related to Landlord&#146;s project review of the Tenant Improvements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3. Tenant shall have until the date that is ten (10)&nbsp;months after the Execution Date, provided that such date shall be
subject to extension on a day-for-day basis for each day of Landlord Delay during such time period (the &#147;<U>TI Deadline</U>&#148;), to expend the unused portion of the TI Allowance, after which date Landlord&#146;s obligation to fund such costs
shall expire. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4. In no event shall any unused TI Allowance entitle Tenant to a credit against Rent payable under this
Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5. Prior to entering upon the Premises, Tenant shall furnish to Landlord evidence satisfactory to Landlord that
insurance coverages required of Tenant under the provisions of <U>Article 23</U> are in effect, and such entry shall be subject to all the terms and conditions of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. <U>Condition of Premises</U>. Tenant acknowledges that neither Landlord nor any agent of Landlord has made any representation or warranty with respect to the condition of the Premises or with respect
to the suitability of the Premises for the conduct of Tenant&#146;s business. Tenant acknowledges that (a)&nbsp;other than the presence of any Hazardous Materials (as defined in <U>Section&nbsp;21.9</U>) (i)&nbsp;in the Premises in violation of
Applicable Laws as of the Execution Date, (ii)&nbsp;that are not actually known to Tenant as of the Execution Date or that could not have been discovered by Tenant upon reasonable inspection prior to the Execution Date and (iii)&nbsp;that were not
placed at the Project by Tenant or its affiliates, employees, agents or contractors (collectively, &#147;<U>Pre-Existing Hazardous Conditions</U>&#148;), Tenant is fully familiar with the condition of the Premises and agrees to take the same in its
condition &#147;as is&#148; as of the Execution Date and (b)&nbsp;Landlord shall have no obligation to alter, repair or otherwise prepare the Premises for Tenant&#146;s occupancy or to pay for or construct any improvements to the Premises, except
with respect to the TI Allowance and the remediation of any Pre-Existing Hazardous Conditions as set forth in this Article. Tenant&#146;s taking of possession of the Premises shall, except as otherwise agreed to in writing by Landlord and Tenant,
conclusively establish that the Premises were at such time in good, sanitary and satisfactory condition and repair. In the event that, during the performance of the Tenant Improvements, Pre-Existing Hazardous Conditions are discovered, Tenant shall
promptly notify Landlord of such discovery and Landlord, at its sole cost and expense, shall (y)&nbsp;work with Tenant diligently and in good faith to remediate such Pre-Existing Hazardous Conditions and (z)&nbsp;indemnify and hold Tenant harmless
from any Claims resulting from the presence of Pre-Existing Hazardous Conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Rentable Area</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1. The term &#147;<U>Rentable Area</U>&#148; shall reflect such areas as reasonably calculated by Landlord&#146;s architect, as the
same may be reasonably adjusted from time to time by Landlord in consultation with Landlord&#146;s architect to reflect changes to the Premises, the Building or the Project, as applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2. The Rentable Area of the Building is generally determined by making separate
calculations of Rentable Area applicable to each floor within the Building and totaling the Rentable Area of all floors within the Building. The Rentable Area of a floor is computed by measuring to the outside finished surface of the permanent outer
Building walls. The full area calculated as previously set forth is included as Rentable Area, without deduction for columns and projections or vertical penetrations, including stairs, elevator shafts, flues, pipe shafts, vertical ducts and the
like, as well as such items&#146; enclosing walls. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3. The term &#147;<U>Rentable Area</U>,&#148; when applied to the
Premises, is that area equal to the usable area of the Premises, plus an equitable allocation of Rentable Area within the Building that is not then utilized or expected to be utilized as usable area, including that portion of the Building devoted to
corridors, equipment rooms, restrooms, elevator lobby, atrium and mailroom. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4. The Rentable Area of the Project is the
total Rentable Area of all buildings within the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5. Review of allocations of Rentable Areas as between tenants of
the Building and the Project shall be made as frequently as Landlord deems appropriate, including in order to facilitate an equitable apportionment of Operating Expenses (as defined below). If such review is by a licensed architect and allocations
are certified by such licensed architect as being correct, then Tenant shall be bound by such certifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Rent</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1. Tenant shall pay to Landlord as Base Rent for the Premises, commencing on the Term Commencement Date, the sums set forth in
<U>Section&nbsp;2.3</U>. Base Rent shall be paid in equal monthly installments as set forth in <U>Section&nbsp;2.3</U>, each in advance on the first day of each and every calendar month during the Term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2. In addition to Base Rent, Tenant shall pay to Landlord as additional rent (&#147;<U>Additional Rent</U>&#148;) at times hereinafter
specified in this Lease (a)&nbsp;Tenant&#146;s Share (as defined below) of Operating Expenses (as defined below), (b)&nbsp;the Property Management Fee (as defined below) and (c)&nbsp;any other amounts that Tenant assumes or agrees to pay under the
provisions of this Lease that are owed to Landlord, including any and all other sums that may become due by reason of any default of Tenant or failure on Tenant&#146;s part to comply with the agreements, terms, covenants and conditions of this Lease
to be performed by Tenant, after notice and the lapse of any applicable cure periods. In calculating Operating Expenses, Landlord will allocate Operating Expense items which relate solely to one building of the Project and its occupants (including,
without limitation, portions thereof dedicated to non-exclusive use by building occupants) to the specific building to which such expenses relate, as further detailed in <U>Exhibit J</U>. Any Operating Expenses which cannot be allocated solely to
one building and its occupants will be allocated on a proportionate basis (based on relative square footage) among the buildings and occupants of the Project (or those buildings to which such Operating Expense relates, and their occupants, if it is
less than the entire Project) as further detailed in <U>Exhibit J</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3. Base Rent and Additional Rent shall together be denominated &#147;<U>Rent</U>.&#148;
Rent shall be paid to Landlord, without abatement, deduction or offset, in lawful money of the United States of America at the office of Landlord as set forth in <U>Section&nbsp;2.8</U> or to such other person or at such other place as Landlord may
from time designate in writing. In the event the Term commences or ends on a day other than the first day of a calendar month, then the Rent for such fraction of a month shall be prorated for such period on the basis of a thirty (30)&nbsp;day month
and shall be paid at the then-current rate for such fractional month. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. [<U>Intentionally omitted</U>.] </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>Operating Expenses</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1. As used herein, the term &#147;<U>Operating Expenses</U>&#148; shall include: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Government impositions including property tax costs consisting of real and personal property taxes and assessments, including amounts
due under any improvement bond upon the Building or the Project, including the parcel or parcels of real property upon which the Building, other buildings in the Project and areas serving the Building and the Project are located or assessments in
lieu thereof imposed by any federal, state, regional, local or municipal governmental authority, agency or subdivision (each, a &#147;<U>Governmental Authority</U>&#148;); taxes on or measured by gross rentals received from the rental of space in
the Project; taxes based on the square footage of the Premises, the Building or the Project, as well as any parking charges, utilities surcharges or any other costs levied, assessed or imposed by, or at the direction of, or resulting from Applicable
Laws or interpretations thereof, promulgated by any Governmental Authority in connection with the use or occupancy of the Project or the parking facilities serving the Project; taxes on this transaction or any document to which Tenant is a party
creating or transferring an interest in the Premises; any fee for a business license to operate an office building; and any expenses, including the reasonable cost of attorneys or experts, reasonably incurred by Landlord in seeking reduction by the
taxing authority of the applicable taxes, less tax refunds obtained as a result of an application for review thereof. Operating Expenses shall not include any net income, franchise, capital stock, estate or inheritance taxes, or taxes that are the
personal obligation of Tenant or of another tenant of the Project, or penalties and interest incurred by reason of Landlord&#146;s failure to timely pay any taxes or other impositions of a Governmental Authority to the extent relating to a period in
which Tenant was not in default under this Lease; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) All other costs of any kind paid or incurred by Landlord in
connection with the operation or maintenance of the Building and the Project allocated as set forth in <U>Section&nbsp;7.2</U>, including costs of repairs and replacements to improvements within the Project as appropriate to maintain the Project as
required hereunder; costs of utilities furnished to the Common Areas; sewer fees; cable television; trash collection; cleaning, including windows; heating (other than for the Premises); ventilation (other than for the Premises); air-conditioning
(other than for the Premises); maintenance of landscaping and grounds; maintenance of drives and parking areas; security services and devices; building supplies; maintenance or replacement of equipment utilized for operation and maintenance of the
Project; license, permit and inspection fees; sales, use and excise taxes on goods and services purchased by Landlord in connection with the operation, maintenance or repair of the Project systems and equipment; telephone, postage, stationery
supplies and other expenses incurred in connection with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
operation, maintenance or repair of the Project; accounting, legal and other professional fees and expenses incurred in connection with the Project; costs of furniture, draperies, carpeting,
landscaping, snow removal and other customary and ordinary items of personal property provided by Landlord for use in Common Areas; capital expenditures <U>provided</U>, however, that any capital expenditures made that reduce the cost of operating
the Project shall constitute Operating Expenses in the amount over a given time period that is the greater of (i)&nbsp;the amount during such period that is generally permitted for capital expenditures as described above and (ii)&nbsp;the amount of
savings in operating the Project realized during such period as a result of such capital expenditures, in each case amortized over the useful life thereof, as reasonably determined by Landlord, in accordance with generally accepted accounting
principles not to exceed ten (10)&nbsp;years; costs of complying with Applicable Laws (except to the extent such costs are incurred to remedy non-compliance as of the Execution Date with Applicable Laws or incurred in connection with the remediation
of a Pre-Existing Hazardous Condition); costs to keep the Project in compliance with, or fees otherwise required under, any CC&amp;Rs (as defined below); costs of any shuttle services provided to the Project or other public transportation
accoutrements benefitting the Project; insurance premiums, including premiums for public liability, property casualty, earthquake, terrorism and environmental coverages; portions of insured losses paid by Landlord as part of the deductible portion
of a loss pursuant to the terms of insurance policies; service contracts; costs of services of independent contractors retained to do work of a nature referenced above; and costs of compensation (including employment taxes and fringe benefits) of
all persons to the extent such persons perform regular and recurring duties connected with the day-to-day operation and maintenance of the Project, its equipment, the adjacent walks, landscaped areas, drives and parking areas, including janitors,
floor waxers, window washers, watchmen, gardeners, sweepers, plow trucks and handymen. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Notwithstanding the foregoing,
Operating Expenses shall not include expenses directly paid for by Tenant pursuant to <U>Section&nbsp;18.2</U>; any leasing commissions; expenses that relate to preparation of rental space for a tenant; expenses of initial development and
construction, including grading, paving, landscaping and decorating (as distinguished from maintenance, repair and replacement of the foregoing); legal expenses relating to other tenants; costs of repairs to the extent reimbursed by payment of
insurance proceeds received by Landlord (or which would have been reimbursable had Landlord carried the insurance required by this Lease); principal, interest and other expenses upon loans to Landlord or secured by a mortgage or deed of trust
covering the Project or a portion thereof (<U>provided</U> that interest upon a government assessment or improvement bond payable in installments shall constitute an Operating Expense under <U>Subsection 9.1(a)</U>); salaries of executive officers
of Landlord; depreciation claimed by Landlord for tax purposes (<U>provided</U> that this exclusion of depreciation is not intended to delete from Operating Expenses actual costs of repairs and replacements and reasonable reserves in regard thereto
that are provided for in <U>Subsection 9.1(b)</U>); and taxes that are excluded from Operating Expenses by the last sentence of <U>Subsection 9.1(a)</U>. To the extent that Tenant uses more than Tenant&#146;s Pro Rata Share of any item of Operating
Expenses, Tenant shall pay Landlord for such excess in addition to Tenant&#146;s obligation to pay Tenant&#146;s Pro Rata Share of Operating Expenses (such excess, together with Tenant&#146;s Pro Rata Share, &#147;<U>Tenant&#146;s Share</U>&#148;).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2. Tenant shall pay to Landlord on the first day of each calendar month of the Term, as Additional Rent, (a)&nbsp;the
Property Management Fee (as defined below) and (b)&nbsp;Landlord&#146;s estimate of Tenant&#146;s Share of Operating Expenses with respect to the Building and the Project, as applicable, for such month. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x) The &#147;<U>Property Management Fee</U>&#148; shall equal three percent (3%)&nbsp;of
Base Rent due from Tenant. Tenant shall pay the Property Management Fee in accordance with <U>Section&nbsp;9.2</U> with respect to the entire Term, including any extensions thereof or any holdover periods, regardless of whether Tenant is obligated
to pay Base Rent, Operating Expenses or any other Rent with respect to any such period or portion thereof. For the first three (3)&nbsp;months of the Term, the Property Management Fee shall be calculated as if Tenant were paying Forty Thousand Four
Hundred Dollars ($40,400) per month for Base Rent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(y) Within ninety (90)&nbsp;days after the conclusion of each calendar
year (or such longer period as may be reasonably required by Landlord), Landlord shall furnish to Tenant a statement showing in reasonable detail the actual Operating Expenses and Tenant&#146;s Share of Operating Expenses for the previous calendar
year. Any additional sum due from Tenant to Landlord shall be due and payable within ten (10)&nbsp;days after Tenant&#146;s receipt of such statement. If the amounts paid by Tenant pursuant to this Section exceed Tenant&#146;s Share of Operating
Expenses for the previous calendar year, then Landlord shall credit the difference against the Rent next due and owing from Tenant; <U>provided</U> that, if the Lease term has expired, Landlord shall accompany said statement with payment for the
amount of such difference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(z) Any amount due under this Section for any period that is less than a full month shall be
prorated (based on a thirty (30)-day month) for such fractional month. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3. Landlord may, from time to time, modify
Landlord&#146;s calculation and allocation procedures for Operating Expenses, so long as such modifications produce Dollar results substantially consistent with Landlord&#146;s then-current practice at the Project. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4. [Intentionally omitted.] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.5. Tenant shall not be responsible for Operating Expenses attributable to the time period prior to the Term Commencement Date; <U>provided</U>, however, that if Landlord shall permit Tenant possession
of the Premises prior to the Term Commencement Date, Tenant shall be responsible for Operating Expenses from such earlier date of possession. Tenant&#146;s responsibility for Tenant&#146;s Share of Operating Expenses shall continue to the latest of
(a)&nbsp;the date of termination of the Lease, (b)&nbsp;the date Tenant has fully vacated the Premises and (c)&nbsp;if termination of the Lease is due to a default by Tenant, the date of rental commencement of a replacement tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6. Operating Expenses for the calendar year in which Tenant&#146;s obligation to share therein commences and for the calendar year in
which such obligation ceases shall be prorated on a basis reasonably determined by Landlord. Expenses such as taxes, assessments and insurance premiums that are incurred for an extended time period shall be prorated based upon the time periods to
which they apply so that the amounts attributed to the Premises relate in a reasonable manner to the time period wherein Tenant has an obligation to share in Operating Expenses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7. Within ten (10)&nbsp;business days after the end of each calendar month, Tenant shall
submit to Landlord an invoice, or, in the event an invoice is not available, an itemized list, of all costs and expenses that (a)&nbsp;Tenant has incurred (either internally or by employing third parties) during the prior month and (b)&nbsp;for
which Tenant reasonably believes it is entitled to reimbursements from Landlord pursuant to the terms of this Lease or that Tenant reasonably believes is the responsibility of Landlord pursuant to this Lease or the Work Letter. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8. In the event that the Project is less than fully occupied, Tenant acknowledges that Landlord may extrapolate Operating Expenses that
vary depending on the occupancy of the Project, as applicable, by dividing (a)&nbsp;the total cost of Operating Expenses by (b)&nbsp;the Rentable Area of the Project (as applicable) that is occupied, then multiplying (y)&nbsp;the resulting quotient
by (z)&nbsp;ninety-five percent (95%)&nbsp;of the total Rentable Area of the Project (as applicable). Tenant shall pay Tenant&#146;s Share of the product of (y)&nbsp;and (z), subject to adjustment as reasonably determined by Landlord;
<U>provided</U>, however, that Landlord shall not recover more than one hundred percent (100%)&nbsp;of Operating Expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <U>Taxes on
Tenant&#146;s Property</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1. Tenant shall pay prior to delinquency any and all taxes levied against any personal
property or trade fixtures placed by Tenant in or about the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2. If any such taxes on Tenant&#146;s personal
property or trade fixtures are levied against Landlord or Landlord&#146;s property or, if the assessed valuation of the Building, the Property or the Project is increased by inclusion therein of a value attributable to Tenant&#146;s personal
property or trade fixtures, and if Landlord, after written notice to Tenant, pays the taxes based upon any such increase in the assessed value of the Building, the Property or the Project, then Tenant shall, upon ten (10)&nbsp;days&#146; prior
written demand, repay to Landlord the taxes so paid by Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3. If any improvements in or alterations to the Premises,
whether owned by Landlord or Tenant and whether or not affixed to the real property so as to become a part thereof, are assessed for real property tax purposes at a valuation higher than the valuation at which improvements conforming to
Landlord&#146;s building standards (the &#147;<U>Building Standard</U>&#148;) in other spaces in the Building are assessed, then the real property taxes and assessments levied against Landlord or the Building, the Property or the Project by reason
of such excess assessed valuation shall be deemed to be taxes levied against personal property of Tenant and shall be governed by the provisions of <U>Section&nbsp;10.2</U>. Any such excess assessed valuation due to improvements in or alterations to
space in the Project leased by other tenants at the Project shall not be included in Operating Expenses. If the records of the County Assessor are available and sufficiently detailed to serve as a basis for determining whether said Tenant
improvements or alterations are assessed at a higher valuation than the Building Standard, then such records shall be binding on both Landlord and Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11. <U>Security Deposit</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1. Tenant shall deposit with Landlord on or
before the Execution Date the sum set forth in <U>Section&nbsp;2.6</U> (the &#147;<U>Security Deposit</U>&#148;), which sum shall be held by Landlord as security for the faithful performance by Tenant of all of the terms, covenants and conditions of
this Lease to be kept and performed by Tenant during the period commencing on the Execution Date and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ending upon the expiration or termination of Tenant&#146;s obligations under this Lease. If Tenant is in monetary default or otherwise Defaults with respect to any provision of this Lease,
including any provision relating to the payment of Rent, then Landlord may (but shall not be required to) use, apply or retain all or any part of the Security Deposit for the payment of any Rent or any other sum in default, or to compensate Landlord
for any other loss or damage that Landlord may suffer by reason of Tenant&#146;s default. If any portion of the Security Deposit is so used or applied, then Tenant shall, within ten (10)&nbsp;days following demand therefor, deposit cash with
Landlord in an amount sufficient to restore the Security Deposit to its original amount, and Tenant&#146;s failure to do so shall be a material breach of this Lease. The provisions of this Article shall survive the expiration or earlier termination
of this Lease until the later of (a)&nbsp;the date that Tenant surrenders the Premises to Landlord in the condition required under this Lease and (b)&nbsp;ninety (90)&nbsp;days after the expiration or earlier termination of this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2. In the event of bankruptcy or other debtor-creditor proceedings against Tenant, the Security Deposit shall be deemed to be applied
first to the payment of Rent and other charges due Landlord for all periods prior to the filing of such proceedings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.
Landlord may deliver to any purchaser of Landlord&#146;s interest in the Premises the funds deposited hereunder by Tenant, and thereupon Landlord shall be discharged from any further liability with respect to such deposit. This provision shall also
apply to any subsequent transfers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4. If Tenant shall fully and faithfully perform every provision of this Lease to be
performed by it, then the Security Deposit, or any balance thereof, shall be returned to Tenant (or, at Landlord&#146;s option, to the last assignee of Tenant&#146;s interest hereunder) within thirty (30)&nbsp;days after the expiration or earlier
termination of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5. If the Security Deposit shall be in cash, Landlord shall hold the Security Deposit in an
account at a banking organization selected by Landlord; <U>provided</U>, however, that Landlord shall not be required to maintain a separate account for the Security Deposit, but may intermingle it with other funds of Landlord. Landlord shall be
entitled to all interest and/or dividends, if any, accruing on the Security Deposit. Landlord shall not be required to credit Tenant with any interest for any period during which Landlord does not receive interest on the Security Deposit.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6. The Security Deposit may be in the form of cash, a letter of credit or any other security instrument acceptable to
Landlord in its sole discretion. Tenant may at any time, except when Tenant is in Default (as defined below), deliver a letter of credit (the &#147;<U>L/C Security</U>&#148;) as the entire Security Deposit, as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If Tenant elects to deliver L/C Security, then Tenant shall provide Landlord, and maintain in full force and effect throughout the
Term and until the date that is ninety (90)&nbsp;days after the then-current Term Expiration Date, a letter of credit in the form of <U>Exhibit E</U> issued by an issuer reasonably satisfactory to Landlord, in the amount of the Security Deposit,
with an initial term of at least one year. Landlord agrees that, as of the Execution Date, Cambridge Savings Bank is an acceptable issuer of the L/C Security. Landlord may require the L/C Security to be re-issued by a different issuer at any time
during the Term if Landlord reasonably believes that the issuing bank of the L/C Security is or may soon become insolvent; provided, however, Landlord shall return the existing L/C Security to the existing issuer
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
immediately upon receipt of the substitute L/C Security. If any issuer of the L/C Security shall become insolvent or placed into FDIC receivership, then Tenant shall immediately deliver to
Landlord (without the requirement of notice from Landlord) substitute L/C Security issued by an issuer reasonably satisfactory to Landlord, and otherwise conforming to the requirements set forth in this Article. As used herein with respect to the
issuer of the L/C Security, &#147;insolvent&#148; shall mean the determination of insolvency as made by such issuer&#146;s primary bank regulator (<I>i.e</I>., the state bank supervisor for state chartered banks; the OCC or OTS, respectively, for
federally chartered banks or thrifts; or the Federal Reserve for its member banks). If, at the Term Expiration Date, any Rent remains uncalculated or unpaid, then: (i)&nbsp;Landlord shall with reasonable diligence complete any necessary
calculations; (ii)&nbsp;Tenant shall extend the expiry date of such L/C Security from time to time as Landlord reasonably requires; and (iii)&nbsp;in such extended period, Landlord shall not unreasonably refuse to consent to an appropriate reduction
of the L/C Security. Tenant shall reimburse Landlord&#146;s legal costs (as estimated by Landlord&#146;s counsel) in handling Landlord&#146;s acceptance of L/C Security or its replacement or extension. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If Tenant delivers to Landlord satisfactory L/C Security in place of the entire Security Deposit, Landlord shall remit to Tenant any
cash Security Deposit Landlord previously held. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Landlord may draw upon the L/C Security, and hold and apply the proceeds
in the same manner and for the same purposes as the Security Deposit, if: (i)&nbsp;an uncured Default (as defined below) exists; (ii)&nbsp;as of the date forty-five (45)&nbsp;days before any L/C Security expires (even if such scheduled expiry date
is after the Term Expiration Date) Tenant has not delivered to Landlord an amendment or replacement for such L/C Security, reasonably satisfactory to Landlord, extending the expiry date to the earlier of (1)&nbsp;ninety (90)&nbsp;days after the
then-current Term Expiration Date or (2)&nbsp;the date one year after the then-current expiry date of the L/C Security; (iii)&nbsp;the L/C Security provides for automatic renewals, Landlord asks the issuer to confirm the current L/C Security expiry
date, and the issuer fails to do so within ten (10)&nbsp;business days; (iv)&nbsp;Tenant fails to pay (when and as Landlord reasonably requires) any bank charges for Landlord&#146;s transfer of the L/C Security; or (v)&nbsp;the issuer of the L/C
Security ceases, or announces that it will cease, to maintain an office in the city where Landlord may present drafts under the L/C Security (and fails to permit drawing upon the L/C Security by overnight courier or facsimile). This Section does not
limit any other provisions of this Lease allowing Landlord to draw the L/C Security under specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Tenant
shall not seek to enjoin, prevent, or otherwise interfere with Landlord&#146;s draw under L/C Security, even if it violates this Lease. Tenant acknowledges that the only effect of a wrongful draw would be to substitute a cash Security Deposit for
L/C Security, causing Tenant no legally recognizable damage. Landlord shall hold the proceeds of any draw in the same manner and for the same purposes as a cash Security Deposit. In the event of a wrongful draw, the parties shall cooperate to allow
Tenant to post replacement L/C Security simultaneously with the return to Tenant of the wrongfully drawn sums, and Landlord shall upon request confirm in writing to the issuer of the L/C Security that Landlord&#146;s draw was erroneous. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If Landlord transfers its interest in the Premises, then Tenant shall at Tenant&#146;s expense, within five (5)&nbsp;business days
after receiving a request from Landlord, deliver (and, if the issuer requires, Landlord shall consent to) an amendment to the L/C Security naming Landlord&#146;s grantee as substitute beneficiary. If the required Security Deposit changes while L/C
Security is in force, then Tenant shall deliver (and, if the issuer requires, Landlord shall consent to) a corresponding amendment to the L/C Security. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>Use</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1. Tenant shall use the Premises for the purpose set forth in <U>Section&nbsp;2.7</U>, and shall not use the Premises, or permit or suffer the Premises to be used, for any other purpose without
Landlord&#146;s prior written consent, which consent Landlord may withhold in its sole and absolute discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2. Tenant
shall not use or occupy the Premises in violation of Applicable Laws; zoning ordinances; or the certificate of occupancy issued for the Building or the Project, and shall, upon five (5)&nbsp;days&#146; written notice from Landlord, discontinue any
use of the Premises that is declared or claimed by any Governmental Authority having jurisdiction to be a violation of any of the above, or that in the reasonable written opinion of Landlord&#146;s legal counsel violates any of the above. Tenant
shall comply with any direction of any Governmental Authority having jurisdiction that shall, by reason of the nature of Tenant&#146;s use or occupancy of the Premises, impose any duty upon Tenant or Landlord with respect to the Premises or with
respect to the use or occupation thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3. Tenant shall not do or permit to be done anything that will invalidate or
increase the cost of any fire, environmental, extended coverage or any other insurance policy covering the Building or the Project, and shall comply with all rules, orders, regulations and requirements of the insurers of the Building and the Project
disclosed in writing to Tenant, and Tenant shall promptly, upon demand, reimburse Landlord for any additional premium charged for such policy by reason of Tenant&#146;s failure to comply with the provisions of this Article. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4. Tenant shall keep all doors opening onto public corridors closed, except when in use for ingress and egress. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5. Tenant may install additional locks, bolts or security measures reasonably necessary to properly conduct its business and
operations in the Premises, including securing the interior and exterior doors and windows of the Premises; <U>provided</U>, however, that any such locks, bolts or security measures shall be subject to Landlord&#146;s prior written consent (which
consent shall not be unreasonably withheld, conditioned or delayed). Tenant shall provide Landlord with all keys, key cards and access codes necessary to access all portions of the Premises. Tenant shall, upon termination of this Lease, return to
Landlord all keys and key cards to offices and restrooms either furnished to or otherwise procured by Tenant. In the event any key or key card so furnished to Tenant is lost, Tenant shall pay to Landlord the cost of replacing the same or of changing
the lock or locks opened by such lost key or key card if Landlord shall deem it necessary to make such change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6. No
awnings or other projections shall be attached to any outside wall of the Building without Landlord&#146;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed). No curtains, blinds, shades or screens shall
be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord&#146;s standard window coverings as set forth in the Tenant Manual (as defined in <U>Section&nbsp;13.1</U>). Neither the interior nor
exterior of any windows shall be coated or otherwise sunscreened </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
without Landlord&#146;s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed), nor shall any bottles, parcels or other articles be placed on the
windowsills. Any such window treatment shall also be subject to the requirements set forth in the Tenant Manual. For the avoidance of doubt, it shall be unreasonable for Landlord to withhold its consent to any requested awnings, blinds, shades,
screens or other window tinting or treatments if Tenant demonstrates to Landlord that such are necessary for Tenant to comply with Applicable Laws [**] required to conduct Tenant&#146;s business and operations on the Premises consistent with the
Permitted Use; provided, that any such awnings, blinds, shades, screens or other window tinting or treatments are performed in accordance with the Tenant Manual. No equipment, furniture or other items of personal property shall be placed on any
exterior balcony without Landlord&#146;s prior written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7. No sign, advertisement or notice
(&#147;<U>Signage</U>&#148;) shall be exhibited, painted or affixed by Tenant on any part of the Premises visible from outside the Premises or the Building without Landlord&#146;s prior written consent, which shall not be unreasonably withheld,
conditioned or delayed. For any Signage, Tenant shall, at Tenant&#146;s own cost and expense, (a)&nbsp;acquire all permits for such Signage in compliance with Applicable Laws and (b)&nbsp;design, fabricate, install and maintain such Signage in a
first-class condition. Tenant shall be responsible for reimbursing Landlord for costs incurred by Landlord in removing any of Tenant&#146;s Signage upon the expiration or earlier termination of the Lease. Signs on the directory tablet shall be
inscribed, painted or affixed for Tenant by Landlord at Landlord&#146;s sole cost and expense, and shall be of a size, color and type and be located in a place acceptable to Landlord. The directory tablet shall be provided exclusively for the
display of the name and location of tenants only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8. Tenant shall only place equipment within the Premises with floor
loading consistent with the Building&#146;s structural design without Landlord&#146;s prior written approval, and such equipment shall be placed in a location designed to carry the weight of such equipment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.9. Tenant shall cause any equipment or machinery to be installed in the Premises so as to reasonably prevent sounds or vibrations
therefrom from extending into the Common Areas or other offices in the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.10. Tenant shall not (a)&nbsp;do or permit
anything to be done in or about the Premises that shall in any way obstruct or interfere with the rights of other tenants or occupants of the Project, or injure or annoy them, (b)&nbsp;use or allow the Premises to be used for immoral, unlawful or
objectionable purposes, (c)&nbsp;cause, maintain or permit any nuisance or waste in, on or about the Project or (d)&nbsp;take any other action that would in Landlord&#146;s reasonable determination in any manner adversely affect other tenants&#146;
quiet use and enjoyment of their space or adversely impact their ability to conduct business in a professional and suitable work environment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.11. Notwithstanding any other provision herein to the contrary, Tenant shall be responsible for all liabilities, costs and expenses arising out of or in connection with the compliance of the Premises
with the Americans with Disabilities Act, 42 U.S.C. &#167; 12101, et seq., and any state and local accessibility laws, codes, ordinances and rules (collectively, and together with regulations promulgated pursuant thereto, the
&#147;<U>ADA</U>&#148;), and Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold Landlord and its affiliates, employees, agents and contractors; and any lender, mortgagee or
beneficiary (each, a &#147;<U>Lender</U>&#148; and, collectively with Landlord and its affiliates, employees, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
agents and contractors, the &#147;<U>Landlord Indemnitees</U>&#148;) harmless from and against any demands, claims, liabilities, losses, costs, expenses, actions, causes of action, damages or
judgments, and all reasonable expenses (including reasonable attorneys&#146; fees, charges and disbursements) incurred in investigating or resisting the same (collectively, &#147;<U>Claims</U>&#148;) arising out of any such failure of the Premises
to comply with the ADA. This Section (as well as any other provisions of this Lease dealing with indemnification of the Landlord Indemnitees by Tenant shall be deemed to be modified in each case by the insertion in the appropriate place of the
following: &#147;except as otherwise provided in Mass. G.L. Ter. Ed., C. 186, Section&nbsp;15.&#148; The indemnification provisions of this Section shall survive the expiration or earlier termination of this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.12. Tenant shall establish and maintain a chemical safety program administered by a licensed, qualified individual in accordance with
the requirements of the Massachusetts Water Resources Authority (&#147;<U>MWRA</U>&#148;) and any other applicable Governmental Authority. Tenant shall be solely responsible for all costs incurred in connection with such chemical safety program, and
Tenant shall provide Landlord with such documentation as Landlord may reasonably require evidencing Tenant&#146;s compliance with the requirements of (a)&nbsp;the MWRA and any other applicable Governmental Authority with respect to such chemical
safety program and (b)&nbsp;this Section. Tenant shall obtain and maintain during the Term (m)&nbsp;any permit required by the MWRA (&#147;<U>MWRA Permit</U>&#148;) and (n)&nbsp;a wastewater treatment operator license from the Commonwealth of
Massachusetts with respect to Tenant&#146;s use of the Acid Neutralization Tank (as defined in <U>Section&nbsp;16.7</U>) in the Building. Tenant shall not introduce anything into the Acid Neutralization Tank (x)&nbsp;in violation of the terms of the
MWRA Permit, (y)&nbsp;in violation of Applicable Laws or (z)&nbsp;that would interfere with the proper functioning of the Acid Neutralization Tank. Landlord, at Tenant&#146;s sole cost and expense, agrees to reasonably cooperate with Tenant in order
to obtain the MWRA Permit and the wastewater treatment operator license. Tenant shall be solely responsible for any costs incurred pursuant to this Section. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Rules and Regulations, CC&amp;Rs, Parking Facilities and Common Areas</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.1. Tenant shall have the non-exclusive right, in common with others, to use the Common Areas, subject to the rules and regulations adopted by Landlord and attached hereto as <U>Exhibit F</U>, together
with such other reasonable and nondiscriminatory rules and regulations as are hereafter promulgated by Landlord in its sole and absolute discretion (the &#147;<U>Rules and Regulations</U>&#148;) and the tenant manual adopted by Landlord and attached
hereto as <U>Exhibit D</U> (as such tenant manual may be modified from time to time by Landlord in its sole discretion, the &#147;<U>Tenant Manual</U>&#148;). Tenant shall faithfully observe and comply with the Rules and Regulations and the Tenant
Manual. Landlord shall not be responsible to Tenant for the violation or non-performance by any other tenant or any agent, employee or invitee thereof of any of the Rules and Regulations or the Tenant Manual. In the event of a conflict between the
Rules and Regulations, the Tenant Manual and this Lease, the terms of this Lease shall control, otherwise the most stringent provision shall control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.2. This Lease is subject to any recorded covenants, conditions or restrictions on the Project or Property (the &#147;<U>CC&amp;R</U>s&#148;), as the same may be amended, amended and restated,
supplemented or otherwise modified from time to time; <U>provided</U> that any such amendments, restatements, supplements or modifications do not materially modify Tenant&#146;s rights or obligations hereunder. Tenant shall comply with the
CC&amp;Rs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3. Except for any spaces specifically reserved to other tenants of the Project, Tenant
shall have a non-exclusive, irrevocable license to use Tenant&#146;s Pro Rata Share of parking facilities serving the Project (which, as of the Execution Date, is two and two tenths (2.2)&nbsp;spaces for each one thousand (1,000)&nbsp;square feet of
Rentable Area of the Premises) in common on an unreserved basis with other tenants of the Project during the Term. As part of such Pro Rata Share of parking facilities (and not in addition), Landlord shall designate ten (10)&nbsp;parking spaces
outside the Premises as &#147;RESERVED,&#148; as depicted on <U>Exhibit K</U>. Landlord shall have no obligation to monitor or enforce such reserved parking spaces. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.4. Tenant agrees not to unreasonably overburden the parking facilities and agrees to cooperate with Landlord and other tenants in the use of the parking facilities. Landlord reserves the right to
determine that parking facilities are becoming overcrowded and to limit Tenant&#146;s use thereof. Upon such determination, Landlord may reasonably allocate parking spaces among Tenant and other tenants of the Building or the Project. Nothing in
this Section, however, is intended to create an affirmative duty on Landlord&#146;s part to monitor parking. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5. Landlord
reserves the right to modify the Common Areas, including the right to add or remove exterior and interior landscaping and to subdivide real property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.6. Landlord shall subscribe to a shuttle service that will operate as described on <U>Exhibit G</U> attached hereto. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Project Control by Landlord</U>. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.1. Landlord reserves full control over the Building and the Project to the extent not inconsistent with Tenant&#146;s enjoyment of the Premises as provided by this Lease. This reservation includes
Landlord&#146;s right to subdivide the Project; convert the Building and other buildings within the Project to condominium units; change the size of the Project by selling all or a portion of the Project or adding real property and any improvements
thereon to the Project; grant easements and licenses to third parties; maintain or establish ownership of the Building separate from fee title to the Property; make additions to or reconstruct portions of the Building and the Project; install, use,
maintain, repair, replace and relocate for service to the Premises and other parts of the Building or the Project pipes, ducts, conduits, wires and appurtenant fixtures, wherever located in the Premises, the Building or elsewhere at the Project; and
alter or relocate any other Common Area or facility, including private drives, lobbies and entrances; <U>provided</U>, however, that Landlord&#146;s exercise of its rights under this Section shall not materially adversely affect the Permitted Use of
the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2. Possession of areas of the Premises necessary for utilities, services, safety and operation of the
Building is reserved to Landlord; <U>provided</U>, however, that Landlord&#146;s exercise of its rights under this Section shall not materially adversely affect the Permitted Use of the Premises. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3. Tenant shall, at Landlord&#146;s request, promptly execute such further documents as may be reasonably appropriate to assist
Landlord in the performance of its obligations hereunder; <U>provided</U> that Tenant need not execute any document that creates additional liability for Tenant or that deprives Tenant of the quiet enjoyment and use of the Premises as provided for
in this Lease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4. Landlord may, at any and all reasonable times during non-business hours (or during
business hours if Tenant so requests, and with respect to <U>Section&nbsp;14.4(c)</U>, if Landlord so requests), and upon twenty-four (24)&nbsp;hours&#146; prior notice (<U>provided</U> that no time restrictions shall apply or advance notice be
required if an emergency necessitates immediate entry), enter the Premises to (a)&nbsp;inspect the same and to determine whether Tenant is in compliance with its obligations hereunder, (b)&nbsp;supply any service Landlord is required to provide
hereunder, (c)&nbsp;show the Premises to prospective purchasers or tenants during the final year of the Term, (d)&nbsp;post notices of nonresponsibility, (e)&nbsp;access the telephone equipment, electrical substation and fire risers and
(f)&nbsp;alter, improve or repair any portion of the Building other than the Premises for which access to the Premises is reasonably necessary; <U>provided</U>, however, that Landlord, with respect to any portions of the Premises that are reasonably
designated by Tenant to Landlord as controlled or having restricted access, shall comply with Tenant&#146;s reasonable safety procedures and precautions related to such portions of the Premises including only entering such designated areas when
accompanied by a Tenant representative (<U>provided further</U>, that Tenant shall provide a Tenant representative to accompany Landlord upon request from Landlord twenty-four (24)&nbsp;hours&#146; in advance). Notwithstanding the foregoing, no such
access restrictions shall apply in the event of an emergency. In connection with any such alteration, improvement or repair as described in <U>Subsection 14.4(f)</U>, Landlord may erect in the Premises or elsewhere in the Project scaffolding and
other structures reasonably required for the alteration, improvement or repair work to be performed. In no event shall Tenant&#146;s Rent abate as a result of Landlord&#146;s activities pursuant to this Section; <U>provided</U>, however, that all
such activities shall be conducted in such a manner so as to cause as little interference to Tenant as is reasonably possible. Landlord shall at all times retain keys, key cards and access codes with which to unlock all of the doors in the Premises.
If an emergency necessitates immediate access to the Premises, Landlord may use whatever force is necessary to enter the Premises, and any such entry to the Premises shall not constitute a forcible or unlawful entry to the Premises, a detainer of
the Premises, or an eviction of Tenant from the Premises or any portion thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. <U>Quiet Enjoyment</U>. So long as Tenant is not in
default under this Lease, Landlord or anyone acting through or under Landlord shall not disturb Tenant&#146;s occupancy of the Premises, except as permitted by this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16. <U>Utilities and Services</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1. Tenant shall, at its sole cost and
expense, promptly and properly observe and comply with (including in the making by Tenant of any Alterations to the Premises) all present and future orders, regulations, directions, rules, laws, ordinances, and requirements of all Governmental
Authorities arising from the use or occupancy of, or applicable to, the Premises or any portion thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2. Tenant shall, at Tenant&#146;s sole cost and expense, procure and maintain contracts, with copies furnished
promptly to Landlord after execution thereof, in customary form and substance for, and with contractors specializing and experienced in, the maintenance of the following equipment and improvements, if any, if and when installed on the Premises
(a)&nbsp;HVAC equipment, (b)&nbsp;boilers and pressure vessels, (c)&nbsp;fire extinguishing systems, including fire alarm and smoke detection devices, (d)&nbsp;roof coverings and drains, (e)&nbsp;clarifiers, (f)&nbsp;basic utility feeds to the
perimeter of the Building and (g)&nbsp;any other equipment reasonably required by Landlord. In addition, no later than February&nbsp;28</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each calendar year during the Term, Tenant, at Tenant&#146;s
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
sole cost and expense, shall furnish such service contracts and the maintenance records for such equipment and improvements for the previous calendar year to Landlord for Landlord&#146;s review.
Notwithstanding anything to the contrary in this Section, Landlord reserves the right, upon notice to Tenant, to procure and maintain any or all of such service contracts, and if Landlord so elects, Tenant shall reimburse Landlord, upon demand, for
the costs thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3. Tenant shall make all arrangements for and pay for all water, electricity, air, sewer, refuse, gas,
heat, light, power (including emergency power), telephone service and any other service or utility Tenant required at the Premises. Landlord shall not be liable for, nor shall any eviction of Tenant result from, the failure to furnish any utility or
service, whether or not such failure is caused by accident; breakage; repair; strike, lockout or other labor disturbance or labor dispute of any character; act of terrorism; shortage of materials, which shortage is not unique to Landlord or Tenant,
as the case may be; governmental regulation, moratorium or other governmental action, inaction or delay; or other causes beyond Landlord&#146;s control (collectively, &#147;<U>Force Majeure</U>&#148;) or Landlord&#146;s negligence. In the event of
such failure, Tenant shall not be entitled to termination of this Lease or any abatement or reduction of Rent, nor shall Tenant be relieved from the operation of any covenant or agreement of this Lease. Notwithstanding anything to the contrary in
this Lease, if as a direct result of Landlord&#146;s gross negligence or willful misconduct, for more than seven (7)&nbsp;consecutive business days following written notice to Landlord: (a)&nbsp;HVAC or electricity services to all or a material
portion of the Premises is interrupted or is unable to support Tenant&#146;s normal occupancy requirements for the Permitted Use, or (b)&nbsp;an interruption of other essential utilities and building services, such as fire protection or water,
prevents the use or occupancy of all or a material portion of the Premises for the Permitted Use, then Tenant&#146;s Base Rent and Operating Expenses (or an equitable portion of such Base Rent and Additional Rent based on the impact of such
interruption on Tenant&#146;s business operations, to the extent that less than all of the Premises are affected) shall thereafter be abated until the Premises are again usable by Tenant for the Permitted Use; provided, however, that if Landlord is
diligently pursuing the repair of such utilities or services and Landlord provides substitute services reasonably suitable for Tenant&#146;s continued use and occupancy of the Premises for Permitted Use purposes, as for example, bringing in portable
air-conditioning equipment or potable water supplies, then there shall not be an abatement of Base Rent. In any such event, regardless of cause, Landlord shall diligently pursue the repair of such utilities and services. The foregoing provisions
shall be Tenant&#146;s sole recourse and remedy in the event of an interruption of services to the Premises caused by Landlord&#146;s gross negligence or willful misconduct. The foregoing provisions shall not apply in case of the actions of parties
other than Landlord, in the case of simple negligence of Landlord, or in the case of damage to, or destruction of, the Premises (which shall be governed by the provisions of <U>Article 24</U> of the Lease). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4. Tenant shall pay for, prior to delinquency of payment therefor, any utilities and services that may be furnished to the Premises
during the period of time commencing on the Execution Date and continuing until the expiration or earlier termination of the Term or, if Tenant occupies the Premises after the expiration or earlier termination of the Term, after the Term.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5. Tenant shall not, without Landlord&#146;s prior written consent, use any device in the Premises (including data
processing machines) that will in any way increase the amount of ventilation, air exchange, gas, steam, electricity or water beyond the existing capacity of the Building as usually furnished or supplied for the use set forth in
<U>Section&nbsp;2.7</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6. For any utilities serving the Premises for which Tenant is billed
directly by such utility provider, Tenant agrees to furnish to Landlord no later than each February&nbsp;28</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> during the Term (a)&nbsp;any invoices or statements for such utilities and (b)&nbsp;any other utility usage information reasonably requested by Landlord, each with respect to the prior calendar year.
Tenant acknowledges that any utility information for the Premises, the Building and the Project may be shared with third parties, including Landlord&#146;s consultants and Governmental Authorities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7. The Building is currently serviced by a laboratory waste sanitary sewer connection on the first (1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;floor of the Building to the municipal sewer line in the
street adjacent to the Building. As part of the Tenant Improvements, Tenant shall install a separate acid neutralization tank (the &#147;<U>Acid Neutralization Tank</U>&#148;) that is connected to the Premises. Tenant shall have the right to use the
Acid Neutralization Tank in accordance with Applicable Laws. Tenant, shall be responsible for all costs, charges and expenses incurred from time to time in connection with or arising out of the operation, use, maintenance, repair, replacement or
refurbishment of the Acid Neutralization Tank, including all clean-up costs relating to the Acid Neutralization Tank (collectively, &#147;<U>Tank Costs</U>&#148;). The operation, use, maintenance, repair, replacement or refurbishment of the Acid
Neutralization Tank shall be the sole responsibility of Tenant. Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and
all Claims, including (a)&nbsp;diminution in value of the Project or any portion thereof, (b)&nbsp;damages for the loss or restriction on use of rentable or usable space or of any amenity of the Project, (c)&nbsp;damages arising from any adverse
impact on marketing of space in the Project or any portion thereof and (d)&nbsp;sums paid in settlement of Claims that arise during or after the Term as a result of Tenant&#146;s improper use of the Acid Neutralization Tank. This indemnification by
Tenant includes costs incurred in connection with any investigation of site conditions or any clean-up, remediation, removal or restoration required by any Governmental Authority caused by Tenant&#146;s improper use of the Acid Neutralization Tank.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">17. <U>Alterations</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.1. Tenant shall make no alterations, additions or improvements in or to the Premises or engage in any construction, demolition, reconstruction, renovation, or other work (whether major or minor) of any
kind in, at, or serving the Premises (&#147;<U>Alterations</U>&#148;) without Landlord&#146;s prior written approval, which approval Landlord shall not unreasonably withhold, condition or delay; <U>provided</U>, however, that in the event any
proposed Alteration affects (a)&nbsp;any structural portions of the Building, including exterior walls, roof, foundation, foundation systems (including barriers and subslab systems), or core of the Building, (b)&nbsp;the exterior of the Building or
(c)&nbsp;any Building systems, including elevator, plumbing, air conditioning, heating, electrical, security, life safety and power, then Landlord may withhold its approval with respect thereto in its sole and absolute discretion. Tenant shall, in
making any such Alterations, use only those architects, contractors, suppliers and mechanics of which Landlord has given prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. In seeking Landlord&#146;s
approval, Tenant shall provide Landlord, at least fourteen (14)&nbsp;days in advance of any proposed construction, with plans, specifications, bid proposals, certified stamped engineering drawings and calculations by Tenant&#146;s engineer of record
or architect or record, (including connections to the Building&#146;s structural system, modifications to the Building&#146;s envelope, non-structural penetrations in slabs or walls, and modifications or tie-ins to life safety systems), work
contracts, requests for laydown areas and such other information concerning the nature and cost </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Alterations as Landlord may reasonably request; <U>provided</U>, that all such documentation shall be of a quality and to a level of detail comparable to the approved Construction Plans
(as defined in the Work Letter). In the event the proposed Alterations exceed One Hundred Twenty-Five Thousand Dollars ($125,000), the schedule, approval, design and construction of such Alterations shall further be subject to the terms and
conditions of the Work Letter. In no event shall Tenant use or Landlord be required to approve any architects, consultants, contractors, subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony.
Notwithstanding the foregoing, Tenant may make strictly cosmetic changes to the Premises (&#147;<U>Cosmetic Alterations</U>&#148;) without Landlord&#146;s consent; provided that (y)&nbsp;the cost of any Cosmetic Alterations does not exceed Ten
Thousand Dollars ($10,000) in any one instance or Fifty Thousand Dollars ($50,000) annually, (z)&nbsp;such Cosmetic Alterations do not (i)&nbsp;require any structural or other substantial modifications to the Premises, (ii)&nbsp;require any changes
to, or adversely affect, the Building systems, (iii)&nbsp;affect the exterior of the Building or (iv)&nbsp;trigger any requirement under Applicable Laws that would require Landlord to make any alteration or improvement to the Premises, the Building
or the Project. Tenant shall give Landlord at least ten (10)&nbsp;days&#146; prior written notice of any Cosmetic Alterations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2. Tenant shall not construct or permit to be constructed partitions or other obstructions that might interfere with free access to
mechanical installation or service facilities of the Building, or interfere with the moving of Landlord&#146;s equipment to or from the enclosures containing such installations or facilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3. Tenant shall accomplish any work performed on the Premises or the Building in such a manner as to permit any life safety systems to
remain fully operable at all times. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4. Any work performed on the Premises, the Building or the Project by Tenant or
Tenant&#146;s contractors shall be done at such times and in such manner as Landlord may from time to time designate. Tenant covenants and agrees that all work done by Tenant or Tenant&#146;s contractors shall be performed in full compliance with
Applicable Laws. Within thirty (30)&nbsp;days after completion of any Alterations (other than Cosmetic Alterations), Tenant shall provide Landlord with complete &#147;as-built&#148; drawing print sets, project specifications and electronic CADD
files on disc (or files in such other current format in common use as Landlord reasonably approves or requires) showing any changes in the Premises (which changes shall be overlaid on the previously existing improvements in the Premises). Further,
within thirty (30)&nbsp;days after completion of any Alterations described in <U>Sections 17.1(a)</U>, <U>17.1(b)</U> or <U>17.1(c)</U>, Tenant shall provide Landlord with any applicable inspection reports, certifications and approvals that may be
required from any Governmental Authority and any board of fire underwriters or similar body for the use and occupancy of the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.5. Before commencing any Alterations or Tenant Improvements, Tenant shall give Landlord at least fourteen (14)&nbsp;days&#146; prior written notice of the proposed commencement of such work and shall,
if required by Landlord, secure, at Tenant&#146;s own cost and expense, a completion and lien indemnity bond satisfactory to Landlord for said work. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.6. All Tenant Improvements, Alterations, Signage, attached equipment, decorations, fixtures, movable laboratory casework and related appliances, trade fixtures, additions and improvements, subject to
<U>Section&nbsp;17.8</U>, attached to or built into the Premises, made by either of the Parties, including all floor and wall coverings, built-in cabinet work and paneling, sinks and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
related plumbing fixtures, laboratory benches, exterior venting fume hoods and walk-in freezers and refrigerators, ductwork, conduits, electrical panels and circuits, shall (a)&nbsp;become the
property of Landlord upon the expiration or earlier termination of the Term and (b)&nbsp;remain upon and be surrendered with the Premises as a part thereof (unless, with respect to (a)&nbsp;and (b), Landlord elects otherwise by providing written
notice to Tenant no later than the date that is twelve (12)&nbsp;months prior to the Term Expiration Date). The Premises shall at all times remain the property of Landlord and shall be surrendered to Landlord upon the expiration or earlier
termination of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7. Tenant shall repair any damage to the Premises caused by Tenant&#146;s removal of any
property from the Premises (including Tenant&#146;s removal of items elected by Landlord in accordance with <U>Section&nbsp;17.6</U>). During any such restoration period, Tenant shall pay Rent to Landlord as provided herein as if said space were
otherwise occupied by Tenant. The provisions of this Section shall survive the expiration or earlier termination of this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.8. Except as to those items listed on <U>Exhibit H</U> attached hereto (which <U>Exhibit H</U> may be updated by Tenant from and after
the Term Commencement Date, but in each case only upon receipt of Landlord&#146;s prior written approval of such updates in accordance with the procedures set forth hereafter), all business and trade fixtures, machinery and equipment, built-in
furniture and cabinets, together with all additions and accessories thereto, installed in and upon the Premises shall be and remain the property of Landlord and shall not be moved by Tenant at any time during the Term. Following the Term
Commencement Date, and prior to the commencement of any work relating to any Alterations occurring thereafter, Tenant shall have the ability to update <U>Exhibit H</U> by submitting such updated <U>Exhibit H</U> to Landlord at least twenty
(20)&nbsp;days prior to the installation at the Premises of any items requested to be included on <U>Exhibit H</U> by Tenant. Within twenty (20)&nbsp;days of Landlord&#146;s receipt of Tenant&#146;s updated <U>Exhibit H</U>, Landlord shall notify
Tenant whether or not Landlord approved the updated <U>Exhibit H</U>. If Landlord fails to respond within such twenty (20)&nbsp;day period, Tenant shall provide a written reminder notice to Landlord. Landlord&#146;s failure to respond to such
reminder notice within ten (10)&nbsp;days after delivery of such reminder notice shall be deemed approval by Landlord of the updated <U>Exhibit H</U> as submitted to Landlord. If Tenant shall fail to remove any of its effects from the Premises prior
to termination of this Lease, then Landlord may, at its option, remove the same in any manner that Landlord shall choose and store said effects without liability to Tenant for loss thereof or damage thereto, and Tenant shall pay Landlord, upon
demand, any costs and expenses incurred due to such removal and storage or Landlord may, at its sole option and without notice to Tenant, sell such property or any portion thereof at private sale and without legal process for such price as Landlord
may obtain and apply the proceeds of such sale against any (a)&nbsp;amounts due by Tenant to Landlord under this Lease and (b)&nbsp;any expenses incident to the removal, storage and sale of said personal property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.9. Notwithstanding any other provision of this Article to the contrary, in no event shall Tenant remove any improvement from the
Premises as to which Landlord contributed payment, including the Tenant Improvements, without Landlord&#146;s prior written consent, which consent Landlord may withhold in its sole and absolute discretion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.10. In the event Tenant performs Alterations (other than Tenant Improvements) that exceed One Hundred Twenty-Five Thousand Dollars
($125,000) in any one instance, Tenant shall pay to Landlord an amount equal to five percent (5%)&nbsp;of the cost to Tenant of all changes </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
installed by Tenant or its contractors or agents to cover Landlord&#146;s overhead and expenses for plan review, coordination, scheduling and supervision thereof. For purposes of payment of such
sum, Tenant shall submit to Landlord copies of all bills, invoices and statements covering the costs of such charges, accompanied by payment to Landlord of the fee set forth in this Section. Tenant shall reimburse Landlord for any extra expenses
incurred by Landlord by reason of faulty work done by Tenant or its contractors, or by reason of delays caused by such work (other than delays caused by Landlord), or by reason of inadequate clean-up. Tenant shall not owe any review fees under this
Section for Alterations that are equal to or less than One Hundred Twenty-Five Thousand Dollars ($125,000) in any one instance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.11. Within sixty (60)&nbsp;days after final completion of the Tenant Improvements (or any other Alterations performed by Tenant with
respect to the Premises), Tenant shall submit to Landlord documentation showing the amounts expended by Tenant with respect to such Tenant Improvements (or any other Alterations performed by Tenant with respect to the Premises), together with
supporting documentation reasonably acceptable to Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.12. Tenant shall take, and shall cause its contractors to
take, commercially reasonable steps to protect the Premises during the performance of any Alterations, including covering or temporarily removing any window coverings so as to guard against dust, debris or damage. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.13. Tenant shall require its contractors and subcontractors performing work on the Premises to name Landlord and its affiliates (as
set forth in <U>Section&nbsp;23.4</U>) and Lenders as additional insureds on their respective insurance policies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">18. <U>Repairs and
Maintenance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.1. Landlord shall repair and maintain the Common Areas of the Project, including those certain portions
of the utility systems located outside the Premises to which the Premises may be connected, sidewalks, parking areas, curbs, roads, driveways, lighting standards, landscaping and snow removal. Costs incurred by Landlord pursuant to this Section
shall constitute Operating Expenses which shall be allocated in accordance with <U>Exhibit J</U>, unless such costs are incurred due in whole or in part to any act, neglect, fault or omissions of Tenant or its employees, agents, contractors or
invitees, in which case Tenant shall pay to Landlord the cost of such repairs and maintenance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.2.
Except for services of Landlord, if any, required by <U>Section&nbsp;18.1</U>, Tenant, at its sole cost and expense, shall maintain and keep the Premises, all improvements thereon, and all appurtenances thereto, including lighting standards, sewers,
water, gas and electrical distribution systems and facilities, drainage facilities, Acid Neutralization Tank, fire sprinkler systems (if any) and all signs, both illuminated and non-illuminated that are now or hereafter on the Premises, in good
condition and in a manner consistent with the Permitted Use. Tenant shall make all repairs, replacements and improvements, including all structural, roof, HVAC, plumbing and electrical repairs, replacements and improvements required, and shall keep
the same free and clear from all rubbish, debris, insects, rodents and other vermin and pests. Tenant shall, no later than December&nbsp;1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each calendar year during the Term, provide to Landlord a copy of the budget for maintenance, repairs and
replacements at the Premises for the following calendar year. Tenant shall, no later than February&nbsp;28</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> of each calendar year during the Term, provide to Landlord a detailed summary of the amounts actually expended by Tenant during the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
previous calendar year for maintenance, repairs and replacements at the Premises. All repairs made by Tenant shall be at least equal in quality to the original work, and shall be made only by a
licensed, bonded contractor approved in advance by Landlord; <U>provided</U>, however, that such contractor need not be bonded or approved by Landlord if the non-structural alterations, repairs, additions or improvements to be performed do not
exceed Twenty-Five Thousand Dollars ($25,000) in value. Landlord may impose reasonable restrictions and requirements with respect to such repairs. Tenant shall not take or omit to take any action, the taking or omission of which shall cause waste,
damage or injury to the Premises. Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold harmless Landlord from and against any and all Claims (as defined below) arising out of
the failure of Tenant or Tenant&#146;s Agents to perform the covenants contained in this paragraph. &#147;<U>Tenant&#146;s Agents</U>&#148; shall be defined to include Tenant&#146;s officers, employees, agents, contractors, invitees, customers and
subcontractors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.3. Tenant shall paint any exterior portions of the Building as necessary to maintain them in good
condition (<U>provided</U>, however, that any such exterior painting is for maintenance purposes only and Tenant shall only use the then-current Building exterior paint color(s) unless Tenant has received prior written consent from Landlord to use a
different paint color); maintain the roof in good condition; maintain sightly screens, barricades or enclosures around any waste or storage areas; and take all reasonable precautions to insure that the drainage facilities of the roof are not clogged
and are in good and operable condition at all times. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.4. There shall be no abatement of Rent and no liability of Landlord
by reason of any injury to or interference with Tenant&#146;s business arising from the making of any repairs, alterations or improvements in or to any portion of the Premises, or in or to improvements, fixtures, equipment and personal property
therein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.5. Landlord shall not be required to maintain or make any repairs or replacements of any nature or description
whatsoever to the Premises, except to the extent damage to the Premises is caused Landlord&#146;s gross negligence or willful misconduct (provided, that Landlord&#146;s actions or damages caused in response to an emergency shall never be deemed to
be gross negligence or willful misconduct). Tenant hereby expressly waives the right to make repairs at the expense of Landlord as provided for in any Applicable Laws in effect at the time of execution of this Lease, or in any other Applicable Laws
that may hereafter be enacted, and waives its rights under Applicable Laws relating to a landlord&#146;s duty to maintain its premises in a tenantable condition. Notwithstanding the foregoing, if Tenant shall fail, after reasonable notice, to
maintain or to commence and thereafter to proceed with diligence to make any repair required of it pursuant to the terms of this Lease, Landlord, without being under any obligation to do so and without thereby waiving such default by Tenant, may so
maintain or make such repair and may charge Tenant for the costs thereof. Any expense reasonably incurred by Landlord in connection with the making of such repairs may be billed by Landlord to Tenant monthly or, at Landlord&#146;s option,
immediately, and shall be due and payable within ten (10)&nbsp;days after such billing or, at Landlord&#146;s option, may be deducted from the Security Deposit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">18.6. Subject to <U>Section&nbsp;14.4</U>, Landlord and Landlord&#146;s agents shall have the right to enter upon the Premises or any portion thereof for the purposes of performing any repairs or
maintenance Landlord is permitted to make pursuant to this Lease, and of ascertaining the condition of the Premises or whether Tenant is observing and performing Tenant&#146;s obligations </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
hereunder, all without unreasonable interference from Tenant or Tenant&#146;s Agents. Except for emergency maintenance or repairs, the right of entry contained in this paragraph shall be
exercisable at reasonable times, at reasonable hours and on reasonable advance notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.7. Tenant shall, upon the
expiration or sooner termination of the Term, surrender the Premises to Landlord in as good a condition as when received, ordinary wear and tear excepted; and shall, at Landlord&#146;s request and Tenant&#146;s expense, remove all telephone and data
systems, wiring and equipment from the Premises, and repair any damage to the Premises caused thereby. Landlord shall have no obligation to alter, remodel, improve, repair, decorate or paint the Premises or any part thereof, other than pursuant to
the terms and provisions of the Work Letter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.8. This Article relates to repairs and maintenance arising in the ordinary
course of operation of the Premises and any related facilities. In the event of a casualty described in <U>Article 24</U>, <U>Article 24</U> shall apply in lieu of this Article. In the event of eminent domain, <U>Article 25</U> shall apply in lieu
of this Article. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.9. If any excavation shall be made upon land adjacent to or under the Building, or shall be authorized to
be made, upon reasonable advance notice to Tenant, and subject to the restrictions set forth in <U>Section&nbsp;14.4</U> (provided that no such restrictions shall apply in an emergency), Tenant shall afford to the person causing or authorized to
cause such excavation, license to enter the Premises for the purpose of performing such work as said person shall deem necessary or desirable to preserve and protect the Building from injury or damage and to support the same by proper foundations,
without any claim for damages or liability against Landlord and without reducing or otherwise affecting Tenant&#146;s obligations under this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">19. <U>Liens</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.1. Subject to the immediately succeeding sentence, Tenant
shall keep the Premises, the Building and the Project free from any liens arising out of work performed, materials furnished or obligations incurred by Tenant. Tenant further covenants and agrees that any mechanic&#146;s lien filed against the
Premises, the Building or the Project for work claimed to have been done for, or materials claimed to have been furnished to, shall be discharged or bonded by Tenant within ten (10)&nbsp;days after the filing thereof, at Tenant&#146;s sole cost and
expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.2. Should Tenant fail to discharge or bond against any lien of the nature described in <U>Section&nbsp;19.1</U>,
Landlord may, at Landlord&#146;s election, pay such claim or post a bond or otherwise provide security to eliminate the lien as a claim against title, and Tenant shall immediately reimburse Landlord for the costs thereof as Additional Rent. Tenant
shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any Claims arising from any such liens, including any administrative, court or
other legal proceedings related to such liens. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.3. In the event that Tenant leases or finances the acquisition of office
equipment, furnishings or other personal property of a removable nature utilized by Tenant in the operation of Tenant&#146;s business, Tenant warrants that any Uniform Commercial Code financing statement shall, upon its face or by exhibit thereto,
indicate that such financing statement is applicable only to removable personal property of Tenant located within the Premises. In no event shall the address of the Premises, the Building or the Project be furnished on a financing statement
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
without qualifying language as to applicability of the lien only to removable personal property located in an identified suite leased by Tenant. Should any holder of a financing statement record
or place of record a financing statement that appears to constitute a lien against any interest of Landlord or against equipment that may be located other than within an identified suite leased by Tenant, Tenant shall, within ten (10)&nbsp;days
after filing such financing statement, cause (a)&nbsp;a copy of the Lender security agreement or other documents to which the financing statement pertains to be furnished to Landlord to facilitate Landlord&#146;s ability to demonstrate that the lien
of such financing statement is not applicable to Landlord&#146;s interest and (b)&nbsp;Tenant&#146;s Lender to amend such financing statement and any other documents of record to clarify that any liens imposed thereby are not applicable to any
interest of Landlord in the Premises, the Building or the Project. Subject to the requirements of this Section, Landlord shall use commercially reasonable efforts to cooperate in the execution of reasonable documents relating to the leasing or
financing of Tenant&#146;s personal property that may be reasonably requested by Tenant&#146;s vendors or lenders; <U>provided</U>, however, that such documentation shall not adversely affect Landlord&#146;s rights under this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">20. <U>Estoppel Certificate</U>. Tenant shall, within ten (10)&nbsp;days of receipt of written notice from Landlord, execute, acknowledge and deliver a
statement in writing substantially in the form attached to this Lease as <U>Exhibit I</U>, or on any other form reasonably requested by a proposed Lender or purchaser, (a)&nbsp;certifying that this Lease is unmodified and in full force and effect
(or, if modified, stating the nature of such modification and certifying that this Lease as so modified is in full force and effect) and the dates to which rental and other charges are paid in advance, if any, (b)&nbsp;acknowledging that there are
not, to Tenant&#146;s knowledge, any uncured defaults on the part of Landlord hereunder, or specifying such defaults if any are claimed, and (c)&nbsp;setting forth such further information with respect to this Lease or the Premises as may be
requested thereon. Any such statement may be relied upon by any prospective purchaser or encumbrancer of all or any portion of the real property of which the Premises are a part. Tenant&#146;s failure to deliver such statement within such the
prescribed time shall, at Landlord&#146;s option, constitute a Default (as defined below) under this Lease, and, in any event, shall be binding upon Tenant that the Lease is in full force and effect and without modification except as may be
represented by Landlord in any certificate prepared by Landlord and delivered to Tenant for execution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">21. <U>Hazardous Materials</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1. Tenant shall not cause or permit any Hazardous Materials (as defined below) to be brought upon, kept or used in or
about the Premises, the Building or the Project in violation of Applicable Laws by Tenant or its employees, agents, contractors or invitees. If Tenant breaches such obligation, or if the presence of Hazardous Materials as a result of such a breach
results in contamination of the Project, any portion thereof, or any adjacent property, or if contamination of the Project, any portion thereof, or any adjacent property by Hazardous Materials otherwise occurs during the Term or any extension or
renewal hereof or holding over hereunder, then Tenant shall indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims,
including (a)&nbsp;diminution in value of the Project or any portion thereof, (b)&nbsp;damages for the loss or restriction on use of rentable or usable space or of any amenity of the Project, (c)&nbsp;damages arising from any adverse impact on
marketing of space in the Project or any portion thereof and (d)&nbsp;sums paid in settlement of Claims that arise during or after the Term as a result of such breach or contamination. This indemnification by Tenant includes costs incurred in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
connection with any investigation of site conditions or any clean-up, remedial, removal or restoration work required by any Governmental Authority because of Hazardous Materials present in the
air, soil or groundwater above, on or under or about the Project. Without limiting the foregoing, if the presence of any Hazardous Materials in, on, under or about the Project, any portion thereof or any adjacent property caused or permitted by
Tenant results in any contamination of the Project, any portion thereof or any adjacent property, then Tenant shall promptly take all actions at its sole cost and expense as are necessary to return the Project, any portion thereof or any adjacent
property to its respective condition existing prior to the time of such contamination; <U>provided</U> that Landlord&#146;s written approval of such action shall first be obtained, which approval Landlord shall not unreasonably withhold; and
<U>provided</U>, further, that it shall be reasonable for Landlord to withhold its consent if such actions could have a material adverse long-term or short-term effect on the Project, any portion thereof or any adjacent property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.2. Landlord acknowledges that it is not the intent of this Article to prohibit Tenant from operating its business for the Permitted
Use. Tenant may operate its business according to the custom of Tenant&#146;s industry so long as the use or presence of Hazardous Materials is strictly and properly monitored in accordance with Applicable Laws. As a material inducement to Landlord
to allow Tenant to use Hazardous Materials in connection with its business, Tenant agrees to deliver to Landlord prior to the Term Commencement Date a list identifying each type of Hazardous Material to be present at the Project and setting forth
any and all governmental approvals or permits required in connection with the presence of such Hazardous Material at the Project (the &#147;<U>Hazardous Materials List</U>&#148;). Tenant shall deliver to Landlord an updated Hazardous Materials List
on or prior to each annual anniversary of the Term Commencement Date and shall also deliver an updated Hazardous Materials List before any new Hazardous Materials are brought to the Project. Tenant shall deliver to Landlord true and correct copies
of the following documents (hereinafter referred to as the &#147;<U>Documents</U>&#148;) relating to the handling, storage, disposal and emission of Hazardous Materials prior to the Term Commencement Date or, if unavailable at that time,
concurrently with the receipt from or submission to any Governmental Authority: permits; approvals; reports and correspondence; storage and management plans; notices of violations of Applicable Laws; plans relating to the installation of any storage
tanks to be installed in, on, under or about the Project (<U>provided</U> that installation of storage tanks shall only be permitted after Landlord has given Tenant its written consent to do so, which consent Landlord may withhold in its sole and
absolute discretion); and all closure plans or any other documents required by any and all Governmental Authorities for any storage tanks installed in, on, under or about the Project for the closure of any such storage tanks. Tenant shall not be
required, however, to provide Landlord with any portion of the Documents containing information of a proprietary nature, which Documents, in and of themselves, do not contain a reference to any Hazardous Materials or activities related to Hazardous
Materials. If Tenant provides Landlord with Documents containing information of a proprietary nature and notifies Landlord in writing upon disclosure that such information is proprietary, Landlord shall keep the same confidential and shall not
disclose such information to any third-party, except that Landlord may disclose such information (a)&nbsp;as may be required by Applicable Laws or in any judicial proceeding (provided that prior to disclosure Landlord gives Tenant reasonable notice
of such requirement, if feasible) and (b)&nbsp;to Landlord&#146;s attorneys, accountants and other bona fide consultants or advisers who are advised of the confidential nature of such information. Landlord agrees that a breach of such
confidentiality may cause Tenant harm for which recovery of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
damages would be an inadequate remedy, and in such event, Tenant shall be entitled to obtain injunctive relief, as well as such further relief as may be granted by a court of competent
jurisdiction, but excluding special, punitive, exemplary or consequential damages. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.3. Notwithstanding the provisions of
<U>Sections 21.1</U> <U>21.2</U> or <U>21.9</U>, if (a)&nbsp;Tenant or any proposed transferee, assignee or sublessee of Tenant has been required by any prior landlord, Lender or Governmental Authority to take material remedial action in connection
with Hazardous Materials contaminating a property if the contamination resulted from such party&#146;s action or omission or use of the property in question or (b)&nbsp;any proposed transferee, assignee or sublessee is subject to a material
enforcement order issued by any Governmental Authority in connection with the use, disposal or storage of Hazardous Materials, it shall not be unreasonable for Landlord to withhold its consent to any proposed transfer, assignment or subletting (with
respect to any such matter involving a proposed transferee, assignee or sublessee). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.4. At any time, and from time to time,
prior to the expiration of the Term, Landlord shall have the right to conduct appropriate tests of the Project or any portion thereof to demonstrate that Hazardous Materials are present or that contamination has occurred due to Tenant or
Tenant&#146;s employees, agents, contractors or invitees. Tenant shall pay all reasonable costs of such tests if such tests reveal that Hazardous Materials exist at the Project in violation of this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.5. If underground or other storage tanks storing Hazardous Materials installed or utilized by Tenant are located on the Premises, or
are hereafter placed on the Premises by Tenant or by any other party if such storage tanks are utilized by Tenant, then Tenant shall monitor the storage tanks, maintain appropriate records, implement reporting procedures, properly close any
underground storage tanks, and take or cause to be taken all other steps necessary or required under the Applicable Laws. Tenant shall have no responsibility or liability for underground or other storage tanks installed by anyone other than Tenant
unless Tenant utilizes such underground or other storage tanks, in which case Tenant&#146;s responsibilities for such tanks are as set forth in this Section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.6. Tenant shall promptly report to Landlord any actual or suspected presence of mold or water intrusion at the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.7. Tenant&#146;s obligations under this Article shall survive the expiration or earlier termination of the Lease. During any period of time needed by Tenant or Landlord after the termination of this
Lease to complete the removal from the Premises of any such Hazardous Materials, Tenant shall be deemed a holdover tenant and subject to the provisions of <U>Article 27</U> below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.8. As used herein, the term &#147;<U>Hazardous Material</U>&#148; means any hazardous or toxic substance, material or waste that is or
becomes regulated by any Governmental Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.9. Notwithstanding anything to the contrary in this Lease, Landlord shall
have sole control over the equitable allocation of fire control areas (as defined in the Uniform Building Code as adopted by the city or municipality(ies) in which the Project is located (the &#147;<U>UBC</U>&#148;)) within the Project for the
storage of Hazardous Materials. Notwithstanding anything to the contrary in this Lease, the quantity of Hazardous Materials allowed by this <U>Section&nbsp;21.9</U> is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
specific to Tenant and shall not run with the Lease in the event of a Transfer (as defined in <U>Article 29</U>). In the event of a Transfer, if the use of Hazardous Materials by such new tenant
(&#147;<U>New Tenant</U>&#148;) is such that New Tenant utilizes fire control areas in the Project in excess of New Tenant&#146;s Pro Rata Share of the Building or the Project, as applicable, then New Tenant shall, at its sole cost and expense and
upon Landlord&#146;s written request, establish and maintain a separate area of the Premises classified by the UBC as an &#147;H&#148; occupancy area for the use and storage of Hazardous Materials, or take such other action as is necessary to ensure
that its share of the fire control areas of the Building and the Project is not greater than New Tenant&#146;s Pro Rata Share of the Building or the Project, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">22. <U>Odors and Exhaust</U>. Tenant acknowledges that Landlord would not enter into this Lease with Tenant unless Tenant assured Landlord that under no circumstances will any other occupants of the
Building or the Project (including persons legally present in any outdoor areas of the Project) be subjected to odors or fumes (whether or not noxious), and that the Building and the Project will not be damaged by any exhaust, in each case from
Tenant&#146;s operations. Landlord and Tenant therefore agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.1. Tenant shall not cause or permit (or conduct
any activities that would cause) any release of any odors or fumes of any kind from the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.2. If the Building has a
ventilation system that, in Landlord&#146;s judgment, is adequate, suitable, and appropriate to vent the Premises in a manner that does not release odors affecting any indoor or outdoor part of the Project, Tenant shall vent the Premises through
such system. If Landlord at any time determines that any existing ventilation system is inadequate, or if no ventilation system exists, Tenant shall in compliance with Applicable Laws vent all fumes and odors from the Premises (and remove odors from
Tenant&#146;s exhaust stream) as Landlord requires. The placement and configuration of all ventilation exhaust pipes, louvers and other equipment shall be subject to Landlord&#146;s approval. Tenant acknowledges Landlord&#146;s legitimate desire to
maintain the Project (indoor and outdoor areas) in an odor-free manner, and Landlord may require Tenant to abate and remove all odors in a manner that goes beyond the requirements of Applicable Laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.3. Tenant shall, at Tenant&#146;s sole cost and expense, provide odor eliminators and other devices (such as filters, air cleaners,
scrubbers and whatever other equipment may in Landlord&#146;s judgment be necessary or appropriate from time to time) to completely remove, eliminate and abate any odors, fumes or other substances in Tenant&#146;s exhaust stream that, in
Landlord&#146;s judgment, emanate from Tenant&#146;s Premises. Any work Tenant performs under this Section shall constitute Alterations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">22.4. Tenant&#146;s responsibility to remove, eliminate and abate odors, fumes and exhaust shall continue throughout the Term. Landlord&#146;s approval of the Tenant Improvements shall not preclude
Landlord from requiring additional measures to eliminate odors, fumes and other adverse impacts of Tenant&#146;s exhaust stream (as Landlord may designate in Landlord&#146;s discretion). Tenant shall install additional equipment as Landlord requires
from time to time under the preceding sentence. Such installations shall constitute Alterations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.5. If Tenant fails to
install satisfactory odor control equipment within ten (10)&nbsp;business days after Landlord&#146;s demand made at any time, then Landlord may, without limiting </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Landlord&#146;s other rights and remedies, require Tenant to cease and suspend any operations in the Premises that, in Landlord&#146;s determination, cause odors, fumes or exhaust. For example,
if Landlord determines that Tenant&#146;s production of a certain type of product causes odors, fumes or exhaust, and Tenant does not install satisfactory odor control equipment within ten (10)&nbsp;business days after Landlord&#146;s request, then
Landlord may require Tenant to stop producing such type of product in the Premises unless and until Tenant has installed odor control equipment satisfactory to Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">23. <U>Insurance; Waiver of Subrogation</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1. Landlord shall maintain
insurance for the Building and the Project in amounts equal to full replacement cost (exclusive of the costs of excavation, foundations and footings, and without reference to depreciation taken by Landlord upon its books or tax returns) or such
lesser coverage as Landlord may elect, <U>provided</U> that such coverage shall not be less than ninety percent (90%)&nbsp;of such full replacement cost or the amount of such insurance Landlord&#146;s Lender, if any, requires Landlord to maintain,
providing protection against any peril generally included within the classification &#147;Fire and Extended Coverage,&#148; together with insurance against sprinkler damage (if applicable), vandalism and malicious mischief. Landlord, subject to
availability thereof, shall further insure, if Landlord deems it appropriate, coverage against flood, environmental hazard, earthquake, loss or failure of building equipment, rental loss during the period of repairs or rebuilding, workmen&#146;s
compensation insurance and fidelity bonds for employees employed to perform services. Notwithstanding the foregoing, Landlord may, but shall not be deemed required to, provide insurance for any improvements installed by Tenant or that are in
addition to the standard improvements customarily furnished by Landlord, without regard to whether or not such are made a part of or are affixed to the Building. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">23.2. In addition, Landlord shall carry commercial general liability insurance with a single limit of not less than Two Million Dollars ($2,000,000) for death or bodily injury, or property damage with
respect to the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.3. Tenant shall, at its own cost and expense, procure and maintain in effect, beginning on the
Term Commencement Date or the date of occupancy, whichever occurs first, and continuing throughout the Term (and occupancy by Tenant, if any, after termination of this Lease) comprehensive public liability insurance with limits of not less than Two
Million Dollars ($2,000,000) per occurrence for death or bodily injury and for property damage with respect to the Premises (including $100,000 fire legal liability (each loss)); and pollution and environmental liability insurance covering the
environmental risks of Tenant&#146;s business with limits of not less than Three Million Dollars ($3,000,000) per occurrence and not less than Five Million Dollars ($5,000,000) in the aggregate, with respect to environmental contamination and
pollution of the Premises caused by Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.4. The insurance required to be purchased and maintained by Tenant pursuant to
this Lease shall name Landlord, BioMed Realty, L.P., BioMed Realty Trust, Inc. and their respective officers, directors, employees, agents, general partners, members, subsidiaries, affiliates and Lenders (&#147;<U>Landlord Parties</U>&#148;) as
additional insureds. Said insurance shall be with companies authorized to do business in the state in which the Project is located and having a rating of not less than policyholder rating of A and financial category rating of at least Class XII in
&#147;Best&#146;s Insurance Guide.&#148; Tenant shall obtain for Landlord from the insurance companies or cause the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
insurance companies to furnish certificates of coverage to Landlord. No such policy shall be cancelable or subject to reduction of coverage or other modification or cancellation except after
thirty (30)&nbsp;days&#146; prior written notice to Landlord from the insurer (except in the event of non-payment of premium, in which case ten (10)&nbsp;days written notice shall be given). All such policies shall be written as primary policies,
not contributing with and not in excess of the coverage that Landlord may carry. Tenant&#146;s policy may be a &#147;blanket policy&#148; that specifically provides that the amount of insurance shall not be prejudiced by other losses covered by the
policy. Tenant shall, prior to the expiration of such policies, furnish Landlord with renewals or binders. Tenant agrees that if Tenant does not take out and maintain such insurance, Landlord may (but shall not be required to) procure said insurance
on Tenant&#146;s behalf and at its cost to be paid by Tenant as Additional Rent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.5. Tenant assumes the risk of damage to
any fixtures, goods, inventory, merchandise, equipment and leasehold improvements, and Landlord shall not be liable for injury to Tenant&#146;s business or any loss of income therefrom, relative to such damage, all as more particularly set forth
within this Lease. Tenant shall, at Tenant&#146;s sole cost and expense, carry such insurance as Tenant desires for Tenant&#146;s protection with respect to personal property of Tenant or business interruption. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.6. In each instance where insurance is to name Landlord Parties as additional insureds, Tenant shall, upon Landlord&#146;s written
request, also designate and furnish certificates evidencing such Landlord Parties as additional insureds to (a)&nbsp;any Lender of Landlord holding a security interest in the Building, the Property or the Project, (b)&nbsp;the landlord under any
lease whereunder Landlord is a tenant of the Property if the interest of Landlord is or shall become that of a tenant under a ground lease rather than that of a fee owner and (c)&nbsp;any management company retained by Landlord to manage the
Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.7. Landlord and Tenant each hereby waive any and all rights of recovery against the other or against the
officers, directors, employees, agents, general partners, members, subsidiaries, affiliates and Lenders of the other on account of loss or damage occasioned by such waiving party or its property or the property of others under such waiving
party&#146;s control, in each case to the extent that such loss or damage is insured against under any fire and extended coverage insurance policy that either Landlord or Tenant may have in force at the time of such loss or damage. Such waivers
shall continue so long as their respective insurers so permit. Any termination of such a waiver shall be by written notice to the other party, containing a description of the circumstances hereinafter set forth in this Section. Landlord and Tenant,
upon obtaining the policies of insurance required or permitted under this Lease, shall give notice to the insurance carrier or carriers that the foregoing mutual waiver of subrogation is contained in this Lease. If such policies shall not be
obtainable with such waiver or shall be so obtainable only at a premium over that chargeable without such waiver, then the party seeking such policy shall notify the other of such conditions, and the party so notified shall have ten (10)&nbsp;days
thereafter to either (a)&nbsp;procure such insurance with companies reasonably satisfactory to the other party or (b)&nbsp;agree to pay such additional premium (in Tenant&#146;s case, in the proportion that the area of the Premises bears to the
insured area). If the parties do not accomplish either (a)&nbsp;or (b), then this Section shall have no effect during such time as such policies shall not be obtainable or the party in whose favor a waiver of subrogation is desired refuses to pay
the additional premium. If such policies shall at any time be unobtainable, but shall be subsequently obtainable, then neither party shall be subsequently liable for a failure to obtain such insurance until a reasonable time
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
after notification thereof by the other party. If the release of either Landlord or Tenant, as set forth in the first sentence of this Section, shall contravene Applicable Laws, then the
liability of the party in question shall be deemed not released but shall be secondary to the other party&#146;s insurer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.8. Landlord may require insurance policy limits required under this Lease to be raised to conform with requirements of Landlord&#146;s
Lender or to bring coverage limits to levels then being required of new tenants within the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">23.9. Any costs incurred
by Landlord pursuant to this Article shall constitute a portion of Operating Expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">24. <U>Damage or Destruction</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1. In the event of a partial destruction of (a)&nbsp;the Premises or (b)&nbsp;Common Areas of the Project ((a) and (b)&nbsp;together,
the &#147;<U>Affected Areas</U>&#148;) by fire or other perils covered by extended coverage insurance not exceeding twenty-five percent (25%)&nbsp;of the full insurable value thereof, and <U>provided</U> that (x)&nbsp;the damage thereto is such that
the Affected Areas may be repaired, reconstructed or restored within a period of six (6)&nbsp;months from the date of the happening of such casualty, (y)&nbsp;Landlord shall receive insurance proceeds sufficient to cover the cost of such repairs
(except for any deductible amount provided by Landlord&#146;s policy, which deductible amount, if paid by Landlord, shall constitute an Operating Expense) and (z)&nbsp;such casualty was not intentionally caused by Tenant or its employees, agents or
contractors, then Landlord shall commence and proceed diligently with the work of repair, reconstruction and restoration of the Affected Areas and this Lease shall continue in full force and effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.2. In the event of any damage to or destruction of the Building or the Project other than as described in <U>Section&nbsp;24.1</U>,
Landlord may elect to repair, reconstruct and restore the Building or the Project, as applicable, in which case this Lease shall continue in full force and effect. If Landlord elects not to repair the Building or the Project, as applicable, then
this Lease shall terminate as of the date of such damage or destruction. In the event of any damage or destruction (regardless of whether such damage falls under <U>Section&nbsp;24.1</U> or this <U>Section&nbsp;24.2</U>), if (a)&nbsp;in
Landlord&#146;s determination as set forth in the Damage Repair Estimate (defined below), the Affected Areas cannot be restored within twelve (12)&nbsp;months after the date of the Damage Repair Estimate or (b)&nbsp;the Damage Repair Estimate states
that the Affected Areas will be repaired, reconstructed or restored in a period of twelve (12)&nbsp;months or less, and subject to <U>Section&nbsp;24.6</U> and any delay caused by Tenant, the Affected Areas are not actually repaired, restored or
reconstructed within such twelve (12)&nbsp;months period, then, subject to the Damage Cure Period (as defined below), Tenant shall have the right to terminate this Lease, effective as of the date of such damage or destruction, by delivering to
Landlord its written notice of termination (a &#147;<U>Notice of Termination</U>&#148;) (y)&nbsp;with respect to <U>Section&nbsp;24.2(a)</U>, no later than fifteen (15)&nbsp;days after Landlord delivers Landlord&#146;s Damage Repair Estimate and
(z)&nbsp;with respect to <U>Section&nbsp;24.2(b)</U>, no later than fifteen (15)&nbsp;days after such twelve (12)&nbsp;month period (as may be extended pursuant to <U>Section&nbsp;24.6</U> and as a result of any other delay caused by Tenant) has
expired. If Tenant provides Landlord with a Termination Notice pursuant to <U>Section&nbsp;24.2(z)</U>, Landlord shall have an additional thirty (30)&nbsp;days (the &#147;<U>Damage Cure Period</U>&#148;) from receipt of such Termination Notice to
complete the repair, reconstruction or restoration. If Landlord does not complete such repair, reconstruction or restoration within the Damage Cure Period, then </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Tenant may terminate this Lease by giving Landlord written notice at the expiration of such Damage Cure Period. If Landlord does complete such repair, reconstruction or restoration within such
Damage Cure Period, then this Lease shall continue in full force and effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.3. As soon as reasonably practicable, but in
any event within sixty (60)&nbsp;days following the date of damage or destruction, Landlord shall notify Tenant of Landlord&#146;s good faith estimated assessment of the period of time in which the repairs will be completed (&#147;<U>Damage Repair
Estimate</U>&#148;), which assessment shall be based upon the opinion of a contractor reasonably selected by Landlord and experienced in comparable repairs of similar buildings. Additionally, Landlord shall give written notice to Tenant within sixty
(60)&nbsp;days following the date of damage or destruction of its election not to repair, reconstruct or restore the Building or the Project, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">24.4. Upon any termination of this Lease under any of the provisions of this Article, the parties shall be released thereby without further obligation to the other from the date possession of the Premises
is surrendered to Landlord, except with regard to (a)&nbsp;matters occurring prior to the damage or destruction and (b)&nbsp;provisions of this Lease that, by their express terms, survive the expiration or earlier termination hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.5. In the event of repair, reconstruction and restoration as provided in this Article, all Rent to be paid by Tenant under this Lease
shall be abated proportionately from the date of the casualty based on the extent to which Tenant&#146;s use of the Premises is impaired during the period of such repair, reconstruction or restoration, unless Landlord provides Tenant with other
space during the period of repair that, in Tenant&#146;s reasonable opinion, is suitable for the temporary conduct of Tenant&#146;s business; <U>provided</U>, however, that the amount of such abatement shall be reduced by the proceeds of business
interruption or loss of rental income insurance actually received by Tenant with respect to the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.6.
Notwithstanding anything to the contrary contained in this Article, should Landlord be delayed or prevented from completing the repair, reconstruction or restoration of the damage or destruction to the Premises after the occurrence of such damage or
destruction by Force Majeure, then the time for Landlord to commence or complete repairs shall be extended on a day-for-day basis; <U>provided</U>, however, that, at Landlord&#146;s election, Landlord shall be relieved of its obligation to make such
repair, reconstruction or restoration. In the event Landlord elects not to complete such repair, reconstruction or restoration due to such Force Majeure, then this Lease shall automatically terminate except with respect to those provisions which
survive such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.7. If Landlord is obligated to or elects to repair, reconstruct or restore as herein provided,
then Landlord shall be obligated to make such repair, reconstruction or restoration only with regard to (a)&nbsp;those portions of the Premises that were originally provided at Landlord&#146;s expense and (b)&nbsp;the Common Area portion of the
Affected Areas. The repair, reconstruction or restoration of improvements not originally provided by Landlord or at Landlord&#146;s expense shall be the obligation of Tenant. In the event Tenant has elected to upgrade certain improvements from the
Building Standard, Landlord shall, upon the need for replacement due to an insured loss, provide only the Building Standard, unless Tenant again elects to upgrade such improvements and pay any incremental costs related thereto, except to the extent
that excess insurance proceeds, if received, are adequate to provide such upgrades, in addition to providing for basic repair, reconstruction and restoration of the Premises, the Building and the Project. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.8. Notwithstanding anything to the contrary contained in this Article, Landlord shall
not have any obligation whatsoever to repair, reconstruct or restore the Premises if the damage resulting from any casualty covered under this Article occurs during the last twenty-four (24)&nbsp;months of the Term or any extension thereof, or to
the extent that insurance proceeds are not available therefor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">24.9. Landlord&#146;s obligation, should it elect or be
obligated to repair or rebuild, shall be limited to the Affected Areas. Tenant shall, at its expense, replace or fully repair all of Tenant&#146;s personal property and any Alterations installed by Tenant existing at the time of such damage or
destruction. If Affected Areas are to be repaired in accordance with the foregoing, Landlord shall make available to Tenant any portion of insurance proceeds it receives that are allocable to the Alterations constructed by Tenant pursuant to this
Lease; <U>provided</U> Tenant is not then in default under this Lease, and subject to the requirements of any Lender of Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.
<U>Eminent Domain</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.1. In the event (a)&nbsp;the whole of all Affected Areas or (b)&nbsp;such part thereof as shall
substantially interfere with Tenant&#146;s use and occupancy of the Premises for the Permitted Use shall be taken for any public or quasi-public purpose by any lawful power or authority by exercise of the right of appropriation, condemnation or
eminent domain, or sold to prevent such taking, Tenant or Landlord may terminate this Lease effective as of the date possession is required to be surrendered to said authority, except with regard to (y)&nbsp;matters occurring prior to the taking and
(z)&nbsp;provisions of this Lease that, by their express terms, survive the expiration or earlier termination hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">25.2.
In the event of a partial taking of (a)&nbsp;the Building or the Project or (b)&nbsp;drives, walkways or parking areas serving the Building or the Project for any public or quasi-public purpose by any lawful power or authority by exercise of right
of appropriation, condemnation, or eminent domain, or sold to prevent such taking, then, without regard to whether any portion of the Premises occupied by Tenant was so taken, Landlord may elect to terminate this Lease (except with regard to
(a)&nbsp;matters occurring prior to the taking and (b)&nbsp;provisions of this Lease that, by their express terms, survive the expiration or earlier termination hereof) as of such taking if such taking is, in Landlord&#146;s sole opinion, of a
material nature such as to make it uneconomical to continue use of the unappropriated portion for purposes of renting office or laboratory space. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">25.3. Tenant shall be entitled to any award that is specifically awarded as compensation for (a)&nbsp;the taking of Tenant&#146;s personal property that was installed at Tenant&#146;s expense and
(b)&nbsp;the costs of Tenant moving to a new location. Except as set forth in the previous sentence, any award for such taking shall be the property of Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">25.4. If, upon any taking of the nature described in this Article, this Lease continues in effect, then Landlord shall promptly proceed to restore the Affected Areas to substantially their same condition
prior to such partial taking. To the extent such restoration is infeasible, as determined by Landlord in its sole and absolute discretion, the Rent shall be decreased proportionately to reflect the loss of any portion of the Premises no longer
available to Tenant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">26. <U>Surrender</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">26.1. At least ten (10)&nbsp;days prior to Tenant&#146;s surrender of possession of any part of the Premises, Tenant shall provide Landlord with (a)&nbsp;a facility decommissioning and Hazardous Materials
closure plan for the Premises (&#147;<U>Exit Survey</U>&#148;) prepared by an independent third party reasonably acceptable to Landlord, (b)&nbsp;written evidence of all appropriate governmental releases obtained by Tenant in accordance with
Applicable Laws, including laws pertaining to the surrender of the Premises, and (c)&nbsp;proof that the Premises have been decommissioned in accordance with American National Standards Institute (&#147;<U>ANSI</U>&#148;) Publication Z9.11-2008
(entitled &#147;Laboratory Decommissioning&#148;) or any successor standards published by ANSI or any successor organization (or, if ANSI and its successors no longer exist, a similar entity publishing similar standards). In addition, Tenant agrees
to remain responsible after the surrender of the Premises for the remediation of any recognized environmental conditions set forth in the Exit Survey and compliance with any recommendations set forth in the Exit Survey. Tenant&#146;s obligations
under this Section shall survive the expiration or earlier termination of the Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.2. No surrender of possession of any
part of the Premises shall release Tenant from any of its obligations hereunder, unless such surrender is accepted in writing by Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">26.3. The voluntary or other surrender of this Lease by Tenant shall not effect a merger with Landlord&#146;s fee title or leasehold interest in the Premises, the Building, the Property or the Project,
unless Landlord consents in writing, and shall, at Landlord&#146;s option, operate as an assignment to Landlord of any or all subleases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">26.4. The voluntary or other surrender of any ground or other underlying lease that now exists or may hereafter be executed affecting the Building or the Project, or a mutual cancellation thereof or of
Landlord&#146;s interest therein by Landlord and its lessor shall not effect a merger with Landlord&#146;s fee title or leasehold interest in the Premises, the Building or the Property and shall, at the option of the successor to Landlord&#146;s
interest in the Building or the Project, as applicable, operate as an assignment of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">27. <U>Holding Over</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.1. If, with Landlord&#146;s prior written consent, Tenant holds possession of all or any part of the Premises after the Term, Tenant
shall become a tenant from month to month after the expiration or earlier termination of the Term, and in such case Tenant shall continue to pay (a)&nbsp;Base Rent in accordance with <U>Article 7</U> and (b)&nbsp;any amounts for which Tenant would
otherwise be liable under this Lease if the Lease were still in effect, including payments for Tenant&#146;s Share of Operating Expenses. Any such month-to-month tenancy shall be subject to every other term, covenant and agreement contained herein.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.2. Notwithstanding the foregoing, if Tenant remains in possession of the Premises after the expiration or earlier
termination of the Term without Landlord&#146;s prior written consent, (a)&nbsp;Tenant shall become a tenant at sufferance subject to the terms and conditions of this Lease, except that the monthly rent shall be equal to one hundred fifty percent
(150%)&nbsp;of the Rent in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
effect during the last thirty (30)&nbsp;days of the Term, and (b)&nbsp;Tenant shall be liable to Landlord for any and all damages suffered by Landlord as a result of such holdover, including any
lost rent or consequential, special and indirect damages. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.3. Acceptance by Landlord of Rent after the expiration or
earlier termination of the Term shall not result in an extension, renewal or reinstatement of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.4. The foregoing
provisions of this Article are in addition to and do not affect Landlord&#146;s right of reentry or any other rights of Landlord hereunder or as otherwise provided by Applicable Laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">28. <U>Indemnification and Exculpation</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.1. Tenant agrees to indemnify,
save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims arising from injury or death to any person or damage to any property occurring
within or about the Premises, the Building, the Property or the Project arising directly or indirectly out of Tenant&#146;s or Tenant&#146;s employees&#146;, agents&#146;, contractors&#146; or invitees&#146; use or occupancy of the Premises or a
breach or default by Tenant in the performance of any of its obligations hereunder, except to the extent caused by Landlord&#146;s negligence or willful misconduct. Subject to <U>Sections 23.7</U>, <U>28.2</U> and <U>31.12</U> and any subrogation
provisions contained in the Work Letter, Landlord agrees to indemnify, save, defend (at Tenant&#146;s option and with counsel reasonably acceptable to Tenant) and hold Tenant and its employees, agents and contractors harmless from and against any
and all Claims arising from injury or death to any person or damage to any property occurring within or about the Premises, the Building, the Property or the Project arising out of Landlord&#146;s gross negligence or willful misconduct. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.2. Notwithstanding anything in this Lease to the contrary, Landlord shall not be liable to Tenant for, and Tenant assumes all risk of,
damage to (a)&nbsp;personal property or scientific research, including loss of records kept by Tenant within the Premises and (b)&nbsp;damage or losses caused by fire, electrical malfunction, gas explosion or water damage of any type (including
broken water lines, malfunctioning fire sprinkler systems, roof leaks or stoppages of lines), unless, (y)&nbsp;with respect to (a)&nbsp;and (b), any such loss is due to Landlord&#146;s willful disregard of written notice by Tenant of need for a
repair that Landlord is responsible to make for an unreasonable period of time or (z)&nbsp;with respect to (a), such damage is caused solely by Landlord&#146;s gross negligence or willful misconduct; <U>provided</U>, however, that in no event shall
Landlord&#146;s liability exceed the amount of insurance proceeds received by Landlord from policies that Landlord is required to carry pursuant to this Lease. Tenant further waives any claim for injury to Tenant&#146;s business or loss of income
relating to any such damage or destruction of personal property as described in this Section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.3. Landlord shall not be
liable for any damages arising from any act, omission or neglect of any other tenant in the Building or the Project, or of any other third party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">28.4. Tenant acknowledges that security devices and services, if any, while intended to deter crime, may not in given instances prevent theft or other criminal acts. Landlord shall not be liable for
injuries or losses caused by criminal acts of third parties, and Tenant assumes the risk that any security device or service may malfunction or otherwise be circumvented by a criminal. If Tenant desires protection against such criminal acts, then
Tenant shall, at Tenant&#146;s sole cost and expense, obtain appropriate insurance coverage. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">28.5. The provisions of this Article shall survive the expiration or earlier termination of
this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">29. <U>Assignment or Subletting</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">29.1. Except as hereinafter expressly permitted, Tenant shall not, either voluntarily or by operation of Applicable Laws, directly or indirectly sell, hypothecate, assign, pledge, encumber or otherwise
transfer this Lease, or sublet the Premises (each, a &#147;<U>Transfer</U>&#148;), without Landlord&#146;s prior written consent. Notwithstanding the foregoing, Tenant shall have the right to Transfer without Landlord&#146;s prior written consent
the Premises or any part thereof to (a)&nbsp;any person that as of the date of determination and at all times thereafter directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Tenant
(&#147;<U>Tenant&#146;s Affiliate</U>&#148;) or (b)&nbsp;any entity that succeeds to Tenant&#146;s interest in this Lease by reason of merger, sale or acquisition (whereby the sale or acquisition consists of all or substantially all of Tenant&#146;s
stock and assets) or consolidation (&#147;<U>Tenant&#146;s Successor</U>&#148;), <U>provided</U> that Tenant shall notify Landlord in writing at least ten (10)&nbsp;days prior to the effectiveness of such Transfer to Tenant&#146;s Affiliate or
Tenant&#146;s Successor (each, an &#147;<U>Exempt Transfer</U>&#148;) and otherwise comply with the requirements of this Lease regarding such Transfer. For purposes of this Article, &#147;control&#148; requires both (y)&nbsp;owning (directly or
indirectly) more than fifty percent (50%)&nbsp;of the stock or other equity interests of another person and (z)&nbsp;possessing, directly or indirectly, the power to direct or cause the direction of the management and policies of such person. The
routine issuance or transfer of non-controlling interests of equity in Tenant over a public stock exchange (<U>provided</U> that such issuance or transfer is in no way related to a change in control of Tenant) shall not be deemed a Transfer. In no
event shall Tenant perform a Transfer to or with an entity that is a tenant at the Project or that is in discussions or negotiations (or has been in discussions or negotiations within the last three (3)&nbsp;months of the then-current time) with
Landlord or an affiliate of Landlord to lease premises at the Project or a property owned by Landlord or an affiliate of Landlord in the West-Cambridge submarket. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">29.2. In the event Tenant desires to effect a Transfer, then, at least thirty (30)&nbsp;but not more than ninety (90)&nbsp;days prior to the date when Tenant desires the assignment or sublease to be
effective (the &#147;<U>Transfer Date</U>&#148;), Tenant shall provide written notice to Landlord (the &#147;<U>Transfer Notice</U>&#148;) containing information (including references) concerning the character of the proposed transferee, assignee or
sublessee; the Transfer Date; any ownership or commercial relationship between Tenant and the proposed transferee, assignee or sublessee; and the consideration and all other material terms and conditions of the proposed Transfer, all in such detail
as Landlord shall reasonably require. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.3. Landlord, in determining whether consent should be given to a proposed Transfer,
may give consideration to (a)&nbsp;the financial strength of such transferee, assignee or sublessee (notwithstanding Tenant remaining liable for Tenant&#146;s performance), (b)&nbsp;any change in use that such transferee, assignee or sublessee
proposes to make in the use of the Premises and (c)&nbsp;Landlord&#146;s desire to exercise its rights under <U>Section&nbsp;29.8</U> to cancel this Lease. In no event shall Landlord be deemed to be unreasonable for declining to consent to a
Transfer to a transferee, assignee or sublessee of poor reputation, lacking financial qualifications or seeking a change in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Permitted Use, or jeopardizing directly or indirectly the status of Landlord or any of Landlord&#146;s affiliates as a Real Estate Investment Trust under the Internal Revenue Code of 1986 (as
the same may be amended from time to time, the &#147;<U>Revenue Code</U>&#148;). Notwithstanding anything contained in this Lease to the contrary, (w)&nbsp;no Transfer shall be consummated on any basis such that the rental or other amounts to be
paid by the occupant, assignee, manager or other transferee thereunder would be based, in whole or in part, on the income or profits derived by the business activities of such occupant, assignee, manager or other transferee; (x)&nbsp;Tenant shall
not furnish or render any services to an occupant, assignee, manager or other transferee with respect to whom transfer consideration is required to be paid, or manage or operate the Premises or any capital additions so transferred, with respect to
which transfer consideration is being paid; (y)&nbsp;Tenant shall not consummate a Transfer with any person in which Landlord owns an interest, directly or indirectly (by applying constructive ownership rules set forth in Section&nbsp;856(d)(5) of
the Revenue Code); and (z)&nbsp;Tenant shall not consummate a Transfer with any person or in any manner that could cause any portion of the amounts received by Landlord pursuant to this Lease or any sublease, license or other arrangement for the
right to use, occupy or possess any portion of the Premises to fail to qualify as &#147;rents from real property&#148; within the meaning of Section&nbsp;856(d) of the Revenue Code, or any similar or successor provision thereto or which could cause
any other income of Landlord to fail to qualify as income described in Section&nbsp;856(c)(2) of the Revenue Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.4. As
conditions precedent to Tenant making an Exempt Transfer, subleasing the Premises or to Landlord considering a request by Tenant to Tenant&#146;s transfer of rights or sharing of the Premises, Landlord may require any or all of the following:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Tenant shall remain fully liable under this Lease during the unexpired Term; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Tenant shall provide Landlord with evidence reasonably satisfactory to Landlord that the value of Landlord&#146;s interest under this
Lease shall not be diminished or reduced by the proposed Transfer. Such evidence shall include evidence respecting the relevant business experience and financial responsibility and status of the proposed transferee, assignee or sublessee;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Tenant shall reimburse Landlord for Landlord&#146;s actual costs and expenses, including reasonable attorneys&#146; fees,
charges and disbursements incurred in connection with the review, processing and documentation of such request; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If
Tenant&#146;s transfer of rights or sharing of the Premises provides for the receipt by, on behalf of or on account of Tenant of any consideration of any kind whatsoever (including a premium rental for a sublease or lump sum payment for an
assignment, but excluding Tenant&#146;s reasonable costs in marketing and subleasing the Premises) in excess of the rental and other charges due to Landlord under this Lease, Tenant shall pay fifty percent (50%)&nbsp;of all of such excess to
Landlord, after making deductions for any reasonable marketing expenses, tenant improvement funds expended by Tenant, alterations, cash concessions, brokerage commissions, attorneys&#146; fees and free rent actually paid by Tenant. If said
consideration consists of cash paid to Tenant, payment to Landlord shall be made upon receipt by Tenant of such cash payment; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The proposed transferee, assignee or sublessee shall agree that, in the event Landlord
gives such proposed transferee, assignee or sublessee notice that Tenant is in default under this Lease, such proposed transferee, assignee or sublessee shall thereafter make all payments otherwise due Tenant directly to Landlord, which payments
shall be received by Landlord without any liability being incurred by Landlord, except to credit such payment against those due by Tenant under this Lease, and any such proposed transferee, assignee or sublessee shall agree to attorn to Landlord or
its successors and assigns should this Lease be terminated for any reason; <U>provided</U>, however, that in no event shall Landlord or its Lenders, successors or assigns be obligated to accept such attornment; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Landlord&#146;s consent to any such Transfer shall be effected on Landlord&#146;s forms; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Tenant shall not then be in default hereunder in any respect; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) Such proposed transferee, assignee or sublessee&#146;s use of the Premises shall be the same as the Permitted Use; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Landlord shall not be bound by any provision of any agreement pertaining to the Transfer, except for Landlord&#146;s written consent
to the same; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) Tenant shall pay all transfer and other taxes (including interest and penalties) assessed or payable for any
Transfer; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) Landlord&#146;s consent (or waiver of its rights) for any Transfer shall not waive Landlord&#146;s right to
consent to any later Transfer; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) Tenant shall deliver to Landlord one executed copy of any and all written instruments
evidencing or relating to the Transfer; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) A list of Hazardous Materials (as defined in <U>Section&nbsp;21.7</U>),
certified by the proposed transferee, assignee or sublessee to be true and correct, that the proposed transferee, assignee or sublessee intends to use or store in the Premises. Additionally, Tenant shall deliver to Landlord, on or before the date
any proposed transferee, assignee or sublessee takes occupancy of the Premises, all of the items relating to Hazardous Materials of such proposed transferee, assignee or sublessee as described in <U>Section&nbsp;21.2</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.5. Any Transfer that is not in compliance with the provisions of this Article shall be void and shall, at the option of Landlord,
terminate this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.6. The consent by Landlord to a Transfer shall not relieve Tenant or proposed transferee, assignee
or sublessee from obtaining Landlord&#146;s consent to any further Transfer, nor shall it release Tenant or any proposed transferee, assignee or sublessee of Tenant from full and primary liability under this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.7. Notwithstanding any Transfer, Tenant shall remain fully and primarily liable for the payment of all Rent and other sums due or to
become due hereunder, and for the full performance of all other terms, conditions and covenants to be kept and performed by Tenant. The acceptance of Rent or any other sum due hereunder, or the acceptance of performance of any other term, covenant
or condition thereof, from any person or entity other than Tenant shall not be deemed a waiver of any of the provisions of this Lease or a consent to any Transfer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.8. If Tenant delivers to Landlord a Transfer Notice indicating a desire to transfer this
Lease to a proposed transferee, assignee or sublessee other than as provided within <U>Section&nbsp;29.4</U>, then Landlord shall have the option, exercisable by giving notice to Tenant at any time within ten (10)&nbsp;days after Landlord&#146;s
receipt of such Transfer Notice, to terminate this Lease as of the date specified in the Transfer Notice as the Transfer Date, except for those provisions that, by their express terms, survive the expiration or earlier termination hereof. If
Landlord exercises such option, then Tenant shall have the right to withdraw such Transfer Notice by delivering to Landlord written notice of such election within five (5)&nbsp;days after Landlord&#146;s delivery of notice electing to exercise
Landlord&#146;s option to terminate this Lease. In the event Tenant withdraws the Transfer Notice as provided in this Section, this Lease shall continue in full force and effect. No failure of Landlord to exercise its option to terminate this Lease
shall be deemed to be Landlord&#146;s consent to a proposed Transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">29.9. If Tenant sublets the Premises or any portion
thereof, Tenant hereby immediately and irrevocably assigns to Landlord, as security for Tenant&#146;s obligations under this Lease, all rent from any such subletting, and appoints Landlord as assignee and attorney-in-fact for Tenant, and Landlord
(or a receiver for Tenant appointed on Landlord&#146;s application) may collect such rent and apply it toward Tenant&#146;s obligations under this Lease; <U>provided</U> that, until the occurrence of a Default (as defined below) by Tenant, Tenant
shall have the right to collect such rent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">30. <U>Subordination and Attornment</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.1. This Lease shall be subject and subordinate to the lien of any mortgage, deed of trust, or lease in which Landlord is tenant now or
hereafter in force against the Building or the Project and to all advances made or hereafter to be made upon the security thereof without the necessity of the execution and delivery of any further instruments on the part of Tenant to effectuate such
subordination; <U>provided</U> that, the subordination to future mortgages, deeds of trust or leases shall be conditioned upon Tenant&#146;s receipt of a commercially reasonable non-disturbance agreement from such future lenders or ground lessors of
the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.2. Notwithstanding the foregoing, Tenant shall execute and deliver upon demand such further instrument or
instruments evidencing such subordination of this Lease to the lien of any such mortgage or mortgages or deeds of trust or lease in which Landlord is tenant as may be required by Landlord. If any such mortgagee, beneficiary or landlord under a lease
wherein Landlord is tenant (each, a &#147;<U>Mortgagee</U>&#148;) so elects, however, this Lease shall be deemed prior in lien to any such lease, mortgage, or deed of trust upon or including the Premises regardless of date and Tenant shall execute a
statement in writing to such effect at Landlord&#146;s request. If Tenant fails to execute any document required from Tenant under this Section within ten (10)&nbsp;business days after written request therefor, Tenant hereby constitutes and appoints
Landlord or its special attorney-in-fact to execute and deliver any such document or documents in the name of Tenant. Such power is coupled with an interest and is irrevocable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.3. Upon written request of Landlord and opportunity for Tenant to review, Tenant agrees to execute any Lease amendments not materially
altering the terms of this Lease </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(including increasing Rent or modifying the Term), if required by a mortgagee or beneficiary of a deed of trust encumbering real property of which the Premises constitute a part incident to the
financing of the real property of which the Premises constitute a part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.4. In the event any proceedings are brought for
foreclosure, or in the event of the exercise of the power of sale under any mortgage or deed of trust made by Landlord covering the Premises, Tenant shall at the election of the purchaser at such foreclosure or sale attorn to the purchaser upon any
such foreclosure or sale and recognize such purchaser as Landlord under this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.5. Upon request by Tenant and at
Tenant&#146;s sole cost, Landlord shall endeavor to provide a non-disturbance agreement from all future lenders and ground lessors of the Project on a form to be reasonably agreed upon by Tenant. Landlord currently does not have a lender on the
Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">31. <U>Defaults and Remedies</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">31.1. Late payment by Tenant to Landlord of Rent and other sums due shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult and
impracticable to ascertain. Such costs include processing and accounting charges and late charges that may be imposed on Landlord by the terms of any mortgage or trust deed covering the Premises. Therefore, if any installment of Rent due from Tenant
is not received by Landlord within three (3)&nbsp;days after the date such payment is due, Tenant shall pay to Landlord (a)&nbsp;an additional sum of six percent (6%)&nbsp;of the overdue Rent as a late charge plus (b)&nbsp;interest at an annual rate
(the &#147;<U>Default Rate</U>&#148;) equal to the lesser of (a)&nbsp;twelve percent (12%)&nbsp;and (b)&nbsp;the highest rate permitted by Applicable Laws. The parties agree that this late charge represents a fair and reasonable estimate of the
costs that Landlord shall incur by reason of late payment by Tenant and shall be payable as Additional Rent to Landlord due with the next installment of Rent or within five (5)&nbsp;business days after Landlord&#146;s demand, whichever is earlier.
Landlord&#146;s acceptance of any Additional Rent (including a late charge or any other amount hereunder) shall not be deemed an extension of the date that Rent is due or prevent Landlord from pursuing any other rights or remedies under this Lease,
at law or in equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.2. No payment by Tenant or receipt by Landlord of a lesser amount than the Rent payment herein
stipulated shall be deemed to be other than on account of the Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check
or payment without prejudice to Landlord&#146;s right to recover the balance of such Rent or pursue any other remedy provided in this Lease or in equity or at law. If a dispute shall arise as to any amount or sum of money to be paid by Tenant to
Landlord hereunder, Tenant shall have the right to make payment &#147;under protest,&#148; such payment shall not be regarded as a voluntary payment, and there shall survive the right on the part of Tenant to institute suit for recovery of the
payment paid under protest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.3. If Tenant fails to pay any sum of money required to be paid by it hereunder, or shall fail
to perform any other act on its part to be performed hereunder, in each case within the applicable cure period (if any) described in <U>Section&nbsp;31.4</U>, then Landlord may, without waiving or releasing Tenant from any obligations of Tenant, but
shall not be obligated to, make such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
payment or perform such act; <U>provided</U> that such failure by Tenant unreasonably interfered with the use of the Building or the Project by any other tenant or with the efficient operation of
the Building or the Project, or resulted or could have resulted in a violation of Applicable Laws or the cancellation of an insurance policy maintained by Landlord. Notwithstanding the foregoing, in the event of an emergency, Landlord shall have the
right to enter the Premises and act in accordance with its rights as provided elsewhere in this Lease. In addition to the late charge described in <U>Section&nbsp;31.1</U>, Tenant shall pay to Landlord as Additional Rent all sums so paid or incurred
by Landlord, together with interest at the Default Rate, computed from the date such sums were paid or incurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.4. The
occurrence of any one or more of the following events shall constitute a &#147;<U>Default</U>&#148; hereunder by Tenant: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
Tenant abandons the Premises; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Tenant fails to make any payment of Rent, as and when due, or to satisfy its obligations
under <U>Article 19</U>, where such failure shall continue for a period of three (3)&nbsp;days after written notice thereof from Landlord to Tenant; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Tenant fails to observe or perform any obligation or covenant contained herein (other than described in <U>Subsections 31.4(a)</U> and <U>31.4(b)</U>) to be performed by Tenant, where such failure
continues for a period of ten (10)&nbsp;days after written notice thereof from Landlord to Tenant; <U>provided</U> that, if the nature of Tenant&#146;s default is such that it reasonably requires more than ten (10)&nbsp;days to cure, Tenant shall
not be deemed to be in Default if Tenant commences such cure within said ten (10)&nbsp;day period and thereafter diligently prosecute the same to completion; and <U>provided</U>, further, that such cure is completed no later than sixty
(60)&nbsp;days after Tenant&#146;s receipt of written notice from Landlord; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Tenant makes an assignment for the benefit of
creditors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) A receiver, trustee or custodian is appointed to or does take title, possession or control of all or
substantially all of Tenant&#146;s assets; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Tenant files a voluntary petition under the United States Bankruptcy Code or
any successor statute (as the same may be amended from time to time, the &#147;<U>Bankruptcy Code</U>&#148;) or an order for relief is entered against Tenant pursuant to a voluntary or involuntary proceeding commenced under any chapter of the
Bankruptcy Code; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Any involuntary petition is filed against Tenant under any chapter of the Bankruptcy Code and is not
dismissed within one hundred twenty (120)&nbsp;days; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) Tenant fails to deliver an estoppel certificate in accordance with
<U>Article 20</U>; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Tenant&#146;s interest in this Lease is attached, executed upon or otherwise judicially seized and
such action is not released within one hundred twenty (120)&nbsp;days of the action. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notices given under this Section shall specify the alleged default and shall demand that
Tenant perform the provisions of this Lease or pay the Rent that is in arrears, as the case may be, within the applicable period of time, or quit the Premises. No such notice shall be deemed a forfeiture or a termination of this Lease unless
Landlord elects otherwise in such notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.5. In the event of a Default by Tenant, and at any time thereafter, with or
without notice or demand and without limiting Landlord in the exercise of any right or remedy that Landlord may have, Landlord has the right to do any or all of the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Halt any Tenant Improvements and Alterations and order Tenant&#146;s contractors, subcontractors, consultants, designers and material suppliers to stop work; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Terminate Tenant&#146;s right to possession of the Premises by written notice to Tenant or by any lawful means, in which case Tenant
shall immediately surrender possession of the Premises to Landlord. In such event, Landlord shall have the immediate right to re-enter and remove all persons and property, and such property may be removed and stored in a public warehouse or
elsewhere at the cost and for the account of Tenant, all without service of notice or resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Terminate this Lease, in which event Tenant shall immediately surrender possession of the Premises to Landlord. In such event,
Landlord shall have the immediate right to re-enter and remove all persons and property, and such property may be removed and stored in a public warehouse or elsewhere at the cost and for the account of Tenant, all without service of notice or
resort to legal process and without being deemed guilty of trespass or becoming liable for any loss or damage that may be occasioned thereby. In the event that Landlord shall elect to so terminate this Lease, then Landlord shall be entitled to
recover from Tenant all damages incurred by Landlord by reason of Tenant&#146;s default, including: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The worth at the
time of award of any unpaid Rent that had accrued at the time of such termination; plus </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The worth at the time of award
of the amount by which the unpaid Rent that would have accrued during the period commencing with termination of the Lease and ending at the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant
proves to Landlord&#146;s reasonable satisfaction could have been reasonably avoided; plus </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The worth at the time of
award of the amount by which the unpaid Rent for the balance of the Term after the time of award exceeds that portion of the loss of Landlord&#146;s rental income from the Premises that Tenant proves to Landlord&#146;s reasonable satisfaction could
have been reasonably avoided; plus </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Any other amount necessary to compensate Landlord for all the detriment caused by
Tenant&#146;s failure to perform its obligations under this Lease or that in the ordinary course of things would be likely to result therefrom, including the cost of restoring the Premises to the condition required under the terms of this Lease,
including any rent payments not otherwise chargeable to Tenant (e.g., during any &#147;free&#148; rent period or rent holiday); plus </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) At Landlord&#146;s election, such other amounts in addition to or in lieu of the
foregoing as may be permitted from time to time by Applicable Laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in <U>Subsections 31.5(c)(i)</U> and <U>31.5(c)(ii)</U>,
&#147;worth at the time of award&#148; shall be computed by allowing interest at the Default Rate. As used in <U>Subsection 31.5(c)(iii)</U>, the &#147;worth at the time of the award&#148; shall be computed by taking the present value of such
amount, using the discount rate of the Federal Reserve Bank of San Francisco at the time of the award plus one (1)&nbsp;percentage point. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">31.6. In addition to any other remedies available to Landlord at law or in equity and under this Lease, Landlord may continue this Lease in effect after Tenant&#146;s Default and abandonment and recover
Rent as it becomes due. In addition, Landlord shall not be liable in any way whatsoever for its failure or refusal to relet the Premises. For purposes of this Section, the following acts by Landlord will not constitute the termination of
Tenant&#146;s right to possession of the Premises: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Acts of maintenance or preservation or efforts to relet the Premises,
including alterations, remodeling, redecorating, repairs, replacements or painting as Landlord shall consider advisable for the purpose of reletting the Premises or any part thereof; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The appointment of a receiver upon the initiative of Landlord to protect Landlord&#146;s interest under this Lease or in the
Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, in the event of a Default by Tenant, Landlord may elect at any time to terminate this Lease and to
recover damages to which Landlord is entitled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.7. If Landlord does not elect to terminate this Lease as provided in
<U>Section&nbsp;31.5</U>, then Landlord may, from time to time, recover all Rent as it becomes due under this Lease. At any time thereafter, Landlord may elect to terminate this Lease and to recover damages to which Landlord is entitled. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.8. In the event Landlord elects to terminate this Lease and relet the Premises, Landlord may execute any new lease in its own name.
Tenant hereunder shall have no right or authority whatsoever to collect any Rent from such tenant. The proceeds of any such reletting shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) First, to the payment of any indebtedness other than Rent due hereunder from Tenant to Landlord, including storage charges or brokerage commissions owing from Tenant to Landlord as the result of such
reletting; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Second, to the payment of the costs and expenses of reletting the Premises, including (i)&nbsp;alterations and
repairs that Landlord deems reasonably necessary and advisable and (ii)&nbsp;reasonable attorneys&#146; fees, charges and disbursements incurred by Landlord in connection with the retaking of the Premises and such reletting; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Third, to the payment of Rent and other charges due and unpaid hereunder; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Fourth, to the payment of future Rent and other damages payable by Tenant under this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.9. All of Landlord&#146;s rights, options and remedies hereunder shall be construed and held to be nonexclusive and cumulative.
Landlord shall have the right to pursue any one or all of such remedies, or any other remedy or relief that may be provided by Applicable Laws, whether or not stated in this Lease. No waiver of any default of Tenant hereunder shall be implied from
any acceptance by Landlord of any Rent or other payments due hereunder or any omission by Landlord to take any action on account of such default if such default persists or is repeated, and no express waiver shall affect defaults other than as
specified in said waiver. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.10. Landlord&#146;s termination of (a)&nbsp;this Lease or (b)&nbsp;Tenant&#146;s right to
possession of the Premises shall not relieve Tenant of any liability to Landlord that has previously accrued or that shall arise based upon events that occurred prior to the later to occur of (i)&nbsp;the date of Lease termination or (ii)&nbsp;the
date Tenant surrenders possession of the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.11. To the extent permitted by Applicable Laws, Tenant waives any and
all rights of redemption granted by or under any present or future Applicable Laws if Tenant is evicted or dispossessed for any cause, or if Landlord obtains possession of the Premises due to Tenant&#146;s default hereunder or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.12. Landlord shall not be in default or liable for damages under this Lease unless Landlord fails to perform obligations required of
Landlord within a reasonable time, but in no event shall such failure continue for more than thirty (30)&nbsp;days after written notice from Tenant specifying the nature of Landlord&#146;s failure; <U>provided</U>, however, that if the nature of
Landlord&#146;s obligation is such that more than thirty (30)&nbsp;days are required for its performance, then Landlord shall not be in default if Landlord commences performance within such thirty (30)&nbsp;day period and thereafter diligently
prosecutes the same to completion; <U>provided</U>, further, that Landlord agrees to commence performance as soon as is reasonably practicable and thereafter diligently prosecute the same to completion. In no event shall Tenant have the right to
terminate or cancel this Lease or to withhold or abate rent or to set off any Claims against Rent as a result of any default or breach by Landlord of any of its covenants, obligations, representations, warranties or promises hereunder, except as may
otherwise be expressly set forth in this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">31.13. In the event of any default by Landlord, Tenant shall give notice by
registered or certified mail to any (a)&nbsp;beneficiary of a deed of trust or (b)&nbsp;mortgagee under a mortgage covering the Premises, the Building or the Project and to any landlord of any lease of land upon or within which the Premises, the
Building or the Project is located, and shall offer such beneficiary, mortgagee or landlord a reasonable opportunity to cure the default, including time to obtain possession of the Building or the Project by power of sale or a judicial action if
such should prove necessary to effect a cure; <U>provided</U> that Landlord shall furnish to Tenant in writing, upon written request by Tenant, the names and addresses of all such persons who are to receive such notices. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">32. <U>Bankruptcy</U>. In the event a debtor, trustee or debtor in possession under the Bankruptcy Code, or
another person with similar rights, duties and powers under any other Applicable Laws, proposes to cure any default under this Lease or to assume or assign this Lease and is obliged to provide adequate assurance to Landlord that (a)&nbsp;a default
shall be cured, (b)&nbsp;Landlord shall be compensated for its damages arising from any breach of this Lease and (c)&nbsp;future performance of Tenant&#146;s obligations under this Lease shall occur, then such adequate assurances shall include any
or all of the following, as designated by Landlord in its sole and absolute discretion: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.1. Those acts specified in the
Bankruptcy Code or other Applicable Laws as included within the meaning of &#147;adequate assurance,&#148; even if this Lease does not concern a shopping center or other facility described in such Applicable Laws; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.2. A prompt cash payment to compensate Landlord for any monetary defaults or actual damages arising directly from a breach of this
Lease; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.3. A cash deposit in an amount at least equal to the then-current amount of the Security Deposit; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.4. The assumption or assignment of all of Tenant&#146;s interest and obligations under this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">33. <U>Brokers</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.1.
Each party represents and warrants that it has had no dealings with any real estate broker or agent in connection with the negotiation of this Lease other than Richards Barry Joyce&nbsp;&amp; Partners LLC (&#147;<U>Broker</U>&#148;), and that it
knows of no other real estate broker or agent that is or might be entitled to a commission in connection with this Lease. Landlord shall compensate Broker in relation to this Lease pursuant to a separate agreement between Landlord and Broker.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.2. Tenant represents and warrants that no broker or agent has made any representation or warranty relied upon by Tenant in
Tenant&#146;s decision to enter into this Lease, other than as contained in this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.3. Tenant acknowledges and agrees
that the employment of brokers by Landlord is for the purpose of solicitation of offers of leases from prospective tenants and that no authority is granted to any broker to furnish any representation (written or oral) or warranty from Landlord
unless expressly contained within this Lease. Landlord is executing this Lease in reliance upon Tenant&#146;s representations, warranties and agreements contained within <U>Sections 33.1</U> and <U>33.2</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.4. Tenant agrees to indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold
the Landlord Indemnitees harmless from any and all cost or liability for compensation claimed by any broker or agent, other than Broker, employed or engaged by Tenant or claiming to have been employed or engaged by Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.5. Landlord agrees to indemnify, save, defend (at Tenant&#146;s option and with counsel reasonably acceptable to Tenant) and hold
Tenant harmless from any and all cost or liability for compensation claimed by any broker or agent, other than Broker, employed or engaged by Landlord or claiming to have been employed or engaged by Landlord. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">34. <U>Definition of Landlord</U>. With regard to obligations imposed upon Landlord pursuant to this Lease,
the term &#147;<U>Landlord</U>,&#148; as used in this Lease, shall refer only to Landlord or Landlord&#146;s then-current successor-in-interest. In the event of any transfer, assignment or conveyance of Landlord&#146;s interest in this Lease or in
Landlord&#146;s fee title to or leasehold interest in the Property, as applicable, Landlord herein named (and in case of any subsequent transfers or conveyances, the subsequent Landlord) shall be automatically freed and relieved, from and after the
date of such transfer, assignment or conveyance, from all liability for the performance of any covenants or obligations contained in this Lease thereafter to be performed by Landlord and, without further agreement, the transferee, assignee or
conveyee of Landlord&#146;s in this Lease or in Landlord&#146;s fee title to or leasehold interest in the Property, as applicable, shall be deemed to have assumed and agreed to observe and perform any and all covenants and obligations of Landlord
hereunder during the tenure of its interest in the Lease or the Property. Landlord or any subsequent Landlord may transfer its interest in the Premises or this Lease without Tenant&#146;s consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">35. <U>Limitation of Landlord&#146;s Liability</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">35.1. If Landlord is in default under this Lease and, as a consequence, Tenant recovers a monetary judgment against Landlord, the judgment shall be satisfied only out of (a)&nbsp;the proceeds of sale
received on execution of the judgment and levy against the right, title and interest of Landlord in the Building and the Project, (b)&nbsp;rent or other income from such real property receivable by Landlord or (c)&nbsp;the consideration received by
Landlord from the sale, financing, refinancing or other disposition of all or any part of Landlord&#146;s right, title or interest in the Building or the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">35.2. Landlord shall not be personally liable for any deficiency under this Lease. If Landlord is a partnership or joint venture, then the partners of such partnership shall not be personally liable for
Landlord&#146;s obligations under this Lease, and no partner of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any partner of Landlord except as may be necessary to secure
jurisdiction of the partnership or joint venture. If Landlord is a corporation, then the shareholders, directors, officers, employees and agents of such corporation shall not be personally liable for Landlord&#146;s obligations under this Lease, and
no shareholder, director, officer, employee or agent of Landlord shall be sued or named as a party in any suit or action, and service of process shall not be made against any shareholder, director, officer, employee or agent of Landlord. If Landlord
is a limited liability company, then the members of such limited liability company shall not be personally liable for Landlord&#146;s obligations under this Lease, and no member of Landlord shall be sued or named as a party in any suit or action,
and service of process shall not be made against any member of Landlord except as may be necessary to secure jurisdiction of the limited liability company. No partner, shareholder, director, employee, member or agent of Landlord shall be required to
answer or otherwise plead to any service of process, and no judgment shall be taken or writ of execution levied against any partner, shareholder, director, employee, member or agent of Landlord. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">35.3. Each of the covenants and agreements of this Article shall be applicable to any covenant or agreement either expressly contained in
this Lease or imposed by Applicable Laws and shall survive the expiration or earlier termination of this Lease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">36. <U>Joint and Several Obligations</U>. If more than one person or entity executes this Lease as Tenant,
then: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.1. Each of them is jointly and severally liable for the keeping, observing and performing of all of the terms,
covenants, conditions, provisions and agreements of this Lease to be kept, observed or performed by Tenant; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.2. The
term &#147;<U>Tenant</U>,&#148; as used in this Lease shall mean and include each of them, jointly and severally. The act of, notice from, notice to, refund to, or signature of any one or more of them with respect to the tenancy under this Lease,
including any renewal, extension, expiration, termination or modification of this Lease, shall be binding upon each and all of the persons executing this Lease as Tenant with the same force and effect as if each and all of them had so acted, so
given or received such notice or refund, or so signed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">37. <U>Representations</U>. Tenant guarantees, warrants and represents that
(a)&nbsp;Tenant is duly incorporated or otherwise established or formed and validly existing under the laws of its state of incorporation, establishment or formation, (b)&nbsp;Tenant has and is duly qualified to do business in the state in which the
Property is located, (c)&nbsp;Tenant has full corporate, partnership, trust, association or other appropriate power and authority to enter into this Lease and to perform all Tenant&#146;s obligations hereunder, (d)&nbsp;each person (and all of the
persons if more than one signs) signing this Lease on behalf of Tenant is duly and validly authorized to do so and (e)&nbsp;neither (i)&nbsp;the execution, delivery or performance of this Lease nor (ii)&nbsp;the consummation of the transactions
contemplated hereby will violate or conflict with any provision of documents or instruments under which Tenant is constituted or to which Tenant is a party. In addition, Tenant guarantees, warrants and represents that none of (x)&nbsp;it,
(y)&nbsp;its affiliates or partners nor (z)&nbsp;to its knowledge (having made no independent inquiry), its members, shareholders or other equity owners or any of their respective employees, officers, directors, representatives or agents is a person
or entity with whom U.S. persons or entities are restricted from doing business under regulations of the Office of Foreign Asset Control (&#147;<U>OFAC</U>&#148;) of the Department of the Treasury (including those named on OFAC&#146;s Specially
Designated and Blocked Persons List) or under any statute, executive order (including the September&nbsp;24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support Terrorism) or
other similar governmental action. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">38. <U>Confidentiality</U>. Tenant shall keep the terms and conditions of this Lease and any information
provided to Tenant or its employees, agents or contractors pursuant to <U>Article 9</U> confidential and shall not (a)&nbsp;disclose to any third party any terms or conditions of this Lease or any other Lease-related document (including subleases,
assignments, work letters, construction contracts, letters of credit, subordination agreements, non-disturbance agreements, brokerage agreements or estoppels) or (b)&nbsp;provide to any third party an original or copy of this Lease (or any
Lease-related document). Landlord shall not release to any third party any non-public financial information or other non-public information that Tenant gives Landlord regarding Tenant&#146;s ownership structure, its business operations, research or
financial condition, whether received verbally, electronically or in writing. Notwithstanding the foregoing, confidential information under this Section may be released by Landlord or Tenant under the following circumstances: (x)&nbsp;if required by
Applicable Laws or in any judicial proceeding; <U>provided</U> that (prior to disclosure, if feasible) the releasing party has given the other party reasonable notice of such requirement, if feasible, (y)&nbsp;to a party&#146;s attorneys,
accountants, brokers and other bona fide </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
consultants or advisers (with respect to this Lease only); <U>provided</U> such third parties agree to be bound by this Section or (z)&nbsp;to bona fide prospective assignees or subtenants of
this Lease; <U>provided</U> they agree in writing to be bound by this Section. Landlord&#146;s obligations under this paragraph shall not be applicable to information that is or becomes generally known to, or ascertainable by, the public or
Landlord, other than as a result of an unauthorized disclosure by Landlord or by persons or entities to whom Landlord has made an unauthorized disclosure. Landlord agrees that a breach of such confidentiality may cause Tenant harm for which recovery
of damages would be an inadequate remedy, and in such event, Tenant shall be entitled to obtain injunctive relief, as well as such further relief as may be granted by a court of competent jurisdiction, but excluding special, punitive, exemplary or
consequential damages. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">39. <U>Notices</U>. Any notice, consent, demand, bill, statement or other communication required or permitted to be
given hereunder shall be in writing and shall be given by personal delivery, overnight delivery with a reputable nationwide overnight delivery service, or certified mail (return receipt requested), and if given by personal delivery, shall be deemed
delivered upon receipt; if given by overnight delivery, shall be deemed delivered one (1)&nbsp;day after deposit with a reputable nationwide overnight delivery service; and, if given by certified mail (return receipt requested), shall be deemed
delivered three (3)&nbsp;business days after the time the notifying party deposits the notice with the United States Postal Service. Any notices given pursuant to this Lease shall be addressed to Tenant at the Premises, or to Landlord or Tenant at
the addresses shown in <U>Sections 2.9</U> and <U>2.10</U>, respectively. Either party may, by notice to the other given pursuant to this Section, specify additional or different addresses for notice purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">40. <U>Rooftop Installation Area</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">40.1. Tenant may use the entire rooftop of the Building (the &#147;<U>Rooftop Installation Area</U>&#148;) solely to operate, maintain, repair and replace rooftop antennae, mechanical equipment,
communications antennas and other equipment installed by Tenant in the Rooftop Installation Area in accordance with this Article (&#147;<U>Tenant&#146;s Rooftop Equipment</U>&#148;). Tenant&#146;s Rooftop Equipment shall be only for Tenant&#146;s
use of the Premises for the Permitted Use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.2. Tenant shall install Tenant&#146;s Rooftop Equipment at its sole cost and
expense, at such times and in such manner as Landlord may reasonably designate, and in accordance with this Article and the applicable provisions of this Lease regarding Alterations. Tenant&#146;s Rooftop Equipment and the installation thereof shall
be subject to Landlord&#146;s prior written approval, which approval shall not be unreasonably withheld. Among other reasons, Landlord may withhold approval if the installation or operation of Tenant&#146;s Rooftop Equipment could reasonably be
expected to damage the structural integrity of the Building or to transmit vibrations or noise or cause other adverse effects beyond the Premises to an extent not customary in first class laboratory Buildings, unless Tenant implements measures that
are acceptable to Landlord in its reasonable discretion to avoid any such damage or transmission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.3. Tenant shall comply
with any roof or roof-related warranties. Tenant shall obtain a letter from Landlord&#146;s roofing contractor within thirty (30)&nbsp;days after completion of any Tenant work on the rooftop stating that such work did not affect any such warranties.
Tenant, at its sole cost and expense, shall inspect the Rooftop Installation Area at least annually, and correct any loose bolts, fittings or other appurtenances and repair any damage to the roof caused by the installation or operation of
Tenant&#146;s Rooftop Equipment. Tenant shall not permit the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
installation, maintenance or operation of Tenant&#146;s Rooftop Equipment to violate any Applicable Laws or constitute a nuisance. Tenant shall pay Landlord within thirty (30)&nbsp;days after
demand (a)&nbsp;all applicable taxes, charges, fees or impositions imposed on Landlord by Governmental Authorities as the result of Tenant&#146;s use of the Rooftop Installation Areas in excess of those for which Landlord would otherwise be
responsible for the use or installation of Tenant&#146;s Rooftop Equipment and (b)&nbsp;the amount of any increase in Landlord&#146;s insurance premiums as a result of the installation of Tenant&#146;s Rooftop Equipment. Upon Tenant&#146;s written
request to Landlord, Landlord shall use commercially reasonable efforts to cause other tenants to remedy any interference in the operation of Tenant&#146;s Rooftop Equipment caused by any such tenants&#146; equipment installed after the applicable
piece of Tenant&#146;s Rooftop Equipment; <U>provided</U>, however, that Landlord shall not be required to request that such tenants waive their rights under their respective leases. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">40.4. If Tenant&#146;s Equipment (a)&nbsp;causes physical damage to the structural integrity of the Building, (b)&nbsp;interferes with
any telecommunications, mechanical or other systems located at or near or servicing the Building or the Project that were installed prior to the installation of Tenant&#146;s Rooftop Equipment, (c)&nbsp;interferes with any other service provided to
other tenants in the Building or the Project by rooftop or penthouse installations that were installed prior to the installation of Tenant&#146;s Rooftop Equipment or (d)&nbsp;interferes with any other tenants&#146; business, in each case in excess
of that permissible under Federal Communications Commission regulations, then Tenant shall cooperate with Landlord to determine the source of the damage or interference and promptly repair such damage and eliminate such interference, in each case at
Tenant&#146;s sole cost and expense, within ten (10)&nbsp;days after receipt of notice of such damage or interference (which notice may be oral; <U>provided</U> that Landlord also delivers to Tenant written notice of such damage or interference
within twenty-four (24)&nbsp;hours after providing oral notice). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">41. <U>Miscellaneous</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1. Landlord reserves the right to change the name of the Building or the Project in its sole discretion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.2. In the event Tenant ceases to be subject to the reporting obligations of the Security Exchange Act of 1934 (the
&#147;<U>SEC</U>&#148;), Tenant agrees that it shall promptly furnish to Landlord, from time to time, upon Landlord&#146;s written request (not to exceed one time per year), the most recent year-end financial statements reflecting Tenant&#146;s
current financial condition audited by a nationally recognized accounting firm. Tenant shall, within one hundred twenty (120)&nbsp;days after the end of Tenant&#146;s financial year, furnish Landlord with a certified copy of Tenant&#146;s year-end
financial statements for the previous year audited by a nationally recognized accounting firm. Tenant represents and warrants that all financial statements, records and information furnished by Tenant to Landlord in connection with this Lease are
true, correct and complete in all respects. If audited financials are not otherwise prepared, unaudited financials complying with generally accepted accounting principles and certified by the chief financial officer of Tenant as true, correct and
complete in all respects shall suffice for purposes of this Section. All such financial statements shall be subject to the confidentiality obligations contained in <U>Article 38</U>. Landlord agrees that a breach of such confidentiality may cause
Tenant harm for which recovery of damages would be an inadequate remedy, and in such event, Tenant shall be entitled to obtain injunctive relief, as well as such further relief as may be granted by a court of competent jurisdiction, but excluding
special, punitive, exemplary or consequential </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
damages. For the avoidance of doubt, Tenant shall have no obligations to Landlord pursuant to this Section during the period of time when Tenant is subject to the reporting obligations of the SEC
and Tenant is in compliance with such reporting obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.3. Where applicable in this Lease, the singular includes the
plural and the masculine or neuter includes the masculine, feminine and neuter. The words &#147;include,&#148; &#147;includes,&#148; &#147;included&#148; and &#147;including&#148; shall mean &#147;&#145;include,&#146; etc., without limitation.&#148;
The section headings of this Lease are not a part of this Lease and shall have no effect upon the construction or interpretation of any part hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">41.4. If either party commences an action against the other party arising out of or in connection with this Lease, then the substantially prevailing party shall be reimbursed by the other party for all
reasonable costs and expenses, including reasonable attorneys&#146; fees and expenses, incurred by the substantially prevailing party in such action or proceeding and in any appeal in connection therewith. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.5. Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease,
and shall not be effective as a lease or otherwise until execution by and delivery to both Landlord and Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.6. Time is
of the essence with respect to the performance of every provision of this Lease in which time of performance is a factor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.7. Each provision of this Lease performable by Tenant shall be deemed both a covenant and a condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.8. Whenever consent or approval of either party is required, that party shall not unreasonably withhold such consent or approval,
except as may be expressly set forth to the contrary. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.9. The terms of this Lease are intended by the parties as a final
expression of their agreement with respect to the terms as are included herein, and may not be contradicted by evidence of any prior or contemporaneous agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">41.10. Any provision of this Lease that shall prove to be invalid, void or illegal shall in no way affect, impair or invalidate any other provision hereof, and all other provisions of this Lease shall
remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.11.
Landlord shall, upon Tenant&#146;s request and at Tenant&#146;s sole cost, execute and deliver to Tenant a mutually agreeable short form or memorandum of this Lease (&#147;<U>Memorandum of Lease</U>&#148;). Neither party shall record this Lease.
Tenant shall be responsible for the cost of recording any short form or memorandum of this Lease, including any transfer or other taxes incurred in connection with said recordation. Upon termination of this Lease, Tenant, at its sole cost and
expense, shall record a discharge or termination of any previously recorded Memorandum of Lease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.12. The language in all parts of this Lease shall be in all cases construed as a whole
according to its fair meaning and not strictly for or against either Landlord or Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.13. Each of the covenants,
conditions and agreements herein contained shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs; legatees; devisees; executors; administrators; and permitted successors, assigns,
sublessees. Nothing in this Section shall in any way alter the provisions of this Lease restricting assignment or subletting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.14. This Lease shall be governed by, construed and enforced in accordance with the laws of the state in which the Premises are
located, without regard to such state&#146;s conflict of law principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.15. Tenant guarantees, warrants and represents
that the individual or individuals signing this Lease have the power, authority and legal capacity to sign this Lease on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other
organizations and entities on whose behalf said individual or individuals have signed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.16. This Lease may be executed in
one or more counterparts, each of which, when taken together, shall constitute one and the same document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.17. No provision
of this Lease may be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant. The waiver by Landlord of any breach by Tenant of any term, covenant or condition herein contained shall not be deemed to be a
waiver of any subsequent breach of the same or any other term, covenant or condition herein contained. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.18. To the extent
permitted by Applicable Laws, the parties waive trial by jury in any action, proceeding or counterclaim brought by the other party hereto related to matters arising out of or in any way connected with this Lease; the relationship between Landlord
and Tenant; Tenant&#146;s use or occupancy of the Premises; or any claim of injury or damage related to this Lease or the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.
<U>Options to Extend Term</U>. Tenant shall have two (2)&nbsp;options (each, an &#147;<U>Option</U>&#148;) to extend the Term by five (5)&nbsp;years (each, an &#147;<U>Option Term</U>&#148;) as to the entire Premises (and no less than the entire
Premises) upon the following terms and conditions. Any extension of the Term pursuant to an Option shall be on all the same terms and conditions as this Lease, except as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.1. Base Rent during an Option Term shall equal the fair market rent for similar premises in similar buildings in the West-Cambridge
submarket as of the commencement of such Option Term, including fair market rent increases (&#147;<U>FMR</U>&#148;). If Landlord and Tenant cannot agree on the FMR for an Option Term within thirty (30)&nbsp;days after the date on which Tenant
notifies Landlord that it is exercising an Option, then, no later than an additional thirty (30)&nbsp;days thereafter (the &#147;<U>Submission Period</U>&#148;), Landlord and Tenant shall each furnish to the other a notice in writing (an
&#147;<U>FMR Notice</U>&#148;) stating such party&#146;s estimate of the FMR. Such notices shall be accompanied by a statement from a qualified, licensed real estate appraiser with at least ten (10)&nbsp;years&#146; experience in the Cambridge area
(an &#147;<U>Appraiser</U>&#148;) stating such Appraiser&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
opinion of FMR. If only one (1)&nbsp;party&#146;s Appraiser timely submits its opinion of FMR, such FMR shall be binding on Landlord and Tenant. If, within twenty (20)&nbsp;days after expiration
of the Submission Period, Landlord and Tenant still cannot agree on the FMR, the two (2)&nbsp;Appraisers shall appoint a third qualified, licensed real estate appraiser (the &#147;<U>Referee</U>&#148;) within seven (7)&nbsp;days. If the Appraisers
are unable to agree upon the selection of the Referee, then the Referee shall be selected within ten (10)&nbsp;days thereafter from among the Massachusetts panel of qualified Real Estate Industry Arbitrators of the American Arbitrator Association
(the &#147;<U>Association</U>&#148;) pursuant to the Real Estate Industry Arbitration rules of the Association. The Referee shall, within thirty (30)&nbsp;days after appointment, render the Referee&#146;s decision as to the FMR, which opinion shall
be strictly limited to choosing one of the two determinations made by the Appraisers. The decision by the Referee shall be binding upon Landlord and Tenant, and each shall pay for its own appraisal. The cost of the Referee shall be shared equally by
Landlord and Tenant. In determining FMR, Landlord, Tenant and, if applicable, the Appraisers and Referee shall each take into account all relevant factors, including, without limitation, (a)&nbsp;the size of the Premises and length of the Option
Term, (b)&nbsp;rent in comparable buildings in the relevant competitive market, including concessions offered to new tenants, such as free rent, tenant improvement allowances, and moving allowances, (c)&nbsp;Tenant&#146;s creditworthiness and
(d)&nbsp;the quality and location of the Building and the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.2. No Option is assignable separate and apart from this
Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.3. An Option is conditional upon Tenant giving Landlord written notice of its election to exercise such Option at
least twelve (12)&nbsp;months prior to the end of the expiration of the then-current Term. Time shall be of the essence as to Tenant&#146;s exercise of an Option. Tenant assumes full responsibility for maintaining a record of the deadlines to
exercise an Option. Tenant acknowledges that it would be inequitable to require Landlord to accept any exercise of an Option after the date provided for in this Section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">42.4. Notwithstanding anything contained in this Article to the contrary, Tenant shall not have the right to exercise an Option: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) During the time commencing from the date Landlord delivers to Tenant a written notice that Tenant is in default under any provisions of this Lease and continuing until Tenant has cured the specified
default to Landlord&#146;s reasonable satisfaction; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) At any time after any Default as described in <U>Article 31</U> of
the Lease (<U>provided</U>, however, that, for purposes of this <U>Subsection 42.4(b)</U>, Landlord shall not be required to provide Tenant with notice of such Default) and continuing until Tenant cures any such Default, if such Default is
susceptible to being cured; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event that Tenant has defaulted in the performance of its obligations under this
Lease two (2)&nbsp;or more times and a service or late charge has become payable under <U>Section&nbsp;31.1</U> for each of such defaults during the twelve (12)-month period immediately prior to the date that Tenant intends to exercise an Option,
whether or not Tenant has cured such defaults. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.5. The period of time within which Tenant may exercise an Option shall not
be extended or enlarged by reason of Tenant&#146;s inability to exercise such Option because of the provisions of <U>Section&nbsp;42.4</U>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">42.6. All of Tenant&#146;s rights under the provisions of an Option shall terminate and be
of no further force or effect even after Tenant&#146;s due and timely exercise of such Option if, after such exercise, but prior to the commencement date of the new term, (a)&nbsp;Tenant fails to pay to Landlord a monetary obligation of Tenant for a
period of twenty (20)&nbsp;days after written notice from Landlord to Tenant, (b)&nbsp;Tenant fails to commence to cure a default (other than a monetary default) within thirty (30)&nbsp;days after the date Landlord gives notice to Tenant of such
default or (c)&nbsp;Tenant has defaulted under this Lease two (2)&nbsp;or more times and a service or late charge under <U>Section&nbsp;31.1</U> has become payable for any such default, whether or not Tenant has cured such defaults. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the date first above
written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>LANDLORD</U>:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-FRESH POND RESEARCH PARK LLC,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin M. Simonsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin M. Simonsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">VP, Real Estate Counsel</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>TENANT</U>:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC.,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>PREMISES </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g335938exhibita.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>WORK LETTER </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Work Letter (this
&#147;<U>Work Letter</U>&#148;) is made and entered into as of the 10</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> day of February, 2012, by and between BMR-FRESH POND RESEARCH PARK LLC, a Delaware limited liability company (&#147;<U>Landlord</U>&#148;), and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation
(&#147;<U>Tenant</U>&#148;), and is attached to and made a part of that certain Lease dated as of February&nbsp;10, 2012 (as the same may be amended, amended and restated, supplemented or otherwise modified from time to time, the
&#147;<U>Lease</U>&#148;), by and between Landlord and Tenant for the Premises located at 665 Concord Avenue, Cambridge, Massachusetts. All capitalized terms used but not otherwise defined herein shall have the meanings given them in the Lease.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>General Requirements</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.1. <U>Authorized Representatives</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Landlord designates, as
Landlord&#146;s authorized representative (&#147;<U>Landlord&#146;s Authorized Representative</U>&#148;), (a)&nbsp;Timothy Stoll as the person authorized to initial plans, drawings and approvals pursuant to this Work Letter and (b)&nbsp;John Bonanno
as the person authorized to initial plans, drawings, approvals and to sign change orders pursuant to this Work Letter and any amendments to this Work Letter or the Lease. Tenant shall not be obligated to respond to or act upon any such item until
such item has been initialed or signed (as applicable) by the appropriate Landlord&#146;s Authorized Representative. Landlord may change either Landlord&#146;s Authorized Representative upon one (1)&nbsp;business day&#146;s prior written notice to
Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Tenant designates [**] (&#147;<U>Tenant&#146;s Authorized Representative</U>&#148;) as the person authorized to
initial and sign all plans, drawings, change orders and approvals pursuant to this Work Letter. Landlord shall not be obligated to respond to or act upon any such item until such item has been initialed or signed (as applicable) by Tenant&#146;s
Authorized Representative. Tenant may change Tenant&#146;s Authorized Representative upon one (1)&nbsp;business day&#146;s prior written notice to Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.2. <U>Schedule</U>. The schedule for design and development of the Tenant Improvements, including the time periods for preparation and review of construction documents, approvals and performance, shall
be in accordance with a schedule to be prepared by Tenant (the &#147;<U>Schedule</U>&#148;). Tenant shall prepare the Schedule so that it is a reasonable schedule for the completion of the Tenant Improvements. As soon as the Schedule is completed,
Tenant shall deliver the same to Landlord for Landlord&#146;s approval, which approval shall not be unreasonably withheld, conditioned or delayed. Such Schedule shall be approved or disapproved by Landlord within seven (7)&nbsp;business days after
delivery to Landlord. Landlord&#146;s failure to respond within such seven (7)&nbsp;business day period shall be deemed approval by Landlord. If Landlord disapproves the Schedule, then Landlord shall notify Tenant in writing of its objections to
such Schedule, and the parties shall confer and negotiate in good faith to reach agreement on the Schedule. The Schedule shall be subject to adjustment as mutually agreed upon in writing by the parties, or as provided in this Work Letter.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3. <U>Tenant&#146;s Architects, Contractors and Consultants</U>. Landlord and Tenant
shall (using good faith efforts) (a)&nbsp;mutually agree upon the selection of the architect, engineer, design team, general contractor (the &#147;<U>General Contractor</U>&#148;) and subcontractors responsible for the construction of the Tenant
Improvements (collectively, the &#147;<U>Project Team</U>&#148;), (b)&nbsp;mutually agree upon (i)&nbsp;key individuals within the Project Team (&#147;<U>Approved Personnel</U>&#148;) and (ii)&nbsp;the percentage of the Approved Personnel&#146;s
time that such Approved Personnel must commit to the construction of the Tenant Improvements and (c)&nbsp;each participate in the review of the competitive bid process. Landlord may refuse to use any architects, consultants, contractors,
subcontractors or material suppliers that Landlord reasonably believes could cause labor disharmony. Landlord may refuse to use the General Contractor if Landlord believes such General Contractor&#146;s Quality Control Program (as defined in
<U>Section&nbsp;2.6</U>) is insufficient. All Tenant contracts related to the Tenant Improvements shall provide that Tenant may assign such contracts and any warranties with respect to the Tenant Improvements to Landlord and Landlord&#146;s tenants
at any time; <U>provided</U>, however, that the foregoing does not obligate Tenant, in and of itself, to assign any such contracts or warranties to Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. <U>Tenant Improvements</U>. All Tenant Improvements shall be performed by Tenant&#146;s contractor, at Tenant&#146;s sole cost and expense (subject to Landlord&#146;s obligations with respect to any
portion of the TI Allowance and in accordance with the Approved Plans (as defined below), the Lease and this Work Letter. To the extent that the total projected cost (as projected by Landlord) of the Base Building Improvements exceeds the Base
Building Allowance (such excess, the &#147;<U>Excess Base Building Costs</U>,&#148; Tenant shall advance to Landlord any Excess Base Building Costs within ten (10)&nbsp;days after receipt of an invoice therefor, but in any case before Tenant
commences the Base Building Improvements. If the actual Excess Base Building Costs are less than the Excess Base Building Costs paid by Tenant to Landlord, Landlord shall credit Tenant with the overage paid by Tenant against Tenant&#146;s Rent
obligations, beginning after Landlord has completed the final accounting for the Tenant Improvements. If the actual Excess Base Building Costs at any point during the construction of the Base Building Improvements are or are projected to be more
than the previously estimated Excess Base Building Costs, Tenant shall advance to Landlord any such additional Excess Base Building Costs within ten (10)&nbsp;days after receipt of an invoice therefor. To the extent that the total projected cost (as
projected by Landlord) of the Premises Improvements exceeds the Premises Allowance, and provided that such excess cost is not due to Landlord Delay, (such excess, the &#147;<U>Excess Premises Costs</U>&#148; and together with the Excess Base
Building Costs, the &#147;<U>Excess TI Costs</U>,&#148; Tenant shall pay the costs of the Premises Improvements on a pari passu basis with Landlord as such costs become due, in the proportion of Excess Premises Costs payable by Tenant to the
Premises Allowance. If Tenant fails to pay, or is late in paying, any sum due to Landlord or any third party under this Work Letter, then Landlord shall have all of the rights and remedies set forth in the Lease for nonpayment of Rent (including the
right to interest and the right to assess a late charge), and for purposes of any litigation instituted with regard to such amounts the same shall be considered Rent. All material and equipment furnished by Tenant or its contractors as the Tenant
Improvements shall be new or &#147;like new;&#148; the Tenant Improvements shall be performed in a first-class, workmanlike manner; and the quality of the Tenant Improvements shall be of a nature and character not less than the Building Standard.
Tenant shall take, and shall require its contractors to take, commercially reasonable steps to protect the Premises during the performance of any Tenant Improvements, including covering or temporarily removing any window coverings so as to guard
against dust, debris or damage. Any and all amounts associated with remediation of Pre-Existing Hazardous Conditions shall be paid solely by Landlord and shall not be paid out of the TI Allowance or included as Excess TI Costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1. <U>Base Building Improvements</U>. The Base Building Improvements shall include the
improvements set forth on <U>Schedule 1</U> attached hereto. All Base Building Improvements shall be subject to Landlord&#146;s approval as set forth in this Work Letter and shall be constructed to a level that is sufficient (as determined by
Landlord) to support the Premises Improvements and Tenant&#146;s other equipment in the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2. <U>Work Plans</U>.
Tenant shall prepare and submit to Landlord for approval schematics covering the Tenant Improvements prepared in conformity with the applicable provisions of this Work Letter (the &#147;<U>Draft Schematic Plans</U>&#148;). The Draft Schematic Plans
shall contain sufficient information and detail to accurately describe the proposed design to Landlord and such other information as Landlord may reasonably request. Landlord shall notify Tenant in writing within seven (7)&nbsp;business days after
receipt of the Draft Schematic Plans whether Landlord approves or objects to the Draft Schematic Plans and of the manner, if any, in which the Draft Schematic Plans are unacceptable. Landlord&#146;s failure to respond within such seven
(7)&nbsp;business day period shall be deemed approval by Landlord. If Landlord reasonably objects to the Draft Schematic Plans, then Landlord must provide Tenant, with reasonable specificity, notification of such objections, and Tenant shall revise
the Draft Schematic Plans and cause Landlord&#146;s objections to be remedied in the revised Draft Schematic Plans. Tenant shall then resubmit the revised Draft Schematic Plans to Landlord for approval, such approval not to be unreasonably withheld,
conditioned or delayed. Landlord&#146;s approval of or objection to revised Draft Schematic Plans and Tenant&#146;s correction of the same shall be in accordance with this Section until Landlord has approved the Draft Schematic Plans in writing or
been deemed to have approved them. The iteration of the Draft Schematic Plans that is approved or deemed approved by Landlord without objection shall be referred to herein as the &#147;<U>Approved Schematic Plans</U>.&#148; Subject to
Landlord&#146;s prior written approval (in Landlord&#146;s sole and absolute discretion), Landlord and Tenant may mutually agree to forego the schematic plans stage and move straight to the construction plans stage with respect the Tenant
Improvements, or any portion thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3. <U>Construction Plans</U>. Tenant shall prepare final plans and specifications for
the Tenant Improvements that (a)&nbsp;are consistent with and are logical evolutions of the Approved Schematic Plans, (b)&nbsp;incorporate any other Tenant-requested (and Landlord-approved) Changes (as defined below) and (c)&nbsp;are complete and
accurate in all material respects. As soon as such final plans and specifications (&#147;<U>Construction Plans</U>&#148;) are completed, Tenant shall deliver the same to Landlord for Landlord&#146;s approval, which approval shall not be unreasonably
withheld, conditioned or delayed; <U>provided</U>, however, that Landlord shall not be deemed unreasonable for disapproving such Construction Plans if Landlord believes such Construction Plans to be incomplete or contain inaccurate information. Such
Construction Plans shall be approved or disapproved by Landlord within seven (7)&nbsp;business days after delivery to Landlord. Landlord&#146;s failure to respond within such seven (7)&nbsp;business day period shall be deemed approval by Landlord.
If the Construction Plans are disapproved by Landlord, then Landlord shall notify Tenant in writing, with reasonable specificity, of its objections to such Construction Plans, and the parties shall confer and negotiate in good faith to reach
agreement on the Construction Plans. Promptly after the Construction Plans are approved by Landlord and Tenant, two (2)&nbsp;copies of such Construction Plans shall be initialed and dated by Landlord and Tenant, and Tenant shall
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
promptly submit such Construction Plans to all appropriate Governmental Authorities for approval. The Construction Plans so approved, and all change orders specifically permitted by this Work
Letter, are referred to herein as the &#147;<U>Approved Plans</U>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4. <U>Changes to the Tenant Improvements</U>. Any
changes to the Approved Plans (each, a &#147;<U>Change</U>&#148;) shall be requested and instituted in accordance with the provisions of this <U>Article 2</U> and shall be subject to the written approval of the non-requesting party in accordance
with this Work Letter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Change Request</U>. Either Landlord or Tenant may request Changes after Landlord approves the
Approved Plans by notifying the other party thereof in writing in substantially the same form as the AIA standard change order form (a &#147;<U>Change Request</U>&#148;), which Change Request shall detail the nature and extent of any requested
Changes, including (a)&nbsp;the Change, (b)&nbsp;the party required to perform the Change and (c)&nbsp;any modification of the Approved Plans and the Schedule, as applicable, necessitated by the Change. If the nature of a Change requires revisions
to the Approved Plans, then the requesting party shall be solely responsible for the cost and expense of such revisions and any increases in the cost of the Tenant Improvements as a result of such Change; <U>provided</U>, however that if Landlord is
the requesting party, Landlord shall only be responsible for any increase in the cost of the Tenant Improvements to the extent the cost of such Change (when added to the then-current Tenant Improvement cost) exceeds the TI Allowance. Change Requests
shall be signed by the requesting party&#146;s Authorized Representative. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Approval of Changes</U>. All Change Requests
shall be subject to the other party&#146;s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed. The non-requesting party shall have five (5)&nbsp;business days after receipt of a Change Request to notify
the requesting party in writing of the non-requesting party&#146;s decision either to approve or object to the Change Request. The non-requesting party&#146;s failure to respond within such five (5)&nbsp;business day period shall be deemed approval
by the non-requesting party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5. <U>Preparation of Estimates</U>. Tenant shall, before proceeding with any Change, using its
best efforts, prepare as soon as is reasonably practicable (but in no event more than five (5)&nbsp;business days after delivering a Change Request to Landlord or receipt of a Change Request) an estimate of the increased costs or savings that would
result from such Change, as well as an estimate on such Change&#146;s effects on the Schedule. Landlord shall have five (5)&nbsp;business days after receipt of such information from Tenant to (a)&nbsp;in the case of a Tenant-initiated Change
Request, approve or reject such Change Request in writing, or (b)&nbsp;in the case of a Landlord-initiated Change Request, notify Tenant in writing of Landlord&#146;s decision either to proceed with or abandon the Landlord-initiated Change Request.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6. <U>Quality Control</U>. Tenant shall provide to Landlord in writing the General Contractor&#146;s quality control
program (the &#147;<U>Quality Control Program</U>&#148;), which program shall be specific to the Tenant Improvements and shall be subject to Landlord&#146;s approval. Tenant shall ensure that the General Contractor complies with the Quality Control
Program at all times during the construction of the Tenant Improvements. Tenant shall provide Landlord with reasonable notice of all inspections and meetings relating to the construction of the Tenant Improvements and shall allow Landlord to attend
such meetings. Upon completion of the Tenant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Improvements, Tenant shall provide Landlord with the quality control log, which shall include all records of quality control meetings and testings and inspections during the construction of the
Tenant Improvements, including inspections relating to concrete, steel roofing, piping pressure testing and system commissioning. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.
<U>Completion of Tenant Improvements</U>. Tenant, at its sole cost and expense (except for the TI Allowance), shall perform and complete the Tenant Improvements in all respects (a)&nbsp;in substantial conformance with the Approved Plans,
(b)&nbsp;otherwise in compliance with provisions of the Lease and this Work Letter and (c)&nbsp;in accordance with Applicable Laws, the requirements of Tenant&#146;s insurance carriers, the requirements of Landlord&#146;s insurance carriers (to the
extent Landlord provides its insurance carriers&#146; requirements to Tenant) and the board of fire underwriters having jurisdiction over the Premises. The Tenant Improvements shall be deemed completed at such time as Tenant shall furnish to
Landlord (v)&nbsp;evidence satisfactory to Landlord that (i)&nbsp;all Tenant Improvements have been completed and paid for in full (which shall be evidenced by the architect&#146;s certificate of completion and the general contractor&#146;s and each
subcontractor&#146;s and material supplier&#146;s final unconditional waivers and releases of liens, each in a form acceptable to Landlord and complying with Applicable Laws), (ii)&nbsp;all Tenant Improvements have been accepted by Landlord,
(iii)&nbsp;any and all liens related to the Tenant Improvements have either been discharged of record (by payment, bond, order of a court of competent jurisdiction or otherwise) or waived by the party filing such lien and (iv)&nbsp;no security
interests relating to the Tenant Improvements are outstanding, (w)&nbsp;all inspection reports, certifications and approvals with respect to the Tenant Improvements that may be required from any Governmental Authority and any board of fire
underwriters or similar body for the use and occupancy of the Premises, (x)&nbsp;certificates of insurance required by the Lease to be purchased and maintained by Tenant, (y)&nbsp;an affidavit from Tenant&#146;s architect certifying that all work
performed in, on or about the Premises is in accordance with the Approved Plans and (z)&nbsp;complete drawing print sets and electronic CADD files on disc of all contract documents for work performed by their architect and engineers in relation to
the Tenant Improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Insurance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1. <U>Property Insurance</U>. At all times during the period beginning with commencement of construction of the Tenant Improvements and ending with final completion of the Tenant Improvements, Tenant
shall maintain, or cause to be maintained (in addition to the insurance required of Tenant pursuant to the Lease), property insurance insuring Landlord and the Landlord Parties, as their interests may appear. Such policy shall, on a completed values
basis for the full insurable value at all times, insure against loss or damage by fire, vandalism and malicious mischief and other such risks as are customarily covered by the so-called &#147;broad form extended coverage endorsement&#148; upon all
Tenant Improvements and the general contractor&#146;s and any subcontractors&#146; machinery, tools and equipment, all while each forms a part of, or is contained in, the Tenant Improvements or any temporary structures on the Premises, or is
adjacent thereto; <U>provided</U> that, for the avoidance of doubt, insurance coverage with respect to the general contractor&#146;s and any subcontractors&#146; machinery, tools and equipment shall be carried on a primary basis by such general
contractor or the applicable subcontractor(s). Tenant agrees to pay any deductible, and Landlord is not responsible for any deductible, for a claim under such insurance. Said property insurance shall contain an express waiver of any right of
subrogation by the insurer against Landlord and the Landlord Parties, and shall name Landlord and its affiliates as loss payees as their interests may appear. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2. <U>Workers&#146; Compensation Insurance</U>. At all times during the period of
construction of the Tenant Improvements, Tenant shall, or shall cause its contractors or subcontractors to, maintain statutory workers&#146; compensation insurance as required by Applicable Laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Liability</U>. Tenant assumes sole responsibility and liability for any and all injuries or the death of any persons, including Tenant&#146;s
contractors and subcontractors and their respective employees, agents and invitees, and for any and all damages to property caused by, resulting from or arising out of any act or omission on the part of Tenant, Tenant&#146;s contractors or
subcontractors, or their respective employees, agents and invitees in the prosecution of the Tenant Improvements. Tenant agrees to indemnify, save, defend (at Landlord&#146;s option and with counsel reasonably acceptable to Landlord) and hold the
Landlord Indemnitees harmless from and against all Claims due to, because of or arising out of any and all such injuries, death or damage, whether real or alleged, and Tenant and Tenant&#146;s contractors and subcontractors shall assume and defend
at their sole cost and expense all such Claims; <U>provided</U>, <U>however</U>, that nothing contained in this Work Letter shall be deemed to indemnify or otherwise hold Landlord harmless from or against liability caused by Landlord&#146;s
negligence or willful misconduct. Any deficiency in design or construction of the Tenant Improvements shall be solely the responsibility of Tenant, notwithstanding the fact that Landlord may have approved of the same in writing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>TI Allowance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.
<U>Application of TI Allowance</U>. Landlord shall contribute the TI Allowance toward the costs and expenses incurred in connection with the performance of the Tenant Improvements, in accordance with <U>Article 4</U> of the Lease. If the entire TI
Allowance is not applied toward or reserved for the costs of the Tenant Improvements, then Tenant shall not be entitled to a credit of such unused portion of the TI Allowance. Tenant may apply the TI Allowance for the payment of construction and
other costs in accordance with the terms and provisions of the Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2. <U>Approval of Budget for the Tenant
Improvements</U>. Notwithstanding anything to the contrary set forth elsewhere in this Work Letter or the Lease, Landlord shall not have any obligation to expend any portion of the TI Allowance until Landlord and Tenant shall have approved in
writing the budget for the Tenant Improvements (the &#147;<U>Approved Budget</U>&#148;). Prior to Landlord&#146;s approval of the Approved Budget, Tenant shall pay all of the costs and expenses incurred in connection with the Tenant Improvements as
they become due. Landlord shall not be obligated to reimburse Tenant for costs or expenses relating to the Tenant Improvements that exceed the amount of the TI Allowance. Landlord shall not unreasonably withhold, condition or delay its approval of
any budget for Tenant Improvements that is proposed by Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3. <U>Fund Requests</U>. Upon submission by Tenant to
Landlord of (a)&nbsp;a statement (a &#147;<U>Fund Request</U>&#148;) setting forth the total amount of the TI Allowance or Excess Base Building Costs, if any, requested, (b)&nbsp;a summary of the Tenant Improvements performed using AIA standard form
Application for Payment (G 702) executed by the general contractor and by the architect, (c)&nbsp;invoices from the general contractor, the architect, and any subcontractors, material </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
suppliers and other parties requesting payment with respect to the amount of the TI Allowance or Excess Base Building Costs, if any, then being requested, (d)&nbsp;except with respect to the
final Fund Request, conditional lien releases from the general contractor and each subcontractor and material supplier with respect to the Tenant Improvements performed that correspond to the Fund Request each in a form acceptable to Landlord and
complying with Applicable Laws, then Landlord shall, within thirty (30)&nbsp;days following receipt by Landlord of a Fund Request and the accompanying materials required by this Section, pay to the applicable contractors, subcontractors and material
suppliers or to Tenant (for reimbursement for payments made by Tenant prior to Landlord&#146;s approval of the Approved Budget to such contractors, subcontractors or material suppliers), as elected by Landlord, the amount of Tenant Improvement costs
set forth in such Fund Request; <U>provided</U>, however, that Landlord shall not be obligated to make any payments under this Section until the budget for the Tenant Improvements is approved in accordance with <U>Section&nbsp;6.2</U> above, and any
Fund Request under this Section shall be subject to the payment limits set forth in <U>Section&nbsp;6.2</U> above and <U>Article 4</U> of the Lease. Within ten (10)&nbsp;days after Tenant&#146;s receipt of the final Fund Request, Tenant shall
deliver to Landlord an unconditional waiver and release of lien upon payment from the general contractor and each subcontractor and material supplier complying with Applicable Laws and in a form acceptable to Landlord. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Miscellaneous</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.
<U>Number; Headings</U>. Where applicable in this Work Letter, the singular includes the plural and the masculine or neuter includes the masculine, feminine and neuter. The section headings of this Work Letter are not a part of this Work Letter and
shall have no effect upon the construction or interpretation of any part hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2. <U>Attorneys&#146; Fees</U>. If either
party commences an action against the other party arising out of or in connection with this Work Letter, then the substantially prevailing party shall be entitled to have and recover from the other party reasonable attorneys&#146; fees, charges and
disbursements and costs of suit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3. <U>Time of Essence</U>. Time is of the essence with respect to the performance of every
provision of this Work Letter in which time of performance is a factor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4. <U>Covenant and Condition</U>. Each provision of
this Work Letter performable by Tenant shall be deemed both a covenant and a condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5. <U>Withholding of Consent</U>.
Whenever consent or approval of either party is required, that party shall not unreasonably withhold, condition or delay such consent or approval, except as may be expressly set forth to the contrary. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6. <U>Invalidity</U>. Any provision of this Work Letter that shall prove to be invalid, void or illegal shall in no way affect, impair
or invalidate any other provision hereof, and all other provisions of this Work Letter shall remain in full force and effect and shall be interpreted as if the invalid, void or illegal provision did not exist. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7. <U>Interpretation</U>. The language in all parts of this Work Letter shall be in all
cases construed as a whole according to its fair meaning and not strictly for or against either Landlord or Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8.
<U>Successors</U>. Each of the covenants, conditions and agreements herein contained shall inure to the benefit of and shall apply to and be binding upon the parties hereto and their respective heirs; legatees; devisees; executors; administrators;
and permitted successors, assigns, sublessees. Nothing in this Section shall in any way alter the provisions of the Lease restricting assignment or subletting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.9. <U>Governing Law</U>. This Work Letter shall be governed by, construed and enforced in accordance with the laws of the state in which the Premises are located, without regard to such state&#146;s
conflict of law principles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.10. <U>Power and Authority</U>. Tenant guarantees, warrants and represents that the individual
or individuals signing this Work Letter have the power, authority and legal capacity to sign this Work Letter on behalf of and to bind all entities, corporations, partnerships, limited liability companies, joint venturers or other organizations and
entities on whose behalf said individual or individuals have signed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.11. <U>Counterparts</U>. This Work Letter may be
executed in one or more counterparts, each of which, when taken together, shall constitute one and the same document. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.12.
<U>Amendments; Waiver</U>. No provision of this Work Letter may be modified, amended or supplemented except by an agreement in writing signed by Landlord and Tenant. The waiver by Landlord of any breach by Tenant of any term, covenant or condition
herein contained shall not be deemed to be a waiver of any subsequent breach of the same or any other term, covenant or condition herein contained. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.13. <U>Waiver of Jury Trial</U>. To the extent permitted by Applicable Laws, the parties waive trial by jury in any action, proceeding or counterclaim brought by the other party hereto related to
matters arising out of or in any way connected with this Work Letter; the relationship between Landlord and Tenant; Tenant&#146;s use or occupancy of the Premises; or any claim of injury or damage related to this Work Letter or the Premises.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-8
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, Landlord and Tenant have executed this Work Letter to be effective on
the date first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>LANDLORD</U>:</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-FRESH POND RESEARCH PARK LLC,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Kevin M. Simonsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kevin M. Simonsen</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">VP, Real Estate Counsel</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>TENANT</U>:</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC.,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-9
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SCHEDULE 1 TO WORK LETTER </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>BASE BUILDING IMPROVEMENTS </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall construct restrooms that comply with Applicable Laws based upon full occupancy of the Premises for the Permitted Use.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall either expand planned restrooms or construct additional restrooms </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall construct structural reinforcing for existing un-reinforced masonry walls where new glazing is installed </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall install structural framing at two (2)&nbsp;levels to support the existing high openings and to create new lower openings
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall remove and abate the existing glazing with new glazing infill </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall replace the existing presumed asbestos-containing material glazing with new similar quality fixed or double hung windows
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall replace the existing roof </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall make roof insulation and roof deck upgrades as required by Landlord </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall procure and install mechanical systems, including new supply air roof top units and VAV boxes with hot water reheat coil and loop
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such system shall include an air-cooled chiller, two (2)&nbsp;AHUs sized to support future lab occupancy, exhaust fans, reheat boiler, VAVs, and
distribution ductwork and piping </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall install fire protection water service located within the Building </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall construct the electrical system within the Premises including all branch circuitry and panels for lighting, low voltage and outlets
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall modify the existing floor slab to establish a &#147;flat&#148; floor service to support a typical laboratory program
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall install stand-by power and all permitting associated with installing a pad or roof mounted generator, including electrical distribution
and gas service </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall perform site work, including excavation and backfill for generator pad, conduits, foundation penetration for conduits and associated
landscape work </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall perform demolition and Building preparation, which shall include removal of existing abandoned equipment, selective demolition of masonry
walls as required, demolition of windows for replacement, and saw cutting the concrete slab for underground plumbing work </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall procure and install concrete, including material for slab-on-grade infill at plumbing trenches, infill of existing under-floor openings,
mechanical housekeeping pads, stand-by generator pad, and slab repair (plus flooring preparation). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall perform masonry, including repointing of masonry walls and exterior face brick, shear wall reinforcing, infill of existing high-bay
windows and masonry wall reinforcing </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-10
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall procure and install structural steel and miscellaneous metals, including structural steel for support of rooftop equipment and roof
reinforcement to meet Applicable Laws </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall construct thermal and moisture protections, including removal and replacement of the roof system and edge flashing and flashing for new
roof penetrations. Additionally, a Tenant shall construct full-height gypsum wall board system around the interior perimeter of the Building, including metal studs, insulation, and a vapor barrier to meet Applicable Laws and applicable energy codes.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall perform plumbing work, including sanitary waste, domestic water and natural gas distribution </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall replace existing overhead door at the loading area, loading dock plate and related accessories </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall construct new exterior entries and doors and new windows along the lower level of the east and west masonry walls
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-11
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>AND TERM EXPIRATION DATE
</U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS ACKNOWLEDGEMENT OF TERM COMMENCEMENT DATE AND TERM EXPIRATION DATE is entered into as of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], with reference to that certain Lease (the &#147;<U>Lease</U>&#148;) dated as of February&nbsp;10, 2012, by ALNYLAM PHARMACEUTICALS, INC., a
Delaware corporation (&#147;<U>Tenant</U>&#148;), in favor of BMR-FRESH POND RESEARCH PARK LLC, a Delaware limited liability company (&#147;<U>Landlord</U>&#148;). All capitalized terms used herein without definition shall have the meanings ascribed
to them in the Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant hereby confirms the following: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. Tenant accepted possession of the Premises on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;],
20[&nbsp;&nbsp;&nbsp;&nbsp;]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. The Premises are in good order, condition and repair. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. The Tenant Improvements are Substantially Complete. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4. All conditions of the Lease to be performed by Landlord as a condition to the full effectiveness of the Lease have been satisfied, and Landlord has fulfilled all of its duties in the nature of
inducements offered to Tenant to lease the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. In accordance with the provisions of <U>Article 4</U> of the Lease,
the Term Commencement Date is [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], and, unless the Lease is terminated prior to the Term Expiration Date pursuant to its terms, the Term Expiration
Date shall be [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.
Tenant commenced occupancy of the Premises for the Permitted Use on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7. The Lease is in full force and effect, and the same represents the entire agreement between Landlord and Tenant concerning the Premises[, except
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. Tenant has no existing defenses against the
enforcement of the Lease by Landlord, and there exist no offsets or credits against Rent owed or to be owed by Tenant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">C-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. The obligation to pay Rent is presently in effect and all Rent obligations on the part
of Tenant under the Lease commenced to accrue on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], with Base Rent payable on the dates and amounts set forth in the chart below: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:19pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Dates</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Square&nbsp;Feet&nbsp;of<BR>Rentable Area</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Base&nbsp;Rent&nbsp;per<BR>Square&nbsp;Foot&nbsp;of<BR>Rentable&nbsp;Area</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Monthly&nbsp;Base<BR>Rent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Annual&nbsp;Base<BR>Rent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 1-3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 4-15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.00&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,400.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">484,800.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 16-27</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32.96&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,612.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">499,344.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 28-39</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33.95&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42,861.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">514,342.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 40-51</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34.97&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,149.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">529,795.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Months 52-63</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36.02&nbsp;annually</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,475.25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">545,703.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. The undersigned Tenant has not made any prior assignment, transfer, hypothecation or pledge of the
Lease or of the rents thereunder or sublease of the Premises or any portion thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[REMAINDER OF THIS PAGE INTENTIONALLY
LEFT BLANK] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">C-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, Tenant has executed this Acknowledgment of Term Commencement Date and
Term Expiration Date as of the date first written above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC.,</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">C-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT D </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>TENANT MANUAL </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fresh Pond </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tenant Design Manual </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Updated: January&nbsp;25, 2012 </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g335938exhibitd.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">BioMed Realty Trust </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1 Main Street, Cambridge, MA 02142 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">617-225-2440 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. INTENT</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. TENANT DESIGN CRITERIA &#150; ARCHITECTURE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ACOUSTICAL</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>VIBRATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WINDOW TREATMENT</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.4</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNAGE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.5</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SOUND ATTENUATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.6</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ROOFTOP EQUIPMENT</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.7</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[**]</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.8</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FLOOR DRAINS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.9</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ROOFING AND ENVELOPE ALTERATIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. TENANT DESIGN CRITERIA - STRUCTURE</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.1.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tenant Loads</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. TENANT DESIGN CRITERIA - MEP &amp; FP</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ELECTRICAL CRITERIA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electrical Acceptance Testing</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tenant Distribution</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Light Fixtures</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.4</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emergency Lighting, Exit Signs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.5</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Generator, Exhaust Stacks</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PLUMBING CRITERIA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Water Meter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gas-fired Water Heater</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natural Gas Service - Standards</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FIRE PROTECTION CRITERIA</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Protection System</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.2</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Obligation to Maintain Effectiveness of Sprinkler System</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.3</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Dampers</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.4</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Detection and Alarm Systems - Tenant Provision</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. EXHIBIT A:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.1.1</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[**]</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INTENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant Manual is
supplementary to the Lease and must be referenced in conjunction with the Lease. The intent of this document is to describe certain features of the Base Building, assist in the design of Tenant&#146;s Premises and to outline Tenant&#146;s
obligations in performing Tenant Improvement Work. Tenants are encouraged to discuss specific issues or questions regarding their space with the Landlord prior to beginning design work. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT DESIGN CRITERIA &#150; ARCHITECTURE </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Section identifies specific design and construction criteria for the tenant&#146;s interior Tenant Improvements. It is the Landlord&#146;s intent to
ensure that Fresh Pond maintains a high quality environment for tenant uses. Due to potential impacts that might affect other building users or neighbors, tenant fit-out and equipment selections must follow the established criteria that are noted
below and be approved by the Landlord in writing. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ACOUSTICAL </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenants must be responsible
for compliance with current City of Cambridge Noise Ordinances, in particular with reference to exterior roof top equipment. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>VIBRATION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant is required to install
vibration isolation equipment for emergency generators and other vibration generating equipment. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WINDOW TREATMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
Tenant window treatment is to be provided by Tenant with vertical blinds - Levelor Louver drape zirlon wheeled system, clear anodized alum head-rail with extruded
3<FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1">2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> PVC blades color: Alabaster. No windows may be
blocked without Landlord&#146;s approval. </FONT></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNAGE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant signage requires Landlord
approval and must conform to zoning ordinances and building standards. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SOUND ATTENUATION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenants must utilize a
sound attenuating generator enclosure, and ensure that the acoustical performance of the generator meets with City of Cambridge Noise Ordinances. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.6</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ROOFTOP EQUIPMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment must be
located and oriented to provide access for service, not impede access to egress or other tenant&#146;s equipment, and not otherwise create a hazard. All rooftop equipment must be installed in accordance with City of Cambridge rooftop mechanical
equipment standards and of a neutral grey/tan/beige color, subject to review by Landlord&#146;s Architect. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.7</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[**] </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.8</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FLOOR DRAINS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing floor drains are
to be maintained free of obstructions at all times. Tenant is to install concrete containment curbs and floor drains at tenant installed hot water heaters or other water source equipment. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.9</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ROOFING AND ENVELOPE ALTERATIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any
alterations to the building envelope or roofing systems will require a quality acceptance program and inspection. The work performed and the quality assurance program should be performed in accordance with manufacturer and warranty specifications
and should include project oversight during construction, field quality inspections / reports, design peer review of details. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT DESIGN CRITERIA - STRUCTURE </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.1.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tenant Loads </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All tenant loads in excess
of existing base-building design require Landlord approval. A structural engineer, licensed in the State of Massachusetts, is to provide structural calculations and design for support of excess loads. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT DESIGN CRITERIA - MEP&nbsp;&amp; FP </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>[**]<B> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A total of two pages were
omitted and filed separately with the Securities and Exchange Commission. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>ELECTRICAL CRITERIA<B> </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Electrical Acceptance Testing<B> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of any alteration to the electrical distribution system, Tenant must submit third party electrical acceptance testing results including IR
scan, Breaker testing and a breaker coordination study stamped by a Commonwealth of Massachusetts licensed electrical engineer. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tenant Distribution </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant must be
responsible for furnishing and installing all Tenant electrical infrastructure and distribution for their equipment (i.e., UPS, generator, etc.) in a linear and consistent configuration. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Light Fixtures </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Light fixtures within
Tenant space must be furnished and installed by the Tenant and provide a consistent appearance from the exterior of the building. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Emergency Lighting, Exit Signs </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Emergency
egress lighting and exit signs must be battery operated or tied into emergency power. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.2.5</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Generator, Exhaust Stacks </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenants must
ensure that the generator exhaust stacks are sized and located to prevent re-entrainment of generator emissions at all building outside air intakes. Tenant shall be responsible for ensuring that associated designs are consistent with applicable City
guidelines. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PLUMBING CRITERIA </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Water Meter </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant must install its line
extension with a water meter and electronic readout (connected to the base building DDC system per Landlord&#146;s specifications) easily accessible to Landlord. Sub-meter specifications are to be approved by Landlord. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gas-fired Water Heater </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Water heaters may
be natural gas fired, with necessary safety controls and drains per code, based on the Tenant&#146;s water heating needs. Landlord&#146;s written permission for using gas water heaters must be obtained by the Tenant prior to utilizing gas-fired
water heaters. The Tenant must provide gas piping to the water heater from the gas meter, gas flues through roof, and combustion/ventilation air in accordance with code. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Drains must be piped to the nearest waste receptor through an approved air gap. All gas-fired water heaters must be approved by and installed in accordance with Massachusetts State Building and Plumbing
Codes. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.3.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natural Gas Service - Standards </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All gas
plumbing must be Schedule 40 black iron, per Code and base building specification. All contractor work on gas piping to systems must be qualified and licensed by the Commonwealth of Massachusetts. Benchtop natural gas turrets and fume hood natural
gas valves must be press-to-turn locking type, similar to Water-saver, in accordance with Cambridge Fire Department requirements. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FIRE PROTECTION CRITERIA </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.1</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Protection System </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
modifications, additions, repairs, or relocations to the sprinkler system, or any other system or equipment installed by Landlord which are required for the Tenant&#146;s use prior to occupancy must be performed at the Tenant&#146;s cost and
expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plans and calculations must be signed and sealed by a Commonwealth of Massachusetts registered fire protection engineer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant must generate a sprinkler shop drawing and supply hydraulic calculations stamped by a Massachusetts registered Fire Protection Engineer.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.2</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Obligation to Maintain Effectiveness of Sprinkler System </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s fixtures, storage, and other Tenant practices must be subject to code and must not be conducted in such a manner as to hinder the effectiveness of the sprinkler or other fire protection
system(s). </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.3</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Dampers </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A fire damper must be
installed within Tenant&#146;s ductwork where such duct passes through a fire rated wall, at Tenant&#146;s sole cost. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.4.4</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Fire Detection and Alarm Systems - Tenant Provision </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tenant must provide a complete fire alarm system within the leased premises, including but not limited to, all necessary labor, detectors, strobes, horns, wiring, etc. necessary for the satisfactory
operation of a fire alarm system using Landlord selected manufacturer. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall tie all fire alarm systems into the existing landlord fire alarm panel. If one is not available then the system should meet owners specifications based on
the site or campus conditions </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of Tenant fire alarm system, Tenant&#146;s fire alarm contractor must contact Landlord for final point of connection to the fire alarm junction box at
Tenant&#146;s expense. Tenant is responsible for the testing of the expanded system in accordance with NFPA 72 and authority having jurisdiction. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire alarm devices must be structurally mounted. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Tenant must generate a fire alarm drawing and submit to Landlord. Landlord will forward this drawing to the local fire department. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class &#147;A&#148; system wires must be identified for direction and polarity. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Current ADA guidelines, including state and local codes, must be followed. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wiring methods must be in accordance with applicable NEC and NFPA 72 codes. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provide duct smoke detector; locate inside supply duct, downstream of the filters and ahead of any branch connections, on all systems. In addition, any system over
15,000 CFM must provide duct smoke detectors located inside the return duct, upstream of filters, exhaust air connections or outside air connections. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smoke detectors must be compatible with the existing fire alarm system. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A: </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">D-7
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT E </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>FORM OF LETTER OF CREDIT </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[On letterhead or L/C letterhead of
Issuer.] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LETTER OF CREDIT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 200__ </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(the&nbsp;&#147;<U>Beneficiary</U>&#148;)</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">L/C. No.:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loan No. :</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ladies and Gentlemen: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We establish in favor of Beneficiary our irrevocable and unconditional Letter of Credit numbered as identified above (the &#147;<U>L/C</U>&#148;) for an aggregate amount of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, expiring at &nbsp;&nbsp;&nbsp;&nbsp;:00 p.m. on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or, if such day is not a Banking Day, then the next
succeeding Banking Day (such date, as extended from time to time, the &#147;<U>Expiry Date</U>&#148;). &#147;<U>Banking Day</U>&#148; means a weekday except a weekday when commercial banks in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; are authorized or required to close. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We authorize
Beneficiary to draw on us (the &#147;<U>Issuer</U>&#148;) for the account of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<U>Account Party</U>&#148;), under the terms and conditions of this L/C. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funds under this L/C are available by presenting the following documentation (the &#147;<U>Drawing Documentation</U>&#148;): (a)&nbsp;the
original L/C and (b)&nbsp;a sight draft substantially in the form of <U>Attachment 1</U>, with blanks filled in and bracketed items provided as appropriate. No other evidence of authority, certificate, or documentation is required. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drawing Documentation must be presented at Issuer&#146;s office at
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; on or before the Expiry Date by personal presentation, courier or messenger service, or fax. Presentation by fax shall be effective upon electronic confirmation of transmission
as evidenced by a printed report from the sender&#146;s fax machine. After any fax presentation, but not as a condition to its effectiveness, Beneficiary shall with reasonable promptness deliver the original Drawing Documentation by any other means.
Issuer will on request issue a receipt for Drawing Documentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We agree, irrevocably, and irrespective of any claim by any
other person, to honor drafts drawn under and in conformity with this L/C, within the maximum amount of this L/C, presented to us on or before the Expiry Date, <U>provided</U> we also receive (on or before the Expiry Date) any other Drawing
Documentation this L/C requires. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">E-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We shall pay this L/C only from our own funds by check or wire transfer, in compliance with
the Drawing Documentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Beneficiary presents proper Drawing Documentation to us on or before the Expiry Date, then we
shall pay under this L/C at or before the following time (the &#147;<U>Payment Deadline</U>&#148;): (a)&nbsp;if presentment is made at or before noon of any Banking Day, then the close of such Banking Day; and (b)&nbsp;otherwise, the close of the
next Banking Day. We waive any right to delay payment beyond the Payment Deadline. If we determine that Drawing Documentation is not proper, then we shall so advise Beneficiary in writing, specifying all grounds for our determination, within one
Banking Day after the Payment Deadline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Partial drawings are permitted. This L/C shall, except to the extent reduced thereby,
survive any partial drawings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We shall have no duty or right to inquire into the validity of or basis for any draw under this
L/C or any Drawing Documentation. We waive any defense based on fraud or any claim of fraud. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Expiry Date shall
automatically be extended by one year (but never beyond &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the &#147;<U>Outside Date</U>&#148;)) unless, on or before the date 90 days before any Expiry Date, we have given
Beneficiary notice that the Expiry Date shall not be so extended (a &#147;<U>Nonrenewal Notice</U>&#148;). We shall promptly upon request confirm any extension of the Expiry Date under the preceding sentence by issuing an amendment to this L/C, but
such an amendment is not required for the extension to be effective. We need not give any notice of the Outside Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficiary may from time to time without charge transfer this L/C, in whole but not in part, to any transferee (the
&#147;<U>Transferee</U>&#148;). Issuer shall look solely to Account Party for payment of any fee for any transfer of this L/C. Such payment is not a condition to any such transfer. Beneficiary or Transferee shall consummate such transfer by
delivering to Issuer the original of this L/C and a Transfer Notice substantially in the form of <U>Attachment 2</U>, purportedly signed by Beneficiary, and designating Transferee. Issuer shall promptly reissue or amend this L/C in favor of
Transferee as Beneficiary. Upon any transfer, all references to Beneficiary shall automatically refer to Transferee, who may then exercise all rights of Beneficiary. Issuer expressly consents to any transfers made from time to time in compliance
with this paragraph. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any notice to Beneficiary shall be in writing and delivered by hand with receipt acknowledged or by
overnight delivery service such as FedEx (with proof of delivery) at the above address, or such other address as Beneficiary may specify by written notice to Issuer. A copy of any such notice shall also be delivered, as a condition to the
effectiveness of such notice, to: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (or such replacement as Beneficiary designates from time to time by written notice). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No amendment that adversely affects Beneficiary shall be effective without Beneficiary&#146;s written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This L/C is subject to and incorporates by reference: (a)&nbsp;the International Standby Practices 98 (&#147;<U>ISP 98</U>&#148;); and
(b)&nbsp;to the extent not inconsistent with ISP 98, Article 5 of the Uniform Commercial Code of the State of New York. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">E-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Very truly yours,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Issuer Signature]</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">E-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATTACHMENT 1 TO EXHIBIT E </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">FORM OF SIGHT DRAFT </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TO: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Name and Address of Issuer] </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGHT DRAFT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AT SIGHT,
pay to the Order of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, the sum of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States Dollars ($&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;). Drawn under [Issuer] Letter of Credit No.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Issuer is hereby directed to pay the proceeds of this Sight Draft solely to the following account:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Name and
signature block, with signature or purported signature of Beneficiary] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">E-1-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ATTACHMENT 2 TO EXHIBIT E </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">FORM OF TRANSFER NOTICE </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[B<SMALL>ENEFICIARY</SMALL> L<SMALL>ETTERHEAD</SMALL>] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TO: </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Name and Address of Issuer] (the &#147;<U>Issuer</U>&#148;) </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>TRANSFER NOTICE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">By signing below, the undersigned, Beneficiary (the
&#147;<U>Beneficiary</U>&#148;) under Issuer&#146;s Letter of Credit No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(the &#147;<U>L/C</U>&#148;), transfers the L/C to the following transferee (the &#147;<U>Transferee</U>&#148;): </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Transferee Name and Address] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The original
L/C is enclosed. Beneficiary directs Issuer to reissue or amend the L/C in favor of Transferee as Beneficiary. Beneficiary represents and warrants that Beneficiary has not transferred, assigned, or encumbered the L/C or any interest in the L/C,
which transfer, assignment, or encumbrance remains in effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Name and signature block, with signature or purported signature of
Beneficiary] </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">E-2-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT F </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>RULES AND REGULATIONS </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOTHING IN THESE RULES AND REGULATIONS
(&#147;<U>RULES AND REGULATIONS</U>&#148;) SHALL SUPPLANT ANY PROVISION OF THE LEASE. IN THE EVENT OF A CONFLICT OR INCONSISTENCY BETWEEN THESE RULES AND REGULATIONS AND THE LEASE, THE LEASE SHALL PREVAIL. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. Neither Tenant nor Tenant&#146;s employees, agents, contractors or invitees shall encumber or obstruct the common entrances, lobbies, elevators,
sidewalks and stairways of the Building(s) or the Project or use them for any purposes other than ingress or egress to and from the Building(s) or the Project. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. Except as specifically provided in the Lease, no sign, placard, picture, advertisement, name or notice shall be installed or displayed on any part of the outside of the Premises or the Building(s)
without Landlord&#146;s prior written consent. Landlord shall have the right to remove, at Tenant&#146;s sole cost and expense and without notice, any sign installed or displayed in violation of this rule. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. If Landlord objects in writing to any curtains, blinds, shades, screens, hanging plants or other objects attached to or used in connection with any
window or door of the Premises or placed on any windowsill, and (a)&nbsp;such window, door or windowsill is visible from the exterior of the Premises and (b)&nbsp;such curtain, blind, shade, screen, hanging plant or other object has not been
approved by Landlord pursuant to <U>Section&nbsp;12.6</U> of the Lease, then Tenant shall promptly remove said curtains, blinds, shades, screens, hanging plants or similar objects at its sole cost and expense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. No deliveries shall be made that impede or interfere with other tenants in or the operation of the Project. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. Tenant shall not place a load upon any floor of the Premises that exceeds the load per square foot that (a)&nbsp;such floor was designed to carry or
(b)&nbsp;is allowed by Applicable Laws. Fixtures and equipment that cause noises or vibrations that may be transmitted to the structure of the Building(s) to such a degree as to be objectionable to other tenants shall be placed and maintained by
Tenant, at Tenant&#146;s sole cost and expense, on vibration eliminators or other devices sufficient to eliminate such noises and vibrations to levels reasonably acceptable to Landlord and the affected tenants of the Project. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. Tenant shall not use any method of heating or air conditioning other than that shown in the Tenant Improvement plans. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. Tenant shall not install any radio, television or other antennae; cell or other communications equipment; or other devices on the roof or exterior
walls of the Premises except in accordance with the Lease. Tenant shall not interfere with radio, television or other digital or electronic communications at the Project or elsewhere. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. Canvassing, peddling, soliciting and distributing handbills or any other written material within, on or
around the Project (other than within the Premises) are prohibited. Tenant shall cooperate with Landlord to prevent such activities by Tenant or its employees, agents, contractors and invitees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. Tenant shall store all of its trash, garbage and Hazardous Materials within its Premises or in receptacles designated by Landlord outside of the
Premises. Tenant shall not place in any such receptacle any material that cannot be disposed of in the ordinary and customary manner of trash, garbage and Hazardous Materials disposal. Any Hazardous Materials transported through Common Areas shall
be held in secondary containment devices. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. The Premises shall not be used for lodging or for any improper, immoral or objectionable
purpose. No cooking shall be done or permitted in the Premises; <U>provided</U>, however, that Tenant may use (a)&nbsp;equipment approved in accordance with the requirements of insurance policies that Landlord or Tenant is required to purchase and
maintain pursuant to the Lease for brewing coffee, tea, hot chocolate and similar beverages, (b)&nbsp;microwave ovens for employees&#146; use and (c)&nbsp;equipment shown on Tenant Improvement plans approved by Landlord; <U>provided</U>, further,
that any such equipment and microwave ovens are used in accordance with Applicable Laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. Tenant shall not, without Landlord&#146;s prior
written consent, use the name of the Project, if any, in connection with or in promoting or advertising Tenant&#146;s business except as Tenant&#146;s address. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12. Tenant shall comply with all safety, fire protection and evacuation procedures and regulations established by Landlord or any Governmental Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. Tenant assumes any and all responsibility for protecting the Premises from theft, robbery and pilferage, which responsibility includes keeping doors
locked and other means of entry to the Premises closed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. Tenant shall furnish Landlord with copies of keys, pass cards or similar devices
for locks to the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. Tenant shall cooperate and participate in all reasonable security programs affecting the Premises. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">16. Tenant shall not permit any animals in the Project, other than for guide animals or for use in laboratory experiments. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">17. Bicycles shall not be taken into the Building(s) except into areas designated by Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">18. The water and wash closets and other plumbing fixtures shall not be used for any purposes other than those for which they were constructed, and no sweepings, rubbish, rags or other substances shall be
deposited therein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">19. Discharge of industrial sewage shall only be permitted if Tenant, at its sole expense, first obtains all necessary
permits and licenses therefor from all applicable Governmental Authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">20. Smoking is prohibited at the Project. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">21. The Project&#146;s hours of operation are currently 24 hours a day seven days a week. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">22. Tenant shall comply with all orders, requirements and conditions now or hereafter imposed by Applicable Laws or Landlord (&#147;<U>Waste
Regulations</U>&#148;) regarding the collection, sorting, separation and recycling of waste products, garbage, refuse and trash generated by Tenant (collectively, &#147;<U>Waste Products</U>&#148;), including (without limitation) the separation of
Waste Products into receptacles reasonably approved by Landlord and the removal of such receptacles in accordance with any collection schedules prescribed by Waste Regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">23. Tenant, at Tenant&#146;s sole cost and expense, shall cause the Premises to be exterminated on a monthly basis to Landlord&#146;s reasonable satisfaction and shall cause all portions of the Premises
used for the storage, preparation, service or consumption of food or beverages to be cleaned daily in a manner reasonably satisfactory to Landlord, and to be treated against infestation by insects, rodents and other vermin and pests whenever there
is evidence of any infestation. Tenant shall not permit any person to enter the Premises or the Project for the purpose of providing such extermination services, unless such persons have been approved by Landlord. If requested by Landlord, Tenant
shall, at Tenant&#146;s sole cost and expense, store any refuse generated in the Premises by the consumption of food or beverages in a cold box or similar facility. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord may waive any one or more of these Rules and Regulations for the benefit of Tenant or any other tenant, but no such waiver by Landlord shall be construed as a waiver of such Rules and Regulations
in favor of Tenant or any other tenant, nor prevent Landlord from thereafter enforcing any such Rules and Regulations against any or all of the tenants of the Project, including Tenant. These Rules and Regulations are in addition to, and shall not
be construed to in any way modify or amend, in whole or in part, the terms covenants, agreements and conditions of the Lease. Landlord reserves the right to make such other and reasonable rules and regulations as, in its judgment, may from time to
time be needed for safety and security, the care and cleanliness of the Project, or the preservation of good order therein; <U>provided</U>, however, that Tenant shall not be obligated to adhere to such additional rules or regulations until Landlord
has provided Tenant with written notice thereof. Tenant agrees to abide by these Rules and Regulations and any additional rules and regulations issued or adopted by Landlord. Tenant shall be responsible for the observance of these Rules and
Regulations by Tenant&#146;s employees, agents, contractors and invitees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT G </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>SHUTTLE SERVICE DESCRIPTION </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Shuttle bus starts at Alewife and ends at 767C
Concord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">It takes approximately 12 minutes to complete a run with an 8 minute return. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shuttle runs every 30 minutes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Morning Schedule:</U></B> 7:00 a.m. to 10:30 a.m. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alewife </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">55Wheeler </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10 Fawcett </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 Moulton </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">45 Moulton </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 Wilson </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">767 C Concord </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Afternoon Schedule:</U></B> 3:00 p.m. to 7:30 p.m. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">767 C Concord </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 Wilson </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 Moulton </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 Moulton </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 Fawcett </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">55Wheeler </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alewife </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shuttle will
not run on the following holidays: New Year&#146;s Day, the day after New Year&#146;s Day, President&#146;s Day, Patriots&#146; Day, Memorial Day, July&nbsp;4</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, Labor Day, Columbus Day, Thanksgiving and the day after and Christmas Day. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All times are approximate die to weather and traffic conditions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">G-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT H </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>TENANT&#146;S PERSONAL PROPERTY </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:45pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">ITEM&nbsp;NAME</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">DESCRIPTION/Model<BR>#</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">CAPACITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">MANUFACTURER</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Estimated&nbsp;Quantity</FONT></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">[**]</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A total of seven pages were omitted and filed separately with the Securities and Exchange Commission. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">H-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT I </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>FORM OF ESTOPPEL CERTIFICATE </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BMR-FRESH POND RESEARCH PARK LLC </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17190 Bernardo Center Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">San Diego, California 92128 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Vice President, Real Estate Counsel
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">BioMed Realty, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17190 Bernardo Center Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Diego, California 92128 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Re:</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">665 Concord Avenue, Cambridge, Massachusetts (the &#147;<U>Premises</U>&#148;) at 25, 33, 45, 47, 51 and 61 Moulton Street, Cambridge, Massachusetts and 665 Concord
Avenue, Cambridge, Massachusetts (the &#147;Property&#148;) </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned tenant (&#147;<U>Tenant</U>&#148;) hereby certifies
to you as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. Tenant is a tenant at the Property under a lease (the &#147;<U>Lease</U>&#148;) for the Premises dated
as of February&nbsp;10, 2012. The Lease has not been cancelled, modified, assigned, extended or amended [except as follows: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]], and there are no other agreements, written or
oral, affecting or relating to Tenant&#146;s lease of the Premises or any other space at the Property. The lease term expires on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Tenant took possession of the Premises, currently consisting of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] square feet, on [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;], and commenced to pay rent on
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. Tenant has full possession of the Premises, has not assigned the Lease or sublet any part of the Premises, and does not hold the Premises under
an assignment or sublease[, except as follows: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. All base rent, rent escalations and additional rent under the Lease have been paid through
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. There is no prepaid rent[, except $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]][, and the amount of security deposit is
$[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] [in cash][OR][in the form of a letter of credit]]. Tenant currently has no right to any future rent abatement under the Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. Base rent is currently payable in the amount of $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per month. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. Tenant is currently paying estimated payments of additional rent of $[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] per month on
account of real estate taxes, insurance, management fees and common area maintenance expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. All work to be performed
for Tenant under the Lease has been performed as required under the Lease and has been accepted by Tenant[, except [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]], and all allowances to be paid to Tenant, including
allowances for tenant improvements, moving expenses or other items, have been paid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. The Lease is in full force and effect,
free from default and free from any event that could become a default under the Lease, and Tenant has no claims against the landlord or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">I-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
offsets or defenses against rent, and there are no disputes with the landlord. Tenant has received no notice of prior sale, transfer, assignment, hypothecation or pledge of the Lease or of the
rents payable thereunder[, except [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]]. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. [Tenant has
the following expansion rights or options for the Property: [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;].][OR][Tenant has no rights or options to purchase the Property.] </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. To Tenant&#146;s knowledge, no hazardous wastes have been generated, treated, stored or disposed of by or on behalf of Tenant in, on
or around the Premises or the Project in violation of any environmental laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. The undersigned has executed this Estoppel
Certificate with the knowledge and understanding that [INSERT NAME OF LANDLORD, PURCHASER OR LENDER, AS APPROPRIATE] or its assignee is acquiring the Property in reliance on this certificate and that the undersigned shall be bound by this
certificate. The statements contained herein may be relied upon by [INSERT NAME OF PURCHASER OR LENDER, AS APPROPRIATE], [LANDLORD], BioMed Realty, L.P., BioMed Realty Trust, Inc., and any [other] mortgagee of the Property and their respective
successors and assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any capitalized terms not defined herein shall have the respective meanings given in the Lease.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated this [&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] day of
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;], 20[&nbsp;&nbsp;&nbsp;&nbsp;]. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALNYLAM PHARMACEUTICALS, INC.,</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">I-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT J </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>CAM POOLS AND MAINTENANCE MATRIX </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>FRESH POND CAM POOL </U></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>The Below CAM pool is the poo| used to account for all expenses </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>PROJECT = Includes all costs associated within the designated campus </U></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>BUILDING
= Includes all cost associated within the occupied buildings. </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:40pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ACCOUNT</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Maintenance responsibility</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>ALNYLAM CAM POOL</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Landlord&nbsp;/&nbsp;Tenant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tenant&nbsp;pays&nbsp;pro<BR>rata&nbsp;share&nbsp;of&nbsp;project<BR>expenses</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tenant&nbsp;pays&nbsp;pro&nbsp;rata&nbsp;share&nbsp;of<BR>building expenses</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Utilities:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Electricity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project electricity&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Electricity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building electricity&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gas</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project gas&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gas</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building gas&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Water</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building water&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Maintenance &amp; Repairs</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bulbs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bonding expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Carpet/Floor Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ceiling Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Electrical Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Electrical Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Environmental Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment Maintenance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment Rental</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment Rental</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exterior Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire Extinguisher</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Glass Replacement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key and Keycard Stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspection Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lighting Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Locksmith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense&nbsp;-&nbsp;Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Painting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pest Control</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plumbing Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plumbing Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Root Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sign Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Uniforms</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense&nbsp;-&nbsp;Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">J-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Janitorial:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contracted Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power Washing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Window Washing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>HVAC</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Elevators:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contracted Services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Permits/Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Landscape&nbsp;&amp; Grounds Maintenance</U>:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contracted Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interior Landscaping</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landscaping Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parking Lot Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shuttle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trash Removal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vehicle Repairs&nbsp;&amp; Maintenance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lot and Landscape - Other</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Security&nbsp;&amp; Life Safety:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contracted Service</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Security Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Life Safety Inspections</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Security Vehicle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire&nbsp;&amp; Life Safety - Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building expense - Tenant</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Property Administrative:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cell Phones and Pagers</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consultant Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Computer Supplies&nbsp;&amp; Repairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Licenses&nbsp;&amp; permits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office General</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Rent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Office Supplies</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Salaries &amp; Related:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative Salaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administrative P/R Taxes &amp; Related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance Salaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance P/R Taxes&nbsp;&amp; Related</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Temporary Help</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Management</U>:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">As&nbsp;per&nbsp;lease</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Taxes:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Real Property&nbsp;&amp; School</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Insurance:</U></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boiler&nbsp;&amp; Machinery Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DIC Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Liability Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Environmental Insurance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Protect expense - Landlord</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">J-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT K </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>RESERVED PARKING </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g335938exhibitk.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">K-1
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12
<SEQUENCE>4
<FILENAME>d335938dex12.htm
<DESCRIPTION>COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES
<TEXT>
<HTML><HEAD>
<TITLE>Computation of Consolidated Ratios of Earnings/Deficiencies</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 12 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES TO FIXED CHARGES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(dollars in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Months</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>ended</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>March 31,</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2010</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2009</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2008</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2007</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Earnings (loss):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-tax loss from continuing operations before adjustment for loss from equity investee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(79,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">add: Fixed charges (see below)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-tax income (loss) from continuing operations before adjustment for income/loss from equity investees plus fixed
charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(52,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(41,386</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(77,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fixed charges:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense on indebtedness</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">872</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,083</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest expense on portion of rent expense representative of interest</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total fixed charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,553</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ratio of earnings to fixed charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deficiency of earnings available to cover fixed charges</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(35,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(42,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(79,146</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>d335938dex311.htm
<DESCRIPTION>SECTION 302 CEO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>Section 302 CEO Certification</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, John M. Maraganore, Ph.D., certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May 3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John M. Maraganore</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John M. Maraganore, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>d335938dex312.htm
<DESCRIPTION>SECTION 302 CFO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>Section 302 CFO Certification</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 31.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I, Michael P. Mason, certify that: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">I have reviewed this Quarterly Report on Form 10-Q of Alnylam Pharmaceuticals, Inc.; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules&nbsp;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the registrant and have: </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material
information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the
disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal
quarter (the registrant&#146;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant&#146;s auditors and the audit committee of the registrant&#146;s board of directors (or persons performing the equivalent functions): </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant&#146;s ability to record, process, summarize and report financial information; and </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial
reporting. </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: May 3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael P. Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael P. Mason</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance and Treasurer</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>d335938dex321.htm
<DESCRIPTION>SECTION 906 CEO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>Section 906 CEO Certification</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 32.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report on Form 10-Q of Alnylam
Pharmaceuticals, Inc. (the &#147;Company&#148;) for the quarter ended March&nbsp;31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, John M. Maraganore, Ph.D., Chief Executive
Officer of the Company, hereby certifies, pursuant to Section&nbsp;1350 of Chapter 63 of Title 18, United States Code, that to his knowledge: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May 3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John M. Maraganore</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John M. Maraganore, Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be
retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>d335938dex322.htm
<DESCRIPTION>SECTION 906 CFO CERTIFICATION
<TEXT>
<HTML><HEAD>
<TITLE>Section 906 CFO Certification</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 32.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the Quarterly Report on Form 10-Q of Alnylam
Pharmaceuticals, Inc. (the &#147;Company&#148;) for the quarter ended March&nbsp;31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Michael P. Mason, Vice President of Finance
and Treasurer of the Company, hereby certifies, pursuant to Section&nbsp;1350 of Chapter&nbsp;63 of Title 18, United States Code, that to his knowledge: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the Report fully complies with the requirements of Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
</FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: May 3, 2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Michael P. Mason</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael P. Mason</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President of Finance and Treasurer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A signed original of this written statement required by Section&nbsp;906 has been provided to the Company
and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>alny-20120331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- XBRL Generated with XBRLMark Copyright (C) by RR Donnelley -->
<!-- Based on XBRL 2.1 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:alny="http://alnylam.com/20120331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2011-01-31">
  <link:schemaRef xlink:type="simple" xlink:href="alny-20120331.xsd" />
  <!-- Context Section -->
  <context id="BalanceAsOf_31Mar2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2011-03-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2010">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2010-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Mar2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2012-03-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_31Dec2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="BalanceAsOf_30Apr2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <instant>2012-04-30</instant>
    </period>
  </context>
  <context id="ThreeMonthsEnded_31Mar2011">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="Jan-01-2012_Mar-31-2012">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001178670</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-03-31</endDate>
    </period>
  </context>
  <!--Unit Section-->
  <unit id="USDEPS">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="USD">
    <measure>iso4217:USD</measure>
  </unit>
  <!-- Element Section -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock--&gt;
   &lt;!-- xbrl,ns --&gt;
   &lt;!-- xbrl,nx --&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;font style="font-family:times new roman" size="2"&gt;
   &lt;b&gt;&lt;/b&gt;&lt;/font&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation and Principles of Consolidation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. (the &amp;#8220;Company&amp;#8221; or
   &amp;#8220;Alnylam&amp;#8221;) are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) applicable to interim periods and, in the opinion of management, include all
   normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. The Company&amp;#8217;s condensed consolidated financial statements have also been prepared on a basis substantially consistent with,
   and should be read in conjunction with, the Company&amp;#8217;s audited consolidated financial statements for the year ended December&amp;#160;31, 2011, which were included in the Company&amp;#8217;s Annual Report on Form 10-K that was filed with the Securities
   and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) on February&amp;#160;13, 2012. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of the
   Company&amp;#8217;s operations for any interim period are not necessarily indicative of the results of the Company&amp;#8217;s operations for any other interim period or for a full fiscal year. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The accompanying condensed consolidated financial statements reflect the operations of the Company and Alnylam U.S., Inc., Alnylam Europe
   AG (&amp;#8220;Alnylam Europe&amp;#8221;), Alnylam Securities Corporation and Meltemi Biotherapeutics, Inc., wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have been eliminated. The Company uses the equity
   method of accounting to account for its investment in Regulus Therapeutics Inc. (&amp;#8220;Regulus&amp;#8221;). &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates
   &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions
   that affect&amp;#160;the reported amounts of assets and liabilities and&amp;#160;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&amp;#160;the reported amounts of revenues and expenses during
   the reporting period. Actual results could differ from those estimates. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company computes basic net loss&amp;#160;per common share by dividing net loss&amp;#160;attributable to common stockholders by the weighted
   average number of common shares outstanding. The Company computes diluted net loss&amp;#160;per common share by dividing net loss&amp;#160;attributable to common stockholders by the weighted average number of common shares and dilutive potential common
   share equivalents then outstanding. Potential common shares consist of shares issuable upon the exercise of stock options (using the treasury stock method) and unvested restricted stock awards. Because the inclusion of potential common shares would
   be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table sets forth for the periods presented the potential common shares (prior to consideration of the treasury stock
   method) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive, in thousands: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="84%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="3%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three&amp;#160;Months&amp;#160;Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;
   31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Options to purchase common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;9,085&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,869&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Unvested restricted common stock&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;658&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;113&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;9,743&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;8,982&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Awards
   &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In January 2012, as part of its post-restructuring retention program, the Company granted an aggregate of 508,928
   shares of restricted stock to its retained employees, excluding the Company&amp;#8217;s chief executive officer and president and chief operating officer. These restricted stock awards were valued at $5.3 million on the grant date and vest in full on the
   second anniversary of the grant date. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company recognized an aggregate of $0.5 million and $0.1 million of stock-based
   compensation expense related to all restricted stock awards granted for the three months ended March&amp;#160;31, 2012 and 2011, respectively. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Public Offering &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In February 2012, the Company sold an aggregate of 8,625,000 shares of its common stock through an underwritten public offering at a price
   to the public of $10.75 per share. As a result of the offering, the Company received aggregate net proceeds of approximately $86.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses of approximately
   $5.9 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The following tables present information about the Company&amp;#8217;s assets that are measured at fair value on a recurring basis at March&amp;#160;31, 2012 and December&amp;#160;31, 2011, and indicate the fair value
   hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level&amp;#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values
   determined by Level&amp;#160;2 inputs utilize data points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair values determined by Level&amp;#160;3 inputs utilize unobservable data points for the asset or liability,
   and include situations where there is little, if any, market activity for the asset or liability. The fair value hierarchy level is determined by the lowest level of significant input. Financial assets measured at fair value on a recurring basis are
   summarized as follows, in thousands: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:39pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;At&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;&amp;#160;&amp;#160;March&amp;#160;31,&amp;#160;&amp;#160;
   &lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;in
   Active&lt;br /&gt;Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Observable&lt;br /&gt;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Unobservable&lt;br /&gt;Inputs&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(Level
    3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60,791&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60,088&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;703&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Marketable securities (fixed income)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;181,121&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;181,121&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;68,832&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;68,832&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,182&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,182&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Marketable securities (equity holdings)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;43&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;43&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;315,969&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60,088&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;255,881&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="56%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom" nowrap="nowrap"&gt;
   &lt;p style="border-bottom:1px solid #000000;width:39pt"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;At&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;
   31,&lt;br /&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Quoted&amp;#160;Prices&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;in
   Active&lt;br /&gt;Markets&lt;br /&gt;(Level 1)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Observable&lt;br /&gt;Inputs&lt;br /&gt;(Level 2)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Significant&lt;br /&gt;Unobservable&lt;br /&gt;Inputs&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;(Level
    3)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;67,024&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;67,024&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Marketable securities (fixed income)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;104,839&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;104,839&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;73,722&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;73,722&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Commercial paper&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,395&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,395&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Marketable securities (equity holdings)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;625&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;625&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;257,605&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;67,024&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;190,581&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the three months ended March&amp;#160;31, 2012, there were no transfers between Level 1 and Level 2
   financial assets. The carrying amounts reflected in the Company&amp;#8217;s condensed consolidated balance sheets for cash, collaboration receivables, other current assets, accounts payable and accrued expenses approximate fair value due to their
   short-term maturities. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Investments in Marketable
   Securities &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company invests its excess cash balances in short-term and long-term marketable debt and equity
   securities. The Company classifies its investments in marketable debt securities as either held-to-maturity or available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented,
   the Company classified all of its investments in debt and equity securities as available-for-sale. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized holding gains and losses (the
   adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&amp;#8217; equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any
   adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &amp;#8220;other than temporary&amp;#8221; and, if so, marks the investment to market
   through a charge to its condensed consolidated statements of comprehensive loss. The Company did not record any impairment charges related to its fixed income marketable securities during the current period. The Company&amp;#8217;s marketable securities
   are classified as cash equivalents if the original maturity, from the date of purchase, is 90&amp;#160;days or less, and as marketable securities if the original maturity, from the date of purchase, is in excess of 90&amp;#160;days. The Company&amp;#8217;s cash
   equivalents are composed of money market funds, U.S. government obligations and commercial paper. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company obtains fair
   value measurement data for its marketable securities from independent pricing services. The Company performs validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand
   the methods and data sources used. Additionally, the Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets.
   &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following tables summarize the Company&amp;#8217;s marketable securities at March&amp;#160;31, 2012 and December&amp;#160;31, 2011, in
   thousands: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="87%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31, 2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;Gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;Losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair&amp;#160;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Commercial paper (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,192&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(10&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,182&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;113,313&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;39&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(48&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;113,304&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes (Due after 1&amp;#160;year through 2&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;67,808&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;47&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(38&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;67,817&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,868&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;4&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;18,870&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations (Due after 1&amp;#160;year through 2&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;50,004&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(49&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;49,962&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Equity securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;30&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;43&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;255,215&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;110&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(147&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;255,178&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="87%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="1%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="14" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&amp;#160;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amortized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;Gains&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Gross&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Unrealized&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;Losses&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Fair&amp;#160;Value&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Commercial paper (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,397&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,395&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;51,273&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;19&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(47&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;51,245&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Corporate notes (Due after 1&amp;#160;year through 2&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;53,592&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;50&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(48&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;53,594&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations (Due within 1&amp;#160;year)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,532&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,534&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;U.S. Government obligations (Due after 1&amp;#160;year through 2&amp;#160;years)&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60,202&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;7&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(21&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;60,188&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Equity securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;750&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8212;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(125&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;625&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;190,746&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;78&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(243&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;190,581&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Subsequent Events &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The Company evaluated all events or transactions that occurred after March&amp;#160;31, 2012 through the date these condensed consolidated financial statements were issued. During this period, the Company did
   not have any material recognized subsequent events. However, the Company did have the following nonrecognized subsequent event, which is more fully described in Note 7: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:6px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
   &lt;tr&gt;
   &lt;td width="8%"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="4%" valign="top" align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#8226;&lt;/font&gt;&lt;/td&gt;
   &lt;td width="1%" valign="top"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td align="left" valign="top"&gt;
   &lt;p align="left"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In April 2012, the Company exercised its option under its July 2007 amended and restated collaboration agreement (the &amp;#8220;Medtronic Agreement&amp;#8221;)
   with Medtronic, Inc. (&amp;#8220;Medtronic&amp;#8221;) to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. &lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;/tr&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Pronouncements
   &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In May 2011, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued a new accounting standard that
   clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective
   basis for annual and interim reporting periods beginning on or after December&amp;#160;15, 2011. The Company adopted this amendment on January&amp;#160;1, 2012. The adoption of this new standard did not have a material impact on the Company&amp;#8217;s condensed
   consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In June 2011, the FASB issued an amendment to the accounting guidance for presentation of
   comprehensive income. Under the amended guidance, a company may present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income
   or in two separate but consecutive statements. In either case, a company is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income
   and a total amount for comprehensive income. For public companies, the amendment is effective for fiscal years, and interim periods within those years, beginning after December&amp;#160;15, 2011, and shall be applied retrospectively. The Company adopted
   this amendment on January&amp;#160;1, 2012. Other than a change in presentation, the adoption of this guidance did not have a material impact on the Company&amp;#8217;s condensed consolidated financial statements. &lt;/font&gt;&lt;/p&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 2 - us-gaap:CollaborativeArrangementDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;2. SIGNIFICANT AGREEMENTS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The following table summarizes the Company&amp;#8217;s total consolidated net revenues from research collaborators, for the
   periods indicated, in thousands: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="80%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="4%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months Ended&lt;br /&gt;March&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr&gt;
   &lt;td height="8"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;td height="8" colspan="4"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Roche/Arrowhead&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,994&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;13,994&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Takeda&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,493&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;5,768&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,100&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,135&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total net revenues from research collaborators&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,587&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;20,897&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Platform Alliances &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Roche/Arrowhead Alliance &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In July 2007, the Company and, for limited
   purposes, Alnylam Europe, entered into a license and collaboration agreement (the &amp;#8220;LCA&amp;#8221;) with F. Hoffmann-La Roche Ltd (&amp;#8220;Roche Basel&amp;#8221;) and Hoffmann-La Roche Inc. (together with Roche Basel, &amp;#8220;Roche&amp;#8221;). Under the LCA,
   which became effective in August 2007, the Company granted Roche a non-exclusive license to the Company&amp;#8217;s intellectual property, including delivery-related intellectual property existing as of the date of the LCA, to develop and commercialize
   therapeutic products that function through RNA interference (&amp;#8220;RNAi&amp;#8221;), subject to the Company&amp;#8217;s existing contractual obligations to third parties. In November 2010, Roche announced the discontinuation of certain activities in research
   and early development, including its RNAi research efforts. The remaining deliverables under the LCA currently remain in effect. In October 2011, Arrowhead Research Corporation (&amp;#8220;Arrowhead&amp;#8221;) announced its acquisition of RNA therapeutics
   assets from Roche, including the LCA. As a result of the assignment, Arrowhead has all of the rights and obligations of Roche under the LCA. The license is initially limited to four therapeutic areas, and may be expanded to include additional
   therapeutic areas upon payment to the Company by Arrowhead of an additional $50.0 million for each additional therapeutic area, if any. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In consideration for the rights the Company granted under the LCA, Roche paid the Company $273.5 million in upfront cash payments. In addition, in exchange for the Company&amp;#8217;s contributions under the
   LCA, for each RNAi therapeutic product developed by Arrowhead, its affiliates or sublicensees under the LCA, the Company is entitled to receive milestone payments upon achievement of specified development and sales events, totaling up to an
   aggregate of $100.0 million per therapeutic target, together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the Company and Roche also established a discovery collaboration in October 2009 (&amp;#8220;Discovery
   Collaboration&amp;#8221;), subject to the Company&amp;#8217;s existing contractual obligations to third parties. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In July 2007, the
   Company executed a common stock purchase agreement (the &amp;#8220;Common Stock Purchase Agreement&amp;#8221;) with Roche Finance Ltd, an affiliate of Roche. In connection with the execution of the LCA and the Common Stock Purchase Agreement, the Company also
   executed a share purchase agreement (the &amp;#8220;Alnylam Europe Purchase Agreement&amp;#8221;) with Alnylam Europe and Roche Beteiligungs GmbH, an affiliate of Roche (&amp;#8220;Roche Germany&amp;#8221;). Under the terms of the Alnylam Europe Purchase Agreement, the Company sold substantially all of the non-intellectual
   property assets of Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In summary, the Company
   received upfront payments totaling $331.0 million under the Roche alliance, which included an upfront payment under the LCA of $273.5 million, $42.5 million under the Common Stock Purchase Agreement and $15.0 million under the Alnylam Europe
   Purchase Agreement. The Company initially recorded $278.2 million of these proceeds as deferred revenue in connection with this alliance. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The Company determined that the deliverables under these agreements included the license, the Alnylam Europe assets and employees, the steering committees (joint steering committee and future technology
   committee) and the services under the Discovery Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and assets of Alnylam Europe are not
   separable from the undelivered services (i.e., the steering committees and Discovery Collaboration) and, accordingly, the license and the services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a
   single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the Arrowhead alliance, the steering committee services and the Discovery Collaboration services are the final deliverables and all such
   services will end, contractually, five years from the effective date of the LCA. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is recognizing the revenue
   related to these agreements on a straight-line basis over five years because the Company cannot reasonably estimate the total level of effort required to complete its service obligations under the LCA, and therefore, cannot utilize a proportional
   performance model. The Company will continue to recognize the revenue related to these agreements on a straight-line basis over five years through August 2012. At March&amp;#160;31, 2012, deferred revenue under the LCA was $23.3 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Takeda Alliance &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In May 2008, the Company entered into a license and collaboration agreement (the &amp;#8220;Takeda Agreement&amp;#8221;) with Takeda Pharmaceutical Company Limited (&amp;#8220;Takeda&amp;#8221;) to pursue the development and
   commercialization of RNAi therapeutics. Under the Takeda Agreement, the Company granted to Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&amp;#8217;s intellectual property, including delivery-related intellectual property,
   controlled by the Company as of the date of the agreement or during the five years thereafter, to develop, manufacture, use and commercialize RNAi therapeutics, subject to the Company&amp;#8217;s existing contractual obligations to third parties. The
   license initially is limited to the fields of oncology and metabolic disease and may be expanded at Takeda&amp;#8217;s option to include other therapeutic areas, subject to specified conditions. Under the Takeda Agreement, Takeda is the Company&amp;#8217;s
   exclusive platform partner in the Asian territory, as defined in the Takeda Agreement, through May 2013. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In consideration for
   the rights granted to Takeda under the Takeda Agreement, Takeda agreed to pay the Company $150.0 million in upfront and near-term technology transfer payments. In addition, the Company has the option, exercisable until the start of Phase III
   development, to opt-in under a 50-50 profit sharing agreement to the development and commercialization in the United States of up to four Takeda licensed products and would be entitled to opt-in rights for two additional products for each additional
   field expansion, if any, elected by Takeda under the Takeda Collaboration Agreement. In June 2008, Takeda paid the Company an upfront payment of $100.0 million and agreed to pay to the Company an additional $50.0 million upon achievement of
   specified technology transfer milestones. Of this $50.0 million, $20.0 million was paid to the Company in October 2008, $20.0 million was paid to the Company in March 2010, and $10.0 million was paid to the Company in March 2011 (collectively, the
   &amp;#8220;Technology Transfer Milestones&amp;#8221;). If Takeda elects to expand its license to additional therapeutic areas, Takeda will be required to pay the Company $50.0 million for each additional field selected, if any. In addition, for each RNAi
   therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled to receive specified development and commercialization milestones, totaling up to $171.0 million per product, together with royalty payments based on
   worldwide annual net sales, if any. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Pursuant to the Takeda Agreement, the Company and Takeda are also collaborating on the
   research of RNAi therapeutics directed to one or two disease targets agreed to by the parties (the &amp;#8220;Research Collaboration&amp;#8221;), subject to the Company&amp;#8217;s existing contractual obligations with third parties. Takeda also has the option,
   subject to certain conditions, to collaborate with the Company on the research and development of RNAi drug delivery technology for targets agreed to by the parties. In addition, Takeda has a right of first negotiation for the development and
   commercialization of the Company&amp;#8217;s RNAi therapeutic products in the Asian territory, excluding the Company&amp;#8217;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a similar right of first negotiation to
   participate with Takeda in the development and commercialization of licensed products in the United States. The collaboration is governed by a joint technology transfer committee (the &amp;#8220;JTTC&amp;#8221;), a joint research collaboration committee (the &amp;#8220;JRCC&amp;#8221;) and a joint delivery collaboration
   committee (the &amp;#8220;JDCC&amp;#8221;), each of which is comprised of an equal number of representatives from each party. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The
   Company determined that the deliverables under the Takeda Agreement include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer activities and the services that the Company will be obligated to perform under the
   Research Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and undelivered services (i.e., the joint committees and the Research
   Collaboration) are not separable and, accordingly, the license and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue recognition
   pattern on the final deliverable. Under the Takeda Agreement, the last elements to be delivered are the JDCC and JTTC services, each of which has a life of no more than seven years. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is recognizing the upfront payment of $100.0 million and the Technology Transfer Milestones of $50.0 million, the receipt of
   which the Company believed was probable at the commencement of the collaboration, on a straight-line basis over seven years because the Company is unable to reasonably estimate the level of effort to fulfill these obligations, primarily because the
   effort required under the Research Collaboration is largely unknown, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company will recognize as revenue a portion of the milestone payment equal to
   the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. At March&amp;#160;31, 2012, deferred revenue under the Takeda Agreement was $69.3 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Product Alliances
   &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Kyowa Hakko Kirin Alliance &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   In June 2008, the Company entered into a license and collaboration agreement (the &amp;#8220;Kyowa Hakko Kirin Agreement&amp;#8221;) with Kyowa Hakko Kirin Co., Ltd. (&amp;#8220;Kyowa Hakko Kirin&amp;#8221;). Under the Kyowa
   Hakko Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to its intellectual property in Japan and other markets in Asia (the &amp;#8220;Licensed Territory&amp;#8221;) for the development and commercialization of an RNAi therapeutic
   for the treatment of respiratory syncytial virus (&amp;#8220;RSV&amp;#8221;) infection. The Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program (&amp;#8220;Additional
   Compounds&amp;#8221;). The Company retains all development and commercialization rights worldwide outside of the Licensed Territory, subject to its agreement with Cubist Pharmaceuticals, Inc. (&amp;#8220;Cubist&amp;#8221;) described below. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Under the terms of the Kyowa Hakko Kirin Agreement, in June 2008, Kyowa Hakko Kirin paid the Company an upfront cash payment of
   $15.0&amp;#160;million. In addition, Kyowa Hakko Kirin is required to make payments to the Company upon achievement of specified development and sales milestones totaling up to $78.0&amp;#160;million, and royalty payments based on annual net sales, if any,
   of RNAi therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its affiliates and sublicensees in the Licensed Territory. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The collaboration between Kyowa Hakko Kirin and the Company is governed by a joint steering committee that is comprised of an equal
   number of representatives from each party. Under the agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to the development activities to be undertaken in the Licensed Territory, with the initial focus on
   Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the development plan that are reasonably necessary for the regulatory approval and commercialization of an RNAi therapeutic for the treatment of RSV in
   Japan and the rest of the Licensed Territory. The Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement unless Kyowa Hakko Kirin elects, prior to the first commercial sale of the product in the Licensed
   Territory, to manufacture the product itself or arrange for a third party to manufacture the product. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has
   determined that the deliverables under the Kyowa Hakko Kirin Agreement include the license, the joint steering committee, the manufacturing services and any Additional Compounds. The Company has determined that, pursuant to the accounting guidance
   governing revenue recognition on multiple element arrangements, the individual deliverables are not separable and, accordingly, must be accounted for as a single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is currently unable to
   reasonably estimate its period of performance under the Kyowa Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The
   Company is deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate its period of performance. The Company will continue to reassess whether it can reasonably estimate the period of performance to fulfill
   its obligations under the Kyowa Hakko Kirin Agreement. At March&amp;#160;31, 2012, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Cubist Alliance &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In January 2009, the Company entered into a license and
   collaboration agreement with Cubist (the &amp;#8220;Cubist Agreement&amp;#8221;) to develop and commercialize therapeutic products (&amp;#8220;Licensed Products&amp;#8221;) based on certain of the Company&amp;#8217;s RNAi technology for the treatment of RSV infection.
   Licensed Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV inhibitors. In November 2009, the Company and Cubist entered into an amendment to the Cubist Agreement (the &amp;#8220;Amendment&amp;#8221;), which
   provides that the Company and Cubist would focus their collaboration and joint development efforts on ALN-RSV02, a second-generation compound, intended for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and
   Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant to the terms of the Amendment, the Company is continuing to develop ALN-RSV01 for adult transplant patients at its sole discretion and expense. Cubist
   has the right to opt into collaborating with the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time following the completion of the Company&amp;#8217;s Phase IIb trial of ALN-RSV01, subject to the payment by
   Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the Company&amp;#8217;s development expenses for ALN-RSV01. In December 2010, the Company and Cubist jointly made a portfolio decision to put the development of
   ALN-RSV02 on hold. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In consideration for
   the rights granted to Cubist under the Cubist Agreement, in January 2009, Cubist paid the Company an upfront cash payment of $20.0&amp;#160;million. Cubist is also obligated under the Cubist Agreement to pay the Company milestone payments, totaling up
   to an aggregate of $82.5&amp;#160;million, upon the achievement of specified development and sales events in the &amp;#8220;Royalty Territory,&amp;#8221; which includes all geographic territories excluding North America and Asia. In addition, if Licensed Products
   are successfully developed, Cubist will be required to pay to the Company royalties on net sales of Licensed Products in the Royalty Territory, if any, subject to offsets under certain circumstances. Upon achievement of certain development
   milestones, the Company will have the right to convert the North American co-development and profit sharing arrangement into a royalty-bearing license and, in addition to royalties on net sales in North America, will be entitled to receive
   additional milestone payments totaling up to an aggregate of $130.0&amp;#160;million upon achievement of specified development and sales events in North America, subject to the timing of the conversion by the Company and the regulatory status of
   Licensed Products at the time of conversion. If the Company makes the conversion to a royalty-bearing license with respect to North America, then North America becomes part of the Royalty Territory. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company determined that the deliverables under the Cubist Agreement include the licenses, technology transfer related to the ALN-RSV
   program, the joint steering committee and the development and manufacturing services that the Company is obligated to perform during the development period. The Company also determined that, pursuant to the accounting guidance governing revenue
   recognition on multiple element arrangements, the licenses and undelivered services are not separable and, accordingly, the licenses and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a
   single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the Cubist Agreement, the last element to be delivered is the development and manufacturing services, which have an expected life of
   approximately eight years. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company is recognizing the upfront payment of $20.0&amp;#160;million on a straight-line basis over
   approximately eight years because the Company is unable to reasonably estimate the level of effort to fulfill its performance obligations, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company
   will recognize as revenue a portion of the milestone payment, equal to the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. The Company will recognize the remaining
   portion of the milestone over the remaining performance period on a straight-line basis. At March&amp;#160;31, 2012, deferred revenue under the Cubist Agreement was $11.8&amp;#160;million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for developing Licensed Products in North America,
   and each bears one-half of the related development costs, provided that under the terms of the Amendment, the Company is funding the advancement of ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue
   generating arrangements that involve cost sharing between the parties, the Company presents the results of activities for which it acts as the principal on a gross basis and reports any payments received from, or made to, other collaborators based
   on other applicable GAAP or, in the absence of other applicable GAAP, analogy to authoritative accounting literature or a reasonable, rational and consistently applied accounting policy election. As the Company is not considered the principal under
   the Cubist Agreement, the Company records any amounts due from Cubist as a reduction of research and development expense. &lt;/font&gt;&lt;/p&gt;
</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 3 - us-gaap:IncomeTaxDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;3. INCOME TAXES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company expects to continue to generate U.S. taxable losses in 2012 and has recorded no income tax provision for
   the three months ended March&amp;#160;31, 2012 and 2011. &lt;/font&gt;&lt;/p&gt;
    &lt;p&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:12px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In July 2011, the
   Internal Revenue Service completed its audits of the Company&amp;#8217;s 2008 and 2009 tax years. Subsequently, the 2010 tax year was reviewed by the Joint Committee of the Internal Revenue Service (&amp;#8220;Joint Committee&amp;#8221;). In March 2012, the
   Company received the final report from the Joint Committee. The review of tax years 2008 through 2010 is complete. The Company did not record any tax expense related to these audits. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company continues to recognize fully its tax benefits which are offset by a valuation allowance to the extent that it is more likely
   than not that the deferred tax assets will not be realized. At March&amp;#160;31, 2012, the Company had $0.1&amp;#160;million of total gross unrecognized tax benefits that, if recognized, would favorably impact the Company&amp;#8217;s effective income tax rate
   in future periods. &lt;/font&gt;&lt;/p&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 4 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;4.&amp;#160;REGULUS &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In September 2007, the Company and Isis Pharmaceuticals, Inc. (&amp;#8220;Isis&amp;#8221;) established Regulus, a company focused
   on the discovery, development and commercialization of microRNA therapeutics, a potential new class of drugs to treat the pathways of human disease. Regulus, which initially was established as a limited liability company, converted to a C
   corporation in January 2009 and changed its name to Regulus Therapeutics Inc. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In consideration for the Company&amp;#8217;s and
   Isis&amp;#8217; initial interests in Regulus, each party granted Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic applications as well as certain patents in the microRNA field. In addition, the Company made an
   initial cash contribution to Regulus of $10.0 million, resulting in the Company and Isis making approximately equal aggregate initial capital contributions to Regulus. In March 2009, the Company and Isis each purchased $10.0 million of Series A
   preferred stock of Regulus. In October 2010, in connection with its strategic alliance with Regulus formed in June 2010, Sanofi made a $10.0 million equity investment in Regulus. At March&amp;#160;31, 2012, the Company, Isis and Sanofi owned
   approximately 45%, 46% and 9%, respectively, of Regulus. Regulus continues to operate as an independent company with a separate board of directors, scientific advisory board and management team, some of whom have options to purchase common stock of
   Regulus. Members of the board of directors of Regulus who are the Company&amp;#8217;s employees or Isis&amp;#8217; employees are not eligible to receive options to purchase Regulus common stock. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company reviewed the consolidation guidance that defines a variable interest entity (&amp;#8220;VIE&amp;#8221;) and concluded that Regulus
   currently qualifies as a VIE. The Company does not consolidate Regulus as the Company lacks the power to direct the activities that could significantly impact the economic success of this entity. Under the equity method of accounting, because the
   Company has guaranteed the debt of Regulus, the Company will continue to recognize its share of any future losses up to a maximum negative carrying value, or liability, equivalent to the amount of debt guaranteed by the Company. The Company&amp;#8217;s
   maximum exposure to loss related to this VIE&amp;#160;is limited to the carrying value of the Company&amp;#8217;s investment, as well the portion of Regulus&amp;#8217; debt, including accrued interest, guaranteed by the Company, which was $5.5 million at
   March&amp;#160;31, 2012. At March&amp;#160;31, 2012, the total negative carrying value of the Company&amp;#8217;s investment in Regulus in its condensed consolidated balance sheets was a liability of $0.3 million. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company accounts for its investment in Regulus using the equity method of accounting. Summary results of Regulus&amp;#8217; operations for
   the three months ended March&amp;#160;31, 2012 and 2011 and balance sheets at March&amp;#160;31, 2012 and December&amp;#160;31, 2011 are presented in the tables below, in thousands (unaudited): &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="78%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Three Months
   Ended&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Statement of Comprehensive Loss Data:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net revenues&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,441&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,309&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Operating expenses&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;5,525&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&amp;#160;&amp;#160;5,459&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Loss from operations&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2,084&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2,150&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Other expense&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(67&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(139&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Net loss&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2,151&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(2,289&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="78%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;December&lt;br /&gt;31, 2011&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;Balance Sheet Data:&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Cash, cash equivalents and marketable securities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,508&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;38,144&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Current assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;32,929&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;38,666&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total assets&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;37,295&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;42,881&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Current liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;22,220&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;12,850&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Non-current liabilities&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;15,817&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;28,834&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Notes payable&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,253&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;11,259&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total stockholders&amp;#8217; (deficit) equity&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;(742&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;)&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,197&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 5 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;5.&amp;#160;COMMITMENTS AND CONTINGENCIES &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;&lt;i&gt;Litigation &lt;/i&gt;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;Tekmira Litigation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On March&amp;#160;16, 2011, Tekmira and Protiva
   Biotherapeutics, Inc. filed a civil complaint against the Company in the Business Litigation Section of the Suffolk County Superior Court in Boston, Massachusetts, and on June&amp;#160;3, 2011, the plaintiffs filed an amended complaint adding AlCana
   Technologies, Inc. (&amp;#8220;AlCana&amp;#8221;), a research collaborator of the Company, as a defendant. The amended complaint alleges misappropriation of the plaintiffs&amp;#8217; confidential and proprietary information and trade secrets, civil conspiracy, and
   tortious interference with contractual relationships by the Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive
   trade practices by the Company. The plaintiffs seek, among other relief, injunctive relief, unspecified compensatory and punitive damages, attorneys&amp;#8217; fees, the termination of licenses that the plaintiffs provided to the Company and the
   relinquishment and transfer of certain of the Company&amp;#8217;s intellectual property, including patents covering the Company&amp;#8217;s MC3 technology. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   On April&amp;#160;6, 2011, the Company timely served and filed an answer to the plaintiffs&amp;#8217; original complaint denying the plaintiffs&amp;#8217; claims, and asserted counterclaims against the plaintiffs. On
   June&amp;#160;28, 2011, the Company timely served and filed an answer to the plaintiffs&amp;#8217; amended complaint denying the plaintiffs&amp;#8217; claims and asserted counterclaims against the plaintiffs for breach of contract, defamation, breach of covenant
   not to sue, breach of patent prosecution and non-use provisions, misappropriation of confidential and proprietary information and trade secrets, unjust enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations
   of Massachusetts statutes. The Company is seeking monetary damages, attorneys&amp;#8217; fees and equitable relief on its counterclaims. In September 2011, the Court granted the plaintiffs&amp;#8217; motion to dismiss the Company&amp;#8217;s counterclaim for
   defamation. The plaintiffs did not move to dismiss any of the Company&amp;#8217;s other counterclaims, all of which remain pending. The case is currently in discovery and the Company expects a trial to start in October 2012. The Company intends to
   vigorously defend itself in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against the Company and the Company could be required to pay substantial damages. The Company has also incurred, and
   will continue to incur during the pendency of the litigation, significant costs, and the defense of this litigation has diverted, and until resolved will continue to divert, the attention of the Company&amp;#8217;s management and other resources that
   would otherwise be engaged in other activities. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company has not recorded an estimate of the possible loss associated with
   this legal proceeding. Although Tekmira has not specified the amount of monetary damages it is seeking, it has suggested that it believes such amount is significant and could include but not be limited to the disgorgement of cash funds the Company
   has received under certain of its collaboration agreements, future milestones and royalties associated with certain of the Company&amp;#8217;s pipeline products, and other damages. Significant judgment is required to determine both the likelihood of a
   loss and the estimated amount of any such loss. The Company currently believes that the likelihood of a loss is more than remote but less than probable, and is unable to estimate a possible range of loss for this legal proceeding due to many
   factors, including: the current state of the litigation proceedings and discovery process, the inability to assess the amount of damages until expert reports are obtained, uncertainties regarding the potential for settlement discussions and the
   tendency of plaintiffs to maintain very high demands until cases reach critical juncture, such as the filing of dispositive motions or serious mediation. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   &lt;i&gt;University of Utah Litigation &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On March&amp;#160;22, 2011, The University of
   Utah (the &amp;#8220;University&amp;#8221;) filed a civil complaint in the United States District Court for the District of Massachusetts against the Company, Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH
   (together, &amp;#8220;Max Planck&amp;#8221;), the Whitehead Institute for Biomedical Research (&amp;#8220;Whitehead&amp;#8221;), the Massachusetts Institute of Technology (&amp;#8220;MIT&amp;#8221;) and the University of Massachusetts (&amp;#8220;UMass&amp;#8221;), claiming a professor at
   the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl patents. The University did not serve the original complaint on the Company or the other defendants. On July&amp;#160;6, 2011, the University filed an amended
   complaint alleging substantially the same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was served on the Company on July&amp;#160;14, 2011. The University is seeking changes to the inventorship of the Tuschl
   patents, unspecified damages and other relief. On October&amp;#160;31, 2011, the Company, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on October&amp;#160;31, 2011, UMass filed a motion to dismiss on separate grounds, which the
   Company, Max Planck, Whitehead and MIT have joined. On December&amp;#160;31, 2011, the University filed a second amended complaint dropping UMass as a defendant and adding as defendants several UMass officials. Although the Company believes it has meritorious defenses and
   intends to vigorously defend itself in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule against the Company. In addition, the defense of litigation and related matters are costly and may divert the
   attention of the Company&amp;#8217;s management and other resources that would otherwise be engaged in other activities. The Company has not recorded an estimate of the possible loss associated with this legal proceeding due to the uncertainties related
   to both the likelihood and the amount of any possible loss or range of loss. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px; margin-left:2%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;i&gt;Tekmira Infringement Litigation
   &lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;On January&amp;#160;17, 2012, the Company filed a complaint in the United States District Court for the District of
   Massachusetts against Tekmira for patent infringement arising from Tekmira&amp;#8217;s research activities providing lipid nanoparticles- (&amp;#8220;LNP&amp;#8221;-) formulated small interfering RNA (&amp;#8220;siRNA&amp;#8221;) molecules to a pharmaceutical collaborator.
   As alleged in the complaint, the Company does not believe Tekmira&amp;#8217;s activities are protected under the exemption from patent infringement for drug development. Pursuant to the complaint, the Company believes Tekmira has infringed a number of
   issued patents related to siRNA and LNP technologies, including: U.S. Patent No.&amp;#160;7,695,902; U.S. Patent No.&amp;#160;6,858,225; U.S. Patent No.&amp;#160;6,815,432; U.S. Patent No.&amp;#160;6,534,484; U.S. Patent No.&amp;#160;6,586,410; and U.S. Patent
   No.&amp;#160;6,858,224. Under the Company&amp;#8217;s contractual right to enforce U.S. Patent No.&amp;#160;7,695,902 owned by Isis, the Company joined Isis to the suit as a co-plaintiff. On March&amp;#160;2, 2012, Tekmira filed a motion to dismiss five of the six
   claims of the Company&amp;#8217;s complaint for lack of standing.&amp;#160;The Company filed an opposition to this motion and Tekmira has filed a reply. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The Company and Isis are seeking judgment that Tekmira has infringed the patents at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including
   attorneys&amp;#8217; fees. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;The Company&amp;#8217;s accounting policy for accrual of legal costs is to recognize such expenses as
   incurred. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:1px;margin-top:18px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock--&gt;
   &lt;p style="margin-top:0px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;6.&amp;#160;2012 RESTRUCTURING &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In January 2012, the Company&amp;#8217;s Board of Directors approved, and the Company implemented, a strategic corporate
   restructuring pursuant to which the Company reduced its overall workforce by approximately 33%, to approximately 115 employees. The Company expects the reduction in personnel costs, along with other external costs, to result in savings of
   approximately $20.0 million in its 2012 operating expenses. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;During the three months ended March&amp;#160;31, 2012, the Company
   substantially completed the implementation of the strategic corporate restructuring and recorded $3.9&amp;#160;million of restructuring-related costs in operating expenses, including employee severance, benefits and related costs. The Company expects to
   pay substantially all of these restructuring costs during 2012. The Company does not expect to incur any additional significant costs associated with this restructuring. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;
   The following table summarizes the components of the Company&amp;#8217;s restructuring expenses recorded in operating expenses and in current liabilities, in thousands: &lt;/font&gt;&lt;/p&gt;
   &lt;p style="font-size:12px;margin-top:0px;margin-bottom:0px"&gt;&amp;#160;&lt;/p&gt;
   &lt;table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center"&gt;
   &lt;!-- Begin Table Head --&gt;
   &lt;tr&gt;
   &lt;td width="70%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom" width="6%"&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Charges&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Incurred&lt;br /&gt;Through&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;
   &lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;March&amp;#160;31,&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Paid&lt;br /&gt;Through&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;March&amp;#160;31,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Amounts&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;&lt;b&gt;Accrued&amp;#160;at&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-family:times new roman" size="1"&gt;
   &lt;b&gt;March&amp;#160;31,&lt;br /&gt;2012&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Head --&gt;
   &lt;!-- Begin Table Body --&gt;
   &lt;tr bgcolor="#cceeff"&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:1.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Employee severance, benefits and related costs&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,909&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,521&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,388&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:1px solid #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr&gt;
   &lt;td valign="top"&gt;
   &lt;p style="margin-left:3.00em; text-indent:-1.00em"&gt;&lt;font style="font-family:times new roman" size="2"&gt;Total&lt;/font&gt;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;3,909&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;1,521&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font size="1"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;$&lt;/font&gt;&lt;/td&gt;
   &lt;td valign="bottom" align="right"&gt;&lt;font style="font-family:times new roman" size="2"&gt;2,388&lt;/font&gt;&lt;/td&gt;
   &lt;td nowrap="nowrap" valign="bottom"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;tr style="font-size:1px"&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;&amp;#160;&lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td valign="bottom"&gt;
   &lt;p style="border-top:3px double #000000"&gt;&amp;#160;&lt;/p&gt;
   &lt;/td&gt;
   &lt;td&gt;&amp;#160;&lt;/td&gt;
   &lt;/tr&gt;
   &lt;!-- End Table Body --&gt;
   &lt;/table&gt;
</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <!-- End Block Tagged Note -->
  <!-- Begin Block Tagged Note -->
  <us-gaap:SubsequentEventsTextBlock contextRef="Jan-01-2012_Mar-31-2012">&lt;!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" --&gt;
   &lt;!-- Begin Block Tagged Note 7 - us-gaap:SubsequentEventsTextBlock--&gt;
   &lt;p style="margin-top:18px;margin-bottom:0px"&gt;&lt;font style="font-family:times new roman" size="2"&gt;&lt;b&gt;7. SUBSEQUENT EVENT &lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:6px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In July 2007, the Company entered into the Medtronic Agreement to pursue the development of RNAi therapeutics for the
   treatment of neurodegenerative disorders using implantable infusion systems. ALN-HTT is an RNAi therapeutic candidate targeting the huntingtin gene, for the treatment of Huntington&amp;#8217;s disease, which the Company has been developing in
   collaboration with Medtronic under the Medtronic Agreement. In November 2010, the Company and Medtronic entered into an agreement with CHDI Foundation, Inc. (&amp;#8220;CHDI&amp;#8221;), under which CHDI agreed to initially fund approximately 50% of the costs
   of the ALN-HTT program up to the point at which an investigational new drug application can be filed with the United States Food and Drug Administration or a comparable foreign regulatory filing can be made. &lt;/font&gt;&lt;/p&gt;
   &lt;p style="margin-top:12px;margin-bottom:0px; text-indent:8%"&gt;&lt;font style="font-family:times new roman" size="2"&gt;In April 2012, as part of the Company&amp;#8217;s alignment of resources following its strategic corporate restructuring, the Company
   exercised its option under the Medtronic Agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. Medtronic has the right to continue
   development of the ALN-HTT program. If Medtronic decides to continue the ALN-HTT program, it would assume responsibility for future development plans. The Company intends to continue to supply ALN-HTT for the program and, if Medtronic continues the
   program, the Company would be compensated for such supply in accordance with the terms of the Medtronic Agreement. The Company would be entitled to certain development milestones, as well as royalties on annual net sales, if any. The Company
   continues to be obligated to repay CHDI for its pro-rata share of funding received through the effective date of its opt-out, with interest, in the event that a product is ultimately commercialized from the funded research. &lt;/font&gt;&lt;/p&gt;
</us-gaap:SubsequentEventsTextBlock>
  <!-- End Block Tagged Note -->
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1457000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">1068000</alny:NonCashStockBasedCompensationExpensesGeneralAndAdministrative>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">2665000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">2088000</alny:NonCashStockBasedCompensationExpensesResearchAndDevelopment>
  <alny:PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">328000</alny:PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations>
  <alny:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2011" unitRef="Shares" decimals="-3">42345000</alny:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <alny:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Jan-01-2012_Mar-31-2012" unitRef="Shares" decimals="-3">46210000</alny:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:AmendmentFlag contextRef="Jan-01-2012_Mar-31-2012">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="Jan-01-2012_Mar-31-2012">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="Jan-01-2012_Mar-31-2012">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="Jan-01-2012_Mar-31-2012">2012</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="Jan-01-2012_Mar-31-2012">2012-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="Jan-01-2012_Mar-31-2012">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="Jan-01-2012_Mar-31-2012">0001178670</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="BalanceAsOf_30Apr2012" unitRef="Shares" decimals="INF">51949931</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityFilerCategory contextRef="Jan-01-2012_Mar-31-2012">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="Jan-01-2012_Mar-31-2012">ALNYLAM PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">5800000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">4339000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">12340000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">13006000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-165000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-37000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">518731000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">609260000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:Assets contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">281917000</us-gaap:Assets>
  <us-gaap:Assets contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">340295000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">152028000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">208539000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">76174000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">137356000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
  <us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">175000</us-gaap:AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">114407000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">117822000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2010" unitRef="USD" decimals="-3">74599000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Mar2011" unitRef="USD" decimals="-3">90590000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">70228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">61739000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">15991000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-8489000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="USD" />
  <us-gaap:CommitmentsAndContingencies xsi:nil="true" contextRef="BalanceAsOf_31Mar2012" unitRef="USD" />
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Mar2012" unitRef="USDEPS" decimals="INF">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">125000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">42721942</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">51893258</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">42721942</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">51893258</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">427000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">519000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-17017000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-11240000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DeferredRentCreditCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">484000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">608000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">3727000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">3202000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">62366000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">48410000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">78487000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">72374000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1339000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">2121000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USDEPS" decimals="2">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="Jan-01-2012_Mar-31-2012" unitRef="USDEPS" decimals="2">-0.25</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EquityMethodInvestments contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">0</us-gaap:EquityMethodInvestments>
  <us-gaap:EquityMethodInvestments contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-275000</us-gaap:EquityMethodInvestments>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">275000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">231000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-04" contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">10224000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Item-01" contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">10406000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-1072000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-889000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-3512000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-1461000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-9898000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-20069000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-10669000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">1780000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">252000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-1970000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">2932000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-2300000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInReceivables contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">724000</us-gaap:IncreaseDecreaseInReceivables>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">162000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:InvestmentIncomeInterest contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">382000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentIncomeInterest contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">223000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">564000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">0</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">163920000</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">142917000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">281917000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">340295000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">80990000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">66638000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LicenseAndServicesRevenue contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">20897000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">20587000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">9000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">87319000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">22287000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-65593000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-6305000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-30215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-16285000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-11368000</us-gaap:NetIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-609000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-475000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">36573000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">31480000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-15676000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-10893000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-732000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">128000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">716000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">703000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">81000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">191000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">-138000</us-gaap:OtherPostretirementBenefitsPayments>
  <us-gaap:OtherPostretirementBenefitsPayments contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">-96000</us-gaap:OtherPostretirementBenefitsPayments>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">41790000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquireAvailableForSaleSecurities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">118210000</us-gaap:PaymentsToAcquireAvailableForSaleSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">28000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">263000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Dec2011" unitRef="USDEPS" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="BalanceAsOf_31Mar2012" unitRef="USDEPS" decimals="INF">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" />
  <us-gaap:PreferredStockSharesIssued xsi:nil="true" contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" />
  <us-gaap:PreferredStockSharesOutstanding xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="Shares" />
  <us-gaap:PreferredStockSharesOutstanding xsi:nil="true" contextRef="BalanceAsOf_31Mar2012" unitRef="Shares" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_31Dec2011" unitRef="USD" />
  <us-gaap:PreferredStockValue xsi:nil="true" contextRef="BalanceAsOf_31Mar2012" unitRef="USD" />
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">4158000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">7252000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">86800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">9000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">847000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">64105000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">53042000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">14643000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">13703000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ReceivablesNetCurrent contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">1468000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ReceivablesNetCurrent contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">2192000</us-gaap:ReceivablesNetCurrent>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-02" contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">26349000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Item-03" contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">21074000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">-400996000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">-412364000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ShareBasedCompensation contextRef="ThreeMonthsEnded_31Mar2011" unitRef="USD" decimals="-3">4122000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="Jan-01-2012_Mar-31-2012" unitRef="USD" decimals="-3">3156000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Dec2011" unitRef="USD" decimals="-3">117997000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="BalanceAsOf_31Mar2012" unitRef="USD" decimals="-3">197378000</us-gaap:StockholdersEquity>
  <!--Footnote Section-->
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="#Item-04" xlink:label="Item-04_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-01" xlink:label="Item-01_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-02" xlink:label="Item-02_lbl" />
    <link:loc xlink:type="locator" xlink:href="#Item-03" xlink:label="Item-03_lbl" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-04_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-01_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-02_lbl" xlink:to="Footnote-01" />
    <link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="Item-03_lbl" xlink:to="Footnote-01" />
    <link:footnote xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:label="Footnote-01" xml:lang="en-US">Non-cash stock-based compensation expenses included in operating expenses are as follows:</link:footnote>
  </link:footnoteLink>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>alny-20120331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Bowne Tagger. XBRL Parser version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" targetNamespace="http://alnylam.com/20120331" xmlns:alny="http://alnylam.com/20120331" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" elementFormDefault="qualified" attributeFormDefault="unqualified" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://alnylam.com/role/JointVenture" id="JointVenture">
        <link:definition>0204 - Disclosure - Regulus</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0207 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/Restructuring" id="Restructuring">
        <link:definition>0206 - Disclosure - 2012 Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>0205 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>00 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>0203 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/SignificantAgreements" id="SignificantAgreements">
        <link:definition>0202 - Disclosure - Significant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
        <link:definition>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
        <link:definition>0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://alnylam.com/role/BalanceSheets" id="BalanceSheets">
        <link:definition>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20120331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20120331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
      <link:linkbaseRef xlink:type="simple" xlink:href="alny-20120331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links, all" />
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <import namespace="http://xbrl.sec.gov/dei/2011-01-31" schemaLocation="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd" />
  <import namespace="http://fasb.org/us-gaap/2011-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd" />
  <element id="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" name="NonCashStockBasedCompensationExpensesResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" name="NonCashStockBasedCompensationExpensesGeneralAndAdministrative" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" />
  <element id="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" name="NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="alny_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" name="WeightedAverageNumberOfShareOutstandingBasicAndDiluted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <element id="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" name="PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>alny-20120331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--XBRL document created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#BalanceSheets" roleURI="http://alnylam.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#BalanceSheetsParenthetical" roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#StatementsOfCashFlows" roleURI="http://alnylam.com/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SignificantAgreements" roleURI="http://alnylam.com/role/SignificantAgreements" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#IncomeTaxes" roleURI="http://alnylam.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#DocumentAndEntityInformation" roleURI="http://alnylam.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#CommitmentsAndContingencies" roleURI="http://alnylam.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#Restructuring" roleURI="http://alnylam.com/role/Restructuring" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SubsequentEvents" roleURI="http://alnylam.com/role/SubsequentEvents" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_StockholdersEquity" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_CommonStockValue" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_PreferredStockValue" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesAndStockholdersEquity" xlink:to="loc_Liabilities" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredRevenueNoncurrent" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_DeferredRentCreditNoncurrent" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_LiabilitiesCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRevenueCurrent" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_DeferredRentCreditCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_DeferredRentCreditCurrent" order="80" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccruedLiabilitiesCurrent" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_PropertyPlantAndEquipmentNet" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AssetsCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_ReceivablesNetCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_ReceivablesNetCurrent" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_StockholdersEquity" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="70" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_AvailableForSaleSecuritiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent" order="50" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Assets" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="140" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_Liabilities" xlink:to="loc_OtherLiabilitiesNoncurrent" order="80" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_AssetsCurrent" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="100" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_EquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_LiabilitiesCurrent" xlink:to="loc_EquityMethodInvestments" order="120" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTax" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ComprehensiveIncomeNetOfTax" xlink:to="loc_NetIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_OperatingIncomeLoss" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_LicenseAndServicesRevenue" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingIncomeLoss" xlink:to="loc_OperatingExpenses" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_ResearchAndDevelopmentExpense" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_OperatingExpenses" xlink:to="loc_GeneralAndAdministrativeExpense" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetIncomeLoss" xlink:to="loc_NonoperatingIncomeExpense" order="30" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_InvestmentIncomeInterest" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NonoperatingIncomeExpense" xlink:to="loc_OtherNonoperatingIncomeExpense" order="80" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="40" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="40" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="260" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="220" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_ShareBasedCompensation" order="120" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NetIncomeLoss" order="60" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_IncreaseDecreaseInReceivables" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInReceivables" order="200" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="180" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInOtherAccruedLiabilities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInOtherAccruedLiabilities" order="250" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities" order="30" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="90" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_DepreciationDepletionAndAmortization" order="10" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_IncreaseDecreaseInIncomeTaxesReceivable" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncreaseDecreaseInIncomeTaxesReceivable" order="210" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="loc_OtherPostretirementBenefitsPayments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_OtherPostretirementBenefitsPayments" order="160" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="0.01953125" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="65" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInFinancingActivities" xlink:to="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" order="2.5" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="90" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0201 - Disclosure - Summary of Significant Accounting Policies" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SignificantAgreements" xlink:title="0202 - Disclosure - Significant Agreements" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/IncomeTaxes" xlink:title="0203 - Disclosure - Income Taxes" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/CommitmentsAndContingencies" xlink:title="0205 - Disclosure - Commitments and Contingencies" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Restructuring" xlink:title="0206 - Disclosure - 2012 Restructuring" />
  <calculationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SubsequentEvents" xlink:title="0207 - Disclosure - Subsequent Events" />
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>alny-20120331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--Extended XBRL Label Linkbase created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negated" roleURI="http://xbrl.us/us-gaap/role/label/negated" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2008-03-31.xsd#negatedTotal" roleURI="http://xbrl.us/us-gaap/role/label/negatedTotal" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <roleRef xlink:type="simple" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-roles-2011-01-31.xsd#axisDefault" roleURI="http://fasb.org/us-gaap/role/label/axisDefault" />
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_lbl" xml:lang="en-US">Investment in joint venture (Regulus Therapeutics Inc.)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Current</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, net of current portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred Rent Credit, Noncurrent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2012 and December 31, 2011</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.01 par value, 125,000,000 shares authorized; 51,893,258 shares issued and outstanding at March 31, 2012; 42,721,942 shares issued and outstanding at December 31, 2011</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive Income, Net of Tax, Attributable to Parent [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development (1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative (1)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Income (Loss) from Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity in loss of joint venture (Regulus Therapeutics Inc.)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Equity in loss of joint venture (Regulus Therapeutics Inc.)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Other Comprehensive Income, Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Unrealized (loss) gain on marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive Income, Net of Tax, Attributable to Parent</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Non-cash stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash (used in) provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">Equity Method Investments Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:to="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based employee remuneration classified as research and development expenses.</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:to="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses General And Administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative_lbl" xml:lang="en-US">The aggregate amount of noncash, equity-based employee remuneration classified as general and administrative expenses.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Comprehensive Loss [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesNetCurrent" xlink:to="us-gaap_ReceivablesNetCurrent_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Receivables, Net, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ReceivablesNetCurrent_lbl" xml:lang="en-US">Billed and unbilled collaboration receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Billed and unbilled collaboration receivables</label>
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Collaboration receivables</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Included In Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non-cash stock-based compensation expenses included in operating expenses are as follows:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract_lbl" xml:lang="en-US">Non Cash Stock Based Compensation Expenses Included In Operating Expenses.</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="alny_DocumentAndEntityInformationAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document and Entity Information.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="lab_DocumentFiscalYearFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="lab_DocumentFiscalPeriodFocus" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_IncreaseDecreaseInOtherAccruedLiabilities" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_IncreaseDecreaseInOtherAccruedLiabilities" xml:lang="en-US">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Available-for-sale Securities, Debt Securities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xml:lang="en-US">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:to="lab_AvailableForSaleSecuritiesNoncurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AvailableForSaleSecuritiesNoncurrent" xml:lang="en-US">Available-for-sale Securities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_AvailableForSaleSecuritiesNoncurrent" xml:lang="en-US">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_FiniteLivedIntangibleAssetsNet" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from exercise of stock options and other types of equity</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:to="lab_PaymentsToAcquireAvailableForSaleSecurities" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_DepreciationDepletionAndAmortization" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_RestructuringAndRelatedActivitiesDisclosureTextBlock" xml:lang="en-US">2012 RESTRUCTURING</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_OtherLiabilitiesNoncurrent" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_IncreaseDecreaseInIncomeTaxesReceivable" />
    <label xlink:type="resource" xlink:role="http://xbrl.us/us-gaap/role/label/negated" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_ProceedsFromIssuanceOfCommonStock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="lab_CommitmentsAndContingencies" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Notes 4, 5 and 6)</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="lab_AccountingPoliciesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_IncomeTaxDisclosureAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EquityMethodInvestmentsAndJointVenturesAbstract" xml:lang="en-US">Regulus [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_RestructuringAndRelatedActivitiesAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_RestructuringAndRelatedActivitiesAbstract" xml:lang="en-US">2012 Restructuring [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_EarningsPerShareBasicAndDiluted" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per common share - basic and diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xml:lang="en-US">Sales and maturities of marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_IncreaseDecreaseInIncomeTaxesReceivable" xml:lang="en-US">Income taxes receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid, Deferred Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Payments to Acquire Available-for-sale Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_PaymentsToAcquireAvailableForSaleSecurities" xml:lang="en-US">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_CollaborativeArrangementDisclosureTextBlock" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="lab_LicenseAndServicesRevenue" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">License and Services Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_LicenseAndServicesRevenue" xml:lang="en-US">Net revenues from research collaborators</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="us-gaap_OtherPostretirementBenefitsPayments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPostretirementBenefitsPayments" xlink:to="lab_OtherPostretirementBenefitsPayments" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_OtherPostretirementBenefitsPayments" xml:lang="en-US">Other Postretirement Benefits Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_OtherPostretirementBenefitsPayments" xml:lang="en-US">Charge for 401(k) company stock match</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_CollaborativeArrangementDisclosureTextBlock" xml:lang="en-US">SIGNIFICANT AGREEMENTS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EquityMethodInvestmentsDisclosureTextBlock_lbl" xml:lang="en-US">REGULUS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business/Significant Agreements [Abstract]</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares used to compute basic and diluted net loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">The average number of shares issued and outstanding that are used in calculating basic and diluted earnings per share, determined based on the timing of issuance of shares in the period.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:to="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Available For Sale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments_lbl" xml:lang="en-US">Realized gain on sale of marketable securities</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase Decrease In Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Increase in restricted cash</label>
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" xlink:to="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations_lbl" xml:lang="en-US">Payments For Repurchase Of Common Stock For Employee Tax Withholding Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations_lbl" xml:lang="en-US">Payments for repurchase of common stock for employee tax withholding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations_lbl" xml:lang="en-US">Payments for repurchase of common stock for employee tax withholding obligations.</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENT</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="us-gaap_EquityMethodInvestments" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestments" xlink:to="lab_EquityMethodInvestments" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_EquityMethodInvestments" xml:lang="en-US">Equity Method Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_EquityMethodInvestments" xml:lang="en-US">Investment in joint venture (Regululs Therapeutics Inc.)</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>alny-20120331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="no"?>
<!--XBRL document created with Bowne Tagger XBRL Enabler by Bowne Software version 10.0.0.56-->
<!--Based on XBRL 2.1-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#BalanceSheets" roleURI="http://alnylam.com/role/BalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#BalanceSheetsParenthetical" roleURI="http://alnylam.com/role/BalanceSheetsParenthetical" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#StatementsOfOperationsAndComprehensiveLoss" roleURI="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#StatementsOfCashFlows" roleURI="http://alnylam.com/role/StatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SignificantAgreements" roleURI="http://alnylam.com/role/SignificantAgreements" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#IncomeTaxes" roleURI="http://alnylam.com/role/IncomeTaxes" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#DocumentAndEntityInformation" roleURI="http://alnylam.com/role/DocumentAndEntityInformation" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#CommitmentsAndContingencies" roleURI="http://alnylam.com/role/CommitmentsAndContingencies" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#Restructuring" roleURI="http://alnylam.com/role/Restructuring" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#SubsequentEvents" roleURI="http://alnylam.com/role/SubsequentEvents" />
  <roleRef xlink:type="simple" xlink:href="alny-20120331.xsd#JointVenture" roleURI="http://alnylam.com/role/JointVenture" />
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheets" xlink:title="0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_AssetsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_AssetsAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_AssetsCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AssetsCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_ReceivablesNetCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_ReceivablesNetCurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_AssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AssetsCurrent" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_PropertyPlantAndEquipmentNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_PropertyPlantAndEquipmentNet" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:label="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Assets" xlink:label="loc_Assets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_Assets" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_LiabilitiesAndStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquityAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_LiabilitiesCurrentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesCurrentAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_AccountsPayableCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccountsPayableCurrent" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_AccruedLiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_AccruedLiabilitiesCurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_DeferredRentCreditCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRentCreditCurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_DeferredRevenueCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_DeferredRevenueCurrent" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_LiabilitiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_LiabilitiesCurrent" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_DeferredRentCreditNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRentCreditNoncurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_DeferredRevenueNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_DeferredRevenueNoncurrent" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_Liabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_Liabilities" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_StockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_StockholdersEquityAbstract" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_PreferredStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_PreferredStockValue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_CommonStockValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_CommonStockValue" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_AdditionalPaidInCapitalCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AdditionalPaidInCapitalCommonStock" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_RetainedEarningsAccumulatedDeficit" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_RetainedEarningsAccumulatedDeficit" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_StockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StockholdersEquityAbstract" xlink:to="loc_StockholdersEquity" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_LiabilitiesAndStockholdersEquity" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_LiabilitiesAndStockholdersEquity" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_AvailableForSaleSecuritiesNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_AvailableForSaleSecuritiesNoncurrent" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_FiniteLivedIntangibleAssetsNet" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsAbstract" xlink:to="loc_FiniteLivedIntangibleAssetsNet" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_OtherLiabilitiesNoncurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_OtherLiabilitiesNoncurrent" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_CommitmentsAndContingencies" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_CommitmentsAndContingencies" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_PrepaidExpenseAndOtherAssetsCurrent" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AssetsCurrentAbstract" xlink:to="loc_PrepaidExpenseAndOtherAssetsCurrent" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_EquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_LiabilitiesCurrentAbstract" xlink:to="loc_EquityMethodInvestments" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/BalanceSheetsParenthetical" xlink:title="0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_PreferredStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockParOrStatedValuePerShare" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_PreferredStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesAuthorized" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_PreferredStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesIssued" order="17.5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_PreferredStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_PreferredStockSharesOutstanding" order="18.75" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_CommonStockParOrStatedValuePerShare" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockParOrStatedValuePerShare" order="19.375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_CommonStockSharesAuthorized" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesAuthorized" order="19.6875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_CommonStockSharesIssued" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesIssued" order="19.84375" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_CommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfFinancialPositionAbstract" xlink:to="loc_CommonStockSharesOutstanding" order="19.921875" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_OperatingExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_OperatingExpensesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_ResearchAndDevelopmentExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_ResearchAndDevelopmentExpense" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_GeneralAndAdministrativeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_GeneralAndAdministrativeExpense" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_OperatingExpenses" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OperatingExpensesAbstract" xlink:to="loc_OperatingExpenses" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_OperatingIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_OperatingIncomeLoss" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_NonoperatingIncomeExpenseAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_NonoperatingIncomeExpenseAbstract" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_InvestmentIncomeInterest" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_InvestmentIncomeInterest" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_OtherNonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_OtherNonoperatingIncomeExpense" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_NonoperatingIncomeExpense" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NonoperatingIncomeExpenseAbstract" xlink:to="loc_NonoperatingIncomeExpense" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_NetIncomeLoss" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_ComprehensiveIncomeNetOfTaxAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_ComprehensiveIncomeNetOfTaxAbstract" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_ComprehensiveIncomeNetOfTax" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_ComprehensiveIncomeNetOfTax" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:label="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" xlink:label="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" xlink:label="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract" xlink:to="alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_EarningsPerShareBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_EarningsPerShareBasicAndDiluted" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_LicenseAndServicesRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="loc_LicenseAndServicesRevenue" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/StatementsOfCashFlows" xlink:title="0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_NetIncomeLoss" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetIncomeLoss" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_ShareBasedCompensation" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_ShareBasedCompensation" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_IncreaseDecreaseInOperatingCapitalAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInOperatingCapitalAbstract" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_IncreaseDecreaseInReceivables" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInReceivables" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_IncreaseDecreaseInAccountsPayable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInAccountsPayable" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_IncreaseDecreaseInDeferredRevenue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInDeferredRevenue" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_NetCashProvidedByUsedInOperatingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInOperatingActivities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_PaymentsToAcquirePropertyPlantAndEquipment" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquirePropertyPlantAndEquipment" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_NetCashProvidedByUsedInInvestingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInInvestingActivities" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_NetCashProvidedByUsedInFinancingActivities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NetCashProvidedByUsedInFinancingActivities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsPeriodIncreaseDecrease" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue_1" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue_1" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_CashAndCashEquivalentsAtCarryingValue" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_StatementOfCashFlowsAbstract" xlink:to="loc_CashAndCashEquivalentsAtCarryingValue" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="loc_IncreaseDecreaseInOtherAccruedLiabilities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInOtherAccruedLiabilities" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecurities" xlink:label="loc_PaymentsToAcquireAvailableForSaleSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_PaymentsToAcquireAvailableForSaleSecurities" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_DepreciationDepletionAndAmortization" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_DepreciationDepletionAndAmortization" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:label="loc_IncreaseDecreaseInIncomeTaxesReceivable" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_IncreaseDecreaseInIncomeTaxesReceivable" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_ProceedsFromIssuanceOfCommonStock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_ProceedsFromIssuanceOfCommonStock" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OtherPostretirementBenefitsPayments" xlink:label="loc_OtherPostretirementBenefitsPayments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_OtherPostretirementBenefitsPayments" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_IncomeLossFromEquityMethodInvestments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_IncomeLossFromEquityMethodInvestments" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_IncreaseDecreaseInRestrictedCash" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_IncreaseDecreaseInRestrictedCash" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" xlink:label="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations" order="45" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments" order="125" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="0201 - Disclosure - Summary of Significant Accounting Policies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_SignificantAccountingPoliciesTextBlock" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_AccountingPoliciesAbstract" xlink:to="loc_SignificantAccountingPoliciesTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SignificantAgreements" xlink:title="0202 - Disclosure - Significant Agreements">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_CollaborativeArrangementDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_CollaborativeArrangementDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/IncomeTaxes" xlink:title="0203 - Disclosure - Income Taxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_IncomeTaxDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_IncomeTaxDisclosureAbstract" xlink:to="loc_IncomeTaxDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/DocumentAndEntityInformation" xlink:title="00 - Document - Document and Entity Information">
    <loc xlink:type="locator" xlink:href="alny-20120331.xsd#alny_DocumentAndEntityInformationAbstract" xlink:label="alny_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_EntityRegistrantName" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityRegistrantName" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_EntityCentralIndexKey" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityCentralIndexKey" order="40" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentType" xlink:label="loc_DocumentType" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentType" order="60" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_DocumentPeriodEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentPeriodEndDate" order="80" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_AmendmentFlag" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_AmendmentFlag" order="100" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_DocumentFiscalYearFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentFiscalYearFocus" order="120" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_DocumentFiscalPeriodFocus" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_DocumentFiscalPeriodFocus" order="140" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_CurrentFiscalYearEndDate" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_CurrentFiscalYearEndDate" order="160" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_EntityFilerCategory" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityFilerCategory" order="240" use="optional" />
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2011/dei-2011-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_EntityCommonStockSharesOutstanding" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alny_DocumentAndEntityInformationAbstract" xlink:to="loc_EntityCommonStockSharesOutstanding" order="280" use="optional" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/CommitmentsAndContingencies" xlink:title="0205 - Disclosure - Commitments and Contingencies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_CommitmentsAndContingenciesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CommitmentsAndContingenciesDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/Restructuring" xlink:title="0206 - Disclosure - 2012 Restructuring">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_RestructuringAndRelatedActivitiesAbstract" xlink:to="loc_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/SubsequentEvents" xlink:title="0207 - Disclosure - Subsequent Events">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_SubsequentEventsTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_SubsequentEventsAbstract" xlink:to="loc_SubsequentEventsTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://alnylam.com/role/JointVenture" xlink:title="0204 - Disclosure - Regulus">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:label="loc_EquityMethodInvestmentsAndJointVenturesAbstract" />
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2011/elts/us-gaap-2011-01-31.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:label="loc_EquityMethodInvestmentsDisclosureTextBlock" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="loc_EquityMethodInvestmentsDisclosureTextBlock" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g335938exhibita.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g335938exhibita.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"V`(P`P$1``(1`0,1`?_$`)@``0`!!`,!`0``````
M```````(`P0%!@('"0$*`0$`````````````````````$``"`0,#!`$#`04&
M`P,&`QD!`@,`!`41!@<A$A,(,4$B%%%A,B,5"7&!0A87&)$S)*%2)6)RLD,T
M)O"QP8*2HL)S)RC14[/#-624139&QD=GA[<X2!D1`0``````````````````
M``#_V@`,`P$``A$#$0`_`/VZ\N\S;QV)NC;6R>/.%MR<S;JS^W-P[LGQ^%W=
ML79EMA\'M[*;<P\UQ=9'?&:Q%O<SW5[N2(1Q0>1@L;%NW[=0T1>=?9<JK/Z0
M;\4F>:,H.;.`V=8HXP\=P?\`WU5.R=CVA02P(Z@#K09`<V^PWAMY7],M_AYN
M[RP1\O<$226VAT_BLV^8HV[OIV,U!L<'*W-TD,4DWJSO"W>2-7>`\G\/22P,
MPU,;E-W^%G0]"5=E_0F@QF1Y?]@;=C_+O4?=F14*"/+R_P`-6+%M&U71MSS@
M:$#KKU[OV=0U<<Z>TVDO?Z-[LU33Q"/GS@M_-]VA_?W'%X]%Z]?[*"I!SI[/
MR,JS^CV\K93(J%VYUX)E"H?F4B'=3$JNGQ\_LH,[;\Q^P\OB$OJ!NNV+F,/Y
M.8^&W$(?M[F<P[CD[A%J=0O<>G37IJ%RW+W/X=D7U+W0Q#]JR#E[A_PL.XJ7
M)_S'Y57M&O5-?IIK06<G,/L<JS&/U`W!*Z!/"O\`K7Q"@F)[^\,S9?\`A!-!
MH=#KK]-.H8Q>;/:#N(?TJW'V]R@.G/'"[@J2`QT;,QL.T==/K06!YV]J5D=&
M]&]S!`SB.1>?^$6\B+W]C=G\Z#(9.T#0_!8:G0$@-NL.5_8J[B#W'JG>8YS'
M$YAN>:N.I75I.[NB+6:W,??%V_=]W;U&A/70+[_4[G\?O>L5T?\`ZGS%Q^W_
M`*:Q4'W_`%/Y\^OK!D?_`)CE_CD_^E.E!8WO+'L/!X_P_5#+WW=KY->9N+[4
MQ]>FGDO&#ZC^S2@PN1YG]G;4K^#Z99O)J3HW9SQQ#:.HTZ$+<WZJW7Y^X?WT
M%A#SC[3O*B2^D&XX(V;1ICS]PI(L8_[S(F8+L!^P$T&UIRM[#-;+,_JGDHYR
MY5K,\S\:-*J@:B3R+.;8J3TT#Z_LH+F#E+GR3K/ZN9:W':6(_P!7N-)6[N[0
M)HE[VDE>NNNG]]!0N>5/86.&Z>U]5LC<RQ#6TADYFXUMORCW::/)YIUMOMZ_
MX^O3]M!K5QS1[41R=L'I=D+F/N`\@]@>*8B5TZMV2:'H?IK04UYK]JC)VMZ4
M914[M#(/8+B-OMU;1POF#'H!J#H=3]?F@V/'\K^Q=RC->^J-]C6!8*C\U\;7
M3,`[*IUMF9%[U`;37H#I\T&1_P!3^>@/N]8LD3^B<N\<M_VO<1T%.?E+GU(F
M:#U<RT\H([8FY?XSA4C4:DRF]?MT'_DG6@UF[YD]HXHBUIZ;7EW+VZ^)N?\`
MBZV4OHOVB5XWZ:D]>WZ?MZ!:67-/M?.9/S/2NXL0GC["?8CBVY\O<VC]HAM?
MM\2]3W::_34T&TQ<G^Q\D4COZN002*H*12<X[+8R.5U[>^'#2H@#="3_`'`T
M%%N4O957`'JM;NFCZNO.VR@P(!\8['PB?O'YZ_;^V@QN0Y<]IK>,-CO4*#(O
MJNL<GL'L.Q(!([CW/@YE/;U_MTH/N,Y9]I[Q0;_U&L,2WD[2LWL+LJ[`337R
M!K+;,VH^FGS0;4G(/L(45G]=<0C$`M&.:\"S(3\J3_E,(2/V'2@P^4Y-]F[8
MJ,5ZN87*`IJQFY]VWCB'^B`-LZZ[A^WI_908*VY9]NYKJ.*?U!VQ:6K:]]V_
MLQMR8Q:(3UMX>.F=@7&@T;X.I_2@VA^0_95"FGK=MF7N8*QCYXQ2^-2.KGR;
M#0L`?H.M!;7W(WL_'&AQWK-M6ZE+$2)=\_XNS15T&A1XN/;LL2?D$#3]M!JC
M<J>Z8G*IZB<;/;]VBRM[3VZ2]OU+0CAAU!U^@<T&9MN2?;F1`USZM\>6SGRZ
MQK[*Q3Z=@!C^\</H#Y3T_9]:#+6/(/M%<0A[SUNV'CY=6!A;V&2ZZ!V4$20<
M2E3W*`WQTUT^:"\.^_98?_Z\[';_`,SGX?\`T_%*4&IY+D;W+BO9!B?6#B>]
MQQ[?')?>S=W87HU7[B\$/!M]!HK#H!(=0?D4%G;\F^Z[21)<^J'$D4;$"6>+
MVIN9O&-/N=86X%A9^OP.X?VT&W66]O:F>)WN^`>*["4'183[!96Z[QV!@WDA
MX6"J.X]NGST_2@UZ[WO[KHC&Q]?.!)W#'MCN/8_=EN&7KIK(G`<_:QZ=.T@:
M_/3J&+/(7O8KD?[9.`)(P0.]/:7="LP^I"2>NH`/["W]]!>6?(/NU*Y%]ZT<
M(VB!D`>'V:SMX64H2Y[3P-:E2C@+IUUUUZ?%!M46[_:QXU:7A'B.&0Z]\0YR
MSDO;HQ`TD'$2AM5Z_`TUH/LN\/:H1OX>#^)WF[3XO)SGF4A+Z=/(1Q(T@77Y
MT!-!K=]O;W80$X[@#@2X(3XN_8C=EKK)WD:`Q<&7.B>/KK\Z]-/K08Y-^^]>
MK"3UO]?``CE6C]F=V,&D"ZHG:WK\I`=NA.O3YT-!D<=OCW6G24Y+U[X(Q[JZ
M")8?8W=%\)4;N[V+#@BV\930="#KK0;!;[K]M)HYO/PMPI9S*RB#NYVW5<1R
M*3]S/XN%%9"J_`^I_2@M[G='N$'_`.DX;X#DC[V!_(YVWK%)X^Y>UAX^#I5[
M^S7I\:Z=:"SEW5[I-<V\=MPOZ[I:OVBYN+KGS?@E@;L'>\=O;\#RB9/)KH.]
M3VZ?6@JQ[F]SS=&*3A[UT6U"`B[3GGD$L7,G:1^,>!0P58_NU[NOQ^V@S,>>
M]L_,BR\8<`>$JI>2/FG?_>C%1WA8WX.T8*VNAU&M!>'.>T@=/_K:<%M'H_D`
MYEWTLFN@\?9KPD5(UUUU_NH+7(;A]KA:N<7Q5P/)>AH_&M_S;OF*U9>]?+WO
M;\&RRJPCU[=%(+::Z"@T\[H]ZO.JCAGU?_&(D+R_[@.3#,K#O,2K"?7Q4<.`
MH8]X[221KIU#8;//>X,FOYW&7KW:Z*IUMN8-_P!YW.=.X:2</6?:H_7KK^E!
MPR&=]Q>S_P`*XV]=FD[3UR/+7(21]WT_]FXDE?M-!KTF?]\00(N+_51AW1@M
M)S-RJFB$_P`5@%X5<]P'[H^OU(H-HL\M[@O'&;_8OKC;RF4K(MMR=R3<(L.@
MTD1I.*8&9^[Y4@=/K09/^9>U0_\`V-X`?^SD?D-/^P\7O087,Y3W,[8!MW8_
MK,7/?^2V;Y/Y11%Z?P_"MAQ-(S=?WM2.GQ04,;?^ZSJ/YOM7U<MG\A#?R[?W
M+%ZHB!/:Z_D\;6!9R.O:=`/UH,M^9[="4#_+OKB\&A[I/\Y\FQ2@Z?;I%_D*
M9"">A^\:?/[*#"W5U[M^5_PL%ZK^#R/V"ZW9RWY1%W)V!VAV7V-(%[M2`!KI
MTH,YZ_<G\D;\N>6]K\K[=V5@MX\3\A6VS;FYX^S6<S.U\Y89/9.T]Z8_(VK;
MCQ&'RUE=10[G_&GB='3R0=Z.5;0!=Y*6,>U&S868"1^`.27C7ZLJ\B<5^0C_
M`,WIK_;02!H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&OA..!.5
MO:QH516DY<VLUQVG4F8<,<;*6?J=',:K_<!06F;RLEM[D\<8D!3#E?7'ENX)
M/1EDQG(_$!70Z'4,MZ=1T^*"3]`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H(C^OE^UQSC[KV1"=N-YKV%&FB_>1=>OG$UVWD?X?[I>G_`'1TH+W<
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M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01RX@@CBYB]K'1NXS<E;`D?]W[6_
MT-XU!7IUZ:?7K04<V5_W<<=*2`PX"Y4902`S:[\XL#%03J>T::Z?&M!).@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$3N#<J]U["^ZF)9'"8;DOB
M3LD,@99/YGZ^<;7K!(^P&/QDZ'5F[OGI\4%;<F06+W4XFQO=$6O?7+FFZ\?D
MB$ZBQY!X9C\@B.LQA)O="RZ*&T!/44$JZ!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!01!X&M)H?9'WENI%[8[WD[AEK<ZZ^2*W]<.,;=WT^@%PCK_
M`/,T&>W/BD;W%X?S7:OEAX`YRQG?W$,(Y]\<)7/:$[-"I:'Y[NGZ?6@E!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"-7$5I%;\Z>V$T>H-YO3BR
M>8=-!,O#&SH"1H`1K'$I/[:"\W".[VIXL_\`(X0YE;_Y[>?#:T$B:!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01.X6SDE][)^YN#**(\%NKA*5'"
MD.[9?A3;<SAF/VLJ?BC33XU-!L^?=?\`=;QC&6`<\$\QNJ:]65=\<-*Y`^H4
MNNO]HH)%4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@AKP3`4]J?>
M:Y.O;=;JX""DE2/^GX/P,+!0-&&C@ZZ_7XZ4&;WE8S'W4X#R0#^"/U^]D+%R
M#]AEFWIZ\7$:LOU;MMV(H)7T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@C7Q7!#%[!>TTL4,<;W&2X<>X=$56FE3C>",/*0`7<0JJZG4]H`^E!D]
MT@'V<X8^T:KQ#ST0VG4:[EX)737370T$@:!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!01-X?RUQ=>T7N'B'"BVQ4_`,\##]\R9/C6Z,X8Z?`%FFG]
M]!M^YY(Q[0<.Q,Z"1N&^=V1"RAVTW7P5W%%)[FT'SI\4$@Z!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!01&X<L9;?VI]R;UV!CR+^O3PJ%D5D6UXV
MR%LX8L`C$R*2.TD`'0]=:"YWW>7MO[E^NEM#+"MCD.%?9*.]A;L,TDEKG^![
MBS>$&0.B1GO#D*0>X`D=-0EA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*"._'4<:>P7L>R(JM+8\+O(RJ`7<;8W`@+$#[BJ(!U^`*#&[ZM$?VL]>
M[THA>WXR]@+=)-!Y5%S><1.Z@Z:B-_Q@3UT)44$FJ!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!01/XJRL]S[7^VN(;3\?%;?]<;B'J2?+D]M;\,^H
MUT4!;)/VG_A0;'O70^SW`X^HXXYT;^S_`*OBL4$C:!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!01=XTM4B]IO:*Z73NN]J^O`DT4`@V^(Y%1-6"*6
M^U_J3I^R@I;_`,@+?VZ]<;`R:?S+BWV(*1@G[VLKSA^5F("-T19/DE>I^OQ0
M2GH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!&?CNY[_9[V5M/&!X
M=H^O\XE'?JXN,?R.G8=8Q']A@U&C,?NZ@=-0MN1,5'+[6>M&:98O+9;#]A\=
M&Q4^<+?P\5SR*K::"(_@#NZ_(%!*&@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4$-.)Y)']U_<)2[&.'CCU31$)^Q6>SYHD<J/^\^HU_L%!V'OS0^
MR'KWK]-H<[,/_P`WXV4_]C4$B*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!01@X\QB6WM9[+9-496RG'WKHDCF;O5_P``<O1IVQ?^I[1-H?\`O?W4
M%[O^ZBB]G/7.T?\`YEWLCV`>'J!_[-%Q89.GR?MF']E!)*@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4$:MB7<;^TGL18B53+;\<>O5R\/<OD5+NX
MYCCCF[=2_CD-HRZZ!=4.FI!T"TY)C#>TOJ_(%D+1[2]B%+J&\:I)B^-=5D(0
MKJ[QJ5!8:]I(!TZ!*"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$
M1..X6'NK[/7![.V3A3U:@71@7UAS?L/(W>NNJC_J!I^O6@W7?RD^Q/KRW>^B
M[;YQ'8&T1B<;L/1V7ZNFF@/T#']:"0U`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H(X;-LFA]I^=[T_NWG$GKZB_=W=;;.\Y*?M_P?O\`]_S0<N0K
MVUM_9#UQM9YTBGO]M<[QV43=W=<2P8O8-S*D>BD`QVT;N=2.B_W4$C:!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01AVCF5?V^YQP`9BUOP=Z_99E
M)'8JW6[.=K1=%[.[4FV/7N_NH->YA@>3VW]-IU9@EOC_`&1610KE7,^Q=K=O
M<X^Q>TQ]`?D_'Q02_H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!UVG+O%4F\)./4Y*V$V_
MHG,<NQUW=@#O!'"1R%&VS^?_`#H/XYD;M\&O:ZGX8:AV)0*#5=[[XVAQKM//
M;[W_`+DP^T-F[8L),IN'<N?O8<=A\/CXV1'NKZ\G98H(O)(JC4ZLS`#4D"@B
MU<?U$O1^UA>>?V:XK2.,]KD9UI'5N[L(\4=N\I*MT.B]/K\4$F=M\D;#W@<"
MNVMUX7,3;GVE9;\P%K:WB?FY39N1:%++<EK8R^.\.)N'N$592@'<P!T)TH-V
MH%`H%`H%!#W94;_[ZO8"4J0A]</6V)6Z:,Z;Z]AGD4===461?^-!N')L,3^Q
M'K#,R*985YK6.0C[T279.-\BJ=?W7*+K_8*"25`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!
MT]["W&\;7@CF2YX\::/?4'&.^)-HRVUK^?<P;@7;F1.+N+;'Z'^87-O=]KQV
M_0SNH0%>[4!!W$\*>OW#7HQ'O*TV]Q1O#>&S>`[[.1<LW"P0YK=G(B[)M+ZX
MW!:[_P`L;_>UAF,]N;$VS02/=29&W:.%`.^,+0<N&_4^\O>&>/\`G;E_DWF*
MT]G,AQYC>2=X[L3E3<$&$P6_\EM/#Y:]Q1VA@\O#L++;-VO?8T)'CFM9+"XC
M\Y<,LY"AZ!<4[GO][<8\>;QRD2PY/=.R=K[@R$:P26J+>Y?"V5_=&.UF`EMH
MFFG8K&WW(I`/44$/?ZE&-Y)R7K#O2+9(L<ABFO>-8,WM^'`WN5W/DKB;G/B4
MVUYA[J&[%I9X[$86/(RWJR6LSLG8Z/$(V)"?GX\'_P!QA^2?^6GR223^[\DF
M@B/:RR'WGR\+3/X(?6C"/#;EE\2S7/(F96:95([Q(T=JBGM(!`ZCH*"7M`H%
M`H%`H(U[<@1/;7E:X"*'FX+X;C=@6+.(=Y\OE=01VJ$\ITT.IUZ_`H/O)LT<
M?L3ZPQ.X5YX^;!$IUU=X]E8MV`Z:=(P3_=023H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H/
MA`8$,-0?D4'5AX/X@.XI-V'C?9S;ADR$F7;)28.RD?\`G$UN;67,"WDB:T7+
M20,5:Y$8G/<VK:L=0TM_6;8+VZ8(YKD!./X<ACLA!Q9!O/)6W'L'\L*M!B8L
M5;B/)C:LCHIEPIO#AY`.UK8H64A(2***"*.""..&&&-(H88D6.***-0D<<<:
M`(D:(`````!H*"._MC;9^\X%WE!MC(8?%YALEL)XKO/8VZRV,%G#R+M*;+6\
MMC9S6]P]Q>XB.>"WD#A8+F2.1@51@0D900]SPCL_>'83_P`+R9O@;=<!U#&7
MLPNYK2<=I715&N0Z]^NO^'0ZZA,*@4"@4"@4$4-LY?O]V.7<#Y0?Q_7'A'+>
M'Q'5?RN0>:K,R";MT(;\33MUU&FNG6@LN9X+I_:CTPN8Q.+6WO\`V!BNFC8B
M`M<<4AK=+@`_<286*`]-5U^0*"7E`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%!'+D[D_=6!WQDMH;:DPUG_(>%MU\N7,^5M'O?YD^`R]KBX,*2+^P7&V\HD9
MVN/XFA/4`+]P:M;\F;AN[>TNO]4K");W'660_'M.)]QW1AEFM4N;M([E;N59
MK=5?M1!]PD'[S`A0%S=<E9A9+JY_U9Q5O9V:1?F1GBS/EX7,WVQPNM\[2-*A
M".H5F#CIV]106TO(V;;%37_^JSVP5)8UE/$N>+"YMVBE>6.P9VN+R,6TH!"?
M:Q_=Z@B@M[GE2[8VL3<KY"V,T;2ZV'$&X9Y)O`;B)NLL$RVL4DBAAWC5E4'7
MM<&@NO\`4')PQ++=<S/XM'E=TXLNHQ%&O:2CR++,1*H(T[ET[B0>[3H%Q)OW
M+,/RH>6;SPF1S$B<4Y&Y@*1@AD<QQ_D.$\;=S`]6.@TT%!BAR'F5GE#<RYB1
M;UTBQ5C'P?F'NDG@<B=&E%N/R(+DN%5]$Z+JI/6@M6Y%S<UWI9\W[A/B6X$]
MA/Z^Y@R-_+1)+D/&Z64+K-^.=%7KJ5#+W?%!F<?OW-9IHY,=RQNW\7PRW"RM
MP#GH1<PN%CMY5N+W%Q0((W)Z!2).AZ=:"[CW5N;\Q8?]7-T/&D"0SB3@?(+"
M+F-(Y)9?S!:1QK/<Z_9$.X+KIH=":#D-XYHI))_JCO91'+''+!_H?>_D0!IQ
M%&\L3XIYPD[PL5?3L:-]0"-#0<!NS<!99%Y;WO-`9I8@EMP3,[EH5$4G?)_(
MI=(O+U5^T*3TU(H*=QO/+P3BTEY:Y!62[E1[>YAX&O);4+-&42S2<;7G@656
M7O)<@CZ]*"O#O7)W+E(.5]].Z231E/\`1&77R6[K'(I_]VUZ:J1_Y1)(.@&@
M5;G=>=@QUS/_`*I[[9H+2XE6=.$9FD+_`/JU:!=L3,\T3=.U8^HU)!TUH-3V
MCOCFO+\6X+<^:RF:QO(M]L%,W=;%?C"YMT.\Q@I,@FVIIY,?Y,='<9&%K=BT
MA9"4T8$Z$,OAM[;TRNW\9<97?.^]M;B_E>+N\_CDX2NK^UL<GD,9:3WF)QUS
M)@/'D4QMZ9$$J-)KJ.Z@S-QN3<``TY5WZ@D5[F)HN$?(3'$A66V"G;;,9-6#
M!2`^H&A(U!"TDW1G(KB9&Y9Y(G'C#K^-P;K#;DF)&1IQM,H\B^0?:3]IU)Z`
MZ!<6NX<_/=+*.4.3I[9WDDA@7A%;>$Q]O:JO.VTO*\8DZJ=5)^.HZT%O<[MR
MUG-,_P#J-S#="W>:1XK?@R2ZMV18ENNQ)(]D+YD16\0[9"SR?8"6%!6CW#G6
M@M9CR9RW%$NI<S\)P>643%B$N4399>)XDC+#M5.U6'=J>E!8IN_(6-O--<<P
M\GW%HB2R27-WP@L4D$<EP4B;S1;&LXU6V8=NK1D-'U/7[J#@-[YA5\B<D<PW
M4<-N+AW3@*0)*'.H0!ME0OYH^W0QC1AKU^109I-RYQ6N0>2^39WB:>5H%X32
M,Q1LJ&.&-VV>D<YC'5"';NUT;7H*"C<;KS%O!YI>2^3^Q9/&K1\)I*T[*3-]
MJ1;0=@O80I8A5[?V]:#`;HY!SUGM_)28;DS>L6YLAC,A9[)QN<XMQ^#M,YO&
M\QM]_EC`I>Y+;$$"W>5RT:1Q1O(I8J=3IUH-(XAY,Y.W_LJUW1N[>^]L1=76
M8R4^)&T>-<+E\)E]IRWSIM_)PWJ8"^6X::PC+3E)/X;@ZJI&@#<]P;SY,L\K
ML6UVAN?>^<_F&]7L]Y-N#BN*SQN&V.VV=S7ESF//8X"R66XM,U9V"6XBE+RO
M-XV5M2`&^W&0W]<W&WVPF_[U[2-KE-PR93CI(!<]MG));/;+^%:W%NC7;*C=
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M/`,D%NDXD>:"/%[RFGNI+#OUBA:1;M1,4[690.[71=`EU0*!0*!0*"'.U[1T
M]]N9+XN"D_JUP/;*GCE#(UOR9SI(29&40L'$_P`*21IUTU&H;ORG;"3GGU<N
MN]@;?/<M((PD95A/Q;EP7+E?*I3Q@``Z'N.OP*"1]`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%!XY>]W*O(6TN;.9L+LS+S8-=K_`-+_`)^Y<M,AC\#A<Q<-
MN/;^\[6QQ=EFUS-O>F?;=XW:CPV\:R"4][2(@8@/3SA/+7&XN'.)\[D?#)DL
MMQML3)Y%XH$AC.1OMJXF[O#'$JA(E$\QT5>B?N_32@['N8I#"_XJVZW'S&9X
M]8M25[P_8.[1E&FHH*PAB'011@:::!%^-==/CXUH'AAU)\4>IUU/8NI[M"=>
MG74CK08O(I;HJF=$MK-1Y9[Y'BB:$QRQLL3AHF_@W&I5B"#H=/KK07MP/#$&
MM[..X=GC3Q@QQ#L=P'=G*,`L:DM\==-*#Y>6,5Y;S6Y>>V,T9C_)LI6MKR$$
M@]T%S'I)$W3Y%!:6[P?S2]M0;IIDM+1W$D9:V*,9E[XYO$%-PY'\12Q.@!T&
MO4+!(;C`RX7%X;%(VWU2YM[A87;S8UV=9;1XEFD"-9=S2*Z@ZQ@H$7MUT#89
MQ,891;F-9S&PA:96:)9=#V&14979`WR`02*"VFLA<VUQ$\CVMS=VJV\][CV_
M'NE(1PKV\Q#NC0O*QCU[NW6@^8^WNK6$V]Q<&Z2'LCMYY7:2[FC6-0TM[(51
M'N'DU)[%5=--`*#'Y*7)O>):1(MMB3:239'*^=H;FW.K>),?VI,DDVL?\3R!
M`B$$%B2`%S_+[4$9''6]D<@;,PVUXZGMD@E=;CLDDAT9X99/NU&O4ZB@OH(#
M"TSM--(T\@E9))3)'"W8J&.V4@>.'[==/U)/UH%O^7K/^4;<C\A_Q3;B0'\4
MA?&)Q(2/R`=0Q7[2-"-/B@I7;7J/:O;?C&V221LB)EG:X_&%O*4-BL(8/<?D
M!-58:%"VGW::A\@DM+_P7:IK+"I:,2J4N+;\A`&62(GOAD>/356`8?4"@NY(
MXYHY(I462*5&CDC<!E>-U*NC`]"K*="/TH,+=_B8:SMY[F_O(;6TNXP"96<2
MO>2BVM[68]CL;=99U"@D!=!J0!09.\:X%M*UJ@DF[1VH7[&*D@.4;M<"14)*
MZ@@L`*!8DFSM2QNB3;Q:F]54NR>P:FY1555G/^(```T%K:V\UPLLN5L[..Z9
MKBUTMII+F*6P6X9K8N\L,#=TL85G0KHC$@$@:D,?<7USAKV>?(S7%WC,C>V5
MO8+!9QE<.7B6&3\R=)%DEM[J\8=K=A,9;0GMZJ&R4&+S&)MLU9/9W#SP:E7A
MN[200WEI,I!6XM)RK^&=1J`VAZ$CZT$<?9A3_E_AA\A90W]U!['\*M&T7C1;
M:Y.ZUACOX?.LK(T*2%M%!<ZD`CY`9GU)M+JP]:N&+.]E,UY;[&Q4=S(9C<,9
MQY3(&G+,961R06UZD4$B:!04(#<GS?D+"ND[B`Q,S=UOT\;2!@.V4_4#44%G
M^)+(UU:W06[L+I97D,\A+AI611:1PJ@46JQ`]2VNI_;00!]A8BN4]BX(R!&<
M=Z6R!9H!-`D-OSAEEEA1$DC<^2)2`VH:-CW`G0"@[<P6S-Y<'\B<LYW9O&%G
MR!MWFO>G^?[[)X#,X3!;VQ6Z1MFQQ-SCMTMNG)X[&YO;T[X>),9<6TR38]96
MBD@D0+(`[,XHV3N+$9?D#D+><5GCMV\GY7"7]]MS&7\F5QNUL1MO`VN"P6#C
MRDD=NF4OXXHI9[NYBAABDGN"J+V(K,'47OOL6^Y']8=V;4QV0L,7<W&_.!<P
M;S)&86HMMJ<_\8;KO+?^!')(;B^M,*\$`T[3-(G<0NI`3&H(B;BM))/=GC6]
M66V6*WX+WW;RQ&YB2[DDGW)@VB9+0D33PHL;=S@%8R0#IW4$NZ!0*!0*!01B
MP-EXO<7DN_\`(6-WZ\<10>/L($0M>0>7CKW]Y#>0S_':--/KKT#*<HS11\Y^
ML,4CHCSY[E98%9@&EDCXNS$C)&"=780JS$#KVJ3]*"1-`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!YU>SW'VP]X<Q;RR.ZMJ6F6O<1Z1<PRP9!Q=0SW5E!N
MC%3'"W-Q9SV@N\2LKL\MC=-+:71F!:,]A-!./CDQ'CW8A@C6&`[-VN885C6)
M8HCA+'QQK$@"1JB:`*``--!0;9<7$5K$9IV[(PT:%M"?NFD2&,=/^](X']]!
M6H*$%U!<B0PR!Q'+)"WR/OA<QR``Z$A7!&OQJ*"HYB.D4AC/D#:1OVGR!="V
MB-^\%!Z_I08TZXUKJ:262:.\N81;Q%)I9$N)R4\32+Y`ENTA7M/:JQ#74Z=0
M'U^Y$_FSV]TMTEBR/8+.'!U9)C&8TD-M)<HR=JN#T!(UT-!5QE_%E+"UR$,-
MS;I=PI+^/>0FWNX&(T:"YA8DQSPL"K#4C4="1UH."WW_`%<EA-X;:[D6:6Q3
MS"=[BUA$:M=-&%0QA)9`"I)_M_0/D218FSGEGGGG_B-<W4Y26:2263L5FCMX
MA(8T.@TCC7M7Z#YH+"2UG[I\U;XX?SCL-O%;/D&2WO+>*5UM'N9$B=8U6.5Y
M%'860N0=309N=)Y$00S_`(SB6%W;QK-W1HZM-#H^@'E0%>[Y7744'SR2&X>!
M[<B#PHRW#21%)9'9PT`BU\G<B+J21H0:"DRVN/6YNW=XHNU'FU>5X(DB1(E,
M4`+)"BHHU"*!\D_6@I9.+(W%H/Y1>P6=V)(98Y+BW%U;31JW<]O/&&2013H=
M.Y&5U.A!^A"HKP7T-U:><N\7=:7;0EX9(I6B5F",-&1NV0$$?%!>(@C1$!8A
M%5`6)9B%``+,>K,=.I^M!K\^*N+?++F+*_:VMGA9,ICI%[[.?M;R?S"%$7OC
MR"Q@H3J5="-1JH-!>VT\&9MX+N,7<5NMPES:OW36ANHXP&BF,8*2-:S!]>R0
M#N'R*"\G<^2"`VK7$4[.)9/X9B@"+WHTJN=6#L-!H#H:"GK;XRUC6268Q(\<
M*R3/-=3,]Q,(XP[GR2OK)(!J>@'SH!0?(K6074EU<3>5P98[54#Q)#:R>%C'
M(GD9)IO)'KY-!T.@`^H?9H)[B5D>3QV?CB9#;RS0W?Y$<W>P:1"J^!T4`C7[
MNH(TH,+8Y')2P"SRV-6/)FYF3Q6TRM#)CQ<ND&2@ED`"LL!5GB)\B/KIJ-#0
M;#!"+>"*'R2RB)%3RSOY)G[1IW2.0.YS]305J".//F:M9MO\5W=@]K?6U[[`
M<18WRF&>Y5?)O2"RN)($B*:7%M,C=KL#'&5+D$+0??5*X@CX!XGL%8J3M%;F
MRB92TAQT=]-%')<2Q>2U%Q_%7N57(/RO0'0)&T&.OK>[<Q7%A,D=U$1&$N7G
M-D\$LT)N3+!"RF2<0QD1-K]K']-107LT9FAEB$DD)DC>,30D++$74J)(F964
M2)KJ"01K]*#Y!&88886EEG:**.,SS%3-,44*992BHADD(U;0`:GXH(K<L[%V
M[N#/[XS>9Q$MY+967#IA_P#$+^RQV0FQ.^KO(V*Y2RL[N*TRZXF]=9HEN8I`
MC/TZ'H$KJ!00X]XKC#V_"-\V][S'V'&\F[>)8,S<B?<4&??=]QS?QC!QO9XU
ML"5/\NOMW2P17HE/8T;*K@PM+H$QZ"'N<^WWEV(6U;S^ON[1%]S`0_B;NQYG
M/;U1C/\`FH`>A7QGY[N@3"H%`H%`H%!%W"9&+_>=R-B"I%POK9Q'E`W>=#;S
M<E<Q68'CUT!$MJ>NG7X^E!9<U)*?8[TRD5(VB3>?-"RLXU>,OP;N\QM%UZ,Q
M0J>A^TF@E?0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00IYUU;E#?,36KS++
MZ5\UB+^+"BW#KN#;HGM%5XRPD973[BP0`_!ZD!*;CUE?8.QW0(J-L_;3*L7_
M`"U5L+9%1']J?8`>G0=/H*#8K2*[5YYKN8%Y6[4MX7[K6*.-G$<D??$DJS31
MD&0%F74=*"X+3_D(JQQFV,4C22ESY5F#1B.-8^W0HR%B3KT(`TZT%%+&&._G
MR"M+Y[FW@MI%,KM#V6[RO&R1$]D<A\Q#$:%@!K\4%=X(GDBF:*-IH!)X)74%
MXO*H63L;3N02*`&T^10?+=IVB4W,<<<VK!TB<R1C1V"E694/W(`=-.FNG6@H
MO+=)>!6BMUQHM'D>[:<K-'=K+&J0F`IV&%X69B_>.TKIH==0%2UCMHH52S2)
M(`6*+`%$0+,68J$^T=S,3T_6@IPV4<-Q/=,SS3S,W;)+VL\$+=I_&A;0,MN'
M7N"_J:"K`UPPE_(B2(K/*L023R=\"MI%*Q[5[7D7J5^GZT""%H5<-/+.7E>3
MNE()7O(TC0*`%B33H*"G-;J'>\A@CDOTMI(8&DD:-6!/D6%W59.Q&E`U;M)%
M!;".URT<1O+,,]C>QRK'/&_;%?V;*Z3V[.J>58I>J2::'344%ZC7)GF61(A;
M!8_QW5V,KL0?*)4*A4"MIVZ$ZB@L<G?7EB;)X+$WEO->0VUVT3.;BUCG;QK<
MQVZQ,)XXY"/)]R=B:MUTT(5KFT'D?(6T$3Y..TEMK9Y998XF61ED\4PC)4H9
M$!U[2P^FFIH+X:Z#70'0:Z?&OUT_9K08PRWG\U2*0%+-H)O$(XS,D[+X2SW4
MI119O&21&H+"4$ZZ=NE!1RAN[-X[^PM%NY'EMH+_`,UU-&EMBHGDFN[BVMXX
MYS/>*AT2-54RN5#,`-0&7CD61%==?N17[6':ZAU#*'0Z%&T/P:"QBC1YK>>]
M2"/(K'<I#''.[:6YF4GM0LHD(41EF[3VL=`=#U"Z[KC\DJ8X_P`7P*PF\A\I
MN#(P:,Q=G:(Q&`0W=J2=-*"WG>X-Y9I;R:Q(\HOXD$#%4>!VMWE+N)HE\B:#
ML!+$]>@U`6>3P-GD[:6V:2[M6EO;;(&YM+J>&YCN;66.6.2&3O/B!\85E`[&
M4D%2":#(J)+B.YBN[=8XV>:%56;R>>V([5D8JJ&,R*3JO73]306&.LI,9*F-
ML[2*'"06K-#-)>W$]V+N2X+?CI#,LNEG%"3H3*"O157M&H#H_P!DH[-MM\;M
M<L(S!SUPH]DVK(BY%M^8J''B1T1C&DEU,JZZIKW:=PUZA\]2Q(/7+B03PP0S
MQ[62&1+>031(8K^^C(BF[G[T/;KJ#H=:"15!;7=W;6%O+=WDR6]M`ADFGDU$
M<4:]6>1@#VHHZDGH!\T%M*C7,8O\=,&N&M&2T,LTZV+K,4D666%-0Y``*MVD
MZ']#09$:@`$ZD`:G334_4Z?36@Z$Y0Q&+RMCNZ3(O(]S8S;(NK:VTDOH[4V^
M>AGL[ZWL;5[:Y:[FG@((<NJK%JH/W:AE?8'FW;/KSQ5N+E3=<-Q>8["S8?&V
M>*L9\?;Y'.9_<N9L=N[<P6,?*75E8/DLQF\G!!"DDJ=[N%75BJD.H-M<O>R^
MWC8;BY[X?XWV7QY=##)E\OLWDC);EW#LVZS]Q%864>9PUYMBQM,K8V&4NX(+
M^YM;E/QT<S)'+&CA0ZX_JA3W47J?V6Z!TNO8KTVM+W[5?LL)_;;A5;IQW.G:
M573J-2/H#0>AM!#7+N\WOALZ+3^'8>N6YYB=`#W9/>N.C3KWDD?^&MI]H`Z]
M3]`F50*!0*!0*"(F$MM/?#DF\,B$OZF\-6PB#*758^7><9?(Z]Q95D:70:@`
M]IH-MY8@CEYO]5Y&2-I+;>7)\L3,I+IW<.;PA?QL&';W+)H>AU%!(Z@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@A%SS;2'E?>-U;W+P3_[)N=K;J1'"K'<.
MU);>X:;R`QRP2!M#V@!23W?2@E=Q\&&PMD!I$E8;0VT&ECD,T<K##66LB2L2
MTJ.>H8]6!UH-OH*!N;<7*V9FC_*:%KA;?N'E,".L;3=G[WC$C!=?C4Z4%>@M
MKK\SL3\+\<2>:+RFY\G:+?N_C&/Q@DS=G[H/VZ_-!927=Q<7BVMB%\4+!KR]
M)BEA5HY.R7']@D$JW3*>[NT*J!H>IH+VXEM08[:Y*'\PO#'%(I83$(6=--"N
MG8#\T&,Q=G#MW%""YO0;>WED*R2]D-O:P2S=EK9VZ`!8+:V1DC122>G4DF@R
MI@!N4N?),&2%X?$)&$#!V5R[0_NM*"N@;Y`Z4%G,]IEK>^L+?(21OI+:SSXZ
MY$5Y9R_N,8YE#^"XC;X)!T/TH+B&=VN+BU:VN42U2W[+N7Q^&[,J,6$!5R[-
M"5T?N5>IZ:T'R.%+/\VXDNKB1)9&NG_)E#Q6L:1*#%;A43Q6Z!"VAU.I)UH,
M;>V%QD;O"Y3'YF\M(;287$]I"T3X_,6-Q`R&*ZC>)I.Y!('B9'31AJ0PZ4%Y
MC<K9Y1)FM7;OMII+>Y@E1HIX)(Y'322)P&59`G<A^'0AAT-!>M/"DL4#RQK-
M-WF&)F`>41KW/V*3JW8O4Z?`H.(@`N&N>^7N:%83&9&,.B.SAUB)[%DU<@L.
MI'0_`H+41B_>SN^_(V?X=Q<G\8L;9+K[)K0B\@(;SV_7R1=1U[6H+BY_(*(M
MNJ$R2*DKLY0PPL&[YHP`>^5>G:O0:G77I04)+JRQ4-G%>WZ1^>>WQ]M-?W$:
MRWEY.>RW@#MXQ-=7#]%4#5C\"@HV>/:"\O\`)3M_U5Z(XY8H9IY+006CS"TD
M2&4`1W3P2`2E1HQ4#X`H+>*3';CL+3+XR>.4/'(^.R$:LLB#R@2Q=X\=Q%&\
M]L$FCU5CVE3UH+^&^A#0VEU=68R+1*TL$,OVM(I"2^!9")"HD^`?N`^:"I%"
MZ7EW,T=LJ3);+'+&K"YD\0D[Q<L?M9$+CQZ?`)UH/MW^:%A-E^-W"XB_(%UY
M=#::D3^%HB.VX`(*E@5Z:'YU`6=GD<?GK2Y?&WC36\=U<V#W=H[(!<V4QAN5
M@F70/X9T*%E)4D$=:#DLU\EKX9FQZY9UN?Q8O-(89UB?2.0JP2<_PV4R!0>U
MCH#IH:#IWF?CW+;IVEA(,#+:WF5P7*?'/(LD&=O;Y+7(KM#>6*W!<XR.YMX[
MA[!)8;,I;_PGAA8*60@&@SW!FQ<KQGQ'L/8F;FL)\OMO!QV.1DQ;S28[\IKB
MXN94LY;B"VFE@B-QV!FC0MVZZ#6@[2@N([A7:(L1'--`W<C(?)!(T4@`8`E0
MZG0_!^E!QDGC6:&U=)7:Y68@K#(\*K$H+B:4*8XN\-HH8CN/04%G:6$EE=W]
MP;UWM+IUFCM)$4"UE[0)F%P6+M$P5>U-%6,`Z:ZT%ZJ2>=YOR&>!XHECM^R/
MLC=2[-,LJKY',JL!H25';T^30=`\BR8\9'=B93)86QAO;;8,&+3+7\%K)-?8
MW<5Q<74ME$TXO/-;2W5LJR01LRR.H&NI[0SG/G$EOS1Q\VTI4P<]SC]R[1WG
MB;/<^.;+;8R69V3N&PW)C,9N/'QLDT^%R-SCQ#,T9\L(?RH&9`K!H&[<;S%S
M+A;3CG<7'5CQOM3+W5J>0MQW6^,7NBYNL)ALU:WDF`V?886""ZNY-VPV0C>]
MO_P/P[29R;>6;2-0Q'O):[`O>`C8\C2RPX&YY?\`75,:(6R<?EWA#S[QO=;&
M@=\3!/<K#+NRWLPW<%@*])66,L0$OZ"'TD4;>]9G9/XL7K7A8H78L-5EW_O-
M[I8P3VOIV0]V@^W4?&O4)@T"@4"@4"@C=B[**/V\WM?@#SW'KGQE;L>Q`PBM
M^2N5W12X'>ZAIV(!.BDG3Y-!7Y5D1.;O5Q78*9-V<GJFNOW..(]TGM'0]>W4
M_P!@H)%4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$(>=>].7]WRQVO=.?27
MG,6EV8UN(UECW)M-WM9K9T6*82%HV"LY#=I&@ZDA*'C22<["V$AAB_&_R)M1
MUN8RL0,QPMB#$MF`?#'V=1HQ`^/VT&^T''M7N[^U>_M[>[0=W:2"5[OGM)&N
ME!2MY)I%<SP?CL)I41/(DA:)'*Q2DH2%\J`-V_(UT/6@JLRH"SLJJ--68A0-
M3H-2=`-2:#'S^6"Y1[4K*SI_$QPD@A[T:=!+?KW`.7B[]&ZZ,-!\Z:ADM`?I
M\?'[*"W1I9))TEMPD*,BPNTB2?D*45F?QC4QA'/;HW4D:_&E!]N$GD5!;SBW
M831.[-")@\*.&EA[6=.TRH"O=\KKKI06=]%=Q(;G%Q6YN1+')<0O&BM?PH"&
MM_R"T?AF*G[';N"D=0109+J5_P"ZQ'UZ]I(_X'0T%&W298$2ZE2>8`B61(O$
MDA).A$1=^W[=`>IH*%X;T+##8HBF1PLER_8R6D:`-W?CEXVG\@7L`5AVZZ_3
M2@Y06T-E;NEI"OS-,$4A!)-*[S/]QU"^25S^P:T%M9WZ7]O,_8EM?6@:&[@;
M_J#879A61H6D156<(K@ZH=&!Z4'+$SW$]HC3N)]%14O0JPB_`1>^Y%JHUM5:
M34!"2=!K]:#)T%M'!';?DR1*[-/(UQ(G>6[I?&JGL#G1.\(!IT&M!]B!GBAD
MNK9(YAVR>)F2?P2#X[9.T`NOZ@"@L\?,&$J1N]S9KW2Q9"6>*03M-/.\L"JB
MII':#M56/0KH.I!)"ZFCFC@$=@+:%U=.U9$(A"&0-,`L0!#,A.GT[OF@Q&:V
MY99>-'0M8Y&VO$R5EDK0F&Y@OXHO"LDC1E6GAF@_A31L>V2(E3]"`N\;>S2S
M7=A=1O\`EX\0>:=89H[6X6Y$CV[VTLJ*)F\2#R]I(235=>@)"^=Y/.D/XY>"
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MK(Z,`596!#*P/0@@]:#7<A>93%7N)ALL3'=8*539W)LEF?(6%P3!'8&.T1%M
MOY9VEQ-*74P!5/:P)[0@#[-Q/DMT<_6DJ!CC.-O6R_PEY<);R/B<E<<S9U;J
M3$W#Q-+C)[B*SB\[HW>0L9`Z#4)1>S'L#MSUHXKNN2]Q64V7:7<>TMF;;V_;
M7$5E<[EW?OC/V.V]M8&WO[E396,V0R5^H62<K'J.W4,RT'76)Y-]F]A2VNX_
M879W#%CQWD<MM?"3W?%FX]WY/<>S+S==[986SN]PQ;FQEEB\QA+#<%_#;W5S
M:/#(D4PF6%D1Q08WW\Y./%7`>'S:6$&1EW%[`^K/'<=M<S3P*K<B>QG&6T6N
M4>W20F>RBRK3(K:1NZ!6(!H)KT$-I;>67WS@N&AN?#9>M,,<<Y,7X?DR._<H
M9(E7M,YN>W&J6.H3LTZ$ZZ!,F@4"@4"@4$:+"_A_WB[LQ?Y`%P?6CCZ_%IXP
M6:%>4>3;=KCS>351&[!>WLZ]VNO32@UOGNXO8/8;TD2UEDCM[KE#E>WR"JCL
MLUM_H#R)/'%(X4I&OY4$;#N(U*]-:"7=`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%!"_G#O_`-6-SL!"47TUYQT_>>Y\C;@VD0%@5)!+`50ZC37NT`!UTH)/
M<=/Y./MBR:,ODV;MA^UD6)E[\)8MHT2_;&PUZJ.@^*#:;2W>VB,;W5Q=DRRR
M"6Y,9D59'9UB!BCB7QP@]JZ@MVCJ2>M!SEA$K0MY)4,,GD'CD9`_V,A250=)
M$(?X/UT/R*"E?VTMY:36T%Y<8^650JWEJ(3<0:.K,T0GCEB[F4%=2ITUU'6@
M^SI:3@6=T(9O*O>+>;L8RK$RL7\3:E@CZ'730'2@X2GQW2SR16Z6\=K+WWTD
MBH\3&6+2'1@`(I%U8MJ`"H_6@IM92OD8K],C=K`MN87QR&%K*8EN^.X/=$TJ
MRKJ1JK@,#U!T&@?([F/+V+2X^\>%96>-+J)(VDC>&4I*/',CJ&#(5(9=1^E!
MDJ"VC4VL<[W-T9$\LT_EG\42P0LW<L7<H1?'"O0$]=/F@HO`;JZL;R'(3I!;
M"Y[[6W:!K2_,\:QHUT3&\K?C:%H^QT'<=3KT%!7=Q<1W,5M=*DR=T#2Q&*9[
M6<HKCOC;N42*KJW:P^"/H:"HA"]L1D[Y%1>[4KY&'QWLHTT[C^S2@P-M:1;?
M:WL["WE.*GEEUA$D8ML-&L4US+.&GD$GXT]P3W*"W:SCM`4'0-@1TD19(V5T
M=0R.C!D=6&JLK*2&4CX(H*4C+,)K>*X6.<)HQ0H\L'D![)#&2="1U74:&@X6
M5O):VL-O+=37KQ(J&ZN!&)YNT:=\WB5(S(WU(4`GZ4'U4:&2YGDN))(G",L+
M*G9;K$A[_'VJ';R?)U)ZCI0<K6ZM[VWAN[2:.>VN(UEAFB8/')&PU5E8:@@T
M%L[8^[>XQ#F&1XX(9+BR.@/X\S-XG,8T)A=XB-?C4$4%U;P);0I`C2,B=W:9
M9&E?1F9]"[DL0.[0?H.E!0NX2\EG*ENL\D-P/N:X>`012`K-,%4,L[*OPA'4
M_4?-!;WMA99A(2T\Q%I=K*KV-]-;_P`>V<AX)VM95$T7<"LD4G<IZ@B@HX[,
MF[O+W'W5E-C[RTD8)%,RR+=VH"]M];2Q:Q/;N6`TU#JW1E4Z:A\,^2LLC=R7
MSP/@S:F>&Z54ADLID=5:UN$+M)<+(A[DD4#0ZAA\$A?0K)<O'<SQRVS0O<)%
M")UDCEB9E$=Q(JJ-'>-=0IZIW$'K0=$>PUY:OM79_P#TUID$M^<N$[6X$ZR,
M;&:;DG;D*7EL8WB(R%A).LD9#:*PU/344%EZB,Y]=N-8VG-R+?'9:U2=Y&EF
MDCMMQYF!3.Y++Y@(]&"LR`C[25TH))4%![=7N(;DO,'@29%1976%A-V=QEB!
M[)&7QCM)&JZG3YH*=[%=S0%+*Z6SF)!$[0+<=H'4KXG(4]WP?T%!0M));6*Q
MLLG?V]WDY8F!EB@%I^8T"IYYXK,2SF)%+CN^Y@O<!KU%!$7F_B["9^XWY=2;
MBO<:F0V_QUC<Q@K26U+Y['XC?%UF<;%D;N^M\C=6EO\`S&YE5&MD@D/53(VB
MA`[PYGXQ'*6U\5CH+V*QS&U=W[;W_MIKV`WN%N=Q;1O3?XVPW'C@5.0P%^S-
M%<QJ1(H<21D21K0==[AVYR_S+BK?96_=H[5X_P!G/D<)D]W7%KNH[SR.Y%V]
MG[;.6N!V_;0X;#0XO%Y.ZQ4'Y5Y>,;A;9VB2W\C&2,(Y_P!3S"Y[<_$_#&W+
M>WL(MOWGN%Z79')9AKFYDR-ID<![2\4YRRLH<3%9M'/89"WQ\RRW!N$,#A/L
M<,64/2R@B*UV/][WX,8A\C>O=G<W!:%!/X8-YYB.#LN1_%DC:6Z;^&WV(06'
MW.:"75`H%`H%`H(;V'7^H+NKY^STWV`/KH#)S9R2=/TUTCH-LYJL(;KFGU(N
MWDG27&\G<@30I&_;%+^1PER%;2+.FA\BJDFJ_HPUH).4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4$,N:C;MS%F[>2>&*6Z]/.<5'FDT"P1;AV<)IBGQXHC.
MO>QU`U%!)CC6%;?CG8$"=4AV3M6%3W,VJQX*P1?N?1VZ+\GJ?K0;FZ"1'1M>
MUU9#VDJVC`@Z,""IT/R.HH.$,2P0Q0(7*0QI&ID=I)"J*%7OD<EW;0=222:#
MY<RO#!)+'!)=2(O<MO"8UDE.H^U#*\<8/]K"@Y-%$[Q2O$AEB[O%(RJ9(N]>
MUPCZ:KW*=#I\T%G!<I?29&UDM_LM)UMF\H$D5RKP13=X#)V%09"I'70KUH/D
MUY-!>V=HF.NI;>X60/?0^`VUHR*"D<Z&47"B0`Z,$*#30D$@$.-_^=;6R?R>
MUM))C>6WEBF=K>/\::Z07TZ&*)^ZXCA=G4$`.PT)&NM!DZ"T7MOH;B&ZLRL)
MDEMVANEBD2YA&@\G8&=6AE!^&Z_J*"K;6UO9P16MK#';V\"+%#!"@CBBC0:*
MB(H"JJ@:`"@^2:017$L,'DD[7F,401'N)5CZ+J>U3)($"@L?TH*?_3J%R%Q%
M';RI;$22S=@>WA?LEEB>77M"*ZCNZZ:C6@Q>-O\`(7K:7MO;6L1FOX41O-Y+
MV".4K:W,*RK&8P\*MY(V5OHRL5TU#*2R+9QPB*V9H?((W$/C1+6'M=VG<,R`
M0Q]NA[=3U^*"UO8/*+>_M)ID>!X[AQ9I`[Y.V6.3ML9&D4ZPRM(&!!4@@==-
M=0O+-[F2VADO(5M[AU[Y($<2"$L21$9!]KLBZ`D="?CI0?5\[R7,<\<7X_V+
M`RN2TJ.G\42H0.PJW0:$ZC]*#XXDA2%+2&(HKQ1M'W>(1P:A6:,`%=8EZA>F
MNFE!5$,2R/,(T$LBJKR!1WLJ?NJ6^2JZ]!\4'"VE>>".5X)+9W75H)>PR1'4
M@JY1F34:?0D4'RY'V*YNFM$AD2:613"JM'&P9XY6F1U6*11HQ&C`'H0>M!CK
M[RXG&W$N$Q45Y<>=)UL(9(K07,EW=Q_F3M,X[/(L<KRL3J7*Z?)%!EI'6*-Y
M6#$11NY"(7<JH[F"(H+,Q[>@'4F@M[2:2ZA,LL'A21BT"/KWO;D`Q22HR@Q2
M.#J4(U7X/6@YRM<^:!84C\)+-<2R'JJKIVI&@8,9)"?GJH`Z_2@C][,I;-LG
M9GY>1CQ<:<Y<#2QSOV]\UU'RQM1[.P@+Q3()LA=!(1JI^USH0="`LO4*RBQ_
MKYL*WAM;BR0)N%_Q+F]_F$EN9-UYUS$;Q52.8+W="H`TZ=3U(2,M)+N1)?S+
M:.VD2XGCB$4_Y"S6ZOI!<:^.,QM-'U9""4/34_-!=4'"4R".0Q*K2A&,:N>U
M6?0]@8CJ%+?/[*#Y&',<33B/SB-?(8P>P2%5\@C+:L$+#IKUT^:".G)EO<Y+
M*;BM6N+O%Q6<&Q\BE]B[V"&XO5M]RW+?RS)I.K&;%2^-BT:B$GO9?(21H&K>
MW_*_*''&UN-=M<,65J>2N:^6]K\0[?W'E,!)N;`["BW':9:]RV^\]AK;(V-Y
M<V.W,7BI98]%GM_RC$MRJV[22(&)L,?S1P#D=H9C?_L!D>;-I[OWM@-C9K$[
MNV7L;:>2P61WI<6&(P.7VGD]HX_%27,=KN71)K"\6Z,EG>L8I%DME$H;E[;7
MF=L^*<0V!VKC]VW%QS%P-97]KD<S%A(\-A;OF39,.7W3;3RVEW^=?[9LF>[@
MLU"/=R1"(.A;N`2<H(BV]E-_O>S&5DM[@6G^WS;.)MKIF!M6O1O+=U_=VT2]
MQ*W'XSPL_0`J$ZGX`2ZH%`H%`H%!%>RQ@B]V=PY;ZW7JYM*QUUZZ6G*^\INW
MY^!^5TZ#YH,SS`RCF/U6#,%[N1-_J@)`[G_T;WVW:H/[Q[5)_L%!(^@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@AASA`D_,-_%Y9+>2;T_Y_A_)[H8H;9),
M[L)?,\A[IF=&/<.@1`I)U)``23XLDDFXPXXFE=999=A[0DDE0EDDD?;V.9W5
MFZLKL=03U(H-Z?N"L4`+A3V!B54MH>T,0"0"?DZ&@I0R.8X5N?#'=M"KRPQR
M=X#@*)?$6"N\2R'0-H.FFM!4DECA0R2R)%&NG=)(ZHBZD*-68A1JQ`_MH*;Q
MS-/#(LY2%$E$MN(T(F9^SQN9".]/%VGH.AUZ_2@IW:3/&L4,:,LT@BN29&A9
M+:166:2)D'<9E&G;\?VT'&T<I&MO)&UN8GDM[99ITEEN8+8!$N`0[.WD0!CK
M]P^M!PLH+VU6Z-]D6R`DN)9X2UK!;FU@;0K:(+=1Y8H0/M9^Z0Z]2:##93/V
M^-.+RDES<R8S(]]I%:P6$DTDDSV\U^MV56)K_6*ULI%6)4)=G`TUTH,OA\M9
M9W'6N4Q[S-:7D,<T7Y%M<6=R@D17\=S9W<<-U:W"!M'CD171NC`$4%W<7,%J
MBR7$@C1Y8X5)5FUEE8)&FB*QU9CI^E!69E52S$*J@LS,0%50-223T``H.#+%
M/&5=8YH94T96"R1R(P^"#JKHP/\`8108[*6@O8X;0P2$.SLE["\:/C)8HRT%
MR@9E=B7^WM4$$'1AVDT&.Q]^]E)!@LKY7NDMXTBR,R+X,MJ.PR+V%T2Y=@W?
M$2"-.X#M(T#)100XB&UM<?8N;1KGQ^.!E$5C%*&8RA'8=MLC@#M37M[N@T%!
M6FM$NKBPO5NKJ/\`#,SI';7!6UNTN(?&5NX0&CN8U&C(>A5AJ#\ZAPRE^,=;
M+/X_(9+FUM5!D2,*;J=(/*6<@%80Y8K\L!H.I%!B<9N2RFL)+F]FDM%MLG-A
MS<9&-+,WMS#(D230P]"J7;R#QJ0K'733XU#9NX=O=K]NG=K^S377]?B@H1R0
M7MOWPR"6WG1U$D;'1E/<C=K#0@@@C]0:"D%L@JXIO%*%M%!M)B)F>T72`-*L
MG<9(R1VDMKJ?F@K6T'XT*P^6:8*TA$D[*TFCR,X35$1>R,-VJ-.B@#K\T%&Y
M$L4B748NK@JOA%G"T*QN99$UG<R=GW1(#\OIIKTUTH.0EM<A#<Q07*R(LD]E
M.]K/H\,\>L<\7EB;NBN(6.A&H96_;0?1)!`8+(3)YVA;\>*64O/*ENJJ\A#,
M99%0LO>WZL-3J:"//LF+@;!V1+=+"\]OSCP'<7!@MVN+=/%RWM)I)0LK!XX8
MUU)D/<4'70Z4&-]2\:W^B&P+I;V[BAM9=[*EI;3L,=?)<[YW#-#=30W$;7/?
M&K$`=R@EB=".W0)-V]S;W2N]M/%<)'+)`[0R+($FA;LEB<J3VR1L-&4]0?F@
MY-/"LT=NTL:SRI))%"742R)$4$CHA/<RQF1=2!TU%!QAA\/F_C3S>:=YOXSA
M_%WA1X8=%7L@3M^T=2-3UH+6^M[R1[:XLKHQ2VQ?6UD;MLKL3&-&-WV1/.6M
MXPS1!2H[S]VH^`\P??+G?;_!,N[=P<@[ORFS-M7^(X.VML3+V,.??%0\B;SY
M8OL8UINF?;5I<26>'RUK901^7(ZV4:I(=4U?O"6^8O=J^PE]G-K863?>RMZ\
M+;OL,[M[>TNWOY<,5NBUEW!@XKS#R9*.YL,]A\E;6M]99&PG2-KK&W1#*B3P
MRD,WC^*MZ[BS&VLIS'OC#[SM-FY&SS^W]N[:VE_E3`2[JQZNN,W1G8[S-;AR
M&2R6'=VFM(DG@LX;AA-XFDBB90ZK]X[W/6W'W$%K@,P<*^7]K?67&9:4R^.#
M(8$\L[?OLK@[K0%Y(,Y!8_B]JZ$O*OTUH)HT$.(`;GWMR7[Q3%>N>+;1DUC$
MV6WMD51XW\O:)1'BW#:IJ5(T;34$)CT"@4"@4"@C-!=P#W(R=B2?R6]9L%=A
M=!V^!.4]Q0L====?(X^E!K_L!>RVG/'I)#%-X_YCS+R/9RQZD&>!?7;EJ]=/
MW&!"/9JQU*_'3]*"7-`H%`H%`H%`H%`H%`H%!:W?YGC7\$VPE[QW?E>7Q^/M
M?7M\7W=_?V_LTUH-9R-SO6U_$>RL<'?HRR"]C6:\BFB=?NC-MWJ$E215*GN*
M]KD?34@.,=YO6XN'6+&8:UMD8COO[B[29@9W"M"MK'<QR:6P!;N*?>=!J/NH
M+N.;=JWBP3VF%:U?O*W=O/>%D$<B=HN(I(U[&FA+:=A<!QH>G4!=-=9JVN+A
MKFR@N[(D_AKC"[7@T[R!=K<O#$-0%`*$]6.N@'4*-Q=[B@25H\=973.IDM%B
MEFC*=KJWAO`X.DKPL0I35>]=#T-!4-WF[;\,7%A#>F1&%V<<Q40RF9A&RB[=
M-85@T[NI;NUT&E!97><S<<"R6NV+V647*K)!+/:*7M5$AE>)Q/V+*2JA`W0E
MNOP=`L_YSN]@2NW(D9RS)')/KX$>)GACN)%D[))HI`%E,?<GU4_2@O+;*;FG
M5`^"AMI5LII9VGN3XVO49#%;6XC#L8YT)T9C]K#0B@C7S3@<MD^3;?,X.QL\
M]EKGUQY:V6=I0Y7"6NXX1O+*[2FM,]<V62REE,-MV=[@_P`2XG2.51/<(-1H
M00[SXSESMEM+8F&S.+CAEAV'MI;FXQT;?R^SR%KBK*"YL&DDDUZ$Z1]BE=$;
M4C[10=CW$W@B:7Q33]NG\.W3R2MJ0/M0LNNFO7K\4'TPPF9;@Q1F=8VB68HI
ME6)F#-&KZ=P1F4$CX)%!PN[2UOK>6TO;>&ZM9@%EM[B-989%#!P'C<%6`901
MK]10<!>1?E+9QJ\KA7\KQ!'BM2BQND=RP?NBDF20%!H>X`T%W04GABD>*1XU
M:2$L8G(^Z,NO:_8?D=R]#^M!0L[MKK\CNM;FU\-Q)"OY`C'G1-.VXB\<DG\*
M3KH&[7&G4#I0<KNV%S&%!1)HV\EM,\8E_'G"LJS*A9-657/U'S0<"L./M[B:
M.!W.KW,R6\8:>YG*J'<("H>:7L'U&M!>`Z@'0C4`Z'H1K]#^T4%DPM\E!>6E
MQ;2/;LTUE<0W4#)%<QE>V3M#@":WD5B-1T8:T%31K?\`$M[6V7\9=(6*ND:6
ML$41$06,_<XU4*`OQ_90?8D:UM^UY)KHQ+(W>_:T\@U9PO3M5G`^T?&M!;F`
M7RK,TMS'!/;*IM6"Q/$S=Q\JNH$\%R%<JVC::#^^@N;BTM[JVDLYX^^VEC\4
MD?>Z=T?3[2Z,KZ$#KUZB@MHK1,78K;8FTB$<)1;>S\S0P1QM(H=(F*RB&**,
MDHBCM&G:`!07<Z2NFD,B1R!T/=)'Y4*AAWH4#H?O34`Z]#UZ_%!QFM+:<PF:
M"*0V\ZW,/>@81W"@JDR@C3R(#T/R/I0<E>4SR1-`5A6-&2X\B%9&8L'C\?\`
MS$*:`ZG4$&@Y.R01.Y4B.*-W*QH6;M12Q"1H"S-H.@`U)H+:VO+.Z@6_B=/$
MR]OFD7Q,%[AJCF0*R:.="ITT;I\T%2SFFN(!)<6LEG)Y)D,$KQR.%CE>-).Z
M)W3MF10Z]=0&&NAZ4'TS2?D+&(&-N8'E:[\D?C21'11`4[O(6=6+=P':`O6@
M2]T$$SVMNDLH626.`.L"SS'5M&D[6"&1OEB#^M!R\4;R17#PQ?D1QLB2%4:6
M))>QI8DE[>X([1KW`:!NT:_`H.@/8>QS5]M'$7%G!E6M\%RCQ#GI4PEK_-+U
M\7@N1-L9G.9&2RA3\IK>QQEK<>6-!(QB!=5+`"@MO4RRR^/X$V5;9W"W.W<G
M^5N^XFPUW87&+FLH+[>VX[_'@X^Z5;BTCN,=<Q31HP&B2#0`:4$@S`\30BS_
M`![>'S227,0@`$PE#L[)XRG9,TS=Q8Z]W77K0<X(714-Q(MS<*9/X_BCC8)(
M_<(T"#[450!\ZGMU/6@Y0R2R>;RV[P>.9XX^]XW\T2]O;<+XV;L234Z*VC#3
MJ*"M0>2W]4/;G)B<0<G-Q_Q9?\KVW,^(X7X>W1_+]TX_;PXNVP_*UQ-G^5<O
M;99)#F-O[7L<\);JWQ8.39$U52`&0)V7/K#P=>_==;(,C=YDU_S-O!-)"@C+
M)V;A4IJBCH/B@RUKZ^<26<L$UMM>>)[942$#<FZG153]T,DF;=9"#UU8$F@T
M[EKB7BRPV5:Y"]VOCISMS=_'>;PT^5N,CDQB\[C-\;?.'R]HM_=W2Q92PN9.
MZ"8#R1N=5(-!)B@BO;9;'M[CY3!):*,JG!MAE9[\"'O?''=,UI;6<C#_`*@K
M'<O)(@/V#N;3KK02HH%`H%`H%!#F**7_`/Z!7L_D'@_V=8R$0][=WF7FO+NT
MC1Z=G;V,`&UU^10;CS=C$N^5_4F^*VY?&<T;L=&DB#SH;G@'F&)OQI"?X)9%
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M>)EMY%AE.@61T\@3KU;L.@8@?`/36@XW-REK$TC*\C:-XX(NTS3N%+"*%&9`
M\C`=!J*"G#V6EN\L]Q-V,[W#O>R(6@$S]_A[E552*$MVJ.N@'R?F@O`=>HZ@
M]01]:!067FN+:TEGNXQ/+$LDACQ\4DC2(I)1(8G8N\I33IKU/Q05;8W)BUNQ
M"LI>0@0>3L$7>?#W>0!A+X].X?'=KITH+B@L[6]ANBZIWQRQEP\$Z>*=461X
MA*8F/>(960E&^&'44#[<?:NSO=7*HTLK,_?<3Z22-(P4*I8I$&T50.B@`4'&
M*TECO;BZ-]=2PSI&$LI/%^/;.H(9X2L2S?Q!IJ&9@#\:4%:3_J(G6VN1&W>$
M,T824H4=3*FA)4.5!7]5)U^E!<#H`.IT^I^?[_VT%H`EF9Y9[QO'/.K+^3(B
MQP%PL:00DA`%=QT!))8T'":Q%Q.S3RM+9R6W@?&R1PM:O*)A*+EB8S-Y0!VZ
M=W9IUTUZT%0O+(T'XS6[V_>ZW+,69NQ590D/80OD\@T/=\`'IK04[5;1$EQU
MO$8XK-4A:$JX01RH74([$]ZLI/P3I04[&V_E=I+'->R3P123S1R7/C06EGKW
M16W>H!>*UB&G?(6=OEB:"K*]Y))8/9-:-:/(SWKS>5I'M3;R&'\(QLJ"5KAD
M)9]5\88::D$!6D_CQS1PW'BDT:/RQ>*22WD*Z!@DBR1]Z:ZZ,I'ZB@Y>2.'P
MQRS+Y)#XXS(R*\\BH78*OVAG*H6(`^!06]C;W=M',MW?R9!I+NXFADD@M[<V
M]M*_=!9J+=$61+5/M#MK(PZL2:"]H*44T,WD\,L4OBE:&7Q2))XIDT[XI.TG
MLE34:J="-:"K01\]G,3=7W"N^(,5%:&^R$VT4G-]/=I;?B6^\<`]W(BV\%WI
M=1V(D,0$8624(LC*OW*$@Z!0=4\U8M<SQYD,:\\]LMQG]B'S6P0SH8-^[9N1
MV"1)$^XPZ'53]I-!VM016QVWTA]QMR[I_,>1\APC@,#^`8T$=JN*W+D+_P#+
M6;4R,]V<L$9-``(@>NO0)4T"@4"@4"@BK'BD3W<N,UW`RS^K-MC"OBD!6*VY
M:NKM/XQ_A/J]VWVC[E^3T(H-HY@!/)GJX!\#F'=#$::_'`O,.G_`F@D%0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00GW%R9O>'WUP_#L.=>/CN^]*N1.3;G
M;JV=D5?>^'YEX^VOC\Z]\UNU^S6^#S5S`L/D\'\1F*%M"`D[MO'-D;;:&XWG
ML_-#MQ+><VJ)=)?QWEM826\UK>Q-;PV]LOB9RB0:2%Q^Z%`(;W0*"A<SK:P2
MW#1RR"->YD@C,DK#4#1$'5B-?^%!\DAMQ*MXZ*)H8I(UET^\12=K2)J.K*QC
M!T_44'V&>"[MXIXF62WN(U>-F!`D20:K]K@'[@?@C6@.\B2V\4=NSQOY/)*K
M(L=NL:@H&4GO8R$Z*%!`TZZ4'*>7P033^-Y?#%)+XH@#))XT+^.,$@%WTT'4
M=304;9X[VWM+MX.QGB2XB29!Y8#+'KI]RAHY`K:-\'Y%!<21I*C1RHDD;J5>
M.10Z.IZ%65@592/H:#'7=[<6]S;6EO9&?\A25E[RD40BDC\RR]L;^("W8E">
MC.`O376@O$@CM_R988RTL[F:0=WW2R"-44:N0J_:@`^@H.`A6Y_#N;B!HKBW
MUF2)I%<P2RPM%(I:)C&Y"2$:@D4%.WOTN+N^M/%+$UG)%&'F`1+KR01SL]MJ
M>Z2.+R!6;X[@1]*"E/>2Q9*"V0I.LT*EK6)/^I@5I75K^61I57\-.T)VA2W>
M?K]`O)'MH)%D?Q)-/VP(Y"K),5[FC@#G0L=2>U2?D]*#E;RO-"DLD+V[N.XP
MRE#)'^@?L+)W:?.A.E!C[3*_F9&^L8[.Y$-AV))D&\8M)+EB>ZTA^_S/-"@#
M/]H4!ET)UZ!DHHHH5[(8TB3N9NV-0B]SL6=M%`&K,22?J:"G#"+:-U#S2COE
ME'E?R.O>Q?Q(2`1&FNB@ZZ#ZT%C:2VNX,5;W%UCI$M[L+-^!E;:/RJ89^Z%I
MK=S*@;OB61->HZ'H?@+^25TE@18))$E+AYD*=L':NJ&12P<K(>@*@Z'YH.%E
M96^/MDM+5/'!&9&5==3K+(TKDM\L2[DZG4GZT%U064-S'=F:WF@>%U>9?Q[D
M1%YH(Y3$MTJ(\@-M.1JNNAT/W`'I0<+O(6^/>V6X!AMYW$`NF,:6T,SO%#;0
M2,SJPDNI90D8`.K=.G2@N1"D"W#6L$*2S,\S:*(Q-<%=`\S(NK,W:`6.ITH"
M(9(X&N8XO.BQR,%^](I^P=_B=E5M`Q(!T!(H*]!1:5EGBA$$KK(KL\Z]@BA[
M1]H<LX8LYZ`*#^WI04_%#9QW,MM:(&D>2ZECMHHTDNKEE4-(_:%$D\H0`LW4
MZ#4]*"O&S/&CLAC9D5FC8@M&S*"48J2I*DZ'3I0>4W]4CDWV-V;PCO\`RGKY
MO;9>R[OB"RXIYHW[9[HVG<[@NM_<68KDR:'D/86+O9#+:X.]W)@\2(+>Z@MI
MKF)RX5XBZ-03FG]B^-K1(FN8^0>Z0=1;</\`+5VJMW!#_P"S[)D;M[F&C::$
M=?C6@N+3V#XYO5B>!-_=L^GB\_$W*5J6U#'JEUL^%X]`AU[PNG]M!U_SKS7L
MVPV9AL?#D,M8YS=O(_%FT]IVV2VUN;"KF=QYG?N`:UPMK?93"0645[=V-M<.
MHD=%98V&H.E!*Z@B%BX<D?>'=4[_`)*8A/7[!0VP$NEG/DGW?.]XQ@[ONN[>
MV6$=^G1)--?I02]H%`H%`H%!'0LO^[:--?O/KI,P&A_=7DN`,2=.T=6&FO4_
M3X-!@/8.YO+;ECTS_&-T(;CV#W':7IMRHC_'E]=.<I%6[+:G\=KB%``!J9.W
MJ!K02JH%`H%`H%`H%`H%`H%`H%`H%`H*$XN28?QWB0"9#<>5&<O;@'O2+M90
MDC'31CJ!^E`C%P)K@RO$T#&/\9$1EDC`C`E$KEBKEI.JZ`:#I0+@7+1Z6KPQ
MRED^^9&D14[AW_8C(68KT'4#6@KT"@QQ3*^:Y(GLC`R2?BJ;>421R%4\1F83
M%945@W=H%)!Z::=0C3R@OX?*6#R&+Q6T\?O[_0WDR[N.0+C"6MYGQMC;>9V=
M?76R;>::^M[D;8R^<R=O=W$7>%66VC?N#::AW)QLUV^R]CS6\-C!BKG9VWKT
MI&T[2BXOL3:W#1VX?_EVT!;1>\N[!NI!7J'8=`H+:-Y8XY9+U[=%$KE&36-$
M@U`B$KR.09?U(T&IZ"@YW%O!=1F&XC66(LCE&UT[HW61#T(ZJZ@C^R@HWMF+
MN-0LAAGA8R6TX!?P3%&C$OB[U24JCG0-J`>OS07:C0`:DZ`#4_)T&FI_::"E
M%'*C3-)-Y0\G=$@0((8]`!'KW,7.O4GI_906N2>YAM_RK8RN;3ON)+6&)))+
MV-(WUMU[ON5B2&';]Q(T'S07L;^2..31E[T5^UE*LO<H.C*P#*PUZ@]10<M0
M"`2.XZZ#4:G3YT'R:"QM1>1M?27TT7B:Y=K15T"PVBJH7R2%4)=R"S`ZA?@'
M2@J3Q7,L]E+!=B""&222ZA$*R_FQ/`Z11B8NI@$<K*_<`W<!ITUU`4LA#*R+
M/:01R7T?=%;RNR*;9;DI'/.I<%7\48[^P_O]O;TUUH/L+I:16L-_>V\M\+>-
M);AQ%:O=.ICCDF2#O/C22=QHH)"E@-:"L(9#/*\LJ2P'Q-!;M"H\$D8/=()2
MS%V=NHZ#MH/EU'<3Q(+2[6U;S0N\OA6X[X$D#31(K.BH\R`J'^[MUUT/Q056
M(<21QRJDO:>J]K-&S`A7*$_0_K\Z4"+OCAC%Q*DDJHBRRA/$CR:`%E0L_8';
MX&IH/A28W"2"<"`1LKV_B4EY"05D\W=W*%'3MTT-!QF2:1$%M.D!$L;,QB$R
MO$K:RQ!>].TR+T#`_:>NAH+B@MK:.XA2075RMRQGE>.3PI!V0N^L,#*K,KM$
MI[>[H6^2-:"FMK*EZUREU)^/+&1-9NH=#,"OCFBD)#0Z+W!E`(;4'IIU#G.'
M6:WDAM8II&<033,ZQR06K:N[*Q1GD'D5?L!`)ZZ]*"BT"65HT5M:F[[7DG2U
M>8,\DCRM._9)=,1W"1R5U(`Z`:#2@Z_Y=WW>\=[.BS^/L1?W][NK8VT[."1'
MDMX;K>^\<)M"&^O%B9'-EC),T+B;1D)CB([AK06'!/(F2Y4XTQ.],Q;8RTR-
MYE]WX>[APYO?Y89MI[PSNTWGLQD52^2*[?"&7ME!9"Y75@`Q#M><2RPR):7$
M<,X(42M&)Q$P*LP:+O34E/H2/G6@N*!0*#R@_J-\)8;GG";NVCO?$[SO=MV>
MR>/-R[?Q^T9=Q6>.WCO':?*%UD[#;V_KS;<HN9]I6BSK++:RR6=O(EP[R3#L
M4H'JU`YDAB<C0O&C$?H2H/ZM_P#&:#S5XSWU[0>V=]R%R!QKS%A^!>*-I<G[
MMXSV;A+KANWW=N7>*\>;BGPV>WAGKK=^0L8[7&9B>-X;*+'*(9XH1<)<%9>U
M0M>?-^9[?6Q_6FPSUMBHM[;;]^.%MA;UN,4__N__`#O96;RF7R>9Q*R7,]W;
M6&<P]G'/;6[M)-;378MY&;QM(0].:"*V)S\,ON+NO:S1D7-IPGA<_',JGM:U
MO-QKCFCD8G3O6>TU4`?&NM!*F@4"@4"@4$/Y6N1[]V"=\PLSZ?Y=O'WL+=KE
M>:,(.\IKV-,D3Z`Z:A6_;0;GSG`LN^_5J4L0UMSU=2JH`(?OX4Y@@8$_*@+*
M3T^HH)&T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$.^<+<R\T[6=IHH83ZU
M^RD+F02%F=[GB[M6-E#1+VQ&1V[QU"C34C2@[_X@01<2\71J25CXZV2BEI!,
MQ";:QB@F95593H/W@`&^=*#L6@4%.:&*XB>&>-)H9!VR12*'1U^=&5@01J*#
M@\Q6XA@$,S"6.9S.J@PQ&(Q@)*VNJO+Y/M&G7M-!7H%!0AG\SSIX9HO!+XN^
M6,HLWVJWDA)_YD?W::_J#0)9_$\""&:4SR%.Z-"R1`*6,DSZA8TT&@U^3T%!
M:)!#CWEN9LA<F*5@G9>W2O;QRSW#%!$9%#HS/*(U7NTT``%!56W>2X,UT+>0
M0RE[!HDD22*-X?'()F:1ED=BS?`"Z$=->M!RUBODO+6>VD,(9[69+B(B*YCD
MB4N8]>DT#I)VDCIJ"/I0+.SCL+6.SMVD$,*>.`2N93%&HTCB5F/<8X@-%!/0
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M&;6&,QEOOB7_``,X;[OUT%!1NK);QXEG8/:*&,MF\:/'/*'BD@D9S]RFW>/4
M`?)/7XH/K7@6^BL/Q[MC+:S77Y2P$V40BDBB$$MQJ`ES*9=430DJC'IIU"K<
MSBV@EG,4TPB4L8K>,RSOI_ACC&A=C^E!;WMK%/XKCR"VN;?4V]T0NL7D*=\;
M*Y4-%-V@.NHU'U!H,!NO&[5W-M[+8K>EK;-ML3P'(#+W!QUF7QUW;W]G>+>+
M<V[0"VO8(Y8I1(C+(@(((%!0X^VUM#:>U[+$;"M\/:[0\UYD,+;X%HY,6D65
MNI<E>36]S%<7*WC7^2NIKF2;O)EEF9CU.I#9[+&8_'/>26-I#:OD+I[Z]:%>
MTW5Y*%62YG/_`*R=U106/4@#]*"^H*$%PL_F[8YD\$[P'RQF/O9`I+Q:_OQ'
MNZ-]=#0))UCFMX2DK-<F4*Z1EHX_%&9"9G'2,,!HNOR>E!TMR>F/M$SZ+=99
MI\YMJ/'7V*V_C;O(9.&RO<D;2YSS>!I5AB6(^(L8QVB,DN`.@=U6Q!MX"""#
M$G4=!^Z/@==*"-^*XEY5V"^X,/QAR=M^RV/F+W)Y3`;=WGL9\]/QYD,UE9LO
MEXL!D\5N#`SYS!W%[D+F:"RR'<]H[!%N&A"Q('1_L7LJPXQVGZS66/M;W<-Y
M=>[7#&<W5G)+)#>97<6\<WFK+/[PRR6$*VM@AN<F"-%6&WB6.%2`%-!Z#4$:
ML7C[%?:O<V42WM5R4O%..L+B[10+N6QARUE<6]I.P;[XH+B:1X]1JOD8#YH)
M*T"@4"@4"@B[-:R?[T\=?=J^(^KN:M0_3N$@Y8P,Q7XU[2IU^:#.<UZG?GK$
MOT_UOOF/_P`SPQRUH?\`MH)#4"@4"@4"@4"@4"@4"@4"@4"@4"@4''N7[ON7
M[/WNH^W0:_=^G3]:#X98QIK(@U&HU=1J/U'7J*!Y(]`WD30@D'N70@?)!UT(
M'UH/O>FI'<NJ]2.X:C3YU&O2@A[S@R#FS8P64I/<>O'LHMJW5X8V3_3)FN9(
M/OANR@=>U70@`GJ20I#NO@8@\*<2Z222@<;;&T>;RB9M=KXH]TJSP6TR.VNI
M#QQL-="JGH`[9H%!;70N9+>1;*6&*Y.@BEFC,T2$.O=WQH\;-]H(_>&AH*[E
ME1BJ][A2534+WL`2%[CT7N/37Z4'"%Y'AB>:+P2M&C20EUD\3E06C,B$H_8>
MFHZ&@JT%I/:B61;A&[+J&&>.WD;O>*-IE`[I(%D190"`="0=/J*"O$)%CC65
MUDE"*))%3QJ[@#N94[F[`Q^!J=*#FP5AHP4C4=&`(U!&G0]-=?B@^T%.42M%
M(L#I',4<12.AD1)""%=HPR%U5NI&HU_6@^QB01QB5E>4(HD=%**\@4!V5"S%
M%9NH&IT'UH+`R2VCWDV1N[<V4UQ;16,:V[1M`LJQ0&&>3R2BX>>[8E2%0`,%
MTZ:D.<K79NH(+=!#;QA)I[AXT>*6+62-K.%5F22*<'M?O*E0O3J3T"Y\\)F:
MV65/R5B$QA)^\1D]HD[>A*=W34?6@6XN!!&+IXI+@+I*\"/'"S_K'&[R.JD?
M0L:#YVW'Y)<RQ_B^$*(?$?*)^\EI#-Y-#&4T`7MZ'KK04KN&XE$+VUQX)89D
MDT92\,T9^V6&9%*L0T;$J005<`]1J"%X/V_/UTH.$DD<,;RRNL<42-))(Y"H
MB("SNS'H%51J306;S3@BZA_ZNT>&+Q6]ND9ED::1#^3YI9HT\21'7M'4CJ-3
MH*"_H%!;P"X1)/RI(G;S3,C1H8E6W,C-"C!F;5XXM`S:Z$C704%A>RK<V\<T
M<5OE,8\;//!%&+J6X^Z,P-;:/X75&!+`@D]-*#H/VG:SN.+HK*:*2];_`%*X
M1DFQD#7)ENH)^8ME0"*:&TEBEGLY6)$L9)1XPP<%=00N/52)K?AG'VC7EM>"
MRWSR_91-96YM;*UM[7EW?$-OB[*V\<8AM,1"BVL8"A>V$$=-!0=]VOYL'Y39
M*YM9$:Y9[4PQ-`(+9PHCMY2\K^:1&!/D^WN[M.T:=0JW7YP_&_"%H?\`JH_R
M_P`IIETL]'\QMC"KZW0;M[0VB$:ZD=*"Y5T<$HRL%9D;M(.C*=&4Z?#`_2@Y
M4$2.?.2<#L\;]QF>3-7%W;<83;KN+C;2V\9P^RUSBX<RYH9')6T4T,N7DE[V
M@7R-`&4#[-6"6%J-+:WT`'\&+X((_<'P1H#_`'4%>@B?[.9K>45UQ'@,+MWN
MVM?\Q\2WN[=W7%]:K!:VD'(6$@M]M8W&)<ID;C-Y2^F@G$KQFSCLH)PS>8PJ
MP2PH(F8;&M_O1WCEVN"T?^AV&Q\5F5<+#(FY+6XFO$;N,3/.DJ1GH&`C'4@]
M`EG0*!0*!0*".LTBCVTQL))[W]=<Y(@T.G;'R7MY9"3\`ZRK_;_=0:W[(M<Q
M[_\`3^:`_8OLJD5ROE>/N@NN%>8[;_`P\G;+(I[3JITZB@E=0*!0*!0*!0*!
M0*!0*!0?"0H)/0`:D_L%!';>/-^0N<C?[1X.V[9<J[XQDOAS*#,P8S:.V6#O
M%*N?W"!,@O(95(-K`KRE@RDJRL`&JV_#O/>\+BUR?)//N3VVBR+<OM+B''KM
M[&PE^XR6,^XKYILODH(D;L#&.,DZL26[2`[?V/Q5:[(MLA!#O3D#<#96_ER5
M_-N7<LN6:2XEMX;4QVOF@!Q]FD,"]L4!10VK=68F@W=L!#XI88LCE[=9F+2-
M#D)?(=86A[5>;RF-0K:CM[?N`-!]FP,<UZ;S^9YF/O@6"2UBOV2SD58TC[S%
MXRR2D)J65E/=J?K0<_Y)`+JYNXKN_A:\=9+F)+@-!,RI,@#)-'*0O;-^ZI4:
M*O3IU#A)MS&R60LF68]MJ+1+GRM^4D8@>W5ED_=$BQ2$`]OSUTUH*BX''@KW
MI)-&CQRPP2R$PV\R%V>:%%[2KW#/JX)*D@:`4%R<78-)-,8!Y+CR>9Q)*"_E
MB,,FND@`#1MITT_XT$0^7,?;6'.''UI"`PGX%]D%@DE:XFN;?L/&_AM8DB7L
M%DL<SA5_YA*J!J1J`[SX(Z<+<5`#[5X]V<J?>'9HUV[CEB+,$C!=HP->GS0=
MEV-_'?K,T<-W!^/<26TBW=M+;,98CHYC$H4RQ=?MD75&'4$T')KZ!+^+',LX
MN)K:6[B86\S6[1021Q2J;E4,$<JM,OV,RLP.J@@'0*L%M!;*ZP1B-9)9)W`+
M'NEE/=(_W$Z=Q^@Z"@KT%DPM\E!=6TT$C0>66UFCGBDB67QD=S1Z]IDA;7HZ
M]#07@4!0J_:`O:OUT`&@_P"%!AG:WP&/NK^\:YN2J_DY"YM[6XN;B=XXEC,J
M6-HL\I/CC`$<*$D_`)-!EHI%FBCE4.%EC210Z-&X5U#`.C@,C:'J"`0?F@Q8
MGL,Y%E,;+!=&&)WL+V.XM[NR64/&K$VTQ$+30LC])(F(UUT.HH+N+\:P%GCX
M(7CC[/#;)%%*\,4<$9(624!EB'8F@+D:GI\F@^&.TQL=_>+'(HE9[Z[\?FG>
M1XX$1GCAU<]WBA`"(!J1\:GJ%U#*D\44T?=V31I*G>CQOV2*'7NCD"NC:'J&
M`(/0T%*82R2+;F!)+.:&=;B4S%'1CV+'&L075UE5FU8,I70=#KT"C)-;XV.Q
MMA%<&.6:''VZP07%T(B8W,;7#HLA@MT2+0RR$*"0"=2*"XN"\<4DT,`GG2,]
MD89$>73[O$LCZ*O<1TU(&OS05E)(!(*D@$J=-02.H.FHU%!1_(C_`"3:?Q/*
M(!<$^*3Q>,R&,:3=OB,G</W=>X#KII0+BXCM86GE$A1"@(BBDF?[W6,$1Q*S
MD`MU.G0=3T%`-O"UPET5/G2-HE<,X_AN>XHR`A6'<->HU!H/D,\=R)E".!'+
M)!(DT3)J4)5B%<`/$XZ@C4,#04(Y;P,B-9*(FN98@T<\>D%I'$3#/(C=I+22
M+V]B=W;J#\:T%:*WCLX9$M8NG=/.(^\_?-*[2N.^0MV^21OKT&M!]22=K997
MM_'<F$.UJ94;MF[-?"9UUC.C].X=/K04<?>K?P&412P/'++;3PRHZF.X@;QS
MHC.B">)9`0LBCL<=1T-!>JJJ`J@*H^`H``_L`Z"@Z?YVV/=;^XXR.'Q]_!B\
MCCLWLW>%C>W%C+D(UN=@[QP6]H+9K:WAN;AA?28'P=T<<CQ^3O52P%!9<$<?
M7>Q^.-OXO.7>.R697-;WW9)>X47L.'67D+=^=WG-;8R*^87K6%JF?$"&=5D;
MQ]Q5=>T!VW>6EOF(+_%Y&S=["0112B1P(;Z)T621`(W\GB5OL<'MU.OTH+R6
M>"U2,S2)"CRQ6\?<>U3+*PCAB7_RG<@`?K0<+6RMK+\G\:)8C=W4M[<D?,US
M,$629S]698U']@%!=4'FO[;WLEQDO8V+P3P6=KZ?7$%Q)/%)#+/-;<@9&X9\
M:LOBBNH/Q;MAY%<ZRZ(`6!%!Z"YO*/@]I9;-P*DCX?;U]E(DN`_CD./QTMVB
MSB$&41OX='[`6`)T!/2@\[/6KUYWIS#Q'Q]SMSORWSSC>;^0;*YY`N8-K<N9
M?![6V5:[C>^N-H[:P&UMNP8C:%[@]O[=N+%E6[QS_FW$1END+22QD,#RGR1N
M#D+CG^G=N#/W<\%QO+V[X]Q6[UM$N++';GGVYAN488;V7'L;9)<-FMP;<MLG
M:HR^*/6&2-?L2@]5*"+F!RXD]O-\X%[5XY+?A_`Y>&[[08[B&YS=G9RQ%P=1
M+;RVX/:?\+@T$HZ!0*!0*!01$OKRX'OGM>P##\5_4;?=VZ]BEC/'S)QW#&1)
MIWJ!'(VJ@Z'4$_`H-F]@`3NWU@T;11["X\NO:&[].,>3NT=QZIVOHVH^=-/K
M025H%`H%`H%`H%`H%`H%`H,5G;>^N\)F+3&3+;9.YQ>0M\=<-IVV]_-:2QV<
M[:ZC2*X96_NH(;^F.>VOMC8$O%>8FLL!RAMO<>>BWEC,C;QX?)[@S%WE9Y'S
MUNL\-G_-UNC(L1:+R%"@'[C1,X3;9U0`NRJ"0H+$*"Q^%&I&I/T%!32YMY"`
MD\+DZ:!)48G7XT`8DZT'(S1*O>TL:IW%>XNH7N4D,O<3IW`J01^R@X"ZMFDC
MB6>)I)4>2)%=69TC(61U"DZHC'0GXUZ4%>@4"@4$0>:I;I.>N+HXYECM;CA?
MV(2Y1H$D[Y8H>.YK1XY'FC;NA*R,\:ANZ,:G0#6@[FX4:>3B;BN2&2-[8["V
MP;HS233W#2?R#&K&(YG9BQ60-WER6.GZZT';%`H%`H+*_FNX81^%;_D7,L@A
MC[B!!`65B)[H]RR?CH5`;L#-UZ`T%9+B&22:!)8VN+<1&XB5@6A,REHN]?WE
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M!7H*8EB:1XEDC:6,*TD0=3(BOKV,Z`]RA^TZ$CKI08ZP;)*;M\M^'$&N%%HM
MO,SQK"5555GECB8RL^OTZZT&5H*-P;@02FU6)KD(WA6=F6$R:?:)&0,X37YT
M&M!S[U!1&9!(P)"=PU;0?=V`Z,P']E!TISSOK<?'?&F7W+@Q:)EQN796"QDC
M0FZ$=MNO>>WMLW-U^+*CQSWUE9Y>66-&!C>2-01VZT%QP'O3<&_..+?.;IFL
M[C.VNZN0ML7MS8QP0P7:[-W]N3:=G>&WM9)8+:XO+##12S1J0$F=@`O[H#MV
M\CN9;>1+2X%I<D*8IVA6X5&5E8AX69`ZNH*G[@=#T-!]MGEEAC:Z@6WG(+/!
MY$F["KD*0Z:JVH`(T^-?UH+B@M)H[QKJTDAN8H[2/S_FV[V_DDN>^,"W,,XE
M3\<PR]6U5^\=.GS01[YOV5LS=DN0FW3@<+DI<;L3*+;Y#(86"[N[.SO;]%N[
M>&^NI(+>XBF,"L+-G)9T[U1B*"0EF.^QM0^CA[2`/W+T?NA7N[E;7HVO4&@Z
M'N?7;;Y6_P`5A=[<E;3V/DYX)[OCS:VZFQ&V(U2>2XO+'$RQ6;[AVYA\M)*_
MY5GCKZTMI!(ZA%#$4'3OMML>.!?3Z^P38;;FU.+/;#B7(7UG^1!B8+7"7V&W
M7L+"XS#6YMVM)"<[NBP@6UUBU@+!&[E52$Y:".&&LK5/:+=^1#0M>S\88RR<
M),LDR6T62Q4Z">!=3`K2.Q4MIW?2@D?0*!0*!0*"*=_9/_O@VMD>PE/]JV^[
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M,UI-'(D$,31^/RVJQB17G>X-T9`@5E'86.A`H-@H%`H%!$7FN*+_`%UXGN'N
M(H)8.'O8Y8%9PDLGEQNP&EDB8CM`MQ`"W=K\ZZ:`D!VGP1D[1N'N'K?R$SY+
MCG;%U:!4FE2:WAP6-+SM<*LD"%EE0]7^\L2NHUT#N>@4"@MGO+=+N&R:32YN
M(9IX8^USWQ0-&LK=X4H.PRKT)!.O2@YW%Q#:P2W,[B.&!&DE<@D(BC5F(`).
M@H,?%:I>W%GE9XKBUN;5;R.*&.\?\>6.Y\:"6ZA@D%O=.(H08C(&:(.W;H6-
M!DI8UFBDB?N[)8WC;L=HW[74JW:Z%71M#T(((/Q08.[MK&2XQEI?V1E@LI[>
M;$W4LLDY.02VN;<JZKW2!DM)'!>4E7[R/F@SD444"".&*.&-=2L<2+&@[B6;
M14`4:L=3^V@L[VR:YDMIXIV@N;23OB?65XNUP8YUDMUEBCF+PLRKW]P0GN`U
M`H*9=LB+['W%G>6UN\4\!N!+X?-&[/!W6TUO()HG=`65@5=00>AH+VVMTM;>
MWM8C(T5M!%;QM--+<3%(8UC0RSS/)-/(57[G=F9CU))-`CMTBEGF4R%[@QF0
M/([H/&G8HC1B5B&GSV@:F@KT%K/I(Z6LEJ9X)TD\SL(F@C"=G:LJ.W<S2%OM
M`4C[3J1TU!8V<6/M(+*!IWBMXQ'&US/+<SLH).LL\S/+*_7Y8DF@^WEI;W]M
M-9W48EMYT[)8SJ`RZ@Z=/VB@M[C%6=Q:BT,9A52&CEMB+>XADZ:S031*KQ3.
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M=#FC?SS122MIXI3*&`B)+*WV:DC6@E-064F/MY;^WR+^0W%K!/!!I+(L2K<%
M#*S1*PCE<A``6![1KIIJ:"NDZO-+`%D[H0A=RC+&2X[E5'("N>T]=-=/K0?)
M+A8YK>`I,S7'E"ND3/$AB3O(FD'VQ=P_=U_>/04'3_+F+Q^6Q.;M;^QMI"=J
MWKV=]E8E?&0WRRR-;16;3=D`S@8%X=&9@HU[=!U#MRP!%C9!NI%I;`D'4$B%
M-=#]>M!0OLQB,885R64QV.:XFCM[=;Z]MK0SW$S*D4$(N)8S+-*[@*JZLQ(`
M%!&?VBFPS?[>[:_SEW8WU_[,<51X'#6F0_'M]VWUM<Y._O,7D+$!DS-CC<+:
M763\3:+%+8)/KK$*"55!&;;\4X]K-^S>/MMVXQP:>4%5621;[%GQLFI=Y$#`
M]W0=ITZZ4$F:!0*!0*!01VO.OMGM[I^[Z\;PT/\`YW).R-1_]`*#7?9FQEN]
MT>ITJ.46P]H]N7<NDA3O3_2_EBV$94*QE4O<`E=0.FOTTH)5T"@4"@4"@4"@
M4"@4"@4"@4"@4"@U3,2*FX=L+Y(TE>7(*$FLI[E9(OQ=9!#<10M'8W08+VN[
MJ&3O4`D]`VN@4"@4$2N:#,.<>)^V-GADXK]AHOLA,O?<MA]C&WMG<MXX1,H<
M@$:NR@`_((=F^N5O^)P'PU;>,1>#C/9<7A50B0]FW[!?$JKHH6+3MZ=-10=T
M4"@4"@4%DD4EO-&EM$AM9GN)KIY+B4R12,$,0@B975DD;7N'<H33H#J=`O:!
M04$:X\TXD2)8%\?X\BR,TCZIK+Y4**L?8_QH3J/TH/C/.9H!$D3VS"0SRF0A
MUT7^&(D56$A9_DD@`?J:"XH%!8V27D7DBN91.B%?#</VB>;N+O(9DC5(D"%@
MJ`#70=>M!?4"@4%#6X_)*]D?XO@!$G<WF_(\C!D*:=OC\>A!UUUH*]`U'0:]
M3\#]=/TH*$+SL)?R(TC[9I%B*/WJ\`.L4C:A2CLI^X?0_4T%>@M;J.Y:%5LI
MHK:59(FUDA\T;1*X,L10/&5\J:@,#JI.M!76.-&=E1%>4AI&555I"JA`SD`%
MRJ@`$_`Z4'.@LYEOC=V;026ZV2BX%]%*CF=R47\5K9U(5"D@/?W:@J>G6@U_
M?&VMO[MVOE<'NBVL[O"3Q1W-U%D))8;-)<=-'D+*[GEAFMY8OP+VVCG5U=&1
MXU8$$`T%CQWMG9.U]IX_"["M["/:]O<7]Y8KC[J7(V;7F2OKC)92[@OKB>[F
MNI;W*7<T\LK2R,\TCEF+$T&YQ"X$MP9GB:%G3\9(XV5XT$8$@F=G82,TFI!`
M4`=/VT%G?/DX[BR>S6*6T,PCOH/$&N2DGVI+#*]Q#%&D)/=)J&)4:*-309.@
MXN-48?<=58?8>UNH/[K`@JWZ'4:&@CYR#+%#B]PXG<%RUI97?'N3@M;C-W"7
M&.QTD]VMC#>Y.22YGM9<A:22^1IXX?+X&T!)4@AWUCQVV%BNH;2TMAW#4@Z0
MH-03H2#0>8'`_KCM'V*SWL'RA[6[1VARMNB?V!WOM78V!S5WE\_A=@<8<=;@
MM;;8>(39^<N;FTVIN2\O,=)E;PPAHKT74=S#XX;DQ4'3W)NX+/%<I>HW%^*M
M-T9[86S?ZAL^#X_SMTT>1PV*P6"X7WB)-D6&:N,G=97))L_<N3OK:V65'6.P
MM/#Y.Z!00]JZ")NU9LL?<;E*"6<'#)Q/M1[6W,;!DOFO<<+F996+*8Y(NT:+
MVCN4ZC7J0EE0*!0*!0*")F4RDZ>]&R,(I'XUSZG\GY24:=?-9<O<26D.A^@[
M+]]?UH-MYZBCDS'KN71&:+V%VU)$S*"R.-C<B`E"02K%"1J/H:"0U`H%`H%`
MH%`H%`H%`H%`H%`H*$*SJ9O/,DH:9V@"1>+Q0$+V1.>]_*ZD'5OMUU^*"VLX
M<E'+=-?7UO=12.IM(H+(VK6Z#N[EED-S/^0S:C0@)II\&@L[N%'SN(F6^MH9
MXK7)+^%()6N+NVD_%\SP(MU%&J02I&6=HI--0`5[CJ&<H%`H%!%#F?QISCPR
M_EB,S<=>PJQQ/.D4L*K@-F--<V\789KF0`*A56^P-W$'Y`=I<`&)N#N(V@$J
MP-QUM!HA/Y/.(S@K(IYO+I)Y2/WM>NM!V[0*!06,`-V;6_/YMJ?!(OX4Q\2_
MQ64]US;_`'`S1]GVG7H"?UH*EM>VMX;D6L\<YL[J2RN?&=?#=0JC2P/^DB+(
MNH_;057GACEA@>6-)K@2&")F`>40@-*8U)U;QJP)T^`:"SGDCQD=U>2&\GCD
MF26506G%NG;'"SQQ]/#;1(G>^G0?<Q^M!7*1W?XES'<2^-"+B(V\Q6&Y26(A
M?*!JLT)5^X#]=#054GAE>6*.6.22!E2>-'5GB9D#JLJ@DHS(P(!^AH+(W.,Q
M1Q^.:6*U-T[6N/MR6_BO'#+<-&A/=IVQ0L?N(^-/G04%QI%9K=7,LS+&2UQ-
M)/*QCA1$`(0,W9%$B)KH-!KJ3UH$JB]MD:WNI84E\,\=Q;&,L\?<DH"F1)$,
M<R=#TU[3T(/6@IVUW'>I-&!)!/'JD\#L@N+?O,BQ,_C=U0RHG>O770CZT'"V
M2/&6]O;7%_/<EY5@AGOY8WN)I7[C'#WJD?ED[5.G0L0-3K\T%TD/9///YIG$
MRQ+X7?NAA\08:PII]AD[ON_4@4%>@HB=#<-;`2>185G9O&PB['=D4"4CL+DH
M?M!U`'7Z4'RZN8[2"2XE65HX@"RPQ/-(06"_9%&&=SJ?H/B@^M;Q-.ER5)FC
MC>)&[GT"2%6<=G=V$DH.I&HH*&0L8LE9SV,TEQ%%<*%:2UN);6=>UU<=D\#Q
MRIJ5T.A&HU!Z$T%5IDADM[<K*S3!PC)$[QKX44L99%!2+N!Z=Q&I^*"G?7T.
M.MVNK@2>!&C61XHVE\2NX3RR*FK"*/75CH=!UH*O@@>>.\`[I5A>*.02/V^&
M5DD8=@;QMW%`0="1]#UH+9)K3*PWD"F5HXKB:QN1VSVSI/#VEPCZ1N0`P*NA
MT.O0T%RUQ%%/!:L7\DZ2M$`CLI6`(9.Z0`JA`<:=Q!/TH(Y^VT$MSP;GX(89
M;EY-S\9]UO%=FP:X@CY,VC)=0O=_$<,ELCB0'[9(]4/1C04O4[\1>+,Q!8*(
MK&SYDY]L[6U$3P?@Q6W-.^HCCUA>698X[*16CC"$1B-5[%5=%`25D194>-P2
MDB,C`,RDJX*L`R%64Z'Y!!%!306]I%#"&6*-?';PB20DLVG;'&'E8O)(VG34
MEC0?;B>.UAEN)BPBA0O(51Y&"CY(CC5Y'/[`":#@T,,[6]T4+O`&DMR2Z=IE
MC*$]A*@,T;$?<-1K01XY@Y0P&V,%GFW'=+M?LVME6EO,I>PP10M#DK:P>/Q-
M%<Q_C7*W2NE[H(>TE#(AUT"0]EI^'::'4?C0:$:'4>)-#J"10=4;PX&XLWSE
M[[/YW;<T6;RUG!C<WE=OY_<FT;[<&,MU1(L;N&XVKE\-)G+%8D6/LNC*!$`@
MT3[:#HCV*XYXWQU_Z<P6ZV6U[CCCV1V2O%VVL;<6F+QUW<7.T]WX'*8B#$F(
M_P`QCQ^S;J^NU2("2$VOF)[4?4)KT$,-D9W+7/O#S7@+JVM8\5C.(MBWN,N4
MA<7=PU[<V2W8GN"W8\<<L6BH!]O4D]:"9]`H%`H%`H(IY6P)]X-B93M(5?5;
ME6Q[_"X#,W+7#T_9^3Y/&>T#7Q]H;J&UTZ4&1]D,O#B,MZT-*R*<A[-[,Q,0
M=96#S9#9/(\2(OB![7.A(+?:".M!)N@4"@4"@4"@4"@4"@4"@4"@XOW=C]G[
M_:W9J=!W:'MU/73K087;_P#/C8EMQ+9)?O('$=B[O%%$T$),3,XZO'.774%@
MP`.O70!G*#6,Z+:*^P=W)>2V%RMY):P2Q6:7/Y4=Q"[38Z25HI&MHK@PK(2&
M35H5Z]`"&ST"@4"@BQS/+;V_-/"A>*%9;G8WL)&;V3]ZTAAVOM.>1T.C-I_#
M!8#34`G74:$.P?767S\#</S!N]9>.=I2))KW>6-\-:-'-WG0OYD(?70:]VN@
M^*#N:@4%"-YFDG66$1QHZB"02B3SH4!+,G:K1,KZC3KJ.NOTH#23BXBC6W#6
M[1R-+<>95,3KIXXQ#VEI!)J>NHTTH/L[2102O;P>>94=XX!(D/FDZD)Y''8A
M<_4]*"HH[@C.@5PNNAT8H6`[E##_`(:CYH*43S2/<+-;B*-).R%_*LGY,1C0
MF0H%!B^\E>TZZ@:_6@Y30I-#)`Q=$D0QDQ.T3JI&FL<D95HV'T(((H"QB*/2
M->YE0`%V/=(R)VJ99""S,=.K'4T'&+NEAB>X@6*8HIDB++*(GZ%D$@`#A6'0
MZ#7YTH/D3R3"=9[8PJDSQ()'CD%Q"H4K.`A;L1R2.UM&&G44')+B!Y)X4D1I
M;8H)XP?NB,D8E0./IW1D$?L-!\MIK>YB2ZM7CEBN%61)HP-)5TT5N[0%@`-!
MK06D\"-:WRY2:.6U=IW#=@A_&M&B"]AD![N^,=Q\@T.A_905+;\DRR/Y+:3'
M/!;&Q\8D_(_</E:9V)CD1QVE"-#^M!]R%U)96DUU%:RWK0@.UO`5$SQJ=93$
M&_YCI'J0@ZN1H.IH..-R5KE;."^M'[XID5BI!62)V56>"9#HT<\1;M=3U5@0
M:"_H+5_S/RX>S\<6(AF,Y8R?E&X[H_`(E"^(1!.\L2===`!\F@J7'Y'A?\40
MF?0>/SEQ%KJ-2YC5GT"ZZ:#J:"JNN@[B"V@[B!H"=.I`).@UH/M!81V?X<-G
M:XU8+6TMY=)(#&S#\;MD)B@T<>-_*P.IU&@(TZ]`OZ"G-'YH98>^2+RQO'Y(
M7\<T?>I7OBD&I21-=5/T-!%/W"FN\;ZY[RDEAN+]K;</&45I^*%NKZ:)N3MC
MPK=7`N(EMUFCD=FD)'8$&NNIH-J]8U=..<XK^4$<Q\]A5F&CI&.:-]"-.[M7
MR(L8`5M.JZ4'?EZ;U;:4X]+:2\"'P)=R216[/H>T2R0QRR(FOR0K'3Z4',1"
M:.#\N.&26,Q3$!>^..Y0:B2'R#N!1B>T_(H*]`H(#>U6D5]SG/<.RV`]*N01
M*(G$<QDCW#.P*,UO<I^Y(0"R.%)_=.IH)Q;?).!PA9>UCB,:674'M)LX=5U`
M`.A_0"@B!R-[:;FMN2=Z\/>O7!.Y/8;D'C&QPU]R4+7=NW..]C[3FW'C+C*[
M>VU/OC<*WUE>;SRUK;]_\NB@+VL4D<MPT4<B,0ZRYEY\BW?D?678>6XYS>V^
M1LY[6\?[2W5MO)WF#OI>+L_@=GYCE9[N?,PR&PS^(W!M/%O%87N,<_D?D,I"
MM'/"H>D=!!WCO*1WWO?[!V36TD-QA^*.-K6.8M*8[JUN3;7K2*K*(T,<\Q7[
M=>[3K\4$XJ!0*!0*!0=`90Z^TVQA]%X`Y5/[-7Y%X;'_`!T2@T_VEL4O<CZN
MNT;2&P]KN.+Y&5NT1.FU^0+;O8?XU[+EAI]"0?I02OH%`H%`H%`H%`H%`H%`
MH.K.7N3AQ3MG'9R+;&8WED\YNK;>S,#MO!36-M?Y3.[IOUQV-A%WDY[;'V=N
M)F[I9II$CB0%F(`)H,?#OCE-89)\CPXF-CB[FD=^1]LS1I$JQL97D6V14C'<
MVI;0*$)/0T&O[2YBWEO[$Y;.[0XIGO\`"VM_<X_!9N[WIA++$;N:S7LNLEM^
MX_$GGN<"M\'MX[UHEBN6C:2#R0]DC!KEWSCRKC]RX/95SPCC;K>&?#7MOM[%
M<LX*_O+';=M-X,IN[--_EZ"+$[>Q\Q6%9)3WW5U(L$"R2=P`=F9??6]-OXB^
MSN?V1M_#8C%V<E_E,C?\B65O98^U@C\D\US<28!8TCB`/7Z_3J10=+Q>Q&3N
M]P[#QW(6Q(>+-N;X&?W#M/-[DWMC(KN^QNTFQ4,S9["76&M'P:9I=Q6T]E`]
MQ^8R'2:.!PT=!WXW+_%*R_CMR1L=;@+&YMSNC#"X6.5VCBD:#\SRK%+(C*K$
M!692`20:#29_:SU>MG\=S[(\"6\G<4\<_,''L,G>KM&R%)-PJP=9$*D::A@0
M>M!:R>W7JA$B22>SOKTB2-*D;MS1QP%D>&2&&9$8[DT=XI;B-6`ZAG4'J10?
M+/V[]3\C,+?'^SOKU?SF.24067-''%U,T4*]TLBQ0;DDD,<2]6(&@'S01$]D
MO:SABSYK]2K38.[=G<Q[NY&W5R[PUM?;O'V_]C9![7/;MXIR>\8\CN'+KFKJ
M#;^#CQ/'-VAF>"?R7$D2!-"2`]`.)<!DMJ\8["VSF;FRN\M@-J83$9*XQTWY
M%C+>X^PAMKDVL_BA$L(EC(#!$!TZ*!H`&YJJ8Z.^NKS(.UMY)KV26^D@B@L+
M=4#/&)>V)([2!4+:N25&I+4%ZCK(JNC*Z.H='0AE=6`*LK`D,K`Z@CH106-V
MD>2M;ZRMLC):S=KVLMUCYH?S+"9XU8%>]9DAN420,H=#\@D$4%W!&T4,<;RO
M.R(JM-+V^24@:%W[%5.YOKH`/V4'&")X1+WSRS^2:25?*$UB1].V!.Q%UCCT
MZ:ZGK\T"VN$NH4GC654?7M$T4D$FBL5U,4JJZZZ=-0.E!426*0R+')&YB?QR
MA'5C')VJ_CD"DE'[6!T.AT(H+&"YEA*0Y6?'Q75U>7<=A'!(T?Y,$9EFMT2.
MX<R2W<=DG=*$U&JLP`7X"ZCA>.6XD:>659FC9(7[.RW[(PC+%VJ&[9".XZD]
M305Z"RF-I>FYQTH\H\*&XB(<+XYBP0%QH-6\9Z`Z]*"N6@A*(S11M,PCC#,J
MM*ZH=$7N/=(XC3XZG04'"*UB@FN9T:76X\1=&E9H(_"G8##$3V0AEZMVZ=QZ
MF@^SPF?P]LSQI'*))%0(R7$?CD1H)0P;6)N_4Z:'510?&DD5[9((!+`[.DLJ
M21JMLJ1DQGL)!D#..W1>HUU^*#G;P+;01P(TCK&O:&F<R2-U)U=VZL=30<%M
M8TNGNE,BN\"P&(.1;Z+))+Y!"/L$[M)HS_)``^E!RM[F&[B\T#]\?DEB[NUE
M^^&5X95T<*?MD0C]#ITH#7,*7$5JS$3S1RRQKV2$&.$QK(3(%,:D&5>A()UZ
M:Z&@0V\=OY?&9#YII)W\DDDFDDFA8)Y&;L3IT4:*/H*`]NLD\,[/*#`)`L:R
M,L+&3M!:2,='90OVD_&I_6@0W$,[3)$_>;>4PS:!@$E`#%-2`"0"-=-=*#XU
MU;I<1VCRHMS+&\L43'M:1(R`YCU`#E-1J`20.OQ04+AK+&K>Y2XD\$?BC:[F
M=I6C6.W#*C^,=P7M#G4J-3]:"N88Y9H;KNE[HXY%C"RR+"RS=A+20AA'(P[!
MVE@2NIT^:"-ON"PC]?\`>$ABAG"Y78(\,_?XF\G(NTXQ(WB99.ZW+B1-#KWH
M*"\]7A`NP-UI;SWEQ''SAS]$9;Z4S2-)%S#O*.41L50K;I*I"*=>U1IJVFI"
M1U`H+:\M4O;2YLWEN(4N89(6FM)Y+:ZB$BE3);W$166"9-=5=2"IZB@LX9(,
M:^,PX:[E,EM)%;SW#S74C"QBCU%U=2=[O.\?W=TAU<JQU)H(T^R/%>$SNV-_
M;QFR69LK[(\6;CX_RL=I):W-MD-MY649*7'W%M?6EWX8#>0@$VYBD(E;4_ND
M!)G#*%P^*4*$5<;8J$4GM0"UB`5223HHZ#KK01,P>T\UP!RWR]NK!\59S?\`
MMSGW=UGOG.;LV3/AI-UX'<&*VEB=O0X'<VW\SE<*N3P9CQ1;&Y"R>2:'S/;W
M2".."1@A%[+X[=&']J/0OD_>-G/M7)\J^WL-@=E_S?\`G,>#V_MOU\Y)PVV;
M3*28V&*PFW!=WF7NKNY$4EQ;6CR*BS2!&9@]HJ""W&$=O/[W^R=[;&-'M>-N
M,<7?Q=Q,SW1M;:]BN2I[0(_Q9$3H&Z@:D'I03IH%`H%`H%!%;/9:>'W9XMP:
MC6"^]8.<LE*VHT5\;RGZ_P!O$.W34EOYDW77Z4&=]AAK<\`C0'_[(SC\]?\`
MR<3NQM1^WI02,H%`H%`H%`H%`H%`H%`H(]>P\4DMGPZ4740^P?$T\IU`"0PY
MF=Y)&+$?:@&I_908^Y:Y]A,DUC9RSV_!&+N;B#+Y*"66WDYCR5O)X)<%B9XG
M21^+[*:-A?70T&:G7P0DV:S/.&_;]WXFS4PVS-G8:VW!O[/V_P"-M/:%NXL<
M?C\7:&*UN=R;CN+:)UV_LO`1LOEE"=TSA+:V5YW50%KLO9F%XHPFXMW;NW##
MD]S92*3/\C<C9S\;'F\6QADD2W0DB'";0VW;%H<;8(WBM8`2QDGDFED#4\#C
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MU=7#ZJJA6=V^6.H3"R7H_P`"\W>D>`XOR/!_$>2EW+Q/L>VOK>+:>*VQ)N%<
M3!@\O-@I=T[:M\/N/"V^XSBQ:2W=M=13Q),7[CH00Z5X,_IP_P!(;A/<4^^=
MH>N7'_$/(-C8WF&R6.Y*W5O<YK;3W$%P<C%C['D/>66Q,5T]H]PJ9/%]_FLY
M)3%<&&234/7_`&U;8.SP&'M=LBV&WH,;9Q8063^6R&*2",6`LY=6$MK^+V^-
M@6#)H=3\T&8DCCE1XI422*1&22.10Z2(X*LCHP*LC*="#T(H.2JJ*J(JJBJ%
M55`5551HJJHT`4`=!0?%1%+LJ*K2$,[*H!<@!07(&K$*-.OTH.5`H,9;P26,
MXB1KJYMKEI7[II5D6Q*@R$=S_P`:07,LATZGMTT&@H+QP(([B6&`/(0\QCB"
M(]Q,L8`!8Z`R2!`NI_90!''.MO--;J)4"RHLBH\EO(Z:,%?0]K@,5)7YH*]!
M97D]W"]DMM:?DI/=K#=R>58_P[<Q2N;DH06G'E14[5T([^[X!H+V@HR^!>V:
M;QKXC]DDG:/&7^S4,W12VNG]]!2,<EQ^7;W<$#VDBB.,=Q<SQ2HRS1SQ,H"Z
M?'0D,#]*"Y1$B1(XU"1QJJ(BC1550`J@?0`"@IPV\-N)%@B2(22/,X0:!I9-
M"[D#ZL1UH*5C)=RVL4E_;QVEVP;S6\,_Y,<9#L%"S^.+R!D`/[HT)TH+:#(3
M3Y&>T6RN%M((R#>R(T:-=))I)"JR!2\1B9621.Y6/<.FG4+VY:X2%VM8HYIQ
MV]D<LAAC;5U#]TBI(5[4)(Z'4C3]M!RG65X)E@<1S-%(L,C#N$<I0B-RNH[@
MKD'3ZT%GBADEL8$RW@:^B58II;8GQ7+1JJFY5&ZPB=@6["6[`=-305(I)3?W
M<3&8Q+#:O%W6_9`C-YA(([CO)F=M`6':.SIU.O0/F2DR$-C<RXJUM[W()$S6
MMK=7+6=O/*`>R.6Z2&X:!"WRW8V@^AH*HA$\=L]W#$;B$I,`I+K!<=FC&&1@
MK:#N(UT&HH+F@LI9+Y;VU2*VBEL94F%U.9O'/;2JH:!EB*D3Q2$%2`0RD@_&
MM!'[VR-F.!]Y_G,RVQNMG=W:">Z0;ZVPUNC:1S%8Y+@*K-V_8#W:C34!R]8(
M;BWV#NN&YLTLI%YOY]8(G<1,DW,.\IQ=$F>="UR92VJ]BD']Q3J`'?ZWR-?/
M8>&Y#I`L_P"082+1^YG4PI/KH9T"]Q73HI']P7M`H/A&OQT.A`;0$C7^V@Z&
MY,Q61SUCNO`MELU:9`<<[BGL9,5+;V]M?J9HE1YX97CACR!E!@0=%$+L2WW:
M`.ZL0ACQ6,1@59,?9(P;0L"MM$"&()&H(Z]:#(4$.?9[-M/OCUNV7;\?Y'/S
M7_.&Q\[<[]DQ]FN$XYL<7<9&Y_(3+7K13R9S<TUE_*TM+#R7/@NGDF5;?N:@
MF-00?XLP<L/N][-;AAEA-E=[&XNQUQ";H&Y7*1XZ.3O%GIJMN;*!?OU_>Z?4
M4$X*!0*!0*!01/W#8R_[X>)\IHW@3U<YXQO=HO8)9^4_7R[T)[N[N*6O3IIH
M#UH+SV>S,&%N/6]YU+#(^TG&&&C`)&D^4QF[K:%CHK]%D(/70']102DH%`H%
M`H%`H%`H%`H%`H.BO83`X_<6R,5:9G#Y_/8&UWSL[)[@Q.VL;E,ME+S"6&7C
MER$(LL(CY>:S>'I<K;@N]N70@HS`AA\US8<?M14XYXJY+RF8TL\/MS"W_%^]
MMKX+'=WBM8+W+2W&`@?'[<PML1+*EO$\[Q1^*",N0`%OL:^PNPK',9W+8GE#
M=^^\_P"+([QW4W%V\!DL[>6D++;X[$64>)9<9MS%JS1XW&QOXK9&))>:265P
MZCR?)MQR-ODS[]XHYZM^.-K9&&3:.R%X6WE<P;LSE@S.=Y;YF2QDM)<;9SC_
M`,&Q;-V)(@N[H&4P10AV7OCF_=EWB+/&<>\9\NV&3S,LUO>[KS/%V=EM]E8F
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ML,D?K1M=3*+2)84F:)]\R11B10=44:`@:$#4$()^YFR>;,%[!?TL,?RYS;AN
M6<!F??6UM?\`+\'%N(V.DDUKZR>P]PUU>2XW,Y.#)VX",#;2Q>/[P1J5%![B
MPQ0PQ10V\<<4$,:10Q0HL<444:A(XXD0!$CC50````!H*"I0*!08RYL;B7(6
M5]#?SVZ6R313V2K&]M?1S=NGG#H9%D@9=8V1E()(.H.E!DZ!04(K=(9)Y%>5
MC<.LCK)+))&C*@32%&8K"I`ZA=`3UH$L`EDMY#)*AMY&D"QN%27NB>+LF!4E
MXQW]P`(^Y1_80K,.Y674KJ".Y>C+J--5)!`(^E!3@B$$,4(>241HJ>29@\KZ
M#]^1@%!=ODZ`"@JT%JCV>2M>Y3#>6DX8=5$D,H5BI&C`JP#K_P`10<'GBNEO
MK2TNHA>0QF*0*P>2TEGB8P/+$K+(H8?<OQW`=#0?<?;2V=E:VLUU/?300I')
M=W)5I[AU&C2RLB1J68_L%!>4"@4%D#%CK=GN;MS'YF8SWDBZJ;FXTBA[PJ*$
M5Y0B#3730=307M!2BGAG\AAECE\4KP2]C!O'-$=)(GT)[9$/R#U%!QN96@A:
M1()KA@T:^*#L\I$DBQEE\CQKI&&[FZZ]H.FIZ4%"QLFLA<!KV]O?/<RW"F\E
M24VZ2G46L!2.,BWB_P`(;N;3Y)H+Z@L;P/,5LPMW''<QR]][:2K$UJ8^PJ._
M4R*\VI"D`CH=:`E[W7SV'XMZOCMTF%X\!%E+W,R>*.X#$-.G;JRD#H0:##;S
MVCMW?6V<MM7==DM_@<M`D=_;F>:V;2WN(;VWGBN;>2*:WGM+NVCEC=6!5T!H
M,9QWL+:G'.WIL#L^*9<=>9_<NZ+^YNLA/E;S)[BW?G;_`')N3+WU_<RRR3WF
M4S63FF<ZA07T4!0``WJ@4%!(2D\T_FF83+$HA=]88O%WZM$FFJ-)W_=UZZ"@
MKT$#_:NZGOKCE/'Q;AOL7;83U-Y7W3;?R/+3XC)VV>Q&1L$@O)KK'W$5W):6
MT-P.Z*13`&8$]2:":NVG>7;F`DD8.\F$Q3NXT(=WL8&9@02"&)UZ'2@ZDY>]
MCN+>%+O%X;=N3RN2W=GK'(9/;^P=F8'*;RWYG<?BX;B>_O<9M7`V]WDY;.!+
M24>9E2)I$,:L9-%(0BYT]G+#D3D/T&M^-+_*+M/??LJ\'(&U]U[0R.U=VVZ8
M/8&9R>W;+,[>WAA[+<FVY;;,Y*VR,<GAB%U';`1R,C:D/5.@A5Q+B=PP>XWM
M#E+RU*[=OL'Q?_*KHA6$EU'M^.VN$5UD[E56MI059>A&NNA%!-6@4"@4"@4'
M0&=T/L_QG\:KPES$?IKHV].&1_;ITH-`]N<?-?MZQ-%")1C_`&\X6R$Y\+2^
M&&(;FA,P*R1^'MDG4=[=P'=IIJ00$OJ!0*!0*!0*!0*!0*!0*!0*"VNS=K`Q
MLD@DN.Y`BW#O'#VEU#L[1H[_`&H2=`"3II08:+/".QDGR$(CGL;Q+#+?C>9K
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M!R1N]%?M9.Y5;M;3N7N`/:VA([AKH>M!RH*$SSJT`AA657E[9W:0((8@I)<+
MH6D8L``!^NM!1R-Q<6EC=7-I:M?7,,+20V:,$>ZD7]V!';[5>3X!.@U^2!07
M*.6B61D>,M&KF-@/(A*ABC!2P[U^#H3UH,=C,E)D7O2;&ZM+>WG2*UGNE$1O
MHV@CD>>*`MYX4CE9HR)%1BRD@=NA(7D\[0R6R]B%)Y6CDD::.+Q`12.K!9&#
M3%G4+VKJ>NOP#07`(8:J01^H((Z?M%!]H,9;09+13=WB!X[ZYD_@0H%N+(O(
M+6&0/W&)UC*EBIU+#Z`Z4%W.\T:)^/`LS&6-&4R+"L<;-_$E)(/=V#KV@:F@
MYE%3RRQQ(9G4%BH5'F,:D1J\F@UT^`3\:T&,Q%^;U+M99!^3;71BN+8Q/%)9
M,T,,PMI&8E+DQB7_`)L9*,#H.H-!F*"C.\R",PP><M-$CKY5B\<+N!+-JP/?
MXDZ]HZM\4"XN(;6&2XN)%BAB7NDD8Z*HU`ZG]I-!R#1R]R:H^G;WH=&*]P#I
MWJ>JDCJ-1046FN!>10+9LUJ]O+))?":$)%.CQK';-;EA.YF1V8,H*CMT.A(H
M/LYDM[>:2TM1<3#ND2V1XK<SRL1KK+)I&K-\EFH+@'4`D:$@$C]/V?W4%&&2
M=VG$UOX%CF*0MY4D_(B"J1-HG6+5B1VGKTH/LDDJ20HD#2I(SB659(U%N`NJ
MLR.RO(';I]H)%!6H/AU(8*=&T(!TU[21T.GUTUUTH(S>U>5W1BO73DV]Q4QL
M,Y:6N"@L[VS>[47$5QN?;]O>$)9L;N&*YM+B6%U#-JA.OVDB@>K$Q_R=O['K
MD5O+3#<Z\YX?%V2]Q3"XG'\H;FAQV'A[I9?':8^T[(H8U[4CB0!5`Z`)-4"@
M4%">26(1F*!I^Z5$D"NJ&*)M>Z;1_P!\(=-5'4@_LH(>>QNP]P[BR6_'VO%B
M;Z[W9ZU<D<=7V/O\D^':Q@S5Y#-%N3RQ8V_?(6]E/*8Y;=#'(1)T[BRZ!+';
MD#VNWL#:R&-I+;"XN!S$"(B\-C!&QC!"D1EEZ`@=*"#=]A-K\.>Z_(7/'(J9
MS&XSEGBCC3C+9F\#;W^2V)B)-L9?<-[GL%N"X2.]39VX<Q?7MI+!<,+6PR-O
M&L3NUS%&I"+_`+.8/+\H>X'I)SUL7!Y>WXRVES#A=C9W><N*O,/_`)DR62_F
MAQLZ6&5DM[K+;4CBOI+2TODLU+7,TCQRM;Q`D/9V@B;Q5E<E/[.^RF,DAF.,
ML[;C62WN&57@#28"8M'%*LC&-C,TFL;`$E2P&G6@EE0*!0*!0*")V[\J]K[K
M<&8I=.S+>OGL'-)_"#G_`,+WKP.\>DIE4P#6\/PK=_P=-.H;%['Z^'@X#_%[
M'\2Z_P!BY#(2?_24$CZ!0*!0*!0*!0*!0*!0*!08_)Y?%86V-[F,E88JS5@I
MNLC>6]E;AF.@4S7,D4?<?TUUH,/9[KVSN#;S9[![DQM_@[N*2.VW#B;RWOL>
MQ=GMA/9WL)FM+DQS@@%2R]PT-!=6V1Q5ECX(KC*0W'ACCMY[JX*++<S16HE>
M:X540>6:)#(Q[0IU)'2@O[/)XZ_,RV5W!<&VD,$XB<'Q2J"6C8=-&4#J/I0:
MSDLM;+N?"V_YL;6RI>V]Y`OAE09"9K$8P2]\RR1R=SMVE$?0G[BHTU#=:!0*
M!01LY2D"<_>LRF))#(W-`1VE57B==@P/K%%J))G=5*D#50I)/7MH-F];I()N
M!>)9K:1Y8)MC8*:*22$V\C++:+)J\#,QA?5NJ:_:>E!W;06TJ71N+5X9XTMD
M,WY<#Q=SSAD`A,4H8>$Q2#4C0]P/TTH*LR-)%+&DKPN\;HDR!"\3,I594$BL
MA>,G4:@C4=10<%*6\<,<DW<Q"1*\K+Y)G"_)T`!=M-3H*#[#$T7E#323!Y6D
M3R=I,2LJCQ*5524#`D:ZGK\T%:@M[N.>6UN8K686US);S1V]P4$@@G>-EBF,
M9($GBD(;M.@.FE!C,A@;/,6N/MLOY+O\"XM+SN266U$]Y:*"DLO@=',1E^XQ
M]W8WPP(Z4%SB\;9X/'18^T+I9VOG=#/*9&199Y;F3NE?3[$:4Z:_"@?I07T4
ML4\:30R)+%(H>.2-@Z.I^&5E)#`T%0_\/V_I06L96T@B2YN_(Y98_/<-'&TT
MKDE5`'8G>Q^%4?V4%RS*JEF(55!9F)T"J!J22>@`%!C7L[:ZGM\I;2*LXB1!
M=6_@?\RR[C,MHTS)*#:R2D-JFAU^#05;6Z=DMHKX06N0GB>4V:3K*0(V`?QM
M]IE6,.NK`::F@NY)8X@IED2,.Z1J9'5`TDC!8XU+$:N['0`=2:#%97#IF+:]
MLKF]O8;2^LC9R16DJ6[Q$R=YN8+A8S-'.1]NNI73Z:]:#(16L$,LT\<2)-<>
M+SR*-&E,,8BC+_0]D8`'[*#Y<74=N8PRR2/)+%&(X5\DBB5Q&)70'N$*']YO
M@"@YP1&%"AEEF^^1PTS=[@.Q?L[ODJFNB_H-!04Y()GN[:X2[FBA@CN4FLU2
M$PW;3>+Q22NT9G1[7QGL[&53WGN!Z:`E[KA"EK=K#)%,@E>-8IRO8RM)!(C$
MA#(G0_##744%9Y8HVC222-'F8I$CNJM*X4N5C4D%V"*3H/H*"DFMK'-)=7?>
M@D>7RSB&%((CII&64(OCCT_>;KUZF@LUQ-LN5.8A)BN);?\`'NNS0K>1KUM_
M*6+=OXY9BO9VZ]W77I0=&>V.4EPOKSR;E8+!<G)8XG'3_P`O;S]MXB[@Q`E@
M/XS)./)$6&JLI'SJ!UH+/UBD#;=Y0C3SR1P>PG.L0N+BXBG:1UY%S9DCB6+4
M0PVQ/C53H1V]1K0229E16=V5$12SNQ"JJJ-69F.@55`U)/Q0%97571E=&`96
M4AE92-0RL-001\&@^+)&S.BR(SQ%1*BLI:,NH=0Z@ZH64ZC7Y%!SH.IN1(U6
M/<DXMHKMFXZW!:W,5O<S66:CQCEI+ZXQURJ2H0NB`*`LGE[""=-*#LC$=O\`
M*<7V!@G\NLNP.27"_C1=H8M]Q;3YUZZT%^45B"RJ2-""0"1H=1H2.FA&M!%O
MV5QV5O,OZ]SV^Z+#%82QY[V%<9O;$^,L;B_W=.V3MX\(<;E;FYBN\4VWKXFZ
MF%O%*UU#K&_8FIH)34$<>-+FQN>>/8)+5(TN;-..K3(%9%=Y9_Y1E+F*61-2
M\8\%P%4'0'M.@UUU"1U`H%`H%`H(C;TQ[/[N<!93O'9;>OWL19>/0ZE[O>'!
M$W>6UT`5;3333KK^R@S7M!D8<9:\"33211BX]G^&,=&)6[?)-D\O?6$4<?4=
MTI>XU`_902?H%`H%`H%`H%`H%`H%`H-#Y-W[CN,]C;CWKDQ%)%A,?)-:VLT_
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ME<CC\#!^%=10"+RVW\IQEBI(T7H_D4!`%T'R&3P.#S.)2]7);NRNY#<]OX[Y
M.QPELU@P5@?Q_P"4XZP616)U(E#_``-#\ZA;;8VWG,%)E7R^^MP;N7(-`;2+
M,V.V[-,,(C<%UL/Y%A<4\HN/.O?^09B/$O;I]W<%/;>U\[@[J^GR6_\`<V[(
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M;,JLT;$%2R,02A*G0D?2@IP22R>7RP-`4F>--72031J%*SH4.JJ^NFC`,"#T
M^#0))95G@B6W>2*7R>6X5XPEOV)W)WHS"1_*W0=H.A^>E`N97@MYYHH)+J2&
M&66.VB*++</&C,L$1D9(Q)*1VKW$#4]2!0<H9&EABE:*2!I(HY&AE[?+"SH&
M,4G8SIY(R=#H2-1T)H.$,UM?6_DB9)[>821ZE=4D"N\,J,K@:CN4J01H:#@S
MBV6W@MK7OC$L5NT=N88TLX"C=LK1ED`AC"`=J`GJ-!H*"[H.#QQR`"1$D"L'
M4.JL%=?W6'<#HR_0_(H,4,F?SY\?>6,EI`3'%9WD\MLUOE'E21I(;>-)&F#Q
M*A[@ZJ"#T)ZZ!?R1216C0X];>"1(NRU5H]+:,@:(ICB[=(Q^BZ=*"KVC[9&1
M6E1"`RJ.X:@=ZH6Z@,1\:_VT%O&JWMO"]Y9"-A(DXMKI8)V@G@D[H904:6(2
MHRAT93JIT^#0<Q<,;MK7\:X"+;I.+PB/\5V:1D-NK"3R^=`O<04"]I'77I07
M-!C,C:Q-')>+*MG=6\7<EZ6\:JD#-.D-TZE7>Q,O61-1W+KU%!;XZ^NY[DVE
MV]HT]OC;&:\%I!>+`;VY\A>2TN;@+'/9NJ?:!JZ$?<>HH,K<1-/#)$D\MLSC
M03P%!+&=0=4,B2)KTTZ@]*#E'#%$9#''&C2OY)61%0RR$!3)(5`[W(`ZGK00
MNYAY(SFV>8!@+S=6;Q^+39/'9P>%V[-CL;!?[RY(Y6S6P,--F;W(8W.7,%LJ
MK;H&BB"@I(Y##50&Y_Y3YDD-W&U]N291$CJ;CDG!_C7320=XBA5>,7"M%.G:
MVO:HUU^X4%&\VUS<UM:^*ZW2+B:X\C1VO)V!06D;%4,4\]SQD_GB"]6T1F'4
MJ1T%!UCRS@]UVG'&Y[WEZZW4NQ@F,CW181<I8J=[G'6F=Q\@-G#8\<XVY?\`
M)F[/((IH9'C';W("30=S^LZ:;=Y,D*7,,LG/G-IN()X_'$MT-_Y@7$UK_"B,
MMO<O]ZOU#`]-.M!(UE5U9'4,CJ596&H96&C*0>A!!H+***#&06-C961CLX^R
MTABMD18;*%(F\>J=R]L*]@4=H.FH^E!=K%&LDDJHJR2A!(X&C.(P0G<?KV@Z
M"@J4$._8W?&9Q2<A[>QV,M)[G&^O7)'(SR9"\O8,?<X;:5SC3)9PMCHQ=09J
M>]N(RC,_B\2,".NH"56V[O\`/V[@;[3M_-PN+N^TD-I^18P3:=R]&T[_`)'0
MT$,]T^Q7+._^:^3>`O63;W'UWN7@^+:-SRQO3E:\W#'M?$WV]]OW>X]L[3Q6
M&VW'#F;[*Y&P@C>6Z,JVT,,W<GE>-T`11YZWSN3>GM7Z'<?\D8S$;=Y;XUY8
MW!NG=>-VI-G\EL[,8/*66W,;@=Q;0SF6QN+_`"["^-TZ75G<?]98S03(5D01
M32![*4$9>+,3#:^P'L=ED$2RY4<9P2B,`,1C<1G`CS`=3(_YAZGZ`?I02:H%
M`H%`H%!&O=B*?:[A:3_&O#W-ZDZG]QMP\1$CMUT_>`ZZ4%C[38ULCB>#V6..
M3^7>T7`F2;OC[RBP;UMXO)&?-%XY%,X^[[^FH[3KJ`E%0*!0*!0*!0*!0*!0
M*!01Q]H,3+F]@;<QWEBM;"?E?BL9B_N(XI;?'8P[TQ<;7MQ%.5ADACO9(%8,
M0/O^IZ$-XYSL;O(\-\G6UB2M\-D;ANK3MBBN'_)L,;/?1".*>WN8I)&DM@%#
M1N"VGVF@WG:^=LMT;9V[N;'3+<8_<6#Q.<L;A#JD]GEK"WO[:93HOVR0W"L.
M@^:#.T&D<F0[KN>.=^6^Q)7@WO<;/W'!LZ>.2")X=TRXB[CV_*);I7M8A'E6
MB):53&H&K#MUH-LQZW2V%DM\>Z]6TMEO&!4]UT(4%P=4`0ZRZ_'3]*"[H/-C
ME7W7S.>GX^V]Z[;4Y.O-P;RW?>8*UR&Z."=^XS;N>L[-FM[AMO;KWA#M#8L8
M\B/+%=7>1CMIQ&(D;NF0T&T?Z@>W^+M<ED\]LG<L..QN,DR%P_\`E3AS[(K!
M);F^9?PN<[Z261[2,E5[5`8="==*#OCB;D#<&Z<IM?\`F.X['/XC>7$6$Y+Q
M8_R];;;R]@,O=V7CAO;&WSF7`#661C#+J5CE0@2,#T#3^>]V;=VCSAZKWFX,
ME%9FZS',MOC[..*ZO\MDYTXLR-U/#BL1CXI\AD&MK2!Y9C%')X8E+,`NKJ&W
M^I64QF;]:.$<QALW9[DQ63X\V_?6.>L'DDL\K;W-J)DO('E2.4K+W:GO4,&U
M!ZZT$@;J.::VGBM[@VD\D,B0W2QI*;>5E(CF$4GV2>-B#VGH=-*"I&K)'&KN
M9'5%5Y"`ID8*`SE1J%+$:Z?2@IQ1RH\[23F59)`T*>,(((PBCQ@@DR$L"2QT
M^=-.E`#7'Y+(8D%J(599_+K(TY=@T7A[/M14`/=W=2=-.E!7H/A90P4L`S`D
M*2.X@::D#Y(&M!]H+2XANI)K)X+O\>&"9Y+N'P)+^;"T$L:0>1F!M^R=UD[@
M&)[>WIKJ`N>\'O"E6=!U0,-02-5#?/;W#]:"TMHUA!EGCM[>[NWUG\3EA)(O
M<(U$CJCR%8Q\:=.NG2@K0&X;R_D)&FDSB`1L6)MP%\;2Z]!*QUU`U`&E!:9"
M*_F2"3'7PMC#,)I8Q;P7`OX45^ZS$DS*+8S-II(#JNGP:"]A:1XHWFB\,K(K
M21=ZR>-R/N02*`K]I^H^:"TA:TM;B:T1I5EF=KQO*9WC+SN$*132ZQ*2R](E
M;H.H&E!<I',L\TCW!>%UB$5OXT40%`WD?R#[Y#*6'0]%[>GUH$JR3)'^/<"'
M26)V=8TF$D2.#+"`QT7RJ"O<.J_(H*]!BK(9*";(_P`RN;::T\\;X^546"1(
M7B7RPW`&D9\<^H1OEE/7K09-T21&CD19$=2KHZAD92-"K*P(92/H:``G^$+]
MH[.@'V@?X>GP!^E!RH,3909B&^R!O;ZVN\=+*)L:B6W@O+57U$EI<,A,4\,!
M4&.302-W$-\`D//CV5FLYN<L'<_CA381>L$LMVUNUW<W,MO[.WD%KBX,=-:D
M12O))))#<AP03W#0)W4'H89),ACB^.N&LY9X1X)I[8O);.=-?):S=G\6/J"K
M?!^=:"\C+(D232J\Q7M+?:AE=1JS*@T&I`UT'Q01K]N\;:WGKWRLMQ%?737F
MV[:S2WM81>NO;F;"02VUE*KP&92>YR0"RKIKT%!<>LMLMMMWE(BXLK@W7L/S
MM>2-8RB6..6?D++M)!,1]R7<3#256)(?7Z:"@D>Z]Z,G<R]ZLO<AT9>X$=RG
MKHPUZ']:"SMI'CE-AX;QX[2UM_\`K[DJRW+MW)V"0'OEG41]TA[0`6'ZT%Z2
M`"2=``22?@`=23_906$GY-TUC<6-Y"MH',LZ^(3"\A:-U5$EU'B4.P<,O4Z:
M?!H(/^U0BM,ER9EI))>S*>G'/6S+$1V<UY%<;@O+G;]U98HM!;S^.]O48B.-
MM!*-3H>WH$R=DQ/!LS:,$D7@DAVQ@(I(=5;PO'BK1&B[ET4^-AIJ.G2@Z-R.
MS>2>,=^;YWSQ7MG;_(..Y5RV(S&\-N9_=+[3SN"SF&VY%M^');=S<N&S%CD<
M%>V>,M5DQMQ^.;6X::XAD?S21`(Q<O<&;OR/,/K=[`;US."QN]+#G7;6/R^R
MMNOD<IB(-M9J&'#[>PV.S63_``9KJ\P)L[B^O[H64"7L]RZHD<<,9</3:@BM
MQ!BVL_8GVAOO.TL>4DXK=8W5];=[;#;CCE1')[&C?O4@#J#KK\B@E30*!0*!
M0*")>^LFUM[H^N^*`E(RG"/L=.>TKXE_EFX>##K,#]Q)-[HFG[=:#;O8O_\`
M%7$J_P#>]AN%/_H-YV<O_P"#H)#4"@4"@4"@4"@4"@4"@4'6'-.U[C>7%6^]
MO6,8EREWMZ\N,-&5#=V=Q79E\$`"R#N_G%A!H=1H=#0;)LS<N/WYLO;6[+)%
MDQVZ]NXO,QPR+J!#E;"&Y>UF1Q^]%YC&ZGZ@@T'5WKG-<8_8E[Q[D.]<IQ'N
MC.\<W"RF0N^)Q4Z9+9EVAE56:"]V-EL;(I!9=2R@ZJ0`[\H-7WM'G9MG[GBV
MNTJ;D?`Y5=OO"\,<D>:-E-_*Y%:X(MQV7O83W_80.O2@S]D+@6=H+LZW0MH!
M<G[>MQXD\Q^S[>LFOQTH+F@\H.0L]N+`\V^O$&QKI+?A?,>QVZ+"U.XDCN91
MF3%+_F.PXX7&`*=D2;I6<QO?D&*Y$RVO_3^*@]/=WV[7>T]T6J-VO<[=S5NC
M:J.UIL;<QJVK?:-"WUZ4$,_7+,[0O]\<6P[6O+#)7(]1MHVF=R5E"L-Q//@;
M_:,&-MLRDD5O?1W=M994R01S1J5@N-5^UQJ&&]NMG;WS?L9Z,[MV78Q9278F
M\/8&YR&-%Y96=]>Q[EX$W-MNWBLY<D8;`1JUZS3EYX9%A!,1,F@H.SO0G:>3
MV+Z9^MNSLU#C+?+;:XHVQA\A#AIEN,9'=65J8I5M+A%2.=`R]74!&;4KTTH)
M<T"@4%":8Q-`!#-+YIEB)B4,L(*LWEF)([8AVZ$]>I%!\6WTNI+KS7!,D$<'
MX[2DVJ"-Y'\L<&G:L[F31F^2H`^E!;9#&09`V[N\UO<6DJRV]W:N(KF(=Z--
M$DA5P(KJ-/'(-/N0D=#H0%WK/^0%[(_Q?"29.\^7S]X`01]O;XS'J====>FE
M!PFN3#/:0_CW,HNI)8S-#&'AMO'"\P>Z?N!BCD[.U3H=7('UH*B00QR331Q1
MI+<,C3R*BJ\S1H(XVE8`%RD:A1K\`:4%"2RCGNHKBX[)Q;E9+2*2*-A:W(65
M'NHI""XF>*4IJ--%)'U-!>4%&&WAMH$MK:-+>&-2D4<2A4C!U.B+IH-"=:#[
M!&T,2QO-)<,O=K--V>1]6+#N\:1I]H.@T`Z"@M/%:9-+>:ZLB6M+KSV\=["H
MDM[J!F6.XC4EU5UUU1P3H#TH+BWADB@6&>=KIP&#S2(B-)W,Q^Y(PJ#13IT'
MP*"BJ6^,MH(+2S9;=98X([>SB3MA$TI[I"G<BK$C.6<C4Z:G0F@OJ"S`AR-L
M1/:N(GD8-;W<05CX)R$=H^Y@49HPZ:_*D']E!7F61XI$AD$,K(1'*4\@C8CH
MQ3N3NT_344%J5@Q=I<S1P2R!3+=SI:PM-<7$S?=-(D,?W2SRD:Z#J304XKA<
MQC$N<=<W%HMW&KVUT;4)/&O>"'_%OH3VE@NG;(FH!Z@&@R=!YD>TMFT?L7A<
ME&UU/)-M[U5M#:P0M<1VD=E[:BZ;)S10R1S($%T5\AU5%#$:`."'IL.@&GZ?
M4ZG^\_4T%A?8NSR)MVN8W+VL\-Q;R1RRPR12P2+*O:\3HW8Y71U_===5((.E
M!T1[97ESCO7#E^_LRRW5GM&ZN8&4N"DD-S:NKGL^YE3MU91^\`1]:"R]9$$>
M"Y71&)C7V'YO[(WMEMY49M\Y%Y6=D6-;@32.75^T:JPZGYH)*4"@H*\KRW$4
MEN4A01B*9GC=;GR*QE`C4ET$1Z'N`[M>E!;A;BV?M11/;R2PQ0010QP+80+$
MW>7?R?Q8^Y!IHH()`TTZ@.F>4[B'"2;HW`_\&*'B;>MO*\8FD,M[*;"6RUL[
M9/+<.%MG_B!@Z#10?N%!V[MU_)M_!2:Z]^&QCZ_<=>ZR@;75_O\`K]>OZT&8
MH(9>Q^=XYMN9O5O;>>QMU<<E9C?EQEN/[Y/RA9VN!P.5VG!OM+J:.XCM8I'G
MS6':))(Y'F92$*JLI(3-H(8\!KDU]FO<@7L]U+9ME^(I,9'/+(\,,3[=W*)E
MM(W^R*,O&`W:-&(ZT$SJ!0*!0*!01$W[8^7W9]<,CY&`M."_9:V$/B8H3=[C
MX$?R&;]Q646V@4]3KJ/@T%_[;92XQ.VN%[FV_P"9-[3^N./9NNBP9+D["V-P
M6T92%,%PP_O^#02LH%`H%`H%`H%`H%`H%`H%!'SA^^.TMR[[X7OX3;?Y9R]Q
MNW8K$#LR?'V];N[S40M^T`!=K[FFO\6PT';%#`?\=!5STQV!S;M[<3M+%M;E
MS'0;&S92-S:6/(6$_(O=D9.]E^Y(/\Q85[W%=Y[`US!9Q?<TBB@[^!UZCJ#U
M!'UH-8WM-G+?9^Z9MLI++N2+;N:?;T4$4,TLF<7&W)Q,<<=RR6SN^0\8`D(C
M)/W$+J:#(8"6^FP>(ER8D7)28VS?(++&D4J7K6\9NDDCC)C1TG+`A25!'0D=
M:#+T'GKS/Z:"YR/$>Y^('W3<93BSD"\WQC=M[BYOW_C]OVUX]AD7L!C+7.0\
M@;<LK"#.7,<T]J,0?+$O;')$5^X-]LL#[7Y'%18_<PPUG<WE@+7+W&"Y0Q=W
M9QS3Q&*\?')D.#[6Y:W7N8Q^7[]-.X:T&Y;!XOY!Q/,5AOK.W.W\?LW`<'6'
M%&%VU87DF8RSY>UW1;9>XW'>9E\+AB\5YB;"V@:`H526(N@4.PH-=]A-ZX?9
M?-GJ3-DVR-Q/D]Z<KV=GB<-BLEF\MD5BX<W3<WDMKC<7:74TD.-BB$T\C=BQ
M0ACJ3H"&Q>FFY<)O'U?X9W+MN^M\G@LMM,3XS(6AG_%N[9,GD+=9K87-GC[A
M+=FA/8KPQLBZ#3IK024A2=#-YYEE#3,T(6(1^*$A>V)B&;R,I!^[I\T%>@4"
M@H(DZSSN\ZO`XC\$`A"-`5720F4,3+Y&Z]0.WXH%Q;I<QB-VE0"2.36&5XGU
MC<.!WH0W:Q&A'U'2@KT"@H1K<":X:65'A<Q_CQK'VO$`FDO>_<?)WOU'0:"@
M-#K/'.)95[$>,Q`KX9`Q!#.I4MW(1T((^>NM!]N))(H^^*"2X;OC7QQM&K=K
MNJ,^LKQKVQ*2Q&NI`Z:GI06]E;/`));B19;NX[/R94#1Q.T0*1>.%G<1Z1Z`
MZ'J>M`@CR*WMY)<7-K)CW6`6-M':R1W-NRJPN&N+IKEX[A96(*@11]FA!+:]
M`KR?D^6W\1A\'=)^4)._RE/$WB\';]O=YM.[N_PZZ=:"O0*"@%N?RBYDC_$\
M`58?&?+^1WDF0R]VG9X^G;I\]:"C-.TIN+6RGA2^A6%V\L;R)$LI)0NJE.[O
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MZD$D::?(H+/UICBCP_+HC,1/^XKFT2M&"':1=Y72,UP23K.W:"VF@ZC0`=*"
M1[,J*SNRHB@LS,0JJH&I9F.@``^304)$-R+:2&ZDC1)4GU@,3)=1]C`1.S(X
M,$@<'52#J!H:"L)(V=XU=&DC[?(@8%T[QJG>H.J]P^-?F@/(D?;WNB=[!$[V
M"]SMKVHNI'<S:=`.IH.F>2C)8VF\+R6"XO0>.]T06]Q!!<2364<\*SS6<H@1
MX6M9OQ.[O=>\$!=0I)H.S]M2)+MW`2Q_\N3"XJ1-0%^Q[&!EZ#H.A^!00ZW'
M[3<A;IY6Y$XB]9^)<'RYF>&I\7C^5]Q[JY"CV!L_;^XLW96F4QNR\?D[7;^Z
M[W);I7$W#7-U$;:-;1502$">)V",',^_<EO[VO\`1>;<&W9=B[XVGO7D[:V^
M]CW&0@S28;*W-QPOF[*3'[@M[2VM\]A<KBWCN[&[BC@\L;E9(XY(Y(@'K]00
M:]9\C>7OLE[OPW\]S<S8_?O&UK:-.Q,4&*_RMEGL;*W70!4@<RL3UU[QUZ=`
MG+0*!0*!0*"/6].OLKP,-!TXYY]<G0:@?G<-J.OR!JU!AO:NR%[M/BY3&LGX
M_LAZ]W@[G*=AM>4=OR^52%8EXP-0!IK^M!)Z@4"@4"@4"@4"@4"@4"@4'2?+
M6$O\9=[?Y<VS97%[N3CW\M,IC;&*6:]W3Q]E7MO\V[<C@@5I+N\MH[6+)X^/
M1B;ZR1%&DSZAM&?PVT^9^.GL3<KD=L[PQ-EDL3EL?.T<T18P93`;@Q5W"RRV
MN0QE[%!=VTBE7CFB770@B@PW$V]LOG['([3WM';V7)NQ7M\7O*RMP([7)1RB
M5<+O7#)KJ^W=YVMLUS;Z#_IYUGM7_BV[T&[;V@W-<[-W7!LJYMK+>,NW,W'M
M.[O0ALK?<K8RY7!37HDBFC:TBRAB:4,C*4!U!'2@ZBVIS5)9&SVWROMW)<>[
MLAVWC\HUOELKMK/7.>$9%CELI966RLIGI[+'QY1.U9+F.W1S(%CU*L%#(87G
M[:%^<@<O;9#;<-FL+VLU\B7PR0E+!A;Q8<W]Q`T)"AA,D9^[IKH=`UC%^VG$
M-Q<O;9S+7.U&:ZL[*SFS5AD!:7ES?7`M((S>V]G+9V`:XDC3NNI(4[I5&OSH
M'>F'S>8R,E['D-IY;;XMXB]M/D;S"7<5\VK@I$N'RF0FB90H8^14U#:#4Z@!
MC]K[CW1F;Z^M<]L#*[1M[:!);7(7^9VWDX,C(9WB>&"'"92_N8&2-1)K,D8*
MN`/N!`#SY]HMX[MA]C?1C*Y+9&<V;!C>6.>+"#<[7=EN2UM(;SUXY(LK2^NK
M#;9RUQ%;Y1XXEC%S!XXY9H^\AU*T':W],_`93:_H;ZPX#-XS(X?+8WC2SAO\
M9E[*?&Y.RN&R>3F:&]L;E(Y[:<"4$JZJ>OP/B@G/0*#A(XCC>0AV"(SE44N[
M!06(1%!9W.G0#J30?(9!-%%,JR(LL:2!)4:*50ZA@LD;@-&Z@Z$'J#05*!04
M(;:&!YWB0JUS+YIB7=N^3L6/N`=F"#M0=%T'[-:"O06T'GEMD%[%$DTD96>*
M%VDB!;4%4=E1F4K^P4%2""*U@BMX$$<,$:Q11C71(T`55&I)T`%!Q6VA2XEN
ME32>>.**5^YSW)"7,:]A8HO:9#U`!.O6@3VT%R(UGC$@BFCN(P21VS1'NC<:
M$=5-!7H+6TLX;*-XH`RQO-+/V,Y<(TS=[K'K^Y'W$D*.@UH/IBMK=[B];MC9
MXU-Q.[D*(K=6*]W<W8B1@D]-/DT%-?QLG;P2E'>$R)<1*XEA):&36)V0]C%0
MZA@#T/0_%!>T'S0:DZ#4Z:GZG3XU_72@MFLK5[R*_>%&NX();>&<@%XH9VC>
M9$/R%E:)>[]>T?I0?;RSM<A:SV5[#'<6MS&8IX)5#QR1M\JRD$$&@N0-``/@
M=!_=048;>*!IWC4@W,QGE/<6[I#'''W#4D`=D2C0=.E!YZ^Q/^5KKV2VYM[<
M&8&$R^X>)]M9G8[-MO<.ZDS6Y>*^78N1QAFQNW[26X0"WQ/F:3S0SB))&A[N
MR0`)$IRWNQ?6^PYAGVI$F\;C9>*W%/LYI9UBAR]^UK'-B"W8+S_IYK@KV=HG
MU7L([Z#'W/)V]8A(D>6V\#:KI<3R\3<PLDDOY#6S"W@AMV+*G;WJ5DD\OP`%
MT<AU1R]O?,[MXHWI@MT[\VOL7;&3Q%Y9[FWMEN+.3<);;8P=OXGR^YA=[AFL
M\+96=A$C2+/>R)!"!WRDQJ30;_ZB9_:FZMG<F[DV7N3$;LV_G?8#F7)VF>P&
M4LLSA+]Y]US"YFQ>3QEQ>8Z\M3<H_P!\4L@[M02&[D4)621I*CQ2HLD<B,DD
M;J&1T<%61E.H964Z$'YH/D444$44$$:0PPQI%#%&H2.**-0D<<:*`J(B```=
M`!04O#;V[W5W';HL\ZH]S)%&HFN?QXRD0D8`-(R1CM74]!TH+:RN;+-6-G?Q
MQ>2&0BX@6Z@*2P31,\9)CF0/%-"X9==/[#H:#JSD^>ZM(\_=)C%NK/\`TZW3
M9S7Z*/R;&>[_`!A'_&908<>8T+SL'U!1#V'M)`=E;:T;;>`T*:-A,5H8G#IH
M;"#0QNOVLGZ$="*"+^"V7NG@?D'EC/[-XH'(N'YNWR=_9K/;8S&#Q6]L=N`[
M>L,.+#=<>[\QBK',;?L_Y6D=A-9W`ELX)#&;9].]@COO7!;9Q_//#N?Y'L;*
MW]B^1.8]K;RQ>V<7>YO<&*XZXZQ.&QNS;K'G<8L['`WESD;C$6SF2>&![F[>
M?\.(I;RRD/4.@A!ZQWD%]S_[LS$?^(6W*&R\9.RL_8UA8[5N?Y<.Q@(UE5IY
M^XJ23TU^E!-^@4"@4"@4$3>2\Q>V?N#ZK8>W8+:9KC/VBDOQH.YUQ3\%S6R@
MZ$@">YU/Q\4&R>S!`VUQF&95#^P?!2ZL0`3_`*BX4A=20-6(T`^IH)'4"@4"
M@4"@4"@4"@4"@4"@'J".HU^H^?[OVT$=[=GX-W/^#,"O#F]\VO\`*KD%1:\8
M;SS,Y:?&7I8?]+LS>>3E:6WFU$5AE9FA;MCNHC&&T\E["S.8N<=OOCZ^L\)R
MAM>UEM\->Y!)VPVY,+-*MQ?[&W;;V[)+/M_+RH&CF'=/C+L+=0@E9(Y0SW'W
M(F*Y`L+\PVMY@MR;?O!BMW[.S'ACS^U<OV>1;7(10R2PW%E?0CS6-["SVM];
M,LL3D:A0T>&"TD]G+Z\CD1[R#@G&6EPBN2\,$_(&6FM3+&/MC6=X)>PGJW8V
MG0&@[YH.@?:2T-_P)R+9@]IN,=C(]>XKH#N'$$]0K?0?I0=_4"@C+S$]VO.?
MJ4MN(1`^_.3Q>L\BK-XAPMO4QI`A#-)WS=O?IIHHU)^A"_\`6F+)KP;Q&,==
M8]L?'A;LY,7,<]Q=3(U_D?#%97$,T,-O+!<'24O'(-%*@`_<`D70*!04)YGB
M\7CMY;@R31QD1E!XD9M'F<NRCLC'4Z:D_04%9N[M;MT#:'M+`E0VG3N`()&O
MSU%!3@\_AC_)\7G[1Y3"'$1?ZF,.2X4_H22/U-!\B_([Y_-X?%WC\;Q=_?X^
MT=WG[_M[^_73MZ:4%MDIKZWM3+CK6.\N%EMP;>20Q=T#3QK<M&P5@98X&9E!
MT#$:$CYH+^@XLZ(5#NJEV[4#,`78_P"%03JS?L%!RH%`H*%N;DHWY2PK)Y90
MH@=W0PB1O`Q,B(PD:+0L--`VH!(ZT%5T5U9'4.CJ596`*LK#0J0>A!!H"(L:
MJB`*B@*JCX`'P!^P4'*@HP)+&A6:;S-WN5?Q^,A&8E$8!F#,BG0GIKIKH*"M
M0*"E*L4J/;RD%9XY(V3O*,Z,I5PI5E<?:WR""*#&VMK<6=Y#;P*XQ-OBX+>(
MR7;3O^1%*Z@,DJO.\@@`[I6D8OKU&HU(=,;UX*M-X<W<8<S2;AOK.?CK'YK%
MG;\5O%^)E;?+XW.68F>^62.[MIH9LP"0O<KHG:1UU`;=OO:V;OMF9S`[:6WN
M9\C>8AL;9W<J6T&/C&;LK[*32W<_Y)FB1$DD2,("-!&@'0@.S]!^@_X4$#_Z
MGN,&3_I]^WL"V,^1D;@7D&,VEO!<WDDMM+B'-\!8VRRR78%K&S%0CMHI[1K0
M=>_TL+C9F3X6YNW#QQ%8IQYN?W#]DLYL>7$XB;`X>[VQ<;R2#'7F)Q$]EC9+
M*PG_`!G*`V\);34KUU(>F=`H%!0F2=O"+>9(`DR-,&A$OE@"L'A3[T\3,2"&
MZZ:::=:"*WL/R*-AW^0D@V[F-S78X5Y3SEU9X:ZQ=I<66!P8P<N8RK396]LH
MRME#<`B*(O-,Y`"]-0%_O[V*V=POQ%QMN1\5N'>^<W]BMN8CB[CW:%B+S>/(
M>=O=O0Y2RQ&%LYY4M[5C8)Y)KBZECMK<:"20,R!@J\9^P6Y=R;K.Q^6>$MY<
M$[CR=WE[?8[;DSNT]UX#?ZX,3S9-<!G-H9/(+:9&WQT(O1:9"&TFFLV,D/E$
M4PB#K3V?Y!R&.Y[].^*K.PM;JRWSR/F-Y9J]"2?S/$Q<;)@(<5)#)UMOY=D+
MO>LD,_>I?O\`&(RA+:A.>@A/ZPV6+_UL]SLO8RW+7E[R]@L;E(9I2T$4^'VT
MWB>VB90\0FCR![CJ58J.W30T$V*!0*!0*!01+Y)L1<>XGJUD"SC^6\8>SMN%
M6,F,ME).$6)DET[495QWVKT+`L>NAT"A[F7DUAL/BBX@B,TG^Z7U@MRHC\H6
M.]YHVE932,O<O:L<5P3W?X=-=#02[H%`H%`H%`H%`H%`H%`H%`H,9FL+B=QX
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MY%5$;H2[*!_8:#MB@4$:N8G9.:O5`JL;!^0N18G[XR[*K\,[Y8/&XC986#1@
M$EEU!T&NNE!E_5R6*;@'C6:%)8HGPUVRK.?OZYG)]SZ']R.1M61?A4(`Z"@[
MWN+F&U@EN)W[(8(VEE8!G*QHI9F"(&=]%&N@!)^E!41UD170ZJZJZG0@E7'<
MI*D!AJ#]1K0<Z!0?&8*K,==%!8Z`L=`-3H%!).GT'6@X0RQSQ1S1$M'*@="5
M9"58:C57"LI_80"*#Y-$L\,L#EPDT;QN8W:-^UU*MVNA#(VA^00106EQ>6&(
MM[=;F;\:WUBM8GD\LB*0H2(2S$2%0V@7OD;JQ`UU-!D*"F\44C1N\<;O"Q:)
MW16:)F4JS1L02C%3H2-.E!Q6XB>XEME+^:".&60&.14"3F41]LK((I&)A;55
M8LO34#4:A6H%!1@F,\9D\4L/WR($G7L<B-VC[RNI(1RNJ_JI!^M!8VM^OY(Q
M=U,C91+8WDB0V]TENUNT[Q1M%/+'X'D4`=R!RX^2H4@T&4H%`H%!Q9E12SL%
M4?))T`^G_P`=!8F;&SFUOO+;2]GG%I=!T<`-_"G$4BDC0E>UOVC2@KF\M0`3
M<1`'X/>-#II]?C_$/^-!%#DKV,W!LKV8X3X-QNVL+D=O\J8?-W]_N>\R-S;7
MF)N\99[CNH;6R@C1K6Z$W\A`8,>X!R1T%!*UKVU1'<SQGQJ6<(W<VB]"`HU)
M)/0#ZF@MWNH+JWMY5O'L3((+L=_CCF$6HD:.>*8,$61-0P/4?L(H.@O;*^*^
MM_-1MIK0J..-S^5GNGB<%K'M18S"I;1U9@6#`KTT!UH,#ZNSXZVLN<T2])`]
MDN6%E-TRQE9X[K$(\,1=N^6."$1@,3J?KH00`E&+^Q)`%Y:]Q.@7SQ=Q/[!W
M:T%075LPU%Q"1W=NHD4CN'0KT/R#06\.2M)YIX$E`:`H.]B%BE[T[S^/(3VS
M>(='T_=/0T%"YS>/MI;2$S>=KRX%NIMM+A("8I9O-=O&Q6VMM(2O>VB]Y5?D
MB@AA[)&UFY`FN(+AGG'J;[.PK';K'/%(`NP=7FU5H];:0KHK=P/>=5TH/FY>
M,\KF,?Z=\TV^V'W_`#\!;7N<L^S<:;&SW#=WN]N-<5M4[DVI+>W%A8S9C;UF
MURO\OFN((;NWO)-&\T4*D-_GN]R\V;_XROK/9.]]B;*XPW,=^Y3+[ZQ2;9R6
MYLU-L_<6W\;MC`X*2XGS(@L7W/\`D9&[N4@MV\(@A\S-(8PCG[8(A]WO0<HR
MBX:YY9#`PK(!9Q7W%\LG?)W(8?)<K&$U[AWKT^XB@],Z",G!W$N1X^Y0]E=W
M7N;QN1M^5>0<-N2PQ=BK>;"06.$>S,=_*X#-<WOE5BH)5.WI\T$FZ!0*!0*!
M01SW[%&?9;UXE[1Y5V7SVH?KJ(S#QAW(/IHS$'^Z@L?:RPBR&Q-A)*TB_C>P
MGKK?1^-@I:6UYDV<Z*Y/S&Q^1]102:H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!
MUSRYMG-;QXWW;MK;K62YS*8P1XO^932VUBUW!=6]W%'<W$$4\L$<I@[>\(W:
M3KI04'W+R:%8IQA8.X4E5._[!06TU"EOY&>T$]-=#I08&ZWAS>CQK9<*[>N%
M8Q"22YY<M;-8PTFDI`BV3>NXBC^X:`%CTZ?-!U;R5A>>=WY;B_<EMQ=LZ0[%
MW#G,KEMNCE^\QUQE[/.[,SNV1!99R#8*O87%A?92.X+J5,D<94$$T&NV&`Y=
MQ\`L,?ZG<?XJRA)2&WL/9C,6=@(S)H6AL[/C6-(>]%[F7L&I(U)(H-FXOP'/
M.W,AR%?[EV#M+^7YG=N/R^P<"G+>7SS[5PUMMO#XZ^Q]QDKW95F91=YZUN[Q
M%4/VBYT8DC0!@]X;<Y\R/).9W!-Q%M3?6S<AAMH0X+!WG.^7VDVU<WBIMQ1[
MDR"06&P[N+)C.6F2LQH[A5_"&B@G4A77'\R+V`>K.R-&N'D8_P"YC,-XSW><
M3'NXWU8/.[:J-=#UTZT%K;;<Y;25R_K!LJ'PW$DMK-'[/[IF#F8.99)8WX]B
M,9[VT"?>H3H-``*#[>X;FI9HA9>L.P;F)NV.9[KV;W/`T<*1.8RD:\<SK(ZS
M]H^5^W4ZZ@`AC[G#<Y*R"V]5./K@O&BSS7/M'N5.PSMI=+$3QO/*1&DLA0_:
M2=/W=>@<AA>=XU_%B]7^/'MT23QRW7M'NZXD/<3V0RO+QS-<-%W,21W,JKIV
MC7I0<EV]SH$B@_VQ<5R01"XF1;[V7WA>]DT[R=R!;CC&XU\@E<L2=%U`'QT"
MA:[4YQ\I:?UEXLM@TC]Y@]HM_/#("LG;(]L.+XXI%[Y">U@>W7N'W`4%VN&Y
M\C,*KZP<2L`PCD=O9O>!7QHKQI*P?B1WN&,;??W_`',QU))&M!>76U>8LG'$
M^0];^+GDBB$:0CV6WRD?9#$((8)#!Q4B2V[0H`48,NGR":"W&T^9Q_'_`-M'
M$K7<,9A@,GLQOIT,*J)T7N?B-RKO<:*S=I)`U)(`%!6_RSS=%*T]OZV\->13
MJAE]C]\@2"5@DP9/]'I(QI&W<000Q7]=#06/^3>;516C]:N%%F0NBZ^RO(2J
M(#^2>T.O#I;[V==%T[55B/\`"!0:^G%_LIE]];3W%/QSPQL+!;<LMQ+EL7@N
M9M_[LDW?/E;>SM\/!D8;WC7;,%D=NW5J;R*823EI"$[0"6`4-H\:>SF#VQ@,
M'NSBCA#D3.X;&6N.R>\\OSWR197FY[FTDDC;-W&'3B>ZL\=?7T3F:1$D8)*Y
M4.P'=0;5:[-YXCC9V]>N`K:X,;0@0\]\B2E8R(TB\5R>)H9(@D?=J%"E2J]I
M^H#7<3QS[08OD7)[QM.->%;';]QM'`X.PVFW-_(]]%:9_$YG<.2FW6LTO&H@
M3(75ME+>V?6.5I(K95+!:#LG:&S^?+/=%WGLWM/B?'8T6N-3'X/'[WW9F9(L
MA;SY2?(9#^;WFU,?X_S'OD(B%MHO81J01H&GYCC?V'&]]\YQ]C<2\@8'=&0P
MN3P..W+RGO7$?Y-BQV#M,7=X/%V<&Q,I;/97V1M&R$CAH^Z>X;[-5!H*DVQ_
M8"4VX/!/KU)''&ULT,_,G(#1PVS2K/VVX'&!5S)+&K/W`$L!UZ4'R+9'L!%&
MRIP'Z\*US-')>1#FC?XMY!]Q\GV\5%FE23[F':`W0@ZB@PM_PWR[EMT8G=.2
M];_56[SF%QV7LL)N*[Y,W[/F\%;Y:-[>]Q]C<MQ2\L-OD(IF\C1NNBEP!JYH
M,W+Q_P"PFHFAX6]:C=1QM!;M-RSR65$)4,!,4XO7M`D0`!5?J>_H>A"QEXSY
M[?51P5ZONMR9A<M/RKRDS2+)$%(E_P#K7NS=Q=UZGM"?`Z@`.<_&G/<_=%<<
M#>J>0L^T*8+WDWDZ2"<!E98YL;<<3W=G+#K"FH?N!/R.G4,K=["YXO;R;)S<
M'^K'\TNKJ%[FZ7D/DB%I@2D-Q=2M;\2Q^2X,$2ZDCN<Z%B=.H6V;XFYTOL-G
M<9A^+?5[!7N8V]E<#;9RSWSR2F5QAR=L]L,A'=1<813W$]FS+-%]\;K+&NCK
M^\`WS%<6\J8[8%IM0P\7MG[3:>/PB[OAR6\(<D^>M,5%92[FF=<<+F6^FO(A
M<%O*LA?4E]6.@4.2^*^5]X\;;CV=MRVXNVGG\U_+)HMQX[+[KLW6ZL<WC<K>
M+*]GMX7L-OFK:QDM;CQR=QBN'Z,-5(8%-A<]H^@X?]3VCB[4M6.[>0VD2!TG
MBFB?R<9MK((9`JL#H26.@Z4&!S/&'LAE,)O#%8[C3U-VW?;IV)G]E'/6.YN1
MY[Z&VSMK/:2Q,L?'EC+^!_&6215E[Y'B0'4*I4)`[1Q'+^UMI[6VR;;C:].W
M=N8/!-=KE=T0+=/B,7:X][A87PTS1).]N6"EV*@Z$D]:#8&N.7]&[<5QP6T/
M;KG=S`=VAT+:;?)[=?G3KI00ZYFX;Y5WA[#^KG,V[<MQ[@L#QCN/*;7N\1M_
M);FGR^<GWSE=G9:QDMKF_P`39V4<5KD]D)%+;N"9X;DZ.K(%8)Z9S/XO`6RR
MY"^L[26Y,L6/AN9E22^NTB:46UK"#Y[J8JNOCB5I"!T!-!B=D8NYQ^%6ZR,%
MS;9C-2ME\S;W.0FR1M[^Z`[[>&YG)?\`'MXU5(UZ=J*!]*#<:!0*!0*!01&Y
M7R\]E[>>H>+C5&AS6T_9I+AF:0.@Q^!XSO(C&J,$8F0:'N!`'QUH-K]GO_U*
MV*NH'?S[Z^+U.@Z\O[0(&O[2*"1U`H%`H%`H%`H%`H%`H%`H%`H%`H%`H++(
M3WEM;^6QL1D)A)$IM_R4M3XF<"619'CD5FB4ZA=!W?&HH+6>YS#X.YNK/'6T
M6=_E]U+98S(7C+9_S)89#:6UY?64%TZ6LDX4/)%%(RH20C$=I#I"VS_M$2WY
MO&_"T2K!%-W6G*.\KJ1Y)'97MDAEXNM(Q)"@#$F70ZZ#]:#.0YSGE(E>\V-Q
MR[M)(!%8;TW#(WC1M%<FZV?;A6E!!4$C0`ZD=-0R\F6Y@CMXYEVGL:9W([K>
M/=.<66+5&8E_)M<+H&7MZ$]2/IK063;AYE4'_P!P-I2,#IVIO#)+J.UF[@S[
M:[-`0!\ZDF@M,UFN?8XO_=_8W&=S.GB\@RV^=QVL+^=E4>%[395RS&V!+2:@
M#3HI)^`Q\6>]C4NGBN]A<6&W6(D3V6]]SRF2=3J459]G0Z1/'^ZQZ]_VE=/N
MH-@CS7,KK(S;.V2G9U56W3F0TH\BI]FFW&`(4EM#\@:?-!R.2YKFCAEMMK<<
MP=Q?S0WV[-QK*H60*G:8-J.H[T5CU_5?VT&O7^0]G0W_`(7M/@N1"?\`](;]
MWY;LH[#U_P"FX\NPWWZ?ITH+_#9'V'G>49S:W#MA''))&C8_>V]+YYP@7LF5
M)]AV2QQ2ZGH6+#3X-!L1N>7_`*87C8_V[GW./_W1-!:W&0YG5XX;;;7&TCR)
M(YN)=W;G2VA[-`HD5=EM([2,PT"_0$DCIJ&!R=W[)Z0_R;;_``<3J/.<GO'?
MJ@#M74PBUV,Q)#:]&TZ:=:#)XV7GMX"<Q8<0V]STT3&Y?>=Y!_B[B9+K"6,G
MZ:#M_7K04!D.?/S/`=N<8&U[F'YPW#N,*0$D8-^,<29@'=573J1W:_`H*M]+
MSZ8U.-L.(!(4!87^5WF5$A![@#;8?7M'3K]:#5)[CVU$RBVQ7KL\!9>YYL[R
M3'($U0.!&FWI%9P-2/N`/Q09BPF]E>XC*8_@X`EM#C\OOQNU0P[0WY.&0LS*
M?H``10;%:R<T-"IO+3C&*?N<.D%]NF2/168*ZR-8*WWJ`="-1KI0+J3FD6\O
MX5IQ>]WVCP"ZR&ZTM^[4:^4Q8QY.WMU^/K0:O/-[/&Y/XN/X(%F.PZ7&7Y`-
MRX*Q^0:Q8;Q(5<MH=&U`'QJ=`V7'/S:]L#E;;BV&[#LI6QN]USV[(-.UU>>T
M@E!;_NE>GZT%?R<R&$,+7C1)R03&U[NAHP.[[AWK9`EBGP=-`:#'7[<]EY/Y
M7%Q"B:)XOS[C><CAM?O,GX]M$""/@#Z_\*#!7+>T/Y/_`$<7`@L^S76ZGY#:
MY\FL8[=(K=8NSM[SKKKKH-/DT%"Q;VIUTR4/K^`0#WV,_(CA='4,A6XAC+%H
MR2I'U&A'76@W"+_6DQVYF;C%)'4_E(D.Z66!NQB/$YN@9U+@#J$(!U^G4."/
MS84!>+C(.7B!5?\`,W2-WTE<GS$:PIUT&O=\=*#AD4YQ:"3^5S\5+<B*4Q"^
MMMW-`T_:/`)3;W:R+!W:]^FK$?&E!JC#VHBN8F$O`ES8AG$\*6?(,5ZZ^/6-
MX9I<HUNA$G1E93TZ@_2@V.S//),YOVXI"K;=]L+6SW6'DNE)UBE$N5*Q12@@
MJP+%=#J#074#<V/)$)UXTBC<*976#<DC0DI(S`+_`#!?+HZJO0C][7Z4%*2+
MG66U+P7W%5I>,[E8KG$;LO+>--%$:NT&<M9)7!!8D%1H0-.FI#6#![3_`)$T
M:97@4VZQH;>YEV]O_ODD[5$D<UM'N@=@+$D.KD:#3M^M!E\;:^Q>JG,YKA;M
M`;N7%[:WP"6(^W1KS=3Z`']G6@S$HYHA6V5)^-[UG/;<R#&[DM5B&HU=4;,S
M%U&IZ`Z]*"Y1>7V:8/<<<HJ2=L3?@;E)FC[%)D*C*?PB')&FI^-?K01-Y7W[
MSE?^PW#7`=MAN/5CW%MW>G-MONZ)=R2#'?Z-[DXXPYQ-WCFE,';N!^22T;M.
MI7\$J`3+W1A+BUX]L[C<=EN[<UT=QYW'8ZVL<<UQ:Q08W'21M)+<9"RQ@>XA
MM\C<RR#616)5(T`)*]Q#L2@4"@4"@4"@AYRW87-Q[B^G>02-S:8[:OL[%/*%
M/8D^0VWQN+9&?]W61+630?)T/Z4&0]RYKNVXQV)<6+2I<1>ROJK]\4`N"L$W
ML-QS;7?>C?:L36L[AG.O8#W?(%!+.@4"@U3?&]=O<=;3S>]MUWCV&W=O6@O<
MI=Q6UQ>206[316ZLEK:QRW$S--.H`12>M!M0.H!Z]0#U^>OZ_MH/M`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H(>;IZ^^O"@'^'U5]BF;]@;E/UN4?\2*"8=`H%`H%`H%`H(T
M<E0Q'V3]8YRTHE7%\ZQHJR3>%EDVQM=G,D*GPEU\0[68:KJ0#]QU"^]H+*WO
M>-L$LZ,_@YJ]=[N'M=D[;BWYWX\>%SVG[E5OH=0:"1-`H%!&WV^)'K9RSIIJ
M=O6Z]=/\6:Q:Z]>G36@DB!H`/T`%!]H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!$#F[BSGN]
MYLX[YMX'O^'Y,KM;C#D?B_-8#ET[UM[">RWSNCC?=,&9Q%]LR&ZN!>6$^P/`
M\,\9C>.Y[@P9-"&(LW_J+OFL0+^W]*;?;AS.+.>>SO.=+O-+M\7Z'-#$136-
ME8OF6Q?<+4S.L`N-#("GVT$UJ!0*!0*!0*")/+V0-M[6>GMB._\`\2M/8E#V
M]O;VVFQ-O7/WZ@G3N4:::=:#;?:"[@LN-\#-<OXXFYJ]>(>X_'?-SKQ['&#]
M`&<@?VF@D30*!00Y_J"7<]AZ8>P]Y;/X[BWV!<R0/H#VRC)8X(=#T.C&@F(G
M[B:_/8NO_`4'*@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@B)S%9W$OM;Z:W
MB0Q/;6:>Q,<\YU\T,MUQUB!;I'_A,4PA?OUZZJNGUH,A[EVDEUPM9M#+X9+'
MF?UPR8;Q>8,+#V`XUN7B9.U@%F1"I8]$![C\4$JZ!0*"(?OQCILMZ=>P./@"
MM+/L*Z*AE+J1#D,?.^JK)$6^R(_XA_?\4$NQ\#^P4'V@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@CCR;$K\_P#K'*40M#<\QA7/=WH)-@(K!=/M['T^[7KJ
M!I]:"G[8'_ZSK+IKW\F<&II^O=S5L"@DE0*!01S]NI!%ZS<URL"5CV'F&91U
M9E"QEE4?5F'0#ZF@D6/@=".@Z'H1^P_MH/M`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%!$_F3*2V7LSZ<8]!JF8S/.L$QU<=J6G$E]?*0%958F6!1]P(_OT-
M!EO;F]ML=PT+N\?QV\?*7`ZN^@.C2\W<?Q1#J1^]*ZC^^@DU0*!01(]]+VXQ
MOIE[+Y"T?QW=EQ#O"ZM9--?'<08YY87TZ:E)%!H));FSESMO:&?W):X;);DO
M,%MO*YNVV]AU63+Y^ZQF,GOH<+BT?['R65F@$$`;H99%UH(.>E7N3R/[3YS?
M$6[N`\MQ+M;%[?V_N'9.?OKK<DCYZ"]RVX-M9>PR]GN?:&T+G'9%LMMF>^L(
MXHYGDPT]O/<K;R3)&P>A%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(D\T6#7
M'L[Z8WPE55Q^<YW[HCIW2_E\09"(%.NO\/MU/[#0<?>#&G*^OU_9B,2#_5#@
M"Y92@<=ECSQQQ>NQ4LO[BV^NOTTUT.E!+B@4"@C)[H6"Y/U/]A+!HVD6YXIW
M=&R)&DK,O\KF8Z1R?8V@74Z_2@[<Y*DLX.+=_2W]SFK/'P[`W5)>WFW89KC<
M-K9Q[<OVN+G!V]M)#<3YF"`,]JD;H[3A0I!(-!XV_P!'WDC;.X\UR;LG$;/V
M5M;([6X_X[FNLCA./.,MC[LWA;QW>;P\>>W?<\><O<JS9N^F2QCN&DOAC^YK
MP30B9969`]T:#BS*@[G954:`LQ"@:D`=3H.I.E!RH%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%!&SE6".3GWU7G9NV2WS?+WB750'\O%V41QHP[B0O7[>O3]*"Z]J
M@#PKF`1KW;PXF4?L+<M;(74?H0#02)H%`H(^^V$T=OZS<[S3.L<,?%F\WED8
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MX-W9?,9/_)TM]!^W2@R7N;E1@_7S<N597<6>\>''[8Y/$[>3F?C^`]LACF"$
M"77JC:Z::4$I:#1.3=_6G%VP]R[_`+_;F]=W6>V+#^87&V^.=J97?.^,O'YX
M;?\`%VWM+"13Y;/9'NF#""!&<HK-IH#0>'_!'O=[D\W^PO'O%&3XZYLVCP)C
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M;^V)/8O:4V[N/MBYZ>?;.,W;BL%S39;%S&Z;?;]]-9W%Y+C_`,>\[PDL)MU6
M`!ZM@Z]1U!Z@CZT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@AYSM;>;V@]&Y])#^
M+O;G5]50M&/+P'O"'^*X!":]_P!NNFIH-D]R,1%G/7O=EA*9`AW)Q5=@QNL;
M]^.Y;V-D(_N96':9+4=PTU9=0"-=:"3]!\.NA[=-=#IKU&OTU`()&M!^2+AC
MG'+;*]QMA;0X^VIROL7@;='M7+=6MKNG^H;OZ:PN&WQ[4\J<3;GNL?ZM8+8%
MOMY'O>:MNS2Y3:#7[)B;/.8^XN&6&6X*A^DSW%QPRWJG[#XPH7%]P_ORV**J
M.2)=O7R_NN0C#]AH.S]Q-;+Q3FOS,??YFU;8&0CGQ&(G_'RN8BDV]*CXK$W'
M=&8LGD@WAMV!!$KJ1UH/$?\`HZX6&TY+YHRQV)R-A+?);&P%QLS+[RM,+A?Y
M%LJ^WIN6[N]DYO"X3C?CZ&3/G?8RUQ8WTYO+F[Q-LDSQ68F47`>_=!X0^VW,
MO)FW?9S/\!9;?_-G(VPMX;NX-SN4X^P_%W",.VMG\>YO<6-L+J*PS6Y=D;BS
MN[[:[W?_`"RTB\?XUU=75U=11SH]A+*`]U[6VM[*V@L[2)+>UM88[>V@C';'
M#!"@CBBC7X6.-%`4#H`-*"O0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01IY<M89>>
M/4VY<+Y;3>/*_A)`U'GX8W>DG:2=02B_3Y%!D?:@:\';I4?+9OCI!_:_)FSU
M'_::"0M!#O\`J`\Q[N]?_33V"YAV%DK;";PV1L26^P.X+S'KE[3;5Y?Y3&X4
M[IN,5(LEODXML09)\@;>96@E_&[91XRU!Y=^E7LGZ0Y?V"W?Q)R1[)>OOL[R
M-M+G/`7_`*?<R[MV3Q+:<T;KSO+7&>UKWD$XC,[`V/MC"9'<<6^?S+)\I9VM
MM>SQJD5U++)"KT'L#[;WBX[U=]@K]V")9</[_NF<A2$6#;60D9B'*IHH77J0
M/UH-SW1;XO(</WMQE<?C\K:6&RH=Q06^3Q"YZR%_@L5'G,5>2899(OYD]ED;
M**9(5=&=T`5E)!`>4_\`2/O=GYRTW#NG$MM5MU;JXMXVW%N==K9SU4F@B?,_
MGY!%FVKZ^;9PN[-K1O<W$GBM=S7%W-:!3;J[2Q3.P>UE!XE>VNW[/EOVKQF+
MQ5M<[)DP]_P-E,!SCMSB[VBY%R&<NL/R'<WN<V_M[=7$VZH.#\/+A9MNOB<K
M;;FM/';PY!I;H21#M4/;6@4"@4"@4"@4"@4"@4"@^%E735@-2%&I`U8]`HU^
M23]*#[0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*")W.5X;;V%]*;=7*&_Y-Y<MV`+`2)%Z\<F7A0A>C=;8-UZ
M#37YTH./O)<75IZO<DW-FC27-O=<?S1(A56_A\G;,9V#/'*@[$!/56'3XH)9
MT%"Y\/X\WY`A,`C8R"Y*"`J!_P"M,@*!-?G7I0>:G$_N5RMS+R;:6/&OHWF9
MN#+?EG>'%^4Y[SW-G!6V;S$7''V\\WL;=6YX>(#E[[D2;'6V9P<SVENZ6^0N
M[=DE$*JZE@D3[S$CTT]IB"0?]`^5.HUU'_N;E^HTZZB@[DC2];B6./'7-]9Y
M$\=*EA>8RTMLADK6].V@MK<X^PO72SOKZ"?M>*&9A'+(`KD*30>/_P#29VQN
M3$[SY0RF7Y9N]R6>0V?BI_\`)%_M?GC'Y^7(YG<5WN"YWEOC(\S[5P%EA=U6
M<]_/CCA<+<Y*"`-*6N7@CLUC#W%H/+SC#U,V#M;D[);;OO<?G2RY/AY'WKS3
M=\&[#]@+O:&S8-O[[Y1W3R%A[-^'U\UR^VKBUR/XN2>+_I[^=+ARR^0J`]0Z
M!0*!0*!0*!0*!0*!0*#\]G%>\L#E?ZHN2QMWS)S3N&YP_.N_\!M?&Y#)V46$
MA.5V?S=D-P\?S[0AW_=Y*WV98Y[:-Q&V0N-OVX%MMW`F)(HKI[RZ#]"=`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H(B<\0-)['>CDH[.RWY0YC=^YU#?Q/6[E*%>Q">YSW/UTUT'4T&Q^X=G%
M?>N/)%O,`4:#;+Z%5<=\.]-N3Q_:X(U$D0T/R/D=:"3%!I^_]A;+Y1V9N+C[
MD3;>+W?LC=>-EQ.Y=LYJW_+Q.:Q<K(\UC?VI(%Q;2F,=R'H=*#\T7%'#G'^W
M><>*L;QKZGX/!>U&RO??-Y/<%ILOT]DLN",;ZN6>^KO;UCNF+V0BQ<VT)LAM
M#B['P;AL<];Y]MQ7F[RV)NK%D#6\0?H&]N+$9+U;]A[`K&PN^&>1X"LS2)$1
M)M3*`AVA224+I\]JD_LH,#[`<5;KYH]8[[C+9E[A;3-;AQ7'0>#<>6W#@MN9
MW!8;<>ULWNG:>?R^U(;C<5CA-X;9QEWB[IK5'D:"[92"C,*#1?2KC7V#X6VC
M=\4<IV_"IX]VM>;IGXUEXSWUR)NS,83%9W?>XL]AM@WUKOK;&):SVUL':V3M
M,5CI%O+B5HK15,<2*HH)OT'YP/<:]N^:O;*]QO-O&\N6XZV;O#8>!X.Q.]-L
M>T&W,+8Y.TW`F.W'R(MKQOQOMM]Z9.;(Y`18ZY;=,N$3LBEC&@D8A^@[CS9-
MAQOL;:>P<5E=RYS&;/P6.V]C\OO'/7VZ=U9"RQ=NEK;7&?W'DWDR.;R;PQCR
MW,[-+,P[G)8DT&XT"@4"@4"@4"@4"@4%K?7:V%C>7S0W-RME:W%VUO90M<WE
MPMO"\QAM+=/ON+F4)VQH.KL0!\T'@]Q?C^3\G_5$&Z\[N6^Q4DVX]ZI96L_%
MLNULIG>'\MLC/;@L]I;OR$F$AGR-]ALM=X.UL));V9+"/`W4R2/)DV@@#IKE
M+,VA]BMRYG$;XN\IYO8;^?;U]EL->\PIR?ZW;-P'L);\:6FR]P[3GY(Q/%S;
M+NMZ8>XVE8?RZTO(IL)))?WV*;1Y)0_2A0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!01WY<L89^8/5>]?O\UAR5
MO_P!2`G_`%7!?)L,K."I+=JCIH1H306_MTW9Z[\BMVNVD.VOMC4N[:[RVZ-$
M1=2S'7H!020H%!^2/8W/U]Q#[D8;#[`P?-6RO7O<?N%<,5SW]1+)6VW8+K>G
MM]N/A7D>^@]5<9Q--8C$2\SS"6]VJN:#V]AG[6ZF=$FF9`_3-[17,=EZV<_7
MDK=D-IPWR5<S.`#XX8-GY>6630E0>R-"="0#I0;U#<VW^F,5Y)=Y"UM/\AI<
MO?XA&?*VUM_E\2M=XN.)96;(0Q??`JAB9`H`-!X+_P!&Z?#1\U<I66-W)O#+
MXVXXFBR>R[K_`"K'MS:V[-O7O(DF7W%GMZLG(6_A?<J;<W9GWQCW4?X5G=S-
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MMC=VQN6MKU(TF1XZ#U`LKVUR5G:Y"QGCN;*]MX;NTN8762&XMKA%E@GAD0LD
MD4T3!E8$@J0:"ZH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%!&?FF[DM^9?4:!+AH5O.5]_12(K0`7*Q\!\JR^%Q/
M]S+JG=I'_$U7].Z@POO/^1_M1YC:U-PMS'A<--`UJ8Q.LD&[-OS(R&62)`JE
M-6/<"%UTU.@H)94`_!T.G[?T_;UZ4'Y9IMX>PN8_J%W>U=T\17&2Y-QGLEL[
M>W%?'N2]/MM/Q;M#`OSKO?:7*O(V%Y]DV._CFW;ZHXK`;LOMUG<,N4.Y;.UL
M88E*O:@/T$>XI=?4;V@\98R?[>>9%C*`]YD/'>X53L"]0Q<C33X-!V?M\.O%
M.$`R;85UX]QH&9[(Y6Q+C;</_B?9-_"D:P/\71OM/9UZ4'B7_2;Q\.*YUY3>
MUY?W5O2US_%<-P<-O:3FLY+<N3P6\L?%GM_[<QW)=_>[>P.U6R^=ENX([`17
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M[N)G2*&"VMHGFGFEDD*I''%$A9F8@`#4T'AIZ?[+VKSO[B\B^PFWMK[>SN%V
MIR5F-W8[)W._N:N/KG`X+D7;>Y=P<3;Z3UFW7QSBMFY3<>ZMO;YRLD.YX,O-
M:9"')75]"HN9'50U;D+=62S_`+";RVA>>[.U,ED=A\QX_;/&V!PV5]@TW=Q;
MO/</.F.WOO/";^VMM/!9'8>^+ZRXJW%;;8QF/RSOBUQSP3$6D,DLCA[]1QQQ
M(L<2)'&@T2.-0B*/T55`51^P4'.@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$/?8SKSIZ,#IK_KYOUOV_;ZT\VZZ
M?\:#=?;F*.?UNY<BD'<C;7)TZ=63(V#H.H8?OJ/I02-H%!^3;/;.V]G/=G-0
M[\]J\3GQQ#[D<87VPM_S[>]@9&V++S1[.[DW'NH66Z>U>,I>1MQ[DXXPW":R
M8^7_`"KA,%97$-TPOKUK2@_2Q[,VB7_K?SY9,FL=UPOR;;M&8FE!2796:0HT
M2!F<=IT(%!E<QG-S[6X8@S6R^/[SE/<^.V;A&PW'N/SF`VU=[JN6L;&`XN#/
M;JNK+;F++0.SF2\ECA[4*DZD4$!_33A3>.P_8W?V^[#TUB]0N-MU\7W<&X\;
M><A<9<BY#>/*5SOJPR=G>XJZV7N;==]MK`X[;27*M81/8XPRRH4MV=`RAZJ4
M'Y\_=3,;IXI]J<IMS:OL7S3A(-XX3C+>MHZ^P7/6-V+Z]SV7*3WV^]P[OV#@
MML;KV9NO:.]-L7:0V>%;(8V*TQV-NNZ&&W8WBA-+^HXVYK>7U]S&P9-P[.WQ
MCMT\AQ8GG+;VV-][Y;C#$WFP[M=R8B\V?L/8?(=QEEY#M(([*)[NSA@MY;<,
MEQ'.8ED"7OJQM7"[(]=>&]I;=B@BPF`V!MVPQPMK'=&+AEA2PBD:Z&-WND6\
M,>][+(TSPY)$O(W<K(JD=H#OV@4"@4"@4"@4"@4&*SN%Q^X\)F=O9:)I\5GL
M5D,+DX$D>%YL?E+2:QO(EFB99(FDMIV`92&4G4'6@\B^!\7Z<\-^U<?&/&O)
M?M7=\DXG)[:XLR2[IY)Y1W/Q%N+(;4V'R%9[2V/E[K.W5Q@,Z=F8/9N;MK5"
M@BM<E8&$2F90M!,>Y]B./=I>VJ^O5GL":UWUR)9;5RN9WOCVQ-O;91I=C\H9
MW#MF8D"9*^N,9A^*[BS61^YE6>%5/8A"A,*@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@B[SO;O+R]Z?S*JE+3F
MK=TLC%B&02<"<MVZE!J`W<TVAZ'376@R7M[<PV?K5R]=W#%8+;:QGF8#4B*+
M(V#R'0D#]Q3]1020H.I>>>8MM^OG"_)_-^[[7)7^VN+-E9_>N7QV&2VDR^3M
M\%837BXO%)>W%I9MDLG.B6\'EECB\LB][*NI`?G3XUX@@Y(]Q+O&X[UX]K=K
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M'W9[V18S=O,/"7L?D]H\T8#92[!XQV'M[`\A\4;7.\<,]OQ]S=E-][AP?&W(
MT&UDO>^?\W-#(DNWX^-,D@B</='V(]</3+>V<'*WLCMC89REEMVYP@W/O;>6
M5VO8IM_"VF7S]Y;>%=S8;$3)CL>+RZE?Q-*D$;NS=B:J'<'KY+LUN'MC6W'.
MU[C:''N-PUOB]BX>;-X7<EN=H6"B#;V0Q6>P.Y=W6.5PV4Q:QSVLQOYYVA<>
M71^X`.XIYX+:*2XN9HK>"%&DEFGD2***-%+/)))(51$10222`!0<8[JUED\,
M5Q!)*8([GQ)+&TOX\I98KCQAB_@D92%?3M)'0T%>@4"@4"@4"@4"@_.QM3,8
M5_ZQPB#>O6*WHO(6\,#<8G;]_#FMS[PVO-QSR+F(=U93')/>VFT>3]HQV$5A
MWQ0V>4O9LEG/RG>T2(L$W\%[\^OP]D\KQWRE@=D;`Y!P.=Y-VE'O*]CO,AGC
MEMG<JCB_CS`I+'M;\NWN]_;5W!+E;8_E^.&VGFC7NCD>0AZD4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$:><;
MJ"WY1]4(YI1&;OF?<4$`/_K9APIRE(L8'ZE48_W4&(]Y!(?4?GP1>4R?Y`R)
M40=)3VW%HQ"GOCT^T'7[@=*"5H^!TT_9^G[*#HSV8V!Q=RKP'RQQOS9G?\L<
M2[UV5FMO\@[B_P`Q0[0;";8OK5ER.53=5PZ6VW)+",>5;V4B.W9`[=!0>4/&
M_'G]/;:/.=CN?:7]63E3=/*V\]T;"OLEM";WYV-N6+EC*[9AM<%LK;>X]G8=
M4;==G/9-'8K80JDEW%(4^YCW4'JG[5$CU;]CRH)9N`^7E0!6[F=^/=PK&H33
MN!9V`T^:#:>,X&?A#CZU5IHG;BK:D"O;W!M+B-FVC81AH+M5=K:9"=5D`)1M
M#H=*#Q>_I+[2P>V^?>?\9#N3<V2S6U=N-C6M-L;+Q]]PK=V&>W%B/R<A?^PF
MS=U;LX_Y>Y:BR>U&FN[6(8G)XQ\C?W%S9*]_)V![[4'@M[S)G;[V-P#[#M-W
M8\YP;!QNP]S[=V%R'B<!Q7RAB.2LNV\-[;YP6W^$-XXCGJVWMA;:UCLK&\R<
M`CMK)WC6.&[&0B#O;^JIC-O9RW]:[7/X+\JPL^3LYE+G>LN`Y1WO@-EQX[:E
MUF;3'[MV+Q'C[_<>X,!O[(8F&Q?S-;VB>$I([I,\4@3S]5=J[>V1ZX\,;6VI
M/'=;?Q&P-OPXVZBL-Q8I+N.:T6[FN_Y9NY(]SX]KNYN'E:&_5;J-G*NJD:`.
MO??*RVO<^K^_KO>UWN:VVA@,ALC=&Y8=L<?WO*KY7#;;WQMW,7V$W'QSCKNP
MN]W['S,-H;?.6JSQ*,7)/([".-M0Z)])>-,7MWF?F#>VT<7[$;,XXR7'/'.R
M]A\8\Z\<7>U['8F-P6Z.0]Q7F+X]W?E-PYC-;EVI^;NMC:8VY0+@+8QP03/;
M210VX>G%`H%`H%`H%`H%!X%6VW\S;?U3L39YC@?,8#&0<LWN[=LY*-.5,;MC
M-V^<VAS!)E^4LCO63,#B#<F5AR5I;9#';?MX1>64VXL@K0M<M<2H&D<U9CD;
M)^P7*&"E]L=GB7CGV'V[:\>X';OL-R1A]S87?7,/)6T7QF4W-QI@\%XL]_H?
MQ+@_\H8_8V+&:QN7N\Q>9/)"QD>65`_190*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!00N]HW=>9/1%4=U$GLUGE
M<(Q7O0>N?.+=KZ'[D[@#H>FH%!V;[7QQ3>N',L4T:2Q2[&RT;QR`,C!U10&!
MZ$:F@D)08_*XC%9W'W6)S>-L,QBKZ)[>^QF3M(+_`!][;R`K);W=E=1RVUS!
M(IT9'5E8?(H/RSKQW'F?9/<O#7%O$>[=Z^ND/]0!.6<Q[&<6?T_8)]^;<Y)V
M=RUCMR;DX_LO8R\Y&P6TUV3QYO+%R;;N]SV&VY+O'[=LYL;"DK0M,0_2+[#V
M?\QX!YMLU*?]7Q'R/#JS,JZ2[.S*:EE5F`T;Z"@U^XP_)69]9\1@^'MT[<V3
MR=?\4;;LME[LW?MR7=^V<#FVVWCUMK_-;8BR.(ESEC&%(>`7$1/=W?=V]K!$
M'T5XG]CN+>5>;+?V4VONC*9G)Q8N3C;E;$\N8_>/"XX]@L\#%=<>;2XVQF&X
MUL>-,Y%O5,EEF2/:$'FL;J.)LC<-`5H/4$_!T&I^@^-?V4'@UR__`$N^8^1N
M5.4-_P`_(?K?W[OW!OS+8W<&Z]I<DY'D;:D.\.3-I;VVANY,O:[ZLL)9\B\2
M[6VFNVMM9""TBCL<9-*L?:LLL<@=D_U3[K(C*</8O+<%'>/&.9R]S)O+=VU<
MQQ>_+.?RMGM?>(V[L[C?;VY]G\A[JO)-KSSME\I<V^($"8QI!^3&%EBF">_I
M)?YG)^I7K]?;@O-IY#+S\9;;:[NMBG"MM-@MH$MHL-)MRWLMORQVMHL<4KV5
MO;6S7"2%((`?$@6'O!GLYMKUMWOEMN;P79F7CR&SK:VGB_S3%E=SID-XX.PN
MN.]N7VQL-N7>V'W/R-:7#X7'WV(QN0R%G=7R30P.R=`BW_3VW3<9_??)!LMY
M3+LZ]XXX]RVV>)+GG'E3V'OMG75KN?D';.YMQY;>O+6U]L;DV7N',YK!OC,E
MM65&N;"YP_GN(X7G52'JQ0*!0*!0*!0*"C<)+)!/%!.;:>2&5(;@1I*UO*Z,
ML<XBDUCE,3D-VM]K::'I005P_J9S7?\`)7$F^^7_`'*WURYAN(-Z7N_\)L:Z
MX>X2V1BLCN*YV9NS9%O-D,QM#:ECGQ:V.,WC=.L<<Z]T@3N)`.H:-!_3ZW'A
M^=4YOVC[5\C[9N;3>?+FZL)M,\8\#[@L=OX_G;?VW^0N5-KX?<6X>.[_`'A;
MV&XLGMV*UCN_S3?VEA))#',%*]H>E-`H&H_7_P"`^:!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"(OL?8+=\N>E5PR
MJW\N]AL]=*2[*49^`>9+7N558*Y[;@@@@C0Z_(H-O]N9_P`7UIYHN3-;6X@V
M-E)3<7K%+.`(829KMU(9+:(#ND((T4&@D1&W>B.&5@R*W<AU1NX`]R'KJIUZ
M?LH.=!^6??F\-J;+]H-]\L[?LMH8W:]K_4"QG&.\?7*P]X_:;`^SV\^0,]R=
MMG:EWRWMGU]P>^K+B"ZQN<O;^'<D6U)<&]ED=I6[WDMV?,R('Z./8&Y6RX"Y
MMNY"2MIP_P`DW+F/0,5@V7FI6*?(!(3I08/;FW\'R;ZT[.PF:3,28+=7#^T'
MN8\9F<I@,V]O=;3QEY$+?-8+(X?*V%Z'[3Y(+F!NX:%@I(H/)G^D[93S\D9F
M^?D;DR^R&W."<?M+>>R]_9SVNW/D]S;MEWT,M-R3O&/GS"V>PN-M[X^,OC'P
M6V+_`"PDBE=S=/:6]K0>\5!XJ^Z7->Y^#?9;>V7P&<V;>;$ON%^*,MSWLOD#
MCS8FY;>UV3;;_P!Y8C%;DV7%F.5>.MZ<A9G)+/>VUSA["TR\=C^);R1+^3<I
M;3AO_P#4AXXVQG<MP]R%:<Q\O<;\J8Z3-8+C:VXSOMZ;AN;.*_VWN$YW<&/X
MXVMR_P`.7,;OB[IH,EDQ<W3-:+%`\*L(Y(PE+_3Y@>U]+/6^UEL[&PN+7C+#
M6MW:X[(1Y6U6^MWN(;^7\^//[K:>XN;Q))9_+D\A<).[I-<2S*[D._>6-G<=
M;]V9/M?E),<^U,AF=LR*V0RSX%H=Q6.XL9?;1N,5FH+NPOL9N"#<]O:-82VL
M\5T+L1B(]Y`(="\29#UDRWL-RON[@[%[7W3R+NC![?V]SIRCQMN/:.?PHSFQ
M[W,VNW-J<B6N$W/<9+';YM(;^\9)Y,8GG@_ARW#-"L<83#H%`H%`H%`H%!I-
MO@,-FI<K=S07JN^4N87>+*YRW61K1_#WQQO+:K`"R]1$OB)&H+#J0ODV;@$G
M_(\%Z\GA,&DF7RTD7C+1L?X#7IA[RT0);M[C^O4T%U?;=Q-]="_NTN3,D;(2
MF1O[>'QD1=P>&"YBA('@7Y'30_J=0Q=IM#!>2:5;*X6(RI-;3Q9_,S+<*\>I
MD[?S]$'<VG;J5;0'Z"@N9MF;>N)WN);6[,TC(SNN8S4?=XT\:#MCR"*$"_X=
M.W7KIJ=:#[+M#`LNOXUP&CDEN(S_`#7+CMF=)%9B5OE8II(?LU[?T'0:!PV1
M<W5WM7#3WL#6UT]O(L\#RM.T;Q7,\7;YF@MFD!"`@^->A_OH-KH%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(R\]O:Q<B
M>J4MPI,G^N]]!:LJ.Y6>XX:Y57KVZ]JM&K`L>@H*/NMC?YOZE^PV,#O%^9Q5
MNR'R(@D==<=(=50JX8]/TH))8O\`_%F.^?\`V&T^>I_]GC^3UU-!T![?\D;M
MX?\`5?V'Y1V%"\^]]A\.\@;GVB$Q4F=,.X\7MK(7&&O&PD2O)EX["_6.=[95
M8SK&4T/=I0>(_I'[?^FNT_9OD#;_`")[)1^R6YK_``_`L'!GL;S!PT<ES1D=
M^\BVV[-O<J\8X#DO;O"6U,O%LK%;@QN)FL;*\:.+&1YDVZRF`*$#W8]E4D?U
MRY]B@C>2:3A3E2*"*-"SO*^Q,\L:)&H[F9F(``&I)H+OA>(Q>O\`Q/`WY2&/
MAW8D1-H&%XI396*0_C!59Q=+I]F@)[].E!Y`_P!,VTVC8\^8\;>SN+R4F0]6
M+K(P1;,Q6+QNXY;1N7%CNI_<U[#=NY;J_P#96.0P-87-Q#8EX;C,IXQ+%,B!
M[P4'A!S;:^B.%]J=XY[E+V0]K\7R#M7/8/>$.S)N,N0=[;$XLNI-XY""7=&S
M=SYWU_WU9[6V7N/=&6-LUW9Y>+&1_CE89HXX"8@VS^HKL'-;LYJV-<[OX]V-
M=\/P\<X?![=YDW)LC@3<M_QG)>9_<V?YOOL!EN8DR&5NN5\OQ_MO%X79F#M<
M??8V\N\[>7ES"[V:&(/0?T?OLQ>^J/"`W%;[1L<_8[)L,9EL7LFVV?C\)B)K
M!YH+3&RX?C^XNMF8'.6^,6#^9V&-;\.SR!FBB`15%!@??N*P?U@WE)?X7<.:
M:SW+Q?D,2^V]R7>SKG;NX[#D_:%WMK>N4W388+=-[@ML;(ST5OE<M<1XR_9<
M;:3#P."1013]"\-C]A<^[KX?R7'^_MI[]XI]5.&MG9FZW3G<?N';C87$\A\H
MQ8B39FY]O[`V3@N0\9N[R-F#FY-<DIF_#N;.PD@=)0]=J!0*!0*!0*!0:]MZ
MZO;E<N+ZX@N);?.Y2"$V_9V16<=P19P,(Y[@":&#17U*MW@ZJIZ`-AH/C*K*
M58!E8%64C4,I&A!!Z$$4'&**.&-(HD6..-0B(@"JBCH%4#H`*#G0<)/^6_V]
MWV-]OSW=#]NG[:#3>.[C\O9V(N/S)K\2-DBMU/$(9)%7+7R*IC#,`L*J$7J=
M54'ZT&ZT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4$0O9V[FM>1O2Q(0A%[[1"SF[QJ/`>!^;[E^W]'[K5=#0;U[8'3UJ
MYP/_`/+?<X_XXZ4?_+0=[8T:8ZP'Z65J/^$$=!<7%Q!:P37-U-#;6UO$\UQ<
M7$B0P00QJ7DEFED98XHHT!+,Q``&IH/+/%>_O-._N8-X[.XA]9N,]R\6["YQ
MR'".Y.2]X^WO'.P]TF\P&8QF.SVY\7Q,-I;AS-QC)+7(&\Q%O-?V]UF+;PRQ
M*D=Q$Y#T`YOL5R7#'+>/=NU+WC+?MJS=[1]JW&U<M$6[T*NA7OUU!!'S0.(%
M1>%N+U#H\2\7;)4/WJ49!M/&`/Y#W)V,O77J-.M!Y$?TO<LUIRQN?'[MC:[W
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MW?\`L[;F+W0T,5C!%B]RS7\5U,KW%A;H)%C#TWF9TAE>.)IY$BD:.!71&F=4
M)2)7D98T:1AH"Q"C7J=*#R;_`*;WLER]SIRC[:X'DS.YV_QFP-Z8N'9^&S&/
MVPD6#QF5S>]XI;:PS.V3+8Y..QDQ*X\K#/=0!;)95F9IF%!ZTT"@4"@4"@U#
M9_8(]P^."V@7_-FX>X6D-Q#')(;^0RRR"YTDDN97):5U_AO(24^W2@V^@4'%
MV949E0R,%)5`0I<@=%!8A03^V@XPN\D4;R1-!(Z*SPNR.T3$`M&S1LT;%#TU
M!(H/LG_+DTU_<;X^?W3\:]-:#2>-VM&V9AS8SVUS;!\HJ36EK/90%DS&069%
MM[EY)D>&8,CDG1W4L-`0*#>:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*"'_L];RS\F>DICC9X[?VCFN)V!4"*-?7WG6-
M';4@G6:1%T&IZT&T^Y5W)8>J7L)D(@2]AQ/O*_4!0Q_Z+#W%R=%.H8Z1?!Z&
M@D/B9/+B\;+U_B8^SDZC0_?;QMU`Z`]:"VW%MW`[NP&:VKNG#X[<.VMQXN^P
MF?P68M(,ABLSA\I;26>1QF2L;E)+>\L;ZTF>.6)U9'1B""#0?D_Y2X0Y*P'M
M?=;:X2])N!]C-PQ[$[=O]C8+!>I'"4:<G[.SO*7'&V.)[*/?V:CNL]#LK;?$
MNWMX[VS>\[$XVYP.>EQ6*A,CVXMY@_4+SC-^/PES!<#5O!Q7R!,!\EO%M++N
M/G74GMH(_)N7E';GH#M3<_#.'AS/*5AZT<?7^T,;_+&S6F3.Q,`TUW98".6V
M.?O\38O-=6F.[XQD+B&.V[E$NH")WI;;<7#VNWAF?6_C[+9'BW.\)6L?*?)>
MZN"=]<03[/Y9P^[[$66SMB7F_</MR6XQ7(?\PR^:S6W<18IB\#=X^VE5E-VL
M0#V&H/SH_P!7_#;P'L%QAN?:N7XBQ>3LMA;9L=OV>9Q'$5QO#-9*;?>X(Y6W
MKNCD3%WU]L;CS#;@N,&\%]YK.R\4^5,4DE_%;PL'?/\`47W0=K<B[-._]\[P
MXXV1N_8>UL#LBZV%@<COJ[WYS5-GL]CL-Q;(,'RMQME]G9O="YN),'?7H@P&
M3F\PN;ZWFM85(>EOJ9A]R;?];^'<-O&.RBW1C]EXZ#.18_<%MNNVBO\`65Y8
M?\R6>3S5EFKB$.$GN(;R[A>=7[)I5T=@[=WY%E)]C[SAP=S:66;FVIN*+#WE
M_BY<Y8VF4DQ%XF/N;W"P074^8M(+LH\EJD4CW"`QA6+:$/$3^D=A=X[1YD]@
M-J;CSLV02+C_`(WSEU9;@VE=;"W",AE\IN"1+C#[5N^#>&KF#;./G2]QSW#_
M`)\4[VD#P+;!I48/=3,WT^+Q&4R5MCKO,7./QU[>VV)L/'^=E+BUMI9X<=9F
M9XX1=7LB"*,NRIWL-2!UH/,[T*L=[+R=SGN'=7'N_MHVF[<9M+*XC([VVQ=;
M<OY[>3<6_P#+2X?<$ESMG;?\YW1C,AN*YCAND4]V"BL/+%!(?X@>H=`H%`H%
M`H-4P4%HXOGQ&2O#!#N?-R9&.>W`$MX9Y4O;%#<P)(+6WNVUCDCZ,%&C,OR&
MUT"@4"@X2:^-]#H>QM"06`.AZE1U.GZ4&F\>6UI:;4L(+"\-]:+<Y8PS&:RN
M64OE[^2>)I[!Y+=WBN&=3U[ET[6`8,*#=:!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"-'/UI%<;W]5IY//WV?L*LT7C*
MB$-)PUS!`?R22"5*R$(!KJ^GZ4&3]M+$9/U?]@[!E1Q<\.\AQE9$CD0C_*^2
M;[DE5HVT[?@C2@[RPH[</B1^F,L!_P`+6(4&2H/R0\C\8;-Y(]Z.?HK;VH]*
MMF/EO8M-G[TW1RKRW?;&]Q-F[AVK[#\4<Q[8P>SN-[IC+N3([3BVBFV-BW\>
M7ML;)A<OWFT[A/;SA^I'FF`W?#?+-M\&YXRWW!H5+Z&;:N5CZHI#/^]\`@F@
MZ"&=W[L/T,VWN3C,;<&_-H>MNQ<O@/\`-V1Q&%VPES@]BX.ZNFS>5W#D<3@\
M5CTL+:8O<7EU!;P@=TDBJ":"/?IW[,<X<U\[;FPNZ]R;3OMM)M;D3<>\^,HK
MSB.?/\$Y*WY67`<*[<Q>4X\WONC-;P3>O&4$^4SES?+/;65Z($AN8WE:T0/4
MZ@_/K_5+L<W=^P]AA]K<;\S;FCY.X'AXWY`AXEW;RE')RG@QDN1\YM;C;);=
MXQQV2L=N`;A@>Q_G.>$4,T>XRD3&WM[V@]$^7./?4_CK:/#\_LMQMM'E#!V5
MNFPY>7_8':^`Y5S6S;%,?D=QV+[TWKFMKY5K3%SY>V$'Y4K6=A!.Z.SIH-0E
M%PA?['R/%>S9^-L)LK;6Q(\6;7:N!XZR>T\OLG&82TN9X,=#MN^V-++M23%R
MVJ++$MF?'&LG:0&!%!MN^'R4>RMWR8:P&4R\>U]P/BL8;ZYQ8R.27$W;6-@<
MG9%;S'"\N@L?GB(EA[N]?N`H/(;^EE>X#<.ZN0=T7N;W#E^3KSC78=KNS$;P
MQV>R&:X^1LCEKN_V+B]\[E]BN=+_`#F"QFY9+M2L4.+BFFB$[F61NV(/:!B0
MK$#N(4D+KIJ0.@UT.FIH/-WTDRO+F8Y)YORW(O*VU-[87-S0Y#:FTML<S87E
MF3:=L-Z[]C%UFHL*GX.W[R3&FUQ:_AK9V4JXGQFT6YAN)I0](Z!0*!0*!0:O
MM9KUXLXU]<Q74@W/GD@,0E"PV4=\ZV5JPEA@/E@MPJL0&4MJ0S#0T&T4"@4"
M@XL-58'70J0=-=>H^FG76@U/9*P)@U6"/)PZ7V4$L.7L[&POHY1DKKN5[;'(
MEFL?76,KJSQ]K/\`>6H-NH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H(G>S^2./W3ZB(%9CDO:W;F,/:8QVK-Q#S/.S-Y
M(Y.Y`+;X7M;4C1A0;[[/$+ZX<\$D`?Z0\AZDZ``?Y5R@.I/0"@[EQ0TQ>-'Z
M6%F.G[+>/].E!TK[3WG(6.]8_8K(<2?SO_56QX,Y8O.-/\M6GY^XQOZVV'GI
MMGG`6/AN?S,T-P);_BQ>.0R3]J]K:Z$/*/@#VTVSN'FK>?\`J]ZP\_WVT<[M
M_P!;\=Q7NS-_T^>4K#+#DZ^PN;M^;LON[=K<5QY:WMHMX_RJY;(Y22*VM^Z2
M2*3QJ[@/9ODXK'QIR$3T1-B[L)^3HJX#(:_M/04$3]Z+9;J_ISR$[&R/*EEF
M?5?;UU'L;%SWV,RFZ1)QYC+NWM;.3'6.6R=O<I*JSA+>UO+@^,K'!.Y6)P\Z
M?Z7&2CW%S_G,DF:RG*N+V_L_V"Q&U]RZY*P?@I-Q>P&)W#O#9&^K&/B?CK"9
M'-\X[D`W)A':>[O[#$XUK=XHU8RR!^@"@\#>3M];8W-[VYO(>QW&^\9MD8V_
MWQQ1CYMD<)^UF*W+M;;7'3[5W)Q-N_)<M<3WYVOR!A>1=S[GS[PV+6;PXY.S
M256%PC!MW]4/E??Z;]XUX3CP&1_T6S.(V%G-PY%O7_G_`)PQ>=;=^],YL[=>
M0S-GQ%D;#;MYAN&=EV(S=QMS<<=[;;BNK^UA>#Q1N]!.O^G]MO`V?K5L3?%C
MQ9MWB3<_)>)L<YOG;NU..\AP_A+_`#.`@_R7C-PVW$U]':KQ^V<VUMVRN#CU
MMX7B211)WLO>0D9S)#NZZXPWI8;%V?BM^[ERF#NL/9[2S.]+GCO'YFWRZC&Y
M."3>EG@=S76`ECQEU-)%/'93-Y$4#M)[E#R?_IK<"WOK][#<X[+W'Q9<\<[H
MM^).-+AH-L;PVUOSCF'$W>:SL,=O?;EV]PWQ&S[]S5QC/YD]G,M^EM!/+)"8
M1.ZN'M-=2^"VN)_M_@P32_?WA/X<;/\`>8DDD"].O:K-I\`GI0>2G]->.]S/
M(/L?OR!,?:[4W/F,6=NVUC!O7"W%^QSN[\MDL[E=K[ZV5LW,V1:ZS!L<?>/;
M6,EYC+.`-91K$EQ<AZY4"@4"@4"@P.`,1BRAAO4O@<]F`[I`UO\`C2K>.DED
MP;_FO:,O89!T<C6@SU`!!Z@ZC]1UH%!;VL=Q%`B75PMU.NO?.L(@$@U/:?$K
M,J'M^=#\T%9B0K%1JP4D#374@=!ITUU-!J>RY<E+B9VR\EO)D/YMEQ,;6598
M%09&Y%M$&2291+%:A%D4,>V0$:`C0!MU`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!#KVN5I-X>EZHK-V>WNVII.T$]D2
M<+\XCO?3]U#(RKJ?J0*#;?="*:?U"]HH;92\\OK]R_'"BE06D?86>5%U?[!J
M3\GI0=][6!&V=N`Z:C!8@'3H-1C[?X'T%!G:!06.4QMCF<;D</D[=+O&Y:QN
M\;D+20NJ75C?6\EK=V[M&R.$FMY64E2#H>A%!C]K;8P>RML[>V=MC'QXG;>U
M,)B]N;?Q<+RR0XW"86R@QV+Q\+SO+,\5G8VR1J79F*J-23UH,Z%`)(&A8ZG]
MIT`UT^-=`*#[0*!0*!0*!0*!0*!0*!0*"UNK*UO;6XLKB+NMKI'2>-'DA+K(
M27_B0-'*C,3KW*P;7ZT&.O=N8?(&%KRU>8P+$L?_`%EZ@"PH\<8817*"3[)"
M#W:]WUUT%!9MLW;;6\%K_+V2WMO!X(HK[(PK&+:".W@5?#=H>Q(85':>ATU(
M)ZT'(;/VZ$2/^7=RH9"G?>7[LIE_YA#O=,_W?V]*#C%L[;D#%H<<8RRE6[;R
M_`92J*0X_*T?[4'SK_VF@X'96VC%!";"3Q6Q4P*,CE%[.UI''5;T,P#2M\D_
M0?`&@9C$X?&8*QAQF'LH,?86_?X;6W7LBC,CM+*P&I)>65V=F)+,S$DDDT&2
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH(M^R&-:\W1ZLWG<H3%^S&V[KM.O<[2\;<J60"Z#Y47>O4Z:`_72@W;V9CCF
M]<>?HID\D;\+<HAT.NC#_)&;Z'0@Z$T':6V`5VUMX'Y&#Q(/]HL+<4&<H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(Q>R%]%8YGUC\KJGYGLYL^QC
M[_AY;C87)G8B_<OWGL.GS_90;'[47L>-]8_8G(R@M#8<&\KWLRJ=&,-KL3.S
MS!>A^XQQG3I\T':>R<A%EMF;1RD"LD&2VQ@,A"C_`+Z17F*M+B-6Z#[E20`]
M!UH-GH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(:>WAG&=].A`9!K
M[D\=^;QLRZP?Z><L]XD[2.Z(]-0>AZ4';WLMCXLMZZ<]8NXZV^2X:Y-L9QKI
MK!=;+S4$RZ]C_O1N1\'^R@WGC=!'QWL*-1HJ;+VLBC]`N#L5`^!\`4&Z4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'SN7_O#YT^1\_I_;0?:!KI\]
M*#X2!U)`'[>E!]!!^#K_`&4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4'P$'X/P2/\`@=#_`-HH/M`H%`H%`H(H^T5ND^6]66:W:;\;VLV!<(X0
M.+5QLSD>(3L2"8P1*8PPT.K@?6@D;N[;6/WGM7<NS\L9QBMU8#+[;RAM9C;W
M/\MSEA<8R^_&N%#-!<_BW+^-P#V/H=#I01[Q_K+?XNQP^-L?8_V5BL\/:6]C
M'$=[;/D\]K:VZVMO%.[\>,Q\4:#[D\;$J-2=3J%/(^K]]DI!(_LU[4V9'=]N
M.Y)V]8QGO3L.L<.Q@AT'4=.AZB@UIO3J]9V<>W/N<A9BW:O+VW^Q=3KHJGCY
ME"CZ"@N7]0\@UO!"GMI[BPO#^]=)RKME[BXZ$:3_`)''D\'UU^R-.HH,A:>J
M=_:O&[^TOMK>B.&&)DN^3MME)6B+EII!;[!MV\T_>._M*K]HT`ZZAD+GU=-U
M<-<-[%>TL)8*/%;<M+!;CM[="L,>W0@)[>OZZG6@PEYZAF[D$@]H?<"T(5%"
M6?-*Q1_8@0$HVV)%9F`U).I)Z_-!:?[.Y_\`#[8>Y:__`-9L<_\`]\V6]!L&
M+]67QDRRO[(^U>458PG@RG+4$T+-W.QF86^V+61I&[]/WNP!1HHZZAG)?7/R
MA`.=_8^()+'*/%R?VEC&W<%=FP;L\3']Y2>UAT(TH,==^L7YCR.WL+[00&3N
MU6TY9_&1"VG6-(L`%3MTZ:#2@U6X].$N)6E'M+[E0%M!V6_.DZ1#37]V)MNN
MBDZ_I09-?4I%:)A[+>VY\7RK<U3,LN@B&LH;`'N_Y>O33]YOV:!D[;U>%N\C
M-[#^TET)%@4)<\NN4B:#4]\8AP4+=TQ/WABRMI\`:T%K>^J-K?.[O[#^UT#/
MKJ++G#,6:*2#U2.WQZ1IIKT`&E!KO^RW'?3V<]T%/Z_[C=T-_P!CVK+_`-E!
MRC],;6*2.0>T/N<X1T?Q2>P>9>-^Q@W9(#BNXH^FA`()'UH-YM?6?'6J*AYK
M]E;HJO;WW7-FZ)')[F;N8H8P6(;3XTT`H/LGK/CI"Y'-7LI'WO%)_#YMW2`I
MB.H5`68*C_XU^&^M!:?[7[(&0KSM[/KY%*G_`.O;N!@H[776,20.(V'?\C0Z
M@'Z"@P\_J+CIT[#[#>V\8)))@]@-TPN>@_QI$'4`C70$4%H?3O'DC_[)'W"&
MBA=![";FT(`T!.ML26_4_)^M!F<9ZJ6.-F65N?\`VIR2J[.8,GSGN&XA8,`.
MQA';P2=BZ:C1@=?K07]SZOX:ZA:!N9_9J%6\NKVW/F_+>8>9"C=LT=^)5[0?
MLT/V'J-#UH-5_P!F6V?\//?N"OU__P`H^5V_]/-N*"XM?3S!6CEX^?O;R34*
M"EU[*\CW:?:ZOJ%N<C+VD]NAT^02*#8['U@PUDI'^LWLO>:ZZ-?\\;XN675N
M[4:WJC4?`_907_\`MPQ?4#E[V)`.OQS5N\_/_G7+4&LW7J)M6[3QR<Q^T<:B
M)8@;;V+Y,M7[49V4]]OF8W,FKG5R2YZ:DZ"@Q`]*]HK^[SG[>C3X_P#LI>7C
MI_\`/;A.O]]!E[#U$VQ8!1_K1[4W@4,-,A[(\H7?<&.NK=^;!++\`_(%!GY/
M6+:LULMM-R5[$2HH&LA]@N58YV*ZZ,TT.Y8G[AK]-*#5I_3+CVX<2-RA[21D
M(J!;;VGYVM8^U=>W^';[XB0L-?D@D]-3TH.,/IEL."1)(^6?:S1&#>*3VJYT
MFA<#7['2;>LFJ'7J->N@H-AMO5795N\+?ZA>P\XB;N*7'L7S-(LWV%"MQ_[Y
M@R+U[OIHPU_909G_`&V;)'[N\.<E_8/8'F4_^EO5C0:KE?3SC+,(Z76]?8J$
M22F9FL/9SGK'2"0N7U62SW_"Z+J?W00NG332@P7^QSBH#1>1?:5/VK[:^Q.O
MT_[W(S#Z4%U:>E7&EF)!'R/[/R^1&3_J_:CGJ\[`01W1?E;\E$;KKT8=0:#8
M[?U/X\MD1$WGSW($[^L_L-S'.S]_=KY&EWDQ?3NZ:_&@T^*#$7WICQ+D9/+=
M;H]@#)W*W=![,<]V8!6-8ET2SY"@C`$:@::?/7Y)-!AQZ*\-+^YN_P!E(_\`
MS/;#V/'_`,?)AH,[8>FW$^/MS;Q[F]@+C73^/?>S?L!>7/1U?03S<C,X&JZ?
M^:2/@T&Q2>KG&DL;Q/F^9C'(-'4>P?."ZC^U-_JP_N-!JE_Z3<(Y.02WF1YU
M9@(PH@]H/8^S11%&(8]$LN4K==5C4#XZ_)U/6@MSZ.\']J(,OS\JQ@J@7VH]
ME%T!3Q_<1RIK)]@_Q=W7K\]:"@/1CA13JFX_8V,:ZA4]L_9H*#KK\'E8T&8;
MTTXA*,B[@Y]C#0B#6/V?]B`RJ'#ET8\F,5E;31F^2I(-!D;OU#X=O[<VM[=<
MQ7$!MA:,K^Q?L`K/']6:6+DN.7S,/EPP8_K0:<?0?UV'1!SA%_\`4O:CV=7X
M^/\`^+IZ4'T^A7K_`*?;=\]Q_MC]K?9U3_\`W<-!LF-]->%,6+<03<P3BV0Q
MH,C[#\]Y0."H4FX_F'(]S^2^@_>?N.IUUUH,TWJGQ"RLH7DE`RLI\?-?,:'1
ME*G0KOH$'0_(ZB@U^\]+.";^R&/NH>59+194F$:>P//%N_E1F=9//;\CQ7!(
M=R=.[M.O44&%7T,]=5U[+;F%"=22GLK[&J23\DZ<I_)-!S'HCZ_*C1H>:HU9
MPY[/9OV.5M0O;T?_`%3[PNGTUTUH,_8^F_">.CM8K>3EUELP1%^1[#\^7;OW
M*ZDSR7/)$KW!TD^7+:$`_04%Q>^GG!F297OK'DFX98C`&;GCG:/^$Q5G4B'D
M>,,7=`Q)ZZCYH,%)Z+>MTLCS28#DEII':1Y![#>Q*,TC'N9M$Y55`2?H`!^R
M@R$/I7Z_01K''B.2.U)GG!;G[GYW[GD25D9WY-9FA[D&B'[574``$@AFH_4K
M@Z.V-H,-O9[<Q-`R3<S<T3EXW+E@\LW(+RR,W>02S$Z:#72@M1Z><`KV]NV]
MWIVH8U[.8N:$TC8("H[>01T/8/\`A08"[]%?6>^[_P`K:.]9/(X=].<>>(M7
M!!!_A<F1Z:$?2@M(_0?U?B8/'M'?BL.HTY\]@BNO7Y0\I%&^?J#09C%>DWKI
MAI3+9;7WD^K,YCR/-'-N9B[F#`]L>7Y$OD5?O)"@=H.F@Z#0+FZ],/76^M9[
M.^V;G[VVN4DBEBN>4>6)=8I2&>)7.^.]$9AKH"-/I0:RG]/WU,C(:+C3+1L-
M=#'RKS$G[RE3KV\@#4:&@R6-]%O6+$$''["S<.G<0).5.7[H:NI1CI=[]G'5
M3_=\CK0;CMCU2X%VAN7#[OPNQG_G^W[N'(8.\RVZ][;BAQ.1@L[RPBR5ACMQ
5[DRV-M\E':9">,7"PB8+(=&H/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g335938exhibitd.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g335938exhibitd.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!SP*!`P$1``(1`0,1`?_$`(```0`"`@,!`0$!````
M```````'"`8)!`4*`P(!"P$!`````````````````````!```04``00!!`("
M`0,#`@`/!`$"`P4&!P`1$@@3(105"2(6,2-!,B0743,*0B5AT5*2&(&A-)'2
M0U-$5#81`0````````````````````#_V@`,`P$``A$#$0`_`/?QT#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=!'07$'$U9OK#E:MX
MOX[K^4;850;7DD'%9L3?683HHX%#L-A!6QZ$T188F,^.4AS/%J)V[(G02+T#
MH'0.@=`Z!T#H'0.@=`Z#%LAA\5Q]4R4."Q^6Q%'+965S+2Y#/U.:J9;>Y*D/
MM[62NIA`@WV5J=*Z8F=6++/*Y7O<YRJO093T#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#
MH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T
M#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!
MT#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z
M!T#H'0.@=!B5QNLEGA;DV\O`:L+/1.GO"S)4A'JQVQ_*I!DB_2&%6?5'+]%Z
M"#0?=#U=L*0?0P\T8J.K,690Y2;)H\Q4,5D74H5"+(U"'"3G@RLCD5J-?X]T
M7LJ=!E[_`&2X-@6@89R5F:^;4/A91#V!K1"+!2$G6!T,,J-?\<OV[O%R]FJJ
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M.W#=PV%]1R7C;1A!0H4;JZ]!-3[HX!]F%`Y!Y9%9*4#&LD;51%<B?3H/JSFW
MB9Z^/]]SK)%/6K;#(8D1#SDBDG^",:1K9WN6*)SD5&JU4:OUZ#G0\N<:$$$B
M0[6AD(#,BKRHVEHJP&S/^.(61WCXMF>_Z>/?OT&>P%0$P(3"]'0JLJ>?^$18
M7OCD[]_^&O8O0?'\D"L$9+28GPR^/QO8[S1Z/D^)JM1O=?%9/IW_`,=^@^,-
MU6SB3FQ$M<,.1*+-+XO1&SPR?%)'V5J*JM>O;Z=`6ZJFDH&X\=A*R-A;$^1&
M*Z9R.5(F*[LUTO9B_P`47OT'\*NZH,O[`DV"(W[.6P05SE^90H'LCF)1B(JK
M%&^1J*O_``J]!V;'L>G=CFN3LB_1>_9')W3NG^4[IT'S2>%T[ADD:L[(VROC
M3_J;&]5:UR_\(BJG0?UDT4CY8V/1SX7(V5J=_P"#G)W1%^G;NJ=!P_RU;\)9
M"F0)``YS3)5=V8.YJ=W)(JI]%1.@^<=Y3RS-'CL@W3OCCE9%\[$>Z*5>T3VM
M5456R+_A?^>@_<]Q6"SM&(-@AE?`XIK9'^*.@:J(Z1'K_!6IW_\`7H/TEM6.
MD)B:>(LH<4,Y4:3,62"$A%=#+*Q%\FQRHG=KO\+T'$ETE#!.\6:W!B(8&T]T
M,A#&/^S?]&SM1RIYL=_QV[K_`/@Z#^_V.B^2"+\H'\A(+;*!JRHGR@N5$:2U
M5^GQN5>R?\]_^.@XH>OS-A8$505T"38BNA80)'(JRPN(B)GA:_NU&HLD04KD
M^O\`AB]!W:&".5B-)@<LOC\:-E8Y7H]WBQ6HBJJHYWT1?^5Z#[H]BJB(YJJJ
M>2(CD[JW_P!43O\`5.@^`Q@IB3*+/'.@Y$@L_P`;O+XB(D:LD+__`,F1B/3N
MG_X>@ZZ?1T0TI$)%H'#*)X?<LDE1KH?D<C(_/NGT\WJB)_ZKT'&379EP<E@E
MY7*#$*0=(3]PWXF""1_,3.YR_P"(X8OY._\`1.@QK*<P<7[IQ+,=NLUI%"'4
MHW\3:#%H&/XL<V0GP?WA:]LB*WR[>2?XZ#[%<K\=!O<R?74R+'Y?-X$I(D'9
MJN3YUC1R1>?;LWOV\G*B)_GH,QK[0.T;)(%(Z6./XO\`8L;V,>DT39HW1N<B
M>;7,<GU3H.CO]SE\Q!*1>6L`#(BHP_"7R6:4F5B2-B@A:CI)G?$ODOBGT:BK
MT'2VG+O&U-4#W]EL:4:E*'>2-9O+8H<T4<JPRK',WNU70R(J/;_EO9>_^.@A
M>3WD]3V`4UFG.&(E`T$*S5)4%@Z>(KQD=$^)JQQ.\"(Y&JCF.[.1?\IT&4`^
MV/KK8C,,%Y9RCQ9+9E&A#BY(X6VDL:RQBR220M;$LC$7LYW9BJG;OT'?X+V(
MX3Y/T!F5P/(V>U&A`$4\RJK)IY"8`ONBPT)?YP1Q_$X@&5J*COKX]T^BHO09
MG9<CX2EK#[JXU=)45%4^Q996EH;'7@`NJ873V*$EEK#!$@L3%555W9?^.Z]!
M],UR#BMAGL_K,SI*NYSNK&A,SEJ)/W'N12._PD`I(UDLL4G;Z+X]N@^D6ZR4
MM^9E%OJV#3@5[;<V@(*ABMA:J291X+(@)7_+"&3*U4B>Y$23LO;OVZ",8_:'
MU_?R7_X;=RGEX.4/E$@3%%$SBW3IK!'NKXHXYQXX9)#F1.6)K7JKT:O;_"]!
M,<EZ#%-+!(LS'PE1BRJZ-$9$LC/D;/(Y7?ZQ.W_]1W9O?Z=!PA]?0%"PG1'1
MH#/&5(PR3M"/_P!F6X*5CGRN:J/4EBM:G;^?;Z=!^1]A0E1QSQ%K]M),\?[I
MT4C1HR(VR.?!-*J>,4K6Q=U1?_5/_7H/J%K,Y8V'XNON`C3D[HZ`69LSF*D"
MDHCU9W1OE`U7)_ZHG09%T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@H-[=T9.CQ7*&*P\C4Y`UV-M"(JV00EK3*L-BLL
M[,PQ[):]T57!&Z2")R>4JM\>WU[J'G2U&2-(O`*J@.@U9E-2AU@=Y<5(68;S
M(PBSADM[2^!=7RIEJ.IAC?#6J,V)2(Q4>K$>]SG!:[6BMT>H`I;(_.$%`4&3
ML**74QD-/'"<3`#85%-8LK"2+!:^M&E>L7C%Y1NBE:]'Q_4(^'RT3R7RU-%G
M:*(^"S?552R$OL%9GY5:)<6H,4;JW+F3BM5S%I6H6K/Y/>UW\>@G?#QY^BQS
M)KB\K#:^WM[+[FCOZ<70D17]M"*H]^#>6(!-LF>E9_O5390RV-C1C('>*(@<
MKAVKBM+/D<\BZXVFDPM2;GV7S,WFCZ30R7=M6S`5!1,J1:`]C_@4@=D44,,D
MSE;,SRB[J&!XS807/)MG3F<0WV%B`-/H#K`T'.W&/UU@4+(P"_JK[*6LK*/7
M1G_'.-9D@,L:Z"-R.EF:BQ.#779U:G!\D%ODQM;K[+:1*%B=1E(JL^PB(LI1
MM5HK4>SAU=-1Z8:R8^5I@%A6EV<+DF=/$CUAZ#8/P?Q;Z_1\E23<G9:U=C9<
MSG<\7H>)K!^0@CW!`@Q(/)9%GQL1E+%X6>F%D`99)%"X<ES6_#,JNF>$Q<A9
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MHO01-6SZ2]%O5T!6?BUKBQ;$+/,,&L`<]5#2N_":$%RBL9.3<0HL\BI$[NDB
M-14\>_09IHZ1=&93G0V$U;JZP4-TS:XR,$ZU@BGB-E!B=,G@75&_!YS1_$YO
MCV1W;MT&3V9(.5-FO[-QL`A<H_E]L]%BD-*:@4(<PR=DF<SY/))%5K&=N_0:
M;/:3W0WH^7Y(J<_8[GB$;+<J4^)R>Z*J1KHO=W5J:P>LJ\D95*]+?'V22/<^
MP1JO&5JQHURM[]!SYN3/=3BZITMUGN6L+RG5T-A49H#/F5T(FBOM-=A!'$TE
M;+;2`0(52MD?*I1,GC*SY$5J*B=@S[!?L!WI=)9'[/B.OUN8<VW$LKC&N4:$
M4VI@2.S$/:6S[>V)KY_)Q:AK*V*)BJU7+V3H.RQO[+>$+IE8'L.*=1GX[S./
M)SQ==1EVDUC54@7W5D0EA(,"0!`-&BN%CDE0R1O9?C:J]!8;">UWK%RU!7WN
M7Y5"I!H*<*6&HV-=9U$*U\E6D8PU@'HE:&0D'W,:N=`K9%<G@][E^G03-G1,
MK8'`S4>]Q5_8WGVYMBR&8-9#JH)'.E2J:$>VVE%\_C[0S$3B0HU?&-.Z]@[4
M[CTH<0&1M%6%F9^<A:8X4LTRQAE.>O>V@@O)SAW3A>7=L,[IOHG:-\?T[!Q;
MD"TSKZTFSKELG#5I4UK?M4N8*:4.=TXDJT(,T08QWS%*]KV!%/3M]>_UZ#@9
M^IN?[*7H9;:SN@+YP<P@ITGG75%B#4'?DE,!$LP`PH[D.P9'\:B$/?(QKWL8
MYO08[#(<I)%[)325%+6AD!3!#L>I<`<,JD1RRE0Z"5\GP%-1XT`[1E1O^9&I
M].@[YEHPNPGO9;.<2CLQ6>+8E05U1600-6`%TE0=9&P6D)G?Y8AD:WP5/D5W
M^.@[T+3OQP\]AI'S5(9<=:]]I/.RYK)B#IG0CRR(&)52#GV*/B1O>)>[&IY+
MY=UZ!?\`)$63I+[3[:DD,I:&F9>3PTU*TNTF&&<Z<@J(.<Y5DG%';\KAT<YZ
M,17-<Y?XJ$$<,>YW`?L&5?@<<Y?:78-?1U6AL#)\0:`).#>2+7Q2C0VL8,LH
MK_'LO\4<K>ZNC:G0<B?CSUOQ^D3;C<;SYRVUFH;D[$BK5U6RS,IH6D`3)6"D
M#C65"/'WD^1J-5K?+^#O\=!/!9F+"KC2@:#--AG%$./NP*<.R`>V4M@L*JV*
M#YIRHI%:YK7I].RJO;MT'[DU]G:(-)3D"25-4<R"X0&6,=QE6Q$CDLJHF1$8
M[[$EO@Z)$\7JGBB]!%&W858R_)29N2\L1CXI+BS.E-BL)8_G9(++G399FCB%
MUT,Z,F1B,^2-5C<JM3H*K>S62P^CQ][EZXHC)VD%X#9QTDE1/6P&V1L408).
M4IZR:$1H16AG:E@/XI]ZCG*BHG=W0:?>0_6?DOC/,0:7182804<M^F+T/%Y"
M67']6,`]7'VE:#2+]P)<AK_.TKBW32GN[_&=$J=!WV%DW)(MY:7NRA@R=)2Y
MO#74[\W+=5]WH]$^>WHZRXHR#I&2*:PY7-E9$YX;I41K5:SH+N_KBM=<1RYO
MZ0VNL3/P^2,"M"\[>6=W4!2AV\<`69FFN9Y@H=16`L8V62,B9BCSLB0<;XT5
M0V8\C5G'/(F'VV,Y:S0.YQABC@:_/W;89L^77-M`_P`>EG0Z^QBC4:H-2-\A
M4+X465B?"_OVZ#%^/,\E%RC:<FV6]VFK&L<@+QACZUM8+/AL]%F'2?,;DFK7
MD7U;<V<O\3YSR;&$E8T^/P3NBACW_P"C_P`?`MY&.7;:VVU^QWF(Y"N.0-!8
M9J'1#$Y][;'+XJTFIZ2BT#\#`3$^(<*2*5[G3/2)>W?L'04V3Y13V,Y'`VY%
MCL,AI[;*\J<$:I]2':4'&!E$,]^KQ5K_`&Q++\4VS+5LHYPD(AL<*.BC5GDK
MT"Q!$6>K7D`G#,GFT,ZG;2625QS3ZR./[@^06Z*JR)3`J5R]HX?NF>,;46-5
M_P`=!^SN.2)JB[80T>[^U!$ES-M5UX9ER;1$3(7*"U;B:PKR6QJQCHOAA'5G
M^6/1R]^@^+-(-G<];V%E9!TU=7#A*=:6HAHU)6#N<L*BVT"H4:=:D3N;Y11J
M^1/JBRJQ?%`Z;UVO^+N0+W1:GCO0LMW4$A.:L!X1B!6B20S.:YC8HQ1ZIE>2
M]/F@:SO.U/\`J7MW3H+=]`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H-4/[*N0+[*T%'C\3?7&?O]>4A%I-`++'"=2#21
MJ8`/>QL?(`A+%<QS$[HOUZ#4Q1YQ*GV`(KK2>*VJ,H<7<63RK`C00A1&4U<9
M1`A%5T;Y_E(*+5HXI4;8HD\N_03D.9;Z+9LKAG$KGV#_`-GG^X#J6$T4DTR5
M]G4+;FDQ%2R1HL:Q"#_5'R?3LU'=!CL[B9S;%:>O%T-<1IY/PL/VEA775486
MW[91G)#\@<-"1*OQE30%2N8Q5>B.5.W08Z$!]G;SF&E1H<2-7B/LP[9]C7CA
M4D9"&(:-,,.,7GJ>61PP-N5"V8V)OFURN16=!./%E5DY>+=/3U]7*FHY-Y0I
MJN]OZ&M$T%C558E6>=1Z>M&.AS4%Q4`L<]9D2>N\'2H[SE>C6J&1F88!-%QS
M0.2E1+>XNJ.>YMH8L@-FZ""N)B=J=?6MM:#\V2+-_M@:U9")'*C/)6K\G0<C
M_P#1>I-(5#>VO$H>V%J0X#Z8;1%:&D-U2UCU$"DM8XP`PJY\_P`?S1PS??%D
MP^*1PD-_W.#\Y4ZZM_:2'U^)XKL\X4O$UG<VNEJ&2098O*C-:4*:)8BYX>""
M*I+<M<HRQ$2*4Q$D?'(JM0):XG#M2M$M>.G]2GIJC43UPTSX>00]?GZ^M,(B
MN[.*U9!`!:1%P-;(-'-,.,G;Z>:IV"?O4GV$OO9BP=)LTSU:?QXUGXN&(D5\
MEJ>=!\0-_%&%8DBDR/8U%4=CU2)5[>2N^G0;"&MEL6#1,L:H^`6:4>[C:+&2
MPF:-K>\#&M+D:!-#+V<YK_D<GT3Z?YZ#I8YGVA%N.9%8U0U0<.6(:2]HXKH!
MF=Y'1N3XV?:]D7R:]7-[?55Z#A7P]H0+9R!6,3*TR$286Q=!'>0)!YHZP@=7
MQQL5X1,'=%5DCU<B_1O01HM0,VS\[P,%1"*^)AI]536U8Y2PYVMK?!L41A?V
M44*Q-9`U[&M_EW^B]!WI(CKFP5MO!.I52.ZQS=[6CSB7`2Q?&PMB,(8R!6-_
MBGQ/>J/C<JKT$@7=`+LLU-6&$RS`6M04`4Q?&/[N(T98))%D@<Z0>;ZJJ/C=
MY,7_`!T%)B/3/`7,O%-)?'6Q>?XFT=3N,SF/@*C('L<[))!55\3I99(2Z`=[
MEE<DC_F?(Y7*GUZ#E<J>L&,U&"O*)>0;6F9%R9;\DVMV=#7MDFO+N/[""%DK
MHF3#@YY\C6P-8R5O=?%4=W7L$-V'HW:YO"93&<>;D.`;-Y+74]Y?7!900!VB
MV[%1MV;4-@*B[/B(_E(,^)[W=E\4_P`=!DN\]=^0,CZ;!<8Y+,T!]]4B/%TC
M,Z2,?:F9P058;,^BTE]&$3-;G#P?,KGR#2.5W@G;H-5F.I\J)ZXX,PKCK,;?
M3[WF,_'#6$C-W#MLGE:$@>,,R\@*K3(1B83H_-S!PYPWD1MC2>5BN<T+4XKU
M"PM[SP%QNS<\ET%S%13["V@#8E4;7,*9'''<BH)9.*I[*P(E;VE5B5S&Q>*0
M/>Y4:&'\T97E'B/G7'\'<+^RG)]AO+:"L"JGD3TA]&(A,OQM%U#I=1:WHU@'
M`J2*Y]:V*9O\O-%_CT%J:JN_9UQQ'5UGY;*<P'RUYXAMC<Q`PUP=M`:L<1OY
M+X:8M*<@'^;26"N,\_\`7]FYJI)T&21>UOM+D"91=GZBV-Y6!3NG*U6(6=#W
M/:.D)QA%!=5]4`MF:<QWV[1K`B*4-4DEEAE1('!VT7NWQ^T"RCO>!^1L^\TN
M0[5%%45C/F*R!D*O&*LKZJB,'B()):V%1X4=_L=XKW5>RA*''WLIZL\L7Y%/
MD=WG:/<5U.39'9Z1K@&"B03]B[64=T8<<;T,1\2?*Z`A[FJQ\7=%:@2[/I_R
MKP(Z_9\>:NLO1B?LH#KD"H<V>G\WCD`!N%/6UG?9+&/.WNQ0V]G(CG*C>@S\
MH"WFJZJSTMA24RQ#N;>U3DA-I2Y"H7#1#3'DCP2D1Q2/;V<C(_-.Z*WMT&"_
MU,]MI"`-,K+.*LLY8;?/4`E1GW5QJ=Q`K28-1W&%"Q?0=L:*SMV5>RJO0<*;
M/QE+32V$0!1=,#:V8`1PI)QGW4<PP0UY7PHY(ASGHQT<L'DY/%W?_"]!WP6?
MO[%T;:BQ"HPXRXK&.L_%?`*<C4:A,1<*,<^!D<LKG+$[OY.5%3Z)T'0&X6UH
M2;.,.D.TKA:8V2G1)AQ*FW4^=9C*4@:.6+\=+`]RNA?W[+]%\N_09O3YR[L\
MY]L=*\:,R<B<H$T-()2`S@_ADK)'1F23!O!F1&I.WNZ1&([Q^O00AN.)M)%A
M2AA0H9;V2!@!-M++!=G3LJRW%5DR&V9%=^.'E#<L"E-DAD@\4[QK_P!705-P
M_".@L-GF(I]9I,;31Q731:S`@0OREE=01/FL!K6G.M[B$NOF@:Z.?LTB.=SE
M5KHU7OT'08OA"XS/(^^#U&)#J0;PY;VJBJ+.G%DLP[4:(,1(LE?&CP#Z$"-%
M(A08XMXB.[*]KO\`4@<GC+A3:>O_`#+;[6K!L[[/;`TG%5`$M]2YVTMB9Z5Q
M#K>!8[,7-K>$.:D3I"QQB2)6([RD1OET$\7G)IDDF(SECQ-O]ZFCA?0:,V,&
MBM,SEIE(5L`?(-Y22ZLRV""G8DD<XD$@D$S4<]W=.W02;J3K7$TL+UQEX=<K
MKHJ02PR&D(O)UI316D1:C315]2.'5U[YE\'M4<9J-_EY=UZ#I]\RV7C'<\G5
M>!`TG)3<,%+2<6U6OA!)VQE$<Y\0Y9MI61%P%-1BH.3',YK8G*UKFN[O4)`Q
M&UNC`!+'DNHPF;+N,]4V%1CA-,63>"6S:=)I<[H3CFCT++*&;O"SN0_Y6HKN
M[OKT&'55C^.SED./`!/"KK.)LU&E_-*7:L5Y0(HD`D.LJJVN9(J#2RK(Z`CL
MOBK47L@8MQ\?S<%;40HVCQS`[>.YOM,:<L5JW.:HB1B.XX;7UMC-%14%14QC
MO0ATODTASF_&G?L@=KQ]L=1R@3M*3D3&PU5ED]?_`$/0+,%:"8?>Y6_:^6#2
M9G[D4A7FAHYK&3M<CED55[HWLO0<_@[UNXQX&Y`@_I=GK?RM^/=$&@6=VJU)
M-<,][07MIQ?,*20/R\8YW.^9[4_ET%W.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T
M#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T&@;]I1]J_GSC-LYQH%125#YX+#\
M'<'`5K)AG2DQ3RAPR#%-MYGK`UO=7Q2KY.[-3OT%"_7^BN/AUUP4?%G\EQE#
M6T%>W1#$DDL?>6AFB7,[>^%22>])SRO>[Y55R/\`-4:OC&B=!+62A"K@X[D*
M%[(7:P_726]$>?>YN(RQ4F,:HK+V7N9^'N18)IR0Y$^)J1^+?]B-3H,\S]=<
MY?/Z6?:$9R4#49HBN+@G$GK@A*>-KY:RUS=3$B'`1%/5L4=B&BDS2N_V_7H,
M6N\_I&W9![K^!VGLZ+(W%QD6V1#ILW38O.1T@,FTC<U*P:G-B2.0*MC54*B=
M\Y:),J]!8*@965F9QV=S*0A34E.8?IVYB2#/6L+;V#\A?DM.JG.,B:YQ#)18
M6HLDS&]T3Q:WH.;CZMI>_P`>A)`^O!S0S;YC[6&K=)K'Q3I)6AHPQ_S7A+&)
MW^W8BSNE;YRHBIT%F[/D'0U7-'$O'V=M*FVH^;QM)>I5Z\"BJS<.W.N>P^//
ME$RQV%A=UTS7((`Q%C9$C7?YZ#')\H*_D:TV.=T>MI[^$67#&QS6]C?3::D(
ML(+8B]DK9V^=/8H0'\4I$OCX1*G_``YJJ'"J2JC'[7;;#%\6W')>')?&&6!6
MTDI.]JFVL2`7EI29NR6.VT;#"'K$<:V/[4<1[I%5&M5>@E3TLX]X"S.4M3?7
MFQT]0TK2V9!-7J2[F2\6&J61DM.&RS8G]FJ:L_SC2:'R%7MV:]>W07U"8XK)
MGS$QW-49YE'6:4XUB-8R&C*DY*50\L7WI"%I#XL:QKOE5WBWOW3H(?P7,7&^
MS1B8(DJ4V_662"-U1:&$PQ0EOKSH-37D1I+G97V0SHY6S-8K5_X[KVZ#*+$]
MD=#\KSP,^=.7*V>RH;9SZJOL*I5D@'A6?QBC<5&WQDCF\8W(OBO01E6R$DZV
M@5YDB5PQMYM+*I=</G*IRCQX_`&Q<(]X<4!L:J3"Q[DC@8Y&LZ"1,@20*8L(
MXD`-9/<N;-<'RO>.1$?"D\0H$9+NTOY!KO!)6?57-7OT$BU_P.J[$2"XC@@2
M68BM\XE$GKH(INZ,(9)XOFA;.G;R5.SF+VZ#LYW3PSUIT<$=H4R'[.PE%G1C
MHHE\7/E@$\N\O>95[I_EK>@BXGD+!LW&GP-R3'4:FKJA[82QMV0HU]-;R2PL
ML@2C$01S*VR16K"Y?)KFHJIV5.@_-9J,LZQ-KQ=-56IKJ:NFMK2(T:$XD2"1
M_:X*C8_[*5DB,5B1Q=Y%;_QT&7BD5D<@`];9U/YHJJ;81"),8E)-31SNB((@
M&3NR-7)W3N[M_+_/TZ#H#>.,3H-167&HQ5.18!0.;02Q5J/BK!$\99Q33!V-
M`FCF):D\3?KXO[K_`)Z#JLEQ9C\7HKG24X\ANT4XIQ5O81D233`7<P[G#L8&
MDDD@8D,/A%]?!JIW7_GH,,GX/XT;["3^Q1D5G4Z^EK9<T9(X\5:<D:6)%;;D
ML\OE#C^+^'@Y$^1?Y?YZ":[:I8V"ZM@;$:CCEIU6MM*D5YQXT)$S#3+"0215
MAG\Y/+MXHJ>"]U^J=!RL_&0^]+,3;.O:NTHZHD3/3!AM^S?&GP37(Y3.Q:CV
M;F_RA<G@R1%[?7OT%&O9,8Z3VAX%DT3-!#QMCT,VM<E%FYGYPC6M5:EM9L;2
MOC>=:J7&1YAUS6/B=*B/?V[=^@Y?+'$]G!SR)O\`/9,T7+S8Z.NW=EE*>M;<
M7@$D+'QP3,?%&?1FAD-?*\ZO:XET;EC<G9J=!`'*U>)Q[CKGD[=;&ULP2"!C
M^,\YG<H%96`]O*DE&%&IEFD3)QB:R=72-/\`"1JMEF1%\>_0:_N<.>>4]=L\
M7Q=7TFJGK\`'1Q9ZAP4IME?2VMI#)/=K>V4SU%@J#8Y&_82QJZ2&1'=^S&]!
ML/\`7G;>S.*N;>YYKY3(.S5@E?7<88*%1-92QUJ5L:3DVG(JHZWOC0;'NPQ5
M52!U14[>*)T%F]O[//XOX]/W>F-S^@U@M-'*)QM1#(VQ@/4J,.>=]BJ*5'12
M3/25)U[>37)_GZ]!K4T?[`_8F[I+<R*\HLW:07P98X5%2.LJ!N<B5S#LM):1
MM>Z:U-0IBR'=^PBQHG=/+H.YK?;GFFX?1?@.3ME);SA'*<PRMJ3*%]E(YRUS
M88HU4F2M<Q43S1/)53OT$!T/MY[0T5[HZF[YAC/TI)5N]8;5)*^CHK%T[8IH
M*6VF:T/25*"HV1@T:K.R9CE:GAT&Q?\`7URKMN6MC[)Y_<<B%\FY0"7$S9T.
M[&C'(J%,I967\<8LRM(M:NULHODA(C11^S/C[^7=.@MAE1[X#=/'KY:1E`"4
M^&^6#/FPP#V#/*6N2B%B8HPEI$*GB9/*K8Y?_H55Z"4K)E<5<6]IH5R?]2M0
M:K\63(-#);S$0)XS+:H9XO5L4T"I`L7T1OT=_+H(KN+G-.HKPRB+O[&:NLX7
M7`==$%4BT=1*6L[[J;.'R-$N/MX8T;+(U/FD&D\_^EG00WH^6\2'XZ.HO@ZQ
M6S?-0AVEQ8#XHX)&_!<59E2"W[N6P-$=(L$(K7,<2K$;]5Z#JLKNHM%/H0<S
M45XET)0FW'QV!]K666@A'55%,I:*+N?(D`;58>,:UA4$G\/'NG09QG=+07]6
M^J#N<P\LZOATH]>H%H!!D*P<M0`D5KHD)#E/MXRG3RL[JV7P[IV<O09F#G,Z
M4ZN+ALKF*ML(GU&D?FZ=\\%E<2O50K*SG'CEE?7QN5['D?2!SU:USO)>@R`,
M*U%T592V<IU<011&5*E@TUF*+:-#A=)6E#C@0K5.&='XNFB)5LS9>Z(G?H/U
M5/E%&K92JR_T_P"/%LH=.17Y&+./F@L'J/)-)521Q&%&P_"DBJQJRRM<CDZ#
M)JVT@KS46DR6WTJ"-&@&2U#:$L#D;`WYXC;51W21L$)5/%?\?"J?Y[=!FM6%
M+/IX+I:"TIGMKI*^:.5X,HDL?FCXGN='(^6-\2I]/'Z*B_7H)&Z!T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'01)NX'K#8
MSG_9F#U@<UBYUE6#V8<-/),YMF/&`C6RO+^Q56,?Y(KO_P`/0:T=1Q1P<%#J
M;#"96+&07N@$K=A/BY9XOSV?"GC+P\KW7CCZYMF>^Z=&U71L\98I6*J(SMT$
M<\F\=<9T=:7;$5-[>W&;#M_ZIEB[4#+'VEZ953#V=[L8+&>&N,'%188A'P(V
M*&:))8D;Y.[AKGK_`&(X@IJF*0[^Z3GZ:_I\VZUU5)7V;0KZWD2ABP)E94B_
M*Z44J3Y:F9['PF*U/FD^-5Z#.P=UF>3K2>KHM$%8G#'UV2HV%Y^/-:?/FT2-
MJV7L[PH9,_/`6$$YTWA!,HB3)'"D7BO07@Y\K./ZB3"3Q7;H)169+.LU,E9+
M95H!3ZV8O3@9@G*A1'%Z6*O$^2`@B)8!9'*YKDE\NX<?!EU&.0C\K*S)S/V8
MM3QP"\,>^/W^&LQ9C)+:F4&MCMJS06+HU:R4PT>-Q#D_]MW^0R&UY"H=7J>.
MA=!;!_B>6(4)XPS1,.@@N2#2SBHC8@=HYMO:(6#`C&1!16-2$]?)/@=]'J&8
MW/'MC9<?6.`WVIW>KS(=J>;302ZDK,V=7:T$\Y8]/./F1@K:PRF5*K!244XQ
M\4GQ/A*8<G?S"JMGEM5E+ZMLW\DFZG<4U>5HJ/2MQ1%3J2);0\"I;3#6N=DK
M*+78]ZGQO'BG;'-*3$QCOAB5_0;=_7\6FMZ+C7=Z:G6UYEGPTE/;ZK15]?5[
M?\"PJ6:88ME;5AA*CBT^HL:]X^Z=W._ZE":]9;7-O1:&@RMJ/E]M99,\S+36
MP$Y1E98.9,.+:D5;)8X#F`F-:]!_E_VJB->G@Y>X4EP>8]TL[R32T^L_\.[K
M&G4E:=L.48<)!@-M+J:;N0/#'7#D&4]V_0I)(QRM@A:`K4<U%55Z"TOW](0%
M;27ACUHZV:9UR_2)$2/7BQ"OFL@[(5S&/KB0XD7L5$Z19OHJ_3Z=!45;CFW/
M<A:`X;1\&:+AZ_QA1N/JZ.OF_/7%#7G.@K:B(&O-6.Y`?2S,F?823,E61CDC
M[,3PZ"Y''9M7?43/X5\@QE:#<PU1GS>08\#/M@R(8E1!0Q(R1WM9X=G]F=U[
MJO=0S85`+":*:>A*A-=<20&-*D:B1R1CO5987N[H=7.8B>*-1$^O?M].@P'7
MFYWC//\`)%LZ:TM3Q:^UW+Z>NME_LC*^699C5K?D1S:^N@F:_P"/^*M8QKO^
M$Z#33R]S'R#[BFI@.-K7*R:B*V@V'&D4Q8L5+8X.P$KJLQERLS/':W,+Q#'@
M/A='"X]L:/\`XQJU0M=+ZM'/QK3J0O3X[7`NS!V3O;NOC*M+2XST3C+VKN*N
MJ09PM/8_:R-2)LS4\O'P<WOT%BN.;#>8Q`N/MVK+\\JKL]$?-*9"Y;*D(,=`
M)+49L0>*:K&\_J4A#B%'=W:BN5._02;R\/I[+CO6U_'4A@^BS\<)C8CI#1Z\
MI"1X#'_9&CJTMT(0ZJGA$J)X>;/%7*WL&JR7V@Y0XVTQ5?L=^9JJ0*OIQ0PJ
MNKL,Y"$D$KCB[%7WOB;<-^[D8'%\+Q9"&R>+I&JB*H30-[2<F7&?"O;JMS[!
M:VQ&O";322A_UJSK(3?C@EI`[2CFLJJ41_:&4]SU'BD[]Y$_]SH+@\6<[U/+
M-1^>&!JS])66A%$9!EHSC+!(6*]D\$<SIH0HXA27JJJTTN&1$^6-%1>W09Q7
MG7D>AT;ZW37I8H=A$?J*RX@$*I\J*)22-=GJ:T_&"D2?/WC,F=Y$O5[E:DC>
MRMZ"*MIMUP%<NQ_'OUEAG#WU-49!':&W.M$LR&1!TM$2/81-4V0F9J.=-'*'
M`C?-W;MT%<^6?>G5<2BR8L',VEER?;YNPLZ2;DB)H*5Y,#T=*)/2Y<`(?5)3
M+.UI#@6Q.'C1LDKYO/MT&K]*WV2]Q=?>7V0KK.Q%KK_/P\C;"MMQ<#49&]"&
M&FM"Z_*(*,5JR+.*)D%6^6=L,*0>3V+-(G@&R?CK@OB_UBQ-A<:F+179<^CJ
M:C9;J],$I;O5W%V5#,,%(<4KW?BX9U9#-##VD)<[L]7IT&$^X/OKZ_\`JKQ\
M+RWR5RCELQQ9-87^*I=#9U-I9-CU9(:E&9+.4]!(##&T?R0=;&1C&Q/;X_R7
MOT'E@Y6_^1YZ'ZN@M*8K*^PUV;<4).4EO\S+G\Y;UL9%^>1/I*Z:<*8.(^N'
M&@^P9\2LE&G5)VOD;Y=!AM5^[CUYR0?&&7'FYPW'&(P,%PVXRG#PM9K*PP^6
M1*V@W<)@3ZC5OU)L38IB!&Q(3X/6/ZIVZ"PD_P"X3UDHL&9S_$-O]J&/R;38
M+,7&8K,WG-"'R(17PS1TM3@"4@LG+1`2(K3R46!Q*?$K.@O@[>D<S\:2\ITF
M*M!">0*,Z.[K=1HQW:D(RKNAFPW]I4QQ2#?G'5ZOAE''[BQV")&QJ?'YJ&RO
M];T..']CN1B<K,/%)JN%<I:Q!W!)4^X*JZ\HBH6PU-V5+*RTM&W$$L3P8HFM
MKXVL<JO^1.@V:1C6DVAR]L-),'-#6N$-977`KTB:R5_=XCHX0A;(A\**Y[#(
MI.R=_B\5Z"3"LG0[J:G==4%=IJ#\4/+#=V4:1V\)]>=+.*WO"D*)&LCE>BL1
MO9SE_P`HO0=T3Q+QL45,>N,H!K`ARJ38UX$-;8$(YKVR1D&@M')FBF21?D8Y
MRMD7LKD543L%6M'WH?9S%<5@<+9"UXRTN1(./MWYJ2[D!MJN=A8Q1!\K8J3'
MC!21HK8Y(C9[.;LK'0*WNH6VS61SM#9Z.SJ:`.H-NK!)K$@6O%`;8/BC1D1"
MM%1K)W>*=EE<B/?_`,]^@R$M*L`:4HJ$:$:-S'S/^V:Y$<Z1K&/<V.-SG.61
MR?7LJ]!3O74O*(ONQQ1J*Z3>'<0&<6:RAN*VAN*T;$U>EE+%+KK36YM:QMA:
M3311JP8K[SQ$=]$B7S54"ZO9%5%5$[IW[+V^J=_\]E_X[]!_$8QKG.:UJ.>J
M*]R(B*Y43LBN7_E43H/B+#+!&YDQ,A3EED>DDK6-<UKW*K8T2-K6^,:?1/IW
MZ#D=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`
MZ!T#H'00#RVZP"@O;Z`9?MZJG(B1DID@XUFZ<-KBG&>/BV4"O%57-A14EEG3
M^*]!J[YUYZX^X/@RM38C6VF!M0:_7QUP*!R51^7OK+X:@;1$J0CB"PQFQF0P
MO\)O*256?]7?H*Z;;35WM7CN6+#CJ$.\NL#5-UMO6[8>6$@3/OD=7!5F698R
M/CE(480A7@DDP,:BQ*U7J[MT&K&,6NKK$.:26(<TE)*;449))]#?9KY(W5C[
MJQLUC2FGK&5SU?$17%S3L<B(.G?H+)>L]#^1WG'Q$63L=25F(K@(;4TT!P50
M$/J+>Q<^WLP9+L6"X/S(`20Q$P-:LSID?.USI$5`VAZ4[0UV8M:K+W@[C*_>
MUD%:?H*JWHQ*C-.I7F2S9LC.4Y9HA%5)#*28(9]W+*0CU^.2)S>@_M-REHK*
MN77-OLO<DCT\E:DT.7=)17FI$F06M)N:RNBK+P*,^9[?B'="D4R=R7-;\:MZ
M#`]%JC:?DZUTM>EF%+PY:YLODTW,M'MOZO16\?W;>*&8N4ZNS-=?OMYU(&ME
MK6S1+,H_W"P,9V#GXK1\Y;G;6N>M]MFZ^SWTNIM*!EUHDI^0;"&P)I6`YS7U
MU)0W55GA0*Z21J*.-8O2<6!6/5LLS^@V2T_$UW24F?I-26)R#3T503]]4>4]
M;<Z:T*?%+,>8#7TX:`$BP"OC&=`X,8ES6_+'Y2>30L)KLD5IJG/P53H:YE0?
M3V@H1CC1V(@4C7N&)DK2AC4\(41J,;,D;G_^XDC/XJ$6<X^R/&7!M%G=3R'9
MBU\A%K95C7@*)8_9$UT,#[@5SBYJXWPC81"K_@@F)>U4^.%ZN:BA"T_O=ZTE
ME#"P\A"!V-G=TZL`O`]%5M#6R%1X&K'-L1`XQ*-\LC&-84T1SWM=&L:.<B*'
M?[WEBGFPFK3AC0\9<CW$PX@]>!I;D!*12)"4K;JDM'M,BNFC&"RO3[I&%*'W
M[+&_MV4->7'NJY[XOM@<IG?6X*ABPF>@RE,%GCYM53SXB6W5]'29XRX'@M99
M`VV,TSF$0,G)&1LC96-5(F!NPJ21`0ZN`S[0$AN;$;/7I`"$&8;.G:8(=J/D
M*:\0IZMDC1',B^1%7ZKT%?.=.;W\39X@:AR$VKL\>^GM-+`;?_COZZ#=_(RK
M.&L)()9+2.$]\;"(6-:U@ZN57(B=!0GB$;FS<^R@O*U#]\3$F8K1.:..=7JJ
MHD;55>I#;:06U4'+%+'3B!5=@V'\;'YQ1M;X3K\JKT%_<KP3P_Q2VVT6#P-*
M+;`2C&Y;X*L?1AT59=7+&E#9(8,!IU55QD$SN46%ZP#R><C6M3R50L8TZ2UF
MLJ>*TBC*F@G<\4@.84P(0@?X8I86?+&XJ-L[^_DCF+_QW3_/0=6TZ$2ZISC<
MX(D$M(372ZU&#3V-?]K.]_X\DN%)YQZTEJ_*W_<K4D545._UZ#73^U?]C%'^
MM_A3C[0QXG?:V]Y?VO\`X]QECCLX5K0,I8P@_G)[O4#0R*;+7R!Q.CBCC\I)
MI'__`$M:YR!J7Y]_:KQYSW^NW@GW+WWJAR1?CZ@_E2MLKO#".)N>,M;Q0];"
MOCVM#*,XN+";^.K2&<B6,D:K)FA\O)R)T$:\7?N3X_,*X6RNX]3.6R=!R/M\
M[PO?V.C^0EF(XTVUW%GP9.88'0655QV27:3M^V%L!A`KD)6N8SS=X]!SU_:1
MQ/CY3L=QGZR[2QT4_LSSGQ;HN*ZSE>[7:Y6S]?ZH/0#:;"X6LI,;G[2KWV:E
MB,K:UA(P;E4AOW420)#*$Y8#_P"0IQ^3>Y/+C^IG.6K6_P"1N+,)RIR%5;&B
MU/'W&.AYV+J:GCNKM#PT'F+.C!((9=!!5KF4I<#8YY9%E290P7V6_=-@LKS1
M><75G`U_8?U#V7C]7]]9['D70<1<=97,F@26E=R$->E\:.)`Q98<3Y3((U:8
MY&+_`+5:Y%Z"\V^YR]<MEN:;C+ESF_)C\S9'%D[3(\?:Q]E5Z37<<;6I&@I[
M3A;?BUN9@VP-X@22'#9\LZS=(Q(WPCO[1(&OG2_MZ]-/UNY"UPO.VUNQM90N
MM-#C>'P*>74\J[.CT<RV8-=K6$_BWX:BFL('R0BZ&0K0!_-%,[Q1%8\/+[[]
M?_)6]R?927,3<;XC`\-\(!;:#58O,N4O6:.VM,E8P$5MIJRK2S+19X6HC$;'
M'#&O=51.Z(J!$7O9^]&E]\?U_B^M&QX&$X]YL#Y%S^N-WV1LUDR=^`,%"W0P
MI3&LD-J);>U20ET;9I&>3^_?OT'G.Z#WH\'?KZX;YBPWKP$SECG.FKJSC_@@
M^SM`;/,9W*W>?RU6?L:H)]B9GX)!P<SL9T2(J!I$SIWLC>YR+V4,MSOZ2OU]
M:7/\F[VQSW(5M=U_'N^MPK[;\B*).[>BUIIH.YO*JC'B+ACL3HVRJH\:3CL5
M%6->@FG]>C^'+'T^]>;1NNT!&GSG!\P]U1:4IA1=[#>&V45O49P\:RFL"2M'
MKRBW,L2_$E@\D*1HR6)R=!N1_6_F*9_L</H]#`)G]#EN*9,;CL9^4EL;'+!E
MEPE7%#8&/8`=8&#0CP222FPD22>:.0ASD<G0;;ME6%D['\;8!Q!8F,T$^5K0
MV1D6]FV-Q03AKD.1KA/M[%C&-&F1GR]^R.5%5.@D[+V)$U7F7VQS_N)GG1"S
M58RQU=I!'V0>8QK158!Y1=E9&Y8E\^Z)W[=!(G0<8<J$I9TB^7_MYGCR?+!/
M`GR,[>7QK-'&DT?U^CV=VK_PO0?R.:=Y!4+AGQ10_%\!3GQN82KXT<_PC:[Y
M&?$]?%?)$[JGTZ#KPW7K&Q,LHZN95*+2<@:8B!K0T?W">P>6"7S(>Q>TC5D1
MK53NBKWZ#ES-E6P#<UI2QMA)1[V2L:(URHSP0B%5^221?_H5/HGU[]!U>???
MQQ(!H3J6TL186*8?412US99I7.>Q%IIB;&4*/XE3LKB7^?;NG;H,CZ#C"ECF
MQ?,.]SH_DEB[OBEA=YPO6.1/CG9')V1[?\]NR_Y153H`LA,L:N*'8-)\CVMC
M9-\Z+&B]F/5_QQ]E>G_';Z=!R>@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T%-_8W0R`9\FD/0Q_YK6@@SHZ2?X9*L.9+
MK[4!8X__`-[+JYVQ-<WR5LG=O953MT&CGVKQ?)9_*\5W+6U%UQZ)7S9/1UN3
MJ)(KHZK$03.DU5;ISG1YVC)SQM0\8Z4F6)%@[2P*Y%<O08=PI]_FO33VHL@H
MZ+/4._Y!J,;A)I@BX[>&JQ)<4MS6[<@]1U.#F@*D^T.#DDC*C@5T:O7Q10IF
MK9;"G_L9YS=105]5-5$9NI&4397PPT*DU]:/-;-&'!JQQV_P-G<Q%;_L54[=
M!//K!N5Q-;I=,+C]MLKJZT;Z>ZO,--%<8&H;%=W`0PP41,PQ<@`40+62?/&.
MT8U)VR+](O(-F)G+>;Y`QX]C35&MU-N^N><<M39T`,89U@]<S;5&DL=$?44S
MBZD.K\XH(I76,8TTCOB5%:JADU?!$N0XSI:Z"37V.GV60!V25M6_9U]=76Q[
M1;:8*&M8/;0%9CO'&1+91"CL:Y58]WT[A6VAY0M-UG.16Y,74:S.G6\.@VE@
M'`-!QG@YJ;XJ@D#06-RRLCL+ZILX)/L01R2_A9XH2L;W(WH,SX\%L=QS]CLI
M06-Y#HBL=+(3_9*NH^SNZ,F:S%KCGF4I9FORH:'UZ30"V8@D4*L(;#-,Y6-4
M+?W?K=I-?R)16=?R7[!Y'3AF5V:MR2-U:I1V16;8CKN4.8"H(;_6K6D+E8V>
M5&?<S-BA_BBR/:&Q*NKQAZUR693S=+D!)`W6TQ03;!\7V_:$^0>$UPHJ60C4
M<QL_BY&KW5$7H-.O[2N0)FW?&=*@-/3PR8G0Z7*EVR2_/9;&Q<%_8`;"*O#.
M.6LILI7Q$DDU<)I#998FRMCC\7J&LSUR`KH^6IM9.%6-;<XHK9BG;*_-#K#1
M0R:VL+SE-$6#,V:RLEEB<%!"V4I\1+O*-CG-Z"[5!5\5Z*7,SZ3,UELZB@$J
MSLP`\1REV#K-3@ZO,HEB`7)95B_P`F)1L1@B><CD?_'H(XY`%KJGAEV7P-AK
M+6]K;@V?B^6+66<Q=[-/IJX,[.;2Z)?!#DX*LR>=M4DDCB5D'>*]C?%>P;YL
MV=F<KC^+<?<&R5.X(R(AP3K:OFGM$D`(SX^KEE;_`+F-E>>?&R54>Y$1_FB^
M+>_05_L__'G('M)F""S-"'II,45:U9Q%21)D>0..K<U`3<64"YC@B+&F/3NZ
M>16RMA55;]$[]!A_O;ZT\B:&+C/D[UO^:MW?'.K;<6^*H["3/P\A4+Y&/DKK
M"<5CWEQA'2_+)#V7YH'*W_#.@L]50VH.$KC=I&N0)N6`3[BDHC"F-%UM6,RQ
ML1,B>Z-',J#[('X8VL[H0]R,3ZRKT'6\=^Q?&.WMI,WGKZX9L0_[":[.7]+,
M!?!`T<"RDUUBPN.,N`61W9T,CT3Y%1?'OVZ#IO4OVGIO9S-:@27+GXK8Y0V8
M70Y.XBBF>)7V$DCZ0V=\#GCMFL0%;)(,Y4F'<[PD:UR*G03_`'M0&D5=-KJN
MAML\$PV(T4JL6U`KHQVS2@6S!B@B(0OA!;(TF=SF-8BHU%5%Z"OF\O\`%YZ@
MNJX;CZ@@R!3YZZ2M`AS"9K1X"XS]C:%V%4'_`**X8B_*`^UG7Q62%?":9K8T
M5_015R$^JOX:YV1#KJ61W(%;17E6)28(]UR%7CL@IB#F$$11ZPC,%,:@R"3$
MV,!+?)(D>GCT%3L-S+AN-%MHN:.+Q*1.0MQ;06=N-FZ8[D>DUMQ&E'G*JQ(H
M1#R$M;^0%LP$GR1I%6&QQ2.562^(9=ZKGY&AY*WW&^PARF,JZODT)>.PB\C5
MF4YQWXR&U=5W6C$!:`W<"V99+90KEP5T$J12PP/%E%GE#(N<.8,?@Z[:#"9;
M!\E.+8/=DTM^'AWMRFA+/_'6,Q?()Z2XC/P0"R*X)EJ<R%6>44<SIG-C4/%S
M^\W]H,V5U=+Q;G<%Q'S5<:KC?*:C.>PZ'4=W7XF6U$AMFA\7PX\TD6CO\\?*
ML$Y+"HXI$A9\4;HVMD<'CVV&QU7(&EM]CM]#;ZK57Y<A]S?WIY%E:V1<G;SG
M+,*?)-*_LB(G=>R(B(GT3H)0X#]>N=/:;<UW%/!>"T?(^H<QYSZVE&?*#053
MIX8#=#H;*165V<SH+Y6J4<7)"-`U>[WHG0>O/T?_`/C[8/U\T'_F'V5TG&W/
MLV3XQT6QNN)YJFXLZ12ZR7P<_,CQ01%Z&W&7XU&^5D<3FN21.Z+VZ#;?OOU^
M^CT_']P/#Z?<9YB]WG$EXVPEK*H.PM,5)-QAK=G+>W0DY,*15E3=00BS-&5]
M@VQB^-L2QQR.0,#X)Y`DQWZWO77DNQ3.TK[;BZXQKCM*2XG+B%8B>UM:"['%
M@C<95!VD><:&&DC?BDFGD^14\$Z"8^&>)^;_`&+XSX7U_(&=J*R@NX=MLN0>
M1J^\#S&2NU@&L:BQ6A:Z=AI6KTC(T46E?%Y"Q.25S43H/!:?8^U'J9M<5M>&
M=MM)Y-=6:JYH`:H6TN:_/55#R$>AN>*B6.:MD(JSPF/,;&B)#]PK5\?/H/29
M_P#'-]ZM#SO^QH+1\_:L.HY=Y;*U^/G2GL#Z.'<G1THUV%6OSI$<E,`S.0YJ
M1\$0DKIIG2SND1K51.@]Y=[#R+3;,LJ3^N6'YF3-49KI[H8-EK,)&^>!8:DV
M6-!;.5J?]LL7='.3O(K4^O0245L:D/0YG+Z:*RK"AK(D>*0FN/@HRY_Q@Q]8
M4ZR&'=3.58YGL:YTR1_<Q31M5SF.1`D@/7Y6PGC%!T=&83,]\40XMH'/,^2-
MK'O8V.*9SU<UDC55.W^%1>@R/H(JY9KM$5QSR,[C^P'"V9>;L6U191T0P@]D
M(#(T?Y"IY&CUR-^/ZRN5&L5.[E[(O0:M-AS)[#/_`%U8OD0!VK_OU5RGDJ+<
MMFH+RDU^GQ[-X_,&NR37A.*/;>E$!R#6U7&:"56K(5#(\972M"Y?&6DY:*YQ
MYFSEIIYER(F5RY^5#L@,Z6%B[ZXJ&-BHB[>&X2X++')ADED&>,UKT[N5Z*YJ
M*&GK?\N>V<_*U561Z[D&#*4?M63QIH9$`GL*>J,/D8/*!:Z`6&.HL/MH$[([
MY_QX,_\`!\J.3MT'I,!FA^)@B%,()#@&C*3Y(W3M>L+%1T[(W.1CY4_E_P"B
M]_IT'%F"D+F)?.UHLL<)0M:8+.[[F.`N&-)IE8]K8V3LE8BM_P"I$\47H/@#
M<0(6%23H7^3EJWV'=T$T\"CP3M%>Z6QCC4)"72.1?C5Z/5%[HG9._0=_T#H'
M0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@I?
M[)UFEO\`[@^AT,64%S,M6HM^U[3$,N'EJQ:EH\KG#0&,E8Z/S1$DA5/+NB]!
MKRW=D6?C[QM*85`5?T-$$*829..):6>MNBUH;BT,1/F($LRTE&F$G1T\%6L2
MJO=RJH4IYK+XQP_IYPGZWU6UR]KSNG-YVJY(!VZ-T6JR;:&TM+*SL\Y>Q1N#
MJAL<<@)%0^9KXX@XV_3S8J]!2;D@"PS=M::$6G!(>EU=AUVPMJ\6T`CL(0W?
M?E#T34_)4<%L]RERE`_"QLO\T5']G=!;7UUXZ'(X*RTH^7LSL5975E8/SXSR
MDS=]117,%Z>9?9M7+865RXDYSI"_DCBB!C':]'_3H+;\:15@MIN;B@S-KA*N
M[Y,SV<XOKZI:T799FMK*K1SFFBS7$4L0^=(?HSC8XAVQM'?)#+Y?)W10S^N2
MVNM3DM_:DQ29OCN\-HCK$T=@5Q8ZT!SY3(,X.])[2.G&&;\ILW9Q2#?,^-Z,
M[M4.M]>;PWU]XKV_!>#IR*S!2Z/5:P_DF:Z;I;2XNMT98Z`T6RK+N(M]:^UJ
MIX;5)8O*-8C6QPLC<SH,F]7B-'3\G1\@4Y.ULJ\7C'/'4.&B<0M7K;;3Z#[&
MS^,<>:$.SO`::.-[R"D^\C'#:JN7NK>@LG!Q%['\B<Z:7>Y'V4Y#Q_'<VI$L
MI:1*'#3#%U(,PK++C=KOPD5B-4!BMG@K[%5^\\R)I))'R1PN8%\3RC6E#5$D
MY+BYDLB)QYG.&GE%>#Y!0!EB*/!91UTSD9))+Y/7LO?Z_7H//_\`M#T(FKY,
MDS%G*6RQS--AJ;7R5,+2RC`ZP@^T99,SB-+1:A+'0R0A->C'R6)$#FJUK9.X
M8#Z;XV^H\SR3I3W1Y.BU>]EX\P\=V8776W]<RE"^YKQU2H/A0JMO;&W)DNB"
MF)*PL5(XW=VL5`E]:-DHXM>Z5T-1!EKFRJ0'T00(<$@EHL=EG*#1.?*,?87A
M*.0FG,9(YSU\HW(G0?C`<?5?('LSP;1UP(;<2#M(.0!`K*F)J+S29^J?<1UI
MUDV::6.1@4TC8B:V)48+/#YR>371]@W1<U\7T_)!E6`=I;VEM6UART`U#:/#
M/<YLH\-F6(.J+"YPHQ3'*Y?\.1G_`*?0(_I.`[$BRPI!T\5=:<:W+[B@OABB
MG'C%$!RAW?V@ZR_;R`7@CU&(A>UT3V3/>B(]$7H)M<2Z]G+TTKBHJD-]C0.#
M2(L,R987H--`?'YM2*(.Y@>YA$?97Q/147MT$.\W[.EQM94TFA2*OO-U8$T6
M8TEM6+K<MG]DH-<?5%6X,W?L@I36M#2/LKO!7KW5KN@USWO%KL!N<?[61`&T
M1,])J\/SOEJBY4^Q/O%!,=G#PR3XGR1TMF=$P\B27RA#'C6)B?&Y[5"2=?R?
MNN-USO.'#&`#2O+LZZ3<Y92PGS;D32VRPP6\]_''\\#R1W?-+9$^8[E_V=N[
MN@V>RVI>SSU;>95M7-9243S4I;F8QX,LIZ"N?5G()+$+(YD@DL"OD:_X9/Y(
MG;R10K=R+Q3=:JBL&@GX[/`CT-O0K560HEZ%$FQ)`@LVP6HJ)'`T,J-8H@',
M^P6;XYY8W/8U4"HE_8[3B7E#=05BV6\DL0Z/$5]E9Z0@@>K/SPD39,K@`3_D
ML!-Q8B1J7\%8^&%\7\G]Y?Y]!D>UDSNLBO+^P&!S8EM-6%[3^R%NX[NX0-#6
M59%1;TI%NA@5&0)I;%`["(=6FEE1-<Y[EDD>H:O/?'V(X4]*A:C:<W\E5N6Q
MUUE&VD=@'K+$GE+V(UV,+*@JL='G*8I&0.S]ND;K`JS^XLBH1A):^8>0.!6A
MXLO;/]Q'-O[#M_6\/:&]TO#?K9K=/74FJXPXC--%TW)XL)Z.S1NYT5J1+/M+
M?/ELB2IAN7DPAN=_CMWZ#7![45&%HZ?C?*9>IL,[I\@5M\?I\J;=0WU@(53:
MVS#@,LYA_D9'9V;F?(D4+E'9&YK8FM:B(@;"_07]$/LS[5CYGE'EBKLN&^!;
M"4(V4@S[,;D_44Y)-<X.?/9>W6+\'1WX$IJC7M@QP43Z^;RB>B=^@]4.._73
MZ]<>`9#)>K_'UGZRV_']3>EP^XG%=N@7-U9<UX4GX?$Z>T^.+0Z]>09XW/DD
M*E(KBHF.A%AC5S.@[QG)_OAZX\C\:XKE[AZL]G.&MY;Y@"^]IN`\K797F3(S
MR]J3-67(.1`;%4SA&F#H4^SDC^4T%R/>J2=U4-B$1<%UH["M'BRM2_35VOCU
M95K6.T(EK"M#KLG%.TWLD0.LU-O7/(!2)$CAK99FN1TCGN4-6/K3QWK;KTEX
M2GXK`)QEWM\>4$1=%6D%G7X?3Y[?<KU86AH:"W84(VEOOLVQ%*L;HV"QRN[=
MV(J!>GU=RE#C*CBGC78\C:'1$<+5\5_H<X;`RNR^4Y!+%,O;$Z]JQV-FCK3B
MREF('8KEBD=]?X_3H-"_%OJ*/R3P94<8G<]7.$XVS=[S%N3,]F4%`TUEI[GG
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MG9:"N&R]QRX#5>`6:M%N!2J.AKK=W_<->Z'S625KE597=T#$]]3>S]IQQQ/%
M^3Y/`V^RX(IS=>Q#8LM9T6HQ>HS,T>8UA-N^S90%3!:ZVDC-8W[NU=6,AFE?
M_'Q"=EX.W\6DYW_#+5U4O)5]P/O:K<6=3F;;1J3E2ZLS4YV<>QKY8[>-*FI)
M<"R97*+++(K%:Z1JH'*V'!G)&BN<R?.<3JSZWVCU')41,,]373Y'`6\<T>>J
M[*K:(V"YDJ8O"*!TWG,&YOR*Y?KT$X>K5!R16\2Q`<L'N+V4>PT?Y.*TD"FG
M;$)H;&`8N4NJA#%EGMAXVE(R)K1XEE5D;6L1$0)>@FO#>Y\E?,7?YI#G,')0
M4%UI`<42S[**/P\1_$4>-8I_^F1WT7O_`"[A\J4:VCV04I\!%;"N>&2,9I$4
ML!I+HW/)^X"'1@H<]8J_&DK&HDG_`.OH)7Z!T#H'0.@=`Z!T#H'0.@=`Z!T#
MH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0:^.==GFL.%K,595!`U=>:ZRV
M=C&[Y]/%H"E+9<_CZ\:)S9:*:Y)3_=X]W0J[_7]?IT%10KN3DNUL.0L36%:"
MBM]GIKNPJHD^$2KN\ZP9X^>B8(+-"1>U0JSUL\T*?'"3`K$\OB5RAHMUQTNS
MT=MK;3.%F?V#?SQ6-SFTDJ[*HJI[JVJXJL8BJ:C:6F9%+(-?REQ&S2R,C[-1
M"$C4.KY=LK_3M#D:@DMXL]=)604EF'027:&"_@<]14MP3$(=?Y>JE>T6PD:L
M*$L\I"HU_P"I`W_\!PYVAX[RM3F)"#@Q<T[,!W852=''<V,;*X89D@)T44=X
MRI%KY(B()'.8,QL3%=\[)6L")N0P=W<\AU.BOY:">DJ`T6LK`Z(P[7#9B._<
MZV)'%KJ]1[NY6V!K91W.1P-<_P`/NAR6N\N@R#*Y"LSE>T^K;:C:[%P%EOT=
MKHYAK.RW5K&3"9X58C''UXI,1L:H0UTTD+&2,4:%CD5`Q"IST%6+&2MCI*\R
M[<%54M_?ZAOQ!VZC/(L*O/XU!2HZZZJ;*)2@;$KZ2U,\`\Y)*L2)`FSUGT6=
MSD>IU_,-E59^GV!F2QCQXDMGG7FH!?H+^N>1/2S)F1=%;VQ,LBP!UM24V188
MY'MD=+$T-MU#.XY:ZSCB)'0B!PQ!,X8]6^WC@A1X$THI?WEO*V*.5R,;),Q[
M7(]5;V7H,&-M+.ZLK>LN<TVX_#E,CI9`YI*AAX2BJ%I#D)@.L7QJ+8PN;'"K
MXI5C5._UZ#SI<W[<@LCD;G"EYKSF>YFO*:VN>6N+,QATKK0&MH->?6T&/EN[
M:DL1;;MG0IXCB)C72_>B1R1Q10$-9T'9\2A6E;QCF==29G/':;2MTNFO7W3A
MW?W[2;J2GCH07O<:-7&R14M>P*2(-\0P_P`TJP)#+YD0A,]29EJFYL:BHIH0
MV$65.3,(12R6(S!CJ5UTXZTCLC!EJ=!2E(Z-J!-^QE[(_P`Y%_UJ&=^JW]+Y
M']L?7"RPFCUP;>.^!M+>3Y8B(:&L9AKR*HSF80Z(H&&61T>EH;2)Q,'QRSDQ
MR^370)#+(&[Z_#==5[)ZBQKX)(W$12GN9`2Q:Z9DX5I!&6U?D%?%]9$<Q[>T
MT#4=]$<G08(%H\LZ\_K-5I`KG0KA&W]6"/82_FYJ88^"L:6G^I08`[&VFBB:
M][VR/E<B-:J=UZ"EW"_N7:\F\Q;_`(*Y,H'X?=93*0WE;0!E061-K'&=^'L?
MF'10_G,DG"4B*!C_`"C^1[/Y)'Y."[^]XXH^5@7Y??40I^>K+;-Z7.F1'&"6
M,%[3DJ3&1'*),*4"4.K'1JL<G:2&=S%[HJHH?S7@4FEJ[+%7M`"]^@HT_P"Q
M/':8E\$&V1A]4PE)()4-C$<K(W++YL257IW1%[A@&!XDPV*XHS&8&.K]"-7T
MXV?K;31#5X<MQ7MF7\+17#Y!)G%`UK_X0#3-EC1S4_@OTZ":``01K@8$2O;4
MP4@97V(P4L`X14-G]JX@AU?`K%56$0.1'N8J^?FO?NJ]PIQRKFMOG=B^MQ:K
M2U-M07D<>A+18*RA.-MJZ(4DN.OH"Q"!BULIU4@M[I`YHV3_`/ML=T%1M'[(
MU=?`4[FFJN*$[(6)^@(L"**OD"J==7V;P0CV\B,4"2ASY=`Q&%#OAJY&!N7S
MM97?ZU#09[A?NHS5J?N\'ZG45C[8<]Q5M5GYLQ6#!7'K7PM;+]I798G47%R^
MIJ-#:TMC4%$QEL';`BR,#6>3X$<0'CT]CN'_`&1Y!C`U7+6SUUOR2?RGR];V
MMQKM7I@N-*\Y,W_Y#M:?`4]W0@@Y>SJESU@DR`SRB%M>#$.B?'T%6L)R=8\?
MDTNGQ6>SBS4%H+LFNO:?,;@3PKQY&S"WK+W)&V$EC8FHCT:V=!8V+W=$G97H
M%U_T[80?EW]@G']+KJ"CTYH^9WO(>4H[RCK]33S::NJ5U=2^>C<_[,YK5CDD
M8/*JM9+V[QJJ?&H>\/*B;'ESUDT=KOFP%5?(A.0,(TPE!;?VNA#!J]V'14TN
M;=1@30SVY^Z404ML<-=`*),/]O&GE\89CM-,[BCC('833VNDGX\Q-3410H.7
MH=;?<@V^DH[C'QYYL,_P6,U6+0O8*2\&![2?$>)6*Y).@RV\QMYC";;%"W)M
MF;I;E%K@QRI7!U]I9#0W8-#<'`SQ#:?.DP/^REF)EB0:>-SG.15^)`Y/&]IO
M;KD0LNXM>,DK(R:^BRN9I@)JZS/!)9-;S::WEN"F@%7V.M[8FG&#JXTE*JR9
M)HFN<R:1`H!Z:6AV>]2/7S2_>Q?/4Z'D//`4444S9#ATYEY1?:4E?(6R=(J,
M0=9.Q+T5PD4\C%14E5R!:K)<CYH3V*XZX?R]?)J]'RAL=5H-%MJ8>.Q,P@5,
MDMG';E4_V;BSCM2,OR$*7VKX@W?#X+,G0:%<E03\(KRURWI.5L53TW(FG]X.
M,*[CS1;7)`V--HX^;-9GL=9WU#9RLE/S5++66\$,3YA_&R?+-$BI(DB!7+TL
M_9A[)\5_M_\`43A!>:-'6^O"ZCB3BR^XZPFZ"TN#U[K'-6M'2W)*M99#Q&2W
MNL;]U&R>25J1?&LSD:U4#_2TUS#1N1LE*%5M+@_&VI?VZ608(]@?'*Q\\3P"
M02/O[.(173CO9)`])6)Y/\>_02?;P$NKD6O>0/,+)"0P<2,9WW+(U[/!EBF\
M8GCS,<J.1',7Z)V<G_(?8TB`0!3)A/-K&B^4'_:L>WRFC9&U7D2Q#M^W?+W^
MKT1.R^/=>R*'/5L<S&^;&O:JQR(U[6O1'L<V2-W;^3?*-[4<BI_A414Z#X$`
M`E#H(2&-.*US'-&E@C?`UT:^4;FQ.:K$=&Y.[51/HOU3H.A+S`C71F5,0PMK
M&T8:0XJ%I\QU5%.3))4'DEI.;+7K]],]C&RM5DBIV7Q\FJ'2/I3Q;8>"*.J-
MJX19XA:@RQ+=/.-,:(CR$:<X_P`9*P>6;^36]I?)D7>-OUZ#G40,I]*\X1VE
MR\E\2ET^LMXZYUQ33$O^0H&6%7VHL"2O[JL;9961]^S%1/IT'9Q@QK=G1RA2
MRC3B5Q[BIV/>/)812$B^$3W$K%'+#!`QSF-A8G\_+R<KNR!^ZPB*!DB6<L4-
MK&D337SS0+(D!)I4=6QY,8X<+TE[JV-J-\D5?'ZK]5#^30CR:00II`+YQP)Q
M)!G(UQL*3*A#9&/9W?$V1K?JU_9KD^J?7Z]!7CW1]P.(?1/UUWOLKS:>6-B\
M.,+'%5U432=#J]%:D-"H,CF`7.8EAH;XYZ1#0]T\E[JJ]D7H*K\2_M(QQ7$A
M_-GN+Q)K?0/C\O88_(8"Y]@;JI4??D;B@=HJ(D&6@@)93->&QS)6F?&D4S7-
M<Y.WU"R>M]_/2_":O^C:[V4XHHM:IM=6I1F:8?[Q;&XJI+RH`3X6RQ*;:U,3
MIQHO+Y)XT[L1W^.@C_2?M+_7[DL5Q_R'H/:;BVNR?*-(%I</927$CUN\Z9HS
M,@Z]B%B'>5!55NFKYPC9Y&,8%/$YLRL[=!)=U[T^H^=T.FRMSSSQ^#>Y"TXC
MH[T*2YC>HUQSPI*<0UL$T+9(#3-\T.5U>R%SUFCC<[Z-3OT']R'NSZY<E!^Q
M,_%?(%=R87ZN.M1>6@<CY&I56U146-P13`6<J0T]J;\57-$JP$/CCG;X/<U>
M@UO^I_[Y_6?V+.U/]\QFM]=,O0\1<><XU^YY%O,=;YFTP7*FJ=CL0ALF/N;H
M_-Z2SNFI&M?8003L5?JG;Z]!:'V?_9SP=P;FKDK#7N4Y3U=#J]_@;^A"UU73
MMRVSP'%Q7*-E3WKSU;/(2E5]G$^`5DY+'&M5&.\'H@49YQ_^0OZV<,^@G%'M
MT52QF\N<G8SBGD&'U8GT0,')`&3VN]KLKHCY'BL-&9('51V!E3%+\<UE\$:>
M,;%E?$%VJ+]K'K+39+EOD+G[99?U^PO'7,6MXCI;;7W95A9ZH[%@#6%\0E#3
MTY1H9E?"1Y2#0J6YL35D<K6IT$S\@?L9]'^+-KQUQYO?9/CG/Z[EG-T.OX^K
M)#+$^#0YW5'15F6LF7%57'TE<W4'S)'6QF$CS'N1WP,D1CE0,]XJ]Q_67G'E
MGE/@WB3EW.[SE'A4M`.3LU0C7<\67/\`-L4P,F@EJH<S:&!SO2,F($TEXLJ^
M$R,?].@LQT#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@U`>V`>DF.W6
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MM+O\]3366D'_`"VONJZ6GC8-BA:;=R6]::#9?:R.):I/?X2(54/K6TIFMCM#
M/QNA'6K,L*YE+6WE=6U8M`QUW?6--!H()2B*RZFOJ2JEEE%<8L@94/G&V&$F
M2((+!KJ4W*67PA6=3)I>23<*")+94HEY2Y+,4Y9-A>FEW5T)8":24V5`Y#9V
M->A<L$LT3(4^H8T:)2RVFD(L^0$Q[K*C8;^%JZ=]_&-Q#+=66=QG)95RS[J&
MO3776>EKY)2'"3L%C9(^*)SG(P++<#\D\-9P"DX8W7,?&A.TT#ZOD`;C:RQY
M$(K,WI%L;NC/HH9DD8J`V-3=-FOA#+`9"!VM2?NG=0V85)X<IXM@V>M.#+LY
M:[\BV&SC:*0,%VIQ`YI(Y`R(GCE/8A;W1-(?*UC?)ZM3H*\<^;CFCCYHEUQY
MFJ/89XIFMT&\D,.=7_C\-3#SRH%B"QHGBKLK*%S97--?"*]Z.?\`-Y+X=!Y:
MO8:R'K)BJ\2[-T57L6:%099-,`19IF[*N#CBU,H88;)USE=<?-/'51O,L24-
M:LZPJC6=!N!XAPMI3\-Y+.PX&LD?D>-<\R#)5\D$9@4\H8_X5]KI-(2!5S6]
MXMG.6%#7/EC!9.]A$S942/H))-XBH=!I)\[)%&`3?2QZ0C7AW3JL<:R`I_M;
MK,VD5E"VY<.V9%=$X<62OD8GTF8Y>W09;PYQ_:Y_$[?G;C6T3(;&^/9DY9[_
M`#\A[#<_1B`4.9MYAJB"Q(>#;#@P6(30TC'=&>^25L;W.1`Q[C[8\J7.2U&;
MV-`?#1Z:M$66WAMY0;*TH;+2:K&:\\>,'[FNKVNNC%DF'0AI$56WSC1\JJC0
MX/K1Q3:E^Q^0MIMER'<XW)9^P,&\*B:+':XY89W).;H2&P'RYO(VPP\=0.]C
M$<]561OEV7H-AVMX+XRM=Y5<[!Y&@.WV?0>WIM$$SQM[5\4$L9`;)Q7Q0FM-
MKFL;"CED[RIW[*KE<H26/,`55`6_SV-6-<U41D9%T2R$BAL2"/\`L!R:Z9\<
MC;",^\=#)&JJC7PMC=]>W<./8E$AEG71D1>FK,T,XN"*G"26U`M:FL)9:P1!
M0K(7:%V["&+%!"U51R>/U[HG0=+I*>EF.L2;:*M;EM-7-J2[$T]\<]#=HQH0
MHPM<YD,`S9GHU?X/6=I2.5?%%Z#M!(M93U,30)6Z6VJ@"@/CLVU@4ALX$-4.
M%'86D)D\@\UJC9BXD1JM[DHV3P1J.<%3O93W-PW&WK'R-S+;3/SN6S.8U(>P
M*L))5O\`/:BN=^)GPXN=J1+B^+V1$I39A8_LW#2P*USI&MD9W#Q[^S='[#_M
M[S=-D]+;[KU-]?[0LG09F?$4%[M=7[$\O[`M9[@*[T-F;BJ6;C7/9=%*6."0
ML>"7O-.D+4^@1QZZ>D/KAZO8NDKLWRU^>@8:%9QV]E88FMWNFKU%`,?:0\=4
MV@M#]S:UN@U4S@*LYXP0<4CO]\IJO%'#7M^[E];:^NV-/S&=TI<V8YEL\YI-
M-=UVCR-_2FP4+XWC7&(NA@9X:RV$E'E#LHF+#\DY(SG+_K50\O`%[<58-M6@
M'3BA7@\(MJ/'X(TR`<B,J*-[G-62-$FB:J^"M5R?Q7NU510VP_HHULF-_:!Z
MU6'Y&6M"-N+^IM7PA6A[RZPO/6,DX#AJ:OL[1T!3QV)*L,3I$B1RI]>@_P!!
M2ZV&O?R%@2*K)5]?Q',7X\O\H3ZV&8'CHBMQ)FES.>@&>56E,I=Q7W=BX2#[
M0BQ'B"B:3`/+(QT@=&S=RYQ*G5\ME8[$8RWY[J\%C'4M&6+/I<Y,L:\<$WEE
M:$)'QW67,A#X1K6Q;"&+&^1Z2OG6-O02'N:TW,/RF>)/+JQ;^HO;&H"N)QI[
M%DKG/$I:*G'$F=:P6=PT13K*0QC%$,EDE<QL;VIT%?[7F;'YC6839\BMKJK+
M66JQBAWH;[4RQI]Y>V^9%RJ5.7BIV&UV9BR&;L/R%LWY8022E2?XONT1`K)^
MO=1M9ZU<KVHI94]>%[7>S_%N"`O9$=!)]IK8]/G5JZZ5D!L0\PEL>0<C$9]U
M#''"SZS-50N]Q,+1TGL;/[!\<_(/J-O60!ZBQ2!H15/7Y&:*OV1!P1,,<=="
M$="Y[HFM:D\Z^,?RQ_RZ#31EOU:>J'OG?^QEAS<EUEN2[7W9]Q>/:/54EI^2
MTAFL/Y:V.SS4+LF/.E56TM;4ZD-Q"I)V^;[AR+XQR*@4PXJ_4!4>HONMZMZG
M(W.NM.0<'R]@[LNCEI7394PBLUS*,`JJNBF_+;V110;IGP0120?(6*C9?!ZO
M:'^C.51FG:O"6&@@NK&YISB'"'C"L&`:"C&0NDLYI2(8:XB1TJR.C:DOSJSX
MXW+WZ#,;>[T$.?L#%I+J>XK4*N`0H&P1NFECMB`1*R1HDI3388H'I+]%3YHF
MHJ^*KV0*L6OLER!91W5-6\>56OBAHYONAPEN;+[J=;8VDB?,ZCKK`$0(PRI)
MA(AEFB/%D<QS(71HKT"*8_83W1JA!Y:OU+N#)@Q)"CL_7[>OM#0<Y26H?Q@C
MNOVT-'8:"TJG2HJPGRS,C[?''+,U(U"+7>]O)!5MR5CS<AQ1/H^.;4HS;9;-
M;F[,TF/*K(HFV=M83PU:B!,I[ACV$L/<(SY_*.))1OB)E#(`_?[DL2DX?FL>
M**K(Q<F7VGJ+JUM])6C56>(76T(M78W3ISY#<@>=G3Y[&(*RB'4B,H;XU1RO
MC8&5^W?N+R#P5SED<93YW%:[$+QE:<DVPQ,YZ[0L.HEC`%OQ/QL4GV6+K-<9
M5(><BO9&^>..1GQ2NEC#"?6OW5Y#YAY.W4=M49F'A3.8"YV^5V40MO#%R-I@
M"B+U=+@CJ9U]3[RDAK'-622G+,JR06?>BSS1O\4"PF8]ZN(Q<7E-YL+<2XLM
M/C:K0%WG''W.IP\>7_&7&B2T'T0SUI"'@5(_W]G%!)++61'P),OQ^,BA5)W[
M/07<P'EECPV/!]S!%6Y2HKJVINMQ;:D;*OW([@!_RL$I!U;2N%LB*U&N<,`3
M"6][8IFNZ"5^"_V=\2<R>T&`]=JRCTE9M.4L5K-]2H;44#7-H<\)-9USKV8+
M0&'U;GT4$BP_)!W)=]6(C$5W03K^Q'T1X]_8KZVV?KQR%H]!BXV:_(\C8W:Y
MA(9+C'\@80Z6PR^A'$*5HM@P*>>1'P2JC)&O7O\`XZ"GWM/^H_0^[W!F*X+]
MH_:C9<A9O&TVS`)C&R5+4A[.\T&2CSV:VFE#AG>C-!@[))#P?MU:QTDKFN5$
MZ#$,G^AOU[S`5S&3R!IM5:7',WJ#S1^=U6?I+BX`M_4AL<-12@GE22$15.[$
M:Z&S3NJ_"]6=GIT&N?5_I@(QGO\`\&>O^(IMC8^JF@]'/<?#Z[FNVX^IM;28
M[6>POL%M^4"\/",0]E9GR!(=+XUCFN8L3&L>WQ7Z=!=([_X\/!T&C!.R?/')
M5'F':GTLVNAS=K3UFH*O-)Z.@'5W&1GY\ZR'.#AMQK<O[Z-&O\72-5BJC>RA
M<SUQ_5AQ]ZT\B^Y6FPO)VL"XX]Q(;R6UX4K:NKK,;QE>Z>(V/1:+$F?(59..
MMG'22N83YLCE>YS?H[L@4JH/_CO<+T.!V&$#YRT@,.J];>$_7%]O2<=YVJ.G
M`X)UL.SRFWU$;KHT?5:@NVA[%.<T9'1+XH[NGDH?73__`!Z.*^0C>2KKD;V5
MY+O[_DSV4Y*]D;<RGR>>S-:VXY)XL3B@G/S5,-E8*5!04H\$P1;9X)$F2;Y&
M/25/C#F['_X]'!VLQ>VX]CYTWE3FN1*+U8I=&='C,;8;:M7U0E.DQ)&%UQR2
M38R*W6S(>;!"/-'),YCW_(C58X+27'Z@.#]->PG:O8Z33T'_`)=]G^7#<S<T
MU$:-9G^T_'9O'NQJBRYV2+\5&*:I5>0R)LT4S41/%/J@:6?>+]5/(W&Z1<)>
MG?%7//,>HY"H_P!=N#U>]T%+QH+Q>-EO4BXCJW78O(E_L6:G!7JY2F&(M8P*
MJ:.0A6N'=)+)*U`WD>I/ZN</ZA^V?/?M/QQR1HJ4'V-K7D;[@*@K1:_B1N\(
MMV6I?(HK32;*ZDU4Z?+%-,QXL)3R)II(4<]K8PVG=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H'0.@=`Z!T#H->GL#*0*=HHZZONMI)!<..O\?DQ(RM'HJ)A$MK9Y
MZL$5/"DO`JMB$,-C1)B19&JY5[]!1>@BW'L[Z.\E\R6'#S*"WU9Y6MI*:NO4
MGUU?FS+FO^?$;/%HOP45QQ_D\M2UQ`+F)Y,#?(Y/Y2=PTVPFW!E_DZXL2V$G
MM63P5:(0ZPS36BW9E+>ZR[<2J@SG`.V8$`X<")-.$DT`R?YZ":_6NDO+'VBK
M])G&2.I,AGM5K"(L_H%(EGT0-`1FK0JF/C=\VG(T9K_CB:JNDK:Q7+]&-7H-
MJ6%JM1#BY-AR%_3(7:#:V!6?+S(0KK?48T(2.IH2"I1&(L^HT.V!LI0B?K^/
MI8OY?R>J]!EO$K]B)F]/3;:LQE9HKR:\LQ#LSG*:FK[G*220C_A)&W+4BDD_
M(2102$O_`.Q-K2K`E45(IEZ"*,P556_+^<J>4'ATGK\-POLXKU]M3T]Y>S<K
M:/35^:HI);A\+BJX>OH#""4/A>B,6&(8A525B=!W>;IJS=\?<=^PW&DT!7&7
M*FSL+#'GWA$M)?:>AMJUD&<2['C2.T9G5#`5!JH3Q:LC%E*199/)0RH/EVZR
M][BKLC@;-<B.QPML1ER@?RD%]7"R#P*<=);SQK096P'@V4D[H#NY<@#9H7?]
MPQ%Z#:%Q[H[#6<=U&N+HS,[%=5OY*?+VD_Y"XKOM("71E"$@HA4Q9!;89$^3
M^<<+$\>SNW05F]M-[5\-NXQY'O!;W=9>[J;KBU^`;$,G'=F=K1&-'M=%LK=L
M@>:--C511T(7RM5[#L5'_P"0\XV@K\ORYR\)QG!D+?/RR<GI82!@&@R.KN*J
M^$J$O&$J+_VDQ&'2C;-1SRJX:`>UM`X4[R1]@WDU(@X+ZFF%J:RUDT-57N2^
M%)@>1%0!5T^>J5))NO*VAFHR;*O>Z<Q55KDAA7^$;$Z#ZQZ2+0!9_4S@HVBK
M";!AM4:0,ZHRL`"O#+I&H$U#&WAELQ&/<WNR:-WE'_GH.]`UO+W$&4X[(`F3
M09_4CU,@>:+#,K[6V_/U]@^W+/=8HD-=<5J`#*2"<J.&>XE43Y%3H/H%H%Y(
MBF,MFC8H*2,#)TN=BI9AJ`F8N&R2>\M&D-:L8`CCK(1D\79A<5HQ4_V?7H+;
M<8I#19RKHZTR09GV5N7454+$DH<S$,!+`[+F$(GS(`-)_P!S"LB]WN[?\]N@
MS1-`)G*AQLM.14U>>*L0&4)T;8(Q0LVL0(=E1R_6)@1XGB3#Y+WDCD1/\HO0
M?,6SQVP"GJ\U=499]/<CECJ;$Z<89"C@-`>'-'*[_N9W02(]?\I!-)$[_+6]
M!F%38UNW#@/`GB(K2`K(>8VHM^Z1%OE<#,-_VKVJLK8VO<DO^6.;]/KT'3ZC
M8U.+J3R]&-%7UD&@@%F(<,^2`P.R>L_WHZ)W>02QC^TST3^,_?H-,_L_^SS-
M<4Z.FR?#N)M^3N5^1M:`,_CW/2?*.%!2UILPM]RF>>KZ/C_.T=8P&0]$<RS*
M=%!#&O=W;H///[?;'G_GW>XJRLO:O&['D'$W-CNJ/C(GB[,9_P!=,+66]C&/
MJ1M()&&S3;R7C\-7'-*(=,YUO)7QN57.9V#B\8<:<Y7'&6:J.:N9:W?69V&=
M?S57%%=GN,,917FAL'TE/QS2:'(P@E:"3[Q[9!IJYS+$9_>57?9]V]!,=7Q@
M!H@RVZJGJ2TPUE^6?8TT0P%1*;3VSP[BVJ]<2U(79ZM8Z&E7-P=F`Q-8?`Q'
M^3N@Y/+_`!WG;P+0U&8SEQFJS:X;.Z#25ES:W_(N"CUP>LG<*)FJ[82F1P4L
M%35PP$6%7X06"'RK]9FO7H/%1[I^GO/G$W)FBT-WB]#<XV^.N["@UM51W$M'
M+7597QV$$9!,3R$'IIIFCK++V:YW9K55>R=!R_UR67-'"/N-Q%S%B.#;_E&Z
MXKTUM<$Y0J`^FK?.G&DJ;66ZN',B@K`L^9:0O,61WBQO\'I]>W0>FO6?NS]J
ML+8-X^N?UIU\]KH="ZJ'E=N-?7V"\H/'973Z2PLL_*U:R")MG!+6P._[4BF*
M@63^$<"(&,\T_MS]WS*>D?H/UD8*[,T1K,Y:0Z>'=[]K;;BNZJZZ>U@+MI)Z
M\ASZZVDCK7"HGX][_G9_L8U4"['"7L=^XWVVS8W-X`?ZS.-\K3;G6\1U)?*%
M54U)C]1A1&9;4:&J@GB8?4C:NR!>X*1$17Q*GQK\?;H.GY]S'[?*8"3<7')?
MZZ=6VBBD,*XYXCH`;Q`ES\>6L0RWMC@>'7MK2"AY%'3M]Q'9D2]E1W?H-?/&
M9/[Y.-</GA,7F..J3CCE[E'DKGNLT$5!1E/:5J#J6'5Z:O`)3[YU6^*B6$86
M-BNBCB5/HCV]PV">HF0_=/ROSO39_P!I?;9O%_"T-9>3[[?XW)9BJVM3;Y^4
MB7`T<T%C71360YFUCBA?$BN^&%55W=G;L%YO37U8Y*]>*WD2RYOWDG(W(>WY
MGUW+I-T,\?+PG%\NAC?A:EPH7Q0S)>Z@\B.2#LCHD0Z1O9)DZ"TO+6)Y=J<&
M'>\)6?'N)Y=XQT6;I:<;3")=T^=(HMKD#MR/;R%_-]Q0W:V,L")!_P#<81ZX
M5\;D<UB]!O!TNYNY"Y:@BGB.-JL`)L2C:"9Q9S]+6%!V%0%24Y"JMHP_XY)T
M1J*^*-J(_P#ST'QYXU9IG#O,PM%HV4VSS.*-64!7H*H-A&*VZ#+6=S6R-2VJ
MO'QC<Y6(R3L]/H[H/,ION8MSRQ98C*6&IKK'.VQN(PU%J[+/7"%Y^?3%A66J
MRU?#G%%K[44BPTE8R?[1J?*X`1K7+&Z9.@OAZY3[7CV[K!,ADN![S?4-+JEN
M>0=7R!OJK0:6Y&E?=B"D6$=@RAK:\ZKI7V4\#VHR,0&2%O\`M<WN'*"QWL;R
MK;\K<H5/.^!XXFY"I=!3["AS%5*3#952:>XLZM]";I8Y)LYEIZ,QCB)1%:>>
M6]2)U6.7H.GP/I9S7=T.3#C]F7U8=8P:NS=]755@!;U&JE;5'V@]F@R+4P"&
MYY]&+)9!,:1/:Q$`$.6OB$8T+2;7]>&VY5(!FE]S>1:N8A]Z$Z.@H,[JG5T9
M]9%'.;/9W\1!ZV#3ZMSON"E\$F6%&IY0P]@_.'_5K9XFST-ZWV>W7Y/09,_&
MZJ\/PW'"&:D,]B+;VI,H@K/L)+@MBDS0Q^#4D<J=NWTZ"(^8?U\<,<>\*\C:
MVKV=SK*._IX3+ZS(B!+HR92=A;&.&SU+4=FUDO\`8-']Q&+`UHLZ,=&Y%;].
M@Q_T`])^#?9SUGRG)>\;N&7<^GUN;TU+%8,SE>2_'Z@C.SPK352,'KH-'G05
M@,8SL^44U\+U\6-1`OIPU^L3UAX/YPI_8;'U6DDY-H2MP166]I?EFQ01[\.6
MONPW#2+\<@<04OQCQK_&!J)XHG0;$.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T%1>1JJQ9>7UW^*F'LZJTCT(-U6AP2
M6%FZK?'#2AR.AECEA;"$C8?F:WSDC;X2*J)VZ"O.+$U'KI[H;C`6M>T_U\]G
M1/[/D%CBCEKZ#E<R:U,Y%H9072MB97V\I'Y$HDCY9)IK1D+6I'$B($'<R?K&
MN#-/3D<57]&[*)IX+6U'UP3&:ZI6OMYM!&/B[N(8@)2#WEN%:\Z"<*(,=D:P
M.D^.6,*7<%^OW*/&')'(@?)-&=AM5G(_M<L;#"V&E9G3:B=MT9E[,8V".UE)
M'D6>6>9GP1R?Q\8V_P`.@OI*:@U/4.KH2VT="=3EXR,N`H@;[2AK;AL5G3QU
MUA\]/571FD6*Q,<0I(]D/.R-JP.8WH*M^\&,L^4_7A>)*C06^>/O]IQGIJG:
M971AT-V*33$U`5M6D;#1UM]8U6=MDFL:Z4>&%.T4GFK4A4IL@6]Y6M*/:5>'
MSW'H](,-AZ6IJK[-&PU5K416L4`SY<_ILI\!&9O8[-('$,?*.H\D3'$QM;*Q
MLD80>1R3M])EN.<R3%7T&$J]%3%CA4%CG'`Y'*5=>PZTJLYD*O%UKQ0FP/<.
M`#*/\$5;`C8I8IFN[!LLX$Y.XMV1UYE\7RUD-,$;6C6>8QV6LQ5)JLL13UH_
MY*`;X!=-5LF(62=L9#GOAC)B?\KOD:O06-FKCJZ$(I'K=$`%.:]Q+!(2_P`,
M2U("((R_M99Y'A1+\R-16R$OC1CG_P`N_0:NO?VK*+GXMXP%N[S-X/2+;FP$
MU!.C#N<UJFT$5/@AZAE2QE3<`_FHWDF55Y++56:/="2H\:)(H:NN/>`-AQ/[
M0<5:H9V1MJS,9C14@57=R.K*G17E]-8%9#2'XNK\1J734]+`9`";$8.(C"G2
MP+%(5,V8-N6<GMKYP$="1EMI>UTI]:4YCH#(M*'-FK:8^2N%$OQGTS*J\F!'
M(>]'/GD!:2YDJC>;`CCE%DF9ER18&?O,%77FH!IXCX9S;62WMKNZC@J\U34M
M;82NC,$<[XPU^5C89.T[O]:*G0;"2LX#K,)F<9J\I&6,<Z<:ZH#3UO1X65Q2
M'1R71R,9+9%160$3YBVNCG4AJN[?[')T'WLN)<[?*]Q<A,328@B(@YH_/-M5
M;*I(G2>O(D<R:S(<)+!'([^<<,_\.SD1>@S^.C.J:X2J:,+<5Y215MN]6M%.
M8`\>6%Q*/C1OW3HYGL\FN5%2)J]E[]!Q8P9K6CKLZ9.60,0(!!,^TJXB%+&#
M`&>;%9-(\XU=8)-]'=N[7HO;ZIT$-6G"V!"!MR1Z`NCF@N$G0C\W:_:!05;A
M;<@\>(<T:20JRKP6,1B*]KI!H?D:]C'-4*:F>RW%?HC@.0[S8LMM;R!I+TF?
M&\;T%LEIR!M<U1QS.S05;AQY9`<W:3-LY8XXO%"#9'H^>1W9GB'FP_9I^WGV
M>X2Y$]5C^:^-;_">M'*X=N5[*5^%OB;GD.C$TEB^0#!"Z2*"$?C#D?-#21F3
MK6$.F#,=()\[D:C$"U]%A=]RX'EJSA(>@S7&53.-JK6@B"IJ>+G#/:J*QW^$
MFT%M=!6FIGL+JCM&S6O9))R2HD>I#'-E;(%HZSTKJ+^_"M_P^<Q^*==5FB=2
M-EN8M+FXX$`)NJ//`_=V@]<1:FQO#KQULF`FPFS331?P2!0SR]]<\(RBXYJD
MT^ED*KRRJR\?'4U>JXYTEH1(^P%%OI`C,^+#45CE;%6VI`IJK,U'/8U4Z#`N
M8N`N(`L??THUK89RW,`L;6?1/CN+(JSTE?1_GYM"78.L*(/[W5`W8Z31,BC9
MX.21JR=TCC"#>-L3F8\/5:W2;3,!5$1KI6Z'46-&W#4C,GDJJT_`1T^[&94:
M0K*NDGL(XWP(@[BIEC>2KYFH&:746&)X_90\AYN/^LW\.(EAT5$`AP&C&M]$
M-JK%0`;2S+'O:K:3@QQA%3O2,`Y\<\4$4L<;D#$SHN!*2@J*:LXWH`RT#U$<
MT3,O3U/:[W5H7K:P?9&60-D/3PA69CB&'/A>9>B21%F2-=(D,8=W<;;`P%7.
MK`KZJ6]IK/.2&NL^*:.UK6Z!O'>:<8%&Z.'RH`5UE$(:'8!K\9D+%+?V6".-
M0PVYI\D%N<5J.0YCF5%#N:P<^/.8NW(-9<7HOW0P-!H/OP1P:.0R=&V1Z0ME
M8<\97/E;_P!(2MI-YQ@/54@#8HH@A]*)D&V5?A&,K0-27I["0J6",@J2:>U<
M"Z(*M82\F=9&/?*L\2M7H,1Y=EU6K*S63P83\SQ^9L(-+R:=]K4@EZ>OR&?R
M%'9TTA,=0VTS\M]9PGC`PR3,20.A&<Q[(5\7A(P_)6/`XYSW(A5+905A%-J=
MAFLR`"TV]K<I4W,+K3)5TB#-FH<Y,!E7D2=V?/,9-X2O=#,U.@YDO(9*:'-!
MWF8ABF*XBQ:'EMT$VK_*W8Y#`+A+?S(>1FSJ$?L*)<HK76+F(DK>Z^70=-/R
MKM%CWI#<[FM$97-+)KZ2WEC"L]YOP8T9G";$F#QM8:K05H8#@T=+'.%-]TC4
M?*QZJ%&KK]A!O!>O&TOMKE[_`(GH[#7T1>>?(-/-664VDML9!<#G:.DF$*E6
MNMJX^"`HR2,APP4<QJ3M:P>0/84+;495WQY-7LK90;S`EG9N:0<LJP^.8"`U
MJ@:5BN'KHI:Z1?D=W:^9%^BJGTZ#G<D141."V\ES0E6;`,H4&T2)PYA%@UU7
M*^!]4XB=&NDCG-?%\TJL5%1_DOAW[AY?I0<=<7H]/+E=F'"VZR>8+.A^2[D=
M>4LTQ<H&VOK78GS7-%A@W#R5P54H]2OY9\,(S)(6N<%R=0A%8[4Z866H$(C:
MI<5<LP,JV=J^",Z[H=`4:+?.L:E:"ND%K(86Q-GF)1DDS"6Q3QA^<;3Z:J)M
MBH=9*VVL2-".$#&#%%2BWM=8/;8E6CYX+<">PL81Y/A#'@-^9KODDG?`L8\(
M,_E]4W2:;D[B?=<E82TO8`ZJ"JI]0?-D=1J8M9E=(Z:/-;^ZV]'GX8>.-7#4
MBS5[1QY%GF:X="A!2!`OSBA<ACM5S)S?B+';!\C<Y_U^HVU#M[>IL0^&;/CL
M*6MN2ZNM=-900-L(;.(R<-QKH"7#0N;\2NE50C??<GS&\L<?<O"G;&?%B56[
MSC^/]"789?*[A[+PVK#UT$%818-KX[XM%LZ>2R#4MPLS6.2%J)&@0!K[K=Z'
MUQ]E)(J63#T`.=XV3,Y&'67$N@K:L.Q,IKR%E_\`&33F0`+G4<$LHR3%/@FE
MF1/GC[!;G]1U965GI#Q\E0`?6A'Z/>6;`[._30G-D,U![IBIR&UM4P%UG(U2
MOM6PHD/S_P"7*JJH;+^@XQAH=<+.=8%C`A"QNF),,GB%%'B;_P!4LY$[V10Q
MM_Y<Y41.@PU.4>-G4%;JF[W(+FKFR?34U\FAJOQ-O;,+G`=6U9WW7V]B=]X+
M)&D4+GO58W=D5$7H.P9N\3+HH\A%KLU-JY?F\<U#=ULM]V'&<9.KZB,EQ\21
M"L61RNC1$:G?H,9MN;.(J+D7/<17')&.K^4-8.85G,&3>@LU%Q`!$V8R0.H^
M52WI!"]'N16HO@O=/I]>@E'H'0.@QC5[7(X4$*SV>DILO76-O79\`V\L!ZX8
MR[MY5@JZH>8E\;)3SYFJV*)%5SU3LB=!R++5Y>FMJ*@N-'0U5[J)RA<S2V5O
M7@VVA)!%D.-'HZXDB(RVF$"A?+*V!DBQQM5SNR)WZ#O^@=`Z!T#H'0.@=`Z`
MJHB*JKV1/JJK]$1$_P`JJ]!@1?*G&@&7#VQF_P`</D+&6,>NTTNCJ6T=@1+*
ML$8X-G]W]H7.^9%:C(W.=Y(J=OHO0=V?KLK5`U5G::2BK*V\G"&IC[&U!!#M
M2;)B/KQJ\DJ>*$L@YCD6)C%5TG?^*+T'2$\I\:B;@3C,K>9*#D(\`FT#Q4E]
M6MTQ%<)'\Q1K*92/OOMH(OY.>K$1&_7_`!T'+Q?(F#Y'"L;+`;'-;2OI[FPS
MUJ;F+H"[%K[VJE^&QJ3)Z^>>.`\*7^,D3E1S5_RG08_N.:N+^.-9QQ@]GL*R
MFV?+EX1G>.LP_P"X)NM19!C?=G_8@!PD3L!KAU1Q)4B,&@1S?-[5<G<)2Z!T
M#H'0.@=`Z!T#H'04QU+K$SFV?*4TZ336(LEV'$;83"2DU`?C)J:FI)CD=!*&
M>7YQ+W9\PA"+_P#1VZ#E>X7"I_*6`I[/*:$/`;/CG4`\BY_>%QF&0T!E8\:.
MS:57"D0H:+85?FDJ/1[$^%O\?^4"PS[8Q:/.(/+->V!%/7VBV0<$HM/;M9`(
MACY)D:]@;;.(ETL#'JB(JIW<B-5>@IWS*W,$ZQM=;L-F;G<M/7\A2R1RFYO&
M9"Q#<>='/<113$B1WXW^GX?BDE7OYI_Z=!KF][SM5P[Q_DJK&+<YVNO@+?D;
M36I-<8+**5F[NKI8*R6P6:OSN?IC8YAYCXI9XT^Z=&J1-=-VZ"JO*GL5R51"
MXC)6(^4WM?79X>QY:NY\[(;7:"VMK%R5`>8AJRG3S6()N@I*Q]A&4-`^P/D&
M2*1T<K9`N/QU4%:LH(675CXQF1XZCLG6=C\&?'-T,](>5<`+4,JVV5[<4%(V
M61("B7H'70S_`.R)BN5`[KCG0V(^IOK#-7G&9&A%XSDTN.H]BE<X\WD7>7MJ
M'"1I(&W-9?#5)E.'+&(-/'&*XIDX\#5+BF9T$O\`J;E-3B>0*'677!'"E>;R
M"'>YP[F;C8F/-6MKF/&"QHZF"GL+.X^8P:.=K((%,@,=6!QSK!V[0CALMJB)
M0B?Z[+:JML#(59558ZP</>G4:3PDB#2,L(GBW#Y4AD89-!)V'8]J?Q<J=!0?
MV8TGGI>3M'8S6"UU"RJR+*V0#468C'C#1V4]&HM2UP=#8:YDJ/AL#&?;20^+
M9&.A_P!BA2"[NLCQ=QE=Q7]C9W[-%*9)KKJ^Q=F=MM)';"U=U1B5,]+;N@KZ
MN@'44>:"N6>`)Y+2N\0KX%D"AFNY+WG*.XX_XV]9N.]QF;/2GUN>;#CK^*WU
M>D;6O^YUFNT9BTV:BH:K,UQ_:<ASXE6#N/']T\MR]!=;"Y+D'U%]DN.<1R3O
M=3:V&EAH-_:9^._6^SU:()<,BT>FC??@%$5N>QU<UY$Y,#(UA1BQ/(<[LU0W
M6Q<GY.TR6CWF%_\`N--:@T=W`(6L]0V66P-`('L"9R)HTHEOJ@T>=@9*#&]U
M1984=(C5#';_`);SAF9O,I?WB`V%?=1L/BC-2BT,0E3;AW]QH*8.[^UL+7/T
M(UH!&0:V!@<3E>U94<B-Z#L\+R)HR-#756D)!M8-`:=G:W09JQ4^<:2E'4\2
M?050GW,-,;:Q-:QZ.=V;(Y/Y=G=!TG*'LMP]P3FK+5:?D=M9GDT#96FG6]:>
MR726)QDEEBH(ONE)E)KRG?\`<#Q(Z0-J+&J-5B]!IBYE_9CS+S3FM9=<;6+/
M5[AK,V(%5;^R/)N=DOI4O5LM!6/.XYX_!C(L9*Z_IF1C`G6:1A3R%LF:YT<4
MBH'FG]L;GV%]</V%<->X?%8?,W)_!W(]9C./>4JO0O)T/(#ICS69[0<FNB""
MM`,;-=6%R,5G+"!K8)"XF1M=*Q'LZ#T*:+$8'<9W;9??\,YVVR0L]OC?Z5H0
M2MLSD&"M`%:YYB6E@!54=FAR?>B6K;`*6S-1\I,T*N^H9?PKRAPE1ZRLSN>!
MDVA3-3G0#9I7!A:RGAQ-K;4TJ5S3;*E3^JD75*<HPPD;&('".*CI5<KIPCCV
M+_8]PMQ%CN8MR>ZY3'XDVTG&T$/Y#)!WX`EJ2?9EY<8N64?3:0HF)U0'7D!B
M"0ODF5"8YVQ*X-87HQ[K>PWL_P`=;WWLY^V&<HL;JM;88#@'@#)5UUEJ@,.D
MT3W:"^NI,_1[8:P&2N1(!5,BJHY;A%5/*!>@O1R'>%Z^/.5NMY!%KJ^%SZX,
M2>I*V90&FJ228[R2WLJS:1Q7#655>V.&F%$-CKBAW0.,\%_@&K7]NW%3?9+T
MUOLKPN[1SA<`ZJ@V-(75V%Y<KR=8:$>?/W0A-4:'1B4-B<FG@D0$<BU6OB%F
MBD9$SQFG"NGH[[$\AL])J&NYE!SNVFHJ"IX=U%1NMC8T%MC<C6<GTJ9$S8#C
M:0K2UM9_763O8<*"*9*K$;"Z:7P:H;++3V1S1%<ZKBUF?W'YZ;&XO.,SMFE]
M6Z=U08.M!7TY&9@UA-S(=E?MG%_>$RR!Q?Z)YWJBR*%BZ^SU]I/RXD^LJX0R
M;C-5>.K1Z<NR.>%<@ZL7;AUEI4Q#A15F7@JA!R!9Q)R5`@<T#^01+Y@U+\@?
MOIX,XBY$N./7T/-VKTN+UE)037QH`8E;"_,6,!5@=GLG=/FFDDN3P(4:T^)Z
M/6.-_P`;4[QN#\>P/[>./^.;7A'=@Y_F'D7CCGNQT7*663,TP6=AGJ,GK+7$
MW&?^"XK2([[45SZ3XG6P44$H#6_$U.Z>;@SKC3]AECRSZU<G>S>CQ'*61XUX
MVI];H>2<(V_&?=7>;O;T$G%7,UZ9`'/HC["SU`D3!HV12@5,$<Z-<*0QZA7#
M&?O#]:+E>*H[ZRYFRUKJ(=Q7[">MGJB!\%H+RCES].;?H7#&+H<J<_[3Y1Q&
M1LB@BD>]%D1G<+4<$^RVUY]_8QRYZMYS*7V?.X]X!T44V^%O*X8ODS/\9US+
M:'5@5"RNJ[^CTHK6D#_9.5Q"N^1'(OTZ"V=T;K@C=3O*VYGL-T_39LR@%E>U
MP*7V6K9!I*Z&`1YAS[7\O7'F-85`YS7G/8[XY4\%#S1?L:]S?8[><7[/A7D0
MRHO:4[FMNR!THD$%O=$!?*EF5C]3$C@WY?\`"W?Q20CN%6<IL;_F<GQM3H/]
M$#(>RCSN`O6'3@Z`4PDOA7@]M'^+-#II=+I;%*@4@6CKK*T%&+&BF8C"U;$0
MS[9',:Y)%1G071!Y")TF+M`CJV88FPQ.])?9C$5E;<?>OK()CZNM&^_T%=$0
MXJ0A8W%>4#V(U(?_`*T:'G&J\+K1ZO)4J99KU+Y%S1>I&,<D]O6LGVE@L%U3
MM`N@$IY6<>6#9C*Z%"ISSWP2#)'X0L4+Y7HA-=I'!7`L-/\`E1)J2D;8.4.$
M&TK54;[>NGDK`V:"K(STLKI0(XI3&*YSW2->SYXP[K`\7\B4M#<Z@"TSD^7Q
M]4W90W-SIYZW$5>G=20S)?9NZ(CCC@I1PI7`11ODC?"L'9\4J(I4P3APSQ-A
M-S0#[K`\FY:VQFA`KJ%E9173==D':K\59VP=ZNCSL-I6U3CRB"Q)R/,:-TDZ
MN;'')]M%T'XN>-=-C>)UM=U=EJ=K+8>AK\U24DC:68.(@B.PM:IKHZZ_MJY:
MQKH21[*)ITH2$.DDCC>TH8,*,_$6/%U.02EG22;0D#[&RF;/+JZ0TO4SMN:O
M22UVDT.6\L*.U$5PEC8PPO7Q^\-8GGT$CY;!&G^KO/>"IJ%V;C/S1HQ.LV&S
MA`K*NU$)_M'SW3QI=7XCYE;R%D94$Q##8`FMD8QO:28.A]`>9QO7;UXH<EKZ
MYYG'R:S=2U'*_P"26*DM)@:P>SM)R76;(BH%TFCE=+7R.1H:`R22NDBB@\>@
MV!\:^YO"7*O(-/QCE;<TO57]=HK2JC'A%MJN<7*R)%=?<6]$;:`U<X[U_C$8
MX>5Z_1&^2HBA`7[9L;R?O_3?29;C<77'UY^]XTFY;K^/XF$;D_A:OU@-AOQ,
MN(Z<64PV046%9HH963/"2=&=U_BH>?OE>S]N8;_%\E9SBG<;3A3CYWL]0_KS
MAH.&%8FBY*L-KP!I>+CN1>*''UX&6^[IJO>9ZNO+/Q5E3\I;HVD3,1P7GX#I
M]1C/VI#+P3A.1;XSDO5<D\A^\Z\P\:VH%'P\=H,.&M?:\0<OV-@P:QKK37NC
MKZRD!%E@DKGD2?*U&=^@RO,AD\6\A^Z_'%;ZV;(K]@NEV_/W+O`OL!J,1:;;
M&:P'19Z>PXW/QO*10Y-1A(,_E9A*3\.V41OY$%6.9(JJ]0UI9[6?L5U.3PM)
MZT:WWBN<[JW>B-#[8$<R90JEWN1YFN^1+L+V6GXYLK;/@?992#*59$%PT88D
M(-L8DL)#DE^H7CXYTGL)Q-S;Q]QO[(:_W#N_7[!<A<U\7\.:?+9NWU.CV?+H
MO*&'FP$W-=IDLS;$28E,A?&Q5AKX(*]X\<LA$S5B1.@J#;\A_M&N0N:\E16?
MM4-[,0\<>RS/:RGJLW#)C./K`V[@C]72?5ZQ/J(:.XG/KIG/6:M)N>P_U);"
MY'-Z"6?9/&\\$>RQ/#W(E%[T<C+E_:;TZ*]9X*[.#Z;U\M/7S/XRM@TG(_(V
MPJ,?H0I.0J;?UMQ-IY"YZ<A7F!.&&;"KI%"7_P!F^*]K]K[3ZSW(XC]<[CD,
MS]8V8XFO>"\].;I8='RT1R-R-1Z'V/FXNRU&)*!H[V/B#$ET8A4L\Q,7Y6:*
M,&9\K%0.J]@=I^VBZH/9.KX:SG+\.8XD8#L<QI["M!#T7*V`]@]C7:.US^+`
M^*.Z)U'`W"AA8R11"*9%=0-C2"694B4-D?ZWN7M]69+&<%<K7',W*NDUE5R?
MS)@^4]+PER9@<MF^'9^4-!3X#C39Z#DJDS.C9R/2TP[&H+95X=A.$V.9T7@Y
MKWAM@Z!T#H'0.@=`Z#\2M1\<C%;Y(YCVJW_\I'-5%;]/_5%Z#S%<L>O3>/O1
M;(UM[Z[<[3\B\&>QOLOI?5'B+CG)7/)=!-=F75U'Q?:[W/16T0S\44.9&2"E
MH9'`.YRJ]>Z=N@LA[)GWGNGZ(\F\#-XIM;OVG]3=9Z=";6KR5?;TV4H_8&M,
MX4W^W_\`$]X*:&VZJ,3G]'802JR26!L37QO1Z)WZ""/;SA_DSE+V?]P>._3G
MCGEF#DKFC@7G',<V;SDKC2PRV4J-")PS/3\-W/KI[%W,8$50;<[+0!UI%=4D
MK')#*83.^)16JH99^O\`XZY#V.8]SMGA^/N;?2N@UWK=PMPW1VNDXZ/I=)4\
MX\7<;6N9Y`Y,Q?&$\;"-,<+H'+,^W0=S]%*K)4E(^CD""/2KB#V?WW[(?0+V
M"YJXYYJ*K^./17V"XWT/,NG)TM?G[K9!<SZ"KI=3:YG69?.W&9.YDQWP64=4
M97UUC7C+$.]Y#8FO4/55T#H'0.@=`Z!T#H'0.@J[59BJTW-[]$4(^KDR5E:G
M4,$7B/+:3%5C*>S/*G1W_<BJ5&Y6#L_Z5_V/3Z]!8&RH0BOO2I!G'33AE0N!
M()<@1*310M6&6)ZK"U'_`&[4[JG9O=5_Y7H.H#JA5S@L-,0K@%5JEBH2AT,P
MJ(X>PKF3HO\`%D+5>UOAV_DQ$_QT%+.9XJINQET$QT]3"5``#7611:C#559?
M^`NB2XJY.T=J)6%.^Z<R9'*WQ^-G^>W0:LOV8ZDRLFR.8TQT%O:9C-ZDJ>"(
MN62V95ZC=BPXPX^@JU)D.?J3`BXY&.8X64</YO+NQ.@[#2<6YR\+RH;L]EXK
M(*PSC4O-7:5PM==4S,RZ5PM-6E$0+:YFMU&G8^%?'YY[,:!6(LB+XAG@F*+J
M:X#\R4.M5:?C?LSXZ,-PM`+GR5+&855D3MFQ.^O(()!7^?>(H656RK\CF,4.
M]S%?EI,^$;2ZVIII:$6ONBZ:BO:"]K:A;Q&U<#F16\D-]GZ-D@",%IK%&0)(
MJO$<Z57]PDSC0GGC:\K9ZH`O(@ZY+24;DBQ,&&,M[>DS[4/9EK#4-5M.#\-=
M>C_*+7*XT4:9[9T:A4?<-E$NBJ\^3>Z*.7-04N39YVUN;IXB7QT3QE;(P)C5
M>^KCJ9F?''#.L;7->OBKEZ#SX\R>VF0.(/.H\P/H[^MY$A*V6K."T-#GZA[]
M(1;U_P!J5;1C/CNBAI6#0W(K)XRH_P"?T8J)T$5<.^GGL;[_`.YLM;_=W<>\
M+T]_H7':V+75?((T-C=Q//GP^6S[RXSH9Z$:VAA.0YD(I$$(Z([SA\4#>[ZS
M>M?K)ZAZ>GXFXOSPL_,1'&S3RM7:I(;K-1C:VZJP[^WL[573-&A9?6L*_&JL
M5S7Q1-5S8T[!5;WBQXM)SK@MMHQ["*/54=[G9$K]O!6%F6MF!)5H/0.<KK*F
M`C#?V)ED8T!D:J^547H(VXIYFILQ37%@-+2$"T-52YG^N':(&<L8RH@J*F$7
M2-C(?3W]EQ\!`X9;"-[_`+\T629%5GQJH-!<<.Z?1\@:V*NOBK6P2FR6@U&D
MV5=?8&NEM+:K.KK<TB8M@U506U2$2XR+S2%?-(W_`.QT;5#6S[3?N8POJU0<
M>XCUN9#['<D[3?KQK]EQ%9-K^,:761ND#T1VI/;YNLB,P2L48,([GQ>2_P`W
M=DZ#'-CM\SR[H*/1\Z1?^5,SQ+8<D:>FQH<4&'XT#Y'TI!&MT[6GDRPR6<6<
M$N1(;@QZ.^^^1&1_R:]$##<?K-YRG7WMW8!W3Y+63(5YDU3?A4^$Q67(J;2I
MKLA;T4B.!OAB*&%U91_:I(JABO9W^1KU0+&T]U4V6KB'R11]K#38>Z6UU&(L
M2*+)BC9`-)*'/V5+?#Q_;UE++&^1LST1X9<:31=_%.@_=!<$7VGT,O'9F?RL
MH&(*XT2JQ4UK>7Q%%I2EEJLU6R7#&T4UV(>JR(4+)*OS^22N;+W9T$2<GX0;
M)00:N&X#`GS&JFGV&AGK`V[:HT>Q'JW7VPU!3)66<](!=`?-`03'&6)/7FK)
M$UKD50T$_M"TFPY?UWKYZ4<4ZRGNN7O;#:YS/[`E8*>-FAK'ZEE9D-7?WQ4[
M'9NLTM@>PH"$5B!/"A+FF>DCF]!L%`H0^)];QKQ?QF+L>6>*?4S)F>L/%VLQ
M5-2WEWI-5(,M=S38+(:0)C*JA(USY_\`[A/*\M8FI$-Y+V7H,[J+<\#*4N8=
M8;O3CY[87-%!?;^[(!L#;L2DJPM&&KZV!X<$(^:CJFGU2/\`@'47[N61)YV(
M\,@Y%T>DR69LM/:`6E<9F\;I<_196E)C2#8YBISR6VJAJ+GD=:0V0NZR-P3W
M0"*<4,5WS-F[S%_"&J#U='YF]F]Y06?I]^NG?UF7Y'-`S2\V9?F.OJ+^OIG7
M<1%N5R"=9S.PU7)HXX'(S[^:,<DQ(UC<G0:_I_9+V*_7QR*RE2#&Z3B;*:[E
M[.9CB#;:#&W%CB#@=&;F=M54KL@?8'Y#3RFT[!C38_,:>81R"O=`K7J'H,]0
M/V7>M/M35TN'KN1@ZS6V(%?<D\?\OZ8;$::YY,B"H:I`J6U'5E+;I*]"ZT%\
M4RG.JBE5L;B6HUP6]I;WUBV/(O))67D];[[E)?ZU@]1FS:JGV]I7QCR*3/5_
M)]O)<"@'7`\,;G_']Y.3&Q/^I?'H)@M`N*]-75><`%XUS22UI5ME:>JSE'JJ
MG/W5>3+<_;16!\+78*%T)GW<\8:*38K/Y3,\E7H(-,P^<K5WU739=MA-:9$G
M&<W96*B$LAI\#/64DPPY60G:Q:.U&+D1D5HV/Y'A**.WZ.3L&E/>?I%];-?)
MJ1N/=YJ^.:W9WU+H\F3I*M+1..B`AS(]1CS3XO\`_H*DX(EQHZ,5289X&P=N
M_0;&^$.%Q^"[#U%V.FLXM+M_2X`6LXXY(>*ZK+Y"#KWN!E32-K/DN=+Q^WR2
MH'JR6O4E(TE:BQKWZ"U3;6ZUI?)L.A)H&2;,\/1[#^F8HRFM9[H>ULZ2TU&4
M'&A<3661K1P#(X&(CVNA5[459E[A4+V)XXX%VG#NUP6P(X\HUUVXH.1]H7I,
MU9C\B:*5EG2Y4^\H*F`%-5@[_75.2;'(0^)!C95G>Y43Y7(&_P!N/7/*\D<:
M<`Z_'%<>Y#CIGK_F\9GU='*NCI3<E7,$#I:N,1SK.(0:=&RR*/$K(RNQ'FLC
M4;T%JJ+BOE_(Y3:69J1<D4=I^`OZ_)4#5HM&/;Y^M+JA+%B$+'E0LK#E8@@0
MA6D]R9(/F>BR]TZ"J9-#%F^,"Y;O.E"LMRM!!5Y^?6"VI%21?U5==B_U129(
MWX^^$M<]/&,TI[4#L5L3)%8*:QW0==R]QCF.4=!Q5=:J]#$EQUN/K,C(1?6`
M640?(`#EZB.QI0/D9:49IC(P+.5ZI4RBSD?+,V%[GH%H]7[,W6PLLU9/XRSV
M:Q60E+(D$*FQ=M269KRC6?BX[20Z*N&J2L^^)MC90)+`)*US8%>Y4[AQ^+O8
M?.\?<9OXWXFQU%3BZ(6?0#)<5&D9Q]G#-==W82,J)(JJ)]M0/*J_N88H4>^$
M@U5+^))&]!!7L'H]3S13W%1%LOZ?<5@!*!VAMX9;YK(W)D(M&H@L->U]CGY*
M6V=`5)'`Q\<=9/.B.5//L%@D$H&<$\2XHV<CD/EG/Y.'/:GF%YT\.>Y!)S9B
M$\BOO[A\<)AV?VKTD/9.Z!GY)7M8QWFJMZ"%N0>4+"7U^Y[%A_L%`07B2JK)
M:8"PKJ'<WJ,MA:JO"0@V2/\`&H#FZ`>:]&^-9T@=(WM\SW-0-1K-;5.K\IDZ
M\H@%F=IML#9WV;*M)(";C1@9XJ#43QG(D#M746S8EI$\/.%LD4B-7P>G0;%/
MT]%YV?V2W9=%:98T$CA?)T1+*R>*19MS0JC-.=!"&LHS-7+&COS3VN1CY57L
MJNZ#T"\P[RYXRXXU&XS_`!QL.6[>@!:4%QY@H0B-9II'SQ0."IX;$@4-Y#62
MJ]4?(U/!J]!K1L/V\\.5H/&]'#PGS'-RWKN3MIQ+:<(?A*4#9<=[GC^NR5OH
M*K0S&V`]$A,=+R#3D0-%GD=.T]&,17M>U`M#SQ[O\2^NW-_J/PEMP+.+:^X^
MTM,-DF!P0RE4)]3DK#0BEZ6"/R(96S'#-KDE3NR(B9.Z]N_00MQS^VWU!V^;
MYDW6@U4_&^3XA]A]5ZTMN-D)(,3L=MCA1B;TS*UXS"#3Z&-)U>PAC58L#4E5
M4:Y.@LN_W8]481+@Z'F_CV4.GSG%6RLC!KL20*.@YSU5EA^*;9Q<3E@=!N-?
M3DUPCO+^94+F+V<G;H(%X-_9[ZT\I7P''.NTU7QAS$[BO7<YWN#OC(9(LUQA
MD]1;9DK57&AB[U`22MJGD+%)(DL<**KD3Z=PS0;]F/H63QQ+S%![*\7_`-&;
MLJ?CJ>^6XCCE;L;T-+*BSTH;HVV/WEG6O0D=JQ]I('(]J^*]^@Y/L_[W\=<`
M>N&)]B<A52<X4_+EQALYPV#CM!05--NK?DF!2,?/-N+\L3*YG/GP)YOL#YX1
MX^Z-<Y'N1.@[G@#W?XJYNY5U_K@9\N(]H>+,%C=YR[PP:4/>OQH.T0EM>VMV
M])]QD-D/!,*K99ZPJ>.)7L1RHY>R!<_H'0.@=`Z!T#H'0.@=!5/W,]JJ+TSX
M/M.=-3C])L,S1W^9I[Z/-M@\\_7:*X&J)-1<2D.;&+04CB6RER_Y9']>@ZCV
ML]H*SU7$XX:!Q[-L]+S)R#'BZ.O#M:')5JW4E9,:^PT6EO)@JD%CA@DC9)/(
MCI'^+$55[)T$9Z7W^`XSYMX_XHYGX>VO&F=Y-HM`=D>5;`VHL\<?=8SC2\Y6
MV51WK9YRVBT65S1KU-\?MI9(D:QRJYJ*&1^NOOQQ7[`<9<J\W,CAPO$'''C<
M#ZS2W]-]Y:X1X!=@-M[C.BD27&-K;$8-\@T-E'#--$GFU%;]>@A33_M"PEO[
M9^F'JGPM6U^HN/:K%:WF@S6;)UIEZ:BX7R+U#0[.(^!)-!M-3:-?'7!-[L2&
M)TTJM8YBJ&U?H'0.@=`Z!T#H'0.@=!0/6;?0YCF6Z,/M24S];:4DM?$\2!3*
MJNG-^+2B5@8C6326.B$_T#ND\E<G9W^>@MADN6<=LC)JZM,E@L(R"QV`GP/&
M*F^P"J337MB<B^/VB7,,<B*O=LODW_CH.-L-<%QH/;7U^72TF'`J7NA%'C:V
MU-N"B&+),R-5;`R"%GDBM1J^;Y.ZK].RAJ#YP]VN)A,_+?4$(N<U\R'SPV7(
M(IX]A=TM=&^N;?,I*^<80:5LJI]JQ\:O=]'M5KOY=!KSU&XY"]R^2*/E,'##
MUV)R$.8KI7UDY(>;S%/7WML;60LTA$,-F<\>>:<<@R%KD&,@EC8B-D7H+N7L
MW'N5RQ6H9>06]U8:NU.VNQ'/TX-R57+G_MJ20NKISJNPQ[H3&0`.FJGCM,!:
MU41LT\DO0<ZON-*%/,015&:$^6CK+$L&H`T9UEGX0$;+-]P=8VTTE"1\KX1I
MIR)#I9J><A#&DO5JM"T^6XXVF@`TE9<0:?*8TJRR.EJ];8/SM?7PB2SO(:D+
MJ^J=HMI<@0M:PF.XG+:2V7S5$E5[E"Q&OV7#'KWG;O1W)-A^7F'N;DS/4X56
M+=[,8H`.-TP.=\@@Y*T$.-D<"/2/Z0/[(]R.\@T2^R/LSR%[BE3<3\'9K0Z#
M":'&V]MQ]Q"#GUR&GM-%G(I3`[_>2.D:*XBCG@>5+7GL6O@CA9_VY"RH^,+F
M^HOH54<1Z_CW4^S&N%VG*^@I?[7D,Y_9+F;'8O32U<=SNI)P#+!0K,JPNS)4
M<0K&M)^K6I\2)&@?EV/YI]%^9)0>-#&Z3UYY[MK:]J<[HC6$XBDY(T)PP$<]
MQHZ^'\D#`93*.VN`$</6F,5[R/(B)LC@VE5R5$&VR\#Y\R'O0,6P:6.G&4<X
MFLDLZ^2TKZVSG<6.9FP)F2.E%?VE=*R&1J^3/)`UJ^ZG#8^WO<=!(79G6(:[
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MJH?,%#CY=JR`C$W=:!"4*1W>3.,B-E\WM5RAE?$7&EJN]%JA:^IAQP?&]I8[
MZU/I1;430Q`7(C<V,5"BMGAN+[/@O<*6Y'PT:V(2/B?$^1O06TSE5E*J$SD"
MW.IE`!0V*VW.45[]/$/745E39["RPV$94)]791W'VLK`&"PHQLCFM\%5%#Y:
M;:V/&U'I-C+56NVLZBJUEV[,HR:PVE=GB,_'8YD^6.`RNAK6ZPKR^VKA)8;&
M496NF547QZ#45PE^POB#WKBVHV(H=03R_F8:K/R<8\JVS67M543Z(LVXT6&-
MA>/('%4N\8F1R1$3BLB^,A)HWN3H*L60F8TG[`.2/9[1:RL=K.%]G5>OW"0#
MM-F1&Z;60\0[+1S$?D:K/B49&PRMD/!*7,P**IA$;V4=TRJK@VSX_)2V%M22
MV].VJC`2HOPHZFHI:_/UD\43`K*DNZW217VHES8J*K%C%,BMR(U^W()GC7RZ
M#S3_`+KO9?G'B/WEWN8X@Y1W?%>5T_&''3=9B,1I+O,9&R+*KOSAHQ62#O#*
ME@0=T6^42%\;7#HUCNWRHLC@KWZ>^F&Y]T^/]-S'?^V>MQ=V^W.Q.JCMJS4Z
MNTLL]-%%)YN.@NX9+6MD+,^0Z-[F_#"CY/"5RJG07BPWZ81,1>Y"?2>Y&]XW
M4VOLA2=@'4'9BCJ4KH7CQL"MQB[B1]9XR(Y$<QCG*J#HB.?\K0Q_*_H\XUO=
M.T#5<V<AB5=A6V&I"N3!:(,R6KK8VFW4*5<U=9%VDQ$TD@X9K)!V'20NG6&-
MLC6-#,\S^F+U9!*)N?\`R[[#?=TKJVYSY^73%EQRS6=F#!G1V&0489[-"(IX
MY,\4#6N%=WC57/8J]!<^/]47"O$4W)?.60YP]CJ[F?&XC3[0'E-E_*[756QH
M:&:_J-#<5E985[+VX2Q!8.H#FMAF\T141W\D#;=Z@U9OL5ZR^G_(?,MPE;R7
MRYP&;KH=3?,K<N;<PU!\X)5K?&5<8,0]?;V8CIX7_'YL'E:^197JY5#HB:"H
MDU$8]*]E7<ACZ[4?V.1AA1$FDDM*:C)IV,5\4=L<7"/-*(3)YQO#KEC:U%<W
MQ#%C(Y:<H".CN(.P.FO%!K-'\4IS+%XP5;J[#XI44:IJH*ZX=:Q>:/>-`'/$
MQ4^5R=!`&<T!)^GL:AU=9TEO6VEFVCV5/3QR/T^<S]*MH=MH39)WJ7="C(H\
M-?%''''&B*G9OTZ#O-1HN6&T4AV'W053I;3C`K93U>OA(G^Y"U=86!@W%Z#.
M(*4.\JEJ%G,JQT:CC9&AO\FP,7H-'7-6<]M=+QCH<K[!NN:+1X3CX'89'F"R
MT(9W&'W8EC)-;R7US(-)=U6GOLU?"TD.;EF<(Q9XOX-6.97A[<.(]$[_`/1C
M]*J\NVCU-9?>O="1@N5A->^$C0)19Q+`FE<5]H=)FIG%L^$ESGRM(C16L1CN
MW8-IO$O+;M5F<]GC:J.ZGO\``N(EU]>M/#F*^R@JV$TN?EL:AHQ95G%%*]D9
M,4`<?_;*Z.*-WT0-%?(/(VP;A-+31U48<@G)&HHM5KKX9^Z`T;++\I*_:$9C
M'Q9T76#NSH3J_P"]-:MVJ1103E2->SQ"V5C9Z&BSF)OAQ:P<=*>IJ%NQ;(F:
MVB'L88*($:DM(QIS<?>'SV#/"=%0B$570ME%D1I#0CXB^O6J?G#8A$J[NNCL
M-E7N6YO:>S2R"AN!,76DTTU9#JS:^NGB4I+!\_P]_.:65S5Z#H:P``JB,4.K
M92V]6;)+LJP=LU\%L,A?RAAYFPK<>$1%&,F+FGF:MI.1/-92AE.C;!`L+(PY
M%;K1ZJ$#."$7?WK*@]\FPU=><[+.CK6&C(XD,N>:XT=W;ASNAK87+'6A1.>K
MH7JWY$#)K+;:#0"YG,`#P#UK_P"Z:ZH?N@*UI%F`T!9@(764@8UI4V5+(JSI
M7_*Q)Y'?"ODQ$3H.IPF5V^I#VF3K`HM-9;K(&9LBX.MBF9GCNC*`.O:X0,$8
M^KF/(RELLL-7`YQ+AVK-_M8TE[.@H&0,69BJRGF(I(5JPKVE$#KJ\H(D>#4Q
MSXV74.FLSK""RO3K2K-E;$I"""S?;PMC:CWJX+K?JKOG$>\.O4O0D7MWH>*V
MI8W%=55%4%=B9T>,&&HOXAJT8HJSQ4S&B3%J[R**<CO)S$Z#?'[:XGGCD?UV
MY2PGK-R76<.<W:K.OIL+R?;5:W(V*/,)'C*O(JY%1)SAJ[YOM^_T9,K7?\=!
MJ-Y`_5+SSRGZ4<>>H^LV_!LEC'NI;CD_ET[`$W?(1\C=!F=4_EG-Z,PE;43F
M&[M*`AI)KI4:C3(T;V:,QJ!8SVH_6!;^PG,F>YKS'/U]QIK<1ZF:_P!=\)8C
M4(5W8YC:W=I26N?YCKC3I'2!:+-%4K7-2#XY)E>K7/\`!5:H0S7?IWT_$A.?
ML_6_G2@RA6`M`)^/:CDCCR#>YX(,[@W+<,[NPT<<QT%C=ZW7+G'6K[!TJ/:2
M0]'(Y%[]!@*_I`T='D</Q[C>>LT/CC^.>$<9SY!?<=*78;RPX)]D]-[+Y4O&
M.`M0A<;3$:C=W(,H:,E1@,L#6*BQ?4,NT/Z:=3HZ_19,[GVG=BN2/5'F_P!8
M.2H8\#&+H9`.1MZ)R-BKK+6`Q[!QQ\A<UT(I8YL9+CPGR-\VN5JH&1Y;]2F\
MN.?<A[2\R\V8JRY?H==QR1;5/&_&D><XVML/QEBH\?25J45P?:',UQ,,35DM
M7S/D@'1!X4;$U$Z";<!Z&<J<-?K[HO3+#:S@7D2TJ[ODM]J1SWQ5:[3B?3Y;
M><D;C>!TEOA`K\0MTE$S3B1,5I"PND"548UCD:T(R]:?UE\\^H!^GMN$?9NC
MGMMMQ'P;B=(;O\$1?^.BXBY"UNJ-95""VP0<.*N,MR#;4(4$L<EA5!1AI"1_
MI<C@W0PI*D423K&Z=(V),Z)KFQ.E\4^18VN<YS8U?W[(JJJ)_P`]!].@=`Z!
MT#H'0.@=`Z"J7NUZQC^XOK/R7Z\$ZB7&Q\@@`")HXJX:T?7O`LQ+%C_LRFN:
MY)%%\5<U6R-[]VN1>@K3[6>H_LO[48[V$XMT?(?!S^-^3+^JI..JK;<6-VLG
M'G'*Y0$+0W0#)YX6.Y0FT1!TP!SE6(-J#N:WR8JJ$0U_ZP.4$YCG/UG/-=R#
MP-%ZQT_JCC<[I:6X_P#*?%/'C..Y\?L[O`;,>S;7C[KD*V8&4?9E#SS-%%4:
M-6LD<BAE_JK^M.ZX'HN?I]YKN-N3-9S'Q5BN%HJ9,%/1\4EXSCFFLJ*@.W6(
M`L((=#I;P0QBVA4;H7O\7)&K4>O0<'U<_61J>#.:_73F75\N"ZHC@3BGFOC2
MNSPC=N<#!4<L:V.\I,MFI-AK;]E+B^-J46$"M8D:GR1,\))UA9'$P-P'0.@=
M`Z!T#H'0.@=`Z#23S_H/<<#D/:38G%96W4/;U<PTD%>05?VU)4O8;2CK8_`P
M(4Z(?M\;F=XHU_\`>[KWZ#]49'["!@*6VL-AZ]Y.33W.DOVK:T-@=L1P;IWW
M1&%62N5[F:+[F2.(LKP^"-XB.;_%S.@B/4\8>YW,A(>AY#Y:P%[3@62.>3DJ
MRYJX`J0)D\/]/JHM%]O36BF6,#""K`SXY&$AKX,>Q7,<'&L/UV4H%K6ZXC3G
M<R7>11`LS-IKT86.YM#AE)=/OE(B,$FSP2/46*.$8>)JHCWR]N@NUE>",K59
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MUF^9N-\5N*(WB?8:76Y;A'=X7''6&IK\Y1/%&T4=7I+`E`(`V>8@<<;9&K)"
MZ5P0@_\`;;^VK&?=V,'IJ[19&SYQTF8XO;#PAN,[LM9C<3(P?'TMC'9Z0@?C
M^+:5=NEC#I"I[(!7C/%D3SE\(PEO0>^/[:@/5_1<I\D>DX8//)7L!E^$+?'T
M6#O+VG*X2U0$=Q><E9U9KY0W,:V3XGM*[PC$(J]HT^B!3(C]G_MF.WV\XOY_
MX:Y`I]CQIR6/2X>XX6XR*)'APUP()';Z`T5]S>`Z^\I\[.+.M-1J5)$D,CVS
M^,;7=!FG[5>2^`.;(_UUT/&>HUGLIR'ZS<:KRAH=IF;W.!9`+.7>5N#AQM39
MD/D-3D*PM*V&&3*R11E%,8\>1Z2M\G!'W$G'^#Y2I,DM"-!G\AM+0KEWDVC+
MC^,C*358$S#,_71BR?%G/L8GO^&*8B999WI"QJ.<G8+,09WCLKC]MM1VE54A
M4]^>P"E%F,DWE4IX@PV:U'QW7F0A!!GS320$,D<&DJMB1T:-7H,DHB\K2Y'3
MRDWU[56]@P#$U?(%8Z.NEFV]P'_60:H&NLIY!S09SI86$E21O@+;*Y(X^\*H
MT,%OOV#>H/#.P3AKE/GO`8?DK`4\,O)%/^,L+*HL<C54I=M9RT,L57/2G\GC
MSUOB#X.;&CY%A^&99$1`A#W*9A/V;^G>IY'];/8NQ8%%I;#?9_88LRTXAJR-
MYD8/M+V+G-+T>G'JVV`L7PAE#G0P!-\9O&;OX(%;M#P1Z4\V>NG%GOWZS\;P
M>N?M?Z!!9JH]N\=M-W:B<.\N562QQ#;:]K^5,=-('LMGR?86<#@"*FQCF.29
M6RP,\72J%>OT+>HM5N?8/V7]M/;WC38LXTQ`>K,XHXPU06Q6OLN8>6JVSN<[
M*DA+B0*^,#)NG^"TL)OB>K&(][U54Z#=5C"JZ:")I8_]5BK(`=-G=#=:"JCL
M+LN@5:]-%;ZR\$`R%ECAAD^`:*&06;Y&^4Q4S?X=!XMOW5EUQ7[%^<65EW6Z
M.(*#"`DW5/?XS359M@-A<]&>M?<X0(6D)"')1T4372%E0QL2.<B61KEZ#;#^
MC^R&!]-N9U,NQ*@.?FG)5I-M+2$%NSZ601,,,LQ(TKU(98D>,<4;(7%_/XI"
MJ=UZ#:;,1&Z[<,;]VVN=H@_@H*U+&$8H#1TY(`)820_D&"QVQKVR*TJ(V2-.
M[%6-ZIV#N89*-2P[&U%B#K;``QK#UO;*$>""*M!BCDLFUE>*8")H[2"28&(>
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MQBHJ2N<@?BS)QUJ5J+K5`Z!-G8X-VIS]80&P)EH)5V<K;,D*O"FE#<`8VN=\
M\WG)*21&L2L;`YRJ&)VU=1F6N6LJJLJV&E5=J?B2:75I5MI0[.Q4/>Y2_*)'
M0"$I:CR:"6QRREB=DC1O?OT&-;S4;?CD72[;C/.XG6U^5-'U%\$3:V`Q=MQ]
M9"OHHAL=]HJ?#<M/$C2O'C2.(>0>6;NGSKXAK)YVXH&YU]>=/@:(;G^@Y8VV
M>VO+%_\`^2BYZOCU]7,8.N5J!Q!8"02+"YL*>>)'%>$RR#)(A">?A.'IS_7!
MQ+N*;]2_H-_Y)%M,9=8/'7`:U<MB_P"]$FM;CSITDK:RJL"2;4ZJ:]01GJC/
MF5J/:G?R0+R</9+36EA3/&@FIS*29YL5GAPZ_,R_($1?H2/;-LYWUUEHI?-K
MI0C4<Z6)R31SHKW=P@#>6L=;EF?UW0QNT(6JN9_QF:R)(1=W7%`2@WN>,@^8
MZ*_T\QU[+(XB-ZQ0JH[HH)8XU6,+):5XQ7%V1%K9J.NJ+C1T&B>A1<4UW<U$
MM<X6THCZ^DT^9:(3LZMI$,L[S91GO9VE29.\?01<"+!=+!3!/+L2+*U<HF?I
M+*$PR&QM!89+C'U_XRSJ:,Z!C565)!X&CE#.;$QD;&_*X,;.R-W@1I@RA;W(
M4`^DD$A"LAZL.^$LK.R'?21R5=`$7._#E,/<Z5)S(D[J5%%Y1PJ_H(F./1IU
M!$<./8OHK.Z&%KFWEB;H;06N89#/+GKF6)Y]FIA=@@ZQ643PPA9$6&65D<D,
M@**@')-H);BZCL745S=7AE\;KK3:"E7!K7%LM-97LS)A!M_5VTBPF@+!4#Q=
MO)D$3$^%H9525<R-"NKRKL*[2VXW(0N.*'+,.Q^5@K2#`H;BOKP*YC16WAAK
MHU'GL'QFR2-GC:L79RA08?,V8)B8V_JX0I0PS*V^HKF`ZCEHOR%J+.'/#DRB
MI8+:G;(418R&@0%R2SHQK&,\'/Z"_'ZU6V%][>5&L=E8LD-'QO<9I0JVP84#
M9RYECJQ;>8MRE$E368W_`'+_``6,%[O_`&U>Y/)`WU^P,=@_B+9+7<PC<!RP
M5[2I^6BQZ4F''`"SQD6%A\>BDBI_-XD3XT=,OBU7]T151.@T2WWM+[<6WJ56
M[+*\P7J\H\H>U]QP/Z27T&1J)I^>..;V3)5V?Y7WF:<UCH*;*EBZ6PGD&:SY
MJL!DJM\9$7H+_>KW*O.7.WM'[4V\G)`#_7GA7+YGU^S,%=3C25FBY]JA!;'E
MCD42U=*Q$AR]D,X#[%?]:(2BJ[^/U#5H7[G>XV<X4_;7C8.>WYOD3TTTN5T_
M$^MY(PU/9[FUX]L0ZXRYUDX%)8KE"^/]Q;/);1S1$O)#@_B]CO%'*&TWCWV>
MY%Y;YR].^,<CJ*GPL?5^B]C?8^.&KD,A*!V.5SXN0JA3HU^*F)N]#:$FP-?_
M`"D&$?V3M]>@ABDY2]A$_8W[&^IEGS)L0>+='ZO?^4^,]'<9W*QV=9OI=;3@
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M)9)I0Y(3NR+*Y5[]!L:V7[G;GC/$"\P\A>O&6K^'^1M/R%DN`;/-\_5FGY!V
MUCQ_R*O'AA.[P#,#7QX.L(*AF)EG!LM`ROC:UA?PR.5&A!'N=^T'D8;8!6O%
M4L7&-OZU<@<S5F@HM%I`C</RO90^CO(G-&(;I7-BJ9!LX/H!H%C8LO:=T+9F
M2=NR($GR_NGV6=QV?NM#Z]T]D?QOZ[\&<_\`M.35<BM"JZ*BYNM*^AI8.%GE
MYV2;D,L2<U2Y&3L`@>C?MHYED<V3H)L]>OVZ@<V^QG&7"EOPB3B,SS=N?:/C
MOBK=?WF*]/M=)ZK:LG-:Y+W+-S-8E/7WT<"3A31'%>*N6-Z=T\N@HS[3^XON
M'Z@;KW*TVSU]W#S):879ZSU'K+:;-VOJ1J.-,5:XT&6J2O!2':TG*^/9>&EG
MNEDGBF0IJR+X,B8@>B+A'D!=_P`<8BPN;G,F[Z7!86ZWM1G;44[\'>:7,@6\
MD9`D<GWE?`9),]XZ3QQK)$G=O=$[]!+O0.@COEPW<UW%O(9W&0U49R*+C=%-
MAQ;PQE?3SZME44M%'9&RHL8H:V7Q^;W?Q1O^?IT'F7I/:'V@SOZU?96]#]F.
M1<_[B^KO+6""]HO_`";1XO7U]5<6,E<3=X'C"^S94.>@Q^HISOE$L&J3.*O\
M7L1R*G0;4OVG<H<S\?<<8?1\0Z/4U>'P>O39>T)W%.CX]K^5<MPN'26!#[VF
M`WQD%<4)&7$LTD+&N)*9`K(&N>O;H*;7G[(.1!_;[A4?'[&\*]8AO3_5\A4N
M<U&1(J][[*[*'B8[D^MUX#R114KZRBH<\J%M_P!/F8<C6-<UCO$)5]&/>?EC
M0<>>Q=-R/E>9.5_:?!<74WLI_P"/3!<56X_39[D4&PL\IB^%3<\=81A4U2D$
M`;X[@C\H^5[GK$B(C>@B3$^X'.?N+[E_K(DI]-B*/@O8<:\W\G<JX'CKDN^K
M=#5\^\2SA5M[QYO:ZTP8UC=5W&SK-!9JN5U<\JP;.^9(XXX_,/13T#H'0.@=
M`Z!T#H'0.@A+6UI\=]<3UM\BG'!UL@%*1/\`9@CFBR?]LV8AL+G(VZE_U2/5
M>S4_ST$67.3,4`N04(!UU`,8:392%!%V%5<6\C9Y:H0AI"BCM81"YC9G*GFU
MC%=X_P#(818XE7#5]E=UV4>"]P/Y:ENBRAJZF,'&*!9//^-DF$+?+!;DS$Q=
MT1Z/<YJN7MV#D3Z#CVGL8;FX?E[0PV(NL=4BS?9SUP(S%4@*!K95CF8][45!
M9$^66+ZI]?IT$%WWLEP+@J?5/TNJS]A#$(VIEKL_I:B:[;DZ64=]95!5[2_E
MF*K$E?,^(A!C9(G]T8Y$1RA6VP_8!QEA;//YGBZJM-+769DML-2XH8.&*]HK
M692BK4`O13L:1I1_%9#U;,K(P!I/@625CF(%#?8SW9Y!]@WKC([(`[C"YDNO
MS68K;.A$HI[#,RH;1Q:$RNL(+R&XMB(&CB0DM'D(G<G=?+Q:X(9];=AF8]+R
M49E>&.9N7#=;E2LI9Y#%9(+:T$&@`LBYM$?N_P"A6.UTLULE@=+YH0)4#^3N
M\<LB?Q:&\_U1M.9SJ#24<_HKH.+*?/9C'Q9ZVUNFSHMAMBZ>KFI*7^HT]Z7)
M/@5S@=<C7H='`4V61C^\B*DO09-S-[A<E<.\GY[C_7\/:AF>V!U5,RQJM+7W
M-[6.FC''$@>BH_/D!$VKD84D),A;6]WP12.[-Z"L-US_`.T/%G*4TFY]4C,E
MD37V=+E#*[8YVPLW66IMGQ52V>AM=`G&U>N]+E^>0T\P<FM1W9D2R_Z^@DK8
M6/+W$V\Y6X_SIG(=7E*SA$[D(BRRN1S>GF`YATEFB5X%2RRMB;8^W97M()^&
M!DE<C(O-9(W(D?03+ZV\;X[CJ_O-J%3WEY1\E9K*[2PY"O-[8[74ZOEME)*#
MIZ"ZX]FBD`R%D2"8]Z0!O4=5:B>+',15#`_:KV`9ZKB#BX2HHM;O]15&S6$V
MPUU?093C,[6R?95]YR=5G6+YZK*QQD(CI?!&1(G=51/KT&H7#4.&XKXKWONQ
MS:ESH-1Q/RWNH.-*6*_DJ1/9_E/[*GK(\MQYG!F%,L,G<6-4R84\1T[(PF.9
MW6-KW=!YQLSK:[CKE7F+E/?B7</KCS9OBT]B]1C:N&'*>MG-W,<UA+89NP*%
M22$[(!TT_P".?\7QS`G.<1$WL_OT&ZR3%Y_"UE-151+[[+XKC*DK\W?YRD*:
M/8<8Z`5T5.(6)`OFT8@HB-SK>9TSI._FCE>G;H(VYP]G,_ZB>MMAS/R?##=5
M57;6HN$HQ@`8-Q8%(221D(+"Z.6"&T*AF-DCC=/X*H*-1J.\450\\^)_?CR$
M_7A1<O\`!>'V/$C-?6W+\;433`W-!2LE1+4?)7,_@E?=*V)A`1,B/08U99$3
MM*J-"JONOS#ZA^X_OG)RS5:[3\2>ON]I\U!I;=^)DGT^$MX:HF(OSRM9(;)?
M,#+;$DTXCIE(57R(G=>W0;5A>7,?ZL?HR(K.'B.*^4]#MK`C&<QV^*MV6%96
M'<G'E29T'E6J')*+(U]%G/CD&@GB#&C>[P6221KF=!YR>$>?=KQC=T=(7L=+
M_P"(C]=DK/D7C_Y9;O*ZJCHK@$P@.VQYIXE1<L^S&5C8I'Q>3?X^;4^J!_H$
M<]^P?H]J]!DMOP7[.`\;[:VX\RF\I/6$[C'?-TO,P>AQHV;R=-EN,\H#;VMQ
M)G)T+GJGLBE(A>Q?BCF@1TB!K\Y4YLP/+WZQ/?RJXQ-=I-KPWQ/%4\J4)66W
MF#,XEM=5M?AFHPZWD.CSVE)BI!W+`/&@L3`X$5C^ZIY=!X>7O?(]TDCW2/>J
MN>][E<]SE7NKG.<JJY57_E>@]`WZA])[-5G"_,0?!K>$:>AAWF3LM+J.0A]L
M9JXI1!#94K:`#*4&D^=E@&LD+Y4'<1"QSOC3NJ.:&W31T/[%QZJHM!=/Z8U3
M-EH:C,#4O&F&YAD+I:6]'DA[ZBFARE@>**(%(XYA*K&9$5&DT43WM^-0['(R
M>\V?LFA&<@>J.:&M`;R6UL!^#3-&(E^U7!K!1V5M;C4DMWIB1)91R)GP0H7]
MS)-\*N:WH,W?HOV`V$=#`)S[PIQ^+HL=8VL`_'?KK";ER;.A*8'^<$<1<%F"
MZZ"I@E@E_(M&A(4XQX[)QECGZ#I\1D/V-8NBTX%?^P2;48A,GN23J:XXPP-W
M15UC:51+2CRFI9/,HJ>R82L+I7^1,#45WP?&Q7(%D_T^4G$'M9^N;`6'-G%N
M^HK[B$/9^N=+RM%R$%59PFPH--8:L:^Q6;JIOO?SD)!:AG130K(Z%J?$UZ+W
MZ#`=?=4.!W-Q10UZ7+B=*ZPJ;Z:WOV;V@K8*VH$GH9,[(C:LW-L+JHG.@/DC
MCC9--.V3Y.S4"9`-;-KV4;(L914I$9U+4R%,LHQ-'5[2:Q0JRLAG/FF`^P(J
M$C;8`Q2/$972NF8JR(Y.@QMF9TTMW&?6\@Z.NR7G?GY"`'&ULN31H\;P)KVA
MMK)P[=-1M(14AB3^2N[M3H,_+"PN$)S8.Y=E*"12:HB\.LK1PL&S.NB;`1E&
MS.D,C*@@U$$<,L$,;5D`:Q$1O='=!_9\!)HLM8DW^G?9`U#I`[FZ$KA_Q'!;
M@KTPFBK)+``DNKM&#TSH%8*9+'-)&^69\;%:G</0UZ?[`/4>HG$Q%4V@VG],
M,-PCM,Q1`<W9T\"O!EU%0F=ENPSQ%9)VCGBD?(.__J\'?3H.W*]A.),M[6Y'
MU9EKKRUV.EK2+Q;4&<"LI\>?<5T]F+G[@5\C;&\/;+/+*/)+%'.QLWAV5K4Z
M#6SM.5^-VLUF"D.EQFLR!FBBUTA''%G8_P!@%M;RUBKS1"+6>JEP]V,P5D+%
M;Y_=1S/)C5T;'>(2X(3FI.*N+P*4FN$O",9IK+..HZD@R[QM0U[7R??#U_Y8
M4?+*,V5LS;!\4SB9FLF^V:]'*$/.R@!O(N(T&PN33_ZQ>YN\I]%0YH_"TPC+
M&*(63`Z*JLIJV*X%K#H'%PGN?!8I#(UCX&C+%*\+F\B\R57+A?\`9*H6.&@X
M_K;[+:/3U>=M`YAM-%9QMIRE,8*3;YZ6:=ZRSLL0V5(U>5YN+8CVJX*T"XHP
M6N%(V9]%#F]#8P1V*9R6FSU]G$F*4LR^K=L"?:U]SGW"0N:@)+PXXOF?,LGG
M\,;PR_A;,447'/.VIY;UP`6_T=_<2\2V.%S)E;2VG&TSWQ<<6.DJ)(D!MMU;
M5;(Y+PU9H_ED>LLJ1]^W01LV$AV&=6W=Z?@;B0&JMZTR"W)TV6EL098YA8K7
M"1C1S4MJ.0;)""05-"*J-8G\HOBD>$G\VZ"MNL]@G\OYT8=+ZCJL]6W16<*C
MLK*Y#?(I:2WM"-875644R0=9I6Q/#'BG>BO2-RO:&&>G6BP7KS[2>L?'%''M
MM/9^QU'RK*ZY-#DKY&6E!`186E_L'S,=705P\$'V-:"'(K%>YLC?)?IT&\#V
M:X1X6]B^#]]Q![#U8-QPWK:ID.Y`L[>6BKI:H(F`]7&VT)(C@QHYAVN>Y9&M
M[)V7Z+T$(<6<&>E/'-;P\7AK+$3U>5U=M_X)-+W8-T'4:>XQPN0/J^/)I[&0
M=Y2Y4#XFBC?(YC7R/1O=[EZ"7,9QCZ_<#YEO!>==G\:%RK>;:V'RYE[`+>[?
M1:AL]ELS@&DD1V%M:DQ.?-,Z%'/8QOE]$3OT$/\``7I]Z687"<O\5<39K,:O
M-:H]V,YA#L+Y=O9D3U0,`L..TMF:06?!#3">'Q!2/1(/+OX]UZ">.._77A_B
M+7['D+$9F"AT.TQW'F(T9[2)'0ORG$]38T^+K8(I%^,$:GK+*5BI'XM>G953
MNB=!6SBCU$]'-8-ROMN-:ZIW1'-06DQNVVPFUM-!;$5*6\$N@SE%;I8OEH0`
M[N")TC`_C5DS6HKO^.@D?A;T-]5?7[1YO:\9\5UM7N<M6Z>MK=Q8'VESJY6;
M,MQNI,L;>R,GEL+&YD=XRSR(KTB1(V^+$1.@SWGZD]<JV@KN6O8A_'V>R_$5
MG)N!]WO3:JBJ,E8,K2ZA]T1>V,@T8;HZ^PEC1ZRM5$=]/^.@C+U7]8_3?C3%
M:W3>LV7QQ^8]AAW:G6;FGO2-B1R;3WB63Q")]898V1MCGEAM"6AQQ3(-&R1W
MQHG^>@[$KT%].2Z-N:D]?./&TC./LYQ7$#%4?&V+C_):&+59S,LF27[E:^JT
M$+28_)ZO5Z?R54^G0=0/^NGTH%V>\WS/7G!/TO)%-J:#4D$!E%`RUFX*E.VD
M534D%25>?FU1TJSG2@PCR33(C^Z.[JH<;C[];_I)QAFQ<IDO7O$04XMS<Z'X
M[6$^_(+NK_%'<<6=A8%79I\Q\TV#LIJIJ2JYD8;O!J)_GH.B&_6'Z4C!\1UJ
M\-UA-;PA&T7CZO,L+$D0&I@.6RK:"TCDG[W]!2V"I,$(8LT(SVHK$3LG035E
M?4+UOP][A]+DN)LM0W/'&AY)U>+-`%>V:@T7+]I/=\D6P3Y))'QE:RU)DF*7
MOV<]R]D1/IT&"VGZ_/4>^U_,.YT/#]+H]'SK46-%R*5?F6EP/855P$.!<B50
M)YLX>>;;C!PH2H+('3+$Q7*JIT$E\(>KO"/KH;L['B#&#Y,SD)<T_8DQ&'G3
M7;\?5/H\TXB0\DES$J:F1T$36>+?!?JG=.@L#T#H,<U^4I=SE[_':,>0NATM
M4936XT4\HLDX!\+H"8V$0.9-"]T;U[.:J.3_`(Z"KE+Z=>GG#'`.QX==QKAJ
M#@R\G)T7(X.J+5:O0%.)883=;.^N#&SFR-FC:ORSSHUB-1&]D^G017R;Z=>A
M1%?R9S3S8%07^8YFU>$W>MU'(6Z-ER=FZCJ0:;"455(ZR$KH\BL",D'KH_.(
MF>9SU\_+H+%&@^KEYN>.Z(Y>*S=_F,G95_'%!+/1KH*G'VF=<!9!4U7YH9!4
MD9CRC=$C49]KY?3Q\N@P#UWX+]-J'.<M5'KC7XJ6GW%Y85')A&+TDEN6VQ#9
M,&ZAELHK`HVI'IFSO:.-&]C(%<OBG_H&(4/$'H)Z><A\"9VJR7&_&_+.I-W&
M,X/=*DDFWT=ILIX[[D6.JFEFE*L+#1E(TJS)>BOE?]7N_P".@O\`=`Z!T#H'
M0.@=`Z!T#H-`?L#[(<WLYCY&HLOPSRA>9RBV3:VZDK0[E`)53XQ1'YDAJI+$
MI+T2665B_;HJKV3H*\77.7NP?+55.0X+WF?<R78I:T2YNU@36S1Z`B,!Y9$W
ME`=&5"R6<Z5WUEE5KF=DZ#`+^Z_8X3%24,.7Y6M+,O6PUU!6W-($VHU+/QQ5
MA<1%!OC;/</P]?,C1'1JC$3P\NZM7H,1F]&_V#[I`@K+C#4.>1*V[B9J]J\&
MI)T/W7Q?9Z!K2/MD'C!>[XS2&ODC1$8B]OIT%G>*OT@<N15%@'RASEE0&VAA
M;PWY/.22Z/.41B#D!5;[@CL-;:.A,2;M8N14(^1._=$1$"YO'GZ8/7O*W`QV
MQWW)_)-0#6QC!Y:RL0,U2)<23,GM=.9'EQJ^>PN[QT,32I)7JDD<36JG^>X7
M2ROHQZK9)E8T?A[+WCZ,V<^AGUXRZPBAG(:K)4II;UQKJ^)6K]&Q]D;_`,=N
M@M%64U12C1!T]77U8L$4<$(]>&.'#'#$UK(XFQCQQM1C&M1$3_\`!T'9=!KA
M_81P';<X8R$W%#9J3?\`&E<;L:5-&W30R$_C?$V..E?1E#`V-@R:#^(Q;98W
MO5J*WZ]!9WBXN$GCO*7>[L+FS?L<Y0V]I%LJ48&*LLR!!Y&A&`OB\*8ADC_"
M,=R)XN;W_P`]!TW*'*=1QR!J[8TFGIQZN&(^W,*EJQ+8.MCGB`CE@`5B'68\
M\$KGQ2-<Y4<WP3Z+T&I?V%][MOK=8/P5ZQL/M='J@*6,#8Y"IN3=77QV=R!!
M8W!F&`F0<$FE">LQ,TB?;N%5SI$<WR3H,(X<]3:#CK6Z3E'V/*'YKY?K=(W1
MA<4#O#/&S[&)XPV^RL(7?:Z/0N5?D01$6%Z_Z^W05)]S>#\3[K^R/"!M;>Z?
M(\M\;8#458&ABE2@X_$@LC;,^D$DXT&DCKJ"SK@6."L#H8D,D:WLCD:[ZAKU
MXJX,CXZJM]!JF<<[#B^]GU'YW`?<&)$3;#/C&U5?JL+"Y%O:7604J*&?,U\@
MSDC1BHJKW"#*XD_TYY'XDX.Y$T(=OZZ>RES,5ZJZZWOW5-WPA;GR_/9\'[H1
M\S7-XTGC<K:V*;^->]&.3LO05:_<<%-@?1=8=?N$T.TY5Y?KY:W*%L&<)D:'
M*V=H.@]',R61;97P1LD:2Y%>..]D7?\`CT'F&]:\"1RES]Q!Q^+"PF?4;_.5
MS1I!%/B):EA$1(-,&G_[Q`1'`K'M_P`*QR]_IT'K^T7%7K9M-#IX-OZV\8J!
M$A]UE3S,16`4N;-`IGY@Z2*SQ<`+;H@`O_9`*0U\#9'*KT65&J@:W/?/@;A?
M@WU3Y,-P6,U/'E/H[7`/=A*+D_1#\?Z>\M8&+G>0)\.63('8D4S6*U\!"*2/
M/W<WQC[)T&FSTV]7>7?:+E1M-Q)DLUL"<".%O=+5[.S_`!&3)HZJT$[UEX:G
M\T$O"5:(K&?S>DJHG0;].$<'^S'B/]A6>]]1_5_U[N=7QK.W$Y?B6TT[J7BG
MBP./+E5.7#"95D-.!J:>(E9AI$ED\RY^S_J]>P5QY(_6W^RWG;DSF;D+<<A\
M;XD?G+9:/=[ZKJN5'#YFUT6M.F-.HTH`U:PZ9(I^T<$ODJPM3_GH(LJ/T,>S
MM],*-5\C<0*0<RW:(MC>R5HCCZ7X)"Z@@V?RB"M)!)DDABE1ORK_``:JN7H+
ME?JMXTUWK]3>U?'FB0V'497DC&9]ESGFBD-`.('.^QN#(YVS&/HB71N8T<)8
M[`R=$CC>WLO<-S-)69*^LCTL[(?.Q?E8#;6:_!FMFZ"4:-)H[G\Z)*SYIF'Q
MIV#L'2%L?VC1?\]!T4:Q@6+@8M09&78B?-H'55)>MA.%>W[6>0D&Y>59B12C
MQ0CCJU6#>,?@B(QK40/G4F`P7<6)#&NKC09(`_E(*PH`ZA)KBC\)*(RA&N=%
M!+/77508="AK7O\`QR#O5$B5_9R!GM*T6LM3+62TO3(C,?;6$C&#5I4DM#$+
M(ZTH:N\9']X56DE/;$9!,Y7R3>*P>,2.3H//YZF?MO\`>#]?7KYN>$N!.'Z\
MCBQ/9?6Q3<V:/)GW<W]WOY'0,R<MC##)5R7H\BI*,R-WW*JY.WTZ#E>P_M/^
MY/D'+;+V@M?7O1<<8'.9&M?O^4*WA`[(UHJ6D[:VPO+<^[%:^PL;QHP[BI6H
ML:]F?1/KW"S&#I.9:#U/Y;]AO8/]O.0H[S!\8TNES?KSQ*?E])O=K3;6I(2E
MIQ29XE96V[DDDB)2*/YPXFN[N:[Q[A3GU&_;ERYJRA./?:'F6K'S=A275/B^
M2+($-=#CK>JK$@S@E^^*!K?ZV8R)L+6M1$2=WRN[N[KT&"^XO"W*/NSKA.=.
M++O1Z[D+4'9WC._R(-ZZ\S<^IJ:H:`6LSNK4OPM[&<>+[@EB]HX7O1K53H(5
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M%L66:GBWL5CGQ=*P"[@22&OCJ4T;2&7>A`+8UJ1YYHXTB-19$56]^@EG0\36
MN#M!J<G\@!4,IGO*-CSZUI+;CP5+$>XS;$6J"93!/:.PZ*-JQS]WQ*CN_081
M;_D,SF6Z!P>@`P90!E%J[T\0P[324^5$6&+$UV7">V\N$.!+:P^P)<Z$D9D,
ML'9D70<^^<695X+3_:3Y/"ZVRH]#EZ8O/DWI%W7I5'TP0=K0&,(=<96)TJ,:
M^%S*RH>_Y28W=W=!P\.>0M1EIGCRU0]ZVQ!S-_E["\.G?=49\P!]"\*`B)SL
M\,V-8`G]U''C1&PHUJ=!S/7`"?EG3\QX*4V;)F9JFDN*K8:92`:#4&0V=H,Z
MC;?$O2P?3UIK)%G!`<P&)S6O\55>_06,YCU3^,N*>(*PH:OU.FSD%QF=B+4V
MT)U;9-UD,B0RG&3ND'MZ$H9JO=\O=(V1-\O\=!_/25,?M>;C]989(JPVN#'`
MH<L99!V%)9Q9^W@6"RT@(ELZ1A.5K&/6(-L?9WA_-G\?IT%R_P!CO&O''+_I
MSS%QQRWH>5,MQYJ:JO!T]WPN%96'(0H$=J&4YM,'4M><0PA\"1S-8B_ZG+W3
MMT&G:'UZ]C>6/5[UBCN>#B2HO77]CW$.G]=[B*J&S&[']4<\+35:\G;2B$C@
M4.],`D+A-9,BD2P*CG]UZ"2?VN\/>YG*GN/ZR\G>OW`UENJSTXP'(?L#QAHH
M+YE/4;?GV`-:RAXET#FR,FDJ+VHEF62/Z)*K>R=!6K/>K'LSP3E^0\E?XGV+
M$XQYW]AM)[%>QAW!]@8!MVZWE?#5UJ52Y.Z#G;<_U7';:10X$@D15GA1']X_
MIT':91W[,./*BF@VE'[?:P7DG@7AO'X2J)@K=%LLI?9SF*]%V,W)*`-2OK]Q
M9\:&"36DST\)!8U5/Y-7H(TQ7K1[K<5\O:G6\?\`%?,O'_)<WJ-[/T7KY+06
M-HG&67Y&;MLM=!+>Y-Q3L]/L-;DDLYJ=IL3X)[-L;FHCFHO02-5<5>^?-"47
M%-.GO)D/5NZYTX`$T6IWVLO,AS_)518R)W.EH7?"'0W57Q_+J8Y&N9!(T=A/
M=D34C1$Z"P>PX&Y8YA_4CQQB/<G*>S^CY[XIY+MKW%%\:\7UO*O-U?9\7<E:
ML;AG27F"/;/3;$&PQ`5<VP<<R5AD<_S2HKU\D",?4._]Q.(?=#GCVB]G_5+V
M4MRN0_6?U[RV<J>$\-KK+#DVP^LMJVZ@7!-N&9S.ZNMJ2!K*X@6%):]RRLA5
M(OX]!Z;1ION!X"%BF@6>&*;X"&?'/#\K&O\`BFC55\)H_+LY/^%14Z#[=`Z!
MT#H'0.@=`Z!T&J#]N?J]SW[8^MNDXTXG%H=AF5S.ILM+P]879^3-Y6T8M9))
MB:&74B30M!H1KEK9BAU5/NT:D:]T7MT&K#FO.^P?+F#]$^*Y^$^:]B!Z,8CC
MJI]@,]QYF:JZ`C]A3>%J4;`VL&3NXI:CD>JXNT0G_P!S@\'Q`%SH_M_'OT$6
MYOU`]V-S[A-Y3W/$6[SW-.PR=E+J;F3'11<+UET9Z]\@X8;DMG*E<^*QCVUL
M1;CA&9Z-Z54,\KFI$CE:J!>'TF];N67M]E;MO%7)WJ<)=^I>#X`CTH&=ES&\
ML.6<6-907O(&,R+)7"6<4$DWR@6,34>5Y]NZJO083Z1>M7M*?[(_K[Y?Y_PG
M-@-UPIPI[)<8;35ZG7[BVS%[`->Q@<=[[44>VM;.RS^ZY)`B^^F@<[S5)/#N
MD3&-0/2KT#H'0.@=`Z!T#H'0.@_/@WR5_BWS5$:K^R>2M1>Z-5W;NJ(O_'0?
MKH*H^R=V[+ZCUUO614\CBN9:G**ZX*+@2)NDJK.#RK(1F/0FT7X/];9.S$3N
MJK].@M=T#H'0.@=!P)[2M&4I)SPXG!"O-,C>1$DHPD3'22$S1>7R1P-8Q55R
MIV[)T$7;S98FJS8^RM-%+79J6%+!FG@*D7/LB$BEE@4LMD)ZUT)#FKV(A@\D
M5/J[M]%#4'H/V4TEKH]O@N(X8][LHZNKKJO3W$KK2CV.FF*6+/U8^>%H@I?M
MB(W-^XF6`9SXT\VSL<O9`IWR-B.2>1+"PUWO)S!_XR(S-*QF+PYM69GC^4ZR
M.[_^^TE93Y8FZG'Q@I)S!P3G.;HGNC_V3K`JL0+4\8[;C&F`Y,9P?QQ!P=4X
M<&IR=]L7.$FY4WHI-,MC-7!VMA76J5^>)65&COC)'G6?M\GQN[]!B]G6)H8M
M184U=5`M)S8Y$VP2XO`T&'(8BBP7YD<X=E-=O(_B1"V(B%K_`.3'/;].@UT4
M^ANV<_A\J65?EBC\-2\GWY>7`FM(+\^>*"LSF,&'/@B%JJ>$R&*4E92&)-.O
M9DB._P`=!P1`L[HKS"UX0\E>Z^T>AN.1=/:0$$RY\DH&NM(ZGY:Z2&R@'ACB
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M!E=(/<QTECXP-1I<WXYL[W(J=V)_'H*8?IQY/UG"&?\`8S9Y_@;E_E%VSJ<Y
MAJW3<<,I8*RBN:XY-`P"XN+@P-U7.Z%4E9\#E?*U5:[^'DBAMXK_`&8]A&CC
MQ#>I?.TQL%Y?W:`6%=AL^!24UI6Q,4T<*KO1(99B3Y%=&9$M?$5*_LUI+_.-
MX?$OG7VBC'K[;'>I?),U36CVIE@;I^=\ED2R&N<Z0:%>/+G#.'&LJ^=?JD8M
MHK$_G!*/]'('.S/*WN!I*"SBB]*I12]8>+*2;'[(8T"QFM18DFJH2*T;!7EA
MI,Y#',LL$,K2U)F5\C'.[+V#A^H.*VF)O_8CD<NBS6"#Y>T&?@'I<OKB-'!-
M>YN>:GWAA-OIL-3L#N"+.QAB^!8PU;*QR#2-5$[!<2RRM=G1#L1#2.+KEY7S
MHBV(%J?:53=&8UL[J0XRXR\>>LVVZO\`E8^+Y)PI&_25K^SN@Q?D[D7E#&'F
M<D82@MB9:VX$H20T/6?46=;7L:"M?,M6&<EH&R94FB%)8?#%W^0J%O?Q:%_J
MGT/Y<U_'F1U6N]F.$*+17A-+L-/BR\1-82_B])`I</Y`^EV;!;C4TU26Z"=0
MI1E57/5!8XD2%`A#DSBZS]>>9;/&A:1=E066539<=663J:":HTD@Z,@+KIA]
M*38330_$^2.2.>$.1J+V\G-[HH:+=G^LSG*N(U>6_P#TS;[%\%Z/F0;G'+\<
MT&=,?7TFZLRFET^J,R=3?D!P7U*]4&68>+M!\:.[HWZ=!;'D'@/W%YEH)^$>
M8?V5>WO(G%U_5&LY$J'2PW6+TF1B43\0-3?'++!-'4GBN8>A;6M<J,6)O\7=
M!2.P_1IP`"(\B?G'DF%):ZPMJ]8:_*F?<A#OCC&A=$UD<TA[Y.Z/2-OCW>SZ
M-[.7H,SROZ3O6&*"JMKG:;LZ$ZHF-_'V-M3A0K&@OQ5T9!`$#B!-':67^MHB
MM1C'?\HWZ]!**_K)]>.(N,N0=;P[RURYE>2>+>.K/9U\PFRG%S3-\`T=K;DV
M!0C*R%M%(KAIV20J]RIW\FI_D*VD_NCY9MLA@^"^3?7OB+9<IYW+B8?3\Z1\
M@QUA=_471(\X]O'!7QBYR$B(1$DD0J(J%TZ(Z2-456*'^AEZ14U'A_U^XJES
M0U)89(G+`&YV7)SC.F/*N18[&SL[\ZJ&6I25I:JZ:<:-(Y&-[HB+].@ZWB7F
M`"U]\Z'C$K&1.N[?U0#Y+!Y7K\W-#/=ULEV;1OIM'IA[."O^&MF&5`@R:Z:;
MP1)$E1%\>@TX^RF=*KO9;EZDBKQ6Z!;<(NJC/L3[VNM[<YAA<+G1W]UHQ'$2
M5S7$I`P>M'5D2LB2%OFY0L3Z3<BUG"<='R3>AG:J5K(\Y9OU%9*E#A2Y;9C$
M$XX'F+&ILY)>2*OS&`2V<RL16.B<U5[!G7+O+FGM=SIM77&"/K+BWI25N`-!
M=2MS]5.2@[A@AR:T4*RE)B_U_CBJYX,W;RCC9)_-0XE5-+J;30TD`IUY-0V4
MQ9,(=W9SUUU3@1QG5;?-B#V$4@HY2C68/E;2PP)'$]@\79BAEE_L;6[K0L=7
MZJUKJRT';G<OFZJ$@VBKM('WM'CRLI#HXJRNK1XGJ/6QC#3'2(C)HYF*Y$"-
M.7;TNJ&H,:$8ZBQH<U7)5,WDL-3]C:@QH?>3C4[`P;*@,M'N<Z&M!>_[F-R+
M+X+T$?XTVS`U-,.T<YM+>$021Z*>QMM31B5K6OL2:"T)T01-SE`)1"HW03?*
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M]Z=U1.@CG`?MF]8-5G>:-;H[*UQE!Q1S]O\`@.G<4`7<7/)=KQTUK[O1XNAJ
M!R;*QH_C1\C9&L<WXV*[R7NG03W4>_WJ)H<])IJ7G'&$U#,'CN1W'3$DCC#9
MCD*REIL66>L@S90IKVXA</'`]J3I(U45J=N@JYZV?MQX+Y:LQ\+RO')PYR<_
M*\J<DFUYB&6N'JN+N,+V.J*V-ONXQF5%3">-,V=L1*QJG?P[J]4:H3S-^S/T
MD'S9VHEYPJ$#`O:7.25C*/4S:<BUTM;'<9R.ORD%))H;$>_JI6D!SP#20D0J
MCF.5.@Q7VC_8EB.&?57$^TW#=-5<\Y#DC:9#&9.WAT\N/P5<NL/+K$TF_P!I
M)0WTN(S%$<&Z&P)(KWJ)-_"5K%[]!DW!/OWQ9RSS_>>H-N^"M]GL+Q/D^6^0
MLWCGV>UXPK:+8R2)4MSG*3:FI!T#98&MD9)((&DS'=XT=V5$"^O0.@=`Z!T#
MH'0.@=!Q#YYQ03211'GDCB$SC@QR,BD-GAA?)")'+)_KC>3(U&(YWT17=U^G
M0:I+#]C_`"/-Z5:/V\IO66TK)N/]'R-6\D\;[+=4E39YFFXW,*$L+0:X@AF`
MM2+9PZ()!&B.>]Z-_P`KT'$]A?VC9/UL]9O6GV#O>';>JLO:&LKM.%B;JRK,
MR5G'%96LU5B%I+&6)62Z5]=810#0(Q9"2$\.[>W0=3#^W[!.VN?F,X7Y'KN!
M+NJ#K7\XF.JXZ\?E>QX\/Y)!XMASBD?DS+DBHK)14E:J1(<K&.5K7>2!(7K3
M^RVCY5DYL%YQXW/]>"^(.-*OGYWYRY@T`QW`&AA+*H]M92UXL;JFW0<-REUS
M6SK"JHC9']!^KC]F^!MO8GTLX+XIST^M"]O\IIN2*W87\.GS45/QU0#Q2B7%
M97?U@]+*PNEE1T,)4P,;851SI$5?'H-H?0.@=`Z!T#H'0.@=`Z#K`+FJM)K$
M:NL!39Z@MP%G$/*V1X)K6^3A26M55BF1J]_%?KT'XN+VHH(12+D\>OA-/%JQ
M)"'*UL]@:KD%%8J(O>6=6+XI_P`]N@I![51'\@[[UZH<CFKW3D\8>P&/VFVE
M%%FBJ,[0QTV@%6W+(D2.,QXLY3/%K%=X>2N=]$Z"[(6GS=D7&!77]*>=*,ID
M08=H$23*(UW@XJ*"&=\L@[7_`$5[45J+]._?H.\Z#H?[+3.(C&A,:3)),4.K
MAFOGBA("^+[B$B2-',@E9\S?XN[*O?H,%;R2PJVJ:D'[=9)[B$(\N8&_953#
M3)-_V]3:+5?:$W$*L3Y(G.8UG_+O\=!'6V'Y)-LL6W,;<)F<(TEM9;J.Z&G4
MXS(PJJNRF:H@(/RMA>QR]T29[ADCA[+_`"7NG0=QR3RMA>.L7J>2"X`1:C+9
MQ#+ZVM@#'-DJQ7L@ESLPHXYEZZSFCG9\42BO1_E]?IY*@40WOMK-SMP)9BX/
MA+<5/'N[JD#!WAYF%KL=E\M9))6$7=\&%>V=M-%7ER(Y!!`I))5<UG\'*Y$"
M.^&,9AO5/";$0;#"Z6WJ8YK6RU\L"7?*>Q.AK&$9HC$Y^2DK8</ED5S)$=<'
M#QB1(OD]W^>@C\_CCD'D7>\<\N<JSRZV[SU.3NP-&S[$G06X!5F(@F7X^JP(
M;+,,A$^56A1OF))):V61[/%6.0)%TLAO*'(.VAXTR=GC+FJJI*?4SRU`4=?C
M9[L5"9-'O#R48(V&X`A>+)6J`MD%,Y9V-^-6NZ"O/(O(%@[,J^NQD-K18KBW
M:TQ_&V6O:Z\T/.O(+()A:ZKRPC)0K>/CO/R_[YCY?A+6-J_2-/KT&K#BNGY.
MIXO:Z]W&#M(\IHJ_@#-\')0GPD"&;,IL=EM3;!YY"6(6=R5H^0.<$E\BNDA=
M_P!PY6]U"3:B*IH9H9KB[JAM^-LMM8VMLAMMG:<ZAFJ1:U]?4U9U6^N-GL;$
MMD2+]T\<N.)[/)B(Y5#QU>Q=GP5Z-?M^IMF1Q+I[/CKAOEK&<B;7C8BR"K+"
MUMQ#H-)8I0RCH\6M#F)5DH\*N<QO;MY=EZ#<J=[A\/\`[<O<7WA]KM3PK:"\
M+Z+@3C3A#`AZ9]>9=Y?4T;9"(K!A@A+RLS8SO<V>(\5'-@\515[N[=!C7JO[
M%WHFLT'J#RO17&@Y>Q/'VSGXXVP=U5)5\IUP90EKCAZ:]MR*VM_,45&2YMDR
M1RD'-'\&-\^Z=!9&@TLO]HJ4(U>2`N*XN-EUEPFA@B5DTE06RSA!>6DDJO(:
M]6RDP1R+"2K6]OJG0:>_WS;>EE']1^.:`NRJ6U_&!FPO<2)9B6^/`L+T^1`+
MNLMQ&0QW5G:@?R)G;&UB/56I]47H+%_I8J+#'>HO(6O&MX[.74\F1&28:KL:
M5)S\]2##U=I87\&DM:FJHX`)9?D=8OD9$@W^I\D:JU5#=O<9K"4&HHYO*BL0
MK@`6;0V0!%WLC@L].*ZZIZ\6?+6UQ$:Z(D&5XK`1[(.)[41\L#7?,@1A,VWD
MC>=7VE.18045[=9\C4:.M&F'I;"=Z5W]VLMB,#15;SA5_@S\F+)W[0M5Z]!U
M=9H:48XE\%/M0ZLP0`X(EX-O7:6TOJQT@A-GERJ7)V4I%%5%P.0*>I:37I$_
M^4\<;5?('W795AU,/NR#@12)?GH7LNZ3/55,'K;2Y=64A6LTB:^?)7MA8$1L
MF<^%C;8F>)K1`2"$F:P,VXYL)QL:.#>Z70V[:XRQ&'&;9YV*T=N)$?%8WM5)
MK;'.4+KFF>]'PNA0HZ2!/%@:R=DZ#H,=:Y#(W_*EY<:*G#J\."!'K*"#<9JO
MEN*.XA:KM%+3V5HVZH[NSMWKYQ!_(;=(Q7(R*/LBAFWK#6<&<B7?*H_N)S'F
M./,?G\E4:WB&SR_+X7YO0TX6AG/+#924\R&9O.1%_;QV!9PHY(LBNB=)\*=W
M!<G1@_KHJI-5I\#S=@]_RC9<</NZL6VY1JI0Z6,6'LVKM4M+$*N@>3`Y?@D#
M(EEL$[^,7?H*"Z?;<;8F]MG17&;'S]NM2_/&&Z:KI]7^>O\`Q:E'5U%B3):8
MVL`)D5`UL8U4J'LCD3OY=!W64`EME#EPMPQ4&KMAB;$Y^BH<_2@WR6\\ME8R
MDW5O5T-?#`]&M(+FFD#G:JM$5ST?T&&5V?M;HFWI*G'2F7V8RI]]86CCZDWC
MRFIB6DUMM=8[65UB3#;FPR-:5(R))F(W_P!M'/\`X]!P<Y'<+9DVF+F=-HI)
M8(Y3+.FBK\)I65HS?B+K+6\6.$;4?;M6*41\3%>O\T<U5[]!,.9RL6N#]GJ3
M\CE:>A)X)T>?T]JU2(P\^+H,O/>VT#X):\D,VRJ7LB19XI")%G>L<G@Y$Z#S
M*>O7`WZQ]52<7Z/V:]H..N$+"NT.DI=+0XS)Z/DBU*I\R-!#C+;65L3!15?O
MIC)6GM'F=]@R%'K_`"3PZ#_3R]1J[C.D]0L[4>M&A!CX1@S6=J.(KJJK"[+/
MLS;@H('V5$OP%&6M>9)(Y[?F9VC55:Y41%Z"&Z[FGD#*>Q'$''@&=R[0=737
M`99HLV;<>5]OIK`=!:ZSC,=?(.$+"CY*EXC8T<_S9(J+V0-6WO;%3A^W6^T>
M=T-9I#+0E^7/#FM\_8$$`"#A-LJ6LI12J&T@LLK]^^9A(D=BL0[I4(EB[)"\
M.YX%.K[3CVHH:?Y[@>B*W:I61D5S:@"+,L0HJRKJTT^UB@8<`LK(?R3JED\B
M]T('7MW#ZZ.VILL3J=1I[VABPE>92WU?H";X2_051)H[([.@R^5.%^6R@[_$
ML2!;,E',58&R-_DH3+6XBRUU'H>3./+;1[3C/EV\J]#E]I5`U86,)6RLH&$A
M![&ON!+H4"\5OA-\-:-*V?\`A/)*UG=H=+J"!?LK"MP6"N'7`>J2NSL0\5;F
M%7D"O:V(*EL]$W2S,L(SK%6PP7XK)QA)'L4N:#_H>'6ZN'9R4[*=#:T^=QU=
M+M5TI-->\B4>DBJV-O@J6.X^8NP-`G\HWSLC'/)8WS@&?$K7J&;\<:[3QXJ0
M&^PV4O:#09N#C-;Z*VTV7TP`X5A-)5)<T%]E0F$'$ME9-\<SHB7!]G1R/C[-
MZ#E5U_CYM31!58F<S!M=HZ_,7&JU?Y,_&4]Z`+*1WJU)#IJR,"X$"6&5]A$#
M#`][53Y?)'J%UM)MQZ#VA]6LW@S<SDX=9;7H_)N:K(X$?>&,H)RP2():X*XC
M6.1S$DC8Z4-B-5%5Z_X4+,^[OJ9G_=7U[TW!.@U-UB5L[?,ZF@U5$R`DJDU6
M-N1K[/F$UQ2*+;5J'"HT@63LV6-R_P#*)T%*JO\`4^/<<65N8Y'Y@),WI7MW
MQ][>[70XG-"Y?+7FKXZ'B`K<]6Y.,APM/5VH@T;S9&+YRS]W=OHG03+[T?KB
MR'O3?T-AL>0=#C`*7B3E;C$=<T&(^ZK3>2@8!!MG0V1*I)5:#,RP)*-)&K7*
MOT\D_P`]!!]I^HJMST^1ON$N<[;CC7<;LS\/'EE8X>EU%;3QBX</&ZTFVK2C
MQ_SMIM)1GV!),CVRH3*Y%5[>@BW2_I$@M:;!9^E]E[6A`DSW'=#["DP\6YZ0
M[G%_&W(YO)--9-:R[A#QDLM@?(&L0T<L4(R-5B>7=.@[!?TJB13F95GL'=6'
M#G(/%/*7#_-.,L<?71WFGS&UTU;L<K/FM**?\E"9D[RH@;.R2*>&Q&\F/1O?
MOT&:X']1A5?ROE^<>4^?H-_R9E=QQ[:@6-9Q/4Y6J3`\38V/$8/(#UHNF*0.
MX'K(&2%6JNE\W(K(X&-^O06`S?HAIN+?1M?3;B#E?*`*X[91D;#D3B"LWN=L
MLYO-/HM)H*6RX[GT@`!,BOT+FPS.-=X20MD5JJOB@5LX>_4#?>LI^TT_K9[4
M:7C[>;;@CC[AX[4V^%!U4P%C@-TFP%T-9#8:'RAJ#@22ZS\7(^9HPDR)%,G@
MB=!NHK(31JVO'LC&6%@.")">>R!!6'&101L*+8,DDJ#M)G:YZ1^3O!'=NZ]N
M_0<[H'0.@=`Z!T#H'0.@UL[G]<63W'"=1Z_E\CZ47CF3V!9SENZR$2%7;H1N
ME9J7\?6:J3VCSA5C$U)NW?Y(T[*WH(P]J/UQ<G^V7*<FVV'.F?SV3P-PR/@3
M!1<?!:W-9#,WN.`S.\_LE);S5X-II;`H/[JL*B<W\:]&^"KVZ".Z']*''55J
M:FHL.=>2[KUYK#Q-S/PJ8P=2;/F(;CVWXW7=R[:0N8P`#\/>DD-K8!41#%B?
M\W:)$<$]>JWZY/\`]'FVY?UNOY2@YIV6]XRH^"\H7I,8,!G<_P`+XR,Q,9D]
M+G);:YCUUD+(5_\`<#7S0H<QO98F=^@ZSUE_6<SU^V/`>_/YGL=9?\)TW,--
M'7P99];03UG+N@GOYLQEXK33:&PRF+RTD_Q!`_,6[P:G:2-G:-H;4N@=`Z!T
M#H'0.@=`Z!T%1>=^<,]Q%J\EA'9.\6TY4.>VLOL['`*]MXCUB^=99$;&?91,
M[.;#W61_T^G;H.RL;IC01-&%]Q?D5#8,ZV]V!#*\'[FJC0XS\L!/XPS6:%/(
M8DL2+)'+V:WZ=N@QF'4Z30#7]6:38RV#:80@'+9Y5(6^SFF+D8ZTFMG(URJ@
MT)$36>7G`D:O5$Z##,!C./N"AN-:>DSM7!:T=455YK5VDLKK=![6PD1V/M"X
MW.("C<;/\;%(7X9).W_ZPDDKER&WJ+C2BVUS/0UCK/(:U("!*X7/WE80ZIT$
M3Y&JRP8;3VCDA^6!%\GR-5JJG05)WGMMB,)F:$FCU6KY>S@])O13PL4TBRN*
MQF/GK?[`FHG%5UI+9U\LRCS2D)V2-JJY?YKT$C<'E\U\O8T+DTK#U66H[>RK
MC^-:NZMNW(3Z6'QF(L[PL1_X*K`L0D5!!!U^7Y.WS=D[]!5$?VSYFSO-O*EU
MRKIN*N/>#^/-E6S6^`U)(H>VQU9]H(6\X@`5JS6%A=-.BE'@?W-61ZO1/B5O
M09![Z<FYWC[(XW2V?(>C)XUY;J-I##P749P(6XY'U&S=2`XFY;L[1K;*B!`L
MK*`B41ZM&,2)&1?S^G06OPT.4]+_`$JX]SNQM[9OXZBJ:@RSE;)9&1Z+32_>
M(,5/;,<RO;#,2D+/G1&,>U&M^JMZ"N/(==KJGF3&61<1U:-=9RMMLI<Y\!;J
MA"T3'M`4*NF+\M&7-;UZ-CB'C:YX_P#U2)X=N@U?^U7//*F>YVY!R^7-U&0E
MXXR.=L13[&^9GX`HRBB!_CI*LES*P]^DT<DL<[E^LLBH#V2>*1$"T^+P,FE]
M?(XV\S9L:P++KM5O\5H./OP%3!RIL9A:[,4NC.H6+K!(IK^08ETK55GE!X?1
MJNZ#+N6?5#G=NUXTY"Y^!PC>&^+\A7!6)G$^PN*RUN])*7%'*?MUU#Q0YLZK
MG)(B]_B%9_)?JG04F]K?Q>?LF3YVX?L6T$\)4.HR)3!@8G<DP?D\Z-B*\IS*
M"VR;&0S`RV$B+,1/`GP+Y>701!5)P4-/1Y\^MPM,D!-5;WHUOI2(MC':3-::
M91Z\X^11*>:R,B>0&U'(LJP+$S^7DG0?Y\ONSR1+RU[6<Z;N0"OK$M^0]#'"
M'5S$S@Q"UYTH`RCR%N=.YLD`[7+W7MW5>WTZ#=S^G.2_S?K5OHJNH.-;ON3H
MK,><:$.&P*+SE;%615N<C(_[G2F#I%)+,'&CH7-E7S^K4Z#<.#14./``O;JI
MR=$,-G[HBC-?3.T9M!E+0\0O0K9#DQ.,S)"Z@9KEF8J*K'/B[_'W3H(8F>*=
M^2LZ&CI&VT"&EJ\@THFB+CT)`X==+FR(D=+CQKYSTD!(C[$./C9"G\'KT'G!
M_;_J77ONUO:%I26@7'M3F\+77K;2YLX]`'1U(\3;=GYI&RA_<R*[O#$B0M5O
M\>@W\?KFX\)Q7H3P`[6Y(RIL##^0-G&0&2'ABKO+ZF81P4.ETI?@*,-8P/A<
M%.>O_=Q^,0GE)_@+)<TVE[QD!Q^M?Q5?:['[W9U5/>K5[*PHLGGZLQ@U5BXQ
M:K3/A.2:'2639"K<OQB@DC1S%\5;T%JN:>']WZCNV.LY6*JGP[+C_/[<`VMI
M(=F"?8^<`T@`&K='-=4UQEO)(JAT782\,:BP^7DB]!BQW'^MJ>%!=_K<%ROE
M<#R-:,,K:O8!6^;T6NO$B;*+<DT=PD>JJ'$/,^><J5L8TT;W3Q=X4[]!#'(_
M$)7-_&$GJ])HJCUT@MJQ#!;RTQU1;&!8U#8+O<6%=R-?JV34V]@;`)-4+&]9
MV)%(\;M$UW04,XJ]&=;@*?F["'>RFTT>?Y,R1F7SNYQ;0VG5XK+.&;;_`-8J
MY'N,*N[H&!(RP8D^XE>[R[HWZ]!E&&_4O79OA'G[AQWL?<RIR?+CK,C9WXM8
M%8W$6->0P>OS-U;$*%>UM;,KE?"+)]T0[O'!W5.@QGUV_3[Z]U,(6%Y@YFY>
MWEMSGM!,!FDR&5RX\XCG5-W+EJZXU%^0FOXRCTNA1Y4[8D;$4,''"2G9Z]!;
M_1?K)]=</;\\8*HY&V-#-J?7B7@+859W&5`93T^NSQ8MC0[W`S"M?(%813`>
M!-L,Y`GJKW([P^3H*1C_`*F.*_O[,_:<Z\I:SAV6>70!9)WDF[T%W'2?;@6H
M&E&<XRTAKYV-E^R@55B=W8Y$5.@BK>>F=ER_Q_QG7;CG;DS$A\>8T;CB+))D
MS[:_TT[;\LRM@*`I45[0Q,S80'I*>GRN),2-%^1KT0/2IZG_`*Z,O4\.<`8K
M3\R>U]S#)2W.:J-43Q5_0[+(UT0K#\[EMJ+*/%%)&4Y)UHY/JLA;XW2+T$2\
M+\16]U7\MT6AM-/R2!Q?IM3G<6>0(34<B#`XVOEL3:[?9&1D3K?DBU*B^<MD
M+7,[+W:OCT'41Z=-'6Z2EG8:(_3<*[0_+3Y_-)?6T6FGP\A.EPM)4^/V!&A_
M("OE^R7NQ[I"7.^L3>@\8/LOZX<0\8_^`J\3V=RN\OM?QR?M=EG,CQ[926W$
M.AL;PZ83CW9OKQW):ZV=\7D^)%<H_EX+V;VZ#_5;_3W"$1^N/@JLJ].+=C.X
MXHAW7E36U^:L9IYAF-G(FI0T955)*=_%/%&O54[N3RZ"?*JUU=/[9Y/-4F2=
MH.-[FCWQ%_R#5B5!4-)L*JWD9!1W]VY%.&+;`J)]FU4D69'2*GBY.@UO_L"]
M=N9M+R]R)R'QW@KZWJ;NLJ*Q]-59V`VZV5O2E5QE/)054[&H1#6GHBSECJDJ
MQ/D>1W;`/T%;<!2;WC"@R5G["9.CX>TK+BUL@1N4)[;-G^<36P?V0:^U"0SW
M1@JSMBB@"\XHOD\I4\4Z"T?".:JO8^U2YH*N\WO$]=:5F6.OLP7?70E_*#._
M\S#9NLXOQZUL,C?`N<5/N"$^KOHJ=!;K4':T^C7CW^C7<F#SEG95=0_/4FL$
MS0M8).Q\%,76H/&";9U`L3U&?$G>-6N8[^3).@AJCXCNS^9S*&6KU^@P6:MZ
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M2LSJNA@:BM86SLJR?Z^_;H-\W0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T#H'0.@=`Z!T#H'0.@=`Z"#.2,54&F!:6WI8=6=0Z6HT./"-L(HS*:[
M'A8(LN=86V2*(POMV2-J?[%[_P#KT%7O9W?"<'<,Z;D5:^GNKNBT])I202'R
M630SK30#Y^VN*FA\B12["&O(:;,#(K6JOG*WLB-3H,UY`N\9C>,1.2MA82V%
M')^)*Q<M%--!?Z*[NPU;2#5$$")*Z&ULK;P^U\501%5W?Q[IT$>>N.AN-UQJ
M/<[)PV;NZS0&U5]EX`R'3V8T)SH\R.>>1'$]M^.8L<AA$#7L>Y.W?H-5/(&X
M]BO;7G6]]8N(+JHP]S5"E1[.JNTEN$AJ7S(/I-"1<D*57@%S6$2S.`'$:+-&
MV%D2HY'.Z#9-Z^_K6XQX2SN>GY!BRO,',*!:*BN]3^-AP@.AS6EEKH;D::MB
MDM#CF1"@#JK)IY465/X^#>R(%^`*O*Y.@H./\I56U=G01S*JF2FF,6"LDKX9
M)$J$))D=,QLT2N;$Y7*Q%[>*HO;H-*VC-"'W')OK/R>M@1=YJPJM'6<D49.D
M(O=7A]+(FP9FJJS^_#LJ/8W5],]LAT)9@D$OFBPPL5(6A"WL/R?Q3N,?QU?W
M60'7EWUMY&M^1P,[RYI[:VK[2"PA^\J\/IGA04L=S:M)L6'##DNEKQI`8Y)$
M5\L:QA?NW]@>.O:#BO%T5,#I6?V6SIB=1K1LM,)G:VTK:J6UOY[#\<212:"J
M_P"T_'0M\9VD.D1K7>7U0)4)PEXS<7^JW^CK[8;(8II%&M)C7T-7F:"DADOZ
M.VL;DEY#FV]F&D8RL'8Y\"]VM1K?X]!YE0])H.<.3<L*03>#W'*W*7]CN%KR
MWCTL$=N=-:ODKV1,4X*K&IZE'HR1K`R)RI%^&-K$B0-]F6X@V#>7^*AN-=R9
MA>/9[*KTEOBQ!+2J&U)%:DT<Q&DBK[IU5<QFQA*K.PPL;'M:[P7H+$_LWC9?
M^K6\XVD+_#D<EU,V0SMRAT0WPZNS[1TT'VY-=9`R0,F;\DKYV.9'&WNUCW=D
MZ#S(^T5B3"5Q3C\J""LU30U9.KLXJDRNL!ZK+(;EKNHD*F.&+87L+`=DU?/&
MG@D$7=%5JQ^(?MF.79VRX.M;!53[*CS]>522UHASZR&$$@6D*-O#BOEMRYS#
M)O".:3Y8GH[L_P#DO</+5Z^>I'%GNURC[6YSDJG@X5!X8O"(*3D3-A6$LIUM
M#=%TIF5N`_EE%L+DX:.2T9-*Q9%4?XD7Q7LH7SXH]3O;[U5S#^/>'[+C/;X+
M$64NI?2[F,[.<@$?VB-AR0#7U;,2-1E&N.=&GV:LF>R)4?\`XZ";I.<_<0[!
M5]YR-ZE!Z+B[CB:WI[6UP7**ZFR+JZ%\[CZLB"_2(L#-C1DN(GDE?*(Z-\?R
MQ2/>CD"L_&WOMZ_30S<J6/&_,?&V%?9G9QVVSV5%TV7QMVIHXIX=P880=$1D
M8)9X9XXD:UE>7''(.Q'=NP>?'W$Y5KN<_9WECD6DLC+6@T^R/EH#)UFFDDJ/
MG^()P\$JM='&^-/)D34:B=^R(G0>TGUV-T+^,/6B7-53Z^\S?`_%]0-L[/0V
MN8!E"S.:*!2IOK`<F>?.CBBPDQQH(SY8K*<R%WFG;R#(=C<CH+]]:7M7?P$6
M0-D<4%:VMSF`:VNT58H]-&,\D-JA,L3VJ%8G?<O(LFI)\,4P\,C`POWIY.Y;
MT'`=M!/R#KB"*!EO'G,[^=N;L`O0Q!MB$S:94FP+HJ^#0@(C7HZ&4OZJ.SLW
M^70;1?8VW&T/H[Z9ZNV'<87#P_@K:Z.1"ZT._L9:2MFI8P*"2P64N2ONX_MP
MFSO:X$0>!6O_`)]FA036<<TQ,%?(?G:XNIO\^/I8A)3FF9VIL+@Z7^QWAL=]
M8GT>G*K[@:2:RKT!@5Q:PH^:16L5X98,%41MK+6YD9'8A4<-=6U@2BPU4-O>
M#NKHJH>7-!T/]'J[RJD=\"C+,&2*YX\H_D_SZ#)D(KR;>V&/-2PJ;/,4K+.J
MOAZ-E342C%N$K\K45XE784N;D'F%8L(8<#0FQM9-X+)(CFAC-R8_+<D9'DAH
M677DGCN[DT-1R-<8ZC*U%!:0`V0M/!,YE9/8[\<*R(B&%C+^9E8XR6=T,SF>
M*AFR<BF6Q4=G:T!-PI<S9M!FWFA5]<#?'%(87IY3L['1MN@SKET<D=:V",=Q
M2,DDB=\?CT$8GI?:"HMDT`^SV$HG*5D^W%O"C:RN=8VAZ$)>UCH`*B:UD-M%
MD(@(=-Y).YSGL?*JN4)'T1]DEM:ZWA?,[4+*4`>>S^FMI5@`2N1NJ,NCZN>"
M>,B[N&Z"_;*Y7LE;\$;&^7?Y&H@69%]WO;O('6=[8\BW/X9<K'%6U,@U2?&/
MHL],YQ&;)>9!*0R`"FL&.^^CB16SR1*KD=$B]!7JHY0YHKZVH!SMX6+Q-.!:
MZ?=Z'7#5A%C/_<:A0")+(Q/GT5FT9\RR#2I.LA"JCE>K>@QK%9JIWNPM,*[-
M`C7I%%:<=92WLB+"M<U-+GKDJIIPJZGMZD<R?["HBEBD61JL\WN^X1RHQP>5
M9_LA><#93%<5<0:S@_';;-;[E(/F`+8<)T_*&U=O@]9,"%=6^HUM!IREI[6H
M#C%'A&<W[5&/>B+,Y9.@_P!*/].M]<:/T1XPO]#J,SI^0+'&5]CN]?15*!9W
M7ZT]KI'6O]8:+7S5L5=&K8&1Q0C1IV[_`!IT%D.0O8#)<"2UMSL,@=90F:.W
M-JK(3*U,UE-8D1M@MT!*B?7PCW\GQLD*F1SD(:[MW[-[]!&N_P#;CUGY2R&M
M=JJ;DQA-0'1DGCNJXF1C+4D07]39T\,]_-2022%/DBE(&<PR2**2+R5JL1P:
MUO<_G'A?V2W?$_XH*U=%GJJ`33Y75V=WE"*.L<L<5#H`P<K9&6A,IF@<,@XS
MS0:Y6N6<\4SXVL4+1_KD.H^+^,^3,U3::EC#J^>KR0EQ,5**-1`7Q<MJ:AYY
M`K9I+F^$G9W:&Y@?R*OPI"WLU`OI8\D86_SPNOT4S<LM/<V8-4'5WY>2*V;"
M4LDI4K"J76-%T(SBJ^9LT9[)(XR8YO\`7W;V>$?;'GCCCC#*E<B:'EW(0+;9
M6:TM<Y-:<?&F%Z$,L:6C;9%5.?HKN[0"`66-TRE0-@3R^5'?1Z!\]?S?Q576
M=9HX>7\S53;>I#JM1GR=59@9O*_F*^.X71"CYH(4@+5$)-XP%+,V:9.SD>O^
M>@@_V,Y*]:;WC:JHZ?D":UVRV=25FH*^UU]GO3*^F8`$7996Y,12A;'\HD32
M2WS0(5Y$*YRN554(EX$YF]5M7?[?!WV9Y?IMG;`38^_T^JT]K:P6%TTL4[0_
MUK0%N*L(+*!R",<UDDD7C(R%CNWET%DN.>$(.*?87U_DQ]AG7#Q9_45^MJ$L
MZP;4S!E@SEUEC9-KAAR+IX#E;$J.>YGU\GM5R=^@VN=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H-<G-_&W-&VUVJT-'
MNPZRIJ:BVAH;6Z=^/RF2MJO2$S"$'(&;]Q,HU8WXII^[98W)\B-15\>@BR:P
MXJK<#2<5\2'!<D;/G%UYLS(R33KMM[<9XF@B5C#]0Q8,Y"4`*0QC6HB.^U5K
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MA;6*D"OB*353U`EFA4(<93Y@<I)73PD/'KRRG$FS2R.C1WE&P-5>T]=^1MOI
M[K8\SAC:ZFN["HMA3*@"^S$M<7:UHF<F!T(I5=<PV>(.H!S$0D@0$8NUD&@C
M*8D2D(&QCBW#3\(^L>9Q.(=BJV.BUN;V&QJKAP8>/IZ"PME_#4U/.)RO`/F3
M<TT=EG()!.=`4D$L#(DDF\FAFWMIR%9<0^O?)5F=K&_FM93QU5=KJF306,AE
MU<'NFC-!J3*JTRM3`94O;)&/)-"U'N^%DSO'Y%#19Z18J/E;W/S^H$J;J2AX
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M=#'CCPBZNS9:L:#>CU+W1C+$17_*9(7,R)K!F.8U'R/Z"1=/Z\87,`5#S;/9
M9&[!%2T'`IS6Z,V;16L7Y.5;>`B<VO-KLW*6\<BT<JAQ"-C=$U9'N:@5^Y_]
M;K/V$]4^7/7_``_,C</R[K,U?'T)=G2UF8D*/IP_SC>(!K3/2@5CPN5J"MFL
MQ2"7OG0<%\9#6JZ-B!YHN<?7K<^EGZDK+!\LI9Y7EKEKV,JGRY=FD'L:B?$5
M]689'-$%7FRQCR$E!,D<JIXR>**]$5&]!HZXJS[=7R9@,W(9%7Q7>QSM=,=.
MY[(Q(";46.<A71Q32=XH5<J(UCW*Y$1$55[=!_H&/%SN4N8J(G/#TN1I0?*I
M_P#(TNH0'^GC#Z"XPQ-=%F*8>VMM+OBB8RWM_&I]D?,@LR,GC:V4/I4%\7_B
M]7#:TV;OOB`&A2XSET9%.+<RYVZT`_\`9YHL6?D@':6Q8P08"U#I2:Y]:1/(
M]\ZM<T(NT65XGV>/Y3PMO$^>GMJBEN<P33F.*MW[0$N.NM`+2:DUYEUE;#(A
M=Y)+DMH7E$WO`\IBI*H6GFY>&VO!&5XMU-$/44^%$"SN9AU%==0?9T=(EG3S
M7K](]LH05<TVJ^%T<[I)YAY89QXO-9HA@P);2>[@KVI#D1L]5NI)-EIM'55E
MM5!TN9^TF^P@@S)]_49Z11S8GR3+._[Z$<6<X:.9J=PR[+TC2`;6ZAFC/J8M
M//'7920$_--M,^!6$02[%CSL]>U].$"5.R<%&61B1*U'2L'149T&*+"<6!8@
M&/6AKB9:\83,$4*\:S/+LAJV&&G-L[*N/&HM*/6LB(G$*L?,>5'Q"3%*U'*$
MJS>+<;2:4>TS5MH([#3\>YQX>H#8:R#*DF$_C@@C<A)=2;/0N6;[,ITSB;*5
M86,6*1'O8$&W6]L\K@-;+#^#4T7'BZTZ1N4_(:'*1M(EL+VJ)K@4--M-52#`
MJA4'8.<%\B3N5?%8WA;GUXU^YVG&^-Y(Y%Q=M8<9E")68.#57=&MC;W-F&U@
M6VL1F3SOK*QB*TFN)+;+!*Z17)(R557H,6LKJUH8M*)D;6M$NGV)>:U#;87[
M0P.^M@H;'XJ6OL[96,AJ1A6E/.)@\31WPH.Q91YOF"N+Y4MCW.CU(5I+;T81
MKRX&(1<VU3%*<%=+%,JO$I8-$="T8S_0JS0*DJNA^+NT,!K&[LW5TG'R5E9F
MA]1]IC(='97#7XNTIX!492Z['&+\ZW.=^^3[*.(=9&C/8K%<K?KT%F[GCN/`
M\Y(/5:/*\R19K$X>8N?)6$@5:7FX<C46>OEI8K1`#7,;::<(L1L<B%21P-B9
M(WXIF2AYF?6WTM]B/8RT]M=[PK[&X3B8#)>V%[G3A=ID:Z[TFJBNH]-;$7U;
M;/S=N1+/3/J1QD$ACA<V<Q'N7LQ[FA_H)?IF'!-]1,/-9;4?E2WJ<R^NTO*,
M63M^/K/97HY+TNYKS+2-@8/8`$P?$[PC$=XHG^A/+OT&#>W^JP/*.0Q!EYJC
M\[QK@->5/L0CF3@6UA:;`4TG,B1Y\UK+X2BA65JRM&B67MXQ.='XJUP:Z-K:
M:JEKMD5I0H+''7&'QCQ[8P6GJ_A/I$F#IO//--$S]"*53`R,<YSGRJLC)"70
MS21-B"<L1Q5Q=I*W$Z2CPD$,>RKZ'1QWN&'UE_J0-J1$^6T/EFI)+H>RD,@%
M\`8K_P`ZE6^3?A@G^%ZA,9WJ_DQK*YR8^,5EC7%RPW50ZKU8E]=&/@$9=SS4
MPV^%BMX]/6.A^WDJ!BX*T9K/CECE^3N'6XCC?C:2[7&EWN1I0=#R=?\`$E3G
MA"Z^RK<?ILW"7?6A:NOM9:S!%M9!$A\[9!YXK1Y3XAU9\C>@FNG]2>%:K"[^
M;D3)UI.@QMW2EU'()V5FDK3\_JBY`ZL"KJ[6HU$I%>42R6"4F>K(0B&=\CAI
MHD1.@ZJAS/KUA<Y5'VX1%O'J.3Z?BJOKLQB;S1:C.:?05C2ZBGUM:,+I:NS@
MCM95F&L9)8J\056M;*/&B1-#^<\X.'@O.X+4+G<B#2W=9-E";:^TQ`EW4NI)
MKFP2;-"&#BGRI8C*ALT!;9U@**D8L:L:Q.@IC1V3+2ZJ-9QS41U61O2[*VS;
MY]$77F6Q^>KQ[R\&SDMK16M8V&Y<"Y)G-F@F^Y<QL;6++$K`S_U<#O=1[B^L
MA-:;IX9^/-?RA)J2]/8-9>V-)>XFS0K,Z0(.2]JWW='I)HTFA&-DA&5$[3JO
M=G0>F?H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T
M#H'0.@=!24[B$#4:;G7C;2V\(N)Y3U%%I(LL9<]K>VA?`.NUCKP8)U,"I+PF
M-WE(U$_FJN[=N@D"/BWC#C9IEE4U=#6%26L0N-=(Q8(:TQH+XW5#S71MC`%L
M2721>?DD:-DC;W[HG<,^DO[/\=#^8$$JX*>Q"'T=*'+$<@U98AM%%0LF5R0J
M)`;-YR/C5RMCC\O\(O8*T>S?!%;SOPMJ.+KQSZ*_^^*T-!<T`/Y7\;]].H01
MH`+)X_RPI39$289[D(=$J^#?)$Z#N_7_`#-GQIP[CL#?K<7EIFXY,69K7,M8
M_P"XAU:%DV>X@89!$5+!;%*TAI#&_%*PA&Q*J=NX3`DLOW8QB#F)-3=M!6#1
MA&FO?6_8U\)PM0/7#2D?<R)*JRU\K6RMD<QZI_ST':L%!A/D>/V,@4D8*U`;
M4E7=W*FCEC*?-?\`E']U5LC>QOF]6)''&BN<J>'08#;+ERB!I;&6R(<W/RQ6
M-D'GKLVPK:V"3[V"OMB!`'0#_,(0QPI$RL)DC7R8Q4=]`U^>QW/0EM2Y3B_,
MYW16I7(VVKZ>T@*AEDK<M75FBI,Q66D-!H$I[$C/E323D@`0K(0VRBG,2/XX
M^ZA@6UW-CC\AS+D,[RH+J;$C;9FC"LRLA:6EV@M38@)##69BKJS*RK94%Q*)
M-*LBRK`1*0YJ/8UK@KO^PO8;`[!\/XRZNW@0`Q7G(:9EE47=W4EJ?2,B%R-Y
M&*B68R8]KED(L3X(::54\2)X2$=&@=7^KGCJHJ<+S9RUH8[>DL-S;!4;FW]]
M$C[GCO(,E/J+ZVV,WVH6DH";ZSF@B"@?\,BHUXTDT,B.Z#T`>O"&VF+DV-TS
M,/O]6:\HLC-!`#QMKPXXP:@$L@`@F,J84.%%[J_^'GX]D5%Z#13[W:'/<M>T
M^OQ[+ER`BYPZD(M*G5"T.BQZ48JBDQUE?/(EJ+9W6A1)0S4@>/,B_P"ISN_0
M557-YVPV5]3U`EM3TP(=6%:T]_HJ`S04#J8"""^O2K2L-F/,GT1=:QE?"^-C
M_($A9$:XF)K@P'8\NX[,U(NFWNPK2LS75Q\%U'8!SR:.X!KS9PJ>GUU0+&^R
ME1!-%(ZJ!&C<9]P5"CV=FN[!7/+>YF1Y0]CC/4;/4NPY`Y=P/YG5[0^.^`L>
M.*?+5](XD>OWQH4OW$+82YA826AMD<"$Z1BIY]TZ#I.)/VV^E6SNN8<[GN7I
M<CJ9JBUHZ)-EF;*F=E;EMS%0S1YYYT#VOR[HXF,@"F5LCTFA;V5S7(@7.TVR
MQ,M;65`=ZV739]3,JZ?14T]=<!SO@J-.;D,Q2UT4\EMO)H[-Y[Y3U@'0=2?&
M5(VQM>'FS_\`D'ZB5G'_``?GAIM<*)I^1=]J;F`EHIF$U&DJ`JZK+U=20[L;
M1ZQ(#(X+2OA\J]%\'0O5?+H-$?H7FI=3[><#@MSUOJ!@][47-E3T=<ZT/FK*
MB7[TN5`F(YT@X[(D?(O;Z,15Z#W2E\3U[*GD?E%F:H;[(DYNCKH]I+>V)<U9
M=VHY5E:5ME-22VE?3`5\L(L=;',Z&S&LKB1[X4?%$UP17FP"\B=%3U=D57MM
M-?B+ZWL;0,*QOZ8NSM*6+/TUZH+Y4-I=!:1Q#FV=Q&.>#]O'.-#+YSM0/N)B
MBG\=<HV5U0!5!SZCD&DOI"K6/'U`57J#I:T6:QT[6K5EB3M<D7YN29I`D;D?
M!%(_^/0?(!-"?8QAG/AI*6DR=>,7@*T_3'VV/TC(JG[MI]>'5G6<<LRW'WD4
M1431"*Z>(Y9&_>-3H*9>T7O]MN,>?N1>)['U:@U63X1BR>@U&S@YIW5Q+^&N
MLX*J[)XN`Q]IF@#`V9^.:)TDLD(D<"!3_P"Q\J,#&ME^S<?@#D/98NP]9M!"
MC:'C/=:J&TY$T.1O,]M.3/MLO'F+PO25XS*`7-55TAS)1F2-):O:=C8E=(T.
M-[`_M1&]>_9':<(B^INAUAN8?<\=Y&\SV[T>JJMR%][8DMY)`..K7K>*-,LD
M/V`[)0Y61+*TE%1$Z"`JC]N&^.JR&+Z\.K^-L_AIMODTR]3IQ'[#4Y73UM?R
M-4UO($-6186L96:T:O2TFBAEHIGS,1%1['=!S=!^Y%[[N*WK_4ZOLN.1*#/%
M!766W.^96XJE.,@;E:3D[5EYED^Q*H+QWQ6AWAXVD)"CJYRJG07<]8/=[E2W
MKJ[E*?U'VV(XL3+<P\[X$O4<I$75+I<WD5GL6XZV!G@BL:.WT<A'R4(L@S6W
M+%1XK5C\5Z"M/%7[B*3GKG#C;CC;^LF@RXO)ME(@6NM]=;&VU3=1DRUXIB,D
M`A6['K3*>0,`-W_^1.R)5[]TZ#:'5[W+1AR3C.`:ZVT5;52P`UB?CK64.:YJ
M+3$"V\".^RN#9[.%EV(OBD3)7N3_`-IRH&?EVY":?CK'U=/6ZNO"FBXKT"V4
M,3H<S)HJ-#+(Q]6$LO\`7\M3ULJ10MB<CD)8LZ]FKWZ#L=WE*7C?2Q\=5N@P
MG+`>QH*>$O59-;YV3KC9+H*0*>&2`5#"*FH#HHW,D<Y@\SY88._:).X>?WUT
M_>%R7^N#?\]>N>.]5^!>=@K/G+DPU==R#17%9L[*2]MST'&L'@"E3.`KY"7N
M:U(DE2%[T1>RHO0>S;]6/[!K;W%X@YY]Q2J_+<"9?CW)6M:[AT3Y-%Q_2$4L
M32=!HK67-BSV4!ZE#JCAH(9")V*G9%^O06`]A\1QY[(>M%!RSAR`F8KB?6V=
MP:105QC/[<R46KR^CS=;$7$S14DK-(*@P3B('1*R)7.<Q'L<X-><D&;XWXVY
M(XK)"R7'9NL?$!4)HRKJY_+9Z^E6FUV?H:]1CK2ZW@)YEA!&UK$#"E(=(DBR
M0JUH6BXD#+L\-CKJVUMX`F`@H-M'5Q1A5\<SL\2RO&E=&V<&E'@=61J5'%93
MP&J9`Q$A57(BA*'$^GJ=`/HC-MQ]<\N:S'!U`U1S+R=<7"7=V9>RSLDGI*K*
MQD6=%CJ)LOB'+'$^26K^.946-Z.4*T^U'JY?9@_^U<,%TTV?J&YJ^WF7FTM,
M,)6:N$,JT$HJ&6V+$WVKJ`ZX^>0'_L6R>-C`WY)DCG6,,K];]!ZIYOB_CX?1
MTV+T/*7)W,@];7C<AZ^TBA;6::=B;6QIPAK<ML!-17!2,<.__1%)&CFJQ//L
M%Q.7-CB,)IOLN/0L*+B$*K;MEIFLO%;K#=TEHZ:F_)6QE@-$L]E5^+*]0UG<
M2]>Z]O\`'0?WF_(61F"Q5L#?WI"V=9)$F86,>;-5T>FM"#J5*BZMHY"`(WQP
MJ+&L;7SPN16S(C)7*T-7')_&>>P]MLS*,6PJ!,:)G@;>LL38PK>N?9WM<2^H
MI0QR9G5.)N+BPF)G-2)L,QH"*V58(WJ@3?Z[\F9;&^\_KSQO54SKHSG'D;EB
MX)NJK1R'47?$\;6%G+:I;&1P37FGJC8$$MPXVHD3U^3^7;OT'I?Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0:Q]<FG&
MY7W'*5L^LJ]!A])8U&("M440G2U<M[/7!Q0%,D9*W/OIG,:0D*M<Z3N]W;OW
MZ"2N*]O2Z2MJ86N++,O`+S.Z>/0DI=%TVNS-T^O@I[*FD^02"M%*KE^UF[(Y
MWS1N7_+>P6*K*Z0IIQ4CUESEU#85VCH20T->!80!-_[LE2G3-C'B2*5LD"(K
M7.DB[)V1>X=Y("R2"M8RW:766%9*$3]T(R%[H0J^1P\T1(K87UR?-&CGH[^/
M_"(B]!BQ*LI(H1`J1J*4S/U3*6M,+#IJ]HT0[YH*V2%_V$8PH\C%1L<;/D15
M15^G0?//C_<%'EK)94[S9M+5V;`X6#A7?QVM4,-;RQC_``DBV8X1*BPSQ(CW
MQM\W._@SL'<&PF&U_P!XK2!K(X:PK*3[&_*A$+@8-(@<5C:#N'2,N:6)&QSR
MM?*U[E:GU7H.(*^J-/K+:".V';>U12%'!V[[&C=>2.E8\"]%E;\,LM6D:-@D
MF9\;6-2/Q1K43H-'5KRQ<<W_`+0,YK2)'5?`GJEQ@?J]'H9(4B"U>CIK>WQX
M%^#^'B&*%,.OK`RL"@G?(,2@TKT8D4T7@%L-#P0-894.RKP*.J@LM=9WTJZ9
M]=!9T$UV6EC>6NA-L(BK+[*JSLTCE:USDG?*R+R8[P<T-'OLCR)K_8/D8[>T
MMECIHJ@-A`5ILS'O%I..\W4,@#;1$Z-+58C-,0,V4@:)8#9WRH+/)+X]!M=]
M.,)'Q3ZS<>)H0H8^0N7JI=^=G^0J^_BUF*V_*+9";`PJR,L"91+2M"N*X8F)
M7>;XH$8[OY?0-T%0'7<6\:"CSLK0Q,AETE/6N@0"N>4"#\IY$$2,?\$99C7O
M^J.5//Z]^@\G?MSQ=Q_RR_FCD,FBRNAV_(Q^E_#4-UGWCUI(INF97.MW1Q(T
MZ+[B=R22$(OWAT:*8Z9S_P"705@]O>#N:J/B?8<=4/(4_'FCL*'%VL^TR]='
M\UE2YH*@J[<^-6RJ43^*_IX`<$R2N6-@<<3$[++YAJ^;Q#R11D7-AR#R()=;
M3<:.CNM=8V#FW5U:3U;&;\?DXO9Q*X@"SJ,EF2#I`H51\<@JQ,\5B8G087Z]
ME:[A?G?VH]E]IQWOH:#V"]>MWQ]4)Q/$/2@5!D-D"-9:NS(?`NFJJZ@`B;<R
MR#31RS2L^*5RL>Y%"CGI1Z?@56FR=7S_`*S.YA.7_9G.,WZ\BA6HE5G.'^'A
MTY**T.BT+'J2(3RY/835P`J.0ETX7DKN[NR!<?W6Q7/6LP'JI;<%A<JCZGV5
M]AO;;EOBH_)[%IFAH_6[+D!Z/-"46J',CL$"L^/<R\N"EN)'RBF5,GQ_4AS5
M#SS>SGL_[&>PI&1H^?MUJMO%Q:FBI<--M*\<70UU5:'CS&P'E-%@,,DD>#$J
MI,Z1(W(J-5$5>@MU^E^A(O/=4:4:N&M),_PWS)ID"(:*KIOQ&0(E1`W&13#1
M'(YZ+&]Z?Q[*J?7H/:)QMH^)]1CJC(:?23GW-WQ^4O)Y22RU()%/3Y/.4QDD
M1-.-5U-:*@%,(U+81D=A-7U()B.D(F<K@JM?2Z^P#HK#(5\<8`3+*JQB:@8(
M:]W%?ISJRGL(B=%IR+2,NGDBK*R9U@6.DXD/C.Q/DED7H)+T)M/"+1YQ=44,
M0=G9P:[7X[+MI[V^NJ0!S*ZC2SRCZ:+56MG(W[9H1,+8&Q_]TY4D_ET&0Y-C
M!\Y"98:MA*`09ZJ"`L1AJJFB'+SE:;H@;JG$%#J0M`1JX6C7\D0Z%VTT3'F3
MDJ]).@PG0!]A=97\C"%?V:^SE*VW_)NLXKIV'2[,)DI<H?!(^VS];81&J@<P
M$L)]:`'/`/+&,7.R0/U;0$GD7E)>5@Y--?C59UUF]0N?=;6%:KH)JV['JZ\6
ML2NK[0H>&1'RS316BQ]BVO[N:H='7Z\.A.*FO]?0T^IUMEJ]#*6;KJAU,%H:
MBX62F+L;-KF#V]M7CD1"NE.CEC)!C@\5\)7,:&2:3>4D<1N>L-?@X?PMSHR9
M*5(,'GZJ6RUV?S]I?%225)XE<''=6XD\[5AC589U0*!6#E/8H16[F7@.?/ZL
MTG8\6Y7^PO6SFHU.SB"Y^@N61"5%X/D9"9*=*WS!F(!B:WX0)HW&#PQ21*K@
MYE_[#<*53]-1F^PG!EZP.`"^JB[CE41NGI0;.%D\$M`8UDP=G]T/X-C56+9$
MAMC:1(^57.4,%_\`)?!^@&K2Q^3.!8[VE%M;*PV^,O,[5Z+.!W)D&Q@MK=EC
M5%B!;#8D5=E+^-BC26LM))W0+&XB;R"3J3VD]8J7-5&#W/+_``D)235FEL[&
MWSC@G6^;MC*:ST`NN`*IZN*&TO\`YH!1D\D66&Q)>O\`A7)T$/Y'V>]6:;76
MVL#YH!;I-/#;UUI1YHZ\6$O3CV$C2ZVO'!%C=71.I>P8+VJC8POHB=N@G[C_
M`-K/5K-Y*JGU'-@Q/'==+8RZ[!!UFEGI33K'2TX5??D%2ULT9\F2_'#RP!=G
M#.@:B*WZ0]@\W<G'W*0_M9[/\\<8^LVRY^XET7)6OBR'(@.7OZDM\MNRQ&K;
MO.-.;&9^.NK`U'D*S_9#!&Y6*WQ^@>OS]*7#?.G*?"O["\?R;@+_`-9==RV1
M0T'&&!-44'/XJF`RDU:/EXK56?V*VO(%E[3'&3R&M;(LC5:]$=T&S'EO`<SY
M#]<W"_!IA,U@_CVN$RW*YG':KH(4HL<R"KS$0;;1I,DF;L96-[PV'W<_QPI&
M^=T[?FZ#4OSUI`7QW=&XV+63!Y/+BR6]Q2W4H%>^FH-4#:Q%PW]J5-86-Q'H
M9!`7)(Z:A*'@1)7K/"G07VX)9ES.(<A>ZZ@#K$(?6)'4P36EOHXYXRP)3["/
M2V33KBGC7[:,=38WK,!-*DXLC)(T3H.)RWK6\78G>\C336;),YQ@)I+>MJ+*
MW(&TVO$$K(:FZ==3%3P3$4$Q"#N>5\BD*Q62,1G9$"QFZXVL\3'QE95#(9).
M5,K1[8:O&IL[G:AMY=56=@OEU6@.%,#)LC;2U*G2$I)05@5C5C5(E50H5[*^
MA]MO:FRX^K-#38]3QJ/0;>]UK(+^*ULH"[-MW7:W-4;`<[?8V\@*&`EK@T&D
M(&D^[8YA(PDL0;/ZW><%,P^8#T;]<9L\12Y+"Z"PBF)R2;ET6.#IK%@EI#Y-
MLJRB'8D\,1CWQ_.B-1._UZ""/9+F?6<:XS`9+C[2<KWL>)#/)RVVN;HX<,@F
MX+/A'3D9PSWU*ORX94;:M4:R0+^/R*Y\L2QA4C*<IV)-W4CZ:9MV>ATE-?W)
M5<X^[5"*B;3BTU);RK)HX==8:"E8?:SDE2CRU$:P?$KIT[A9OU9U''V7]W>'
ML?DZ.Q`P]_:<S4'%=/4@C2TV2;59(W06C);#[>,D"D<R*6",5KT':7(G\%?V
M7H/1#T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!
MT#H'0.@TL^W?'UF5><S<X\G6X-7QSPFLVFQV;GU<U4&UY3X*70:K?`55A%H4
MR!(C$D2,)\$Q<:HV/L]5<H=YZ\WQUUREREQ9:7@F1VP>2NM28)FZ!?"WQ6G?
M+=XCEVA,3[V)=/\`E99ZJ<`V3YB65"/='&Y5[!?G'#VE504`<NM?;':&8<B+
M1G1#4\-Q?`05A)KR@VOD?-)HHP_BD8WLH\C9&HCE5.@QOD37V7'E;=:>0`B6
MSJ9'@/SX]D"]FO;=AJZS,%&LS6N?'56;T(B8V!DL_A\<3'(O017L_:VFXNXS
MT/+FQ8RDI)S*2OS3))XW!ZC9UDT.;MZMSXIR%JUDG%E^,)88G.C&=(CNZ2(T
M,OXIY/=SEA>,N7(L%=9-N]=I[V%^EF.4')KE=5+2G0V%B!;B%B!;FFSS+.M?
M\+P%A&3Y/_>;Y!.AUWGR324:5"X,>20VVB;/"T_*E$5!I5><5$?;K`DEG)`V
M2O5HKXT<WS:B?61H56]B/:_#\8<6Z<2&X<-HY-`3QMI2!B,Z$F.T6@S@NG?J
M-2,.EU8B"_A;2$F-L81A1,13)48Z-?F0*`?KLQ&I=5<E[F5F9T8_*/*-?/:J
MZT6,O;<$<:8H1E.)E*BWLFA17E_R59Q5GV[8QA',K9)I)GQ%CR2!M1M+&H@U
MD=YO..ESL0&!TLD%W:R5AK[#.S4A!-OGK/,UE7;HMP&-!VD$!0N.0>)R_/(J
M-'D#RFW.0_M1/'_&X!F?H0><N7P(Q,<5!;UUS&1O*0"Q,I$,2(3*V2TPJK-&
M+#;WHS2%[U+7O[3J'J(K<X"+ML9CZ82LN<)87\9L`.BGL++4!-RT)4!5HXXX
MBOL7I";#`)\$SBOB<*Z63[ATR+"$K>V'(1W&W"U[=56?M=/;V-IG<W64](Q)
MK*8F_N@P'$Q"N5&%PUP\CR)XY%;`L$3UF>R%)'M#S%ZSE?55V@MA2P+NQNZ@
M*LDG+DKH1]8-8EDI4CY^*G?31$R&9.JD=&@]?/./".BSH-,J?"H<GE[CT78[
MF$6OU-+8U2"%5U"1/?:"V"JJ"0?,641U72!T%>2$C)*:9(&3AR0(TB1[V.=*
MKN@KKNN+:[,UVNOJ>EPQM147FI;DI\_/8V5Y>:2_I1#S`K#"K716.9EA@->L
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MMPS;>X$H3ZN""ZL:"RMZW42P:.FBR-3$V<`5#!IF$5\"-BG9\`O01;%64T.J
M%S[M)G)+*W3(ESZ2R:!925$.BB.*C85,922!RS%TB&.DFMCJ_P"VL)!7C.8K
M9XG!FVROUS=E;PUE.,_1Y>IO8KY65Y4VA-?.Y8W1UA5N3'2ON*RP_A*7]V/7
M'")\GF^!?C4.,1;:DW\H)8F$H**5DK!E]>.$L*Z'-&8=^EK)&FP16=AI++\<
M6.]L,#1V!_=1"C@O^!1Q@SJWOK.H$S1UX;=,;22Y.KT[.0PHDM*6LNZE=!:%
MVI&3T<-C7;"V!*IB`J:.UG'CH07+)\))I($`5[]K<7F=?J?3[)W@UQ>\6Z'W
M@H.+]Y0UUW>BW>BL:O$V1=9Q^656"C:@<PU)$LWTM1*^E^TB65'S6#8N@N![
M`<3_`*L/1&RXRS'+W&'KC23<HT]\#E0MKO.2M,X;155_9H8/H!=7=6FH!P=/
M6(,T`VPCC&-DDD=%'_URR!5?ES@JX/J\@7PIQ)Z)\69O5[^L0;9VG`67YGL=
M#7%5M782$YL#12EUH/'[X=-G`A;6.5\=C8$+%",&P$N24+/\/^A%]]P5GO8V
MG],>1*G0&MM`<I0^K/&F,ON-6!Q21VU`#95],R2X-N2GPQQ'VB0B0CS2OA>L
M4;W($W9_T2]*N'Z,1[?6S@,.VKJZ'1:/0[?%9$M"2K!K(*.FJH;."&K=95KT
M;`R."2.3[I'/:LSE[('WH.)O6FODML5#P;ZT5>_U>IGTXAHN:Q-)E[S9UCD4
MC.7%]J1((LQKJ8._8HPA'PO./@L.[I$:]>@TJ_M7]\\)ZI\6>N.A]**_U%L=
M5<\F<GU')L`G&O'&X.IR>,Y`:^JI2ZB3,Q5XC?OKX]QI+'.::]T7@JMC\N@U
M2<#_`+6/V4^Q'(^<XSX2QWK@3N6UE];015?`'%F?>1'71S6EMH[>T6IA2.>O
MK_*/Y/)D;1T\?%?\]!O$]8/8[]KN=8?Q9[(>C6&YI%KJ"QNJ&RXNDXXS.IHZ
MN$\\-D0N>A1*?5PCZ.GC9812S#D,";!(BJV-BO"P/`W[J^&+3(W`GM-367I_
MK..=U/B]-5:>O=?TTO(#ZR^*N*?CZPI_*()]36P"6BNL`'QR2*\9LKV%?0-]
M?ZQ^9^+N;E;O\/O@N2*#:NHB`3$,DEM2B9`IR(+&[K3J<2Q+T\4#/,^\51WV
M3?K]O"QOU"XWM)4<MYZ'ABBXDS<5]Q^'R=0"[X"ILPJC[/CT.0H.*BTES96,
MA,V54HJ?[D9&?'Y0L9W_`).;T&AGWDX^J,_SYRG4`#55]DA=3FZ3,#'QTQ-1
M46<85;HV4TM<S05+;QI-W-6DBUP,$3I)PXH/MU(_'OE"Q7`[K1_&/&<4AU^X
M(6A(SEUJ:^X*JJ_."9K3":"RFOZW\F^[S8E(X91QD^Z0$$R6-QCRB&QQ]!,!
M>=XVV%9HLB79.GXWVPT\I%.^G.!GB.CF;FM<!.3#;6(%U8/T@4DL<PE5%(8S
M^<LLCE<G02;R/MK08:AR7Y*DV%'Q11A8(2JJP1<XV<3)UU'86AT<^D`N:*VJ
M1@ZWX#[I1`!QII%%C$?(B.<$_:>>WKM/:3U>(QN@RMC5T%E-QU9;G-0"[$2]
MJ(69"G'K8,]96U>EI;2R-@F4*.,Q(7*1,P9CFH&'<@3M;Q!69NQS6!!V<5F=
M7W$&7U57..:^Q8TEE@957=+%$VSFKE2:!KV/DC:WR^%\'CT&.\C;K$$<0:#B
MRHKME71ZFBO+>J<968Z.+50",^ZFL:<(BB!'N`+3[)DDTT41$8X;(IY_A6:-
M_0:DHYEH[,6TO%HS[:EH7[*TRB$V==E;7XJUU16W#RZ(%+FXU+5LQHHIZUS9
M&$0BOE<P$:9\P6;]([>VKO<'@G+D!5-FK'\L0$@`0:Q@U6;+0%6UT0"3K93+
M%J4!7BG^[XI%8BQ.>^1R=!Z9>@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T&MKG'U+T?(_)&ST5W9XW^D\GU8?%NR'*!(
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M3KUB,.>&RP`44**41L?R^+_*5\<B]Y(U<&1:D*6S-I!&5-%9GV#B:JQ%L+42
MN)M`J>M=<M<TN-B$K<5,X*?"U6200-E_F]L2O7H-)GNUR"#H?8'.<4U-`[$R
M4@X%-IRKNORAH^@.M+60,JTTN@L+>L^QB'&#'K4)L&Q-('C@4.9X\L?D&XW@
M;A6@&XU6XU6<B=>ZHN.\O*(86K`4*VJ(Q*"%6PTQA(H%O)744$940\T,;$C9
M"^)LL"N4*A>]=2;Q-Q3R?H([L)N?)SUWC<A6.L6`G!7?+/V>?CRT,"W4]J1(
MVND)E=*CH7%JO@KAXFNF:&HKT/S$6^]NJB]CSS+6MXVPEKOD!U(EH5/JKC9T
M<8V3!PY6A;51/&IL\Z*PKK',A6#37.\(WC@^!CP]#G!$*7'+&HTMIF(J`VDS
M=!DB;>2Q4D#2ZV-I4=O)25TTDGXPT2LKA?NY&.5Q/R-16-^)9)0U.?\`R,>'
M_:7ECA'@.V]1N2__`!GS7PIS;2\QXV6'9OS*ZF.@K;`"]KR17HP*Q;0#6++1
MT1/F+*$*2V1%56L>&OKA&VN.0A*EG)%&1QKI-Z'N=#?T-BMGI+G-:+./6?<;
MZ+9T26PS=AMR8WL#JZR0R4265K(F.>GQ]!<T:6I+T>4!HZ(^ETMMG=/+,V_-
M"$@2"`\>PM(&'U[#*_27U+&=\T,0Q*Q(Z=1.ZRPR1L"N^]Y5$UEQ+46CS`88
M+OR?JJ&B09U[0XF.6`MNHVL0<+\C>5H]HX&2OL!XV1CW"SLED2%R('X916V^
MSEG84N?/K*.HI+&IOYUNZN""`75#R6@KJ\,57M/#9`*D7XUZQDQ2O267Q:O9
M0UG>XWN)QSZG<Y8CA,FGOMZ5SK2Z3E`;=NT==94N!IR;*W"#GN(&-AATAE+7
M4ROACC:QLD<T<J.\W>'0:[2_:OU$YA]J<96\<[KVK'Y)EL."\?E`Z^SE'X_Y
M>+VA@,T./J'9@PRUQ^GL[77#036-FP:,8>KGD\9"$BA4(!_^1/+K:WE+UNR=
M[C^?J"KI>--"+6;/F?D^IWE7S/\`BM`RO?R-D*JN2$W/RQS/FKCI;"&`PY1H
MGN8GBO09/^E:DEH?7[E#0DK<9F#D_E3^@MTM8/'<)H8ZS)A'T-*32RP2PCQ4
MNI<\B`J2459)Y%CC=(YJL0-W.=I+?4F5^-CN`:B]T>KIJ8DFINB(H\\;<V&C
MGM9";)P%S65UBDM2ZJF?/)]K%;BPM'<^"`^0<,VY5XAUW$7(3\'LPZJQ_`5Y
MY.J(%L6Z#+ZW%C9JT,?I+6?+5=HEAX36`M9HQFO4F59GDA1M2*-9@Z`N^R8U
M>3"4^<2;,5(A5;G;^LL*,PRWL[%(JO54<5JQT.A;G*)R+2PE3LC8]J0K$0U/
M)0Q?!UEQ!HL&-6#974@3Z^QDQN-/GM"YMM>29\NXO8<^!1Q6.EMPD?8R/(*L
M0JVL@A``DC(C@?"\D,AN@J<:SLJ^MTPUP2>V:4>TX^DRFJ?:LIR,]=V+2P]A
MIZ(?2DUUZD=99$?ZE'G!9$KV"L)E:%6?8'C^HT>^_7S2:HB6[Q^X_9-P;2:\
M6HTLL.0UUH7`ZON5RY=781[FKKQ:F=[(G&05MDUGR*J>*1N<%+/WPC;G9_MZ
MMN!.%LSC^=N3"K/+9#BC.6>++-VP,SAZW2!AS6]C:#U.@+N;J,PEDB1M@D@*
MD1K48]J-#U/\,G<S`\&\39SG6LPV(Y%IN,$-WF"PM5FZ3"<8TBNM-+#0U@U]
M\6FJC9;?S$M)1X"@QVS#0!/E>KEC#MA=*)#95P!KWWL,DEK:55`4BDPVUAG8
M(C8))Y`E=;6N3KBY8B!9FOD&^ZA9'.K&.>U0H7^T?A_V%YEXZXES'`@GWFDQ
M'//K]NM1G\/83DZ+F+`4(N=M0]4^ULWBTSR!2I)3Q0QG.^6%Z->QRIW4-6G[
M&_U">V?+W*/OUS/Q;[,D\D36'L92;/C3AD&\-%+WU?;-U"VQ+R4DKJ2DU'&]
MK][5MB5(XYI(YT^57M[*$;^R_HKE/6S]"/)F6Y4R])/SYQY[9Y[D;,:AM'!!
MR`)3[43(YTL38V\192C`QCVUH.@2/DC=+'#,J^;F)T'GY_7W[/5WJ'[,Y?F2
MTP\?(8XM'J,FS-D7#Z0-Y&SJ9:""Q.*9'+\X=8\OYGP.[,F1OBJHGUZ#WE55
MC(2RWK,S,;93P5L9Y)=;8ETTDMQ$"#<HTG4!L,1!&9$JM>]C%;^8#^V=`V3[
MI[V!Y^?<KAWCK)^X5'H]^^IVM+[:<>\I<G1<=\NQZ[.X_)\JYS.5U/0CXP//
MT-M<ZS7\Q!43\S2"Q1?)56=U"0_S43Q>'JL_^/[M^"]SQ_QCH>.S[..SRM&5
MG]E5D<8;_,5])?E5DX%/FJS<[;,Y.+D$7-C*X,@X097R&=E<QD:*O0;V/:W"
M<L:'C:ZIN`"`A=M)R1@KEXC#T8A><@O0K7:`64=A''7+`;$620X=\\<<JO\`
M+S:Y$8H:!?<NIS=CSERZ=@JW%:?$Q:`X^IL&:>AI@UN22*T307XM=^7LM!KO
MZWH*Z(<62N@_)2V%;*VOB)G&?#&$B^N\99>*QEO5W%]<H/4#9?:-;4VQ62T-
M'/KZUP]MHP9ZH04S+,MOCG))4C[6<Z&+[V:)R/8@37671M)/71C:UA\M>!?7
M-!:/$9H9[+3`6I5=J5@;()4SYMM)-$^/['X9FQ,18Y)&D->B`JH,/+QERM7[
M/)QW)S("K?CD:B?:5F86GI@Z_022$1&RR-O\[-I=G9$QV&?-NJ.&15CL283H
MY@A0LES3+Q396)9NEJJK0V5;B\-9C9\8>UI;:SSI&:A&W<%-?4[G%ZNO`IYE
ME>@+7D,8US0HWR.5%#"-6-5/%.K,QA%U^IH,[E-OH"]/]]09-P@EDR>349^W
MGB_&:";+7CE&67[ML\B,^W;$^+LO09N1?<6WVKBY*L;[2T6I3CO:<3D9U<S4
M#!WUGI:\[-GP<?5)%R5/FI<_/3(^2*.-%<Q[?-%159&&HLC+ZO'6%@R>4.'2
M4L66"`.FN\D769^C"+4`&>=L-X38P&:B>.&O*!%@(BD.-B=)+%!&2Z`,^];M
MC=@^[_JD>=J=E31?^4-MQ[JOR,0.@L]K:7F<*=F&)9T#S:8&OOXU^\L99IXX
MD'C5())Y_&-0]8_0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H'0.@=`Z"*]?K<`MO_3=>95-:2&R5L!SU1Z2RO\`XN<J?2"%6HB)
M(O;_`&?QZ#HV[BMMB!H:EL>BF98$L?'4C1OFSM_&4="*==PQ.^1@YHDR/9W3
ML^.%[_KY)T'3T.9FB^XE#T1'RZW300Z4N$EIH]0-E7/MF9FHA):^!E+8MC,9
M,KD67XK!W9?X,[!Q[K\J5;2#BQ@K%%"('!0652YXMB16R(2/J*N2%OW1-:`U
MB*^*1RI+`BHU/\=!C==39FNKK,?,+F\I3C3ZJS&J:>(<.NK>2@SYH;37"K\;
M9!BY-7:E#RP2_P"B5D$;FIV<O0=B=0V7WE-1'6^@BOIL]I*_\A#74*(Y3,K7
M@VMF-%+%]E."9ICH9VR/3_68V*%/]+U3H,V;"J`UJ&_9DVEI:5=694W-D0%%
M+4$U[@"GF4ZN^WBN"ZMLLBP-1(I)41S>Z(G0>?[.TUGR)[I[1^:LQ022"^4[
M_+UUJZBT#A0Z:4'";&X!V]G'/J28[#0YXK[6H>_[B-Y/E&GV*0=@WXX&Q6BP
M6#&K*@3*$64,U96Y>[M#H65,WY6P+)K"A27J83:ACPOA?(G=%(7NB_'T&I?]
MK-R97YWB2OOR[[.80[1\BO*KK#0?UNO(1V8/DS-[8Z.='Z//F9FV8XV2&O>Q
M)*R*:*?N++*U0^WI+Q7+./[(<@005`9]]R'-A*/^MCR29.[/S0L3;/5,M+MS
MH=-5Y=L*Q?>=_MY7-<3*GRJJ]!M@]=DJK'%G::LJ!ZR#2Z2RM$8.<;9BO('9
M!4DR5Q1RN5:V(@&2(58NT3AV-5O^>@TQ?LSY`&MN;KK)&5.BMPJFCP>3KRJ;
M>G4(>;UFCLSKH`V>@JIHQ-*XD6I<I`U@CX_AA6!R+&4YJA#W$M"%C[;/:-E*
M3J;#&'P.N;+/&2_?3ALA4C4Q000]Q0)K6[_W`M8U'0*GRP_1.@\Y7_R#?>#E
M[@35<"U'K_H=;C;#=5NMW.FY3JX"J\/14I!X=#1\=PV,B)!=25(5$AYYD?9Y
MSK%LKU5'IT$R?KS]G.7?>+B.LY.ERL>3U+]CGN$8[/\`LD!H7*.Y,S!<,NL.
M`D_V9YN+SPQ*3_,B06<M@*GUD$B[!`N^_:'SSB/<J7A+"$T.WXE]<<;?[;G6
M@^V#JC]/0<85QFEY(%J*,UK/M2Y!JQ5_%JGS3HGT14<G0:</V1^Z7#'N/[70
M>VO%W$/(@7"TM!347)7'>QTL;AF[HN@EK[-:DBI>B4=/<3,');'&C6/(BD1$
M^O0:N.*>1Q..;RHNBP+6U_$[?#:S[$"[*I&%PY*TDL)A7&A/8:*9*Q_88F)S
M9!G_`,FKWZ"QWOI[1<;^U/(>"UG%^#Y!XYH,IQG1XX^@W_)UUR>01H0BSS+>
MZJ+*ZFFFJJVSE+:J"L[(CF>2_5>@W]?KYAX]XV]%O7JK?HO@U_*(W*_(8U7H
M<[:7(4YSM998NVCJ3Z=/LURYF>`B&G#E5#WVK'_'_!.@V)/NL-;PQVF<OWL;
ME.'*:QGDO+*AL--3Z3)"^!#Z=UHU:M(9+1DRA01HXO[Y'LG[N0=>@DO,</<L
M<M>OP/MP?9"8@"Y;J,YGL;JKO1IRM"]N>,B).NAJPAB)B=NQ[K'1P>*7<GV`
MK!51G=%"/[N"PSNMSYN3K,VI2YHJ*0\*FNHZW)_"Q)=)(W1"N12LB1FE<MP&
MGDI'?R;_`+^_03'PYQ1I>9N(>3]YR%%0\:YG&:W^F!9@H,\&^V&?JM0^VJ-K
M1CZ290==16&8ECK)9W)]L.2Z6"/M",.C0Q"XM<KGJ:KR=_M[385]BZY741A2
M$LR?(%-4$;>XK]#0UQ4;;@T/#YTZMHG2EHC96Y^Q?'WF%J7-"I'O!G]-%Q_P
M-SV[=W[[3B;W!X1LS-(<(,#:YD0BV!=EM+3GX]1@C3VT:.80A;7ANB1'UR-<
MC^@\UG["_8;5<Y>\?,7/^KU+QN0!.2-6),+0=LZW/CXO5VF<PU)E2J-T)<*`
M9>K$52E=YI)W55[+T&X7UD_^0UK:K@;ERG]@!=CS#S+QS18:/U)JKF&73"V\
M;#\Q%RG7<Q;V5DNKLJ&/-Y"!X4#Y%ACA6:)?XN^H;1/UZ_N5X]_83R94\-/X
M/Y0X^YRN<CR;N=;?8"S".XHKA<SGS-U<$&`3(MM7YM'YF`6&!JM:B2JB)Y*G
M07TJO=GT\Y'X:Y?]BN%N8=+K^(\;=.R^UU^GQQ=:'F;.WK*\K?&GTH<45U5W
M$@T;HZEPZH`X;P8Y$Z#$>-O97ACG_/THV!U&=TFGV`6KYBXHR@=?HL,5HN&9
M.6.28`>3QR24C0FJP+L)7"6[7]VNM5+:W^#F=PT,?_)"YZJEJ./O7[#:?7?=
MC;HRXYP#;16M-E=?<5F9K+#!6YQIK6!V1X\6EL5@0%7"D0HV21/EA9V#S9>K
MOKSRE[0\T97B3AW+R;':64DUQ#0PD0BR%55#X6%P]DLZMC18@HW+V_RO_'0?
MZ!N2ICS=1?\`%G`4^8N.6^-./HZ/:9:G+I8BN.--/>9NNS.7O=+;++0DF2Y+
M-6[C""%5V<DK7)'XOG=T&O3>^X?ZZ:_]CMWG_;2UNZ!?3+@#6@\>;'1V%EKX
M7^UPW,?#W)?&VDPI@:S%'!U=>*7(R=R_"1!'+W_TO1.@WN?IV]PN+O:;DW="
M>M&\S^FPO'>C@KW<$4EI8U,?%V&ME<#=\E8ZI,^.,X2UT1JQ3.$[PRI,Y\/:
M-KN@]$VR8$?:::MGACIX8,==3AVLLD3GSVAP%N);K^'&[6!@[:]HLKW/_P!1
M#41C/YM7H/*=OC<P)F\QE`!:M^4S=V3B;7+5E$=-FCLO86P\NJN,3JID_/YG
MDK._?DZ`6GDD\+`JQ^QB3Y'(G065];Z6MNN%\F/3ZU+LMVM,P@<M<%9@SRYN
MCOX%O?EM\VZ/+EEMHY/EASY2*UU@U!Y$^5Z=!9"FI4DDJDL(_$V4TZ6]&MK0
MEEO6L9&1G*`IH)3WA$6*YRJ$$^=B?<J1&L4Z_)"]>@C2QA^;C75:=XV?U%97
M5=AN"*&:DF"O1DI*)]652Z30G-CHK/?7%U:7+"+NL\:DT5\$A:.?)%T%O.22
MKJ;:XN.C"L\N92\3XG296LST4S;;D"PMZ(.LLZZ8O/(V()N?#MHHQFBJDCS(
M6$P=IXH50(YPH&2G]G_5\7.W94C.2.(?8K>UU1JZW?:\3DJ&80H>6Y=M37SY
M#/V)!2ME,@.5+*QJU2)_=J=!+G)?'6JI.`>.+CDNRJRN0UJ/S>@K\!EYW8DH
MEY-58"55414M;`MK4V$WQ!,E[BDI-(]Z+'$G05+S?KYQURY7ZC8VK2L%K*.W
MF8F;M*\&FM()P"Q]G/IXI:ID>:CJ#AJ@SR>B?'$2']TJ><+%Z"M'JC<\8<3?
MLJXCX@PUC<3<?VVAVX.!OS5@LUN-4/F#+&\GV`!2*1&9HQ/D0.P1/N(SO!SE
M\.@]8'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z"EW,-'Q+2Z"XK=:FQHK;E":<B/3T$!E@X\VBKONXJ43O$6P!@(WB4
MC$^**6;R3_/?H,2X@]=AZ&_FTN$Y2MKK.G8E<YN&$`N%?K[8JDH[W-:6OLH_
M%Z1$!6;FS/C[^0SXXFJUT2JH6;')@RV3L/C8I-6AR2%-J0WRK70,BJ!"J<V*
M<J0E2"/&3RF<J+'%(CU3^/=0KIC.;LUR!9\NZ<.YDRV"XAMG\<ZLK65T45#8
M6=6UCR++&G0S^<E8>')\7W,CW2LD^G9&_3H(GJ_:_P#N;=WHLC#'>\89&KO@
M"-/;1M:!>/S;J[%JA:3Q"3$7+.1*BW!"F@F^&>01[^[6(QRAV<_M!8VX8:7&
M.=/H,:3ERH,U"39P_P`RQ2)7'3VK3Q$L'1UT+WRB3_<"(]ORK(]T3>@[Z316
MV>)VG*=SRB+7<-14>0DRV)JL!`3J,Q:R#E.(L=7:GRVEMLPT*E5:Y1I*^0"%
M'M<Z97,[!1O]='&&'J?:_F/656B9M:6N>/+@M,!-:K7Z!VP&CE,T;6VUV??E
M$3PM1KX"HT#"C\7C(QCT1`WB0T=U/KK*XMYJ,NA^P&!I*Y:E)+0)\<K2BBWV
MDDB]V%SM9WA\%1%@8Y%1>_<(,Y&`CNZZPDL<_C="XFHO3JS+:4PTP#5W,3V$
MUY4L=C5&FUU=4#@R$I$(UD\4D2-9(ULCD<&O[U[O<;QMZ_YD2OA6HN+#?6]5
MI>*:*BKM18\4:#:<@VH.IJB;'727$UBY"NX9EA8FOGFA;YHV*/LU`L/M_?WC
M+UV&S^9Y1J+$=K:6<FVTV/&`M,9GTI*W\EHWV)XQ@47C'7P364:!1OC00B!$
M:BJY&!I<V>VS?L)L-;SM9:*IESE]?`:2MT5=H;*QJ8\U1PO7"E3!D);5@<9%
MG=U7V$DK9W0J49.QT)`D$D8?O5\JF5^7J[D>R=EA9XEBM;[):&"+7E%AEIFF
MY_-R4Q,8=[^%T<C:^"__`!\A03G?ZF,7_8@>*+WXU?L[[6?M0H.+^:<_%Q%5
ME\J47"_%>-UZ(_BG(X^N)$XTGU%!%?3&9V:&[952VQ4K7O8ZQF=Y]E3Q0+E4
M_P"P_7_KUY'M?UK9/T]RF@Y%X9Y)TO$F&,SVZOC2-5K]YJ<JD6SG93GLCU-K
MO*@(%XXJ$,'$DDB0;XNSD4,D_87G[STXY0_89R3=^O\`/R?J_8WB`3%VG(DF
M<"JLAZ]:#1W.9KY=+10$R?EF&'S%J(DZ>7B4GV\KI&RKT'GA]:O5GECVB74T
M'%5[D!#JTO-PV5#JMF'DF6_Y4@YE<5$A[V!F#ULPSUD>_P"D"R-_QY]!&/*G
M!7+/"NR+P7)&&O\`-Z84.>T:"4!,_P"]I("SP_SP$D+9(RJ6:6KG5A+56-S8
MG+W[)T$9/CK_`,?#(R<AUFXE[9AEA:@S!4;_`*Y&3>7DZ5S_`**WMV1.@]A7
MKGGF&\1\$<:V==5Y3"Y/UPXCO,X?-<A4#"+O:TL&TTJZND[$#6D]SO+(APTQ
M"M+E@:UJ-?&J1M#8?QMQ]Q)F8,I<6NVXQT1.*J*:PN=+I[BB)O;^XL*F:OE+
MJL=/<6;<4`M-71,<\?S('EEB3Y&,^#N&9#:#B:[`F/AY/IC"".2\K6T!=URG
M@QZPJMLPKBJ+`T]-86\8[3JJWL:\T6U5(Y495^1B3LB1O00#I-YA:"2#5:KV
M!XDH_MH*0(=?S&4NUR5<3.MGK#2M))I]5<Y<$:+O/!*#][)%:*BQQ)'_`*4#
M#/\`])WU(J@)X[7VPX7%GJ#WU55^<MQ;[8?CR+S1V5.)=OJ\L*(4\RQ-*(G*
M^22!/G<K(H8F10*%"_:+]W&3X&YLCI?7#C_A[V`IQ\%%G-QR;JK37ZPC4$6=
M:2EEFJO8D$46F>#7'M%9^7C=!<)71NK(2H@61P,"BGLA^SW7^T'J_>8L^B]<
ML7IYM[7VC1LYC-D?R;.H=D-;2Z3.7>MV=OD<"$".+\+F4M>%*3'W:[^;E?T&
MHC59FI$S%9I!BMA?6VA.LK":XL*A`:-*R(X@)DCB73V))UF66/(^1[Y849W\
M?!W_`%N"Z/J49Z[<><"\J\N[CG6SSW,";_$<9U/!M7EZ<V;9\5[6KTL?(>I*
MN["N,LVU%;7"?8SQUQ5<7%*="])'?3Q#:-^J3VQ]1O7/G_2\Q\4<%\G5RZ+B
M;E+A[2X@_6&VF-T(&NH3H9;2OOSH$DK3J^OC66(0PE\<BN2-SXW*TA@9'R![
M%8;UI]&.4_4VNP_.-IM;7E7G&H#'';@Y^-):37:`^$S/ET>?P4YQ[ZXE59/.
MVVG^V*8X>`AT+&L0.;^N+]G?KKZX6?$W/?/6FYOP_)WKOZEV/I]B>,ZJ@@OL
M]S94;#:<F:G365I=:$)T/'62S-K/0PNBJFM,<4,3(]ZJ]R=!N,JN2/UT?L@X
M[X\XAY'UF'Y<;DZ64YMS=I:#%\/U.YMP66-?37IAHDDMU1(0;.K)9)&/:QBM
M1%[-Z#4;QY^OHZM]GB>4/TY<F;*HQ\_&NKQY_*_-&8_'YBLUVPJIJS2X7BPR
MS$_.71E%7*])+B8=8H)?K$YZHG074]5L=[:^HK:S"\?Y/U0KA>4]C;'['EN^
MY!W<6FVW(5O76M54&\@;$J.5UJ3J"`#9PJU(^_R'E/=Y(JKT$+:_]0NCYE=R
MURMR-[!\*\:<M\M\CNT-?88K$S:[!04%+E4JG5"2:)D=D)35F@HI82)P()9&
M.ADD<WX53H-UW_Q_O4>;T?YMML@;R`/N2BJVNH)2Y:+/9<0*ATU5/9ASUEZ+
M3QV.J;>:1L3XPYC)4&3LD;GK].@];]G7P$7%[7D22D!7TM?`9#7P1N^-Q(@P
MOQ6KT(<0UD4-?Y*Y&QM=%.C51W0:]/?WU=XYUM5Q@7G:2DQFBCTQM/2$T8H-
M>*\DNJ-LI?GSKQ%S!KE"K)VJ63$DP;7K)$KWHV)X4K]<.,<U@:UG&E9R!6U=
MOD]=3:6DST8@=,ZMN-/O*0@RHV9-=6TP^A=H"!D/)B1GR#-&9(220WL^(,?Y
M'YGXYX>R5G="MAUUK5ZO1MJ:/(A.)UGW9&OL9[//&T%*!'KIJ>-Y$<L]E-(=
M'($L:$?.UJ2=!6.W]J=$1%`/J<-97`-Q>2TTF3Y`+MS,W869C=!][1/H+YTD
MUI@!MI(USA7SD_F;"3Y(28DB'8*%X?;/G325X81=#7AN7+Y7#TJBR%7U*<ZV
M-CIJBW;B2:.Q<O&T-0EO\L2OCE628&)GWH[_`.:A_,-I^00_7?A[9TU_1E7F
MBRDW(..R-3<1\8PAGZ6OCGKL)22C&D5-)254RN=9,5IGW\G>%KF1KX]!7[E3
MV:YH>/2TL`-+IYZ?0Z"PS]`EX%6MK(0K:SMZ[2F5`Q%F293V(]K/6DS/00*0
MFKD@B@5S$5H5^_\`+',&N$@++NZZN@.M[RTN*D/4W$Q8U_\`TW3$([[@NP[P
M5-E60MC"DG:D+/A<#*LOSQQH$B^N&"J]][O>H>MT`FALK6@U=MOZG8O6N.L7
MW%ME2B"*:Y,-;-92$@",<*?WBBG@A=X-<C?Y('K%Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'01;N>2,?FLYI=,5(#=`
MXVFT]O;&!O!LA*.?.54IY@=G.R9_XTV:)BL2-_B]5^BIT&H>N]PN:[GT+XFY
MQFUF>I][S#L]M;X"+$9&Q%I:WC@8G2A82G;0E1QFGP@T+*]2)FHUKGK\L?\`
MK9VZ"IV>_:C[&9\^JP%GF,9K3M(+5T)DL>9U-3/HMAHI@*V>S*TCQ)<PUS@1
MYFP?[D;(Z)7S)%'&YW02&O,%=AN$N2N`[3@CD'C[+:Z]NKC4;TJSK=1$_0:#
M0LALS2BF6)0,EK:SRJT0,5R"BIV;++$O091QH9A,?ZJ\*<48OD2WV-)QR=!7
M6VVO*(2//;?,W)-A?#4.U$!6RN8[#(6MJX9\?PM++,CD)1GB_H,R-I7;881U
MAD%?+NG%D/N^(WZ&PSFQER]GG0L[1Z>Y)*-*K9B@@3O"``8,91X#4(6)T/A(
M'`U/(]774.KJEO``:6S%HJG6_DB="S)R5D,KAJ0$&2NK;FYGL@X?EC$2+[9T
MS_X)\ZJDC`M'^N3C"WX]Q.OY`V&86F?R/=Q:K.6K;.CT-FW#"5@.=SU9?24=
M6T6I*@'KDC'#`))\PV13%-&(?(-$&R1V@B-J"[&J^5K@BU&FC/$>!(CAB(VE
M1?'9OKVM62%5^.1STC7R1R*J=!JW]J/9\:BWXG$W%ADVWY$EV@]KI0X),\4W
M'4(-7(1<4VI(M=3E2<[5,B5I#'PS1K.-',D;B)/")P:CC/9/E?CZHUU7Q)>D
MTM+B[T$"S@)'H#JF^L]C;3?CMT:$'2[=+E++2SRQDQV5]"("/V+@//<[[-`A
MH^3C/V7Q7-V$Y[L*">.WXFM<S6<D97?7M)9X3<4EX"%)FLW#;4.9`L[;;,TQ
ME?9R?BHIAV`OC9#]O)%(T)IP=.^@H(,O=X^HH#;CAN/,!9O.Y\FS9)G:F&FH
M\=EZ&AIXPLO:VDL.:6;SD)C:(0<LDY*R21P.#DW]'#OB,D#/F*<4ZG#KB*T+
M/`!P36Y"W<9B5U9+"+5EYV0BP9]K&Y\4<`TZ*0^8U$\U"J'-7K[Q7N>=N-.=
M+?%X7;S^MVFI9,'=<FC%U^8LX=O4EVY6:V^=_)6Q=I76>HMC[$!(X&/=$UA#
MIV>*1N"GF._6?P52>VV4]SZ*YW7+/,:\\9/;TF?LC1#<YC.1Q="7:T@FNI*R
M*.U'R<:53&9>-D\DI(==%)*]G^Q&!HN_^0+[1;CF']@O+U`_5'MK**FI,?L:
MJGOK)**YOQBA[^[BLJ/N**/]KH((9&BRQ.=!+"URJKNR]!HZI]$?2QS0"/?%
M"7,,\UPTTHAD\`\C9'"--@<V:&"?Q_DB=_KV7_*=!N/_`%L?L`XZX/Y5Y<Y-
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MR0,O6'QP,<1\<D?R?&%#^)_TD>FF&MC.(/9/B#ENQT`#RYM!K='<P\>V]V6!
M<N(@;D[O.U5]@LI'65+?MXQCB)!M*O\`T%!O?YH&PK!_J"_4('@()CO7V5V2
MM;6R+I=#R%O$B+!M[&GG%O9[&]@@'R=53Q?>#3U"SW,P@D:CQ3.=8#DC=!$<
MOZ0_UAA"8AF!X;(W.=NK47$7.LM=/KS[NMELJW0Q@75Y2&KC;+)W!]F,L`A9
MPD5,0T6$YDZPF0QO"NV!]2_TQYGG.XX9R/K_`%W('+UGS3J.!JKA[G"EY)K!
MSM!F:];#82U5H%;B6D8IU<,]V>=*.*2R?M([Y4\8W!,>:Y4_^/7D<6-Q(_.9
MH+(<G9NVBN.&PN+MK=;F72YK=7$S(*P,_36FNQ=M57`YC;2LM&@3'U#('PO:
M_NU0BFEA_1$[1Z*[PF4P^_PEGR;@L(*/FN&-*7F:?6:VQ=;8_#6S;S0A6X(E
MJXFSCKCW3P?:6"R0'-E9&,SH+H@>Q'Z@>%N&^7N!(<+;<6WE?L-KQG<\6:OU
MHTI]]C;-*,NUY5UFPVV=BNP3\CF<XJ$SVXSHUIAD^289\:.[A#MA^ROT`EXK
M=OL__3-#QCQ'&@.YJ*OB`JL%R'WVXM`L`?,RP#2])(V-PY]U!VE^"SEF5\CQ
MV*D2!%UYRG^K7V6]>]3BMKE-CHR^,+^;D;EB^_\``-SE"9L<8^>SHJ[-5X8L
MN@@J>2_SK"PS1O%TYL:3-:L$\GQA4_B?]$T?.@/*7,>6Y`WGI%PIR9;55OPI
MZ[Z6%VIY,S]=+)6OR^JY/EJG`RLS-B$.19_CH7N/C@B7YD9V17A;_C7@3]J>
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MRS"DM8YXD;569@>WZX(%=>`V43X&Y_450M=/;A$B@3R_<H6H<S#))U^_@^*=
M.Z(QDD7=BM<_NK6AIO\`>#VSW&!L+[B&[RT%KA<?R/F`EOVGU]7<D96'-I;A
MP27+9KK[:P0VKD<DD<;K$V;P#01)R@V$!7K-\2>\^^I*[DS#\=8J\Q6^_K6X
MR^BU]Z%5VM)7#6\9T-?=Y>-K[6Q+?5"2!5\Y!H$,,Q"/.3X&RQH$I<-^H_N!
MP]S[<>P$`/!-MJM>`'2F166[&%K*:LCS0=?`PX&3/V15.^86..2W_'%E_E)'
M?,S[>.1(8PKW[GQ>PNXW_'G%/.,7%1VDJTEDSQ?'-//DJ*XH[<D<N"KM+>G3
M;7%7%D;VBG2$J$=)V2N+2$=[V.DE#-S^'.5N4<W<X;EGFBQR>1JL?=.XWVG'
M6<"O-0%H)PX8,]?F61@%76V/&E:=$XA(CR;"&`H!''SL6=6#AS;W@[D;:<'\
M8\*:JEXV'CXLD@UM9JP\EK,U7QC68_F'F`,I9W@)!`UPQ[96B`6U@11-5$DB
MD7NO01H9^O/DL^-NC`Y?R$%LM:['E_=X@&+7D1ELK#COORJO<N+JZ"%YL#F`
MSPRH!.1&8V=R/E^Z#(J;TL=A:VEO+[=4QM+"^XK;$2RKV.<E[8E`@OJCMS$0
MW*[..UMJL66&2&=(PW0S*P?YI7-8%DL!P_4F>Z_`YN;T'V5!EM!=Z.4BFJ7#
MVFB@9CB+$%NSM_OH?Q?Y.WA:QL2@0DG1_P"F5L;7=!OLZ!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0:POV06^9XZ]4^3
M\!@HFY+>>R>OI^'Z,RD>M685O^42QJQMY-*[_P#>FPC2JXE6_1T?=%Z"A'N7
M0'X0OA?@:7<9JGS'#?!.(Q%36Y*C(A^>\K1*<#7P35T#5^."Y%J0GU<;?Y#1
M?<I)V^5.X:\N'@+W0<Z"UAQH15?PZ9<\AV@U>!<V-:#5W90=*".'1)`L%7K+
M*C-/<)))_J,M!@TC56P3J@;$^`>/V:7<<TQ<D2A56*XXQF=O\E2OT4-C9[8O
M1C/L:,F`*VF8$$'`,J(0-W7[>S[*G^.@BTK/ZO*32@??T=IIP+X2KJ\_)7ZV
MN'J]A=V+Y\/96R48,K;/*9_'FB"$`PH\A+*`J4='0/:]0W&8KU8X\FL\[;F$
MI<759B!P;BLIK22#&Q:LV60VTV-5G998;$,AEL/.*SSC25\,_P#-$<CN@U7>
MR&JWFB]<-5S8%*G'.OXR]B<WPF+G95KI\SH%"U@6=AMLW:C-?HA[`<*Q5PP9
M\3)&F*WY$1B]^@V;9B;D'%8'!YRG+L*5<]A\S_8:369ZQL\&^X)H:N";*-/R
M,!TH@DB$NF5L*.3Y7>#.ZM?V"===:\GUE:)GN/JG(@0`@J^1+@#5N&A&I59+
M93!NSXID$!,\JI$$`:K'$HU5D1&N3H-%>[XB#@Y,V>KHK"'5[O9DZF]SU78C
M2EN)BTTH)<6?+U+O&/%4N>LJ9UJ/$(Z2%THGQ]_C69$"JG)_J;[#6=_F!K&7
M"6V;3$V.QT]"V[V45+37UQ3,IRJR>VO!`(QKO*1P^-%#(JOGL6N=,UK5[]!%
M_+&/Y!X4PW'F<DIML3R9M]I5;S)V5J"9?UL?!>;Q4^3T4.8M*L6=EA?AZ76,
MD'KG=_\`M(6S]U5>_03IQ[KJ^X!KR/P=X,8RO'AM+>'-,`!Y")!DJ\M3:'<A
MQRNLZ*DSAIDC[*8!OSDA_<?Q^9(TZ!NN4L_F2@>.M#64[+G75`\%_K-)LC\S
M)G<3H1O@M-$67$UL(]4>J]ZI6N2QE8K9'L:JKT$!\R;'2T2QCTT2G,U4!OV]
MWK'OJ@JN:2Z),I;',#ALD==7SF%NA%<]/$07[A$[1,B50F:TM./L)PY>^S_.
M.ZOL9Q!C[6`JQV!]6/55(,F1S05;<T_'K`E9-9;>TM;MX]<V5%^]&G>0S^3'
M]@_SU?;G.[[:[75^V4^"N<[PY[`\G[BQXUT9D)"5UU$/833.&AG*<I"FQ!(V
M25LG9WDKNWT3H*>=`Z"S/J6J2>SW`D%5#=3?+R3B$)!K[!*XX\J*Z&D?`(;&
M]K!F2O1$8]ZIX?55[=!_I`\2^]7+V6*VK.5\IF=.%`XS[&>NNZ2R+TA4U?"'
MFL<+84L\T4D]1!"E4_LK6C+`A;^T;T7H+:\0\]<6>QE<6:-H;/&6\EB#+>X'
M;:*,6USY==:0DQ8ZL#;)]ARD'J*N)S"8A)'O#(C:Q>Q/=G07`THTP\05KGJV
M85EKY9[,9BLBS5Q-KW3QE'A,*.N3()*PNL('0::$_P"-%18WR.1HSU0-5/LW
MSSHB-]I*(6&FL^.L!#@#5JBP3MYBR2G"Q$\D::M+H8RYPPJ)ZNK[',M<XN_E
M17"L<WLO01]NO9SDCE7.T/#%`I>"C*K_`+6>H@^:&26#,$6#@J>VV.A$@CLK
M$0&LB<#91(M=\9#6*]4B>J!VGJ%CN)]=I+#F;D+5WF(M<GE=0=K<T.=7XG;Y
MYY\<]!37P6OIBB,'LH;RY''@('IIBHY)B8IR/B5'(@3QZF_J%]4M%R.;MJ%K
M+'E7&;P#EW5>P-U576PWO(6UT)GWY8)M[K5'B!J&5$CA)!X/YM5?*/NSZ]!`
MGN)^BG@;C`G0\ET/K+PKRA%L)KVLFN:/&G`<CYS^PW1UY87L@L,B4VCUUHDZ
M!QW,TC3!'3^36_&U5Z""-GZ">@?'?KC#L%]#J+C,OF0?.4=YB8--'::6CU/'
M5Q50UXU5&`9)1+J*THZ%YER-(Z`F68ETCV]G]@R>7T[X(Y;7.\=:7U\P&-RW
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M\6\_X/\`\B#.U`HF"S-970Z:WQ\9I=?5Q<A:BN9#Y6+=%82_:D6,_>&&*1A#
M7>,O=0UUZK]0WH]S)#R=>#9C4\&<@9RIM\Z1M>&;Y;.TA&@;4YN^H[CC*S*A
MJ:YU2&5-,"8+W206,LEG:5D:J%@_U#?K?K?27VJN.;KCVF3V1XNM..M15L!W
M=`;4:W&Z&N`D&:EK9'#M@%G!IU<+-YR(CIG-:SN]4Z#T3T/L/G^0-RZH6JT0
M&;L3J2;,:*>@%KJBH".%%*<8^WL%AB2IT<S/A%([)&2L*MA57-<G0:2OV;+2
M7G-G-0]<3+1W``&KJ+&Q2R*EHR1M3CZGO`?)?)!44Y&IAKVUL,D;EB6:>,>-
MZ3%)T&[SU!L'`^K_`*REVM*,')_2\YEKB*E+_L#FLJ@V0T\Z,S3C08J^IG>V
M4R6=R-"'CD65>_0<83VBX2D]TU]-+1=+'SI?<2%\A53E,E.PU_E:D43[LV$J
M+RC$N09)F=XI4:4D?:1$\'-50H5^PNN$H/:SURUUFOQ65H=DZ.[H(K\YK+`9
M^@.C9I<G5`1NNS@Z:1T;KN<:-[(&$1/*\(FN=T$ICPF!$\SV'*-OGZ+$<9MT
M-Y2T.?K;S77_`"Y2SO&MR!AJ"H'FM2*ELE:V)\6?C(>8U[F(U5D7H,>SK!75
M9U2*(LX;A]`\N-M4=5R44"%2J"*@QJH54%UJQ*QE7.C+8H=$8Z/LO0897%&Z
M]CCJJZ=FJ.SHTWL=K9V*Y$>MK]:=`W+U4V+NE'M!+6X#!*EDK6-66&3PD<B,
M^'N'\6Q&%RM-`916#PH+W6U%8;-#86%/=7-G-7#5]BH*M>,<><R5T<<Z)VK9
M&*^3Q^9R]!E63J+RA]IO7NIOK<^UT>5UKQ-?/@M!7S#O+MA_QL`VN8)*XEM4
M*3.SY`9&^<4".[HC?KT&]?H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@=`Z!T#H'0.@=!K2]B1Z[ECWF]4^-2'$M`X.`U7L=I)'/="(A(
M`LE1CF1]T2$B5ML.Y\ODO\(_JG_KT&GCF[0B<A[SEKD,NGF.AT]C))075'90
MO%@IJK2Z"K!F+N"TDCAT2D9V998843Y`FLC<J-_R'0^O^6.*SUSIKP%F@L]O
M=7#M-KJ66`:<*'(C"29J0B1(EFB&8/9N2JAB7X:LB,A8T12W.Z"SG&%!R#R=
ME#MWGJ7139;'ZVRJ;2ZU`0U1:1A0635")JI&.#MOL5A3S?VE;_N[.17M7LH9
M!E<=M=3LF8G&ZD"=]S?125E[7#35]'/:Q`BDVEEJ<C9SV15=8,MX#!FSM=\$
M)D;Y8T8Z554-X>7AH+2DH3/FD'M:Z.**0I>]:<<:$.%6V*=YFQE$5Y=B,WR1
MR>$TK6JO?Z=!I#]PL[:<P^VO#WK""1G$XXAVV-Y"EX[N*2J'QM[MJ#4!Z6ZO
M-6)35@A%W8A,"62!L4D?<I&.F<K47H-L]D,(VYLK.]%HL[4NL6W,1E8:M=9H
M00R$.MU-Q')7D2GW42Q("-&SR?!%%Y=T8J-0*?\`M=["<D>L^EQ5;D_7XKE*
MEWX]J3HK2JF:FO*UDMC605YT]I")%4UE`"%(Q6&O\9DE@8[Z-9(CPI_NM&#Q
M?7ZF/FJFPP]U4UQO,<-U@M#EZBCLJDZ-IURW:YEE:ZHL.1FF1C"LF%&@DL2T
MC:Z-?-SU#6O/F=9[IQV,VBL;6HXOPEY("^<7)Q)/>G_>^82U4LEE;545H"6B
M/'*?'`)*J=G,5W\N@T^?OJ_8MR1ZS\U>O'K[Z_<IJ-R!PU@*T_F9M<Z>TS?Y
M*SL9=+E,N?5:`BXFEFGJ;&.SM(YIYFRF$M\?%D43&!2?U?\`VO?L3]EGZ7AS
MB++>MM1J*_/;#D(W9VO'%90#BT-36$6%WGTEJJ4NI@ET3Y)F#LFB8DY92IYH
MYW?H-H>#_8;L>&\5FZ[FGAWG'%<L-I[VLVLXV.!Y+XA(M[RR^51,A5_"ES3#
M'L=]^UI*DMA>G_;M9&B)T&;Y+VMX)Y1Y#HVX3FOBJY==P,IH'[-(J*Q`UI1-
MA;&4(%9L1'VL!UD+#!+#9_,@0X\:0)'W;W4/+]^Q?W*YJ]B?8SG#CBKYAV.L
MX7O.6*Z:AX]&M"H<++IJ*DILA]Y49N"3\6QWY*OE;%+%&C9O)943_9T&W7]\
M_`6!],/UV_J5]3HY1!>9:_!Z'ECDBK^U?':23ZVO@4@\V5C_`+>-D!Y:#MC5
MOR*K5=W[=TZ#RB=`Z#;A^F#&)H_;@G13T]D;!@>+>0](';@U45DS.:1,^4+E
MK69Y$$PXCXKJ:+XWKV?Y_P#1_+MT'JWTD]T924TLH$9=K=NLY*$NCU%L/G3&
MSVTE.62')"<I)15RV-&FE0?9EU\GE'WE5.ZAM2K<(#0\29/'7%!26"XBOR@%
MM6E9JP06?7[,R$FOJ:K45]E"25:B2S%C"M>U"&,'BED7Y9)'*$]$447KS+49
MUAO]994W95H15CD!E)-5V=&6"^MN:<X>SAI1:8ZY:LCYY)9BF23_`,$1SNX5
M\YJ]8[&_X<M/:*FL\GGAN4RT,J\U:XZ@#?CKT&!U11:"OLI!5!91!,C0CX9E
M5D<RHZ!60=H4"@-6.;DI-MI;6P=EHJ"I)L#K5L;ZO2N%B:+3/KS-X=(7<OH+
MJUBE,!ED(=9DOM7C^:A1Q1(%U?5WA/5['C"]Y8SO'>N%X[T]@Z"I%,KXW6!D
M+*V6$XH^E802DI-=:LGA1O="B@25:DT<,GPL"YOKEO\`D7UVSCQJ#,42F:*Y
MLYC!=+FCS]9;LJQY97TS":HBADRU%5HU(JV$U\\;G.3P<C>['!:;;^P^CT2U
M1-GG2:><K%`VU6:)!)89>UI],3*"EU1NE;*4EE"\7YG,>C7C#R1HK^_FY0TZ
M<HZ:[3>GDE'5%S%5:L6>DKJP_075NZLSM@+-8L:-2FCU]*<:09-&\I/A"FB+
MG1_S?`]4#IL,9#9\@9_7QSD?EYC(G5>=-M'.HQ2"A+2$<^V("(KG1Z=CYD=$
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MXVJOQ<EKJ<[G2A+O6[/C\:Y_J<U)]^9-F]"+*T6`^^B<-']M8"M8QLC(E8WO
M&]RA*''L.@VD5ANK$6ZNZE-#2VU*Z\`JJ>9;VK>:24(4*D,LNFM8X2HSWR^:
M_*X>"-J=W/[A;#/X&VK^.=GLL+3R3BB"6C2]$RUT%.&/;S02/.N8PR;$ZGD(
M\'KY%QB(0LO:.5SVKT%5Y:(P>"\"S8ZR$6#:@BT?>36`2U&)IX*VV9:#V`:3
MLA?-;%/F^V+0P@P:9JK*CD7L&4\NNS.JU-GR5/2@7$>LR="5:V]9"@M%:152
M)FWA"PV$++BI,<:$^)"H7"I-"JJY_>.)_0;+?2YD5SP%Q^MC$?GB\16VP5(2
MRQM9D%!5I57$K&GDF5T\@XIZQ.<Z.2)[E;(QK7-\N@[WDYG#V(Y1X_YFT?#C
MI^<1`K'BK.:]M`)?:MV,OXW2V\4>K\&V4])&HZ/(8LJ*B+W^-_\`CH-6/NYR
M%0[+GKUA=EQHZ,^ZSXXD`5R++7U981>HFF@B$8HCK6&L%M*J224ERIWF2)?C
M6-SF."3:NSEJMQE)0A@Y;V26H$`"N%OZ^DHWP7\D3]9,3-:CS09"261[6201
M5\!!+D1['-5$Z#GTHTT0^<LA92KQQ!-@1H8LZ6'&%4@LK73UAL%(K@(M7(#9
MO6$PDA[)(E:KF/[_`,>@X?KOP]8C?W+;^P6SE,O0#[.PXFM*,B"V$#RI$BC6
M=<7E[0+\'IKDH)B1E3+$D8<,<,8\:?$SH,BOQ*%V*IX(+"O86#=7]6/:34(5
M(P>`MT)M:JCH/'#<%RUDJM[R1-=$]C'*J?7H,6S%=9<'>VOJS9\I6\$(7,M@
MF>QYA=[/J"]9LF4$X(%CI"ZYX$5C='5TG_;G%-E52?%5\U;VZ#?5T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@BS=9K!
M&NN2-``(#9Z?*6.1*U2K&`7%3&1RL=5I=(]I0K9I)U5J1]U[KWZ#RT>U5-C\
M8S28"JO8I2ZJQ%XLQL@0]E1<>9&@SR#"0J&6.AXFIN[JTMG+:VD[?O99&O;'
MV3R50LUGZYF.XNP>/&-KZ*\SN=!>Z8C.VWX2PL`?F_L!D,H\P!US$0(8UT8C
MFS2EMC;\2M<Q44,P%Y`US./+S)5MJ'I<'R-K0C*BV%(L8S6T#(&P$.T`!0`5
MX#4965OA\$,;BV^*(C7=N_03!ZHP9;B+2<I<U:\752\?GZ"/.9PR*O-T4XKB
M9471RPD`AF:2U$L=/\D\4+H15BCD3Q:]B>70;/-KH\CELG<[R\B/L*&A`EOR
M2>QQ-U6`L%AOZN$8!\(]E/).<D;FQ*DC4<U6N5$8J(&H?TQSM[R_[9;#VU.G
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MP8=)C<IFY+VGV-^%B/Q9.CJP(H(R&$1_8L*>JO6MC\EC0/\`,Z]Q><KGV4]I
MN>^<KR\_L9/(_*.NO@+A`(JN,G.K;$!Y5D%;"R-@`PF9%$ABA[=XXXT:O=45
M>@W%_ILX2YJ.X#]J^9.)N6&<-6UZ3CN&*/42Y9FM!M+4LB39&YVU"**"KPQC
MJR@D5DTKW^+VHO@J(O0;-(M/[@9;-6^8Y>Q7_G+FJB.R;;WDOBC9#YCE0#,S
MQQNS0UUA+_+Q\?P7<U*B016@%J>D`KO.=C.RJ@1ER3O_`$%Y=O\`0I[,<0F\
M#;8S,A8F/_RIQO=8VC`KXED.CM*C>YQEN*;?EV'G!#9BGR!RLC561K&Y$Z".
MM!^J7@_38`;D[T^NL2!:T=_B.3<[RC:[.3D.MJJ08V*`,2&AHEGM)I9->`UL
MC#*U9Y62M:R/Q_ET%?OW.4'OA[J<S\9<J<P9'+R:C*\197C$''X\PM+$^;+A
M.;;:H.G-'@9!#J"VLE6%CD6&14:YJ?54#SV:;![+&D?:ZG-7-'-\[Q$2P`(@
M8ID2]I@VRN9\3BX'?1\:.5[?^4Z#$W-<QSFN:K7-56N:Y%1S7(O96N1>RHJ*
MGU3H/4!^EP27C+UCY4Y&)SP4<O(.^KZ`6WL9K.MG.ILZ"0?.C!QW02Z'/UUG
M'%,0H[^PLC&O<C^WBH;W^%L%9<@<F<4\:,=GJBNM7/TH-A#8IE;^\%<4ND*O
MSZ#0!DJ'#7N>H\T%2PN22%GW3E;*]40-EAA9A_*G'E=<ZM0,K:<JVFIO<S]B
M3<`74,8SA:C0X>*ON,W97<H94$+6&SO7[1\C7]B7SHU`X?L99"\@:W<404MP
M:7;<EY.&4.J'L*XHG0/"7*6+3M#6#78FK*'SEX^>(,>()R'L;]V]JL5>@L1[
MUZ&')9>@P%D'NM'A^/,YB\8_BVNST?\`3=UI2A1I(QWDMI:]'&-8Y$FFBC)$
MA8BJV)TG\>@UD^R7&'*-/Z^7?+<0&<H:C4"5-=^.K3Z_6WYF?!*3.&:0?.:[
M\=31PY@559'8N%L9&>+7,;"^-J]!Z1_0@/ACC_UEX5XPXKU8%[34F.K`:^U<
M2:DFILRARM%<%"DW!I9.@LXR3"7&2Q2S*BQN549$V-C0G._I*T678WNW@SFK
MIXAC2;!1Z^$"PH,\-7R%0UMF.V<I]]\OQ>;7S/B\%3R8SZ=!KNK:2#D[&:6S
M:RUSU+LZ`:0?[J]FI]C4X(BY*M,M^$H!/O)J:O+4Q6S2Q-^,@21K'M:C4Z#4
M9[&8Y,M+LAJ*PO*JPN[<P2$''WE10V9"9$,,2MXR9<`(6++FC9[XLV6*PB^\
M[ND:*+.CIF=!UG'5=?0RY\Z^KX;;08-HLL68`?44!$\,S&7I(\U]84][5A&Y
M\FOC8DUG!.1(R1RPQ`_];0O9>60Y&)H:5]/-QW8%_,RMDTMR%IIR+*:+[N3M
M9C?-"/<6!LKVCN:$Z1L/BV-7,1&]!C_&-Y1V4.OW]]]J+FLE9#Y:5=(45G:6
MGH!L;%2W&MT1$]6,ZQ"=K*]\:LA:"I#RUG\&KY*@166EQR+P!?8CC3$34.KM
M:`X7BV^Y&/K)<S+=S7CRGZ`4)LCK2Q#8)`JBI$Y(DA>R5$>YCN@K2SD+D2PY
M6IMMR*?;FZ3`@Y;C.2=Y<@.FUMN):Q3UH559"+)6IES87?+(EHR%Z#_ZUD^7
MZ=!;#EG6Z6AYIW]6Q8J?/9?+0KK-[-0.V:9:4:JK;*2UASE3/6'$TT09BP#$
M>4LKG3OD^-\?GY!BV/YUKK8A]HV#7BY0;/9@[#4AP5?+55)%K<21":NL%!"J
ME9-HY09)'R2G(RN@_P"55?",-[G&%+64?#&/K"JBH$O;NH&M;O+I:V,DT0DR
M_*4@`L*6Z6\D?R)Y2)$L1'?NY5Z#N:3A?C"R$UUS2@T\M5H,O#FSZ2I_+-<$
M2!&4T@*4I3E(CBCFE1L;6"#DQHS^3GIV:@0!IO3NPLN/`\T-I*`;9VRR#CW=
M^.7:2CYMH4@\F7,GD0.#25;PFQ^0[Q0GM1O=LC9&_*X(8&XJ]W^/LT'0<:;:
M2>FG`U<J_B:_*/K*22&MG#"!87;3^1!K3EBDIV0`H-W3Q+D7MY]!77VNL/='
MAL?.W6SYXFO:XQ9(,>!89C+U6CS^C:*.I.ML0J8FR;<5%6:][8OMWP3,B5/)
M'*OBH:S]?SCREM.?<N?S!O\`7\@B![?CT6#5:/'5N*3,U45G2)(E/84]97V<
M`@NK;/-!',/]W.))Y$#HU6LZ#=)>6I%7SAH]]5<<+R5K-51MXSO-`1)->#ZV
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M^"*U0WJ]`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H*+^WE7=CZ3BCD>RY'HLOP_Q85>Z7E'(W@9C(].-."\.E-'N!F/C
M@EJ#U1R#O3_=W^G0>>>&BJ/8'F7)<*'7TT4O)W*0-X&*#6R%5]$[$'3:$ZLL
M9HG22".N11H&#JB>,RR*LBM\DZ#T.FPZ"JT@,850'6T=5DI;`VEES$%HVFKJ
MYKJ\(0:26%[(;2>4UTT0R/657L^O\%[]!#>CXPKK.%UZSCW'A<A6WW%306E;
M;B9^IL?N"DEJICZHPJ("74,D[><#)&>#E7Y>S?KT$-:&AWMWM,!QQQ[M8L5I
M:_,E<I:K&4-U6U85QR#FUD$#B'MJU]TS1UDTD;V&5]='.BS_`,7O9W3H/I[B
M>P&@TWK_`!0!ZZGX^ULX55FM!0<D5]SA;LS77H909%:'3E`)]^0GVL[Q899(
MFPI+"^56-E8JAG7H;@+C@7@ZIX]M*6S#+MECY%U"$9PZS,FS5O(@M?`$+1&W
M@SS9;&9CW#0DN?!"KGO8QO?H+A7DVG^YM2T;FK"ZI*U*YE9?$4E?1&53G.<[
M5PD@6$QN<#EE<L3AWL69SF=W-:U>_0:]^?O=+C/A#25."Y/+(&O*J3,VIUCG
MZFPWM96UILI-@&9-_5U.M!Q'2OEC=+\2L8GPIV[*JH%$N2N<.+6@:/E#CBWR
M>U,(#OA0B]<`?%5ZF'6^8Y']BXAU0^>V;PZ.21JM)`$*#AG2)TTT;'.=T%*>
M?_9WCSB3]7_MM[=5O#^6XPTLO'TWJGBFYG67WSZ[<[]K@M'/?45\"%"!!7-F
M>^)H3Y58G9D:/C1'=!_F_=![BOUU\-V_'OH+Q!@M"@F.;I1[ODK2.KK"!KMD
M/R!)%6Y*<D$#[N[FMQ*T8L2,M1TAK7DM65[&2=^@L.50OM265-3=%@OM86YD
M.0>KOO(@T<-T-#7U]6H3K`G0#QL1LQA<D2M;W<Z)&_3H.'O`/SE#2BZ>MSG(
M].74UHH07(-=6/Q8QL?G40Z^9;166JW-0>/-6CHL3'-=!W6#X7QRO"N/)?J1
MPSDY(MO-DMSQC!<5M;HC-E@=Q'AR["\SUL!5SSF9RB*L8:JQ809"RM@>.V,R
M%72]FJSNH5YY=X@YOQG*63J\![9W^R/S#'WF<S_+%:-I*>D%U4+4/Q^QTH3?
MO[$J>IGD6><9)4@;_+Z.3MT%6N1-QSN3%=U6IX)XEU_'''NQ*NY68!8;C+E4
M+_-]AJWNO(P],4A`+XV`D11OE<C4\XT<B]!0SVUY1]-KWA@`7CCBJQCYQT5A
M&&1;WM#=8MN$RE:2\X-:1B".K]B793$S#E3SOBE:WQ5&_P`4[AZ%OU_X_4<>
M>N_%'$MDE@MK2<2'Z+1495;7NDJJ7E":*WIXG,F5S(7ZR8!HH\JN;(Q9.\B-
M9W7H-L?K:2Z*QV>YB`L*(.SI:C("MV/QVLM3;(0L5UM^-;*UA`LZV@)B189T
M$241LR.>DBQ]N@NED[ZSQ4!]M3@9XNR.,LK%6UPL6QTU-D`FT=4^QG(IW6CP
M:^P$6`[Y(6QA1BDL)EE8Y41`RWU\RK^8O8KA@:ALV6&;P!UMRC:'B(9!0V(5
M%9-DBJJ_(V<%=9170=X3`LEGWE4I'IXM=&K7*'2\T9ZZY\]NC\5P]IA["^-L
M+G7R_P!IJ2:TMNSI1GA%5;LY;V@L@(&=%9XRELC^W5J>35<]>W0;*O7M?:U;
M&;C7V6]<>$*/%X_#5E52;;CF^L-=3Z,P5Z"/A"R=KF&34-?8C-;(2*UTKV3*
MY$\F(DC@GV^X(X6K<C98L+'Y['A:&"U;0EQO_'AUFKOXGMC91#H:*2&?(2OS
M)#`D:/1BM[=E5O04HX1S7M!F!=9P)R#5OJJL#,6DY_*3P(BH.4BK@E!*^=+8
M.PM#*\VGKU2-P$,,SY6>7S_`WR=T%?3-KM^/M+H@!;,+-9O/724X!+K#.Z.M
M!D&K8JZ#,6.F#LR!\[0VL0K9066;AG.>O:-JN:J=!K@YP`GT-_J,]OZK1'U#
MZP'1V"Y6J--T[*Z]GEAK]5GK<>.'0M"H[AT8TVA>!^/%)(9'\RH]>P3SZS<3
MTT=!3[ZTA(TFDOS"B<^#6#RZ.:SPU0#+2:*PT0$17GKM/0Q%-<6-$W[Q7*BN
MC1J]T"5KC29H+61\5R;'-Z-`FP`TEP:92G&SZJ"!B-S1=/";]\1I,Z[MV@1&
M%!=O"=K.W04KY0+YEV'EBDF=:U6QY&D&OF"0R#0M3$C/&'KC\5\:66PK;20/
MS<,(Q\\<JRN5CHO]G03+ZOXS83ZF"^%<S'YW)B6&HT96Y".8#C1JN1XUA6E/
MMGP0@G3!_)$&-$G>,4M4\>[>_02;F^..(\5K]%:/Y`"@$Y:V\Q6<#/T5/;_)
M<&-==PQ4$YLK1R@QR%:W[-SV21JO=/IT$.[S2K%AKO\`M\-2'8['D22@YH=$
M?:6D*7)\P\-!2YH?,CV-V,&P2.'[20AD8$*-D21Z1]G*%FN%ZZST6DXYX*.O
M!?L\M<@_GHB**MC8?EF*:90YD26O>7(77F&3*TJP<K8H5149Y*J(H;$^:$O<
MW?TE`1?+""+\QJ7UA16D$E,#52,GSF>I=`!!\I9;R8FMC?\`&UC_`*(]$;W7
MH.DH?9:,>^'DO;H3%E66HCB0N\&8W.V<#(V1P`1:2A^]KCAW$.D5SR%@D1Z]
ME[KW3H+@T_(^=V6MKDJXDMH`!Y88KVKL:D^F0LIWV\T<+6%J6LJ.CD;W^)>S
M6+W[*O;H.Z?76F8N(8!H4?F[HV<<N$%UL0?$6;%(D)PT48,E>"KB5;\ROE9$
MUG=R+Y(C5#6W^U>5_P#3^)6AI7360&CG*!AT!#(AH2HP45MA91R-B+*@%C\D
M1!%GF?.Y&K"K>[D#SNREGQW%+8/5;=H>OK+@>R2UMM.15YB8T)6P\DX.,%]%
M@*`.S:7$\EUE.X<E\,:.=\CDC#>-K:(*MT==K*3>S4DMP)16]?<9#14=-)!E
MS65PQ<.>/MK6&DA878>(W_?N@(=*]K(6JJHJA,-*^]1V3NZB@#RZ[!#JA`K(
MTI&RMB\XPZV,.^:.4VXMFI\CY?YQOE<OA(GTZ"->8^`N1M=I.']JW<6F*X[I
MKE<]S1A"<T0+H=?4U[V2"29_332,(CA:Z9K9HYXNW;NL<G9JKT%C.5R,/25F
MZ;G`"*^N#L,1:K8/@K;8<^0&M="5//!.=\@=?5UD4:GR.:UTC$3LUZN^H01Q
MT;D'>UG"$EA=@5VKMOO+&@IJ(\V,8L,ZKE))EM/ODC)>2<.BN0-PK&0M_P"B
M1OTZ#==T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`
MZ!T#H'0.@HU[^'32<,-RT%H90OTUJUT]R*!#:PP@447Y0ZN.K)T5A8US"SX%
M_P#R/+R_RB=!HG]*<85N^6=-S?'9?@:O%9F[@I70LF&G4_0'/E<;>20_QK_Q
M0T<0PQ4:HY\;?%_?H-Q."N=3;R\>B4.IT)%KH;:REU`Q$R6=9#!7A/;!:!V3
MD^6PJ^R(LS7/7X7.1>W0='QU[-\?::>Y+HLYN*W,9J[N<#9\K7M776]=F-S5
MV2CF$V<Q\23"51TJ=H)V.\)45&I]>@G#.?\`C?><M[FTJ3*NPU.#<-GK*`/[
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M`'\%Y\7*442A:>ELJ\2)\+"6N^,IC',5)$:J!4[]?6YX2XAX^T.:]BO6>+;4
MO*5KN-B;R7I*+(6F;H\T)*J)2W=@H21W$EQ*,URDQ1>9#T8DSI'(SL%$/_E5
M;+UIXT]#.._7OU]K>&N(;'D[E;-\X[3BJFIALOKM4*14LGKMC4@US(!;%63R
M-89)-$DOBB>*]NZ=!X.?6?BN\YNY^XFXIS4-41>[;:5-16#WA+1*:8E)'%I%
M:$/:]L8#VC*DOT7NQ53_`)Z#T::[DC]Q(U^98U?%G#+I<V#?<24AF+H<;7D-
MRB.CS($E>$V*%Z"T4->Z80N9B.B<]\GU7H+0\Y:S]D."%YBS_#V5ICP"*O"0
M<2@57]2LLF-%-0C)R7>TGY`;\C/R":>LGW)`\\;7,55=]/IT%1QN0?W0VE#7
M)9A9Z"ON9(ZLJ"@K<L[;9FBJFC#V<=$9]I/!3'DBL\VP]_\`<YGGW[.Z#I.8
M.1_W"6%)%@:B+D$RJCMH$S-@=38\2AK*B-`WU%S3'"B0SQ:N_?$Z"U\U<Q[X
MV(B=UZ"N>8WO[%+/EW;[;F[-7-KR3F.+C?Z76WE7%5%$6E=']K6/RXHC8H9+
M!Y*I-.K4_P!S6=G=T7H(.L#/V3&T(QUX9=?(*2$ZGK75H)%M/9?=S$##O"A@
M^-WSR$N>LDJ.1%7LO;MV0,&NSN6_9;V+]9_6X?!`TW(^;T594V5+;(&09?[8
MRS=H='86IS&*Q031!?X"_P#3'V5O;ZIT'KKO?MHJBPGHT/$HP<]8X>OFKW_?
M"TAA].X(_/"E2-?)-C'V8,D1BS=TA:_Q;XIT&P7A7&6%!ZH<2V(U>-1TVL%=
MNJLDBPL2;!=(4JU=2#65))3R;Q\S8O."$E7"#L1'>/;H+I8+3\:,XL`HZ$PH
M>2M#LIMEIY<M-I-!R?:VY7VVGCDMIW,K:L.0F)1)!7L<T22%5C[)VZ"=O1\>
M!V.Y[Y?R]7GP:Q)_Z#F#UO28*I:RG=%^3;X*Z6VJIJ]9V(Y\KG.EF8GQ=F)V
MZ"/.!<KRI><[<K<_8JRQ%R[&LO,GF1](;#\%L@\3H@Z*8R6.?3`K8$_[);.>
M=T?C]&M1.@W.XFQN+;)Y^QT#JEU\75BRW*43IY*>*T6-$/'K9256>80<E'1L
M>[ZO1O?_`)Z#HM=LIA,W96.0KPM1="N,@JPS#(JRIGN:]T:OJS;@E6PUI1#7
M.9"YR+Y2]DZ"@W&&\K:WD2W#+X#Y:Q6G>!K]3^.Y#T`UWD*.R8/*9-:UY$L,
MS*JLNIV>"6$"L\T<C7-5%Z"AW+]O1S;*NNF'F4EEOZ\>YL;^`<\BFD255EEC
M:%,_\30Q`GR.BC.(A68N-O>)6M5$Z"GW-61TUC<&:_0:B2W&H7U8<<=;#:7&
M<975[%*EA#%22/L'*.4A)`0J1CEDQM21KY&M<@2=BAKV>N!&QCZI^0XD,JM3
MA[*M&N;"[KK!TK+&Z*O`)IEM*`^W(\8_M87I$-!W[MZ#+])%Q;JZPSEVLM`Y
M=T7OKC27KR63DVM98V`+0M)<756.D1LE6'+&L;(>_P`DC421ZN[]!]<7MBJ$
M&G-CGHS=;:));<9Z6*O?.E9I8D;4F#45M`UIE?KEH4<3%`CD^>-ST7NO08KS
M!Q$*1B]%EJ?DNZKM#L'F[(]\Q4@N9O=*YC"![+8U$CNU87;6$:!>,R*YZ.<J
MIVZ##Q..J'*>GF]EL3,OJMB)M*'29K<:R%+%1]B/)%'K0,E"7W&B"I&-<)')
MX>#8V]F_7H,+X_Y(Y,YVM,SPP,5-4Y9+5EOIBL<1_1@3P!R_&IJBC9G+)<YF
M3P1'5[5<I*=V2>2-Z#8M^MOC*VSG+7+MF:#A#-/D;R[ANS*\5E/'51E2-91U
M5+$,R(3[8T'^)+V)\44OCW3NWH-KMMGJG1QVU/N*N`ZM+?`36"V),5B#1V2]
M_P`@@ZPQ-*\8)U3M(KE<YOT9V3H-8_MUQAQ5QV-Q_D#!JK36'(W()1&LLMI2
MUIN'J,N99P!GH3FDB:$RN98#HBLBC2296M65RJB]!E&HX\R/"DB"9_87U=F9
M-/6ZJ(,735EQQM'8U30(*X+,48,9#LI96,C/]4;/C^TB<COIV3H.EM?9G57/
M(E?275C2PI1<A9I0*>T9;V4^9-D@?/39TJS!FAI9M&8WN0KQ6M*=$B_[6KT'
M)]J]=6<MXK+`TV@ST&HSW(2QZ2UE@'B36S#5L@L5:#*<,35VCJR&=$EC*BD1
ML;4[.\NZ]!YS]ODBF%TN3.SP=E-QGR#1YP&D$."+E1X>A@NJNQHB[X4AY%U:
M_EIG#5\3FU@T/^R!&2=UZ#U&14A_)UGG+BP*S/%B85E0$JVUF937.FM)Z2!B
MQ3V\AT<$-]"V1L$39W.1CGN=&G?MT'7-XW+!U#H,M0U`,]]87>9V)KSY:B33
MZ:2M6:W/)8.^**:QE8OQ/,>GF[MY.?V7H,>Y$XQVO%V&V7(E3E,A87''O&`N
MTESE3H")?S!&;AE.L8;"`EY2J>4UK"&3Q=XG/B7R15[=!GO#NDU_+OKUG^;A
MMU0UG_DC-5&T?66-R04+0TT#24M1S";!&O8XPQS8B'QM8^%(T2/QZ##<)DR+
MWE+@TY+Y/ZO^?L;VWRT%*-$C=+V?(!*+=GI);LI7N1)D5DSD+_\`J3MT&W7H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=
M!IC_`&@ZZH_L_'^7N#;$2NK:&^N)A_OR*>N/LY87+6><ZM0*P'C='VFB5\<B
MI_%JJO08)^M+$5)OK#^0N66.6?RIR5O+J\'4=@X[X&RBBUD`8?8N&NI'?:_+
M&+\LC.[G=VHY>@V-8+)40(A$8QM2RHOX;("IKF%ENJZ.!C?Q.@,H;02>.99K
M=[H72C*D3HG(Y&O;].@I[S!ZEI@.!LCQCF;"ZU'&!O,0FTYZ"N8;6POS,-(>
MZ4D3*B5TQ$K)*XWPE8R>:21(VJ]7*J=N@B;A_GSC47VE]C.5Y]L0#C/Z;F.,
MN/!]#+>16-Q'GJS[2,_,U91DX]5&-!XM^6,2&<Z6-[I)$\>S0K#R!PYPUK>:
M<&W$[??5%]#C^0.:=W>4UX4?+,330+8":6`@.S<&IQ\8J"$C!1#31"I(Y\DS
MV)X!J[O-':6MLNO&=<6;]SH["_B>N=N+S-'A6SWTCY*B2`RQ6V4%C_E0*3\C
M^2?W9,X9>TK`V'`8]**TX^RUFHV>K>.LK+19JOL8Z^^&TUF4#$<=>!\91DVO
MR%7*R_[A"+`XNK<[^?96^;@YD)M]1;/5VE!&!F8I<*VJIJ*VBS^LH&M/'')N
M!K6GOCZ^EN2`BXU?("0$C6CN:Z-T$L+W3AVZ:JC#KZ]-_C:+3CYJ4.R?Q6/.
M!@%VV>!'==":6JU`M!LBL?E:6Z!CD_#CV<X9,BL<Q1O%6/#P]_\`R,^:Q^9?
MV)7[E\)+G$X/(YC0E#$3RU\MJE=$:\4&`XJVM!8ZV*=L#D(/,<]S5<U8VJD;
M0@O]+'&,VV]PZ[7/8U*WC',VM_*9]O;2/K+6PB=74UI]W4Q,EJ8*^59)'DJ4
M&K51L:2?[/%0]5$[A,L15+OK"/?7ER414:'0`9RKL4,^)QI](RPGRU=-5FU<
MX[GM>A,Q%G!/X/\`GC=YM>',?>J:R\%EPEQ%=AF2G4\PWG;58`-0!XG@R8JT
M&BJ]/3W(;5D*`"DK+-\?=4FF_P`*&,6EM5`G:&SH[2:G"T#1;EEA4_F:SCHH
M(L(.MK<OC,N.T6X&IP!V?*23(=)#$V1T3(T>U\JASK&NSMSCP$BL8M?HR<["
M*\,9MQ36Z,&TT`HA>'(D(,HV!YV-KYI%G=/*T9?DD?Y(G<*;;&R,TO,CDTAE
MI97-S"?C\GMY[Q7I0ZD0![,^ALM;.H(,UL6QGQ22MA$<K>\J-;W7H(U@SE_7
M@:"]#NGET/$80QNWNJVS6U'MK&U'^75F3.%6<P$6TN(GN?&(Z=*]RJG9&JG0
M4>_57E*/E/VN]K?:P@S.5A/#]8ZSQPE_'=B99MSM+F>H$M);:L4O1"'U8%0Y
MPJ#L^X(EG[HYG94Z#>-5Z6IV-K64>.I]*RJU)X.2IZ`.SLY1;2?06(\]\-7D
MB.BNRKFS='*]D-G!+*^%R]W]^@]#_(/%65XQ*R/'UX`%H\IFZ7$%M"R\UG3:
M_`V\.>@,/O;.K/BN&6-=`)(B0"0.G"\T_P"YB[JO04P]M>5Z3AOU<R-#P_L3
MRMEJ;>[@IVZ;/QV^PO<OHC""B1KN'^MK2Y:Q&=/\40]-$K1H8W3.>BJUG0;#
M>,]G?<<?K9X^O1\[-B+=P-5+<6&=CKX+R69UI'*3H"*]4HA;A+$2"45I=B5`
MB^:.>V1S6QN#./53V!X+X0J,M@M+:\BY+1<HW!&L6PU7'U;0PW.EOIEE&RUU
M8U9%XZVTZBO1ZO@?\2Q_7RC_`.GH-FN?M%FHK:ZCTUYHZXQ4/KB&U(01=?6N
M:KO$>.4(-I*Q(USG.D8KNR?1O?H*%^V\Y._UG%G$-93'66:Y&*)TP>V3:BYT
M>LOZL$J`.O-KG3!%T[)VO<0.6E?9(\EG=J0NB17!UW$_$N_X"H=?_>M=M]+B
MM#5R65)/-MC=8ZFNH()892]ML[$FSMIF2$JQHQ0(;AV)V5PS.W04@K8J:\Y!
MY%I-;!2D6H-,EEK)-%J[$?Y*&)OWAU6#6RES`VUUH1YV$BV<%G70AR.<U0W*
MB)T$:^P@(5518ZTX_P!B5=4\PP3A,W9&&[22BI%+\VS[2("LK[2J=2QNC;&5
M<E.?)%_.%OV[D5@<CUDVIMS@+NZKM/0002D6XC+240S^MVAPA3&6A%M<`S33
MTTLPB.0:.*,V-G;R3Y%_CT&=<1V&5OCM+5;"C#RMH.R\36W]B)/2!CNKC)I:
MV+R.5\S1"ZYK'1(9\\Q2N\U<B.1O05S?SAF`[?D6LQ++$VETNM`"XJC(IFDC
M![<6IA>[4QE^`5S5"PEQH.T!C86BL52972-<C.@ZJCFY?U(NSRO,4-/2'Z+\
M./->5LU9=&3[."X#G@!!MGQ#,*`'%3[@PJ5J(^+RBC3OW?T&-Z6NWFPRM-0:
M./*6]EQM-:56R(K4N*S"0BF$O?;!6?R0NJUL'3K\L;%:Y?B^B]O^KH)RP'$G
M#^+P(G,K;P;32TM!,1K*R,VVH:WQ,G8*V'%1]IRPM51*K2:=P3G_`':S/1RM
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MS76<\6P774YD60J;([,7T0D>4SHNB`;591[JRO@LIU!E*9,1)$^S8:^9L;E%
M@[/:&UOV/PP7(^>XMIN3<Z=8\=YJQX_Y'TT(OE05VBERKZ=N0!UF8@N!9S@?
MRZ02DOB>;,U&-59'M[LZ"W]YS%7WVQS-H!0&,L+&!5=EQ6V1M;:AGC-K+S[6
M*PHQ2+&F.$3YH98YZ\J+OX+$G;RZ"4Z'EO"`F$YHZ.PSS,#F2QZA1*A7T6KK
MB0F,_!&5IMU9Z_Y*]'JYS6^`W@[R=.J_P0(KT]IB[#CWDT\/#:2(.S"Q8U-F
M"RS/L[9#"28RRA4K+$AM%GK6)DHJ0Q23%*Z1KG0_3H(]R%^1#[#^M^'KZ4#0
MTE*IY]1(PHRH(PM2@;F#CQQ$"L`TR`JY8?N8QXYI/_K;$OUZ#=!T#H'0.@=`
MZ!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@UZ>_P#Z
MYZ7FC#)>\94N3T?*-!36-6!0[64B:GM,V>KGVD0-:.U5DT<+G*\&=SF,BE_Z
ME[=!]>"LU<\9\383CZ\X_%XY.SN=K,\ZSMSG$9.?46QY9,CP1AXRR9C9VPI/
M\CU1D4CUC<O9._00(?[&9_AWV?MS>2)]3C:NU+IN'>/,'<Y^2GQ^I<07!97/
M,<4TL+Q@:Z6R?]H\EJ^$DKX6?]3TZ#8,[2`6NJMLW1G`K:C"`VUU3ML'6DS9
M+KQ*"?8BBN2"OJ[$/^$4LDK4\G(GBO0:N_<CU8XJ98<E<NT5W2\>)7TU_=\G
MYR\L20(C"HAPB(SLJGV#@A)I_OXE3P)A8T@A&,:JRHG049]0^%^1^1-IQYN`
MZ$JO=ISZ.2NN;/\`/Y^Q,XPS!I(.ERY#F5$X:64T$\4A%<4.%XPSN669WRM1
M0V?>S_IAZYZHF+97.9ON,(\08S6D:_C:U)"S(E;F7-.M$NZ<*"&CH`X0HG^#
MXW".CE7Y7,E8UW01/G>/.)^:(,[+Q!['8?>ARXJ"ZK88:0,)SL5'"LV>O;EU
M"^[L3[^)[U%FNY#*A"/'Q=',K>@AV]]:-;A*2NY#S>)?RF#2#["<NSS&USUX
M,(0;&K;RI+J(H[0LH:L\2&2(WYI8O"-\KHU5T:!$%!84`FB2KVD-$[(XZ(7D
MO9<5(<F@OZS+\:4=AR/=UEB5!&)I`[A*JD?VH"P@JZ3Y6+*2J>+7!_E\^S7)
ML7,WL+S3RJ,^R<%O>2]CIZUMO(DEC!5VMX:56BDJU\C&O%"D9'XM56M1O9/H
MG0;Y/TP9(7CWBS7[R\T`V,ON;[>USV-!T$X8TW(>/PPPQ=\+CLP=94UKM56R
M^ZAEF#6<(91Y72.2065K`WF45]&;;S%9;0QCII"*:FQ.<H+$+2@W)`0!%C=0
M`F944\O<7\=.PGX80:]DK$BD=Y3?;/<H8L5;RYFYUVA>86*"?]Z#7G7#+5*N
MI+KQW%#,BMIUA<V](I46>22:(4F&#NWXE7^/0<4:D\LB@K$,D".SH`YMY4#S
MR+86%Q*TVYMZ*$B0DFFHXZY[)GP.&B?\<KG*V-4>C`E[/0V>IXZ%FJ#1*JAX
MQ-/L:'+4.)N8Y[/`!#PQDW.=V+H)Z;217UB!*MDP4F=(8XVI/\,:N?T&I'(0
MV=]/R?85;)KNQUNPW&EK\?3YZ>NIC4&IS74-!;W!QK(<N>5.Q%:TUPD3WIY1
MO^+N]`K>%S:5Q+ZP^RMEG,L`ZH(#+<7#;RV"05.HVJ*,75UTHSY8'E4AK)$D
M1TSH"I$62'SB5KE"<OU,>I]74^H+N?;"X(EW7->ZE)H;"G+LTCSN?QQQM:=7
MW=7").'8Z2S.;*;6*L<L4$`I#I/%%15#<-Z<\=ZFP]Q^*3;VAC&I>.+8W;;R
MEHBWR3_?TDXZY.D9&R-/OK+1MG^]>3*\3Q<Q8VO^J,<&\W<<VT_MYSQI\4F3
M7C,3C;)BVS]IK+(2MN)6DM^&T$ST6>)/L+VE6=BL(.GC:$._NWY%[=N@@O><
M'8/EG?<,\*ZX.XVM2FSKML6-Q]I8+8(PP,V,G/S.AH8"K5F#`K1F261;21HY
M#"%C>UR-<U`NA[P25HLW%_$]1D;3"2V6[SF"R^EKJ^.RI2Q;U/(RB+HK.R!#
MLL\=6C$PD$01G/KWR1O:SY51.@EW(^H6MXRW.6,SG-&HT/%N=4LUO`_)&4"U
M63KK%DK6-M<OR0VLEU-1'3L<YPPJCO>:Y$1TL;%^@;%9S1:NNAE,>Q1D^*&:
M9D+8!XVR?Q666)SO`8=%7L[NO9O?LO04I]E./.0MYM^/@H\_A[3BA+_-64]X
MY*X'1YV2FD-L3B9[$JQK"T!BA8R45@*SI(B2_,QK417!7WV7OZ_C[^K40NP%
ML[27^Q$YVNU6YSE+9R7#B&,@CH,NIP3]$CV.1H[(/NX7JO\`T_)V8H:NBZPB
MPSIVLH=M;W.I9:VU"+5V5(/')JSK$I!6-K*<>*P%LZLV"3RAE.+`A>B*O>)R
M(U`PWE["<S<09'(M`V&)!R7)"#`Z.G)M["8BLAJK0BD<$"34U9L.C,&(17S,
M-/2.K8]`T6=)6*T)DP'%^7N,4+GRW6]-R1J;5^LSZY.P9E,WM0<^*^N*ICJH
MB!9:-BM(0F2%@2K]M'++\B]N@ZWV`<?L#\KG2J>PS%IFJUX6F)+LPS1SZR$1
M'YF\TE\&8]D-4%$C0U?8#QRO+C5O?Q1%4(:X>%7"A96YLZ.3+FFZ*^*DY$U,
M1IMZX^Z@2LA$J\\4(/6Z,=[7+*Z9)!YV1_[/!T*-<H6&+HL!=<O5.4J+*BNA
M;`BG%U)X=]-]A)9P(PC[$+M#]HTF:5W='LD;\\<DL+4_BKT"&N>2-PA5WC`,
M]9UV!)T-=>YB$D`X"(D^S*94&UED4YD#=(+7M:JH2Y%C;&G@KG.3H+(6M4N7
M]6N1JO+0/U%]FHLS?X>R'#!FS=M,9>I4K69RGL9P%<H0\K7C$N*\WJO=D2HG
M9`V^Y'.LP7'/%^-KRDI33,X%/.T\B6RTT5X94-M+,VS2.59FI6V!7R.ECCE@
M@8WQD5C7(O03K)>)G:&T,M3J,@*@%*L2#A1Y7)*@-9*5-86\<$'QUJD2L\DE
M;YM<B]T7OT&E3AO%<W\O4?*G+/%N2X*!_(ZW7U%GG^5KO\V+8U-Q!&?9T&)U
M^1/.,SM=97<3BIGD31O)>Y47XHTZ#:%P.1N['C7*P\U9FLQFSL*2&(<#)E!6
M>9IW5,*A*%5GUJGBN$LQ@TE8Q9"46)W9'_)W[!-4$9`%,P*NFD,!EG<15V%U
M7R'ABQR13.D"3[=%,&B%>Q>TL\4+41?%%553H-4?[$?9BZQ>IR?#F7EKZ.3D
M/)%&<J+<9B+55M;6O'0>@+)8Z_J184?,U%:@,IDCH_I)"B)W4-3F"XWX4Y?P
M<,6G;R*[4OVTV*O-SE#:K0<=SV><5+1^I*XYOQ..MZ;5M-:\,9(&C10#?'\+
MCX5BF<%^S_8+U?I,UA<]RWKKVT%-ACAMJ[7XNYIW44-#,P6OMPGUI5O7YZ4[
M[1I<<9EDGW40GQI$R9S(Y`GNHY*XWL,[#I<5<XJYHS229:C0!:6JL&T\X34@
MGMVU<.BGLGUQ<B>+`W/',:_^$L3'HK>@[Z^M<P@T5^&'7Z8''@6NCT#20W58
MU'?PPSP0&7'WY@&JKZ)Z.D>Y\C9*M\<S/&1RQ]N@RC!V&'N<50UM/K2P*C3T
MV4N5S-A+);5.;EL]$4Z24<FJ$GN7#6TOW$@9\C6"011L19$\N_0=9-A[;&\I
M\$7`Q68U-C;\G'A&"A:82[*;41P2.K;^,Z)P<HQ+1&]W#1L^!W;^7D[H-M70
M.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z
M"L7+/*1_'FZKU#QNPULZ449TDE=7-9EJ+/N.4>YN+.Y5B]CQ.RJT9%^21BIV
M3H.0SFZ`M`*_3YRXR!9%C(D8&KIU2*_HF0.FGMPI6,6(>`#R1DRN[*UW_P"!
M4Z#F661XGVE[C>2[C%YC1:(0(@4"\2&&TB`S*D1D(7YJDD#XA3*Z!S?).\,B
M_3H.OXX]>L3QSIM?<Y>VO1F:F^GT8X!=]-<!#6EJJF64HC#Y)"$A(<ODP5RJ
M.,G_`+2(B=!EO*7$5;R1F-SDR38$K>0LE;9RRKC&)*(I9H[(&70OQ_[X"X&H
MBN^-417-:O\`E.@@/A?BO0>M?%N5XH&UQUK1XX<ZCSUCHZP0J^U1=B@P<`BP
M#,>2)1@$$+(^=O:>6)B*]5[+T'9\RX+?<A<??T#C[DF/C37:#2UK/[:S("EL
MKXZFU"M=&+\+&+)"7:TXDX4;IT\%;-Y/^J=!]==0<P9`NGCX0SO'OX[3SW-/
MJK!8ZN!U&#&#VRE_55XD<;#K*_LV.4UDZ*)`DGEV3LO04=_7AR?I-J9R!Q[R
M/'G0/8'C_4<BI:6%./0U?B.?>1*775=&(D>7L&52CJ$24K72$JU"GJJR=^@X
M?LSH.#?8[U>]@K@+369G&=G?:_B?EOE#-5[?SU3F:2@.DV1%=I*V)ED`RI9!
M*)),(_M*R3P153LG0?X_?((N99R#KPL&TN3)1ZFX$RB%RR$&S4S+&>"J=/+)
M_LEGF&1BJKOJJK]>@]@_J=4\U^GV!]0]!R'^OWF78!X#%`.HM7B*:HY.Q)U3
MRX#H[^[M;H/(L+T`AP+3&G25BHTJ*9CW.3M(_N$]TOM[P-REJR>1\US)C<UO
M-!>G`,P^ZJ!.&[YU7C9!1K.RK<X1!6OQIL8Z/$A^W:Q2(I9R'=Y(G+T'?[K"
MC[O(OI-17WS\'NV!W>BJX3#QPM,9/81,4,D2B>MLEA;-1!XBI^T+Q7?.Y?#N
MO06)Y,Y%BVW&-;C;GCBEI;'B^XU28J:EG)K9;QY_P5-;0MMO)C;N$6CB&E9,
MYSHGJZ:5?_?^H8=DM?JLO75Y@V@%M*L7,&8J+C"TMG.H*"UTBB4NKI/O17(B
M-UE/,L"Q]T&@1R2KV:QR]!K<]B:7&X3E#8;W+5NC_K/)E'#=6]:/:R?BZVQR
MU.3,13_-&]`SYW,&4(:!_=K?D1$_@J]!K$]W.1;4?UZXFX!R++8-O,NY(U%T
MR2%XE/J*V&T4#"%-#>UKH;O/A.8$8B_2)\*M[)VZ#T&>K'%TG!?K7Q;Q)3V]
M[!-3?UN,$-DZ05V>V5M-HX[V*TB([0V-GK&6<Y5=.WZR!IXPKV1_0;`/3F3/
MX[$<F:^UI;4PX'11R8VH<77EV-/5XLY9Y!;F['<L93M+<N1S8E>KTC:JI_)G
M07LRECRI,D*OIKX^AY--L(3<\<)6MJ*2L/"8HM17VKF-CAGK!F^4`['>7?\`
MFQ/C[=!/_IS52:CGK3ZB.NM"Z_BK,6A69CL*@TP6%]U%^+!!AO(4\[/;2I0?
M,0QSE:\(@?X4[JO02+8>SLF[YGS67TG&YS]AQ\8>;8Z[%V5J(!D:2V^(8:DT
MX<BJ?-<6$C%6>NC12!GLC>]$:[H-@M?HIRR8([#1*0,$X*O*K5&97%%V+S8T
M"N1#6>,[Q)D7Q?$]>SE3_P!?\AW:YG,03#WU1FQ6STEUH3G#LJ(&ES6=U/%'
M=V(TDZ?+&\N2'SD?'_[R)]?\)T%=^5_:?+<4:LO+[,'D`:M`%&AEV8>/--IO
MGUTC`JF2L8!!("?_`%Z21$)5Z*YGFU5^CG=!07V*W/\`:^3[E:S4!B#6=`!6
MUUE^*R!Q5L+7T9!OY&QJCH?R4*'",?\`$D:,6'_+NS>_00D!Q5656>OHM739
MZ3+K1Q;,KD$ORKS([H4^=\)D!-0YLNI:YLZQ@O-18FJOPO\`XL;T&#ZC;"5$
ML=#0%\C77'^HI#YX[?.QU]()!FL\'6&F`9"L1GC;YD&_+?\`EYVHOC</="]?
M%R)T&6;ODWC+!4MH9O-#H9G'UXZ3968FF*L*L30A0?\`8ESC]S1'7<4+92/A
M5/B@C=X]G(G09I2-;KN*Z(.V/MP0S#B*6@8^G&%&S]N)4IYY@:*./\I*#6LD
M1A7W7>!JJKW?R[]!K@TNYY#LX0N*I5I**QR%5G\;3VT^A95D_>4VQL"*W*T#
MBW-#(XY^PD@A_.)W6<YTXGFJ,<B!8^EJK#,W/'QNVH%TFSUG(U;;#LRP4HV"
MJKK$R,02.XM:Q/LWPRPG2M29[O&9[5A3O\G;H+(<S!T-%]E=7^LTFDV&X2CM
M,O?6@BC7-48;$A.AH:Z&1B!5M%65CE@(C:C4:U%_^OH(ZX#Q>LY<Y=Q.`H2;
M"?/!ZVKV._'#N[&.L"PV!D/,HP!P'N02JKKFZNYX(ZI$1I<8K)G(J(U>@W!<
MO3:0:\;J:"KI2*4ND+IQB;RHKII:UQBP4UW5*^5OW(=;8_-`PA7]F/2'LOTZ
M"B.NW/*-SAN:L]H*^ZSQFCS*XNJM:NE[H`%")(#=Q$TV8:MK75XF9?+]C.>C
M8HR/"1J]DZ"SOH1;8?(8*OXBRPYEJ3$98VVCE/,,L;L6V.D64NPOQSOX!Q&2
MJOBT=/MHW=VL^G07OTH1L"16%90UMU+61035HI'VXR`$0$-;/-!*[M(DC@)Y
M?!K?HCF=O_JZ"NGYBR$YGN\K,7<8ZLS^!^^Q^CDMB:3#%W>U=,I-:=CW/BH]
M?944D:2PD.1\HOU8[MYIT&@[]BF+VAOL$PS1ZLBV,V041N;Y"QETL+:\`3.5
MM52V%=1M?(4+%,L/V<T(*(,PU9R7HC9>_09!QGQ]88ZSX7;>GVH.<SNN1>6^
M%L=B*V>BU67M!Q@V5LV5J(W8\8*HT`"R.)$7\F7V;+.OFO00[R:#0;?WR_)\
M4&O-X[H][FDH\F1)1T[::2=RU6A2D%TZ,JZFSSE44236-E[2L/B9]O\`]TZ+
MH+,G\-8_3:G14C<++L=K0Y/06TW)=]=C#<C0A0$OBCL!+J:2(VTL@8T284XE
M%BAD[+"OCVZ"W5LN%"$HK/*G0/UP/&V:PNJWNUKH:79;_.A#3.U&.!UR(VIO
MK+L2V*<2?RA>K)7-^K6]!T.C/D-R5AE<L12T@6HXCVU?45-2;%75.5#1]=3@
M4R72JUHRC?DT(K3HW)&$9(2]RHJ-7H.1PIG[1O)/JIDR*S56&BX\HB+7EW<Q
MK&9>AZ0>!:BI35ZL]?.^H;2&5L*1QJLD[W),SNQ._0;N.@=`Z!T#H'0.@=`Z
M!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T$.\F'H8H])7:87
M'Z$<H&2LL[AL:U1Q%C)\`M0HI$[![1+25/A=&YKG-7_I^O\`D,0MM#*;7`/O
MJ`.VKH'$"#RSFP^4-DBE!VA<A[T:Z$&%12&1HQCHY&_'W[JG00X35Y*0ZP2E
MUU]CHR+L*+19*^88/E(Y0Z@B9\]/9@HW\;->"$".F=!(@\\<+F_&U[E=T'UU
MXFRXTH+V]S$6HY`J,U6&VE3A<V4'>;2UON_W-&9F/OB1W.#.KNZ/@DG5)F_1
MOCT&&\,^T5%I,_9`#\=\SYN]XZ"KZ6VBV=`^MA=?32%#S#!DW!5N4MF^:.-I
M#$G=$J(B-D5455"PU-SQCW1$VL.@`G04MH^Q",()"FJK)D=2(4.$XQ'`E2UY
M!:-DC'5C7.[HB.>G90ZC8S7";`/245<9223VM6-$^P2MDJKBIFB>MM(&^:H/
M(H+MH[_*2-45IS>T7RQN<CVAR<UAL5E[V;9VMH:!=Z>O%!4,JZNX`4MB873N
MCAR\QLD0GC$[N/%"]HPS5\(8V+WZ#L7\48TQUCO<;0B/T)F7M<Z%;(&+,==_
MD1;`'["[-L@DT@U>"<4JN5"T?'%W:SLU$;T&EWWF]>N4N./0(_TEX1;3-Y%Y
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M^<I\U>J^JL[V.\_\?U')1^JXW+!LQ_NHJJ_IMD_4T(YZ(B3S4D`T<#0^XBN;
M*OSH&*[[`^_&3DM[8:G]</;,48S6!9L>L*EXB+P]R7#10F%-R"NM,;K#[`6L
M%@&C:/##&^%(F*Y&HB!@)?/_``S1UGWO(.;YXX2T5K=9NMVM=R%Q/9SY^AU]
MM\5%HI;729HMP.C%&(B<_P`6P)"M=-'&J?Z58\,VS8?%'+&8I1^.S\QR3;ES
M;A]?;U&@H-?)GEQ(1!4FA`R#)*TXN%:=DL\-:1&K7JSX4^J]!H_YNQHUC^SS
MU8]7]&9":%A='2QWAD8=G?)/<:\H[>'S6U.A#WLG4\Q$.@@5@\'\^S48U4Z#
M?I;RFTD&X'K:$ODP6^"2^T;33X3PLA>4>2>.!6T)H_XZM9D)U,(CB@(1TCQV
M#L"C_P!4RN#<EPWZY\HY+U(HKEW'`W(.`N<K)?V5%@7"E:*IF%%AN23;BO@G
M;^7MP(V?`%\$C2(!I)&M[2JUS0R.MM=]'H9<;`#K-1;YVE$0:'=9>XC#H[P'
M-CA[.BD%&!`@GHP+ELP`J"$11S?$BM7M_)0['$VFIP/'-PP$T/"LO=A7:E*W
M'M+*Y*F/RE;*$/8E153*<.3/D1D3>3B6QQ011P0MCE?&YZA43B;V%P/&VZVM
M5R)4:7+Y[D"VM*,/EJ0^ZN#LI*Z[I])=6];77=G=3UANMMQPPVD"25\!$KT^
M"*)\"O>&_#CWV/X(V>;RFAXCUC"*8\Y<I9W5D7>4E:!9/I%,K6E1G'5["BRV
M,1[6))-,QJ]O'R3QZ"P@L]6;5-6RN3(J;0CUL@6CJ/@`1)3AXYG_`"*'".I8
M^AE*E5DT@J++(KT5$6-KN@I+S9?<M9OE[%9FXQM,WBR0>^_K>TO)^PT<6:K'
MVLE0=#7AS'U-C%((/^-D,*G4OY2)&^+HV#S!3BZGL[>^Y1,U8AMILYZ^DQ^3
M$IJBDT&$/J[`*?05M5>FWZ&W8F4N+$:,4]RQ(3,0]&0_`Q5<@9/;W5B1<VEP
MZ&:&F5)P;.R`G-/SD3\.]XJUE8/=%GV%#>UE@&4,'$]+&)L0[59-(QR+T&NO
M"E:7FWFYMSGK6SN^.*S22Z!U]<6!--'E,(-->7]VR;C6JJ*:BI*."PK%FEGA
M6::TLK!5D:Q'.;(%B0.!<SS_`+C5\GSZ<;!\182X;I9*RU`GIG"DT#XAK"$V
MSH"GSK2!U!,K7N:]IZ$E0QPR-C5Z=!(&6T&/DSM559(*0\#,46BL;LM-,:$V
MV"U]^88-$/),ZR)DM^R)*PB;Y"7O=\;7)'V7H((YUN\1R#SCZU3655'*%1V>
M.N=WI<M6%&:2+!V-?J;,0>UIYAX1#IZ/3M)_(?#*UKH&/<D:JQKGA=OCB[];
ML[@P@[;4VM?:V>CW.@SUM<!$24K,]#<U4XVB.S3)(A8I"#XX80H7-?(J/_CX
MN=W0*S[W0[?D77F<S:6\GH<55LO\[7U=T`-)G='8V\SZUV[IQGJV:C#!C3Y!
M1N_F3+_J>JN_ET%WOUVP4\]]L-3,4`9;V@WX/-6=2"#1L=G*4&K())FI)!OD
MIB?N+!?FC1>[)O-'JJ>/8-G5"A6AC+F'BK3\HP:V0``USR6VI<T[X7Q6GW3I
MFL;`8)(J2>"M='-_%$1OU#''28BSN",N;15U=:W4XA6UCK_PK'R$#Q_(/3ZR
M-(8IK2GL1V+%&L[)&3,7Q_QT'.P^*XR.T,6XS=!5!W=/7-I(;>K@"&?/6FI^
M1:%*0!'$\\0=Y"I&KU<UR?R3OW[]!!?M3R/MLK9Y\C&SR/'J"$6>OG!<E/I;
MAS5FEQ5H839!@?9WM'\[ON'Q^`<X\?\`-SI/C4-9EY[.:[DB>G"6UNJ:C@BU
M`.=SMK1_V%5M(3(A!;G5#1)9U]+0U$<\K0"$D*G/\$1(F+V5`I(7S5NA>6BG
MB!?V%ELM_-#EK*#79/)$K.)"@M<(0S[6;\991*K62(HH;9E6)8GOC>K@RO*Z
MA3A6Z5FI#@&\-*10U&8S,@?$&:LZHJZ!.SY4`WW@=WH<K9`QU3C!Q?.RM892
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MH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'007
MR>[$VYHK;-<D9:86SI--<0W[);%]31@S,L7V,0E9.\T*S@:_Y`WR1]OD_EV5
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MX]T_&E7H*`^UJ>7`9P[#"4<&;&=+8U6R.TKJ,JKU,UA4E".&@;8M(:0-(',6
MZ5S6!,5+[8\%\J9W(75/;X_6YO<5<-GGKK4!%A9(^&9&5LP8-\5268!Q\%P9
M#`0U[!VQ1RN<JJK5;T&OSW?_`%`?K$_8!0BW_*_#*9#9Y>I._'[/CRU)RS<X
M!/:S3V5;8ET#;O#@C1W$CWSPJ*TV-?\`J:UGTZ#RU>W_`/\`#=Y)H;*[TWI]
M[9<?;*KE(/-SV$YF$FQ-\-6"`#V(%:#M*%EO6ZP[[)_U*97A1)]%D5J>;FAI
MUVWI]^Y;]=MA&NBX=Y^$Q^2<9EO[;Z[::[O**RFEREU=L(NY^,S+4@X45IL1
MA<]N%'')`&R%[DAD3R#A<6?O3]U^#=%HJ/GO$9_D&Q*"BKK$/<8EF(VU4\1/
M&)/$>OKFA$&Q-^$N9XB%RQ*O:1K_`.70;'L5^\/@3GG+9[C_`%'$_*O$VGF8
M<39D\<9R#E.`\05635)]925#J.\`G"**6M%_VN0>(9A$GRS3.Z"ZV(]X>%]U
M85F/OO8K"VV9F"#4>LUEM%#IJE:,:,L46\X^T&>K"H[Z@N$D;<03&I+,R?YV
MR/\`MW1.">`O5?U(W7'>B,Y%X9SF5/!P<^U_\P^MOY'*WU;3U]/:;`K3`Z/C
MPQ`VZ"CJJZ1]M7EJQ#0G/D8YBL\%#4-^D[TYI/:+V@]R?8LO:[7+XW',-!X)
MYBUYTN@O"23[PX6<0BU*@F,=9GYM($:3$SY(X5D[-1CN_0;F[;UUW%-H*W&D
M-H=*&S4ULN^APAS[*739'.P:*VJ=@ZBIG&#;&SS%#53RC1!)`E*,7`R=9)C/
MB:'I/]<HLM54^9CS')572V&FSL,[\[Q^V8BA/?6D`"UEZ9D[B$.US=\Z$I$M
M8HF?;2JCE[L5.@N$=OJ;,P(=MM/6U<,$I=.0[0T[J$:RL`(Y"Y_Q1)[T4J&6
M-$2)&(]K_P#*=U7MT&@7G?E*&J(U%G5,J'VO*57::2J^P$LI5&'30V\512$2
MUMBHX1<59(<:L1)43A(YU^03S>*Q0UGUB%;/79G!Q'HPG1;'*XH$5:F&ZD(J
MR+X%;.5UY8%UE!K;$;.6UC+:RI/$*ZN8R`$D:T:LPX;L?7/B.MS.8Y?L-=@!
MS)L=)I*GBOB^RL*FKK;_`%@%'/,>O'ZZ35$YF.Z$L$^1EJXFSC=_UM)B3^/0
M9Q^O67=0<0;&YT.GO=!6S;JMSN0#M9C+66JL*J5`'/J)SZM9S2A2!S(ID0F<
M=WQ_)!$V)6O<&V2WQHI'Y2P=!^;%LJ^%]EFK"-"1+,X(@(V`P1A$T$8=@]06
M]FN\8W3,B=WB\7.<&HWES&4=+['@V-&^G8RK#!W$*9NVI6D-H*=K["8F\$O=
M)55DDF8,A1DT[CCYF0>3T&=&U6]!32^]WN']C/7$"X^6(2XHQ\[=Q2ZL6/.T
M1-K8VMI+M8+K+U5F^II(Z6<1(R&L(1H+QHXV*6I,;`P?C34<='W?+F4=RI79
M8&7&STV?HMO0:?.B[&&UK@K<^H?IA&PS%T01!PE@SXF`3EJQBI-Y-F'8%^.#
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M[>KNNQ,0!-(>IT`?QU3QW06-J.C3A1'HZ2,]RL<UZ)WZ"EC.4-MQ//:ZC/\`
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MH:(5\48B%"V$!/\`URD)&]CV,EA9(C'*SZ!KPF]+C\G:04.>T-5*'6`'G"%7
M>1T@)\D!%T&7:Q0Z#%WJT<X\XOE`'"57P'`DN:3$Z>-CX'!VK?3W'\>4Y5_?
MX;5^Q&@N,X0W=ODV<HU[EI*0"$_/4>&SLIR#2QV-P3*Z&(LI5'[?(]\BN<JA
M%G(?ICQ+B;/C<^FY1-X/UO*-];UW&^!V&6*Y"H0-UHLA%$:;4Y/(VV0KZK75
MP4,TII+S)`9'1->GA(CY)`C[)^A7*/'G#]CEZNVPN\Y`M-X#R->6CP;84^;1
MY&[%+_-TX5V31F6%A8P"Q-A+C)B'J3)(YG(>R%8"`_5C@MKQ9)?&:'`Z'-4P
M8E-865L,-<'D1Z:6Q>:\=+'.AVKY*.ZFD6/[U(Y":X5J?2%>[4".VUF3UD15
M=`Y8)Y[FDOYS1*BVB>159_.TYL>[OK$<,U;>@*4WY0:F1HY$<LQ,_9&$0R*&
M:\=U5C+PKR7L-,"#H^;K"X#,H:&FFT.-XZY#PX.OKJ?-U(I5Z/%HJHJ__,LA
M)(G&?,*2L;O&6%&K('28>E/VON;PA@\?9CIN\!15W.6FTOWR%4R<:GF1T9_'
MPIP%A84=C;`'3]OB$6-T\3%)5&L1S.@]`O0.@=`Z!T#H'0.@=`Z!T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z#1?[?A[;)<]Z/<A4)X;9]#@3\
M_M:NTG@;9E9BV>;24NP&#=*RVSXEVKQOL9&(DPZ)'-VB1'=!DO"W/T6PS6?,
MGN-<`M<;'<_E,NHIX`ZU5G;`I<VU27(RTDHJ]Y(]24,R-\COM$5J*WQ<H6OR
MVBY+<5&`4'FKJ0.QL:"Y.@U$%80&RW'FMUAAH+=X_P`D(PEA&;"^=6)V5T2?
MR1.@YO\`Y8K`9+BUO:33YR^*`41TLM>R.F2IN.YHR.><OXYA=.-'][*0U59,
MC?JO;H.\)U/%^F+D>0"ZS75-E44BUH2"`GN@6OL+$61U0Q\U7:-)-C;\$J(Z
M8J!9>_\`)R=!RHLJ>I:V59K`:L.;YHK9/Q@5O925\DAX]"%<&PO=`+(9>(U%
M:Q%F1\:Q*B=UZ#^0YG7!21535@MBTT`+7'47E"4V%2(I;<:16^:#$`GI"08B
ML^W=\:,5[455Z#F"[>2_G2>(.W`KJ"&QS>KC((+*IBIZLAU*5#,-7P.M!C`K
M(5Z,GE8V2.5/'M]$3H.8AMHRH^&Y!BLZU@D-P:[94%W<0'D@W?\`7P<\%76=
M/-.#.151P3.D=&A!!"-D8U6/D<T.DAX[XP5Y\]Q@Q<JYJAIHJB@F5BV#9[L$
MBDJ`:J`?[=]`9VED^TCBAG?(CVHBKT%;=CZ_;#+5I.GX!TD<V_0?1T!M!H(I
MX0;TJ<^2]$EJK%DDP0%M5H2L)J!L)0ED:1=_+R3H,FW?'WLE4\;9\2R@S'/)
M;J9\7W&DS*5VP'('F;?T(KX:21X++QLTD@?U>T*-L#'/?W=XJ%&?_,QF'TF>
MR_-UOL.-Z.T@TNCGXZO"JW69'5@6`;J@&PVYLLK&52&WQLP<)93XY)YAH`HF
M.5\*/#)^9?6_@CV2]=]YD]AQ5A]5E&8S47IMG)BZ@_EZ6I>QT&6$1]N$`^M\
M+:1GP(//**^%$<DJIT&K7CG_`..APIZZ;K!^Q7K9736F^]<C-,?KN/\`D"P/
M*PG+,.XXSK)1*LC0?$ZUIY,0^]F6)60O^X)A17HU?J@>=/V?_P#C)?L"I=B/
MR!Q9<<9<MU/*VQTIP8F<U;@=!E%FIY]@</H(K.,=CXZ^,MH2S#R2M=*]B.[*
MJH@0'3?KS_<[ZOY3F+%;&'G/AKB@?#W0W)`-9866CJ-)C;RB+@NJFIK*MY\E
MD9?T$DH@L<2-69\R1(O9W;H/81^HCUR(X&_57PD!#EAJ_0<RY_3[BWJY*\R(
MPX#5VI<M55'Q30H=!I`LW,(.EBK4B@?'+&B]^@BC(TMO@>7K/.Y2YNY9\[:Z
M,LULT,N:U-%54E=7KJ,OD-'W?'4BV0%R0'.V7M)<C?9DPHY:J=&A/'K_`,PT
MN?X](S&OFOD)M#<T3;:2IE0[1NHBM4\FJ@ETS',M()J@=B"%@PQJI`\DB1^;
MY$3H+=<G[_$<:6N'R?)W&FFY%N-567^QQNJTNI.UH&%G/ED!,2J:]S4BUE8C
MFMD80U))@6,9XHOUZ#6_ROE-X.==5N[$V67NZ@*35Y$O-`>%UKLJ#;@YY"[%
MU=]PRBSFZ5Q4I)TK6G0N9&$3''`V"1X9AZ-9VHV/LNRUY)NSR\EPWG[YN$`M
MF6*9ZEYAMZ2T%@T-W=6800U]<R"68HHU;`KV#3C0O3OY(JAO!@Y%4=NH"M@M
MEJ%S$M34$;&LR=R:%IKC01-JU91ABUDM/-EZ%9?BF+*E&22!OW*JK/KT'5<6
MF04ILL><U,0V*QCM#31U=G2/K]"EZVRO2-"(!<N:T>#879UEY_EI41$9%`Y.
MW^Q$"QYG.E'3\>!6ANA/@B^PJ80A[(F876QP(;'16A]]8OA2"P^W*L88_O!?
M..>:)\S%5J+T&M+VXWEX5PQO[\<][=";-6\(T=Q;5H:11'Z*Y&M;?4G4T;61
M"UN?HX'K'#\GC+/XS2=F>70:+]'*+9VM:857`U%IILD32ZC268TL+]':FZ8Z
M5(;JMCBBIR+*P`6-3F#KVED&<Z!%D65C`LSP+PUG.5!-OR";E*2U7,XR]QE`
MD<^GM0-M=/MZX87D"@HK04?[121<(\$1(E=#&-&3&JIV;Y!NF]3/63.<L<8Z
MK`<XU=-R'QAQKKH,MP^`8R.+19T"KJVS6PFCO:DU"K&[&L++MVD<J#M:Q&KW
M1>P5I]A;K6^MW(_(/$]!(TG):LJQNT7.`K*/C,UH[@JVKJ6>(^9\I-M85[V-
M+2'O),OE(J-B\7*&%V_LGR+>XS&,XFIJ3.:$>>B,LK<R%^AK<]D`3%,TFG">
M+%+.0RVHA9ZZ!K_],L<,?Q=WND1`R>^(SUQ3ZG14.'L&9<^"#<VF+M0QIZ\Y
MEBLJVEPV&G0FT&2&B!(E&`8Q7,<2J]D=W[!C_+^OL2L5<6#;X48;DPNISX"Y
MJQKXZL,^N1M/8UY-B=\;:,4MT2M0A4^[KH5\9&H_H->'(UUM;@`&6DLCQQ:$
M#/U,.?V4(5J%5FQB3EX\$*ZKVSE`3UN;+L)*=58U\T1,*DI&C(?(.NSI.8@D
MJ!FV5A7U'Y>+2&QR5T)1)``T([3I:UOB[/.)4J*)WXUTK9+.:(N>3XU'8UX8
M%!2QV]725C*6X$5+.L_#"3BD!@BPES36I]=I=O.@YMB)<P,[RP-C>4V9R#1-
M=&O?H.:*31PW%213MM<:7GHBK+17?&!(KY*R`DX^(NNI#1K#[S^U4Q+2A"&G
ML8D0?PHGT8SN%E\9[E^V/',A=-PWR!?%#5T/]C_#<N&@:;.19JWJ(A<G7+97
MD@\&4M`@,^]\L]3(6`1.<J_+]XA4,8;%^!?VE;BVXT7:\W\%[_6\<0QI5Z/G
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MLY`K:+-'$25!DUM7B-JRR-0FMAK*<`E(XX:86-J*K$C50W":_P!5]P75#Y[*
M\O"56BLZE8AZJ66//FU9!5W"\2\`&#0J5Q57G632_&J(R8@-C%[(Y7-"N<G$
MG+?"O/\`ZU:4]VMSN6/V(-%L;[(U/]H%/+U,#U_K.C2@A+.&K$O&L'A,G;$$
M`#*Y'/3MT&\;H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.
M@=`Z!T#H'0.@=!J*]R<!R94[K7\I<!BRE7-%-1Z7E/"6Y+$J-YFJ&@%-.+I`
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M.0GYD[1P0Q,:$G9#2,@)EQF2V5_6U3,WM2P!;"8$T[06`#]*#-_2!G#K8D63
M(\U`\F#Y8VHEDV2+Q>]KD#O:3G/E6&L&MP8LSJ\O3P?>3Q96[?+I:RI=$VHO
MSKD0\-D"BXXXB.66:3Y&^"/56R*WOT&9`<OB:!`(K^YJ/[22=NA*Q,XQ!;%P
MN=(@L(\KI5O1"*D2\M,V4(P@@6/X9[!)&BN8G9$#(CF9*6[,-;1TQE9)G##]
MJP64FIW8K[&*:X3/'UM2L=786@458Z..+S69Y,/97_(Y5>'8NXV&%REG:YW0
MVEE)!"EI2@PU0L%[0@2.$/OA*K.UOXZLLM$)$V%P#2(WHRP:U9%<[Z]!C^1L
MK6B;>P*33V]EG:,6]J0J>NM\Y3:'-GC_`)(BUKR"R+`61LFJEFC*0=D,HLB*
M*UB,:CN@_+[^%EN(@@4=".VURQ<E5/\`>I8``"T,^@=L#03WR)0GC&D3UA3W
MN+1C7L:]CGHUR!U]E2X?ED1N0T.)J=)3:RQO/O*+15Q)%?'6C5IUFT\BQ0R,
M@"JLK=PT;XIUGA;(Z)\38WR_Q#);S`XVYDIZ[3!AXB]MJH;C*>:$BN?%J**.
M-L'X0.O&#^PCD61K1X)/]<PZ=O%4Z"*ZKB.VJ=02P3EK5//JLV'^9"M:V$%-
M'HIB-3:%R-.:CJN8PMEBD$D<434!#%C;&C4D5.@Q>WRO*M3/BY+ZA;L<^+9&
M@Y&&'M!'5KH<7<NT@I]Q5_;_`&F.)B&'^W)E1RLFDE1?JUGB':5'-SX*'8MY
M#I+H>FQ,!]=-3Y(1NHN$J\T(I!I39)X'6EA99V5K9AHU?)+.UG@WNKD3H)HK
M-3Q]I,0'7!#9*V=NJN`+&#Q@052I$7')#$,70*ULV=^T-@G6=K>S(B$7R3NY
M5Z"IEWZ6<>[K5LTL1)W'W'PN+N\U;:2!XM5<6-W:E!T$=1%#8QDN)8ZV_).E
M,F>L\;"88!7QPRSI(%;P?U^W]=<XJ(;<5.IXS<E3/311/ER][)8T]Q]]5PW.
M=$9']V)`<"R$B>1/]DSXYD5JL1>@L3;\?<WV6EIH#L&A%DE3#A['^Q3YXVO.
MS=<K[.CE#N@ZT<ZA#A1Z61H'=S8#7*WNJ?7H)!R-!=24L%.5`-;[X[)V%<[6
MP!A5UK:#U)5:),':#'36LS:*NSMR*<./+)\4)"I*R/R:JJ&K>\L^-,I[+4>>
MUH;>++7*;N9EUJL99&&6EIL-A4DB<;7.C'F8*/:&V4E5,\FR8YY<K/!G:)8X
M54+@9W3,CXX*RN/Y!LMQR>3>$@U-KJ606$^KA6%1-G=+?V8A#M)15`'D<^"1
M6$?(B1Q2.7^?09-!K3@-5L1V:BAI;C(Y?<MTS#?M3[RMNM32-,K]Y:$3--@C
M*K="&592@`)/.T56L8V%T':0*B\F^Q:;%W&5)?GVF-8N$;5[1XVO&+J[LJG(
MR<>CY72A!KAXY5T-->*]83/F?\.C&D=&C&'L<'8\E<>YW3\:8GCJ:051I'":
M?YGR_8VQV\U1*9JMEG.JUJ)3[@NM/21'FNDCCC162O\`%45`I;6>N%&I.BV.
M/O-?`,=7#C+5T$A)A15[$R*PFS8=M*3#`"'451044<H<;"XQ(F]I7M<B]!.6
M+Q6OQ./DK9ZF:TNW&W6JTEY(:)+/:;Q]4ET25+,]!"9[P;/9:JBCC[1Q+%70
MM5%>I2EAZ&?5'"?^-_7[CC/SRV+BGT,-Y9.M[-UH4PZ\3\F4UQCT8U(FK/\`
M1C4:R/\`PB(B=!IO]Z>8YKSDK3,GQ8E-GL1R(ZFL=G"^,>?1>(,.8I:UY38F
M3%V)-B/),!*OR##HJM=Y=DZ#&N/;W09T&G;65E%69:)=>&5=:2N9\^C_`*M6
MYDX&S6XD8Y7X2&O!E83/$V.>&(0B1W=9>ZA-,'*E+BGZGV5I:&B7/9/,6-IR
MC'@K)I-5#KDJ'!#B5=:A'R201.M:]Y+V*Z**J+>Y&K-(B(&F.@.L:?8E5FKO
MK<O#56IM;)*"GT)DD)*:Z)VITD]4`<YTDC=L.8D`QDBN=#_[SE27H.TY(T15
M>+&LT^9$U;PC,>-:1$0_AIAIE&D-!S-T1#(IFT*SE&#`**UGBQP-LL3V.A7Y
M`ZJ.ET9H6=LI)JW13/S-S?W5N#2RQ9Y:F*0(NIDI:DI(PB*54KF!6$DS7D64
M[XWHB(JIT'0VD@(E=:R?$-GX<A0BV0A]+)8F%ZT-H,@3MA:11VZA,)K[<ED5
MDIR2S!/\91T:UO;H,9B0.]FA/*_L(PG_`(^.JIFE*')8TX3-EH`[R31TC(HJ
M[/4H&GF(BF.D28=A,@T+H'(L2L#[1W4XU!=7>:H;&<C.YL-UF$8:32D6DM1)
M89LO0-M&&PV+-*E13PUA\HRPS.E:4$US?I,X-OF.:7QQBN.>':RP0;4<<8;-
M_DZRD80=IB-,?HJ>70?#H$L)-#<YBQN+P`><LZ4B5W=73MD2-&J'.O<E1\@W
M`]9IN*Z#?:.H!9<:_479=1G1L#@-+=%4UAKC]QG0JNTO+$6NB:.&8']N001"
MJQ.8C4=T'*3C/8>MG)ET)DN9N1N.7B4-9_3L_2ZN\YMQ\>+KGV%=EM=M9-4X
MK1ZDHJ:*MFM22K`H@<2X^."2-ZRNF"[_`!_[D<BBO"IN0:_';=8ZZ&8_2Y>M
M,RL\UA"$1VAAQMM:6<TYDUW]O\DD1GA&(Y'QPNE:K'!IE]Y>2-%H^;N1^3;"
MJU6"I-M;U&7REAI\],C"<[4TT%*P+.*V21@%Y?CP_.0;,3*-6*[OX+&J,0+)
M?K=]8BH\?G-W8TY@YOL%S2ZZU568-85=>;Q1Q$9?&9LRHI9)Y)Z(>R.O`IC!
M99I$0Z.5RIV<UK0]"!$-(!I;?3'!4\4]=G46>X^TF=<Q`!.G*+9+/XN8X*")
M_DQK/Y]W._RG04*;ZA\K97F;CGD+B?VJY"QV#_MTYG(/%FTF%V--OZ)35L_Q
MV?6T8^:B::%W&BC8J?:0/5\:)(B+T&RSH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=
M`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=!7WD80JY)T-?0FK`1!84TFJD''#
M)+?FQZB(VZR[)[%6-J9-32N^)D\7DR-5[N:JKT&L/D'@8[CC17'(_`B%19^M
MI:'17F$%DFHJEN<C9=35@0CHX9TIWVJ*(Z=1845&)\<KX_Y*X*\XO7<-V<BY
M@>U-S&XRI]G9:?/4HXN:H[J[EN,IIM/0R"V1,8-Y-G!;F)!W1-#&M)"E[=DB
MF64).ON.P+%U[+5VV>UA5*>+<6-JP^FK3:R(R]A*.'&`,'+DLA+#N@DPX#YI
M&*Y8XIWM^G0=>!#R2%QK#F\S6BT&KSUD>E3874T>U'R\YU5+%:B56I#NAY;B
M"$>OA'LB'GV!TX#!971S.=+(@8K@_8BMS=UF[3DDS*Y399TFEI";<RAT4!_]
MH<^F()7)P0&?U4X8RG^.58Y#9'.$?_LE\I&(.$OZGV)T'"F9)T,CL=H<'+MI
M:VW)SR&6=36":0`TK1C'B+,?9Z/(U]`Z8^>(6T?-5/C654<L;1)@E-WLQQYH
M'Q'\G%39'!%19R^S5F$'E$SMIQO=ND'XT>#?7QPUUF)W!M1Y`9"P$3S->0(D
MD4K>@E&XQ>+"$RK\1I-!H*\B]%M=+99F\.J(PLA(-^0"\*JZN!:[_P"Y/62Q
MGE=`>;/".DT*M:L#%#OJ'D'CVG`7+C>Q&8VOV%]7!T-/N;RFR.DL0"CT(M*%
M;1@PU^6X+NQ9)7@LCD3P\W)]7H'XS'.ZZJ6CCHB*W2_$IQ(IV,T6.2OS-K86
M4X)+=%=MM8IRF-C8Z"26'/3").BRMFD\D8@2O'S3QM9S%1V-E1G#C),77F:N
M<2HCJ94E*$<P2:RG;91!DV%6QC89WH1*7(K6?Q^-O0<@LK&Z:J262IDAH3LT
M<V328]\"BP`^3BI<X7'*0EY`1!?1QRRRQC1N0AX['_P<KE#JSLI$T+[&FT27
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MM:@I"6V8#KJ*U^%\22.9-$T5K8G-<CW-#&S`M:D,EV357INTO<C]C6'9D6],
MJ(4^XGJSHASV'PN<6:+`V23YXQV,2%4:USE:[H,KSW,U);6%*BR[>EL),U6D
M>.@RQ`LC2(7?;5D]:XN!D-BEW#$K;$.0KY!!^WRRM_Z$#-)A>(-'46V;)!R^
M7KME]U^9*RVJ'SUR0-9G)/23CW#V5IT>B-LJF43XAYF>$<*1^3H$A\0U+<N>
MJM!SE[*1U4]_R%06';/D:L_0*]:7*`5=G!6O.IK6]@?EZS<&U"QM8;$278EO
M:V9K8U&8D@5RV_JKS/79SB\G,;::HJZ9^B7*T5NFU?R0=GJN"9^7I]#J<KR(
MVEIM))61)`\0O.D/^=?`.6=%2'H/ILMUR89_4,X3FB,Z'9D5]W1::$82LR`<
M]WGJB7126MG5YZ'6Y6?1&_'-9&A&1VE:.XQI<44XG=`_/,&%"J,]0VE_<\;N
MUL4PQF(/Q_\`9]%1V@E:BR:F"OMLM:Z,?4SH09%#7DM^]-M*;NI3)ISYD%#N
MBCWD7-4RPO';#/93,Q-V==H])C]Y:QY;11M&8;@MEC[0.J'T@(D[_&COZAQ+
M3$C6.$V".1G0<[DAD+M`*+1%1XTNAOZRV+OK!T(&>J&16*9T>YH+"+21YFRD
MDP]0.,2R*'QA5L;!8XFL590L)>5]9MN9LYQ_FZRXVY'(/(&/CTAFFS-O!3-J
M*5N<OXKPK85PXPAL!>(K`XAF,:$429"_[H>05L+W!LH]_P#EC6<%^O4VDP$P
M,=L9<TV!"II:\JQGLDVSOZB$RN"KIH"F.J"K*(N2=O>(,>!\TJ?%&]4#0%%M
M];;74>9O"`S%M-+:U>5%UXT^AG9G<81(Y:TNP\SJ@6/.'S.+B4V<,DZ1Z_#*
M]R?&T)IHN2Z9NTJ,AR8?6UX>.#,$5YMLT2O-_L6>9@-L-3!-6:K8.=7UE*E=
M,3,3.4PTN66!RP/=T&7;S$<6Y?+4?''&30[*E@C`"42Q^&&OLS*\Z#91)<34
MAXXMA6-(IXB)Y8WS2M2KC2:-S9(H7!A_M-ZN\;<%\*X73TN>TC=WO-+R88(<
M7?K<E9GC,L0JU"J+`>]8Q'DR0*R$5C72+$2[M"YS41.@UU2YZS>HB:!0[>=]
M37'9((JW%+KJK0K50VN>,;#!GB):TBJKKAL![89$=]U:R)W=X(JAVPD6HK!Z
M:ZN+"^LVQAV"U50E\R.R!U`@!EB'6F5!,).1BL1;<!X8+5CE#F@^!9HWE.<C
M`C`5M`/IMD(7=U-S8F\BBZ&KX^JP!!0(82#!TL\*TT*#RUIOVKY/MPC`'P"B
M_)*21+(UD*AV+12;579R(:S((LM'H[&T/*2LSX#;4#,5$LEC7E&7EHA%?*95
M-8^OM61@/+'0A1YR))B$#,O7&$WF;E/CW+6M,`21N]C'26#[-:PBPFS%?A]%
MO=E?;`&50X9;2T3,S,KG`3,'+=.5(Z-\`,:FAN;X'JP-3SUR%M+>)$XBXKXY
M)V5N9'2U0MFEX41#'G<$)H<W1FZ*^9GY:^*S=8162N>5!$SP-<B3CAW=6(;E
ML5A;;0.'CR&\/TDG,QU((\MD_%,FZMQN,WY<^W!L&0R0RP+.>L]JE>'"]$#&
ME:]L+`SC:'R7QF5Q>O%+SN=RC[%V7=15^UN@`\%KCI[O.LDO9:2B,.GT4#<X
MPRK2!@E2:2,(@[H@V3S!66[PX]P;1YJLIB4G)V]@=3`MJ(<R+5\DT-<9LL7V
M1^Q/#?JJJSS2G4X)4%-#8VPT<+?YS?+$'>9EUD!F</A[#8@/_**VAU7'.GRZ
MW.!XX@HN],71U-]R8!J6%IIC8'2F2#A+(JN5_P`L0_BU`S'CG4:OA7F2[Y!Q
MF'BT)5Q7SX(ZN;L^08,X@?\`8C=XS6X[C*WM+K(YB*ZI]5"A-E7%$C6I,;G>
M8WQ*%$&4^QG+VTT6DXNW_%W+6QP']4FA*L>-)3(5#O:>X@TP^GMHC[3Q2])E
M.B&KZ]\H!P#"IOC;&R5T+VAA_&7M-[D1\B^O&>T-%6<B\=[GFD4/1G_:5>ET
M.6XYL/*OS9]995+:H@DZDLWLELK&4&*#XFN\4:B=N@WX]`Z!T#H'0.@=`Z!T
M#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H-;?M)S)'Q=R=,6
M1.>'1VN:7):`8:O^X#*=]BS01WED3\D/VXC1"4!DDC^2>-K$<C?'MT&OZ3VL
MV./YFR$MLIEW@Z7`7F7J@HRAGUAE6<DQC-GK)WJQ+.SG,+:&X1R)&.R/NURJ
MUW0<Y>2/5;VIX]NK7?8S.<>Z2YN*6O?J*$>&.VK-?%?T]/1:MQ,9D`VGI3;6
MK!9\3'P121#S->YL;)'H&1R^I]RU+BBX:WX\D)-/L*>VQ_)7Q'GW9(.@9/FF
MYHDN2D+`A`\?C&(A?++,CD\HVI_/H(>XWXG]E^/\ID5N<:=>6\`QI%=:-Y1Q
M.0)<77CU3+>1\L=O<YBBN*C/6`M>1(')9-M(QFC1+_VZ3SA'.\Y2JM:?=XGV
M5K-?F\O8W%[$+-=9T6AKK8#!4X\R7HAM&-:J)*H5IVIYR'`SEV=2CY8D8K(G
MACO+6BTW'V8J>-:2DJS>!KJ:IGFKI-!0W^VM#)KNIO`B77,98PHEUI@Q4&>"
M&DP2PRR/,*B@;*YH9[QOP\#F..-95\C6`VMI]OGVMR>?TP`OV?'3AJ\2"B>0
MP<VS&&CM0F,8HRR3,\4;$/+"J/[!,;/:JNS>'DR.=_&Y_4YZNI*NJN[+/66N
M"@(I*P"L>#/%%'%E6!4EDT)XS2K2)!Y)YJY\CHGPRN"GXO'_`#;M=^7R1NFF
MU&HO=`K(]!F<#6W\BV]3.!-)9ZB+[C[FQQ<CY(")A5AK;&U6-M?!$KUA=.$U
M$<09@/D;4\AS45M19-C)0JH#+XC:)K+2]?50FT+)-$P:JHEH@)W+\-<3"*B/
M7Y9Y&M5%4.'_`.;N2,0/=:+;ZT;`<41G5@&-ETN"*U>L(N9]:%54HMEFR:MN
MHT!3["6J!,*>)"^$5'JV)7PS2(%IL_ON3)+O"4TF)=QG<!`Z'02PU#"H<#JI
M4N5(.E!J;.5E\,#R3:-\X(9V(:-+4?,Z%L38DF";$]A:[%Y4B/26S]%F;6K)
MN![2P$L@M3JJD$WX:*^JP:BA^>;3:"V1!H"YD@^[1/DAC5W\>@EGC'GSCW;Y
M07D-@=K7Y=):"N&O:,N4FRLKFFBFH[)MJ"R.,R:%()>R2JG9$C^K6^+5<$VY
M+D;C;D^F.#BG%/##BTF<K[7502TMA8"UK9(K$\$V>)CYZIKIA8$D:Y'N?$]W
M;R8O8,!Y-XOUEOGN04X`MJ+CWF/19J3_`,<WNPIB+>AS&EIR!18[@4:63X9X
MYJY[U<V+^3F=W)]._01+QW@_;R(+!5O*]WA"1(U2)IM`?-9,72JYY<)3$\5&
MD^WLXY7QH]6HUDRM1W=G;H)VMW;_`!MNXJX!@E!ESI)GXVE$C6BH3+NZIV7L
M0]N^9)Q)T)B=,$JQ_<&RV)+NS6")YA\6[:E&D1L8=U1MKQM$DP86C`(DC:R.
M`MUJ*GW,2+-\$,D+)%:L,+9GKW5Z(G01O9\K4/(:V1\V(GU@4E609.`4\BHN
M*!E<^2NO,]5P*^-\SPKH9Y9<T;>TX\G9'>7\$#Y8.LX/Y?I=*81GF9VU#I<?
M:ZNV."+/K::T$%<&+75"$J'&/01QU3YH?HV2=;!_=[9%5K0P6WXYY(R_''(E
M7D;7/:>S-EPIN=I[76MM:99JR]M;P^)E#IHJ*SJ[0FI0=`1I)GHI;(V.E^#R
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M>2=+:@OS&*O,LW[:\JWORX!P@%E19P:DT5_;B$YNU6X;'3T!(0`\#""F$(SQ
M4%%D5D<TH7OXM]X>7>-*C![&TK*#;UFCS$FW6[TM(/26=E$>7D:<H6SMZ8L^
MOIRZH0T@2OB&AGL5#SPXDP\4TQ#8POU[,\J\5^POK-0:*:W.H0S.0Z,0"SI9
M0["]@A!L!`]8=2QC3R+&.VE.(CE85]M(L2NC<C9'-10I*%Q3GZS)YBYK+8W1
M8W"5>HQLI)E8(7=7%6)`R@38Z$ADH\5IH([\0AQ!W=(*\!S',69?Y*&JG:4-
M``?=)?:<JPSX7)6G3/Y&>FL;T55-JTT,0M1<K",H\]7QBUHX#BY6K'96$9+F
M)&V14"QOK]DZ;0;_`(7XOX_,N1@3S88J;1$6;-JP<2W*'V5Y5:0-'QQ/(<)0
MB`G2#/F52%:L?>!)E0+*>\'-W%_/NH!XQQMMJY]=QN'K:&AME44/-,AJ+*6@
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M3;B]I@\E8U]=(+X)+"YZ#S?;_,Y`O/A=IH*_CW<XR*LOL;9<[%9JUT6Q#COJ
M.FH\[B9AJG1X_-F$YWY!-#?U+WQ5,)`XXTLLKFOF9W1_06KW4]!L.0X+#(7,
M`.;SO&M5F<R;L0[G.Y@LD6W4<D,,P:J,JI[&40-DSIV!$(-%)YI%Y.3H-+W(
MW/7*XVQY!YBXFY@(JI-#=\D9=O&RM)N:PVM77%9[D$K-&7A`IN=SN8T:5!<E
ML4'!(&T^KDBC61Z0=!,GK[R;OGYD7D1L&:O=#QIS)68^E$_*MKDU$M,('>6F
MZT=E<2.+T\-I7..6MC+%",@M`8Q@'%/LNT02E;ZF;)0YS9;(N`V3EH*G,B`D
M(!C$JIJJ_D2WX]N+ZZ*$K(=!=-1#IK$7S6%[_E':4UR0]!)=);4HY^AO[6X(
M'NP[*[UMW2[Q]K\G'#A&5H9)510XX:ZM9H+&@E$&D%.B!;!\3S1QWQH]S@Z%
M.,*JT]<.)^8M(5):<C\L<F[YF&T]*?:.ILCF='=@24@\&:MZX2ULLU2$<?BV
ML`[(VOGL(V/B:KBO!0J'GN0G7/MIZTG8N]M,NM9[,9,K470*M@K==0VB_P!2
MK,S10@6$[R!=`1.LYH!(PI(X2O+?`D;%>@>N#H'0.@=`Z!T#H'0.@=`Z!T#H
M'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=!HZ]C,0RV]JN=+?1P_W"B=
M1YJ*FH[F]A$#RF@7C@"&K.KH)9&OC$NRV+!-''V5[T[_`.5[]!K9T=J#7YJI
M*,!M#@99;&808^<2UO3WC1Z2RSE$RFG:K($#H+II)@3V^#I1I(T_E&[L%2<)
M;O,R>GS(U0\N+,R3QCW$3*\`2`^<`[6YN9!)$;^0EG^T+@F'C\HH!YU3LGBJ
M*&Q3)[#=<BTD1%_?S:)MX)4F9*,6!T)KX:>M://9YG8#+'/G]777L;4<_P`F
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MH'-C<Y5[QIX?7NB]N@_L.UM:^D=-=Z'%O&LQIK^BU)E60[,V-(GB*(QQ`4;1
M'6[T:DTD4345L+V]T[]^@YVDBN+FOM*R^XSQ=^(29_VA5BP68`V@,;\DPQH#
MF/-`N1Y"F0KY.1BO?\G^&JO00$SB_@?87DIFCX_;E=4%5'B60F,M2R>]140/
MS3LU>M">V&Q_K:Z0>Q>C4^"&=!ID[OC^@5TT/H#@MS/3W'''/MP$2^I`OJND
M@^+^H:+.",<'4L(IXO'RKIK!$GL9(T1TTB+Y_3OT$"+Z@>PO`7)A/];`6ZX9
MV=J/:;FICMRRZUK1%.LK\L2MBD^Z(M=+?W))/D__`*73=D_QT&7Z3DC#U^[&
MRN9QAU9?(H]&[)7%=9AE$!'I6P/=$3$K)*60X)SXO]SD25(?F_S$B]!,M0=J
M#!QZ6ET%Y.:9=R9(&PL#Y3LXRTV#F@S4-NL3W34IEDQ4@CGA5$8Y$5BIW7H.
MKT/N%D,%L]-E]?R%E:PC,5]%8SUJ0V--8VER;.66X^C9Y?9QM<`:Q[AVIXJ4
MU\?;^';H,EQ?O1A-+J+KC2UO[>\2S@KK.C.ED9$!89Z&E?"M>I@<?W(=Q;NB
M>2R-ZI(LL+Y$_BUW03%L^1/7V_=7`:>*75**M2]Y.$"(,G"JXZ6R/83<&5*L
M*:)#4#DDS-F[M^,21S4\N@I_H\WCLS9RRX?3V`@#M':.<<2?:?D;Z??CK_7W
MW<P\S+(8622?[R$$1S8#87,G>WL]>@_/%F[Y0R$5_DC1M+R`!G`1,?;LFMVD
MCY"^%)%*%UFNCLO)]-&V@J`U<UR+7L.?"V%K5G>JA:S(7EM0R.L]K;&:3$:"
MXJ'Q$S5H1HYGY<X48\6*>)DM,>R(T@?Y)X>TOEY-8Y%B7H,5W?\`720Z?28>
M]`9#33UPWV5[)45+L]7W+?Q,(\-F*U7V5`.2[[ID97D#'#_K[(SZ=!F$G&-U
M>C&6UE6A9\FTCHVTVQPEG$RH(O8#K"NCN2)*OL)5G"P2_P"YO9!I"A1^Z=NW
M8.Z@R]]0MHR\OL+C%&U&IA#O:O1T%8K-@4!(V:W^2ZGA>,%8;*GJ)YC)D3_3
M,>CD5/DZ"M=CZRY2TM8MOH>)(=+I:NPL+FUUV>VEC\NEM;2T[R4DX`Q+#BJX
MYSV#!P1-;$UJJ[LK>Z=!6/G?U"P&O82[+6V_HUAH<[0@9727-BRAI#8[6>[L
MJ(:0F5J2AV[#&V\D+E6>6R(FF<JS.D50G[->F-!JQ;//;;54A>7$J\9!QM?Y
M.XGT$-0'`\PNRIKO-$RS1BE%:4PN9\ZM1OW-@UO9'RO5P9O2^BE30^O!_#M-
MR)8'B;O;5.IM*[D4I1)JNRH=&-<V4%%&UT<M.^X:%'"2/$K8W=VN1%5O0=%R
MAQ'['9<68!,M0Z.KJ`BH*2THI(`JG,Y]M")7".)&-:L14<TL#X91T155R+(O
M_7WZ"AW.&+$W%98TFYP6PXPU-:&)FL%DJ89,]G-II;2EK+"DU@]I'&P6O).)
M_'H:-(Y(@P`QQI/I+*BAT'Z__5+D+9^P7&^BL-,5G<YPLD^OY`OJ`L1D5GL:
M6R$@$Q8;&(GVE>8LQ41CT1(W@3$Q,^DB=!=CF+TXXWJHS*$3CFVQ=?;:?4Z(
M5V=)86,19DI)=.KYPAE^Y$I1&R?"#(S^#W_SE1W0:N.7.&L[BM?3!`Z3;7VJ
MH]`1M<QD!6A5Y]/?*'J1Z,/5-/[0GUM\/(0Q8X^Y$GQCS+V[+T%>KF_,@QC1
M-/7I7A&R'T#+1@I@=O5NNP@=%H&BV_T^_P`W-)G7UY\L">3R&*.U?^Y^H=Y3
MAZ.XLP;VQ_LS13A+\*P+#>.7%5V@EP']U&ZZG[NKG$5;%2-SE5\<"JJN\45.
M@Z;0!MJ["PL`9Z2P<R5+BE^&RT8]`S+J+..#5T&:%GB&4EIPQ9UC4.9_J>8D
M\ODV7H+;<4C;CAOTXX[NJ&JB%TG)UEH^6.:!9,M,=?YG)W9MWB^%J\0J9DD>
M3S,A@[[\2R'5K1K$"**)&HKD4.HX?Y/Y\Y/Y'&I;BGPW)#K1;LVQV=YFC,E8
MUF,P57-JZFW7D#'2`7$Y1)5+Y1CQ/8*9:-A>$UK_`"[AL*NZB3)YGCB_S%9=
MG::SR];R)L\('7W)JZO'$UL,%:,&R]GGU<+]=.U8Y&'2OLPY&.;,Y4;T%=)_
M6JEY<,+L;'(T>&EO[>602MKMQ<D14UD-%5:@R*X!NR9P:R3/"2"MG'<BC3P*
MCT3XID:@6TX;X$R?%/"VAX;QW(8UGCS9M0[.6Y8(,%Q_;+6M,T')!)EG5Q0-
MASE/5#N)\`UC^:")('JJ2M3H(.DOJ/#5EC:6/(E,)DJVEY(LAGSDM.BYCK6S
M/&SA400T<XWSQRHQ($$9&Z0I%7_\/0<C>\>E6M1Q;EF?UD#5[;*Z,R]000&O
MV4U=H@2-_P`H4-G2BM\I::6QLJX'XE_@B6_G(GW35<@0;L[;1W#<G@MYRSB<
MAH>&<M5IQ_D!-;^"?G<YJ*\TH%==FK7SGGSV.M:H&(M\J/</$`V5/YO:O01;
MP[PTO+WMIZ>4E;!HR`\7[%F>Q/Y8*2<9U3D\723V;X];7M<C%I;31#MKQ9R$
M<Z5L[8(NS7=N@]=O0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'
M0.@=`Z#2][K7/L=H/V"^N?$/`7L[HO7BSN/6;F_9UXTN7$W'%^NUM/LN/:@"
M/D/+VT<U3-&)26YB!D.9\\)#FK$Y'?7H/X=M/W<$"?@<(%^MO:6%="M>3K9-
M#RK$78NF8X=FG?GZ^Y<+7,`G5'3"JU$DD_C&GC].@CO&>C?[6M[LX.<>:/V<
M'X_D[.!TH^=X9X<PN=']>ZTM]-5G7P&PSI([S=.DMN20.LA'G)*/!!)_GLO0
M9MO;7]WN1HRJ?.7OH?H%:66"-R;K9=/EC5%@9(<RVESS"X:%"%BC^W<.C/X)
MWE5.R=!K0]Z<9[\\#\*\7^^_M_[X7NF)XN]H_6FRK>+_`%G%@Q?!5-E+C>56
M9UC[V*J>ANZ"M!;%S5E*=)\**KE^J?0/5_\`FQ__`.XW_P#.7_\`%T&AWW2X
MHW-_S[RKR=1L:#%1ZG(Y)E+I*J:#-;7.:CC6JJM'-)=@$O-CD\7_`&U>0Y(V
M!'QJYK5=_)0HIS[P-K>-QKZ*WN;?=V=1BT;76=53R0O/'"@KC&G@6$4J3N/K
M[<NS:OCY.*6?PD7_`+AR]!C]'PUA9^"N+]E=W5+GN1RZ<"YJ7+.-.%/!<ZR.
M!"YJ(@AP.;+K;(`*1X,<3%,LXXH516,>K@MQCN(BJV@>?0VA-9G*(=8K9TE<
M#J3YV#9^4<#/BQBL`G%B-AD<UTDLHA(Q3D<Z27Q2)0^D%'8:V>#`7V4K[WB0
M#>O)S=9DM&Q]T)3UE1^,@O-'M!%JK6\.M[.E9_N9#.DI0KI))299G2.`!6XJ
MOY('KWC9CD+EFJ)S==DZ`O-?>Q0T-R0VSN\]0<B$G716?N+.&!\^BL)E"6:4
M6$69KHF/'F#8[R7R?94^4L*>H-JLW<L"FK91C[H/4F:1:^45HURC:162;&NS
M_G]N74B003Q+XL3RC<K%#"YN&1E.)UF]I:V^U8C*Z'.!EJ\YH3KD`-:6SN`!
MZBL'(U8L+5B#(#A5115:(U\?VZR."U^?IDD25PKK`>:Q""J=%7UD4$YL3@([
M!H##29P0Y+K[=Q2U\$Q<!`KQHECE216MF4,^GCL#3WZ>GJH!XDK(*56V8-:\
MTDFI_P#N`"OK91:^9T@QX+8GC13M:B2))"]%:G8.P'/+GJKD5E??04R@)H*N
MTJJX*&%\7RJRPHHZPL=Q,-BUR/=*R7YFR(JJQZ?1J!^BJL2CI[,C/2Q!4U[%
M4Z&*,P*PL$19`@:8B(VN0^`Z0.:KC@<C&-8Z.=KGR*]55O0<R6AE>PB>Q^T(
M)D#C"5*$"(:$RL)^-E:,4TR4P\:9)F-EFD14:YD*=F*C53H(O@J:.U(2RN\M
M]C_39[@L.]&G^W-?3&SN06YA)KZRO@,JM"%WC)KY(/-B=_D<_H,7U.7UN;KU
M%I^83B166(Y)H&C;);"F5Q/D4(T@\>99ZL(N.*3XG1.1W>*/X^WEW4(7N[RU
MR\%VS9X+*:^L-N<G8%7ML++6V5HZP*FEAC2R:1/86L]3"+6P`SD^#VSGJV9W
MQ,<G0?'/0<+W1TO'#*'DKB+?96F=IJL:AG'#EG>40YPY%2(B35M@489*W[97
M1O\`]G_0YB]!5+V']/\`CJCPHW+&$N=;R&:%L(G6@4=0_1;`X`2WLK`FO$#,
M22,<`4^=3"N\;HIYE<K%C8K6($=<0\>US>:+"\HR]I5<@[#C&RTM9B0*JAG!
MOPF'XRA3EO0YKP&(&,H;:\,A8"+,P9@$Q+)(?*5R]!`]OB.?<Y_Y?VW*5O+A
MM%DL\?>94[,1W&4O-AI8[-E!-5X5]$S,U!6>$IK!?Q++>,J,,J=\<<*,<YRA
M%.7W6[.OHW!GWQ^%8([94$&LR,3<54Z>;'BOFGFVK2K"UK:EP,7_`&BQH\'P
M:V-&0?1C0SOB#VTMR1]?K@-J_11$\?Z"SE.(GICFV%'.9F9]'IK,*VQ[=4:7
M5TDJ#O0BZ,>!$;\*^4<;$Z"U7#7O/1%5<];@;RN*HJVIS@LV%$KZ*HJ"\X+=
MQ%GKDZRMSYN3&MW"GJR.!`(9;5\RO58Y(U<X+7.MN*3<W:ZS,T/]++(IP3##
M0<Q14NZ-K+IRK/8DDQVQ-!!3M<[X!ZURM%)9_P`JS^/02=Q6M@+G<=H\MRH!
MF:B.@DT]W5W@%^48==ELDB+>-EQM0;#906)8DA!B@P)`YZR$0-\9V.:&?3\J
M6U1]J5K79G;B5)*WY&I@G6F=6?>2UL,#L\*/6D6`4<PI[HAHB27RE1_-%,Y5
M:K%#\/;@#+F?4WH$M%>3DCPZ'23W$*G0MK`9K.N4NOJJ6'Y81YHXW`F(QKA9
MT209$<U6J$AZ"L`V,$^=W`V/UD(S*0XRHNQZUMBBI4!,"W(K"0Z:;YZJWDF5
M/BDC5$?W8^)>S.@AJMX1ILC<A73W7''<P>MU-S$%5D`L"OV3YT&`O07+J*CK
MB[1]DN4AE8*67/+(HD+Y9I7MC:T,UT5-LH(!*(Y]!R?02155L^'0L8?8C641
MT-D(D8;F?E!TLT:U)'N(D:*J)(V-&M5.@R)NAO8+0Z6SBO`P[JS-%-):=#I\
MO4-K/]TM+;AG!QAU:1L_ULG&1$E7LCNSD7H.#?<@\>:W+W5?>9%^N5;%D1V>
MN1:Z-A=/=FRUA`>?)?\`?.?(&"#%-/'!\;II6=FO5?)6A(F,XFXOXFJM9:Y+
M.UF7/V-<.7>$MC?\MBVJ"(%K)BHY_-K2H0BDC<QJ=W*UJ*CE1.@P_88?-E5=
M!9DSWUELJ9*T/+;#\U"VTK+XAJ`LG9'']N.;.%+_`+)()6.;-]4\53Z=!J%]
MQO2?D>QTG&7(^:Q%+K:H'02:;ELZ&[O[:RQHX%QKKP_48.@^]GA9?;HS613R
M1G)90NB:L:11PQ1,0/R^GXEQ66/JM(=F[33IQGM\^W1\@CQ)KYYK<.NT7]<H
MI#*PFKH+FH'=!)'81M:Y?B9!$L'C]`E[$^A_$/)N)RVOX#Y)GKU3C"OR\>;M
MQ<N;.`-8VH^KG"+AN<V<Z%+FQ#5TKRPGV3'+W29(>\+@U)<K<&<FLN[;#<=Q
M62E.YJJ\B6*/46.WK,Y`-)_3J@&_O;//[&]L,M2S5*M2BF/$&)'C0^62*<B9
M\P;E_<*LAX=]+EPUS=9^4"+.87"07E*&/6@P7F+MXMCJ](Z6D`J6TDO]IK/@
MIPGEL#B?.U5CF5?C>&G/@F_3,>QHZYBG71TW(-OCN*]]A@TCLFID=*<+2AWO
M(C+LQZRG&0W$ME2'T,4$#+@:#[]T,/F1$&U'6:-]EL5J\Y_W%/!E@\WG*ZD%
MJ+-^9RP]:/4+,VRBM`@ZDN*K&:8LP31E9).Y8UC<CDZ"):/;7^.T.AR\&<KB
M:-:@<JNRV7ABM\DM-GK<XLO04.HEECT!&DD?*/!HH4DA6W(*D2!TS>\@P2LW
M>.(KI*6UN'6=#FL7OWZ*G'K\[6%:O.[&C(KWU=-!H:R,ZYT.?'MI8`(+8E:V
M&16P3N+<^.2$(:Q.)R/%&$SV(P=O6&TD6KTA0U/$;>NV("ZV%Q=A11:G0UT%
MZ56V5S*YT8S[<6.`94:']G%XQH$R>NV8XXYVY/Y#PNKV]M3BX;-S9![F7%3D
M-^=N.2#JGD+7F5\U'2"::HKZLDB&JA@.N[5OP#-2/P1_D\)'YT_5B=R%^97,
M<C*:\^*M^\/VPCX]F?#0H3'GJ6HY+R;Z+:Y841+*:8HT8I#SW00#SRO$^6%X
M5Z"I^0^*O;3%'Y27,4M(;[!<8\0"UED-7Q)29\QPL_(&>SI5%%4V.HC&="Y1
MI+B4R(9[OD^/[A$D0/0]T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
M=`Z!T#H'0.@TL\V2SS?NQ]8`1R*V;S](>?XK&KO96RQ+3%<B<9MG-R4"3C_8
M:V,V.%CIIF%1RUSB(&1QS21SQAYL?7\_3\5V/Z^`>$=+8<*[RQ_;3[79CDOF
MW2G:'.<9WW#.>Y(NX0>&.5KP6U-`T=EHI>PU+4'J.*DBL1DK7_R4-WWI)[N$
M8KWU_<IB^3'2"<64>DI_9KA`L^P*+NMWG,9QX#Q1R^#AX"'LBDH\UL.,8H/@
M8/&YEB>_LLC7H]0TE8GV.Y7YEXOP</ME=:`/09K]]O&A^JATEC:M"I.,.8.,
M;;68_!%@4RK7CY\?#_8)*!'`V)Q1,GS-61>_03;[)8D>F_2U[H7W'&X/TWJW
MR#^P;(7/J72V%W::*+(\2UW.-$&X&F-(F4@//6=Z//*")*JH+&GC(B]^@]F'
M@[_T_P#VI_\`CZ"J'*E"54\[W[1[40.FTV,?R'IDLY7V#3OZD$ZJK,^VI,24
M.&I,)&1SYXO%\<KO+LYW05#K,M<ZS08T6W2O!KK(J<A,?"1*7H!`M93.'(N;
M**P('=15&8U5*R4>%ZN5WR^4B)\C4:&-ZS@7A2EXMLZ#>7F5N!XOMBZF2L`G
M%?22AZF"1#[:<<4L^TM[C0.F8%$U!QX"YF*KO%R2-#GQT]3D\=13X^46VQMM
M9!5N\L5N7U_Y\Z&1IF?(C(D:@\>AB*:UI%5(]?)J*J3S/7QZ"5#<MQX?`-O;
MDS-YFTAJHN.Z&Z(G;QU.S.`_(.5/!2&PCA9N>W(EDA2*5A#AK.&3XYNZ>/0=
M-ZW\`Y;/`[#EBH"5D-'H2JOAVG0X&J+O;&48^KG,T-E;3F4=V9;E'S,-D4N?
M\B^"*980Y6(V8/Z9ZOPE4;JFGYDT]3JH[F[OXRM-B!M?$/H[B.0^5*(RB2@L
M\]055W'$VRF`4U'QL17OB1/)`E*LY7V.-RV19SVZ&V-I+QX%;R/QS"-:8@6N
MK3C:>G(T,M8=;:2R;]S"Z)9/MQ&,D<LA"PN7P0,NQ'*M6^PM7F35FE#B>^O=
M!GC[#-OJHT?2D2&SS::4..86B:2V*9R'.^8B2-L$+UE7Q"QF>LS[L*IEU+Z=
MUH>/96%N.VW`IC*R@1A$E=/-5(?<^<\KAH6.(CFA1K9?+NG96]!G0,UI%%7O
MEG0:Q('2*\&EN9;#["=*]B12&E"U<PD!C(41_DY8(GN_DB+_`(Z#@6,D0Y<!
M5A;#ME+KZ\5I"H=<@.$`^W.<8Y0018XR3963HKEGCC<C6.\7*OB@?61D,QY=
MPA9-</(<0T8R,,YXI!!PD((?Y-\\8Q,@S667G&D;/MXE:J_-_P!2=!CI4%U+
M;USQ'.E;&5?I`'4M+%$/_'-<3-4Z"2S&F@>)?2(K&^+6(Q5_UO>G0<<,L,)$
ML_PC7ADUKH+6A^-)"121H?NZX`P-8IB9H:TV,@:`CPCC1K$\4<B(O0<'8X_(
M:FI66V@+K1"<[][9GOE&4=H989D[HG+*KWO8,01\4CF1M6.3X^W943H*E<D<
M4ZNPXZTVB;<&S<F9VDD=1Z$$>9-.(+*!*M76U\\':$R(-S(YN\:2-CA:YZ=G
MHB*$B4\FA^S@-I9/RX-K%'+%HZ68>"^H\G;.="55(&2\4$FS*/@>US'>4HZ,
M[.7NO0=0T,&;D?*/S3&4-V;4E'#2%YZ`'1U4F8LZ^L+KK*Q'E,L1"M`TMQR`
M)\8144ZR2=G1QJH=?[:UNOW/"MQ0)?40!8Y-(E-R&1G+30Z'(F(5(7)I":6K
MK[("8=[1ECBC<Z2.5[4;V\^RH%-.1^$LG59#CNPT@-M5SZFB&S=+>"`W67S#
M:P/LM7A'8)&DS9M7,>B,(L8Y!B6]D69>@U.\MT^AXJW)^'T\>OKF%6]9%GJX
M>ES(+LNZC*M"ZLV]E'^&H*R,TTTQZN@*)2^B?##(-+\,+7!V_&&!V&A'*?5W
M%+1O/LKNH')EGB\2K(BIL`W6MW5Y7/PV5?7F#7Y$D,+H1'@/?$Z"661OA$%W
M\A80A6C,R'3G4+*<"HTP83JEC4(7`A,6Z5E>1I-%`8#6RQK/)5R_/]G_`)(:
M/]8T"YYQE]+273=1M`(;3"T-.8+?4V:%N68\I*:*ZJ*<9:.:E&*)0-Z2SL(+
MJX!D<P4="AD6?H,<K^3J.$#'G\A,T%FU)"AC*^GK)J,2_.,#&T=)LVC#07$8
M4S(2BOLZN60D,FSD\8"G.C8QX73RNAQ^\C,K1J3ST55FZRWDR@!,+*O8C2M4
MJ&@4B\_#WPVKKHF?'+$8T5PJO54A5B=^@Z'/A8/DFA_L-7'J<KILE:SJ1G]/
M8A$E"'5L\?WDA3F37)LE4']RX6)9G-")=%\GAV[2=!+4.1U%9:Y^;%:F-^8O
M+IMAJJO11DWT<<$8=HVS.K#!GV@$I)R`"Q10,(A@'^)7IY.5T;@QBSY"L"SZ
M$R[R4E8%.ZY2369S^:/8HQ0(TA,!3*^T@F*J_E<\>:"-88V.D^1J(U%#A\CZ
MG=YK#$6F%K\UJ[^2R89;37!D5/GW5-N4C+*%E0DTZ_"*,GQJ6_S8DJ*[NJKT
M$*<1Z.GYRW9.4T68LL%:5>LAT=4%7#D!"SU?'\T+JN6MN%C?#95YIMP2Z1S&
MQ1RP+$C5<])%0+=\P/N1XJTRIO:_[FGN*F%*FP9\<ET;<VD,<%=\LGB*U(Q%
MD?`_^21S1L=(G@B]!&]]H;:ET&@!AI59(3?+,0Z]063[&T&`\Z35TK6R1BA5
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M3A[[C?A"LUV5YT396L6AT@UM#6<AT4!5%5W9U[:$5N>$ALHK2GM`5>2")%+&
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MYEM=:"^/C#K*JOK`W23V%I8S(D<`\+8_*25R=D3NO;H-`V$RPNT]G_7G5VE8
M8R9^ZK-K<U]A->&O.U.X*7>06-;82PBB-&%*&B(69X\$CA>\/QM8[SZ#T4]`
MZ!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H-&?+=HX+][W
M!,<$=.99D_K_`.7*ZIK[!M2ME*\WF7BN4@RA8?9AE3SUK1OF,06.6>*O9/*C
M7(Q>@UYP_KN]_3_4KG;T/U?'?K*9BN4?:7=>Q!OL;:;W7U)./HM5RQ'LFG9S
M!G8=0QMW3NA6,)5N60QL?\JR.7LSH,RM/U[<F[V^]2+G7:<+AKFWUO\`9_V-
MV'L)&)9RZA>3O3;F[F_2[RKKVV%973/MH)WU]`*,`4T;NJD_&CO"3N'2\I_K
M(]ILG[0\W\X9NMXO,]>>1?V->M?N@^NV>Z;1VE/D^(,!J<MKJVNJ#J=U.V:V
M'NPWA#22Q^3P4B>K/XJ@15^R+U>M/5ST8]K]%QMS+5:/TB]I>=>%N4>'>&8J
M."R(X1Y/VG*=&?I*K%ZF@LC:%>-=38HYD`T:/8%/)YH_Q144/67X?_@;_P#G
M]!3+F6[X_K>6KFD?K5K]PPN+D"2SO@#'YVBS5'3Q#WM8R9C%CNB`A8_O(Z_N
ML;I'>2IWZ"%Q,27!:/W5_;K,&>&ZI"-R;VD228X@JPM1M8DYRLE31&%GR03C
M._C&PAO_`"Q.@BGF>0=_#NGJUUM9"\LRH)9<F@#1IQEGH""9Y4M6HGE;V5I,
M%`QL3N[(GHLG_/?H(0-S)(O&!M1B;!VOQ-9HZJ]V>=EO9OO;>4X=MG.[.*:K
M9#[1XK5^*"'NORJD;?\`/02!LN&<7[)3\?\`)O(%SJM%:X!*RHKJC##R,I[*
MJIF-,KQ;3%BN\#;:TN'.',"E:LPI@TGA_)R]PV.:6M`SV/XNPV0S@U0$(.[4
MV&>KEMJA8I[!DL]O6K2#L6RBMVJ620T>1J2M*A[(GFWMT&8U8X-6QUFQRB'%
M6XX(>C;`]NKIG/\`"::DL*`]J6!+B8V=YHY&(R1GU?\`3H.MT.8#91V<09@!
M5=1G/98'4U*/568=F5:3WS(Q0A6J'I*I_P"2^W6&-'.?,BR/_GY=!&F?XX!R
MH5Y:@5%B!8H78'5H=78O'TX]`>7%86\%S#"CK184NGP-,C1GVJM5JJJ(C^P6
M2RXF8$J*6C$K2/LBAZV25+*IM91%;:.F1(AS9(OA&-G+E<LS%=X_&Q'.[(B=
M!S*9T4A5R-#H'0%]CK>T"'>%;-.&5JUHY8=4*LD+0F.B6)T'?R=,BN[=UZ#+
M:X(<$2L<$0&8/9S1S4TEU$Z`L05(DE@J6M1$DFD&ADG1OR(CH^_@OT:G0?<Z
MN%(B,!DBLF%/A>:93`GO&!,CD)B1SOGF[0R-6.!C9$1?XL<J?\]!TPXPMD-5
MCK`^R0XN(>5MK8E0D_;C0*/9FAI(K)"6CL3O&[_IE[(Y.@ZJ,P(PR6&*1+:`
M^Y.K9E+%G!LVVP4GSU<9Q<S62O`&[2-8J?Q='V1._0<LBNHXJ\(*SA"D<'/)
M'95WTFD0,H]EC&QK(%<D8TUS"S^;^S?#Z+]._0<:.4\N-U@%6E1RU5.;'3Y^
M-T`S'3SQ2HXB(J14GB(:(CHD8[^/=R=OIT&*NI*R4)DQ8[",M:2##UDCV-_(
M&7,DKT<;-#'XQ5LH4B2-E5_9K_%%_P"I>@YE#GH(C83F@K`>S3?-7$GR(4VY
M6NK"ZJ.\',#\T:;+4?ZW-D5&.9"B?]:=!^;W\'JJW1R`1E1VXXR3&U;Q2H-`
MM>V56RHL7BB/[31MD%<Q%5C>ZIT&"UJQ?8L-U&;`M[*^"L!;V7[$DN>&OA:J
MCE."\'V#EEI/!\\D;/MXY.[FNZ#43SYQU$9MBA\;]]J\)^5%LK>:3+A6'])&
M%.%EA"NG72)#)F]O4BQBQ%=U>EA%#\?UD7H(IJZJFSMDF;KI(B,;;1WF@7,A
MJM1?+*:8QXL95G=_!/-<`013O$BC=\G8.6-4\59W"XF!M<]<CR&NA=]O.0)5
MGT0E02VZK8Z4)E7]EH)3F,6O(L[5B3BME5))G=HWHKOIT$MG8<>MO;*TJP.1
M:;7NAS%A/JLI36%N\S\<P]Q8.AR93/ZKH[.J0J!L=)W<](U?*U%5%Z#`C;"U
MS4^(KM?7<>Z%=C879:ZVQJIAN2#+Q[[`F[J*N`QL=>X66J$#C9*)W/K"7J-"
MU/!.@[`1=@7;0V+X9'9K-SR'/RUH=:Y(W)V5AW'>++5O9';6EO`QZ$1>2*I3
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M>3,YJ]FRS2.1W^/H&<;NP,/(IW_C4M@B/AMJZW#@;-,/`0<'"+6*`O\`.`@V
M-[XT.[=H?)%[IT$66NUSMC82R#6L)D]I/8U]C03@RD6$D$=@HUNRJC(:DJQ1
ML18GL?V;(Y%='WZ#*`<_7,=H1GC5]OD[6U)F3&R%UCI;>T$)1@DN>CCE5WPU
MX]<Y%A=V=+,KT1.[5Z#H?ZAG(:^2ZJ9;_"%92TL1W!RS)(</-L>T1))RL<Z8
M9K`Y5;$QOT:JM5/JQ.@[%AO-&<"MK,(PC<2!'SD5C07T,X>AKYIXHD%00.1;
M81]8CN[EE;\CT14_ST&,4.H)H=)>/T&:T0%X555=W!;6KZ<DNRM[(HV"UQF7
M%.<RYFKP:T5LZ^;49X/1$7R140,LI/Z?R89;U^AL`^1<;>@@A.P-S2!PB5,`
M<U@;67(U><B$LEF(AD%<D'_5)$CE[*WOT$467J+AJ+46H?%Q_)G&]%/15-L3
M0\>[_14F/43/V#;2,?\`K9,3\P2?96$*0SL;(YQ`[WQSJD;E7H.B3_RVVO`.
MQ1E9LJ<]P5+'D=UE/_$VM2`)["K4K#RHR+/WY]D+XPSSFO:+(K?J[NJ=PE:;
ME%HL`]SNN'-_GRYY;(G:UDE2>N5$'<RR&"/)OWL;66$5?0US7S]G?!"XA6M^
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M9V`^CNLU<OP-;5-A?-73-A2IL!DL!F"-1ZHZ21>R?7Z=!N?Z!T#H'0.@=`Z!
MT#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0:+O8O/09G]X/ICR5JBF4>;
MU_JSSGQOE+2(LH`NZW=-<9W??U:.=[4`*D-H<^2]!6/^>>-KD[*WOT%:/:3V
M8YY_8]O^-?4_A7B?>9WU\VG)%R%RMS%06)S!*G.8H'\K-6\@WE1VAX^4\X5?
MB'ED:<2SLL351>@V"<3WWK1BL[R75\C<RA4MEJ6D<`4NIWO)-<[>6F`RY6C_
M`*F=8I.7]YG&UI=R:.#+,C$<,/!+Y+YM50ZS2^UW&G'OI3OB+749KE6K]>AJ
M:CYA?4L?L9;'C8LZQ9#9T$8:3IJ=#99*NF^W>.LB2'#R*Y>Z+T&LCWWU4VP_
M2OZ_\<X:BL?SG+G./!N)X,X_ESLV9V&SRL'*%995L4>3.C86'9PYM%F*C:U%
M8UJN3H/3A]J1_P#ZLW_YC_\`\704X]AS<?#H^09.1L?)?UL>3AHZ>60M0<^>
MM^J,;231"OBLUT!4SD7[J-RM2+LWM].@J#>V^A<.)N(+.N"W%?5#<5V=3MH)
MILY:84^P(*KIRV)(@,C_`+(MHT$B11D*2,OG)]&KT%/]6!=7]AKN,VS`+Q[9
MY"&PM`!KLN\OM$)1:!8LQ4B1ODB)'B`OC)RE0:6.2)@S465_T3H)=R]U=U<"
M\64%I/QT-26M!<:&:GK@[.V==WT+)X+BZN+,8TJ,N$CQ>:KGS!QP(K(HD3Z=
M!*O$?)\_!/-&ET.ASEG;4?)0N>I:0G(5%-=VV.MIBB6Z?>6`<(H*LSF@LVRE
MG$#^"R/E1[H>RM[!:#7\H.T7)\QE/FDFN/RH&;K=*)%56E(M)7A2W4U@8EC'
M*"3<VS_",.!L<9L**]K7HCE:H9Q!M;*PO$M+N2[>RE.KKR:OKF`UY]A8P>4*
M#V!=#7CE%CUWDC7!E*Z(J!SHG_YZ#.V(+FI3*Z2QH5M[9ADA0U;"/6TPH-DJ
M%O-S]5:BV%763BND0@U7-7[XA[E_]$0.,3]U/:MD//,U?Q"5[34BL#Z*LTX9
M41M8R8RE8R2D?!%!*QR"H/"\F5OS-E;X1^`2]G!/P-=21%S1VH8$+Z^<IQ;;
MAX84BK%&9\U@I>@F'1LJ#/?,5-\<:]NZHB(@<XW,)?"Q`):J/]E=LCKY<=;O
MS95$$/&C9@Y/ME^<^/NBK(-)]'=^_P!.R=!S98;6M2#/V14MA41N5D!IR1&%
M6E<X5P\-:3.UJ&PGBSHQ5+=\DDW?R<[R[JH?G-AW%9F!1)(CI362H&":<0[1
M%-$+.F=*,420V(MX0K&HGR3.D<C7(G^&IT'&I*.NC#+!JK&S6S=;GJ-/I!UL
MSP60%J3/71R%+-(RJ\D516N=_"-41G9.@Z2V0F0)60`"%3%V)`]542"!`SQ6
MT)D\[3F2D?=3$L@C<YS>Z]E5Z]^WT3H.".PX<N(PQL5!`%)%4KG(WPJNB,*5
MS_%RM':PH:T?/,C&R(]1Y8U5JHCD3H,C19%NF$$U8K99R?.4]P\D4I25\T;1
M:H;XI?H>,S^+7+_&3_E.@Z-DA_QW2SW!M!63"QQR1$BC3A@US4=(^4()6*H5
MZCIT;)\J2,E5ODB=UZ#D0AV-9GEK3@FV-G9Q`AP60L\U:E^'`\B8:9J0OC'!
MN&!3*]S%:C)9^_=/Y=N@C\MIE=/69U:F:Q7[2Q&&MM0:95%N:.])Y)R)*N>`
M:PE(<[XF(QD?BC>WT17*H=9R!;VL,`,CJS0VCCJN(\P"L9!!7V!!@_:VMZA)
M+-MA(?GH>T[PH2!XGQ?5WFJ]!7'UM+BO.1]W.EC=VP#,Q)EJUIPM(_*:\PZ2
M&=YK2((`[PLRLG;YL"BG=^/%F[++*]6JP*PS\#"9:BY%T-MH0Z:CL]#>SZC0
M9U!HIN-;X6R%6GV+)[I]V8=#6$M8.3]PP@9@1<C9X9?)B('5X.LDY)T]XFSX
MSVW(^9S=\)4ON*R@DBN-_=B"L-'M:YEF>##6"NA1(I2`H1R(X?JB.7Z]!;>C
MQNPL"-'B[&JN(K0NE'KQ-44+$=:YX6)B29JWK*[0$W%:\D6!T(IXQ"D!2R!.
M='!V144(NY/:8$P"G=;+LSB[X9A9K*H9+NROG4XU49+C*^DKJFC<77S4;SF*
M^)K)95>/+_I6%C`ZO7U^LN)9)<WKMA0R9@VLL-#2Y:CXRJI+F>)C5;47\.FJ
M+];^JEC:LJ$1NA-A)3P9(QO\D#JB=F1:[@6_U2270Y4LDU3&2=-!;6Y*_<1A
M:>RI:6*IERZ`I!(/"-'9SP+'`Y_BB/3N&:T6K=0H$KEL)+F[KI-#GFFDQD9N
MYK$MQW'WG'Q\4:-J("Z@.:"QJUAAG2,1Q#"?.1W<,MX<9R*5[I<@<C6V@)GX
M-QO&X^&S%-FK82SPU/=RU4VAOIM(1+]Y8$V7D.R*!C)55CI$1>_=4Z#+[GVN
MQ%'=C3W'(N7S%-R!4D5%?Q[JSC\_8TLXTLL]?IAXVL(FKJO1M>C425ZIXJU[
M6)W[=!`^K]WJR/;W6#X-P`E>%G.,X-9R1RKK@9-!"33YJP>'99_"A1C_``ZJ
M^KK:1T1GW"(V1QS)(VM5J]!#">ZXFSQ68?1Q[[+"[?3J`5L=1:F6=7D2)R48
M709Z%'#_`/8GHUD3&2>,=?.0U%[HSH,'O.<=CRR=9VUJXS`4N>;+F(2*Y@H^
MBM=']FCHY<L=6316=V6&2W^'R.6`.;O_`)3H+:<8:*GTW(]85C+X2UJK3AP(
M/$MVQ4%4RVVX]N2/I[&"=SVG)?U-D,2UC!Y&^43W-\O%450M<=><GUHXT!SZ
MK3V;Y@:RF=G6$3U+5;\BW&;LZ@TV9+<4R%T3GD*O:)SO!JKV^H?3`\@8D]H4
M%U3W^,L":E@R'0AE5H11T!2DF5P0MBA!M,6\N)$:QLBHK$[^2)T&=UFCAN):
M-B,;I`X2(0F!7\06D,N*YT4B6<SE<X)N?UHI4CD+A5)&M&:WLQ45.P==8XKC
MBUEL=<3E(,V-56T<`-O47,J4UJ0L:U<9$45:,PRK)KG#Q*C(4AD>C49YHQ5[
MAUKP-CGJ"HJ<;M+TTVP6RFBKAR:R.#Y)1""1JRIHK<8V]@K()HTD5/OH2F)W
M<KGL56J'=&<E<@95V?J^0:,ZR,)(N2Z^\SS#:!!H*Z-'B.O@NUP#8/D9,UC_
M`*1PJ]JN2/LO9`[*\Y(R5T+6UMYM[O"6DL$-S9VE!9CVM84-22^"`/M0PIP&
M?EH)_DEC'AAD[L>QR)\?0=MR'Q+P_P`_YJKK=G@LSO(:F2GU.2LKL0&ZA@N:
M(EEK1VT1(LL93)0;(6*1JM<UWR=OJCD^@54V/I#D=*29G\-;[3C;3CBB::6'
M[!;GB:_M(X$:+66P5S,<194T9G\I`W/\V_7L[H*7<C^N/L%QWG-_-:XC?,)Y
M*H<_5<D;;UTM:N*PD,RDSPJ*'(9\0(+0"98L!R33#D&SO#<QS8U1)'(H1]P!
MR-R/@HQ<Q><C;"X^\$G^.TN)BZX_(&T<QP\(N0??R6`5=5W.=+*C/'D#GL8K
M1'3.E<,O@@7(]=A-S([@Z/([(2O&FY#N).4,[JJ!"[6\S0<DML`N<,!0$"NG
M(*8U5(1CHW?]4;6_\!N$Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H'05S]G?6?!>T?'HN,V;#0+;,Z.EWW'&QICBZK1X'D;*ELLLMK**
MTKYAS1B*^QA9\K&/1I$"OB>BL>J=!KMX^YET.6NQ_2CDS'8?`>Q^]W,LW(>C
MR=4!G<]R_P`8E>7Y7FW+"$5_XJSLK(1J#68$TRE#3N>Y$D3LG0:N/WD^EW"8
MGL/Z/5>2XBP.5`]KMG4>L')FS(JIAZXF@JC,Y<T-)9.!GAE)LR:&AF`#>Y%D
MCC>[LY.@WP<W<:^L'J?P+3W[LEG<3PYPWFDS3^-:#/PV$&SR<[%"@Q%9GHE8
M;I-!(00LE?&BOF4ASG*OBZ1>@H[ZHV?&',G[!=OC^7["WKN5?7;'U7(7KQZT
M3T%N+@^(.-MQ"')6;RR//^:ET7-!T)+6R$#?&^L&<L34\NZ]!OGZ#3I[9[8W
M+>S>H)2%MF;3\24Y7'U-<`SV%&;M;8R4-?D%BE[H,.*B22E_')]IV[HG?H*G
MXC8Z^Q>)0:MHMU'R)2V#(+&S-H9!C7`*A$MG3N2=Z"4,QP;H022&(_R:YLB-
M7LJA@)E#8VL5M<,.M!9;ZL)(;.#1#1/RT^>E<%-7G%UDLTM;7&QRM>V,67[>
M9[5F:Q'^3E#."=C#:`/K'SWE)72PT-79C3?A*$:UK70L@'SU7?S,)NR;*R3^
M;)I"7OB5?_Z*?5`RD6CQN#'J?_'^IVEGH[8&N5D=;)6[K8U9)AK0YJDRD.LX
MXW6%V+"CRTB)@4)J?P147SZ#L]%AK.ML8[L?)W`,A5Y,5*%Q5/?ZJZC-@F@$
M:?=<86-[!6P:2K:UQ;BH;R*2+M_J;.B*B!;4'2B@;G#X6W87KK#2AB&7^@(C
MO,;LZ\&05WW)5_2YDIM+=#/@[N0N$]ZPRM[.@DD^O03-;R*'?AU=M<9&6^=8
MCUM$;!"0^OESQT#7=Q,^>9//=V]9!X1*]TL\*HGS-@8JKV"4*^EM:T(=T=J/
MGKH<_P#%,_-`VMMEOM?E;,79%-CGB<7,2`JL':38?9#++_J5._@@2\+-_P!K
M'8*'GJIH!?XXES3:^(=]2CF*SY"(A9VB-EF>DC1?/LBJG=W=>@X*B12%Q-/`
MBKK93C2P9(0WN>;9^'8<Z.VKVQ0.A6'LQWW<*.?_`(5%Z#[1$);O!0\@:LM2
M1"JW\:?'*A2FB2QO(<`?']A+*CXT1[DB7LYKD7_"+T'QK82AY9A9!;,QC+M]
M@1$AA(Y`+8FQM#E$CE)(:<&5*SN^-2&M1J=_C_X4.DLBA,C?U,9;+>K%NKV4
M`,L?Y[(<DVS:Y[9K$MTK8@!VN7LJSL>D?_3&].@[6(8<ZQI#R72CDR2VH*#"
MTK4CAL$(^:0R0F99GA.>,Q&_1RMD[]T^O0=A'2"MN[)KG$RRS)\H;;.%\\4<
MJC3(Z2L*_FL*1O>BN7LCFJGTZ#I8`Y*N44V9#NV?K;:9T;E\I;6:9?YN;!)\
MKE<(]?..55\G]NW9.@Z"Y0&SG=VCL3+YQ@L$()@!`0EFZ<&(H<4HF!?MIPXT
M<KOE5$5)$[=_IT'*:Z<N:NJC+CY72BJ./3&"ES0!V$#9"W'%6T:1(VP'_FR.
M-_9B,\%^J_10Q9[+!"*:M;$X4^OK+!UB0<:PYXT2+-'70/).AD&@:>3*WLYO
M\D;_`-:^"*G05=]B,O5Z>DLPU0@*SKJY0*46O?86`]9+="MB"M[$RILZ0"*5
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M94^5S6O9Y*UP;`.8\@.3EJH/+3B4H`T-A!(7&$RRJT'E!9X(<ZMBEUDDDKXF
M2)*!.R5[V^4RO:JHH:NN8N$SL?&[;&RU=U,+5-=)H:9EQ76%C=:J>,&O=8AG
MJ'56YI"RHD9$0,,8T:>#X9.ZOZ#":O5[7/XVTK`-PFAR>4GN*3%X4_"U>GUI
M8$3V#VQ<>AK_`!S7V$4C)$1LA391X45L+YU1.P=;H23LS7<7YJ=E5ES]CC]S
M7T5QG;"XGR$N5T<;SJ1HA&E<=H>P-BXK[N!T0Z(YBCC2HV1>@L+PAI</Z>>M
MU#QB1<UF^N-&:#H6Z,6&[:&=+=W$(EK:O)BS<A`T.>?,UT(QJ/)1&N1SY&]N
M@I7R[Q-?\H<Y\A[&LK0H<[>7>:+#83*EG%J([.*`===3K9@3%5X_PQHY@[&B
M!#=O*.-._;H,II#=IB=O'6P4MOLAOO#0BD@IQ\HE]GP_FCL*TA\$YM9($),J
M%*4.D4TOFV29BN5J-#D`<:9GD<.T#6CT3'RR3#6&5KXXFU0`XY$YQ)84S9X1
M[1T(CDFF=###++)$UCWKYIT&O+,<=V(]AJ]4/57QQY*VC+8*&Z.;<4%1//+#
M(H%!(0,F0%+8W_82UZD1/55\7_\`3T$N\7;?E+/`Y*"4",W$BSE$C,TN>K!C
MLZ1J#)#*M]3>'D":2LFEBA0![(`VL6.#SD1'/\U"Z^2YCV==8NMH[6W=54J%
M!GOB'ECKVVLS&E2Y.ILW#6,U*X82%TSR7-+17Q1JU[//QZ"VE'R)9<@[>:^:
M98$0T>0'.%KKHYS8;"5ZLC/GDK["E&)M"FURO5R5\KW=D\N[?\=!V/$_).:W
M`.D_#95_VF=M7S,<(-9U]H80.A$4%G9A$I875P*UC453@6#3EJWLCY5:^-@6
M!SLMQ5U,0F*Y"JB9=$56Z:Q!/%`0BN%*1`B'R!'DAL^(PZ.-DKGR_<>+6M^!
MK_+H(^;RN;6W6IL;3,2PRCJ'8F:AK*&0(EX9;0#)++\6??6H4X`,CY()Y1:M
MCD1&-?.Y4;T'7'^R6(R3KALW(5?4WEE]KH(*V,^^8*>TMWS-&@FTP4(.?EA#
M?V<.>L329.ZQN1/X]!(>`V6&W=0'^`"R!M/=V:E!39ZS"JWUZ/C(;8,N((:4
M$:5UCYRJPX4;[8F=TC4F[M5W0===\;YNK>ZGJ];=8$!A@EF-+*]#S*!L<\DB
M4N==D+FI?#/93^+VBEC6?W'^6L[HO098%I.8\RY-!.8N\K39HH`JT987UQ*.
ME0.864^I$L"Q;>)S%E\W0Q0Q1_ZY&.D17=!W(_,H3(]51:D/[*G!NPJBM*S!
M.F%MOCM`T+)^Z71U%#XJ$8LZ?,,1,U\:-5$:JHWH,SS''7"MW&'8!YS':%:4
M]UA6VIK1+FX'LK0$NNGL3YC(E,&MK``N6!RR_P"R2)53_'0=3;\`5PE]AKC"
M[>[XV&S.FJ[*SIJR&HL0-74`*J?U*5;L8N>IKC(U5CW!.BF\%5$5.@L;T#H'
M0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=!#_,O!/&?/&9
MFS/(F>@L$:WRJ;X-SJ[4YLQKDDAL,YH1/CM*@J*9J._U2(Q_;L]KD^G0:O/9
M?C+V"H)<#3;;U^9[WOPW(=%O/6GD$>Z"QVLP?+PC"J\2WYJC(EAHQ,Q64#W,
M2VJA97*YK6O`?(]TW06NXE]3=M:\@KS=[8\C.YEW0%HEUQ7@HJ^&LXTX*BL:
MT-ME5T%5`K6;"_'/9(UEU8L<0R-/]#(4>YO07:9F<Y'?2ZF.@I8]-.$VMGT3
M*L%EY/7M<U[`9K5L"'2B,>U%2-TBL1?\)T'=]!HJ]XUJJ?V+W&GL]525E3D.
M.:*]6:[T46=+IM':(H0]<#:6*PUC:RY$3S?!)(U%D<JI]5[=!K]XZRU/R!K:
M2*CL<!98(AE[:T-`)<MLC]2T.H8PF6C-JC""9ZU;GNCE@18$+5S5[.[IT%FZ
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MVY=I)6BV\2$2RLI@`)8IH3!T'5C1O@21A'QN:YR=^_0=!7<V\5W.P`QU;S1Q
M3M;T^R*H0\KG.0<G#I[C44!39KJK)H%.<XAP`R*A`<37RQ>/\NW03LR*S#:,
M;70'15@\Q\Q0<T$DYXR(U[6B@A3_`!K(*YZ>37,<YZK_`(14Z#YQ"?<C0/?6
M%,G/K3;"9$9,!9L.)5C9)!V2-D$`.D@8B*WY6O;V[>/;H.,6;!$13T=G;T\!
M%Q\$N3K+:W;5Z8DRL8UYT$+6.<^UF$'1TKUC1RI_]3>WUZ#M-29)63TPO>*0
M?0W`]>9*<I<K`6-B5[9!/@%G'CFDD;V_WNCC5?\`ZN_TZ#E.BA(MFM%N$9<"
M.*20<IBMDE`?]59$,[P^09LSD[3-14^G;OT'3C@S&DUP)H,DTP?WX]Q.`:2.
M($XM4G'DC9,UBE_<-B1%5BK\2_3_`)Z#OZYTK#F(L%A.(1"3&LYJM51W#N3M
M&L*IY)'*QO\`%W^%Z#A"DMC!KK&OB*2O\C82$.E2.0;SGD1A*QS-2:9_SKXL
M1/\`I:O_`*=!@)U>I*%')$LIS6?8V$`ATJP0V*D,(BE.K8F/=9J1(V-)'CN<
M](6JBIT''T=79LHB`:N"NG-+.D&T<7VJCP1R&AN:M@&06^-T0P+.[T\^R_Q[
M=N_05?*"O='_`$/(@:*&::YNC`K48F4`]+7/9^3PM6C6]3*3758L$,:.B;))
M\KG?3_/TZ"QN1R3:SD:QW(OV)%#69@JH,M)OLB[=SX)?N((!B@7RJH-<'"K%
MC<OEY.[]N@D//R9KE.LI=PVN,&^.0]*4F29("TCCED%::GV[U\55S%=&U_=6
M+_E.@[[6YNOT%,5670E=>4DU>0)8TM\!%9UY\,L:QOE(C?`0Y\S(U7MXL[JJ
M_P"4Z#6+F?573YSUHVO#]R7<@C<><B[,GA,S(!$5]I/C=22^UK,U#)&XRPEK
MVD&_"^9S72K%'X]FM;W0**<\G>UOJW:YBK(UVZA9L^.X6'Z:KN;.:2OL8YXH
M1,]GXWU\]'D;ZOK`5^;[:8MQ8S7N>K'*Y&A%@7O#[$A1&6ML15["MC!!MOS-
MS69<89F1,'?5UT0L`]L6*R2"P>C[&=_BDC4<Z)5D[-Z#YY#W(T>EN,14<@`&
M&:%S?PX)N)$#B'L\Y6/<7<U0M$UH[C5NI9%:+/(UJRM;Y2*SNB*$PW?-?&^V
MX_N<]D,KJ;FZ037<@T>3@F#N_P`"S.'Q)>I:W\$LD.;O*@2)TT57')\2212L
M7^:]N@O+Q[H^+;W#<=Y>MY!AIOS6/AOM%L8+&N'<L;Q?RD0!E=8QN4F(5PR_
M=O\`]?@UJ^'DO0?O38@>EL,Y9YC6I2;/5`SRYV\(;73"$!BL6`#[2&0CX2Y;
M5K?D!'5K>[%1/IT%4=)S)-CM?^(<X*TN<:LEAJ]GH?CSP-GI?M"$2!&->]:Z
MKJ187MM2RV#B1JL:(YZ=EZ""J7]@7#>_(J&8_7TUO/5:4FDU,.%LJC1/)O38
MB491-,HR9G.HKA(WQLF8BJYZ,7_"=!E>?LL3R%R3;V65&'I"MF%/E@R#DDL&
M6<D"?D1AI8!E2VL+QLS?%R+!V:[ZN^G03%%G<YJ8+B+,`BRO>AK-CFY'"7!5
M9J7PH6N<VVG'EE;C'HD+;"-9VPR^,K86M[?7H*R6%9QS5L"'+V$<>TH-#&36
MX&KY-H::^L+V[&?XFU.6(/\`.VB\A4>Z-J2_&/"^3ZN<C>@LAG]EI(+V*.TM
M+@/27%K#!0/`I[6*[@BDKW"ML<^96`GULD+E?_NKY',?,U%5Z,Z#OL%$WC3=
M6SPY+&D,K\09=UA0X]T`))=C#.;J+N\F@&+-M*,J=[R4B;$WQE<]@J/5']@C
M&#WG%RM;-3<LQ8S#@Z2[^#+<M/T`&4H2L\$,!8Q1#%7#X;26+4SI+-_&%S@)
M8^TW@YW;H)^.YVMRZW;3-SU7+F'9>K(EGIMG64I=I77S6?/:5C;M@0VB2.O1
MTZV(LA#B9$:R&-7JG08GNZJGT.-XV`OZ>H)#_L=-%%I*6&4[/6V:G%B+)S-A
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MSNC>@B#DTC1\=\AZ/E'>\DT'#/J?QW-FZNW:$691B$DO+&KW$;5E@%`2029;
M64`M?(.Z6)WR=W.3LO07-AQ.[C*S5MC>1QC\^;H:JYNXM15I=.FQ*1I,E'DR
M&2-2LE)CD1S"'^2IW1>@GCH'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@
MU!9+]JX^W]A.&/6>BX0O4Y.Y5YFYUQME5E:?/]\9Q#P6.&EIS99LB,62>BT=
MK80A`CQHLZD.[.;].@F?!_L!K=GZ2<H>YO\`XQT(U9QC+RBIF#::`R\LAN,;
M@RL+F'))FC#@<?$&LK&R.;XHO9>@B/V0_9%R?QMG^/-)PAZV3<P!7_K</[3[
M.&SWN=Q;Z'CI9(?O*>J,MS!Z\W60#/?,UDLC!WL;V1_=>@_/)O[+]V;N.!^+
MO5+UP)Y_Y%YO]9R?:$*BL.1<?@P*[')^*%#HH]%>6(](;H9+6S6&1&S?"U(7
MJCE[M[A?"_YEO<3Q;@=-OLG!E>1-U+FL\['/L77-5G]SI6,CBI;*\I8C4GK@
M3G_%*4.R1JHBN;W3H/MJ>4=OQUQC#OM[D:04ZN+C;IZ6FT"DPB`S3-&B(KK4
MT<4)5?*Y'*XET$4;%_FY%[IT'Q?SG*#ILMF[[*%4<^DXYT>_E*D-'LJNJCS_
M`/N>&3>52E4LZ$!JDS713O7P7NB*GUZ#%I?9ZM*S/&T]!75UML.5\[KM)CZJ
M6WCKJ0D#%CD'VLQ%L8V*2*!X8_\`K?\`&K?-Z*[Q8BN0/I3^R[=CQWQ/N,3C
MC+"?E>]_`@UQ5@&4)1$1?<(7-:6]%)9@3"12#.:V6![XWJJ=EZ#FP>RM0VJX
MR,MJ`ZGM.0.0#.-R*&>1I!]-H0'DQ3LE^U22-(E4;Y$^16.2)[55._TZ"*Z?
MWBH]+L=-0TF)NV4F*YZJN`-->VB2"^&FM0GD0'54$<4K;"N6=\3/-KO%J.57
M*G;H)4IN>[W?<@;_`!7&.(_+P<3:R+';^VT=@N?CCMB!6'QNSC'Q2I<B1BJO
MG(BM1']FI_ST%FN[O_R?_P!J=!Y1?_D@\?:LK@OD6VS=C-4)::/APIE?4UI%
M_#L!ZR]%GOAM]D@HY['29:F':I#UC1J0Q]V]^@\RG$G*G.GKT29M\)665)8*
M7R\+@>8^.\)84>'H\UR-NZN#=<@8K!7L,UC4Y*:K1T00WCYQE1/G;_QT%B^0
M.6=YR\=EN..+>4N5_9O,^K?N%F/8?U\YTV^=*K]O?PX;C<?7<L\>&.G##"L!
M2)@IA*DDB-WS$.;&WR<GU#DZ\OW`XOK?:[FO6NMN(M'[T<G>M?/'.6FKXFT%
MSP=PAOR8""^.[[1G@6%?G2FQN:RP*;"L<2?61G95Z"&_9;0<VZ?AB\XFYI]D
M+^UMHY_5+_\`1<XPX3`#U'&?M3QT9N$+M-AOM0!GQK0[<X<=[(O)OVS1X6_P
M3XE1.@W._M=XDWO)?O*"%C^*^*-_593]66=(O2.5,3<ZXVGJ*CE;(_V0WA6S
M%5]?7<P9ZI(E*&FE[OCCB5%8Y7(J!T>4]D_<*IYO]J-IHKSENEX\XTXAOLMK
M_5MVBEJ=ZG#]9D0*WC7GK@L!<\5!5[8(LAI-C;&3E.09C_\`2O;MT%8+_D'V
MEYMS_'.CUU]R7SQK.)LQ[>9KB;VGRE1K*S>YSC<6&F.IQZ6ZH:Z@IM3;1`.G
M")O90VDN>.Y1^RHB]!M'XD]AO='9>TWKGZ:<.\V;#6\#ZWC[UU]RAN?[<O\`
M(W7''KEC,3)E>0.$]K.X6OU=A9;WDD.?QL;UQ!4J0JQ57Q1>@P/]@?%=EQ)[
M9^_7-?JYQG/Q=R`#Z7\)7/$'*6*XKKAK"EY1WO-U!0:C58:P%JEE(TMAG[.6
M2R)B5#G0HJ>2-15Z!H/=GW^X>]B^>_2ZUY+Y2V'))GLCZHF^M3Y,)?W-OHN!
M[V@K+/FK31:2(10B\A4,DE(LV&$.D':QS6)W^G00F'[,\[Z[V=].(]CS=SZ5
MCN"?>GE_+\\>U/&EQM-3ZY\I46SS+]9EP*QEX(VPX]H:JI!_$V]1XK7`$@JL
M?97]^@V!_LDYLR_/64]$/8WU.&Y$THF;Y0]DM/QWL<?DM'!3`S8GA7DH>RO[
MR3R8R&"71@-_'2S1N88]&K&G=43H*D77-O[#>/O67<0F<V>S=]G-EQ5Z7\H\
MD\D&5M[;\S\&Y'D4^N;SL;QHD#FF_F0@YY5^WC1TH$/\T1')T'H\]3^<.`N0
MZTCC_C;<\F\@/X2Q6-BLMSRA!HRK#0U>\IH[RIMIM?H6(7JK:8&=&F2>3GP3
M)X/_`))T%HPB?B'G:T>W`-K#_P`>#&Z:4B"PA5DI=?(^7NOD`5W[/<G;Q1$;
MT'8?FR"5"F/KRF-%C$.G:"DWD/,Y)$E^9JN[$"-[?X3Z_P#KT'(F.2M/^5T=
MP<TF-LX\JHBB1..F5(:U(6(BM>Q&^2*Y/XI_ST'2;N3[VKEK):M;`F<EY%.*
M&;((TB2M@^<E3K*#LZM^-KW(BHODYW9J?YZ"`>1]!+68$V*OD*SZB6;VRV2V
MDEN74%R51)"0UT1_=YA90T<C(48JK'.YKNR_XZ"&>&2,U%P=2"@RW^,M[TFS
MT&181`1</K1G'O2"0RD);(/%+;-:KIX_&-[_`#54Z"PF3W5/@*&IDTS@;:?E
MKD8VE#K,RCR61F&C?%+(E6=-]T\1L8:N-^-$C&^1J*U$7H+&YO-5^4!=54Z.
M'J&322@5J(Q!ZUDSG22CB=FH]L#YGJY&JJHU5^GTZ#LK.UK*4*:QMSPZRO';
MY$&GDPB"0M7_``LI!#XX8T5?IW<Y$[]!K-S7M?QCLMGRB2SD3DN"P,V7];S>
M$K[>NG5P-#6Q@+>48%<,Q]'5%&,?+,I4KGO5'2.<L:)T$]:$G!<CT&=&U+ZC
M85BTSB+#.6=AD=16O0;YP4M8;0B!\D=HDRJ[Y!/A^21BM9(Y[>W0:;^??0Z@
M;?9:RXJV];;`Z2^CSZ4C;.`?4PV,L!!<E=EI;6&S,LV_']9W3R,(^V:]OR(O
M;H*.KPGR!6\B#UX\M-EMAC[.-=#?7L6CM,]KLW7E2@FY^N(JI0[:3.5=<,UH
MZ.FD(%/5SF_Z'-8@;,,_PI8T^J%Y0U-N1F6V/&]D%Q-1D@BZ726.7UD255K+
MOI[6#\11:"O<.DU)-"V*"0=.Q3)7HY7!KJJ8X;&^O='8$0S6%=:Q`":_.W+8
MJ:,2G/2*R%U`VE0J.?33QM1PJ"PM"=.U(HV(QZ]!G^$]@;3(Z:R'A)KS;?-@
M$#4N=*L&V43$M+!]P.9K3SHYFS6UP+,GVXU>L$S5_@UWBG;H.A]CQ[$;@OE7
M7Z(;6QZ[D[*\D[$TV+-5CJXW-6F=LX1*C*U,<<QA>C`<Z.L^*=RQ21M23Q5Z
M(O0:&<!Q[[.X3B[T?R>8T>7Q]KRQ:W]]&3B\(!A;`'-XO.WE[EPN6[4,:,T*
M:?01C"^<RLE*>]\:N\?IT%1*WESW&AXSY%WMO[('T>UB+$+M\A2B:#_S4)R6
MZ[2>ZQ64.@B5V5"M*R/Y)9H5:QD3O%JIT&UOTW3V.VF?Y]]R>&N5^?L'L]7[
MX^L.$VG&EC1RW>)Y%PFIQ57%I='L:"6%Y[&A2B2))<1+&B,<B.7OT%G^>/5?
M6^T7[4?V!YCCF^S5`7QR#P?RSQ@'=XM\7)_+/,/&&6U%KEL7Q+O8&0/I>,G:
M1(VVS%?)]XBLBD<K7]!7'DWE+VNQE#C='P;RI[;V')NHR.,"]U-#J,U81+Z\
M\^ZK;UE':#860^J<V(Q:4B>!M>%YCB"M29JHO=$#H^9.:_9W)`\]XS><U>VN
M>XFX8K_;#COB/ERI%I@>2.>]Y)8R#YOC#EG:/HK&`^AKLZ8QP32$^.9)'(U[
M95Z##^7^"^7MGZY_KA@Q=72!GX[U@Y02>WYCRT',^5!GL^'M"69F]CD+`4RX
MS5U<V$\D-,0?,Z`,[LZ%C/)&J&;9D[VUUW-?KAPWQOR]9>H68RO#?&$7%.;Y
MEK-U)677&%;CKHS;Z\;&UBS4/)6B@T4:2U(MBC3J[QC<))&B=N@KR1[*_L)A
MXUXPXVB]F.4./<L)MN9\!MO=#4\D\SW/'?-G+V4LI!^-R)]_&6[3X/)C52QH
MRB54SC"6.9)`YRJO06PTWN+[^'\VZ[$K[!\Q6K.'_3#88;D,W'+R@(=L=Y3X
MK*7^2]C>-\.>9/1"&'7%S*+7V82P$E/9,Y?)J-1`L'E?9&SS][ROQ=[0<U>X
M=KHX/3#)'^M6<0_D<JH]F++>\6Z@/DNWY;J<Y8`)R?KQ-":(+-'I)2X@8^WQ
M,:J=!-WH</SWQ?77W#?)NJU_+O'UM^K/+\EB8GDJ_L9(>/.:QL]/5V^/PHVM
M)M1>-*Z&K\8W`CJR%9D\$8O05BSO`_-'K5Z'Y[VMH-+<V&\Y:X,QOJY05WKM
MQ]?<);CUVQ3;'8:B/7<JAX#\+J]A>9G1$Q`.G27R(;*Q95?%V1`X>\N?<'VQ
M]0N:<QR[R?SOO-IQ/ZA^M4V>XS(I=I%EM-S#)SR&&?R%I,PT^4'D.ZJ<F#`<
M:%XJ^.*-5?\`R=WZ#T0_JYY$YUV?KGE<=[":'>D\[X7EB?(<JZNT4NK#.T8`
MT9E.S*U93Y1R.,;2BC2,6"-K4'?_`!5>Z=!NUZ!T#H'0.@=`Z!T#H'0.@=`Z
M!T#H'0.@=`Z!T#H/+1^O7;93BC]KO.=-RG:!Z8_VH=S"_P!;]1<5RAKQ;)QQ
MM@(>1.!:4P^69[7Z9A,-[XL>CB5B7LSQ;T$_<=6UE9?I&]L%LM&2^X_I_M9,
MV:51)+(>NAM]`R&!19Y2O$5D*)'Y*B=F.^G9>W01YR1."REX_IIW1L>S])AA
M3XT?#Y,#C^1DTC$D@=/V8D*JG:1K>Z?5%7Z]!#F-W\V0YBXAWF$O'TUW2_H2
MW>CP.RL8ZY2I+[+_`#VM7(I5I'+)"ZB-#CF[0*SR1R))Y,5$Z#=MZHS)[7^B
M'JQR)R_I2+S5WW'F'Y`,V@Y$5;._:1#JOYR-&QP!_,TOR5K59X>7943_``O0
M1#R5MIN2?1WFP;2;\3<S<?[>WR/]I'*JJ>T-DRNIBA#%TRV53^$FMXU:V(B.
M")6D=OXO\U\N@D[9GEQ\^<5RHP.%DWJ3N9SWF"6T%,2^.NBG'"-EB/;3R@,(
M57/&>.\AL:JK'HB]N@B'/`Q:V;TPHZ[34V7L;WA/V'@K*W(S0UE*42;23URE
MU`4PC5<'4DFI,WNYB-<B*Y'?7H.OXB-!M>#_`$+K*Z0_CA8N4[*BEJ\N").)
M:F4@MN+8LL9[)2IQ(K*6)T[YX'H_Y'=VJC>@RO5GAY(#U=!DMK`N:G]J[C,A
MV!UK)HF6Y$ZGJ^2YL'NDCFFE3_VTC7XXU3Q3MVZ"H-!9Y3"7O/\`*[>1DT87
M[1N.);@JY)&&CHCK>IA\J2"8.#Y3$<6^)L<;O-_=_P#GLG07U]KMD+ZB2Y[G
M+'7QL,?)//7'&9WV5*.'=G;O^^6`^781/"^.0H$J)Q;)8Y(4\U>U$7LU>@V-
M_=-__)__`&K_`/R]!4SFWU7=RON@.2*C>6F+U=0&-6@E`@@6$!%4WM]]56`]
MG`5!(`;_`"5[6-:]?+ZN[?3H(9O?UV9K4&'VNAVCK.YFMRCJVU(S%-*755;X
M&PBYX9DC'`MJAWM21$;`V1'M;_)41>X1I?\`ZLJDZ\#M:_ES2*(^6D&O:X^L
MH(FVM?32./"G\Z>IJX1K6MN$9-!*R)'/1B,F61G=JA8+0^FYNUK]!6:_?!'1
M7X`5;9D"9"L^/1"BB?9=]146C[.IL)VC)X(Z..%JI]6M8[ZH$&YC]8@F1?03
MUO+]^18YW1NO:_1F4.9(U#&N<Y&5[K,VG-@=1BALC%@!6!6#CL1L3XU_ET%H
M\OZY["F(T*VW(-7;QVU?*RM(&S,U//6V4Y7R23G0@W$<=N*P55;%$KHFMD1'
MN1W^.@G?,933TB!_?:Y;)C)I?OQ%JA81"!_A2*!L#HU85$0Q6HYTDDDWEV[=
MDZ#M-5E$T$3Y1#)JZT4.2N87]Y=-$0(B1'D1RU]9<544TSNW\)57Y(E_Z5[*
MJ*$)Y7U4XUQ/(_)/,V:`C#YCY=KLK5<@\F&-(O-)>56-_P!.?SL#;XRSJJ/*
MUH2N;&!7C"Q.GD?/(KYG*_H)E?CR"Q3([+26Y1TYGW8)\<=9`M*C5:L(]>']
MC(%+%"K55%*C)?W<O\O\=!]Y,DZ1)T71:!/N#6'*Y"14DB>V7Y7002H(DD(D
MO_2Z)%\%;].W0?.[Q(=_1V.?L3B9`+,246>/[2I1BNG^1D\[X/Q_VQ"D#RK%
M(R5CXI(U5'-7NO0?;.8;,96AK\S25`%?1U@(P`50"$*!4"P#*YR-"IPH1ZL!
MDTDCG/9!%&QRN7NG9>@^.DPE)I2Z.Q(2<,_/$R$5\X4GPQR1S#N$F!L1411;
M*NE@>J?#,Q[&K]41%^O0?P;$@C1,ACG=$UT20E?:"@@I,UC8FP_"P0:%@?@D
M2=TC1$=W7Z=!W3Z6.0]I<A$SX(Q1QXA>_BC)('2]IUE8J2/<YDO96JOC]._;
MH.6M8*K/#M+X_;O&3M/*BI$]WD[LJ.[H]7?_`%?YZ#\%5(A44C%6:&21D4?W
M(\\D1+4@7O$K945?JU?_`%1>_P#ST'0SY)C(8!:@\BJ%^6PE/2-\\Y)<E@L;
MY9XYY"$0<ELL?FUWBYK7?X:B?10C/><,VNTJ@J/^VCPU0MR,<X>SH66[Y0X"
MAB'*TB0^"<6\1L+FQ'0.B="K_)K?)$Z#N1N)7U09HE#J+"J261Z@M000R*"-
M8_&)3U,;,3:F#O[.9/++\C53_/\`Z!7>[];N>DW\'(>9Y<X@?:#"57VHVUX*
M)TJU-S#&,+?WV9LF<B!$YNST@D;VD2CL5[U5B/<]K.RA>89)VCP-*?'*4V&)
M"9(6.CADG1C4F?%&YSW1QOD[JUJJJHGT[KT$0\]\/A\[\8:'C"QNIZ`#1L@B
M*M!:\"T*&;!*D['P`6\15.4Y)6-58RQR1WIW1\;DZ#67E/U><B8:OT%=F^9^
M)W+;`3,CM[/A?=1WA=F<,/6V,NE)SG/6=!N*E]7$YD(L0XCHG/5KI7CJL"A*
MN?\`U^[[/;G$ZV#G>@,`S>)#QMOG)^%\F)6V]=5'1F4E,)%5F!#!9&GFDF)'
M`GB+?!8?&1',QR2)*&Q.AP60SHZQUN:SXI$R2O/,$HZL*>P**8C3BRW""0_+
M.:J=Y57ZO_Y[]!S3<AE+&0.4_-41LE>6ZP!>35`S.$.>U&/+&=)`Y82'L:B*
M]O951$Z#B:W!Y#=54]'K<_6WE24H7W8)H[7P%QUQ+3`QR4;XNF%A)8CTC5?!
M53ZIT&LGD']7M#N-7J-(FOK`8K+>#;.@#BSD<4M2,)$C(,](6,3$_P#%0RHV
M5L<*1-5S$1R*U510Z30?J(X^/N:ZXSW*^PRT4.D32W5$)64)U7?SM59(P"9S
MPI[,0`:9RK`V&5KAT_C&K4Z#/M3^N,K1Y.\S$'-EC2R3_:-RUJ#B,T\G,1P,
MC81"]A$<B7<);UEF1I#NT,SD5GT3MT$(B_IQJAZ"OJ2/8+4VELAHQ>@U9^/S
M?YS110E*3.`8X9(!H@"D:R-8HF1HUB=T7R_R'3M_3/-%8M>+[-7M?2DV-M<W
M@`/%^'BM+NVL$<@TQ.B>R6TA$"547X(W-CD5/K]%Z"SGK9Z!Z/UTS&FK*_G&
M;0Z3;WK#M;IIL%5UC+"A%`="!G@Z46S?7`1CGJDSIT1\KF=XT\4[*@3=1>K<
MC=K5\H['3T5[RA04D^5SVTI<7!FS*?,6<B.O`!Q([8\60P]L,7QE2-=+`K%[
M=T<J=!()_"]M,44\/D.[^TL(1HC$N`:^Y.205JI&8+-*R`".P1/XI-(+)(C.
MZ=^_9>@C76^J#3(5@P^EHL^!:4<-'L,WH<9#H\CL&--4\@VUHP+?.^!I)7C+
M(Z.5J2S-1\J2?XZ"I9'ZLBW7U_>"<ZG5\.EL'V=OG:W-6U)F#"I&IW0JHSVW
MIX3!$DBA>@\ZR#^<+7^'R)Y]!G,_ZWRD*5*CV'Y&SU6XF&V<+5N*>?\`G((D
MA;/^7L;DXQU%+$KF.J'*ZL8UWE%#%(B2=!U,WZU]%+G;S*R>RNP.I-,$:EV'
M8YNN<.^TFE8T0JN!KSZZKK@XA(F)/"V!9"YT=-)*KGN[A+X/HR-4YDJEJN6]
M@-9V@HH]M?/%K99C'UM<-74TB5RQ)6)!3,@5XHKXI!(7N[MB3H,&J?UU)#+=
M-T'.&PT(MXM=,;*729M]HLX_R,M!P#2J\MF;J[J)6?+!4Q@>#VJYBM5R]!GL
M7H?D9PGB7NPM+A"JH.LLDCH\U2M/^UE54E*?1U=>06Q(.S60S/DA:YJ.\57H
M,C']0YZRKJZBFY@WXT(?W(5@6<9%:V%U0^#&5M460:R5(7`L=,SYXD9*Z-Z-
M5>S&]@XW'OIX_`/>H7*&B6)]A93^`05?6RM`-2-XPB&C0H8LX!(\;TG5ZR3-
M\V2*YCE3H,R3UH6#8T&T!WU\$=66@QUK7@PBU]5?Q"*GVT5@(''&V2:!$^DB
M_P`E[KWZ"U'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=!4T?T:]5!S<U
M:+PYG"+C'<V6GL5E+HJ6SGN<_P`PW81%;:Z^JLW'?>"26`!3XIA&O^QD;V\H
M55K50,0SGZX/3/(+R''F>'(Z:OY5PNKXXWE"'M^16YB\R>X-?8ZL1<N_6OS]
M?879LCGRGBC0G]U[-F:GTZ"5[CU.]?;^KAIK;CL,JO@X<=Z_Q0?F-'#X\0N3
MLN-5\%Q$YXOU7_N'*IB=U_V_7H(TY'_7=Z;\L8+.<:[CA6K/RF1XT)X=SD-9
MH]GFK>JXQ-'C%-Q<.ES6CJ-%)1G01-2>&0IZ3=N[_)>@G6OX%XHJ^(<[P.!E
M6"\59.CHLYG\J/;7D#*ZFS7V_P"%#CM(;*.Z>T+[2/\`D\ASW^/\U=W7N';3
M\/\`'!7'IW%168$+P-D+.&;GC2#C1YQR)/FE:X@LJ<U'?*B.:Y)4<U4[HJ=!
M]-!Q)QWJ*^OKKO,`ELJ:B*AK#FK,/<U]/%$V%*X2\&EAMQQ9(VHDC&S(DG;^
M7?H.AO\`CSATA^+R5W#2A65=77%7A:Z2]6LT+JZ<!1;L>B5#H+<V/[&3_N/B
M5ZM14<[M]%Z#I:['>N:T6#S-,SCEE/C]&=5\>AU-Q3L_%:ZOBFAMJZAD$-^5
MVC'B?(A4+%<2WN[Y&I]>@^4.5]<B\;0-%+X^FQ'$VJ_(U9HNDJ9*/):T(N:&
M3[VSCL'"AVT)QKF21D2)(DK^SD\E[=`BX9]<C;FVIA<O@)[XG8U7-M[2C25D
MUE/K$BE$I][:5;9I"7/E8U[8"I(_C>YJ^*JJ=!R+;'^N^SMLYMKUO'NJ**TT
M1>2L;2ZJKFK,V-?%(*/-1#D'$59N@KXV.;&D+'S0N:JM1KD[H$]=D_\`1/\`
M^"=!_>@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0
M.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z!T#H'0.@=`Z
M!T#H'0.@=`Z!T#H'0.@=`Z#4/^U/&Z3E`+B7BRF;QOF*#:0\CA[WEO7<K5'&
M6FXZH&9$IE$3EY23JZZ.KB=[-4RVKP9HY(PQW-\N\B-<%%,9ZZZ734W'5BSD
MCU<P&N9[=4%AQW2XKV&J[O\`%W.?P+L]NK:B*\_&^Y9T\+'6!E!"R>1(W*Z1
MR+W=T$"<?^J&_P`QZ/\`,F7J.6_5W85`_*F3DVA=-[79^+BW4664XRNL1=G;
MW:HT@+(Z7;[$^#0E@S/26,D?MW5R(O0;)_43AK?<3<L<#V;MOP[RSRKG_2KB
M7CGF**GY=J[7;7&?35V)M7M8ZELI!]OC:@,B6&KM)(8X;%8WM;(J]!K9YD]'
M>0=AAOUYF<8^WGK%A\-Q=[U";/+XYG-5`E%MKV+?%VNA&XSVHV@6#<<@%4Z%
>"R9F))WL1TC?%'-7L'K6\)O_`.ZG_P":O_X^@__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g335938exhibitk.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g335938exhibitk.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"<0'!`P$1``(1`0,1`?_$`(X``0`"`@(#`0$`````
M```````'"`8)!`4"`PH!"P$!`````````````````````!```00"`@(!`P,"
M!`,%`P03`P$"!`4&!P`($1(3(10),2(50191,B,787$D@4(S)1B14@JAL<'1
M8G)#-!GPX;)C)H*24W.3L]-T)Q$!`````````````````````/_:``P#`0`"
M$0,1`#\`^V3M#EV6X?BFM#X;:RJ>PR#L7UZPZTE1!"*\V+93MC&*C*Z]_P`H
M3M$&RH)$@#W^$<UI/VN:[PO`S[-LWRG$<FJA1\.EY!ATK&,CF3)],B2KQF6P
M)-3_``-".$21&C@A6\`TQRR7JY&E"QGT1RNX'5X#FVQ+C,)^.9?BE3"JFX1C
M^70,EHYA"Q!V=S8VD&=A$^,:3+(Z[H`UXSGD,<P!62F(-%]7J@35P('W?G-Q
MA=KH:)4V;:T6=;XQS!KECAQ'K94UAAN>W)JQBRP&4;CS*(#_`&%Z&\#5$<B*
MOD.]V7OS2&F)5)#V]MW6^KY.3*=N.!V!FF/8B^_=$+&#+93-OK""MDZ&6:!I
M?A]_C4XT=X]V^0E*5,B08DB=.E1X<&*`DF5,EF'&BQHPF*0IY$@SF""$8T5S
MG.5&M1/*KP(9ZYYE<9_J'',LOK`%G8V=IFXOOHPXXHYX%7GN3T]/\38O^@Y@
MJB`!GNWS\GK[*JJJKP.=LK*[R@S/1=+4RA@AYKLBUHLA$\##.ET\'66>Y*P`
M7O\`W1B-MZ.*]7M_<K6*W]'+P)AX#@.`X#@.`X#@.`X#@.`X#@1;L;.K7#KO
M4E96P:Z8'8.RQ85;/G$DL-`K7X7F>3OG5J1_V%FMDXR(?J7_`$_C*]?\R)P.
M_P!CV>84NO<ZN=>44#*<^J<.R:RPC&;282OK,BRZ#2S96-T5A8"1Q8,*WN!!
MCE,U%43"*Y$^G`H=K[\C.NL@P#1.59R6JP*ZW3KHF=MHY<+-9\?%HU!7@9G%
MKE]U7XO,H\$PV@R1LF"RVNI<.$4@%&TKS(]C0F?6W:VKVAB-YG554QL2Q:#%
MG6V/6FSC6^NBY?B<&,>5_?\`4TV44T"]CX3+C1B2`2Y,<*DB-:;U1A&+P,GT
M[V+C;*LJ##;?#K^BSN7B%AE-\^N$&[U[#CUUC75D6739L"0P-S49C]\LRC*T
M#7R802J9@#"<+@2`NQIG^^+-2)3"^P75!-C.R'[QWSI,;EXL9;3?Q_V_I\2A
M<I_F^7SY3U]/Z\"5N`X#@5VV)NZ;A.Q(.$`H06(IH=3.^^?.6.\1-G;3+KAR
M?`D8OLE2$+IC?W)\RI\?[4_=P*W1^^1).*`RF-K])H'6T:LEBC7K6I#9)U#L
M'::2BD)6>4:A<$6N:BM1'DD_*B^&>K@[_-N[H\-%FJOP9\Z5B$1LAL5+H`'6
M?MFFDL*<YBK#?\#13=S"(OGSY^Q<W]2HK`]F+]V'W^0X+C\G7[X,S+X]'+D`
M2]&8U1%O<IWKBX#D1L!&G8!^CRG5?V(]+%K$\*%5>'-#W0&7'J'($P.0YER^
M/_T;;F,A&#+KW5&?$\&<#T5XV[5#"3PU44L-S_HTC6M!DW=RFQJ?D$0^&RC-
MH-@8_K\B?S$1AS3,CVULC4T*Q0*"(HH@K#7)93T<J.44IK/HX;O((W=VGFUY
M[6)@=@:$+`8&>#<V\@O61%GZ]U5GXX0B,C*+Y/AVF"*A/*L5\5[_`/*]J(&4
MIV[IF8OLW*SX1=-K]8:5S_<]BP=G7/-;0<`RW96*2Z&O148P,ZQ?K8T@12N0
M362AM=]6O7@6BQ2^'E6+8UE`8I80<DH*>^%#.YCSQ!W%=&L&13/'_IO*!LA&
M.5OT54^GTX'?\!P'`<!P-4'Y5MZ"U1HC/<IK,KN:R#HS![K<6Y8>)+<U.0,U
M\V%*JZBA!L2IS?#/]O;?-[CVCQ7!2?;30!,.$..]4E,"Y^L]_8MDFN<@N75&
M24]QK7#*_(<FQ"W=#G9"M(7&2W]'=5%C%MK6LR6ERFLA$?7SQS2I(<QS3.&9
MI&-"<,3R.)F&*XUEM>"7&@93C]-D<&-/&P4Z/$NZZ-9Q@3!#(88I8@RFM(UK
MW-:]%1%5/KP,@X#@8#M#9&.:BP/(-BY;]_\`V]C081K'^+BI-GJV?9PJF.D>
M*I0(5RRYX_/E[41OE?Z<#"A]A=?$NIM"O\\.?7YAL#")"%J'-"MQK7$8N:Y(
M01$.ORU_\),&L<J)_K%56>$5%7@2EB.456;XIC&9T)"EH\NQZFR>F*8?Q&)5
M7U=&M:\AA(Y_Q%?$E,5S?*^J_3SP.-G694FNL*R[/\E)*%CN$XU>99>DA1#3
MY@ZC'JR3;63XD("./+DMAQ'JP3$5SW>&I]5X'099M?#\+U79[DOI4N-@]3B8
MLTFS&0C%FBHC0@SV&_CV_P#4..D<[54:?O1?*?KP,[^Z+_\`P6__`+[O_P#'
MP*Z]HHS)..:E0KF,''[*]>I;G/>C&I]KL^A,SZK^KE(U$1/ZKP.7N6AC2<IQ
MK($R$]-/AXYD%*&.:7AY:B4"SLZ&8^3*HLK&]DR=$)5HP$@:L^!IR-5?]1/`
M>G2=6V/D>23_`+T4PI:BLAE>.)K<;G*&;..TI)6$1(UBYI/N%<@Y:_;H]SG!
M3V4CE"4\YV;B6NIN!5^43)$67LO.(.NL/%'A29G\AE=C475[%@F?'&]D$#JO
M'I9'',K!-^+U5WLYJ*$"]IX39V5=/VN89WVO;/%I[?B:KF-=%U3N#PXZ^%1H
MD^3]5\?N\<#1U_\`$5$NV7W3LK<DIL>QRNN<IN:UI-::QV/=W&Y(.?Z7B:=H
MIY\ZKI=C@>M;BYM)0;VX"1E?[K$CR6D,:*Q0VY?EDFTU9^,?O9/R`$N340^K
M.X#2X]?-'!F%],-LOMV1)AHLH0SK*]/3V$YKE\(J)Y\H&DW6(ICZ_6.8V.Q<
MLQK-)73^%38KKW'LU)CT5^71]:]N)E?F-1A(U`',+Z,45BZ/7QI,=4!7LE2G
MO6,%&AN]O[3)!)^-$5O*//O;?,:YF4SS#5IIDUG5+:$VUER6L:UHBRK02.<G
MA&HYWCQ^G`V!<!P'`<!P'`<!P'`<!P'`<!P*<=PKZ5CD#3MG72S0KF/L#.9=
M">*R&6:R\K>N.\[6K?`!8,)7R)P9,%""'(:H'N9X)^SSP**_AE[V;U[>]#,W
M[-=DX?\`+9MB^Q-HU,JIPW$5JBFJM;4M0R73T%#!`\5I:EL8DM&MC2I[)$TK
MAL,S_P"]P!6+-Z31%?T7ZN["N]PZ`UW`R;"[2%)IMN2=K9%;9GANV,LL=B.U
M]AN/:OS/';&TS6)DF0N"6$2AOAC5'`^%B,<]P6SZ3T6/Y)J;)\5R+#+!D//S
M9-D%MAO:/'XQ,X_L?+WRJ2_P6JQP>5YF$F*6]90MEP!S[@<QT2S3[VMBN3XU
M"$M1=H<BSC26G=U4_7K;FN\YTS26ETS9:4\2FZ]Y[CP3I4Y1H^)8NL*_*G4F
M8P/@9C<./228X,HB0480KF$(8-MM;.;8]K(\I8LF&61UEKYCHLL/Q28:3=D&
M>Z),:J^12@O$K7,^OAS7?X<"S?`<!P-778W(/XGN#CP))V"KS8YTT"UAB-")
M\ZQ[:Y9#81'D>UCU"QK??QY5$5//ZHBAK;TTZ6_3.<GLSN(=DK"B1WG+Y1OI
MU%[!RY)(Z/5OAKDGL8]41/JB(OUX%ALOIY.2[`WB(H1C%56&5XZ'Y"*<$P`=
MT]#[X!5"K$"PC7M*QGU<YKF^?/A4\!FF"BB3+_4V2PHA&%F4&*12N02^RQ*3
M*^^MF#QX8CD8XK2D1/T\*BI_CP*O8;9V[='8GDQONA"Q:TQNM<(:22O.Z\ZN
M](I/L@W(]YVAF2_HI'.<COT7QYX$GYWA\^3?[8*UA9:_[S4\\(FM-'8,M5W(
M[;3HDIPU7Y7.$XJ-=Y1S7)]43QP,92XDXKKC-(AX+V3,2ZQ8H6.%6M5MA\77
M_I",[1J1A!>!&E_$OLSQ_P`%3@9S=;2JJ73VUX!:BWM3[;T1L;150*N$$GV%
M[E^Z^Y%4MS9I(1J-I()L>,IU8PA/"M1&N3RJ!NZUN#[;7>!1O"-^WPO%@>J?
MHGQ4<$?A/^">O`S3@.`X#@.!HL_*9U+O=PZX[C4AL*WKLR'O+353*UUC.KLS
MSE^%V&RL`K*VOK<,V#K7&9PHLL\N971+6OL#A+#D_&:.=1O"%#A,6B]$CUOB
M6],QQ.+M^EU!C/58&D]65&Y\MRR\R$];AE)DEG.D8_C68H.]PC`Z)A8M94QY
MK&3)C8Y9"L8%P'$#97IX?PZDU:+QX^+7.$#\?X>F,UC?'_R<"1N`X%2.]<)U
MEU6VG!8XC72?[('["5$>B?[C8@KO"JK?"*U%1?KY\>?'UX%6K*5'K=N"C*B>
MM_O;NC[-5GM[$AZ!JR%<BIX:Q$97.155'>?/C^OG@7\Z]QF0]!Z0B#;ZCC:B
MUL`;?")ZL%AM,-C?">$3U:U$X'%[(Q`3NO.](DE7("1I_9(BJWU]O0F'7+5\
M>S7-\^%_JB\"%>RM/_)=$-@4:,5R2='5T%1HKFJK?XBJ&K/VM<[PJ-\+]/TX
M%U.!4;N+/)!Q32K1*Y'V/:[K/6?L5B.])>U:%"_^(,K51!,7RGCSX_147PJ!
MV6\7!B9C43PZRN\JL$U_E$&1D\&WR>MC"HCV=1)LL,A#QJBR0LF^O70F''\P
M0,](_K\R>RMX&.=>25DC9N:2`ZVS;&I[M9:X`'+[NQRZ?CD['8]EEO\`#X%$
M7**&@0>4824IR3V@9(:T4\'^LY%1$"#=Z=FL<S7=/7#5V',S"#/QKN(3$=E3
M;6A%18LP6'X5D@#TK<DO8Q(EC,O;_**8]7&KWLGV`!F>-R!"=K@M=OIC"Y7U
MF$YK7._]0$$S%5/*L=&UAL\WLW_!?#?'_+@:COS2Z'UWLW8G4_8^W]\]<]+:
M]U=_>U>ROWM@<_;]QL?.\PSS2LO"L6UMJ*IR'&[?*+\DS%"(V;%?+-5R"QWM
MC/5_N,+S_EQ+`'^+_O86V2V6M_\`2_M;^091E!'N'Q7XK-:<5>6?YC"DD8Y6
MHI45J(J^R+^G`TW6&+[#'KS7]GCV(8EC&.Y=I5^&UF_MBTM,^JQ&RA=?>Y$^
M1E53<S4MOX#$L*M[ZK;8R:N`88`6,]9:/$4G`W;.QC[8?XY8LBWCY*?%[,2K
MD<:229%NI(NL&>5I;J%+5S4/%M7&<8;E:J.81/5&IX\!?/@.`X#@.`X#@.`X
M#@.`X#@.!0[O2@QP]"6$B?,K(5/LS95M-G5I7QK6)&B=4NQ7R2ZJ4R/+6)8P
MVD^4)/B*K"-148]4]5"AOX#+[#L1_'!+FEQB?JS']<;%VA%RN!E62XOFMS7C
MH(=5D-ED64YWAV+8I4YC;3ZBQ9+ESEC'F*JJ(YBF&Y&A3FLWHR[ZV:!UYJSM
MKUFP>GQ_6>7Q+ZGS#LUH[7F0.G9ELBPO`5=A59CJ;<MP)U/JZ>.+6OCS:6;2
MV,EIW,(4/H()`U]D76/"=)V4C#^S76+4.[-4;&RG.-15C^U>MMJX);UF=5U#
M#NHN09M9PX%ML*PO<-@2H,NPM*D-G%626")ZQFL?P-JNDL-O.P-CK38658W)
MP/1>K1X[DVH]8N%:0HV3[!CT214V)%BW%;37\+5&/)*?_:-?81XLN2573Y,8
M+&PAM"6@'D.[Y64;RJ1`]1:0ZM\?19$G<N0#1WGS]5:.*O\`3^O`MUP'`<#6
M#VLU;@6Q.QV*GS'$\<R4E;$ZH0X[[ZHB6CX\.?V:R`LR)#62-ZQ1V(8;FF5J
M_O:U$5/IP-7\S0>EZC3]PZMUCA?\MDO\K&JRNJ!M6/)K.EFZ,EA+ZB47RM9*
MKQ&5K?U<U%_1%X$V9[IC2V,2]M3DU'@4A\;((XVQ1TD8;'2+;=W3N@9X)(;)
M<)Z/L92.<W]4,1/T<O`P'6&F--Q*WK%&?J_#Y-AE+L2K)QOLD&\+;6-^0:W)
M.D?"1KRA&F.0D^GZJ$:(OT\<#&`=;-7@U)CX$P>N?8R\OIW./%)91W?!$U1T
MTC&1JCFHQ\;[VTE/5RM\^3.1/'A/`3G>:-TC_/YW)G8%1($.TJE(QB2KAIF$
M/V1[B(UC9*6J'<4\2D`+RKE<Y!M_KP(HV+UCU)+J<J#785'BG!H1PU:"WR<0
M_E%K;HY+*<@P6_\`J&82R.C?**U/G7RGT:K0[K4?7;5U?CG80MOBCE'CG3_8
M&4P3-RK,VP8UX7LKW#:.Q'_^L;0F=#JXD9JHY'#3U]E3V>]7!]#V'(U,1Q9&
MN1S4QRD1KD7RCFI61?#D7^J*G`R/@.`X#@.!CN7C*7$\H%'*(!RX[=C"<Y7@
M`$KZV2T93''*@O"(;U17/:<*M1/*/9_F0*/:]O(%E^/'+KRCJ"T8TTAN%74R
MYD;/C5US5TF6P[B'_>!9=@ZX>&[B'1'MD2!B^@F%(QC7N"Q&%;"Q37W6K`-C
M[&R"LP[%*#4.!W>39!?S&0ZZFBOQ>F^8TZ49?">#G:Q$^KR$<C6HKG(BA,])
M<UN1TU3D%-*9-I[RNA6]5-%Y^*;6V,<<N#,%Y\*H944S",\^%]7)P.TX%<.V
MJHF@,W:Y6M0LW!@*KE1$_P"HV'B@/JKE1$\_)P*3V]1E%9G-S-RNIL:9_P#O
M[W8O,5981DCI9XE+Z^.#6W<)SD]C5TPJ$^(C5]7?5%^J<#8SI,?Q:9U&+]/C
MUC@0_'^'IBM2W_Z.!B?:BR%3=9.P]N;Z!JM(;4LC?YO_``H.#WDHB?M1SOJP
M2_HBK_@G`PK>1E/U!R$GKZ+,UIC(_C3Z>JSFT8?C3RB+X_U_'Z<"U_`IYW'$
M^15]<@,151_</KF5_A$7PR%F*V"J[RYOAJ+$3Z_7Z_TX&0[=D1+K9E'AC!6H
M+4&O[?*Q6H*"PR"L'$'D573.@$BU5W63OOSED_(Q4&]GQB=Y>URM1P=UJ+""
M8[FN9WA,BRZ:ZXH,5KG8]94=Y2XG5OIY-ZO\Q1BN9$Y7W%V*:P4[XS*WTA`7
MT:JJYX:NLBPV_D]P]3S`8W?7^/?^M'/,_M,?EX@S$J_'R-QB5CL/;K\U%&)&
MS6/1GJWP8M6X[33A6[)WP-_COF<&R;L3:.K]@]0X[4:Y;?L<2N7V]OHQ-(;E
MGO<WU_[R?9)^OTX&B'\^N*Y;M?L9T+U5BEEJ'$9,<^2[1?GF;Z\S7)=CUB8A
MMS1,):?4.=Z[PK.LGUG>SQVJE+,)'C5I?A&DDWAC6*'TXW-)3Y%5S*3(*NON
MZ:Q"L:QJ;:&"PK;",Y45\:=!E#+%F1B>/W#(US')]%14X&H3;&N\PRCJ%JG/
M\7H<5R/']/8)V9S2YQZ0&R=F.1662X'LG"<6Q7`9%1"E_P`,MG-RDK;&0-/N
M4B#2.!CU,]&A<>VM5)D/1!D^O=53+FQNC?QGAR?QLT77+-IYJ]R&:`J?9M0@
M_JQ'?L^K4^O@+D<!P'`<!P'`<!P'`<!P'`<!P*1]YK=M#@&,7:P+2T=1&W)?
MMKJ+PV^FMI^KN^)18M&_^0J7#MCB16QW)+BJA%3_`%A_YT#5I_\`#*P,6M/Q
M95L>ML`Y1C=UNO=;I%3:)&FMK!3[T"R,8MZZ3%=+%)B1GL'*%./8/,3V*V06
M.47@-V=AU>ZSV[WDM>NVB[,A/H1]AJ3`)KR?HO[W2<?(KO\`*GZ_X<"@WY!>
ML>AM>]5\[R#3.F=/Z8V6VVP6!B.U->Z#UL2_P"RM\_QN&?)'OA8-:S:^D!$D
MF98S(T8LF-%*\@O4B-<@;9HK7LC1V%?\I&@$TA/*K\CVC:CW^7?N7W<GGZ_7
M@5OC5S%[BW-NC&(1O6C&:YY/9WR.8[:6621,5GCU1C7,>J+Y\^57@67X#@.!
MKTW=9P"]HJBB0JK9LA]/K)\?T=ZM@/W]MQS#*7_)Y=)JU3U_7]OG@:SM9W"9
MMI.7;S`O!)HHH+`'[TDL,>\_'1MHKO12-1\90Q[)JKZ^/=SOK].!-&Q9CLBS
MS<F+1(ZNAQ\P3[^>-S'OC7&,=N>H3&5S0^S?84F&]'D<OA6-8GA%\\#J\/JE
M@93IF20Z2*ZGU?K^WK51C/*6=?3=]SS9#R/<24Y/LK#T]'KZH[ZHJKYX$=XE
ML(%IK35TQ0';'E9*D"Y*5X5^TE2-=]%+4`W*C?W/>&Q8/Z>J>?/U\?3@=EGE
MW>2_]VFFC&KHE1MBDGQ9A4,%9;*7?G>R9(BM:@!J,C(HA$55_:YI$7S_`%4,
MNJ+L*Z^RF9:2C*2NT+4I;S))"2".+/U?^/4)"D(JO,5[_O?JJ^7.55X$@F$R
M9H_MK:4KAI(/TGVC"C$%[`>.4_<G:XK4]U]1C04AZ^JM1/"HJ_7Z>`W"82)X
M,,Q$!'*X@<8H!$<JJJN>.JB,>Y57ZJJN3]>!D_`<!P'`<#%<Z?%'A.8OG1S2
MX3,6R!TR+&&$LB3%;4RUD1P"DM?'*8PD5K6D16.<J(Y%3SP*#];*'":W\9L?
M&<(DDGZ^AZ/VY2XW++4OH9$K'`LS:%'))J7AA&@S%`U6E1P(KGD1SU`!7?$P
M/+N2./!_&;G0#SBTT.-HG#(\BWC.BK*H@,A8V'^8BQIHR1;`]2Y$,D9RL61\
M?HQ['JUZ!=32K?73>I6I9ONT;K/`VI<D$(!+?QBU4G\F\(%4(7S_`/Q5:Q?5
MJO\`"?3@29P*B]ZYDV#U>S^37/&.<V]U0.,\K&%&TDC<6`1_W#(BL?Y0J^$5
M/"KP*5;5NP6O>C=>*_+;+-I])EDA9.R$A:5H[O0>U&M'28ZXI!4LE7@>^9-8
MQBS$4;'(OVR+P-G6B7&?H_3;Y*-20_56O''1GGT0SL1IU*C?/U]?=5\?\.!A
MO;NI+?=4^RU*$OP%M=";=KV&\-=\;I>`WX?;P]XV+X]_T5R)_P`>!&W;2;/Q
M[I/GDRN:C;&KP#$/M&K]6ME!ML9$+RB*WRC7_P!/Z\"Y_P!?\4_]B_\`U\"L
M?9T0BQ=$?,[U1G9S2Y6)Z,=[E'=3'#:JN:JM_=]?*>%3Q^OZ\#F9R>JF[C-0
M4NYI6);%?HO(;)V"#K7WB1L*7*H,*1L^NJ_8(6W=1=D'""1RF1_R>BA<B<#'
M="YIJV[V-L#%\!W%DN:6^.8'JV=D6N<F!E8)N'Q[@N8@JLW5N60XL]"[(=4R
M$(U/(T=5>6HWV7R$":8V;AFRNU&?:<RS2V.0\GUEGFY-E:^SVN44Z)%!@USA
M&$/M);)ICS:W8]^7;]@8Q8[6`;7&<S_,9R(%C>P-0MEL;J),1"N_A>PT^?ZL
M1%9_J:&W7"5QO/U1K&R55/'_`'O'`U#_`);.H.^>UO<KIQ`U55;A9AF+8#E.
M0[&R75N3X_@$84?%-^=?\MK<>R3,LMBEIY$">E6:4^FB&CVEB"&1!J\32,X'
MT,^?KX_Q_P#HX&KQTB-BWXJMA2\BR+):*+4Z-W2>SR7&@P39761QV6:/?.IH
MUG+JZ^3:1QN3X1',$9'(C7.3SP)*O1&/GOXV?0!5!%GYO)*Y_P`KWQVLZK9W
M$B_<ND-8=LAR2T1WNGM[^47@7YX#@.`X#@.`X#@.`X#@.`X#@:[OR&#2PQO5
M./2;P.+5&1V>_*N_RF1)E0P8U2EZ@]A/N[TTR"(\Z*"K56F(0`R&:-CE8USO
M"<"F7_PYU#3XA^-+$L7JMDX;M(./;6V51GRS"**\QRC)(@3*R+%K/L\GQ;#[
MZ3/AU8XWRR941YI*O1[C%5?*!O=145$5%147ZHJ?5%_Y+P-?/Y4+9V/=#M\9
M,+':C*I..1<$N(M)>6#JFNE%B[/PI'.?9C@V!J^0`#WO"80VE85K?0@G>"-"
M^U?-AR&EBQI(3&K?@BS@C.AR0Y"QA&;'DO15<V1\!&N5'>'>KD54^J<"LL&[
M<_N_D^.?&3U!U4P2[4WNWXO:7MS8T%H_C]?;Y/$)5\^WCQ]/'`M7P'`<#6/O
MVJG.[:1+N`BMD(#I!6*\K7M$Z''[`[IE3!1WM=X*913U\M7PC?9%55^B<"@.
M(4A<-ZXYB,(/ADBP\IP(A$:0IJG\;V0Q@^7D>@T(CI7HU?/C]J*J_KP+#Y*M
M509_N6W)Z"8;/:V5)D%\-<XUWVBZK0G#(\;%^CY41&^?"JO]55?KP(>U9:O3
M#NN#+`DDT_(M2UM1#>Y%(=]E;8'WLM8;7(]4_P`HF>/JO_=3@1=!Q(L/1>'T
MXAD69*V;CAG*=_Q(HH^']`X,U6H]1C]4!#7T3]RJJ>K555X%B\HKHEO#W$P[
M6(LW/$:TZL1[A.-LGN?(0R?5%51@1_A%^GA5X$>;"K)]=%SZDJ&HZ-;:-QFO
MG,&Q1$215XO^.V*R0QS'M:GF*)ZN\HKE1B?7Z>.!GVF,GBBUCV0J[J='B0Y?
M3O(9T))\IL4LRQRGL#W<,&!&^=[7%.L"J:X8F>7JQKO">K5\!O'HV(.EIQHJ
M*@ZNO8BI^BHR(%J*G_#PG`[3@.`X#@.!B.P"1A8'FQ9C)+X8L1R0DID)&K,?
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M;?=6,PGR*"PK)E?62XM?CLVS(.)(.SWE.<3RP3Q.8@;E=,#^'3VJ`K^HM:X*
M-?\`]C%ZMO\`]'`Q7M`9D?K9O\Y'M&,>F-FJ0CE\-8S^S;E'/<J_1&M:OE5_
MPX&%]I8\>;U6SB*CVOCRL;Q0(WL\.:]AL@QQHG-]D5%:_P!D\?3]%X%J.!3+
MN:62R+U?%&<9OW/<WKZ(ZA5Z*L85S:RS-(K/_N+DC>'>?HJ?1>!7_NU1R+3>
M&!R;CKWANQ,0'J7((+-D/K:2YV!69),RN$1F#@AV.[],RHN&R:V,MB8C73V%
MF"8SU&J*Y0S'HE04%;>[AM:S4]+K:SLHV$1[*9&P>@QV]O8L!<H;7!L[^JWG
MNR9=UU6I3+#C$)7`@K(*HF%<8KFA`?42GL2_D2[(Y*.%?6=,-O9.CE91,QDD
M6HKKI^WM+F!B`<A4,>,28ROK7'&`37N/%&TI'N4;>!L9W$<3-A=8@%?ZK)W/
M>()OJYWN8.C=P&:W]K7>OAC7+Y7PB>/UX'QZ=[=]]=NMG7R+O78>G\IW%VZ[
M9[_[GMQ#;V6;2V!889B$;2?:&;@T6CR#`A;$QZB?4PM9"#64\2OBHV&H6+^G
MLO`LE^.6[SQF?_BKWD[!B:2R7LQOCO3K7,:G%,YRZVQO:W7;"-=97E&H9&=X
M;8[#S[$*C,:RQH(A7+#<$H9<0KVHQIWLX&]'(;'+*?\`&+G-Q@D^NJ\SAZ3V
M':XU.M\3J<ZK`W*3;Z;"^]PN]CRZC*(YS.1CH)QN9)]O3QY5.!(NY\^Q765U
MTNS+9<J-C@5SAV+/,L-L04;*]A:MN<,IJ@-?"1P8Q+3*KR-#&-O^F)2>/*-3
MR@7BX#@.`X#@.`X#@.`X#@.`X#@4.[X5DRVQ/"8=5_(?SCX^^&4:U$84VU2T
ME=7]T0(B5L,QXH94]YI;6B&\HV.>J(YS6JJ\#11TUT[?Z,_"'K+64YMSK_(<
ME[>:FEAU_D@H%/F\:/G/8K`961ZKR/)#`B5F>WL:B?8JMO3@CMEQ!,#&3Y0.
M(X/K%$-@1C")OJ,3&#&U%5?5C&HUC?*JJKX:G]>!0K\F-9!M>G^P(]S>PJ/'
M1Y!K0V2?RH'GI;FG_P!R<4`;'[Q1460%C55H4[$(=H1*!S6O4X412-#G=(#T
MD<_;/&J[(B7UMCW;W:RY&,V*BQ!:N;?0<8O84*-#'.FNO8#:R:)&73D`MJ5I
M2?$Q&HJAG];6O3N_F5PK7_&_JKK6L8[]OQ^X=N;6EE:G@:/]_60SSY>J>/'A
M$^JJ%J^`X#@:S>Q.=X1C'9FH@Y3F.*8U-/8]1YL.)D.0U-+(E5\#9^Y9LN='
M#92XSSPXL@`V%(WRP;G-1RHJIP-;P=IZVR/2,5S-A8)_H#`*[B,S''2#-`M/
MQWFK5&SS8H\@F6,Y&/56M5ID]$\KY3@2-NC9VLI%YMVN%L+!ROL=AX!+B%9F
M&.K'-70>]V@8\T[)*67Q/:.#6?*OA?\`PFN=_E:JH&,Z\RS7PK[1\(F=X22/
M@6J=96D65_?F.O\`:U76/>:'/BO$*T>%TF(V:'W]E]O8XT\?5OD.VC[!UD;'
M=:0B9KABMGY!(DC]\FH1L`L:BZ0(Z3*5U@Q(ZC#'(17/\>%$_P`^/5?`8WFV
MY,0'C^=_Q69XM]X[;F.LEH#(Z8ZNIW95WB_D2M:*P<]XU^V3V?\`5GJ8;D\M
M(Q7!*K\CQ')HF2DEY+C<@<[7&-R"*"^K8Z))-CO0D`_5B6#B!:TXG*HW.7PC
M'-=Y\.X%<>R<.E+J^!DM7:Q+*RJ*C%+83JZQCSI44D%WY$O65*97S0)!&$F1
M-1Q2M*)'%8U1^Y&*@?3!C:O7':%2*JD6EJU(JJKE5ZP0*Y5<OU55=_5>!W7`
M<!P'`<#!MGL,36NPAQY((1WX/E;0S)1S18T4KJ&>C)$B5'_ZB,`+OW/(S][&
MHKF_5$X&I>1<V5UHW"<7DXY@,>1D74[L8IW3+")-V;CL<^#[*C5\.BL7V`Y$
MW"##"P2V;8;@S"*A$:)'HP86'[E:OG[._'+D^M*6)%GY%9ZFP*-C,,^2XQAA
MIE]3BQVP@0JS+LO\4V.6D[^/<`,Q5:82D\B<TGJJ!=?4<!U5JC6-6^""K?6:
M]PRO?619PK.+7/A8Y6QG0(UD!7`L(\1POC8=BJPS6H]OT5.!(?`I+^1F:.#T
MQW84JG:,\'#:YZQOE0JI;;&P^K]?8"*<8W+,\$>-/D8-7.9^Y$X&K_:&0VNN
M-F45Y0:G(*SSOKWKK``GEWC(M?D&-V&@%J[:QQH0X\R?'75D:UD?*VR9%9-1
MKFH\:L]WA<KLT)UQIWIY$3(]RQ(]G`$63KO04C,8>U\W8+1UI-B3\-M,.LZD
M46^US9#!;1DNC+0'(-&2F$>H&\#HJ&XS3*_QR=R)>:YG=YIF,JJ[45E@6^QR
MSPW*L:("EN:ZMQ'),5LY4L./Y+25K`?>@@G+5K(*XD-_V[QH@6?[7VJ8WTSR
MBS>Y42OQO6B*OJI55S\NPN,B>$:]7^SB(GZ+Y\\"YW`JGVHKFV+NMJ.>K/LN
MUFH[%J(Y6^[H@<F>C%\(OLGA57POT^G`A/N9N[$]8YMC59FQM`XWCBX%;9)/
MS[?VMI>9XI1?#>QJL,&9?T^75MEBX)[CJK/GK7PSN:[_`*IKV*-0Z/H+F2[!
MS+?675&7:AR;`K"LU1&Q`6B]0P-8ZY:L6)F4BZOZJVF9)=YOFY<DD6`D=(L0
M18<=L-&P5*CSN0*B:>SJZU_^1UD:D98SZ3;.S^T&M[JHR27;8U74K39].S2?
MFV,PYLN9$S*;(F:_KJZ.H_A3[204HAHP;O4+'_EBGVT3#NJL>HFS*HECV\U3
M&DV\+^086NB#;;RBN=+K#1Y4`$SX$C%-[*QH#/1["#5S%#6+M+\8F],BVEI2
M#MCI3A_;C5'5K;'<S)<`KR[]UGC6NMW89VWSNSV%7EV;@VQ\:E9)B>6:OL;9
M&#%7FDP"28J%$JL?X0+L:CZI;RG=A>BY:KIYJ#H]U=Z2?[^9G"PW"=PX]LDF
M2Y1M_!I>#5F+8?BN*8ACU;C=7!+?6%I8SI!?+RN8,(W*\CD#8AU7@XSL;J-J
MVNOJ>LR'&,EP=\.UI;B&"RJ[.&^QGADQ9T*8)X)0"D&OLU[%:O`JC^3:Y6BR
M/H=`C2:N$RV[>ZTIAAMHL>16RA&N*:.M>C90),8,XL<CDAO<UKF2$8K'L>C7
M(&V#@.`X#@.`X#@.`X#@.`X#@.!K9_)'EEKBF"XD:@9&?D$S%>U2T2S)`(<0
M5M4]/-ZWT(\F5)\@C@"6L17O?^U$_7Z<#07^+TVSXWX).M\G746UR"W)WZT\
M*::>3^!M<5PF7V:U]'SR=CD>NLY)[F)$BGL!"`KD+*A2B/<)BM5J!]C7`H!^
M3B>"EZ?YKD9\%_W,_MW--.V8,&7(+''TO9;MMX7714:ZLC2RW4BM-/26"N*S
M[:8>.QA5:SRY`\>@E?7PP=N"1;Z/D<\W=/>8[Z>-KV2(EO#E4H"4<P:V%@$9
MJ.*@H[4$D<;A-:_X1N>[R$@RMBXGCG>`&!W5DD7)]C:&Q^-A5>HWO=;/Q3)]
MDY'DC6O:U6`_CZOT*JO5/?V1&^51?`7`X#@.!J9[%!J']Q@2LAQ^IO('W72>
MC@MN*.#:B#(N-@=EUD.C&E1910HI`@<5J>HU^-BKY7QP-:.J\.Q"BZR7%Q=8
M=A\E(E=C]@KS8U1G>R+5_CXPDDUK3EK7$]26,TIE\)]2K[^/9?/`L9=:<P%^
MU]Q&F8+@8J\>UCOJ&LPC&6N@B?W&Z^R`H)1UB':,L3V`J>R(HB/;X]7.10Z+
M!L0UQ9X7J.]=KC7T"3<=?JV?]N/#\<<C[-^G>[\YA!(.I0TB9*=`$5WA'/>X
M3?'U:W@010:KP86IL"F)@6$GG1]KT>->TG#:(RO@3('X],?F@*"56.8:.YDF
M8KFE:OJ^21?HKW^0F38N@=3FJ-H%I=6Z^B2VYN.+#F1\(Q9AH$8V<]ZXX!QU
M'5",R.UD2(WXA>$5(X4\>HV^H8=E^OL`IA;:I;'6.OGM-KW`2T1'89CR&9'?
M-_'G1F,KTK_(G22W$E7*GA7*5_\`5[_8.=BD?KSC^@\SH,QU#@_]U[1T)'Q;
M#[>GU3C,R50Y7;97W8RB%=64[^,4M!'96X`YJS_\[9`X[4^JL]0W[]>=D%V_
MHW5.SS8_*Q0N<8/09"_'9LH<Z34+.A#?]H66(8AR%:B>4>C6^6JGE$7RG`F3
M@.`X#@.!@>TY<>!K'8TZ43XHL+!,NER2^RL^,$;'[`QG^Z1IJL]1L5?*!-X_
M]Q_^50T-X_D1-A2^O>=TL;"8'K^.;?5_=5(:ZUCS'X_D%-L6)@(`S8DEE/11
M0&JYGW4(H/O0F?);\35$](X37L"\H]A_AFFS,_*;L'3S]<P:ZSM=D4*5,O.'
MQ<_95@L:ZEII]E+#(K)<=HZ-X3I-*D6.7]AW>J!>/KKV3Q3-=B6G7&EHI%3)
MU=H[36=ULZ;*N?NKK%<SHQ1:Z1_%7-+"L:D<"1"?%<R?(_D7%"]2@']%<%TN
M!3/\@LME;U%VQ=OKXENW&GZ_RM*>PEQ8%?<DQ39^%Y$&HL)TY4@PH%H:L:`Q
MCJ@1"(YQ/V(O`UL8EMV@VCFKK653_P`(_'I_;9^4V\R572<5N,@V!JRLN\<P
MS"<G<9!9@/#/F2((@F-CL(<38OM[N1H6/Q:/LSL!T7Z^Y.0/7#,)M!;64O.K
MO/L.R[(<4Q[`,-EYMBA+O7H:JXQ>^_O+&*>NB`E&9(".P8*<P2I\HT4)0JL<
MC8[^/'/G19.JK+'\NU#GF:XU*T[KRTUI@5ABV?T<W(:&;$Q*^O,CN&6-G76S
M)$Z3+E/D3)17E>UBN]$"6NWE-_+=2\VJ$07A]5@"*A6M<STA9IB$EZ(US7)[
M^D=?3Z?YO'CZ\"W7`K#V8LXM;(ZZ?=J_Q8=GM9U@$8QSU65*K,M^W1WJUWJQ
M'C\JY?"(B?KP)/SG26F=GV,&XV3J76FP;:LB+`K;/-L&QC*K"O@J=TI84&;>
M5<Z3$B+)>I/C&YK/D57>//UX'EKS2FG-1$NC:IU1KC69<D="?D),`PG&\/=>
MOKDD-KWW"X]6U_\`)/@MEE02F]U&A'>OCV7R&:OQZ@)+BV!*.G)/@G?*A37U
MD)TN')*DE"28LEP%-'.1)AD<]CD<ORO\K^YWD,<R_7&+9S<8)=Y'$+,EZZR.
M7E..!^1OV26TS';G%R$L(A!D%.".MO3N&UR)\9T81%\M3@9WP/QS4<U6KY\*
MGA?'Z\#!]:Z^Q_56#8YKW%4EMQ[%X3X%6V>=LF6D=\J1+5#G8(+2N0LEWU]4
M^GC@=5F^HL*V'EFM<ORR!_+3M4W-OD.*P)3(<JG;=VU2ZH;:3H$R)):>;4"=
M\T$K%&2+)1"M=[(G`D[@.`X#@.`X#@.`X#@.`X#@.!7#L%UOQ3L63!:W.2/D
M8=CR[-@Y1CPB3(ALIQW:.HLVU%>TPK:OEPY],Y]1FQB?<`>A41GJU6J[V0(T
MQ?\`'EU5Q+0^M^M-;@MQ*T[J/8F-;2U_C5SG><7<NAS'#[E+_&IO]PVF02L@
MGPZ>S:C@19$DD=C&M8C/1J(@7:X$;;3U/AFY<;BXIG46SET\+(\=RJ,.JO+:
M@DLNL5M8]U2G?+IYD,\B,"PBL<2.57QS(GJ1CD^G`\=8ZAU_IZ#DM?K^B91Q
M\PS"ZSS)%21)E&M<IO\`[=ME:RCRBE*0Y@PPC\JOE6";Y55\JH1?/ZUT=UVP
MJ>T5Y.;.M,1U3$UW@E.,<J,^@L9=IF)LLOI,@<M(MHR[I<CCQ!!('S&6.][7
M*I?VA9O@.`X%4-B=>;C,]KFV)%N:./$+8:%FMA3(TPDT2:@R/9-Y/491L>!A
M[-F;A''<GCT4)/=?#F\"K\CH/GQ=8MUT+-<%CQI-98U5H]M9>J,T:9URJ=,B
M^V<U6.`0.0U39KG>BHZ#_IHB$7R@9QF_3K861V>>6%7F&+0%RO,Z7)(#RBMD
M-"@U_8'7.V9<,ZCCO1QSXYA!(35;^W[DS%7PQ%7@8=CO1C8M-0ZGHY.68>==
M;8!B^+2)D5;D;;.SJM1]C=>V<J.`L-%##);;FA2@>[OD448_LC7?&C@[5.D6
M6#H<9IG7^+BCTF:"RNP(X]FY)*1KKK5;-0:O@^&O./2D\7J[PC?NP?N_\16A
MV=KU#V3/J,GC1<BPO[N\R.%<C0A;5XFQ@VO8RT((BI7N1#J3<<!&_1S?,61Y
M_P#N?N&-Y9TAS_)[7)ISKC%&-N*.BHH229=F\`HE1DG5V\_ZB**`C/F1NBY[
M1D3V<CI,;ROA2(P,6+^/7,I]-D3;#(Z(-O5ZQQ6BUY%IIAH-1)S:D+V;!,3+
M/N*.88.(&K]]B>UL+TE.D1'*O^FB,*&QO26I\?T5J?`]18M)M9E!@./Q:&NE
MWDY;.WE#"XABR;">H@?=23R3/>YWHQ/K]$1/IP)2X#@.`X#@=#E./Q,MQC(L
M5GD,&#DM%;4$TL96)(%$N(!Z^00"D:]B%:&0JM\HJ>?U3@43R3I..AU^G]CY
M+;9#F^&=;-M:3Q"ONW0*ZLR*9G==D9J^3:38H4?5_%=7:,:1WW#HL9J(Q[?>
M4Z0&0P.E./OZ04?30^2S6X\W!CXM=W648_C&?S9)+@EE97+S5N0UY*20:+=V
M[RPCH)"1W`"YCO9OLH9+H'I[0Z"V]M_;E?GN5YI9;=IL"IY</,4#92,5C8)0
MPZ"/78M<.*LFKQBQ9!;+)4B&R(.>0LAJ?(4BJ%Q.!6SMYK'(]S]><_U;BHF%
MN,T?A]0Y7NKT^VIUSS&).2V#!VI0UTDU9CD>7(&`SO20\2#\.5_JH:L++\8^
MPB.GCB6=H^GK-Q[$V?B.,SK&BL*2HCZ]86+IZJQZ#_)PH>.)MH!&$M"#:U]<
M82.(GT:C0LG4]?MN]:M-=1,/PBDSG;&%:GS'8V2[RUUK6ZQ#"<CS%VR19ID%
M8(]-?WM9C>9XIB6:9@]D^D=<11SFH*6JG2,L<@9)B>H=\0_Q_;@UB7&[N!L'
M(J3=`=-:QRO,J7+<EP+#<CL[H^I]9W^9`FNQ^;*Q:EDQXS&CEGBU\9!0VR3M
MC_.\+%=I7N@=:LF9/5&%1-<0)7[F-1II6>X=`*GLKD9_XIE_KX7@6AX%0>V;
M"EM.I@A(Y4?V^UJ\WJOA$%%P[94U5?\`_8^\9O\`V^.!;[@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!ZS!%($0!QL,$K580
M1&H]CV.^BM<UR*CD7@8_BN(8S@]2VAQ*FAT-.V7/GMKX#',CI,LY9I\^0C7N
M>J/E3#O([Z^/9R\#).`X#@=%=WL6C=4?>&B1Q6MO%J&&F26Q1I)F-(D80G.:
MY"R9!F(,8_I[N=X\_P"(>C+<PQ7`\;MLQS3(:?%L5H89;"YR"]L(U;4UL(+?
M8DB5-E$$$;?Z-3S[/<J-:BN5$4*`ZZ[]8SN7?MGI/&\6R2BQK(:/Y-5[#V%4
MR<5QO<,^''DV.8T^!(KUN23Z;&_CGQVS0Q'RXWS/:U/@<BA/4;$AQ+&NP:R@
M9NR_R6LO9\W(*O;EE$EUU5$MA#"E>K+"NEE)%CDC,1T6&B1QO:PA7.=[$#J+
M?*<=K<KC8/;;)SW6MS&AQ98F99F&%@B7%7),2KA6<>5=OFFL&DL8;PHWV0Y)
M"+[#=^O`S]V&Y3&#$GQMJ;)RBL8B3_:J_L<K[``6M:^"$H*2*TGW?Q^4>QR.
M1ZJK7-7Z<#L"T609%4LDUYL^J7LCJP@;[)YE%<R'+&:<+QQ:0BPPG66C6&5S
MV)Z*[U^OZAU3\.S'(F^+&/:5#:XQ@`2QRN_F$LQL!6%6<.3C^4P21(\A_P!P
M!L<C7O<J->]41/5P9!!QF3:#KL<ML5R:FI*"U-/I+<6Q)LJ49PT(8!;%\2>*
MUD@*0SFI'E/.-/IY141/`52SSM;*E[XQ'2.)8]>9KLO';T=GDF`Z@R6!DI\>
MH["K+&B7N][M8T/&-38M'/(<]L.RDDNK'R-\"$?U>K`[K"X_8^JVM$N]USXU
M_<7UOLB%K2OPVUL\+P3'L1EQ:FT@X?=XA%NLCBYED-96X^\P\EM7?/\`=23B
MCAB!(@T#IJK;V0X;N[6%?L+)LBI:W(\0S$]CJNU/+MI&(2968X/B=;FUWD#8
M*?>5R9)D42K`"09X8<>V9*&1XOD<(-B/`<"H_>BOF6O6/.:^"I$D2<CU$WR'
MS\GP,W-KXLOU]5:OC[1C_/\`PX%N.!6#LE7BL+WJZI&.>Z#V?Q2P"C6^R(6/
MKC:C?=Z_HQK!D<OE?ZHB?JO`L_P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*<=GNV^J-'#C8E/HIVW-IVKJ]U%J
M+$JQ+^[9_)R4@P;W*G#BSP8?C@WO>1\N0-\DL<1G1(\E1$8@5)P'J5MSLC94
M^TNX.0%QC$:*7-N,#T+B-S/!KNH"23//%MK6GO6S)G\E,AR5,>9-,MJ!RJD;
M^,;[1V!`??\`V=I]^*83JG4QZJ\[":<NJS(M2V^LHTK%J[4MK6>YL1SB8\\>
M;@\FAA7\((YGSRA1YD,DB*QY2R'13AL&U;L/:F^+35\VTQ.;KF]PJ."'MG+*
M.NI+/'KZ:3'(I<WPS&IF2L#E./XU:9G$C_9%:!;0\`;3%'#<C'*%N*O6.`5.
M'P,`CXI42\/K6R&Q:*[C_P!Q1/:9*E39AI+K]UE(G29<N:8A2G>0A'E<KG*J
MKP,1%U]U951,@CX=CY-<FR.OCUTN=KFQGX:>$*')%+AGIXU-(CU=5,BG"BL(
M&.U?#G-=Y8][7!D']I9G7"R8M'L>QDR[9:9]%&S"FJKZGQA:R..+.#%'5,QN
MZL`7@QH\ZRIQB#D*I!N:U5'P,-AW_8NIF1P7VO-=Y=!*<`36F&YS84$J,*1;
M?;NE$H<JHC"(R#3N209&6*O>5KAB8[Z.4,<R6BWEMZXA5W\J?2&HA$SJASBH
M"R-*V_L*">M)28[98=G&+Y4^)JFF(:86P'*$T]^TL4")]JA'^`YVEM44W7_`
M7X'JG2>*8120KN9)CUU/EKILS)B3G/D6&9YAE%K4/OL@S.ZEO5\V78EG3917
M*\LEZ\#I++(LHG=A=95%[6`J(886220PAW1K!K)A<>R-!%"K:N%$FI,A0OD>
MGNI(SF>%;X<URA#G8G'K+)=Z9GC4*9-!7Y!TDVJXT!@(SJR3E<;8.$@QNY,J
M0R3S6U2-I6A1A48UCO91N<UCF!?;'RE/14QCD>8QJN"4I2>?<A"1A.>]RK]5
M5SE\^?Z\#N.!7GM.GMI.^'X\_/E6J8RI_BDG;6#QU3_V%X%AN!5WLE<MI\BZ
MK,7YO-QVBQFF;\/Q_P":3JW;LC_5^1%_T4;$57>O[O\`#@6BX#@:[<)[V4V8
M?DWWC^/X4:""1J+K)JO="6CR,^_M,GS+*;^-D5&!&G5%!2XI-Q^4HW,0B+,>
M[ZL3R@;$N`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X'29'DF/8?1VN397=U6.8[1P3V5S>7<Z-6U577QF^QYDZ=+(*/&CB3]
M7.<B>51/U5.!JSS+MKN;M/+M<"Z85-AB>$0,I)B.>=ALNKCXY:U];]E))8V^
MM\>RJF<&-$"Y0L#:3PEDR5*OV<'Z-EL#N=+4G7+JYB^3[VRFOL+23C]4*BO^
MSN8PCCRO:5B^[)'N#PL?1LJX<$5K/>LBVDC%]PYQ"J1L/U(@5[S;LSN/NS8G
MP?5%/.UOH2+?AQ;9.:09F+Y!?93B>3UTJPKWT>,7<,$Z-]Y75A$;*.%`H60Q
MD4%D]Z.$%I.LW0_!M?X[CK,AQF,LO'I5S)K<AE65G9Y;DT'(I(K`4W([:PFR
M;%;RN@,CUK)Q7-L&0XJB#]F$B@X%U,_NP:CP0-IC%-CP00KS!Z!L*QF?P53%
MI[C+*;'YQEFAC'01:JJLC&C#>WU,=C!*YOR>R!*425'G18\V(1#198!28YD1
MS4*`S&D$1$>UKT1['(J>41>!%N]MA6FJ-09_L:EJ@7=KB./R+:#5RDDK%EG$
M4(T9*^S_`.J2,Q"J\BC_`'(QJJG`EACO9C7?1?9K7?M^J?5$7Z+_`%3@>7`]
M$J2*'%DS#JJ!BQS23*B>500!N*14151%5&-7@0.N]BMQ=<V+K/-PXH>#3659
M://B2NM(-_\`9LJSQHC,D<4:FD3PL<TJL<U'^?'A%\!C689Q<?[DZ??,UUDT
M>>R;G*5\'^0QDAIJKBKOO/M_2[^%[H<;R]_LYO[?\JN7Z<#`<LS!N0[6S1A,
M;R/$\IHNK.R"/!9#JOO?LK"ZJS5AZ^PK+*TCM,LB`1R#\H]'-1SD\(WR$(=X
ML5@99^,G8NTI]WF>/YIJKI;M+8V&W^,YID6+3Z?+R]>+I!W4XF.6-8&TG54E
MZ28SCM>V-,&TXT:]J+P,Z_$Y*M;7H%H'(K\]M+R+)JW+;J]FWMK<W-I-FDSS
M)X,:1*G7T^QL"JM5`C-;Y*K58U%:GU^H3-W;LIM1UUR"=7,828/8&AAA&1SV
M->DG?NL8QD5PW,>B_`5RIX5/KP+8\"I':&.LK,NG`T<U$!VQI9SVJJ>SVQ=)
M[Q1$:GE%7U(5JKX\^$3SP+;\#\<OAJKY1/"*OEW^5/"?JO\`P3@?SM.KG9C<
M]A_\0AB??FWUWL.%UY[-=LMA]5L6V#8T]HF#6..9I5Y!J77M?%NI+$"J+/UI
M%DQ53P$Y89D`KO4C6A_1,X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X!?I_P#EX&B9T;,NX^QLSJ^REK8M)KS.\DQ2KZ@42"'B
M9_M)ME%QW(+Z[%%+8AFBJ`P[,M_8M4`FV8APF"&8;B!(^R.TVGM4+6:SQ/\`
MM_;VVZG*7XECFB]<W,3%\0H9DT:AHXUB/(W1*Z^<.PE"9)L9,Q8@['ZO,%S_
M`(W!BF#=)M^=D;C%-K]ILH-&#%@6T*=K%E:_#I,0=2.SKL6BNB5Y;'%[XRG&
M*0EE(A1AQ1.8Z#%$1B2"!LIT5J?7%#CF.W]+3U0;$D,4S[*)'D1H=/<H-L2U
MF1X-A_YJN0F(#XID^>XMB96*USV,7XT"Q$Z?#K(<N?...+"KXIILPY%\#C0X
MPW%D2">$56A")BN<OCZ(B\"@L79F!?D9U784VI5R1^E9.?4PKK:IQ!IZG.*#
M",LKKMQ]16<65/=DE1EBU8UA7@4;#9'<]4=\[?C:%[\?IHV.45+CT(ARPZ*I
MKJ:&24132GQ*R(&%&=),[ZFD."!ON]?\SO*_UX&$[FP^US_5F<8?135KKN\H
MI$:IEH=8S!V0GCE0F'D-81X8DB1':,SFI[H)[O7POA>!^5F4V.90*!:4DC$+
M1DX)\GJ;NH9+L:\581&6^.R(CI(&!^\(JC#8!(4*HU'B^5%\<#VY5DUC@$&3
ME&03XMCC4<T>)*"")&K9->^TNECPIQ9DJQ^*0&..7'B?`P?S&*[W;Y<[X^!B
MY-@6=[KR9>K30HZ3<+L,CF05MQ_?5E%88]+GU\J0`\4#WD:]J"*B,1OLCO55
M5JM4,"A/CSNI>#+DY'XD!^$:U'-/(8.8D502\='#(X,%2L?'N"B%Z-5$4;)*
M?(UKFN1`S.W_`)&UVCJ*3>Q&49:HF;2*@'WXYSKDLS%S0Y8/0`F(!];$<A5>
MY?#_`'5&_I]0KQLN5+7MIF.-1KZU<F2=,=BVO\+&!!'15DFBRB@J(]E93F?+
M8_SLU,A<R.CVM&R(PJM]G?Y0BK\@N4X]0?B%[,5\VVJ:>QO?Q_;;C8_4RK..
M.99O%H2R21%J1R",DVA(PCM]OC:YRHJ*OZ\":?QGRZ(_1_K]%HK.JL15V(2(
MLO\`BK&)8LBRUOK@Q(\DD0\A!240B*YCE1R>?TX$J=O8K9NC+2*]GR-+GVDE
M5OMZ?46[->G8[SX7SZ/$B^/^]X\?UX%FN!6;L`!I\WZJ^R(JQ^PK)+$]6*[V
M9I[;8T5KGO8K$:AE\^OERI]/'A5X%F>!$>[MD0M88#-N34<W*[:YFP<2Q7#J
MV3$A6.6Y/D9'0ZZDC39[V0H(U$A9$F05?2-#CF*J.]/50T,:B[L]?-V:"P#L
M!J^OU#MG6.UMZZ+Z;8AU?!J:_P`*G:VWAK3(LOO]:8]!N+?(YL/#[.,DA]E5
MVYZH4%ZOAF$0+'O>T/H1U[G5!LS"L;SS&"G+29/6!LH;98?MIT1SE>&76V4;
MV?\`:VE5.$2-*%[.^*0)[?*^//`S+@.`X#@<5DZ$26:`R9%?.CC&4\)D@+I8
M!&15$0T='J88RHU?57(B.\?3@<K@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.!J;[=:2RK:FWJ2[ZJW%1!V+G--9Z\WIE$2&4]%6X33'!&;
M.F9O36D'^WLZIY\<<1U>K;`]A$`,98B-BL(T+*=;>DVM]!UBS;&1+V1L"UDU
M-SDF99<P5H>7?5=:.#%E5P[%DN7%'`<I7QG%.8P7&?Z/8WU&P+H*B*BHJ>47
MZ*B_5%1?U14X%5\KF8[IC<.*Y9./7UU%LPY\&M)UB>!"95V]W<5Q\6!7R)#T
MEG%99/*,)T02(-I;%TAR_LX'9ZV<4_8GLTPF0);PD@Z0:&B<>45N,D)B5\^3
M%6*9[H4=+<:BEK\;6O)[_P"IY1!\"7?.MM0XP`7G!]887`,.)%%YH<*Q>%(G
M'>X4:.S_`,LJ8QIDHKE:QJ-<0CE5$557@:_^YFY]R5FXNKFL=#[8JL'B[V@Y
MY7MOFTN,Y563;-B8J[$K<4BSB6#70@?>G\+&5R&0Z.5A?1K>!X5^D/R9-&'^
M0[B8`BC5SY`P:SQ<Y)/[_4`0RBX*%L5PPK[%>HB-*1J(U@VN=X##;3#_`,BN
M/99BV.$['ZIR;+\V;+CR)$75M)$+CF)TA)$NWMY\Z+CH"QJ9Y9,.'[.7YONS
MC^W&YR&<@=;2:I[K.UC?:^9M_0LO!=?6$2M9,R+`;>702ZK&D?97)[&VE$-8
M9!+J;"(PTDZHT9)"O8KE<)_`QWI_L7/\MVYO#3>V<P@54JMU9J^559M28O24
M<"?B7Q93C;\+/*R@]A;1BQ(\V-8"`00CL-+D/<[]&(%XLGP0V-:SG1J/)K[/
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M9$+8P#;7AY';9+9?Q00'S&S)&C+)CCGS5!&9'<]H'%\/#;+W(N`T6D'V$ACR
MA3:F@HCQB_SO6PWIKN`-&_1?_NLAOGZ?IYX%IN!3_LW.D1]H=)X8%;ZV79N8
M*0CFH[VCQ=`[NG+Z^?\`*Y"QVKY_IXX%P.!3;L7HUA4B;IUIALK)MK85E,?-
M#4+,HO8Y,QJV8O>X=?4]+6SKI,4C9'_;U^4]?\D<8S3(S!.>/Y7$0/F@UU^.
M//\`2#/QBWNMLHJ[G;&C<NT'?][^NN*4>=1[#;%QHZ1L>RZ];#Q^JLL0AQ\8
MS^KB9'-H;&SO&T\2;5,]RRR,KO\`4#Z:^J_6*#I;'J[+,J?/F[MR>MN)NRK"
M%G&<6F%LN\MR29F%O4XSB%G>OPVJKJ2=.2%&D0JN$0H(Z.5&?(]JA;W@.`X#
M@4'UJ6[=^1;M"$D2B%C8^OW74D2:%EZ#(IEX6YV:EB*:.2=<>FUL*O'%^*3%
M&DE'E4)W>K!)P+8;&VIBVKG8$W*5LFIL;8N-ZNQTD"$DL295E;9RTS+$CC!;
M"@'?`>Q2K[>"*UJ-57)P)(X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@8AFF>XAKNF+?YE>PJ.M8]@!.DN>2783#(18];4UT=AK"XM9?Q.0,6*(
MIRJU?5B^%X$(5<S:6^*V%//"R?1.!%O*RZJR1[6!'VME6/USI!AQ;RO2OM:W
M":_(I;(YG`')/8I!:HRK'(9XQA.F&83BNO<>A8MAM%5X[1P$*H:^I@QX$=QI
M!7R)4LS([&(>=-DE<4YG^Q3%>Y[W*Y57@95P'`KQV'?AV1:]S?%KO)H=.:HQ
M@N76S3WBXU'9003/#+'/R0@W1*@,Q4<)".=\@#*,J-3U:[@57P/O7TJK\^RF
MZI>QFOY]1EU'AC;N9.NI(K&MR3%X=ICI[#(EGUL(BMG5T2)%++<YR-EQOC>@
MU5/(4U_+=FW6KNOH'7W7?$M\:=M)%WV"P.TR4UD:)F%'CU+4XEL:>"QR*DCB
MDD)%E6\:-%CJU$>V9("J*B?7@1?U_P`IU2MM^&_5F*9QC6:Y3JG3H,)R&)B<
MH$UM3(H:/!8!OO8A(Y#THVSZ='C:9HB?"BM;ZN5J\#Z2>!5K#!/GZ_VCN0Q1
MW&79W#R]T*36%+(^PQ+'9%]5X1BM4ZK>=X%A1!*>0L9SB%LY)RJJKZ-:'8Y-
M7@NTUKHVE1U;`F559E.>QA(9[Q:_H%CHM4:0-8R?<9CDS`PRD<OR%C,F*K%\
MKP*&=7L6G9'^2ON7GDL-2?&<2UYC6O2ME_,:RDY%D&=W>5"0D%\+^.CP*>BH
M`M"7YG&(*2Q$8QC$5P2/AF39!?=4^R>L+;`;MC<.U/GYH;*2/2ARG,;'/&[)
MN2P:S#:V*V/43P?],V.PH$2<21[^KOWJX-CV'B,'$L7#($0$@6.T@CA*UK"A
M,.LC,*(C&HC6$&]%143Z(J<"KN85-P3N_IVZC5LF%3QM([%K[+)27+?X^V)(
MO*PL7#08\P)"I8B,QMFLU[QC^&/\3?+E\<",_P`H>0XYB/3+L'DO\9C-]L^K
MTIL^3JO&KB.6QN<HNH^/.D3\>QJG@JZZLYEK&$P)&0AD*B.:Y6JC?'`IC^"R
MAR;76CV:7FSTNL6U+I;1.-55U#K<AI:F1=/G;5F741*B\B-!7Y+!`>,RU9%D
MR&J]`N(T*N:UP;/NX%5_,Z89#4+#-;MCK_+<UZN1&_9;UUW*:1/4HE5PWB1R
M)Y5/*?H[]%"T'`JKV!JX]AMKIN<WR*6JWSDMA&1CD1ORIH'<<5SB-\I[M:*2
M[Q^OA?"\"U7`Z'*<FH\*QC(LRR>P%4XUB=%;9+D5K(:1P*NBHH$BTM[$[0L*
M9P8-?%(5Z,:YZM8OJBKX3@?*;UI_^(ZZ_;2_*#FNK"X'9T'7W>B:MU!IC=1W
MSI&06^>TEG>U^-6&4X@&,0E+AFR;+-?@K7-5TNO5@2S6,9)>D8/K0X#@.`X#
M@42U=_8!?R!=KR5U6O\`N2#377&'DMV>3$<;^V4=L.705,2&RCAS05WW<R09
M2DG31ED?(UC`*-Z$#U]]:\=C2=6FDD9G&=$[M=<K$#L'+=,L2R(5]:%%&MQT
MPWH;$SIY2U26YD,<%"$([RQB*%[V?1C47ZJC6^53]/T3].!Y<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'Z<"N.7]B*8<JSQK4L`.W,^I;^BIK3&Z2P
M)&@0_OK-8EZQ^3I7S:(EKB\0+RSH:&0D1SA-DN!\C54.@Q;%96671[FRN(V;
MYKC=[=EJLLR&AIY4'7L;)9SEM<5P^9518E7;2<4CP`02N8I'+(`[[@RN>1G`
MM2%CAB&QSD>]C&->]&-&CWM:B.?\;?VL]E3SX3Z)P/9P'`I_V'[J:HZ_6L3"
M2`O=E;;M8[I%7JK7D45SDH0.C&D1K')R?*V+BM/(4:(PDA72I'LGVT>0[PU0
MI7/ZW=HNT]`?9_8"7"QC'ERJKSBKZLXX$515Y53U<18)*C+[B7"D6)\AE51E
M+!E31H9E@$37ABA57(%@\LZS=<;G6N-;:UOI/'KJ/AX+7)'X7(H319N94;ZY
MU/F&+V$:R*R:#)X@:]Q82D?^VWAL:Y7,,1S@FVCZN]6,HQJIMZ[2V&K3Y'CU
M?+B,ET,B%*)46E8$D0<V+(>*9'DCAG:BL*B&"3S_`)7HJ\"-^J_771-9CM+F
M5?KC#GYY@N9YQC@LWK&!,ME;8;?W>#+DD-L*PEUL:;-K:Y&R&-8QX92$:YC"
M-7P%[%\^%\?K_3_GP*GZ(USG^'ZMSW6M_CM'0U,6[RL.MX1)%;<CETV3NDY#
M+FY`D(;8"I(RR[FI]LT`VCB-8Q6N7RY0Z.S?LZD[>X0:KH23\!R'6%%AV87@
MZN3,BT1Z8&T,G]A3!_;AJ@3[9E:!SU4S5<0;%:Q7M7@4(T]V#U7UZ[F]X;+:
M.17<1^>9CA$'$:RHQ++,G86#0MR=;J9+F4T6RBP5!:72"^$K!%1C?9OD'Q^`
MN96_D6Z5L9/L%V$['3.4ZVB6.M\\K9SDK#_9/=.:/$W$+]LY5\>5=Z"_=]&?
M7@3YK+L_H?<E;E=KK'8E9ET+!I57#RS^-KKT<JC-=B*:H657S*J-/='L1@(H
M3#$\+_C>B.\L<B!!5OEU!;=N\-R+%;&K-/R+0]Q@]9,NZJV$T<XV9EO83HT.
M4&ODF($M6\A&>1>\=I$1Z.]>!8C4>=#V73$EW==6NRO%9Y:JUFU\"0RE?/\`
MB1?Y'%I=BI)SJV='=^OLCV/1XG*JL^H1ODG90E`F;+&Q7[P.%S\ZKBHR2<IY
MIL,L<`KW2&```A0Q9A<X52O7W6.R,I%1S554#@[HSN-E>EY5R6&ZLA0NP>K\
M28UQVR22&X_V/PO&FSO]-K/3^2D1/D8+Q[,:]&KY5%7@6Z^1/_=)_P#TW_\`
MU<"MV[)T.)MGJ5'E*J$LMQY?$A*B.5%ELT)MV:C%:UCOHL>*1?*JU$\?K]?"
MA97@5Y[=&6-U0[.R$1RJ#KSNDR(Q%5ZJ+6^2O1&(B*JN56_1$1?KP/Y9O6+H
MSW-UUGW1[M=DO7[:F$Z0G]M.IU!2[*RO$Y5172IMCL'"#U95KI307@:.S&TT
M>-;GBA@%G>@6F<]XVN#^MQP'`<!P'`H'J>AR.)^1'MYD,ZF-#QBXTKUHKZ"Y
M6"<(;NQIW;&??C_D"":&=_%-L(C&#&Y4CJ0BN^I/#0S'N-DEACB]7OLH+)8;
MSMOJ;'+"1\-68U5#MZ[+H_\`(B2VK9PPC23\8"E`6%*:,ZH(_ERB*%RF_P"5
M/U3Z)]%_5/I_7_CP/W@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@8IEV;X
MO@D*OL<KM@U$.UNJW':\QAG)]S<6Q'C@0ALCB,3V+\;W.>J(,0V.>]S6-<Y`
MK+D%;LCL?"IJY\[(M5:]))R`.94^.WL(=ME4*+9B#CX%SVC5TQM3=U072),.
MF()'"D((MA^UX7A..%::P'7U2^BQ6EC5E+*K5K;*L"$(X5B+[.+`]W11#'&@
MJ^-%3Y6Q&`9((JD*CRJK^!)<2'$@`'%A1@Q(PD\#!'&P0F)^J^K&(C455^J_
MXJOE?KP.3P,-S_8>$:LQ6SS?8F44^'XI3B^6PN[N6.)$"JHOQ`%[>33)TIZ>
M@(X6D.<BHP;'.5$X&MBS[%;^[FN3%^I-;9ZKU'.EOA7O8?)(CH64283(LHDR
M/AM#-B%=BTY#"8+WEC-9H]ZL4->1OS(%J.OG3[6&@_6\`.3G&RI'W);;9F6O
M+9Y/.E3O"3CADSI$TT5\@;6B<12$DD$-K2%?XX%L41$1$1/")]$1/HB(GZ(B
M<"!]8:ORC6^/Y/266<2\JJY-371L:@$#+`_'S1:N8.Y(*QF3[&TF$O;>2LM7
ME.YP7+Z-7U:G`QOJ,N:Q]-5%'G<>5$ML2ENQ"'%E5\F&X%-CU95P(+`RY922
M<@CN<PCFV9$82:B^[F-=Y1`E75NNX.L<;GXY7MK6AG9CG67D6J@2*V,29G&7
M7&6SBDBR+"R5)I)=P]9!&$:,QO8C1C1WHT)'X#@.!B,C`,%ERI,V5AF*R9LQ
M[B3)A\?JBRY;WJKGOE27Q'&D.>Y555>Y?*KY7Z\#CEUKKLS_`)#8'AQ7_'\*
MN)C5.]7"]?3XW>T-4>Q6+X5%\HJ?3@:Q^@`(=5VN_)4``:BLJH>P]/?:QJUC
M(=?`B"IMBC<)([G*.O&-PG*HFJ@6JJN8C4=ZH%OLGH@9#VXPHSH5"]^+:A?E
M,>R7)6MR+W=F4JC^S'BK9*O=3*"U(5+!0^CCM^#Y//[5#*-(U\2_U3C11&D5
M-C%M<MF`9%FRFFBL-FN1M8.8!YFEE0I3`K_IR$5%3SX\>.!7.'D&+AV+G&(Y
M1(JAYA<97N.VKQQUER!CQIEKK&)8(K4%&K2AE$K`ND#D%0X2L1&^R/7R'HVK
M#DV_7"="$C5>;NGKMY$<YJ>(T#NKAT^1]%0:>R1X;E1$157_`(_7@;&^!4C?
M[WKOKH_'8Y4^3=>RS$1/'[A1NLVZG.1?I_E1Y&K_`,_'`MOP/68(I`B`.(9@
ME:K"B*UKQD8[Z.81CD5KV.3Z*B_14X'#LJBJN83JVWK8-G7/)$,Z#/B`EQ'&
M@2@3H)ECG807RPIL41A.\>1E&U[?#FHJ!V'`<!P'`<"@6H[0$S\B'<2L!DBS
M'TNG.L?WN+LFG*RDE68]D2`V98*B;$AGMH0F-1S'O*1@OWHUJ#]@[;O#C\/(
M4ZH)*O*FD+CW<;3N6UG\N:Q".TM:"+E1H]3"^QJ[(,JSEQS&^"/)6,`CF^?E
M:]C&N"\_`<!P'`<!P'`<!P'`<#Q<YK&N>Y?#6-5SE_P:U/*K]/K]$3@<.NLH
M%O$%/K90ID,WM\4@*JHWJQRL>B>414<Q[5145/**BHO`YW`<!P'`<!P'`<#\
M543]5\>$5?\`L3]5_P"S@57SC=>7Y6E+C_6VLH<SE9&.Z9(V;8R?O\#Q!*.X
M=06;'084B+)R.^!.$90Q'28$0B`<OW+E1!/#M=2Z&_MITG+=A7619AL?(Y$*
MURV7=9;9WU&2\@0YE6$E'4_!44=52,K92M!71Z^/#C*YSD&XSB'(%DF,8-C1
MC8T8V(C6,8U&,:U/HC6M:B(U$_P3@>7`<#7OOW\@NO->YE_LAIVN)O/L'/.:
MHCX=BY22,8Q&Y=&E&C#V#D\!DEE:9%B%]H$-LF>UPE:9L5'-)P,!U9TRVIM?
M+*[<O>/.Q[&R((CGHM/P(8H>ML*^Y.,\6"+&V2;"D^:L$ST60-\F?*]O^JG'
M1C6(&SBLK*ZF@QJRI@PZRNAC^*+`KXP8<.,/RKE9'BQF#`%BN<JJC6HGE57]
M5X'.X#@.!7#>NW<FUMF'6_&,7IHELW<.\(NO,D.<;2K3XR+!,VRVSL0*D^&X
M$L3\:$C2*R0WU5S/C]GM<T+'\!P'`<!P'`TT]3?Y2YW#^5%V/T@K.Y=E>$XQ
M75(2152QNHV-;"F`$5IIBU8R25OP$<1Z`5S2(IF^Z*JA:'-["-CO9[69;F+`
MAV<G6.K\9+?`+8!LBR[+9=PS^`,8\X%:2DE38GR-8@/NGF1/9SF*C.!F.@RQ
M\3K;#.;W)ZZ/B>;6%9AF)0G6#CQI62Q,_P!@1&DI$0$<*_W02WCL8SPXA2QU
M=Y1GCR$*;K=DEI,S77.O/YB-E4^_V;G]K_;%/@4@1J*G7!XM?7WE3G$>;"G2
MLAR^?&*&8X?PO;62!O5/*^`\\-EWV0=6*JWRF14V<C(.VU)95-C65\FJ=851
M.W54E;9V=7*8+^/O)B1G%D"$U`->[_3\L\*H;+.!6+<M4*=O;J!/>1&EI=B[
M2EA'\BM4BR]";'K2.0?JJ$0;)G]53U\^?KP+.\!P'`<!P'`<!P*+ZCUX:J[Y
M=P]FFP7(:9,QUKUJQF-GLF!)#C&:PL1K,\D,KJBQE)\<VVQ6=?R1S61O]$+)
M(/?R5R^`[ON-B&79>[K'_:29FW^U>U>KLRR<V&QX,MS,/IX631KH&1QYT<_M
MC$M;(0Y;PJ*0!B_*-_EGJX+F)]$1/\$_IP/W@.`X#@.`X#@.`X#@8EGU:>YP
M7-*B-,%72;7$LCK8]@=7("`>=3S(HIAE8>,]!12%1[O!!KX;]'-_5`P7KK/J
M['16I349W3*0.`8O75%@\CROM*ZIJ(E7%M5>5SRJED.'\R>[GN]7IY<Y?*\"
M9^`X#@.`X#@.!%.RMQX?K/[.ML"R[W-;N),DXGKG&0LM<XRYT)$0K::F:42L
MB-,YHRS9+P08RN13&8G`P2OHME9]'!;;:'"P^$V9#R/'L.Q.ZMF&QN56".P$
M#,,JA2XD;+3R#G0SPCBC@,<-BL0KF(1P3!4T,NCKQ0:Y!`8C4FE096?ZD\8@
ML?%(\L8AI(;!['.-((]TCV7SY55^@94(CO0#)+@LED"CWB8_Z*]K6_-\2.7W
M>,;W>//^"IYX'OX&*V^75E6R2P#)=S8`8_UK::.Z=(>=KFL^V(0?_2Q#>Q&^
M4,0?JUR*OTX&K;L=E78;L-V>A=-<*V)6:'PUNKJ;:6>3Z(TV7G^5X_97-M1W
M>*)?Q6QV5D)8@X[T!6DCG.I2?-,:%B!,%L:S2&NNH77K/"Z3PNJCY%A>LLMG
M5-K(JB6-]>6E53VEK6ALI%3#?<S0GL_7V!&:I'^?HCB+[J%@-32+B;K/`K'(
M)LN?>6F(X]:V\F>L9TQ;*RJ8DV<$[H@(L971I1WB16#9^UB>4\^54)"X#@.`
MX&E;8UMF5C^2.JI7RXU-@V+[WT+>,$C1?<Y,*PZS[V#;O?./'*R/'KK^/"<X
M#5:1!PS/5S6$3R&V;:F=+KK66<;#BU[[UV(8O;Y&&KB(\Q;1U9#)*9"C-![$
M*64K$:Q&_5SG)XX&(:>V3>9]<[2K[F/5QV8=DV.5M8*N'9-*&%>X!BV6.C69
M9T<4:1819=V1BNC/(-1(Q5]7JK4"<N`X#@.!I[ZD[$I=;;3[ZW3X&09`Z7V(
MHX1UK*<TD#&Q,4:I'FFU<:Q,2P"$KD<(J*4GQM07EGCU"1-L6M?M+L-A1`OG
MUSL<J]69?;X?/P[-9^23,3P_:63S;:V6A#B)T-563Y`X,8JO8K)ONOT43?8)
MHT/F&`3M,!UY<'M26$`V6P[J+0XCES"4C,GR7(+>I;#F0J4Z0+`E+:B*%X2?
M*-R^6^KFJC0KEF&:MCU/8W)<::8.59T:'UAT=)N*F:&R9"3^W,+CR8^3T-/,
MR:1_(YA<W-TQ);E.PT1'+\:?NX&06=A`QWJ#KB!B,^TG1*OM9I[$X<^Z':1[
M23'%VSQFM(>66VC0K"7.=7>7&(]JO<?W:]5>CTX&T7@5=W1:?8[YZ?P?9$6W
MV#M.,C5:Y5<D?1N>2U\*U?#51`_U^G_;XX%HN`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@?BJJ(JHGE4151/*)Y5$_3ROT3SP,(UUL'']HXK#S7%7RCX]93+:+62
MID*96R);::UF4LP[H%A'BSHK/Y&O,UB$&U7L:A&^6/:Y0SC@8/LXD<.M=A&E
MO4<06#Y824]&-*K([*"P<9Z#>>*PBM&BKZJ4:+^BN;^J!#G2^1CLSJ9USEX@
M&1'Q67IS7TK'!2J[^'D-II&,UQJ]35/\A;?Q;WQWM<L?[J0@?/HA'(B+P+-\
M!P'`<!P./*EQ8$8\R=)CPX<4))$J7*,./&C1PM5YCG.9S!!")B*KG.5&M3ZJ
MO`@F%LC*MHL5^H*\$7&(]_!AS-A9C66`:'),=+#^YL+36D8)HT[(2",](PYD
MA@:[YFJ\;I+$7@9]A&N:;"8D?UF7&3WS(1H$W,LOG.OLMLHTBSEW!8LFZE,^
MY'6,L9I'AAB4<2,WU8(;6M1$#(K1K9J%C#>>0R.H63(,-_P24>9PC1BI)0@2
M"0;4]E1KD]FJO_+@=/+G/L2,K)1I,%4G/@$L(B2@19SWC>.1#CO"921);4(G
MHXJJGE%<WZI]`]\AQ8EE739$><93&)`BQ!E&9\5SA?&24]7/&A(YAQF.<B>S
MFJJO_P`>!'/9/))&'Z;R?*H]C:5:X_.Q"TDR*B5'A3"5L7-,>?;07R9+"!%`
MLJOYH\I?'E8Q"(WPY47@<UNRM=8B\..X[56DH0\.B["*#%,<E2XL7%K+^097
MW<\PQA3Y;5U,=&(]72"*)5<GZ*H4?PBSAYG^36VSBA:^?CTCJMAK8MB8IHJ`
M#?F;D\$L:$A?60MG6V<97N*-'"^)48O^=.!>+L;$D6'7W>-=$DS8<JQU'L6N
MCS:Z0*)/A&GXC;Q!S(<D\RO""3$>9",<XX4:YJ+[L_S('CUQJ#T'7W1U)*@D
MK9=3J/7%9,@F*TQH\NOP^GAR&%,V3,:8OR@57/\`E*KU7RKW*JJH31P'`<!P
M/GM[PU609!V)VK"J:6-E[?YC^-B0IM$2.S%#SNB79>.Z<N05UBV**%=V4R/&
M27?#9"84Q`#^J"=P-D=`VUQ+\;V*COUD5ESCG4S%07BS),&DDULVLUG6BLG&
MDJ#(ZZK="()Z^6LF"%Z^&J]$1W`DSK:^*Z;M8<7[U&QK_!XJ,DDNW1QB%JS#
M?B9$;;?](QK'.>UWV/M&7U3RY2>Z-"T?`<!P/Q?HBK_@G`U(=+SPI^P_R,2<
M[I36U%C_`&1IK09P5I5%:+7X16SXTBMB")]](D5L5T<)/W*)QAN]?U>B!+NX
M[J?BG9JAG8O;1`2)&NM=N940:RR3+;45AFNTSN@S<NL&MH$PJP.`;&5II2!C
M3F)(()K5&Y0R?3DP6MNJUMLBF$:=F>51K8_Q0'P;$EKG)K^PP[&HM6(KXT:4
M0EBL4+`D*UCE;X<K/+O`0)<5>1Z_S:/K'";-0SM#Z_HLW+DTX3W51-@[%N\;
MU9CEK:8K!C1,?G-LHY<JNEA?,C!3U$1&IY81@2E>UK;'KQB<8I/=1]SJ66JO
M^(B/)![B2)",$T2((2(0'[6HB*/QX_5%7@;%>!3[>C5+V=Z/B1'*@LTWE.<J
M(JM:@-$99%17+^B?OGHB?\^!<'@.`X#@.`X%#^]_9K8/6?!J/(<`KL-GV-R:
MPC,%E@[R3\QHI*SW^R#3*,84A0IA3N?*(P)B-&!'C<1KE"V&U\X_VRUAL'8G
MV#+1V#X9D>5,K2REA"L"453*LAPRS&`E.B"DOCHQQ$$16-551KE3PH5FS[?'
M8+4^"TNS,WUEJ&RQ25D6LJ2WC8EL[+R7\0.R<UQ?"HTJNC76LH$">6LEY0,S
MAD.!"#$Y$<U53@1/L[OKFV![<RW`(FG,+7$<6S"WQF1L/,MRDQ**RLQO#L&R
M?(,KET\/7>22&Q03\W;718$<LF=))$(9S0A<UW`N]I'9;=QZFP+:#:=U`W-\
M>B7J4[I9)_V'W"D:H63#0:PT@2J/V8XD8!%8J>PV.\M0)3X#@.`X#@.`X'B_
M_(_]RM_:[]R)Y5OT7]WC^OK^O`IET%LQ6G7"J=&Q5,(AUNPMQ4$#$OOS6CZ2
M!CNU,MI(8S3Y,.%)DGL`06S'N>U[D=)5/D(B(]0N?P(]VY&2;JG9T-8SYB2]
M>YI%6(,\6*24DC&[(2QF2ISQPHSS^_JA#.:)BKY>J-15X&`]4<3FX'UDZ_85
M8A''FXKIK6M#)CBE!G#`:LPZGBE`V;&D2X\Q`D&K?E84C"*GLURM5%X%@.`X
M#@.!'.5;+I<?D@I:T,S*\LFV8*>-C..`6SG0YTJ'(GA-DA`*L?%JA(<9Q7S)
M[P"1GCT]W.8QP8TNLI^>$I[?<)HUB:L(22'`*&PGDUT*2DKYX$NVB3`QI66V
MM>)C&H26UD-'^SF16KX=P)G$(8!#"%C1!$QHQ#8B-8,;$1K&,:GT:QC4\(B?
M1$^G`]G`XDYIW13,C,5Q2,4:>I&B>U"?L<1CWM<Q'C:OLGE/"^.!Z0P71JX<
M()6*4`/0,@@&*UIFM7XS."U4:JM=X7PBHO\`QX'(8(WRJ\Q1%&C!?$SX$:\1
MVH]I2H7W=Y0B.^B>$5OU^J^>!`7:R#(L]!9_7Q!B.>6''PL`:AAY..0BY71*
M\#J*P5L.P0PT5OAZH@_/R)]6)P(RF7KJW/,JG7,:0!<@ZWZFQP,:/%.H(MW;
M76V?('UPWF+#CH=48]57U1J-17>$1>!4WK,(<7OY<5RNAC;"Z:Z/<,#!O&=)
MK,9QF)(&P7Q>H6"@L"K_`"1RHUPF\#89VF-%C]9>P\B<ZQ'!!I#:AIA*>0^)
M<#B"P>\)()3RQO&^+;#"URQB(J*,Z-<GZ<#M.N<0\#K[HR%*E3YTF)I_6L<\
MVU^[_E990X;3#?)M%GO)-6R.YOL?YG*12J[V^OG@3+P'`X\N5'@Q9,Z89D>)
M#CFE2CD7P,$>.-QCF>OU\,&)BN7_`()P/&#-BV4.+803#DPIT<,N))$Y'"D1
MI`VE`<;D^CAE$Y'-7^J+P/GP[HX=G%MV,V_<089:4^19:&BP*>2YCG%;R,?Z
M+[NKTFV=;5+:+559<ARM!0@WP84>9(KWEC*9_JT@;,,@QV34?CL!BF7?%:S*
M?K!CE%D["-NIT>UEU6!U<&YCG'5U5CD,B-9'C$&1@(9):L>K6C1_CP$A]<GS
MY.2;TF2O9T4F9X9&K_-E$F,C,B:HPG[RL#`9)?9T8JZQ,5B1IP02'>?F\*TK
M?`6FX$<6MI##M3#J8MN2/-G8?FEA$I/C\BLP5UCB8)<[Y/"HPM8ZQ$WQY17-
MD+^OC@:\3=BNZ&?;2W%C6CL?T;=8CJ#9<G"+V?E]O9TDP$=]9$MH9%/!6ZCJ
MO\?*:]I_56E)Y&HAKX\ADU=>?E/>*66=A/6`KE^X9`2#FEZL<_RL(D"<T[Z%
M7CB!5C7E&YI"$0B(US?"\#I^G76'?>NZ?NA(V[3Z^QW(^Q.QAY/CD7'<HM\D
MJ&19>O*>@N)ME)%#K+"L:_($F/CQA*][!(URD5SU\!W?8($YW9/"\<I9DP5R
M+7NL!5KXLAD>:20N1;B%%='DE:Y@Y*RX`W(Y6N]53V\?3@9?I*J%>8!UEP&V
MKG+7X\')MNY("5&K[2J$;&,DMFX<*PLWS8AJZY;EEP*TC/:`R.)4F:1R*U7*
M$*8OF`\WQ[L-M&/(B6E9M#-<=RK'K&!_*S"3=?1\VU?B&MR1@2WQCQ(C\?IR
M3RB2%X^><]PR^OGV"<LRN8<?26NIDF*&N#*[@X=6.BQ1.8UTJ1VC/71W?&4Y
M?:1/F^A2JCU1Q".<U$\HQ`OMP*R;:9'7L)U/(5[6E'>;D2,U4\N(1^J[)KVL
M_8Y?*!]E7ZI]$_KP+-\!P'`<!P'`U6?E#QF1DN`XA#?$FK6GRBA%*E-K)<^J
MD$'D%/*CU5@:/.&.N(4P$."20"M"8#?WN1RB<%S>VE??W'6#L'58E26.39/.
MT_G\.BQVGBDGVUS;2,9L60:RO@@13RYDT[FL&)B*\CG(C4553@5D[$;$I=I:
M1Q/6F'X]M.PRN=LGK@Y:J1I3;M2(<7&=QZZOKZ1+L;K#:NJ@PJFKISG,8TA@
MQC"KE5?'A0HON*HS#".RG8;-Z7%<Z67;[5DY9/%+QO<,BLMTPO5N*`P6;A;,
M8Q"\I[5UX1WVT5U85[4M8QUGB5S4\AM=Z,U)Z/I[UPJY&-Y7AQHVI,05V*YU
M52*+-<>0]:.2RGRVFE-;(J\C@,,@YH'HBBD->W^G`M9P'`<!P'`<!P/`G^1R
M>7)Y:J>6^?9//T_;X\+YX%1>C-T3(.O=7:%IHM&XFPMS1&Q(=)6X\&0RKVYF
ME6RS=55#6UX)-LV%]P9P_/R&(]ZJJN7@6]X$9[IJYEYIS;-+71!V%A<:SSNK
M@0#"20*=-L,6M8D6&4"B.AQR3F:Q6*Q_LCO'JOGQP(TZ:#K8W4_KA!JIH9T2
MOTEK.O4@I$20H)=?B-3`LX!OL4;&CR*JUC'B%`UK/MB`<%6M4:M0++\!P,9R
M+,L:Q7[`=[;Q(4NW?,#1UBO^6VOY<"">QDU]#5B]YUS8MA1GD0$<9"N1OT3@
M1@]NQ]IL@&&6SU/@4^MK[%4&\(-MS)GWCRGK)2(EC38?7FA,8U[A/EV#FE<W
MS%(GT"2,/P3$L"@RJ_$Z2)4"L)K[.UD#^21975H5C&&M;RVED/9W5H9@VHZ1
M*,8RM:B>WA$1`RW@.!Z),J-"`65,D`B10-]S29)6``%B?J\IBN:,;$\_555$
M3@1#D'8OK_B>01\4RK>&H\:R:72GR.+0W^QL0I[:101I'VDBY!!L;>/(+6AD
MHK'&:U6(Y%3S]%\!'C.\O3$MN6@!VKZ]RKL#O0]5#V[@TV>!RL<1$-&BW9BB
M\L:KD5R(BHGG].!RX_=/J5+D28D7L9J"5(AG^VDBC9Q1G<(_P-E-$[XI;T5Y
M(KVE9X5?<3D>WRU450QG<NS\!W#UAS'+M3Y;C>QL7FWM'C@+W%YRY#2RK*KV
M908_D$$,JC(4A)5-8!.$WQN10&"[W\(UW`ZZ'<1L>L<AN+UDR%`NNKVNJZM^
M*LN92SK*M-L=\VOKSQXDEK98@V$9%"KW'>\S'>/JGD*6]/LBA91WXSY(-W#D
M/P[JOI7$+NH"=5FUN11<'U]9V55/')']RDFI_EVH8;%]1D*B$52(J(&R7MC9
M,I^KG8VV)"JK)M9HW:UA_'7E2"^IK!T/![R0R%:T<J7`C7-?+>-!FB$.%D@;
ME&XC$=[(&9:2E7,[3>J)N15U=3WTO6^#R;BHJ!N#5U=D?&*LLVNKPNE3G!A0
MI+W#$Q3F]6-1/D?_`)E"3^`X&'["D,B8!G$HH221QL/R:02.*=)JRG8&EFD>
M$=G"#(F5Q"M;ZH<0WE"J^[6JY$10]>MW,=KS!'CCMB,?AN,O9%99'NFQFOI8
M3D`VXEB#*MD"B^OW16,+(\?(]$<Y4X&B3M?$U6[?G<6WS)E95V<V91X[13;2
M1+BU>37$'H_L,U_`G0&@*_)?X'$K0<@C01+!L%BL(YKGM]&!NAZSN,_KGH5\
MAD0<@FF]9D.R`L]T%IB8;3/(D-UJ"+9NC>[E^-9`A'5OA7L8[RU`EJOHZ6ID
MVTRJIZNLEW\]+6]E5\")#D75FV)&@-L;8T80R6,](,((4,97D^(3&>?5K40(
MSVSG5W@\W5#*>*R5'S':M%A60.)!-.'`Q^UI\@FRK-RAE1%@+&EU8&))>I!"
M4OAPW([Z![K>^KP;DPVG,^O::7K[-+*/(.L1DEHP7V&0U9$DF\&4<E\UON,3
ME]U:U7)^UJ\#3OK+.-JTF1=Z?]OLQB8CDN7?D`T;K.HS>!04F5R:K%LUD8A6
M7,F/6Y(^;17%I"I[.1''\[4&%$1$8BC:G`F#,"=A]4[]AZ6#W@9B5;EFLZO*
ML<6TZ^Z:**SV!D&P;3'ATU/'&RK>>TMX<:1)'#8JH8P%0;?+E8X*WZT["=Z<
M\ZK]A]ZSNWV,8UG^BI?8&-%P*7UEP6?1Y<32M'*N(C8]BS(JZ>@;5T9&3'!<
M\L9KE7XVJB(H7&%EF2;$[E:_BR+^U(V@TIU@S^^Q(N+NAXC$LLSD]A7SLDH<
MP,<H[*\G%@BBGJV"$^'&C",Y[_G:UH=#C]S;1]"9=F>'BCGRW?F;8EU9U):R
MG5&'9`+"XF2W&$3<DI<FGNL29+#B'F99E].Y!-65%^/XQ(WP[@2ML.E9C%?M
MJEC1K!E-14FJ*VN:L25+C%KJ#.<$@_<!9$19<VQ2'#:I6"&J.>GGS^]6M#V9
M9$BWV@]7.B^3AC]TL(L&N,\RN4M;V[D/>Y'*Q_NX9AKX_P`K%1/HJ)XX&Q#@
M4ZWB<B=J>D4-KWH,][V!D&8U[FL(V+IFQ&Q",3]I&M++:Y$7]'(B_JG`N+P'
M`<!P'E/\?Z^/^W_#_GP'`T5]YM&4>'[?A9=G1^V%[I;-:C-,BN3Z>R*=D<RM
MVQ/NH,NFI:_'VCD-QC&(M<)Q6M^%PY1E8U7(P!.!=;\8N+[(Q+IMK>NVO7[)
MK<UEW>R;J8#;US-N]B&K+G9.5V..3LC-8D+,KRV&/'BF#`>O_0`(P#?VL3@7
M^X#@.`X#@.`X#@.`X'@3V^-_HU'/]5]6N56HKO'T17)]4^O]>!37\?\`$P^O
MZLX-!P@MZ6HBY'M04Q,GH8^,9`#(_P#=;-'Y1#MJ*)8V\.#*AW[Y`O(I)F&8
MUI?;R140+F\#\5$5/"IY3@5=R?7>4:AO+O9VAJ2/9P<AM67FU]+C*.!`R\GH
MYMMFFN%<HX&/[4,!&N.`BBK<@4;4D*"4J2U"6,0V]K[-\`=LRER``L2BQIY[
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M=:T^1V]_4XK&9=Y7N>7A5F.KA9!?1`SI,&KL?M1/>3T>@GM0(ME[H_(]LS!+
MC9>*`ZLZ$Q"WQ?)IV#XW85FR-\;1!F&))?Q;#!\HL@R]7X#775A:4SHHG`CS
MPBDB(QJRD5OD.GS;4V\,BZ]QMZ9AV_['YU`ETVG]G1JK7>3XCH2MEXM,F8O)
MS2G?#UMA-%<Q:V[PRQEDD-D6LA\>0U7B(+PWU#/-W](NL.,VG7JYL=;3L^A%
MVYCFM\H-LK.=E[7-D6+9WCV5XU#JLC3.,JR4%O6ERRRK91G2AD9\@&.<OA%7
M@9A=]7>M6`=QNO5[C'7G4-3-R71VZM8GL8.!8M%%$H,4N]<YMC]4**D)L=21
MYLRP<%S`J5@RF17HQ?50F+&,4UWC_;K8--78SC==/ONO.K;=E=7XO30HOV&/
M[`VK52)931(0?>04MZ(7J_V51C1/*-:B<#OM,BK';>[45@8,%`U.R<"1C&B"
M[X22]*Z^D*-H_1&QAC$YJ,8UJ(C?KY7RO`J9J;`[3/.K_:W"\'J5M;&R[G]E
MS4]./('XB&0ZF[*3+J;#C9!&81]:PB59T1WKZO(JB=X8Y50);QO-.X.+8ICN
M/4_5R!$B4M'6UL&M+M/`[A]9$A6#Z6'5S+>1E]82TEQ**,&=(DL$UA$(X(VJ
M5OU#7%K_`&X+J-W9V_FF]L>SB/,V!@U#%/4AQ&@OK.EM2K0BK?XO*\&A,Q<N
M&RJ>H1`@D376HC>/ND5RKZ!:'//RJ]0<FHKW7F9U&TZ^IS*BOL3R:+<8:^L)
M'K[JID09L*0UTXT@*V$&41@CM&\:.5%15]F^0A+4_P"8_K;KB)4:BRVRS#)H
M-#4QH6O]DUV'1JR#E..5Q(E/58SDU:VPBQ<>VA5#D1(OV;/`+UJI)A>KU+$"
M%ES?E[ZB`CC*2RSIA2?;N8QV%3VA5DF`VP&BRGG8!AE$[PK'.16N16K^[PBA
M[/\`\+WTS8]6GS*SCL03G(<U8!@'2&?<_+";_P"8*?[@/VK_`&51M'_E5'.:
MY'<#$-I_ELZ83\!RBF@93>W[\JQ6PJX`8U,2%!E1,FI"!BS)=_*>M33P3QYC
MB,<=WSG$)[HX3^$10YNL/RL=.*3!];XO=;!A5LZ!A>/5$LT)D0U("?2T\*NG
M`BNCSCR`Q1RP>HFE8Q[1N:KVL^O@*XY7WWZWT6U<OW)HK?6I1VFRY..S<SUK
MM_!4DUF0V^%T0<.KLDQG.,6MH>6XG;NQL#H3G3(%P`OA/4;!^>!GV+_G;Z?0
M(X(^Z4O=7G0#GFR;&6,V]JXI&&#'<&)EF"`D7D"0IY#&_!:4U:5'*J)[HB.<
M%EL;_+-T3RT8I5!NZBL:POW+4N(OL>M&:)++`/#.\/R213VSA*)`J+W5ZM3Q
M]>!#/97NWTAWAK^CHTWK0$%`S"+;R:>(>=3Y-.2#!N*F96TTV97NBU-R^-9E
M(%TE$#(8)X?<2D:886*%^0'I5>UM6J9["O*](P94,G]IWMN."&,<T8SGG%42
M6@F4T^&0$@;'+(`<#_+?#%>@:V-`Y5"SJ'V1V'B5E6V4+(/R;=?9-(*JLZF9
M1RHS;+#+&KG#LX\=?N'VT.X",Q_"%^$`VL;[,57AEF8A[V;*V+&SJ]U!18]V
M7P;"=29;3:MQ+/JL5/8X94]CLS:`>8E?DBTN018$%73I5<.YB-LH\4)6D!)3
M[-`K7BECOQ_3;LS6UVDL0N-/9_@??_*=T;9=<A2QUWF;L,R22VBQQ6VL6]EP
M)-T`(XA!5YD/#*8I9$9PF,*&U[35N:=M\MO,R.PR?7^O>KW5_-*?Y,ME1L9Q
MX>08]L\$O*H``,;492^Y@0$-*DRSJ\4>.%XD<KN!'O4.\=DT'IWC$?&<FD8_
MJ[3Y<@O8E8D,T+$\YV>RX7#/]RL>L(L.VH%K,+I9YZZ6W_7;)MV,>%J/4C0L
M+LJKM(-_NZUEE:R@D_[/+%`&>X\AUD_:%0LB0Z$WV=%B2(X0"(_Z)X&_Z>$]
ME#E6S:P6FM4#IK:5=5\GM5AA!V$RL;4&*9_8Z5.G1E@M1&M#`FC*`9/'DXQ-
M*OU?P+P\"HFXH39/:[IM*5SO-</L2=K$8]4<I]=T\17J]&J-OHA_'A515]OI
MY^O`MWP'`<!P/GR[18U>Z/W=NC*,[_(]C.CW[0UV*FC2+G')V9917XBI;3XZ
MBRQ:)'C5./Q*.#*18]M&,RPL$$U7H-&_4-Q'4J)AL#J]U[A:[SVQVE@<73FN
MP8?LFW">/9YYC8\6K&T^73P2F#DAE9!!1DI[2)[M<3P[Z^5X&M3\J;MHBR7"
MI3LDVO4:@AT&/S**-J&+<R3FVW6[3Q:SR"+L!,=&MF2DL=3QIHJF.JN::Q]D
M3Q]?(77_`!V%W2?I]J$V_GYF_8I8F3$7_<8`(N?MPM^8Y`NM$S2,"/&6/DJZ
M[_C%EC,BRV%54D.4_P`B\"W%_EV+8HZH;D^14N/+?V3J:D_FK.'6I;6S*Z?;
MOK:]9A@I*FMJJN3)4;/+T!'(_P`>K'*@=5K_`&1@.U\;!F.M<PQ[.L5DRIT`
M&08O:Q+BJ).JY18-G!29"*439E=-`\)Q.5""(U6N1%3@9MP'`<!P'`<!P'`<
M"H'5O^+U-5V'6B[+*JLHP?(<_N</!=B@1)6=ZRO,VN<AH\RII<-11,D-#CWP
MHMV00Q2(EDCON`C:4)#!;_@>!2C",AC$8((F/*4I7M&,8QM5SR$>Y4:QC&HJ
MJJJB(B<"LN=;ZNSW<O`=)8=)SK-(LD<*UR.\CV=+J_$#$^U7WNK]L)\S(S"'
M/`]T6G&?P,J*61'3]W`B[,.N.=P<EK=_462TMSM2AC3I658+:1V8MJ_9\$BQ
MY!@W(ZZ7]O19Q208`X=+DA6R2!B,^ULDF1GN<((#S'\MNCX<?7U5IC6>QM^Y
MIE6U*G2V14N"5U?'PG1FR[X-A&I:3>FWROE:TU\.SNH20PG%.G_,TXC!:01&
M*X,AVHSM[99'JF'O7<5-I36&QLFRW$KC'.K()@<BJ+-V.GR37E?E.^,]KI-W
M$!>)06-?*DT-'1$;8&BC`=??V<'8::Z\Z@ZY]D,"D5N')=V&_=,E$?96=3;/
M8^=RMIZV/_.SG2]@9O*O<G')S3"\OE&*(4L48G\$BM#Y\J@=#VAC9O37/:O4
MV!8]D.>W6]]6XEM'"L#IPPXYIUC'GUFE]H"QVSE3:<%?;4S).-Y"Z0^2OVCV
M/,K51_H\,TZ=[/PLNMMOQLV6MP?$HE_$W$Z7EEA"IJN)3;EP^+LO+Y)RV<KT
MKVX_L@>4AD(9Z*%8;G*UC41$#N]#40,VZ9[4T2E@[*#Z^?OGKPVR*]3GN(U!
M+OZ_#;`RL:(;CV&)6M5)11>`N^1'#\#5K4#,,N/D>U^G>N,NK8&1R,O'7:$V
M42KJX)DR=]UB.581D^1U<>N0:$=8O_C)D=PE:UKO*M7PGUX$S;,PVZNMG=?<
MQJ8KY,7!LRS!N1N84+$C4&4ZYR6F20497L><3<@;7IZC1ST<K7*GJURH'4.P
M;*A]K)&U7OC!U^+KPS!#D))$,O\`=8]C&R5'D`_P1(L>D<Y?E\^C5>J+]>!T
MD05WJ"Z[3[CGT4[)L5R*RQ+/L=K,6GUD^[NJK%]38O09"L"+83*RNB2DE8^5
MPV'E"$9C/?W;[<"BG5+=?8O!,9W"ZKZ,;KS+#<\WQM#>6K<SKL\T-1,SG7N\
M+=-H4LQ])D>SX%A2VU3_`'"6O.$BO$5\9AF%]3(U@6+%W'[!J162?QM=L@-4
M3G,>++>KDI'&:U'(%R,WZSXT?Y\(]5]?*?7Q^O`]\'MOO4$BX-;]`^V3X93`
ME5$6$3K461"B_911%@'+'[$&2?+?8#,;Y/4+6#(T?[E9[N#M9/<'9P!->O03
MN+(>\1"?#'A]?C/:K'.:HB.7?3!M>]4:K4151R.\_P!%\!'V:[IIMN8?<T>T
MN@G=&=2Y%"4-]A=AAVO9HY2@+[@1C\<W8>&"QA2((9425&DB-&DM&8)&&;[-
M#!]8]LML8'?2,"R/I]W<SK5\2A--Q'/[W4=#+V'228)X$0&!YWXV#.;G4IT$
MA#P\AC$0A`@^&:Q\GQ),$X3.Y&*QRM9;]2>W<-KV*]9$[KQ\H41JL14]@7DD
MA%;[(J^K7(B)P*95?:G&G[.?%K>K'=JRN,9F[5^4]5U-M:VOGU^9Y32W#4J+
M+[^Q@V)*E&PQO/)CL0[7*HS"]3-4),F=HI==:X[!EZ5[<T%AE%F>-`J;;JY&
M5DYM9'D3[(`X=5&N9QXJ5[VD3T>I@-$\KU<OD2A*>M=H0,^RN/C>0:XWWB=?
M$PW)\NRG)]B];ZK$<(KA4L6L\0`Y7<XG&(VV8^80@(R`*24T)7>$:-$4.\M-
MQ0M0YUBV)V>D,JSC666ZU9L*NW?A>F[K)WEL27$>L#@U]C.M,$L4!DTJ@DI8
MCEE2&`@5^)1H_P`JH44V>[I3M;*;++[/H]VEUOFD20.4NQ<+ZQ[0P*[LS,^$
MP9R.J,1-66=I&E#:YOWL?Y?U<J_N\*$>P-Q9+I.9`HL0HMI[DQ%8DR2*%M[J
M)M*[MH<HCA+'6=?GUJLM:R,(I`JXE\*1X8J,AJC$^4+/:>[$0=C'SG,TZC[9
MJ*^+A5+AEA_9.F<LJ:6'E1(.36=A<6&`[%QK7^43%C/<`<296U-K\0"HUTMZ
M%4;`YM-E^)[CQGJ5H_0>LLM9:P]D:*W!O#+"Z7S#56#X'3:A!39/?&R^XRK%
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M=B%+:Y3MS`-<6<>ZK-;9+60:&6VNV!@PL1J:BQM*L\8TZF8:66,LDCU0`29F
M&3Q)%KLO*'W]/D5#G.-:%G5%UC\V3(QRT"_;=>Y]R,PQO6D@OBC<YRDDO$A5
M42O]VN3@9CF$Z>W0W7DE?[L?,[HZOCD='&CVMK2=E[+[I55ONWX20AJBO\^/
MW>?/Z<#8[P*O;4M(</LMU2KS#>^7<#WL*$]KE]1+#P6IFR'$;Y\*UPA^J+X\
MHJI_CP+0\!P'`<#1KWFC6.M.QF8[<I]X].==6V4ZEI<>=BO8_'K#)B2ZO&RV
M,F+D$JK!$GQQ/=9D>`1QH,QXC/A5KU8QR!M;ZSW$S(NNNB\@L+#![:?>:CU[
M<3+365:6FUU92;/%:N::PP6I."*>LQ*80ZDKP/&-XHKF-5J*BIP-?O>0F=@W
MA1$ZTIV2+V9-KRD"@=7KC<C43</CY79R*-^UHN7R(U)&B2+LDL9#-<LG[5%:
MUJIX\!?#JZ?L1)TGB1>U<'#Z[>BFOTS")@<A)6+L`W(;1N,N@F8\@5DDQ9(3
MIB#51)-4J,_;XX%&/RTZ:)L35N%9I_N3KG6P<$=L+'2W>T[^PH,9HA;;PXN#
MV&=UCJROM9=OFF%4AI9:J$D=Z')(?Y^B*UX27^,74S-6:4VE+BY=@>64VS^R
M^YMDXRW7$L$O&L7Q>595F'T6+.^U#%BP[^'"PULFUC,"+[:SEG$YONURJ&QW
M@.`X#@.`X#@<,=A"+(?$')$^2-2->%'?ZC5"@E*BI_\`8(9GG_[9.!S.!%FU
M=0XGMNHK8EZR56W^,VC,CP3-Z0C(>6X%E4<+PQ<AQFS<,BQY"!>HI$<C21)\
M5[X\D10/>Q0JV#M\;6%VW1FW(HLY["".D'%(^LXH!T>U:_PSXLC.Z78FK=96
M\`1Q/NZ:QE?/$1Z2(*3(I&>@3D/7^9;2IXIMRS1TD"TQF?0Y/JO$K-+/"[%\
MVX%.%8R[JPI:Z_FRPP(H8JM3X8RHXZ_&YI&JT(+O.XV')E=_HWJ-A2]G-RXF
MV'%S"LP^[K:#5FKRRFR(E;,W#N&4*70TI/:N,Q:ZK#=7Y%BE8V%Y8O@.#JC*
M,K[.X+VGZA]MZK%J7;5`F38!L*LUH6\JL6RC2>Y*.S?K?8FNY%[+-DA*N9C<
MN5429958YF1T<]J-&C6,0*Z]<-(R-T8AENK<^QS#,)RG2^H\BZ8[4N,26?CF
M<3,NQJ1$G81L7^VZP4/#[7"\FQ,E'FN,RC1FS:^RG'8%S!_*-0LI;6%QV4Z3
MW-7;)_`;A@PBX9.2^KG/7'NQ>KLC'60),N'&*PHH,W8F/1Y8'C>U25TP;VN\
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MS_4;WC3P]H2+H`B&T1I4S7N(TVI=<F1[F.&YZ%P^G(CE&YSW,54=^BJJI^BJ
MOZ\"6^!^>4551%153]4\_5/*>4\_X>4X'XKFHBJKFHB+X555/"+Y1/"K_1?*
M\#R\HGZKX\KX3_G_`(?\^`X&-0</Q>ND/EQ:6"DPCR.=,D#69,5YG?(7Q*F.
M.=OR*B*OAR>?"?X)P,B8,;$1&,8Q&HC41C6M1K4\>&HB(GA$_P`.!1?8Z9^7
MO-UX%/\`M'ZLC8[G,_'WD&%\\6P"8+FT&\#%*M<`@H+L=)'>5/NI#E*K/#`M
M5WRA<#/%:W!\S<YR,:W%,B5SU:YZ-:E1,57*UB*]R-3Z^$^J_P!.!B^(99C-
M!@F`1KJ\JJLIL,QD@&2Y21T(%:>*UA6?<*UZ"=\:^%?X7Z>%^O`SZJO::]$0
MU-9PK,(E$TA81V2!M4P!R1>7C56K\D<S'IX7ZM<B_P!>!VO`*J(BJOT1/JJ_
M\$X$8S-V::KI<BOL-MZQ@SX@S&EPIF>XK%EQ0QYC:XY9$8]JPP1AL'H![G-1
M&F5&+X=].!^NW7IMJJCMM:R:K328[D=GF*HK9$-S62P*BVOT-%>]$(W_`#,5
M41R)P.U39VME&4J;"P=1`(01R)EE"HPE"!)11E?]_P"HR"C*A'(JHK1_N7Z?
M7@:G=U[7P)_8SM%38GMC.L2S'-M-]1<6@Y/CNU\-)BKL;RN^[`RK;)=4XU:0
MKB/%S/$L*H[NTLU$.06X#&@C`C'C:YP;"^H^-2,3ZWZCHID&+6'B8I'(2LB.
M>\,%TN7+G-`YI)UFT,MB24^<8S/`$_NP7J)K&H&OK>V-U&M]V7[J[(H6(8+N
MZXHJ//-=/L+6!%L)F(YK093/V)@_H$T?'+M)=O"#=@C/%!LX9_F*%T@;R."P
ME56P_P#T_P#7Q:\<V##LNSV"7$2',C6,/X8CMV7%I%""LM&1I59$)$&UXP_&
M-K$5%:Q$5.!L0X%/-P(I.X'30?ZH*A[-S%3_``^+$,#B([Q_P^_\?]O`N'P'
M`<!P/G8_)3JJMJMS;YSN]WCUDIXNR]1XQ7T&N]WW;8$R-.7"<XUKF(I[00YL
MJKIAT%E!R6GFL1"K?U3$5$:-BO#=AU="R+UMT'#%E]/L$$+3>LX4?/<>$(%#
MFT>+A=*$.64X`BCB#69`-B2@M:-B(,J?M;^B!KM_(#,LM/[ZU;V%QSL;K71>
M8?V3::OI*O*L+R3/;?-X-Y?P)EC'D8W0(=DRHKY+8[@&(-A(Q5)Z$\/<G`OY
MU+R#/\LZ_P"O<HV9M'7^Z,LR.!/O3;-U94.HM?Y53W%M/L<:DXU5%5TB)%A8
M[)BQ2(5SBND`(YZJY5X%/_R@Z5NMP8MJJ'CEUK\V1SYVRM88[K;95\.BIMC7
M>VL!FTL;^VB2G)!D;&PN%52;6F0S7-8X)G)X5$10R+\5VL+[6G7C-)&3Y+K>
M_P`@V5V!V[LZW@:FR),KPG"K&[M85+/P6)?#*2+.N*&;C9%M/@:,([(YV-1W
MJI'ALKX#@.`X#@.!B*W<YL>2>=&C"AC0X9#HICOFQ7K*+%`1T8HX[BA(B(OL
MUS5547U]D\+P.G:OV@QG&T;V0QQY$FW67(1KJLI!CFC(.4CFQR_9A]W,]U(S
M]4_7SP.DN-F8;K#%06F574AS+"PG!QJKB0[&[RO)RF-(-6U./T$(<RZO;(P&
M(QB!&YOAOLYS6(KD#%_AV?N*)9QK$.0:8P&UJ<>=!;'EAK=QNL6V+IN01SSJ
MNQM*K%ZXL&,."J#4LYWSG>PH5:)W`C/L[=]2]":;RDV[DAT./9;86.1"KL;@
M6EEMK/=@4E<:^=<ZZJL4#(S[*-IU4>J6<*55L).AH#YWO&)CWH%'L@Q[N-M_
MKY2;+WGDD^/UXQN929;9:)P"T&#>&_>NAE67,M]W[0U_+%"@9G%P^>&Q-C.%
MF#`N%KR!E6)$FK%`%QL_QS!-(8EJOLCU]QO&:[76K<2A5.38]K:FA`H\EZOY
M"6/=V\K&JJA8"%+/KPCQY36*$9"FCBGQQ>7SW*H=!VEJ+_`=CZ0[VZAH[K.@
M8+5RM=;\QC7M*7*LFV9U9SY67(KS&Z>K0MIE5YIK.60LFK8D-AI4BJD6X8XR
M%DL&\(JU?N*CR+NKG_8C#L2V3AG77-M1:CTAEF>9SK?,-85NT^P4C8=BFL[:
MHQW/:3',DEU&'87>2*:9D)XL:$23:0H#'G?']0A?.;KW&L>RZ;/IOY`$_:6Q
ML=S+*:_[GYZI]GB6+`K?Y2+7.1@8#[&)CD`<M[?93E&QZ_N^O`FJ/&C1!(")
M'#&"CB/0,<3`B1Y7N(5R#&C6(XA'JYRHGU<JJOU7@>_@.`X$?[!VA@NK85)/
MSW(8N.0\DR*LQ*DDS&E^.?D=RI4K:H#V#>Q)<IH".8URIY:-WCSX\<"!.N^+
MU^R8=7V0S2^#L;+,N=;6&`V*,D)A.#81*LYXL;%JZAG`"E4Z]QI(Y["V(Q]E
M9D([R9(R""T.5VHR&-CLKK:6?E"XC4RNR^$"M+(E_P#VW72XL;%LZG`I+6<\
MH(DB!:6$4#%BF<@Y+VM:GEWJG`=C4J\ASSKQJG(ON9^);<RS8V+YABK9,Z-6
MY;CL'4697LFLN5@D`\D*/)@".C5(SR0:>%^JIP,(UOKC#]$]J:O6FJX$S$]?
MY%U[RG+;/#H]Y?V=+(RBEV%@./UU\V+>6MG]K*@T4PD4?P^C$$]R*GU\J$HX
M!DF4V':/L9C5A<396)XW@77^7C=(0KW0*FROV[2)D4N*%SE8,]JE;#^5S41'
M(!GGRJ<#$^L66VU\/MF6RLK2Q3%>U6W<=J4ERS2WU]748WA,F/6UJG>OV\*/
M(EE<(+%1@W/5$\<#I\?R;+I'X_B9I:WEH+-C];[_`"F3D4F8TMP"\=A=C:CM
M'S@-$S[^,=&D0C/7U>U%1?IYX&<[DR&_J]?Z+E5%Y:P9MWN7KY4V<Z`8:GM*
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M^;9OAM+$6CB@%73``H:X(B_()[SN"Q2*]S$7@99D.Q,R3IGJ_.RSWV&69I3]
M;QY!8)!CF;9"V9F.N:?+B&@*)D=D:SJ,CEM(U&L03"JJ>JM3P$J;CN[G#;#K
MQ38F2+6UF2;MH,'OXBP02F2L.;KS8MNZH!\\62L1K9^/PWM(QPG,07A'^%5K
M@BO9'86BUIVMP37=KD[P8U::+S/);/$,=HYN47<C*_\`='5F&85+?3XO6VN1
MQ1%;DM@!KWB9"\*\A7M0*N:'LPG-^S>>9IN"31XI7X/A$F;KDFL2[C$'^8HH
MX:T8-AUUO@&(V0[V/)M"B=,KC3+0:(D@?N-J->%`E.MT?.LH]FFV]FYCM;^0
MF6)_X<ZQ<+PZ'!+>_P`Y45P<8Q!*]9R4+&#B#--E2BR(PT0ZD<Y[G!&L.BP"
M!UW@;%E:KU9<7@<6#(5$UYC@84AD^_&8HFPPUGN&*245)#QM\HIT^1?9WU4)
M]DZATTGHDO5VL_\`7DD0:'PC%E^67,\*;U^2L_>>5\2*[_O/]4\^?'`B.:30
M%7>Y5597@NNX4:#E,#&?@E8-CAHYKBVPTN0J\RLJR->27CL<_N\G[OB"HU^B
MM:H59Q72NJ-C]IMQ7+,7QRDPC',-ZTY3@S(&'5M$#)!5>*;@'`!23WPH,J'3
MXU.GAEN'7H-A"L$U[E8U6\"]/75)":(U&LH[Y4DF`8R:1)(Y'D.8]8`Q"O>B
M(CG$<155?Z\#5_\`E<FPXL/'_P"\Z>^O-11\9VW>;4;18&W-:RNQJAU58R:_
M^Z',L*-M8>ZLR2(,)#RQ,E.,H6&`1PU4)\BY;'9UKZ:7'W$F5'R3L1IJ!`++
M89\A8]WG-VVO&]DAX9`TCQ7-8GR>Q!M8GM[JB^0V5<"K&QX$N1VOZPSDCC="
MK\([&(22I&(04B9"U4,`F"7R1S2L&155/")ZIY_5.!:?@.`X#@:$>\N/7^%=
MG\ZV,*#T4F)L_7N,8=08OVXR`,L62/PJNNK0^01<:E5DEE+)'[R()Y/N@95?
M#8Y?J)W`W/Z4K+VEU%K.JRBFQ3'<DK\$Q.)?T&"`!%P>ENH]%`%:56&QXO\`
MTP<5@3FD%7M'^Q(C1^/IP-2/Y0==0"YY"SJDVYI'&,RFZLJ)MMA6Z)EB)&8C
MIO<&'[$K,OQ5E%2WEH`3\X=`K+)K0.+/!)2.)WA2-0+T?CLUIC.HNF6B\&P_
M8=#M?'X6-3;B+L+%6##BV22LMO[?++<^-1F?6'0P;B[D18@7^"B`!K2(TB.:
M@1_WRU_D,F[Z^;ZQNIUIFEEU[RW*,B@:[VOE]?AF.W5O?TT.%49+1V]N:/51
M\XPZ77H6M(9[/B^<KFK[>$4.F_%=@MCA'7_84F[E:R#D&PNR&YMHWN&:AR>O
MS#"-73LUMJ^<'7,*]J3R*@TZDJQ1SRA17N#&-+437$]5(\+S['V_J[4%6*YV
MAGN+8+6'>HX\K)+B'6I)<W_,D8)R)(D^GG]WQL=ZI]5\)P.LU;OG3&[8T^5J
M79V%[!'5.:RS'C-["L95=[N]!OG01D2;$$9WT8\@VL)_W57@2UP'`<!P.FN0
MP&P)II,D-6A&`0MDKQQG,>(J+$^60JL5S&G<B(U7?7V5J?KP(GFLLKVLNX6,
M6,\-F&+_`"L&[G5D&QK323Q(33K%IRDC2[*6^&][&#FM\,(7V=[>&(H=KK[3
MF$8+.LLIA0IUOF612Y-I<9AE4P]UDSEGL&G\3"ES/*4&/5\=C`1JR"R-"CC9
MX0?NKWN"`M[]OH.*;$J>L^B(-%M3M?F,(TJJPN;:/A81J^C;#9-D;#W=D4!#
MFQ['*R`9LH%-%0F0WJ*QD..T#RS8X5%ZC"EX!W#VQ@'<"=7[%[<9$!+/5F[;
M5/2MR354RNERY6$:EPHA95/I_%HKJZPD,KH)#3;,(9([.;828#CE"YVJ`$Z_
M;-L^O]D=&:KSJ1<Y?UTE24<H:*01TNZV#H]3D5!-!C+RNM\;`B)_Y&:1%9Y;
M6?4.5IO&I^@K38FG+FO2-U^J(DG/]3YE9&@Q\7Q#%<AGR?[MT[=29"@!6Q\+
MO3OE4RG51$HK!D9KO_+W^0YNF\FZ\X;:3^FN';LQC+<]P7&;?(5U,W-J6SV5
M@>K+:]+$I(4ZLJ)3<@K<;QIEL"LK9,IK9+8K(Z.(]R(1P4AR`G<G9T[+^FD/
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M>R^O[7#'L@RY"7>;U%#F4RGQYMB`C8]#+M8K)(XTR0PHF2%8U&.>YG@(MU.S
M']CTW2#!X=UG-)K/*>MN9Y+1T6+Y;G6'V'C'8.JHV/)D5YA^21P2I%/2WA0J
M.8<I"R".(/T]2-X%JLPZ?Z8SZ+6PLV#GV6UE/8P[>%3Y'L_/[VG2P@8]98P(
MYZ6UR"75S5-36\EAF&"1ARE^9Z.,C7H%+\YZ:P<-RG4MAIW+M^9+C^"W=B:!
MK3-=P;@6NQ855BEO6QFX+M`MI99-@0[PDPD20*6VVK;93($R``U'H&;:]JM(
MY-L61%N+OL%@&P\>P;(L<N,?V5LW:51L^K3*,LQ?(K"'C\_^?+%S##UGP8[(
M5I1GL*YJC>$9F?ZC%#+JG!M)UFV=H95_NIM:K/D-)@],2YK=M[1/)M'0HM^T
M=;)`DJ5%&['6Y*(T%HV^X4G?+^CFKP(6ZV46H:S%-K3[#>VT(DS.^Q>_\TKH
MM9M#.FLNJ9F26V"TQY[WA(TRVE-CP)1">6M/,<DAJ^7-X',=CNB8W57)<37>
MFWE97Z1%17&+7.V\SB0ZH(,#GPV8_;.E_;QZX=O$85DE#&8Z9X5?=5\+P.#>
M6^$;)Q+%<=U=DF_,WA4\G7!XF>WFR\GPG6>.66.3:F\ILHQ^\GXY.R+.&5TH
MHVED4L"9$.,3@/EL\/5`R>VZG8?L<NNJ?>/87;F]"U.0V-RL!^8-I,5PDEQA
MUY'A3&8[#ISVEXV=]TZ+&+?RYZ_$<K6(C5>U`G.-UPP"/LF3E%-LS=&,WB8+
M"Q*+=4>=P($(6&Q[N?>5N)U]&_%7UT&IH[*6<L9&,1XT.YBJK/5$#ML,U)34
M.6;<E#W/MJEL[_/06=JI,VQN<^SDBUKBF*1+$D6=B!Q5Z@BP!?&)B(Q31!D>
MCO9Z/"'=/Z9K*S!=B5\WL%O"G!9;5WF<^.%RO#!CG?/GN6&FS7CD:X'/&N3,
M>^6=K'?;N<=7!1&>O`[3(=$NK>N>M:N#N'>1::(7KC6U5/(O<5GI'AT6;X>M
M6,SFX-&D2?4/P_</=X^1(HW*C51WL&:;1T!)G76G(>2;JWMEM8;<-3*2LD9+
M0T@XI:[$<XLFR%M,)Q+&;T<8S8ZQ)`UEH$\60\3VJKT5`G7&M;81KW/*0&$8
MS5XS'-BF3LF!J($"*.8LF]J;(LB?)1RV\V62>8A/8CBL\D>KG(Y6^0R[&_C#
MEVR#.^00UL,?<XAC"2,J#QV(A'A8GA0M'^A%?_F<GG].!F+K*O>$SASX3T8A
M6.<R4!R-(-KE>QRM(J-<SQ]4_5.!4^+8,+U`II$U(S3R<&I)18ICM1JH^U@O
M(KE$X;OC8K_*JGA$_JO`EC?^:Y[A&G-BY-J+"3[0VC3XS9%P;!JV90!F7&4%
M"Z-3IZY%>XW5R(\*:5L@X'3HQ3@$\8G_`"N8BA6W)JK-,.ZC5F:;DJL:K=ET
M.(9'GFZ8V)R9UOCI<ZR#`<BJ\HL<<?;`2YG!C6MNU:T3T22`8Q";[J-$<$#8
M#(K:C?V39??8]C]#7XQJ+JC@];FT_95;+FY/.A8KN>MDT(L&263^S9.-W&1N
M&R89@B7+9CQM]EB^B!LBTBP(M.ZO'&:C`,P/%6!8U7N1HVTT-&M1Q%5Z^$3_
M`+R^?\>!0#NGB.5;%WGH\=)CK;O#<)O#5VS'2[R?!QY\#,K#`XE+CF55L*7]
MM,BY@8I00GRHDP*'C$9_T[W--P,@L:%9V@^GL..Q@X])VTUO."$@&`2/74^Q
MLT;"C!CM\-"D6.T8QHG^5K4X&S#@5?V1>B@=J.L%(X+R%O\`#.QBB(WQZ1TJ
M8.K)1"$\N15]T(C$\(OU=P+0<!P'`\"D8$9#%<C!"8\A'N^C6,8U7/<O_!K4
M\\#YVNU?6C-N\V29WNKJ7)TSV'UGN$L?&%RW,[L\.#KF_P!<X+LK1>58G"'-
M%'G'PV9*S6196`Z]CCELJUGT<GK[!O7T?@$W5&EM1:MLK9M]8:VUA@.`SKQJ
M&:VXEX=BM3CTBT1)#WR/$\U<I?\`457_`+_W?7SP-.GY1L#UA4[XTQM+..Q>
M+:D6]!A=58X?98YD62Y;EJZGSFPSW7L/&DQR%/2AQ:WV!;QP9'(FC>&5#&V.
MU'H][.!?_P#&_JFFTMTAZ[Z_H-D4.WJV'A#\A9LG%H7\=C&62LZO+?.K&QQV
M"Y5/%HV6.1E#%8;_`*AH!M0R-+[M0("_)KHW-=K.TQ?T5KKB'BN(NV'%RAFS
M[F!48Y76ME2UE[A-^0=K9U<"X:N28D.H/$4K7OBVY'+_`*32*@9=^*?5V4:K
MZR7\/)<&P_6\?-]\[JV;A^&X7E%5F]?1X+G&6EL\9@S<PII4Z%D,Z-#11,/\
MQ"LALCB(J/&J(&!=H,PB6O:"ZP#4_7;3>XM[8IJK$<PO<DWW=PH./8[B=U>V
MU;C]=BD*]*R&8I9\(Q)3X;QD:1[?=JKX50]72M=4]C=G[/S'..LNO]&=J.H&
MW2ZZR2]U1:QG4&1!RC7E=>5<\5UB[JZ%E5):8OEBC/6V3)S(,X*$8_Y6M<P-
MMW`<#BS9L2NB29\Z0&)#AQSRY4F01@@@C1@OD2#%(16L8,(1N<Y55$1J*J_1
M.!!]AM;)<FNKO%M18@Z^EX_(P]+G,LJ?:XU@@:[*&'GR96*VW\+.'GUE4486
M'='@.2,CY8&$DC5SD0,IQ'74ZGM[7)<NS*[SS(K1JQAOL&"JL<HZQ"->RKQ_
M$Z][JR$)RA&XISNE33%;[.-ZJC$#,)F-P)3WF_U!G*3R0_RG4GP/DAD&CA>,
MPB`:]P&^OJOAOA/HOZ<#7[MOL'L_L?(S;0?0/*<;%D--6V]1LKMM80PY?J72
MF0!8^,W`<5;%DK$V#OAQF^#PAN+`Q,3FR[1I3J"MDA[]*Z+T_FW7JPPS6M1?
M:@V_BV>ORG-,ER.9_<FZ<6[04(!-G;$V+ELE16.R+3*A>BFL2D9$R3%9Z!`@
M(9V!$$![/T3(W[7;"VW47+M/=H]'5Q).:8O7/4"0MI8G('D%;F^-7TO[>U?@
MVSL=K6%J)1U+%<,$1CFL=&LXYPNAI*_I>YW6G56;[%J6UV0_R=%E$P6/6DNI
MN<0V3KW(7(.PA%"L:]P^Y?*KE=+JI3138D:::OF,<BE:\(G_`"<=",L_(UH:
M/UWK^T6Q.L^"V=]%M]BDUMCE)=V>RJNM\2*G$;R5;S(1H.-1;<8YIP1WHDTH
M1,-["9Z."CNJKC\.'X,+3`^NV79WA&"]H]EX?C-ADNRKC",XS7>F_+*VM1XP
MS(<CR6DI<WNH\C+<JAN6/1-FCC#=Z_`!6-:[@;\Y%I70P1),V=%@!G2(4.&^
M>8<+[B;9%8"!!$DIPG.G3#E:,0?'R/(J-1JN^G`B+.L^K==;*UD&WJ):UNV+
M*1KEF7?>1QU>.9/&@SL@Q*GLXQFM+XS,@)D2*5CU_P"O8$*M53M5`I9VFQ+$
M)'>KIA=;NPJEV+I;.\<VSJ##8>6M?;XA@790T6JV%@V03,0FO/C=O=YU@.(9
M!50)TN*4U=(AL''>-TQWL%[\PTEIW8.,&PS-]6Z_RK%#P35JT%WB-%/K10CM
M]2!B1C07,@JBHCF.!\;QO1'-5'(BH%/]>/R+J!O?!>NEED619AUOWLS(8O7>
MWS"WG9%DVF]DXG2R<IN-"6656IY=UDN"Y#AE9.ML3DV)CSJ]U9+K"&*'[#T#
M8AP-?WY`K^VIZ/K77U6-!R3^Y^T&(4MFV1KAFPVTE./`-F6]CD<<KHQWX/9T
M8:O[B%=!5L@4Q@HS/;[IS5"I_5W+<.T)K/\`&D_,[W(XV*4W33+H,[)LL#E(
M;VL!:2M)1H>2;`Q\=;$'0UORRF-L9]G$`RC*9K"N")YGH&ZP!PR0BDQBC/'.
M-A@'"]I`F"1J/&8)&*K""(Q4<US55'(J*B^.![>!@^>ZYP[9=.E+F%..Q"%[
MY%98`/)K;['Y[PN`EMC605IHMSCMN(3U1DF&<)D153V5JJBA5Z\P'.=9L([(
MZ^?O368)RVI\DJ2QL;WGB(1%<B&N04RT=%M6HKJUZL+($D.[6.)/8-B7PJ!4
MOKI0;KS[0^H*C3M'*JZH.-6+K3:&Y(EEC^&7E1FES;98LS$L-J"5F=YR(T2U
M$,19B4L-&$<X4AZ^?(6RT]U<=`R/(<DWJJ;0R"#=T]CALFZDA+A-.2-43(Q9
MN*:V@LBXGC1(3K(L:.4T639)'8QSY3GN7P%VFM:QK6,:UK&M1K6M1&M:UJ>&
MM:U/"(U$3Z)P(YI:2UB[-SV^E10LJ+C'L%AU4IJC4TB13/RA;(9FHJD:V.MF
M+T5?'GY'>/TX';/S6G$90DCV3#^YFO&^$C'L0#_C0I/<C?0141%8Y?HJ*GZ*
MJ)P/9%R6)**5KJBS8Q50L:6D'[F+.C/&UXY09`%(Q4?Y\>//GZ(OE45.!R+&
MXAQ"&`ZHG3'>@T18]?\`,,R&%[JWW\)X8T?T<KO#47]JKY^G`B['P4ES7Y1I
MV6MW$C1JX\C&SV`C1)Q\8F%<*-8TTPJN)(7%K<J`$1ZJ4?I'>[S[HJAWT?\`
MDLNPF?6LE'CYEBTN14+-1Z!)_<M"K/M+%SE^J0;P/QF?^B/C27-_QX'HN+69
M>XA2[#IZV>V]QMQ[&1CX)*+*,R.I:_+,;>@Y4:%-E,&$R1E*[X5E"$1/'T7@
M<BUGQH]CCN>5TJN/AV25\:KR%QBQ1Q30[51&QZ^:0CF`-Z'-]L_V>]SQ26HU
MJJGT#E!I*ZCR]Z&#`/499X-60RPQO=77\.*=UBL<B`:`42TKD:_T5RO4S2>/
MH]4X&/TF/T<>QR;5]S7CGP71[#(,76;!$X7]N9!*-_*U<62]A&*^CNY#V^OT
M<T!P+ZJB>4#PIL3J\LQ;(,/RFLKV9'6/)13+9HX2V4Q8*,+CF:1_B<0\6456
MBE!<]&.9+$]41$\<#&\]*[->MVVJ++8K#6]?KS.\;RJ(]'#::QJ\?L1+:17(
MHWCCVC!#G13,5JL:1JM5KF^4#6QCI:O&.VW8RQL?@L(@];_C[`KID.,Z+8/G
M5V^E1["#A$#+/6GM0G8YJ..I4&YY$5Z/X&WC4;6MU;KQK0BCHF&8XB@#_P"$
M%_\`%1?D$+PJI\8W^43POCPGTX%8\OMY;P[:61&F!M(_8;1,.-;RZ8$:,>D?
MF6M&5E3&L!$86U#!(TY%]T;\:2D5/9'>>!@']Q_R.(Z/J@5!*?%JKM!JZ%C1
MY\L<JSL2S"Y9<VS9ZA1@D)'N?<8U:QB.;X_545>!L>X%0MH1GG[E]3#I_P"'
M!UKVE(_]KU_?)'I*./\`>B?&U?5'?1515^OC]%X%O>`X#@<*R0CJZ>T0T,5T
M*4@@N:KT*10$1@U8W]ST>[PGA/JOG@?.SUHZ5=O<RT&CL2[6[#Z2&G91MB!7
MZ73!8\9<3L9&:9-'%E<:(7(J>;(_N<Z?RXDDA0A1F:CE<GU4-_\`KG';G$-?
MX3BN1Y+*S+(,:Q/'J*^S&>Q13LLN:FIB0;3)YPE*?X9=]-`^65GN_P!7E5/9
M?'G@:5N^FN<:W/NS+<GTWO\`T#$V3K_`L"'MO#-P7+8M'B..ZBVI$VCC.01;
M4$">&%[Y:0,*["U5*6,\<=_K\BM4+V_C(QO`,0Z*=><<UAL:)MW#*O&;T4#9
M5;1RL:ILOLC9KD\K)[/'Z*<P<RMQIN4GFAK6%:CU@B$Y?*N\J$6?D)P*YS+)
M]/7]9J7%]Z4.NX&=S<]U[FVS<>PC#OX;*`TE7575W"MK.$=)=?817/B3E8H!
MJA!.7R1/`05^+.N[.Z=G66D\DZTU6`]<,NMMP;TQC9=/M"GS:CQV\SK-::SH
M=0XC5TLZX$/%HE=93B1I3IAO*1'*Y?D(Y$#)?R#Y3TVG;9I,*W]U^W9L'8D'
M$8MKC>4:GJ+@5O8XR:1-^]JZVRH[VKG6\*AD%?(EC^,C8A"-=Y:KOJ$S_C0S
M#K/=X'MC$^LND=GZ6HL%V-&A9J/:]!;5&29MF-MBM--?E"V-[:V]OD(TIA18
MKY!"-8,@'"8QOHOD-EG`PS,<L-B[*9L;'<DOS7-J*M:N/TI[@-4QS7%+97C@
MF!_'50QL5JF\O5".:B,?]4X%;DUM9;+GO#V.RL.459K")(AZFPQME7ZB`L15
MDHS))\M07VR/C,%%..=]K3*U6L6`Y55[PM[%CQHD:/%A`!&AQ@!CQ(T40P1H
M\8(VC`".$36B"`0FHUC6HC6M1$1/'`]RJB(JJOA$1555_1$3ZJJ_\N!JJ[6=
MJ[?,KB]TSI?)\DP?5.%9A'P;N5W"Q&!&GP^N\6=#`>3@&%3)*O&_9EB*PC`N
M<@C@G0M=PYPYLQGW/JV,$E4G7NCZ3UT+,^G6OHS=0RSCL]VZ*Q,DF>?,H\D#
M/O\`=VNT+(EEMMWL:C)-RA2N?FL1KOF(ZS9&.\)/RZJ_GRXUVQZW3099>%QZ
M(/(L;HID(%1O_6@B'(/')IY[@Q:[.L0,8\C'YIOA/$F(>ME*R/),@@L0'"<3
ME9?%VA_`CBYN;$Q8F:Z7YHUB;&76#;T%%:!$;[:8&NM2$,!#-(Z,4QOB<U"D
M]@I#M?9,;J5V&AYK+IDH]([REP(NU+'[T:U-9GHHOV$/;$*N$-6TO\?71(\/
M+'%4:38+HU@-'OKYJO"]V64BY?B&2XY$OK?'79/C=S21LGQF:L*^HG759)@!
MOL?L!^WVMM6+)21$,GGT,QKD\^.!J$ZN_AA_'9H[-J/:>*T5GO?M;I?*;.PG
M=D=]9]D&X]P`V98XJR)$LLU);V;*ULJFK;8<VKA)%CL@_,R1&]2.:;@7BIW_
M`/JPT+GFL=D!3"MGT4Z=K[8L>@*Y)>!;5Q8L*ZQK/,0<<I9(ZXYVU>4XZ<CE
M<2%(C^ZJY"(@>-5][VCZWY+AN4-CX[MC'I$["<G,Z*([,(WSK6;#G4V7UL=/
M=%KP9/!KLBK%:ODM=)!^[]Z\"K/:S<&L]N]%Y%ML+.\7T]O*GM:RXU[6WWWB
MY-C7;O0F:QY5-3XOB56.;FF2#3:.*_9?%613GGT4UWJU12%\AD'5S:'<+MCK
MFYW`/86)Z'C&V)GN+Q-09;U_G7.88,'$+LE.E#E\^9LNCD&R6*8+V36I%$UA
M6JUOT^O`PW0M=GO=/9-)FVU=P7-MA_3G?UA,B:U!H*#J-][NS'L+M*.IOKC+
MG[!SN?/I\1J\[F--2Q6PWCM?5DTCT#\+@VXRI4>%&D3)9PQHL4)9,F3(*,``
M``-Q3&,<SQA"(0VJYSG.1K415543@5!9>Y/VDM:21@\^RPS0.'YSC&3NS\4>
M9`R/>%AA]L&[!2X/'FAC+5ZJ6VA`9.NWM*Z_"P@(#6Q7K,>&:9M%HG]EM0#L
MR@/+O-4;KH@TLF91OC6-<EEK.;;.D4<L+[FRCM&U@WE$[[02%]#M<XPE0(^6
MERKJ3(?,Q"MN<VZNO5Q;7!JT4R\S70'R&4DF[P<)),BQRK3T5CW/D8\!A+"A
M&CB5J&AM^Q"%I19K03J;%\BI9T>_Q_+Y%0.DN:8XI]?-BWHOEK+*/)`YX3P)
M#%:[Y&N\>KD7_AP,MX$/YQ)R_'\0RZ[N;_&R4=707]A8,'0S8\K^-CTU@YPA
M'==%"V0A4&[W<Q6JB.;ZIY14#B=:P_;]=="A]?5!Z9UBU&_^ZG]E4BHW]$_R
M^?'`DO*\C@8AC=YE-K\G\;05<VVG_%Z?(D2!'?).K$>YC5<@QKX153@=Q$DL
MF1(TL:.:.5'#(&CT\.1AAM(U')]?#D:[Z\#I,KRJGPNE)?WI#AK13J:N(2/'
M)*(V3>W$"BKD^(2*_P!"6-D)KG?HQJJY?HB\#F2:"CF2%ERZ>LDRE]/,D\*,
M20OQO:5B?,\:D\-*Q')]?\R(OZHG`["+%C08P(<,`HL2*$<>-&`-H@1P":C!
M!")B(P8AL:B-:B(B(GA.![_'`P_)Z&QL9N-6]')B0K:AN0D*26-[PS<>FJD?
M(*E_Q_N8^3%]2A=X7UD@&J_M]N!XDH)L7-!9+5?9MBV]:RKRH1GG;(,RK20:
M@F0&L]H[I`#3#"/[HCGA>WP[_3:U0]=3CTVDRF]E1'"?C611XTX\1YS?/79%
M'18LLL4*^0_9W$/XWE]5:YL@3G+Y^1?`=?2XM+!#RG$+:)&D8=(.=,;<PHFF
MCU-F!KY5.2.$0R`6JL'F6,;W<_X7#^J.9]`X?P6#L(+2Y-:"J<@JV&CQ+EDN
M-]R5E;+^"IO@$^-Q`.LXS!J?PQ'C4KV?X*H>B61<JK*3(J0E7<YAB%C&(6/6
MVJI#`:<(`\@J'ECR6L:DRFDJH6R$?ZN^$CF^41>!DEK76X\AQZ]J!M^W(5U=
MDU?ZQQE-721/)&G_`#*J*LBHGHU7-1SOD"1Z(BJC?`=9=43P95'G1Z9UM29?
M"-CV:0T^T=$8($0K*JSE0BL%]T(@2EAR7*\BH%PT:-41RH%7J],9C;V[25-Y
M64L2G!C?7^GHH=(1GW]U.%C.5S*:NL(@2+*!D()0$#`&QHQ.@"&OU_>O`M#I
MW[Y-5:[2SBQ84Y,-QY)$.&1Q012)5QD6.TCB%^1X?\KW(Y6J]%\?3QP((W&^
MFDTN50HMG4UTH'8/0!;M8LZ&V2P[<RUM8#%<-^9CHDBQKH[6M:;U4@%:K45%
M3R$-9K&?/U)TJ^U5PP,[=:WG*UQU`[[2-;[&E#&C9!'E.B>C$^-%5RM3S^B+
MP-DG`K1G(4+VHZ^E4ST6+K;?CF@]U03U/*U.)2J/QX<0:-\([SY1'*G]>!9?
M@.`X#@?-]<]3NP<CO]<[()J/8TW`B?DFU;N*'DL.Q""C#K>GTW<TD_+#!+?E
M^^QH61E$%X6B8X9$?Y#^YO`^D!?T7Z>?HOT7^O\`PX'RL[=Z8]@[S<F3WECT
MXS#:&`IO?;NP9M8F8T.*EV1BF77-<['L)L+JHL?YJ+AE9+H6VJ`>Y225FD"O
MPM<J<#Z$^GH[T/6G4<?)=$TW66ZC8V6+,T1CW\?_``VMTBV]E&BTL%:K_P`O
M<R1#$.6Y1^?+Y#E57.\N4-/_`&UZK]@,R[F[+R`&L;[/M6[EF:3;G641W,3%
MHO6[1\&9G>::J8D:6*[;G><9I"#'KT"B*I"-5J/8Y_@+K_B&U9L_4/3.HQK:
M&*Y%KXMEM/<.78#K7*S'?>ZVU5E.=VMM@6%S8TA7%KEJZ@WNT#O#FM,CG-&]
MSAL#S[%9Z/\`]1U/:6_77/\`=<?K:7&\LPW)-/W[TS37V39[16<:Z?>X>"=1
MS,AQFZH@,&03C38)4;X)'0K&*H2UJ[LQO3<NR\<I:'J;L+6^HP$N"Y_M+=%K
M58;91Q@JY3\?KL#P&/\`REYD\VUNQC'+-(="C0HBJ]'$(YK$"\'`XTP9S1BC
MC'^W.YO^F7XV%1JHJ+X5A$5JM>B>%_X+P(C)]I/I["2L503JFWE5-]''(D?$
M*4..%Y`1([B#8R)8(0+F(-'HQ"HYJ*J+P)6JQRA5T(<PC2261@H9S4^GN@VH
MK?/E?=6_HKO^\OUX%&.PFX<YV/M,?3#K=D<:@V98XU%RK?FW(DN(65ULU%<R
M&PHD^CKR?)_);LV,'[B/BL9[7`JFL?<36.`&-'F!ZM$1*KJE7XUU'S_%ZBLU
MK(69C^EMJ#A@9BNSVW!ILN=AFU'S9$I\??-R4\B3.DR_,7,S&-*`_P"[=(B,
M#A9^/:_47%LH@:FQ>VV/IBTKY9,&Q^)816WVB;OXU<3%*V3;':V1K;($5S*,
MLA[@8M9N&"1XJ'L=!"2.H&F=KZFPR5,VOET&?E&<D%E&3X31P(`<:Q/*I,*N
MB3S5\^&,`K"_NFP5FY%*C!BU]E?RI<N-&`,C6J%P.!&.U<GT_BF/QI>Z;[7N
M/8S>6L#"(4C9%C05U):W>=&3&*[%X[LB,&%-L,H)8?9,BM5Q)32N'ZJU7<"@
M"[AV'TNV!A>I=CE6TZYMEY,/#<[O90IEG6:XD2_N*>H-D3FPWR[C0D&(GWL"
M0(DF;A,I;$<B0:CL$*%B-PD)H[.XW:3'QNG8#>UV/XGV,KJY6G;_`&9%.46&
M[G@""PB2I>LSVY&6SF.1#8Q),9?=U?':H8%VDVGA74[,\#[56>05E9@6:V..
MZBW)50GOL[C+ZR^.X&L,TPK%J<4Z_P`[S'"<AGLBOA5,:7/ET%K(<T9&PA(P
M(AI\6[?]A=JY9M?4[+#HOIG9N(TE)E5EL/&Z?,>R.P++&9T^-CV?8UJNQE3<
M!T=:NQF2Z$Z5D*WEQ)A)#^XJ8I8C$0+=:/Z;Z'T);V>;8OBQLGV_D+"NR_>N
MR+&1GFY\QE'$(,D]SGM]]Q9Q8\D8!M6#7I!K1-8UHHS&M1J!4C09NO[1[N'L
M.?D<'+(_:SLQ%E0:BYVL*,1Q-GWA1DCQ,/,.H.0L,S'.<-CGM([U<ONGT#D]
M00$E9/EAM\0Z=N=P-F62Z6E8;,W7,`[`0U,%T:1D3,B"*F@2UM9$QXA3/D-]
ML@R2'*?RC0NOLS3,_<.40:_/,E!,T9`K8IY^HX%<6,F?Y4&Q28*1L2_6:Y]M
MA-6*,%14(`AC3I"N=.?("UD?@3F_XH$-4C@&P,2.C0Q@M:(;1`8B#CA8U&L&
MU&-1K$1$1/I_3@?.%4?D![%3>P'2G?&Z-=ZCI=0;7I.RF'4+ZJ#F57?:XH[B
M-K*[J,XGVEM8W<?-UIS8X6JO`0!5GP-860]@QEB>P;%,#_)KU\R>A6=?;9UM
M3Y#)9<UT'"%!D8;N3?1)-A`I0I*-\]:D+)RUCSPT>\17Q3#<[T5'H@5[-W!T
M'J"YN]B:RW7K>9JQOV>?;,T;7VEA$EP\DAR+&SSN_P!-"G1UAUM[""\3[7'E
M5D"]*_Y8;XT][TDA:[&>\_6G(`UV00.XN!3:.^JB6=7"EX\&N)&25#'+CQK`
MIF1Y4&TJQE19%?*04QKFJTC&JBIP,$SWMMU^R3`-C8Q,[L:<R$6283D4*)7Q
MJ2#'G-8^K,DE(98-^BRE,.4(:*YJJ-Y&+Y7V1JA"N'?D"U_K34&I[8W8;3\G
M"\=PW5$++JYW\86[Q7#)&.5-!<7PZZ+;_P`Y*D858J&39".,;APU._Q[`^-P
M6!R#MEUZS?',JQJ9WGZ]6M'DU%98^5*^'5EE0C3:YPRR0'@9F5DMGVXRG$QS
M/!$7RUSF)]0S$?;S2\((I+>Z?6^/51!QW_;2_P"*CC2")D>.QCII\X88(WD^
MBE<QWA[T;X\IX4,:RO=>N,UK2TMCWBT'+J'Y!B,Z5#'6XW&0$FLN*W*J>LDV
M8,R>Z%_+'K!HSY484P5_TU\K]0L/KK<$;:=#B^1UV=X)8UKMK9-A!9V`7$7(
M:3*I&.LO!Q8$.QCR9_\`&SE2$V1,AO)\P'!<)SO\0LUP'`\7O:-CB/<C&,:Y
M[W.7PUK6HJN<JK]$1$3@?J*CD1R+Y1R(J+_BBIY1?_9P/W@.!QS1(LA["'CA
M,\32-&XHVO5K2HC2-3V1?VO1/JG]>!QZ^IK*I)"5E?$@)+-]Q*2(`8/N)'QL
M%\Y_C:WY3?$-K?9?*^K43]$3@=AP'`H;KC)_Y7N/WNQS^WL7@?V9K#J\5F2U
MM.X&77Q,EQ?<$YT7);=))%MH=`V`U*P2"&L5LDZ>7_)^T+2:5*0VH=9&,?[D
MI<%Q<A)"@6*IWOIXCG%6.YSG!<15\JU5545>!"VP`ULB3F['U4-CV;\T&Z:3
M[2O*ZR*&RUY)CRCN*PGSG`)6L;[JAAM&GHB?M50P654-C:JZCP9$B#/+&[`8
M9,9*@S0VT0IO7/YORQK%C$8?PPCO+V(B^?*?X^0OCP*C;`L2-[I=:ZEB*HSZ
M8[)V)?W*C4^SN-'Q1^6(OAZJZ>OCRGT^OC]>!;G@.`X&O+LO^1'!NL>T`:KR
M/6.Q<QN["IQ^RIB84"KG/NI.1R[*%!I*JOF3(<N?<?/7^/A"CWO5Z(U%5/"A
M"$K\MU-'<=&]/>VQG#8]1JFM)HO=6B1[!%<43?A*\[D9X3W3]7(JHB^`RS1'
MY6M6;S[!X%ULC:@W'@NP,]@YM-C?WM54M9#I5P:@?DUC%O8R6SKJ#)DU36J-
MJQ/*$(QKO".]D#:AP'`<!P*,ZRN;&?W\[3U1+J7/J,?TOUR'%ICR;!\;'K&W
MD;,FS%@Q)$A*\27,8(2%?&!Y]Q(A2N5S1L"\W`<#UF,,`B&*]K!B8\CW.<UJ
M(T;'/>JJY4:B(UJK]5\>$X%<,2OGY=M3*]@#M<G/A=;046$8UBQ<=L8U+)N8
MQ9.47.PH$J491V19M7?PH+2,`!P612,12JY?0(][7]F\HUGA=#B&@\._W0[1
M;H)D&,Z(UE-..HA-N*6`DK(]@[$G2U8+'-8:UB'%*MIA%1)!SQ(`561.#P(G
MZ^=>]/91I6-6X3F.<U78?#\LN,JV-NC(($*D[$5/8C(X02YKD&RJ91!K)X<A
M]11UI3CDXS,Q\,:-"]X88AF!--5G5=L$]EU8[5XA25^>Y326J5L9!25UUO/&
M:58[I^6:QLRD?(J[^F>H9LRC+)2]H"J.2%Y@-%-X$]ZLP:ZU[A,##,ASV_V>
MZF/.CU>49B""N4FQ[[LKZ&LR.PA#$'(K:EK5'%)9D$*1/^)#'13.(]X23P'`
M^>GN909;+[&9G6=G)A[^@O:_(A]>(326<C5Y=63(%;'R&/38RND-EU6/[6HI
MDGX,AGFLTN)D98TB$@83E``.9J6YF]EX./\`5'8FSWP=J82%96F]DY%)S">;
M9.J("N,]D=^4U&'5U]V%U`GQOL92TA&W5"O@OB/.LOC"0-!=D>P5>FS.C&JM
M/T>X=GZDNUPY<NR&Z/(Z\Z)P^<8\$V/;?S1BGM<H6KKO2PQ?%JILG(YN,V$.
M%9)7DAR9KPS7H9T_SK078S<-!V&J\A[`WF`4.(6/5_MEE=+#B8GB.H<HKB0+
MGKIK##27EU#U/::SR6JDH4L!JS+NAFP%FS3D`K4#<HB(B(B?HG`_>!JNZ/7N
MYX.-]E&8SKO$<KH97>/N/+@W-EM&3CMFY';QR8'V9Z<."W@HS8_PJC7),<KF
M(WRUJJJ(%;]57]K2X+F<'3><9!?P<K[F:Q'LG-P[WC9'E&O5RO*,1QNY@TM%
M<ZOQ^$;'JG')46P*>4$[+E7$/*(7W>O`V*;,ZX0-TXFW"<V[*[2GT0YM1=M7
M',@PO$+AMK0N86%8_P`[AV/TUJT39*-(4"$2*555KV.:OKP.=BFC8VM<'@XE
MA?97;$>HQVD%$K'65]K;)+)P@":@YDZQM\(D3+2PEJ'_`%#F(YYWN<Y54CE=
MP/G.Z]U8;-?Q"X[<T<IN-755N<<NLO76\F/L"GF93K$]O;/EE,&L)4&M,J*&
M1"("(4A&+%8AQQW$<'T$ZLZT:7C7NP<`R/4V`Y.F"V\!U#F<S'Z-UO.H,I@N
MLZJBND$U\TM[B$$3(+IY50LZ*T!G?ZCR>0Z[*^L>A\.VSKT4+3>%V.+[5FVV
M*6U""FK0,QO(:G&,CR<6=Q6M8.4<%Q659*FS:KGM]WP7M1JM(K@QW>/3W4N%
ML7;.L]3XO,D0Y^)@S[5;J]'8IL2@!=U%66[C5[3QAT&RL,H"%+5W`7-1P0K&
MF#D!^)0!-][U+ZZ1\8R0])I[#1SSTUS)@GAUC&R$GFJE#')#<TC$$1[XXO5&
M*U%<U%X&"Z0ZD]?9^C-/1LDU)A%G;1M;X(&\))KXDTQ+N'BT&'=!ER(QS!*]
MUA\R21L>X+S(JJCG(CD#!=(=*NL)O]SZ\^OM<Y=5XKNC)*O$YL&O("YQVJKZ
MRI>_!\BG1#1WV4C$;6SG0HRD1SF5B1A/5[A^ZA/I>E754Y0D+HW!'L!&DQ11
MOXTC8B"F(ULGWC-D(`KB-8GA7-56JGEOA55>!QYG2[JH&H+%726%#BQ'@M&J
MV)*^5DVJ01H<UYW36E/(C_:L3V(]?=B*QZJQ7(H:T.H(9B=:\JHXL9PWU?:S
M;MI<2ZF)&B@L(+=G:ZK+";804^^LQ'MJ*ZF'&Z+(:^.$"C>Y1HY.!MJC4^EF
M.=#B1H+%"/XW,#-MV(,"%,S]SDEIZA^:*]OE5\(K%3^G`S["DQ$=?+C8<HTK
MXMA(%+$(TLR`L?;S*`_[PA2B,URHKF>41/**B>%\J%(NWA;61G,"I'D-Z"D-
MK_"Y<W&J2XL:PLN:'L[I<<>U<[Y8%0T/V;SPY#?N4E28DDHFB*SV:H;#4_1/
M'Z>/Z<#'+K(?XJRQVIC0G65A?V+H_P!NR0R.Z#51@$/9W9E>Q_O&@>!L]$\*
M\IF-14\\#C6.3MC9528G%`LF?8Q9=M/=^Y!UM)$\1TFE<C5;\DJS,,`F*J*_
M][D^C'<#P/=S)N2R<;JAD'_'5HIMG:O"(\"+(E'"L*M7P=A_OY$1I"*WQX8)
M6.5?W-3@</&\C<0.4LM+$$V/B<\D*=?L''AUZECPA3;.-ZLDG<QU)\OH=[T9
MX=Y3PJM<JAD%9D$&RH8^1N;(K:R3#6P:^V&V"44%6J1DJ2-Y%2,,@$0B>ZHJ
M,5%7QP/Q^15\?'W9+8?/55PH+K`Z63&1Y,<#&*_U*)"$:AGHG[6HYRN541/*
MKP-?NL)5%5]O.]^0S,MIH\[86"=68U;B4^+:U=]12ZO6&Q"1Z^TE3H0*:QL;
MD5BI@QJZ5,*!@G(9!O<UJA:K5N6T>/ZHU!`FE,DJ=@6)LCQ(48\XC$95T44A
M"MC(9P8XRV0E5[U\(-5>J^K7*@15L&K4$C/+,03BES^PO7N*]XY)R!/`AY-K
M@RO2(SY(4,[UE%&4R,0Q!-8A'^K!^H17>W"Q-5=#75DU90;3LQ@56:5'9Y9)
M`3%=MDEHJ%:U4'\L5?*^/*>/*?TX&Q[@5'S6$\W=OK_-]7**'U_[&C1R!=Z(
M65F&@T\.D>?1%5@__#\>5_S>?"<"W'`<!P/EO_-OE63X5O[%=B8L8D"STEB^
MG=S@F54@$>W!%P79]I;V4YK_`$/)"CO04-I&`.YCI2>&*KF^`^GRGN(=W25=
M_#>JU]O5PKB*1S2,58<^(*:![F$8,K%4!454<UKD_JB+].!\LW5G-)&?_EXU
M#L!6?]!L.U[97]3.(JRTL8$7%K6D1\.7+5LE(\5]:L9?15]7@^)6(C//`^JW
M@.`X$;X;M/$<[RC8N(8W9Q+2XU7>P<8SD<&;"E)C^26-1#R*-CUH$,ATV!<?
MVY:09ZB,)C5BS@/8YWLJ-"IFIKO"I'Y#>W^/0Z'%H>P:S3G6:TO<AKXU[$RN
MZQ2T'L:/CT/(W2HS*"T@U-G73_LI$0SRL:5P2L:HVN<%^^!XO>T;'D>Y&L8U
M7N<Y?"-:U/*JJ_X(B<"N6R]EXK+P/,;FU6;'PK`Z21ENPC-(D8YJZIC&N8>)
M17"DC-_*Y)'#&,@E3]\.0P3T:^0UJ!,M/(D6F/XO<$@/Q@IZZJM9M++<-YJI
M9E<)\BFDK%<.(X\)3J%SVHHVN9Y:GZ<#7MG>L-UZ&[1;#[C:]Q`G8#%,[U_@
MFN]@ZD#%AAV[K/$L&=83'3>L=O+E5E'?8Y8V%B2ROL/FLB3KNS8V3#L'E&""
MH31'A:P[4T51V#ZW[*%C.R*T,FAK-C44(C)PI%3*^:SU/O#`[0==8V-;7V7^
MG84-N*);5)U<2*^'(7Y%"Q>$LR3(,8QFRVEB&.4N?5!#$FP:J:W)J>KNP#EU
M)KC$[N=!AV+8-O!*0@'D#'F#C25"9/9'^0D#@.!\V^Z,P[!;D[1YU*U5F608
M?D\_MH[KUH7:\#.[VTQS5`-/56*!SO'\QT-#LZO%\KP_*<JAY`6UD2FDGRPL
M^`9!M:PL<)OZ_==L.["3NS>*[CV1MC%-]AL\9R';VALTM,1R1=!;[QIT^3KO
MM!UGRD^.4\TNM,OISF?43'BD0;B*XL2T1LL,V*T*YZ#TSN'O?;EH\=MKO3VC
M]1;4^SR/N)J_.?N+O>]SKJZE5\J+U,FS,.K)M!BV1I$8RXR[Y2`@-E3:JJ28
M1CK`8?0MIS3&L-`:]H=6:@PZIP?!L<&;["FJAD<X\R85TFSNKBQE$D6=_D5W
M.(^3/L9ICSITDCS'*0CG.4)/X#@.!J9ZMXM565/O@K.T&::U<;N)VO.W%,=R
M;5E;!@N'NC)PR4%"R3%+VY$TQO)2(8RN4I5>B,:YK>!JYDX+5YOD7>"=;XOD
M%7/H]G=1:-NOLK9INH;NV1E>T;6-?W.37=#KNE_DL;S-\>%&2P$5D&Q,)&2"
MFB?1`L-=X?U_R',8T"9K3#ZC(L+R[(79K5S-:XH9]=C]7A4JBH:DV+U^-5@,
M\B1<CG'2J%$6RJV&8<IIA""C*H9%D6K-?6.88?D2Z3I`_895LG'[W'ID;`K#
M!\6I\:FDQV26.:KG0))@AK6$85PSL#4HP<10_-`5I@I5I@G\GL+\0]17XMB0
M,;J8.86N)$QZQL"3+&JMLIU?=KE4FOBSK&@IZM1U0$KHP'OE)`)\QT`A/CX'
MTQZYP>;0;@[!YG(HC5L3/[K79H-L:T#*9D+<7P*!1&E1:L2JM2*`5JQ54J(6
M0\;G_4?Q\#OLVKK*;L;3,F+12;&NJ[O,IEK<"<B1\=0N$6T&$>4B_5S;*3+^
MV9X^J/>B_IYX$3]OIL6OPG64N;D47&XPNP^CD<67F3\'9<'+G$$,'&AV_H^-
M,/D%@049E>?P&P5_P*OL]O`FK<))@-2;0+6S9578"UYF;X%E`G.JYU;,;CEB
ML6?"LVQICJV5",C2CD($JA>U'^CO'A0POJU+K9_7#1UA3SS6U;/U=A4Z)<2G
M51)EVV7009!+V<:BA5M/*GW9R.EG-&C@$<IG$0;?;QP,(ZIR+P[^RS+RD)2.
MB]L-O1ZEKJL56.TH_AQ@];=@00(_\@RR&=7.E.1SS$1WE[O"+P+8\#C37.;#
MEN9\:.;&.YJE3R+V03U3Y$]F^1^?U3RGT_KP-)W3+`(F9:?R?9%]FZTW\7V5
MV)BII,T`ZA`LHMG"#%E2+"5-K75,IJH@D5K/=RHU44BO]7!LAI\:T54>&PMC
M4Z/`-0,87.Z0S806D0BQ(S#2'+'B@,K5:-?*,5H_ZL8J!,>$5^)Q8]W.Q*S@
M7`+J\-86L^OF5LX1+84"OK"C*>L:T*R`0X`6.1_DJ(B>R_IP,/V7H[$=H3P6
MUT:RCVD>+CM<,\>2\L-:S'<_QO8PHKZF2I*U9$J]Q:*BRT&DL04<T1&>R^0F
M3RC&^57Z-;Y55^GT:GU557Z?HG`B_&B1)\F\VI:'2-`D5YHE(64Q8[*["ZI7
MRBS3(48BB_EI@B3'J[S_`*+0^%\)P.%1R@5%1DVTK5R/-D00S*P1OCCD;C@'
M/;B%0-2-0@)-BLU".&YSO$N8Y$_HB!Y_>6F"X.R?+BBFYSDL^(-M6:S=(#(R
MK(I(Q`JXIY+A.?540RJOQ#\*V%$?Z^53RH=?,Q^,&-C>IH4!LVNLPS;;.);I
M!/1]/\QR6GW/SD)(EGRJ\E?%Z*]SD"IE<O[$\AD&6,;D-O3Z^`%7UCQAN\M<
MPB";'H:^0-:NJ<W_`#%3(;./\3F(U6.B1Y#7*U5;Y#!=T9B:OB646J`MB+!Z
MV)F>25K(S'@G/%,$S&\?.^0)0D9-DM?,*,3VF:.&Q'>&%^H0"&RB66VN\N-9
M+E6+6BP-;ZK=78]$Q^'76N+%9J[++.;;V=C]N^;9%GGE,E03%,1L)@E&!6N:
M5$#-M+Z^M'XW@N;W);;(*ZYU#IN#7U-79QRP(A*K%:`UA8S*RU']I+EFG@4H
MY07M(H2N;Z*1K'(&&3MC,M<TW-A<'):^HOZ+L=USESZ8\,);V#B>9AP"*%\Z
M&8SV`%<SJBP#%DN:K?DCD:C7*U'.#KH$<5MIWHS**\A7`WWB-I%>[XU5SDQ3
M;+6*Y6M8BHD0[O"HB*OT5?Z\#8EP*Z9(D5>UFH_D\?=MT?O%T;RKO*L_O+1[
M3^&HOJGA')]5_P`?'`L7P'`<#YLOR-Z[C[I[_P"::K#'B6$J\_'-MV4V"1@Q
M227=#9BR+'OMYTTA(\=R%@.1ZB'[M&1?JUSFN0+P]4.RJ2?Q`X1O/(K"?5V>
M#==LCQBYL;*3+C60LJUD.ZUFV868V58V#3SKZ@$44A[D*1I6E5@_;U:&L?HQ
M@<;#^V'XJY<ED-U[L#K1V&W':2)D%E=92)VT/[_RA'"`%Y62"PJB=&CH=?7[
MB.-"HC5<]%#ZI.`X#@5$Z]WF*66Z^X%3C:'?88YM'#HF9R"R*LPRY38:XH;1
MXXK(E5!L0!C4<F"Q6RSS51R*@B-8GQM#HM5T]H'O#VQOC6=6M1.UUUWK(%+'
MD!DVPYL"MS8]A:V367\\]:`S)@0QP/KZ]"(-Y6ND>ZN8%V.!#>POY;,J_P#B
M,1**46),(Z;5S),RGKK6QK9`9,*OLKVO!+L:J#!G1?FD(,)&S&,^V5/4JN:$
M:[0U:N0U6K=-08P;7&KK8U+G6X)EA91FVEM085/_`+V)+GP_=DNU=ENQJZIC
M2_C9\#8Q2#?ZL5K5"$N^&X@NL=6=0J/-(^`W?9.?+B[.V">4Z"'6'7FL-'AY
M[9K=,5!8UEVTY$T6'8K*DO")+:S(<;U+#1C@AG-39[^-ZSP:'I_.K3>F@L[O
M*['L8ZF;%R.=;;9P])MC650F=<=W9+)EBMZ8,JWB1H.(YO-%%*<XHU==17D%
M$>%:-@]HY5UW1PW,.H&I]F8%F6S-?WNN\U3-M9Y%K9F]=[DFXO=X+C&;:WS:
MOQC^=AZ&Q*FM#YGE8C!MZ&AN@K!)81F.0(;_`/'BWQZ.I+E$.LK\D?7Q5O8=
M+-DV5-'MOA8D]E3/F0Z^9+K4DH[X'F`$KA^%>QKO*<#N>!PK.QB5%;86U@9L
M>!5PI=C-D/7PP$2$`DF29Z^%\-$$3G+_`,$X'S)=4\OZZZS#U6[2[C#+Q+(L
MSO.R':G9^76F&Y7?6>%S-YDR>?C<#()&'45A)I<=M96569XLBW&]'/BA`YXB
MI%`H7R[@1^J?<NWU?C&KMAXUD?8J>*?54EU@&T18E)@:7LCUL_8V-[]%26=9
MDV4Z$OU2&Z=B)5#(OY[11XSXS739(@V2:!TIBG7K5.+ZHPN7<3Z''!3""FWE
ME(LI<J9:SI%I8E`AB$!552SI9/LJZ(@H%;$0<6*(4<0QM"9.`X#@.!KZ["ZS
M_'GB5Q/N]O\`7K0N:[,S*:>V#C8=.8+F6V-AW=F=%DRH=4M.6ZN9\TP_<\N2
M]@D1CB&,UK5<@:%=[8!I2?VNUY2X-I[3/6JLRGM_TCP['*_$*J@C;,&[&KK:
MD?,7$J,5;'Q*5KJSL@#C31O%:55A/@_&\J/;%(0+^YE=8U5BP&LR;=D;+Z+-
M)&TIM=M>R7`"5.R*2WV->1H&+TT7,7T^32K+'+,L"OM_C*S'ZWY&MB"&@QLX
M'-P?.L'H+?7VO;S7^J9`=HPMV;--E<`A<JI*P&H*[$(*?[:33P,?K"T5B>T?
M)$^1%A`N%5I2)(:YY7!1'3Q_Y#<GXC;.GLD,%?\`>>1,I)T>HKRTT8&Q-<XE
M8Q74P/L@MSH1@!6Z'%8VL@*K7Q1*52O,'UI\!P*A=TX^$R]98+'V#!NIF./[
M`:'(IL=OUQ^ZJKF)LBDFXY;PRI%E.LPPKZ-'65#1!J>&XWA[51.!,N^G*S1N
MYGH%)"LU5L)Z1W)(5LA6XE;N0#FQ'BEN:94]503FD5%\-5'>%X$<])[&%;]/
M^L-I6A-&@6&A]62XD:3&L89XX#X93D9'+#MW.M8;PHOJH9"J87CT?]47@=+U
M*BY'&3LP_(@6P/N^W&Z)5%_*QXD="XXKL=!5GJTB18GS5)$`]1$*CS/=[*Y[
M_HY0MQP.JO51*2Y5S"$1*JP56!5R&>B1#>6"5C".0CD^C?#7+Y_HO`TH?C^M
MY+^N=A0!K9QZ"5V%W7EEB:XI;0L>-+HMWXM6U];(E5GSK83)U?(.9D9L9R2#
M,]U]1M7V#:XN2:H-X$;%C/>]ZQWM/JS(D\N.U%)\GRXNC4$54\.<O[%=]%7S
MP,FQG*L"^&!!Q\0J-MQ96,:#5OQNPQDTRQA@238D2MF5E<7R@41SC.8C">$1
M'*OC@2%P.ARFJ/>8Y>4\6::MD6=5/@AGQR/">(63%*(9QE'_`*@W#>]%\I]4
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MMD.#(&$ZQCP9NA,RC-5XI8@))5PR^[F>/#'_`+4<K5\J%].NT^:?6..5$F"2
M)&Q*DQ;%:^4]@V#N(]3B%`TEM%09S_\`2GEE(-GLK7+\2KZHU6JH0#+$R3E&
M_)U58"-:B[4Z,AVH3P4&*'"J\3U!(6O;+8QY9:EKYCSM7SX$4OCPW]R\#PL;
MW_\`Y_T:F6Z`%+O]Y8>%!PAM'%2;,U;MN2$8!,5S1A1`^?HJHGCSYX%]>!4#
M+?E+WNT6U/?X(O5WLH=_A7(/YI&S>LH`^R)^US_C&3U\_5$\^.!;_@.`X&EG
M,(0K/\X&!ULMDHL*9TBV&PC6.]1#0^04D"41'A"JHKH\M!HA7HYKG^S%\*J<
M#5L3-\AUO^.?\@'49)?PYU0=PP:>Q2JAS(D>R^PV_=55A4+5P)'VMM8-L[RC
ML6#?-,1TDKG,^1&B4;0V1R<"@X!^5OH#KJH**+5:PZ69I3PZ<$0<"%%A5./7
M^+1VUE:TIS01>_N]S'N<C$5&(YWA/`;S.`X#@4FZPRYDK>_>H9X0H<2NWKA5
M=7N%8/F+/%_L?KJTD6!HR29$:J,67:/&L=B"(Y!(8@T4J*X.?J*FO0=Q.WN0
M2PP7X]9477RKIID?(\6L)HIU5A]^6YK['&Z_VRW&W?\`7QS")9JR-.&1'PVK
MZF<H6PO[V'CM::QF(4OKX'&AQF*6982R*C8\&"%/W'ER"*B-:G_%5\-150.K
MQ>F?";,N[$;QW=W\))PWE&=M?&CH3[.IBO&$2?;1/E>]?\WL<I'(Y45/`1QC
M=KCL[)=G[BM)6#.H\6CSL'J\SI;*7-EP\2PEKK/.8F42B%_B8AJ7-V6#""C,
M]A,B>#/<]/08:].MVPBE3:O:WL7J&_EX9W!E5E[AVPP5+,^QK7W6"GB$K]+Z
MUV;BP02<AP:(2HG3,GM3L@S*1;#(I#Y4D+V>C`_-+:XRS8V4Y%EFOM4Z[35F
MI-G5-IH>CVC:BV3JS(*63+-(F9_UWV!6?W#<:UG08=;%*&+"6;C@I)1QAPH9
MXA#-#92?2FN9.U*O=RXW$A[/KJ.9CQ,EA/,$]A4V#8C#QK4"/2'9'`&",,>4
M02RX\='`&5H7N&H2QP*];1[.:GU=;AQ";>CR38\X)B56M\8+$L,IFN!]O[-E
MH:3%J<>&GW8E^6RDQ&*UZ*SW7PU0TY_D'[3;LD]8.V-EF.60-$XE0ZER+%ZC
M&=;71K/.96>Y_"I<=QVBR;;%6)\&L)2OR%\B6E"-`N15`66Q\24BAU\37FKH
M>7VNI.I_:+8EAG-%J?3>K]38_@NY<.V_6,O)`)UGGUO90MB@V$_%]44V*T](
M*XDA.(D5LI!0FK-D@:4)6R'\>&R<5;:2;[96B=^9+E>6:ZV1F<O=>&93KX[K
MO"Y,B'%J,-LL)LLCH,;PRP@22U\:I+6'B1V,:[T>4T@A`AP^D]E]7J)N0Y;J
M[;?7S2V,Y:`5ML+K9W:R/,*RIQB5,FT6&Y#,IML9%0UM?1I86U5&L(1*:7&!
M7_*HVH@FNX&7ZPS+;F<"FDU=MCO9OF=4XMKC*[>+1;#Z_P`&DQ5,W=DD8--?
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MF^=[=R74&;R,.UCGE?A>5V)LBM,ZW#CTFNFV5Y9FC,C5@BRX\<,1X?`0[8V+
MTFJ,V_MS85'<81G5SW^ZA4V`RMI9GC>=[6V!B>+9;F63U=NF75T8=K:TJ4XG
MRPQWO+/K(36-E.:YOG@1U<"K`]1>NE1!J<>L(471VZW5U]*R['=@TT=V64^=
M7ME>1ZZU;;SK:KH<DI?G/>,FEL#7`R,<0:(0Z!->09[>76S>L<^@A0[F+,U%
MVDD9N*AH=>Y?G,C-*7)=2F;6T\*W@I61X\;%K=HT`;[EM=&?7L9\IFB1X4_T
M]7T\C?/XL84T;C7XB['@R1UD:GKJPHXFT,3M(1YKXKBVAK"L?$(&04D:`&WE
MJLM$>D@:C#ZW.`X%(>^F/4V4ZPU;36VP8VM9!.S_`%SL,?OYEU(H(\_(J/9E
M/>5V*/L(U-<N5V7MKB5S`O\`M1G?(0;Y`T=^X)[["6):S0&[+:,PSI-=J/8M
MG$8&R2ED+*AXA;RXK16[D5M0;[@;4;)<GK'=^]?HU>!T/4^VO;_K!UYO<GB6
M<#)+K2^M;>_AW<V#97$:XLL0J9ED&UL:O_RV=8LF&?\`.:/_`*!">7,_:J<"
MP'A$\KX^J_K_`,?IX_\`F3@?O`ZB_=Z4-V_Z?MJ+)WU543]L,R_54151/IP-
M/70$&03](R2U&*2K*7(WGON]/6-C08/V9J[<5$V<,]R4L:N-*:"*5T<:,]3E
M8ID>GE/(;,K?:618[%A2KO6M[$'-F@KXPP6M)/DO,6#(FN4C8\Q01QB2*X;G
MD*UBD<QJ*JN3@<"FLIFT+[%LA92OHO\`;S+<GK;VOG3:^7,BSWX['#&]"U\@
MXW-."X158JH]B_1[6N;P)YX#@17!C1\-V'/BC7X*C9*EN`A:,OP#S.MC!#:(
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MY%9;(BP<-QW`;0M3F/I5T=`R=J"8>^@47PV$F/<UYBL--*61X6/+E.$Q?03/
M`7!T\1AM3:R.-"M%(P'$)`FG1R':(]!`*)#-<YRM*@WI[)Y7P[SP*C8W.2FS
M/L8^QB6]D^[[C:SB08%17"M9D.+-UMJ*MAVDZO=)CGAT/WD,[C2_KX&Q[F(Y
M45.!BLJI+;:U_'4Y[FB_B=^XE=$&$+1B5(NH]RQ!B1BO?\3$=.1R)[/<BIX\
MK]5X&RG@57O*\I.[&L[3P]01>L.Z("+X'\;33=I:+/\`1?\`Q4(X<'_[54_X
M\"U'`<!P--%H*,;\Y6'&3[ATF'TJS9BH5XD"-DC*<.5711M:TCA^&HA%<KE:
M]Z(B(COH%%^W>CIDW\IFH-/U2MC8MOCL!IK=V1T8*ULBGN*K4T"US?()MS71
MYL5TJ3]U2V06R2N7X'6!2()4\JH7WVT*0_\`-1U-.^L0L4'5W<016BC5Q(DD
MW\R]\=A$\?$"0)G[_/GV>C?T\(BAN(X#@.!2_J[C]12;=[LRX=Y)M;;)>PE3
M?7E>>LJJYF.O34&NZ6MJPDJI<EUJR1`IFS&RIC03B#DL:\?Q,"]X=3I_&(E!
MWF[A7ME9PF7N?8;UZL,<IEJDIYI\/Q?&LAI+*S#,+(<7,V1LF,X4B4-C1U:%
M!&<B.)[/"Z%O1U=Z`4:UB-E"!('*C_ZA0DCR1(J#D`.`@C`,UKE3V8Y%]7*G
MZ*J*$0[8R6ZU#K7,<Z'?R;2-CE-82HE9+IV64^59SG/BTD*,:&X4DSR7DZ.)
MC58]$%^W^GMP-;G8_3.83]+=2.BV`[0F8/*[%V,['M_Q*2DI9=OE6HXE:[97
M9W-P7$U_W6,V61V<I]4V3'&<)9^6L849&>/`2MV=N=Z:TU7*TFS;F)LMMGCK
ML(TUG&(A!KO<E5:CFU`:^"_$Q7>.X5E8YA/BJG?Q5UB,LXY30PD;,>%%"QW5
MC66M,<Q6GRS$09(S,V8S7X)LJYN\?R/7%AFF6XR*%%NLIS'7,U(-,_,)UC%>
M5UJD<\DXSN1)D@;E>X+9\#6Q^2WLOD&FM1'UGJR\_A-U[<P[:=M4Y!&-Z3-5
MZAU1A<S,MX;O)_HG0+L'Q9@H52YS?!,DN*YGU;[IP-:G7&K?H?0FKZ&Q^7+L
MJP'J!.R&_P`3S>]PC+<FL]B2L7Q.)]YLFM^*WN=@9I+V%91@UDN4+Y7Q3*LM
M/9P_(='V]L`6&&8OJX=I3OSW9V]="Z[GTF.XIB^.2<GM\&KB;1S>="HL;==/
MDTA[\<,<YH&@AQ#N)&<UQ&N>8+)ZF_&MT3VQNKM6D'6F18SGVJMEZ_UY:916
M6`ZTH8L+2FN[>-6XI**MG+;1%):GF%(1`'6UEG,W_($JA-MO^-78&#BD.ZY=
MS>Q>L0R#RI!Z?(]A6N<8J$13NE(P5/FC,KK1M$H`"7Q&:BQV/9Y1'NX$76__
M`.$LJZBXPC7=GH+M%BV,(V)+QW(,4F:PJ3S*E@;&NQ4VQ,7_`+4Q\XEF0V`*
MZLJ)C([7HTS41J(\,U_'SN&16[UWYH+*.G^+]:LR2+B>QLOR37F2X5>X3D>4
M3ZNNQH.'?:8_C6+9$.ZJ*VJ?-=(EQRQ'#,]!%\HYB!D7>[6]3KVYAYYB5[!Q
MB/V+R*CUCM/$5-1P(>07B5]K_:^U&.M(AE%(Q]_QP;]S"1D)7&#,88%C"BG<
M%8I.076;9+#K-G;0R7=LC3.5!H<$J+-V`XI!DPL=LZ>.'/LLP_(<BC56<9_&
MD@C",>04S[7^4&L*+'<Z0!0MCU?Z4Z!V1I2NS_9&"1;S/,\SXVS2W`1DP\^O
MLHPK9LVWP]-7U&+V(Z[51L=G8]%>;^&(PLN2TJR3R&O\<"]6ONN>C]5Y9EV=
MX!K3&,<S+.;"?99)DL6$I[>42TL)=O8PX,N822^BI9MS829I:^!]M!?,DF.H
M?E*][@UG]T8P%W%7O(%#E?W'_',P#FB8LF*"1D.9BLFPI*!+*BEL($1X2N#_
M`*CAJC?"HOA0U4[*B[4I<"U#5W)RX]B='U"SC&)]5AC+MT>IRIP^RE70W!=<
M64.)EK&Q,-96R(ET&7++),Z46=7N&-Y6!L2C9;K:Y2HV#G,JRM\MP3(M@851
M9)79H\!;EF6FQ(>Q;'!\D'BE=<BIL-#C3)MW.EP)$]UF*0".1T9`HP-975O9
M.'VV[?Q7A9F^,OK_`.!SP<[)K#*(X,AS8=+;ZHQ>AR:RL;"-4),F.=$2EC,/
M\E@X4*0OCY'>W`^PF).A6`OG@3(LT/E4^:)(%)%Y15:J?(%[V>45%3QY_IP.
M5P(&[!:>E;IQ_!*(,^KB1L3V]KC95I#N(LZ5`OJ[!+QMT6A>E=.@'`6<48W#
M*KB":0:?(,C%<U0YW9(T./UUWQ(LI1J^O!IK9AK"='CNFR($,>%W3Y<V-%;*
M@NE2(8$<0;$.%7O:B?(SS[(''ZQ5M73=<-#5-')ES::MT_KF%5S9\D\N=-KX
MV)5(HDR;)E3;&2:9+`UI"N?(.[W<ODC_`/,H3GP'`Z3)GH+&\@*KG,0=);/5
M['>CF(R!(=[->OT8YOCRB_T7@:;>AI*HW6EKK&%95EY8[@VY9OOA9%=4M0+'
M*_L'7XW(24.%9QH\>UO$,J-3P^09S7>2*K_J&RXJZ2G"A09%Z^P%&6-]F&5=
MY'9#]T&Q@V?]6:2R4Y16*>[7^Z^I/+T\-\M#.M:X_K['JFW#KED-E7/R&=9V
MZPYLJ>A,BD1H(IY919AY!VS'1HX$(U7(OT153RJJH2+P'`_%1%\>41?"^4\I
MY\+X5/*?X+X7@?OC^O\`5.!T-E329EA%L(=O)JR`C28QQQXE>9LYAE&X/W)9
M48LE$AD:KAM8]C55Z^R.^G@.+0X],JG3WV=],R(DX<02DL(59&>P<:,V.1'I
M6Q(@I"R7(KWJ]J^%7U;X;X3@=Q!JJVLK04]=!C0JN,!8L:OC!8&''C>%1(P(
M[$00@,:[PUC41K6_1$\<!_%5W\8M,L..ZJ6&M>L!XT?&6$HE`L51/]FJ'X5]
M?5?IZ_3@:[,(D2=@=E_R+X?F)Y%]ANM1]?(F&XU+DG2GJ%M]!CR:W8V"PK8<
MH4JSDL/Z2!E8POER)]5X%W-.A^VU+K$'[D^+`,/9ZO*\[V^M!7IZ/,3]YG,_
M17+]7*GG@4RJWME9ON^:58XY#.]FH:A99&#<4\"HU[J.5"@*<A6*Y@),\WQ,
M^B#>5WJU5<JN#(H4.)#P3HQ60#K)@CV;3$A'6.L1QXD?56S9(".B^SD`JC5%
M]?*^O`OEP*HWUZ8/=W66.,"C@S^L>XK4QO?PHE@;-TS'"SX_1?;Y5EN^OLGC
MU_K_`$"UW`<!P--,H5>/\Y-(1LF26SD=*LH>^,C?$>+%%E.("\JJIX<A">J^
M45%]G(BHOA/`5B[>;CJ<0_+UU:RJ.L.8F';#U]I6Z^6>T@X8]T8M?XK+/XE&
MKXE9*@S<VA/<-2D\C"\B,<1Z-X%K]CQS?_AJNN$H<UH1+U.VP(\)Y'^9;13W
M.8H1M54]@DD(Y?9$9X:OA?;Z*&X3@.`X%'^I6.VM#MCO/,FT$2EKLL[.@RBF
MDAK,@ARKV.73FKZ&5;SY]V]8UN0LS'W-$2N8R`,#6#:CB-(1X6'VIJ#']HQJ
M>:67/Q;.L0DR;+7VR,=^`&683;2HZQI!J\YQ%CV--9"]1V-5,8:NL@M1AQ.5
MHW,#$=6;:OSWSM1;HAU&-;HK:^39Q'T_W(\.VCB\0Z1TSC7Y9I#'"B>6I9TL
M@K[&H.JH[YHK@2S!Z=[S`9!;:UT^VQLHDO8>0%M)L2M:0;K7#L*+73,P@S;%
MCFK6PC1;0"*]G^L1ZHQGKY<1@4:RC)M`;"[F[KM>P,88,!TIAVNNM^L;J]J,
MM9ACM@9"-VZ=K6$+,H4!E'C&44<=N*PUDCG131OMO52HXC6H'45>,5>V^S%Y
MK;"H-QL876VIQ[:>L<M[#ULG;NJ2WN1S:&RJEPW9\")79#72(4N$A:U%N<F^
MUE59)#HD8T:.JAN`A.EOAQ7SQ`!.=&`Z:&,5\B,*6HVK(%'.002&`PRN1CW,
M8YS?"JU%7P@<G@?.MV6D_P"]VB.[79^866,O9;/==?CXZV28<R-#LH_7F)O6
MEUCG]WC$BS9-KGBVUF-AE5\5R1GLFU%97-*Q[`(O`[+(I$#/*;VILM9JC(<W
MVYI&B63!CQK*4R#DN:XA89=39U=X]1TD(>07S\+FQ4A5KY5%6UTH<TID^W>Q
MH=2K;G=OY%NK.-Y#4FH+''"[DW-?5U22-%I:M]9F2XMB4RL!3B1DW&\QJ,*L
M"QYSY96S1D1'_-\K"(&X#KQC,&GV?VZO(]9?UDS*MZUTRR;<X:[&H<\E;JK7
MU7%M,>O'2SIG=1-A@8O\BT84!(:2%X<L57*&4;$$2ZW+K##K><Z5A-_BN>S+
M?$5E-!%N[NBF8E-I9MG'9ZRK.NK@$DHZ-[?;/>5JF8]$8G`S".ZZR]JBH9A,
M+Q"LG6=69L.O2)DLV32V,JND"@*9IJVHJW38+E8](YR28Q&O8HO9%X&J#J9L
MO%L*RC\DG;S/Y*VN/5F]J/75"R$.5:7X/[$QJ*R)B]9CH8I74MO;9/L=D1H`
M_+(,0GS2G)Y>C0AJ;=;1VSMW;,_:%]74.>TN*MK,RV]C-7?7N*=/\.L<RICU
M.`8=6W5*:AV3-V8$<9(<<4`LO(;*%_)6#V5L>%!:$I=J:?5&L^LF)TO5_`LD
M/LG`]P81F<+,\LT1N#-,N)=VTV7!SK96;6Z8>/*,PR"WJ9\A+*4\IG%4K&O8
MH6-$T//I=WSP?3W6736`;T?_`&GMJ-.AES;$;Y<DQ_(\9Q39&99=?QLZMJC+
M:*!91JVMC..\<!7GM)4(;"M:KG.:T+<;!_(UUH_M6835N_M3R<L985;(JY<+
M-`8XZN#:P7Y"I)M9CIR?=K0+(6"Y$<(LKT1?9OMP-6O>KM3H39TO.)FO-EX3
MFT<VX>G>3T=9Z9U$%;2M7W.?2LN+86]=BY3T-9!2SK&)+`Y'C_U'M5JHKD"M
M':WM'@F:7EB>3LQ]W!-62\8Q[8E%$V'!/*K++6&PB3O[<D*V?G[*[%;[(6U<
MVSMC1G-+-D*&.2.C$4+A4_8?2+Q8,D?,<&J!7>U,#R*1%D;SRX$ZDH<>ARS9
M).D6\?&R6,>!C[#O^$2RI+[*4\I_W(<[&AKUZ-6^O,YL/QMNSK9$?/\`8)=J
M[PKJ?7%J[&IM/KK6]7O6)05KKS#A8[0V:2LOQ^LI!U\XI+0*J-IE:!QU<X/J
MLR;KCH83!Y0W755C\_$HEY95$S"36.#FJI$V,5]G8PAXE,IXS;*2U/+I#QD)
MY1%\_3@<CJIE4?-NN&F,IB3KZTBW&`T1XUGE%Z')\CL@"C_;"L+O(8ZN#<6<
MU@$*:0U?]1[E7]>!8'@0CV7#7R.NF^@6\TU;4ETWLL=I8`CR)9H5:[#;E)TH
M<6&J393@1?=WQA5#/\>HU1ZHJ!Z.KR!3K9H+[9L-D5=-ZV?$;7U\VI@I$?B%
M0^(L2LLE6Q@`='<U6BD*IV(O@BJ[RO`G7@.!TN2M1^.W[%^-4=2VK5^47SB\
M.@G1?E`BHIA_7]S//[D^G`T^].*&1(Z4EN[&$UN11.P.PJ",.*!I4##3M4.R
M4@BRG'/*)\E<'W<TA8Q4#Y8(C?5%"R-Q+>*4Z]L17--)<^OR%P;9LV)$)<08
MCF9%&@8=4-EV4-+;PU\B5`>0<@KO1XWL.K)86(ZY1H\;%\P;%D0IHC[&R&:V
MQ@F60&R;/KZ2:.?\S_:01)(3M5BF(8WQ>GN1Z_7@6!5S45$5S45?/A%5$5?"
M>5\(OZ^$X!KV.1JM<UR.3RU6N14<GZ^6JB^%3PG`>[/"K[M\(GE5]D\(G^*K
MY^B<`U['?Y7-=_\`:N1?\%_HO^"\#RX#@.`X%"=>U])6=B/R'2XV*;"H+7)$
MTK)LLER\D!N!9](A]?HM9#-JIHJV),)$Q^!!;"N6FD3%2R8Y6J-J^B!8_3N8
M4DW5^K/@)->MCB&+0XJK4V8AN.VF"-6J]\1HP`1T9Z->]6C\(B>?*HBA7+#'
MQ%R#>)JZ&QQ'=Y<?#9?R$9)+3R8VM=2I)E1$&[V"H(B,0)'?5A!^?'CPO`Q:
MPG2FXQ^.,5<L@()NYZZ*=R,:OR5,;0NYY#4>K%*@8TA\4*M]E:]$\(OA55.!
ML=X%0;>&\G?3`YWQO^*+U,V@!"^7_&A)>W=4N4?CX_17N;%1?\_GPGZ?UX%O
MN`X#@:9_W%_.4(HXZ*R'TGOH<F0[Y?#72LKPN6/POLHD54$B(GT7Q[+X^OE0
MT^[@PG+=O:4_(#W2QELR;>Z[[PZPL]8DN0CO@UT+1UF::YU/?SY!JN?3_P!Q
M9I$$C9<%(U>V)]&O16H@;729%7YQ^8?J?G$$D9(N4]%\RR:&0,UDL<L>1I5V
MD1L9XQ@%(8D*2YZ&8U4>QJ?1J*G`W>\!P"\"H76>/=U^RNXM?>6%X57=B17%
M+4W-M96@JS';C4VM25TBD'.DR8U32VTF-(*.'$0,<9&O<HD*\CR!;W@1KM'5
M.([:Q\-)E()8)%791L@Q?)J62M9E>%937>5J\KQ*\$QTFHO:URJC7M]AF$YX
M3,*`A!N"@>O.Q5GA6[]NU?8O+I+ZK2V#&Q'#]D_:5M5K7<5WC6/'V1L>]K8X
M99(^);CH<<."+<4/@87`$Z1`<^.0@@AP>I-WO+7/7*JV;L#6>&93CN]9.2=E
M\ZM@9I58?F>-%W792=@-K<QI\X##PZU+B&-6D"F&0-N!/AKA,<)/'E`B70V0
M5N"5]!F^S,=V'GFQ9VR+'+36NE]:9SB;\"U+)@`%4W5KCV&1_P"'W#@\R\$)
MTD56EY'@BM1C"\D6$UZAMCP3<FK=FL\X+G>.9%(:IVFK(E@,-W%)&(44D<VA
MF?;74$@"!>CVF`Q6^J^4X$"]^]UR]!=2MPYU2R6Q\SL*.'KO6Z(4@C%V5M2W
MK]=X+]LH4<=2P\CR4$E?1%<T8'.1%\<#YY=W5NWZ.XZ^?CQTSF5-FU=I'8>N
M9>F:[:N&3LXK+7+M2ZTM4@Y)8WYZ_7TF72`R/9U`9SY4PBP;^M*0)3C^G`M=
MCD/O!KMN0`W+TCB;%AY#F>3Y!-S?!MJ7R6^)55Q*MRVK\?I;/'<D(0$:5E=B
M<-8EK$J3`<)1L&5A54,]_'[6Y_LCO7M?:NQ=;9Y@JX?J+&,?HH>?SYUE80I\
M\]G_`"TAHA7>1T^-.M)]G8K!JQ3C"BU2#:)C$14:&SWK/B6<8WL'N%99;69)
M4U.8=DCY#@@KVQG6$*TQ5NIM75/]P8XV58V$:MJ+"[K9@$BQFQA,+$<]P4*0
MCWA/%M@SK38V'9]_-RXP\3H,MI?X`84^SM#906A>RRE'0S7(:J'2N8)JL<BI
M)>OE%3ZA%M7FG\5J7<MVYI:M^(9!MV-&?,E2):K)@SK.1!DM=!&22$4V5(8\
M81>Y!->C47V3P@:8=/M?7]5.GU2>+D0/]]^Q.Y.V>01\9R#*X=S'K\)E9'E5
M!_+9;@,#([:KH6WI:1"V#D,Q!,`(SU<1_`N9@-39!ZHZAD29%EDF0=D^V.*9
MGD5N:><D^^QR^W7)S2D+)GN=%F/KJO4F&5T=@B*YWVD5!.:J*YO`VQ\#4>F'
M8SG?Y5-L5&9XW3Y'2Q>NVLI@*G(8GW<.3,'/MOCN10YKCULY:]3+'&UC&F$\
MI'_5J.X&PB!URT+5@/%KM/Z\AQ9)_N3QH^*U(P/-\ZR7/^%(WQM]S_N<B(C7
M^$1R*B(G`YJZ#TDJ&;_M1@'I(<0AA)BU0@7D*CVD+\*14$AG-(Y/=$1WARIY
M^J^0]/\`Z>]%I,/8-U%KQDV3(=*D2!XG3"(60X1`N*]1Q&HKE&9W]/U<J_K]
M>!C\SJGUNL#!D3=*:[D'CBAA$9^.0D(@Z]$;#1[VL:XK@-3PCG^SE3SY5?*\
M#2%N?"<&Q#\S75S$\.QZNIJB!@LF0''XD*-#K(=@_--;VDFUJ2C5SG6"!BB<
M5A51RC:[T141O@/H;S`K8^)90=T44YH<=NRNA&20X,QHZV2]8IFQ$=*<(Z)Z
MN02*145?5/;QP*L?CS*$W2;K42/C>,X='_VOI&`Q7#$R),5QX`GR1"J*#^[7
M/R5U9!&Q!B6:OW#D3RY$\^$"Y7`]90BD"(`XAF"9CA%"5C2"*-Z*UXR#>CF/
M8]J^%145%3@`A#'$*/'$,``C8((0L:(0A#:C6#$-B-8,;&HB(B(B(G`]G`<#
MI<D178[?-:11.?36;&E;Z^1.=".U")[?M\L5?/U^GTX&NC\:=+59GTX@Q;R$
MC@RMT[_D2H0I1&$BSJW>>;#:QQHAD>U[#0T>GAWU:K5_7PO`N@S1F!L7V0-T
MI?CDA:=^07#Y(PS2&++&&4^8Z2#YR2'K[,>US4=X:J(C40.>/5%3$@OK*G(\
MVHH+YLBQ(*FR69%,6;)>)YCFG%21/+[H%$5JD]%\JJIY55X'>8[@E7CLRQL?
MO[V]L;-T=3SLDM3VYQ,C1R11`AH5&@AQOB,[V8-C?=SE5WE>!W@L=I`*UP:Z
M.)6!$!GQH]B,"!#-$-B-<B,:-LAZ)X\>$<O`X$C",2E1Y$.3C]6>)+%\$N,:
M,P@)(?"I\1Q.\L,-$7Z(Y%1/Z<",;C`:&BS_`%%,Q2FI*)D;),FD7`X+AU9Y
ML!<`RF$%C`!^/^50%A."Y0N]FL3_`%?'D:*@3OP'`<#'K^[6E)0-032)<Y!"
MI%5SE;\?W8)94(WQY\N;]M^GCZ_\.!KRKI6$;*RSOCD+:VX?.H\;UCD55:V%
MJ.P'26$?1<N;4V&)0`)[XW90GC=]X@SO9,?X1Z>/=K@O?JA&MU=K9&*JM3`L
M/]57QY5/[>KO"KX5415_7Z?3@4GKI,?^\MK';.."+#[S86(#81Y$.2/()>N\
M(K9S)IXKVMF0K*%-`#X'M]/1%0GM[-5`R2#3R78MT*%81S0IE'L9C9$,R*,C
M)472&VHCT1J#&UXF^KE8Y6M]FJCO">?'`OGP*SS$"[N+CRJ?_7%UIS!6Q?#?
M_#+M'!T=(1?\R_N$C5_HGT_QX%F.`X#@:#-Y[$CZM_*/V(V,>;$KA8'^-[.K
M]IRSGP%=:5]EAYZW_7:TJ@.:5+"%I4&[U>X2-]G>6H';]&=`-N?PUY;2V="0
M^2=B,0W=NF]@VM3)/87.0YK,N+'&Y,FNM)C`%G'I*.I;%*-0QWL8$[6(JJJA
M23\;VQK+9O>OHK;W/B19X_\`CVS;7EE,:><$+K+6>2KA/J&%8QU(=Z0*P:$D
M"+\)WHKA>1-8B!]6_`<!P*];.UKED7(%W!I:7"KMFQ(4>)DF*VQW1</W)CM:
MTCHN,9.9HSK0Y'`:]R4]^$;SP7.4)V'AD>)H9QJ_:N-[5IIT^H'/J+K'[4^.
M9GA]]'6!DV%Y1#8Q\RAO(#U5$(C"-+'DA<6).C/8>,4H7M>H=SG694F%T<B?
M<W$2D=)CSP5LR<B?:ML`UTN:-3/)ZQQ!"*,XI'F<,+&,57O:WZ\#47V=H\3-
MT.QO4^RJPM%8=XMV8?CV<A0DK);K'A[1R1F9[FRF!)AQY-N-V,ZPQJY.*PB,
M8M.-!%8Z,(#5&$`]@\__`-F-0/UY8[)V)V+Z^;?RO'M8:^RO&SU&[\5;`ERV
M&HL%V4-N08]GVN=E0I<`$6FLJZ^#%NIOVZ#%"L6_`0-V'77`K_5>L*+6%OB^
M$XQ4X$`6/X@#!,@RF_J)N-QAH^)-DKFD9,BKK9YB$^X">78K\BJY))//T"/]
MQ].M<[FS^MV5>6F35^35P*V"PL.T,2(.L@V-;.D1:F,9W_ZO2K,5=\)Y<)PC
MN817*JN8-6!K8[ITE7CG:#JAH>ESO-LDPK&2Y/VXVMK_`&7DUML#"<1UWJJ1
M#PC&K@3Y#96T'S#9+L&4:J"*SDM;84@2O8@0F<@15U1U:EIWQTWD46PRN1\V
MEI'8?,,4R+,+/*ZG$+O=$V_M*`%1$M#R+6K6-AE%C#".GD*4DAC58Y%:JN#Z
M,N!X-$-KR$:-C2%]/E(UK4>3XT5&>[D3R_T1?">?T3@=+&R6CF7DS'(EE'D7
M-?!%8S(0G*]X(II4B$Q[WHGQ*Y)40C'-1RN&YOAR)Y3R'>\"B/Y&,Y_VBZ7[
MXR.A`"+:2L5LX$`4<C(+YEQ=#*`"?Z7K(E'G27(-[1HXQ4>J?IY5`UR;GDY/
MJ*!J#6^*!N2S>N?1/"\6L1#MH>/T57?9V^@H\@%D-?C-[7WTFYOZ_$(S(WI$
MEU4&21ISJ/V&YX2-E]1V*TWMO1W6;7NQF[=R,4ZP[`8'0[.QM@ZG6V-8YK9^
MK\+T^R]PN31.D8?03:ZYM?Y6V(^5-G&:%SVI\:.">%VG^4__`*;XM`:)+[DB
M)($3(SCD#8]RI->PO][MBO:)HE5J+X7R9B?N]7>`I]LO0_Y6LLWO:=@];5&I
M-1YOD6)8QB5VHY8;N,.NQB!.86`PR;$+_(UE](L4>Q%BA-`D!]FO<U5<\.$N
M/_GU^2/YR/1SV)'F&*Q84,/F=&<H8T9Q0Y9[,ASV(QW['*K%]G+Y_P`BAV,S
M"?SB1QG/'RS6<\AU(1\3^2D1GQVMA.)]K',W(#QC>IRHT16-CN(K5]T:J(JA
M^U^,_G29+`&1D.I&Q'PUD2TD2G&9[R(OR@K8$X-F>8R2"6C4>8[!HUOLS_![
MPXTB1^=4:D^SK-6S0A!7F]9$T4&:=TU59-CL*A31&$J"I[+X81##5/54_H'1
M:IZF=^,D[T:0[.=F<<QJ>W#@IC5S)PJX\!APYDFMFQLADK)(-\F/"91"BGC!
M![D<92O<C4^H?0GDAXL7';^5-24L*-2VAY:06/)-6*&"<DA(@QHY[Y2B:OQH
MU%57^/'`KYTOAX9!ZJ:&CZZEVTW!5UU1R,3/?0+FJNTHI@WS*^-;UF0##<UU
ME"`=`F`=C'"(-6HU&HB<"SO`<!P'`<#%\W^9<,RY(['DD?VQ??`,?K\CS?Q4
MKXF,]_V>SG^$3S]//Z_3@:..H?;P75[34'3%YHGL%D5U39EM+/YMGB.O,<M:
MNTQG.-G9'E$5U42-E%=,E'C!OVM><\<2L&%RD1OAC>!:P'Y2,+(0PS=9.UD7
MX"D`7Y\&PQI&&&C7_&X"[!0XU(-R.8KVM:J>4\^?IP,J9^23!F&>*?UW[85R
M-"A6'-J>OD1I!'.7UBQSP<ME,+*>%JE:U/HX7U1?/TX'(!^2S3)QSG-UCV/4
ME8.$6QC#U#-DR83;`;"QF2`Q;8SAR%0K4<)?]1CG>%;P/%OY,M'*80':_P"P
M(B2?OUAB/JUX),Y*Q&_>)"@%NV6,H@GN1JC8%2>53]OA450\G_DRT-'4GW^%
M[[K!C=6I]Q/U18"CN9;^?XT[2LL"M^WEJQR->OAJ*QR*J*G`Z*;^0S2&0V6+
MWL'%]Z#BXY/N9=FQNK[)DP2)3VM>L4T5)97E0A7^?1&JJ^&N:O`[L_Y.^N45
MTQDFCW:!\$D(1V%U)D+7HZP8%\9&,\JYRN:=OEOCW3Z_3Z+X#]/^4/JQ"@$M
MK.1M&JJH\"79RK.=JG+VU\6!!C.F2I19@(1X[A"BL4GD;GHJ(J)Y<BIP+JX=
MLO#L[AP)V.V;SALZ"DRB"DR'+K22<?R.!'LJ6U`.<$"GA3XDEJM>SV:CT<QR
MH]CFH'6;,K[&>_7DBM"^0.GV/17-FT4=TI[:D%==19!AL:,GA1GFB57_`$]6
M^5\HGG@4:IJNTQ7*OR%4T2CDS_Y2FU?BF-G@P(D&+<6+NN;4L9:PZ[_H**LK
MY,EQ#.>..%OU:SW>YB/"VY-E46G]"X%F>20[R=51,>U;1EC4E:6SNWRLG=CN
M,P%!5#?]S*>.?:#<4;/8B,1RM1RIX4*\:RPQVPF[ER'^8M*6MG]M!;7QM'5B
MJ:Q@XE@^`A=3S8I/MY-5]Q/K#C/\O@@GHGT5/V\#EUUR"IQ;\><21\TEUUG$
M.ICN57J5TE.NNVYC3F^1'O\`V"AO<_V5/K_7S^H7ZX%/IABN[^XZ!%=\`NGV
M9&<G[O3Y9&Z<$8Q?U]%=Z17?JGE$_3^O`N#P'`<#Y+?S`W]EB/9+M3*J3S26
M^Q>LVL--4]?6I[6UK+S7.<!G2*BK&L>1]U\D#'2_-':K/G;)1'(OAO`^GC2V
MNXVMM&ZKU4,4$$?"-787@[QUL+[&O1:'%ZZED.AUY$7[6.0D9SF">BJU%\.\
M_7@?.5T=U7$UC^7\N)/DG*3"]:]FJBN)(>2,ZQCIEF`,9+2&K(\=Z-@R!>OQ
MB:C5<]S?`U3V#ZC^`X#@.!`^S]/S;Z\A[/UE;0\)W100%@5U_*CG/CF8T;"?
M<OP/9-5#>,ESBL\[4^.4SS8TYE^XAO1?D"8*I;>W-5[DH*+1MUB<_']IYUFL
M326Q]67%B0<S&JK+X5I*R?,(4B!\*9-AAL(QNRL:*W&C8<]H_B>ULALB&T.L
MSF5FN6=Y,5@:SP^DV!C72;0TJSL\<FY1_:MLW:O8%A:'&(U)8'K9]/,MZG4F
M"V".!.)"`UF0A>IF>RJ@0IN<&!;AWAC\#<^`89IC2$S7V04G8.BV7C+L:S3^
M3N:ZQ/!B0MTZK-8XL))=A(KR#D2,HB($$"9ZQI"RP&"%8=J]H,VTI^2O\>_X
MN]6]P)TBEF;`N=T[)C;`&Z3L\^@*36612-=:"MMB7M;(A;<B9_E_NM=-C/3(
M`UU0]E@<Q!))*%]]$?E'UMV"_))V9_'GAN&Y'#M>L&LZG*<KV#D,6=1Q\BS.
M1DT:HO,:Q>BL8()<_'Z*OM(9&W/LD:>9Y$CH\+6&(&O3:,J7V-[3]E;2IEP9
M8]M;GU?TSUE8/QB/G#:&GTGD-M3[!O@C';1%QH%/DDS8$H4\T68T<Z,(HOC0
M+RH%XNC(ZS-NY7>S9]2*O=0XYG%9I+%%KT9]O5U>LZ6@P@]0!HG?%&!&E86_
MT8B*BC5JIX_J&W/@<"UE.A5=E-8HD?$@3)35.J-`CH\<A6J95*%$$BL_<ONS
MZ?\`>3]>!4/K#4Y`[(<LR/(+G+YI)6,8;&B5N4%J)*PG64>3D]C.;,IA#8>;
M92;IK2A(28R.D=K@&\'(W@7+X&J+\I#8F;Q>JW7R5+^W%O;LOK''IC60V23E
MJ*++J"_OF`,9$")S\=ASD*)7-=(B?/Z_^&J*%8<XC&V[W5SV/'Q*IO(F3]B-
M5:W27;SL8=;4&*:ANL7;FK<:'C\F1ECJJW;KNX/:1;)00R!&!CF/1ST8%K=7
MQX&Q?RE=B,WC4Y9T;3NIL!U6S)O,A8T"]D5_]R6%.%_W3!->H\Q.UXU$YKWC
M<YJ^PW*@;3N`X#@.`X#@.!U-]5_SE'<TOW1(7\O4V-7]X%C"&B?R$,T3[H0R
MHHWD!\WNU'?M54\+].!A&E]8UNE]3:ZU-3S"65;KO#Z+$8ED:,*'(LQTD`,)
M;*5%`YX`R[!XE,5&+Z_(]WCZ<"3>`X#@.`X#@.!^*U%_5$7^GU1%X'[P/SU:
MGE41$]E15^B?54\(BK_BJ(B<#P<$3U1SQ#<Y/;PKF-<J>WCV\*J*J>WJGG_'
MQP/%T>.__.`+_">$]A,=X3PJ>/JU?IX7@>"0H:*JI$C(JN5RJ@!(JN7QY<J^
MG^9?'Z\#TDJJPWGYJZ`7RY7+\D.._P`N5%17+[#7]RHY4\_X+P-?7Y1:&"_H
MCOR+7TT5SV8=(^")"CQHI'L#Y,H8JCCO5"(UBN8-B-<5Z(Q%17<"1M9V]!C>
M,Z!=E]C70,:?UFPF,B69:T4,UM&K,;*$KD.1)Y71:]A_7U:X34(Y5_<J>`LS
M5[$P*U$Y:K*Z&8,"M$]L:PCN4*_"IFL>-'(X?^@Q7(BHGT1?\.!57&Y$0N8=
M^;:MI*,*E7$_&00;@4N5E+XG7K'WA=<UK+`Z4ZU3"MC!>X4;[J/ZD_>GAZAU
M79&='K^D=59SV59XM?C&H;.4.X'D1XQ60)6,350;\1([(0SO<"*`T5RD&;U=
MY5$7@17U/S]<2TM68Q35>.).D[BA5.8TD:ROVI05.TL/_NVEG*6ZC64R=<2X
MA8QOMBRG.5A_8Q6$3X5#.XE<>WHOQMVSPNCLK<O!9GCK\8U"2=UIVM%&QX7-
M5_\`INEK]&*GJOZ_3@;#>!5@M>]>[4"T5KOC9U8MJ]K_`$=Z*\FVJ60]J/\`
M'HKFM$U?'ZHB_P#'@6GX#@.!\R7Y.<,RS).Z=!E8-0['V)@FL<HT3FN7@PK!
MK[("Y#5X<>MRZ5C<.1]@RE.L]L%02'"D*8+7HJ^%&HWA?</Y9810K(?TT[>A
M`XD9HCKK(Y&J,[6JXKA^XBHT;WM;X1%5R.14\\"HO6O*+'</YA(>YJC5.W<`
MP[)-!;.L)3ME8/<4:1<B>S6N/2(*6?VQ*89)Z4:RHXG2?G()ST0:(-RJ'T8<
M"J>U>ZO7C2&QH^LMJ9C.PZYD5M59K=S\7R23A<,=T>3&K(]MEU;5S:6EDR21
M7KXEE"-C?"N>U'-\A.V"[*UYL^I2]UQG.)9W3^ZC=98CD-3D,016HU7@.:JE
MRFQY`_=/89/5[%7PJ(O`S;@.!J?[;X#5;FW_`(M`QK(AXKM["8B8-@N2UYK<
M5KC]ELNOCW^2S<F?5,9&N-?LU3BUR9]/*E1%-+:TT<L24L>6P(%Z";0B]BQ=
M@=C1-_W^J^T63[/R[:67ZUHQXSF%1*T]6QEUWI6ZJ,)NH%A9YK@<["\(C28L
MN*:%;!F'?%E*(CFH0)SZ'3@;`M,_[$XEA5?G<7>V7'QG:&<'N+;$)]/*PN9;
M2FC;JC(IF84K:Q)60O>8=?D$X\>44D=[`K'=$CA==G4K0'_J?D=R).O:FP[$
M/U94Z9K=@V;5GS<;U[4V]U=_P^+1I'O%Q\UI.O3).DQFLD2@M&)[U$SU4*,Z
MGT,3\<.NOR/]R]S9?C6T-L[EV[N+LW:Y/"JS50*K#(&.5N/Z3TS7'MREG1HF
M/4./0*Q_@Z1S2C*]/"?7@50Z1:JL\;D1H(JJIN['K_U^R_8N8[(R:ED8WC&7
M;OVU<9/6YDM=8UUF_8K*BKB1,O>Z;+:CILJQ<>(]H4]B!=+\/^'QJCJ=&SED
M80)&ULQR'-7.`[[B,2)-D>\;[&>0\F7/KVG,?X2'>I?5?W>%\IP-J?`A??\`
M87T+6%U%QFCK<CN\@DU6+Q:FWL!UU<:/D%@"LM3R"%8]DK[*G/(,R+]/NB#:
M+V3W\\#'NM./5%3A>17=53OK%S;/\HR(\N5"9`L[V)%+&Q;&[>RCM#'4;WXE
MCD`(&.&QS(@1-<GLBN4+$\#4=O2<#8WY2^J>&S`#6CT)K7;N\[LLB(EE$">-
MC;,1JK!2M$X=).B3<^$X3GO0SVC54;ZJU7A`'4:XI\E[CZEJK_*<8=L$^![P
M[%W-#7P*[[1H=FYSD$7&L>I\KK4BAR6RJ(>42K$H);76<,<H@W_.T+I/`LE^
M,,T_-;;M[NZ6T'VFU.PN4RZ0@K);-[JBONL@D5XWE4`4$"+56L40&HGE`L:B
M^WAKE#:]P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`H#^4)T5O1G?KIC
MX#`LQ"07Q926PHCS1_\`J(PWS7,<R(Y\@3/5ZJSZ_1'-545`DS1%?+>#1DXL
MNO;&!U3P2#(J5:C)19AA8T=MA$$CG-2'!;&<(B*UOJZ0SU5?W(@60C6]%-FK
M#"%ZRU,<:_+4RP-4D=BN*JR#Q!B5/3SZN]O#_P!&JO`I#A]<H=D_DL(V'#7[
M^RP1HDCA:KY3!=6,*`T,MC'M0SVN56HGEJ^BHGT_7@9_NK6.7;0ZGT^"8*&,
M/+74>I;&F$:VFXY'`?&+?$[J0Q+2M**?!^.%7%1J"*-[U1!_(WV\\"O.D<<S
M@6O\YHLEJ?YK*,1[58^'-)-.V4:(8&-8#A3YUZPD^3)G.B#CL$I'OE'<CU5K
M2JB(J!.[2Q),3HFM="_CJ^3=I/A5WN\OV$-.OF?EC1%(0TA[UB"D-9[*0BKX
M^KG?JH70X%8"7<;_`-9\/''#*LQ>L%G=C*B)\#8R;6J8)AO7S[?*0KAJU$3Q
MX:[S_3@6?X#@.`X'YX3_``3ZIX7Z?JG^'_+Z\`B(B>$1$3_!$\)P/W@1]F6I
M]:[""<.:X-C&1_<!)'*>SJ(9YC@E:UCQI-^)LQK%:QOT1Z)^U/\`!.!KUSG\
M3^B9LZ?DNG<GV)HC-YTV%*7),"RJVKC,2O)%+"&XD"976QGPGQO81"2WN]GK
M\GR(JIP,#F:C_*5HPL@NL^PN+[ZQJ!70XM=0;@Q^LLC*04@#Y5C8W3#XSEYW
MD&4K2(^\-Z"&Q6IY]E>$^]+.Y6>]D\>W?-V'JS',&F:/R"KQ*=;8?G297CV7
MY!)QEN5746N%,JZR=C_]OP;"`PK9))#7DE+X)X&[@5"[`;6L*W3.P-E5V00*
M6RWQC)M'=;XN36%O@-KD>XNS^3PM=XO`H[FRC,J+FHP^IG_?Q+%()Y$1'%*/
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M,X,`#9-B$;2E=(=,*<CR$*5ZALSZ;X:3`NL&E,=-*'-,/`Z6S+("P0PN?>@_
MFD:%@!A`T(63T8Q&,8B-:GT3@69X&)Y9BJ90"N:EO;U1JBP'<0VUTQT:',L8
M8RK7,N@,;[V-9%FN8=T?W8TKQ-1_LSRU0XNN<&I];871870QVQ:VFC$:,#)$
MR4)LJ9(-/L2!-8'E35#(L912-:0CU8C_`%1?"(B!FJKX157]$15_]G_/@:$)
M>:0K#L_^5;?B2ZYM;JSKWA/7BA.&46IGCRO/(]K+<Z5:SXY:RD%(F@HFJ<C2
M-&Q&2"(T'JG`[/',/TUC53W\V+D-16SZ71/7_1^)UN9GG4ZS*_*L%U5?[5/9
MX=M#%3PTG2*?*<RAI&L0K&DU]F,\8'PQFC$@9_\`C'NL@ZP=7M-X9O23%LL;
MV0:;<XUV*!4BHJ>_O[RY=44^-;6A@DS(F*Y19PXL5E9=%,.NOT<UKFQ)KD`8
M-SW`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#71^5UHS=%-XPR/&QMAC
MY(/@Q3@CE20"2CPR"QW(]@BC:J?H]%7PBM7SP)MU]+F8YC.F%QZAM<FFQM!X
M57CIHQ:^M&.L2%0C^_-9VDF/'0\=P6M4"*YZM<KOZ?4)0'G6P'D,-VGKQCFA
M4D=W]U8>X4@C1*5X%)_*-<!RJGHUSF^JN5//A/KP*Y8_8N(;OQ-/"QRLLQ2*
MR39P:><EEE,*9_Z9\'-]ME[Q%6"EA&&C6P6@5K'PD&]5\N55#/\`:.=Y3@G5
MVOR?`)5=!S<^(Z_J<*9;P9MG`/D>3/H*2HA&@PX5G+ED*>Q1!B]6M*1$8\H6
MN4S`Z?2V1XR?3$/(`YS675WM>-87\C(&X]#Q@F<9F[%C`O):52!C1GVM@S'#
M%<`*)\(XJC9Y8+SP(L<Z>)_XP@0Y<@,<MD9UD,9%<V9$9U3V`]@)#_9ON)LM
MPW^/"HKF)^G`V)\"G[`D)W[D2%1/BB=/X86K[)Y0EANB<]R>GGV1%;6)]?'A
M>!<#@.`X#@.`X#@5TSK/,DK^Q&C==0XML/%,FH=F9!?6T2KG.KG6^.5U0/'Z
M:QOQR$K8K9(K*8=()0O/*>%A1D8R.1I`L7P*_P#:G._]M^N^X,N98!K)=;@>
M1)7S#"$?X9TJN-%`4<8Q!#E%!\RD0:N3V]%X&LSJCC)]$_C-P:NH)4ANTNVM
MC99C0SH\6182Y>1=B,EBKBDZ<L83'QQXIK6UK%.\SQBB"KE&I&,:U4"6-_X?
MAN;]A^F?3BLS&+@%;I3![_LA'D0R8H:?&M-<0Z[3^C:Z!19C67L&V.S(LKL;
M9@R">YSJ#V15>B$&&$]B)N29-V$T-ULSS8,O9^S<:E2=WX;1:Q--T9E684V-
M1)"651E=Q.%E&!/D2$@_=B6'*QT_PQCC')"AOA.&UW`HU8F/1[6!@:ZYDY$]
M]Y=8Q)KL?K[:+<R_#9C[W^V)=C3S+=_Q(A#BDR$(B-7Y')XX&:<#45^2^JOH
MNY.B66Q'V\?';7/]T:)M)M/?`HY$/+-Q:P;<ZQ1[YT*562/YC,]7!J@H4D1Z
M2;`:`D#,YB\"A'9Z9CF7],.IW7R&;$ZZTUQVR77635-^Z\@Y#B%YJ`M_FE3:
M0J^09@QQ68S+JK(A[)OJD6<$S'+[(YP?1!KS/=:Y!CU5$PK.\3R>#5Q8E&,U
M+?U5A_KUT08/@>R++,YDA!A\JQ?W>/K_`,>!):*BIY145%_JGU3@?O`<#K[:
M<RLJK.R+Z_'7U\R:3W7PSTBQR'=[+Y3PWP/Z_5/IP/E'Z][_`+:QPS,=>8K3
MX+DN:]KNZVP\RRR57[5-67>&8%U\R'!ZVQM<JHQ8_/\`@QBYNJ6+51`17#E+
M]\62=5(KPM";]D[2I3]*>R6HZ3&\Y!_ZC=^UEMBN?T])4ETS>8[MC<EG2BQ#
M66<UG\=C643J3'M-V+;.)$CA&UDX<A%\2T]0WZ:MUA08_HK!-47>/U$ZCK=?
MT>,W6.38(IE)(0=4`-I`+73DDB+!=+4B-&3W\-\(OE4\\#"M%Q&8+FNU=+P,
MZ)E.,8,/"KW#<=N;*PN\OU]09?`M7NQBVO+)JR[3'AV%05U)\QI4F+#]HY"J
MP040+-<!P'`<!P'`<!P'`<#$8&;T%GEUMA,.04UW2TE5D,Q&@)]DM;<3+*!#
M?'G(GV\@J2ZD[",8Y7#5J>WCRG`R[@.`X#@.`X#@.`X#@.!KV_*>>#&Z);^/
M9B8:M'B1UFM<-2%0;O+!/B(UKR-GMDN'\#F)[,+ZN3QX\H$^ZUBRBU>I2PGS
M(U]$T7BC9*VSR-KGQ#5U8B@EU(7AEI;CLA#<]ZO]&"]V>/945`F^!*L'S'0I
M<ZE-(B@`6=%A(9LL/W`O`2_$601PHYCB)Z*Y%]FM\(JJBKP*2U-NA;;\DD1:
M:BA?P=M":ZR@Q%'9WZ2NK&`V?W&12TD^TT\))'VH$3XOBBB8W_[+@2'N?$X>
M5]9:&JL;/)*>NAP-5VLW^SY%;#O;"/36F-3G8_$F72OK(D:[6/\`:R"G:5K(
MY'KZ.7Z<"J^B,CE[$Q+7F27-S_<4,6RLT#0!,..>OQ8%;UWMV,9%L&T&/V<I
MB2+$Q9$N9':1DEY&A1@$&U0G^!5C@L_'W5J2OF/JHKQCEUI?NZ\OV/6_*(I)
M%9*<U'&A'1_D1/HKQJB_UX%W>!6F-#9_ZQ+B>JI\G_IIQN&U/9OMZ+M'*S/7
MU\>_CV1OU_3@66X#@.`X#@.`X%']N&NXW>CIV.M&IJFRU[V:#DWIDJU;XH(-
M-KZ12R38ZL(S,IBOL2N$B(8+X12--^]OLB!>#@:C_P`NV1V=[J/6O6[%G$?E
MW9+:F':WAACB"\XJO(\@JL6LYRG))$2!'@Q,B))(5HR^P8Q&*B-5SVA:69`6
M;V*U+IRHJGPM=Z<P)<XCA@E2OJHDBEK`X3C-!*A,&CK(;&7\:9!8Q&QH[JLB
MN>I$8/@5*UK?8'L'</;K=>V="9=L37NP-LQM)83FU=@T?:F,Q-?=::^5ATDY
M\<J0V6;XXP^U[7+)*S`UY0'8@7M(GAGD/#JY17>P]Q;JG:ZRN/J?#M?6]7C6
MC[>AS:BVJ/+L$.:5)OZJ[P+8LW*<ZQ:+&/6`^1C28TL>48P1QGK'=)>&X-/^
M/U7@.!!'9GK[A?:71VP-&9X6T@4F<5+(\3(<?F&K,HPW)*R9'N,3SG$K6,04
MFLRG#<D@1;&`9CV^LB.U'>6*YJA\[N=TUAJK8L:B[QQ-181M)^50JVGV'NW`
M;[-.I'9>EK,5I\5H,PG9X<-K"P+8UG;1RG!#ESJC)J;^3GPU?9UC8[R!TFP^
MO^'R<&RS-]9:YV3IC8MLV\IL*'HC>%[LC5U'DV'VMU48];U]!D,6;6V8ME6T
MD23Z>IF2YU-4/<<J!6&9!A-6HK[:F,X7JYA/R,Y1A&5W.$BL,OQ?9>K;>YP5
MM_%AXXS-BX/L:@L`TL7&*+(Y"0X\VVB2I!$DC3W*1Z\"8]`]T.^.R,6GY?K6
M'UK[48A%SK/\8@3<,V168SF\@.&WV18@QLK!\E_M"8,=E>8X8]>Y)+C3H;4+
MY09&J@3T7\F6<ZQKQ2.S/3O?FJ01G-%=936X;<Y/AL%(QEBV$Y;BDC6]9]L4
MKA$C,%-D(X9FM<3W1R('EM;\J74^]T?MJ5A^RXT;+JG"<C*W';4D2KNP'KZ]
MLB[B&&P]@.OLJ>L.I2AE(-WMX&J>Z^J!INZS]?0Z!Q7!-@QL9N]6=N++2\_L
M)G>7V]]'R2A=J?*85WMZ]FZ\)'RA*JF%FF0PY=;,KZVL9;Q94$,@W@`''*&Q
M/<>O71L;_%)U'BE54G3H^R<H`H*R9*A/Q2BQZ1*FO<`D)(Z+89U9L:2(#T5H
MWJU!HU$X&^G@4`T5:WMAWZ[V0+4U6^IH<,ZJP\4CQC336D2!/Q?8%E<K:#.(
M,6$*;=F(^.,"E:1&O(YZ.56-"_\`P'`<!P'`<!P'`<!P-3^-%M(&;Y#`I<BR
MX$I)U:.2.$DVAR)];([39M#8:9"EUL^0ZML2RC1Y/K_I,@B8K'``5'O#;!P'
M`<!P'`<!P'`<!P'`US_E:/)%T@VX")+-"/8185:A@@%(<HYKRB.!6'<T/B0!
M7,3V7PY[D:GA7(J!F&NZZQD;`QJA3,KG'[<>"9%+J!K0PGW)L<K\H@0&(:5=
M5D^/]D!I@C56*C)7@9`JK$<JA87'<:R:#F65./:3BC6@QB(/*9<6H?*R"2V1
M?G,R3&BUD0,=]$$XAC]'*Q[3*KF([]S@I>$LNHS#O`"#?`M7Y1F.0"S&,*O>
M`M.VEZA:XC50I)3C&`\ZR>,,H;8KE"P)G->J.8J($W=HK690]1[BYJ:Z3>S*
MNAU_+A8S&L["G_NYXKG'$9B9YM17V5JV)D;%^T*.,T1S,*HV'`KOF8$>=<=?
M6E=UPJ,IRV;;_P!QV++[8=0/(V2(&11G7&M%Q8]!>5Q/0D*VBQ8QA/&UQW"$
MUG^H]Z.>H=Z*U%!NOQT5Y0HPUU7WT001JKF1R1>LN2615]B*CU8(<1S$5?+E
M]DX%Z^!4F/.5>]UQ6>%5!]2<;G^?IZM4NX\KCHGZ>WEWP?X^/V\"VW`<!P'`
M<!P'`I3M?^SB=X.HH[A;<F81];]EY6%Q@P&DHVQWP-;1LIM;"T;:"?$L(,,D
M:-&`Z&9LAE@5R$&H51P76X&GW."L[`?EET]AHEC2\:ZG:VRS;F1PI@W)YRBW
MA%P7"I<%[/N8\D\2TS*:5/;X7B?!5?W*U$0+C:>NL=LK/L3V&O+BMQS&\CS4
MN&T>76]O70Z*/@6FXLC"P7H;::8=;"KIN;&O3H0OJCO=OLKV(/P%<,+T+W`T
M)J>9JC2>P=/;YTD_&<GK<3_E26FC=[4H\HD6DR7=4VUL2A;`UOEF7&G79YS;
M*705*$L6H4CO]1WJ&'=4MAZKTO7FU_V$PS=U%NO3<N1;9%MG?>`TF2/H:K89
M+^=6GI-T:_L,XHAZ\)!K9812)-F$0?C>*0@7M40PVR8]D-#EM'4Y/B]Q6Y#C
MM]`C6M)>4TV/8U-M631-/$L*Z?%(6-,AR@O1XR#<YCVJBHJIP.XX#@=1?8_0
MY34S*')Z2HR*CL!_#/I[VMAV]5-%Y1?CEU]@&1$DC\IY\/8Y//`HY;?C$Z32
M+FLR;$=-`T[EE$6>>ARC0^59EI6UI#6L:?#M7UH]<7^/50OY2):R1R4=&>T[
M)!&O1R/<BA!&4_CJRG68,BSW4/=C>.$)38@-9,79>-ZUW55M@8BV-:QI1Y=W
MCV.Y2.;!A4H8X)8+,$L`1-]2*Y%50U+[>+O?KO4=:<B[,T'3S9U9OS6ZP<"!
M7WV9=;;O!R5N+6VP\FCW\D.&;3Q"MJK-V<`H)TZN*"TGL(%K3>[G.4,IH^QF
M>8E"K:BOK.U.#C)D>.U%*#260XEV>P&SJ14*W>/0#T&(9QEHRS[R/4R*R#&_
MMN.L6OB$LKH*2B#8\,C7MAU/L4V579K*T9F,BRSJ=+N*/M/UHK,1S+)LC%%C
M4>9Y/8FR8&N\A+`L$'#KD?64\V44@B(R,1C_`$X$X[(K\\WM;V64Y[CNJH%I
M?X--UGC28/#RVVK,$Q3&H%C8XMB>.3*2/-M9\/9<?._7+T6O8*A@'%7L]Y#G
MM<$A:@V$3MW^2C#LP=@5UKJET+UXPY9.)9!(QI]G3W^4AR?)1@CS\?E7<2RA
M.K,EIR,&PL1[8Q&.*(;U0:AO:X%)-)7]Q9]R>Z---BU8:?'*CKJ"BDQ:.+"N
M)RV6*998W#KV\$,<B]9$FD:*"TONL0".:CO#T:T+M\!P'`<!P'`<!P'`<#4;
M46%W6VE37/B06+-NL!L)SGV,NG)#QZ][,9(&911`V<DUH1@D9%0X930`G3!J
MC7L5K`\#;EP'`<!P'`<!P'`<!P'`UM?EI9,7HMM\U>0@YL(%981W!9)<;V@R
M'22J!T9I'`DLCC>X1'L(-A6M5S7)].!,\2K2QV=@E6L_+:.ACZ-HCR[:BR`V
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M@<VLA??3/QV3T:-?XZHMY7L/XWL:V5UHR.'_`*1"(I58JR41%8J>4_7Z<"]/
M`J-6PR.[WY?9*J*-G4W7]<QJ+]6N7;VQI;U<GCZ>_LGCZ_7U_P"'`MSP'`<!
MP'`_%7PBK^O_``_3_P"7^G`JST[V[EF\M.2=C9?)HY4R?M+<M%4DQN+*B4G]
MLX7M'*L,QU(++!S[$S75="-Q#'7W.5SB-1HW,:T.LV._#&]QNLHK>BR63FAM
M=[\-AV00&`/C-5#B1\$'DT#(6NKCR(,NRCSHZP3-D@:1PB#\/\^.!:NUL8]1
M5V5M+>P<6K@2["2\IA1QLCPHY))G$.=S`A8T8U57O<C6I]55$^O`TQ=&;ZYF
M0>^_<:UL\6AV6Q]P6.O]36^5/^TIX-7@XU@4%?93(`)!`8]:[4SDX'LC?(0Z
M@]T\O5B\"7>V`L>KXO3?J/9Z_;EM+G&?-V9MW`]<8P&TIC:UT#"#GV6R3X.5
M)1;'"<AW);8Y%/$>I"2!37C<AW*]C@@+/,)T_0;*U33]$*S:FK<AV=F*5>T8
MNCMJ3M0Q-359%KRCS3)NK>U*ZPUY+`YDF28Q'XP!AUAO!\OW,@3D#,<YZ#=A
MY_\`N&7+-D4/8ZYW!LO6]SFNQ;>*+56>U.N,`E+34&"X_B>/$!@#*_&\)N;P
M+EB2:M+B;?3)$P1%5@E#<K'C1X8`Q8@`Q8L<3`QXT<3```$;4:,00B:T8A#:
MB(UK41$3].!7O<O9[76E[_&L&FP,VV%M/,0$GXQJ34V*3LZV%8TL>;'KYN3S
MJR&Z/68MB%?)DM::VN9E=7(Y',:9Q&JQ`P/#>Z6&VV6XU@^T=6[LZV9%G-B^
MFP+_`'YQ&DH,=S:_^>:*/C%#FV(Y5FV%IE<\,/YHE7+GQ9TP9&)'&5ZJQ`N-
MP'`H5^1*EV5>:*!7:YOHF/.N,NQW#LBE?R\BKN9M1L6>+78ZBC"R!-AVY[&?
ME0D-$.X"%`QWH1K_`!P*G=T,DIJOLAK_``IV+XADV,ZOT1!B6E+DUYD6/P(%
M7F>7AFE_MF#CF,W[+O-GU^HXPJ6"=[1"D.0Y!$`-[FA"3&85-QB=0[$ZP0;N
M9:938X1@@-BXN3,*6-@M'JJKO[^I7,-5TLO*S;`8RT>&?=_#]C)K%='28XH/
M4@8%.A:.R%F+9!5YGLB#63[?.H@L-A;`UYMW$\9CSK[%HUYEDS66W*^HE7N'
M8[3T@8<%\8ED:NBE<)R*8A)#PQ#-.HNK)\V_W-KO$L+%8X+KFQOK@M#IS.^N
M>TZ;+F6A0SR4MQH3.,*QRONY%>.N<*$)GWF0+(B$(A`,$A`GW\*.K8E%F/<3
M+23,@LS4VYKO!J&7F5I99#E*8_"<"K$:;=WQI.2'9+3%!J%+`CYS8R#:?R1'
M/>'T!<"I.F<Y'D79GMSAS*_+8G^WTO2L?[JSR.JML1L&Y/@4B\0N-4D2I@V>
M+607JX<\$N3.^=C8YQ."TBB0+;<!P'`<!P'`<!P'`<"CV#]:8.,9JE1*DY6:
M%70:ZW;??QF)#Q3*YJ[0R/9TN&>.D&;;UTV)<VPQ&`A`A*-C)`/C,CW(%X>`
MX#@.`X#@.`X#@.`X&O?\IE?!G=&-\/L94N%#KL5E3SRH8T,\(FB+%,Z1'^"0
MLF#\$MZ'&C?9XE<B*WS[(&6Z*I;2ZN=3V,V6EQ1@ZHZ?'D<*9&@2X<K()$5T
MBBN7E+,+))+<(=AZ>!$8WV<[Y$5R>0N";&\>DFD2)%'4F/,\?=&+`BO))]1_
M$WYWN$KB^!?M3SY^GTX&OG&P,BX_^3I\)S8ZDV9DXXXHJO:>-]MU7T]#&K6.
M:K!?ZHU4:,16(WQ_7RG`N[BN)U0'T.8N6>MZN!4>,E<ZRFK`_BXS&6"-2I4W
M\:V8LPJN=)07W#FHC%?Z(C>!1_7\"97GV-DT!(4O^#VGLJZ%]Z2,U)ZS-/7(
M(\<#9)W-G?:R_P#1*QKU5HD57>K$5&A-)K=]MEG2>?.'$AS;FHRNW?$AB2/#
M'+/I22:1&@QT<]`QP)-?\;$5?4;?'E?'`MUP*TU\H+^X.5P_E9\X>N."R%!\
M:^_PGV5G[$*IO/A&>X%;Z^/*K]?/`LMP'`<!P'`AS?&W8VC]=2\_E4I;\4?(
M<,Q]8`I;X+6.S#+:;%63Y$ID*Q<*+5NM_N"^!+[,$K?+?/L@0?\`C]KIU7UF
MI8\^!05CS;+WY81H6,7-=D%*"%:;UV+8Q&1[6JF381SH*2B2&-<WX)/R"5C%
M9ZH'GL%^5O[W=:H];9Y#"Q,>A>R4[)H`9LU,5N98\ATG#I`3ZQCVUQ;V":<0
M\:21KC!`TPQJC3$\AR>_6X8>C^I^XLV/9PJR6+$K2#7NF.C.4Y#Q2OGCCQ9+
M7MG&93ADO^)K7.<UJK]$150*[]6\(NM3:!Z#=9RM<N19)06&Y]O-LZBHN_BA
MP8Q=EY7#L@63YZUTJ3MG8-5&B2PN<6+]NJ"(BL:O`[['ZO;VT>YG8'>6L;O7
MKJ?2U3B75/':7.J*[/"N#`BUVW-Q'K,IH+,$['9SLCR6DK"/=7687.IW(K/+
M?"!#$F;8[;[B6.6[33(LSU-C>(1]39CI;7]+7[]UQC>RIES(@U^17UO5RXF4
M81">CWE9)_M0,@4N/)^6U;$$0'`W!4-'5XS35F/TD9T.IIX0*^NBND2I;H\2
M,Q!A$LF:>3+.K&(B>Q"/>O\`55X';*J(GE5\(GZJOT3@4.V3HWL1A._<U[(=
M8+K3V06NTL-P'#]I:NWC"R.IC6(-7DR1^)V.OMI87'M;G$3DC97,'+K["HMJ
MXQG-D#^W(XJD"'>P/8C#\DU%E&I^^G7+;_7O#LT%1X]8[0KFU>VM08SE%QD=
M77:\R*FVSK21.N,2R:LV`6NDTLNVI:<D>S9%=^U[FIP+-=0-RY7L7#LHUQML
M#*[L'U[R9VJ]RPF#**+?38<,4["]K8_\WETC$]PX4:)>Q'-5R1I,B5!<[YH9
M40+<\"$]XZ;;NBDQ2K7*['%9&&9_B>RJDL:LJ[FMFY+@T];K%6WU59A]I]76
M9"&/.4()$0A21F-4J-\\#0&39':?87?/?NKL.%@6PJJTN7:NL,YFYZ73-#LN
M_P!1ZRIJW/->TF#IC&Z*T&64),CM)3Y%H^+&D1(4N+'')1D@P`L[M78_9"#:
M`R3/NGG=;6EI9UPZJRR/1&TL'W1@.)U,&<.O2OI\`U^',KT1KZII(A'20XL]
MP"6!V?+'"UZH%<R=K,-R'';JSSCL5I'"L_!B!X>)T?<K0UQKO)<,KDDUP\QU
MW+M!V&N,JL:FTNT',/(AP%1Y8#8KCRD:1'A,.XX&,WVJHVRL:H-24^Q]71,V
MV),C:4R=N&ZRRS#<-G7Q928]GL%U7EF-Y;G&/P#2DFQ8MI$"!?CE-0,Y#/"4
M?P5K3.Z</D.M;(F>6V9V-YGF-YA7S*C9F+3[&)$>&+G42S:VPL2V,UDR5"M6
M./`LXQ4+$,0?Z!NEX&#8WKC$L2RO8&:4->>'D&T+*BN,TD.LK*5&M+/',?A8
MM5S0U\J6:!6&'15L<!/M1A0R!:XB.>GMP,YX#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X%`?RB-&[HEV(4TL<$0L'EG?(,B.$UHBA<X;VK(B,53-\L;[%&
MQ'*BN7U1>!FVKX;\9R/4<@T-PH=7UKPS''0ZT\VSL9,H4>D<PO\`$P0D`:NI
M@Q7B=,5?9"2F,8GJ]R\"T;,IA.$8JP+UB`<9CF$I+!I2*#SY<$7PJ\K"(G['
M-14=_3]>!1J-+_D\)_(D1]C>F:++\PCJ"UJBUX:@+>O6N98ZZA(V8<UE`4<A
M2D)\<=XYQCB]'?'[N"]^/(B8Y1HB>J?PE:B)]4]4^P#X3Z_5/'_MX%2K#-JF
MNUQ0TK`HZ;=V^W:0[XM2UCX\NNQ;/<C?+DMAN$")'/`C(BF57*3Y6)]'D^@8
MP=)$O//QQ2XCU%`;CF=R9(">4,09^NQF1&N\?3R)YO+O^/C@7WX%/Z%'%[Z;
M-?[>61.J.G`^OLB^KYFU]T%<OIY\M5S8C?KX^OC_`(<"X'`<!P,'N=E8-CV;
M8=KBZR.!79OL&/?RL+QP_P`WW^1Q\6ACL,B+7(P3Q.93PC,(=7.:C6O;^JKP
M,BJ+ZBR`<TU#=5-V*LM)]'8EJ+&'9#@75498UI437PS&;%M*V0BCD1WJTH7I
MZO:B_3@4][_3L9K-!0+',(4ZPQZ%NSKX>;%KY,6/((?_`'FPL=7[LE5=LDV$
MEL\'W0!L"<D7Y/C,)Z(]`]/X\73UZPTC9KJ)6#V5O=M:F-YA!SFI'5NW;GQ8
M8@Y#61(,$A@H16EC,$U81$='>KR#<]P3EN7347:(<:OJ>]F8-M+7<^5=:SV+
M5B21,QRPFB$"VJK6L>04;)<+RJ&!D6WJI"_#+`C7L<*2&.<0:=^\>Q[_`+-[
M"ZM]'<OPZ#BNT\GW1C,S;^(I9/F!37-/)MK.\V;K^P'^ZRP?(L-Q*W'$.5K)
M<4LQ8<EL>2Q?<-H=I?8'B>7]A.S-W97+8.F=8%P2WCV<!U324M-@%;:;4R^;
M02S^$MA7+;R&$TE&?&PM8@F*Y4>G`U\]:HNF\9ZZUF89[DN>8%VYR7'\@WYM
M.OQ>YRK2^?[(V5GQKK92XI$J+]*_#MB6#'7$:EA,6/9,,R-'&[V&Y&N#D],]
MG994;AB8YC>K0U&3=A)-_L/;<W8.`2<"S@T7$HCU=EALAJ#5L6WAUCLFJXSJ
MZ7B5!+%,NQN<U72)!V!NNX%'>SO>S176;.L-U?MZ)F`8V?U[I%OE%?0&EXEB
M6-SB3ZS^7R*>&2*P="67%<(ZP`RB0V/:4J,9]>!R-91,)S.`:^ZK]LI5U3F?
M'</&9>4T>Z\,KAL5"/A#KKR0[.L>5["N1PV6X?B<OU&OIZ<"N/8>5N?;.]^G
M?4/:V.8'+J,GVE8=E-AY'KF_N'TUAK/JTE+D]!59'B-_"CWE$3(-WW^)N$HY
MTZ*]L0HU([U<C@F7M_69%I#+L0[Q:[@EGIK*N!AW:#%(0%-(S[J\6RD65KD4
M43512Y;U^N;`V45JI^XM4ZXAHCGRQ(T+Y5%M67]35WM)8PK>FNJZ%;5%M620
MS:ZTK+&,*9`L:^9'>0$N%-B&8416.<P@W(Y%5%3@=CP-"79;4.6Z4[&914TF
M3Y!C&!]ALLN=_=?\OQ^)2,F8#VYC`I'["P"V+.AD_D:#.J>F7+8A328:AC!R
M&*]\B.]@6AN$Z][6D;GU-B^<VM&[%,J,R?1YYAY9`Y1L/S_&+*7CV98V0X_H
M45=?5QTCD5&J>(X1O'@B<"3K[&<;RJ"2KRC'Z3)*PWK\M=?5,"X@E]'(]GR1
M+"/(CO\`1Z>4\M7POUX'SU?EPT1T>P+6&71,)T1`P3L)<5-175N>:$UM;8[:
M8?"V5>GI@'S+(\"B55)BV*YN2IL(]E)E.4DB)',WU>YPT<&S?3W7"))Z\:!N
M\0O9.O\`=6*:NQH=!M:-10UMY<2RCQKV;C>=T)7"#EN&7,DW_4ULD@W@<]31
M"1)*-(T+'ZBV;?Y@?)L,S_%EQ#:.O4IA9G7P#/L<1M8]\.P=0Y9@UV_P:PQG
M(V5$EXPR6"L(!1/CR1^[$(0)JX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@4+_)D!\WI;NNJ3[?XKG&RU4Q9<=\F(R!*=_UA90FB,B!")GO[.:K?=K6K
MX]O*!+V!17UDO"LZS2QC80V!JN/BL>@L+JD)7VT<,>FMI.2$FL''='DU<6N]
M%`U_PB$<CG>51%0)F+F5:2<V!5$@W)W,3_2A6U?]Q\_Q"DK&2*XWSJ1L(XS+
M]/"#(U5\(Y%4*!?W>^FPG\@ALOE38`K7:.?5.,#L3$GPHPXO7?6TC^,`8;S5
M]6*5-^X<(9'@%(E/<B>2$\.#8U5M1M/7,5OT;60V^OT1?"11IZ_3Z)P-<5`=
M"KE4&TM9CJA-A[E>CPQR@'6P).D7%F_QL&6>2X8T<I9`@C=\;I2O>C41SD0)
MM?'KXF;](JZID29=5#Q;-OXV5,'\,N3`AZ@A0H4B4%&M04@T:4USV^$]7*J>
M.!</@5AQZI^'N+M2Z<!&.F]>-+P6R$(URG%$V#NLC1J-$]Q?"\SOJO\`F]OI
M^G`L]P'`<"G&RW_+W1ZQ1),[(0Q@:]WQ;U]?"ALE8S-N!0,0JR2,@D_QABUE
MC"J+,R5STE@&9"R6.&1R,5@85^/NEO*?&NTC[JP-8#NN\W:&^HE*ZK*.'C]A
MF4=($"/(JD:,XHI`D1WS-22(RO$7V<-7N#,>]D\,'1]0,^'8[G[+7=W7ZB;B
M632K2%"M"76X\-KV$A2:C_JQ7M8IONX"N\QUE@8AT^'WX'GT))1'ZSXU*QF`
M:GHI>=;LEP:8QXLE*E9.ZM@&FPH\F+$@_/$;8.,\3BC0_H]$(KG(KE"PN#YE
M/RZSV",U:"#48GF9L3I9@Y+9)+H==35$NTLWO$]X!#';6!HK1IX>QT9WNB+]
M$#2"S'Z/LMWX[4=DO[[F8G'Z+:W=1:YV1B;F6,FAR:^<M_=B$]\9*_(L7E8M
MK^=#OJ`_S@G`ND]5$5!&0)1W3MG-MD=3L#ZWV.+6]#V*W/FV$QM@Z_SJW+;1
MH>`23V78;9EO`R1@8@LBU2;`\3GXX.3$55J7RQP9/I(#X>$0=CN_>0[4T)+U
M[=0(76O++&]Q*$S:];!HMY8!#L(KA7-WC#*$43^[,>R`%5\<@0R5A9*!(%J-
M^.1Y0-EW5#&^JN7,#M_0%Y49C<XS7R=79-F>-.OZRB/9_:TE]E%3!Q.V.2JQ
M6-/LC1+`\.L"".PR":Y7_`U&A>'@?,#W1S['-P_E"U#B6:0`95K/7VT<$PFZ
MQ:#C]AEDK(JBAK[W*<FA'QRHCS;')(H<K]6S(0P&5(\-Q'C(-JIP+O9-T4_'
MCLU+_.-';/)H'+,?BW5K<W>G-CGQ*5C`1A+*NI60838RA2:B($)GJ9CQ0D$Q
M[FM5GGZ!0W\;U]NOL!^3)^56^W]@;#UUUHT#E^-LS#(Y46-:Y50YME;J["L5
MRI(2$_DPW!H<B^((SBE9*J8KGF5P6(\/J-.`,D)HTD(I$>0(@#@.-A0G"5BC
M*$PB(YA1%8Y6N:Y%1R+X7@:^.L<BSZT[7R7I3EIA,U^6)=[-Z:WAB2%6PU.Z
MR67G6D))SM4#[_0=[<B96B:1Q#X?/@*UG_027-#89P*1_D1T4_?W4O:..U41
MLK.L)KA;=U8[P;Y&;(U@Y^58_`10>Q%AY6"%)HIP_4C3UMK($YCVO5JA7;I!
MOC5C<ER-*'+(\?7VVM78WOR#;W)CTN+TMX&U%AV40/Y6ZCUE62WLJZRH#R4C
MJ,#7M5K&?1R-"TN>]XM#X4VR'`LLDSV;4F!&L!8+B]O:U4"1-/'A5R3\ME1Z
M_#XH[&QFQXX5^_<XI3M]&N1'*T/GU[:9QV<VGW<H`*7^S.OO9ZUPW5$/#J?,
M:G(!W>1ZTQ:VN*.+E,.11$!)LJ'8<DLDY:W[FOBC](QS&<=1D#Z@=4Y/6Y)A
M]>*)#ETUCCK!XUD6-60PAM<9OJD(P3::<*,0L5WP^$>$T=SXDF.]A0.<)[5X
M$+ZZM-AE[>=D*2^I\DC:[K];Z$GZ_NYA"DQ>UL+-^R4S.+2M^1P`6M9,AQ4F
MM]4>YA0._3QY"V/`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`Z+&9TVRI(4VQ+7
M'F'^Y4Q:D<H5>]!RSB$L=DPA9*>`L:CO9R^7HJI]/'`[W@.`X&N[\J\R37]$
MM[S8;I33Q\>C/:L1X6%>QUG#8>.]3QY(4CR@.<,JN;X0;G+Y1?"H%UJ#':V;
MA>/5\AI"Q%QB!$&,I1S&A!)@"16B?("1A/C$_P"-JN:J*-$145.!R!X13#E?
M>#//;-8/XV2F2`LDB<Z*.(4PS#CM(PL@0FJ]?/A53]$3PB!0&Q#%DZ6_(G%-
M0WE>@=I;$`=F1/CDD7BLU=K=P\EJ#10QE;130HQL92(XJ$C$5SW(B<#8@LRU
M9:5=4"C=(HY-+,/,R+^1AC%`GQWP10*I:M?^NE+8@.8GSL\""@/5WU>WP%2"
MU\"FQG8C8<[^1/*M-COFS'!-$;%E5VKY0W)#&0SG3!-$W]WRM56KY]4]4\J'
MINKK[#<W0NG:B$;>X7MQ%*P?R,1*S4^,RVO0GEB"1_GZ+ZKY\^/">?H%WN!6
M&BN7%[F;/Q]&O^.#UITA;/?Y'Z*2RV=OV(QGCT^7W:RL557V]?"I]//E5"SW
M`<!P*2;5=/3O'U+^VR6_@PW:^[$ML\6C4,V5C=^$=/ACXUK:Y(.U%`J+*@E$
M:R/%)",^6V8YS2C02M>'YT8PJ7A>(;Z67@UK@']X=N>QF>0ZNYB)"E7-=D><
MG6)F0`-<\:UF8)#=/B$:O^M',Q[D1[G(@3?V*U%_OEJ#+-=QK,%#>6#:NVQ+
M)30DG.QC,L8N(&1XMD$9C7CD1Y%;=587(>.]DD+5<X3D>B<",=7[@QO%\#SO
M%;;7E9IK8VJ*7(,KRS4T-HTH9"3#65P3,]?6-971197KW++LA7`L`1AR0R"N
MCS(\>6UP>!DA+J-J+K'8Y3=GK*JR!@UCDMM)A!+'AOS/*PFLBH!OE\P[C9);
MH(;G*IRIZJOAR^$#6;T@U7D-WT5QJ.P`DO\`N3OR7FV:_P`Y,`&T9J2-D\6#
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MCMIFR5F1RJ.*&3"D>"%^0C"J&QC\@7<?4NZL)UAKO6]?`H,ES[))5SL[-\SQ
MJIA6VL=.X=5S[O++-+WYY41'74>*HQ?%+,PXF*)XE^Y$UP27^!O6KHW67/\`
ML=.B+'E]E]IW5WC7R^$EBUCKIQ\#PZ/,^)&Q"2#6T&XFJ\7EJI,1/*>OJT+=
M8UW#WAD4S9F6X]U0R'9VCL5VUGVM<4R_5>P<2G[%NXFLKL>&97DTW6.9DPX$
MRM?FM=;!@-J+BQE28<%KUCM*5!\"%NQO:;3&XJS1I=>6V=XUV7P#LMI"[P/4
MF5:QS?"=S&=:YS&P_9>./Q3*:2IEBQB_U';Y`.ULF$)4"KF/.\ZM8Q5#;SP/
MQ4145%3RBHJ*G^*+]%3@?*M#OL%T'I5Z;"QZNRRMUS*M<2QLN58M-LZZOAZA
MS_9Q<V2,['X>:Y!L*BLL5QNNAPXU36I.E6<9U?']GQW20AMKP/I1:9[C6`W6
M;;OMFBK)4#*QV^JF6-3?9A."LTF-V>1Y+F\C);&L_AZ"V?$#65L6NBPFF>Q&
MJX07#"F><:1UC:?D^ZPZWQ3%9/KJ_'<BV??9G?Y@[+LBN+FRR$,ZMKI`+`M@
M6D"KM23G-BC;&`K2/(K&.5/`;>]H.Q[`-J:=SUEU#Q:TV+G,73V0,+]Y\.>@
MM<5RV]Q:G)%BQ),<V155WC['P9<AP4CPGRPH1?F8-P0QJ2LR,'Y"^X]M84UA
M%QVPTSU7B8[=F>1U9:FKO]V7W46"S_PA2JV1-']QY_<]I1>%5$5&A??@.`X#
M@.`X#@.!%UG8WHMQ8C5BLSLQJ5@69RIU,R"YT>1=1KK$65ME(LD$YHB0X1I(
MA`5[4(AWN]7*Q%:$H\!P'`<!P'`<!P'`_'+ZM<[QY]45?'Z>?">?'U^G`CK4
MM>&KUUC$*/86EH`<2204ZZ`2+9E9)L)DE&2HY0QR!='^;XVM5B>&,3_GP)&X
M#@.!K9_+;(L@]#-Z"K`/D%E4"#,QGU_Z<#_O7->%",?*%(+%8)PFH_Y&D5'-
M5GMX#8)B"N7$\75[6L<N.TBN:QOJQKOXV-Y:UOE?5J+]$3S]$X&*XS$M0[#V
M+)DQ"CJI0\76MF$',8DF0*#*;/&%YE^R*`#5"B*!$7W5Z$\N1.!1RLN<>/J?
M\C$JMBRX8*K=^T*S(UGV;+))%W%UGK=UC/B/-!C)75AH4@"LB*ITCN1_J14<
MC6A??7K<L;C@W9D89;4UC<G`@Q""L>H/;SC4<0C0R)3'FB4SP"<_Y%4CF*Y4
M:JJU`HYDCH=WDN5BKZFYFW-'E/8:GCE9+>1]B2;HJGE5[J^/5&`.TCVOWXA#
M#+84PI051$:K1KP)/MJ-P]N='RRQFCS:'#=J0WQ9(G,D!*?5^-19+#M<Y%$8
M#P(Q[515]E7]/'U"YG`JWC<3QW-V]8>C$^3KCH6"A$_SO2/L7L!)]7_L3PUB
MS/V_N=_F7Z)_4+2<!P'`UW6.T-5[0[V:1J,8S6%=WVM,8[/8]9T5<@(YJK-,
M99JRFS"OMYY+R+*L'4L'+8C'UPJZ6)II#)+CA<#T>&;]&)UU;X7O"YO&94R3
M9]K-^NA?WB9IK1]+796VEI3PT'&B!!CLJMK!EJQC:K65[Q?555>!=K@1#M[3
M&*;?J88;A#5>24*RI&(YC5L#_-XW,E-#]R,39".AVU':+&$RQJYC2U]B%B,,
M-5:Q[`U&_D>W5MX/7^EZJY50TE1OO=N=X]JO$L@H"WD3#-@U.1W=?B<7.,"D
M!21)H\AKYM_&D3Z"60\FK<U2#)*C-9(4-FF#X/B.*93C=#7Q,+D8)UDU+18'
MB-Y*L#6&<8=:2*6-$OX%J3YAU]5")KZCIS/,\:RI/W+U]AB14(%2>IV29_`U
M%L7L'?ZLKMG81VDV/GW8R3<4>38V')XNL+X\>DUC5W&-YB''Z&W@8_I3%Z5H
M2,MW?(%B^6-<J\"&="Z=QO=.4Y)<Y+L6KUQV&H<M-L3KO?ZAJ<GUG<XQA,^)
M'<>+=8NVJH]?[#UWE0@"!:5*+D$4L-S_`/S4A"1I(0VU:CR38>38<&1M7!0X
M!G=99VE#?55=;`O,<MC5$IT8.5XA9L5)9<3RB,C)D(<P89\495!)8AA.5P:\
MOS#;%R;&^J0M8X(SVSSL'L;!]08V1Q7#C17Y!<@?)D3OB*$_\>1P!1S.1XV,
M'(5SWM1/#@U[S=84VL^\F3Z]MLCQ>_P7J1T5H_XJEW!7&7#%P,*XL^?0GN\/
MKZN773(5C/<:EEO#/F-=ZL4)GHPC0I!L:BL\@Z][0["S=17Y<P[I9_BVFNI:
M59X=K246N;&]B4-E48K'G64_+:W([.)4!K029,'[:?4QU5'.^Y>UX?3K:BQC
MH;T3/!Q.K,:JZYZ"!38I3*YQK'(<DQS&A5..5I"1`R7R[S+\P>`3GC&1QI<Q
M7(CE<B*&(=>M3=I.MVF-9Z^K[K7.ZX&.XU2AN865LM-:YR*VF106>725RBJ!
ME6/Y1:3LGFSY#C2JZM(9Q6_*3V1Y'A8W$MQDO+ZGQ7*]6;.U]EUI&EF!'O,9
M'=8VW[(33SF"V!B$S(<.&UHG-5C9$R*<_E$:+W1S&A-_`XTV9&KX<J?-,.-#
M@QCS)<@KD:($:,)YSF(Y?HU@A,5RK_1$X'S3:!R6\HNNC=N2M=3MA?[G.VIV
M/NH\VGI8^*8QC[I&VMOX[:&8[*HTBK+E^'VE2&/,M504DBM3[=KF)'X&ZCKA
M4Q>O'331M0ZBRBVK\$TY@SK2KI8Q\JR:&,M%`GVJ!A0OFL<D+4FF%]TC--+D
M,$KAC*14:H4MZVFQ3;WY,^R>U,0`*7C6`8)B.'5M_`(0L&QLYF/4TR>R6.0&
M-*K[:/.R"R:4!&*]A/D1_A_LUH;(=QP%G6&EE4_P"@[JQRP+Y6K49O@QK,!A
MCD'90ICB>\DS%9]LH)3"-:]A$:US7!%VILPO+[MQVYQB<E.>EP2DZ^0J&1'J
MXL.[AKD.(9%?6M9960I)9=Q#=),R3'4HPMC*9[&>_ERH%O.`X#@.`X#@.`X%
M?K]S1]G=9^E18R2'TYM81KEIZM*BI`/*M8%'%/&?`+<NL[4R_P"B\<D,9!`*
MA&$>HU&%&[#L]W6S7;F^]9]?M9ZPS\6D,OK*R=9Y#D@<2^:/D%A9S*RAE,GE
M]RR0T=65CYH&>BD1BH-R/]N!VT?:?Y7&V;FS>K^D1TKOY522TV_1K(B,:9'5
M!&,^^8TB+'\I)1Z?M\>S7+Y\('<,W?\`D)#&>T6DNO\`;R(D!"SRKM44`8)"
M?9K\SD^]\?QYAS`JUZ>'->9J*U45%X'<U.\>_P#/>X;>L.K+9\24,-FF/;AQ
MHZQ0%-,$Y?%CD$)6SXSHR(YCT09%1_JJ>J>0PS/.S/Y#-:87=YSDW437LBLQ
M>OAS;:/6;5QQQK#WGAB'#5/+E:**2;[P:,:5CAM<QW[W(K44)!/OCO@L&6>+
MTZKFSA.`Z+"D;!Q)PBL6=)!,`24+,D5"@B($PB,&YA_)&JT:HWV#'F=D?R`B
M]/N^C`'-;.*`ZPMF8D=%B,<@120>V2,,KC.\E5JC]1B1$1SWN1J![;3M)W9@
M!=(!T:R28-XA?`QN4XVZ6DDL-#/#)BU^1VGQ#!*8\2D1[FN3T5/'MX0.LK^Y
MO;9YU';]!-LUOVYQ@.T,J!9CEHX354]?-@3#!0'S$1/)6M\(CE=X\?0/).XO
M:B4&]99='=OTL)S"@I9=.T5K?^ZS'-^X+4EB_;K&97HU5)[HY3._:-43@<6C
M[I[<PW'ZVB7H?VD.*HAPJ^$$6-7EY,.)@W->>=<?QDMAC`42H5[GO(9[D<U/
M#E\!ZE_(QLP?G[OH)V^@N=7S)+!KJO+[%13`$(R-`DEKL;,%'S&M:]KAN(U&
MN^OA4\*':POR'YE."Y(W23MN>7';%-)#_L]GL-#1Y/M\GV*3\6C?(>$J>IFD
M<Q$<U?57M5JJ'>5??S*)YI3973'M94QHB/1TJPUEDXD*X9F!<X05H$(X'L3Z
M._S+ZN5&JU$<H50[P]C\C[%=<-AZHH>K7:^HM[JMC2(AY.H,J6(8@2.(Z#*+
M#@K)B?)Z*ONUKU:B?N:U'(J!N4'D=3C6-4I;-TUHQUD*/Z0ZFTL3HZ-'&`O_
M`$U=$E'1K"#5//KX\?7].!C&.[HQ2^'DSRQ,AJ%Q>YGU4MEA06[G2Q0_]0%E
M"9%AG*2/.C^",$YK9"-5/8:(YBN#7O&^_J]/=\QQZR1/F[:[%;2O,2&@O,=U
M$S7^KJR1;7SB$C)C42(.E.]1SG1I)/5JC8[Y1^P;8`/&0(B"=[B>-CAN\^?9
MCFHK5\K]?JG`UB2D`.TV$2..1#>6[[#2&C)(_P"K$YO7_'1.(LB&UBM<CFM>
MQXE'ZM<GT1Z+P+&6Y1IN/J!&<7Y".P/;4@3E>XJF^WPS!0O)\JJY7JK9GGV5
M?+O/GZ\"VG`K3C$^,3MMN"M_U%EQ]&Z0DN7P/XDC'S#=#&(BH[Y?D4K'*J*G
MKX_1?/E.!9;@.`X&EO2TJD/^01(U3B&4XTAMF]TK:=*RB*``<ER.GJ-'8]>Y
M%B:S1UMH/&+?^1"\/VX9L&49AR?=>1C9P)/Z>Y/G@-[Y+B6,V%+=:*R2Y[9Y
MW?755/;9A%MJM[$1L4%BSR7\6KS6'9UE0"60X$CFJHZ)\4>482`5`VJ\!P-)
MV_<?Q#MG^2#!-49>YA<$ZOZUR[<=]:U%K88[DN$9I5QH-/@^2PK4+D-$LJ^Z
MSE]E`F0R,4)Z3P89&)]0Z/+L^VAK[H+NVPSJ<.CS+M;GM!B.J]Q2)L0]IE8.
MSM[6ZVQ.[RJ@K:OXL4OM<:T04F?]L%U66-#^\"H/<P@!)79HNK]!]4;%N+;R
MR[..NEO45NC2ZZBPJK=6.1*C)*-:JHJ:O*\8LL>S[$X<>@A?:0$9<2O,H\4`
M(Y2F")X75ZN8?-T?I"EP/(,3Q_#,/UM0%G4M]6YG9Y1!M*JR29E.07,M^2T.
M/9#0G;8SI)9`)0W-&CD1C_5/1@<GK;W$TKVCZW8GVOP*TML>TMFH;F=C^2;)
MKA8,Z534^36&*)D!0V<UXHU%;V=<YT&0\K6R@$&]J(CVIP-<';6_P'<WY)=!
MZOV2:$;3?6G#+K:>S8]U76-ECS\JRB"2%B42]C1H%E`!3L/-JY1)4Y(T1CQ(
MGS*K58H:X,]US/["=]=F]7NO=T*/J_=6786#8V28_)G6M=C^BM35\2ZLQ0;.
M0Z1$6M#:S5CU<?V^)9QH[!.0#4]0NK<X=E^UOR@=2>K=A881<Z^Z,:[L-T9(
M+"<<M<0I8P05M54:MIYV/R[F_BBM(-K9TIVL%-<,HXSB?$B-<B!?GO+DV(9'
MGO5'K9F604U%BFTML&V7LE]U;BI(DG7FAH4?+*ZJ=8DGUKHLC(-Q6.)Q`*,J
M'<JO^)/9JJT)Z=I[8>/#CV.F=\Y)%AI'(2'C6U1NW'A<YAQ.=&5MM-LZG8<<
M+54:L>*^(Q!L5$8ONY>!S->;R=.V+D^EMF6FL:7:6-Q:*?$J<7S$YSY/67-8
M*8ZP@8UD-?5W,1\4[E^0`"V30@(%Y3,4K&J%C^!0?\F.Q+7!.G6T:3%1V4S8
M&YV4O7[7M51%A!R*PR3=5O$P&06A)8GBUX+&AQJXL+1#R""C1AP7F,]@AO>@
M:I'5.%ZSU=BFH#R-=X_D&QK#!M<8V3#4Q2^PS/;ZTEX7H[+\;PM"6DH+GDPN
M02?:LGD1THS)@HX&OA"<4/HDR_)J77N(SL@LI-134]("!':6SFAIZ>,LJ9$J
M:V*68]B@A!++E""Q?7PCG-1$_IP-.'X_M8S-YUO8KM/CV03]0[8VIN[,K2BS
M7#G5]Q6V%"DJ78X[29Q326CI-CT=9`MHD<@I(0G&Z*KX4J.XKG(%[KO8F54$
MW#(79."/7/\`9N85-[`VU@[9]UI[.B)5V-*M??EF"?::K)./<_6-<J6,TS1_
M;V!W>?4+=UX*4Y"7]6&K*:[B02EN8`XA"6T$0G.K"$L8R*Z?%&$[E`JO>QK7
MKZ?15X':\!P'`<!P'`<!P,0R3"ZG(S#L'/EU&01H1JZ!D]*5D.^KX1Y,::6+
M'EO$89(A9D,1'@,,H7N8GEB\#Y#MU668K^7F@Q"CV%L>HPK-MLU]#M<=1D^6
MXIC.7R8!K5*W^\AX59TL&'-2!(,K3-<)SX0A^G^DWU:&X<^`:N6982)$R9;T
MYQ1(:CF[^VFDH'\O"=6N?1G'L0()\^LLK,4@8UCL%_U",1WK]M\`3-H31VKL
MLRO/\=GOL[^LQC'<$DP3U>R-G`4%AD1\L-,/)^'/)/\`U$^#60RO;[-&CT7X
M6L%Z-0+&VO4?6DFN6-2VFQ<:L'?"K[2MVMM12*HW-<7U`7-W"9\R(Y$7ZN9[
M>47Z?4(VR'I+674>15GSW8MQ53"T96BR+:NU;`-4^KM!V4MW\2F8BJ<C%8N$
M-JQ[`9([&"1/1WE54+W\!P'`Q\^5XW&*4,B[K@%!);#,PLD8U%*>5`LC/5RH
MC3N*J-1OZJJIP,@X#@>D,B/(0BQSA.@BD`50D81!G$OJ4)/15]"C7Z.:OAS5
M_5.![N`X#@85E6:Q<4M\$ISU=M8&SS*28M"D5T<9HM2<6/W>1DL+HCS#?&KE
MC43PH]C2*L@HFJB(Y7($9V5B#'^Q^)TM?8/BNV+KO-+6_HTK5/$LSX!88?&J
MLA6R2:-*VTA`RIT1Z+'+]W&4;5>S[9B."M42J2LT]WXDEH<8QEEYNC:5PR;1
M9+)R;^X6OP7`*K^YLE9*FRA8SDLI]5]O)J1_"&,.*(BB:IG>P7SJ:8`I8[[[
MJT=*ET-55DB&LICZH083I$EAXU0XJP(U@=\QR&.QB%,QC&N56L:B!K=M9UMA
MMWLR]<"ABT>-Y5V3L[4E@LDS:J'7=?,-GPK"D8YKQ6E<2Q&X4T!%8KGD?Z.1
M!JQ0E9M-8Q=T]#DD6#ON*_4N]2W,9KY*LL+"?B.JWRY#&F.=S(D6Q,]1C>Y_
MQM(QK5\-X%[^!3?!1E?WL[%2'#>@@]>.M<,158Y&/5V8;^DE8QZIZO5BD151
M/T\IY_7@7(X#@.!IZT))WC?=RWS+QDK,M581MWO!C+[S(L92\R+5I)%GJ1VL
M,.K\Q^\@R<-QFXIBW$F'6DKY#9=?(B/9+^)@VN#->G6A*7'MYYKG>47I:[<V
ML\@[3X-/PB9&<V99ZSW/V-E[5UIG;)<V625*IC8I!AQH+XZ%BL:0D=7",`@4
M#:AP.MN+.+35-G;S3,CQ*R!+GR3D_P`@@Q`/.1[OU5?#6?HGU7]$X&BCI9)N
M<NK^W?9>9D[ZG8':SL%4]:M;9178I)S!E0'73+.IM9W]J2S!KXT!<PM,D*=2
M'?!C`@#<_P!VC^)X7%WI?Y7E?<G0FM,!PB)GU)UNUWDG8G/,4%=0\?5^1YD.
MPT_IN'7'G1A8N.XK(#LIL01I9H[5:`9!J/U:Y0A?;%WA]]V"U.6'@^/=9\;F
M6ML[=^3;(KLBT'L63/E09`<<FX?L7"Y(,-S"Z-+<Q8Q/YB6-CQN4R.]&?$$F
M?DCT1VAV#^-O>&D^G6S,ON>PV4XU78_@689/D>/BNLAJ,FR^JK\KJ;_)OXNN
MJ&5)]>6U@!\IL=)*1QH1CGR?#W!IK_)1TQV0'IA^&W\0-)O:UP[.,NV?B.(;
M`S#56/@Q[64G5'6#5]AL'8V69-ATR6^=<T&#&KJN371CV`%L+-HY$I%([P,+
M.=$MVV.(F[N?D"V?A67Y?B6S,W?@U-L^MG8V"$W%M1#G5N/U#\8L\C@63HUW
MDE\VO'*A"E>9*,`ONT3BM#J/Q>5FI-Z7W;+=^\\LK\?V_E6SXSL:'39XW7>3
MXOA]'5!S&T/AI\=MZ&_?12\BMBCG@,IX+VU@1F8Y&O\`<,H_'%N&DH<\W!VO
MV/\`[@Y9<=X.X='U5T.Y*F+>W+<=U[19//+?V,AI(!1XQ"2JG+=V,8:1$6G:
M48%$Q"<"Y=3LW#K[NGVQVAGV%Y9E.N-/8AK_`*JTF0T6`&V+CE/,A0$W1N1]
MS58W&O,M"DJVS&CA'(E<6(CZ)&J]I6^JA)N3P.M%#K'-=QZ$S"YQW^T*B5DU
MA4=?\\-5I-(.0XBP[+7)1WF)PIDJ7,>CTFTHO4A/8[F(U'L#L>H^O<9W;UUH
M=I;GPZLS;*MWV5WLJRM\UHJ`UY-IK.2VCU_9M%6"=68U*FZQQ^E(0%4H(PRN
M<K$^JJH>^EZY=C<-V=>%P/L$N-Z?GQ+"?C.,S*FQS1<-L1SP!J\7;3YM=W3;
M#&Y%.U2ED19U=)',^5HVM"\30AK^[K[2V#)[*Z@U)O%V(V.+=?\`7^P>U%WD
MVIKZ[P^QE2+*DN=48(2YI<EBY#%Q\E-02,VNK!4G38XJN"IFO&1C7(&=:FZY
MV-#@^I=H=L*2\VAB,N'C&S9,O7<.-`PG!Y$VL+.HZO9FBJJHEK/H,'J[5@B7
MU8>84RPTE6$82M<3@64WK+R;3'6/;FW]$YS0[<TS"U1EV5UFO<WOF9''KD@X
M[-D49M3;(DI;_P#3QK*/&;%I[IDV(AD\"E1$3TX'7_BBGT5!U-U[K.?D)W[+
MQ^)-GY;BF15Z4&8U0;"QELI#2JE[1LMJLM-%!\%M"4\":UOLPKG(_P`!LTD1
MX\N.>)+`&5%DA)'DQI`F&CR`&8HS`.$C7#*$HW*US7(K7(OA4\<"K>3:KRK4
M<2YS+KY>)45]95V]Q.T7=1B6>M<FE18IIHX>(!C>MUK.ZGD'\0EJWDJO9S?:
MM>[R[@39BNP*B\HL)FW)H.*9)F=/43A87<6D$.0P;>PH69!-QI81"BDR[>GB
M?+\XQC]D:![_`%1J*J!GW`<!P'`<!P"_3_\`'_Z_IP(KUSE.59R!<IF#HZC&
M3DM8,"BC#L9]TLBOL7UZS+&XDMK8HO!89D^W#$(Q4<UR'<G`U.=7+*J9V3[?
MHM596C7=YWAL*&/6QYXCRZOKC<%*RI@'FR8\B&9LUA_9I&^#?*OQB]?'`VGN
MOL6$]J_[095[C]7C>+7D,BM4S?=?1XW*K'HOT?\`IX=^J\#W1<U@QYM"*GPN
MVQMM_F,?'+)]WC),?-(:2@M;04V*QOI]\-KZY@?F7V:Q7*W@3%P/`A&"8\I7
ML&,;7/(0CD8QC&HKG/>]RHUK6M3RJK]$3@8_3Y907]C;U518"G3*)M:^S:!'
M$#'9<1$L*M[9346-(9.@N0S%&]Z?&Y%7QY3@9"KV(YK%<U'N15:Q7(CG(WQ[
M*UOGRJ-\IY_PX$<C=9?[O2VN)9?PZ:WKW"$K"_PZ62Y/9I((,GO\"V2Q4$CT
M1OM\2-55\>.!DE!<1<A9;N;"8):F_LJ0ONHBH:16O&Q\EOJGEB/4GA$=X<GC
M_EP(WPW*+.-JW,,DN;*0>1C]SMT@YTV,OO'K,:RS*AU;$`KE^XC5];!$,2^?
M]40VK_7@96V9?9/K2MLJ">P5_>XO264*P0(1C61/APIA3M`9'@&TPR.\-7RC
M?;Q_3@4;P3;=AB^<]B\2QJTIK*CQC$M\;9D-I22KB0/8,'9=]7V-=.LY$*(Z
M':5(X3`RZ^.&0(,ASO4I/">P1-H,?=+<VI<%W+7=K,;PV%GT0XZW$<IQ6@R@
M4.S=86=97Q8^2,@T_P#.2IBL]_C2,WP436,:]$<YP3H;57Y"8,.4:M[):NFS
M4$QD6+9:]^<*_%\[$>^2D`+U(5KV.=^Q/W(J(OCQP(:L-F]X]5]@-!ZTVEL?
M5E[2[DS^=0JF-88K#AQFEQVYGFLD&]L"1"F2[-D)KD<<C4&TR(@U>Q4"X>('
MRW9NQY$W8=,^+7:HS:YC85%H!?#42K6-$L*@6:WLNPEMM3RI%+;$`*'&&^%%
M>0ON601$^$)WR6;4TDEF2'Q"UOK:LA/AQ)]%CP[B\!!LSA?-@UQ6JV<V.8D$
M1)`AN1KU&-7(Y6M\!0+%XD@VA.^"S`2A"N^Q.\#Q&2&?!(=#E0<.BM3T*4;!
MN$0)!JGEGJYBHJ*]%\ALJB,4<6,QWZLCA8O_`#:-J+_1/\.!J,R.02XK,Z@&
M04R;8;R['5]C#DREC'O<5K</I<ARZJ$V%]FPHI&.T1HAOW-<K)'[_?V<C@NA
M+&%^Y>J:BCM`P6J]PG`%$15BQUJ=3A;':[ZKZB;(8S_CZIP+5\"K."PT;V][
M"SD>UREU%UYBN8CE5S/@M]SE;[-5C4:C_G7QX5WGPOZ<"TW`<!P*SYC@N8:W
MS+)-RZACGR!V6&JYVV=2'*WX\V6DK(5,'+,#EG($5'LJ'CM8&&@#E95W`0"$
M;X#L')0/1<4F$]G,1QK9>L\OL,.S_&'V#\'V#60FARK!,A^)`76%YWC$_P")
MUA4K*:P%]C-FC&&4;7(H3LCR1AWVMMTFL\G=J':=?#PO=E93?R[ZB.^1_:VP
MJ.+\09N;:ML[!!GNZ`$@C$G0G^;*E*5@I;/1PI!@@?\`)AN%-,=/MJ9`!K"V
MMO5$QVI!XC%,27/C2C^@HT@X/G)*'#='8K5\L*=CO"HGA0P;J-KV[U8O67KG
M"-)B5NC.MPMF[B2$($"#<[BW!8%C0X]J""=0E.VS!EEC\2H1B.<$GGV:->!@
MO5VAR[=^:]H^T>N]^"Q'*MC[PR?#L;H8$/#=@X+8ZBT.1VJ];GR[$B%9E,"?
M:6=!=V*K$MZHJLLWK\;7NX'6=09U%N'=6T.R5+`D;I+L"'C^C-EWF/Y".HUU
MCK:$,2\?:?[2YY"C7#JZU@6,.0UJW5^>O"8P8X0-*89`V^#&,(QA"-@A"8T8
MA#:U@QC8U&L&-C41K&,:B(B(B(B)P*"?DXVPND>FFX=@U46*7-V8[)Q#`Y3O
MB!:0[W.$3'SK36+A$-7S7U4@Z^S'#]_1&JY$7R@:9O\`:K:$D/5?\;^/V%-E
M>"Z-U_2=ENQE#`A!UE,@/G3V97?8-EV3I_<U2^XK;/*7_:2/LQEDOE-?)\%:
MD@01[A^W\<T[^*3L]>S,%<7.-P[GV>?5>0W.)NFU%\+*<BI,)<2ESI89J]N0
M8Q`@V(OMWGC2XJ17N1%1KGN#=WI#K'ICJ5U#Z_7&SZ&BM;_I?JK*]D!S,HRJ
M_%LSNL.N[3<V38^J(UPCY*VWM(SU<-Y'QC^B)[.\J%:-/];]W4^B<+S2RU1C
M5CN39\V?N#+]TZXR>VQ7>>.DVWE-GM?),;R"IM;G$!Y/9X\+)/X*N8E\L**@
M&/\`LT&+XB!U;L!S79V+R\*S3.\*NNPEJRQH\;Q+=VIKO6VQ`5K[Z2VLR+$]
MJQ"8?EE_84^-J.:>&^7>19Y*TC'%]2O(,-E^P>PFB>L%_P!9M'9E<$QB[W[E
MP](Z%QNIQ^VLQ7>08UB<J\=4^*>'+#15E5C%,\I)4I0Q`M:B.(BJG`LHL@"&
M2,I@_<J)3-C*5B'<)'>GRH)7>ZC]_I[>/'G@?.?96EUV#[,[.R"ER&I+2]K^
MQ--UAKZ6#%G%R&3UEZV2;2JVG:$MI1S8\_`LLFT&81)$>*S^2987412*V.XH
MB!]&((X(H`Q8P11XT80P1P!&T00`"Q!B"$;$1@Q#&U&M:B(B(GA.!IU_*QK+
M%\7Z^V[M<6\S6N:[WV+@6LY-'1K'=@VQ+.XR6%E$EV5X%*E0:6RM_L,4D+][
M"?`M#M(\3Y!&O]>!-FN*["7X)I_2G9;7<_4^S->XY18QKS8M==S1XY:6T*DB
M076>I]TTX::;26MD[W:2BMDKK`Z->%\6:#R0@39(S+>6C[FEK<]KG[QUCD.4
MXGAU%L#$:T%9L[#Y64W,'':^3M#$0J.CR/'H<V<,L[(*9T-\6/[E-5H-CC<"
M7]\+#_V,W,Z<:0&"FJ-B+,D08I)\P$5N(7'W!H<(!!&F2A"1RC$Q[7$>B-14
M5?/`T9]4X4*U['Z9JLAR#7X<BU;M["@XW(`DXM_G#+'\>F*"N8,_^1QV,%<@
MHQ6)"C1DI94.*C1&(YRJ)@?1)P'`<!P'`<#\<BJUR)^JHJ)_S\?3@1AIK&+?
M#]=45!?08M=<PRW)+"/!L)-I%<>;?6<])(9<LT@RLECDM+Z*[P+W]$1K6HU`
MU0]885A*[(=A;?'4@DM:;NEF(:^KM'C!5JEQH*P<>9/DPP'L0$11D2.WXT>C
M"K[)Z_50VM.F[H0;/7']<.)[)\B+DN1,:C%<JJK/&.$5SVL\)X7PBN_JB?7@
M=O`J;C("5\K/*+'H\[';MEUCKZ><6W&&0E=,KON7DLJJ$:',:"P,S_11?V._
MS^%<U0SW@8WF3'$Q#*AL\>Y,;O&,\N8Q/=]9*:WR\G@;$]E_5W[4_K].!2OI
M'5QZ21L&F^UKHMO48%U@K,G'7W$^U<S((6BZ$4@$E"ED5,9\>`D9C'0#&#($
MC2N>KG>$"SF;9/CF,[!U\7([6#2`DTV=?;6-J84&N:4/]L(^.2SE$##CR9#3
MHHAN=[F1C_5%]'<#N8%QBEADY,DK\HQV>$]`"F$Z'?QY7EP+*9*)Z@$9\-&^
MRJU7HJD5S%:J(C>!C6GK&=)KMCR+>6K@@V]L2)6EDO1@@U$:W:"`(9'L&GP,
M:U4:O[D_P5>![+Z'4P=39S1)>5CG3<8SP[C@DQ"-%_/1[N<YXF/*-I1A=-5&
MJY41R-^J_JO`[BEM8E#K;$U#8PW.BT.'5@BHL4J%(8-57M:..R7'8XAD)X:Q
MCU5%5/5KU1&N#7MV@V;J+IA3;)LMJ7TJE@;IPK>DS$LLK8^0SK%N06T.=E62
M45S24=?81(!"6%C%96VHA^[U5`D'Y;\C@KSUHRZWCY=UHZVY[BN5X;DVI'X5
M98W6W5A)HZNRC$AY/9WN2VU1.A2IMO.LR@?%I!O8P8@12/4P3E(,8;V^!K`[
M@9WBN#=K>J.593+/&QO!FYS<Y/*JX,R[G5SKFFD46.NEUE:&1+!%+9RT5"JU
M$1JN5//A50+88+L?',XNJ79&O'&O,8VSK`.08Q(E1IU&RXDT5J1D-9#)M*DR
MO-.@6Z?_`'V]'C&!$&#_`,1>!-]#/R&<$CL@Q^-0G1H_04:['=L>YS?)6J5D
M"`K?B=]/\O[D^OT_1`J?85L=-(]HFR1T8F3-@;9F'=C(OMQ%>,T1@CV#7D*U
M^0N9&8V<]%:CY#57PU?KP+72UR1%QG^%'2OA.G#3*'6QYXY@J7^,F*CZ)(@#
M"D6O\LD9JMD.&'[=2N]O=&-<&J+$92_W+L^F):0P5[++NS9FHD8U;$DF31XG
M&BV`ED`1[&!CCG>WJX@7_.WSY5/#0MJ:[2-OSIY3E88Y[K1&\)'S-1GQA=60
M]$$*21[>7-^X63X;ZKY547S].!<K@5%UW.DG[I]GH*N:L.OTSU?>-J-3V;*G
MV^_G'57^/*HX,4?A/T3ZK_7@6ZX#@.!2/LYOGL7IO+L>?K;KK>[?UF3'YMCE
M=YC2-M+F%:1I36CJ8=/7S7W0BEAN4B$_CY87HU41S7^&N"B#?R%Z#O<QC[`Q
M8F0==^P=B"'5Y%B6U*6ZI<#VV&N6/'CXUGL*)%==5EU5/L%#"R%*MMA4._TS
M-E0O]!P7SPS9G7KO+AJBJ+O^)V#@-D"46'"M:R!MK2F<$B.;"OL?M(CI@E%+
MC$58EE#=+I;N"]PG_.%Y@(&M?MSG.5['[L](.C6Y).-'_E,^'G]AE$0S(N/;
M.Q[5YA[,:,M8*<"9BF<3X&&QX4ZJ*X@"NLOFA*6.3U&&RF1391"P_M+G&KZD
MM7V.W)!S5NOJ'*,YHI`;J;KK&IF!:HOL>,T!HE#B-D,<6W<)Z2!QC6)'F5'%
M<W@41R78>CM#=7:/!LTZ\WFI-WZGTY!QK!+SL#BLO"L5R7*,3IX\,II/9_6M
ME>X%5&R"RC2)023<GK4+(+Y(X`R*5`OQT]U_F-+K7`\TN,N=`B9IA5;D=[JR
MDLL,S3"JS+KQ1V<G(Z'9%16DR'(76D0C%.XUM;QRO?Y9*D>J2"!<W@:!?S4[
MUH,7LM$:\OWM-B6+V-KO38=2]Y4'DM;AT6<+'<1$2#)%85]C=3P2&#DM1JQF
MD^5CD<WR@<OJ-UVW?H[J%L;MQE.S/?<F[-:WVY-MXEFM!$S"#:8N+&K2XQ'%
MA9=)E`SG'9R8U+4YW?>S(X9\I4=&>T*-4-?G7J);[JOOQ6].)$"ON,0ILQV;
MVQSN-36<YU9(P:)FF3Y[BILJA&KQ-A6=7;UL:K/#*AA/_E6?#+5IOC0-_/Y!
M?&=:^U=UAC6QJJ=VQW/AVJ;8M?/_`(R[#K"C;.V?N292S4,)8TY-<X--AC)Z
MF1I9S$4;T54X$R/P[L?A+YQ,,V=B^U*=R165>+[?H68]=5PQ.7YV,V-K^&-D
MSY0KX;]WCYR(YK?8J^7+P,^P#+,RRTDR%L'4%MKRTI7QY(),V^Q3+L;LS/$X
M2RL:N:6<^Q<HG.*W_K(%?(02HJL3W5J!IPS_`*Q=W]L?G=U#OVW3'5Z,]5]!
MW%GKV=F%=%FI_N=NVGL,0V'2Z_@5LZ%/E9Q';CD226XL4("GK93@":5TIC!A
M3GK)L3>M7V8_-[^4BUWC,V?H_7,O8O4#K[AUO0A(Y^5:"/42L:B8&&BEEK!X
MM6[0RR9CJB9$=87<Y[I1E(=WQH%X>BVM<7TEMS`L2V!F>-Q+74/7NHB1)%RD
MW%I>0[#W+D,HF2V(P7B1(4V0\F&37(@$:?UL&N,WV>U&AN]@6==:QQ3*N?"L
MHAQM*"7`E`F1C"?_`)2"D1WD$1COZ*BJB\#49^0+*0;"[*=,>LMC56L:BR':
M$[-KB7*-4BJ\L%CU=65XZ>I`66>7,/!3)S%-[QV+Z"+\3D<Q7(%W.ZL[%:7J
MGN^VS.BC9%B5/@EA87='(K)UN&77PB1RO:VMJK&GLI)8ZL0@VQY<8J/8BM(U
M4X'/W_>9/#P'7),9LBU(KW9^IJW*2_\`D@G2L,M,@KVY#2F?</\`0"7\5R05
M6$[^0:^0GVR^_P!4"ONE:R!3?C:OHUM9S9U.7478"UE24MZ2\LX5-=V6Q[EU
M4^\I;NQH;2RH8$_[-9`9OPD+'\^1_5K0H9U>PV]N=\Z!SB?<R<DK1;)QPHZW
M&8E/<2,*C5_2'%*VD=LZ57W-X[&&VQR23HY`0DL9<F*_QX9\Q0^@O@.`X#@.
M`X#@.!I_A]6NZ^K<_P!P9KIBZZ_H?8NZ+;;4,F8P<IL'0IL[&IF%!*4%:6E6
M:DC&$CM/%(1%#+1YF'*U4%P,JB9!^5W'`V,W+(_6;(HL&@N;(I*;#\CI:^+8
M51?N(PEER-I2[&;%M:P)%1$B"4!'-]WKX5JA,G53M3FFYNN6);9S'%JK^ZK7
M<F5ZJO:[&ONH%5%;0;2NM?.O(,>?+MIC8T$%>PYQE,KW*TB_Z?E&-"^*+Y1%
M_P`4\_3_`/%.!Z9,:/,C2(<L(Y$64$L:3'*U'B.`['",$K%\H\91N5KD7Z*B
M^.!BN,:^PC"I=O.Q+%Z7')5^&BCW!*>"&"E@#&*@%!CH3C`U@OBI:2,.)&:C
M404<;6)^UJ(@9/+A0IXT#.B19@D<CT%+CBD#1R(J(Y&&8]OLB*OU\>?KP/4*
MJJP,08*VO"Q'N>C!0XXV(]ZN5[T:P:(CWJ]?*_JOE>!["5\`P"130HA8QGJ0
ML<D8+P%(YWLXA`N8HWO5R>5545?/`Z`N"X2=7J?#\6,I`_;D^7'ZE_R1_'A`
M/]HB^P43_NK^W_AP.ARZ%C^)8M+LH.%4D^/2I&LAUXJ^!&BQ5JB#D`G,8R(3
MXRUJ!0@5$-Q&O8WT\+X5`C_8^`:SW77P6['Z^46TXD,+A4_][X[AUQ&%6W8H
MI9IJU]T:7(A@D#&)3#^,9'*/PK?+4X%4->45'%_(9D$,>*#H%B:$!:P:J4&%
M+'#+%M\<K&SZ^0]3$CO$IB!8HE9Y:CE:B-]E<&Q.OR[';>WET=5:1[*Q@Q`3
MIK(*NE1XT:3)F0PN)-$UT/Y'2Z\PU&A%(UPU]FIP-9V$Q]A9'H_NWG.P(]3=
MR<]3(;'"KZ$6I@DOJ&JUP+'H`'5LV:8&+SJ0];]DHY(HCGG"LAPU<57N#+^J
M&/W_`/LCU2ENG$Q.S?I;3\6NN#U,G(X%I/+09K/OL:#7R+.*"L(M,X9_OFHQ
M_P`GHC_E148@7+BTV3"VA.MOEG2J\6#UU:Z3*+(C44R>_()<M&@K12R166T"
M#[_)(:!'D&83%)ZL].!3G+L[O'ZUV11&BT+$R+.^S`[J#!@&C?<5V$6/VL2:
M%]<Q"/(ZT/%9+DD_U3N.U'>Q'(U0V.`^H`K_`/HA_P"/_N)_BB+_`/)P-6^#
MT=?;Y)M&`&94!2ZS7N%4OOIOM700#?B6`5@SSY@V>(D.OCG\2#L4:J@W$]7.
M]G*$O8K&R.5O#K;+RX$>/:4.&]GJ&G9%&1@#XC%M=10<=GM4OAYEG5<$!4+^
M[Y6D1R+]>!>_@5%UA#(/N1VQG/:1&2M:]6HXG/:B,<D1F[WO^)455<C7RE]O
M/CPO`MUP'`<"JF(9MG-WW`W)A,N9(?KG!=0ZLF4T-KZUT(>7Y?=9?*NR$^W8
MVS2>VIJ8?[)*N:P+T<)?!7(@3-L34.J]MUS*C:&NL+V!7!>TL>-EV.55\D,S
M/;TD026,4YH$D?NOJ0+F/:J_14X&M'</X;>M&87$7/M*W6?]<=M4994K&\NP
MK)K?(:$*&8,C<;N\,RRQL8<_`'V$8$A]-#D5X!%"A(KHQ?\`4X%3<`TC=:XV
MOO7+.V5]1;9W6[2F/:PUCKK(W7%'*LY66;*HL<H,PQK-)$RSEY,'(L@K:.-7
MW-06/<X\."X4R-'E$&\H4\W)HSM_N#OV3KOU3V.+`5ZG]7LYTCI'=$C8&:8Q
M(J\/ET&O['8.-YYCE73V4?+\BF9-?T5#`RX2?"(E7(/)AFL8R?&$/:*_-AV5
MT(+,L*W1_M/OS6VDJ_&M%S=?S<BB8WDF2V%))L8<W.J'?V4_R5'M:XR[&S5P
MFU=I#BRS2W>9A`%.I'A]*'XU\=R:DZOUEO>:PO=%T>QL^V1MG6NB,HDQCY'I
M?66S,JFY=B>`7<:"4]=13X8K,LQU1&>X%*DU(#/"1O5`ORJ^/JOT1/JJK_3@
M?)?VJO8&Z._&3;8VKKC;^5=9M';?Q_"]J0L#QZ7;M@/P&`"9B=5?IY;%2JR6
MV&.TL(C7C>:I*C55%*-S@V*[)V)TQV!U)WQM?JAM;^S+21K')+&SP?&,YM<%
M9)9<0GQ9U;D.GK\SJNM?-CG()?M:L#T>[P,B.7SP*S?@9U1)O<Y[+]D[`3'T
MU#$P7K!K9JB>!D")@M3&O\Z6-#22>."4=T^C#+.BO?)E@.3R+W>%`V$[3R_2
MV>][;&BW9_!R-<==]&U^-U\C,*23,PN#NGL)<LN;%"Y&^N/18YEE+JS!:]H7
MGEQ9+8N1N0?T,BN"S]9IUH*P=IUZW]EN,0'#.VJJY%Y!W/K!5(V0<8F5.4RK
M&XBQ!G.UWQUMU`1!(K6^/*.:$ZZ_%L./CPXVSI6)6&3QY,D3[3"XUM7TUG!:
M_P`0IKJNZDSIE78'']3QVR)`1O7P,CF_H&;\#3A^2U^-X70:*T=K[$L:QVFV
M#NJZW]M.JI:RLH,?MJ#4HG9Q8FR8,6."E+99_M^VQU"%LAE#9F&5LAIT^1JA
M$..XSOG85?B^89OHO/,]TILC%#PLCK8F08EDQ88<.R"E/49Q78MAT[%3$_O.
MHARA5==3PHL)8C&%,(ASL,((ESVQ'J[#MD%IJ+(]4[(GWL6WAV4+%]UX'+AR
MK860OQS7"YE7VU3C6.6.%R<AK&D-!!94LDKWC]$:1B`"S>$XQ4Y/^2G5E7*6
M/?V.N.KD'+,BR*T$:1DY\YM+(AXUQ.>X<F$^3;T-Q`^>P#(;[&A(+U\K]0OS
MWHQR[S#J=NO%L;6.Z^O<4;`JPRY]'5QY4HEO6/2,6QR1R44-)#&*SWE(\7E?
M"M<JHU0P[NU%2PTOK`<N75047??7$QY4NJL;H+7_`.Y>,M<*KB5-9:N;8RWE
M^&*9[```XB$?(CM;\K0BKJN3&Y'XP6MG1+_*L+)JW?D!]1%F2<LR*UQ+^YMD
MP&4,";+(:3>V):?Q%![O>KW^K/*HGG@<'\;U&[';_M'4$@VU2.LR?0550U=]
M7U59>`PZOZTZR%CTF^ATI9,$5]*,Z6DQ'$0Z&&J.&-B#]@VC\!P'`<!P'`<!
MP'`P_81'!P'-RM>$;A8ADA&DD2F00,<RFFN:XTPB.'$$U4\N(Y%1B?5?TX&L
M#\;1J\W5K36-9%8QV?W;M#?^95<\1&`?<VU-O3)+**"`1X0#D@,"4Q_LP;ON
M!?N:[QY<H;6"W$8-Y"H'?NF3:V=9C7Y0(K8]>>%&(K@*1)+D<2<W][6*QJIX
M5456HH=:>;+L[BUQX/WU4D&OJ+`5P%@U;(?,E3$)&C_.(@B(%D)&F3PJHA4^
MJ*J<#HL+=+L#VDY<NM;<%5=W5!*KY;*A0"EUDPXR(\L.I@'88/RM3U]G(C6M
M15<OERAF42X@RZT=JI6Q89/D7Y9CV1VL09G@57N>Y&-1SQKX^OU14X'%O<DJ
M<<%5FM3J$5S>5&.P'M8I&DM+R4R%6@7U7RULB21&^WZ)Y\K].!V)[&'&F0:\
MQF#EV7W/V07*B.D?9B0TA&)Y\K\0E]E_HB?]G`P+<N0W6(ZFV1E..ML'WN.8
M3DEW4MJ:R+=6;I]9529D=M?4S2"B6,Q2!1!A(OH1_A%1?T4(CV!42\?UU+SR
MXSC)[62ROHI3@W>1UF*TL=DDX$G-+7P(=+72Y4^-*^)8[V.4IFL0(FD<Y'!G
MEOM^/BF`V>Q<HP^_QW"Z6GC7$J9,-5.FAJ""1RG)3BG.LHSP,<Q'!*QAT<]$
M5B*CO`:X>O\`M7$<N[ZVMQA-EDUWC.1Z0NX,<F<?=LO*F5CV05=M/!72)15)
M*J4#."UHY".(!A6JTC41P^!.G3ZJFV.P,PV#:1?XZ=>8,($.,KS'>_&YFUMG
M9%4M<4(P5#71I%L<2L"CW,:QG[W-5/`0;VBW]@\37FW*;+;O&\<S"WQ_:6/U
M$6GK[?&;>]'39':8P:ILS_)>XE=GLQQ@QHOW_P`;O<KY'_3HB-:$##V?NS6&
M8_C?U+K[:^#S->Y=JJZR:)CW\)66CH*XOI_(TQ^"LZKLDMYL.H9<1&'1K#LE
M&![>1JJ*T-F5'O/84*P=6WC<?R-D:MB/9:U--)@5]K*EOJX];_UH[NP'#D63
MON"$:(,@0?E']6H@FR@KQ8&J,EZO9=LJ:6LD66.=BMR>RP&2J6+XR7;N0:[R
M/&R.N6C;(2.VS1)+W>X)$F"A!.\?&]`V-YED608Y'B2JK'Q6]<D*Z/;SS6:0
MGU)85:X],-(38<LTYMO9>(Y'L\?:M7Y%:1$]5#7G1QJZNH]QT4*M4-?6&[:Q
M[_[M6R7QK5-?X!+LTAM9'9]K&EGLGJHFN*CFN5?*>R#&%E9TR$/L/UGKU*T9
M3:.W/)@1W+X(08)&E!F]6_\`Z$1&^?\`#SP+8<"KNN[>/)[8=FJ<;?$FJUUU
MLDR%2.C$<RS=NA0*Z2CU4[T^S<GJK4^-$3ZK[>$"T7`<#\<OJBK^OA%7Q]$_
M1//ZKX3@:\^O>28MFW=+LSG6(QRR*?+=/:!EQ,F;*F!BY'%J+39V-(BT4BOB
MK"E4]G32P_.9[BG$YBL:@O55#M<)W?;47;SL%KW+\G9;T%]D&E,7TWB$.>P]
MM69++UID>6[`B&@V%NP0([*6K%;K]H)G_1L(]6$(UR\"_'`UU[IP+'NP>Q,8
MQZ]VA6XJ'"]B2MAUDR'/#3YWB=CBD:5KO5UE@MG-A-B^)&VY\F:1DE3Q+*3"
M'#^"4)Q$:&IJS_$5W]U+LH^Z=-=R)V3[<V:NZK7?.=VF17>M<>?27FQI.P<5
MU[@."P'W]+'9;Q<EMA,EW260*6Q<Z0-[1O`R,%??PH?BPF9_,_\`4YV8QJ/<
MZ\QW;-IL#5]-DU=@YY.[-M8\<F/QMSY#!P4]AK\NO<(?7>F,_P`3\8,AM!NN
M3J6,.O9P/KZ1/"(B>?"(B?555?I_BJJJJO\`Q7@%_1?IY^GZ?X_\.!K]Z#QJ
MJVK.W>5E<LO)<U[P]CAYLLN$D66(^%W=9K3&:>4-XQO/'JM>XA4ACO<B_)&5
MCD54<BJ'$[&?C&ZM=A!FLW8?'UEG*!.V'FVO(D&HD(8@WL&MO0H#^"NXK7$5
M7C((;R>?_$14:J!D_0KJB3H=UK+I>\V/`SNKQ_-=DYQ&RA,9A8@.KQS)[R7D
M0:ZS:*7-+:2J>.]ZGL)1GF+Y]?+1#&UH0/T[VMF-9K+.M^[`TEFF18MVFV?G
MO8.KSG7<:%G/P:LN5C4&FXN2822;%SZ*4&EL4HR**!7V(?E,3PC55?8+!8KB
MO4C:UI8S].9)&USG\I?N[5-47=AJ'8$2:>"$2R\FP'XJATN;]JUC'MN::2QS
MA>'-5P_VA=.#%6%"B0W2I4YT2,".Z;.(PLV8X(FC=*ED$((GR9"M]R*UC&JY
M5\-1/"(&);(SRHUC@V29Y>BDGK,;@?>GBPO@^\FE(<,2'`B?<FCQ_NITZ2,(
M_=[&^[T\JB<#0;V3PGM?V:K:;N/K77FI]EX#D6GMGZVKZ*3G+]<Y7CN)5.RK
MNQUWN6EKL_65@LBXFXH:S6P@R+:*V6*3$;\@A-,S@;"=-=]NIV)4.NM-9E8Y
M?U@N*;#<>H,/Q7LKA\K5,*TQR@IHU742\<V&59FF<I@R84%OP$J,@EC,B(HT
M\*WR&P*UNJ&-CDS(I\F-*QP%6ZY/-`-;2(:J&!)OWH&1&25G`6.B$9\32*]/
M"M1?*<#5?T>MXFYNX7=+L'4"=-PU]SC&LL&MIU195DT<;'JF!6WL>'&M&1YE
M3%,;&8WS0RA$[Y1H;U8XCF\"U/?_`!5F;]/]WXF4ZQ0WN-UU>62T5D50,+D]
M$[Y/6GB3K%C4<Q/8C!N:)OE[_`VN5`Z'NC&PL^JM+BV+"6RJXW8WK980XU?>
MY+CSG9;4[%H+'&#5SL1CNE6Y8M[%$458=!UTUK%')<T/MP(?T/<1L\_%=?6V
MK*6XR),FTAV'DX?C4N0<MQ:V5M8;,)#QH)%H(\H1BV9_LXS%KWE$WXVJPJIY
M>&0_C[MCV<[?42<ZOA6V)3-#8/>XN&O=%NL4O,?Z^8`6WJ<HLGTU)_<EV*PL
MB-?/8,@'-&@F/11/"$-D7`<!P'`<#T$E1A(KBG")K7(USBD8-K7+X\-5SU1$
M<OGZ)^J\#'YV;X76.8VRR[%Z]Q7/:)LZ_JHCB.&)YR-8DB6-7N&`3GN1/T8U
M57Z(O`CB][):%QQC26NV\#&Q9'VQ'1<CK;!L5_PR#H2>Z`>2VNC/'%(C3'48
M7O;Z-<KU1JA"60?D:Z78S(;$M]]8>"4]"N8#Y9?LH@6@*<YW/?&&$(!SY+6H
M\CFM(GES/9J>>!7S:'Y1^MUA69Y@6,1]AY=8R,6N*ML[&,/E7<8,VWJ_MH15
M@U9I]S*J@NL!OE2PQ2!C#1ZO5/54X'KZ,ULC%.K'3>+9X_/KKJTV5FS?L\HJ
MK:LGU=-E5GM7-X18-9/B5BP%/"2*\*_"B"`_T7ROE.!L7F5!2;@H;[P1`0M<
MY15O?\+U%\D_(\4E-:LA'?&PGK7*OJJ>53ZHOT7@9S&L8\N=.C!4#UK_`(0G
M*R0%Y!G,Q#?;E`U5,!?B5KT]O"/:Y%3RGUX&/8C0)C,/($<I7DM\HR+)3M)Z
M(B%MY;I3AA5"D10M:B(U5]?^2<#`MEY9\>CK?,:^H1$?1UMF&FEMBD1C)DZ"
MU\<_P/-$5XF2%7V8YR(YOLU?/A>!W6R(,&56X)%GE&$8-@8/+`^1*)'<LNML
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M*-%]G)P,/Z?L@0,JS>MLA0O]P_\`;C4=EE*U=DI::NK9<;(PXSC]-`_B8?PU
M=?`B_*PI)$@CR2")ZB\*C@@["M>5`?R&FPG*ZO&,AC5.@\YRYP)M=%LHI;7-
M-J1+I[/XV;"(%)D&).&1\PC4>]YU:UR^R^0N'>ZQU)7;DP;)QZ_P&LD:QPO)
MY<:TK<%K5NJF%D@&T+*^OF5M24U?5EK`SOEBA^-QT]?H]C5;P)2A7&J\]9(B
MQ&5MLP$]\"0-]+.A^L\<@PWB5TFOBN<]LEQ/+D56^SE7S]>!4RC,'(NM_9ZJ
MKJTAX]!NK>N,5`;:/`I8SVX_GA8T?[!B/<R)`J#,=&!)+Z%.L7[A43Y$7@6X
MV`4T\V$XC'*HW9-D,>1/?\+RL_AL8CNR*>U[T$40DE2(0(_E[F?^,JM=[(B*
M&OAP)$6=V/DBR@AX4B7W:G6%,1:B36*\N':T;`?8/$59M:>L!'\,8KPD>`JJ
M5/JURA/]U5G/V[ZIV:L8.+5]<]^QU&B+Y'*L;30J,1B_5J-8&&]OZ^?JG`NO
MP*;ZC]G]SNY!5:Y&CPCJK!:Y47U<X--MR:Y&JJ>%]4LD\^/\>!<C@.!PK(K`
MUT\Q7*P8H4HI'HBJK6#`1SW(B?55:U//A.!IE_$T1+-#WN.VN<Y!KHW5?K5&
MQV]R9);*";9RKW<=S9%QM_V==16$N7"GQ361:X/J*0YHI"H9%:@>^TRG#Z;\
MB*5R89L.]RF[[08;32,B':XR'",5)+Z=9+/K;6>D"0*Z)!+64<B!#K;!BRFV
M,LTD7M'D"\!N!RF\AXUCEW?6$L4&)5UDR864=CB""H@/<QSQC<QY$^3PGJCF
MJY5\(J>?/`U71VQ=J]EM$:G!:XYG6*4.1Y'N_)S,Q>+6W5%4]:P?[?TM5D=R
M>$65DLJX[6YK/O(!$<(`6U!?B52,(YX3'V@M+SLCL6-T7UU?SZ2AG4E5F'<3
M.L?G)'M\/T?=$F`I]04]B`C3U.?]A"UTJ&XK/]>MQ4%A+;Z&/!>X+Z8[CU'B
M-!28KC%37T.-XW4U]%C]'4Q`0*NEI:F**!5U-;"C,''AU]=!`P(1,:C6#8C4
M3PG`[G@.!K*S@N4='>P.S-\#Q^_R_J+V,LJ+*=X,Q*EL\CR7KCN6FHZG#C[@
M9BM(&7;9!J'8^+TL%F4/@QY$V@LJUED\9(<F6^,%]-<;8U?N#'XV5:IV)A6Q
M\<EB&4-UA&34^35_J5OLUA9%1,ELCG3PJ.&3U(QR*US4<BH@?NV,#3:6KMC:
MS6]LL7;L+!LJPDF1TS`$MJ,64T<ZD+:UHY2+'?-@CFJ02/\`V^[4^J?KP*@8
MP3NOUYQ?%,.)JO379/`<5K:_'($S3]P?0F>8_BE##!`J8T;6NP)^6X/D,F'5
MQF!8.-E%4TCQHC1-14\!,&H=G:@[0CO+K^P+.CV#IO.&XKF&';2PZ%1[-U;F
M\6GKL@@!/ZFLV#%88[D,:;7V-9.DU\^'*1X3/:KT0+/\#7S^2W;T[476C(9D
M*86O;E'\MC4J4*5$KUD!D8O>RG58[9U_C]K123MCK*;/@D)(ALAO(K?C]W(&
ME+"]K=@XW7D.BA[:N=C8'=ZZ@:\'@694V-`O*V3%RRIA5M/BNTJ"%7RZ/(ZY
M@S8`6%.'=0H>7AIS(]]=D4,PPE*^W%IQ>JY/QZ:OZ_9+A%'VQSNEZ[:_L`9J
M_>&NFBVZ2K!E5U!_OV=.S/"XZZ(B6^55D,U6VO@FKIX/DC3(,I!AN0T]+O<W
MZW7VMK^S77F::7M+33^53]6QH\5L)=4S8#ZFPPVMLAW;Z>OS#!XU?)BQRL+(
MBQ[!&L7W:Q_`H[^*_?&E\3UAD6'Y=LRDKMEYQLC*M@6$3)"/JY36Y1+I9`:8
MU]:."VZF0[F\,(:E^*3]7->SRQSG!<CO9FT>ZZI[5I-89_7BV#>U%&S#C8EG
M/\5D##CS/&UF6]5-QVUC7#HU/#:4\I`$1I8XB"?Y8YR*':[>WWTGOHE)1[<V
M7K'*"8)F>(9Y2QBV8[>34Y_AL]EQBN1UH:9QU_F::R#\PD'[?&Y41S/5Z(X,
M9M_R3=+L4',5-H5;HT5P2RRU<`C80?O"QQ"D'*1(H``,>6QKC/\`4;7JJ.<C
MD5$"N%7^33IUKI^R\PPNHVS:R,MD6>T<](7'9AX4:3755+3#L!F?+F#A5MM`
MBQFQ'@58!%17-<CG.\AV#/RL3KJQFT.'=0^PUU?K`%85%5+P_(:V9/B2(D:?
M'GMBR,=:Z5"+!F"*BQGF56D:OZ+YX'NA]W^YN?09-WKKHSLFNJ6'C5,5N;5W
M\'*6UER)S!2C1;NWQZ])5`C#$26]E9\,1?+?F(KFIP.//V9^7V_D7-AC?7O2
MV-P:#+H58S';[8])'LLIQT]/'-8W6-W8H^45$J'!N&.8'[MU9(>,CVN&[T85
MP=&NH?R_9;-96V.Z]'ZVHIX$2?>19=IFMK"\FCHTD2BK<,PA8]F**QRO:&V=
M&*][FHK6JUR!D2]&N[N56N-S<[[\7-77Q\DR9V65F!8I=1)%CA\BO6/C,.@L
M+'+6UU;="L'+(F/EULT2)X8#U\>S@Q\'XN=@RP!3->RF69]8COZR\D6LFSR+
M%"V+ZW[A&?=Q*":0"22-(WW(Q4]E5WT1$8B!FT'\9&JJ4L`DS6X=A'FNRR9<
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MMS9TF_J7^0F_;459709U@++<AK7&+`"CXS6(YRL^W5Z(ONU5"2Z%F<V#YLT>
M#[$&-MM$IS#D[;BSHQ!37J.?9PT%8'BNKZAX_26@W?=,>YS0C<K7)P.TEPK:
MHQ$]5_M+F,JHI#`Q05#49\R7+DU-2CI4>ZK&SY`&S()U$-HG$*R83Z,>-JM7
M@1JS/+S,<QUJUFL]J8QAE/EDJSS&^R/XIL*CGT]1;DKW3)5;>'CQAU]R]HIJ
M&80;1F54_P##X$FP]Y89?W6-2<LILPP(LV-L*NK,:SC$2`L,@K:RT!4S;C[0
M8+"4"HG1:]LR(OEK95?+80C?'[6!F^O<GJZYU?B\6[-DU!;2[A^$9''BN+$!
M"BN^Z7$K63&9\,252`>HX1"L`V5#&QJ>Q6/5X>W!=+U.#9_GFQ19!D5Y<Y[Z
MCDQ[L\23$HX3;JXO6U=&1D04T%6*9<D00"%(P3&HC415<JAWVV-3X5NK!,@U
MUGU<6?CF2UY*V?\`92BUUH$!"A.YU?:Q5;,@%4L=BJHW(CT;ZO1S%5JA41OX
MW-$`*(L/*-U1QQ10@PZMNT;A*(`*T;@P8W\0,`XSHH@J@WM^CBB;Z.<K57R$
M5Q/QA8S67<F]_P!X=MA2)2X[0TD7$;JMH9!X=<>3*EQKQQ*TS)-)#GS'EKX`
M7B#%9Y;^]Z^W`EC4'4JZTELV3NN/G^9;0R`^$R]=RJO/XU3)N&T![>'?134E
MQ5?9I$-&LH_J496K'+&1&L8PC&N>%@\4R>=&S[+H]]B]VF47%;"N!,KH\`L&
M#A]8:RK<>AN>6V6P+/ESQRGD=\+`?*;PGAJ*Y0FI;%6P`3GP+%'&:-70FQD)
M.`XC551F"-[FHX;D\.5'*WS^BJGUX&LZBF6.4ZBW-4?:6L6AE;<[LK?04!<U
M5I+L*S-+^XQ4(IL>3&2(LEXW$]5(U93&^!KZ>_`O71R)-UGIY92&%"Q'"Z:+
M]JL4:1S6N4M2SF2`F)`:9I(D"M`/P*4YBH94()KFL>X-;55<7.#ZJWQL;'K0
MC3T-1VERMEV2KKCR%L;JNUM>TTEX94>5`.6!$DN9Z2E)\J,]5:K41J!>JZ3W
M[*Z4&GU:#2^X3HOT_P#NE[J$".\(C4\JB_X)^O`LGP*GZGBR!=J^W$HB^02J
MCKJV-_IJSU2/B.8-*Q2>C6E5"/\`;Z*Y4]O"^/IP+8<!P.GR%6-H+QQ"$$-*
M>S5Y1*J%&Q(1U<02HURH1C?JWZ+]4_3@:DOQAT(\>RC.PP&RSTTWKUUB966X
M(<D>'7`:4>S(HY6#S9-A*>^"V'-"R8!XA'')1"$<7Y6NX%C<^PO4VHNQ(]M[
M%P6MK<0V!EN)9-7;4AEL!5V*;WK\5E:SCVNTRK8CBU\+*\,6KJJ:<42U425`
M5DAP9$L#RA/'8S*KK&\",7'*"URJU\6-TE!2UBV\ZVB8K3662-K0PFE&XSKB
MUK8D%K6^[G.E)X8Y//@-<&E-CU?6W6W8WL-D339W-QRRP#J?J+&J&+)+D>U-
MK:Z;+J,BQ+&PF0*3+[9_:_8N1Q5<QGJUL93E*X07.&%_NI>C;W2NLBFV-:0,
MHWSM.]F;2[!9M`&YL7(MI9*"/_(U]*XJ?<!PG!:R/&H,>C.7_IJ6MCM5/D4C
MG!:'@.`X#@?/9^8O:6F^DO\`MWML'XY-J;FN=I7T?!']A>JV4$T[GF`9I>6H
MX]147]_JP;=J6%OD$29,-5D9!G19DMCH3WL+(:UX>.@>\TG:&`YUGW1CO(?L
M_P#[:WVM\0RWK/W)T[<8KM?![W:610L8P[&[;-Z#&]8;$J;FRG.(HY%Q59&K
MQA,]SG^J+P-G=Q9_D%RP9J*AP[J_ISY93HYM@V^=;#W))B5KV.'_`"5%K^%A
M&KXTVX"7_4&"=<BBJGA">WE6<"6^OO7^GT-2Y4KLIR38VP]E9.[.MM;4S-T!
M<HV#F;ZNOHV6,B+51(-/04511U,6!4U$`(8%7`C#")BK[D>$_P#`UQ=E=:9U
M8=E-7[2O,:S38?7S"*5;[+L.P^K#DTN5EU%%R6HQ&O%K^'9+<Y>)9F;&MIA4
MAD:)E:`#&'<14&%)=W:STUN??E'BO7#KWC$VJMXT_P#WGR;"MIS>L6R<8M<W
MK1X+:)&P7+*P>+Y9=P\:AQI%C5RJ`DE\:'&DCD,EQX#7!7W9'5?5FOOR":@P
MK;_;#,<8P[0^N,G[/8?GV-O#K;9L3;F52EQ*LQW*+W'QVV+;$B6E/49IED^'
M*I(XEG7DU11T'8/8X-T.C<HA2^R.Z(N,0,L)AF?Z_P!9[(#>Y#AV2XG%FY?1
MNM];W\B&N00*EEDZ[H:&G.I0QF>5`Y7.<U6(@>CM-URU=V(OL2U_;XMJQV6V
M0+/([?*LAPAUQL*KP>C:R`:3@=_!+5$J;4>6756TKY,SU^T>7XQ$)X<,($P?
M\/\`UCQ3):');>XV9E[*C'KC'YN+6>7S8>'WH[H*#/)L:V"YMLKHID0P!??J
M%I5<KVO1RMX$W8[^-+I1C@ZKXM&8U<RZB+910VF4DG9-92EM&%$>78R+F3+2
M?81HQ$#%.1JDAB$-H%&C4X$I5/3+JE2,M65_7_5C$O&PF7"R,3K)KK%*[S]E
M]RZ:&0KE`J^4\>/K_P`DX$[5^&XC4N5]7B^/5Y'5<"C>6%35\8I::J$T-94F
M**.TAJVO$U&@`Y5&)$3U1.!D(Q#$B-&-@VHB(C6-1K41$1$1&M1$1$1/"?\`
M#@>?`<!P'`<!P'`<#!L[A/L(^.1F1W2$3,,>E%]8T66R.&%,^Z)*.&8]@$CA
M07U?X>0;E1S&^Z-5`SE//A//U7^J_IY7_E]?'`<#!=G3)-=KO-9\,\J-+A8U
M;RHYH1'"E#,"&4@U`1@RD8]7-\>6M5WU^GUX&24+(0Z6K'7,BCA,@QV@'!;Z
MQ&-:-J.:!/9ZHQ'HOZJYWG]55?*\#',\MYD*OKZ:K60"WS"R7&:RR9!/,BTY
MY%=/G&M)S@JC8K(T*O+\#R?L=+43%1??PH8]D>.5T/%\<US7B&VOM)<.#+CK
M\B2YE9`..TNS-?&^+VF3GC5T@KFJURF>KD\N\H$H3(,*Q`Z-/B1YD=_LC@2@
MC.)R/&\+T5A&N:J/"5S'?XL<J+]%5.!6^^ZN8>\\RSUMD^:Z7N9CS23EU]<,
M9C\Z<4OW*2K;"[Z-<XM-_P"I3V<@XT<CT<1ONB%)[!Q;I_97"#23U8<>V9C0
M9>&1*^*PHJK,W1#R%B9?96KY7VM/(6(YS)0A15&JQ_<;4]VHO`Q>1VIB8OF-
MW1["$'"AI+^PQ^!E]3D.*1;&3&0+)LJ!G-O`9C%I3E7W)'*U&$=_D<UOJ]S`
MLIB^?T&5"A?9G^*9.$>0&`YS)!%C`<C5D-E0W2()8Y&N1S",*K7M<BHJ\#-G
M^_H[XU:C_5WHKD56H_POJKD3ZJU%_7@8).=LL<MB5P\-D0$4#C/F&N03%'[$
M22,`P13`^?T1JL<YWJJ^4<B?14#EU<2?_==M83BUSG)25,$88@U^Y:J2[*21
MYBE"TK0*TK$8U".8KD>OJU?JX/9`M\LD69XT_$`U]6P_K&LTR.+,*>.JC1#$
MKQ06$CD_<Y59\CD1&_YO*^.!1_'=;VN58ME62A)D7Q1-]=E+.UE9N%T2X=5E
MJL^UU7S*"&`SVOHHQ?@'7^SW/DU;6%11*_T0+=ZEDNO,3!E)HS0?W1Z2@L+`
M="FDJX0!U54^Q:6/'D&.:!":]%(CU0;VM1[V(URAE[,-Q%E3-H&8OCS:*R":
M/8TJ4U<E381Y(11I`9U=]O\`9RQ'C@8Q[2,<CF,:B^41.!7?*9\H/<[2E/':
MU()^O.^Y\OZL3U6OSC1,2&QK58XGU6Q?^BM3PWZ^?IP+6<"G&G9D@_<+N?&>
M9[HL&CZQ"`!5_P!,1C8;G,F21B>/HXS"B1W_``8G`N/P'`AV'M/"-C!W9B>)
M3CW-YJ:?.P3/*X]+9PPU^43<-K\I!4!/<0H=;=M/0Y!#,I(Q#QO!T8YZ.1S4
M#6E^+2NPXUSE62X['LZ"^E=9>IE3F>'7N.8W26]/.C5VR9U)+,3!AI@3QR:.
M:..T%4K8X1Q!JUC6/9P-O]M4U=]63Z6[K8-Q3VL217V=59Q`3ZZQ@RAN#)AS
MH4H98\J+($]6O&]KFN:JHJ>.!J%[)6I^I=186=I7Y_G'6_4L25FV-7=/:VW]
MXZ$OL1BNSVEPK*LD*K;&_P!!9C>4=14LD-.6;3CD/B3BK5^Q`AQ.I^K_`/<;
M;.KL0FWL3+=8_CZQ>`2]L`MAR:W9/?'=.,ES'8V:&D0VRZRP74V'9])<)PSD
M5EUEYGN<IH37(&Y7@5FWWV_Z^];'0JW9^>`%F=Q%=+QS6&*5UEF^U,G`AF1F
MR*37N+1;3)CUKI96!=/*`-<$CVH4X_/`I/MO\H>9:[Q#)<[JNE6V'8]B4"=;
MW8MK[6T5IK*`U%>"#()+%A,_-LJRS[F0R41!131`R6K%*IV`;ZN<',J/R@T6
M;XULVCK=>7.`;4J)`,#UT^VNL5SW`\IVME=+B<W!Z*-?XC;D(AIRYY72Q1IL
M>`Z>"/+$!ZF`YG`Y4;\E%EA69Q]=[>T;F$236Y5.Q:]SK&'2G02UU+CL^[GY
MK'P3):7&\S?!-YJV?:00V#FOM6I\G[1M.%#MG?\`Q*/7#1=KFL/L;U4[3:VQ
M'&MOU6`XKM$6'4V9ZLSFBFY1/BU.;P,HK[",F/VK\:IS7\>BG@#9GC1B,C_*
M5C4<%Y:W/3=E^WFB;364C&;SJ]E&%5_9:MRZJ%CA@;4!A-4^!@^803P*^/E8
M7UN;Y]"$X5T]6L2K\!"(R/=P-K=A80:J%)LK.9&KZ^$)TB9.F&'&B18XT\D/
M)D&<P0`C;]7/<J-:GU5>!S$5%_1?/]?I_@OZ+_V\!P*>=LNQ>8=:Z_&,OJZ#
M`,RQNPD2*^SPZZS*?A6Q;VP))K8-5"UD4E#=XQDU],L+,($K9QJUQ7&:YDCP
MQZ<#K\EV]HG,_P"+QWLMJ*VUO;(R),BLW5@<.=C%;92&/$-M)MBE3(]?@M`J
MI&M>"W!):C5=X:BHJA#7XX,*Q"XB=ENQ^--E6&.[Z[$Y>+5]A87MME,9--:4
M8FF\#/C5GD,VUM(N/WEAC=S;1@LDK%8*T\`8,2HS@2V"5L9WY$K",:%ESM1"
MZB1GP[-9(5P,.Q_]V$6=`2,V^>9N6&QAP2*Y]6-$AL_;*?Y<%@3CK:_#FF>;
M<R*OR.SM:7&\CB:NAT\FHC0JJFN\3@BL,ND4]FTA9=XD^TOQQI!7?&()Z]0M
M8KAO>X)LX#@.`X#@.`X#@.`X#@.`X'27M%%OXT>-+]?2-/A3V>PF&;\L&4*4
M)?5_T:]I0M5KOU:Y$7Z^.!W:?1$3ZKX_JOZ_]O\`QX#@=)D=(+)**TH3RI<(
M-K$)#+*@&='F`&7PCWQCL5'A-Z_HY%16_JGUX'!PO%8V%8Y!QN'/L[,$$UF=
MLZXE.F6!GVMM.MS(:0Y$5[!&GN8-/^X)K6_TX'`S"AK+NPP4]B5K'T&8@O:T
M3HS3_/8AI+N"%J$5CG17,#/(Y"(K?T]5^CE10]\6LM3YM:W%@/XJJ#50*['6
MCL'&%*)*4LFZFR:U1M9#F!*,0!O1SE>)%_Y(&8\!P'`ZF]@U-C46,2\JHEW5
M%A2FSJJ;`CV<:=%?'*.1$)`E#("6V2![AJ-S51Z.5J_15X%1<!TM2YI746:4
M5+::/I@DL)6'8QB%NZJGMHKYJS9SLVH*Y2XP.])<.25&$Q9B0&L0;G.4DD*A
MF.31>Q6)5D(%%<P=B#9"L3VD](=7CN4)*%8?=5\:JBR(-ICTIJU?_2JA_B4Q
M40BO$BJG`_</[`USPS*#84+*L!R:L''99RLPHA5\`!ITB/!C2P6<1JT,JO=*
MF!1"C*K6J5$)Z>KO4/.7(V389A*M]5Y)@MY&DPJ<.4MR(<V((R5;;#[&%3RJ
MV59+'ER$L'..]8JL"WU\_(Y48@3O1DRG[0`[Z+5MF-A>9!X4PI1$G_M_:P:P
MX_B,JJO[OH[PB?3Z_0**81E&60-*=KLAL8UI:"@6FZ_[8>:=)N"6!697L6$6
M#609DH;U!52ABC@B#(QQFL00T158B!:3!<CK\2U'J)IH\DW\AC6NJ6/'C1G(
M\3[6#2UK#E"%I6QHT0LMBD3SX&WS]?">>!-?`KI?UHG]K]76JN<IP:%W7":S
MPGJT)\[T:9SO/CV]G/$B?X>$X%B^!3_3$"8'MAW1L)$=HHTY_744`Z>OM)#"
MUG8(9R^%5?`I4A[4\_7Z?X<"X'`<#7UUBG(_=7?ROR+-,.M8-_V:J:+&J&LD
MF5:94Z_:N#-QBV?93SCG99)>,DV5%C#&P()`D]%\JY0]W3K7VMM-W>0Z\/BT
MO!=[U&"8!B&8_?6,^11;2PS7,2PK,.V'K@LTZ5]AC;8UF4,P,,,<U1+>L64%
MGJ`A@OX1[1C>1R^&C8Y[E_P:Q%<J_P#L3@:`>WNXXDC+<SR.57R;ZBK\LQJK
M+B8'O+89/'U>V%OC)\26FL`1/NA;$SC_`&HPQ1*)'JMN47N4;TX&VCI_H5G6
M_KY@>M);JZ5F'PVF9;0NZNOBUD7)-M;!MYN9[+O@Q(;&!!#FY?=2FQ!)Y2/!
M&`+?V":B!7;O;VZRS53Z_0N@BU+^P><8E:YC893<1&6^/Z(U=`DOK)6S,@I5
M>-MYDU]8B/7XA3%<P-M:QC$.[[.%*1P:\]"ZPZ]:SV_M&\WIM'.];5MB/"#6
M>P]H['@Y)E6]I^2BF39=ILWLM4`BUU.1MU:_Q1,1K)<"K6#40#)\D<06C#>C
MA6B])810AIL*UE@572&A!!_TF/5,MUE!^W^(*S[.2"5.NFOBO]4)),9SAKX]
ME3@:QN_1\$U_N_4N?X]JG'K.5U<UOM/NSML]!21*^VN\2U72#P37V,6)*F#]
M]>'=>Y3/O:F&YIR$F8DQ@$8_U>P*7=KL[C]N]I8+)V!A,^@EU?7[6^*6VGI5
ME'3*-<[5W-*Q_:60U3)L\<>E?FM:M?B8*.>`H#0<KAPZ:P08<A'Y"V/2>UP"
M%^/K)MC;!JL'VW$BVN?['U9J7)XM5E;,+P>@MK'"-&8745V40)V64E!:.IV2
M:4-JDBPI(]]]BAG-!XX$O:IWG_:&W^PV]>P_^WNK=4X4W#^M]/G7]Y5%5@>'
MY1A+`7^88A6Q,@J\?R"PLLKSW8"P&OA??13RJ)H1>7(BN">^PV>8AN[1^!4^
MK;1-MXEV#R;&XM=+U9D&*68LPUUC\],USYE9<6%Y7TQZ:UQO%Y-/-<,Q"L=/
M^)6(Y7*P*.Y;V7I=;W=YA/6C8V::]SO`IDDF7:#[-7UI45TR78FJBP:S$<IW
M/%FXV^`H9,B61(68A\`:UD<?^N%R!>MN]-XX=GVH,"S?"=5YG3[;O"5-/LS7
MNP)]:*+74.(7F79=D-O@MW0SGQX,*%3#$!\6YE@?)G!81XD<BN"B^TB;.SZ\
MUILS>&4Y3IRRPS:=9G^+X3MW2#LLT>^-6V]C:XY35.S-4V@\MPTLVOKZH]T[
M(I$F,V=6N5D7[=[/<)\[(=T,KUQU:VML"=@E';EF8I/PO7>P].YYB^U<!G[8
MSR9&U[JNLL(4Q*#)X#[O8F1U\?X/XZ<@G.<U[E]7+P+K=<-.T_7S0>GM(T(8
MXJ[5VNL3PQ'1F(,4N;2T\6+:V?JGE/EM[5IY1%_[Q#.7^O`@6UD8G2=UME9+
M66[+S:]1TWIYT?64;#2K?3\7A[$S&7!LZK.B#'$GQK?((:07TC#,(&0@I)/+
M3#5@3?UIP2TUSH[7N.Y$..S+Y%,[)\[=%4BQS[`S29*R[.9(E+_J>ALINY:M
M1?T;X1/HB<"=>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@<.57PISX19<84@E=+;
M.@O(WRZ+,:$T=L@2_P#=(@)#V^?\'+P.9P'`<!P.!:B4]98!1%52PI0_#51'
M*CPO:J(JN8B*J+_[S?\`FGZ\"K/26ZD3>OF'8Q+H[.EE:UBP]=R'60D"EN:A
MI:@[[>`-HAM;!,ZQ4/JGNC#`(SW=Z^>!;7@=9/I:>U$8%G55MB&0)X3BFPHT
MH9PE14($S#C>THB(O[FN147^J<"(;?0N+'?>V.+VE_@F0WMI"O#WV,2XHI#+
M:OKAU<8GVUA"L(3H#X<<+#1/C^W*@&>6^455"/K`W9#5H'VDZVP/:F*UT7W.
ML^?(P7*A"CB))DD,62"QQ^Q5@!N8UWRQ%=Z,<Y$\E=P*OS"7(.M&P*^ZNKZI
MG&SG9N35E5!#-K8T>HSC-93PQ;JRJ%EGL*<,C*'R6$`AY*C>PS1>&,<T+-3`
M0ZFIU#+A6V5)3:KO:#`+VIDW3*[*PV5[;XIC]$S)1QQCK[RLCQW#^XCJ!KYD
M62PT<C?K[A;C@5QO;>*#MKK2E)Y67/Z_;DF1T\_1H86P-)MDO5/'U\J<:<"Q
MW`JIJ2S^Z[.]NJ[V\K5.T(GKZJGJDW7EA(3]_P"CO9?/T_I_V\"U?`<#39A.
M18Y-_("`=KL>GILDA=B^R6(8OK>`VOBVNPI#>O.C,@OIIQ8^.!#FP\%QID>3
M*6]'*MTD%8^,9(WJS@;0-K:GH=JTL.'.E3Z#(Z"Q#?X3G%`0<7*,)R:(GB)=
M4LMXR#>U6JHI<,[20K&(]\>2-XGJG`KJG8.\PO'<OUOV/'#PW9E7C]RZAR_'
MY$>HQ+;F*QXKH\S8V"2;R0L:@N:&*59UYCT@TB72#&XS'2XGH;@:TJ/'V;V_
M(+I#54BFQ"+4Z=QR'N/;E=A4J3<8L7)\;90[#D-#9&00)1K?9^8:Z*I6"0,E
MF+G1J"8OQ*'T`S)<6OARITV0*)"@QCRY<HST&&-%C"<8\@I'?M8((F*YRK]$
M1.!\U_7MW8'M'MO=&U-22,5CYCOW&D[#3+3<+<J%A,'5,//8^']*\+Q(^$6$
M?(Z4$[`<&M<DE22_>QG2+)YAQ?:41$"3-OZ:R#`%P["-E:EV;B&MLNW1J6@S
M+/ZG*:+;^OEQJQR>'DV86E_,94OSPI<TR"C#B\"#,JP-KH=F)0$^0OJ@;P->
M[AU1L^.]==9YBV3_`&9#1)-;56<9+6L-#>0!XEA0E4%O5'BO`YCA'CB<Q6*B
MHGA?`4*VY(WGU][8W&V*7!L%WQBG:2+@.F,9Q25<6&O,NP)^LL.V+E\;&/[N
MNJR_UY8PL[NYUD>*RR/3)(L9`XC'N=Z.<&BGLMDFPL+QW>,S=6L=FZ3V1M[,
M;PYK3;.(R:_5D/(=]93_`&=460-NT]C=ZKL(NJJ21"KL@-#MXBGQ^JQR[`P=
MACLCP&QKL+UOUOJ*!>99IS9U?=V^W-/85!J;%),VPQ7$]*],,/K,ZV#>U\[$
M;@@[S,-I9C1XS]W9(Z+)D3V0A.*1K7H4)1U5KZYRCL#T0T-FPKC)#=>='Y?W
MIWG99$)\\=EV'W-,L<&P&/D;94?X&Y%5W.6YM;PFD5LB*^L`1C?V->@09D>*
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MD+E%%1$ETTL@/DI7U!AH]7#(PGAZ!"E?^/\`W%-SOJ[CF?TW5^XU5H/9^-;`
ML]G8%C>885M7.J/56,W*:RPG-\(M).38_=E?GQZ:VE63KLZ,)0C<V,CR-5@;
MDT^GT_PX%+]H:'K+#L)5[2^XSF^G[/QG`=/7M#6Y#"H<?P;#-:YAD>X39I#.
M`3+]TG(<E;!J;..)Y!S8Y(XG(%GN]P70X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.!X%&,PWA*QI!%8X9&.3RU['HK7,<G]6N1?"I_5.!UM-14N.06
MUM!4UM+7L>\K8-5"CP(J%)ZH\B`C#&/Y'HU/*^/*HB?X<#M>`X&)YS<3J#$[
MRXK3UD:=`A//&D73T'4A(BM1"6)72(C0Q6HJJYSBC:GT\N1.!A%S@TJ5C%@T
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MN`X&ES7MKM#+_P`@M=-D54NYUQ@W9;MKB"Y"/#J"&_%2_P#IZT=84U;+NZ>B
M64*JMITF:P<NPF"L)YAM%Y-&:)@PW1K]/K_AP-8'<:77[9UY289LFDE1L5R#
M=TUU9*C0Y%7D6*X#KJFM;?+=H5UC)?$E5EQC&.4EQ/`Y&>2,(%/C.!ZH4*]_
MA?H=D9U6]G>T^YJ"+3YULO<=_KC&RQK>+?):ZZP*\N\DAY))GPZZKAQ;^YO<
M^D5]K"BA9$@R*%D8340'`N;^2O8%OAO4O-L5Q2[?CV?;[N\.ZVX%;!C%ER*R
M]W?D,+";2\CB`YI4)BN&3[6W4B?M`V`I'^&,<Y`U8=-]C=JH%WV.V/U#USKO
M;VG![*QS4N,X_E$G+*.8[!]#X74ZLQM^+9?+LS**K?*Q2TE/`"MF`'(MON0C
M<PS4>%\2_D'U1E-1?ZL[8:-VSHM^05Q,6R2)?T,_,,0D)=L6NG186489'7((
M;1K(&X<LM;!>-I&G&]J,]VAW&A,NZW=A)S=/Y??:PWCE>&UQ[O4VXJ2UI3Y5
ML/7D-PZDUJ#(,>E0\JH=CX$Z1'J\GC-*`[BNC3E;Z2T:()BVYU%O,UU]>X3A
M6[<SIF26TL_#P;%C0MI5&O<LQ20VTP[,,4EV2U>=5]WC5[#AR@/6[*U%C>GK
MZE-[AUNN-[;=S'";6IV=HNHS"VQNSGZSVO`U?>5>1-ILTJAQ@VJ6NO<V9C\Q
M<7NX,V/;06@DV;ST\P!/1SB>B!HRKL%ZE8W4:TNLVIL]PU^;:1#BUQG.K]IY
M3I/>4C+HF6ER';E_>X%D$#'\9V?46^=EJ:N&*=]\"8R`+XP28ZE>,-F'5W)=
M>=1<)W%VO[<]B,C=,['[<%B%+LW?M3CV%Y"'6&DJG)<3U73Y-68C04=%3$94
MT=Y=39OVD:,5]DZ051J7ZAKTTC+V9G%/O'LP&UQW'KS8X[.XUS:W?\?92<-W
M1W;V=)KI,HPI\(SD)K7IOC^%D"!7H*.J2&%&]/G:P)YZKR:J)3X0EM48_CN"
MSL'RG>.7S;F7ELJQL<FVC3V>`:*H;BF2N99U=;3:=PLMM<9%).*#(<H0)(<Y
MSR,"T?X9++)\MZSYAMG.-79CKG+-[;AR[<GW^54E)2PLXP+*(M16:;O\1947
M=P=<9#J+'Z0`P360YD0S2#(%5\E(&WC@.!C<BVEMM94*(R/)2%%$9\-/D9,D
M%.PBC8$SU;%&C51JN]O/AJ_\4X%6<6R"GSGMOE>16EE"B"U=A@-,X+4R;$/W
M5CG.6`K=F;86-7(<C33\>QRNQV.\HD7T820U7>/*<"Y7`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`Z#*:5F18[<T9'*UEG72H:J@X95_P!8
M+F(B,GQID)555^BD$1K5^OCRG`BO3>M[7!7W<RQ<:(*XA4\>-C[KB1>Q:9U=
M*NI$@L>QE.^8TFU?:H64OHQORM1&JYJ(O`RTFKL8D9W*V'+;/EWDF/3QVBD3
MI#ZV*VAC6T:M?%@^Z!"0"7LMZ.1//R'<[]?'`CM=:W%>_&/ORR\D6%O^ZV$*
M1\PV)4U5S"RH,!'"FLL2+$IAV[8[1@)&\(Y'-5K$43@L5P*YV?A_;/#F^4\Q
M^OFP2>O]?$G8>N1^?\?'^AP+&<"L^IB!7L!VO$UGK(9D&H'G<B,1",)JBG:!
M?*/<]7-03D7RB?3QXX%F.`X%1LP@7W7;,\LW#C%989-J//+/^Y=X8A4P)MSE
MN,9(&JI:!FVL-C!*0UE1Q<>H@"R"F$-YU#';-A-<5AX\@+#2,VII."_WYC$H
M.6TLZA'>8[*QXPK./D,>=&:>H?52(SBAE!LG&&@WM56^'^R_1%X&BSOM/CZQ
MU993KBZGVMUBNMJC1TG%9-%,KY$25L4;]B;<N:3,AC)'LK&ZP'"[JA?'@BDH
M(=XSUD>)"1^!L\T3@VR>MG3C5>)T>$1MC[4Q/"*2WS?$V91'QPV2YYDDI,IV
MI_"W]P"97_RDC)KNR+`9+?'C'(@Q/-&&[Y!AJ2_(-W%I\ZV;A^0:\C7]=.Z4
M:<V3V"O\>S?#[JJN<:[#[3EV'6G0^%W^/S)M:^HS<!+3*+"J*]DR')"QLN*0
MH4&0@;/_`,9FC(6@.FFG</CMG)*LL;K,FLRV*O\`O)4NTJZ\(IQV/E2W#-8U
M\(,@GL]7N*5SGHCE5J!>"YQZBR&(2!>TU9<0B_YXME!C30._15\CD"(WZ^J?
MTX&N;>GXK^MNSX)KK74*]T)MJLOX.8X=L_5=[88W>4>0UDP<_P#COE"\Y08;
MDWQ+#NJZ(L=DV`8C$5C_`$>P*\Z7J?R)8C0WW^U^ZL>V[<8186&&YMH[L$IL
MCO-?Y7`8DP(%V,&539EE%1;0'1I%38OL"`G5LMIE"TS7L&'`G=ULYT)O&NVQ
MV2ZR;$T959=7Q-<;GM,5NJ_8NO+&JJ72)FO=M?9PP55["L\3GV,BJG(`$PYZ
MBQ:]5*D`+&A9_J%M?K9M[KC7:\P^ZUAMJWPT^Q*>/K#(BU<;(+,U'G65AJ'S
M\*SJ,'(*0.1(`1@EFP1M:P[7JB-^B!!O<G\>_5CM-I,NI=QXMNG0U,2#DK<5
MM<5R2?DN&Z^N[RG!'OK6%01;/+L/''M:I2P##E08PS@)(:%0E*AN!5"5HGN?
MN?KAC6J<6/H;:$;K[,OM77AL;+.UUMN#M;&L$?JRCS7*JVPGS<&SFHH]3Y9,
MM**&.YII<K^5J_D,%8IE>$>]X=LU>G-3;AA4E9NKJ]?;%BZRZ]2G9UK:%@V(
M7>N,HPVFTPUF/Y#23;ZFEP^N>)W5E<QI;+)PI+O$9GNB.5`^E36E;AM)KK!*
M37<FMEX#1X?C=)A4FGEQY]47%:BGAUU`ZNG17DC2X:5<82#(-RM<U$5%X&;<
M!P,.R=O\8&PRV1*&R-C=':6#1MB!=(&R-%))G>)!I483QGC1_'H16-:Y$7W3
M]4"J?5O)]9;[L9/8'7\IL.$,>34"8398W+Q;,L=M\CG4=C8W&?4=U&K\GILK
MN:FDA,^*<(OS0V",$KA/8JA=W@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X%2K1DMW>O"'(\R0&=3]F_(Q/H!\M^W=4()SOW>5*P
M+7^/I]$<O`MKP*?Z.:1W:#N\9WLHTRW1$0?E55J?#HW&I+T:GZ)^Z;Y7_GP+
M@<!P'`I1D6)S>LUI99-AU`&ZZSY'8V=_MG7<8!94O4MQ,D_R]EMK7U:GR#-A
MQ)[7R<AQV*-JQGN=95S4<V5&.&J_-+JH[@]KNFVO:"]N\DPO)<AD=F<RK\B.
M^ZKXF*EE5NP6T<%L=XJ]N!W-/JO&104*TSC1,N:0GAQW^0^B?@?'9O\`Q:O[
MX]H<&--<>MO-Z]NLXRS65MCTZ@#D>,Z'ZWQH.@<`RUQ;`)RV,/8.7?=Y"REL
M8MG#"*L23'`$\HCU#Z7,>VO?:-#4X+V'KL?QK&82P\<PK=6*0I-=JJW@1PMC
MTU?F,$Q)7^S]\*&%@5;,.2DE%:JQI@U<V*P+;-<U[6N:Y'-<B.:YJHK7-5/*
M.:J>45%1?HO`_>!KP[$[BP7K1V$!MVXB9E/E6^AAT&28]C4"I92W4!F[->XY
MCF47DPM@.QFW6$RLYE-CC2,]!5<Z;\;WE5@'!?3(L<HLNH[/&\FJH-Y174"7
M6VM78QV28<V#.C%B2XYA$1?V&CF>Q514<B.^BHO`U,ZD_'7HK86'Y[3[`KZB
MQS#"MV[FQ>FV1@-Y`KLI+B1,N=<XO"R>PQ2:]8V74M9,`":TQ!6"E$JR412>
MB!DC.HO=71\FJ;UO[=VN58;71BQ5U[OVN%G%=%@1P!_CZVFLYZGOX[!N&\;'
MI:1T8QS45JHQ7."N5WV\[*=2M[U&U>S?4NVJ==;>)!UEM7-=`2RY=CD;)H<T
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M/(3[VGS'(L;UH*BPPKH^9;'R?'\`H9+:QES]@"ZEN/DMHZK(,PI@ZW$X$XBM
M>Q[$?Z^S7)^U0X]_H![Z_%<OUK<!UON?#<3BT53DD6$KL:R2$$0C&P[96,QS
M-'DV&2YX_9C4(RPJWJIH,D3_`&^0,CU5NIF7V<_7V?4;M;[GQR-\][@MA,25
M"NZQCW`9FNN+UXXX\UP6P*-59(&P<R"Y4#/CQC>K7A/'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"O$WU=VPQG]K?8/7C./W^$]O
M63LG7G[?;]?55B^?'`L/P*I:/K2Q.P'<RQ(K7-N-CZH,)4]O*#AZ&U]`1CO/
MT\M<!?T1/HJ?U^O`M;P'`<"OW9NSR06H<CQ?"%DIG.QOL]=8P6$6(&75ES"4
M*FN\H$^9+@B1F%XQ)G7!?4B%04%RC17^$X&B+HY-I=*[N[(=P<=Q$`>I>+2#
MZHNK1UG'B2]/XE:'BYU8[!J()C28L_7^,:]H\%3((B212H"%DS8X/+)$4@;7
M-]]PL&OOQZ9KVOZ\997YKCNQ]5^=$Y4`-I!@9%DNRY0L"UW/'%EPXET**F67
ML8A6J!IVA$]R-^G`U;_BGU%%R/M]M3-)%S5[`Q/JWJS7'5_768P[.-=5=K,U
MA42Z2YRRLFPH,"+*M[?,;K*02Y+FN,_[1BO52/>]X;T.TU]4XMUIW[DE]C?]
MXT=%I[8MK<XDA"")DU5"Q2T/84$<H1&*.7;1&/`%S6JJ%(U?I^J!@/3O=4G=
M6`W$M<>;C-;@MCCF"UE>V8&T0PXFO\2OSS1V89LQQ0H_($B_"?UE!)%?\JJK
MT\!;C@:2/R/UEZSL#C61"K\GR>AB:'Q"K'B5;6U2TQ\H/V_TC.K;<UU-@V[P
MV-=!B'.2*2,H20(YGM<A$16ANWX%,.EF+2<6J.R"20FCNR+N)V%RH(I%5<U9
M_MKK)HKP%?\`S4:,6R')8'Y`RH_O"*!S$`]1M3P%S^!"W8T>-$T%N;^\'QPX
MV+6>:2K63)ASK`<,,/'Y\H<](-4&1:2S5YPM.)D4;Y*D&WXFJ3U3@50POIAU
M>[!=:="IL##<2VBA-2Z]F%SL502L7-YDG%:B1+RFS@F@U;K!]S/5\QK;&'\P
M7E7]@W*Y.!K3[-_A&H]<5;-T=,MH[.U1GFHX&2Y'B&*T5Q?7=?9?S,*OK\HQ
M&LQ(\R?C`XV34,%PQMC5T<@I[0R/=5$B<#S;F/YFNI<9(]G3479_!:8XR#N8
M,5&V]G4C110PC!;6US_X=?\`(9R.MZTORB"W]_O\?`E#H=L/)^\W?W9O:7,,
M`RK!:3K/I/'-.XK59%7`K:YVT-LO'?YU-I#0)=E!R)M'B5"`+9;)DH(Q7BL$
MY?9[G!M<S:CJ<^W]K2%*@Y&.;J.MM<XB636PQXN8V4@-0-"TCO:PE7$4-<01
M6)Z`9%FJB_(Y_P#I!97@1ILS5.([2K($;(H\N+;8_-_FL1RZBD?QF7X7D(P$
M!'O\7NA,<>#8!&16O&Y"190E<&0$P7.&H=3H+(LBRK4>'W.69)19AD)!7$"R
MRK'(Z0ZK(24F06U(&W9#8P8(<Z?%KF$F!"UL<4QQ6!1!(Q.!,/`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`K#)MPIW/I:%419!.L.3
MV['>5\M"':V(PRHJ>/'A[SL^OZ_MX%GN!4O1UA]WV,[J1&N7XZS/].Q_C1KF
MM84VA\'EE<BJY6.<1IV^51$7Z)Y\\"VG`<!P-6GY']HT.,X9D,N9/QB,S5>&
MSK$UE>9/(H96&9]NAAM1ZWR<$8$Z*"8*NQN[RJQ826P@!&KF*)S931\#73VG
MZM;7RS\#&2:&UAI+(]J[C[;2\.M[/':9"V4G!S;XV907I-A6,4%A7N-5:>UT
M>)[`8OQL=7L^02,:1&AD_;7"];="=#]'NDVM+2ZEZEZP8SL7M)EU5D&32SY5
ME>'=?JB1'P?#863633#B6&:=@-M5):T95]0-J_B8K!B]FA?3\0FF9&I>G&'S
M[DHI^5[(GV.=Y%;M6,<TZPM#/6>]\V,(22AFO5G26JY%<U9*IY_1$"XO:Z[A
MXUUHWOD%ACT#+H-+JO-;.9BMI(?$K\EC0J.8<U#*ELGU;H@[8;%!\OW($&I$
M<I&(BN0*^="<WMLM7LS46>-9-B<;7>]H>$X_1Y'4_P`>RJQYFH-89/"I:>>*
M7*B9+7X_*R4\%;$:,4Y8[FO]WL4CPV"<#2[^0K![+-M_4\2'(KC>=+ZNC5].
M^),L;F3=#[>ZPM!6%=`GQ;[$Y,:N@P2J=I*Q9[5>P@ID08WD0-T7`IOTKM(-
MIB&[%KX%]71Z[M7V(J'1KO*7Y:%)-;GTR/+?03WU]:M=CSY*.^&M^-_\83Y(
MWRF^/Y7A<C@5)[FTN0Y=IC+<+IL>#;P;G#L^L[J99^R8Y%!C.'6UI!J,A<*P
MA'2%D]J@(J_LD"^'Y?E$]G[5#).F\*/6=2^L]9%K&T@*W1&J:]E(ST05)]EA
M%)&=3!^-$3X*IPUCC\_N]!I[>7>5X&'?D#!/E=+.R4>KR3$\0L2ZOO60\DSN
MS'2X=5&5`^I<CMRPK)E=5E3_`$B&4!?1'^4:J\"6L^SVJUGHB\SJVF@JX./:
M\+8)-"KR1H\@=%_T*@>QBD<)TM1M$J,55\M\)Y7QP*H_B[PS^W^I6.;*LXZ`
MR/L'?9'OO(9Q5,A[&+FD@;,.GRVF%'0)":\JJESF#&,3'*OHU$7ZA._7A:/-
MIF<[RIQ6+8NS;AAJE]I.^^*6BJ8P*BOFP&HP8ZVGN8=:"7'C#3QZ$0CU>1ZD
M4+0<#@V9$#6V!556H*#+(KD?\2M1D<CE5"*\:#5$3_-[-\?KY3]>!3[\=TBK
MF=).MTRFM;*\K9FN($N-=6\:)#LK99,Z><]C,BPI$N.$LR01Y/"%([PY%>YS
M_95"Y_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`JX:
MK1W=6MNE`WV%U<NZMLGZ^_@^V,?EO`O[_'KYCM=_E\^?Z_TX%H^!3OKR`O\`
MZ@^\TTC%:V3N/6``N\HON*#UUU4)7?155/!GO3POA?IP,7V;W3C8CNO&](T6
MOLDFVLKL#J+2E_DUU_'4^-$#M'7F4;%=<8E*/8_>7DC'*W&_BEA='8KB$]0_
M)X<\86@W#KR5M;7&3Z^BY9=80_)X0Z\N38Z0X;JNC?=QY$G^.D1ID"1&/)"%
M0J1A6/8PBJB^>!JIR3$_R']-L>R3-J;?V*;SU5C5<^TG4^\&,M+&"CR&$T,/
M*F/QW+XU:`Q`>!'L+)1#5_HCO"(@:W-ES)7Y(<4Z[8[NC#\5K9_=K>>'YIDF
M`5,_^\<;%K;4TIN#Z^8"<:-!?8U:56([*S&"Z4-"@DCCJ1J%"T;0^K52UM/&
MBQU?$KH@FAA0Q>1QHXVL:T,:(!O[6-5&-1HV-^J^/")P/DM[R[(E]E^W&RL&
MQ%]W/#M/>NJ>I.)SHT&[AK7:]ZMV;LWWR>JLF(E9?U68;GV/`Q]\02'\'B$(
M<3E`).!O>T;V?K(&OZ>DFX8RJJ,?[4S.E^'QL=G?R`A@Q$;J*FRBWE6HJ=TI
MLI]4])38(3(`K_5JE:,IN!93LO@65[2Z^;GUQ@LV)6YGG.MLNQ;%K&>00H4&
M^NJ:5!K)<HAX%H!L>/+,U[O>.9GA/JQ4^G`BWJ)H'+=#MWTW+KTUX79&ZSYQ
M0%).A3_AQF/KG7F%P22"1::G*.VLYV)RIDQAUED::0O@[V>J-"X7`UD;YU3E
M6[>\&*8,>SS_``_6U5UVQ[81,UQ?',:6L_W$P/LAA>5U&-+F5ICMC9`GV]'2
M&CS:ILI@#U,LAD$AVC,,-F_`PG!-=XEK6NN:G#:U]57W^797G5G'?.GST-DV
M;W<O(LFGL)8R918[+&YG&/\`"QS0B4BM&QK?#4#-N!#W88D,.@=X%L:\%M7C
MU!LI\ZKE0'VL6RAMPVY65!E58XD\EE&E@]ADCM`=QF.5B#>J^JATW5F;%L>M
M>A9T`4`%?*U!KL]>"KJR4=<""3$ZET0$&G,"*:LB``K6#`\(7C8U&N&Q45J!
M'_?7'+G+^GG8'&L=BCFWEMK^>"LAFE5L($F2*5#E?#)EVX9%<",\<=WRN*QZ
M(/SX17>$X%3OR99/=WN@--=<,:CSSY-VISO7&I#%@!25/J\>R2170\FN@_&0
M45SJ*MDDG&5_D/VT4JJB)^YH7TVQ`7!-!7V*Z^D4V+RJ_"0X/@C9QV0J^M?_
M`!HZ*G!%$B(LDT"`SV#&8GL91(Q/"*KD#(])CQJ/J_#XF'@^/&H51&@U,AL=
MT:/91H;?MDM(3'O*4M?/<-2`*YSE*)S7^SO/LH2IP.HR!2-H;MPF^Y6U%DHV
M>KW^Y$A&5C?02H1_L[Z>&_N7^GUX%4/Q\UT6JZ3]:(,(DTL06J<=)'=8T<K&
MIK121EE,#(HIMI=3*Q\=#>GQ%EG>B-15>JKP+C<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<"N_S#=VR4"O_P!877=IF#\+Y^,^RG,(
M_P`^/"?NCM3@6(X%5]/J"#M+N+)BDC_<LVAB<N1]'*HY#-$ZV>%92(1RN\A8
MQ?HC?+/'T7]>!JU'*R3,N\>.Y.D?&@R;W=73K*+#((9W1`Y4P/6S;3KQ0Q;`
MDLD!E2"00%;&<C"R4,]R.0C?#@W([AV%+PFNH*ZC9'DY/EUZ"HK@.L*>-*KZ
MF.W[[)\I#!MYD1+D&,4XW'+%`KCD]FHU/'E4#3A^2[?,S=?5C1^$Q1.U+)[/
M9!]DHLP,DN5A>.3KN)C%1>Y;4UJLGS;&`"U):.J([3J0D)X'*YX_"A#'64-U
MN?O/M#,-`453:4_57%:34N(9$VJK<:P:'/)$FZKJK"HQ6)+:&CBEI\'SJQ:H
MPHC&9F)[!O;Z/<&[C;5I0=?M,;"WMGISYO.U!K[)<[#_`#9`^K[>@H[*<"%3
M@``<2-974TB0@F:%9+E*QJ+^C>!HI_'_`*9R_).]>#1<VK;VI3K)H*NL\\HK
M"PD6U4_L7MR[M]O[=O8LK[MT&LG3,KSJH4D4+RC?]FI/MX[O=6A96KDQZ'76
MF+(`?[KH<9_*[M;);@>/8PS$95<&B7<4R1'G0H3*HV2VN/63G,=+>,[K%P&H
M=5)Y(@;B]';>QW?NH-<[IQ*MR.FQC9V)4^94-7E]5_!Y1!J[N*R7$!>T_P`\
MG^.LF#?X()"$1J_HY4^O`E7@.!4R;K/)_P#UPT.Y0UUHN'CZO9-K:RN73X*4
M8+HFT,;RBMJVUBRELUMI$44@RG^!(Z!%Z*3W\,X':1-_V61;1QW",1Q=UCC\
MS-<ZQ;(K^>.QKY-1"P.G"Z=="B'BC;]G8Y85:V`\BH&Q8(YP$5`^I`L_P'`A
M[L,MTF@MWKC=!-RO(DU%LA:#%ZU?%AD=TF'7*U=%!7[6=XF6T[XP"_T#?O(G
M['?Y5#INK%9DM-UIZ_U>9T[<>S"#IG6<?*J!@$C,H\C'AE*EU3MCH(+0_P`9
M9?(!6HQB(K%_:W]$#"N\;<]?U1W0S5Z9&NP7XU%'BJXB6:#)1V9;VI'\U/(K
MJZVF`E!C/(Y7LCE1K$<KD]?94"H\"9*WM^4&EI9\6/-H^FVGC9#+E!EPG`!L
M#9D(V+4I9,".A2LDV-9-NRQV$<+[9M=[>KG/8K0N5OJQL+*XQG%*.+C]K/A1
MYN0.B39`5NJO(I18E)@5G$`0@EA0UL)<TI)+?D,K(CV!&]RN<P+&U,):ZKKX
M#G_(Z%#CQ7$^B_(X`FC<151K$57JWS_E3]?T3].!V'`ZJ^(\5'<E&*0<@JFQ
M(,,7Y4E&>R&9S11E`YADD$<GAGHJ.]E3PJ+P*^=-;'.[?JOH6TV74Y%0YQ8:
MTQJ9D%'E_P#)KEU/*D0VD#5Y4^Z(6W+DL"&X0I[Y+E.^4U[GJKE5>!9C@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5`1LI>_)'^SOL
M1]0!-1OE?191MSF57*GCQ[($">%\_HO`M_P*7:0(C-K=^;#PBN'NC%0?O:CV
MJVOZPZ7(U'-5A$<Q%.OE%1R?7]%_3@:MZ398LR[?8#B\6;_+%Q3>71H<_'H+
MZR&.FG9'U5VUFQI?\971:R;7T@*X@Y2"6,HW'$UKGL&SXD#='MO65WG<EDZ#
M,KWQH&-7=3'II2RHQ9,Z^)!C2+`-O$3[^GF0*D4AL<L5['.(?P3RU&JT-`/:
M?<):3NZ_+\-;(I<"Z2:3R?),4E40*.94S<H+0R=3X#KPPRRW_,*ZV=?*AT`B
M$8B-&[RJJ1@;'?PZZG/KSI]6Y=8BK_Y3<^99#L"-)@1Y0V'PJO2)@>N3L//1
M)LB/=X=B$:Z;[(UB%MRJQJ([RH>W\I^P:&)A6B](7TJPCT&W-RT>9;/)6XX;
M*B0]$=<#0]V[.G3J84J"AZ:5/QREJYKE.U11;0A$85!N&X(\_#3B-A;:6S_L
M;EH5)G._-AY1E<TCQO`R!26MU89'6X_#@*\PZ^+4@NQ17":YSFNB>KO*L\J$
M+7.0V%?K?!EGX/B]4;,OR8=F:B/61\EKH5>JS<7W,RBRZHGCR'.&2<MN20@R
M&Q&27O$:4="Q`L"0(0LC^)79VP=@:8QRESB7BX`X!UZZL1*_&J[,)^4YQ27>
M7ZXF9-F9-EDE64@+["=;/&ZKDCBQ4+!:J)[HW]H;;>`X&.9?DU3AF+WV4WDZ
M#65-%62[&;.LY@JZOCC`)SFNESS_`.C#"\GAJD=]&^W]?TX%>]%U1;K,LPSR
MTI+ZLLZRJJ=>-?D$:%\93QR/RS(9..3OLHEG.J)%O>-&I_'V$K[9A8J)[%5P
M6GX#@.`X'097?1\6QC(LFEIYC8]1VUW(:BJBO#5P3S2,;X17>SV@\)X\JJK]
M/KP-<_XPZPF7Z]V]VBNXT1^7=FMOY+>2+N(641EKAFNILS`<.8)LMJ/!$#)K
MK,XF-5XU24KVN5KDX%G-.5,7*MA;GVO.2--)>9/5X?C;OLI`7P<7P&N;7"![
MSQ,.3[O(Y%A-1PT:%4D-]??Q\C@LWP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`K:,`E[?2Y*#9\S.MM<!Y?'[U$39]H08_/
M_N(\3U_YKP+)<"I6I*P@LY[KL1_W)K3;U8=@$(T!6(;KOJ..$'M'53"1Z"\L
M(OA_[O*?HG`U0Y3@XR]@*?"K,<[3N3[IS#K]KW$MF0,WJX^8DE5?2_/14MS4
MXS=SY-I>6>#VL:TA.!(%%?,(]LEHW)'(7@6-G:N_*;H%M4FM-EZU[(8C6#G"
METU_'_M3+"1_O"R8?V=9D4J5$G%=#","_+D['A>]RB1S/`VAJ0V]KO:F,:VD
MXGF^"9/2]B.V/8AD$%'?2&#E5=50Y93U6I&P@414">#9[*S^HN)9EL7M'(A'
M1B>C'%*&]+'MZ[,ZS6&O>NV8Z6/G5'1X_CF#83F.EZS*H=,<%53RX>*XJZ!G
M,=*A<B7'J$2&5E^^(V0YK%(Q[T&T-1_Y&]OW78'+\NM\7PG+PQ0V>GNE6*XI
ML.A=B-OA&<[/<7<_8?)#0S2CVW]PP],"K:YC8GR5SD8]TE3I]JUX;O+E;_IW
MTQJ6ZOPJ9GV0ZQQW#80\6KZB9,GWTJUR6FK\KL6U=88<U4ALN)=B;T<YXHX'
MKX=Z^%#7I09_5)H?`9;;/'Q01=\^UU=.MJ+'\8K]>'M*23O+*PS;RGQ:-7OC
M4XX<%PK*4+_S!922"RRN,1Z.#-.L&R;'KCI7M%N2YQ#"+V%KGK[UQV%"@ZBI
MQ4>.9R.#IJ;:7#<3ESHTK-Y5;972'_CV7;Y4N,,K1B_T_"*&R#K?V#!V$K-G
MSA8A;X<76&V;[4L^+<2(9RVMGCM!B]U-NH"1"/<.ID/R5!`^5&$?\#G^/5S5
M4+'<"#]Y620*G%V38U3)QV3EM;_=BW\]M?0P\>B#DSIMC;*6!-C6$2`6.,BQ
MB/`A%1'*_P`,5JAV6CL)=@N`1:TX[P<^UM[W)[1,BS&;GEJMAD-G(L3(3))R
M,?*B#85C(HAL&&+$:,+&-1G`E[@.`X#@:^OR;[9M]5]3\P%B\G[;-=EVE'J;
M"U:!\@Q,ESZ9_"U<>*)KF-),E22H(357PKG^5\-1SFA.>%X52=5.K>'Z[QB%
M.DUFH-88YAM8*BA$EV$Z=75T*E6RCQ2%*]YYUN9TLSB/5K5>]Y'>$<O`E'5F
M*2<+P+&Z&QDFL+J-7B+D%O*4+IUU?2?)[:WL"@51%FV,TCRD5JJWV=]/IXX$
M@\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*
MJ1;I%[P7F.^J^S.JF+77MZ?1$+MW,8/K\GO]%<H?\OK_`$\^?Z<"U?`I]I6?
M)L-E=Y@H]C$K]U4%?$*]4&C%3K3I>2KGE3ZHP9I:_5?\OUX&N"GJ,FO^XFIJ
MB_UYD5Z?"-W=>IK<]I,:M<FQR0E-TOSV3+S#-,@O@EB8=7UUA:2J^LG5;F_>
MV,\8#>"&(JAN]S')J_"L3R;,+7V_C<7H+?()R#\?*^+40#SS""COHXY6`5K&
M_P#>>J)_7@?.IHZ@R#L7^8ULF938P/3W6O2U9L_XW9'-R#,:[=5S*M&GQ2X=
M)BE%-I\;RS:-DZ)-(<,G[S%TCMCLCQF>0^C'*,CJ,/QK(<MR"2R%0XM1VV1W
M4TBL1D.IHX$BSL93U(YC$;'AQ7O55<B)X^JIP/E)ZD4>5]E.Z^D8UM"2("6+
M..\>\0.%\$&1F78C+'YG@E<=L"78$_DJ;3.+T..`+)+'(*"/]H%:9",#Z#._
M-A'KNK.P"2LTI->QYEMKJF+EV2S+N!0U;+_96(T;V6DK'*RWN11K)M@L3_2`
MK%>=$,\8%(1@:V)>N*5FIM4@R*+KZS+C'?WMIG6OX&8Y72U8LUL68_O\E0+%
MK6C/6P`VP\;GS624,QYA#B2'RF/>A2\##\"H3`ZW_D2QUMMAN*9!(Z[]3X19
M5?F]7>5>.Y#.T!"#7P)&>RL@P&1;1'3B"2!;3[R$PX#C4)P@8S@;,^B=Y7W=
M+V'%&;!=:8OV4S+"<F/#E7<L[LBQ;$<#@SXUH^Z+)1MG#:YC7MB&-"0:L^-_
MGV1`O7P,>RG%:#-:63CF45H+BCFEB%FUDKV=$F+!E@G1ARA-<UL@#)<9CU&_
MRQRM1'(J?3@=\-C1#8-OGU&QK&^?JOJU$1/*_P#).!Y\!P'`<#4]V1B0^Q7Y
M`>K&AB&--Q/1!;7LAL6A.`JU=A:8G$BK@#IT>3#)$GMJ\RO*69%*UZ?"<1$\
M^R)P+K[@--R;/M2:UK)4+X9-U/SO-($@DMA9N(XO$4$2$QL<HQO'/R:QBN<T
MJ$$\<4C59]4<T+%<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`JW%J@-[K7=XC&_<EZMXM5/(CG*Y0`VSF$P;',\>C6M)(<
MJ*B^5\KY_1/(6DX%$-:$N*^1^1.TIZQUU=MW)>RZ.G"0:DMY\#K!IH596-<J
M^@RSIL9`HCE3Q[(J_3@8[CU3:ZTUWAO9_0`7["Q_*=/ZYE[?P"M@++R+9U#A
M^NX%/AN4ZS"R8L6EV%CD`38YJ=K7QK>)[`:Q)X8ZE#KMG[>PS+NHE3?.V34W
MF&Y".TS.XOS9!\.49;JW49S[`V-`#`=5T<TF62:_&G4]C6?9QB1ON2,,,:M<
M-`A'\..`Y/\`[;;PW_G_`,1,VW9MRTKY,@<<XOFAZW-95F1RFF,T;9(;;<5[
MELL9!,09`%%^XGJCN!8#\G>2J+K%+U''GR:^;V6S;$]"2Y<!9?W]9@66RRV>
MYL@#_'HLX$?'M+T.02C2!^/M6,^3RBHU%"H_X=,>B[,-OSM])D1)[MDYI+PC
M`Y$"6>54#UQA[8%'BLG'PSBR)L"@LL.H*4M>UZL>Z$YGNUSU<8P7=_(+8T%O
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ML'(<B$*)6J[]R+P+/<!P'`<!P'`]$F0.)&D2B^?BC`+()ZHBN^,(W$?ZHJHB
MKZM7Q]4X&JWH!CSMD[V[B=PYWW@O]R<SI-/8;7&^\^R@XIJX4NVLK"&DPA/$
MNVO<M2%,<'T"Y]*Q/1KF+P+V8;*CY9M7861_;FC+AJ5^OJ]7$"8-@)(@+^?9
M-</W6.1)MFZ/\*N1R-"CWM:KTX$V\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`KA`>,G;K*6>?]6-URP15;X7Z,F;+V'X7
MV\>/JZ%_\G`L?P*@]>+J"FP^Y[I1HT2)5=D8L21),40@H1^B],R2..Y51@O1
MLE$5SU3Z(BK].!%N%9AB^MV=A=$9U&=6ZXPBU!M'7M]BLL%['@Z9V9/GW];,
MB4U%';:5,#7NQJBWKFC$&4P8!1'(Y6$\-#65^3[)Y>"TV?;.ZY5>/91-S),4
MP;8^N\>DU;KY,@MLCF65GGL^*ZQCMP^WV798?C.(B92.),RR5=)"LA#,`!PA
MN9Z/UFOL>ZHZ-Q+6U\+(J'#L$JL4L;%63(UD_-*)BP]@CR&NLVCMZC)VYJDY
M;*),8R7'F.>PK4<B\#4S^6/:=V?;<R/C4R6@>M>@;T%&R':NH8<WL;W0)8Z1
MPBGM;IMI4()^+:/A9;=K'<<7L*2,C/<S0MX&)],N[.LL(T=KGK5JNRE=>X6/
MN&/+]Q[BUS>XY!-26R2[6/:Z>P?)JO'9-O$)1DB-BW=U'#416"(K@SE&K5"T
MPK6FS+X5Z3I_?[+.9"N]R=N<O-`VG>Y]7*69CEE3XSB-S*B76T)$6#)FF@^K
M:[!:<XD:`<IZ_9J%@]0F2DIK?$>L,"IVIM"Q(`6W^TV=,FGP61E@?>/9+:W4
M.6^SV#D%)]NX(<:Q^0*HI_(P/D5[$07`M3KG2%%A%H_,[ZWMMC;4GPG0;C9>
M7*$UNZ&4JR"4^,U8&,IL&QAAG?Z==5ACB<B-<=QRHI7!-G`<!P'`<!P'`JGW
M<W7"Z_=7-P[,E?&Z15XA:0:@!%,B2;FWBEKZX*?;M<9/]8_MY:GEJ-\_TX&#
M=6,*!U"Z':XJ[]K77.$:HDY]FS9CQ0G3]BY>R=L#,(9#(BC&Z7FV12(@5\>$
M9\;4:B(C4"Q6C:.71:QQL=E3)CUQ;,GY'=TJ6!;5*RWR2RF7<^"VQ.KC2AQ9
M$Y6-5?T1/"(B)X0);X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.!4RE!-=WGV1*<XJ5X^J>FHP6>?('3";:WD:05$\_0R!8
M-J_3_*B<"V?`HEUMJ/Y_*.^,=DVQKR3>V]K'#.JC`!81S5^B=%1VNCDE1Y<5
M5]F*U4*(@W-545J\"K_;O0>X\GJL'S;#Z'!*_9&+VDF+>NSB7E6O\;R[57\Q
M`R>7K^[S;1D7)!FNBYKB-%8P"V-*M:\(3@E#5ABM4-7>3Z=[4Y/EM=E?;*M:
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MG!>UJI\B._;P+S:X[`:8VV-7:^V-C&126-$X]6"Q%&NXBF$([&2Z6=]M:1R*
M(S55'"3Q[)_CP)AX#@.!@P,YC2,QL<0'5V)"UHFEE6@6C)`C(E?'L"-F>7,,
M!59,"P7HTORO>J?3U=X#)*6\ILDK8]SC]I`NJF7[K$LZR4&;`E((C@D6/*CO
M(`S1E8YCE:Y41S51?JB\#M>!JA_(5%#O+;_4'J`PYG56P-P4^R=F1HX4D-EZ
MXU6I\OO*:6YK%="C9`*F6M.3V9_IV")^YKE8X+7]K""N\>U]J^ON8$6_SG9V
M"EC8S*B39#,LQ_$<FILAR*I,2')A@@5HXT<1I3CO<(L49`((SB(S@6N:B-:C
M6HB-:B(U$1$1$1/"(B(B(B(G`_>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@5]J!L=VHS\J-1'"T#J03W(B>SOFV'NE[4<
MOCRJ-0'T_P`//`L%P*F]:ZJ9%N^VSON6AD6O:;+9L60V.)WVXG:PU)%`KA+Z
MM.\?VR^5=_F_KP)T2QSJG`9]I2UN1#9,:T1Z"6Z#.6`1XV?,:LL_(/G`KG.<
MT<IWLQJ>/W>4X&-WI-:SHA,COZP]'.:HYS9DN+88YD#IL)2C@"%(B.BS)DY[
ME5``:\BF0GJC7(Y44*"9/H76>\=KQXEKBU)_*FD0SO$2CB8SFD>-A,N!;DCY
M+LS6YZ'*UKDR,1/FKS2SCD%DD:0"C0BM"L_87\;V17N4GR7`MNYUA^<W^+W>
M"YA#S"F@]A<5S_&SRPVE%>W3*J=K3-<5S7"(Q#0:>_63\Q(ZDCV*S1/&UP63
MU%UTPC75#D4N_P`2C9^._P`=;36&5NK(F89*_#CT@8C=:-K0+07>&8=5*(GV
M=5BE=!K7"D+\[94AKI9`S._T_@VQJ9N(85G^04R$UN365;41K9N6TM-@*3X#
MK7$Y6%9$6ESF)&RVGB"B6B-*LH48#5'($<(B.#KM@V/;.<"ID57\1=U=0_"0
M1KC2N1VF&W->N-YG$N\EFV&I=@RJ^;:%R3"(3JE:I;.6UCC.+]&B]B!+V[.T
ME+5A?2XO14>22Q6MQC,['MC4U[0R<FS>!75-[2:PP^EO*^N+DF0Y]42)3:ZQ
MCMEU030RH1[U&0:!"N^>JW2:-:_^;:YR;4>1VL''I%ME.FB'Q>MH'YSE$;$L
M?E7M;`DKB,B5-RZ2T+2)622J1GERHU4]@Q69HCO+UZ:M#HKMCA.TX<DPO[5U
MQOE`TV41X*HQ"0:NY5<D!?F5T<KT3X*QJHTGAZ*Y%&'?P_R![DU9)#6]L.HV
MS-;@')=#/FV$QDSK$)B1XQOFGPIM&6UJQQ2R8SGHV181SL"4?^DY5X%N<`[D
M=;]G5RS<1VECTJ7]F2:.AE'2#D<@#0&DL6!2RE'*M'$CA5Z-C(543Z.\.1R(
M'697F5]@V"93FYYQ;#,<XQR$FOM5V=Y$=:AR"V>\"QJZ;!BMM)(_N[F,XZ"$
M5D"/&1&*B(KE">=:8B3`M?87AA[*1=2\9QBEIK"[EN5\R[LH%?'CV-S,>YK7
MDEVLUA)!7.3V<\BJOU5>!G"JB(JJOA$^JJOT1$3]55>!JFZY#MM[_D,[,=@)
MT0;<`T5AU9UQU4=R(45OD606,;+-D9+$]R$='/%@4=5#1WH%WQ2R-5'HOMP+
M,TM[$V?VKN$K[&;9T>CJ(]-.KR5:P(&/;%LHJBDR8MF5CC9`6UQG)5`[XW"C
MQ70GM]2E57""X'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`JSC]X5_=/:N.(QBA!UIT?<.)Y3W0I]E[XAM'X_P`WHK!*
MOG]//`M-P*B]5YYIV3=POE<BCA]NLL@1D3_NACZCTM[(O^*_<O(O_;P+=<"#
M=T6@_P"(I`JQ#4[+#^XK29'M&PR!9CJ)+J(S!C*DBQ#;9$L6*<+&$:X#B,(G
MAR(H5ZU7!)<XZEYB5K8EM[6OHL.BI&R6`*=*@3)0"7F5F/"A6,5(C*OTEPG#
M1?W?Z;G#>YSN!4+:78+']@W.&Z[U[O*#UTG:[VI+/;YW?RWXA(RZG9(MZK^'
MHUE7V0UN17YYM6T,FNR:16GD!.&6L?U*-$#T3-Y]I^O]59YKMG'\0W[I6PM,
M==@&P,5;+R3/9>/6.8,IXU/D-YAD1K#EHH!6VA+^5'$%(Z`"Q"G4J\"SVJ]Q
MZT[&Y!%P2!`S#'<TC8^#9SM<;-P^%=V%)C<R_P`DQ44F;D<$MM!QA[+?'CB8
M-D\4AYD]!^_J?T">+/`\M@&5C3V(*]S'R`PT(+.ZQ9(8Z&0#:_(V-MZY"':H
MV.B64?\`[JKZ^?9H8P>2::+^W,OQ[&,Z-#?`NI44**8Z%8QB5186,9R^2.ME
MQI,=L@7V5TI&E:JL<[V=[!#UKJO33+&HN*S^1P+(\.LHLW&1S)9;&&"V]ER"
MKKXF!;6?(H)MC7V@7&C,K9SD#)8YXB#*XCD#(<_UG9WV<X/EN:5ALGNJ6=A.
M09%?X`;&,3L,DR+4V0ERK7M?44&7+96U?%N'7CP6,:%?-!)&Q['IZ$\<#E;"
MWYL0F?+7XK/@4E;'DT4B/B^2U\6I//I68UD"YA`R`UT^'*;D43+SUD:,E266
M)C/_`!$7R5$#--E]7.OUCK<5E:ZXIIM]08R.OJLDQOVH,FF64OX8T8O\_1EJ
MI4LDFV.CD>1Z^/D=Z^J.5%#6AB>K<]UMGV86W7GMFW#CXO1X@8M;VCHZ&31W
M6!WT6[H\:GXEGU*<SDA#M-?V;8\.PJ1SP@C.4O@#D>X+(57='MUJ&KB-[!]4
M<CSRI<R3(%MK0!8N=X+8484_Z#(RFH9-I*AQ[@;Q$1AXL/T^5?5'(U4:$K0O
MR6=6L]U[L"SQ?/AP<IQG$\DM).%Y,*1CF1I_'1)",2.KE>`KY7K\@%`9Y7B:
MI&M_;P.H_&?A;]4=)<?S^TC39^5[J-F?9G(80D)+L[+_`'#*^[Q6N@`4+9II
M;-?0J>,T*H1_W*.1%\*U$"7^EN(7=!B&8WN4PB1LIRK*CV-^:45Q[&1=6#Y6
M7Y*&P>4QS1RU.:9G:PF1G/<D44=HFJK6M\!<_@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@52Q:N5O=3<MNX;D^?KOHNL
M85SE5KV0\[W;+4;&>$:Q!OGJJKY57*[Z^/"<"UO`J)U/B_;VW;(WU_Z_MWL>
M4JJ]K_/QX7K.`G^7_*B)"\>%^J>.!8G.)1&TKJN))@Q[.]D1ZJ`VP64@)"2#
MC_D@L^S5LATE*=)#QM:YO[VHJN:U%<@1/NNJK(>.UU31Q0"R":@:FK$))OSD
M@++:P056%.KW_"Z^L(RO5YF^ZO<O[G<#.<+U+B.'0Z1L>M#(LJ,A)$.R.*/]
MU'D'C28CVQU`(0HT2/$F%```FL"$"HUC4\<##]J]6]$[EC.9FNO*`EJVR9?0
M<GJ(,6GR>LR6.L5]?D\6VA@821=U<B!'+')*;(8T@!^S'(U$X%-LY_'IFM;'
MM+[K[V'R/66?0ITJYQ2PG5*RJ>;=7%C>3\GO=H0*6=6#V7D5NS*[5@)$H(@0
MGR`O9&<L4?D,RTGC?9G$-IUV*97B8HU+D-+EMMG.S847%2QJZ**1,F:\J(V3
M4JX^S*\HB7EW,;(@$Q>)%!&*4Z2R.5ORA?VK!=0T,&SF1[.,"-$;#ELCJ"TE
MR&,*L\T]C'-@I\K_`$^)H6L1/#O/ZIX#')IL5M)`:^_H313VTZ+%C):5CV#L
MI\4!;&*-DJ.IAD?&8`CV*]S4:K%\?54\AT$C4^(RJW^+IF0PU`0?;CHY(`9#
MCSE##^P"R5669)`RM'\+/*(]CU4:I[)[/\A'1M27-5&(`*$=&>IYB`HBB2H6
M25B#)'D8QD3[VK^21_JO<2*R&QC">GU57/X&,RA9-'=`A2H\:VKZV&\\NLNZ
M!:=BFL)1&TS#0LD'<XS))#(Y&JD>?#4YB.>YK'-8U@8S9PL6<^KBH#*]6"AW
M%%?TTZHMI55CBVE7/-9@]J>[%<:MFQ9,SU(P<:6KC,%[?L]6HX.-;X,J`<^-
M18)<'L[2URHUU@,&AU=GHHQ:BWQF1-/+R-MU@F1SR1LFF@DC=+B!]99#";Y5
MS7A'6%XMC6#[8U'4UV=Y#K;#]?@I*'&\+SU,NH[=U!A6N\@QI^"T\P;5UWG-
M)E$RY2_GS$DNG19E<H_4@F^(P<CLWU"H>SFR\>FW^I];;!UU>2\9A760R`XS
M"=%P0$>X#L(5S;U8:[8]ID61P[ED:A=76;(T%PR&,C/"LD!BVRL.M,PV%&P2
M9B%UCV%T&P\(P#^-B!LL:K\:Z^ZOJ)>0GR/$LVC6$*/8TF7UTPT*T@5[3645
M\<87HP+2D8%P="Y0\5)B-&1'&BY?3V^?QKJ>AP6UI:YA<VN93*\E>L=7,94U
MER#W.5XT:BC$C4=^U`LHR5&(5X!G&\PU<A!-<BO8K?7V1S4^K?'NG_MX'(X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!6S
M%C")VOW$'Y&J>/IG2OD7G][1&R;;;FO\?T8Y[%3_`)IP+)\"J?78@KM_9^)#
M(:G>/LYL2L)-K%CCELDBQG!/DG"4P9(&RG*]/J\;D54\JB^>!,T'%,J#D]39
MVN7LOJ6I!>+'A2::-!LTF6200P"GG0#!ARA5\0<EB^8S'$4[5^BL57![KK`8
MUYF=!E\NQ.O]OA1D:J^VB.`XC"'.TK9?QI,&CY1!%(SV5KGQ0^$3P[V"0.`X
M#@.`X'XK47QY1%\+Y3RGGPO^*?\`'@8Y+Q2GDRPSA,DULL)Q'<:GF2:I92B*
M(OQ3F0B"%-`10HUS2M<BL5S?T<[R'6VL3/`SY4W'K3'Y<(PFJ*COX<T*"D,1
MK5<"ZKBD*$)FM\JQ\4WJ[RJ+]?H&7GC`EQWQI@`R0F8C#@*-I0%3Z*K7C(CF
MO9[)^BIP,)G:]JS@LQ5L^WQ]UG%/%5]3,\#A-D!C!5T&#-',K0?"D5KAL^%1
M,>YZHWR]WD(,-H3((#CMK9.-3HXT,Z(^$R9@=E,(26*1ZW8*`$_#;3Y/)'N*
M6G4CBJGLCF*YO`R4^KLVQ($F3@EG1WA!UZPJVAO_`+C%8@FD(U\A3'QZ/.QN
M7(.Y553&I'$]?=BN5#/5`Q>=UY6L'4V&`1?[$M(.(ICT2+@F4V>&P,?D2;8=
ML2;$QN)%EZ\R*;73Y,@HSSZCV>-Q`>/B.YB!UCM%[GL<UMLPS39V*9\F/X'E
MF&:LA2,0EXL:([.W5_\`<UIF+JF[EUDJZ6)31H46;`BQ59#)(]A>Q/'`EC6F
M#Y!0`C&OZ^HCGH*`=#BX`2F3ID".T`(D@9;@4.$Z1'E0JJ`)?D$XBK&1[E5R
MJG`[76FL(6$.G7DE(TC+,@C!2_L(P%`PIGS9US-$WR4CCC)>V\L[7N\.\&]?
M"-:U$"6>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@4^P,<A_>+L:=[G?;"T)UJCA;[^6(4F4;[,=R,_1KG-:SRO]41.!<'
M@>H0``^1`!$%"E><OQ#8/Y3$\?(8GHB>Y7^$\N7RJ^.![>`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%;\RW9LG&LSL
M\9H^L>U\WHZ^LOIHLXHKC7$.ALYM3CBW5;3U\2[S"MNGR\BLW,K(Y"1AQQR7
M.<8@Q,<_@86#LKMQ(V-&L.FF]X\C(J>LM94*'::ML7XF>=8V\*339+)9G(([
M;6KCUP91FPUEB4,P:,>\B/8T);SG;&185@]!F,;2FT\XGVL>*>TP7"(^*669
M8XZ17K,)'FQK/**>FEGB2$^W(D>:1OR?5JN;]>!"8NV.Q2SYL=W3/LU&@1H>
M)SX]F:FP=XYHLGRJ+C,J$*%'S8M@.VQ,$O\`D[0+A_&*M$4@B&<UK'AUTWN/
MG$#^04W2OMH5D'&9&2,?`PO%+'[X@IRQ@8Y#'$S1YWY'*B(DCX%8C1L7U5ZD
M\L0.4G<3*49;O+TU[>,_CMB3<#AM9KW%3/NZZ%63[!NQZYH<Z?\`%@4XT!8T
M<LE8\YQS"1T9B/1>!E7_`*HKA_W0P]9>S!),41'?`37L**.4<"&^:-$FR,@'
M"*Y"!1C'^Z!(KVN8]S/+D#PB]I;LW]T_==8^RM;_`&N"I.J2<%J3/R);%\(<
MJ/BK(.2RENI%0Z8JG:U6(K`$<Q7HU/(=,3N2(&4#QJ5UK[71Q'6,R/D_^S5A
M)Q8Y95-;W2#_`)&%92I,=`CJ?MBO*!C1SI4<"_4BN:'G'[EP#QR'?US[70_6
M[NZ0+9VE;0'W2T1PQRV@%2P+YI[1YD^P,J)]WX7U1$^O`Z*5WMHH4^RKS]:.
MY#WUE_3XX^5"Z_W=A`L)MNHO,RFEP[(PK:EJ&E\SIHO,>/Z._<Y4\<#,`=P\
M4/D28U_M!V2CR4V9DNLGVDW2&70\=8;%XI)<G.?YTX602:UMA@(RLMV.<.P*
MQ!B8KGC1X<"Q[MZWJ;"LK['7'8N.EM2YA>Q;`>@MCS:IL?#G3OF@RYL"FDI!
MN\B#7N)40C-9)GM()$8UY$;P,<SCM@&VUS<9UKYNS<*%AU3B&4Y/#R7K1L/,
M\GFTV;RYE;3U-!@\.TQ>YM;Z*:.DFP##?*-6Q?"R!L5_T"NDWL;OO^+6\@;Z
MDI!?.2+&C&_'EN";92GFIY5T`4:IB[2!<O8D.`]$(X#4><@PI_J.1O`Y8>RF
M_*K*FXW>[RQR0:/E8,.G!'T'WS$3^5E284()Q7@ML3*-E(V38B4E@KG1!C0C
MGN:T;W-"R/4Z=,V+D^W-Y6&5RLBF9&[%-6DASM(YMHV35MU>[([1DI*3/+JY
MM<@C7*[!<\-B!1P2#$UHO=4>J!=G@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'XGZ)_R3
M_P";@?O`]3O_`!1?\B?_`#-X!?\`Q%__`)2__G<#U/\`_O-?_P#73_\`MIP/
1:/\`S/\`^0__`,W@>W@?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Regulus<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Regulus [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">REGULUS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 4 - us-gaap:EquityMethodInvestmentsDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>4.&#160;REGULUS </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In September 2007, the Company and Isis Pharmaceuticals, Inc. (&#8220;Isis&#8221;) established Regulus, a company focused
   on the discovery, development and commercialization of microRNA therapeutics, a potential new class of drugs to treat the pathways of human disease. Regulus, which initially was established as a limited liability company, converted to a C
   corporation in January 2009 and changed its name to Regulus Therapeutics Inc. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In consideration for the Company&#8217;s and
   Isis&#8217; initial interests in Regulus, each party granted Regulus exclusive licenses to its intellectual property for certain microRNA therapeutic applications as well as certain patents in the microRNA field. In addition, the Company made an
   initial cash contribution to Regulus of $10.0 million, resulting in the Company and Isis making approximately equal aggregate initial capital contributions to Regulus. In March 2009, the Company and Isis each purchased $10.0 million of Series A
   preferred stock of Regulus. In October 2010, in connection with its strategic alliance with Regulus formed in June 2010, Sanofi made a $10.0 million equity investment in Regulus. At March&#160;31, 2012, the Company, Isis and Sanofi owned
   approximately 45%, 46% and 9%, respectively, of Regulus. Regulus continues to operate as an independent company with a separate board of directors, scientific advisory board and management team, some of whom have options to purchase common stock of
   Regulus. Members of the board of directors of Regulus who are the Company&#8217;s employees or Isis&#8217; employees are not eligible to receive options to purchase Regulus common stock. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company reviewed the consolidation guidance that defines a variable interest entity (&#8220;VIE&#8221;) and concluded that Regulus
   currently qualifies as a VIE. The Company does not consolidate Regulus as the Company lacks the power to direct the activities that could significantly impact the economic success of this entity. Under the equity method of accounting, because the
   Company has guaranteed the debt of Regulus, the Company will continue to recognize its share of any future losses up to a maximum negative carrying value, or liability, equivalent to the amount of debt guaranteed by the Company. The Company&#8217;s
   maximum exposure to loss related to this VIE&#160;is limited to the carrying value of the Company&#8217;s investment, as well the portion of Regulus&#8217; debt, including accrued interest, guaranteed by the Company, which was $5.5 million at
   March&#160;31, 2012. At March&#160;31, 2012, the total negative carrying value of the Company&#8217;s investment in Regulus in its condensed consolidated balance sheets was a liability of $0.3 million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company accounts for its investment in Regulus using the equity method of accounting. Summary results of Regulus&#8217; operations for
   the three months ended March&#160;31, 2012 and 2011 and balance sheets at March&#160;31, 2012 and December&#160;31, 2011 are presented in the tables below, in thousands (unaudited): </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="78%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Three Months
   Ended</b></font><br /><font style="font-family:times new roman" size="1"><b>March&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Statement of Comprehensive Loss Data:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net revenues</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,441</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,309</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Operating expenses</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#160;&#160;&#160;5,525</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#160;&#160;&#160;5,459</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Loss from operations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,084</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,150</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other expense</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(67</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(139</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Net loss</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,151</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2,289</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="78%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>March&#160;31,<br />2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December<br />31, 2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2"><b>Balance Sheet Data:</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash, cash equivalents and marketable securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,508</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">38,144</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Current assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">32,929</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">38,666</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total assets</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">37,295</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">42,881</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Current liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">22,220</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">12,850</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Non-current liabilities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">15,817</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">28,834</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Notes payable</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,253</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,259</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total stockholders&#8217; (deficit) equity</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(742</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,197</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for equity investment, or group of investments, for which combined disclosure is appropriate, including: (a) the name of each investee and percentage of ownership of common stock, (b) accounting policies for investments in common stock, (c) difference between the amount at which the investment is carried and the amount of underlying equity in net assets and the accounting treatment of the difference, (d) the total fair value of each identified investment for which a market value is available, (e) summarized information as to assets, liabilities, and results of operations of the investees (for investments in unconsolidated subsidiaries, common stock of joint ventures, or other investments using the equity method), and (f) material effects of possible conversions, exercises, or contingent issuances of the investee. Other disclosures include (a) the names of any investee in which the investor owns 20 percent or more of the voting stock and investment is not accounted for using the equity method, and the reasons why not, and (b) the names of any investee in which the investor owns less than 20 percent of the voting stock and the investment is accounted for using the equity method, and the reasons why it is.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382943&amp;loc=d3e33918-111571<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 32<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6903645&amp;loc=d3e32787-111569<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 35<br><br> -Paragraph 35<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6903645&amp;loc=d3e32847-111569<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestmentsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>19
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]"86QA;F-E,3PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970P,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E
M9%]#;VYS;VQI9&%T961?4W1A=&5M93PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M
M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7
M;W)K<VAE971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H
M965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM
M87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0\+W@Z3F%M93X-"B`@("`\>#I7
M;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M
M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K
M<VAE970^#0H@("`@/'@Z3F%M93Y3:6=N:69I8V%N=%]!9W)E96UE;G1S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A
M>&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5G
M=6QU<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$
M(E=O<FMS:&5E=',O4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K
M<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O
M;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$P+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^,C`Q,E]297-T<G5C='5R:6YG/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#$Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5B<V5Q=65N=%]%
M=F5N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`\+W@Z17AC96Q7;W)K<VAE971S/@T*("`\>#I3='EL97-H
M965T($A2968],T0B5V]R:W-H965T<R]R97!O<G0N8W-S(B\^#0H@(#QX.D%C
M=&EV95-H965T/C`\+W@Z06-T:79E4VAE970^#0H@(#QX.E!R;W1E8W13=')U
M8W1U<F4^1F%L<V4\+W@Z4')O=&5C=%-T<G5C='5R93X-"B`@/'@Z4')O=&5C
M=%=I;F1O=W,^1F%L<V4\+W@Z4')O=&5C=%=I;F1O=W,^#0H@/"]X.D5X8V5L
M5V]R:V)O;VL^#0H\+WAM;#X\(5ME;F1I9ETM+3X-"CPO:&5A9#X-"B`@/&)O
M9'D^#0H@("`\<#Y4:&ES('!A9V4@<VAO=6QD(&)E(&]P96YE9"!W:71H($UI
M8W)O<V]F="!%>&-E;"!84"!O<B!N97=E<BX\+W`^#0H@(#PO8F]D>3X-"CPO
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M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%!044^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;CQB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&]C=6UE;G0@86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D%,3EE,04T@4$A!4DU!0T555$E#04Q3+"!)3D,N/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C`P,#$Q-S@V-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1O8W5M96YT(%1Y<&4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C$P+5$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT(%!E<FEO9"!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^36%R(#,Q+`T*"0DR,#$R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!;65N9&UE;G0@1FQA9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XR,#$R/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!&:7-C86P@
M4&5R:6]D($9O8W5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y1
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^+2TQ,BTS,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A=&5G
M;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!8V-E;&5R871E
M9"!&:6QE<CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^16YT:71Y($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,2PY-#DL.3,Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%+
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0Q/CQS=')O;F<^0V]N9&5N<V5D($-O;G-O;&ED
M871E9"!"86QA;F-E(%-H965T<R`H56YA=61I=&5D*2`H55-$("0I/&)R/DEN
M(%1H;W5S86YD<RP@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,3$\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0W5R<F5N="!A<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C$L-S,Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,"PR,C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DUA<FME=&%B;&4@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3,W+#,U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C<V+#$W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0FEL;&5D(&%N9"!U;F)I;&QE9"!C
M;VQL86)O<F%T:6]N(')E8V5I=F%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR+#$Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P86ED(&5X<&5N<V5S(&%N9"!O
M=&AE<B!C=7)R96YT(&%S<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-RPR-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT+#$U.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-U<G)E;G0@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,#@L-3,Y/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34R+#`R.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36%R
M:V5T86)L92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,3<L.#(R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3$T+#0P-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@
M;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPW,#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PV
M-#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DEN=F5S=&UE;G0@:6X@:F]I;G0@=F5N='5R92`H4F5G=6QU<R!4:&5R
M87!E=71I8W,@26YC+BD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DEN=&%N9VEB;&4@87-S971S+"!N970\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(W-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0P+#(Y-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X,2PY,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C;W5N=',@<&%Y86)L93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#@P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E
M>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,#`V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3(L,S0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XV,#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0X+#0Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8R+#,V-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YV97-T;65N="!I
M;B!J;VEN="!V96YT=7)E("A296=U;'5L<R!4:&5R87!E=71I8W,@26YC+BD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!C
M=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-BPV,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX,"PY.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0L(&YE="!O9B!C=7)R
M96YT('!O<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,C`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,RPW,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1E9F5R<F5D(')E=F5N=64L(&YE="!O9B!C=7)R96YT('!O
M<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R+#,W-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<X
M+#0X-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3W1H97(@;&]N9RUT97)M(&QI86)I;&ET:65S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW,#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,38\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!L:6%B:6QI=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30R+#DQ-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$V,RPY
M,C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UI=&UE;G1S(&%N9"!C;VYT:6YG96YC:65S("A.;W1E<R`T+"`U
M(&%N9"`V*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U
M:71Y.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F5F97)R960@<W1O8VLL("0P+C`Q('!A<B!V86QU92P@-2PP,#`L,#`P
M('-H87)E<R!A=71H;W)I>F5D(&%N9"!N;R!S:&%R97,@:7-S=65D(&%N9"!O
M=71S=&%N9&EN9R!A="!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB97(@,S$L
M(#(P,3$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,2!P87(@=F%L
M=64L(#$R-2PP,#`L,#`P('-H87)E<R!A=71H;W)I>F5D.R`U,2PX.3,L,C4X
M('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG(&%T($UA<F-H(#,Q+"`R
M,#$R.R`T,BPW,C$L.30R('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG
M(&%T($1E8V5M8F5R(#,Q+"`R,#$Q/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#DL,C8P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$X+#<S,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06-C=6UU;&%T960@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64@*&QO<W,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C4I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-U
M;75L871E9"!D969I8VET/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@T,3(L,S8T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#0P,"PY.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@<W1O8VMH;VQD97)S)R!E<75I
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y-RPS-S@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3<L
M.3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,T,"PR.34\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#(X,2PY,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D7V1C,3DV-3<Q-3(V-0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8C@U,S%C,5\W,3-E7S0R,C9?
M8F%E9%]D8S$Y-C4W,34R-C4O5V]R:W-H965T<R]3:&5E=#`S+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%-DY!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY#;VYD96YS960@
M0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A5;F%U9&ET960I("A087)E
M;G1H971I8V%L*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYD96YS960@0V]N
M<V]L:61A=&5D($)A;&%N8V4@4VAE971S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T
M;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R
M:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T
M;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3(U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K
M+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU,2PX.3,L,C4X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-#(L-S(Q+#DT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@
M;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q
M+#@Y,RPR-3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,BPW,C$L.30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P15A9044^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^
M0V]N9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-O;7!R96AE
M;G-I=F4@3&]S<R`H56YA=61I=&5D*2`H55-$("0I/&)R/DEN(%1H;W5S86YD
M<RP@97AC97!T(%!E<B!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P
M96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M(&-O;'-P86X],T0T/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYD96YS960@0V]N
M<V]L:61A=&5D(%-T871E;65N=',@;V8@0V]M<')E:&5N<VEV92!,;W-S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(')E=F5N=65S(&9R;VT@<F5S96%R
M8V@@8V]L;&%B;W)A=&]R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R,"PU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(P
M+#@Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/
M<&5R871I;F<@97AP96YS97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D
M979E;&]P;65N="`H,2D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(Q+#`W-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\<W5P/ELQ73PO<W5P/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C8L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&9N/CQS=7`^6S%=/"]S=7`^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D=E;F5R86P@86YD(&%D;6EN:7-T<F%T:79E("@Q*3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L-#`V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CQS=7`^6S%=/"]S
M=7`^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PR,C0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/'-U<#Y;
M,5T\+W-U<#X\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M=&%L(&]P97)A=&EN9R!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,S$L-#@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S8L-3<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F
M<F]M(&]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#$P+#@Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PV-S8I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R
M(&EN8V]M92`H97AP96YS92DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!I;B!L;W-S
M(&]F(&IO:6YT('9E;G1U<F4@*%)E9W5L=7,@5&AE<F%P975T:6-S($EN8RXI
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X.#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,2PP-S(I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y);G1E<F5S="!I;F-O;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C,X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3W1H97(@
M:6YC;VUE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&]T:&5R(&EN8V]M92`H97AP96YS92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0W-2D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@V,#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&QO<W,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$Q+#,V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M-BPR.#4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@;&]S
M<R!P97(@8V]M;6]N('-H87)E("T@8F%S:6,@86YD(&1I;'5T960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,"XR-2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#`N,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y796EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@=7-E
M9"!T;R!C;VUP=71E(&)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!C
M;VUM;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0V
M+#(Q,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0R+#,T-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUP<F5H96YS
M:79E(&QO<W,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,2PS-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,38L,C@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^56YR96%L:7IE9"`H;&]S<RD@9V%I;B!O;B!M87)K971A8FQE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<S,BD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E(&QO<W,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q+#(T,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-RPP,3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/DYO;BUC87-H('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;B!E>'!E;G-E<R!I;F-L=61E9"!I;B!O<&5R871I;F<@97AP96YS97,@
M87)E(&%S(&9O;&QO=W,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$9FX^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E
M;&]P;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8V-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1F;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I
M=F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,2PP-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$9FX^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-#4W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&9N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&0@8V]L<W!A;CTS1#4^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1I;FYE<D9O;W1N
M;W1E/@T*("`@("`@("`\=&0@=F%L:6=N/3-$=&]P/ELQ73PO=&0^#0H@("`@
M("`@(#QT9"!C;VQS<&%N/3-$-"!V86QI9VX],T1T;W`^3F]N+6-A<V@@<W1O
M8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V5S(&EN8VQU9&5D(&EN(&]P
M97)A=&EN9R!E>'!E;G-E<R!A<F4@87,@9F]L;&]W<SH\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?-F(X-3,Q8S%?-S$S95\T,C(V7V)A961?9&,Q.38U
M-S$U,C8U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S9B.#4S,6,Q
M7S<Q,V5?-#(R-E]B865D7V1C,3DV-3<Q-3(V-2]7;W)K<VAE971S+U-H965T
M,#4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5#2$%'/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D-O;F1E;G-E9"!#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L
M;W=S("A5;F%U9&ET960I("A54T0@)"D\8G(^26X@5&AO=7-A;F1S+"!U;FQE
M<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^36%R+B`S,2P@,C`Q,3QB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@;W!E<F%T
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B0@*#$Q+#,V."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B0@*#$V+#(X-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^061J=7-T;65N
M=',@=&\@<F5C;VYC:6QE(&YE="!L;W-S('1O(&YE="!C87-H('!R;W9I9&5D
M(&)Y("AU<V5D(&EN*2!O<&5R871I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N
M(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,3(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PS,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/DYO;BUC87-H('-T;V-K+6)A<V5D(&-O;7!E;G-A
M=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPQ-38\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$R
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0VAA<F=E(&9O<B`T,#$H:RD@8V]M<&%N>2!S=&]C:R!M871C:#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.38\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,S@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!I;B!L
M;W-S(&]F(&IO:6YT('9E;G1U<F4@*%)E9W5L=7,@5&AE<F%P975T:6-S($EN
M8RXI/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5A;&EZ960@9V%I;B!O;B!S86QE(&]F(&UA<FME=&%B;&4@<V5C=7)I=&EE
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<U*3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY#:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"
M:6QL960@86YD('5N8FEL;&5D(&-O;&QA8F]R871I;VX@<F5C96EV86)L97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#<R-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#,P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YC
M;VUE('1A>&5S(')E8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,"PV-CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!R97!A:60@97AP96YS97,@86YD(&]T:&5R(&%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY,S(I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PY
M-S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#$L-#8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#,L-3$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<R!A;F0@;W1H
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U,CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S@P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R,"PP-CDI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.2PX.3@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@
M86-T:79I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S`L
M,C$U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8L,S`U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T:6YG
M(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!U<F-H87-E<R!O9B!P<F]P97)T>2!A;F0@97%U:7!M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R-C,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R
M96%S92!I;B!R97-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#$V,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!U<F-H87-E<R!O9B!M87)K971A8FQE('-E8W5R
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q."PR,3`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-#$L-SDP*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V%L97,@86YD(&UA='5R:71I97,@;V8@;6%R:V5T86)L92!S
M96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPP
M-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-"PQ,#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@8V%S:"`H=7-E9"!I;BD@<')O=FED960@8GD@:6YV
M97-T:6YG(&%C=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#8U+#4Y,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,BPR.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V%S:"!F;&]W<R!F<F]M(&9I
M;F%N8VEN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&5X97)C:7-E(&]F('-T
M;V-K(&]P=&EO;G,@86YD(&]T:&5R('1Y<&5S(&]F(&5Q=6ET>3PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#0W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!I
M<W-U86YC92!O9B!C;VUM;VX@<W1O8VLL(&YE="!O9B!O9F9E<FEN9R!C;W-T
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#8L.#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y087EM
M96YT<R!F;W(@<F5P=7)C:&%S92!O9B!C;VUM;VX@<W1O8VL@9F]R(&5M<&QO
M>65E('1A>"!W:71H:&]L9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,S(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYE="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A
M8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RPS
M,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T("AD96-R96%S92D@:6YC<F5A<V4@:6X@8V%S:"!A;F0@8V%S
M:"!E<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M."PT.#DI/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S+"!B96=I
M;FYI;F<@;V8@<&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW,"PR,C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XW-"PU.3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',L(&5N
M9"!O9B!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-C$L-S,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`Y,"PU.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D7V1C,3DV-3<Q-3(V
M-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8C@U,S%C,5\W,3-E
M7S0R,C9?8F%E9%]D8S$Y-C4W,34R-C4O5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4U5-34%262!/1B!324=.249)0T%.5"!!0T-/54Y424Y'(%!/3$E#2453/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL
M(%!50DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O
M14XB(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT
M<F%N<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G
M9V5D($YO=&4@,2`M('5S+6=A87`Z4VEG;FEF:6-A;G1!8V-O=6YT:6YG4&]L
M:6-I97-497AT0FQO8VLM+3X-"B`@(#PA+2T@>&)R;"QN<R`M+3X-"B`@(#PA
M+2T@>&)R;"QN>"`M+3X-"B`@(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/"]B/CPO9F]N=#X-"B`@
M(#QF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^/&(^/"]B/CPO9F]N=#X-"B`@(#QF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("`\8CX\
M+V(^/"]F;VYT/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXQ+B!354U-05)9($]&(%-)1TY)
M1DE#04Y4($%#0T]53E1)3D<@4$],24-)15,@/"]B/CPO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^/&(^/&D^0F%S:7,@;V8@4')E<V5N=&%T:6]N(&%N9"!0<FEN
M8VEP;&5S(&]F($-O;G-O;&ED871I;VX@/"]I/CPO8CX\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP
M<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!A8V-O;7!A;GEI;F<@
M8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<R!O
M9B!!;&YY;&%M(%!H87)M86-E=71I8V%L<RP@26YC+B`H=&AE("8C.#(R,#M#
M;VUP86YY)B,X,C(Q.R!O<@T*("`@)B,X,C(P.T%L;GEL86TF(S@R,C$[*2!A
M<F4@=6YA=61I=&5D(&%N9"!H879E(&)E96X@<')E<&%R960@:6X@86-C;W)D
M86YC92!W:71H(&%C8V]U;G1I;F<@<')I;F-I<&QE<R!G96YE<F%L;'D@86-C
M97!T960@:6X@=&AE(%5N:71E9"!3=&%T97,@;V8@06UE<FEC82`H)B,X,C(P
M.T=!05`F(S@R,C$[*2!A<'!L:6-A8FQE('1O(&EN=&5R:6T@<&5R:6]D<R!A
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M=6)S=&%N=&EA;&QY(&-O;G-I<W1E;G0@=VET:"P-"B`@(&%N9"!S:&]U;&0@
M8F4@<F5A9"!I;B!C;VYJ=6YC=&EO;B!W:71H+"!T:&4@0V]M<&%N>28C.#(Q
M-SMS(&%U9&ET960@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!W
M:&EC:"!W97)E(&EN8VQU9&5D(&EN('1H92!#;VUP86YY)B,X,C$W.W,@06YN
M=6%L(%)E<&]R="!O;B!&;W)M(#$P+4L@=&AA="!W87,@9FEL960@=VET:"!T
M:&4@4V5C=7)I=&EE<PT*("`@86YD($5X8VAA;F=E($-O;6UI<W-I;VX@*'1H
M92`F(S@R,C`[4T5#)B,X,C(Q.RD@;VX@1F5B<G5A<GDF(S$V,#LQ,RP@,C`Q
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M;G1E<FEM('!E<FEO9"!O<B!F;W(@82!F=6QL(&9I<V-A;"!Y96%R+B`\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I
M;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@86-C
M;VUP86YY:6YG(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',@<F5F;&5C="!T:&4@;W!E<F%T:6]N<R!O9B!T:&4@0V]M<&%N
M>2!A;F0@06QN>6QA;2!5+E,N+"!);F,N+"!!;&YY;&%M($5U<F]P90T*("`@
M04<@*"8C.#(R,#M!;&YY;&%M($5U<F]P928C.#(R,3LI+"!!;&YY;&%M(%-E
M8W5R:71I97,@0V]R<&]R871I;VX@86YD($UE;'1E;6D@0FEO=&AE<F%P975T
M:6-S+"!);F,N+"!W:&]L;'DM;W=N960@<W5B<VED:6%R:65S(&]F('1H92!#
M;VUP86YY+B!!;&P@<VEG;FEF:6-A;G0@:6YT97)C;VUP86YY(&%C8V]U;G1S
M(&%N9"!T<F%N<V%C=&EO;G,@:&%V92!B965N(&5L:6UI;F%T960N(%1H92!#
M;VUP86YY('5S97,@=&AE(&5Q=6ET>0T*("`@;65T:&]D(&]F(&%C8V]U;G1I
M;F<@=&\@86-C;W5N="!F;W(@:71S(&EN=F5S=&UE;G0@:6X@4F5G=6QU<R!4
M:&5R87!E=71I8W,@26YC+B`H)B,X,C(P.U)E9W5L=7,F(S@R,C$[*2X@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^57-E(&]F($5S=&EM871E<PT*
M("`@/"]I/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/E1H92!P<F5P87)A=&EO;B!O9B!F:6YA;F-I86P@<W1A=&5M96YT
M<R!I;B!C;VYF;W)M:71Y('=I=&@@1T%!4"!R97%U:7)E<R!M86YA9V5M96YT
M('1O(&UA:V4@97-T:6UA=&5S(&%N9"!A<W-U;7!T:6]N<PT*("`@=&AA="!A
M9F9E8W0F(S$V,#MT:&4@<F5P;W)T960@86UO=6YT<R!O9B!A<W-E=',@86YD
M(&QI86)I;&ET:65S(&%N9"8C,38P.W1H92!D:7-C;&]S=7)E(&]F(&-O;G1I
M;F=E;G0@87-S971S(&%N9"!L:6%B:6QI=&EE<R!A="!T:&4@9&%T92!O9B!T
M:&4@8V]N9&5N<V5D(&-O;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT
M<R!A;F0F(S$V,#MT:&4@<F5P;W)T960@86UO=6YT<R!O9B!R979E;G5E<R!A
M;F0@97AP96YS97,@9'5R:6YG#0H@("!T:&4@<F5P;W)T:6YG('!E<FEO9"X@
M06-T=6%L(')E<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA
M=&5S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$X
M<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CX\:3Y.970@3&]S<R!0
M97(@0V]M;6]N(%-H87)E(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!C;VUP=71E<R!B87-I
M8R!N970@;&]S<R8C,38P.W!E<B!C;VUM;VX@<VAA<F4@8GD@9&EV:61I;F<@
M;F5T(&QO<W,F(S$V,#MA='1R:6)U=&%B;&4@=&\@8V]M;6]N('-T;V-K:&]L
M9&5R<R!B>2!T:&4@=V5I9VAT960-"B`@(&%V97)A9V4@;G5M8F5R(&]F(&-O
M;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<N(%1H92!#;VUP86YY(&-O;7!U=&5S
M(&1I;'5T960@;F5T(&QO<W,F(S$V,#MP97(@8V]M;6]N('-H87)E(&)Y(&1I
M=FED:6YG(&YE="!L;W-S)B,Q-C`[871T<FEB=71A8FQE('1O(&-O;6UO;B!S
M=&]C:VAO;&1E<G,@8GD@=&AE('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F
M(&-O;6UO;B!S:&%R97,@86YD(&1I;'5T:79E('!O=&5N=&EA;"!C;VUM;VX-
M"B`@('-H87)E(&5Q=6EV86QE;G1S('1H96X@;W5T<W1A;F1I;F<N(%!O=&5N
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M;&]S<R!P97(@8V]M;6]N('-H87)E+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
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M:6X@=&AO=7-A;F1S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F;VYT
M+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#XF
M(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!B;W)D97(],T0P('-T>6QE/3-$)V)O<F1E
M<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI9VX]
M,T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@("`\
M='(^(`T*("`@/'1D('=I9'1H/3-$.#0E/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#,E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#,E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<B!S
M='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/CQB/E1H<F5E)B,Q-C`[36]N=&AS)B,Q-C`[16YD960\+V(^/"]F;VYT
M/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^36%R8V@F(S$V,#L-"B`@(#,Q+#PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R
M9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^#0H@
M("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^
M(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$
M=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT
M+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]P=&EO;G,@=&\@<'5R8VAA<V4@
M8V]M;6]N('-T;V-K/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^.2PP.#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C@L.#8Y/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M56YV97-T960@<F5S=')I8W1E9"!C;VUM;VX@<W1O8VL\+V9O;G0^/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV-3@\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C$Q,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B
M9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^.2PW-#,\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C@L.3@R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U
M8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4]
M,T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*("`@
M/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^(`T*("`@/'`@
M<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM
M8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT
M;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^4F5S=')I
M8W1E9"!3=&]C:R!!=V%R9',-"B`@(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!*86YU87)Y(#(P,3(L(&%S
M('!A<G0@;V8@:71S('!O<W0M<F5S=')U8W1U<FEN9R!R971E;G1I;VX@<')O
M9W)A;2P@=&AE($-O;7!A;GD@9W)A;G1E9"!A;B!A9V=R96=A=&4@;V8@-3`X
M+#DR.`T*("`@<VAA<F5S(&]F(')E<W1R:6-T960@<W1O8VL@=&\@:71S(')E
M=&%I;F5D(&5M<&QO>65E<RP@97AC;'5D:6YG('1H92!#;VUP86YY)B,X,C$W
M.W,@8VAI968@97AE8W5T:79E(&]F9FEC97(@86YD('!R97-I9&5N="!A;F0@
M8VAI968@;W!E<F%T:6YG(&]F9FEC97(N(%1H97-E(')E<W1R:6-T960@<W1O
M8VL@87=A<F1S('=E<F4@=F%L=65D(&%T("0U+C,@;6EL;&EO;B!O;B!T:&4@
M9W)A;G0@9&%T92!A;F0@=F5S="!I;B!F=6QL(&]N('1H90T*("`@<V5C;VYD
M(&%N;FEV97)S87)Y(&]F('1H92!G<F%N="!D871E+B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!R96-O
M9VYI>F5D(&%N(&%G9W)E9V%T92!O9B`D,"XU(&UI;&QI;VX@86YD("0P+C$@
M;6EL;&EO;B!O9B!S=&]C:RUB87-E9`T*("`@8V]M<&5N<V%T:6]N(&5X<&5N
M<V4@<F5L871E9"!T;R!A;&P@<F5S=')I8W1E9"!S=&]C:R!A=V%R9',@9W)A
M;G1E9"!F;W(@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q
M+"`R,#$R(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN(#PO9F]N=#X\+W`^#0H@
M("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M.C!P
M>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/CQB/CQI/E!U8FQI8R!/9F9E<FEN9R`\+VD^/"]B/CPO9F]N
M=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@1F5B<G5A
M<GD@,C`Q,BP@=&AE($-O;7!A;GD@<V]L9"!A;B!A9V=R96=A=&4@;V8@."PV
M,C4L,#`P('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K('1H<F]U9V@@86X@
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M<&5N<V5S(&]F(&%P<')O>&EM871E;'D-"B`@("0U+CD@;6EL;&EO;BX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&(^/&D^1F%I<B!686QU92!-96%S=7)E
M;65N=',@/"]I/CPO8CX\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/@T*("`@5&AE(&9O;&QO=VEN9R!T86)L97,@<')E<V5N="!I
M;F9O<FUA=&EO;B!A8F]U="!T:&4@0V]M<&%N>28C.#(Q-SMS(&%S<V5T<R!T
M:&%T(&%R92!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG
M(&)A<VES(&%T($UA<F-H)B,Q-C`[,S$L(#(P,3(@86YD($1E8V5M8F5R)B,Q
M-C`[,S$L(#(P,3$L(&%N9"!I;F1I8V%T92!T:&4@9F%I<B!V86QU90T*("`@
M:&EE<F%R8VAY(&]F('1H92!V86QU871I;VX@=&5C:&YI<75E<R!T:&4@0V]M
M<&%N>2!U=&EL:7IE9"!T;R!D971E<FUI;F4@<W5C:"!F86ER('9A;'5E+B!)
M;B!G96YE<F%L+"!F86ER('9A;'5E<R!D971E<FUI;F5D(&)Y($QE=F5L)B,Q
M-C`[,2!I;G!U=',@=71I;&EZ92!Q=6]T960@<')I8V5S("AU;F%D:G5S=&5D
M*2!I;B!A8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L
M:6%B:6QI=&EE<RX@1F%I<B!V86QU97,-"B`@(&1E=&5R;6EN960@8GD@3&5V
M96PF(S$V,#LR(&EN<'5T<R!U=&EL:7IE(&1A=&$@<&]I;G1S('1H870@87)E
M(&]B<V5R=F%B;&4L('-U8V@@87,@<75O=&5D('!R:6-E<R`H861J=7-T960I
M+"!I;G1E<F5S="!R871E<R!A;F0@>6EE;&0@8W5R=F5S+B!&86ER('9A;'5E
M<R!D971E<FUI;F5D(&)Y($QE=F5L)B,Q-C`[,R!I;G!U=',@=71I;&EZ92!U
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M9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!A<F4-"B`@('-U;6UA
M<FEZ960@87,@9F]L;&]W<RP@:6X@=&AO=7-A;F1S.B`\+V9O;G0^/"]P/@T*
M("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM
M87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P
M86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(]
M,T0P('-T>6QE/3-$)V)O<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA
M;&EG;CH@;&5F="<@86QI9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A
M8FQE($AE860@+2T^#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$-38E/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/B8C
M,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#8E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P
M.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`[=VED=&@Z,SEP="<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CY$97-C<FEP=&EO;CPO8CX\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY!=#PO8CX\+V9O;G0^/&)R("\^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,3X\8CXF(S$V,#LF(S$V,#M-87)C:"8C,38P.S,Q+"8C,38P.R8C,38P
M.PT*("`@/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/C(P,3(\+V(^/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,3X\8CY1=6]T960F(S$V,#M0<FEC97,\+V(^/"]F;VYT/CQB<B`O/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^:6X-"B`@($%C=&EV93QB<B`O/DUA<FME=',\8G(@+SXH3&5V
M96P@,2D\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CY3:6=N:69I8V%N=#QB<B`O/D]B<V5R=F%B
M;&4\8G(@+SY);G!U=',\8G(@+SXH3&5V96P@,BD\+V(^/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY3
M:6=N:69I8V%N=#QB<B`O/E5N;V)S97)V86)L93QB<B`O/DEN<'5T<SPO8CX\
M+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXH3&5V96P-"B`@("`S*3PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#87-H(&5Q=6EV86QE;G1S/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8P+#<Y,3PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/C8P+#`X.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/C<P,SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V
M,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY-87)K971A8FQE('-E8W5R:71I97,@*&9I>&5D
M(&EN8V]M92D\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@;F]T97,\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.#$L
M,3(Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXQ.#$L,3(Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^52Y3+B!';W9E<FYM96YT(&]B;&EG871I;VYS/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-C@L.#,R/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV
M."PX,S(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY#;VUM97)C:6%L('!A<&5R/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-2PQ.#(\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C4L
M,3@R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M36%R:V5T86)L92!S96-U<FET:65S("AE<75I='D@:&]L9&EN9W,I/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-#,\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C0S
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T
M>6QE/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@
M(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF
M(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,34L.38Y/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-C`L,#@X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C4U+#@X,3PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF
M(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/@T*("`@/"]T<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L
M92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D
M;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL
M93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\
M(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#QP('-T
M>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O
M='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$
M,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@8F]R9&5R/3-$,"!S='EL
M93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE
M9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#4V)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@
M/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^#0H@("`\<"!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P.W=I9'1H.C,Y<'0G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1&5S8W)I
M<'1I;VX\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^070\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^
M1&5C96UB97(F(S$V,#L-"B`@(#,Q+#QB<B`O/C(P,3$\+V(^/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CY1=6]T960F(S$V,#M0<FEC97,\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^:6X-"B`@($%C=&EV93QB<B`O/DUA<FME=',\8G(@+SXH3&5V96P@,2D\
M+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C
M96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P
M,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY3:6=N:69I8V%N=#QB<B`O/D]B<V5R=F%B;&4\8G(@
M+SY);G!U=',\8G(@+SXH3&5V96P@,BD\+V(^/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R
M+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY3:6=N:69I
M8V%N=#QB<B`O/E5N;V)S97)V86)L93QB<B`O/DEN<'5T<SPO8CX\+V9O;G0^
M/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,3X\8CXH3&5V96P-"B`@("`S*3PO8CX\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY#87-H(&5Q=6EV86QE;G1S/"]F;VYT/CPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C8W+#`R-#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C8W+#`R-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S@R,3([)B,Q-C`[)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^36%R:V5T86)L92!S96-U<FET
M:65S("AF:7AE9"!I;F-O;64I/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X-
M"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT
M9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS
M+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]R<&]R871E
M(&YO=&5S/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,3`T+#@S.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,3`T+#@S.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C
M,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E4N4RX@1V]V97)N;65N="!O8FQI9V%T:6]N
M<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C<S+#<R,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-S,L-S(R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI
M9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[
M('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V]M;65R8VEA;"!P87!E
M<CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$Q+#,Y-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,3$L,SDU/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO
M='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^36%R:V5T86)L92!S96-U<FET:65S("AE<75I='D@:&]L
M9&EN9W,I/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^-C(U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S@R,3([)B,Q-C`[)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXV,C4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T
M<CX@#0H@("`\='(@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-
M"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/E1O=&%L/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/C(U-RPV,#4\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXV-RPP,C0\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.3`L-3@Q/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O
M;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P
M,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P
M)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*
M("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A
M8FQE/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB
M;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY$=7)I;F<@=&AE
M('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"8C,38P.S,Q+"`R,#$R+"!T:&5R
M92!W97)E(&YO('1R86YS9F5R<R!B971W965N($QE=F5L(#$@86YD($QE=F5L
M(#(-"B`@(&9I;F%N8VEA;"!A<W-E=',N(%1H92!C87)R>6EN9R!A;6]U;G1S
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M:71I97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@[;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO
M<#X-"B`@(#QP('-T>6QE/3-$;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O
M;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CX\8CX\:3Y);G9E<W1M96YT<R!I;B!-87)K971A8FQE
M#0H@("!396-U<FET:65S(#PO:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T
M>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!I;G9E<W1S(&ET<R!E
M>&-E<W,@8V%S:"!B86QA;F-E<R!I;B!S:&]R="UT97)M(&%N9"!L;VYG+71E
M<FT@;6%R:V5T86)L92!D96)T(&%N9"!E<75I='D-"B`@('-E8W5R:71I97,N
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M=&4@<')E<V5N=&5D+`T*("`@=&AE($-O;7!A;GD@8VQA<W-I9FEE9"!A;&P@
M;V8@:71S(&EN=F5S=&UE;G1S(&EN(&1E8G0@86YD(&5Q=6ET>2!S96-U<FET
M:65S(&%S(&%V86EL86)L92UF;W(M<V%L92X@5&AE($-O;7!A;GD@<F5P;W)T
M<R!A=F%I;&%B;&4M9F]R+7-A;&4@:6YV97-T;65N=',@870@9F%I<B!V86QU
M92!A="!E86-H(&)A;&%N8V4@<VAE970@9&%T92!A;F0@:6YC;'5D97,@86YY
M('5N<F5A;&EZ960@:&]L9&EN9R!G86EN<R!A;F0@;&]S<V5S("AT:&4-"B`@
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M97(@:6YC;VUE+B!)9B!A;GD-"B`@(&%D:G5S=&UE;G0@=&\@9F%I<B!V86QU
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M,3<[<R!M87)K971A8FQE('-E8W5R:71I97,-"B`@(&%R92!C;&%S<VEF:65D
M(&%S(&-A<V@@97%U:79A;&5N=',@:68@=&AE(&]R:6=I;F%L(&UA='5R:71Y
M+"!F<F]M('1H92!D871E(&]F('!U<F-H87-E+"!I<R`Y,"8C,38P.V1A>7,@
M;W(@;&5S<RP@86YD(&%S(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!I9B!T:&4@
M;W)I9VEN86P@;6%T=7)I='DL(&9R;VT@=&AE(&1A=&4@;V8@<'5R8VAA<V4L
M(&ES(&EN(&5X8V5S<R!O9B`Y,"8C,38P.V1A>7,N(%1H92!#;VUP86YY)B,X
M,C$W.W,@8V%S:`T*("`@97%U:79A;&5N=',@87)E(&-O;7!O<V5D(&]F(&UO
M;F5Y(&UA<FME="!F=6YD<RP@52Y3+B!G;W9E<FYM96YT(&]B;&EG871I;VYS
M(&%N9"!C;VUM97)C:6%L('!A<&5R+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT
M+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@0V]M<&%N>2!O8G1A:6YS(&9A:7(-
M"B`@('9A;'5E(&UE87-U<F5M96YT(&1A=&$@9F]R(&ET<R!M87)K971A8FQE
M('-E8W5R:71I97,@9G)O;2!I;F1E<&5N9&5N="!P<FEC:6YG('-E<G9I8V5S
M+B!4:&4@0V]M<&%N>2!P97)F;W)M<R!V86QI9&%T:6]N('!R;V-E9'5R97,@
M=&\@96YS=7)E('1H92!R96%S;VYA8FQE;F5S<R!O9B!T:&ES(&1A=&$N(%1H
M:7,@:6YC;'5D97,@;65E=&EN9R!W:71H('1H92!I;F1E<&5N9&5N="!P<FEC
M:6YG('-E<G9I8V5S('1O('5N9&5R<W1A;F0-"B`@('1H92!M971H;V1S(&%N
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M;6%R:V5T<RX-"B`@(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E1H92!F;VQL;W=I;F<@=&%B;&5S('-U;6UA<FEZ92!T:&4@
M0V]M<&%N>28C.#(Q-SMS(&UA<FME=&%B;&4@<V5C=7)I=&EE<R!A="!-87)C
M:"8C,38P.S,Q+"`R,#$R(&%N9"!$96-E;6)E<B8C,38P.S,Q+"`R,#$Q+"!I
M;@T*("`@=&AO=7-A;F1S.B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T1F
M;VYT+7-I>F4Z,3)P>#MM87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P
M>#XF(S$V,#L\+W`^#0H@("`\=&%B;&4@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,"!W:61T:#TS1#DR)2!B;W)D97(],T0P('-T>6QE/3-$)V)O
M<F1E<BUC;VQL87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@86QI
M9VX],T1C96YT97(^#0H@("`\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@
M("`\='(^(`T*("`@/'1D('=I9'1H/3-$.#<E/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B8C,38P.SPO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#$E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E/B8C,38P.SPO=&0^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#$E/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-
M"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(@
M<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,3X\8CY-87)C:"8C,38P.S,Q+"`R,#$R/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M
M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D%M;W)T:7IE9#PO8CX\
M+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY#;W-T/"]B/CPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1W)O
M<W,\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^56YR96%L:7IE9#PO8CX\
M+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X-"B`@(#QB/D=A:6YS/"]B/CPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^
M/&(^1W)O<W,\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^56YR96%L:7IE
M9#PO8CX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X-"B`@(#QB/DQO<W-E<SPO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E
M<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0Q/CQB/D9A:7(F(S$V,#M686QU93PO8CX\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@
M+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(@8F=C
M;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N
M,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CY#;VUM97)C:6%L('!A<&5R("A$=64@=VET:&EN(#$F
M(S$V,#MY96%R*3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXU+#$Y,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXH,3`\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-2PQ.#(\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG
M;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@
M=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@;F]T97,@
M*$1U92!W:71H:6X@,28C,38P.WEE87(I/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$S+#,Q,SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M,SD\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B@T.#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$Q,RPS,#0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY#;W)P;W)A=&4@;F]T97,@*$1U92!A
M9G1E<B`Q)B,Q-C`[>65A<B!T:')O=6=H(#(F(S$V,#MY96%R<RD\+V9O;G0^
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXV-RPX,#@\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C0W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,S@\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXV-RPX,3<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY5+E,N($=O=F5R;FUE;G0@;V)L:6=A=&EO;G,@
M*$1U92!W:71H:6X@,28C,38P.WEE87(I/"]F;VYT/CPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3@L.#8X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXT
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXH,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$X+#@W,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/E4N4RX@1V]V97)N;65N="!O8FQI9V%T:6]N
M<R`H1'5E(&%F=&5R(#$F(S$V,#MY96%R('1H<F]U9V@@,B8C,38P.WEE87)S
M*3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C4P+#`P-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#0Y/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^-#DL.38R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1T
M;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M
M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^17%U:71Y('-E8W5R:71I97,\+V9O
M;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS,#PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^,3,\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(Q,CLF(S$V,#LF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/C0S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE
M.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P
M>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@
M(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P
M/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED
M(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C,N,#!E;3L@=&5X="UI;F1E
M;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CY4;W1A;#PO9F]N=#X\+W`^#0H@("`\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXR-34L,C$U/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3$P/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^*#$T-SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXR-34L,3<X/"]F;VYT/CPO=&0^(`T*("`@/'1D
M(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N
M="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M
M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^
M)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B
M;&4^#0H@("`\<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z
M,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&)O
M<F1E<CTS1#`@<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T
M97AT+6%L:6=N.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0X
M-R4^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X@#0H@("`\=&0^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0Q-"!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D97(M8F]T=&]M.C%P
M>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D1E8V5M8F5R)B,Q-C`[,S$L
M(#(P,3$\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^
M(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#$^/&(^06UO<G1I>F5D/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/D-O<W0\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CY'<F]S<SPO8CX\+V9O;G0^/&)R("\^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,3X\8CY5;G)E86QI>F5D/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/@T*
M("`@/&(^1V%I;G,\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS
M1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@
M<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY'<F]S<SPO8CX\+V9O;G0^/&)R
M("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,3X\8CY5;G)E86QI>F5D/"]B/CPO9F]N=#X\8G(@+SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0Q/@T*("`@/&(^3&]S<V5S/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^1F%I<B8C,38P.U9A
M;'5E/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B
M;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\
M=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z
M,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-O;6UE<F-I
M86P@<&%P97(@*$1U92!W:71H:6X@,28C,38P.WEE87(I/"]F;VYT/CPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE
M/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$Q+#,Y-SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M.#(Q,CLF(S$V,#LF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P
M/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,2PS.34\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@
M#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY#;W)P;W)A=&4@;F]T97,@*$1U92!W:71H:6X@,28C,38P.WEE
M87(I/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-3$L,C<S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ.3PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#0W/"]F
M;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^-3$L,C0U/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A
M<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O
M;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L;W(],T0C8V-E969F
M/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G
M:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M0V]R<&]R871E(&YO=&5S("A$=64@869T97(@,28C,38P.WEE87(@=&AR;W5G
M:"`R)B,Q-C`[>65A<G,I/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^-3,L-3DR/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^*#0X/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A
M<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-3,L-3DT/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@
M(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F
M=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^52Y3+B!'
M;W9E<FYM96YT(&]B;&EG871I;VYS("A$=64@=VET:&EN(#$F(S$V,#MY96%R
M*3PO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$S+#4S,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N
M;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,X,C$R.R8C
M,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R
M87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,3,L-3,T/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R(&)G8V]L
M;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@("`\<"!S
M='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E>'0M:6YD96YT.BTQ+C`P
M96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^52Y3+B!';W9E<FYM96YT(&]B;&EG871I;VYS("A$=64@
M869T97(@,28C,38P.WEE87(@=&AR;W5G:"`R)B,Q-C`[>65A<G,I/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^-C`L,C`R
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXW/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS
M1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,C$\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/BDF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXV,"PQ.#@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z
M+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CY%<75I='D@<V5C=7)I=&EE<SPO9F]N=#X\+W`^
M#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<U,#PO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,X,C$R.R8C,38P.R8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#$R-3PO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/C8R-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ
M<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@
M<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE
M/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-
M"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C%P>"!S;VQI
M9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R
M(&)G8V]L;W(],T0C8V-E969F/B`-"B`@(#QT9"!V86QI9VX],T1T;W`^#0H@
M("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HS+C`P96T[('1E>'0M:6YD96YT
M.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^5&]T86P\+V9O;G0^/"]P/@T*("`@/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P
M.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^,3DP+#<T-CPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C<X/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M*#(T,SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXQ.3`L-3@Q/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US
M:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P
M.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\
M<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P
M>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S
M='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C
M,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\
M+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^
M#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T=&]M
M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQB/CQI/E-U8G-E<75E;G0@179E;G1S(#PO:3X\+V(^
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA
M<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@
M(%1H92!#;VUP86YY(&5V86QU871E9"!A;&P@979E;G1S(&]R('1R86YS86-T
M:6]N<R!T:&%T(&]C8W5R<F5D(&%F=&5R($UA<F-H)B,Q-C`[,S$L(#(P,3(@
M=&AR;W5G:"!T:&4@9&%T92!T:&5S92!C;VYD96YS960@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E<F4@:7-S=65D+B!$=7)I;F<@=&AI
M<R!P97)I;V0L('1H92!#;VUP86YY(&1I9`T*("`@;F]T(&AA=F4@86YY(&UA
M=&5R:6%L(')E8V]G;FEZ960@<W5B<V5Q=65N="!E=F5N=',N($AO=V5V97(L
M('1H92!#;VUP86YY(&1I9"!H879E('1H92!F;VQL;W=I;F<@;F]N<F5C;V=N
M:7IE9"!S=6)S97%U96YT(&5V96YT+"!W:&EC:"!I<R!M;W)E(&9U;&QY(&1E
M<V-R:6)E9"!I;B!.;W1E(#<Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1&9O;G0M<VEZ93HV<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP
M<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE('-T>6QE/3-$)V)O<F1E<BUC;VQL
M87!S93IC;VQL87!S93L@=&5X="UA;&EG;CH@;&5F="<@8F]R9&5R/3-$,"!C
M96QL<&%D9&EN9STS1#`@8V5L;'-P86-I;F<],T0P('=I9'1H/3-$,3`P)3X@
M#0H@("`\='(^(`T*("`@/'1D('=I9'1H/3-$."4^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('=I9'1H/3-$-"4@=F%L:6=N
M/3-$=&]P(&%L:6=N/3-$;&5F=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C.#(R-CL\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=VED=&@],T0Q)2!V86QI9VX],T1T;W`^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D(&%L:6=N/3-$;&5F
M="!V86QI9VX],T1T;W`^#0H@("`\<"!A;&EG;CTS1&QE9G0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY)
M;B!!<')I;"`R,#$R+"!T:&4@0V]M<&%N>2!E>&5R8VES960@:71S(&]P=&EO
M;B!U;F1E<B!I=',@2G5L>2`R,#`W(&%M96YD960@86YD(')E<W1A=&5D(&-O
M;&QA8F]R871I;VX@86=R965M96YT("AT:&4@)B,X,C(P.TUE9'1R;VYI8R!!
M9W)E96UE;G0F(S@R,C$[*0T*("`@=VET:"!-961T<F]N:6,L($EN8RX@*"8C
M.#(R,#M-961T<F]N:6,F(S@R,C$[*2!T;R!O<'0M;W5T(&]F('1H92`U,"TU
M,"!E>'!E;G-E+W!R;V9I="!S:&%R92!A<G)A;F=E;65N="!O9B!T:&4@04Q.
M+4A45"!D<G5G+61E=FEC92!D979E;&]P;65N="!P<F]G<F%M(&%N9"!M;W9E
M('1O(&$@<F]Y86QT>2!A;F0@;6EL97-T;VYE(&QI8V5N<VEN9R!S=')U8W1U
M<F4N(#PO9F]N=#X\+W`^#0H@("`\+W1D/@T*("`@/"]T<CX-"B`@(#PO=&%B
M;&4^(`T*("`@/'`@<W1Y;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL
M93TS1&UA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M/&(^/&D^4F5C96YT($%C8V]U;G1I;F<@4')O;F]U;F-E;65N=',-"B`@(#PO
M:3X\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY);B!-87D@,C`Q,2P@=&AE($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD
M87)D<R!";V%R9"`H)B,X,C(P.T9!4T(F(S@R,C$[*2!I<W-U960@82!N97<@
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M<W!E8W1I=F4-"B`@(&)A<VES(&9O<B!A;FYU86P@86YD(&EN=&5R:6T@<F5P
M;W)T:6YG('!E<FEO9',@8F5G:6YN:6YG(&]N(&]R(&%F=&5R($1E8V5M8F5R
M)B,Q-C`[,34L(#(P,3$N(%1H92!#;VUP86YY(&%D;W!T960@=&AI<R!A;65N
M9&UE;G0@;VX@2F%N=6%R>28C,38P.S$L(#(P,3(N(%1H92!A9&]P=&EO;B!O
M9B!T:&ES(&YE=R!S=&%N9&%R9"!D:60@;F]T(&AA=F4@82!M871E<FEA;"!I
M;7!A8W0@;VX@=&AE($-O;7!A;GDF(S@R,3<[<R!C;VYD96YS960-"B`@(&-O
M;G-O;&ED871E9"!F:6YA;F-I86P@<W1A=&5M96YT<RX@/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M
M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@2G5N92`R,#$Q+"!T
M:&4@1D%30B!I<W-U960@86X@86UE;F1M96YT('1O('1H92!A8V-O=6YT:6YG
M(&=U:61A;F-E(&9O<B!P<F5S96YT871I;VX@;V8-"B`@(&-O;7!R96AE;G-I
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M:"!A('1O=&%L(&9O<B!O=&AE<B!C;VUP<F5H96YS:79E(&EN8V]M90T*("`@
M86YD(&$@=&]T86P@86UO=6YT(&9O<B!C;VUP<F5H96YS:79E(&EN8V]M92X@
M1F]R('!U8FQI8R!C;VUP86YI97,L('1H92!A;65N9&UE;G0@:7,@969F96-T
M:79E(&9O<B!F:7-C86P@>65A<G,L(&%N9"!I;G1E<FEM('!E<FEO9',@=VET
M:&EN('1H;W-E('EE87)S+"!B96=I;FYI;F<@869T97(@1&5C96UB97(F(S$V
M,#LQ-2P@,C`Q,2P@86YD('-H86QL(&)E(&%P<&QI960@<F5T<F]S<&5C=&EV
M96QY+B!4:&4@0V]M<&%N>2!A9&]P=&5D#0H@("!T:&ES(&%M96YD;65N="!O
M;B!*86YU87)Y)B,Q-C`[,2P@,C`Q,BX@3W1H97(@=&AA;B!A(&-H86YG92!I
M;B!P<F5S96YT871I;VXL('1H92!A9&]P=&EO;B!O9B!T:&ES(&=U:61A;F-E
M(&1I9"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!T:&4@0V]M<&%N
M>28C.#(Q-SMS(&-O;F1E;G-E9"!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T
M871E;65N=',N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D7V1C
M,3DV-3<Q-3(V-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8C@U
M,S%C,5\W,3-E7S0R,C9?8F%E9%]D8S$Y-C4W,34R-C4O5V]R:W-H965T<R]3
M:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^4VEG;FEF:6-A;G0@06=R965M96YT<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYA='5R92!O9B!"=7-I;F5S
M<R]3:6=N:69I8V%N="!!9W)E96UE;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4TE'3DE&24-!3E0@
M04=2145-14Y44SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M
M+41/0U194$4@:'1M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4
M<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ
M+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E
M9VEN($)L;V-K(%1A9V=E9"!.;W1E(#(@+2!U<RUG86%P.D-O;&QA8F]R871I
M=F5!<G)A;F=E;65N=$1I<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T
M>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&(^,BX@4TE'3DE&24-!3E0@04=2145-14Y44R`\+V(^/"]F;VYT/CPO
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4:&4@9F]L;&]W:6YG
M('1A8FQE('-U;6UA<FEZ97,@=&AE($-O;7!A;GDF(S@R,3<[<R!T;W1A;"!C
M;VYS;VQI9&%T960@;F5T(')E=F5N=65S(&9R;VT@<F5S96%R8V@@8V]L;&%B
M;W)A=&]R<RP@9F]R('1H90T*("`@<&5R:6]D<R!I;F1I8V%T960L(&EN('1H
M;W5S86YD<SH@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE
M.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[
M/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$,"!S='EL93TS1"=B;W)D97(M8V]L
M;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI9VXZ(&QE9G0G(&%L:6=N/3-$8V5N
M=&5R/@T*("`@/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*("`@/'1R/B`-
M"B`@(#QT9"!W:61T:#TS1#@P)3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0T)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF
M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0T)3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\
M='(^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF
M(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(@<W1Y;&4]
M,T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\
M8CY4:')E92!-;VYT:',@16YD960\8G(@+SY-87)C:"8C,38P.S,Q+#PO8CX\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(@<W1Y;&4],T0G
M8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR
M,#$R/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P
M,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#$^/&(^,C`Q,3PO8CX\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE($AE860@+2T^
M#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@("`\='(^(`T*("`@
M/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO
M=&0^(`T*("`@/'1D(&-O;'-P86X],T0T/B8C,38P.SPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E)O8VAE+T%R<F]W:&5A9#PO
M9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,RPY.30\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXQ,RPY.30\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O
M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI
M;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY486ME9&$\+V9O;G0^/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q
M/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXU+#0Y,SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^-2PW-C@\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*
M("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D
M('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N
M,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/=&AE<CPO9F]N
M=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C$L,3`P
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXQ+#$S-3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R
M87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS1&9O;G0M<VEZ
M93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ
M<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O
M<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T
M>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP
M('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P
M.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+6QE9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG
M('-I>F4],T0R/E1O=&%L(&YE="!R979E;G5E<R!F<F]M(')E<V5A<F-H(&-O
M;&QA8F]R871O<G,\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^,C`L-3@W/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO
M=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,C`L.#DW/"]F;VYT/CPO=&0^(`T*("`@
M/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF
M(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$
M9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P
M.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D
M97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P
M,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO
M=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@
M(#PO=&%B;&4^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z,3AP>#MM87)G
M:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/CQB/CQI/E!L871F;W)M($%L;&EA;F-E
M<R`\+VD^/"]B/CPO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM
M=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^#0H@("`\:3Y2;V-H92]!<G)O=VAE860@06QL:6%N8V4@/"]I/CPO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@2G5L
M>2`R,#`W+"!T:&4@0V]M<&%N>2!A;F0L(&9O<B!L:6UI=&5D#0H@("!P=7)P
M;W-E<RP@06QN>6QA;2!%=7)O<&4L(&5N=&5R960@:6YT;R!A(&QI8V5N<V4@
M86YD(&-O;&QA8F]R871I;VX@86=R965M96YT("AT:&4@)B,X,C(P.TQ#028C
M.#(R,3LI('=I=&@@1BX@2&]F9FUA;FXM3&$@4F]C:&4@3'1D("@F(S@R,C`[
M4F]C:&4@0F%S96PF(S@R,C$[*2!A;F0@2&]F9FUA;FXM3&$@4F]C:&4@26YC
M+B`H=&]G971H97(@=VET:"!2;V-H92!"87-E;"P@)B,X,C(P.U)O8VAE)B,X
M,C(Q.RDN(%5N9&5R('1H92!,0T$L#0H@("!W:&EC:"!B96-A;64@969F96-T
M:79E(&EN($%U9W5S="`R,#`W+"!T:&4@0V]M<&%N>2!G<F%N=&5D(%)O8VAE
M(&$@;F]N+65X8VQU<VEV92!L:6-E;G-E('1O('1H92!#;VUP86YY)B,X,C$W
M.W,@:6YT96QL96-T=6%L('!R;W!E<G1Y+"!I;F-L=61I;F<@9&5L:79E<GDM
M<F5L871E9"!I;G1E;&QE8W1U86P@<')O<&5R='D@97AI<W1I;F<@87,@;V8@
M=&AE(&1A=&4@;V8@=&AE($Q#02P@=&\@9&5V96QO<"!A;F0@8V]M;65R8VEA
M;&EZ90T*("`@=&AE<F%P975T:6,@<')O9'5C=',@=&AA="!F=6YC=&EO;B!T
M:')O=6=H(%).02!I;G1E<F9E<F5N8V4@*"8C.#(R,#M23D%I)B,X,C(Q.RDL
M('-U8FIE8W0@=&\@=&AE($-O;7!A;GDF(S@R,3<[<R!E>&ES=&EN9R!C;VYT
M<F%C='5A;"!O8FQI9V%T:6]N<R!T;R!T:&ER9"!P87)T:65S+B!);B!.;W9E
M;6)E<B`R,#$P+"!2;V-H92!A;FYO=6YC960@=&AE(&1I<V-O;G1I;G5A=&EO
M;B!O9B!C97)T86EN(&%C=&EV:71I97,@:6X@<F5S96%R8V@-"B`@(&%N9"!E
M87)L>2!D979E;&]P;65N="P@:6YC;'5D:6YG(&ET<R!23D%I(')E<V5A<F-H
M(&5F9F]R=',N(%1H92!R96UA:6YI;F<@9&5L:79E<F%B;&5S('5N9&5R('1H
M92!,0T$@8W5R<F5N=&QY(')E;6%I;B!I;B!E9F9E8W0N($EN($]C=&]B97(@
M,C`Q,2P@07)R;W=H96%D(%)E<V5A<F-H($-O<G!O<F%T:6]N("@F(S@R,C`[
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M;F0@;6%Y(&)E(&5X<&%N9&5D('1O(&EN8VQU9&4@861D:71I;VYA;`T*("`@
M=&AE<F%P975T:6,@87)E87,@=7!O;B!P87EM96YT('1O('1H92!#;VUP86YY
M(&)Y($%R<F]W:&5A9"!O9B!A;B!A9&1I=&EO;F%L("0U,"XP(&UI;&QI;VX@
M9F]R(&5A8V@@861D:71I;VYA;"!T:&5R87!E=71I8R!A<F5A+"!I9B!A;GDN
M(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*
M("`@26X@8V]N<VED97)A=&EO;B!F;W(@=&AE(')I9VAT<R!T:&4@0V]M<&%N
M>2!G<F%N=&5D('5N9&5R('1H92!,0T$L(%)O8VAE('!A:60@=&AE($-O;7!A
M;GD@)#(W,RXU(&UI;&QI;VX@:6X@=7!F<F]N="!C87-H('!A>6UE;G1S+B!)
M;B!A9&1I=&EO;BP@:6X@97AC:&%N9V4@9F]R('1H92!#;VUP86YY)B,X,C$W
M.W,@8V]N=')I8G5T:6]N<R!U;F1E<B!T:&4-"B`@($Q#02P@9F]R(&5A8V@@
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M;@T*("`@86=G<F5G871E(&]F("0Q,#`N,"!M:6QL:6]N('!E<B!T:&5R87!E
M=71I8R!T87)G970L('1O9V5T:&5R('=I=&@@<F]Y86QT>2!P87EM96YT<R!B
M87-E9"!O;B!W;W)L9'=I9&4@86YN=6%L(&YE="!S86QE<RP@:68@86YY+B!5
M;F1E<B!T:&4@3$-!+"!T:&4@0V]M<&%N>2!A;F0@4F]C:&4@86QS;R!E<W1A
M8FQI<VAE9"!A(&1I<V-O=F5R>2!C;VQL86)O<F%T:6]N(&EN($]C=&]B97(@
M,C`P.2`H)B,X,C(P.T1I<V-O=F5R>0T*("`@0V]L;&%B;W)A=&EO;B8C.#(R
M,3LI+"!S=6)J96-T('1O('1H92!#;VUP86YY)B,X,C$W.W,@97AI<W1I;F<@
M8V]N=')A8W1U86P@;V)L:6=A=&EO;G,@=&\@=&AI<F0@<&%R=&EE<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^26X@2G5L
M>2`R,#`W+"!T:&4-"B`@($-O;7!A;GD@97AE8W5T960@82!C;VUM;VX@<W1O
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M("!E>&5C=71E9"!A('-H87)E('!U<F-H87-E(&%G<F5E;65N="`H=&AE("8C
M.#(R,#M!;&YY;&%M($5U<F]P92!0=7)C:&%S92!!9W)E96UE;G0F(S@R,C$[
M*2!W:71H($%L;GEL86T@175R;W!E(&%N9"!2;V-H92!"971E:6QI9W5N9W,@
M1VUB2"P@86X@869F:6QI871E(&]F(%)O8VAE("@F(S@R,C`[4F]C:&4@1V5R
M;6%N>28C.#(R,3LI+B!5;F1E<B!T:&4@=&5R;7,@;V8@=&AE($%L;GEL86T@
M175R;W!E(%!U<F-H87-E($%G<F5E;65N="P@=&AE($-O;7!A;GD@<V]L9"!S
M=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4@;F]N+6EN=&5L;&5C='5A;`T*("`@
M<')O<&5R='D@87-S971S(&]F($%L;GEL86T@175R;W!E('1O(%)O8VAE($=E
M<FUA;GD@9F]R(&%N(&%G9W)E9V%T92!P=7)C:&%S92!P<FEC92!O9B`D,34N
M,"!M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN
M+71O<#HQ,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CY);B!S=6UM87)Y+"!T:&4@0V]M<&%N>0T*("`@<F5C96EV960@
M=7!F<F]N="!P87EM96YT<R!T;W1A;&EN9R`D,S,Q+C`@;6EL;&EO;B!U;F1E
M<B!T:&4@4F]C:&4@86QL:6%N8V4L('=H:6-H(&EN8VQU9&5D(&%N('5P9G)O
M;G0@<&%Y;65N="!U;F1E<B!T:&4@3$-!(&]F("0R-S,N-2!M:6QL:6]N+"`D
M-#(N-2!M:6QL:6]N('5N9&5R('1H92!#;VUM;VX@4W1O8VL@4'5R8VAA<V4@
M06=R965M96YT(&%N9"`D,34N,"!M:6QL:6]N('5N9&5R('1H92!!;&YY;&%M
M($5U<F]P90T*("`@4'5R8VAA<V4@06=R965M96YT+B!4:&4@0V]M<&%N>2!I
M;FET:6%L;'D@<F5C;W)D960@)#(W."XR(&UI;&QI;VX@;V8@=&AE<V4@<')O
M8V5E9',@87,@9&5F97)R960@<F5V96YU92!I;B!C;VYN96-T:6]N('=I=&@@
M=&AI<R!A;&QI86YC92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z
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M>6QA;2!%=7)O<&4@87)E(&YO=`T*("`@<V5P87)A8FQE(&9R;VT@=&AE('5N
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M9&5L:79E<F%B;&5S(&%N9"!A;&P@<W5C:`T*("`@<V5R=FEC97,@=VEL;"!E
M;F0L(&-O;G1R86-T=6%L;'DL(&9I=F4@>65A<G,@9G)O;2!T:&4@969F96-T
M:79E(&1A=&4@;V8@=&AE($Q#02X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
M;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@:7,@<F5C;V=N:7II;F<@
M=&AE(')E=F5N=64-"B`@(')E;&%T960@=&\@=&AE<V4@86=R965M96YT<R!O
M;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!F:79E('EE87)S(&)E8V%U
M<V4@=&AE($-O;7!A;GD@8V%N;F]T(')E87-O;F%B;'D@97-T:6UA=&4@=&AE
M('1O=&%L(&QE=F5L(&]F(&5F9F]R="!R97%U:7)E9"!T;R!C;VUP;&5T92!I
M=',@<V5R=FEC92!O8FQI9V%T:6]N<R!U;F1E<B!T:&4@3$-!+"!A;F0@=&AE
M<F5F;W)E+"!C86YN;W0@=71I;&EZ92!A('!R;W!O<G1I;VYA;`T*("`@<&5R
M9F]R;6%N8V4@;6]D96PN(%1H92!#;VUP86YY('=I;&P@8V]N=&EN=64@=&\@
M<F5C;V=N:7IE('1H92!R979E;G5E(')E;&%T960@=&\@=&AE<V4@86=R965M
M96YT<R!O;B!A('-T<F%I9VAT+6QI;F4@8F%S:7,@;W9E<B!F:79E('EE87)S
M('1H<F]U9V@@075G=7-T(#(P,3(N($%T($UA<F-H)B,Q-C`[,S$L(#(P,3(L
M(&1E9F5R<F5D(')E=F5N=64@=6YD97(@=&AE($Q#02!W87,@)#(S+C,@;6EL
M;&EO;BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^/&D^5&%K961A($%L;&EA;F-E(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E
M>'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@26X@36%Y(#(P,#@L('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A(&QI8V5N<V4@86YD(&-O;&QA8F]R871I
M;VX@86=R965M96YT("AT:&4@)B,X,C(P.U1A:V5D82!!9W)E96UE;G0F(S@R
M,C$[*2!W:71H(%1A:V5D82!0:&%R;6%C975T:6-A;"!#;VUP86YY($QI;6ET
M960@*"8C.#(R,#M486ME9&$F(S@R,C$[*2!T;R!P=7)S=64@=&AE(&1E=F5L
M;W!M96YT(&%N9`T*("`@8V]M;65R8VEA;&EZ871I;VX@;V8@4DY!:2!T:&5R
M87!E=71I8W,N(%5N9&5R('1H92!486ME9&$@06=R965M96YT+"!T:&4@0V]M
M<&%N>2!G<F%N=&5D('1O(%1A:V5D82!A(&YO;BUE>&-L=7-I=F4L('=O<FQD
M=VED92P@<F]Y86QT>2UB96%R:6YG(&QI8V5N<V4@=&\@=&AE($-O;7!A;GDF
M(S@R,3<[<R!I;G1E;&QE8W1U86P@<')O<&5R='DL(&EN8VQU9&EN9R!D96QI
M=F5R>2UR96QA=&5D(&EN=&5L;&5C='5A;"!P<F]P97)T>2P-"B`@(&-O;G1R
M;VQL960@8GD@=&AE($-O;7!A;GD@87,@;V8@=&AE(&1A=&4@;V8@=&AE(&%G
M<F5E;65N="!O<B!D=7)I;F<@=&AE(&9I=F4@>65A<G,@=&AE<F5A9G1E<BP@
M=&\@9&5V96QO<"P@;6%N=69A8W1U<F4L('5S92!A;F0@8V]M;65R8VEA;&EZ
M92!23D%I('1H97)A<&5U=&EC<RP@<W5B:F5C="!T;R!T:&4@0V]M<&%N>28C
M.#(Q-SMS(&5X:7-T:6YG(&-O;G1R86-T=6%L(&]B;&EG871I;VYS('1O('1H
M:7)D('!A<G1I97,N(%1H90T*("`@;&EC96YS92!I;FET:6%L;'D@:7,@;&EM
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M"B`@(&5X8VQU<VEV92!P;&%T9F]R;2!P87)T;F5R(&EN('1H92!!<VEA;B!T
M97)R:71O<GDL(&%S(&1E9FEN960@:6X@=&AE(%1A:V5D82!!9W)E96UE;G0L
M('1H<F]U9V@@36%Y(#(P,3,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
M1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD
M96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/DEN(&-O;G-I9&5R871I;VX@9F]R#0H@("!T:&4@
M<FEG:'1S(&=R86YT960@=&\@5&%K961A('5N9&5R('1H92!486ME9&$@06=R
M965M96YT+"!486ME9&$@86=R965D('1O('!A>2!T:&4@0V]M<&%N>2`D,34P
M+C`@;6EL;&EO;B!I;B!U<&9R;VYT(&%N9"!N96%R+71E<FT@=&5C:&YO;&]G
M>2!T<F%N<V9E<B!P87EM96YT<RX@26X@861D:71I;VXL('1H92!#;VUP86YY
M(&AA<R!T:&4@;W!T:6]N+"!E>&5R8VES86)L92!U;G1I;"!T:&4@<W1A<G0@
M;V8@4&AA<V4@24E)#0H@("!D979E;&]P;65N="P@=&\@;W!T+6EN('5N9&5R
M(&$@-3`M-3`@<')O9FET('-H87)I;F<@86=R965M96YT('1O('1H92!D979E
M;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@:6X@=&AE(%5N:71E9"!3
M=&%T97,@;V8@=7`@=&\@9F]U<B!486ME9&$@;&EC96YS960@<')O9'5C=',@
M86YD('=O=6QD(&)E(&5N=&ET;&5D('1O(&]P="UI;B!R:6=H=',@9F]R('1W
M;R!A9&1I=&EO;F%L('!R;V1U8W1S(&9O<B!E86-H(&%D9&ET:6]N86P-"B`@
M(&9I96QD(&5X<&%N<VEO;BP@:68@86YY+"!E;&5C=&5D(&)Y(%1A:V5D82!U
M;F1E<B!T:&4@5&%K961A($-O;&QA8F]R871I;VX@06=R965M96YT+B!);B!*
M=6YE(#(P,#@L(%1A:V5D82!P86ED('1H92!#;VUP86YY(&%N('5P9G)O;G0@
M<&%Y;65N="!O9B`D,3`P+C`@;6EL;&EO;B!A;F0@86=R965D('1O('!A>2!T
M;R!T:&4@0V]M<&%N>2!A;B!A9&1I=&EO;F%L("0U,"XP(&UI;&QI;VX@=7!O
M;B!A8VAI979E;65N="!O9@T*("`@<W!E8VEF:65D('1E8VAN;VQO9WD@=')A
M;G-F97(@;6EL97-T;VYE<RX@3V8@=&AI<R`D-3`N,"!M:6QL:6]N+"`D,C`N
M,"!M:6QL:6]N('=A<R!P86ED('1O('1H92!#;VUP86YY(&EN($]C=&]B97(@
M,C`P."P@)#(P+C`@;6EL;&EO;B!W87,@<&%I9"!T;R!T:&4@0V]M<&%N>2!I
M;B!-87)C:"`R,#$P+"!A;F0@)#$P+C`@;6EL;&EO;B!W87,@<&%I9"!T;R!T
M:&4@0V]M<&%N>2!I;B!-87)C:"`R,#$Q("AC;VQL96-T:79E;'DL('1H90T*
M("`@)B,X,C(P.U1E8VAN;VQO9WD@5')A;G-F97(@36EL97-T;VYE<R8C.#(R
M,3LI+B!)9B!486ME9&$@96QE8W1S('1O(&5X<&%N9"!I=',@;&EC96YS92!T
M;R!A9&1I=&EO;F%L('1H97)A<&5U=&EC(&%R96%S+"!486ME9&$@=VEL;"!B
M92!R97%U:7)E9"!T;R!P87D@=&AE($-O;7!A;GD@)#4P+C`@;6EL;&EO;B!F
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M;B!M:6QE<W1O;F5S+"!T;W1A;&EN9R!U<"!T;R`D,3<Q+C`@;6EL;&EO;B!P
M97(@<')O9'5C="P@=&]G971H97(@=VET:"!R;WEA;'1Y('!A>6UE;G1S(&)A
M<V5D(&]N#0H@("!W;W)L9'=I9&4@86YN=6%L(&YE="!S86QE<RP@:68@86YY
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY0
M=7)S=6%N="!T;R!T:&4@5&%K961A($%G<F5E;65N="P@=&AE($-O;7!A;GD@
M86YD(%1A:V5D82!A<F4@86QS;R!C;VQL86)O<F%T:6YG(&]N('1H90T*("`@
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M9`T*("`@8V]M;65R8VEA;&EZ871I;VX@;V8@=&AE($-O;7!A;GDF(S@R,3<[
M<R!23D%I('1H97)A<&5U=&EC('!R;V1U8W1S(&EN('1H92!!<VEA;B!T97)R
M:71O<GDL(&5X8VQU9&EN9R!T:&4@0V]M<&%N>28C.#(Q-SMS($%,3BU24U8@
M<')O9W)A;2X@26X@861D:71I;VX@=&\@=&AE(#4P+34P('!R;V9I="!S:&%R
M:6YG(&]P=&EO;BP@=&AE($-O;7!A;GD@:&%S(&$@<VEM:6QA<B!R:6=H="!O
M9B!F:7)S="!N96=O=&EA=&EO;B!T;PT*("`@<&%R=&EC:7!A=&4@=VET:"!4
M86ME9&$@:6X@=&AE(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO
M;B!O9B!L:6-E;G-E9"!P<F]D=6-T<R!I;B!T:&4@56YI=&5D(%-T871E<RX@
M5&AE(&-O;&QA8F]R871I;VX@:7,@9V]V97)N960@8GD@82!J;VEN="!T96-H
M;F]L;V=Y('1R86YS9F5R(&-O;6UI='1E92`H=&AE("8C.#(R,#M*5%1#)B,X
M,C(Q.RDL(&$@:F]I;G0@<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!C;VUM:71T
M964@*'1H92`F(S@R,C`[2E)#0R8C.#(R,3LI(&%N9"!A(&IO:6YT(&1E;&EV
M97)Y(&-O;&QA8F]R871I;VX-"B`@(&-O;6UI='1E92`H=&AE("8C.#(R,#M*
M1$-#)B,X,C(Q.RDL(&5A8V@@;V8@=VAI8V@@:7,@8V]M<')I<V5D(&]F(&%N
M(&5Q=6%L(&YU;6)E<B!O9B!R97!R97-E;G1A=&EV97,@9G)O;2!E86-H('!A
M<G1Y+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ
M,G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY4:&4-"B`@($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!D96QI=F5R
M86)L97,@=6YD97(@=&AE(%1A:V5D82!!9W)E96UE;G0@:6YC;'5D92!T:&4@
M;&EC96YS92P@=&AE(&IO:6YT(&-O;6UI='1E97,@*'1H92!*5%1#+"!*4D-#
M(&%N9"!*1$-#*2P@=&AE('1E8VAN;VQO9WD@=')A;G-F97(@86-T:79I=&EE
M<R!A;F0@=&AE('-E<G9I8V5S('1H870@=&AE($-O;7!A;GD@=VEL;"!B92!O
M8FQI9V%T960@=&\@<&5R9F]R;2!U;F1E<B!T:&4-"B`@(%)E<V5A<F-H($-O
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M;&EF92!O9B!N;R!M;W)E('1H86X@<V5V96X@>65A<G,N(#PO9F]N=#X\+W`^
M#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O
M;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H92!#;VUP86YY(&ES
M(')E8V]G;FEZ:6YG('1H92!U<&9R;VYT('!A>6UE;G0@;V8@)#$P,"XP(&UI
M;&QI;VX@86YD('1H92!496-H;F]L;V=Y(%1R86YS9F5R($UI;&5S=&]N97,@
M;V8@)#4P+C`@;6EL;&EO;BP@=&AE(')E8V5I<'0@;V8-"B`@('=H:6-H('1H
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M"B`@('1H92!P97)C96YT86=E(&]F('1H92!P97)F;W)M86YC92!P97)I;V0@
M8V]M<&QE=&5D('=H96X@=&AE(&UI;&5S=&]N92!I<R!A8VAI979E9"P@;75L
M=&EP;&EE9"!B>2!T:&4@86UO=6YT(&]F('1H92!M:6QE<W1O;F4@<&%Y;65N
M="X@070@36%R8V@F(S$V,#LS,2P@,C`Q,BP@9&5F97)R960@<F5V96YU92!U
M;F1E<B!T:&4@5&%K961A($%G<F5E;65N="!W87,@)#8Y+C,@;6EL;&EO;BX@
M/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G
M:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@
M/'`@<W1Y;&4],T1M87)G:6XM=&]P.C!P>#MM87)G:6XM8F]T=&]M.C!P>#X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/CQB/CQI/E!R;V1U8W0@06QL:6%N8V5S#0H@("`\+VD^/"]B/CPO
M9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^/&D^2WEO
M=V$@2&%K:V\@2VER:6X@06QL:6%N8V4@/"]I/CPO9F]N=#X\+W`^#0H@("`\
M<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T=&]M.C!P>#L@
M=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("!);B!*=6YE(#(P,#@L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&QI8V5N<V4@86YD(&-O;&QA8F]R
M871I;VX@86=R965M96YT("AT:&4@)B,X,C(P.TMY;W=A($AA:VMO($MI<FEN
M($%G<F5E;65N="8C.#(R,3LI('=I=&@@2WEO=V$@2&%K:V\@2VER:6X@0V\N
M+"!,=&0N("@F(S@R,C`[2WEO=V$@2&%K:V\@2VER:6XF(S@R,C$[*2X@56YD
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M(&-O;6UE<F-I86QI>F%T:6]N(&]F(&%N(%).06D@=&AE<F%P975T:6,-"B`@
M(&9O<B!T:&4@=')E871M96YT(&]F(')E<W!I<F%T;W)Y('-Y;F-Y=&EA;"!V
M:7)U<R`H)B,X,C(P.U)35B8C.#(R,3LI(&EN9F5C=&EO;BX@5&AE($MY;W=A
M($AA:VMO($MI<FEN($%G<F5E;65N="!C;W9E<G,@04Q.+5)35C`Q+"!A<R!W
M96QL(&%S(&%D9&ET:6]N86P@4E-6+7-P96-I9FEC(%).06D@=&AE<F%P975T
M:6,@8V]M<&]U;F1S('1H870@8V]M<')I<V4@=&AE($%,3BU24U8@<')O9W)A
M;2`H)B,X,C(P.T%D9&ET:6]N86P-"B`@($-O;7!O=6YD<R8C.#(R,3LI+B!4
M:&4@0V]M<&%N>2!R971A:6YS(&%L;"!D979E;&]P;65N="!A;F0@8V]M;65R
M8VEA;&EZ871I;VX@<FEG:'1S('=O<FQD=VED92!O=71S:61E(&]F('1H92!,
M:6-E;G-E9"!497)R:71O<GDL('-U8FIE8W0@=&\@:71S(&%G<F5E;65N="!W
M:71H($-U8FES="!0:&%R;6%C975T:6-A;',L($EN8RX@*"8C.#(R,#M#=6)I
M<W0F(S@R,C$[*2!D97-C<FEB960@8F5L;W<N(#PO9F]N=#X\+W`^#0H@("`\
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M="!C87-H('!A>6UE;G0@;V8-"B`@("0Q-2XP)B,Q-C`[;6EL;&EO;BX@26X@
M861D:71I;VXL($MY;W=A($AA:VMO($MI<FEN(&ES(')E<75I<F5D('1O(&UA
M:V4@<&%Y;65N=',@=&\@=&AE($-O;7!A;GD@=7!O;B!A8VAI979E;65N="!O
M9B!S<&5C:69I960@9&5V96QO<&UE;G0@86YD('-A;&5S(&UI;&5S=&]N97,@
M=&]T86QI;F<@=7`@=&\@)#<X+C`F(S$V,#MM:6QL:6]N+"!A;F0@<F]Y86QT
M>2!P87EM96YT<R!B87-E9"!O;B!A;FYU86P@;F5T('-A;&5S+"!I9B!A;GDL
M#0H@("!O9B!23D%I('1H97)A<&5U=&EC<R!F;W(@=&AE('1R96%T;65N="!O
M9B!24U8@8GD@2WEO=V$@2&%K:V\@2VER:6XL(&ET<R!A9F9I;&EA=&5S(&%N
M9"!S=6)L:6-E;G-E97,@:6X@=&AE($QI8V5N<V5D(%1E<G)I=&]R>2X@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE(&-O
M;&QA8F]R871I;VX@8F5T=V5E;B!+>6]W82!(86MK;R!+:7)I;B!A;F0@=&AE
M($-O;7!A;GD@:7,@9V]V97)N960@8GD@82!J;VEN="!S=&5E<FEN9R!C;VUM
M:71T964@=&AA="!I<R!C;VUP<FES960@;V8@86X@97%U86P-"B`@(&YU;6)E
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M:&4@:6YI=&EA;"!F;V-U<R!O;@T*("`@2F%P86XN($MY;W=A($AA:VMO($MI
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M"B`@($IA<&%N(&%N9"!T:&4@<F5S="!O9B!T:&4@3&EC96YS960@5&5R<FET
M;W)Y+B!4:&4@0V]M<&%N>2!I<R!R97-P;VYS:6)L92!F;W(@<W5P<&QY(&]F
M('1H92!P<F]D=6-T('1O($MY;W=A($AA:VMO($MI<FEN('5N9&5R(&$@<W5P
M<&QY(&%G<F5E;65N="!U;FQE<W,@2WEO=V$@2&%K:V\@2VER:6X@96QE8W1S
M+"!P<FEO<B!T;R!T:&4@9FER<W0@8V]M;65R8VEA;"!S86QE(&]F('1H92!P
M<F]D=6-T(&EN('1H92!,:6-E;G-E9`T*("`@5&5R<FET;W)Y+"!T;R!M86YU
M9F%C='5R92!T:&4@<')O9'5C="!I='-E;&8@;W(@87)R86YG92!F;W(@82!T
M:&ER9"!P87)T>2!T;R!M86YU9F%C='5R92!T:&4@<')O9'5C="X@/"]F;VYT
M/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM
M8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A
M;GD@:&%S#0H@("!D971E<FUI;F5D('1H870@=&AE(&1E;&EV97)A8FQE<R!U
M;F1E<B!T:&4@2WEO=V$@2&%K:V\@2VER:6X@06=R965M96YT(&EN8VQU9&4@
M=&AE(&QI8V5N<V4L('1H92!J;VEN="!S=&5E<FEN9R!C;VUM:71T964L('1H
M92!M86YU9F%C='5R:6YG('-E<G9I8V5S(&%N9"!A;GD@061D:71I;VYA;"!#
M;VUP;W5N9',N(%1H92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870L('!U
M<G-U86YT('1O('1H92!A8V-O=6YT:6YG(&=U:61A;F-E#0H@("!G;W9E<FYI
M;F<@<F5V96YU92!R96-O9VYI=&EO;B!O;B!M=6QT:7!L92!E;&5M96YT(&%R
M<F%N9V5M96YT<RP@=&AE(&EN9&EV:61U86P@9&5L:79E<F%B;&5S(&%R92!N
M;W0@<V5P87)A8FQE(&%N9"P@86-C;W)D:6YG;'DL(&UU<W0@8F4@86-C;W5N
M=&5D(&9O<B!A<R!A('-I;F=L92!U;FET(&]F(&%C8V]U;G1I;F<N(%=H96X@
M;75L=&EP;&4@9&5L:79E<F%B;&5S(&%R92!A8V-O=6YT960@9F]R(&%S(&$@
M<VEN9VQE('5N:70@;V8-"B`@(&%C8V]U;G1I;F<L('1H92!#;VUP86YY(&)A
M<V5S(&ET<R!R979E;G5E(')E8V]G;FET:6]N('!A='1E<FX@;VX@=&AE(&9I
M;F%L(&1E;&EV97)A8FQE+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
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M061D:71I;VYA;"!#;VUP;W5N9',N(%1H90T*("`@0V]M<&%N>2!I<R!D969E
M<G)I;F<@86QL(')E=F5N=64@=6YD97(@=&AE($MY;W=A($AA:VMO($MI<FEN
M($%G<F5E;65N="!U;G1I;"!I="!I<R!A8FQE('1O(')E87-O;F%B;'D@97-T
M:6UA=&4@:71S('!E<FEO9"!O9B!P97)F;W)M86YC92X@5&AE($-O;7!A;GD@
M=VEL;"!C;VYT:6YU92!T;R!R96%S<V5S<R!W:&5T:&5R(&ET(&-A;B!R96%S
M;VYA8FQY(&5S=&EM871E('1H92!P97)I;V0@;V8@<&5R9F]R;6%N8V4@=&\@
M9G5L9FEL;`T*("`@:71S(&]B;&EG871I;VYS('5N9&5R('1H92!+>6]W82!(
M86MK;R!+:7)I;B!!9W)E96UE;G0N($%T($UA<F-H)B,Q-C`[,S$L(#(P,3(L
M(&1E9F5R<F5D(')E=F5N=64@=6YD97(@=&AE($MY;W=A($AA:VMO($MI<FEN
M($%G<F5E;65N="!W87,@)#$U+C4F(S$V,#MM:6QL:6]N+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!M87)G:6XM;&5F=#HR)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(#QI/D-U8FES
M="!!;&QI86YC92`\+VD^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX
M)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CY);B!*86YU87)Y(#(P,#DL('1H92!#;VUP86YY(&5N=&5R
M960@:6YT;R!A(&QI8V5N<V4@86YD#0H@("!C;VQL86)O<F%T:6]N(&%G<F5E
M;65N="!W:71H($-U8FES="`H=&AE("8C.#(R,#M#=6)I<W0@06=R965M96YT
M)B,X,C(Q.RD@=&\@9&5V96QO<"!A;F0@8V]M;65R8VEA;&EZ92!T:&5R87!E
M=71I8R!P<F]D=6-T<R`H)B,X,C(P.TQI8V5N<V5D(%!R;V1U8W1S)B,X,C(Q
M.RD@8F%S960@;VX@8V5R=&%I;B!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(%).
M06D@=&5C:&YO;&]G>2!F;W(@=&AE('1R96%T;65N="!O9B!24U8@:6YF96-T
M:6]N+@T*("`@3&EC96YS960@4')O9'5C=',@:6YI=&EA;&QY(&EN8VQU9&5D
M($%,3BU24U8P,2P@87,@=V5L;"!A<R!S979E<F%L(&]T:&5R('-E8V]N9"UG
M96YE<F%T:6]N(%).06DM8F%S960@4E-6(&EN:&EB:71O<G,N($EN($YO=F5M
M8F5R(#(P,#DL('1H92!#;VUP86YY(&%N9"!#=6)I<W0@96YT97)E9"!I;G1O
M(&%N(&%M96YD;65N="!T;R!T:&4@0W5B:7-T($%G<F5E;65N="`H=&AE("8C
M.#(R,#M!;65N9&UE;G0F(S@R,C$[*2P@=VAI8V@-"B`@('!R;W9I9&5S('1H
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M;W(@04Q.+5)35C`R+B!0=7)S=6%N="!T;R!T:&4@=&5R;7,@;V8@=&AE($%M
M96YD;65N="P@=&AE($-O;7!A;GD@:7,@8V]N=&EN=6EN9R!T;R!D979E;&]P
M($%,3BU24U8P,2!F;W(@861U;'0@=')A;G-P;&%N="!P871I96YT<R!A="!I
M=',@<V]L92!D:7-C<F5T:6]N(&%N9"!E>'!E;G-E+B!#=6)I<W0-"B`@(&AA
M<R!T:&4@<FEG:'0@=&\@;W!T(&EN=&\@8V]L;&%B;W)A=&EN9R!W:71H('1H
M92!#;VUP86YY(&]N($%,3BU24U8P,2!I;B!T:&4@9G5T=7)E+"!W:&EC:"!R
M:6=H="!M87D@8F4@97AE<F-I<V5D(&9O<B!A('-P96-I9FEE9"!P97)I;V0@
M;V8@=&EM92!F;VQL;W=I;F<@=&AE(&-O;7!L971I;VX@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!0:&%S92!)26(@=')I86P@;V8@04Q.+5)35C`Q+"!S=6)J
M96-T('1O('1H92!P87EM96YT(&)Y#0H@("!#=6)I<W0@;V8@86X@;W!T+6EN
M(&9E92!R97!R97-E;G1I;F<@<F5I;6)U<G-E;65N="!O9B!A;B!A9W)E960@
M=7!O;B!P97)C96YT86=E(&]F(&-E<G1A:6X@;V8@=&AE($-O;7!A;GDF(S@R
M,3<[<R!D979E;&]P;65N="!E>'!E;G-E<R!F;W(@04Q.+5)35C`Q+B!);B!$
M96-E;6)E<B`R,#$P+"!T:&4@0V]M<&%N>2!A;F0@0W5B:7-T(&IO:6YT;'D@
M;6%D92!A('!O<G1F;VQI;R!D96-I<VEO;B!T;R!P=70@=&AE(&1E=F5L;W!M
M96YT(&]F#0H@("!!3$XM4E-6,#(@;VX@:&]L9"X@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P.C$R<'@[;6%R
M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
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M('5P9G)O;G0@8V%S:"!P87EM96YT(&]F("0R,"XP)B,Q-C`[;6EL;&EO;BX@
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M("`@87)E('-U8V-E<W-F=6QL>2!D979E;&]P960L($-U8FES="!W:6QL(&)E
M(')E<75I<F5D('1O('!A>2!T;R!T:&4@0V]M<&%N>2!R;WEA;'1I97,@;VX@
M;F5T('-A;&5S(&]F($QI8V5N<V5D(%!R;V1U8W1S(&EN('1H92!2;WEA;'1Y
M(%1E<G)I=&]R>2P@:68@86YY+"!S=6)J96-T('1O(&]F9G-E=',@=6YD97(@
M8V5R=&%I;B!C:7)C=6US=&%N8V5S+B!5<&]N(&%C:&EE=F5M96YT(&]F(&-E
M<G1A:6X@9&5V96QO<&UE;G0-"B`@(&UI;&5S=&]N97,L('1H92!#;VUP86YY
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M9V=R96=A=&4@;V8@)#$S,"XP)B,Q-C`[;6EL;&EO;B!U<&]N(&%C:&EE=F5M
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M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@
M9&5T97)M:6YE9"!T:&%T('1H92!D96QI=F5R86)L97,@=6YD97(@=&AE($-U
M8FES="!!9W)E96UE;G0@:6YC;'5D92!T:&4@;&EC96YS97,L('1E8VAN;VQO
M9WD@=')A;G-F97(@<F5L871E9"!T;R!T:&4@04Q.+5)35@T*("`@<')O9W)A
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M<FYI;F<@<F5V96YU90T*("`@<F5C;V=N:71I;VX@;VX@;75L=&EP;&4@96QE
M;65N="!A<G)A;F=E;65N=',L('1H92!L:6-E;G-E<R!A;F0@=6YD96QI=F5R
M960@<V5R=FEC97,@87)E(&YO="!S97!A<F%B;&4@86YD+"!A8V-O<F1I;F=L
M>2P@=&AE(&QI8V5N<V5S(&%N9"!S97)V:6-E<R!A<F4@8F5I;F<@=')E871E
M9"!A<R!A('-I;F=L92!U;FET(&]F(&%C8V]U;G1I;F<N(%=H96X@;75L=&EP
M;&4@9&5L:79E<F%B;&5S(&%R92!A8V-O=6YT960@9F]R(&%S(&$-"B`@('-I
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M<&5C=&5D(&QI9F4@;V8-"B`@(&%P<')O>&EM871E;'D@96EG:'0@>65A<G,N
M(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C$R<'@[
M;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1H
M92!#;VUP86YY(&ES(')E8V]G;FEZ:6YG('1H92!U<&9R;VYT('!A>6UE;G0@
M;V8@)#(P+C`F(S$V,#MM:6QL:6]N(&]N(&$@<W1R86EG:'0M;&EN92!B87-I
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M:6QE<W1O;F5S(&%R92!A8VAI979E9"P@=&AE($-O;7!A;GD-"B`@('=I;&P@
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M<F%I9VAT+6QI;F4@8F%S:7,N($%T($UA<F-H)B,Q-C`[,S$L(#(P,3(L(&1E
M9F5R<F5D(')E=F5N=64@=6YD97(@=&AE($-U8FES="!!9W)E96UE;G0@=V%S
M("0Q,2XX)B,Q-C`[;6EL;&EO;BX@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE
M/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI
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M;7!A;GD@:7,@9G5N9&EN9R!T:&4@861V86YC96UE;G0@;V8@04Q.+5)35C`Q
M(&9O<B!A9'5L="!L=6YG('1R86YS<&QA;G0@<&%T:65N=',@86YD($-U8FES
M="!R971A:6YS(&%N(&]P="UI;B!R:6=H="X@1F]R(')E=F5N=64-"B`@(&=E
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M(&-O;&QA8F]R871O<G,@8F%S960-"B`@(&]N(&]T:&5R(&%P<&QI8V%B;&4@
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M=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D7V1C,3DV-3<Q-3(V-0T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V8C@U,S%C,5\W,3-E7S0R,C9?
M8F%E9%]D8S$Y-C4W,34R-C4O5V]R:W-H965T<R]3:&5E=#`X+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^26YC;VUE(%1A>&5S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^24Y#3TU%(%1!6$53/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!50DQ)
M0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB(")H
M='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N<VET
M:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D($YO
M=&4@,R`M('5S+6=A87`Z26YC;VUE5&%X1&ES8VQO<W5R951E>'1";&]C:RTM
M/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O
M;3HP<'@^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CX\8CXS+B!)3D-/344@5$%815,@/"]B/CPO9F]N=#X\
M+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T
M=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^5&AE($-O;7!A;GD@
M97AP96-T<R!T;R!C;VYT:6YU92!T;R!G96YE<F%T92!5+E,N('1A>&%B;&4@
M;&]S<V5S(&EN(#(P,3(@86YD(&AA<R!R96-O<F1E9"!N;R!I;F-O;64@=&%X
M('!R;W9I<VEO;B!F;W(-"B`@('1H92!T:')E92!M;VYT:',@96YD960@36%R
M8V@F(S$V,#LS,2P@,C`Q,B!A;F0@,C`Q,2X@/"]F;VYT/CPO<#X-"B`@("`\
M<#X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T1F;VYT+7-I>F4Z,7!X.VUA<F=I;BUT;W`Z,3)P>#MM87)G:6XM8F]T
M=&]M.C!P>#XF(S$V,#L\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C!P>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^26X@2G5L>2`R,#$Q+"!T:&4-"B`@($EN=&5R;F%L(%)E=F5N=64@4V5R
M=FEC92!C;VUP;&5T960@:71S(&%U9&ET<R!O9B!T:&4@0V]M<&%N>28C.#(Q
M-SMS(#(P,#@@86YD(#(P,#D@=&%X('EE87)S+B!3=6)S97%U96YT;'DL('1H
M92`R,#$P('1A>"!Y96%R('=A<R!R979I97=E9"!B>2!T:&4@2F]I;G0@0V]M
M;6ET=&5E(&]F('1H92!);G1E<FYA;"!2979E;G5E(%-E<G9I8V4@*"8C.#(R
M,#M*;VEN="!#;VUM:71T964F(S@R,C$[*2X@26X@36%R8V@@,C`Q,BP@=&AE
M#0H@("!#;VUP86YY(')E8V5I=F5D('1H92!F:6YA;"!R97!O<G0@9G)O;2!T
M:&4@2F]I;G0@0V]M;6ET=&5E+B!4:&4@<F5V:65W(&]F('1A>"!Y96%R<R`R
M,#`X('1H<F]U9V@@,C`Q,"!I<R!C;VUP;&5T92X@5&AE($-O;7!A;GD@9&ED
M(&YO="!R96-O<F0@86YY('1A>"!E>'!E;G-E(')E;&%T960@=&\@=&AE<V4@
M875D:71S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O
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M971S('=I;&P@;F]T(&)E(')E86QI>F5D+B!!="!-87)C:"8C,38P.S,Q+"`R
M,#$R+"!T:&4@0V]M<&%N>2!H860@)#`N,28C,38P.VUI;&QI;VX@;V8@=&]T
M86P@9W)O<W,@=6YR96-O9VYI>F5D('1A>"!B96YE9FET<R!T:&%T+"!I9B!R
M96-O9VYI>F5D+"!W;W5L9"!F879O<F%B;'D@:6UP86-T('1H92!#;VUP86YY
M)B,X,C$W.W,@969F96-T:79E(&EN8V]M92!T87@@<F%T90T*("`@:6X@9G5T
M=7)E('!E<FEO9',N(#PO9F]N=#X\+W`^#0H\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D
M7V1C,3DV-3<Q-3(V-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\V
M8C@U,S%C,5\W,3-E7S0R,C9?8F%E9%]D8S$Y-C4W,34R-C4O5V]R:W-H965T
M<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS
M=')O;F<^4F5G=6QU<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/E)E9W5L=7,@6T%B<W1R86-T73PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y214=53%53/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM1$]#5%E012!H=&UL(%!5
M0DQ)0R`B+2\O5S-#+R]$5$0@6$A434P@,2XP(%1R86YS:71I;VYA;"\O14XB
M(")H='1P.B\O=W=W+G<S+F]R9R]44B]X:'1M;#$O1%1$+WAH=&UL,2UT<F%N
M<VET:6]N86PN9'1D(B`M+3X-"B`@(#PA+2T@0F5G:6X@0FQO8VL@5&%G9V5D
M($YO=&4@-"`M('5S+6=A87`Z17%U:71Y365T:&]D26YV97-T;65N='-$:7-C
M;&]S=7)E5&5X=$)L;V-K+2T^#0H@("`\<"!S='EL93TS1&UA<F=I;BUT;W`Z
M,3AP>#MM87)G:6XM8F]T=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/CQB/C0N)B,Q-C`[4D5'
M54Q54R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT
M;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY);B!397!T96UB97(@,C`P-RP@=&AE($-O;7!A;GD@86YD($ES:7,@
M4&AA<FUA8V5U=&EC86QS+"!);F,N("@F(S@R,C`[27-I<R8C.#(R,3LI(&5S
M=&%B;&ES:&5D(%)E9W5L=7,L(&$@8V]M<&%N>2!F;V-U<V5D#0H@("!O;B!T
M:&4@9&ES8V]V97)Y+"!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I
M;VX@;V8@;6EC<F]23D$@=&AE<F%P975T:6-S+"!A('!O=&5N=&EA;"!N97<@
M8VQA<W,@;V8@9')U9W,@=&\@=')E870@=&AE('!A=&AW87ES(&]F(&AU;6%N
M(&1I<V5A<V4N(%)E9W5L=7,L('=H:6-H(&EN:71I86QL>2!W87,@97-T86)L
M:7-H960@87,@82!L:6UI=&5D(&QI86)I;&ET>2!C;VUP86YY+"!C;VYV97)T
M960@=&\@82!##0H@("!C;W)P;W)A=&EO;B!I;B!*86YU87)Y(#(P,#D@86YD
M(&-H86YG960@:71S(&YA;64@=&\@4F5G=6QU<R!4:&5R87!E=71I8W,@26YC
M+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X
M.VUA<F=I;BUB;W1T;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY)
M;B!C;VYS:61E<F%T:6]N(&9O<B!T:&4@0V]M<&%N>28C.#(Q-SMS(&%N9`T*
M("`@27-I<R8C.#(Q-SL@:6YI=&EA;"!I;G1E<F5S=',@:6X@4F5G=6QU<RP@
M96%C:"!P87)T>2!G<F%N=&5D(%)E9W5L=7,@97AC;'5S:79E(&QI8V5N<V5S
M('1O(&ET<R!I;G1E;&QE8W1U86P@<')O<&5R='D@9F]R(&-E<G1A:6X@;6EC
M<F]23D$@=&AE<F%P975T:6,@87!P;&EC871I;VYS(&%S('=E;&P@87,@8V5R
M=&%I;B!P871E;G1S(&EN('1H92!M:6-R;U).02!F:65L9"X@26X@861D:71I
M;VXL('1H92!#;VUP86YY(&UA9&4@86X-"B`@(&EN:71I86P@8V%S:"!C;VYT
M<FEB=71I;VX@=&\@4F5G=6QU<R!O9B`D,3`N,"!M:6QL:6]N+"!R97-U;'1I
M;F<@:6X@=&AE($-O;7!A;GD@86YD($ES:7,@;6%K:6YG(&%P<')O>&EM871E
M;'D@97%U86P@86=G<F5G871E(&EN:71I86P@8V%P:71A;"!C;VYT<FEB=71I
M;VYS('1O(%)E9W5L=7,N($EN($UA<F-H(#(P,#DL('1H92!#;VUP86YY(&%N
M9"!)<VES(&5A8V@@<'5R8VAA<V5D("0Q,"XP(&UI;&QI;VX@;V8@4V5R:65S
M($$-"B`@('!R969E<G)E9"!S=&]C:R!O9B!296=U;'5S+B!);B!/8W1O8F5R
M(#(P,3`L(&EN(&-O;FYE8W1I;VX@=VET:"!I=',@<W1R871E9VEC(&%L;&EA
M;F-E('=I=&@@4F5G=6QU<R!F;W)M960@:6X@2G5N92`R,#$P+"!386YO9FD@
M;6%D92!A("0Q,"XP(&UI;&QI;VX@97%U:71Y(&EN=F5S=&UE;G0@:6X@4F5G
M=6QU<RX@070@36%R8V@F(S$V,#LS,2P@,C`Q,BP@=&AE($-O;7!A;GDL($ES
M:7,@86YD(%-A;F]F:2!O=VYE9`T*("`@87!P<F]X:6UA=&5L>2`T-24L(#0V
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M;V8-"B`@(%)E9W5L=7,N($UE;6)E<G,@;V8@=&AE(&)O87)D(&]F(&1I<F5C
M=&]R<R!O9B!296=U;'5S('=H;R!A<F4@=&AE($-O;7!A;GDF(S@R,3<[<R!E
M;7!L;WEE97,@;W(@27-I<R8C.#(Q-SL@96UP;&]Y965S(&%R92!N;W0@96QI
M9VEB;&4@=&\@<F5C96EV92!O<'1I;VYS('1O('!U<F-H87-E(%)E9W5L=7,@
M8V]M;6]N('-T;V-K+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
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M870@4F5G=6QU<PT*("`@8W5R<F5N=&QY('%U86QI9FEE<R!A<R!A(%9)12X@
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M5&AE($-O;7!A;GDF(S@R,3<[<PT*("`@;6%X:6UU;2!E>'!O<W5R92!T;R!L
M;W-S(')E;&%T960@=&\@=&AI<R!6244F(S$V,#MI<R!L:6UI=&5D('1O('1H
M92!C87)R>6EN9R!V86QU92!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&EN=F5S
M=&UE;G0L(&%S('=E;&P@=&AE('!O<G1I;VX@;V8@4F5G=6QU<R8C.#(Q-SL@
M9&5B="P@:6YC;'5D:6YG(&%C8W)U960@:6YT97)E<W0L(&=U87)A;G1E960@
M8GD@=&AE($-O;7!A;GDL('=H:6-H('=A<R`D-2XU(&UI;&QI;VX@870-"B`@
M($UA<F-H)B,Q-C`[,S$L(#(P,3(N($%T($UA<F-H)B,Q-C`[,S$L(#(P,3(L
M('1H92!T;W1A;"!N96=A=&EV92!C87)R>6EN9R!V86QU92!O9B!T:&4@0V]M
M<&%N>28C.#(Q-SMS(&EN=F5S=&UE;G0@:6X@4F5G=6QU<R!I;B!I=',@8V]N
M9&5N<V5D(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T<R!W87,@82!L:6%B
M:6QI='D@;V8@)#`N,R!M:6QL:6]N+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
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M<R8C.#(Q-SL@;W!E<F%T:6]N<R!F;W(-"B`@('1H92!T:')E92!M;VYT:',@
M96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,B!A;F0@,C`Q,2!A;F0@8F%L86YC
M92!S:&5E=',@870@36%R8V@F(S$V,#LS,2P@,C`Q,B!A;F0@1&5C96UB97(F
M(S$V,#LS,2P@,C`Q,2!A<F4@<')E<V5N=&5D(&EN('1H92!T86)L97,@8F5L
M;W<L(&EN('1H;W5S86YD<R`H=6YA=61I=&5D*3H@/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$9F]N="US:7IE.C$R<'@[;6%R9VEN+71O<#HP<'@[;6%R
M9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*("`@/'1A8FQE(&-E;&QS<&%C
M:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@8F]R9&5R/3-$
M,"!S='EL93TS1"=B;W)D97(M8V]L;&%P<V4Z8V]L;&%P<V4[('1E>'0M86QI
M9VXZ(&QE9G0G(&%L:6=N/3-$8V5N=&5R/@T*("`@/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*("`@/'1R/B`-"B`@(#QT9"!W:61T:#TS1#<X)3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V)3XF
M(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0V)3XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V
M,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@
M86QI9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L
M:60@(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY4:')E92!-;VYT:',-"B`@($5N9&5D
M/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/DUA<F-H)B,Q-C`[,S$L/"]B
M/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT
M<CX@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS
M1"=B;W)D97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB
M/C(P,3(\+V(^/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(@<W1Y;&4],T0G8F]R9&5R+6)O='1O;3HQ<'@@<V]L:60@
M(S`P,#`P,"<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$Q/"]B/CPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^#0H@("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X-"B`@(#PA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O
M;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@
M<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP
M,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/CQB/E-T871E;65N="!O9B!#;VUP<F5H96YS:79E($QO
M<W,@1&%T83H\+V(^/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(S$V,#L\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY.970@<F5V96YU97,\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPT-#$\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXS+#,P.3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N
M;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO
M=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D]P97)A
M=&EN9R!E>'!E;G-E<SPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.R8C,38P.R8C,38P.S4L-3(U/"]F;VYT/CPO
M=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S
M:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#LF(S$V,#LF(S$V,#LU+#0U.3PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G
M8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G
M/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O;&ED(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^
M#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*
M("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N
M=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/DQO<W,@9G)O;2!O<&5R871I;VYS/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^*#(L,#@T
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^*#(L,34P/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[
M/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C
M965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/D]T:&5R(&5X<&5N<V4\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXH-C<\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXH,3,Y/"]F;VYT
M/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@
M(#QT<B!S='EL93TS1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@
M<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q-C`[
M/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@
M/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P,"<^)B,Q
M-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X('-O
M;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,7!X
M('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L
M:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M
M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/DYE="!L;W-S/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B@R+#$U,3PO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#(^*28C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O;G0^/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXH,BPR.#D\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W
M<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/BDF(S$V,#L\+V9O;G0^/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE/3-$9F]N="US:7IE.C%P>#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B;W)D97(M=&]P.C-P>"!D;W5B
M;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@
M9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C-P>"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]P/@T*
M("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y
M;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO
M<#X-"B`@(#PO=&0^(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/@T*
M("`@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X-"B`@(#PO=&%B;&4^#0H@("`\
M<"!S='EL93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I
M;BUB;W1T;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN
M9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&)O<F1E<CTS1#`@
M<W1Y;&4],T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N
M.B!L969T)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@
M2&5A9"`M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0W."4^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q
M-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[
M/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED
M(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#$^/&(^36%R8V@F(S$V,#LS,2P\8G(@+SXR,#$R
M/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P
M,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA
M;B<@<VEZ93TS1#$^/&(^1&5C96UB97(\8G(@+SXS,2P@,C`Q,3PO8CX\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4]
M,T0Q/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^#0H@("`\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^
M#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E9F8^(`T*("`@/'1D('9A;&EG;CTS
M1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X
M="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CY"86QA;F-E(%-H965T($1A
M=&$Z/"]B/CPO9F]N=#X\+W`^#0H@("`\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q
M-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT9"!V86QI9VX]
M,T1T;W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM;&5F=#HQ+C`P96T[('1E
M>'0M:6YD96YT.BTQ+C`P96TG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^0V%S:"P@8V%S:"!E<75I=F%L
M96YT<R!A;F0@;6%R:V5T86)L92!S96-U<FET:65S/"]F;VYT/CPO<#X-"B`@
M(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,R+#4P.#PO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,X+#$T
M-#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R
M/B`-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F9CX@#0H@("`\=&0@=F%L:6=N
M/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T
M97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/D-U<G)E;G0@87-S971S/"]F
M;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,S(L
M.3(Y/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@
M;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V
M,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXS."PV-C8\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P
M.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(^(`T*("`@/'1D('9A
M;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUL969T.C$N,#!E
M;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY4;W1A;"!A<W-E=',\
M+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXS
M-RPR.34\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE
M<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F
M;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/C0R+#@X,3PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q
M-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!B9V-O;&]R/3-$
M(V-C965F9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4]
M,T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/D-U<G)E;G0@;&EA8FEL:71I97,\+V9O;G0^/"]P/@T*("`@/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C
M,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR,BPR,C`\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-
M"B`@(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/C$R+#@U,#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`],T1N;W=R87`@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/B`-"B`@(#QT<CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@
M/'`@<W1Y;&4],T0G;6%R9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM
M,2XP,&5M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/DYO;BUC=7)R96YT(&QI86)I;&ET:65S/"]F;VYT
M/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE
M=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,34L.#$W
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXR."PX,S0\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W
M<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO
M9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@("`\='(@8F=C;VQO<CTS1"-C8V5E
M9F8^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$)VUA
M<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CY.;W1E<R!P87EA8FQE/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^
M/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[
M/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R
M;VUA;B<@<VEZ93TS1#(^,3$L,C4S/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO
M=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I
M>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O
M;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXQ,2PR-3D\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX@#0H@
M("`\='(^(`T*("`@/'1D('9A;&EG;CTS1'1O<#X-"B`@(#QP('-T>6QE/3-$
M)VUA<F=I;BUL969T.C$N,#!E;3L@=&5X="UI;F1E;G0Z+3$N,#!E;2<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE
M/3-$,CY4;W1A;"!S=&]C:VAO;&1E<G,F(S@R,3<[("AD969I8VET*2!E<75I
M='D\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXH-S0R/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXI)B,Q-C`[/"]F;VYT/CPO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\
M+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S
M(&YE=R!R;VUA;B<@<VEZ93TS1#(^,2PQ.3<\+V9O;G0^/"]T9#X@#0H@("`\
M=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C
M,38P.SPO9F]N=#X\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"B`@(#QP('-T>6QE/3-$9F]N="US
M:7IE.C%P>#MM87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q
M-C`[/"]P/@T*/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
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M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;6UI=&UE;G1S
M(&%N9"!#;VYT:6YG96YC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/DUA<BX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#3TU-251-14Y44R!!3D0@0T].5$E.1T5.0TE%4SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M
M;"!054),24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO
M+T5.(B`B:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M
M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A
M9V=E9"!.;W1E(#4@+2!U<RUG86%P.D-O;6UI=&UE;G1S06YD0V]N=&EN9V5N
M8VEE<T1I<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R
M9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXU+B8C
M,38P.T-/34U)5$U%3E13($%.1"!#3TY424Y'14Y#2453(#PO8CX\+V9O;G0^
M/"]P/@T*("`@/'`@<W1Y;&4],T1M87)G:6XM=&]P.C9P>#MM87)G:6XM8F]T
M=&]M.C!P>#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@
M<F]M86XG('-I>F4],T0R/CQB/CQI/DQI=&EG871I;VX@/"]I/CPO8CX\+V9O
M;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN
M+6)O='1O;3HP<'@[(&UA<F=I;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/@T*("`@/&D^
M5&5K;6ER82!,:71I9V%T:6]N(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y
M;&4],T0G;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/D]N($UA<F-H)B,Q-C`[,38L(#(P,3$L(%1E
M:VUI<F$@86YD(%!R;W1I=F$-"B`@($)I;W1H97)A<&5U=&EC<RP@26YC+B!F
M:6QE9"!A(&-I=FEL(&-O;7!L86EN="!A9V%I;G-T('1H92!#;VUP86YY(&EN
M('1H92!"=7-I;F5S<R!,:71I9V%T:6]N(%-E8W1I;VX@;V8@=&AE(%-U9F9O
M;&L@0V]U;G1Y(%-U<&5R:6]R($-O=7)T(&EN($)O<W1O;BP@36%S<V%C:'5S
M971T<RP@86YD(&]N($IU;F4F(S$V,#LS+"`R,#$Q+"!T:&4@<&QA:6YT:69F
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M96-R971S+"!C:79I;"!C;VYS<&ER86-Y+"!A;F0-"B`@('1O<G1I;W5S(&EN
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M86YD(&1E8V5P=&EV90T*("`@=')A9&4@<')A8W1I8V5S(&)Y('1H92!#;VUP
M86YY+B!4:&4@<&QA:6YT:69F<R!S965K+"!A;6]N9R!O=&AE<B!R96QI968L
M(&EN:G5N8W1I=F4@<F5L:65F+"!U;G-P96-I9FEE9"!C;VUP96YS871O<GD@
M86YD('!U;FET:79E(&1A;6%G97,L(&%T=&]R;F5Y<R8C.#(Q-SL@9F5E<RP@
M=&AE('1E<FUI;F%T:6]N(&]F(&QI8V5N<V5S('1H870@=&AE('!L86EN=&EF
M9G,@<')O=FED960@=&\@=&AE($-O;7!A;GD@86YD('1H90T*("`@<F5L:6YQ
M=6ES:&UE;G0@86YD('1R86YS9F5R(&]F(&-E<G1A:6X@;V8@=&AE($-O;7!A
M;GDF(S@R,3<[<R!I;G1E;&QE8W1U86P@<')O<&5R='DL(&EN8VQU9&EN9R!P
M871E;G1S(&-O=F5R:6YG('1H92!#;VUP86YY)B,X,C$W.W,@34,S('1E8VAN
M;VQO9WDN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS1"=M87)G:6XM=&]P
M.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT.C@E)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4]
M,T0R/@T*("`@3VX@07!R:6PF(S$V,#LV+"`R,#$Q+"!T:&4@0V]M<&%N>2!T
M:6UE;'D@<V5R=F5D(&%N9"!F:6QE9"!A;B!A;G-W97(@=&\@=&AE('!L86EN
M=&EF9G,F(S@R,3<[(&]R:6=I;F%L(&-O;7!L86EN="!D96YY:6YG('1H92!P
M;&%I;G1I9F9S)B,X,C$W.R!C;&%I;7,L(&%N9"!A<W-E<G1E9"!C;W5N=&5R
M8VQA:6US(&%G86EN<W0@=&AE('!L86EN=&EF9G,N($]N#0H@("!*=6YE)B,Q
M-C`[,C@L(#(P,3$L('1H92!#;VUP86YY('1I;65L>2!S97)V960@86YD(&9I
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M<PT*("`@;V8@36%S<V%C:'5S971T<R!S=&%T=71E<RX@5&AE($-O;7!A;GD@
M:7,@<V5E:VEN9R!M;VYE=&%R>2!D86UA9V5S+"!A='1O<FYE>7,F(S@R,3<[
M(&9E97,@86YD(&5Q=6ET86)L92!R96QI968@;VX@:71S(&-O=6YT97)C;&%I
M;7,N($EN(%-E<'1E;6)E<B`R,#$Q+"!T:&4@0V]U<G0@9W)A;G1E9"!T:&4@
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M9',@=&\-"B`@('9I9V]R;W5S;'D@9&5F96YD(&ET<V5L9B!I;B!T:&ES(&UA
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M;W5R8V5S('1H870-"B`@('=O=6QD(&]T:&5R=VES92!B92!E;F=A9V5D(&EN
M(&]T:&5R(&%C=&EV:71I97,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL93TS
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M<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3AP>#MM87)G:6XM8F]T
M=&]M.C!P>#L@;6%R9VEN+6QE9G0Z,B4G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^#0H@("`\:3Y5;FEV
M97)S:71Y(&]F(%5T86@@3&ET:6=A=&EO;B`\+VD^/"]F;VYT/CPO<#X-"B`@
M(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X
M.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY/;B!-87)C:"8C,38P.S(R+"`R
M,#$Q+"!4:&4@56YI=F5R<VET>2!O9@T*("`@571A:"`H=&AE("8C.#(R,#M5
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M#0H@("`H=&]G971H97(L("8C.#(R,#M-87@@4&QA;F-K)B,X,C(Q.RDL('1H
M92!7:&ET96AE860@26YS=&ET=71E(&9O<B!":6]M961I8V%L(%)E<V5A<F-H
M("@F(S@R,C`[5VAI=&5H96%D)B,X,C(Q.RDL('1H92!-87-S86-H=7-E='1S
M($EN<W1I='5T92!O9B!496-H;F]L;V=Y("@F(S@R,C`[34E4)B,X,C(Q.RD@
M86YD('1H92!5;FEV97)S:71Y(&]F($UA<W-A8VAU<V5T=',@*"8C.#(R,#M5
M36%S<R8C.#(R,3LI+"!C;&%I;6EN9R!A('!R;V9E<W-O<B!A=`T*("`@=&AE
M(%5N:79E<G-I='D@:7,@=&AE('-O;&4@:6YV96YT;W(@;W(L(&EN('1H92!A
M;'1E<FYA=&EV92P@82!J;VEN="!I;G9E;G1O<BP@;V8@=&AE(%1U<V-H;"!P
M871E;G1S+B!4:&4@56YI=F5R<VET>2!D:60@;F]T('-E<G9E('1H92!O<FEG
M:6YA;"!C;VUP;&%I;G0@;VX@=&AE($-O;7!A;GD@;W(@=&AE(&]T:&5R(&1E
M9F5N9&%N=',N($]N($IU;'DF(S$V,#LV+"`R,#$Q+"!T:&4@56YI=F5R<VET
M>2!F:6QE9"!A;B!A;65N9&5D#0H@("!C;VUP;&%I;G0@86QL96=I;F<@<W5B
M<W1A;G1I86QL>2!T:&4@<V%M92!C;&%I;7,@86=A:6YS="!T:&4@0V]M<&%N
M>2P@36%X(%!L86YC:RP@5VAI=&5H96%D+"!-250@86YD(%5-87-S+B!4:&4@
M86UE;F1E9"!C;VUP;&%I;G0@=V%S('-E<G9E9"!O;B!T:&4@0V]M<&%N>2!O
M;B!*=6QY)B,Q-C`[,30L(#(P,3$N(%1H92!5;FEV97)S:71Y(&ES('-E96MI
M;F<@8VAA;F=E<R!T;R!T:&4@:6YV96YT;W)S:&EP(&]F('1H92!4=7-C:&P-
M"B`@('!A=&5N=',L('5N<W!E8VEF:65D(&1A;6%G97,@86YD(&]T:&5R(')E
M;&EE9BX@3VX@3V-T;V)E<B8C,38P.S,Q+"`R,#$Q+"!T:&4@0V]M<&%N>2P@
M36%X(%!L86YC:RP@5VAI=&5H96%D+"!-250@86YD(%5-87-S(&9I;&5D(&$@
M;6]T:6]N('1O(&1I<VUI<W,N($%L<V\@;VX@3V-T;V)E<B8C,38P.S,Q+"`R
M,#$Q+"!536%S<R!F:6QE9"!A(&UO=&EO;B!T;R!D:7-M:7-S(&]N('-E<&%R
M871E(&=R;W5N9',L('=H:6-H('1H90T*("`@0V]M<&%N>2P@36%X(%!L86YC
M:RP@5VAI=&5H96%D(&%N9"!-250@:&%V92!J;VEN960N($]N($1E8V5M8F5R
M)B,Q-C`[,S$L(#(P,3$L('1H92!5;FEV97)S:71Y(&9I;&5D(&$@<V5C;VYD
M(&%M96YD960@8V]M<&QA:6YT(&1R;W!P:6YG(%5-87-S(&%S(&$@9&5F96YD
M86YT(&%N9"!A9&1I;F<@87,@9&5F96YD86YT<R!S979E<F%L(%5-87-S(&]F
M9FEC:6%L<RX@06QT:&]U9V@@=&AE($-O;7!A;GD@8F5L:65V97,@:70@:&%S
M(&UE<FET;W)I;W5S(&1E9F5N<V5S(&%N9`T*("`@:6YT96YD<R!T;R!V:6=O
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M90T*("`@871T96YT:6]N(&]F('1H92!#;VUP86YY)B,X,C$W.W,@;6%N86=E
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M;W-S(&]R(')A;F=E(&]F(&QO<W,N(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@[(&UA<F=I
M;BUL969T.C(E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/CQI/E1E:VUI<F$@26YF<FEN9V5M96YT($QI
M=&EG871I;VX-"B`@(#PO:3X\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4],T0G
M;6%R9VEN+71O<#HV<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M:6YD96YT
M.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M
M86XG('-I>F4],T0R/D]N($IA;G5A<GDF(S$V,#LQ-RP@,C`Q,BP@=&AE($-O
M;7!A;GD@9FEL960@82!C;VUP;&%I;G0@:6X@=&AE(%5N:71E9"!3=&%T97,@
M1&ES=')I8W0@0V]U<G0@9F]R('1H92!$:7-T<FEC="!O9@T*("`@36%S<V%C
M:'5S971T<R!A9V%I;G-T(%1E:VUI<F$@9F]R('!A=&5N="!I;F9R:6YG96UE
M;G0@87)I<VEN9R!F<F]M(%1E:VUI<F$F(S@R,3<[<R!R97-E87)C:"!A8W1I
M=FET:65S('!R;W9I9&EN9R!L:7!I9"!N86YO<&%R=&EC;&5S+2`H)B,X,C(P
M.TQ.4"8C.#(R,3LM*2!F;W)M=6QA=&5D('-M86QL(&EN=&5R9F5R:6YG(%).
M02`H)B,X,C(P.W-I4DY!)B,X,C(Q.RD@;6]L96-U;&5S('1O(&$@<&AA<FUA
M8V5U=&EC86P@8V]L;&%B;W)A=&]R+@T*("`@07,@86QL96=E9"!I;B!T:&4@
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M<B!O9@T*("`@:7-S=65D('!A=&5N=',@<F5L871E9"!T;R!S:5).02!A;F0@
M3$Y0('1E8VAN;VQO9VEE<RP@:6YC;'5D:6YG.B!5+E,N(%!A=&5N="!.;RXF
M(S$V,#LW+#8Y-2PY,#([(%4N4RX@4&%T96YT($YO+B8C,38P.S8L.#4X+#(R
M-3L@52Y3+B!0871E;G0@3F\N)B,Q-C`[-BPX,34L-#,R.R!5+E,N(%!A=&5N
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M('-U:70@87,@82!C;RUP;&%I;G1I9F8N($]N($UA<F-H)B,Q-C`[,BP@,C`Q
M,BP@5&5K;6ER82!F:6QE9"!A(&UO=&EO;B!T;R!D:7-M:7-S(&9I=F4@;V8@
M=&AE('-I>`T*("`@8VQA:6US(&]F('1H92!#;VUP86YY)B,X,C$W.W,@8V]M
M<&QA:6YT(&9O<B!L86-K(&]F('-T86YD:6YG+B8C,38P.U1H92!#;VUP86YY
M(&9I;&5D(&%N(&]P<&]S:71I;VX@=&\@=&AI<R!M;W1I;VX@86YD(%1E:VUI
M<F$@:&%S(&9I;&5D(&$@<F5P;'DN(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1"=M87)G:6XM=&]P.C$R<'@[;6%R9VEN+6)O='1O;3HP<'@[('1E>'0M
M:6YD96YT.C@E)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/@T*("`@5&AE($-O;7!A;GD@86YD($ES:7,@
M87)E('-E96MI;F<@:G5D9VUE;G0@=&AA="!496MM:7)A(&AA<R!I;F9R:6YG
M960@=&AE('!A=&5N=',@870@:7-S=64L(&$@<&5R;6%N96YT(&EN:G5N8W1I
M;VX@96YJ;VEN:6YG('1H92!I;F9R:6YG:6YG(&%C=&EV:71I97,L(&1A;6%G
M97,L(&%N9"!C;W-T<R!A;F0@97AP96YS97,L(&EN8VQU9&EN9PT*("`@871T
M;W)N97ES)B,X,C$W.R!F965S+B`\+V9O;G0^/"]P/@T*("`@/'`@<W1Y;&4]
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M/CPO<#X-"B`@(#QP('-T>6QE/3-$9F]N="US:7IE.C%P>#MM87)G:6XM=&]P
M.C$X<'@[;6%R9VEN+6)O='1O;3HP<'@^)B,Q-C`[/"]P/@T*/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/C(P,3(@4F5S=')U8W1U<FEN9SQB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/C(P,3(@4F5S
M=')U8W1U<FEN9R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3(@4D535%)50U154DE.1SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),
M24,@(BTO+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B
M:'1T<#HO+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I
M=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.
M;W1E(#8@+2!U<RUG86%P.E)E<W1R=6-T=7)I;F=!;F1296QA=&5D06-T:79I
M=&EE<T1I<V-L;W-U<F5497AT0FQO8VLM+3X-"B`@(#QP('-T>6QE/3-$;6%R
M9VEN+71O<#HP<'@[;6%R9VEN+6)O='1O;3HP<'@^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX\8CXV+B8C
M,38P.S(P,3(@4D535%)50U154DE.1R`\+V(^/"]F;VYT/CPO<#X-"B`@(#QP
M('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ,'!X.R!T
M97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!*86YU87)Y(#(P,3(L('1H92!#
M;VUP86YY)B,X,C$W.W,@0F]A<F0@;V8@1&ER96-T;W)S(&%P<')O=F5D+"!A
M;F0@=&AE($-O;7!A;GD@:6UP;&5M96YT960L(&$@<W1R871E9VEC(&-O<G!O
M<F%T90T*("`@<F5S=')U8W1U<FEN9R!P=7)S=6%N="!T;R!W:&EC:"!T:&4@
M0V]M<&%N>2!R961U8V5D(&ET<R!O=F5R86QL('=O<FMF;W)C92!B>2!A<'!R
M;WAI;6%T96QY(#,S)2P@=&\@87!P<F]X:6UA=&5L>2`Q,34@96UP;&]Y965S
M+B!4:&4@0V]M<&%N>2!E>'!E8W1S('1H92!R961U8W1I;VX@:6X@<&5R<V]N
M;F5L(&-O<W1S+"!A;&]N9R!W:71H(&]T:&5R(&5X=&5R;F%L(&-O<W1S+"!T
M;R!R97-U;'0@:6X@<V%V:6YG<R!O9@T*("`@87!P<F]X:6UA=&5L>2`D,C`N
M,"!M:6QL:6]N(&EN(&ET<R`R,#$R(&]P97)A=&EN9R!E>'!E;G-E<RX@/"]F
M;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P>#MM87)G
M:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^1'5R:6YG
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F(S$V,#LS,2P@,C`Q,BP@
M=&AE($-O;7!A;GD-"B`@('-U8G-T86YT:6%L;'D@8V]M<&QE=&5D('1H92!I
M;7!L96UE;G1A=&EO;B!O9B!T:&4@<W1R871E9VEC(&-O<G!O<F%T92!R97-T
M<G5C='5R:6YG(&%N9"!R96-O<F1E9"`D,RXY)B,Q-C`[;6EL;&EO;B!O9B!R
M97-T<G5C='5R:6YG+7)E;&%T960@8V]S=',@:6X@;W!E<F%T:6YG(&5X<&5N
M<V5S+"!I;F-L=61I;F<@96UP;&]Y964@<V5V97)A;F-E+"!B96YE9FET<R!A
M;F0@<F5L871E9"!C;W-T<RX@5&AE($-O;7!A;GD@97AP96-T<R!T;PT*("`@
M<&%Y('-U8G-T86YT:6%L;'D@86QL(&]F('1H97-E(')E<W1R=6-T=7)I;F<@
M8V]S=',@9'5R:6YG(#(P,3(N(%1H92!#;VUP86YY(&1O97,@;F]T(&5X<&5C
M="!T;R!I;F-U<B!A;GD@861D:71I;VYA;"!S:6=N:69I8V%N="!C;W-T<R!A
M<W-O8VEA=&5D('=I=&@@=&AI<R!R97-T<G5C='5R:6YG+B`\+V9O;G0^/"]P
M/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+71O<#HQ,G!X.VUA<F=I;BUB;W1T
M;VTZ,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CX-"B`@(%1H92!F;VQL
M;W=I;F<@=&%B;&4@<W5M;6%R:7IE<R!T:&4@8V]M<&]N96YT<R!O9B!T:&4@
M0V]M<&%N>28C.#(Q-SMS(')E<W1R=6-T=7)I;F<@97AP96YS97,@<F5C;W)D
M960@:6X@;W!E<F%T:6YG(&5X<&5N<V5S(&%N9"!I;B!C=7)R96YT(&QI86)I
M;&ET:65S+"!I;B!T:&]U<V%N9',Z(#PO9F]N=#X\+W`^#0H@("`\<"!S='EL
M93TS1&9O;G0M<VEZ93HQ,G!X.VUA<F=I;BUT;W`Z,'!X.VUA<F=I;BUB;W1T
M;VTZ,'!X/B8C,38P.SPO<#X-"B`@(#QT86)L92!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.#0E(&)O<F1E<CTS1#`@<W1Y;&4]
M,T0G8F]R9&5R+6-O;&QA<'-E.F-O;&QA<'-E.R!T97AT+6%L:6=N.B!L969T
M)R!A;&EG;CTS1&-E;G1E<CX-"B`@(#PA+2T@0F5G:6X@5&%B;&4@2&5A9"`M
M+3X-"B`@(#QT<CX@#0H@("`\=&0@=VED=&@],T0W,"4^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-B4^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T>6QE/3-$)V)O<F1E<BUB
M;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^0VAA<F=E<SPO
M8CX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY);F-U<G)E9#QB<B`O/E1H<F]U
M9V@\+V(^/"]F;VYT/CQB<B`O/@T*("`@/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY-87)C:"8C,38P
M.S,Q+#PO8CX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CXR,#$R/"]B/CPO9F]N
M=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS
M1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTZ,7!X('-O;&ED(",P,#`P,#`G/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS
M1#$^/&(^06UO=6YT<SPO8CX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X\8CY086ED
M/&)R("\^5&AR;W5G:#PO8CX\+V9O;G0^/&)R("\^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,3X-"B`@(#QB
M/DUA<F-H)B,Q-C`[,S$L/&)R("\^,C`Q,CPO8CX\+V9O;G0^/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO
M9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ
M93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<B!S='EL93TS1"=B;W)D
M97(M8F]T=&]M.C%P>"!S;VQI9"`C,#`P,#`P)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/CQB/D%M;W5N
M=',\+V(^/"]F;VYT/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#$^/&(^06-C<G5E9"8C,38P.V%T
M/"]B/CPO9F]N=#X\8G(@+SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0Q/@T*("`@/&(^36%R8V@F(S$V,#LS
M,2P\8G(@+SXR,#$R/"]B/CPO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT/CPO=&0^#0H@
M("`\+W1R/@T*("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@
M0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`@(#QT<B!B9V-O;&]R/3-$(V-C965F
M9CX@#0H@("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R
M9VEN+6QE9G0Z,2XP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R
M/D5M<&QO>65E('-E=F5R86YC92P@8F5N969I=',@86YD(')E;&%T960@8V]S
M=',\+V9O;G0^/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT/CPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^,RPY
M,#D\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$;F]W<F%P('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N
M97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B0\+V9O
M;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N
M)R!S:7IE/3-$,CXQ+#4R,3PO9F]N=#X\+W1D/B`-"B`@(#QT9"!N;W=R87`]
M,T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)B,Q-C`[/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S:7IE/3-$
M,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT
M:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C(L,S@X/"]F;VYT/CPO=&0^(`T*
M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$
M,CXF(S$V,#L\+V9O;G0^/"]T9#X-"B`@(#PO='(^(`T*("`@/'1R('-T>6QE
M/3-$9F]N="US:7IE.C%P>#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M,38P.SPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V,#L\+W1D
M/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS1"=B
M;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@("`\<"!S='EL93TS
M1"=B;W)D97(M=&]P.C%P>"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P,#`P
M,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HQ<'@@<V]L:60@(S`P
M,#`P,"<^)B,Q-C`[/"]P/@T*("`@/"]T9#X@#0H@("`\=&0^)B,Q-C`[/"]T
M9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C,38P.SPO=&0^(`T*("`@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT
M;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*
M("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E
M<BUT;W`Z,7!X('-O;&ED(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D/B8C,38P.SPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<CX@#0H@
M("`\=&0@=F%L:6=N/3-$=&]P/@T*("`@/'`@<W1Y;&4],T0G;6%R9VEN+6QE
M9G0Z,RXP,&5M.R!T97AT+6EN9&5N=#HM,2XP,&5M)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/E1O=&%L
M/"]F;VYT/CPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S:7IE/3-$,3XF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I
M;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^)#PO9F]N=#X\+W1D/B`-"B`@(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/C,L.3`Y
M/"]F;VYT/CPO=&0^(`T*("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM97,@;F5W
M(')O;6%N)R!S:7IE/3-$,CXF(S$V,#L\+V9O;G0^/"]T9#X@#0H@("`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-I>F4],T0Q/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CXD/"]F;VYT
M/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@
M<VEZ93TS1#(^,2PU,C$\+V9O;G0^/"]T9#X@#0H@("`\=&0@;F]W<F%P/3-$
M;F]W<F%P('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3IT:6UE<R!N97<@<F]M86XG('-I>F4],T0R/B8C,38P.SPO9F]N=#X\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<VEZ93TS1#$^
M)B,Q-C`[/"]F;VYT/CPO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3IT:6UE<R!N97<@<F]M86XG('-I
M>F4],T0R/B0\+V9O;G0^/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ=&EM
M97,@;F5W(')O;6%N)R!S:7IE/3-$,CXR+#,X.#PO9F]N=#X\+W1D/B`-"B`@
M(#QT9"!N;W=R87`],T1N;W=R87`@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M)B,Q-C`[/"]F;VYT/CPO=&0^#0H@("`\+W1R/B`-"B`@(#QT<B!S='EL93TS
M1&9O;G0M<VEZ93HQ<'@^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3XF(S$V
M,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@
M#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R
M9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO
M=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$
M)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@
M("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/B`-"B`@(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@("`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R+71O<#HS<'@@9&]U8FQE(",P,#`P
M,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^(`T*("`@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O<F1E<BUT;W`Z,W!X(&1O=6)L92`C
M,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\+W1D/B`-"B`@(#QT9#XF(S$V,#L\
M+W1D/B`-"B`@(#QT9"!V86QI9VX],T1B;W1T;VT^)B,Q-C`[/"]T9#X@#0H@
M("`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*("`@/'`@<W1Y;&4],T0G8F]R9&5R
M+71O<#HS<'@@9&]U8FQE(",P,#`P,#`G/B8C,38P.SPO<#X-"B`@(#PO=&0^
M(`T*("`@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`@(#QP('-T>6QE/3-$)V)O
M<F1E<BUT;W`Z,W!X(&1O=6)L92`C,#`P,#`P)SXF(S$V,#L\+W`^#0H@("`\
M+W1D/B`-"B`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T<CX-"B`@(#PA+2T@
M16YD(%1A8FQE($)O9'D@+2T^#0H@("`\+W1A8FQE/B`-"CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?-F(X-3,Q8S%?-S$S95\T
M,C(V7V)A961?9&,Q.38U-S$U,C8U#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+S9B.#4S,6,Q7S<Q,V5?-#(R-E]B865D7V1C,3DV-3<Q-3(V-2]7
M;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY3=6)S97%U96YT($5V96YT<SQB<CX\+W-T<F]N9SX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E<75E;G0@
M179E;G1S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4U5"4T51545.5"!%5D5.5#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO
M+U<S0R\O1%1$(%A(5$U,(#$N,"!4<F%N<VET:6]N86PO+T5.(B`B:'1T<#HO
M+W=W=RYW,RYO<F<O5%(O>&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L
M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#<@
M+2!U<RUG86%P.E-U8G-E<75E;G1%=F5N='-497AT0FQO8VLM+3X-"B`@(#QP
M('-T>6QE/3-$;6%R9VEN+71O<#HQ.'!X.VUA<F=I;BUB;W1T;VTZ,'!X/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ
M93TS1#(^/&(^-RX@4U5"4T51545.5"!%5D5.5"`\+V(^/"]F;VYT/CPO<#X-
M"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z-G!X.VUA<F=I;BUB;W1T;VTZ
M,'!X.R!T97AT+6EN9&5N=#HX)2<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ=&EM97,@;F5W(')O;6%N)R!S:7IE/3-$,CY);B!*=6QY(#(P,#<L('1H
M92!#;VUP86YY(&5N=&5R960@:6YT;R!T:&4@365D=')O;FEC($%G<F5E;65N
M="!T;R!P=7)S=64@=&AE(&1E=F5L;W!M96YT(&]F(%).06D@=&AE<F%P975T
M:6-S(&9O<B!T:&4-"B`@('1R96%T;65N="!O9B!N975R;V1E9V5N97)A=&EV
M92!D:7-O<F1E<G,@=7-I;F<@:6UP;&%N=&%B;&4@:6YF=7-I;VX@<WES=&5M
M<RX@04Q.+4A45"!I<R!A;B!23D%I('1H97)A<&5U=&EC(&-A;F1I9&%T92!T
M87)G971I;F<@=&AE(&AU;G1I;F=T:6X@9V5N92P@9F]R('1H92!T<F5A=&UE
M;G0@;V8@2'5N=&EN9W1O;B8C.#(Q-SMS(&1I<V5A<V4L('=H:6-H('1H92!#
M;VUP86YY(&AA<R!B965N(&1E=F5L;W!I;F<@:6X-"B`@(&-O;&QA8F]R871I
M;VX@=VET:"!-961T<F]N:6,@=6YD97(@=&AE($UE9'1R;VYI8R!!9W)E96UE
M;G0N($EN($YO=F5M8F5R(#(P,3`L('1H92!#;VUP86YY(&%N9"!-961T<F]N
M:6,@96YT97)E9"!I;G1O(&%N(&%G<F5E;65N="!W:71H($-(1$D@1F]U;F1A
M=&EO;BP@26YC+B`H)B,X,C(P.T-(1$DF(S@R,C$[*2P@=6YD97(@=VAI8V@@
M0TA$22!A9W)E960@=&\@:6YI=&EA;&QY(&9U;F0@87!P<F]X:6UA=&5L>2`U
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M92X@/"]F;VYT/CPO<#X-"B`@(#QP('-T>6QE/3-$)VUA<F=I;BUT;W`Z,3)P
M>#MM87)G:6XM8F]T=&]M.C!P>#L@=&5X="UI;F1E;G0Z."4G/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.G1I;65S(&YE=R!R;VUA;B<@<VEZ93TS1#(^
M26X@07!R:6P@,C`Q,BP@87,@<&%R="!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS
M(&%L:6=N;65N="!O9B!R97-O=7)C97,@9F]L;&]W:6YG(&ET<R!S=')A=&5G
M:6,@8V]R<&]R871E(')E<W1R=6-T=7)I;F<L('1H92!#;VUP86YY#0H@("!E
M>&5R8VES960@:71S(&]P=&EO;B!U;F1E<B!T:&4@365D=')O;FEC($%G<F5E
M;65N="!T;R!O<'0M;W5T(&]F('1H92`U,"TU,"!E>'!E;G-E+W!R;V9I="!S
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M('1H90T*("`@<')O9W)A;2P@=&AE($-O;7!A;GD@=V]U;&0@8F4@8V]M<&5N
M<V%T960@9F]R('-U8V@@<W5P<&QY(&EN(&%C8V]R9&%N8V4@=VET:"!T:&4@
M=&5R;7,@;V8@=&AE($UE9'1R;VYI8R!!9W)E96UE;G0N(%1H92!#;VUP86YY
M('=O=6QD(&)E(&5N=&ET;&5D('1O(&-E<G1A:6X@9&5V96QO<&UE;G0@;6EL
M97-T;VYE<RP@87,@=V5L;"!A<R!R;WEA;'1I97,@;VX@86YN=6%L(&YE="!S
M86QE<RP@:68@86YY+B!4:&4@0V]M<&%N>0T*("`@8V]N=&EN=65S('1O(&)E
M(&]B;&EG871E9"!T;R!R97!A>2!#2$1)(&9O<B!I=',@<')O+7)A=&$@<VAA
M<F4@;V8@9G5N9&EN9R!R96-E:79E9"!T:')O=6=H('1H92!E9F9E8W1I=F4@
M9&%T92!O9B!I=',@;W!T+6]U="P@=VET:"!I;G1E<F5S="P@:6X@=&AE(&5V
M96YT('1H870@82!P<F]D=6-T(&ES('5L=&EM871E;'D@8V]M;65R8VEA;&EZ
M960@9G)O;2!T:&4@9G5N9&5D(')E<V5A<F-H+B`\+V9O;G0^/"]P/@T*/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@
M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\V8C@U,S%C
M,5\W,3-E7S0R,C9?8F%E9%]D8S$Y-C4W,34R-C4-"D-O;G1E;G0M3&]C871I
M;VXZ(&9I;&4Z+R\O0SHO-F(X-3,Q8S%?-S$S95\T,C(V7V)A961?9&,Q.38U
M-S$U,C8U+U=O<FMS:&5E=',O9FEL96QI<W0N>&UL#0I#;VYT96YT+51R86YS
M9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z
M('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQX;6P@>&UL;G,Z
M;STS1")U<FXZ<V-H96UA<RUM:6-R;W-O9G0M8V]M.F]F9FEC93IO9F9I8V4B
M/@T*(#QO.DUA:6Y&:6QE($A2968],T0B+BXO5V]R:V)O;VLN:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N:'1M;"(O
M/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T7S9B.#4S,6,Q7S<Q,V5?-#(R
7-E]B865D7V1C,3DV-3<Q-3(V-2TM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 3 - us-gaap:IncomeTaxDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>3. INCOME TAXES </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company expects to continue to generate U.S. taxable losses in 2012 and has recorded no income tax provision for
   the three months ended March&#160;31, 2012 and 2011. </font></p>
    <p><font size="1">&#160;</font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In July 2011, the
   Internal Revenue Service completed its audits of the Company&#8217;s 2008 and 2009 tax years. Subsequently, the 2010 tax year was reviewed by the Joint Committee of the Internal Revenue Service (&#8220;Joint Committee&#8221;). In March 2012, the
   Company received the final report from the Joint Committee. The review of tax years 2008 through 2010 is complete. The Company did not record any tax expense related to these audits. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company continues to recognize fully its tax benefits which are offset by a valuation allowance to the extent that it is more likely
   than not that the deferred tax assets will not be realized. At March&#160;31, 2012, the Company had $0.1&#160;million of total gross unrecognized tax benefits that, if recognized, would favorably impact the Company&#8217;s effective income tax rate
   in future periods. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 136, 172<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 109<br><br> -Paragraph 43, 44, 45, 46, 47, 48, 49<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6881521&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeTaxDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQKAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 61,739<span></span></td>
        <td class="nump">$ 70,228<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
        <td class="nump">137,356<span></span></td>
        <td class="nump">76,174<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Billed and unbilled collaboration receivables</a></td>
        <td class="nump">2,192<span></span></td>
        <td class="nump">1,468<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump">7,252<span></span></td>
        <td class="nump">4,158<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">208,539<span></span></td>
        <td class="nump">152,028<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities</a></td>
        <td class="nump">117,822<span></span></td>
        <td class="nump">114,407<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">13,703<span></span></td>
        <td class="nump">14,643<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in joint venture (Regulus Therapeutics Inc.)</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">564<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
        <td class="nump">231<span></span></td>
        <td class="nump">275<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">340,295<span></span></td>
        <td class="nump">281,917<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">4,339<span></span></td>
        <td class="nump">5,800<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">13,006<span></span></td>
        <td class="nump">12,340<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
        <td class="nump">608<span></span></td>
        <td class="nump">484<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
        <td class="nump">48,410<span></span></td>
        <td class="nump">62,366<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in joint venture (Regululs Therapeutics Inc.)</a></td>
        <td class="nump">275<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">66,638<span></span></td>
        <td class="nump">80,990<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
        <td class="nump">3,202<span></span></td>
        <td class="nump">3,727<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump">72,374<span></span></td>
        <td class="nump">78,487<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
        <td class="nump">703<span></span></td>
        <td class="nump">716<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">142,917<span></span></td>
        <td class="nump">163,920<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 4, 5 and 6)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized and no shares issued and outstanding at March 31, 2012 and December 31, 2011</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 125,000,000 shares authorized; 51,893,258 shares issued and outstanding at March 31, 2012; 42,721,942 shares issued and outstanding at December 31, 2011</a></td>
        <td class="nump">519<span></span></td>
        <td class="nump">427<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
        <td class="nump">609,260<span></span></td>
        <td class="nump">518,731<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
        <td class="num">(37)<span></span></td>
        <td class="num">(165)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(412,364)<span></span></td>
        <td class="num">(400,996)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
        <td class="nump">197,378<span></span></td>
        <td class="nump">117,997<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
        <td class="nump">$ 340,295<span></span></td>
        <td class="nump">$ 281,917<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 130<br><br><br><br> -Paragraph 14, 17, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e681-108580<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapitalCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br> -Section S99<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Publisher FASB<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Concepts (CON)<br><br><br><br> -Number 6<br><br><br><br> -Paragraph 25<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 133<br><br><br><br> -Paragraph 22<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15E<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 16<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15C<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 13, 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4, 5<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6379932&amp;loc=d3e22054-111558<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26626-111562<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15C<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15D<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 115<br><br><br><br> -Paragraph 17<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Staff Position (FSP)<br><br><br><br> -Number FAS115-1/124-1<br><br><br><br> -Paragraph 15E<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableForSaleSecuritiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7<br><br><br><br> -Footnote 1<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 95<br><br><br><br> -Paragraph 7, 26<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 9<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14326-108349<br><br><br><br><br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 5<br><br><br><br> -Paragraph 8, 9<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingencies</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name FASB Technical Bulletin (FTB)<br><br><br><br> -Number 85-3<br><br><br><br> -Paragraph 2<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 13<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph b<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453417&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6600647&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Chapter 3<br><br><br><br> -Section A<br><br><br><br> -Paragraph 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 48<br><br><br><br> -Paragraph 6<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 323<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate sum of gross carrying value of a major finite-lived intangible asset class, less accumulated amortization and any impairment charges. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 142<br><br><br><br> -Paragraph 45<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6905858&amp;loc=d3e16323-109275<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FiniteLivedIntangibleAssetsNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total investments in (A) an entity in which the entity has significant influence, but does not have control, (B) subsidiaries that are not required to be consolidated and are accounted for using the equity and or cost method, and (C) an entity in which the reporting entity shares control of the entity with another party or group. Includes long-term advances receivable from a party that is affiliated with the reporting entity by means of direct or indirect ownership.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 24<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherLiabilitiesNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 129<br><br><br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 5<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 43<br><br><br><br> -Section A<br><br><br><br> -Paragraph 4<br><br><br><br> -Chapter 3<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Section 45<br><br><br><br> -SubTopic 10<br><br><br><br> -Topic 210<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Paragraph 1<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseAndOtherAssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 7<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph b, c<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ReceivablesNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Principles Board Opinion (APB)<br><br><br><br> -Number 12<br><br><br><br> -Paragraph 10<br><br><br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher AICPA<br><br><br><br> -Name Accounting Research Bulletin (ARB)<br><br><br><br> -Number 51<br><br><br><br> -Paragraph A3<br><br><br><br> -Appendix A<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6228006&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 1 - us-gaap:SignificantAccountingPoliciesTextBlock-->
   <!-- xbrl,ns -->
   <!-- xbrl,nx -->
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2"><b></b></font>
   <font style="font-family:times new roman" size="2">
   <b></b></font>
   <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Basis of Presentation and Principles of Consolidation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The accompanying condensed consolidated financial statements of Alnylam Pharmaceuticals, Inc. (the &#8220;Company&#8221; or
   &#8220;Alnylam&#8221;) are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) applicable to interim periods and, in the opinion of management, include all
   normal and recurring adjustments that are necessary to state fairly the results of operations for the reported periods. The Company&#8217;s condensed consolidated financial statements have also been prepared on a basis substantially consistent with,
   and should be read in conjunction with, the Company&#8217;s audited consolidated financial statements for the year ended December&#160;31, 2011, which were included in the Company&#8217;s Annual Report on Form 10-K that was filed with the Securities
   and Exchange Commission (the &#8220;SEC&#8221;) on February&#160;13, 2012. The year-end condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. The results of the
   Company&#8217;s operations for any interim period are not necessarily indicative of the results of the Company&#8217;s operations for any other interim period or for a full fiscal year. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The accompanying condensed consolidated financial statements reflect the operations of the Company and Alnylam U.S., Inc., Alnylam Europe
   AG (&#8220;Alnylam Europe&#8221;), Alnylam Securities Corporation and Meltemi Biotherapeutics, Inc., wholly-owned subsidiaries of the Company. All significant intercompany accounts and transactions have been eliminated. The Company uses the equity
   method of accounting to account for its investment in Regulus Therapeutics Inc. (&#8220;Regulus&#8221;). </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Use of Estimates
   </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions
   that affect&#160;the reported amounts of assets and liabilities and&#160;the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and&#160;the reported amounts of revenues and expenses during
   the reporting period. Actual results could differ from those estimates. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Net Loss Per Common Share </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company computes basic net loss&#160;per common share by dividing net loss&#160;attributable to common stockholders by the weighted
   average number of common shares outstanding. The Company computes diluted net loss&#160;per common share by dividing net loss&#160;attributable to common stockholders by the weighted average number of common shares and dilutive potential common
   share equivalents then outstanding. Potential common shares consist of shares issuable upon the exercise of stock options (using the treasury stock method) and unvested restricted stock awards. Because the inclusion of potential common shares would
   be anti-dilutive for all periods presented, diluted net loss per common share is the same as basic net loss per common share. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following table sets forth for the periods presented the potential common shares (prior to consideration of the treasury stock
   method) excluded from the calculation of net loss per common share because their inclusion would be anti-dilutive, in thousands: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="84%">&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="3%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Three&#160;Months&#160;Ended</b></font><br /><font style="font-family:times new roman" size="1"><b>March&#160;
   31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Options to purchase common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,085</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,869</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Unvested restricted common stock</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">658</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">113</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">9,743</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">8,982</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Restricted Stock Awards
   </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In January 2012, as part of its post-restructuring retention program, the Company granted an aggregate of 508,928
   shares of restricted stock to its retained employees, excluding the Company&#8217;s chief executive officer and president and chief operating officer. These restricted stock awards were valued at $5.3 million on the grant date and vest in full on the
   second anniversary of the grant date. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company recognized an aggregate of $0.5 million and $0.1 million of stock-based
   compensation expense related to all restricted stock awards granted for the three months ended March&#160;31, 2012 and 2011, respectively. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Public Offering </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In February 2012, the Company sold an aggregate of 8,625,000 shares of its common stock through an underwritten public offering at a price
   to the public of $10.75 per share. As a result of the offering, the Company received aggregate net proceeds of approximately $86.8 million, after deducting underwriting discounts and commissions and other estimated offering expenses of approximately
   $5.9 million. </font></p>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Fair Value Measurements </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   The following tables present information about the Company&#8217;s assets that are measured at fair value on a recurring basis at March&#160;31, 2012 and December&#160;31, 2011, and indicate the fair value
   hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level&#160;1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values
   determined by Level&#160;2 inputs utilize data points that are observable, such as quoted prices (adjusted), interest rates and yield curves. Fair values determined by Level&#160;3 inputs utilize unobservable data points for the asset or liability,
   and include situations where there is little, if any, market activity for the asset or liability. The fair value hierarchy level is determined by the lowest level of significant input. Financial assets measured at fair value on a recurring basis are
   summarized as follows, in thousands: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:39pt"><font style="font-family:times new roman" size="1"><b>Description</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>At</b></font><br /><font style="font-family:times new roman" size="1"><b>&#160;&#160;March&#160;31,&#160;&#160;
   </b></font><br /><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices</b></font><br /><font style="font-family:times new roman" size="1"><b>in
   Active<br />Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Observable<br />Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Unobservable<br />Inputs</b></font><br /><font style="font-family:times new roman" size="1"><b>(Level
    3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60,791</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60,088</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">703</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Marketable securities (fixed income)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">181,121</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">181,121</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">68,832</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">68,832</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Commercial paper</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,182</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,182</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Marketable securities (equity holdings)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">43</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">43</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">315,969</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60,088</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">255,881</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="56%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom" nowrap="nowrap">
   <p style="border-bottom:1px solid #000000;width:39pt"><font style="font-family:times new roman" size="1"><b>Description</b></font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>At</b></font><br /><font style="font-family:times new roman" size="1"><b>December&#160;
   31,<br />2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Quoted&#160;Prices</b></font><br /><font style="font-family:times new roman" size="1"><b>in
   Active<br />Markets<br />(Level 1)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Observable<br />Inputs<br />(Level 2)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Significant<br />Unobservable<br />Inputs</b></font><br /><font style="font-family:times new roman" size="1"><b>(Level
    3)</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Cash equivalents</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">67,024</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">67,024</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Marketable securities (fixed income)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">104,839</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">104,839</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">73,722</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">73,722</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Commercial paper</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,395</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,395</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Marketable securities (equity holdings)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">625</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">625</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">257,605</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">67,024</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">190,581</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">During the three months ended March&#160;31, 2012, there were no transfers between Level 1 and Level 2
   financial assets. The carrying amounts reflected in the Company&#8217;s condensed consolidated balance sheets for cash, collaboration receivables, other current assets, accounts payable and accrued expenses approximate fair value due to their
   short-term maturities. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Investments in Marketable
   Securities </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company invests its excess cash balances in short-term and long-term marketable debt and equity
   securities. The Company classifies its investments in marketable debt securities as either held-to-maturity or available-for-sale based on facts and circumstances present at the time it purchased the securities. At each balance sheet date presented,
   the Company classified all of its investments in debt and equity securities as available-for-sale. The Company reports available-for-sale investments at fair value at each balance sheet date and includes any unrealized holding gains and losses (the
   adjustment to fair value) in accumulated other comprehensive income (loss), a component of stockholders&#8217; equity. Realized gains and losses are determined using the specific identification method and are included in other income. If any
   adjustment to fair value reflects a decline in the value of the investment, the Company considers all available evidence to evaluate the extent to which the decline is &#8220;other than temporary&#8221; and, if so, marks the investment to market
   through a charge to its condensed consolidated statements of comprehensive loss. The Company did not record any impairment charges related to its fixed income marketable securities during the current period. The Company&#8217;s marketable securities
   are classified as cash equivalents if the original maturity, from the date of purchase, is 90&#160;days or less, and as marketable securities if the original maturity, from the date of purchase, is in excess of 90&#160;days. The Company&#8217;s cash
   equivalents are composed of money market funds, U.S. government obligations and commercial paper. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company obtains fair
   value measurement data for its marketable securities from independent pricing services. The Company performs validation procedures to ensure the reasonableness of this data. This includes meeting with the independent pricing services to understand
   the methods and data sources used. Additionally, the Company performs its own review of prices received from the independent pricing services by comparing these prices to other sources and confirming those securities are trading in active markets.
   </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following tables summarize the Company&#8217;s marketable securities at March&#160;31, 2012 and December&#160;31, 2011, in
   thousands: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="87%">&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="14" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>March&#160;31, 2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized</b></font><br /><font style="font-family:times new roman" size="1"><b>Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Gross</b></font><br /><font style="font-family:times new roman" size="1"><b>Unrealized</b></font><br /><font style="font-family:times new roman" size="1">
   <b>Gains</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Gross</b></font><br /><font style="font-family:times new roman" size="1"><b>Unrealized</b></font><br /><font style="font-family:times new roman" size="1">
   <b>Losses</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair&#160;Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Commercial paper (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,192</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(10</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,182</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">113,313</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">39</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(48</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">113,304</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes (Due after 1&#160;year through 2&#160;years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">67,808</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">47</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(38</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">67,817</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,868</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">4</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">18,870</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations (Due after 1&#160;year through 2&#160;years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">50,004</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(49</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">49,962</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Equity securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">30</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">43</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">255,215</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">110</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(147</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">255,178</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="87%">&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="1%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="14" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>December&#160;31, 2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amortized</b></font><br /><font style="font-family:times new roman" size="1"><b>Cost</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Gross</b></font><br /><font style="font-family:times new roman" size="1"><b>Unrealized</b></font><br /><font style="font-family:times new roman" size="1">
   <b>Gains</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Gross</b></font><br /><font style="font-family:times new roman" size="1"><b>Unrealized</b></font><br /><font style="font-family:times new roman" size="1">
   <b>Losses</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Fair&#160;Value</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Commercial paper (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,397</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(2</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">11,395</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">51,273</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">19</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(47</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">51,245</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Corporate notes (Due after 1&#160;year through 2&#160;years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">53,592</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">50</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(48</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">53,594</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations (Due within 1&#160;year)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,532</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,534</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">U.S. Government obligations (Due after 1&#160;year through 2&#160;years)</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60,202</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">7</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(21</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">60,188</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Equity securities</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">750</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">&#8212;&#160;&#160;</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(125</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">625</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">190,746</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">78</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">(243</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">)&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">190,581</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Subsequent Events </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   The Company evaluated all events or transactions that occurred after March&#160;31, 2012 through the date these condensed consolidated financial statements were issued. During this period, the Company did
   not have any material recognized subsequent events. However, the Company did have the following nonrecognized subsequent event, which is more fully described in Note 7: </font></p>
   <p style="font-size:6px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table style="border-collapse:collapse; text-align: left" border="0" cellpadding="0" cellspacing="0" width="100%">
   <tr>
   <td width="8%"><font size="1">&#160;</font></td>
   <td width="4%" valign="top" align="left"><font style="font-family:times new roman" size="2">&#8226;</font></td>
   <td width="1%" valign="top"><font size="1">&#160;</font></td>
   <td align="left" valign="top">
   <p align="left"><font style="font-family:times new roman" size="2">In April 2012, the Company exercised its option under its July 2007 amended and restated collaboration agreement (the &#8220;Medtronic Agreement&#8221;)
   with Medtronic, Inc. (&#8220;Medtronic&#8221;) to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. </font></p>
   </td>
   </tr>
   </table>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Recent Accounting Pronouncements
   </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In May 2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued a new accounting standard that
   clarifies the application of certain existing fair value measurement guidance and expands the disclosures for fair value measurements that are estimated using significant unobservable (Level 3) inputs. This new standard is effective on a prospective
   basis for annual and interim reporting periods beginning on or after December&#160;15, 2011. The Company adopted this amendment on January&#160;1, 2012. The adoption of this new standard did not have a material impact on the Company&#8217;s condensed
   consolidated financial statements. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In June 2011, the FASB issued an amendment to the accounting guidance for presentation of
   comprehensive income. Under the amended guidance, a company may present the total of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income
   or in two separate but consecutive statements. In either case, a company is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income
   and a total amount for comprehensive income. For public companies, the amendment is effective for fiscal years, and interim periods within those years, beginning after December&#160;15, 2011, and shall be applied retrospectively. The Company adopted
   this amendment on January&#160;1, 2012. Other than a change in presentation, the adoption of this guidance did not have a material impact on the Company&#8217;s condensed consolidated financial statements. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 22<br><br> -Paragraph 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.1.0.1
 *
 */

var moreDialog = null;
var Show = {
    Default:'raw',

    more:function( obj ){
        var bClosed = false;
        if( moreDialog != null )
        {
			try
			{
				bClosed = moreDialog.closed;
			}
			catch(e)
			{
				//Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control
				// that somtimes causes it to throw when checking the closed property on a child window that has been
				//closed.  So if the exception occurs we assume the window is closed and move on from there.
				bClosed = true;
			}

			if( !bClosed ){
				moreDialog.close();
			}
        }

        obj = obj.parentNode.getElementsByTagName( 'pre' )[0];
		var hasHtmlTag = false;
		var objHtml = '';
		var raw = '';

		//Check for raw HTML
		var nodes = obj.getElementsByTagName( '*' );
		if( nodes.length ){
			objHtml = obj.innerHTML;
		}else{
			if( obj.innerText ){
				raw = obj.innerText;
			}else{
				raw = obj.textContent;
			}

			var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g );
			if( matches && matches.length ){
				objHtml = raw;

				//If there is an html node it will be 1st or 2nd,
				//   but we can check a little further.
				var n = Math.min( 5, matches.length );
				for( var i = 0; i < n; i++ ){
					var el = matches[ i ].toString().toLowerCase();
					if( el.indexOf( '<html' ) >= 0 ){
						hasHtmlTag = true;
						break;
					}
				}
			}
		}

        if( objHtml.length ){
			var html = '';

			if( hasHtmlTag ){
				html = objHtml;
			}else{
				html = '<html>'+
					"\n"+'<head>'+
					"\n"+'    <title>Report Preview Details</title>'+
					"\n"+'    <style type="text/css">'+
					"\n"+'    body {'+
					"\n"+'    }'+
					"\n"+'    table {'+
					"\n"+'    }'+
					"\n"+'    </style>'+
					"\n"+'</head>'+
					"\n"+'<body>'+
						objHtml +
					"\n"+'</body>'+
					"\n"+'</html>';
			}

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write( html );
			moreDialog.document.close();

			if( !hasHtmlTag ){
				moreDialog.document.body.style.margin = '0.5em';
			}
        }
        else
        {
			//default view logic
			var lines = raw.split( "\n" );
			var longest = 0;

			if( lines.length > 0 ){
				for( var p = 0; p < lines.length; p++ ){
					longest = Math.max( longest, lines[p].length );
				}
			}

			//Decide on the default view
			this.Default = longest < 120 ? 'raw' : 'formatted';

			//Build formatted view
			var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ;
			var formatted = '';

			if( text.length > 0 ){
				if( text.length == 1 ){
					text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ;
					formatted = "<p>"+ text.join( "<br /><br />\n" ) +"</p>";
				}else{
					for( var p = 0; p < text.length; p++ ){
						formatted += "<p>" + text[p] + "</p>\n";
					}
				}
			}else{
				formatted = '<p>' + raw + '</p>';
			}

			html = '<html>'+
				"\n"+'<head>'+
				"\n"+'    <title>Report Preview Details</title>'+
				"\n"+'    <style type="text/css">'+
				"\n"+'    body {'+
				"\n"+'       background-color: #f0f9ee;'+
				"\n"+'       font-family: Arial, san-serif; font-size: 0.8em;'+
				"\n"+'    }'+
				"\n"+'    table {'+
				"\n"+'       font-size: 1em;'+
				"\n"+'    }'+
				"\n"+'    </style>'+
				"\n"+'</head>'+
				"\n"+'<body>'+
				"\n"+'    <table border="0" width="100%">'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            formatted: <a href="javascript:void(0);" onclick="opener.Show.toggle( window, this );">'+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +'</a>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <div id="formatted" style="display: none;">'+formatted+'</div>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    <tr>'+
				"\n"+'        <td>'+
				"\n"+'            <pre id="raw" style="display: none; font-size: 1.2em;">'+raw+'</pre>'+
				"\n"+'        </td>'+
				"\n"+'    </tr>'+
				"\n"+'    </table>'+
				"\n"+'</body>'+
				"\n"+'</html>';

			moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes");
			moreDialog.document.write(html);
			moreDialog.document.close();

			this.toggle( moreDialog );
        }

		moreDialog.document.title = 'Report Preview Details';
    },

    toggle:function( win, domLink ){
        var domId = this.Default;

        var doc = win.document;
        var domEl = doc.getElementById( domId );
        domEl.style.display = 'block';

        this.Default = domId == 'raw' ? 'formatted' : 'raw';

        if( domLink ){
            domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed';
        }

        var domElOpposite = doc.getElementById( this.Default );
        domElOpposite.style.display = 'none';
    },

	LastAR : null,
	showAR : function ( link, id, win ){
		if( Show.LastAR ){
			Show.hideAR();
		}

		var ref = link;
		do {
			ref = ref.nextSibling;
		} while (ref && ref.nodeName != 'TABLE');

		if (!ref || ref.nodeName != 'TABLE') {
			var tmp = win ?
				win.document.getElementById(id) :
				document.getElementById(id);

			if( tmp ){
				ref = tmp.cloneNode(true);
				ref.id = '';
				link.parentNode.appendChild(ref);
			}
		}

		if( ref ){
			ref.style.display = 'block';
			Show.LastAR = ref;
		}
	},

	toggleNext : function( link ){
		var ref = link;

		do{
			ref = ref.nextSibling;
		}while( ref.nodeName != 'DIV' );

		if( ref.style &&
			ref.style.display &&
			ref.style.display == 'none' ){
			ref.style.display = 'block';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '+', '-' );
			}else{
				link.innerText = link.innerText.replace( '+', '-' );
			}
		}else{
			ref.style.display = 'none';

			if( link.textContent ){
				link.textContent = link.textContent.replace( '-', '+' );
			}else{
				link.innerText = link.innerText.replace( '-', '+' );
			}
		}
	},

	hideAR : function(){
		Show.LastAR.style.display = 'none';
	}
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business/Significant Agreements [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">SIGNIFICANT AGREEMENTS</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 2 - us-gaap:CollaborativeArrangementDisclosureTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>2. SIGNIFICANT AGREEMENTS </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The following table summarizes the Company&#8217;s total consolidated net revenues from research collaborators, for the
   periods indicated, in thousands: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="80%">&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="4%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="6" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Three Months Ended<br />March&#160;31,</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>2011</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr>
   <td height="8">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   <td height="8" colspan="4">&#160;</td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Roche/Arrowhead</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,994</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">13,994</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Takeda</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,493</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">5,768</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Other</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,100</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,135</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total net revenues from research collaborators</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,587</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">20,897</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Platform Alliances </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>Roche/Arrowhead Alliance </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In July 2007, the Company and, for limited
   purposes, Alnylam Europe, entered into a license and collaboration agreement (the &#8220;LCA&#8221;) with F. Hoffmann-La Roche Ltd (&#8220;Roche Basel&#8221;) and Hoffmann-La Roche Inc. (together with Roche Basel, &#8220;Roche&#8221;). Under the LCA,
   which became effective in August 2007, the Company granted Roche a non-exclusive license to the Company&#8217;s intellectual property, including delivery-related intellectual property existing as of the date of the LCA, to develop and commercialize
   therapeutic products that function through RNA interference (&#8220;RNAi&#8221;), subject to the Company&#8217;s existing contractual obligations to third parties. In November 2010, Roche announced the discontinuation of certain activities in research
   and early development, including its RNAi research efforts. The remaining deliverables under the LCA currently remain in effect. In October 2011, Arrowhead Research Corporation (&#8220;Arrowhead&#8221;) announced its acquisition of RNA therapeutics
   assets from Roche, including the LCA. As a result of the assignment, Arrowhead has all of the rights and obligations of Roche under the LCA. The license is initially limited to four therapeutic areas, and may be expanded to include additional
   therapeutic areas upon payment to the Company by Arrowhead of an additional $50.0 million for each additional therapeutic area, if any. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   In consideration for the rights the Company granted under the LCA, Roche paid the Company $273.5 million in upfront cash payments. In addition, in exchange for the Company&#8217;s contributions under the
   LCA, for each RNAi therapeutic product developed by Arrowhead, its affiliates or sublicensees under the LCA, the Company is entitled to receive milestone payments upon achievement of specified development and sales events, totaling up to an
   aggregate of $100.0 million per therapeutic target, together with royalty payments based on worldwide annual net sales, if any. Under the LCA, the Company and Roche also established a discovery collaboration in October 2009 (&#8220;Discovery
   Collaboration&#8221;), subject to the Company&#8217;s existing contractual obligations to third parties. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In July 2007, the
   Company executed a common stock purchase agreement (the &#8220;Common Stock Purchase Agreement&#8221;) with Roche Finance Ltd, an affiliate of Roche. In connection with the execution of the LCA and the Common Stock Purchase Agreement, the Company also
   executed a share purchase agreement (the &#8220;Alnylam Europe Purchase Agreement&#8221;) with Alnylam Europe and Roche Beteiligungs GmbH, an affiliate of Roche (&#8220;Roche Germany&#8221;). Under the terms of the Alnylam Europe Purchase Agreement, the Company sold substantially all of the non-intellectual
   property assets of Alnylam Europe to Roche Germany for an aggregate purchase price of $15.0 million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In summary, the Company
   received upfront payments totaling $331.0 million under the Roche alliance, which included an upfront payment under the LCA of $273.5 million, $42.5 million under the Common Stock Purchase Agreement and $15.0 million under the Alnylam Europe
   Purchase Agreement. The Company initially recorded $278.2 million of these proceeds as deferred revenue in connection with this alliance. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   The Company determined that the deliverables under these agreements included the license, the Alnylam Europe assets and employees, the steering committees (joint steering committee and future technology
   committee) and the services under the Discovery Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and assets of Alnylam Europe are not
   separable from the undelivered services (i.e., the steering committees and Discovery Collaboration) and, accordingly, the license and the services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a
   single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the Arrowhead alliance, the steering committee services and the Discovery Collaboration services are the final deliverables and all such
   services will end, contractually, five years from the effective date of the LCA. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is recognizing the revenue
   related to these agreements on a straight-line basis over five years because the Company cannot reasonably estimate the total level of effort required to complete its service obligations under the LCA, and therefore, cannot utilize a proportional
   performance model. The Company will continue to recognize the revenue related to these agreements on a straight-line basis over five years through August 2012. At March&#160;31, 2012, deferred revenue under the LCA was $23.3 million. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Takeda Alliance </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   In May 2008, the Company entered into a license and collaboration agreement (the &#8220;Takeda Agreement&#8221;) with Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;) to pursue the development and
   commercialization of RNAi therapeutics. Under the Takeda Agreement, the Company granted to Takeda a non-exclusive, worldwide, royalty-bearing license to the Company&#8217;s intellectual property, including delivery-related intellectual property,
   controlled by the Company as of the date of the agreement or during the five years thereafter, to develop, manufacture, use and commercialize RNAi therapeutics, subject to the Company&#8217;s existing contractual obligations to third parties. The
   license initially is limited to the fields of oncology and metabolic disease and may be expanded at Takeda&#8217;s option to include other therapeutic areas, subject to specified conditions. Under the Takeda Agreement, Takeda is the Company&#8217;s
   exclusive platform partner in the Asian territory, as defined in the Takeda Agreement, through May 2013. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In consideration for
   the rights granted to Takeda under the Takeda Agreement, Takeda agreed to pay the Company $150.0 million in upfront and near-term technology transfer payments. In addition, the Company has the option, exercisable until the start of Phase III
   development, to opt-in under a 50-50 profit sharing agreement to the development and commercialization in the United States of up to four Takeda licensed products and would be entitled to opt-in rights for two additional products for each additional
   field expansion, if any, elected by Takeda under the Takeda Collaboration Agreement. In June 2008, Takeda paid the Company an upfront payment of $100.0 million and agreed to pay to the Company an additional $50.0 million upon achievement of
   specified technology transfer milestones. Of this $50.0 million, $20.0 million was paid to the Company in October 2008, $20.0 million was paid to the Company in March 2010, and $10.0 million was paid to the Company in March 2011 (collectively, the
   &#8220;Technology Transfer Milestones&#8221;). If Takeda elects to expand its license to additional therapeutic areas, Takeda will be required to pay the Company $50.0 million for each additional field selected, if any. In addition, for each RNAi
   therapeutic product developed by Takeda, its affiliates and sublicensees, the Company is entitled to receive specified development and commercialization milestones, totaling up to $171.0 million per product, together with royalty payments based on
   worldwide annual net sales, if any. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Pursuant to the Takeda Agreement, the Company and Takeda are also collaborating on the
   research of RNAi therapeutics directed to one or two disease targets agreed to by the parties (the &#8220;Research Collaboration&#8221;), subject to the Company&#8217;s existing contractual obligations with third parties. Takeda also has the option,
   subject to certain conditions, to collaborate with the Company on the research and development of RNAi drug delivery technology for targets agreed to by the parties. In addition, Takeda has a right of first negotiation for the development and
   commercialization of the Company&#8217;s RNAi therapeutic products in the Asian territory, excluding the Company&#8217;s ALN-RSV program. In addition to the 50-50 profit sharing option, the Company has a similar right of first negotiation to
   participate with Takeda in the development and commercialization of licensed products in the United States. The collaboration is governed by a joint technology transfer committee (the &#8220;JTTC&#8221;), a joint research collaboration committee (the &#8220;JRCC&#8221;) and a joint delivery collaboration
   committee (the &#8220;JDCC&#8221;), each of which is comprised of an equal number of representatives from each party. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The
   Company determined that the deliverables under the Takeda Agreement include the license, the joint committees (the JTTC, JRCC and JDCC), the technology transfer activities and the services that the Company will be obligated to perform under the
   Research Collaboration. The Company also determined that, pursuant to the accounting guidance governing revenue recognition on multiple element arrangements, the license and undelivered services (i.e., the joint committees and the Research
   Collaboration) are not separable and, accordingly, the license and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a single unit of accounting, the Company bases its revenue recognition
   pattern on the final deliverable. Under the Takeda Agreement, the last elements to be delivered are the JDCC and JTTC services, each of which has a life of no more than seven years. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is recognizing the upfront payment of $100.0 million and the Technology Transfer Milestones of $50.0 million, the receipt of
   which the Company believed was probable at the commencement of the collaboration, on a straight-line basis over seven years because the Company is unable to reasonably estimate the level of effort to fulfill these obligations, primarily because the
   effort required under the Research Collaboration is largely unknown, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company will recognize as revenue a portion of the milestone payment equal to
   the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. At March&#160;31, 2012, deferred revenue under the Takeda Agreement was $69.3 million. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Product Alliances
   </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Kyowa Hakko Kirin Alliance </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   In June 2008, the Company entered into a license and collaboration agreement (the &#8220;Kyowa Hakko Kirin Agreement&#8221;) with Kyowa Hakko Kirin Co., Ltd. (&#8220;Kyowa Hakko Kirin&#8221;). Under the Kyowa
   Hakko Kirin Agreement, the Company granted Kyowa Hakko Kirin an exclusive license to its intellectual property in Japan and other markets in Asia (the &#8220;Licensed Territory&#8221;) for the development and commercialization of an RNAi therapeutic
   for the treatment of respiratory syncytial virus (&#8220;RSV&#8221;) infection. The Kyowa Hakko Kirin Agreement covers ALN-RSV01, as well as additional RSV-specific RNAi therapeutic compounds that comprise the ALN-RSV program (&#8220;Additional
   Compounds&#8221;). The Company retains all development and commercialization rights worldwide outside of the Licensed Territory, subject to its agreement with Cubist Pharmaceuticals, Inc. (&#8220;Cubist&#8221;) described below. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Under the terms of the Kyowa Hakko Kirin Agreement, in June 2008, Kyowa Hakko Kirin paid the Company an upfront cash payment of
   $15.0&#160;million. In addition, Kyowa Hakko Kirin is required to make payments to the Company upon achievement of specified development and sales milestones totaling up to $78.0&#160;million, and royalty payments based on annual net sales, if any,
   of RNAi therapeutics for the treatment of RSV by Kyowa Hakko Kirin, its affiliates and sublicensees in the Licensed Territory. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The collaboration between Kyowa Hakko Kirin and the Company is governed by a joint steering committee that is comprised of an equal
   number of representatives from each party. Under the agreement, Kyowa Hakko Kirin is establishing a development plan for the ALN-RSV program relating to the development activities to be undertaken in the Licensed Territory, with the initial focus on
   Japan. Kyowa Hakko Kirin is responsible, at its expense, for all development activities under the development plan that are reasonably necessary for the regulatory approval and commercialization of an RNAi therapeutic for the treatment of RSV in
   Japan and the rest of the Licensed Territory. The Company is responsible for supply of the product to Kyowa Hakko Kirin under a supply agreement unless Kyowa Hakko Kirin elects, prior to the first commercial sale of the product in the Licensed
   Territory, to manufacture the product itself or arrange for a third party to manufacture the product. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company has
   determined that the deliverables under the Kyowa Hakko Kirin Agreement include the license, the joint steering committee, the manufacturing services and any Additional Compounds. The Company has determined that, pursuant to the accounting guidance
   governing revenue recognition on multiple element arrangements, the individual deliverables are not separable and, accordingly, must be accounted for as a single unit of accounting. When multiple deliverables are accounted for as a single unit of
   accounting, the Company bases its revenue recognition pattern on the final deliverable. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is currently unable to
   reasonably estimate its period of performance under the Kyowa Hakko Kirin Agreement, as it is unable to estimate the timeline of its deliverables related to the fixed-price option granted to Kyowa Hakko Kirin for any Additional Compounds. The
   Company is deferring all revenue under the Kyowa Hakko Kirin Agreement until it is able to reasonably estimate its period of performance. The Company will continue to reassess whether it can reasonably estimate the period of performance to fulfill
   its obligations under the Kyowa Hakko Kirin Agreement. At March&#160;31, 2012, deferred revenue under the Kyowa Hakko Kirin Agreement was $15.5&#160;million. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>Cubist Alliance </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In January 2009, the Company entered into a license and
   collaboration agreement with Cubist (the &#8220;Cubist Agreement&#8221;) to develop and commercialize therapeutic products (&#8220;Licensed Products&#8221;) based on certain of the Company&#8217;s RNAi technology for the treatment of RSV infection.
   Licensed Products initially included ALN-RSV01, as well as several other second-generation RNAi-based RSV inhibitors. In November 2009, the Company and Cubist entered into an amendment to the Cubist Agreement (the &#8220;Amendment&#8221;), which
   provides that the Company and Cubist would focus their collaboration and joint development efforts on ALN-RSV02, a second-generation compound, intended for use in pediatric patients. Consistent with the original Cubist Agreement, the Company and
   Cubist were each responsible for one-half of the related development costs for ALN-RSV02. Pursuant to the terms of the Amendment, the Company is continuing to develop ALN-RSV01 for adult transplant patients at its sole discretion and expense. Cubist
   has the right to opt into collaborating with the Company on ALN-RSV01 in the future, which right may be exercised for a specified period of time following the completion of the Company&#8217;s Phase IIb trial of ALN-RSV01, subject to the payment by
   Cubist of an opt-in fee representing reimbursement of an agreed upon percentage of certain of the Company&#8217;s development expenses for ALN-RSV01. In December 2010, the Company and Cubist jointly made a portfolio decision to put the development of
   ALN-RSV02 on hold. </font></p>
   <p style="font-size:1px;margin-top:12px;margin-bottom:0px">&#160;</p>
   <p style="margin-top:0px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In consideration for
   the rights granted to Cubist under the Cubist Agreement, in January 2009, Cubist paid the Company an upfront cash payment of $20.0&#160;million. Cubist is also obligated under the Cubist Agreement to pay the Company milestone payments, totaling up
   to an aggregate of $82.5&#160;million, upon the achievement of specified development and sales events in the &#8220;Royalty Territory,&#8221; which includes all geographic territories excluding North America and Asia. In addition, if Licensed Products
   are successfully developed, Cubist will be required to pay to the Company royalties on net sales of Licensed Products in the Royalty Territory, if any, subject to offsets under certain circumstances. Upon achievement of certain development
   milestones, the Company will have the right to convert the North American co-development and profit sharing arrangement into a royalty-bearing license and, in addition to royalties on net sales in North America, will be entitled to receive
   additional milestone payments totaling up to an aggregate of $130.0&#160;million upon achievement of specified development and sales events in North America, subject to the timing of the conversion by the Company and the regulatory status of
   Licensed Products at the time of conversion. If the Company makes the conversion to a royalty-bearing license with respect to North America, then North America becomes part of the Royalty Territory. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company determined that the deliverables under the Cubist Agreement include the licenses, technology transfer related to the ALN-RSV
   program, the joint steering committee and the development and manufacturing services that the Company is obligated to perform during the development period. The Company also determined that, pursuant to the accounting guidance governing revenue
   recognition on multiple element arrangements, the licenses and undelivered services are not separable and, accordingly, the licenses and services are being treated as a single unit of accounting. When multiple deliverables are accounted for as a
   single unit of accounting, the Company bases its revenue recognition pattern on the final deliverable. Under the Cubist Agreement, the last element to be delivered is the development and manufacturing services, which have an expected life of
   approximately eight years. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company is recognizing the upfront payment of $20.0&#160;million on a straight-line basis over
   approximately eight years because the Company is unable to reasonably estimate the level of effort to fulfill its performance obligations, and therefore, cannot utilize a proportional performance model. As future milestones are achieved, the Company
   will recognize as revenue a portion of the milestone payment, equal to the percentage of the performance period completed when the milestone is achieved, multiplied by the amount of the milestone payment. The Company will recognize the remaining
   portion of the milestone over the remaining performance period on a straight-line basis. At March&#160;31, 2012, deferred revenue under the Cubist Agreement was $11.8&#160;million. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">Under the terms of the Cubist Agreement, the Company and Cubist share responsibility for developing Licensed Products in North America,
   and each bears one-half of the related development costs, provided that under the terms of the Amendment, the Company is funding the advancement of ALN-RSV01 for adult lung transplant patients and Cubist retains an opt-in right. For revenue
   generating arrangements that involve cost sharing between the parties, the Company presents the results of activities for which it acts as the principal on a gross basis and reports any payments received from, or made to, other collaborators based
   on other applicable GAAP or, in the absence of other applicable GAAP, analogy to authoritative accounting literature or a reasonable, rational and consistently applied accounting policy election. As the Company is not considered the principal under
   the Cubist Agreement, the Company records any amounts due from Cubist as a reduction of research and development expense. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 07-1<br><br> -Paragraph 21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 808<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CollaborativeArrangementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0E6NAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">125,000,000<span></span></td>
        <td class="nump">125,000,000<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">51,893,258<span></span></td>
        <td class="nump">42,721,942<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">51,893,258<span></span></td>
        <td class="nump">42,721,942<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 4<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6959260&amp;loc=d3e187085-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 12<br><br> -Paragraph 10<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 129<br><br> -Paragraph 2, 3, 4, 5, 6, 7, 8<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 02<br><br> -Paragraph 29<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfFinancialPositionAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>26
<FILENAME>0001193125-12-208797-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-12-208797-xbrl.zip
M4$L#!!0````(`"V(HT!"U-!S8UP``-5Y`P`1`!P`86QN>2TR,#$R,#,S,2YX
M;6Q55`D``R;RHD\F\J)/=7@+``$$)0X```0Y`0``[#UI<QNYE=^W:O\#5G.4
M7,6K24NB)'M2LNQQE/C06G(V^90"NT$2X[X&Z!;%_/I][Z%/7M8MDD:J/&&C
M`;S[`/H!>O67Z\!G5T)I&86O=YQ69X>)T(T\&8Y>[Z2ZR;4KY<Y??OOO_WKU
M/\TF^^>;+Q_8>Q$*Q1/AL8E,QM3VD:MO[#2*ITJ.Q@G;/7W!!E/VY0M[&X6A
M\'TQ9<UF/LD;KF%L%)K9NBTG>W<]4#X#?$+]>F><)/%1NSV93%K8W(K4J-WM
M='IM&>J$AZ[8,3V/?!E^6]$=7P\`7M[]>J[_I$>]G</#PS:]S;MR/YP6/?'!
MYT'+C0*8V.EV>CTG[RAU]++K'*Q"VO3(!P!?1YS'Q8`AUP/JG+U`"$ZSXS1+
M&#B?O`5;\*U7#JAVWF^;ET57+1<Q!'HZ[7]^_'#ACD7`F[,`/#$SNQ9N:Q1=
MM>%%%7\0+&.OD*]'FF;Z(H:,^'R43&/Q>D?+(/9Q6FH;*S%\O8/<;N9L;EUK
M;X>US42H/Z=1F(CKA%T(-P&U-=H#[]RL77JO=]YP'[$]T9^'_^XYH)Z(DD$&
M>HHPD<DT>X)GZ6'+4`K%"$E18TA.V>G9WW=^ZP!;G(/^_D'G5;L<ED_<KLW\
M*A9*1EX%#C$Q^<WPIP?\>=7.V_(9*F->M3.2OD??6^'"E)UUHJ_3=+H/1I^1
M7W>=Z.L^O/S63#\?3GZ=DW@=Y?>RV>O<E;Y+<%3B(S2,];O0$]X:.1D@1R5O
M(3[_EKOA#HBQ;"TZBM"K=#/:G+?=CAM_XR'"0;;^&]@`,S770MXU5G1OQHKN
M[5D!0>EK*(N`E,>C%-N0/5\OWKX[ORBXX<DKH*0$COT^I0'F5)$JFN%%(+A.
ME?@M2Q^.8)Y7[;RQ&-Y>/)ZF?2O"*)#ALHDIJSC28ZZ$7C;S_!2OVA4*3*<9
M@B]HQH+@[X-;.`N0.S?%4E949\`DX9T/:A7.)PF4@(J1#-D;/W*_L4L^&D$V
M^BE*1-$G2\..+N0H!'5SP3V<N&Z4@JZ%H_/(EZX4^A+$;Z;(=.$+9BY++>%7
M/SD&V&\_GU[^Z_P=&R>0=Y]_??/A[)3M--OM_^N=MMMO+]^R?_[U\N,'!HDX
MNU0\U!*1YWZ[_>[3#EN0I5U^:5_C7`X.SGXVD\K(EI=`]M1L_CI*CHF7&2)+
MF0#9.+L=`Q9,CI)NA'H17//J>O;5$)C(=#+UP1?@[^:0!]*?'B4R$)J%8L)4
M%/!PAVGY'^C2W<'1.'"0_VB7OW""=9^]&'TC$'$^?\`5R*V91/&1TXVOC[/G
M090D47#4B:\+U.]'L]-B%U\_?CSY\B_V^7=V<?;^T]GO9Z<GGR[9R>GIYZ^?
M+L\^O6?GGT%_S]Y=L"7HTT/\74+V'Y$._"'Q!ZPZI6;1D)V#]P'/P,DM\-"#
M!AFZ$A8A]!I6%QHTW#/OB0*Y0D+W(?&8H=^`I17&M:/^+_<C^7(L&`<K#6(>
M3L%.T2_!Q+C6=@N:X&$(SASHY3Y`@`;TDD3XB5GBLG/PSP%W19J`X?NZP<Y"
MM\5V$YC^5Q[$QS_UN]W.\:F!4[0XQRQ2A@5EIVS*2J<7#)P_2T.>>A*10?Z/
M^95@`R%"%BL1PWN/@6="4I2'2:399N"%`X)NA<!&M!?A^U-\+^+$C$5<,2+#
MTP72:.B#"`D4L=T*@N]/3L[KV,4Q>#<^\`5+(I@J@3$!,Z%?([:-?/XHEB%J
M",P,HN`C8B2^=?W4`TGX/G$CC("9/M&IA)LJA01P[X]4)X;SR9@GQ)10N$)K
MKJ8(F43#AEPJ(`W!@=*FOA%4%&.H!]B:#2.5O8TCA>1FF+88:L.,C)R#8WTK
MI2#!@`I$,])!NV$#LB>=#BA]EB0#G%+J!.,NRJQ!'$#2]3A*?0^F`4PYB0BZ
M_I&&)C937Z)C$<:YJGP?WYP;4\$5$YB6,UA9B6`@E)G1V>\<]YP&PXRWP29C
MZ8[91`#O,ZD5RK,(CY,P3`'>%V(U\N!W$"V#A>[?C0PG'#"0?KXMAM-<H,0A
M$`M=<.+=M3OFX8A`!%+COMN<;5V\.ZTI)<(2`Y6";I1T.#VBHVM$C20W@>2*
M?`=F"0:\%R)AP#9.*'J@(5?(07`A!6\7L;/!!BF,B]#C1$E5L9DGM>M'F'MI
M$.B?J42M&$P9FI/!IZ*N0!Q1OXBG,ZH,KV=LSE@&@,^M`]P@=/'`1A,@(YM_
M!MQ-04705\T"A'?TG@U3H'0(E`)7D+TM=A?'OSA(KY'G5V+H0XZ<^;2"1W5.
MDNKF`>)KZZ)EHD*C:'N7*AA,G#AY7W.Q]1Y5O2Y'EW8"`!785QF</PH?,)7L
MC21I\9CBDL[A3\81.)YF-`F!/G1&TI.@)&*6@!;``K++?-:(W<W),\&%/#RC
M])F[A@]E<!*^I'60\&K>%9)EH0D4&D(R)1X$(AFC+@VK80O<>O9$&B8!G`RO
MA`D$Z'F^B%'JIQIG+PC-HF^%H5FO*B?OJ)K]I\B[OFJRTG<:QF$H+E#:H+3*
M1#ZCE$#+0CLR,0T$&X`2F!"`[C#WC[J2):`F!/P;:$S.%-([KG4:Q*1V1+3)
M#(9#L,[2[=>B/0^,UJ*>:2TR_?4E'TC?F!,\U\>6KAM'X=(55!-Q6C:!\0SH
M0'*3NHUWF8._"'<EKD289EP0US%.#H$JQ5PIXT0^D-(_<M1@T6Z"`3GW_2ZE
M&)X$ABD3W<`&=87)ZVPEGR!$?XBT9N>`/*8&H&FTB[)III)[1?2L*6HVYHDN
MC$@8J)TNE0&DB)V04-H1POR!]I50Q//=>9(H"0E)GIKG0Y/(_08Q`+(:C3.@
MIDP$?H04GLFYKL"70KH5II@&&ITO@8+ZI0DFL`BU[M8+`CSIIZBPST'"=]%'
MBR$$,1F*(TR]T0)-)V*`P0R=T!7WLQ4'1+,:W><S`_/9LWP>P68MD+&FA'\:
M1R95%M<01J5Q\D0*9!$F=.ZFFL(>=$H4;=5-LQXF/+X@[%,*@0*71QKXX^)/
MTXM/N,*ES!OA<@BR-!%EH3KSP[/TYDA.T!,0\;#@P,5)LV`1I7:0">0KNMAL
M!@A8U\W*F<V)5YHXKWD`T\YJ]ESW]<X7AY`W11.2#\F3G#]P!\)6OHR:XY%I
M7<+T75B5X\#(:(TGRG@YKP&5).D%:%"V^,J<-D08[KNI7XQ?+I%!J1I2591C
MDB\W:]+/UNY1JD'Q]-'-Y4.<10[6Q(/BZBP/#H7=+YC9\-P5OJ]C[E*Q16>'
MGF/N>?GS1'K)^/7.P?XO.VP0*6`I-6=(F9:F"X+DL19'^8],5[@/R>X1\\4P
MV6'T\'K'13&J^O9CN1=\24C]%1?H,YNSB<)'5CY[.6[]E[\LHC;QY@9<93@8
M-A7$]6XX_HD[;0"Z92(])YYY<<V04W<?Y!J<1835C./[7'JD:<'FT4Z@87]6
ME6>,(;-!)[YFE)BRGSKTO[OZ2Z>>KM%7WY(6\_VW?*8OP2NRM(%B[8=!Y"-7
M[K@$3+SK.8U5&>*C2N]'U,7N\^HB[OT]F[Q_<,8[:V-HM3`._F=%$)\-]&\B
M;WJ#0#^FI0A$^AO&^;)_*;&7CS-VE==A@Q%,$4'&])/K"C$<[BR5"N1Q]91H
M-B_''.K(:74Z(J@GXDW3>+]L_'.V7(+,.4[!K7,M:DO#[V6IZV+IM]T#N9\W
MR!ZIWOA^B!PV.OV]&^$01A.%9;OF_W?6B!U6P"L0Z3?Z^X<;(.`[)5'/[+R^
M+MB]L<[KZ71[?Z^_`9IMQ7M'1!RGMP'B79F'S6^A91MDWY7>;?=H[CQHWG=F
M*PG:D%V\C%BUN[<^8"T?'YF/#[P$N9NLK/=<EMD?O-P$_VD%?.?,_K#?W0`!
M;W6`[(&']:(4MY2>U+,_$%S+R4?GY`TW+1=M2+;I2VD=TJ+/LO6OLJMJ=E81
MM>B#_(HOO'=V&/YL^<^7<O5\0;4/)U3[L&FU<F<A^QL/L4Z92I,;6"41<T4%
M)%CN&$<Z:=).0>HF5-[%E*!R@@C+RZ.1XD&M$)Q!2VC."3`^&BDQRNK0]CK@
M^[O]LL(E*R2;*2'!&GZJ<4VXQ`I1$<1^-!5"-[*J@[Q`96&I_%B*(=:WN&E6
M:SR4KE!4M8(U$70<D9Y,SZQZ%F;,>E)!D1;+*EM,Z3D8:XH$)NSGO5:/`9-]
M*GLPU35$OZF^0T"XV8)%#%2;;+H8%@@LRH,NH<3+'%``6=U%.<%ZUZ/D`E=`
MR2B$E_,R_[G3VBOX@]R`!J=D6%9^U,3K'DSU#Y9PB5";.I*LKA``^%2NB-6X
MOK]4-KGBY<4P"7[Z90%]\<W.%LQ\A,T.%G0)-7/"`":/\?SAE?"GZUQ]>`Z^
M7[KL,Y9.HOYNELO)ST9D/J?J/F#E-Z]'_<9^=Z\!4:[B.205D);[EBCO*!V-
M<7`*F*J)DDF"AV`,JZ*<55BBBP>27&.(H%54))7W8C\[G=;!'E4N955A)QI&
MF*+5W$CSV>K(@RD(.JI18H^54.`G837IF:K?&)ZNJ;S5G[*?^_NM?FX0X'R'
M"4`%305GBZ@6=.`#U@&7)>]N<1C%/)N3$7GEK%>26U3GS@(GZL&#'>;PUUG?
M?^=2L7^@XV4?S1EB4ZV\07I/\!<4\A7E>A`FL!@].TDQB-)D^0DK4_I=G$3+
MSE534,(C:"9&F6-?Y2$V<P`,NJSR@ZO.7^'[["B/*>XL81%U$%053EW$,GQE
MZ$F$.P[EGVEV\J(XBI%(GT('F*$'B84*(.HSG;KCRMPM!CXC.S?8J+3K<@@=
M9OH@P&U7SEL!KG$*;,J`L#_3B$[<H>UCL6MH3O4)[X4YOD@Y`VC!MZRRDIGK
M"_`X4<9P:*N4VK?8[R4NQ("5^'1G\:$37G$D:X<*HX$6Z@H5HV'X`!G9#.(%
MV@US)@93#%4<2IA*`2X49'XU@^%J['JSV*5AB4H-U3S`$D^J+)F6QP?SLV=:
M)FEV/FDRQN0IH?^"&D+_!&F40SS9U<CX;J2`YS&60S%5WQ4U+]7.1YIP]CJI
M.`^8'/+)],#4HW:R""@'7A7G(3)QW\JL5);8I0&08M(AG=FZWM`ZUL/N^M:Q
M[NW?LX[UIN.?N)-%]P=']TY%!3DY,[NF*S>2EE7='1-/CGJ'\9TW>V<*\-X*
M[2I)55,W3]-LX>+Q2;*"70]7FUSA5EDI/9<B+NI5"NNQ<;3%L\^D@_]+N6=)
MS#DEH4\B<VG.PYU08EZ=^J/)T:M-NY3.,N>%59)G4)+*M5-5H7PN%A#5UC-:
M9RP07M<*;XV$][6R_ELLOD=W`$8OB(>L]WS*<<.O87<OX=^<TO=3KL?5H\GK
MF\3=B\R?[V30#U@DVFD<'#HW0L(6PFR88#M]6P"\?8(]Z-BZM>V3:O'1I;MP
MD;P!$K_3;M(S)QEF>9==<E'<,[8[E-=TWY\;!>+%FB<>3U:>ME;UQY;J-1RT
ME52OK,]]Z-54[]%64]G5B71AIMC6Q=3:%)\[?:?A=.VR:HM%O/D)FQ6]M6XK
MXFVU[D=<CCU:EH*W1[/WT950(=V%&PT`+5/493.61]XN[#?ZO4TX+V<E_,.Z
M-"MZ:]Q6PEMJW-NRSQ($>.<U]UG,8Z%LVO*X>K_7<#;BE+\5\`_KV*SHK6U;
M`6^G;6_1-V_S%ZH8_K$1&8[TNG_VWGCEM[=/;;-T-]^U6=%;P[;2W4+#7KG1
MLND7SFWG3:*6CY:/EH_;Q\?MV/.^C!+N;^ER\;F/!?2<O<;A1OR%"BM9>S[+
M"A8&=O?V&OV^K0[</LG:M=]:K_VV]8ILRTG+2<O);>7DK$LNGF]S`?X\!14O
M;J]S-)*WUSE:=+<9W57)W7?)L=<Y/L1WIG6Y:.N)KG.<O\&;F)/]M?D<SK/^
M4>P?60OLA8I62>R%BC^@\.R%BK=<7=D+%=<IC;H7F<^]2;Q_T.AT7]X(";O[
M;P5K!?OL@MW\SSI6XC^:Q.^TU[.>!T_L98L/-LA2;:G>:*I7UB=L3$&DO6SQ
M2:.YTWG9Z/=LC>06BWCS$S8K>FO=5L3;:MV/N!RSERUNG\(?]!H'77NUR19+
M>/-=FA6]-6XKX2TU[FW99[&7+3[I4LQI]`[W-D"]K81_6,]F16^-VTIX2XU[
MB[YZV^L6G[AZJVM]VQ:+=_-]FQ6]M6PKWFVT[)6;+9M^Z<9V7LQF^6CY:/FX
M?7S<CGUO>^'BXZ4;W;V#QG['9I3;)UE[?FM+!>L<=AI[]L+%+92L7?NM]=IO
M6Z]DLYRTG+2<W%9.SKKDXOE^%RY6;EBLWKAHJ*9+%VL+P?XO]PL];U,EPQ%+
MQ@+^*2%8`"/'F@F8WF,?N7+')?4]I\&Z':?;P/Y*L`G^)XQ8HGBHAT)I-A#)
M1(B095<Q,0Y\R&[V(5*',N0A55IQK46B6^P2(+M<J2FBP8,H#1/-E!CZPDWH
M/"_A=AH%,0^G12`_.-;,C9`%&CK!+UKL<QPQX#Z`$$R/!0!@PTC!_'K<8'1+
MY``/U,DH!!"ND'2SC6ZP".EA;JH45K`;U!J,NZY!)^93DB52`XTJ!3#B.D;@
MFO$X5M&U#/"<WI!+A8J:"N;!OR1"Y*4BTO4X4DDS$2I@T#?[@-MBWUM_+[J)
MLWX1I]._VTV<BU1NQ:6>=TYN_.PJ'_PA\<=9>"5T@H<%-,JW_+)-J%V47[<)
M:5DPIICE1ORJ4+7_^'9T62HIT(3T`6WP3UR[0FO2P%PSB>B*-J!6^5$XRG6C
M^,[OB4%";\U'?J-%!7>,Z>0P71^T5@Z1:Y+86F/Q[*25"@(..$I2_['P/6!7
M,]/.*0/+X5=<^CBN"7;4U!PF&'`T.;"@(7=A=L3/E<I-`YT8ZF(E-)E18MP*
ML`UP8G$*OH3&8FN5CI.$">Z.ZY;+T)KSN837(.J3112#3?H^BX:+")]AX0SA
M\]35F:I$#%):U*\&!PBM&#Y?3@TB(D/73SV$#P#24`D(:_\!&K(*#C;B,M29
M3FCT+[M`-!'/O3]2`Q(=2PGQ!1(*;BD-4I\\8.;-@`@EQN"DY)7([D5@NSCI
M"W!M]#H*Z<#.$+0]<K\A!N##*SXVXUJ+?<FQG,..*U0IU%P9POM4Y]%$Q\+%
M*\681/NBR\7([P8B&4>><:5*Y.P@1V_P-IBVV-D06;22\CQ.`!J`A.L#"GG`
M,.^!-'PHA=6HJQ#$#8DTDP854F;B"I%VR8$+G`F%AP/!861(3,829(QM!6#P
M5QGKNIUC0TLRYH"."/`8MRJB5]<Y1OH;3`+GHP99IYY!%&$8J\T47T7I:(QR
M&X,C(\Q0W9?$0#!%@$K*"2RH:P(*KJ[FGL3E;8(A$=(G4DP);Z0B1`Q`C,E&
MNS+(U>LVJOZE8F%>F5ODH3462D9>#7PMIB^<R.@`*$O5Y#.?6KF(#-F)L"(E
MP=-#BI$[L@8;@L<VPD))`DMR9]1`L1UVRCCI\:E&QP=I`68`(4%:3-Y=P8&&
M9E$!WLS"7LX:))<X4269N(*63#YYB-F;F&;XLF$:>D`$'=`;+3R@9[SW3/G[
M+7*2)TY6JTH;#1+R1>@-"#%C\8'@.E6D^\A]3OD?ZNMB&9*D$+M8$(H0<"1>
M2L[PVD.\Y;1N*<`=F"_0M!CQC$.#[,\5H.HP&[J+$,&3\,&UZRA$B&$F[&0,
MXD>L<%;2A"P6!!`B$.H$(G'F"):CA&!`LN"V(.!Z15PTCM6(E"C7$6@==$]!
M-R#(>IY$?,'33>M>L"`*V11-,#6^DB``U%NZZ37+E4'#"L5>B=]@2CK)<^O7
M(I\(,#>.,<?-Z%\XE!@_L#,H<BU((R\5I\A(40[O@<UDJ5OE@FI-E74(2XYH
M0I312H/I-`"PT&OIJF:QGD)2L60M1BR<OT`Y>PW_S:[0!=:F&OKJHSLM.>SE
M_V87(L.M?W#/R_^=];GOW:)KT;W1AX8;[1_ZC_SIZ1$N7W9>/N_MRTL\^ZH]
MCT?EVH^H`\_]AQ:"2"6XPEXA](>[5/LTTJO^L,.Z?&7>/C&_5[#X?A(1?RUV
MEAX37,%S0QTNR*Q>6;UZ8+WZ0%N-5K&>0;%^Y[*RJ/P';K&L35JRY(/K#_$W
M&&:V[-CNVU30[A&0Z)2LG`JNMO5(Z',7E>TUG$-[/<_VR77SBP6MQ&\'?]?I
M/+M47UBQ/H*#[F^"@[[3=LNS)R"UJ\E_Q/SCGAG^`YY;<'J-GM/;`$VW(KXC
M(O;>ZFV6[N[+_K.+=POSC[61+SGHSB8<&5R5BOQ_>U_:W#:2)/I7L-KN%^X(
M4N(A4I1GNB-D6>Y6KRU[+7EFYWV9@,"BB#$(<'!(UO[ZS:,*J,)!4B1H'N9$
M3)LB@:JLS*RLS*P\=LD[4J*<V*-8A'G=)(VKZYC?'^IHK7M/],\:@];FQ=Y!
MZJV-PJ=G!^KN+W5?=3>_>0\ZRWKE<WL7=O`N>D]FM$PY>%(VJ:@/&H/^YN7:
M0:RM3RDY$'=_B?MJ\][^@TJR7NE\MOF;NA_%BS)723EX5+9J>_1:C=9..!D/
M%%X2D%TPQP[$7?H2:/-W?`?M98V6QWGCO+]Y!74_'2I7^>H>!V5CS0$)NZ"'
M'ZB[K*5U"";:8^K^OT.`\X]*^M-=V-@SW2>[7NMV/_LA'/!XP.,!C_N'Q^_J
MR3[T.=G!))M.K]?HM`]]3O:/LNTMR(H[4+7^7,<MB,O<0S_SINF*<KA]M@NQ
M2WMMWNUKLX,#)@^8/&!R7S&9%\GIWZNU,M&D^*%\+%/^4#[V`.X^@SM+N=L*
MM7X-)=HV73ZVNO@W+>4^7=3W0]R/R`:'"K+;0(]])_-^5_H\5)`]\-4Z^.I0
M079CC'6H(+N5$;.'"K*;]]FWVXWN^>9O8[92?NTT80\1EC\:Q0^IQ_M(51+0
MNQ#;LI2_9>,:R*&$[+;$A??:C<[9+L2&'RB\K"C;?';I@;KK4S\.05U[35^4
MSZ>[KHCLDG/D4$!VZ[=$M]$[]-_9:PH?XL_WF+J'HO?[35^2S[M0CFH7?2>'
M`K+;R?1M8/KN02G98PH?B+O'Q#W<V_VPI"?)O>OJRNYX6`[%97=K>_1;C4[K
M</;M,84W?X%P(.X:PU/:&R?OP=FR5O'<'FS>G[:?SI9#<=GO?10=//_[3-Z#
ME?W#DOY5N[/Y*(:#(K)&160+Z+NB#V772Q#M9R7*`QX/>#S@<?_P^%W=V8<*
ML[N8A'/>:IR=]G=`K3A0]H5V_BYXK`Y$?:FK>0N:3.RAB;=INJ(8[@TV?XWP
M@UMW^UJ"\H#)`R8/F-Q73.9%<OKW:@5FM8JR[4%U2=FECQI/UC#"#RY^N$WN
M(_'O!".6KA[AOQ&#Z*8G4/KX+$.P#/Y^&?BFI3KX>;7ET/QW8V%=!I.I[3];
M`M@DL6,Q!#7!@[]H04%HQ:'M1[;#T5CQV(ZMP'&2,,0'*2SK@QTZXXS0LMQD
M)PW/BF&2(:;/P8=(6$Z`"XC@=?A$O@2:=.3ZMD\5B*(8OIC0]$\B%)8;18D8
M'EMOD]#U'V`4-[*F(G2#88/&5@L8ND-:E!_$UMA^%!9^.8&Q0APU%$[PX`,"
MAE:4T8V7>6S]$3S!Q[`P(`^$7XX"SPN>$``_\&<,UK">QJXS!JBM20#0CQ+/
M@Z%$Y(3N/3SO^M9-`,@X>VTMS!F9?M*OL7*RN?$7*H&L%5#.UUG.UV%6U6A;
MK9_S&E5U(>0\3R^O;,L13W\^,KQ"2@6FY=2@>0XZG?Z+`&KG`*IKO?JZ9OG!
M:EO_M6]=3$/7H[UN[AOQ#6N)X0YW481,4718">SZD+[X,X$-T6FUSBP;=OD0
MY0C(_%#0OD>I`/QWCPFW^)K]$`H2!M8KG"+%>NLO'\0P#@/?=:P+]4SZ:_LO
MO]":,?'%2A]L6->^<VR]*AM$?]6*`X2Z&20@ZT:TM%ZKV6O!PJ8HN4ZF83!R
M`65C&S:X'8*`?&`8Y=,7[V^:?]S=6<,P>6@.Q:/K@`0$Z>`%4WH,WG\([0FM
M>Q*@@`DL&Y#\;'OQ,W_K>H"/P!>6!R_[$<J=*`X3)TY"<3Q7<LP[:+-CU)HE
M;=JFM)EUJLX2-V4GW`S)5=\!_5E@D4/KPG&"Q(\1AY^`V/#9X?,EP\=NG-FP
MYS[8SU3,F7?<N_30U-9X&P,'V>$P`@T*_C'X_=W%[1N#U?EP!>[#*>ULD$@.
M0B<^K=OQ[-`=N2*BF>WI%#B3]RAPO2/"V(:C37QS(WI_9+LARJ%$6!-A1\"U
MQ/D/"1SW@'YB<MA.\`^/-W0CQPOPN0B.VK#B?:F`X+:#[>%.2&`DO#M`K@%X
MC@VS)'X`AW+X2,?<J_>X\ZPNK-6?)GC8WZ$&@>M-%PE_B]%(@)(#FQ&E#F[1
M:,I?T.KO[<AER&S?3P#AN``7*VBZ$Y!=4RRW#%"P7A)9]U@<TL=O$#^AU)2*
MM;G;/:[-?6RH8O80Q(\8LJI#0I*EBV_]:</DX;,V`"M;_#Z])RD2%Q:)ZDRF
M&V6:D0N3.C2Z)L33L)RSOT29RL:,,$]MFR^?2G7VSG?90'\F(%2U'00;(MT$
MOH9L$,G$Y]F62'D7N6`*C`J/J0T@$3.!K\<HK@'#K@]_@ZS^0@<?C26/.S50
M`ZC@2))/8%_+,>G9&.^0:&>5#,J@XR]P0I":/H(5Q_)78LWB`P%\%98.9PF7
M?G.1\7$S>:2EPZ*3((DRPE:!0XL/Z/WX*;`B,;6I7,8]G)_(+,)):&/I'`*4
MD+,Z=F1@`M@V!(7:10,#B*"0(FQ0JM,5Y5?L!4`@.NT9<=EOC9(W9Z!"&\F6
M8R&YJ]^@Q2/&U>/V!!F&WBIGB'?(/F!=@^;":P:9VL@8A#!M""22AR`?87#*
M;VD8PD>)')GD&X\#,++D<YD8FB>`>$S0:,#VNY?B7:!6%F>"T'LN%5.$@9>(
MJH^$3)#DR&_.&+4GY!U]2TE\Y.59N@5KD&4KR;&_GB11\\&VIZ]OLW,G.X,_
MP;@.D/4.9-<;+W"^_H9(^JOR;]!7UIW]\``SDS78;&9/<&'AZF?4S)>9HOPH
M+C(M]&UZE*;3TW:&/SZ+T:]'0)AFJ]U$6OP3;/=FES\?_29=,&\_7M[]X].5
M-8XGGO7IRYOWUY?64?/DY._=RY.3MW=OK?_YX^[#>ZM]W++NT#?@(HEL[^3D
MZN;(.AK'\?3UR<G3T]/Q4_<X"!].[CZ??,.QVOBR_-B,M3>/A_'PJ+K$<A$3
M':MI+8&%W`S?W7$$K'][_?O-];OKRXN;.^OB]\]75Q^N;NYNK:W7/.\,#XCT
M'R03F!4>BBHW&TM$8Z.A9`[14Y*@I@=3H>4GT(6D67X!"B\4>S`P+5T).5@.
M:IUBV+!8UB41JI!+^5(VT8;JK+_%;:A:*[:A.MV>SD,[!NZL2\J%[AYJ\"!]
MGV&S3@3]S78BN!N'0E@?X+UQA(<R-Z!0G2:*/NU9(GJMV/P1>6/#72I0'=H8
MO7]PQ&]/F[**:\GE^X$48!\+C,2!DW?!<S=[/J/8Z7K>G1DVLS.%)3X'SEB<
M@%40/(V!;`NZS3>^L7<M&*S;.-^)XFX'PNXI89?2D38LF^[LKV)H[ZE(VIH4
MQ%[C]'SS$<C[)YJVB,!G_5W('-@/A8I<]P>9M>9CM]%N'6I>[#>!NX?,^$,&
M[5Y$J>\G'M=H4:PW[WCA"[8]/<4W;3-W,#'N4#YQ+PD[V(G^O'M]:N]K3M0!
MDX?LLO32BZ+1/WEV/`K"B77A>2X&O:T]O4Q74CIUI)>E:\G=PZ1+RJ^HGG74
M'C$L\U7,+!?;'W*,DN=.7!4&.4W":1!A/.>%YS][]L2Z2L)@BE&H>)U*^5^4
M[,%I'1RKNVC&R_O+"R-VGZ)4WV'RVF@$@/O-][9%F+;>QV;8/W_[QHZ$9XR`
MLQ??YBR9.'@0%*A)TV@C-*S\R/J8>L`S`-P@M'!*W+UP;(PV3@-;7=^Z2!Z2
M*"Y![T-H^Q@OQA/;F'77%-\<+Z%86H4^&:5=%GN&\;&>!S-AM/X4B1#&SQ@V
M!F-@6)8U%!X,%3XW0^%1:%KI&UE*@QVI_![*9I2?<8T(ALSOD02=3#`%"B3C
M_W+\&B+2GHHD=AT<>9@X*I=AE/B46YFF2WZ^N>#8WA'P"^X1@Y`W%ZZ.[0;F
M'_X+0)Z%B70%&`4:VKP^O<8^O>N&0VMJAUC2EL*S;X)'BA7&H-U60]'!Y_29
M89JT$5"<>"$1!!-&'ZD^+E)962"$"TK]L$/*BDQSHG3"8)(8+C0S7(!E@I!3
M-P1\.X$9-`JBT(YD@IDDB449JGX,D_#C"`4S'BWNHQ,'<FUMV*NI8/JL9E1-
M'W%9.@&RNV1S'RFT(.RV\^_$Y>!61`D25*,_9QW9421B:9\1:G4$R$4<6Q<1
MYH6)*/'2W#)X$8Y;1ED&]QB8$T.WY4.D[D:$:9W."`R1T<`58U7M*!<)!K#;
MF+8J11LRR"A(0H.-[5#8,A0=DQ?NA<SGX<=Y,1C"/911OH5]0`-8R12P-+6?
M]:0+)0/NG[4E`O`8,)Z.9_W4:QVW,%/.0T2C)*9(?^V)_&R`8QSD>7L35`@`
MX$\,F76!1LR`,A)6D;5,3!H45;MU:KM#X^F?.F?=XUZ*,]@3R118$`!U[&BL
MR,#[7^&1(FU!\G*<O@*E(K0^#MW[A)DMA8C61%"E-*+=72(3E42`!>FT;_"V
M&HU<4!NP!2N,$U$&!;)L?N^;YPAF4H"(BCWFRU`X`@^0+,%2+9HY$:!S`0:5
M[H*I#YCT-C3R-RE5PD:AP_GC#0YTQJV;3"F9T^=-_@!G^8,\+'YJMW1^G0IS
M.\7`6"+&D?1C5^6$ID#>VYBZ`.\_!:$W?'*'0B6DH=^'@,JX_$LU6G`)4J1[
M48#9="!%W6A,N8`DU_%HS*DFKBXX6^>&8'RKWJ&57^KO?8\#:ULW=$%_E.A)
M,Z6=A$HND,X`*`:>=+ZB&@G[#=7#2F7PDI^_I><_J>=+4Z%U#8XS1DE#;)`\
M59LJ/1R.I?SQ!>LEG%4U%A+8-!V'SUF5:S8'G!SS`<L1'K3U<S+U`@LW%>N%
MEIY[)>/]-R(6L/R'Q'^(K-\G]W]4X*1$F?Y=A!.-;_.J+^AODU1?G`NRB9XH
M\+BN1`RRG0]B[6Q'15C75-GN4-JJU"O@V=RDL&4,P&4NJR:C4MQ/0TQ8)Y'5
MRR365N\QSD5Y-O!(<$EY/TP/NE22IB+[IVZWK0GF["Q1\I%MU;2P!VLVE"Z:
M&S2G@R(&C0.W8?UTVM'.W^SQ.=N'6-:@AO:N26A:=7$$,W,OT_"PDDF(JP%(
M!\>=='AF-F*&P!%B&*'Y,Q1@DX24%DCW"W@@%"6%&Z4XVUZ>(0!TE`P%;EG7
M%YSRSO9-J7VA2Z<H8X<X4Z(;9;M>[DRR?B93+W@6*NTSBH4(^;B;@+X=HT;S
MZE^!2\O*_T0#C!*L`P$(<<9^X`4/S.OI,[^D8AFSX%W'T)#2@]H\I'.IG:@4
MY%#20`D1)?;LY.@':N.&7RDFD<5R^.3PK0D8,^[4@_/$D[R=)>U)A.C.D4J!
MAL>%'W!M`DXY1K<>&52Q-'&(>EBC1V'AE7LLCJN1CO-5H.<7]O?@BD.TT;SG
M(J@&PA&\>T'6'%@>=,9%67IU`O@@BR;%X+'U]['0L&/P'M49X4<Q5Q4E-WS)
M2Z\:T#Q34&^,2(TN(\O4!@2$OLJ;Q6183X=`/]DRBRR3C.4(U9`AL5.!7!-K
MI1#P&'@,1HGT(Z0O/;E8L`K)H^F+2*`1:OJ4"IWQ1>9]RGEQME=6&9([2BM9
M*4^!)*@\[MB5Q1O4E%14UR("_*`5V82C3\BJ%D@1'5?HITLB8?"/@RX.O%BV
M(S"M[^'D4`4XM'(%'E7:`)2RO\;(X\=4=P\$"O&@))VAT^=L.,DRH8"1@,/D
M_*!_HD^-"W10T8W4M0#Z#[K+20A-`F`=4Z(1DTAOE9"6(-?PTI%8#P*5*R]U
M;F+6^T5<52FM43Q8347B"7;[3YWN<7=%7:STWJ)>OW_J\N?PYAWR]"O7"U?8
M:0UR-:U6=]\KC%3;*?*)3V`*36R'_`*PJQ0([Z4S[E5A3&,DK)F!Y[20*HSA
MMDCU!.6>MC4OI>&2B729GP>]W%4/,\L'<^[Z1N:M:"B71O,>M@J*L._GRF_(
MU<,9`21C'Y-AEI8Z^#."PK$[5#4(A;G?@3>HPH9^%="`C>4G(YMJ=C6L)&47
M[7*@B/9U.4CNI.LA]?.F)@`(,,W/RTL3WI"+QO@.Z9?LYA4Q\#G6+1FZD;#E
M>O+.7]"=3:XDB&4A#\TS',@J(`6/LK;^S/V&93M(5YG#E_(;M[(F@?0[J(ND
MJ;IE143Y7`2'M)P(Q!9:\:$;!VA8LOE#RK!\I&Q3L-R71;JZVZM2E+F8E8->
MN9F+VSJ9CWC:+5RXQS9W%YBONO]3\STC%_FPD9IH;FA&#9<>A9.QRC&M#X\W
M(/@W,UI#%2$DHP`58D\JJ4!F9.Q/9!Y?7U_3JHV+*%G]SU4VMBVK_VE5_^@Z
M,)4+<M?D/<1%,2L9YXM/F^TV9E_V2#J-Z89%HE'NTF%V68@C/@6)-Z3-IGFT
M):R2:.2??PKT6Y!TB)(K$EH];7?>P!$[_,E_W$`+S8E93E9Q@*G':^Z&K-06
M'J7RZ<*%1(D/I>@J)\W?Y*L@/TKEO5")5Y^MAU2TE#%<>CT`+/=1%A\RQFV`
M0J9/@RH:K\X$S729#U[P&BF+\O*5W3\O?;%MO4+=1!5ORMS/N@*1+?Y.+?Y#
MNGC3NWD]4G0DQJ!3AL4^*?7:03[C#BY*F8$T\GMA5OO*"XVY=WS,O)%DU>SN
MPQ`4QL53U86\>?G$0!9NGNCJ1[MZ6NBRJ?H6J2@C,LXKW"K]U#YKYVZ0).@+
M7QMQ-,8"5T?;>G!]RKF@9FNF-H5[\<$4RJLN35WG\HQJ5Z31!F7:,*@\(0M#
M%+D@UZ2<59H07]]%FIR2RJ54P`K6@!9IL-:K,N64-71!B1)$1^[<9-F8S:OB
M.3+]J\'6O`):9!=$"NO2BY3B$ZF@,[["+Y;'355W70S3(38'H;D=+I=$<1!\
M%N(T(S<$^]L7#P'HNL95^L)V417BJZZPHTH-DI3.-+ZC;$RL&_SY]F^J/K"Q
M1,4$I;J(4GKR"A'Z&V%/V>$LE,1\%T=X==QI2E*E2OL+:C<P>%%M*5-YV#&3
MNUJ.I.>8I:]ML?^[[&S._(OY/?7GW=VEN8/4."4I$#CKC*$^7QI#R1*//%K*
ML\9HI@^^..+;RQQP="(!UM*"\50OD@IG<[`+'(PHG1,*PX*O0I'52'Q4V1TT
M"A)OBZ7V7>[>>_'+EH*`3^W'PGT+TT:_0\%OD2<:%I*32(A4^*4AKVB+O*6%
MK14\^BFDADOQ/O5B2@V&W9"Y\)=R:;^M=R[S[DX*F%:X^JS'^>7O3_B^1KNK
MF7^C\CUO4VJY29&2=/';E'+]Q;-!1DM:D9I]GRX!ERXO29"7F:F!QU-<Y>4*
MGP.>.R*/EA]P6PJJOAKA`MB'M=6R8];MQV+F(Z%ZIJE#+YH6'BLQH,)/4ZN1
M46JP`Y!%8(`!661A<,^LS9*"#DE9;5XI$\:9T9ASJ:!1J/1:QD5123.2N5%^
M.9._ED%?0^*-4'KQ'8>F+S8P^@/+>GK/^H3L-<O=ZFB1$J7BC3R+J,;!6(G_
MU0^>_)?=ZY3=Z5Q$ZO8[LY3DCB8;/]<4AF1T=M5C9[L6IN)Y%&$*(8'R_)7Z
M$>F>H/'@\?N0>H=U"+E(:7K3!2R!,L@<&H,C4D"E>'(S5[0L'ET%T=*W2(53
ME*Z4^N=+72D9R6,[W2#BD[3\TQ2;+!5H-])LTI7\UW/P9%M_V%^_!M9_N2%F
M5NS<S9OF+ZSYZJT$.]6W<,6'+P-0?-['0[-W3.&YJEA`>I`660I!^65:$0K;
MMTH38-RXXH8,C:\_[:G-1R#?MP`IOPJVR]!`+>88*0ON3AFN!H(JS.=R:Q`F
MSEO)[&^6@Y`JIXY&,&RF+F6F/UO1L^\\X^V4]>B&261&7][^S8#(]4<<?L;*
M]`Q*6Q1ZDEK9K39=ZCP!WDC_RUR*\&-3NNR<HIU/G002[EMBQZG-QC:_:<";
MF2.FT_U2#6-RC:[MA`)=+YS8,1_A\@(@<^X%21S1OS+$I4!9P\'D*E\+'P^X
M$2Z3>Q?T4/,Z.BKIHL0/&F3)&IZ!@A0\;:]Z61&R.X./*"%"DU7%1V==<^B)
M%DJKI,C.[(1,3V3#PU6<)M<I8P)GO![>:D"P3'*#IF#E/=%G@Q*`6;FK3EFH
M\C:ST['4ZUHJ*G"'@;Y40,A<9[WR1A6WPO;R9]%5=B_B)P&*9=D),<Q;!V5.
MM9)(/1)E51XHPL$+O%!:QYMLSY2R;YIV0A>J9H\TS\Z\M7FY2F$>9`&67+UF
M+APVG$D+CF%S^-7T;V1>;!D8`7,[2:2N3.@8/:[:@]$4[]+!"FN@X8=,*#O%
M\<U307YG$&8:>F'M::<KS:SSP1J-(CM\SE+"Q$/B\:EI3P$]C[(UU:('<O4.
M<[65IYR%7?JJ#Y1<D+F!&IHH2J936(:RG:3V#60J(E;=O<M7LJ,I\4%T1"5O
M\*4D&;"X)A7*@N[N#!LD>?(`Y-B"8\,SUB#9FD;RF&_&D?!&U.&+/6I,<.W"
MY7G&Z]LM=;2+!!DDL;#3=I86-L=_6Q1._&N&0NKVID<6(Y"9=I5I5B8[CBF"
MY^7>55I['1Y6[%WRZ`Z30F#S`H[1"<:1WK_,;;FZ#Y23&-<44;X+K(\G8II(
MGCK:Y&UQT=F&R)!.(*"$[AI::&N0/>+&IE//#+,&P,E%",/C9`9)S=!E0/DW
M,6S*7"Z.OM,BNHI@<#[8C)UDW."X*AN(3F[RL>5]3K.$`$=D\5IGN2\K,3HW
MN!OS1N"8>!IS6(2+FK=?Z2(MIUKF**6U4S?;THCU&4M=VF4W"WWDO0.CH5=B
M-&QK9+A9$4;:EKOCI+I..]I1[O.B+BIY*5SNIM*M[$)^KT10J9]J5KV1\J"$
M5V4^'NG^-%P0F;FF0C_F!D'D`C?*E4GEI>%J`'D(]'!DE5!7[J?!&Y$08UQH
M6T<"`U.:#\)7@:P(4I/7P!./W7O4XPI%3?(T1$1*I)OD+.D*FB=.,4E9O6'>
M^-/UD4K8!5V@[%99@X/C/=D0@4?<,,])\*B*2,BL!UDL!4FH4-C!2(@BKI0K
MJT'^0XK>1@HF$?=C%$,PHT/D(GB<PV\O49L'%4TQ+P(>A.X#'>]YK!3PRR>(
M7)O`)KYH->:-A,`7S;&-6K4L9B+/-7V-3A#)@-9TB<=6/C;,S,%6%"E$[,ES
M0YJ3:E^EW,<'XQ!+L%"8`!IG<8H29?!%@<?U<$*1DD8:@<=RR;1Z%6[%\3@<
MOLM\9L:EE05592!)@X4OPE1B,@^9AN.K'NQLD&2^GNRH0WFG=_7C"TN\NYH3
M^Z2"I^\!(RZWJ=4V:RYJ3?FZ[I]U\K,U*F.71T)D7@56LMW)/5`S=579O@H$
MXWHQQCW<`H+*V!],%I-]VB0>5']4&79;L2UIRWG8LW>HKA$!BR[R#J!<QFI-
M$V4AZ8%OA(*499&HX\`;UG+W5JH:UWCWMM$$!(EY+6&^(&O<_`$M'WF!,Y:#
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MEQ;;2Z-?>52A"$MMD,YFZK>NQJ;\"T.:V%]EZUT-@)E$Y-P`0?V\\<G<(F-T
M%YD[]AYT1I3B4YDV5;HQ=L.7\P+W94&6E_@L<7N6!)#FG##RJ%<J/UY>S'9V
MIBR39]`*_V?!?'"C\GA4+7/5N&H@;7!M@:BJ!L]RP:A1=33J"Z-)H^\>3KJ9
MXASE)I@>3EJ()I6ILHOQ6R,-*GT4')`RY:P8&5_*XAPOHKZ1<PW];'14[5^0
M::FJ.#N<<S9VUA+@*1VHJ4O3"/7\OK&8'$"[0CQF(PW(5#[;#0=C%ES0^9HB
MLE`MB_^JU5&@K_%\V4*J&&MI_W+AD&.G<OMX4)=3>7/1.W,]4>H)KCJ8>J"`
M\6/V8DIQB,0HM1!,U4FK:TQUKG$W+^S&:BAGH%1,DO(U53NP1O"&DE3V\-'6
M`L[+O%A>0N=>B2LKPTL:>N8;^>7'UKL@-,YVY4TTK0FIE[C^8^`]"EIF:G2H
M\!7V#5$NG[DBZ0>*5,`!P!SQZ9F&3>!BI#E*X114G8XOUD%5<Z?HD\+]\A`&
M420%,,4FB2FY1FD:95^D)0(QD*6!=_GDV(F#AG0R&VUSV#_.$4N^?`!$.N@9
M)*5_O[CX!$,TE!5IWT=4Q!MK:90]BT+89A42-/<D'H,%S8$UNH(%;(E81DE+
MWKST(,!Z*K84T'P3H/RSWC-/A;I--M`4RW<\<Z@$;>R+*,]->`0HUXPL:Y=A
ME7@S]=/,WF9<6I"1S:(T`BU4EFB3KW*ZIL!M)65C9=9HZDVME$5_/4FBYH-M
M3U]K:0B/XB+C2ZP_Y@41X/$.A-`;+W"^_H:K^>M_R-X0])5U!P8F+/TF@/.U
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M#23%HDN][596S,OT68IU389N',VZ^,`094FCUCE17%IBMPF<3/].Z*1@N8UW
M'ND3I`W"0>^*ITPA_I.<%I>IKT+.6PFL?NF<>S=7642K6M(IELE.3^C,_N63
M/"OKF!M>=8I`^`E,M7!&B"K41$N68:^(55.E'[I#BXL>XM:A<PS'D0=12:E`
MHL;V*LOZVI0<B<Q2B.QF1Y["E=Z#@!GA'ZQKH:K,_FZ.)GZT/=GXP\8[1!4R
M@^0`J,G70%H@79Q0UJGG?@6C5XH9T"T1NYHS3MHJ.+4L^TI6%3Y%+GZ*;QC.
MMGAT#61L#ZV?6L?M$C-])$M6LH:8^"D*AN;*V??ECC(<#1OJ7MY^#$(RQEV8
MSHDK]Z#>\"85O"BX.:K(5T8T6WJS&"C3<&:=M>M0::[^G8!I]$&`@CJ\]A_!
M="7E>?\5G%--P5D<"9M6=TZ/,Y[_?/7[E_=?=D#E@5/@5DSC-$"GV'#+ND9+
M;GY"$CYF!#7I_2T^XV5,@NXODOM<"]])-*N.I)$J5=Q8+-EMXCIAD&_UTR"O
M%HI"EQ)?GBS'`\F&SV/Q&\[200^TM(;C\9/]3#^/$T"/JBYTG,&L+F%5M!0>
MTT;S#D[VYW*.GFM+EX9<:$/=%_*Q95N7,CXM:W:4NT;G!5/O%U8Y?&SAA<T$
M&"(\,+-T'2+$MAY_E6UURF2VBE;2.0E^2+-#J$.7B-@9E%(GRX+)^I=)/!52
M-Z/9N9L(G+HC+N,MY4C@4%0M0$Z]A(5\M&O^=`PJF#:CD")'M?CR;.+54IR$
MWMY'YP"NN*`73F"G#;7R\LNW\,3^2BXCTQ=.WMWL<C>;?>KB66WV%\H@,/3'
MLK`^FI)I(QLCY,OIP1I`:477TH6\JU/*"#=DP3!&;3*M?5BK4=8%@4+"8CSC
M'Y!4*LJ5&[%(O*&'EZN)RF1"'.O6]H.1JT*+3"`%'3_H59,GC\9["RM%#<8&
MHD7.%3SY4O29Y#CM_=RP3OL_T[/G/S?4S;$L)JBC1"W)T"J1D9&,-KD1<1-/
M!>WD5.P2.FQYAP=/W@=V2)%I7&PM"+$:K(/.24K%M8=@JN(=.C\G;ZEL&<`0
M"[Q;C0*^-W\:@V%`MU0<^Q[)NLC<%L/1F^W(6ZMT,1_H`$JMJB)0VM)QGK0>
M2ZGNIUH]H.,N+TRR']5UIO#<!S>][>'J@64+R!">+61[)>^=X164-J4,7*`>
M[BR/TVMD,@FXVFY$=D;HDFM#"5T.)'DVCOR_75\5ZG7!\&ES#AA1(HV/O#2M
M`X4.QH1$?';".#DK,!"94Y2!S?!OF^Y3SW:^2D=T\"0H"8VY1MZ89YF)G#J.
M9@2V\T/VM@D:S93`<-T`Q+8*@6*&5"4FC3Q+*1DFI)GF;YKS95STA*@'..CQ
MG!(JZ.`^UKB[)`*IO((^B;LQVX=D)TN+1OJB9.`.[%80+LD$J\^QB]NQP_`9
M#P(T)07YWE.=A6[[7/A!B[O.;N0(4@UZ,_#&H&"A^K,"`PQYTMIQ=(34M.@!
MT2E/H30MELDVH9_EA<E$=A;+SER2W@E*E.OB`=>H5SD'HH:)+&Z.VZ!1C0"E
M*-*=7D]K.61SE%G%23'_%&&KN8*`BZ%`.[7P(_(.!J;S'9NVR6!-MD?R`#1;
M<@9(Y58IM:AXM%9NBO"=Y9_<F7R'Q>I?&6*22-WHS=C;Z,6COE?Z-5D)(_%)
M3(?(BEY>^I`CBUW),MQ01\94%WYNTZDG;_NRLNHQ1]50V0AYC18DD8T%-UXE
M/OG8Q/"7UTN%3'=,5_&,&D.S/,4$(>C9GA>!L`8Z_'K4.J*_IZA2R[^?W&$\
M_O7HK/_SD<7MS^EKLR$Z72U.(_%:?9",1SW57UN8>'5DR0;K#J6E'%5X+KBK
M^1_8ER?G?.`VZ$;/=@6;8NR7-I=7`_07?/\[/[0#X&:%I@KD*9(KMYREKE'F
M8VE-P^+U.>P3^**?9^7<9I![L#W]9M$98/UGB_ZWK/!MFSZQ.Q)W'TC<$;Q7
M*/)F>,7N0^NDGJF+\G&6,VZMI/H1&:^S6<;#HW!C]/[!$=_>FHUFG-E75)B^
MZL3.G^IO@N%S\52W[A^P.0^H%?\)]J$8C8XJ5P/*CJDWY#5ARO!N'[=:8F*J
MODW^LJ9K":K_K6+34",.Q1CT?K0DWJ,!]M:.[=>+WU-L>.>\5`WYSB_MY:J7
M.KXVS/XW(E8QD]&6L_2R2_QIJ7-"_DFAI:O-WVV<GK87@L$/GD)[^NL1_WM4
M*Q:V\C3><;IV6^<[0-=98FEWSNF/4Q7+K7+D]U1<K:C?UL??&B`EGWJ-7J>W
M`]Q_(/^:R'_:VWGA5Q:N6RT`-Z)H%J6M-$_I?J#<-IWE']Z>:0]X7#,>=]$<
M(4N;`J>S>Z'#.;]>0?^JTV@-3C<NRW\YG.7K)'&[U]H%$N^)L4+IE-)0.<BO
M-3-W_VP7./M`WV7IV^YNWM)8570=3(UM5)$/>/QQ30V\^<#(RCT]GC?M'2>5
M<_/7'GMX,&\!93N#PXF\Z9.D"R)]&"08@_%=CY*:YCU@<NV8S+-_^K<9Y5,6
MP7-"<<3E*]!VS"%FV3O$+&\%N$MIH(<(QOH#AU5@\B&P=$-D27-:-&*HK):-
M$63!H^B'"CA](U.5;C%5Z1!>>@@OW</PTDL[&C>X1$.6,1O)]'CL]DU;.A).
M$E+R\9:S_;)HV+3)WNTT>JW!0D`<HK5VBK"#1OMT\W?W/\J][B579I`5X/94
M6&W-Q1](K?/.YAV-^R>UMH?"@T:_W]\!"N^B[G5'Y3`.HNJ[,/)9HW-^"(??
M8PJ?=AJ#P>;O,W\T34M5U-E?VW!K.+S3:70ZFP\2/<BPM5&X#3)L"\*`]U/=
MN@G\IG.06M^=IWN-07OS`<`'J;6^<VG0&'0//J[O)\=B:JKZ3!$@!^FU7NG5
M;G1ZW1W@[0.%5Z'P+C@Q=U'G8A<759@>!]Y0A$9IT5=8IMEQXU]DG=*#,%MS
M8/#9:6?CC+Z'`=];0^!VHWV^"ZKV@M%&LP-?K:),(Q!5K+C1UVU&OYS2R->L
M6=+B?7O6T3J)FY+1C!?^\#*@TLW"=\!PW?_V23VM?=++$+%`"Z49L=!+,[XG
M(\=Z6@>ERX\?/ES??;BZN;NU+F[>6I<?;^ZN;WZ_NKF\7D\KR9K6@!]<_/`>
MR,==OQE:-P6P7KC_8NDJ26?%LNGI_`3NG?@Z<4/;JEY+/2NHL_#[1S]?&KW=
M;\A6CVH]&*?U*0QB]]$F<-^X@=E"BIHJC5P/NSM9COOH>MROT,:.A_8#]FDV
M>L^I0NIOL(8\]HW0,'8K'+T)^6TR&@7>5W@S\>-G^)-:T(7X=TCEZ-\$V*.\
M`:N((ML9)Y&(8]DX/N"^-5IP<B-K8FDQ>.YH%"G0?<N><)%Y#7I*/;`NO$O;
MY]7?"6?L@Q'_0&VA"XV]^,GTB_9??FE0`V'9,UCOU)QK1M#@]A[89-`?VJI[
M>PE(GB<>@*(3-Z)V.-/0M76490O3U6`0VB-W*/M\(7;X31%C<7[7IV;NW"D1
M?@.!.J2`O%`@,A5)_6@*_.`\-]+F4S&UATBX150X$J%(FPA1+R2;>T91VPJL
MXC)VIU&N$01-R%ACLB7^OQ+JH!*ZSI@[4NACW8?8)ZDA_U6+=B?<21H[HOG8
M,QR^?P@"[(%(+7Q\^H1=TT$'P9XCB4]_(UI%+)M,C6POH@;E`E85T6,,$#W*
M[9X=,<6^$KQZ0M,4(7,=D5\8TT]CLTB(KPWL$`(,Q:VV`2^N&&$/@7\E/C=@
M5%\E/K8RPK8O3'OA1\@SC*YI@HVGX.FA/;$?D`]M$`^A+YX-FH^$ZER.?=I=
M/V63K,&7:FVI@9GU>@\*=%(=6A!*'W26:)SVG*-#&#@`QU<=OF9VVRCI*:;W
M$E'=P:C'G6HU43;2A\LNK$]NRN?M[;%!`("\O8!MYV5"J:\+)85K',A[!HX)
M'P7WD<IDE!_)QCW5FST`-9^:T&92`Y;PK+!8(2'@VXD4G1@O0CWXJ)&'"/DW
M0Y9G@QS#JFAQIK3M#-:PLJ(X7'1A+U\7-4#)Q(P20MAN$>AML\S0?V?10ZB@
MOK&!%6'/H.P1YFED=PQV3L6M'_A-['^4MKH&*I1)]U5D>(E475&":AW]'MU`
M"GA:/+QI',>P5>PXB45D]JUR620B\4`F\BKF"S2"A%PY9+ZQO,2SGMOT:&2E
M1GAZO\Z,%U%Y4/T/JQEG$JA.@D,W`H)$E3)(GS?M8).Q2>$H4(V;)X!L?7Q$
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MB@(/Y6P!*'Z:MP-BT-<UR#+6T_H8DFXM]9<(MI(C%0E>/N&4?GYR`5K`KO`?
M[`=NG\2O96WFMO>TSE,[:[/.AY6(8FI#F6K=01117T3JTP;2+W!<:A&&RC!K
MBT0T\<#ZCB,$[]`+#]M'/8Q3<TO-ENE_9F.YO*R4[<NE*&W@GSA$E#S`C[%J
M+>ABAW(0E8\"?\)>Z3P@OJGQ'#<E1!*R)@8$3&+5WSS770Y$"&SRA[1=`B7X
MC!*2`AGV:.T(D.P6B;R)70$U'9$EMS*,Z`!["`6-"_PO._4!R02:>O($"(-G
MVXNY*:*!ZT64SZD[10663MQAXJ0&(W%GNN%O-;S\*QD^<`>TR)`60\&J-7;A
MA+EY.W^%P<>![(5&ZV>FD!M9L<Y0(RJR&9$%GS1E32:V4P*F:GMN+IY'];*G
M!O9P(*"7"ZGH"3K!X$M8]CV>GKQL%]O+V[*G9\K7=L;2(397)KN!"G-24^(2
M7@891T-,%-5'MFR1FFKUK[DMH0R00;5`%*6@-B0C+3NKZ)=(&C6@X<H^>]B[
M$?LX1OD>C'*'L#3$@RW$78Q-#;FC:7"/K()",SM<D*>POV\X3`5VVB`;UXXJ
MC<=,CX`E4<0-CC7S*-8DO';J$V[@#^1.6L[8A7T_A",;]PP#B8<USH^:F8/I
M<`Y,2]8A;(*&W+J\3E"<$4)J_!H!L=@D9*6%NKE&Z"L!XWP"N)1ZR%+BMM2O
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M@T5)W2HWM,MB`%0\03TZ??(IA@W%"7`^BM"G-JCH@_Q7P%S"#S:4W+U+@%J>
M<K<<YQE462IDL-,+)<Z%P&RB+IE,'J?*GTE^`NO/Q'NN<'YHL^8]LK3\G`L4
MD:0IZAX[WR)XPRHQZTMXN9$Q$7Q]?4?D(Y)4N5ZQOZOT7.27G%]9^Y275D"H
M9O7"+O$?N!4YGV=,&O22FM2AY4L*F:Y!=<+I.CD:Q(1K::UI#O!VB4MF,92D
M8J=@%*,*"Y90,'.^.6/@VVF3]0<P'.%`5!V"<UVA*\!E*0,04TMUY'4Q)"14
M=W>MXCITF@3H+"KZFL)@.D7*\7),?ST[F/B^`.VQE.]A/)@!-@R_%8PP'@6L
M1TWWUUDIU?*D(C^!4QRX@DYR:0-&J;69F=V+FMS+6-HVV@2AZ@>>>*PBPD1A
M`K*G9)N1ZP5QP59MSGS5`"!57C:U9OA8,4/;UWN6)0*>I;F:LD)=%NN+K=5:
MK<+96C2^GE=*"4_RXJ74X%`'D&E8F%"`=#84^NU5"@LWJ]?^"+TH3-1,(\SB
M-K9<*_S3]A.PW+53XDQO7:XX*]7P5M7M:,GE^IU"*;XEW=*NCET[I!LP;L,@
M'S:V5WJEF>T/>76$KWGN%!4'VP]`J(,1`[9GTU!]WM]\TA2?YB\(R"1A01!-
MT*>IKA1QN,\W%\;;D0O?&*K7!+0@)_'X-`7=:6R'$]NA&VI25;)KUV/"RD4D
M+U+3MMXIMDUB#`,120<(R>529&@XX);A8#$Z<>KK(*O_FYA,26812LMPCK08
MA@F(`)C'"Z;XY;'U*0FC!,\7*10JX$R/#=V/I(9';O(3<H-+KH!#-X&OU2V;
MDL'H[$7<DB0!&F4W:W3=K1GR7XYO`39>Q4V@Q:*<-?KGO<9YJ_.7ZF?ZC4%O
MT.AT>K.?:?<:I]W9X_2ZIXW3P>GL9P;]QFF[]1?69K+G"!&E<)T>PUY3E"MW
M^&NWVQA31[X3O()QQ`*HL8(GT$_PPO@Z<B.3D*R[T`^*Y%'BQJQM.$$S=2B0
M>I,W-)4\2?=WI<HU0F^!/*<B]QNKV*PXSSA5,YF$W.K98-#!TZB$DSLS@^2N
M*-#@1)VRGX(A8:TD2!4!G7,5W*&8>MM^J:LO%==!I$,YH!3]U'M(2D?Y!B5U
M0>Y&]-=&='<(DDR`(/-95G"4`&!+^,@ERC\E!R'%,Q5$#>TNC9RZD2RYI#KG
M:;M9*57E-V[;B_V["B:U';HCHS""P'.=9V)6^#;$_8IZ#RE=C!/>9JC%/?@P
M-KO8%))@UTD]F^]Y7H"+=<2)OBQ`<1VQHI]!Q0T3]$;"S`##9SXX+E*^V_^(
MT;X6,;H,.C8<-]K7A#1BWOI\=7OW^<OEW9?/US>_KR-8M-Y-?YWJT475V9`"
M;P([I'N1MR[L;G2L6!12\:@N28V01#C62`NC'P$H=$4\N`[P;CA%Q5$%/FGT
MMJ:::I8Z*](A05PDCB`SW`K(`^"!P1E^924!SGZ"YINRI;O=GQNDO!K?MML]
M"Q1'+W@6>0-47=3CG#07F_1X^Q]&@>\++[U"]C#FC&Q.MFF!'.@:3!\@`1B!
M88^O1_8C7;U(3=&$YZ=."W8>4,F3D^'JB(V"0F_6[3TXWF:W\?$X%'AKXL?C
MR&*'3[&F;9'3:`FF^Y%4(Z%"2E*&,H(S2_@JQU/L$9$NA9^ZQ^<9(`KK,);Q
M3E-I[_)`\TMHH8?6*7Z2CBG?P2`EX8N1*U4$8[P*I@ND4_(YAP49C@*+C?)+
M8_!D)$0QA"2UM'B.+':"]"KI3,),KWR,1+ECQ9A[>UDQU2!'8*,&3\267`\S
MF<#4\&24FGV!3^KA#/7<1'BJQ:0,5<H;?`OL6R6%"^1E0I!$>$?Y>BGM9P/U
MX0>G6UP?OG6H#W\`=Y&'EDK&/=1-?Y$0SM5-OQR#9)+U6LJ58%5-??6YKJ5-
MJ8]Z-P[Q0FB!^5-LK@9$>?W^M:_]T!A@0PQ^03=#WX?!/]GNDLR]]-PI"68P
M]Z$YQ0_$@Q?H]!/##'-V?."_$MVB(CO^1^C%<?4B<WB>!;0M8F/7:M@WSEN[
M4"#G0->75@OI=7:A8.Z!KB^LQ]?H#G:AE\@L&[KTIJ[ZF-I($Z#BF;CW?:0/
M>#S@<9OPN)0;;C&=MKO6FG@'5?6@JA[H>E!5?W"Z'E35+5`-]K6]^@&3!TQN
M&R87].W.K7R:Q9TN$^:XCNC3V^0^$O].0$V^PES):%]#3,^T$-/*-2\01SHK
MU'CI@\R3MQMGQ];MES>W5__]Y>KFSKKZ&_Z7>*CB/F-KHD<3#T-'6V=FW@7=
MA%&(E,RZ^""&<1CXKF-=J'(D5"`(@SZ%S&E,\W0P*.OSS86+WZ>E,55.%BTZ
M#H4=JT=]D83!4#P(GX*Q'JF:"DF(R$HH\0KC!VV?HYY<?Y1@E0DK>HYB@96M
M+M[?-/^XN\/@==LO3&PYF(XQQ.#"&.,98A7L..:H>/B_A5,WTJ0Q`[@_Y%.!
M;\26`83"CD2C)-054QGNA?`51F@!G)=G%G:A\+P,L5EZ5`FR*8GT)GA,RW>U
M3()1QF_ZFD$^6RLAPW->_O'VVGJ'B<6RTE*A<B<^H:>4-21TO%IZG\8<<F"B
M*^,=L>!-+D:VU_I9Q>C1E1'A07ZA"`?//X3VQ$JF:<$[RL_'I%2:T/8I(3Q2
M28ZV1RQ-^6$PG><ZC%$@-::M<KZ,C'[,9PJ^4[FA;_'MB^$$P*=(5(HF#66J
MH1T2LP%+"#C.L`8*YN-AS4E9:41.-;&'8GOC*:]EA449LFMC%Y,PGA4S2:>W
MXOTL03B+QW2IA-V<P-UB=+#X)D(']HR,`.?DOYD<CZP`SS6#)`6XUVKV6BI2
M\P1+0KB`DS%F%]DAY?$JR'7N0BYIPEYT'5-(*:ZCO&I9>\Z6M91DMK4JLR2+
MA%*5!;E*H'H&]%A6H4FSWU1Y,5I[3C*6<#[L[I$V'-=MB_2!RMZB\E:<M6U'
M43(A(DP#@%.6`D*!)BM&&0L'69HO/YBESNN5T:($-M=S.J\2D!KF``8=<O5R
ME$KZ%%9=6CVI8G-I-5=@#*HGA/E&<E:0RYB[%`[MM(XN26<19EEYI9+RKFPF
MS)&//198JBJ6CI2LI)91S3$KK45Y>7Y"H@>XSO8H()B2RHTII:!/\1#@[,&]
MAZ*+IP\%1HJ3$,4UXX8`+#5A&]F2FV%U*$J1W])*83$'#''^[&@D'%GTEA/L
MY:["W=)@7%'*,"PI+8$B'M.L.UL5^Z)Z5UD)`R#'!/<I2('_18I@<BY55THH
M%T"E.<\0>)F:7*FJ+:H+VY[__/HF\"_M:'R+#4W>P($[O%0<`P+D2L9L_TZ:
M@P>ZN"[.'X6A"-]A;L.'`%,;KG`U_^RV01_&VA='%I80IH>^W+X]HNTWL;WH
MUZ-F]^BW]FGO#*R2OYZL#L]:UE6EX,]>5*L_V-"B5"4B&.BMMO_J(%6GW^^]
M<%7ET*QA34N1J=,:O)1,<Q?TR7ZFG,EW0?A9@/[NP.$E/HXPFS+P:6SX184!
MW=G?_@["!%L)@3#ZR%*,2JJMO+9N1UM:/4!IJ_R[P*,8K'*,8GH0-Y3O_W%T
MB^+U8Q*K'&U`H^L@JEPOX:BF%W(A#1CEUW;:Z9YJG+@<,/6N9CZ-*I;2[[1;
M]2QE*-S7%UA'"$G]SK,?%G-44"7ZOYX4WLX&E:V1W[F18WO_`/8'>KW%@W&A
M\9O-=@?^XAFJALHF>QLXR21]Y!.6%1R^@^\6VQ*__;><J'*8JID0F!?,@_\M
MFRD=IC@/`_$BW.%_FZUNBK[2H8HSW3U/%YR@W6K^MSDTOIN->(5JW?.EP`H4
MWC5LTV__)9X7&QJ8NMT^&_3/6CQ!Z5"%F3*)Q/M%8WICVC<V5N42%]''T3^[
M+;#"YNZVZYMW1[_UVN>GY^<*G?/GS,/W#M38\!*M,[15%\+#A>,(#STO(#'H
M=7UN8[S\9)_!!D0UP(]OJ-+<0K.]O_G'^XL/UJ<_+CY_N+B\^G)W?7GQ_K9A
M7=]<'NLSFX.;KL\+KFD0?>*>G*HU>B7^VV^%,U]]Z`U:+.EF3[,B*'R&S#D<
M3[O=\V5`P?#N]UG&8DV(:<-Q5L!,^52K0[00?MK=5JN_)$2)+*WT$9V$J$*%
M8HS&_:.X]L$`$N^#*+H1\<<1Z!FK8J[9EAKIDO.O"_B%D-SLGM4(>YJSC)DP
MUZ#)3MW8]C39MO+V;0_.NFT3XKF3U@CD0CCMM\X[_=9J0$:1B*-5L=49M,_;
M.?K2P"^<;*%5@_CHG/<6G*PNH=7KM*2)43K^<E,OM%PPVWIY^3UCZD?;]5"H
M@XES:WOB5CA)R!>)XC[._JH)+V?]]MFI"=O+`%@7]`L*_K-NK[\&\$=!&!DO
M_QZ"+/LLV!7VN^WZ*-NNOLFZ$20`[\:V?R<FZ`$/GZ\G4]L-R8JMP3]SUBM?
M8YU@+DK(F\!W:MJ3[=/3UMF"U,NFK170Q=@,#(-.9T5`T5F#E:G@'^QI^@@O
M8:VJ^-(.0VS3]#?;2\1<E+;F;.?3WKDI:A::MEY(%_+.G;=ZYZU-0[J8B&QU
M<B?'QG`Z3YUHGW771'TVX4&M"_&B^ZW@?^MQJ0/+MA>`NAR$FH!?2BXW!Z>#
M1?"]$.35]>NL;Y'[VG>]7X]B,&J.7L[/)VN8JH(A2Z:2:NLG._P8TJW[D+@.
MD$+^BY<NY^K3;<%/TCINM<U2@',FK1/*4DRL%TIV_%PD\3@(Z6[N)3BL\#6U
M.[U6SN,Q8\8Z0"LB[GN`=LWE?6O`V&GGK-,^/^W,@(HG6Q6BA1$%1N]YM],;
MK`K10F[,6A%5<&*N"%N=*%L$MEHT#<!3%9.7'=2+S[Z0]M!KG[]L]KR[I]33
MM*Q6T&R?M=H%=%1-N1QLRQWZ[7;GM"",%@/LK1@)K&OT&<[>2_C7C6LRXT\'
MIA%?.='J\"SHV!K4`T]]UF;W++>[9DU6"UB+.<,ZK<[*8#T*/ZGKWJ/?Z?;[
M%1#I\ZP(RV(7'X/3=FM56.ICH3/0]ZMX*#?5ZA`MA*"S3O>L:N?/@0@DEL.]
M[^"S)_`#1O-,L&_]_\H`VCJLN_S=U2(SKPCK<M$U[4Y[14"O[!`KST=*?U\Y
MGJ1H2&"$0NNXJZDK<R9='L*%L%@*7J>W+'C8O/KY@P!5'LQE#/$N>E"7V+<:
M42MF6!6,Q6[0.CD_[D+`O,.`>O$>HSZO?5!#'[!?$5\@@)*Q\L5/#J39L]4$
MV6+7)KG;NY=`5A6=*,/B+'<(VG\L)LW6Z5$]4J[5Z9AR>`X(R\+;/EI=TK5;
MI[GK\A<!F]WMO@N#R2)[97D;H'5F*D<+S;TJN$OZ`G.NP.5`-3R$UWXNT*,>
MK'9[[0)69\^["IA+&EFG_7:],.84HWI0>3XX'\P!,S?O*F`NATJ@=;_`FJL!
MR;P-YBU&&&-&0GW,V6[UYT);.OWJ,"^%WOH!I5O:8@!3/>?4V:`U![D5T]<!
M]7)Z>6^>L%H2XD^8>>,.%>O+LP[.0!ZO&.JR/$^?G\W#^B+`U+Z@Y>AQWIU'
MD#H6D^V7FHC0Z;;F$4&;<UGPED+I64YW7!$R;G(IZ!:R!FVQ/X_<YHQY^)2N
MP[+P6N:AU4+3[B`/6OED2X"TW-8@'EL>G@B4FA%F%&-J,F;,N4/7#D&47:@N
M+GAA^R=F0_\-'D]"L;)IW.OG66\%8+[/NA:R'M>SI*J#;9G@IW[WO&,*I,JS
M:[%I%PME.NWD`ST7F1;00A=!F&4EPHBMF34$G<Z;LC8`EPU471K`FKSS@];Y
M>277E'K#ZP^W[_?[W<$+87"D!G`K0DR]C^JTPCJMP7F>C2KF6P:L)7,U>X.E
M8+H1,9ZBGZA?M!B^>?X2H</KG>L#F;#$4-9/N0[<F:;6XI/7`O12F,6P_K5"
MS>=%_:CN=#HYEE@<@%H`7\Y]T._USKOK!/NCZKI6,[Z;_6ZKMPC@)0#4`OAR
M^.ZV.NW:P,Z<D#59LOW.H`!<-LFB\R\;>-'M#Q:>//#3=G[\C'*FU\-;K9P,
MJIIN&:B60\]I[BIG09!2-E(U`^HQS?J],U-J%.9Y"1C+U11HG^:\78O"4/NV
MZ?7/^N605/'O/%B6W$*@*E60I1*0BN2^+WXH\TS^X-(+*MWDHY\E0UR$+M9)
MXJ:R'`9=;Y386<X9M2YH-X"3Y;PUN52%[X@/S0BH,>2FW2^NIW2F&B!:+.2F
MU5T>HO6>2H-V$;)%3X'%H5N.+\]7A.U3$,6AB-V0RGJ]D4VH5*68FL1TMV3S
MS)YX-4B7$^+G)5OB)5"J;^^""^??";Q2G<Q6"UY/VV<YG\4+(*@'].5XMCWH
MM-<%.&CSP/KQ\R<L97KA#]%]5&/MJ\%LL"MGKP7JY3PF_6X],(?RVND[9QTM
M-F_-L"Z9>[0ZK.O(0"HD^<R>LB;P%L\4J1L\F?>S0G:?@O2D_LFJT;+`9'J.
MSO=9WE(S+KE&SK:I.2ESI2D62\:4U_*EU_%UY:&T>X/\'IDW9YU`+A@TGPLI
M60+(P!%B2)%]N+$0`J,^80UN[GZ^_M3<21>!D1G\"Y9:!HT;%@86(5Y)R-!L
MLXHDGK01/,;5(VB.C]-BP<=Z[A[6"N^F4+,<Z4_/M@$SJ,["@!]LK.(=/W\<
MK=E,Z)^V<_[Z):&I?TE+D;'7;9WFY4P]ZRE7@VO(!FB?]D^[>9`K9ZL%KD7K
M_+26A4L+G<*+E)I*UYSF;B)*9UD-D,6R)-KGG9<#4E84N)AKT*DG-P(,N]/S
M'(PS`%@.UFX->1%@[.>2Z5X$*!:1%T.5[Z25QWLK1J[CKLQS38#M/.?[F3]K
MC5`NEN1TVNYT^WDTO@S*\C.L)E]4KI!3^5POAF?)"ZI<\;*%@*D]#JO=/CO/
M!=#,"VRJ/]:J?7[6/1LL!,1_-)OO@B#VL3W`+78^"'S5)<!S_:^O1_+']_"'
M]8V^BI^GXM<C`$\@LQS);\,`^Z=H7:N^W8<>]:T"'NF>X,\G^.`1#:Z&]P+'
M&!7^QEXP:E!@3%CA?Z;I9?PMG.S"2Y/._NG=>\H\6V;8=NFP[56'[90.VUEU
MV&[IL-VR817I+D)S>!#":A#X.(=N\HF3D>W$336B>AV[6.3H("<*?CU2;$48
MWB1D[:V%K+.UD'67@,P`2S4X>HEXR`,D6=R8^MO$@^_]!Q!`?O/+[=%O-R"P
M'`S.CU#"->]1X%N.?K0(%03ADLU&S;NL]*XL^YF:':F&3-'KOYX8JV.9:'Z'
M0O$W[,R"BX$/_P=02P,$%`````@`+8BC0"/\/FIK"@``?G<``!4`'`!A;&YY
M+3(P,3(P,S,Q7V-A;"YX;6Q55`D``R;RHD\F\J)/=7@+``$$)0X```0Y`0``
M[5W=<^(X$G^_JOL??.S+[@,!DLOL96IR6^1KCJO,A,K'WKY=*;8`U1J)E602
M]J^_EFR#;60A`BF+U-4\3,#=\J_UD[I;+1E_^>5U&@=SS`5A]+S5.^JV`DQ#
M%A$Z/F\EHHU$2$@K$!+1",6,XO,69:U?_OG7OWSY6[O]V\7];1"Q,)EB*H.0
M8R1Q%+P0.0DNV`O%P2,:CS$/M-PU1<\Q?'A>9!<?V$B^(([S^P>][I'Z=_JI
MW<YN<($$-`B7=`O'1[WT2DSH[\]P*0#T5)RW)E+./G<Z+R\O1Z_//#YB?-PY
M[G9/.KE@*Y7\_"I(2?KE))?M=7[[=OL03O`4M0E5]H8K+=6,2:]W=G;6T5=!
M5)#/0NO?LA!)W9\;<06U$NI3.Q=KJZ_:O>/V2>_H540MZ(,@^,)9C._Q*-``
M/LO%#,@19#J+%7#]W83CT7D+Q70!+?2.NR>I_@\7*%;V/4PPEJ(5J(:>[@=+
MO$HA1M.CD$T[ZEJG(M_9Z_V',`2HG&!)0A1O"Z:BO#.R!PE#6(UF<3>ZFV&N
MB11]&EVRZ8SC"::"S/$M$R[=MDUC>T5^B<3D)F8OVX(LZ.V.)YE.$5_<C1[(
MF)(1\$-E/PQ90B4XER&+24BP$T#'AG9'7&A_S'':*2X`S7H[XQF`(Y[B1_3J
MU$TEZ9WO?94Y=1BLU]#/<C&@(\:G>@0[@+&K[XP.YL^42-W/>C;ID0!QRVU`
M6;5WQG:/A>1)*!,.K3J@J<CO8=X]"_Q'`M9=SUT'\)I*A@)\:IC$FK5;N&<)
M#7Z5F$8XRO&HEIPC2-80D4JGV^MU@W:P=$3P-Y`2@7>$V`]_"9CBD<XLLE:"
MM)G@QR>*DHC`E9_2D`B08Q:68,8J&#->[K4,I8ZX(R2>==B%;&>,T`S";Z_7
MP;$4^3>J?WOM;B^+OC]D7__WEJ!G$A,)XP;&T8-DX>\3%D>0S%S_D<"8S^\9
MHV<<:R0.*IT&#'&";@5;&"A]7L:->)BW!G^61LEZUI-)=(3R^:JU-K`[S?5'
MG$U=^S&#P.K!,PZ?SEM_AY0W$0"*S=0-51;Q@LEX(B$=;H:.>RP1H3BZ1IR"
M3Q`0[)*IZET<76&(,T0:Z'%1:HRNS02YP,\(^X=WA!7`WD$NRDOI71J759+W
M'<N[$01H`WM;M^`QE5O;DO':ZWI'K,H4&-4F_XKB!!N86Q?QF)IUL%G??_*N
MZX?0%N8<1];>-TIY3(`1K[>!J!!E[;G,`64")=19SQ][U_-7V3"YQY"0)_@[
MHV'"5:7#P(-%U@=6J@18X'KKC%:8J;R$_XET9,0D[C<I)L2'X*`N:]DP"?G(
M@0GGH3BH^MZO$_2!@0KJ&@]5)</#/'5]^KH0LB9[$)RLH?9Y6<@3'#DY*8NL
MQZQ84'L;,[*M`S%$"[4?::7$*.@W'T;(WH:1OA"%>G"Q\[,+38`:T#D6Z?[`
M@/9'(^AS)+%057(2$<354D,(%NIO8='Q;T:H_!7$$VY<*.W87F/CK4Q./L9V
MM,;?(#KD;(:Y7`QCE&Y<P?IQINS\CDWNP2[N&6EVL-ZNNU)C+"ZZ?-VS3J^@
M\]8)JUU_M1$*_ZEQ,4>QWAJ5EXCS!:'CVM*GFU[#K-2$2D?PWJ8Q]SC$@!JB
MO*JDUT^1&CD_2:D!Z^W,Z4>P$-%0AHA$`WJ)9D2BN%!F-SDM!R6/2]@N\/TE
M;(Y(K,;7#>,/,.4?<)APG5%?X6>Y^F0).=NVX.=,V]J,C-*?#XA2:XW63<VW
MC,()=$;5J7=4W1`*UMZ2.0:_(1$=$S`EM=2<8V]2\(R>37#SM8]_V83>J"_4
M%ZQ3QR;L0W&D2HL-KU/Q<,8)@VFV:'(S?`;!]OIUI@[%0=JJ3=JT.G+2\C,\
M.4'WMY209D[?L)RPJ%`O,7!4*^G#1*HAIQ9S3H@E[VN;I].73N6HZ;N>/ZT\
M-)"UNCR,VMOU,&KP8^D./[W#>=IM'BVHV'?L>-AV=8N`C8)2NX%JN.GCMX9S
M9983=E;IQD*N`=43Y1C%Y$\<_0N6882.OR)"57_?T56ZU^=$P*4K?6A\B&%"
M11;;W^]6C7DI!_)+X?]=K/>V;@H05P<M#0.B<OT06*Q`]K;"D#EC.K828)1J
MC`;C<%E.'Q-4;[O_EH19QOB`^1P^B.P4A_%@4*UL8U18AL_JG%`M[&5&[!LM
M2[.RC-XZ)U8R/M-@@+MYLZ#=V&Z!P&"[VO&X@L$2,[WYER$W[AI8Y9OGI3J.
M5CL(5N#>^JVOF()E,<#N1U-"B9#*SCFNIVBCAK\D;83N[:[;=T99V374$V21
M]3/26P!GA)QX1\C*FALPTKWNXJC7'%&;!MKJ.(Z3(=XZOA7*U)(!E9C#-]9S
M5%710Z"I#KNWODZOF[=Q>)L4_&=IDP5;'#5^]XIFS>]V5(I])V\K]D%[@6ZP
M\2*?\9A.6H@!<CA&`E_A]'_G(TIUZ@V5:A2Z(6=S`MQ?+)Z$VCV\(131$$9@
M/X3,J.X1O&V4FRORO('"0M7'V4"?JW$F(]*0\$:*C<H?B6*C@=[&RB%::.?Y
MR/HA=`#'M0=N3?NT6R@WN7+8<A`O]W*W,,_?"DJ-_<NU[ELFL5'Y(TUBHX$>
M+T7*1@YHY4E`\SIRDXYO4]8R9`N+RDU6Y2SZ%V[7P5<>BW*B<4WG0]"X9E5.
MHW^S\6&".-:__ZEV"6')DOUXW!IW=8('2%B=*0X':_Z_T_Q.G)@WG@_![16>
MIG!R>27Y`V1J@T7+O,._Y'(=>78`,@^[QH.03J2Z-?0AV'8S-?>EEB*>/\,@
M1;[VE+T3\[6Z'X+L6NOR:>[?XP]@=XAQI#=J!D(DZO3HW4C'?/%$`358"4LN
M,M=G.XRI@%HR"Q"+$W5@33]M=:?-,PV)=[Z?;\/(4C(M/`;]GCWB[?&;M1),
M_8-$+O4IF[9OH^(M!2J;?9MWPIN*'L7!K5##$/Z&U,]*R\7=:#O"W]K2(9+_
M5ENS@7#FW62_PC..U<]O`!SX.\::!1KUIXQ+\F?=,MI-S3>&'7('-\.\]=WK
MJ4_AE_Y7"QRGE+!&\P!)=;8M3P<MQ/K@L%?9B/W'`QQT?&/SS7F9Z2<%3KU^
M3E,O2H9,2`Y.ANOS%!>8XA'1%=>ZLVA.6KZQZC!'G>S*_:ZEH-;@<OQCGBW<
MQ>MN<=BP>]3MG9V>]([K)VW-XZ!-1UC]3A822JQW0QV+IV45W]AU2(4W&Y47
MO^V$;L?A^AMLU#?+11EDWO=XEO!P`HA*,0&N7$]G,5M@%?7_0^1DDC['=_<<
MDS$R547VVK)O#&^(LWNU/<^JCCR?VLL%W(AQ45K`?>7@Q>ZS!T#S)S^O7[.Z
MC@Y=CQ-$'_%TQCCBB\%TA@BO<_GO=!_?AIA#B'BGGMB\VF[JEP5<7T^7W2$[
MF`OC-6@'5T2$,1,)Q^J4;MJ0.G];:"I8M16LO>MNCU:8WV%7!7V\!KJ(=/WE
M=_L#6'J]71762156*AV4WX:W/S#VU]N5T:D#V+E\\4]$HR!5#DPOQ]L?6.OK
M[JH]>5KMR8*VAFQ^7=[^T%9>AU?%]ZF*3V4.@?D=>ON<X]47Y%5Q_;P^FW.5
MH/A2O2_+5[_"A_\!4$L#!!0````(`"V(HT#UB5!<<AT``*UZ`0`5`!P`86QN
M>2TR,#$R,#,S,5]L86(N>&UL550)``,F\J)/)O*B3W5X"P`!!"4.```$.0$`
M`-U=>W/CQI'__ZKN.\SM755VJZC58VV?U[&3HB1JPT0K*2+EV)6Z2D'@B(0-
M`C0>6LF?_N8%`B`P+Y!`SUVEG*7([I[^#;KGU8V>[__\L@[1,T[2((Y^>'/Z
M_N0-PI$?+X)H^<.;/#WR4C\(WJ`T\Z*%%\81_N%-%+_Y\Y_^_=^^_X^CH\E+
MAJ,%7J"?SN^OT;7WB$-T'42_/GHI1GZ"O8S\]B7(5N@\_A)A-/>62YQPZDGD
M/8;DC\=7\>,L?LJ^>`DNU$&G)^_I_[[^YNA(M'=.Y"X0^8E).'M_RG\)BR8)
MF"C]X<TJRS;?'1]_^?+E_<MC$KZ/D^7QV<G)A^."\`VG_.XE#6K47SX4M*?'
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M'Y.1:I,=A=Q6./M3$J_--!+MQR;4_PH?PUT,-0`)3N,\\;'-<R6#_V.<XNNJ
M^L8]RC4BHS1AH1,8CHX>9F_^5&7X`\*,Y;OON9D>5ONP/[4Y"QIG61(\YAF=
M/%$6HSLR8T89^F<AZW]V<0WG&M>!]QB$01;@]")/J%H:UU`QP+B&'D+5->34
M4*ZATZAA8X(*A27C\)YAK76%880*"(ZYP#A:6,\5YNS@[F$$3^(L2EX'7,=`
MOZ9)3L?GT^OI?#J9H?'-)9K-;R_^]I?;Z\O)_8P,WG]_F,Y_AG2L3IA*=D3V
M?ZAU0G+![<9IBC/#24=""^-02L6KWM-*".4J"F6D$XS'>(:?6VQTY;1NS2A<
M)R.;=L.8]5;<J_GJ;<'("!3/?E@OTVD[FTWF,SCSO/#2%9E:Z#]T/GCV0N(X
MZ3B[\)+D-8B6/WIACB4`#7EAC-D*6-7&C1@'-WT+K9I#.&%B\S_[4&$?(2]#
MA03$1/3B+!N<!/%B$BU4[G(0A#[]@*L(,?DV?D)<A1[1S3(OR0#P/>)E$$7T
M^?6+TF#`ZP4A],PMUA(FJQ,G%J':Q>?NT#5<A]XE,3'0[/6.//F,&`HUDLV:
MJ'2#9?VK9H'I;A,8U=Y7T0\^C^B5:;AFP3)"C(EYZ99MA`@CU("S!QB&`I<H
MHB:*X1QC&CWC-*.*I--H_/1$]NQ>AM-9_I@&B\!+Z/8_36.??4MP_C4.HNQ'
M0IZ3CI7TS9XR85SK(!U1];V]!`[NG`?0MF'P%9DHB)C9CQ?/-!Q.HP]E(R-4
M;6:$RH9&C(FUA8K&H#R^WQZB'?0+P_G,6=#;>[S,PSQ%\Q5.O`W.L\!/T33R
MW[^#7I@H5R2P2Q'Y&J07E\IH\%^_$Y<\?I8Z((ZW@$ZWE"<9@';F^W%./.W.
M>Z712LU*6$(,9(=*U6MVV4HY_-&60HVF80AB)*BW)YY@1UV=M-]P:E`#3W*\
M:(8OY3!E]&!FK@:P8^GMQ!#&KM*DS6(H/6H+&P.:?"<,^&6#H[2Y@AK.ZB_Q
M$R::+NZ)LA?DWR!36[V"'L;JM0"J5B\EA@J^:11J&$Y!CWJS=I6K=M:6,B#.
M(?55")LG*_M<LY21$4-;>YOJ[:9>I80[[S.>5]V94,UF4OT4"CF:WQ"8E@-Z
ME07:RN4PU,-Z2>_.R+ZKDWIP9Z>0-(PC>-`F3NB+!PX,^N9`:N-^R>;,T&_A
M'0UZ:->0`%#,`3T[A9D1M6JBLB#&H+*>X3W:$D-28##S:)`Y63\9.S`+:Z;?
MP:VZT;8JZ;(7L]6>=NI5Y$>>H5S1(6/"PF58;JHJVZB5$BH"+%6Z'OAMD`'$
M>R4ZM$1&B\&+D8YX/M`(3=,TQV`Y)5WT3[G^_W7R_N04;;P$/7,D7X].3D[H
M?RA=>0G-B<ZS59P$OQ,>&N**XN*'@&%F7\9YQEZ>I1DV7H8^$S-9H0^G(T0,
M^HQ17&(?KQ]Q4GQ["IC-%Z_7<:1UI2894(Z>1-U:.MX.S?"9=ZT*-!.8&)E3
MOF.GN<QK3L\4?O-']/7IZ-N/'T9G7W]KZSQ_1%^=C?[[['3T\:LS/:]#7C;V
M_7R=A_2-WMMLA1/2@9L$KW"4!L]X&OGQ&E_':7J#L]NGN?<B/T"VDP(68N@"
M=B?P8","(AQAKU_;`7\A!3$QJ"8'<4'H+17UCJ5-T8T!D0<8P3@P[)C!]FNP
M`P$[I+#A?/8>9UX0X<7$2VBR;%I1FVS:`C^0'0>8,,)XICFDJC/JN0;W/U.5
M&K97,**"$[VMFJ-@;EC=4`[6&5<5Q()3PGE.\ZU#"=PV0E<*)+1Y0I-J<,N7
MJ;!/*0&80P=C)/SL(6VIZ.#$H5CK:[;Z@Q8)&_CQF1*.S=O=,(E[9EKIS[?8
MAL+$YH8\/[1!9/(FMRN'>&08NDUF&9V]V+;S#B<SNKLS.N&1,[MPU*>#)C_]
MDW%"Q2IMM-,?M6V/"P;WIP/A$,<VA!_%">(2^"$.(C(0$^**?S%ETO'V#,:H
M9YI,+OB3#(K<CW8YW/"?=JWT?M,X3P/V'VL<PF\X'QI+<<#Z"C^&M>B!@L$=
M'ZE#T/D'IP8.-C55,38DEV).5C#J?AVTPH#UA=OR6-T"?HW+':]H`:-SC0J+
M$_[1T,?822J<+GF*#:"ZN\1R0"`A5,N-C!$G>*#59@MCP`:U_C)631/NA-NY
M[(W`[3U+!9[AAD7)`>XW)EL5!;D#?F*XN*_[!_P.I3,"]_8F#2C*C8F4VA%?
MD&]))*20J3L&J_@VLW$HA<<<@5N;D`8$_0Y$S>*(^6OV'BIZ>$?0+]+;O<&!
M/4=W+&[N-G9S;HI\&TW)4"-.,%<Q!;7C,3HVP%64F6IMIE=)AJ))4,.7T#V4
M]IRUFKHV<ODZ@YLXHK6^O(QX.%=]PM^]UWB6`1^,7QD#JGJ5E@G*IPP5:]@D
MSZTLT@I%.85WPWM55_VK?-ND4,'ZS@G'N2W4$UKIJE<KZ&$<10N@ZB!28BC'
MT"C4=(BM-16U189WANXZ%PQ.6/X]3C%]1V$<+2[Q,PYC5AU2J"B!KN&!R@TV
M`%)/"U8P`&0$:[5I20;F/.*=K"U786%P6<![8EE4L+P]!<RA_X0CXK4A`3)>
MK(,HH.Z:D86AVC^T7#`>8@BFZB,:EL&]Q$B?AFT)+E$)M,H'[2G[X_'J>$"]
MI3$EFDZ=SJR:C%9+,(G!$C4DF<!Q8X4$OT`R7A@Y8,'ERV`Z=%5*8"MN*MUJ
MQR497`VG4H<K@H5G<W_&V2I>5.H=2[K>D!>JGK<%L'K=;@-&@/K<QEJU5)FN
MO/Z):#<5K_%P":@BXK"C4^L=Q`?')\`$$3ODI.>#G2MI#[7><`0NQ#T#'/HT
MRC#I6]FYCIP<^G:`=O7;"__7::$.==3ZM(P6_&=QSCGX<L5:W6T)_2)(4'``
M+E_H0;'TE%:VDM$P`2UJC*#4UC=*CL%G3A-U)"?]RO-RJ*EC#SSM'NU`6,PV
MSN%<&,PJ_`6S;[4U&;%_;0UYN1/QZA+I`G0`G&DWM#LT0(;>IFC-N*L$@X_I
M+:TW30!G]<(W3A4M,$5`E_A0,\T^.@Z\UFK),WF($NR%-.OV+W%(4ZT^>4%$
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MDM[&BU]R$>R8Q_>8>D`0XMJ^8QX?QLG[:0JH,&Z/W5:KGMM#.\.7V.T-1+-X
M9MD4G2"WC:'F603Y^7`..]1P#->5R;8K(W'@0+^EGWW:BYMJ+^9%+QH-\H.F
M6I!]1XHO,?^WTBT7WB8@RU#-$&8C`"SIPA+B3N:%(3=<*-5.P^8Z9$7^PNPZ
M](IULLN6619AI7#D\,N1O=$5`M#;0L0[BK0<S808)]8>DL47CR<?8/N@%.34
M]L$`LL'V02'%L>V#5E/M]B$H)+BX?;"'I]D^;`6ZMGV0=,!5$'EDL;"_"RL%
M.>7"!I`-7%@AQ3$7UFJJ=>&G0H*++FP/3^/"6X&NN3"KHW!.5@H+>@")H]2C
MEQ1*>DM&#%3J7ZEZK=Q_*^7P)?\5:C3+_E/BHT=*C:KD4'M/*^5OXNB(;0Q9
MW0V!PE>@@-P%CGT_SLD^]\Y[I4?KQHOS!I\K>SX)(/56;X<)(L'>1"/3/4_!
MC`0W8*)Y)UA;_3?M^D,ZS,[5N,;(&WRN.(P$D-IA=IC@7B$RCV+L'09Q;-6M
M@-@MW@:12&>EVB$B3V`)=_LC96L*<;[<>KP,6'#;>Q4'\V/_MSQ(,$%*%,Q>
M[PB*;!PMZ&M#[$U^20?9"``JPVT-L5:1VYA[^.+<EJHURUH+`30H(D2@0L8(
M,2DC=KZ\%03UGM_^4(E2*X]6;8F?:-R',3-L^##8&*Y\ZV^5IU?@<P@:^"S?
M<MBX]VFE8[.\`F*W8W%79GFI:H<X('9JEK=#RF;Y,HQ<#2ZW'?P[YY,MIX=[
M'S\ZYI,*B-W.N8'>R;+43VZN52-M.]IV^&3[<"?:@)G:1%$RP]-_Z"S_[(5T
M)<"ST7>W[I(.LQ,!E,O=`68MN=N"?_A*U=;*M0>9Z(*-?:A(&8EW+5#+<2',
M3'D`M-1#WRXJIYX"&MD;^T5'L`^X;``PTA0LH^`I\.E:G!]NTO=%XC#PR<@Q
MQR_9.6G\5UGTP9`9*!)E!:T6F3+B'#Y29:%6,W)5,J.2&Q7LZ)]4`&(2``.?
M/&5R[KU<!JD?QFF>8)T1JED@RRRI832K*[73`Q554BDCJZ5$>%#)Y(A)2<H(
MF1N8C0`8<[.'6#4^<^[!3=%6-5E5J&9%+_?LE-Z)$7#EZ`HD9N,SCNC@;&ZK
MMD+@KFZQA[I[F8NY!)#K76S5:[TD10CAJ^>JF$/:KQ=&K]0JSTX^")NDW]#J
M(G0=S"YV::28%,4PVXLI[W3+_N*&M=-#P:<6NZ^LP6SW,(JV)1WQ?1^3B<X;
MJ5-EP?EMD>UQO6#XT%DB/?6$K(9X+_`6L9]3X6V)@SWAFZ\P\I;+A(6#D+>F
M6PP:LXF(HY&61FS#F[V*O#.\WH3Q*\8HP>L\8C%C8@M^Z*4IV:80`B\E/TFJ
MKA=5@]\//=S)*F)W[F&Y0%>'/%T7V`UZ,FD.#GMJ5?<9^(J*Z>-&!7AWAS[+
MWI`7A7=X^+/$>/@!<"DOI;_7$%C=L:38?[^,GX\7..";%?)A=X]"OOK7A*P^
ML]=[O&0Z1-F-M]X=]N1DPPYF.G7I$"6C&6S@42O0W,DR4E32(DH\[,._(!Y%
MS'$:+?#+W_"K%%"##NKQ2Q2N/_\=(@`#:-5`9@&"&#%J1,B'LH%+,:;.B=@6
M*/6?AW_B;>H5#[KZVZ#/M]EPX[$6)(C2#/TL>61K0I;W9,I2Z+]#!_=T6Q7>
M?<PU(I#GW:*!_,&+(.B$[GH)^5`V,":-+Z@"5Z&W>_%SR^_#/_-6!8MG7?MQ
MT&?<TG+S19&"!E&BH9[H19[0XF-70>I[X<]DZRQW;#GI\,]9IW;QR&5T@SY]
MM1+-0UQ.CC@]H@R#.SI?.%P%(4XN2+/+.)$OW7:HH!9NK<K6EVTU$H!%6TO[
MLB4;(T4%[<!K=L7M[/(%J9();#5O`&5G::^]FG[8=;Y6'>FBGW'RHZ01XLRH
MP@V80)01LZ8SW>V32#[TPKLX#>AIAJ:^A!DK4/*0!:Q:ZI`!W_")0\9*M00A
MR38SXD>741J'P8*^ZX'./4+E8V*)F!9I<J)F0@F2IZ.PR&NCX*NY39I)`3=/
M&[`22S41`6FTYOJ9VN]6.'NKJ%[EEQ;L<\VBZ5GU%2W38FZ^+2S@MBJ%(3',
M!CVD%4J4Z6AR-#+$I#EA:N/%@LT&9%[P@L4T$B7I*@L62?^8,$*5@S6%5"_N
MJN,"*-5JIE)+M=""$5%.FH$N>$>U!25<X=3]@6T(YQ%+K6>\<!YTCWT</-.B
M("E]R8=O^R7`);0P?J)4O.H:K82#>X-"BY:,FRTM*]I/S)[30UF\C?+G01C2
M*'"T0'GTR/_PXY!(C$6L."FEN52(I@)2T@T:'E<*T+0`41>?J3`X4*FIH8UI
ME:9[N5WM!\/JXF-K-'LYC!VPSM40NN"Z^+_@]'<)IE-Q47Y)9-"0+1N[Q6C,
M:CD;]XF9,%>&"1OHZO'#1-)^`\L!#==<V69)#\ZZS6%B/LOOU.15OX=.ZR3H
MPGQ1JWQ4_"39<!]8MJO)GA8=8Y?W:2#8P1108ZWWR08M&B$?*I7"MC_#77@Q
M4#^I:Y26@T90]%.MZE@YIB28IE`^D=DS_M)3$>/#I)DZ8%6'3*0O\EIH;2<6
MO9I&3W&R]A01(0L^@)'2!M!V%#1A&G:$,]=(GJK$JJ7QD&2%N^\Q2>MF_4$;
M++VZT*-,++DBW^RNF964<%EY$J6I,Q!.4XU[,7UE^W)KJ.;K,&(8.^"I@6:6
M4*.%MH46Q=NM0:'U0/905U5G$2)9\R`V<=!;L]BNR_>3'"^NR_N2C+=S4GY7
MMMD:@(5U=4;6F[790#&].XKME84$5!$Q])9@7WP%A.9)`&`L]-D+0GK`=A4G
M,R_$Y:7:E_@Q*_]2QWBLI0!%2;N!+;QM3Y2]^9P]K(9E%A*.R%KP*"4R4,DV
M0E1,[0N@R-)AP'YVZX9W.2"RX?4[NEV5U35?:\+2.Y@<#X!7U0!8NE+)ZY;S
M*#$YYC%7011D^#IXIJ=(&5$T()KQ,_@;+/,5'1.,EYA!*?S#',.`EPXDL8_Q
M(KTBN*9IFM-,V=LGGK3]$"UP0E9,Q*J(SN-HT7Z#$RV.+LX%@VC)3O=N-_0'
MV8*^YS:!KC88HB,+2QJT!WL;HOONLF8HC[?'KP\L6J09CN(EA9PVBK:ML@6^
M[!8U=B<#F1&VC8MS;=$\Q/0`VY_X!2=^D++^9`$1%'/.2L240F<II;RZA$-W
MK<BG5MD@9B/!D=M6]""W`TQW=#T&^*TU4U_0L79K751U7PJ$..EG+Z-JO=X^
MV=MG5VGPTV<'\&T38T?4PSWP2[Q)L!^P@9=\#C$+`46+\3I.LN!WU3VJ9JPP
MC](&UO:<O0.>_H[<S0`T3M\K;/3013"RZ:_*"K$T.``D7MA)@6/(_/4T2W*?
M^G6T)"CN<4AGB_(:"?,BM-U$066_=X==.-HA\/;F>!T!MA2O+,4PLQ6"JE=G
M&]:D'<(Y#P2;9K>@^\EL?O]P,7^XG]Y\@O-0%E6IA%.T9Z$J!AAOTT,H?,I,
M=\B`Z[9,/BV36N1D&X=;)=RN!%N5X.2A5B-4/6]FS,%(;C'(*&$ES]Z-W4MY
M^*!_*=.`#WY'H@2D/I13(!GX8*VNNOGA&.3KEX=!$U30^!Q-RJN31)A5/8V?
MGC!;+/AQVLSH[_59:4,(N]`XPQ'C0"4+XCSLW4&(IV2-HZ*Z)U2/>E*]K>_+
MW6KM$G;U>XX%,1+4X"]I=M,^X=2#]W5EC:36M$+8;Q=K+UDS5GE.)2&Q[D-A
MSVE.LM%$N6C=59EG9M7Z&C:^W4'[,(Z61QE.UJHN=^)B'(F!*3F<N_)F=\UC
MH7UO-J]6U^JF&@BCWT]]OW;1SMN;."/_?#5"7[-?OVE<33E@8E3CVC]-/2`5
M`U`2E!;"-O7)6/?>W$"I;..&Q7R]]I)7%OO67;;H0,F?EFO^-,:DY'#FHD69
M.5EHWYL]J=65WZKHB,E(KN,C0^Q?XR#*?B1_$$2Z,<E:BE.7*NK`%N:V)\K>
M3-`>5C,4L,S#W`V+U![S:VS1@M_1^)3,_CHC@XM$*6R.QV%J,2@7S,_HGD>-
M"5K*<&[[HI]Y]T((L<4QFIW5UW.Z8)VBS$IK91;URTM&G%`A!&-091#!&DV/
M8003]64%<P0;LS?Q#J`XY@5\_6@_2"TU@(H#O^ZU@`ZTW/62B'AT>H>3(K,W
M\.E5F$&8RRLE:;F`EK-F8+;+5SL4_2U7M6HW*N8+#OJF-L\T'R'&Q2Q,\$'X
MB3V4&YRAD%:CWE"O$$$VRHJ.T.,6TJ)'2*K(0\W#995:!QB>M/$&$T7KH8;V
MD:?W'MW6Y>$[?UJ(7*)N6<%''!*\I<2-D\EA^M=<;59:G86/1<&FOM[J4/5R
M,T%D)^)G5RUS-WX)%;;L"@LL@AGNDUNNR4Z@Y&QP+*314UGE>ZC061C[H:<$
M?`FUY@("B]<Q^C[R[)Z.U>9OM5/1>VF6UGZ@])5J]\9FDFH&,!;N4=93\L"$
MQ%$Y4LJV,>Y4&QZRN&F_`^Q^KW8);I3%2/`/.8J:>>'_W[?7*I6?G_$X28C>
M[`81\U<QK"1`'2U:@RP/%CNCZ_%8T0:.HM;W,W&UDMWTW8KAC/,Z\,68.,/)
M,_DC%>M,B2DJZ&$,3PN@,#-CS7LS*I6JS3P_?SNY%M10>Q-;W>F!A]B&B(4\
M40B39[JJ5/*/$\`AF<W_=W&:)3@C4PUUS7,<X:<@2XMY2+9+-N$$?"W'#%3M
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MJE5O?1=Q[3%<7+M'_)[`7XU[IRBG->.RF*UMB91F&)R]?MH:-(>YFN*@G3-?
MX6V_1-PN:&4XWC7TC5QQ_UU<L9%LY67L,AS6=>RJU-#/0QX];G8?+M(G:/>E
M/'UB@>G;8&3@7"!>M(]T*=FCH"Q84R%$A>K;P(4ZG&;#ZN7O?8W&`8H)DYU1
M6CL-_I00,[G'7AC\CA>?O""BX>G)BRC4QW9A\Y47S?%Z0Y;WR>N4;*>"1+7'
M[ZDMX'+%?71<[<[E/AH:_IKF_E#(*RJC*[+=G]5C,(BUAXH&$6V17VJ_;5-$
MW6BK:-LLJK0+%8D;LA.W';2D'41G"=J/[D6!VNX,)8O4P"=]22__,@YJ[K*Y
M4FRF'8[NJMTJCQ.W[385DD?("SYZ&UO)R>YR<R<(;@<IH'?3;I'X+4CVV$(5
MYYYDN+O'&Q&RK14L(;],UILP?L7T_.H?0;9:Q2$;&A[#8.FUU<X^J&2`+=9A
M.V6[Y3J,V&&W8(?469X%02?;4CS=DE7K^+"?BS9H?A*JM((JS0SMX0/V$(T^
M)&4/[=0&8C_CHH<RTD-?RE9@MF?.=PN*RV8`=U&S_#'%O^4$S>39X&163@ZS
MZ-"I7UULR&@'7V2H%6FI/U"0(T[OQ$MHNR!T&4L*>C=,IS4;24O<B_&8!%[5
M"K7$6L]GD[\_3&[F:/(C^?_!,U*M%6Y:O1/I49*8I%T$T[':![M)((9:]Y;X
M(5>S\5(8HT2<%%5H(?([S-4N?Z7;JU]H@0;TS"LTH+>\#D.8HOD*)]X&YUG@
MLWN^W]?>`Q*?KXD2Y&_R%_E`3W')'_\+4$L#!!0````(`"V(HT"[;N#E$A``
M`&#P```5`!P`86QN>2TR,#$R,#,S,5]P<F4N>&UL550)``,F\J)/)O*B3W5X
M"P`!!"4.```$.0$``.T=77/CMO&],_T/K//2/MBR[.1ROKEK1OY*G3JVQO8E
MZ5,&(B$)#07J0%*V\NN[`$F)%`D(%$61Q'7NX61I%]Q/8+%8+#_^\#9SK05F
M/O'HIZ/^R>F1A:GM.81./AV%_C'R;4*.+#]`U$&N1_&G(^H=_?#/O_[EX]^.
MCW^[?+JW',\.9Y@&ELTP"K!CO9)@:EUZKQ1;+V@RP<P2<#<4C5SX8[2,?WSV
MQL$K8CAYOM4_/>'_OGMW?!P_X!+Y,"#\)$8X.^E'O[B$_C&"GRR@GOJ?CJ9!
M,/_0Z[V^OIZ\C9A[XK%)[^ST]+R7`!Y%D!_>?)*!?CU/8/N]WWZ^?[:G>(:.
M">7\VFLL/DP17O_BXJ(G?@50GWSP!?Z]9Z-`R',K7984@O]UG(`=\Z^.^V?'
MY_V3-]\Y`AE8UD?FN?@)CRU!P(=@.0?E^&0V=SGAXKLIP^-/1\BE2QBA?W9Z
M'N%_<XE<SM_S%./`/[+X0)^?[E;T<@07S4YL;];CO_4VX'M[??X03(`&4QP0
M&[EEB=E`KDS9<P`FS*W9?QP_SC$3BO0'U+GR9G.&IYCZ9('O/5]';&4&VROE
M5\B?WKK>:UDB4WC5Z0EG,\26C^-G,J%D#/JAP<"VO9`&,+D,/9?8!&L1J#E0
M=8I3XT\8CH2B0V`Q7F5Z[F`BGN$7]*8EI@QTY6=?QY,Z&.L-R#E8WM&QQV;"
M@C6(4:-7I@[\9T8"(6?A3<(28-W2,R@E=F7:GK`?L-`.0@:C:E"S`;\'OQOY
M^$L(W-TL=`TXAU*9BI\\0H-?8+"080T*LN#QTV&*].$K833W\+`,&?@MP-3!
M3D(('T9[`8L'(@''.>WW3ZUC:S4/PF>P"0<F9P@]X),/,XPC`IMX%"L:QOK[
M9XI"A\`O_XA69*#9]>P,F2Z/!3R6%5=,I5CPQ\@?B54?@JT)0G-8_?O]'G8#
M/_F&"[9_?-J/%_]OXJ]_7Q'\.+XE%`@CR!UZ/N'B&HS`J)`=),]UT0B[@AI-
MM%X##`U\'\2J('T38$5DVE(&+$LP8G8R%'S,F$D^ZHHA>G,15AS;4^*N+&S,
MO%D9$<9$>,6T>\S![-/1&03<H0\D>7..S6,88&:,&</.?<2YE%A!*<3.(\_'
M`K9)M5V%C(MLJ_9R<$TIL=C:LNK*$5N/UN:,>`P62=B`-:-"'O?QI1#^N_D2
MD@5RQ>(87"'&EK`L_8+<$!>H5!.O615++#/1M"8/AFK^"=L8>(:-N?^`@UA4
M!9J6P+5:LQ*:8TV^,TR3&9%LFWY;KKD-6F.-]2L[7^`%R&V+PH;,FV,6+(<N
MBC9*,/O,>50!QEJ@/S5X.U=1-<V&.N(=7<"63FPO[^A@/"8N@7#1YYLLXA#$
M8)L)4O-L\2T();WW\0L47W&\=EI&1:9BTWEO2O0LG:_;JK^$.C.GYGN"1F"1
M`1&V]QQX]A]3SP5.?3Z#!4O%+D<?M4N[5WVN8H/XMON>F>)Y^^96!=R4HLM:
M<8&ROY8-<'R>X`_1DN\7%%&T!+`%.MX64TLH-U>C+`32<_(I5JH,MA-ZE1%?
MSUS<N&JO8]J?@,DK^)\H\A8*V/:K5D&\H7NG-<<+3$/%/"P#[))2LY37LZ5I
M7*-:$W`W9U[%E-L_-6H_E)^('CQJEYATT^`M4&RI<%C-C?%KK)BE--6=@^VN
MKG.LU+/B-CPEJ^?B[NDO0[R9<W&I;%0;\T^[ZE8CZ]0W;1H>)L0+YF7'\(50
MS:47=15:2+:AZ0A><^A1I1;S(.U789YF0^.A@>.0B)$A(LX=O4)S`HM"BO^B
MO)(&4OMUK,.%H>F(@6V'L]#EQ9^/P12S3-U^5'#-J_<?</`X?D%OQ:G%<B-T
MP![*LF1H9N,)!XA0[-P@1@F=^"FYP#:"V*2XCFH[4OM-0(>+O47?+5-[7DI:
M<7<7U%I$]==YP+_#P7[W-E3;.4J47WE=;Y7R!PM$7'X&>NNQ9^3B9VR'3(CA
M&H^"]5^*`\.R([2[VK(L-Z;&^%(Y*-.?>F@M+>/2HMV<FIY;0DF`[R%0A8U,
M@.B$`.^1B(JK;K<AM%.MVZBN*39K0J-B"Y):R92NJ@+NVNJMXL6<\ECE7=W"
M%-J6F[W=4;"2F;V%Y<VK>,CP'!'GYFW.K]P"J\*RMUUGT<)J==BEQ8&IN^C(
M]'_&P=1S4G<!"A0MA6R!/V_1L)3T6*L7.ROU(E(JQ1.><\DX[\?>YKWY>F_3
M;W1@B4==7:WO5[U:;_T]\X3_7[7?_[DB"/B1"6(=<8HSQ.QYBMCVHT8Y8I<N
M-^CRM)J+S9J*L^P+7OU!"',6(W^N9P2I#>01NJO[/"^)SK\S7^=WOA]JZSL!
M[KJN$SX2/7]_\A5H^C$,1$,_T7!(2]T9C*[K/,-,HOCW)]\;IOG4`7V)!5X+
MJTL6H,508@47)^<&FX'&VJZ$[JC:Y:OZQ<F[]\;K6[JN2R$[K>?-%?WBY/VW
MYCNU>DE7@W=:W86+^<7)Q5G_`)Y]@%Q+F1ZR&[F7,\VVANM'6-[8RHQK\8%;
MU.@P*B_;Y#[^5BL1HS="$S[]@(-U]5P!$QN_-W+8%AD@G<1):U6S1@5L"R:<
M,H:T.G&3<V1H1<03J`=$R_OC7>,%=CW1O"EFO["Z40G?E-ZWFNVZKE%)OZ%W
M$W[$%.3C`M,#9T8HX;()P!OD>MZ*T7I-;^7`4(_."4AGYNZ`/@MHWM>=A%;5
M+J[X5(8*A5!=7W73O!BIVP>/>EEFD]H`>92E@=-1O6MP9NC%DK6AWX(P]2LE
M-/&:L@=M\U[WB-3BQ]"H;,UC)(<[&F!06-$D(`?MD*YE+)@:B/%B+ZF89+6K
M"H3.J'H;(X;.ZF5T;8*:MVOX$(TY.A;S9%-\>^MJT:HPMT`>R5UA1:"KA=51
MM6OQM@IS#C$O'EA^)4Q"[2JF!8&R"_:?*</(Y8?9__)<?O;U(R*42^*1KJ]P
M#1CQX:=K\6:Q(09>'$6G@OH>U2&KJD\(>\M88-8>\U1(N-P4WBDC4?*QK^AU
M3TMV_LU\_!L>G/$7'HES=/&.7<X3,"2DGJ10@34W=/@50MUSOSV/W<'E?,\2
M2):U1J]Y5;&AXA.UG<U&-EP3EE*+(Y6S(9DX6A<-53$AV5'=SD8D'_`K-2.Y
M0`Q-OB5]BY("8)`,L;D3$3<,"FLEMV)T<*W2XFMO+6":OVA\3^SXINTS9@OX
MPX_;_!;H6P';44TK..K*<O$K)I,I6.4`'H0F^"&<C3!['`O#3=6!JKVYTD@=
MU'TE?E?7HFHWC0.7TO)%\=;U7O-5L^>[5<W">)88L$75LBLF]4IC"\`;JH/E
ME`R9MR"@V\OE9S\3\PQLB$VBA(NB+F*'05K@W%*-I=*>I?DRYU7CNY9('_JL
M;&<+/FAVNYD^RO\-X\J-%^\)VQZUB8LS[+YXU=V_GL=TUY[JD8<Y?>&2O4]V
M?URT7$H`&^LT5*,_K=K"2G@VM.DW2(YAX/8:1_^G9!6W/E=,/&603;:9,G(X
MZ,EVHX8$PL9DP?MM2NHW5?!-F4MY?Y`;08:ARE%-81>L%JH][O26O%RJL..;
MECWH#62"H>AQ6GD%ZHH%;;R\5\M8<C@FV$6.*4.K1?.<;[R:3LL$<C@FF$".
M*5-?_J6_[:N4`.OROK8,EW7<&6N1640W*"KF1Y6#=#@_JN3+G#0&K(KQMFY@
M?PD)PR`'<(5@.701#2!ZXI>HBBIPN.C*(+=LQM"P_55#N!)<UK-!:?><46FN
MZ+)AE.&REI<BM<@NXG9,U=82Y2`=7DN4?)GSEFA][BN91.NF#`W;+V\@AG8L
MX-SS2A3XCR^;"^3RI36Z^K"Y<2NZ$%`*O0M31CF.:KD'V1X[&(!W,+8$1Y"^
M\E@'[_=VW.?<4?<%S.PM>I@+NP(:66"J\@U2_1X359'B;VB36XJ"E)Y(S=LV
M"X&-]4M2]$Y)9;@F9"RES-7T%J?&XP*(B&R,'=&WA??CY:]VB:M-_<\4>`89
M@>S)0I0C%Y87\.UX?.,!1"[N+SP*X1394\W/ZVZ$6K-@S*E+RZ6%Y&_&U$F=
MJ;!;9DU5<F<J-NLYFVUZ-N-<@JO\C`+.Z/)Q7,Y.=AVIPS:S*\OFO,/R&@/%
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M)++5"44=QGN(G@_A;`8\/8Z?R822,;%YD5]TAX`W:?1<8J=2=4D3"#!_Z]BZ
M)K[M>G[(,.\($0W$>SVDAK+68UFKP9JXOZKB[@5$=ND6[Q1U$1N9;7($J6Y\
M*X`;\_NM#*RNV&JJH<Y<UR&\,<7FA&&<F?_7SG>6<[ZTQZT1F]B/LPFB<>IQ
MW0XF2DL.4X)*O=)RW2A&];:\_8S;3!-8%QCQHI9Q`\80G0BRUAI434"EL!M[
M#=4^M;YN(UN"\X.UZ#K`+)#*W^9]_WS3]R-H*P)O++<"CU]3I;[_+X=N+C64
M(4CECFKP!D\/MND@F\^1,6"2&UU[=LCG"WYG!>*%8'E'(?:?98X3$[_B/<T2
M^/1'1!TK0K;2V/M(3:C(4[6/UL/;W95\;)],O$7/P23R(OBPZ3SPU>_1PY_P
M1+1#I<$#FA6=O!6#-=9(MHS45SU`"UF0N\JA9'\%?##DWH%+O/T;+Z7"S\%U
M4/HY'N1)Q_K%G[#Q`L,6%29D?NZ4L+.DRTN4#B?C85+*>PWQHD+8&W"=E/H&
M#_+SM_K%/P!Z'$[3K8LF1>F$[.^=$O<&[8JCJ\.9^2U$8\C]#T;L%KXIROE*
M(3LE>RD7BE+O0VLA<D,]/61@.ZR)#!^*>QCUZ^(J9"QC(/*Y7P[:*4W(V5`T
MES]4D'E+7,RN@)J)Q^0AY@94I\1?R$$2W3?B`G'(NSY'C2XDI!J1RV-])5('
M]:)F*%&3-$8Z0)Z!4TBBTTO1=5Z<36!:?&[VW6;Z+H4ML@U9_&;>629C1RO#
M5Q*_H=>R;2=1G90O-T"#+V\KK\O4:]Q*,6E2[E"4.(5V(%Y5F/?B=YM>S--[
M5A:I`;O.$``Z>\(NKRG0:E)2`K<)E]U*GI[C[C9,4^Y;6I^)Z^[&IDD._!R.
M?/PEA-%N%L6'Z-_G*U@2%"O&::)098-NU9M)I*"-=(C?H$995".';:R;P1:Y
MKPI1Y*2;Y#X_>80&O\!@X!IYU_EVTW6>\"1TPT8<1E*1#I->F@>5'Y4>H9$W
M\A43J;?JE4%NR@%WU.-JLUB"Q68=]6./$SY"/H8__@=02P,$%`````@`+8BC
M0!D!A1V%!0``6R$``!$`'`!A;&YY+3(P,3(P,S,Q+GAS9%54"0`#)O*B3R;R
MHD]U>`L``00E#@``!#D!``#M65MOVS84?A^P_\#IJ0,FR[+7#@GL%KFUR)#5
M@9.N?2MHZ5@B2I$N+W;R[W=(2;%\=])F%\P($,CD.1_/^3Z1AR)[;^X*3J:@
M-).B'\2M=D!`)#)E(NL'5H=4)XP%;U[_^$/OIS#\=#J\(JE,;`'"D$0!-9"2
M&3,Y.94S`>269AFH%O&&UU1I4#4ZB=LM]_?R51A6<*=4HSMV>?-.*RY[=))#
M00E&)G0_R(V9'$?1;#9KS;HMJ;*HTV['T:<_KFZ\75`:'M^-%&<+YJZE=NA&
M3&A#10*U/6?BRQ9SUSW"^![@5^RK:.*CHZ/(]P;$4)6!>4\+T!.:P(,YY>*>
MTZ*5R`+1XTZ[VXUK8->WEZ&00MAB?<BI49&YGT"$1B%:@6()*LG!"?56JN(<
MQM1RTP^^6LK9F$$:$&J,8B-K8,'`BH;)G-K4/(S<).IE5'8&*!PA/2J$--2@
MW/ZW:YE,F!C+ZB<V.*:.E>1PB_$2]_!A>+F6`-<7_2Z9,']B%E:A%BSM!PLM
M#[@U<@IC)IB/H-UI_TI"<LYTPJ5&:_PQA,QRJWO1LO$RCL57<R!>^^>)`HWC
M^;RNL*'RKDRV>2:4)Y8_P7$>V6:_JK7F\LD4W]B1AJ\6,[R8XC]=TKS2NH/J
MWY:IG@.0$N%`>H/T(6BC;((O,2ZU)>.+33OH?K5,MULNR`+$@>\&WV>R*)AQ
MRZ$^$>F9%`89PE+'H'K?MQGLT.+ELA8-+$)%2A;0#K(T9#FO-A-(^05R9.XO
ML5BHPD==ZK+58JLP;2=+O5EI/#I%2BC2P#K(TI#E$O>`!=S2NWIV-!MVS(;N
M\FPH?8EW/K#<++PL$[C12BB^W9D"OUFKJ^_:KAW,=U9*\!R%S&$.&BQL?HJ"
MJOO!N,EXDDCK5^QKR=F\1.QINT.E>'6CY&&)'"\*]H!,:NB#<DWE,+/RA1Z,
MSZC.WW(YJX5:V[55E[CKRL6#HR_B(@7AOE#Q2:,"J?_:G6,[P1PZ\?#DQ0=!
M;<K0YN>#3AMT&DQ`^7#+/5:!J>?(,9O"E=1KQ-MAOUW1SM,4;8Y"W#`'93<H
M>TJY.U&YR0&,OJ8*4\W!X.K%2R6W]&]7+H[W4ZX:@)0C-'4B+Q;&.^BV4;<U
M4NU29\]YM5F=_X$:[I\[/QS"F/C3P6-W/M</-"LFW)TJ^K9<P;@?.('"^KCO
M,Z;;NBMX;>+PMYQ3>D&7&:H&KB&H2E905DXO$43B:FMPF]$\_"Q#9\:Y7S>&
M(6X<_0NA'".-OEORJ-ACDU\2^9ER/YN/\DRI<SIZ;.KH`OP9D[YR^&O3[47-
M@UW\M7CPV\-LI3)$K!R%[W%L79[_7\G$X^WV?%\Z(I/MHS#NA/&KUIU.ZUCW
M#&7ICF"?&+R+^Q76?BZ$K@NA&S\UA+D2CPNA]GMT"!Y+0]+*Y#1*@;E[ASAL
MQZ&[>=@0PUH?]Q#.G?<;?4SUR&=B=9A1.ME[]+6.$7"CZY9-L52W(K[LN1GX
M^;T4;AM_8V3RQ5])N2T@UC,_ZL6=>P0]Q*4/IU6.^]!SF`*7$P<2^)3ZP3=!
ME`N$O[\Z+J0`@Q^#EUA<755!$NQ(XW2T#NF=DG92FV(E+7!\QG$5<)/5*.OF
MK^_#><UD>NN!4ZNJX[2R;U269>R`$3/?2,L[$+A#YYC225I@R=3&#3:%1Q&S
M&>2_3,VE2+A-(;T4U5>,R.JNDY%+,7G<Z[,7'JV>ZIR;!&(/^CP+?9N(VG9X
MNTS"?K;_L@0_`LMRW-*>3%&2#+`4C4`-QC<Y?GT,K'%EP=VEHZ@L<?.><6O<
MQ6J9\E.]%Y)VQOIO3?J:WOO/Y;=2#6%B<4G#=W8P=K<>4OB7&'LN<+\C[\&=
M&7]D)L\E=ZD,1IQEY1=]3<+W0ONGUHI$05HO%KVHK%GX^!=02P$"'@,4````
M"``MB*-`0M30<V-<``#5>0,`$0`8```````!````I($`````86QN>2TR,#$R
M,#,S,2YX;6Q55`4``R;RHD]U>`L``00E#@``!#D!``!02P$"'@,4````"``M
MB*-`(_P^:FL*``!^=P``%0`8```````!````I(&N7```86QN>2TR,#$R,#,S
M,5]C86PN>&UL550%``,F\J)/=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M+8BC0/6)4%QR'0``K7H!`!4`&````````0```*2!:&<``&%L;GDM,C`Q,C`S
M,S%?;&%B+GAM;%54!0`#)O*B3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`"V(HT"[;N#E$A```&#P```5`!@```````$```"D@2F%``!A;&YY+3(P,3(P
M,S,Q7W!R92YX;6Q55`4``R;RHD]U>`L``00E#@``!#D!``!02P$"'@,4````
M"``MB*-`&0&%'84%``!;(0``$0`8```````!````I(&*E0``86QN>2TR,#$R
M,#,S,2YX<V155`4``R;RHD]U>`L``00E#@``!#D!``!02P4&``````4`!0"_
)`0``6IL`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EQAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">ALNYLAM PHARMACEUTICALS, INC.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001178670<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,
         2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">51,949,931<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document as an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EXYAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="4">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th" colspan="2">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th" colspan="2">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Condensed Consolidated Statements of Comprehensive Loss [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Net revenues from research collaborators</a></td>
        <td class="nump">$ 20,587<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 20,897<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (1)</a></td>
        <td class="nump">21,074<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">26,349<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative (1)</a></td>
        <td class="nump">10,406<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
        <td class="nump">10,224<span></span></td>
        <td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump">31,480<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">36,573<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num">(10,893)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(15,676)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of joint venture (Regulus Therapeutics Inc.)</a></td>
        <td class="num">(889)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(1,072)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
        <td class="nump">223<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">382<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
        <td class="nump">191<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">81<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
        <td class="num">(475)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(609)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(11,368)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(16,285)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share - basic and diluted</a></td>
        <td class="num">$ (0.25)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">$ (0.38)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares used to compute basic and diluted net loss per common share</a></td>
        <td class="nump">46,210<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">42,345<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">(11,368)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(16,285)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) gain on marketable securities</a></td>
        <td class="nump">128<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(732)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
        <td class="num">(11,240)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="num">(17,017)<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract', window );"><strong>Non-cash stock-based compensation expenses included in operating expenses are as follows:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment', window );">Research and development</a></td>
        <td class="nump">2,088<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">2,665<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative', window );">General and administrative</a></td>
        <td class="nump">$ 1,068<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
        <td class="nump">$ 1,457<span></span></td>
        <td class="fn" style="border-bottom: 0px;"></td>
      </tr>
      <tr>
        <td colspan="5"></td>
      </tr>
      <tr>
        <td colspan="5">
          <table class="outerFootnotes" width="100%">
            <tr class="outerFootnote">
              <td style="vertical-align: top;" valign="top">[1]</td>
              <td style="vertical-align: top;" valign="top">Non-cash stock-based compensation expenses included in operating expenses are as follows:</td>
            </tr>
          </table>
        </td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration classified as general and administrative expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_NonCashStockBasedCompensationExpensesGeneralAndAdministrative</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_NonCashStockBasedCompensationExpensesIncludedInOperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration classified as research and development expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_NonCashStockBasedCompensationExpensesResearchAndDevelopment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares issued and outstanding that are used in calculating basic and diluted earnings per share, determined based on the timing of issuance of shares in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e540-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A5<br><br> -Appendix A<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 8, 9, 10, 11, 12, 13, 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508144<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e557-108580<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomeNetOfTaxAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasicAndDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 19<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 6<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 11<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income derived from investments in debt securities and on cash and cash equivalents the earnings of which reflect the time value of money or transactions in which the payments are for the use or forbearance of money.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 14<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_InvestmentIncomeInterest</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 1<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicenseAndServicesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NonoperatingIncomeExpenseAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e653-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920433&amp;loc=d3e998-108581<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 24<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 17, 22<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph c(3)<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 141<br><br> -Paragraph 51<br><br> -Subparagraph g<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 2<br><br> -Paragraph 12, 13<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 86<br><br> -Paragraph 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 7 - us-gaap:SubsequentEventsTextBlock-->
   <p style="margin-top:18px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>7. SUBSEQUENT EVENT </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In July 2007, the Company entered into the Medtronic Agreement to pursue the development of RNAi therapeutics for the
   treatment of neurodegenerative disorders using implantable infusion systems. ALN-HTT is an RNAi therapeutic candidate targeting the huntingtin gene, for the treatment of Huntington&#8217;s disease, which the Company has been developing in
   collaboration with Medtronic under the Medtronic Agreement. In November 2010, the Company and Medtronic entered into an agreement with CHDI Foundation, Inc. (&#8220;CHDI&#8221;), under which CHDI agreed to initially fund approximately 50% of the costs
   of the ALN-HTT program up to the point at which an investigational new drug application can be filed with the United States Food and Drug Administration or a comparable foreign regulatory filing can be made. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In April 2012, as part of the Company&#8217;s alignment of resources following its strategic corporate restructuring, the Company
   exercised its option under the Medtronic Agreement to opt-out of the 50-50 expense/profit share arrangement of the ALN-HTT drug-device development program and move to a royalty and milestone licensing structure. Medtronic has the right to continue
   development of the ALN-HTT program. If Medtronic decides to continue the ALN-HTT program, it would assume responsibility for future development plans. The Company intends to continue to supply ALN-HTT for the program and, if Medtronic continues the
   program, the Company would be compensated for such supply in accordance with the terms of the Medtronic Agreement. The Company would be entitled to certain development milestones, as well as royalties on annual net sales, if any. The Company
   continues to be obligated to repay CHDI for its pro-rata share of funding received through the effective date of its opt-out, with interest, in the event that a product is ultimately commercialized from the funded research. </font></p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>2012 Restructuring<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>2012 Restructuring [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">2012 RESTRUCTURING</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 6 - us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>6.&#160;2012 RESTRUCTURING </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">In January 2012, the Company&#8217;s Board of Directors approved, and the Company implemented, a strategic corporate
   restructuring pursuant to which the Company reduced its overall workforce by approximately 33%, to approximately 115 employees. The Company expects the reduction in personnel costs, along with other external costs, to result in savings of
   approximately $20.0 million in its 2012 operating expenses. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">During the three months ended March&#160;31, 2012, the Company
   substantially completed the implementation of the strategic corporate restructuring and recorded $3.9&#160;million of restructuring-related costs in operating expenses, including employee severance, benefits and related costs. The Company expects to
   pay substantially all of these restructuring costs during 2012. The Company does not expect to incur any additional significant costs associated with this restructuring. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   The following table summarizes the components of the Company&#8217;s restructuring expenses recorded in operating expenses and in current liabilities, in thousands: </font></p>
   <p style="font-size:12px;margin-top:0px;margin-bottom:0px">&#160;</p>
   <table cellspacing="0" cellpadding="0" width="84%" border="0" style="border-collapse:collapse; text-align: left" align="center">
   <!-- Begin Table Head -->
   <tr>
   <td width="70%">&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td valign="bottom" width="6%">&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Charges</b></font><br /><font style="font-family:times new roman" size="1"><b>Incurred<br />Through</b></font><br />
   <font style="font-family:times new roman" size="1"><b>March&#160;31,</b></font><br /><font style="font-family:times new roman" size="1"><b>2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amounts</b></font><br /><font style="font-family:times new roman" size="1"><b>Paid<br />Through</b></font><br /><font style="font-family:times new roman" size="1">
   <b>March&#160;31,<br />2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:times new roman" size="1"><b>Amounts</b></font><br /><font style="font-family:times new roman" size="1"><b>Accrued&#160;at</b></font><br /><font style="font-family:times new roman" size="1">
   <b>March&#160;31,<br />2012</b></font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   </tr>
   <!-- End Table Head -->
   <!-- Begin Table Body -->
   <tr bgcolor="#cceeff">
   <td valign="top">
   <p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Employee severance, benefits and related costs</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,909</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,521</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,388</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:1px solid #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <tr>
   <td valign="top">
   <p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:times new roman" size="2">Total</font></p>
   </td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">3,909</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">1,521</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   <td valign="bottom"><font size="1">&#160;</font></td>
   <td valign="bottom"><font style="font-family:times new roman" size="2">$</font></td>
   <td valign="bottom" align="right"><font style="font-family:times new roman" size="2">2,388</font></td>
   <td nowrap="nowrap" valign="bottom"><font style="font-family:times new roman" size="2">&#160;</font></td>
   </tr>
   <tr style="font-size:1px">
   <td valign="bottom">&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   <td valign="bottom">&#160;</td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td valign="bottom">
   <p style="border-top:3px double #000000">&#160;</p>
   </td>
   <td>&#160;</td>
   </tr>
   <!-- End Table Body -->
   </table>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 146<br><br> -Paragraph 20<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394695&amp;loc=d3e140864-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0ECHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num">$ (11,368)<span></span></td>
        <td class="num">$ (16,285)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump">2,121<span></span></td>
        <td class="nump">1,339<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Non-cash stock-based compensation</a></td>
        <td class="nump">3,156<span></span></td>
        <td class="nump">4,122<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementBenefitsPayments', window );">Charge for 401(k) company stock match</a></td>
        <td class="nump">96<span></span></td>
        <td class="nump">138<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity in loss of joint venture (Regulus Therapeutics Inc.)</a></td>
        <td class="nump">889<span></span></td>
        <td class="nump">1,072<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Realized gain on sale of marketable securities</a></td>
        <td class="num">(175)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Billed and unbilled collaboration receivables</a></td>
        <td class="num">(724)<span></span></td>
        <td class="nump">2,300<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable</a></td>
        <td class="nump">0<span></span></td>
        <td class="nump">10,669<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="num">(2,932)<span></span></td>
        <td class="nump">1,970<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(1,461)<span></span></td>
        <td class="num">(3,512)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other</a></td>
        <td class="nump">252<span></span></td>
        <td class="nump">1,780<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(20,069)<span></span></td>
        <td class="num">(9,898)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(30,215)<span></span></td>
        <td class="num">(6,305)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(263)<span></span></td>
        <td class="num">(28)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Increase in restricted cash</a></td>
        <td class="num">(162)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities', window );">Purchases of marketable securities</a></td>
        <td class="num">(118,210)<span></span></td>
        <td class="num">(41,790)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sales and maturities of marketable securities</a></td>
        <td class="nump">53,042<span></span></td>
        <td class="nump">64,105<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
        <td class="num">(65,593)<span></span></td>
        <td class="nump">22,287<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and other types of equity</a></td>
        <td class="nump">847<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
        <td class="nump">86,800<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations', window );">Payments for repurchase of common stock for employee tax withholding</a></td>
        <td class="num">(328)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">87,319<span></span></td>
        <td class="nump">9<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net (decrease) increase in cash and cash equivalents</a></td>
        <td class="num">(8,489)<span></span></td>
        <td class="nump">15,991<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
        <td class="nump">70,228<span></span></td>
        <td class="nump">74,599<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
        <td class="nump">$ 61,739<span></span></td>
        <td class="nump">$ 90,590<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payments for repurchase of common stock for employee tax withholding obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>alny_PaymentsForRepurchaseOfCommonStockForEmployeeTaxWithholdingObligations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>alny_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 16<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7<br><br> -Footnote 1<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3044-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 8, 9<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361293&amp;loc=d3e6676-107765<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 7, 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 323<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6382870&amp;loc=d3e33749-111570<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 19<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Principles Board Opinion (APB)<br><br> -Number 18<br><br> -Paragraph 6<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 11<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 9<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.12)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncomeLossFromEquityMethodInvestments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or  income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInReceivables</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15, 16, 17<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestrictedCash</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from financing activity for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash inflow or outflow from investing activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 26<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6880815&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6920043&amp;loc=d3e565-108580<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph A7<br><br> -Appendix A<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 130<br><br> -Paragraph 10, 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher AICPA<br><br> -Name Accounting Research Bulletin (ARB)<br><br> -Number 51<br><br> -Paragraph 38<br><br> -Subparagraph d<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Emerging Issues Task Force (EITF)<br><br> -Number 87-21<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Article 5<br><br> -Section 03<br><br> -Paragraph 19<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28, 29, 30<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementBenefitsPayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund non-pension postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherPostretirementBenefitsPayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire debt and equity securities not classified as either held-to-maturity securities or trading securities which would be classified as available-for-sale securities and reported at fair value, with unrealized gains and losses excluded from earnings and reported in a separate component of shareholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquireAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3213-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 17<br><br> -Subparagraph c<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total cash inflow associated with the amount received from holders to acquire the entity's shares under incentive and share awards, including stock option exercises. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 123R<br><br> -Paragraph A240<br><br> -Subparagraph i<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph a<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 15<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 320<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6871852&amp;loc=d3e26853-111562<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 16<br><br> -Subparagraph b<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 115<br><br> -Paragraph 18<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 95<br><br> -Paragraph 28<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6943989&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.6</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
   <!-- Begin Block Tagged Note 5 - us-gaap:CommitmentsAndContingenciesDisclosureTextBlock-->
   <p style="margin-top:0px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b>5.&#160;COMMITMENTS AND CONTINGENCIES </b></font></p>
   <p style="margin-top:6px;margin-bottom:0px"><font style="font-family:times new roman" size="2"><b><i>Litigation </i></b></font></p>
   <p style="margin-top:6px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>Tekmira Litigation </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On March&#160;16, 2011, Tekmira and Protiva
   Biotherapeutics, Inc. filed a civil complaint against the Company in the Business Litigation Section of the Suffolk County Superior Court in Boston, Massachusetts, and on June&#160;3, 2011, the plaintiffs filed an amended complaint adding AlCana
   Technologies, Inc. (&#8220;AlCana&#8221;), a research collaborator of the Company, as a defendant. The amended complaint alleges misappropriation of the plaintiffs&#8217; confidential and proprietary information and trade secrets, civil conspiracy, and
   tortious interference with contractual relationships by the Company and AlCana, and unjust enrichment, contractual breach, breach of the implied covenant of good faith and fair dealing, unfair competition, false advertising, and unfair and deceptive
   trade practices by the Company. The plaintiffs seek, among other relief, injunctive relief, unspecified compensatory and punitive damages, attorneys&#8217; fees, the termination of licenses that the plaintiffs provided to the Company and the
   relinquishment and transfer of certain of the Company&#8217;s intellectual property, including patents covering the Company&#8217;s MC3 technology. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   On April&#160;6, 2011, the Company timely served and filed an answer to the plaintiffs&#8217; original complaint denying the plaintiffs&#8217; claims, and asserted counterclaims against the plaintiffs. On
   June&#160;28, 2011, the Company timely served and filed an answer to the plaintiffs&#8217; amended complaint denying the plaintiffs&#8217; claims and asserted counterclaims against the plaintiffs for breach of contract, defamation, breach of covenant
   not to sue, breach of patent prosecution and non-use provisions, misappropriation of confidential and proprietary information and trade secrets, unjust enrichment, breach of the implied covenant of good faith and fair dealing, as well as violations
   of Massachusetts statutes. The Company is seeking monetary damages, attorneys&#8217; fees and equitable relief on its counterclaims. In September 2011, the Court granted the plaintiffs&#8217; motion to dismiss the Company&#8217;s counterclaim for
   defamation. The plaintiffs did not move to dismiss any of the Company&#8217;s other counterclaims, all of which remain pending. The case is currently in discovery and the Company expects a trial to start in October 2012. The Company intends to
   vigorously defend itself in this matter. However, litigation is subject to inherent uncertainty and this matter could be decided against the Company and the Company could be required to pay substantial damages. The Company has also incurred, and
   will continue to incur during the pendency of the litigation, significant costs, and the defense of this litigation has diverted, and until resolved will continue to divert, the attention of the Company&#8217;s management and other resources that
   would otherwise be engaged in other activities. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company has not recorded an estimate of the possible loss associated with
   this legal proceeding. Although Tekmira has not specified the amount of monetary damages it is seeking, it has suggested that it believes such amount is significant and could include but not be limited to the disgorgement of cash funds the Company
   has received under certain of its collaboration agreements, future milestones and royalties associated with certain of the Company&#8217;s pipeline products, and other damages. Significant judgment is required to determine both the likelihood of a
   loss and the estimated amount of any such loss. The Company currently believes that the likelihood of a loss is more than remote but less than probable, and is unable to estimate a possible range of loss for this legal proceeding due to many
   factors, including: the current state of the litigation proceedings and discovery process, the inability to assess the amount of damages until expert reports are obtained, uncertainties regarding the potential for settlement discussions and the
   tendency of plaintiffs to maintain very high demands until cases reach critical juncture, such as the filing of dispositive motions or serious mediation. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2">
   <i>University of Utah Litigation </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On March&#160;22, 2011, The University of
   Utah (the &#8220;University&#8221;) filed a civil complaint in the United States District Court for the District of Massachusetts against the Company, Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. and Max Planck Innovation GmbH
   (together, &#8220;Max Planck&#8221;), the Whitehead Institute for Biomedical Research (&#8220;Whitehead&#8221;), the Massachusetts Institute of Technology (&#8220;MIT&#8221;) and the University of Massachusetts (&#8220;UMass&#8221;), claiming a professor at
   the University is the sole inventor or, in the alternative, a joint inventor, of the Tuschl patents. The University did not serve the original complaint on the Company or the other defendants. On July&#160;6, 2011, the University filed an amended
   complaint alleging substantially the same claims against the Company, Max Planck, Whitehead, MIT and UMass. The amended complaint was served on the Company on July&#160;14, 2011. The University is seeking changes to the inventorship of the Tuschl
   patents, unspecified damages and other relief. On October&#160;31, 2011, the Company, Max Planck, Whitehead, MIT and UMass filed a motion to dismiss. Also on October&#160;31, 2011, UMass filed a motion to dismiss on separate grounds, which the
   Company, Max Planck, Whitehead and MIT have joined. On December&#160;31, 2011, the University filed a second amended complaint dropping UMass as a defendant and adding as defendants several UMass officials. Although the Company believes it has meritorious defenses and
   intends to vigorously defend itself in this matter, litigation is subject to inherent uncertainty and a court could ultimately rule against the Company. In addition, the defense of litigation and related matters are costly and may divert the
   attention of the Company&#8217;s management and other resources that would otherwise be engaged in other activities. The Company has not recorded an estimate of the possible loss associated with this legal proceeding due to the uncertainties related
   to both the likelihood and the amount of any possible loss or range of loss. </font></p>
   <p style="margin-top:18px;margin-bottom:0px; margin-left:2%"><font style="font-family:times new roman" size="2"><i>Tekmira Infringement Litigation
   </i></font></p>
   <p style="margin-top:6px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">On January&#160;17, 2012, the Company filed a complaint in the United States District Court for the District of
   Massachusetts against Tekmira for patent infringement arising from Tekmira&#8217;s research activities providing lipid nanoparticles- (&#8220;LNP&#8221;-) formulated small interfering RNA (&#8220;siRNA&#8221;) molecules to a pharmaceutical collaborator.
   As alleged in the complaint, the Company does not believe Tekmira&#8217;s activities are protected under the exemption from patent infringement for drug development. Pursuant to the complaint, the Company believes Tekmira has infringed a number of
   issued patents related to siRNA and LNP technologies, including: U.S. Patent No.&#160;7,695,902; U.S. Patent No.&#160;6,858,225; U.S. Patent No.&#160;6,815,432; U.S. Patent No.&#160;6,534,484; U.S. Patent No.&#160;6,586,410; and U.S. Patent
   No.&#160;6,858,224. Under the Company&#8217;s contractual right to enforce U.S. Patent No.&#160;7,695,902 owned by Isis, the Company joined Isis to the suit as a co-plaintiff. On March&#160;2, 2012, Tekmira filed a motion to dismiss five of the six
   claims of the Company&#8217;s complaint for lack of standing.&#160;The Company filed an opposition to this motion and Tekmira has filed a reply. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">
   The Company and Isis are seeking judgment that Tekmira has infringed the patents at issue, a permanent injunction enjoining the infringing activities, damages, and costs and expenses, including
   attorneys&#8217; fees. </font></p>
   <p style="margin-top:12px;margin-bottom:0px; text-indent:8%"><font style="font-family:times new roman" size="2">The Company&#8217;s accounting policy for accrual of legal costs is to recognize such expenses as
   incurred. </font></p>
   <p style="font-size:1px;margin-top:18px;margin-bottom:0px">&#160;</p>
<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6952336&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name FASB Interpretation (FIN)<br><br> -Number 14<br><br> -Paragraph 3<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Statement of Financial Accounting Standard (FAS)<br><br> -Number 5<br><br> -Paragraph 9, 10, 11, 12<br><br> -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009.  This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <Version>2.4.0.6</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>7</ContextCount>
  <ElementCount>90</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0202 - Disclosure - Significant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/SignificantAgreements</Role>
      <ShortName>Significant Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0203 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0204 - Disclosure - Regulus</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/JointVenture</Role>
      <ShortName>Regulus</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0205 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0206 - Disclosure - 2012 Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/Restructuring</Role>
      <ShortName>2012 Restructuring</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0207 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://alnylam.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Process Flow-Through: 0110 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2011'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2010'</Log>
    <Log type="Info">Process Flow-Through: 0111 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 0120 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 0130 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
  </Logs>
  <InputFiles>
    <File>alny-20120331.xml</File>
    <File>alny-20120331.xsd</File>
    <File>alny-20120331_cal.xml</File>
    <File>alny-20120331_lab.xml</File>
    <File>alny-20120331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
